PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chen, S; Yin, XL; Zhu, XY; Ji, SY; Chen, C; Cai, MM; Zhang, SW; Zong, HL; Hu, Y; Yuan, ZH; Shen, ZH; Gu, JX				Chen, S; Yin, XL; Zhu, XY; Ji, SY; Chen, C; Cai, MM; Zhang, SW; Zong, HL; Hu, Y; Yuan, ZH; Shen, ZH; Gu, JX			The C-terminal kinase domain of the p34cdc2-related PITSLRE protein kinase (p110C) associates with p21-activated kinase 1 and inhibits its activity during anoikis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; NEURITE OUTGROWTH; GENE-COMPLEX; APOPTOSIS; PAK; ACTIVATION; EXPRESSION; FAMILY; 1P36	The PITSLRE protein kinases are parts of the large family of p34cdc2-related kinases. During apoptosis induced by some stimuli, specific PITSLRE isoforms are cleaved by caspase to produce a protein that contains the C-terminal kinase domain of the PITSLRE proteins (p110C). The p110C induces apoptosis when it is ectopically expressed in Chinese hamster ovary cells. In our study, similar induction of this p110C was observed during anoikis in NIH3T3 cells. To investigate the molecular mechanism of apoptosis mediated by p110C, we used the yeast two-hybrid system to screen a human fetal liver cDNA library and identified p21-activated kinase 1 (PAK1) as an interacting partner of p110C. The association of p110C with PAK1 was further confirmed by in vitro binding assay, in vivo coimmunoprecipitation, and confocal microscope analysis. The interaction of p110C with PAK1 occurred within the residues 210-332 of PAK1. Neither association between p58(PITSLRE) or p110(PITSLRE) and PAK1 nor association between p110C and PAK2 or PAK3 was observed. Anoikis was increased and PAK1 activity was inhibited when NIH3T3 cells were transfected with p110C. Furthermore, the binding of p110C with PAK1 and inhibition of PAK1 activity were also observed during anoikis. Taken together, these data suggested that PAK1 might participate in the apoptotic pathway mediated by p110C.	Fudan Univ, Shanghai Med Ctr, Ctr Gene Res, Shanghai 200032, Peoples R China; Fudan Univ, Shanghai Med Ctr, Dept Biochem, Shanghai 200032, Peoples R China; Fudan Univ, Shanghai Med Ctr, Dept Mol Virus, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University	Gu, JX (corresponding author), Fudan Univ, Shanghai Med Ctr, Ctr Gene Res, Shanghai 200032, Peoples R China.	jxgu@shmu.edu.cn	Zong, Hongliang/F-9366-2013	Zong, Hongliang/0000-0002-5855-5733				Ariza ME, 1999, J BIOL CHEM, V274, P28505, DOI 10.1074/jbc.274.40.28505; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Berry DE, 1996, ONCOGENE, V12, P1809; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; Cai MM, 2002, MOL CELL BIOCHEM, V238, P49, DOI 10.1023/A:1019950819784; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Dave BJ, 1999, CANCER GENET CYTOGEN, V108, P120, DOI 10.1016/S0165-4608(98)00138-1; Dickinson LA, 2002, J BIOL CHEM, V277, P25465, DOI 10.1074/jbc.M202266200; EIPERS PG, 1991, GENOMICS, V11, P621, DOI 10.1016/0888-7543(91)90069-Q; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Gururajan R, 1998, GENOME RES, V8, P929, DOI 10.1101/gr.8.9.929; Ibuki Y, 2000, BIOCHEM BIOPH RES CO, V279, P872, DOI 10.1006/bbrc.2000.4018; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; LI HM, 1995, GENE, V153, P237, DOI 10.1016/0378-1119(94)00801-X; Loyer P, 1998, J CELL SCI, V111, P1495; Maller JL, 1991, CURR OPIN CELL BIOL, V3, P269; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOCK BA, 1994, MAMM GENOME, V5, P191, DOI 10.1007/BF00352357; Nelson MA, 1999, CANCER GENET CYTOGEN, V108, P91, DOI 10.1016/S0165-4608(98)00122-8; Pandey A, 2002, ONCOGENE, V21, P3939, DOI 10.1038/sj.onc.1205478; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sauer K, 1996, MOL BIOL CELL, V7, P1759, DOI 10.1091/mbc.7.11.1759; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; Sells MA, 1999, TRENDS CELL BIOL, V9, P355, DOI 10.1016/S0962-8924(99)01642-6; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Shalom-Barak T, 2002, J BIOL CHEM, V277, P40659, DOI 10.1074/jbc.M206650200; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shi JQ, 2003, J BIOL CHEM, V278, P5062, DOI 10.1074/jbc.M206427200; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Souopgui J, 2002, EMBO J, V21, P6429, DOI 10.1093/emboj/cdf644; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; Trembley JH, 2002, J BIOL CHEM, V277, P2589, DOI 10.1074/jbc.M109755200; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; XIANG JL, 1994, J BIOL CHEM, V269, P15786; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhang SW, 2002, J BIOL CHEM, V277, P35314, DOI 10.1074/jbc.M202179200; Zhang SW, 2001, MOL CELL BIOCHEM, V221, P161, DOI 10.1023/A:1010932211745	53	40	46	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20029	20036		10.1074/jbc.M300818200	http://dx.doi.org/10.1074/jbc.M300818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12624090	hybrid			2022-12-27	WOS:000183078000060
J	Cho, DSC; Yang, WD; Lee, JT; Shiekhattar, R; Murray, JM; Nishikura, K				Cho, DSC; Yang, WD; Lee, JT; Shiekhattar, R; Murray, JM; Nishikura, K			Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNAS; DNA BINDING DOMAIN; PROTEIN-KINASE PKR; B R/G SITE; GLUR-B; CAENORHABDITIS-ELEGANS; IN-VITRO; SUBSTRATE RECOGNITION; CYTIDINE DEAMINASE; CANDIDATE ENZYME	Adenosine deaminases acting on RNA (ADAR) convert adenosine residues into inosines in double-stranded RNA. Three vertebrate ADAR gene family members, ADAR1, ADAR2, and ADAR3, have been identified. The catalytic domain of all three ADAR gene family members is very similar to that of Escherichia coli cytidine deaminase and APOBEC-1. Homodimerization is essential for the enzyme activity of those cytidine deaminases. In this study, we investigated the formation of complexes between differentially epitope-tagged ADAR monomers by sequential affinity chromatography and size exclusion column chromatography. Both ADAR1 and ADAR2 form a stable enzymatically active homodimer complex, whereas ADAR3 remains as a monomeric, enzymatically inactive form. No heterodimer complex formation among different ADAR gene family members was detected. Analysis of HeLa and mouse brain nuclear extracts suggested that endogenous ADAR1 and ADAR2 both form a homodimer complex. Interestingly, endogenous ADAR3 also appears to form a homodimer complex, indicating the presence of a brain-specific mechanism for ADAR3 dimerization. Homodimer formation may be necessary for ADAR to act as active deaminases. Analysis of dimer complexes consisting of one wild-type and one mutant monomer suggests functional interactions between the two subunits during site-selective RNA editing.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Nishikura, K (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.							Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eckmann CR, 2001, MOL BIOL CELL, V12, P1911, DOI 10.1091/mbc.12.7.1911; Fitzgerald LW, 1999, NEUROPSYCHOPHARMACOL, V21, pS82, DOI 10.1038/sj.npp.1395328; Gerber A, 1997, RNA, V3, P453; Gerber A, 1998, EMBO J, V17, P4780, DOI 10.1093/emboj/17.16.4780; Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8; Gerber AP, 1999, SCIENCE, V286, P1146, DOI 10.1126/science.286.5442.1146; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Hough RF, 1999, NUCLEIC ACIDS RES, V27, P3424, DOI 10.1093/nar/27.17.3424; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; Jaikaran DCJ, 2002, J BIOL CHEM, V277, P37624, DOI 10.1074/jbc.M204126200; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Knight SW, 2002, MOL CELL, V10, P809, DOI 10.1016/S1097-2765(02)00649-4; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Liu Y, 1999, J BIOL CHEM, V274, P18351, DOI 10.1074/jbc.274.26.18351; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 2003, J BIOL CHEM, V278, P1391, DOI 10.1074/jbc.R200025200; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Morse DP, 2002, P NATL ACAD SCI USA, V99, P7906, DOI 10.1073/pnas.112704299; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; Niswender CM, 1999, J BIOL CHEM, V274, P9472, DOI 10.1074/jbc.274.14.9472; OCONNELL MA, 1994, P NATL ACAD SCI USA, V91, P10596, DOI 10.1073/pnas.91.22.10596; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Ohman M, 2000, RNA, V6, P687, DOI 10.1017/S1355838200000200; Ortega LG, 1996, VIROLOGY, V215, P31, DOI 10.1006/viro.1996.0004; Palladino MJ, 2000, CELL, V102, P437, DOI 10.1016/S0092-8674(00)00049-0; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI DOI 10.1128/MCB.15.10.5376; Poulsen H, 2001, MOL CELL BIOL, V21, P7862, DOI 10.1128/MCB.21.22.7862-7871.2001; RAIZKIN O, 2001, P NATL ACAD SCI USA, V98, P6571; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; Slavov D, 2000, GENE, V250, P53, DOI 10.1016/S0378-1119(00)00175-X; SLAVOV D, 2000, GENE, V250, P45; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Tonkin LA, 2002, EMBO J, V21, P6025, DOI 10.1093/emboj/cdf607; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; Wang QD, 2000, J NEUROCHEM, V74, P1290; Wong SK, 2001, RNA, V7, P846, DOI 10.1017/S135583820101007X	56	143	161	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17093	17102		10.1074/jbc.M213127200	http://dx.doi.org/10.1074/jbc.M213127200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618436	hybrid			2022-12-27	WOS:000182818600087
J	Lange, T; Guttmann-Raviv, N; Baruch, L; Machluf, M; Neufeld, G				Lange, T; Guttmann-Raviv, N; Baruch, L; Machluf, M; Neufeld, G			VEGF(162), a new heparin-binding vascular endothelial growth factor splice form that is expressed in transformed human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR VEGF; EXTRACELLULAR-MATRIX; TUMOR-CELLS; RECEPTORS; ISOFORMS; IDENTIFICATION; ANGIOGENESIS; MICE; NEUROPILIN-1; SEMAPHORIN	The splice forms of vascular endothelial growth factor (VEGF) differ in biological properties such as the receptor types that they recognize and their interaction with heparan sulfate proteoglycans. We have identified a new VEGF mRNA splice form encoding a VEGF species containing 162 amino acids (VEGF162) in human A431 ovarian carcinoma cells. This novel mRNA contains the peptides encoded by exons 1-5, 6A, 6B, and 8 of the VEGF gene. Recombinant VEGF162 is biologically active. It induces proliferation of endothelial cells in vitro and angiogenesis in vivo as determined by the alginate bead assay. VEGF162 binds less efficiently than VEGF145 but more efficiently than VEGF165 to a natural basement membrane produced by corneal endothelial cells. VEGF138, an artificial VEGF form that contains exon 6B but lacks exons 6A and 7, did not bind to this basement membrane at all, indicating that exon 6B probably interferes with the interaction of exon 6A with heparin and heparan sulfate proteoglycans.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Cell Biol & Anat, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Biotechnol & Food Engn, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology	Neufeld, G (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Dept Cell Biol & Anat, POB 9697,1 Efron St, IL-31096 Haifa, Israel.		Neufeld, Gera/F-1524-2019					Ancelin M, 2002, P NATL ACAD SCI USA, V99, P6023, DOI 10.1073/pnas.082110999; Bates DO, 2002, CANCER RES, V62, P4123; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; CIUDAD CJ, 1988, J BIOL CHEM, V263, P16274; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Joki T, 2001, NAT BIOTECHNOL, V19, P35, DOI 10.1038/83481; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Liu BP, 2001, CURR OPIN CELL BIOL, V13, P619, DOI 10.1016/S0955-0674(00)00260-X; Mattot V, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013925.19218.7B; Meiron M, 2001, BIOCHEM BIOPH RES CO, V282, P1053, DOI 10.1006/bbrc.2001.4684; NEUFELD G, 1988, J CELL PHYSIOL, V136, P537, DOI 10.1002/jcp.1041360321; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; NEUFELD G, 1987, J CELL PHYSIOL, V132, P287, DOI 10.1002/jcp.1041320213; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PERETZ D, 1992, BIOCHEM BIOPH RES CO, V182, P1340, DOI 10.1016/0006-291X(92)91880-Y; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stalmans I, 2002, J CLIN INVEST, V109, P327, DOI 10.1172/jci0214362; TISCHER E, 1991, J BIOL CHEM, V266, P11947; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VLODAVSKY I, 1980, CELL, V19, P607, DOI 10.1016/S0092-8674(80)80037-7; Whittle C, 1999, CLIN SCI, V97, P303, DOI 10.1042/CS19990016	32	45	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17164	17169		10.1074/jbc.M212224200	http://dx.doi.org/10.1074/jbc.M212224200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12598527	hybrid			2022-12-27	WOS:000182818600096
J	Merienne, K; Helmlinger, D; Perkin, GR; Devys, D; Trottier, Y				Merienne, K; Helmlinger, D; Perkin, GR; Devys, D; Trottier, Y			Polyglutamine expansion induces a protein-damaging stress connecting heat shock protein 70 to the JNK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPEAT NEURODEGENERATIVE DISEASES; JUN ACTIVATION DOMAIN; SCA1 TRANSGENIC MICE; N-TERMINAL KINASE; HUNTINGTONS-DISEASE; MOLECULAR CHAPERONES; APAF-1 APOPTOSOME; CELL-DEATH; HSP70; PHOSPHATASE	Polyglutamine diseases, including Huntington's disease, designate a group of nine neurodegenerative disorders characterized by the presence of a toxic polyglutamine expansion in specific target proteins. Using cell and mouse models, we have shown that expanded polyglutamine led to activation of the stress kinase JNK and the transcription factor AP-1, which are implicated in neuronal death. Polyglutamine expansion-induced stress shared common features with protein-damaging stress such as heat shock, because activation of JNK involved inhibition of JNK phosphatase activities. Indeed, expanded polyglutamine impaired the solubility of the dual-specificity JNK phosphatase M3/6. Aggregation of M3/6 by polyglutamine expansion appeared to be indirect, because M3/6 was not recruited into polyglutamine inclusions. The heat shock protein HSP70, which is known to inhibit JNK during the heat shock response, suppressed polyglutamine-mediated aggregation of M3/6 and activation of JNK. Interestingly, levels of HSP70 were down-regulated by polyglutamine expansion. We suggest that reduction of HSP70 by expanded polyglutamine is implicated in aggregation and inhibition of M3/6 and in activation of JNK and AP-1.	Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, CU De Strasbour, France; UCL, Sch Med, Dept Immunol, London W1P 6DB, England	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of London; University College London; UCL Medical School	Merienne, K (corresponding author), Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, BP 10142, F-67404 Illkirch Graffenstaden, CU De Strasbour, France.	merienne@igbmc.u-strasbg.fr; yvon@igbmc.u-strasbg.fr	Helmlinger, Dom/T-4419-2019; Trottier, Yvon/H-8852-2016	Helmlinger, Dom/0000-0003-1501-0423; Trottier, Yvon/0000-0001-7230-4810; Devys, Didier/0000-0001-9655-3512; Merienne, Karine/0000-0003-2549-2315				Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Helmlinger D, 2002, HUM MOL GENET, V11, P3351, DOI 10.1093/hmg/11.26.3351; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kouroku Y, 2002, HUM MOL GENET, V11, P1505, DOI 10.1093/hmg/11.13.1505; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Liu YF, 1998, J BIOL CHEM, V273, P28873, DOI 10.1074/jbc.273.44.28873; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Lunkes A, 2002, MOL CELL, V10, P259, DOI 10.1016/S1097-2765(02)00602-0; Lunkes A, 1998, HUM MOL GENET, V7, P1355, DOI 10.1093/hmg/7.9.1355; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; McCampbell A, 2001, P NATL ACAD SCI USA, V98, P15179, DOI 10.1073/pnas.261400698; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Palacios C, 2001, CURR BIOL, V11, P1439, DOI 10.1016/S0960-9822(01)00426-2; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Theodosiou A, 2002, ONCOGENE, V21, P2387, DOI 10.1038/sj.onc.1205309; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; YAN MH, 1994, NATURE, V372, P798; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yvert G, 2000, HUM MOL GENET, V9, P2491, DOI 10.1093/hmg/9.17.2491; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	49	63	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16957	16967		10.1074/jbc.M212049200	http://dx.doi.org/10.1074/jbc.M212049200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12598532	Green Published, hybrid			2022-12-27	WOS:000182818600070
J	Narayanan, K; Ramachandran, A; Hao, JJ; He, G; Park, KW; Cho, M; George, A				Narayanan, K; Ramachandran, A; Hao, JJ; He, G; Park, KW; Cho, M; George, A			Dual functional roles of dentin matrix protein 1 - Implications in biomineralization and gene transcription by activation of intracellular Ca2+ store	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; OSTEOBLAST DIFFERENTIATION; NUCLEAR EXPORT; BONE-FORMATION; EXPRESSION; TRANSPORT; LOCALIZATION; PHOSPHATE; INDUCTION; PATHWAY	Dentin matrix protein 1 (DMP1) is a bone- and teeth-specific protein initially identified from mineralized dentin. Here we report that DMP1 is primarily localized in the nuclear compartment of undifferentiated osteoblasts. In the nucleus, DMP1 acts as a transcriptional component for activation of osteoblast-specific genes like osteocalcin. During the early phase of osteoblast maturation, Ca2+ surges into the nucleus from the cytoplasm, triggering the phosphorylation of DMP1 by a nuclear isoform of casein kinase II. This phosphorylated DMP1 is then exported out into the extracellular matrix, where it regulates nucleation of hydroxyapatite. Thus, DMP1 is a unique molecule that initiates osteoblast differentiation by transcription in the nucleus and orchestrates mineralized matrix formation extracellularly, at later stages of osteoblast maturation. The data presented here represent a paradigm shift in the understanding of DMP1 function. This information is crucial in understanding normal bone formation, remodeling, fracture healing, and skeletal tissue repair.	Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA; Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	George, A (corresponding author), Univ Illinois, Dept Oral Biol, 801 S Paulina St, Chicago, IL 60612 USA.		Narayanan, Karthikeyan/D-1957-2010	Narayanan, Karthikeyan/0000-0001-5136-2296; Cho, Myoung Rae/0000-0002-8191-8045; GEORGE, ANNE/0000-0002-9008-7642	NIDCR NIH HHS [DE-11657, DE-13836] Funding Source: Medline; NIGMS NIH HHS [GM60741] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE011657, R01DE013836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060741] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adebanjo OA, 2000, AM J PHYSIOL-RENAL, V278, pF784, DOI 10.1152/ajprenal.2000.278.5.F784; Beck GR, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; GEORGE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1527, DOI 10.1177/42.12.7983353; GEORGE A, 1993, J BIOL CHEM, V268, P12624; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; HARLOW E, 1998, ANTIBODIES LAB MANUA, P421; He G, 2003, CONNECT TISSUE RES, V44, P240, DOI 10.1080/03008200390181726; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731; Lundgren T, 2001, CALCIFIED TISSUE INT, V68, P192, DOI 10.1007/s002230010015; MacDougall M, 1998, J BONE MINER RES, V13, P422, DOI 10.1359/jbmr.1998.13.3.422; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Srinivasan R, 1999, CONNECT TISSUE RES, V40, P251, DOI 10.3109/03008209909000703; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x	28	191	200	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17500	17508		10.1074/jbc.M212700200	http://dx.doi.org/10.1074/jbc.M212700200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615915	hybrid			2022-12-27	WOS:000182818600138
J	Schweppe, RE; Melton, AA; Brodsky, KS; Aveline, LD; Resing, KA; Ahn, NG; Gutierrez-Hartmann, A				Schweppe, RE; Melton, AA; Brodsky, KS; Aveline, LD; Resing, KA; Ahn, NG; Gutierrez-Hartmann, A			Purification and mass spectrometric identification of GA-binding protein (GABP) as the functional pituitary Ets factor binding to the basal transcription element of the prolactin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; RESPONSE ELEMENT; SIGNALING PATHWAY; INSULIN; CELLS; RAS; FAMILY; KINASE; ALPHA; COMPONENTS	The Ets-binding site within the basal transcription element (BTE) of the rat prolactin (rPRL) promoter is critical for both basal and growth factor-regulated rPRL gene expression. Here we report the purification and identification of the factor that binds to the BTE. This factor was purified from GH3 pituitary nuclear extracts using ammonium sulfate fractionation, heparin-Sepharose and Mono Q chromatography, and BTE-affinity magnetic beads. We purified two proteins of 57 and 47 kDa and identified the 57-kDa protein by mass spectrometry as the Ets factor GABPalpha. Western blot analysis identified the 47-kDa protein as GABPbeta1. Co-transfection of dominant-negative GABPbeta1 blocks prolactin promoter basal activity by 85-88% in GH3 cells in the presence or absence of FGF-4. Additionally, expression of wild-type GABPalpha/beta1 selectively activates a minimal BTE promoter 24-28-fold in GH3 cells, and this activation is dependent on the Ets-binding site. Finally, small interfering RNA depletion of GABP in GH3 cells results in the loss of prolactin protein. Thus, we have identified GABPalpha/GABPbeta1 as a critical and functionally relevant Ets factor that regulates rPRL promoter activity via the BTE site.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Program Mol Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Colorado Canc Ctr, Denver, CO 80262 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Gutierrez-Hartmann, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Program Mol Biol, 4200 E 9th Ave,Box B-151, Denver, CO 80262 USA.		Gutierrez-Hartmann, Arthur/F-1295-2011	Schweppe, Rebecca/0000-0001-7502-0151	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046868, R56DK046868] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39730] Funding Source: Medline; NIDDK NIH HHS [DK46868] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boccia LM, 1996, MOL CELL BIOL, V16, P1929; Bochert MA, 1998, BIOCHEM BIOPH RES CO, V246, P176, DOI 10.1006/bbrc.1998.8560; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Briguet A, 2000, J NEUROSCI, V20, P5989, DOI 10.1523/JNEUROSCI.20-16-05989.2000; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Castillo AI, 1998, ONCOGENE, V16, P1981, DOI 10.1038/sj.onc.1200204; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Graves BJ, 1998, SCIENCE, V279, P1000, DOI 10.1126/science.279.5353.1000; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GUTIERREZHARTMANN A, 1987, P NATL ACAD SCI USA, V84, P5211, DOI 10.1073/pnas.84.15.5211; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; Jacob KK, 2001, J BIOL CHEM, V276, P24931, DOI 10.1074/jbc.M102826200; Jacob KK, 1999, ENDOCRINOLOGY, V140, P4542, DOI 10.1210/en.140.10.4542; Jacob KK, 1999, MOL CELL ENDOCRINOL, V152, P137, DOI 10.1016/S0303-7207(99)00043-X; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; LIANG J, 1992, MOL ENDOCRINOL, V6, P885, DOI 10.1210/me.6.6.885; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Ouyang LH, 1996, J BIOL CHEM, V271, P10425, DOI 10.1074/jbc.271.18.10425; PEERS B, 1992, EUR J BIOCHEM, V210, P53, DOI 10.1111/j.1432-1033.1992.tb17389.x; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Schweppe RE, 1997, J BIOL CHEM, V272, P30852, DOI 10.1074/jbc.272.49.30852; Schweppe RE, 2001, NUCLEIC ACIDS RES, V29, P1251, DOI 10.1093/nar/29.5.1251; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Treier M, 1996, CURR OPIN CELL BIOL, V8, P833, DOI 10.1016/S0955-0674(96)80085-8; Wang YH, 1999, MOL ENDOCRINOL, V13, P1094, DOI 10.1210/me.13.7.1094; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK B, 1997, TRANSCRIPTION FACTOR, P251	40	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16863	16872		10.1074/jbc.M213063200	http://dx.doi.org/10.1074/jbc.M213063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618435	hybrid			2022-12-27	WOS:000182818600057
J	Stockklausner, C; Klocker, N				Stockklausner, C; Klocker, N			Surface expression of inward rectifier potassium channels is controlled by selective Golgi export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; ER EXPORT; MEMBRANE-TRANSPORT; CELL-SURFACE; LIPID RAFTS; TRAFFICKING; CLATHRIN; PROTEINS; SUBUNIT; MOTIFS	Traffic of integral membrane proteins along the secretory pathway is not simply a default process but can be selective. Such selectivity is achieved by sequence information within the cargo protein that recruits coat protein complexes to drive the formation of transport vesicles. A number of sequence motifs have been identified in the cytoplasmic domains of ion channels that regulate early trafficking events between the endoplasmic reticulum and the Golgi complex. Here, we demonstrate that the following trafficking step from the Golgi compartment to the plasma membrane can also be selective. The N-terminal domain of the inward rectifier potassium channel Kir2.1 contains specific sequence information that is necessary for its efficient export from the Golgi complex. Lack of this information results in accumulation of the protein within the Golgi and a significant decrease in cell surface expression. As similar results were obtained for the N terminus of another Kir channel subfamily member, Kir4.1, which could functionally substitute for the Kir2.1 N terminus, we propose a more general role of the identified N-terminal domains for post-Golgi trafficking of Kir channels.	Univ Freiburg, Dept Physiol 2, D-79104 Freiburg, Germany	University of Freiburg	Klocker, N (corresponding author), Univ Freiburg, Dept Physiol 2, Hermann Herder Str 7, D-79104 Freiburg, Germany.							Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Aridor M, 1996, NATURE, V383, P220, DOI 10.1038/383220a0; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Boehm M, 2001, MOL BIOL CELL, V12, P2907, DOI 10.1091/mbc.12.10.2907; Cosson P, 1998, EMBO J, V17, P6863, DOI 10.1093/emboj/17.23.6863; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Delling M, 2002, J NEUROSCI, V22, P7154; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Griffith LC, 2001, CURR BIOL, V11, pR226, DOI 10.1016/S0960-9822(01)00111-7; Hagemeier C, 1996, Methods Mol Biol, V57, P45; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; Nelson WJ, 2001, TRENDS CELL BIOL, V11, P483, DOI 10.1016/S0962-8924(01)02145-6; Nickel W, 1998, HISTOCHEM CELL BIOL, V109, P477, DOI 10.1007/s004180050249; Niethammer P, 2002, J CELL BIOL, V157, P521, DOI 10.1083/jcb.200109059; Nishimura N, 2002, P NATL ACAD SCI USA, V99, P6755, DOI 10.1073/pnas.092150699; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; Pfeffer SR, 2001, CURR BIOL, V11, pR109, DOI 10.1016/S0960-9822(01)00042-2; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SHEN NV, 1993, NEURON, V11, P67; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Stockklausner C, 2001, FEBS LETT, V493, P129, DOI 10.1016/S0014-5793(01)02286-4; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	37	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17000	17005		10.1074/jbc.M212243200	http://dx.doi.org/10.1074/jbc.M212243200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609985	hybrid			2022-12-27	WOS:000182818600075
J	Moumen, A; Polomack, L; Unge, T; Veron, M; Buc, H; Negroni, M				Moumen, A; Polomack, L; Unge, T; Veron, M; Buc, H; Negroni, M			Evidence for a mechanism of recombination during reverse transcription dependent on the structure of the acceptor RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; STRAND TRANSFER; COPY-CHOICE; CHAPERONE ACTIVITY; IN-VITRO; FREQUENCY; GENOMES; REGION	Genetic recombination is a major force driving retroviral evolution. In retroviruses, recombination proceeds mostly through copy choice during reverse transcription. Using a reconstituted in vitro system, we have studied the mechanism of strand transfer on a major recombination hot spot we previously identified within the genome of HIV-1. We show that on this model sequence the frequency of copy choice is strongly influenced by the folding of the RNA template, namely by the presence of a stable hairpin. This structure must be specifically present on the acceptor template. We previously proposed that strand transfer follows a two-step process: docking of the nascent DNA onto the acceptor RNA and strand invasion. The frequency of recombination under copy choice conditions was not dependent on the concentration of the acceptor RNA, in contrast with strand transfer occurring at strong arrests of reverse transcription. During copy choice strand transfer, the docking step is not rate limiting. We propose that the hairpin present on the acceptor RNA could mediate strand transfer following a mechanism reminiscent of branch migration during DNA recombination.	Inst Pasteur, CNRS, Dept Biol Struct & Chim, FRE 2364,Unite Regulat Enzymat Act Cellulaires, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 1960, F-75724 Paris 15, France; Uppsala Univ, Dept Cell & Mol Biol, Biomed Ctr, SE-75124 Uppsala, Sweden	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Uppsala University	Buc, H (corresponding author), Inst Pasteur, CNRS, Dept Biol Struct & Chim, FRE 2364,Unite Regulat Enzymat Act Cellulaires, 25-28 Rue Docteur Roux, F-75724 Paris 15, France.	matteo@pasteur.fr		Negroni, Matteo/0000-0003-3005-8871				Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Clodi E, 1999, EMBO J, V18, P3776, DOI 10.1093/emboj/18.13.3776; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Hiom K, 2001, CURR BIOL, V11, pR278, DOI 10.1016/S0960-9822(01)00138-5; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; Jung A, 2002, NATURE, V418, P144, DOI 10.1038/418144a; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; Moumen A, 2001, NUCLEIC ACIDS RES, V29, P3814, DOI 10.1093/nar/29.18.3814; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; NEGRONI M, 1995, P NATL ACAD SCI USA, V92, P6971, DOI 10.1073/pnas.92.15.6971; Negroni M, 2001, ANNU REV GENET, V35, P275, DOI 10.1146/annurev.genet.35.102401.090551; Negroni M, 2001, NAT REV MOL CELL BIO, V2, P151, DOI 10.1038/35052098; Quinones-Mateu ME, 2002, J VIROL, V76, P9600, DOI 10.1128/JVI.76.19.9600-9613.2002; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sharp PM, 1999, BIOL BULL-US, V196, P338, DOI 10.2307/1542965; Svarovskaia ES, 2000, J VIROL, V74, P7171, DOI 10.1128/JVI.74.15.7171-7178.2000; TELESNITSKY A, 1993, EMBO J, V12, P4433, DOI 10.1002/j.1460-2075.1993.tb06128.x; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; VOGT PK, 1973, POSSIBLE EPISOMES EU, P35; Vogt V.M., 1997, RETROVIRUSES; Welker R, 2000, J VIROL, V74, P1168, DOI 10.1128/JVI.74.3.1168-1177.2000; Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Ye YJ, 2000, J VIROL, V74, P11955, DOI 10.1128/JVI.74.24.11955-11962.2000; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	34	59	61	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15973	15982		10.1074/jbc.M212306200	http://dx.doi.org/10.1074/jbc.M212306200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595540	hybrid			2022-12-27	WOS:000182680000067
J	Salim, S; Sinnarajah, S; Kehrl, JH; Dessauer, CW				Salim, S; Sinnarajah, S; Kehrl, JH; Dessauer, CW			Identification of RGS2 and type V adenylyl cyclase interaction sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; CYTOSOLIC DOMAINS; KINETIC-ANALYSIS; ALPHA-SUBUNITS; G(S ALPHA); EXPRESSION; REGULATOR; MECHANISM; BINDING; GAIP	The production of cAMP is controlled on many levels, notably at the level of cAMP synthesis by the enzyme adenylyl cyclase. We have recently identified a new regulator of adenylyl cyclase activity, RGS2, which decreases cAMP accumulation when overexpressed in HEK293 cells and inhibits the in vitro activity of types III, V, and VI adenylyl cyclase. In addition, RGS2 blocking antibodies lead to elevated cAMF levels in olfactory neurons. Here we examine the nature of the interaction between RGS2 and type V adenylyl cyclase. In HEK293 cells expressing type V adenylyl cyclase, RGS2 inhibited Galpha(s)-Q227L- or beta(2)-adrenergic receptor-stimulated cAMP accumulation. Deletion of the N-terminal 19 amino acids of RGS2 abolished its ability to inhibit cAMP accumulation and to bind adenylyl cyclase. Further mutational analysis indicated that neither the C terminus, RGS GAP activity, nor the RGS box domain is required for inhibition of adenylyl cyclase. Alanine scanning of the N-terminal amino acids of RGS2 identified three residues responsible for the inhibitory function of RGS2. Furthermore, we show that RGS2 interacts directly with the C, but not the C-2 domain of type V adenylyl cyclase and that the inhibition by RGS2 is independent of inhibition by Galpha(i). These results provide clear evidence for functional effects of RGS2 on adenylyl cyclase activity that adds a new dimension to an intricate signaling network.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; NIAID, Immunoregulat Lab, B Cell Mol Biol Sect, NIH, Bethesda, MD 20892 USA	University of Texas System; University of Texas Health Science Center Houston; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Dessauer, CW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, 6431 Fannin St, Houston, TX 77030 USA.	Carmen.W.Dessauer@uth.tmc.edu	Kehrl, John/AAE-6292-2019; Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280; Kehrl, John/0000-0002-6526-159X	NIGMS NIH HHS [GM 60419, R01 GM060419-03, R01 GM060419] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 2002, METHOD ENZYMOL, V345, P112; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Ingi T, 1998, J NEUROSCI, V18, P7178; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Luo X, 1999, J BIOL CHEM, V274, P17684, DOI 10.1074/jbc.274.25.17684; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Oliveira-dos-Santos AJ, 2000, P NATL ACAD SCI USA, V97, P12272, DOI 10.1073/pnas.220414397; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Scheschonka A, 2000, MOL PHARMACOL, V58, P719, DOI 10.1124/mol.58.4.719; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Smith MS, 1998, ANN EMERG MED, V32, P65, DOI 10.1016/S0196-0644(98)70101-5; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; Sullivan BM, 2000, MOL BIOL CELL, V11, P3155, DOI 10.1091/mbc.11.9.3155; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tseng CC, 1998, ENDOCRINOLOGY, V139, P4470, DOI 10.1210/en.139.11.4470; Wang CR, 1997, PROTEIN SCI, V6, P2264; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zmijewski JW, 2001, BBA-MOL CELL RES, V1541, P201, DOI 10.1016/S0167-4889(01)00144-6	42	108	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15842	15849		10.1074/jbc.M210663200	http://dx.doi.org/10.1074/jbc.M210663200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604604	hybrid			2022-12-27	WOS:000182680000050
J	Umenishi, F; Schrier, RW				Umenishi, F; Schrier, RW			Hypertonicity-induced aquaporin-1 (AQP1) expression is mediated by the activation of MAPK pathways and hypertonicity-responsive element in the AQP1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY CONCENTRATING ABILITY; N-TERMINAL KINASE; WATER CHANNELS; C-JUN; HYPEROSMOTIC STRESS; RAT-KIDNEY; MEMBRANE; CELLS; PROTEIN; TRANSCRIPTION	Aquaporin-1 (AQP1) is a water channel that is induced by hypertonicity. The present study was undertaken to clarify the osmoregulation mechanism of AQP1 in renal medullary cells. In cultured mouse medullary (mIMCD-3) cells, AQP1 expression was significantly induced by hypertonic treatment with impermeable solutes, whereas urea had no effect on AQP1 expression. This result indicates the requirement of a hypertonic gradient. Hypertonicity activated ERK, p38 kinase, and JNK in mIMCD-3 cells. Furthermore, all three MAPKs were phosphorylated by the upstream activation of MEK1/2, MKK3/6, and MKK4, respectively. The treatments with MEK inhibitor U0126, p38 kinase inhibitor SB203580, and JNK inhibitor SP600125 significantly attenuated hypertonicity-induced AQP1 expression in mIMCD-3 cells. In addition, hypertonicity-induced AQP1 expression was significantly reduced by both the dominant-negative mutants of JNK1- and JNK2-expressing mIMCD-3 cells. NaCl-inducible activity of AQP1 promoter, which contains a hypertonicity response element, was attenuated in the presence of U0126, SB203580, and SP600125 in a dose-dependent manner and was also significantly reduced by the dominant-negative mutants of JNK1 and JNK2. These data demonstrate that the activation of ERK, p38 kinase, and JNK pathways and the hypertonicity response element in the AQP1 promoter are involved in hypertonicity-induced AQP1 expression in mIMCD-3 cells.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Umenishi, F (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, 4200 E 9th Ave,Box C281, Denver, CO 80262 USA.	Fuminori.Umenishi@UCHSC.edu			NIDDK NIH HHS [DK 19928] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Berl T, 1997, AM J PHYSIOL-RENAL, V272, pF305, DOI 10.1152/ajprenal.1997.272.3.F305; Berl Tomas, 1997, P1; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hoffert JD, 2000, J BIOL CHEM, V275, P9070, DOI 10.1074/jbc.275.12.9070; HOFFMANN EK, 1989, PHYSIOL REV, V69, P315, DOI 10.1152/physrev.1989.69.2.315; Jenq W, 1998, BIOCHEM BIOPH RES CO, V245, P804, DOI 10.1006/bbrc.1998.8518; Jenq WM, 1999, BIOCHEM BIOPH RES CO, V256, P240, DOI 10.1006/bbrc.1999.0306; King LS, 2001, NEW ENGL J MED, V345, P175, DOI 10.1056/NEJM200107193450304; Knepper MA, 1996, KIDNEY INT, V49, P1712, DOI 10.1038/ki.1996.253; Leitch V, 2001, P NATL ACAD SCI USA, V98, P2894, DOI 10.1073/pnas.041616498; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Nielsen S, 2001, DIS KIDNEY URINARY T, P109; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHRIER RW, 1979, AM J PHYSIOL, V236, pF321, DOI 10.1152/ajprenal.1979.236.4.F321; SMITH HW, 1951, FISH PHILOS STORY OU; Umenishi F, 2002, BIOCHEM BIOPH RES CO, V293, P913, DOI 10.1016/S0006-291X(02)00316-9; Umenishi F, 1998, GENOMICS, V47, P341, DOI 10.1006/geno.1997.5125; Umenishi F, 2000, BIOPHYS J, V78, P1024, DOI 10.1016/S0006-3495(00)76661-6; Umenishi F, 2002, BIOCHEM BIOPH RES CO, V292, P771, DOI 10.1006/bbrc.2002.6709; Umenishi F, 1998, GENOMICS, V50, P373, DOI 10.1006/geno.1998.5337; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Yang XY, 1999, AM J PHYSIOL-RENAL, V277, pF176, DOI 10.1152/ajprenal.1999.277.2.F176; Zhang Z, 1996, AM J PHYSIOL-RENAL, V271, pF1234, DOI 10.1152/ajprenal.1996.271.6.F1234	43	144	156	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15765	15770		10.1074/jbc.M209980200	http://dx.doi.org/10.1074/jbc.M209980200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600999	hybrid			2022-12-27	WOS:000182680000040
J	van Huizen, R; Martindale, JL; Gorospe, M; Holbrook, NJ				van Huizen, R; Martindale, JL; Gorospe, M; Holbrook, NJ			P58(IPK), a novel endoplasmic reticulum stress-inducible protein and potential negative regulator of eIF2 alpha signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; EUKARYOTIC INITIATION FACTOR-2-ALPHA; TRANSLATIONAL CONTROL; TRANSCRIPTION FACTOR; MAMMALIAN-CELLS; MESSENGER-RNA; ER STRESS; CELLULAR INHIBITOR; GENE-EXPRESSION; KINASE PKR	The unfolded protein response, which is activated in response to the loss of endoplasmic reticulum (ER) Ca2+ homeostasis and/or the accumulation of misfolded, unassembled, or aggregated proteins in the ER lumen, involves both transcriptional and translational regulation. In the current studies we sought to identify novel ER stress-induced genes by conducting microarray analysis on tunicamycin-treated cells. We identified P58(IPK). an inhibitor of the interferon-induced double-stranded RNA-activated protein kinase, as induced during ER stress. Additional studies suggested that p58(IPK) induction was mediated via ATF6 and that P58(IPK) played a role in down-regulating the activity of the pancreatic eIF2 kinase/eukaryotic initiation factor 2alpha (eIF2alpha)-like ER kinase/activation transcription factor (ATF) 4 pathway. Modulation of P58(IPK) levels altered the phosphorylation status of eIF2alpha, and thereby affected expression of its downstream targets, ATF4 and Gadd153. Overexpression of p58(IPK) inhibited eIF2alpha phosphorylation and reduced ATF4 and Gadd153 protein accumulation, whereas silencing of P58(IPK) expression enhanced pancreatic eIF2alpha-like ER kinase and eIF2alpha phosphorylation and increased ATF4 and Gadd153 accumulation. These findings implicate P58(IPK) as an important component of a negative feedback loop used by the cell to inhibit eIF2alpha signaling, and thus attenuate the unfolded protein response.	NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA; Yale Univ, Sch Med, Dept Internal Med, Sect Geriatr, New Haven, CT 06520 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Yale University	van Huizen, R (corresponding author), NIA, Cellular & Mol Biol Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE ON AGING [Z01AG000511, ZIAAG000511] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; GALABRU J, 1987, J BIOL CHEM, V262, P15538; Han AP, 2001, EMBO J, V20, P6909, DOI 10.1093/emboj/20.23.6909; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Mayne M, 2001, J VIROL, V75, P11641, DOI 10.1128/JVI.75.23.11641-11650.2001; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Melville MW, 1997, P NATL ACAD SCI USA, V94, P97, DOI 10.1073/pnas.94.1.97; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Samuel CE, 1997, INT J HEMATOL, V65, P227; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Sood R, 2000, GENETICS, V154, P787; Tang NM, 1999, MOL CELL BIOL, V19, P4757; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang Y, 2000, J BIOL CHEM, V275, P27013; Yan W, 2002, P NATL ACAD SCI USA, V99, P15920, DOI 10.1073/pnas.252341799; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	45	197	207	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15558	15564		10.1074/jbc.M212074200	http://dx.doi.org/10.1074/jbc.M212074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601012	hybrid			2022-12-27	WOS:000182680000014
J	Vischer, HF; Granneman, JCM; Noordam, MJ; Mosselman, S; Bogerd, J				Vischer, HF; Granneman, JCM; Noordam, MJ; Mosselman, S; Bogerd, J			Ligand selectivity of gonadotropin receptors - Role of the beta-strands of extracellular leucine-rich repeats 3 and 6 of the human luteinizing hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL REGION; CHORIONIC-GONADOTROPIN; BINDING; DOMAIN; PROTEIN; MUTAGENESIS; ACTIVATION; MUTATIONS; RESIDUES; CONTACTS	The difference in hormone selectivity between the human follicle-stimulating hormone receptor (hFSH-R) and human luteinizing hormone/chorionic gonadotropin receptor (hLH-R) is determined by their similar to350 amino acid-long N-terminal receptor exodomains that allow the mutually exclusive binding of human follicle-stimulating hormone (hFSH) and human luteinizing hormone (hLH) when these hormones are present in physiological concentrations. The exodomains of each of these receptors consist of a nine-leucine-rich repeat-containing subdomain (LRR subdomain) flanked by Nand C-terminal cysteine-rich subdomain). Chimeric receptors, in which the structural subdomains of the hFSH-R exodomain were substituted with those of the hLH-R, showed a similar high responsiveness to human chorionic gonadotropin (hCG) and hLH as long as they harbored the LRR subdomain of the hLH-R. In addition, these chimeric receptors showed no responsiveness to hFSH. The LRR subdomains of the gonadotropin receptor exodomains are predicted to adopt a horseshoe-like conformation, of which the hormone-binding concave surface is composed of nine parallel beta-strands. Receptors in which individual beta-strands of the hFSH-R were replaced with the corresponding hLH-R sequences revealed that hCG and hLH selectivity is predominantly determined by hLH-R beta-strands 3 and 6. A mutant receptor in which the hFSH-R beta-strands 3 and 6 were substituted simultaneously with their hLH-R counterparts displayed a responsiveness to hCG and hLH similar to that of the wild type hLH-R. Responsiveness to hFSH was not affected by most beta-strand substitutions, suggesting the involvement of multiple low-impact determinants for this hormone.	Univ Utrecht, Fac Biol, Dept Endocrinol, NL-3584 CH Utrecht, Netherlands; Organon Inc, Dept Pharmacol, NL-5342 CC Oss, Netherlands	Utrecht University	Bogerd, J (corresponding author), Univ Utrecht, Fac Biol, Dept Endocrinol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Bogerd, Jan/B-8858-2011	Bogerd, Jan/0000-0003-1120-7974				ALI SA, 1995, BIOTECHNIQUES, V18, P746; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Blomenrohr M, 1999, MOL PHARMACOL, V56, P1229, DOI 10.1124/mol.56.6.1229; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hong SH, 1998, J BIOL CHEM, V273, P13835, DOI 10.1074/jbc.273.22.13835; Jeoung MK, 2001, J BIOL CHEM, V276, P3443, DOI 10.1074/jbc.M003774200; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KAJAVA AV, 1995, STRUCTURE, V3, P867, DOI 10.1016/S0969-2126(01)00222-2; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; Phang T, 1998, J BIOL CHEM, V273, P13841, DOI 10.1074/jbc.273.22.13841; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; Song YS, 2001, J BIOL CHEM, V276, P3436, DOI 10.1074/jbc.M003773200; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Vischer HF, 2003, BIOL REPROD, V68, P262, DOI 10.1095/biolreprod.102.004515; Zhang R, 1996, J BIOL CHEM, V271, P5755, DOI 10.1074/jbc.271.10.5755	21	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15505	15513		10.1074/jbc.M300634200	http://dx.doi.org/10.1074/jbc.M300634200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598521	hybrid			2022-12-27	WOS:000182680000008
J	Horiba, N; Masuda, S; Takeuchi, A; Takeuchi, D; Okuda, M; Inui, K				Horiba, N; Masuda, S; Takeuchi, A; Takeuchi, D; Okuda, M; Inui, K			Cloning and characterization of a novel Na+-dependent glucose transporter (NaGLT1) in rat kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION TRANSPORTER; MEDIATING BASOLATERAL UPTAKE; PLASMA-MEMBRANE VESICLES; GENE-EXPRESSION PROFILES; FUNCTIONAL-CHARACTERIZATION; NA+/GLUCOSE COTRANSPORTER; LOCALIZATION; TUBULES	To identify novel transporters in the kidney, we have constructed an mRNA data base composed of 1000 overall clones by random sequencing of a male rat kidney cDNA library. After a BLAST search, similar to40% of the clones were unknown and/or unannotated and were screened by measuring the uptake of various compounds using Xenopus oocytes. One clone stimulated the uptake of a-methyl-D-glucopyranoside and therefore was termed rat Na+-dependent glucose transporter 1 (rNaGLT1). The rNaGLT1 cDNA (2173 bp) has an open reading frame encoding a 484-amino acid protein, showing <22% homology to known SGLT and GLUT glucose transporters. a-Methyl-D-glucopyranoside uptake by rNaGLT1 cRNA-injected oocytes showed saturability, with an apparent K-m of 3.7 mm and a coupling ratio of 1:1 with Na+. rNa-GLT1 mRNA was expressed predominantly in the kidney upon Northern blot analysis and reverse transcription-PCR. Reverse transcription-PCR in microdissected nephron segments revealed that rNaGLT1 mRNA was primarily localized in the proximal tubules. A clear signal corresponding to rNaGLT1 protein was recognized in the brush-border (but not basolateral) membrane fraction by immunoblot analysis. The rNaGLT1 mRNA level in the kidney was significantly higher than rat SGLT1 and SGLT2 mRNA levels. These findings suggest that rNaGLT1 is a novel Na+-dependent glucose transporter with low substrate affinity that mediates tubular reabsorption of glucose.	Kyoto Univ Hosp, Fac Med, Dept Pharm, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Inui, K (corresponding author), Kyoto Univ Hosp, Fac Med, Dept Pharm, Sakyo Ku, Kyoto 6068507, Japan.		Inui, Ken-ichi/AAH-8748-2020; Masuda, Satohiro/E-6691-2010	Masuda, Satohiro/0000-0002-3589-5989				ALLIKMETS R, 1995, MAMM GENOME, V6, P114, DOI 10.1007/BF00303254; CHEUNG PT, 1988, AM J PHYSIOL, V254, pF711, DOI 10.1152/ajprenal.1988.254.5.F711; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; INUI K, 1981, BIOCHIM BIOPHYS ACTA, V647, P150, DOI 10.1016/0005-2736(81)90303-5; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; Kawai J, 2001, NATURE, V409, P685, DOI 10.1038/35055500; KINNE R, 1975, J MEMBRANE BIOL, V21, P375, DOI 10.1007/BF01941077; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee WJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1552, DOI 10.1152/ajpcell.1997.272.5.C1552; Masuda S, 1997, FEBS LETT, V407, P127, DOI 10.1016/S0014-5793(97)00314-1; Motohashi H, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134866; Nakajima H, 2002, KIDNEY INT, V61, P1577, DOI 10.1046/j.1523-1755.2002.00300.x; OELBERG DG, 1994, BBA-BIOMEMBRANES, V1194, P92, DOI 10.1016/0005-2736(94)90206-2; Ogihara H, 1996, BIOCHEM BIOPH RES CO, V220, P848, DOI 10.1006/bbrc.1996.0493; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Phay JE, 2000, SURGERY, V128, P946, DOI 10.1067/msy.2000.109967; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; Santer R, 1997, NAT GENET, V17, P324, DOI 10.1038/ng1197-324; SRIDHAR R, 1979, IN VITRO CELL DEV B, V15, P685; Takahashi K, 1998, J PHARMACOL EXP THER, V286, P1037; Takahashi K, 2001, AM J PHYSIOL-RENAL, V281, pF1109, DOI 10.1152/ajprenal.0346.2000; Takenaka M, 1998, KIDNEY INT, V53, P562, DOI 10.1046/j.1523-1755.1998.00808.x; Takenaka M, 2000, KIDNEY INT, V57, P19, DOI 10.1046/j.1523-1755.2000.00834.x; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; TURNER RJ, 1982, AM J PHYSIOL, V242, P406; Uwai Y, 1998, FEBS LETT, V438, P321, DOI 10.1016/S0014-5793(98)01328-3; Wright EM, 2001, AM J PHYSIOL-RENAL, V280, pF10, DOI 10.1152/ajprenal.2001.280.1.F10; YOU GF, 1995, J BIOL CHEM, V270, P29365, DOI 10.1074/jbc.270.49.29365	32	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14669	14676		10.1074/jbc.M212240200	http://dx.doi.org/10.1074/jbc.M212240200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590146	hybrid			2022-12-27	WOS:000182516100013
J	Kametaka, S; Shibata, M; Moroe, K; Kanamori, S; Ohsawa, Y; Waguri, S; Sims, PJ; Emoto, K; Umeda, M; Uchiyama, Y				Kametaka, S; Shibata, M; Moroe, K; Kanamori, S; Ohsawa, Y; Waguri, S; Sims, PJ; Emoto, K; Umeda, M; Uchiyama, Y			Identification of phospholipid scramblase 1 as a novel interacting molecule with beta-secretase (beta-site amyloid precursor protein (APP) cleaving enzyme (BACE))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE MEMBRANE COMPARTMENT; HUMAN NEUROBLASTOMA-CELLS; TRANS-GOLGI NETWORK; ALZHEIMERS-DISEASE; PLASMA-MEMBRANE; TRANSBILAYER MOVEMENT; LIPID RAFTS; CATHEPSIN-D; CLEAVAGE; NEURONS	beta-Site amyloid precursor protein (APP)-cleaving enzyme (BACE) is an integral membrane aspartic proteinase responsible for beta-site processing of APP, and its cytoplasmic region composed of 24 amino acid residues has been shown to be involved in the endosomal localization of BACE. With the yeast two-hybrid screening, we found that the cytoplasmic domain of phospholipid scramblase 1 (PLSCR1), a type II integral membrane protein, interacts with the cytoplasmic region of BACE. In cultured cells, BACE and PLSCR1 were colocalized in the Golgi area and in endosomal compartments, whereas they were co-redistributed in late endosome-derived multivesicular bodies when treated with U18666A, suggesting that both proteins share a common trafficking pathway in cells. Co-immunoprecipitation analysis showed that both proteins form a protein complex at an endogenous expression level in the human neuroblastoma SH-SY5Ycells, and the dileucine residue of the BACE tail is also revealed to be essential for the physical interaction with PLSCR1 in vitro and in vivo. Moreover, both BACE and PLSCR1 were localized in a low buoyant lipid microdomain in SH-SY5Y cells. The dileucine-defective BACE mutant was also fractionated into the lipid microdomain, but much less stably than wild-type BACE. Taken together, our current study suggests the functional involvement of PLSCR1 in the intracellular distribution of BACE and/or recruitment of BACE into the detergent-insoluble lipid raft.	Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci A1, Suita, Osaka 5650871, Japan; Scripps Res Inst, La Jolla, CA 92037 USA; Tokyo Metropolitan Inst Med Sci RINSHOKEN, Dept Mol Biodynam, Bunkyo Ku, Tokyo 1138613, Japan	Osaka University; Scripps Research Institute; Tokyo Metropolitan Institute of Medical Science	Uchiyama, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci A1, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		EMOTO, KAZUO/G-4992-2014; Kametaka, Satoshi/GVT-6091-2022; Kametaka, Satoshi/AAA-7407-2020	Kametaka, Satoshi/0000-0003-0659-6426	NHLBI NIH HHS [HL63819, HL36946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063819, R01HL036946] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; BIEDLER JL, 1973, CANCER RES, V33, P2643; Boman AL, 2001, J CELL SCI, V114, P3413; Bouillot C, 1996, J BIOL CHEM, V271, P7640, DOI 10.1074/jbc.271.13.7640; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; GOLDE TE, 1993, ANN NY ACAD SCI, V695, P103, DOI 10.1111/j.1749-6632.1993.tb23036.x; HAASS C, 1993, ANN NY ACAD SCI, V695, P109, DOI 10.1111/j.1749-6632.1993.tb23037.x; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Hooper NM, 2000, ADV EXP MED BIOL, V477, P379; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; James P, 1996, GENETICS, V144, P1425; JARRETT JT, 1993, ANN NY ACAD SCI, V695, P144, DOI 10.1111/j.1749-6632.1993.tb23043.x; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Nishiyama K, 1999, J NEUROSCI, V19, P6538; Riddell DR, 2001, CURR BIOL, V11, P1288, DOI 10.1016/S0960-9822(01)00394-3; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Shibata M, 1998, BIOCHEM BIOPH RES CO, V251, P199, DOI 10.1006/bbrc.1998.9422; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Sun J, 2001, J BIOL CHEM, V276, P28984, DOI 10.1074/jbc.M102505200; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Waguri S, 2001, J HISTOCHEM CYTOCHEM, V49, P1397, DOI 10.1177/002215540104901108; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; Yamazaki T, 2001, J BIOL CHEM, V276, P4454, DOI 10.1074/jbc.M009598200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	49	43	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15239	15245		10.1074/jbc.M208611200	http://dx.doi.org/10.1074/jbc.M208611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586838	hybrid			2022-12-27	WOS:000182516100085
J	Xin, ZH; Tachibana, M; Guggiari, M; Heard, E; Shinkai, Y; Wagstaff, J				Xin, ZH; Tachibana, M; Guggiari, M; Heard, E; Shinkai, Y; Wagstaff, J			Role of histone methyltransferase G9a in CpG methylation of the Prader-Willi syndrome imprinting center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; H3 METHYLTRANSFERASE; GENES; ESTABLISHMENT; EXPRESSION; LYSINE-9; PATTERNS	Imprinted genes in mammals are often located in clusters whose imprinting is subject to long range regulation by cis-acting sequences known as imprinting centers (ICs). The mechanisms by which these ICs exert their effects is unknown. The Prader-Willi syndrome IC (PWS-IC) on human chromosome 15 and mouse chromosome 7 regulates imprinted gene expression bidirectionally within an similar to2-megabase region and shows CpG methylation and histone H3 Lys-9 methylation in somatic cells specific for the maternal chromosome. Here we show that histone H3 Lys-9 methylation of the PWS-IC is reduced in mouse embryonic stem (ES) cells lacking the G9a histone H3 Lys-9/Lys-27 methyltransferase and that maintenance of CpG methylation of the PWS-IC in mouse ES cells requires the function of G9a. We show by RNA fluorescence in situ hybridization (FISH) that expression of Snrpn, an imprinted gene regulated by the PWS-IC, is biallelic in G9a -/- ES cells, indicating loss of imprinting. By contrast, Dnmt1 -/- ES cells lack CpG methylation of the PWS-IC but have normal levels of H3 Lys-9 methylation of the PWS-IC and show normal monoallelic Snrpn expression. Our results demonstrate a role for histone methylation in the maintenance of parent-specific CpG methylation of imprinting regulatory regions and suggest a possible role of histone methylation in establishment of these CpG methylation patterns.	Univ Virginia Hlth Syst, Dept Pediat, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan; Inst Curie, F-75248 Paris, France	University of Virginia; University of Virginia; Kyoto University; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Wagstaff, J (corresponding author), Univ Virginia Hlth Syst, Dept Pediat, Jordan Hall,Box 800733, Charlottesville, VA 22908 USA.	wagstaff@virginia.edu	Shinkai, Yoichi/N-3909-2014; Heard, Edith/D-7197-2017	Shinkai, Yoichi/0000-0002-6051-2484; Heard, Edith/0000-0001-8052-7117				Biniszkiewicz D, 2002, MOL CELL BIOL, V22, P2124, DOI 10.1128/MCB.22.7.2124-2135.2002; Bressler J, 2001, NAT GENET, V28, P232, DOI 10.1038/90067; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; El-Maarri O, 2001, NAT GENET, V27, P341, DOI 10.1038/85927; Engemann S, 2000, HUM MOL GENET, V9, P2691, DOI 10.1093/hmg/9.18.2691; Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Nicholls RD, 1998, TRENDS GENET, V14, P194, DOI 10.1016/S0168-9525(98)01432-2; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Reik W, 2001, NAT GENET, V27, P255, DOI 10.1038/85804; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; SZABO P, 1994, DEVELOPMENT, V120, P1651; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Xin ZH, 2001, AM J HUM GENET, V69, P1389, DOI 10.1086/324469; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25; Zwart R, 2001, GENE DEV, V15, P2361, DOI 10.1101/gad.206201	22	126	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14996	15000		10.1074/jbc.M211753200	http://dx.doi.org/10.1074/jbc.M211753200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586828	hybrid			2022-12-27	WOS:000182516100055
J	Yamaguchi, Y; Katoh, H; Negishi, M				Yamaguchi, Y; Katoh, H; Negishi, M			N-terminal short sequences of alpha subunits of the G(12) family determine selective coupling to receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; STRESS FIBER FORMATION; THROMBIN RECEPTOR; G-ALPHA(12); RHO; G(13); ACYLATION; PATHWAYS; MUTANT; KINASE	The Galpha subunits of the G(12) family of heterotrimeric G proteins, defined by Galpha(12) and Galpha(13), have many cellular functions in common, such as stress fiber formation and neurite retraction. However, a variety of G protein-coupled receptors appear to couple selectively to Galpha(12) and Galpha(13). For example, thrombin and lysophosphatidic acid (LPA) have been shown to induce stress fiber formation via Galpha(12) and Galpha(13), respectively. We recently showed that active forms of Galpha(12) and Galpha(13) interact with Ser/Thr phosphatase type 5 through its tetratricopeptide repeat domain. Here we developed a novel assay to measure the activities of Galpha(12) and Galpha(13), by using glutathione S-transferase-fused tetratricopeptide repeat domain of Ser/Thr phosphatase type 5, taking advantage of the property that tetratricopeptide repeat domain strongly interacts with active forms of Galpha(12) and Galpha(13). By using this assay, we identified that thrombin and LPA selectively activate Galpha(12) and Galpha(13), respectively. Galpha(12) and Galpha(13) show a high amino acid sequence homology except for their N-terminal short sequences. Then we generated chimeric G proteins Galpha(12N/13C) and Galpha(13N/12C), in which the N-terminal short sequences are replaced by each other, and showed that thrombin and LPA selectively activate Galpha(12N/13C) and Galpha(13N/12C), respectively. Moreover, thrombin and LPA stimulate RhoA activity through Galpha(12) and Galpha(13), respectively, in a Galpha(12) family N-terminal sequence-dependent manner. Thus, N-terminal short sequences of the G(12) family determine the selective couplings of thrombin and LPA receptors to the Galpha(12) family.	Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan.		Yamaguchi, Yoshiaki/K-9418-2013	Yamaguchi, Yoshiaki/0000-0003-4126-542X; Katoh, Hironori/0000-0002-8191-8117				Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kuner R, 2002, EUR J NEUROSCI, V16, P2333, DOI 10.1046/j.1460-9568.2002.02402.x; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Negishi M, 2002, J BIOCHEM, V132, P157, DOI 10.1093/oxfordjournals.jbchem.a003205; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Ponimaskin E, 1998, FEBS LETT, V429, P370, DOI 10.1016/S0014-5793(98)00638-3; Ponimaskin E, 2000, FEBS LETT, V478, P173, DOI 10.1016/S0014-5793(00)01845-7; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Vaiskunaite R, 2000, J BIOL CHEM, V275, P26206, DOI 10.1074/jbc.M001863200; Vaiskunaite R, 2001, J BIOL CHEM, V276, P46088, DOI 10.1074/jbc.M108711200; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Waheed AA, 2002, J BIOL CHEM, V277, P32409, DOI 10.1074/jbc.C200383200; Yamaguchi Y, 2000, J NEUROCHEM, V75, P708, DOI 10.1046/j.1471-4159.2000.0750708.x; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5	21	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14936	14939		10.1074/jbc.M301409200	http://dx.doi.org/10.1074/jbc.M301409200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594220	hybrid			2022-12-27	WOS:000182516100047
J	Li, Y; Inoki, K; Vacratsis, P; Guan, KL				Li, Y; Inoki, K; Vacratsis, P; Guan, KL			The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; TSC2 GENE; CELL-GROWTH; MAP KINASE; 3-KINASE/AKT PATHWAY; PROTEIN; COMPLEX; ACTIVATION; HAMARTIN; AKT	Tuberous sclerosis complex (TSC) is a genetic disease caused by mutations in either TSC1 or TSC2 tumor suppressor genes. TSC1 and TSC2 (also known as hamartin and tuberin, respectively) form a functional complex and negatively regulate cell growth by inhibiting protein synthesis. 14-3-3 binds to TSC2 and may inhibit TSC2 function. We have reported previously that phosphorylation of serine 1210 (Ser(1210)) in TSC2 is essential for 14-3-3 binding. Here we show that serum and anisomycin enhance the interaction between TSC2 and 14-3-3 by stimulating phosphorylation of Ser(1210). Activation of p38 MAP kinase (p38) is essential for the stimulating effect of serum and anisomycin although p38 is not directly responsible for the phosphorylation of Ser(1210) in TSC2. Both in vitro and in vivo experiments demonstrate that the p38-activated kinase MK2 (also known as MAP-KAPK2) is directly responsible for the phosphorylation of Ser(1210). Our data show that anisomycin stimulates phosphorylation of Ser(1210) of TSC2 via the p38-MK2 kinase cascade. Phosphorylation of TSC2 by MK2 creates a 14-3-3 binding site and thus regulates the cellular function of the TSC2 tumor suppressor protein.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, KL (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1301 E Catherine St, Ann Arbor, MI 48109 USA.	kunliang@umich.edu	INOKI, KEN/A-1202-2007		NIDDK NIH HHS [R01 DK124709] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Au KS, 1998, AM J HUM GENET, V62, P286, DOI 10.1086/301705; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Knebel A, 2002, BIOCHEM J, V367, P525, DOI 10.1042/BJ20020916; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Liu MY, 2002, CANCER RES, V62, P6475; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Shumway SD, 2003, J BIOL CHEM, V278, P2089, DOI 10.1074/jbc.C200499200; Soucek T, 2001, ONCOGENE, V20, P4904, DOI 10.1038/sj.onc.1204627; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; [No title captured]	45	135	138	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13663	13671		10.1074/jbc.M300862200	http://dx.doi.org/10.1074/jbc.M300862200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582162	hybrid			2022-12-27	WOS:000182405000015
J	Lozach, PY; Lortat-Jacob, H; de Lavalette, AD; Staropoli, I; Foung, S; Amara, A; Houles, C; Fieschi, F; Schwartz, O; Virelizier, JL; Arenzana-Seisdedos, F; Altmeyer, R				Lozach, PY; Lortat-Jacob, H; de Lavalette, AD; Staropoli, I; Foung, S; Amara, A; Houles, C; Fieschi, F; Schwartz, O; Virelizier, JL; Arenzana-Seisdedos, F; Altmeyer, R			DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; DENDRITIC CELL; ENDOPLASMIC-RETICULUM; ENVELOPE GLYCOPROTEINS; TRANSMEMBRANE DOMAIN; CANDIDATE RECEPTOR; ENDOTHELIAL-CELLS; TRANS-INFECTION; IN-VITRO; T-CELLS	The hepatitis C virus (HCV) genome codes for highly mannosylated envelope proteins, which are naturally retained in the endoplasmic reticulum. We found that the HCV envelope glycoprotein E2 binds the dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN) and the related liver endothelial cell lectin L-SIGN through high-mannose N-glycans. Competing ligands such as mannan and an antibody directed against the carbohydrate recognition domains (CRD) abrogated binding. While no E2 interaction with distant monomeric CRDs on biosensor chips could be detected, binding is observed if CRDs are closely seeded (K-d = 48 nM) and if the CRD is part of the oligomeric-soluble extracellular domain of DC-SIGN (K-d = 30 nM). The highest affinity is seen for plasma membrane- expressed DC-SIGN and L-SIGN (K-d = 3 and 6 nM, respectively). These results indicate that several high- mannose N-glycans in a structurally defined cluster on E2 bind to several subunits of the oligomeric lectin CRD. High affinity interaction of viral glycoproteins with oligomeric lectins might represent a strategy by which HCV targets to and concentrates in the liver and infects dendritic cells.	Inst Pasteur, Unite Immunol Virale, F-75015 Paris, France; Inst Pasteur, Grp Virus & Immun, F-75015 Paris, France; UJF, CNRS, CEA, Inst Biol Struct,Unite Mixte Rech 5075, F-38027 Grenoble 01, France; Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Stanford University	Altmeyer, R (corresponding author), Inst Pasteur, Unite Immunol Virale, 28 Rue Dr Roux, F-75015 Paris, France.	altmeyer@pasteur.fr	Lozach, Pierre-Yves/H-7072-2015; Schwartz, Olivier/AAZ-3765-2021; AMARA, Ali/ABX-9903-2022; Amara, Ali/E-8803-2017; Arenzana-Seisdedos, Fernando/E-5835-2016; Fieschi, Franck/W-2748-2019	Lozach, Pierre-Yves/0000-0002-9966-1452; Schwartz, Olivier/0000-0002-0729-1475; FIESCHI, Franck/0000-0003-1194-8107; Foung, Steven/0000-0001-7149-6160; SANCHEZ, Corinne/0000-0003-3895-0194; AMARA, Ali/0000-0002-0283-1815	NATIONAL CANCER INSTITUTE [P01CA034233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006596] Funding Source: NIH RePORTER; NCI NIH HHS [CA34233] Funding Source: Medline; NIAID NIH HHS [AI47355] Funding Source: Medline; NIDA NIH HHS [DA06596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Agnello V, 1998, HEPATOLOGY, V28, P573, DOI 10.1002/hep.510280240; Aizaki H, 1998, HEPATOLOGY, V27, P621, DOI 10.1002/hep.510270242; Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; Alter MJ, 2002, HEPATOLOGY, V36, pS93, DOI 10.1053/jhep.2002.36389; Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Bain C, 2001, GASTROENTEROLOGY, V120, P512, DOI 10.1053/gast.2001.21212; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; BERGLUND P, 1993, BIO-TECHNOL, V11, P916, DOI 10.1038/nbt0893-916; Blanchard E, 2002, J VIROL, V76, P4073, DOI 10.1128/JVI.76.8.4073-4079.2002; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; Chanel C, 2002, AIDS, V16, P2337, DOI 10.1097/00002030-200211220-00016; Choukhi A, 1998, J VIROL, V72, P3851, DOI 10.1128/JVI.72.5.3851-3858.1998; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Cocquerel L, 2003, J VIROL, V77, P1604, DOI 10.1128/JVI.77.2.1604-1609.2003; Cocquerel L, 2002, EMBO J, V21, P2893, DOI 10.1093/emboj/cdf295; Cocquerel L, 1999, J VIROL, V73, P2641, DOI 10.1128/JVI.73.4.2641-2649.1999; CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; De Beeck AO, 2001, J GEN VIROL, V82, P2589, DOI 10.1099/0022-1317-82-11-2589; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; Dubuisson J, 1996, J VIROL, V70, P778, DOI 10.1128/JVI.70.2.778-786.1996; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371; Flint M, 2000, REV MED VIROL, V10, P101, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;101::AID-RMV268&gt;3.0.CO;2-W; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Hadlock KG, 2000, J VIROL, V74, P10407, DOI 10.1128/JVI.74.22.10407-10416.2000; Halary F, 2002, IMMUNITY, V17, P653, DOI 10.1016/S1074-7613(02)00447-8; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; LANFORD RE, 1994, VIROLOGY, V202, P606, DOI 10.1006/viro.1994.1381; Lerat H, 1998, BLOOD, V91, P3841, DOI 10.1182/blood.V91.10.3841.3841_3841_3849; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; Lin G, 2003, J VIROL, V77, P1337, DOI 10.1128/JVI.77.2.1337-1346.2003; MAEDA N, 2002, J BIOL CHEM, V20, P20; MAJOR ME, 2001, FIELDS VIROLOGY, V1, P1127; Matsuura Y, 2001, VIROLOGY, V286, P263, DOI 10.1006/viro.2001.0971; Meanger J, 1997, BIOTECHNIQUES, V23, P432, DOI 10.2144/97233bm18; Merola M, 2001, J VIROL, V75, P11205, DOI 10.1128/JVI.75.22.11205-11217.2001; Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200; Monazahian M, 1999, J MED VIROL, V57, P223, DOI 10.1002/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4; Navas MC, 2002, J MED VIROL, V67, P152, DOI 10.1002/jmv.2204; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Petracca R, 2000, J VIROL, V74, P4824, DOI 10.1128/JVI.74.10.4824-4830.2000; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398; Saunier B, 2003, J VIROL, V77, P546, DOI 10.1128/JVI.77.1.546-559.2003; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Soilleux EJ, 2001, J PATHOL, V195, P586, DOI 10.1002/path.1026; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; Staropoli I, 2000, J BIOL CHEM, V275, P35137, DOI 10.1074/jbc.M003868200; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; Takikawa S, 2000, J VIROL, V74, P5066, DOI 10.1128/JVI.74.11.5066-5074.2000; Wellnitz S, 2002, J VIROL, V76, P1181, DOI 10.1128/JVI.76.3.1181-1193.2002; Zhu XG, 2000, BIOCHEMISTRY-US, V39, P11194, DOI 10.1021/bi000432m	58	293	313	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20358	20366		10.1074/jbc.M301284200	http://dx.doi.org/10.1074/jbc.M301284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12609975	hybrid, Green Published			2022-12-27	WOS:000183078000100
J	Gastaldelli, M; Canino, G; Croce, R; Bassi, R				Gastaldelli, M; Canino, G; Croce, R; Bassi, R			Xanthophyll binding sites of the CP29 (Lhcb4) subunit of higher plant photosystem II investigated by domain swapping and mutation analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING COMPLEX; ANTENNA COMPLEX; ENERGY-TRANSFER; PIGMENT-BINDING; ZEAXANTHIN FORMATION; PROTEINS; LHCII; DICYCLOHEXYLCARBODIIMIDE; RECONSTITUTION; STOICHIOMETRY	The binding sites for xanthophylls in the CP29 antenna protein of higher plant Photosystem II have been investigated using recombinant proteins refolded in vitro. Despite the presence of three xanthophyll species CP29 binds two carotenoids per polypeptide. The localization of neoxanthin was studied producing a chimeric protein constructed by swapping the C-helix domain from CP29 to LHCII. The resulting holoprotein did not bind neoxanthin, confirming that the N1 site is not present in CP29. Neoxanthin in CP29 was, instead, bound to the L2 site, which is thus shown to have a wider specificity with respect to the homologous site L2 in LHCII. Lutein was found in the L1 site of CP29. For each site the selectivity for individual xanthophyll species was studied as well as its role in protein stabilization, energy transfer, and photoprotection. Putative xanthophyll binding sequences, identified by primary structure analysis as a stretch of hydrophobic residues including an acidic term, were analyzed by site-directed mutagenesis or, in one case, by deleting the entire sequence. The mutant proteins were unaffected in their xanthophyll composition, thus suggesting that the target motifs had little influence in determining xanthophyll binding, whereas hydrophobic sequences in the membrane-spanning helices are important.	Univ Aix Marseille 2, Fac Sci Luminy, Dept Biol, LGBP, F-13288 Marseille 09, France; Univ Verona, Dipartimento Sci & Tecnol, I-37134 Verona, Italy; CNR, Ist Biofis, I-20133 Milan, Italy	UDICE-French Research Universities; Aix-Marseille Universite; University of Verona; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR)	Bassi, R (corresponding author), Univ Aix Marseille 2, Fac Sci Luminy, Dept Biol, LGBP, Case 901-163,Ave Luminy, F-13288 Marseille 09, France.		Croce, Roberta/ABG-3595-2021; Croce, Roberta/F-1174-2014; Croce, Roberta/HGU-9554-2022; Croce, Roberta/N-4067-2014	Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; Croce, Roberta/0000-0003-3469-834X; bassi, roberto/0000-0002-4140-8446				Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1993, EUR J BIOCHEM, V212, P297, DOI 10.1111/j.1432-1033.1993.tb17662.x; Bassi R, 2000, PHOTOSYNTH RES, V64, P243, DOI 10.1023/A:1006409506272; Caffarri S, 2001, J BIOL CHEM, V276, P35924, DOI 10.1074/jbc.M105199200; Croce R, 1999, FEBS LETT, V456, P1, DOI 10.1016/S0014-5793(99)00907-2; Croce R, 1999, J BIOL CHEM, V274, P29613, DOI 10.1074/jbc.274.42.29613; Croce R, 1996, BIOCHEMISTRY-US, V35, P11142, DOI 10.1021/bi960652t; Croce R, 2003, BIOPHYS J, V84, P2517, DOI 10.1016/S0006-3495(03)75057-7; Croce R, 2002, BIOCHEMISTRY-US, V41, P7334, DOI 10.1021/bi0257437; Croce R, 2000, PHOTOSYNTH RES, V64, P221, DOI 10.1023/A:1006455230379; Croce R, 2001, BIOPHYS J, V80, P901, DOI 10.1016/S0006-3495(01)76069-9; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DAINESE P, 1991, J BIOL CHEM, V266, P8136; Das SK, 2002, BIOCHEMISTRY-US, V41, P13087, DOI 10.1021/bi0204802; DEMMIG B, 1987, PLANT PHYSIOL, V84, P218, DOI 10.1104/pp.84.2.218; Dolan PM, 2001, J PHYS CHEM B, V105, P12134, DOI 10.1021/jp010271b; Faller P, 2001, BIOCHEMISTRY-US, V40, P6431, DOI 10.1021/bi0026021; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; Frank HA, 2001, BIOCHEMISTRY-US, V40, P1220, DOI 10.1021/bi001160q; GILMORE AM, 1991, PLANT PHYSIOL, V96, P635, DOI 10.1104/pp.96.2.635; Giuffra E, 1997, BIOCHEMISTRY-US, V36, P12984, DOI 10.1021/bi9711339; Giuffra E, 1996, EUR J BIOCHEM, V238, P112, DOI 10.1111/j.1432-1033.1996.0112q.x; Gradinaru CC, 2000, J PHYS CHEM B, V104, P9330, DOI 10.1021/jp001752i; Heinemann B, 1999, BIOCHEMISTRY-US, V38, P14088, DOI 10.1021/bi991439a; Jegerschold C, 2000, J BIOL CHEM, V275, P12781, DOI 10.1074/jbc.275.17.12781; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; Morosinotto T, 2002, J BIOL CHEM, V277, P36913, DOI 10.1074/jbc.M205339200; Moya I, 2001, BIOCHEMISTRY-US, V40, P12552, DOI 10.1021/bi010342x; Pascal A, 1999, EUR J BIOCHEM, V262, P817, DOI 10.1046/j.1432-1327.1999.00457.x; Pesaresi P, 1997, FEBS LETT, V402, P151, DOI 10.1016/S0014-5793(96)01518-9; Pichersky E., 1996, OXYGENIC PHOTOSYNTHE, P507; PLUMLEY FG, 1987, P NATL ACAD SCI USA, V84, P146, DOI 10.1073/pnas.84.1.146; Polivka T, 2002, BIOCHEMISTRY-US, V41, P439, DOI 10.1021/bi011589x; Prince SM, 1997, J MOL BIOL, V268, P412, DOI 10.1006/jmbi.1997.0966; Ruban AV, 1999, J BIOL CHEM, V274, P10458, DOI 10.1074/jbc.274.15.10458; Sandona D, 1998, BBA-BIOENERGETICS, V1365, P207, DOI 10.1016/S0005-2728(98)00068-1; Simonetto R, 1999, BIOCHEMISTRY-US, V38, P12974, DOI 10.1021/bi991140s; Tracewell CA, 2001, BIOCHEMISTRY-US, V40, P193, DOI 10.1021/bi001992o; WALTERS RG, 1994, EUR J BIOCHEM, V226, P1063, DOI 10.1111/j.1432-1033.1994.01063.x	40	30	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19190	19198		10.1074/jbc.M212125200	http://dx.doi.org/10.1074/jbc.M212125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12601013	hybrid			2022-12-27	WOS:000182932200063
J	Shand, JH; Beattie, J; Song, H; Phillips, K; Kelly, SM; Flint, DJ; Allan, GJ				Shand, JH; Beattie, J; Song, H; Phillips, K; Kelly, SM; Flint, DJ; Allan, GJ			Specific amino acid substitutions determine the differential contribution of the N- and C-terminal domains of insulin-like growth factor (IGF)-binding protein-5 in binding IGF-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; EXTRACELLULAR-MATRIX; HEPARIN-BINDING; SECONDARY STRUCTURE; SITE; IGFBP-3; LOCALIZATION; FRAGMENTS; RECEPTOR; REGION	We have previously reported that two highly conserved amino acids in the C-terminal domain of rat insulin-like growth factor-binding protein (IGFBP)-5, Gly(203) and Gln(209), are involved in binding to insulin-like growth factor (IGF)-1. Here we report that mutagenesis of both amino acids simultaneously (C-Term mutant) results in a cumulative effect and an even greater reduction in IGF-I binding: 30-fold measured by solution phase IGF binding assay and 10-fold by biosensor analysis. We compared these reductions in ligand binding to the effects of specific mutations of five amino acids in the N-terminal domain (N-Term mutant), which had previously been shown by others to cause a very large reduction in IGF-I binding (1). Our results confirm this as the major IGF-binding site. To prove that the mutations in either N- or C-Term were specific for IGF-I binding, we carried out CD spectroscopy and showed that these alterations did not lead to gross conformational changes in protein structure for either mutant. Combining these mutations in both domains (N+C-Term mutant) has a cumulative effect and leads to a 126-fold reduction in IGF-I binding as measured by biosensor. Furthermore, the equivalent mutations in the C terminus of rat IG-FBP2 (C-Term 2) also results in a significant reduction in IGF-I binding, suggesting that the highly conserved Gly and Gln residues have a conserved IGF-I binding function in all six IGFBPs. Finally, although these residues lie within a major heparin-binding site in IGFBP-5 and -3, we also show that the mutations in C-Term have no effect on heparin binding.	Hannah Res Inst, Ayr KA6 5HL, Scotland; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Glasgow	Allan, GJ (corresponding author), Hannah Res Inst, Ayr KA6 5HL, Scotland.		Kelly, Sharon/K-4611-2013	Kelly, Sharon/0000-0002-3516-1387				Allan GJ, 2002, ENDOCRINOLOGY, V143, P4310, DOI 10.1210/en.2001-211191; ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ARAI T, 1994, J BIOL CHEM, V269, P20388; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; BINOUX M, 1991, ACTA ENDOCRINOL-COP, V124, P41; Bramani S, 1999, J MOL ENDOCRINOL, V23, P117, DOI 10.1677/jme.0.0230117; Carrick FE, 2001, J BIOL CHEM, V276, P27120, DOI 10.1074/jbc.M101317200; CHERNAUSEK SD, 1995, J BIOL CHEM, V270, P11377, DOI 10.1074/jbc.270.19.11377; CLEMMONS DR, 1993, MOL REPROD DEV, V35, P368, DOI 10.1002/mrd.1080350409; CONOVER CA, 1989, J CLIN INVEST, V83, P852, DOI 10.1172/JCI113968; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Firth SM, 1999, J ENDOCRINOL, V160, P379, DOI 10.1677/joe.0.1600379; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; Galanis M, 2001, J ENDOCRINOL, V169, P123, DOI 10.1677/joe.0.1690123; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; Hobba GD, 1996, J BIOL CHEM, V271, P30529, DOI 10.1074/jbc.271.48.30529; Hobba GD, 1998, J BIOL CHEM, V273, P19691, DOI 10.1074/jbc.273.31.19691; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; MANAVALAN P, 1983, NATURE, V305, P831, DOI 10.1038/305831a0; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; Parker A, 1998, MOL BIOL CELL, V9, P2383, DOI 10.1091/mbc.9.9.2383; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; SOMMER A, 1993, GROWTH REGULAT, V3, P46; SOMMER A, 1991, MODERN CONCEPTS INSU, P329; Song H, 2000, J MOL ENDOCRINOL, V24, P43, DOI 10.1677/jme.0.0240043; Song H, 2001, J MOL ENDOCRINOL, V26, P229, DOI 10.1677/jme.0.0260229; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Vorwerk P, 2002, ENDOCRINOLOGY, V143, P1677, DOI 10.1210/en.143.5.1677; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7; WU J, 1992, ANAL BIOCHEM, V200, P359, DOI 10.1016/0003-2697(92)90479-Q	35	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17859	17866		10.1074/jbc.M300526200	http://dx.doi.org/10.1074/jbc.M300526200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626499	hybrid			2022-12-27	WOS:000182838300035
J	Hu, YZ; Mivechi, NF				Hu, YZ; Mivechi, NF			HSF-1 interacts with Ral-binding protein 1 in a stress-responsive, multiprotein complex with HSP90 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK FACTOR-1; SIGNAL-REGULATED KINASE; FACTOR-I; TRANSCRIPTIONAL ACTIVITY; MOLECULAR CHAPERONES; SYNAPTIC VESICLES; PUTATIVE EFFECTOR; ACTIVATION; GTPASE; PHOSPHORYLATION	Heat shock factor 1 (HSF1) regulates the rapid and transient expression of heat shock genes in response to stress. The transcriptional activity of HSF1 is tightly controlled, and under physiological growth conditions, the HSF1 monomer is in a heterocomplex with the molecular chaperone HSP90. Through unknown mechanisms, transcriptionally repressed HSF1.HSP90 heterocomplexes dissociate following stress, which triggers HSF1 activation and heat shock gene transcription. Using a yeast two-hybrid screening system, we have identified Ral-binding protein 1 (RalBP1) as an additional HSF1-interacting protein. We show that RalBP1 and HSF1 interact in vivo, and transient cotransfection of HSF1 and RalBP1 into hsf1(-/-) mouse embryo fibroblasts represses HSP70 expression. Furthermore, transient cotransfection of HSF1 and the constitutively active form of RalA (RalA23V), an upstream activator of the RalBP1 signaling pathway, increases the heat-inducible expression of HSP70, whereas the dominant negative form (RalA28N) suppresses HSP70 expression. We further find that alpha-tubulin and HSP90 are also present in the RalBP1.HSF1 heterocomplexes in unstressed cells. Upon heat shock, the Ral signaling pathway is activated, and the resulting RalGTP binds RalBP1. Concurrently, HSF1 is activated, leaves the RalBP1.HSF1.HSP90.alpha-tubulin heterocomplexes, and translocates into the nucleus, where it then activates transcription. In conclusion, these observations reveal that the RalGTP signal transduction pathway is critical for activation of the stress-responsive HSF1 and perhaps HSP90 molecular chaperone system.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; Med Coll Georgia, Dept Radiol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Mivechi, NF (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, 1120 15th St CB2803, Augusta, GA 30912 USA.	mivechi@immag.mcg.edu			NCI NIH HHS [CA85947, CA62130] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062130, R01CA085947] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Guo YL, 2001, J BIOL CHEM, V276, P45791, DOI 10.1074/jbc.M105931200; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Liang P, 1997, J CELL SCI, V110, P1431; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Park SH, 1995, ONCOGENE, V11, P2349; Pishvaee B, 1998, CELL, V95, P443, DOI 10.1016/S0092-8674(00)81611-6; Quaroni A, 1999, J CELL SCI, V112, P707; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Soncin F, 2000, INT J MOL MED, V6, P705; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOLKNANDT W, 1993, FEBS LETT, V317, P53, DOI 10.1016/0014-5793(93)81490-Q; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3	56	89	95	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17299	17306		10.1074/jbc.M300788200	http://dx.doi.org/10.1074/jbc.M300788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621024	hybrid			2022-12-27	WOS:000182818600114
J	Mott, HR; Nietlispach, D; Hopkins, LJ; Mirey, G; Camonis, JH; Owen, D				Mott, HR; Nietlispach, D; Hopkins, LJ; Mirey, G; Camonis, JH; Owen, D			Structure of the GTPase-binding domain of Sec5 and elucidation of its Ral binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B COMPLEX; CRYSTAL-STRUCTURE; EXOCYST COMPLEX; TRANSCRIPTION FACTOR; ANGSTROM RESOLUTION; NMR-SPECTROSCOPY; EFFECTOR DOMAIN; SEC6/8 COMPLEX; PROTEIN CDC42; DNA COMPLEX	The exocyst complex is involved in the final stages of exocytosis, when vesicles are targeted to the plasma membrane and dock. The regulation of exocytosis is vital for a number of processes, for example, cell polarity, embryogenesis, and neuronal growth formation. Regulation of the exocyst complex in mammals was recently shown to be dependent upon binding of the small G protein, Ral, to Sec5, a central component of the exocyst. This interaction is thought to be necessary for anchoring the exocyst to secretory vesicles. We have determined the structure of the Ral-binding domain of Sec5 and shown that it adopts a fold that has not been observed in a G protein effector before. This fold belongs to the immunoglobulin superfamily in a subclass known as IPT domains. We have mapped the Ral binding site on this domain and found that it overlaps with protein-protein interaction sites on other IPT domains but that it is completely different from the G protein-geranyl-geranyl interaction face of the Ig-like domain of the Rho guanine nucleotide dissociation inhibitor. This mapping, along with available site-directed mutagenesis data, allows us to predict how Ral and Sec5 may interact.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; Inst Curie, F-75248 Paris 05, France	University of Cambridge; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Owen, D (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.		Mirey, Gladys/H-5676-2019; Mott, Helen/AAV-3873-2020	Mirey, Gladys/0000-0002-0095-1864; Mott, Helen/0000-0002-7890-7097; Nietlispach, Daniel/0000-0003-4364-9291				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; Dauter Z, 1999, BIOCHEMISTRY-US, V38, P8385, DOI 10.1021/bi990256l; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; Huang L, 1997, NAT STRUCT BIOL, V4, P609, DOI 10.1038/nsb0897-609; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Matern HT, 2001, P NATL ACAD SCI USA, V98, P9648, DOI 10.1073/pnas.171317898; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nietlispach D, 2002, J AM CHEM SOC, V124, P11199, DOI 10.1021/ja025865m; Novick P, 2002, TRENDS CELL BIOL, V12, P247, DOI 10.1016/S0962-8924(02)02293-6; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Owen D, 2000, BIOCHEMISTRY-US, V39, P1243, DOI 10.1021/bi991567z; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; Scheffzek K, 2000, NAT STRUCT BIOL, V7, P122, DOI 10.1038/72392; Stroud JC, 2002, NAT STRUCT BIOL, V9, P90, DOI 10.1038/nsb749; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Vetter IR, 1999, FEBS LETT, V451, P175, DOI 10.1016/S0014-5793(99)00555-4; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200	51	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17053	17059		10.1074/jbc.M300155200	http://dx.doi.org/10.1074/jbc.M300155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624092	Green Published, hybrid			2022-12-27	WOS:000182818600082
J	Wahl, JK; Kim, YJ; Cullen, JM; Johnson, KR; Wheelock, MJ				Wahl, JK; Kim, YJ; Cullen, JM; Johnson, KR; Wheelock, MJ			N-cadherin-catenin complexes form prior to cleavage of the proregion and transport to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; TYROSINE KINASE SUBSTRATE; ALPHA-CATENIN; CARCINOMA-CELLS; BETA-CATENIN; REGION; IDENTIFICATION; EXPRESSION; P120(CTN); PROTEINS	Cadherins are calcium-dependent glycoproteins that function as cell-cell adhesion molecules and are linked to the actin cytoskeleton via catenins. Newly synthesized cadherins contain a prosequence that must be proteolytically removed to generate a functional adhesion molecule. The goal of this study was to examine the proteolytic processing of N-cadherin and the assembly of the cadherin-catenin complex in cells that express endogenous N-cadherin. A monoclonal antibody specific for the proregion of human N-cadherin was generated and used to examine N-cadherin processing. Our data show that newly synthesized proN-cadherin is phosphorylated and proteolytically processed prior to transport to the plasma membrane. In addition, we show that beta-catenin and plakoglobin associate only with phosphorylated proN-cadherin, whereas p120(ctn) can associate with both phosphorylated and non-phosphorylated proN-cadherin. Immunoprecipitations using anti-proN-cadherin showed that cadherin-catenin complexes are assembled prior to localization at the plasma membrane. These data suggest that a core N-cadherin-catenin complex assembles in the endoplasmic reticulum or Golgi compartment and is transported to the plasma membrane where linkage to the actin cytoskeleton can be established.	Univ Nebraska, Med Ctr, Coll Dent, Omaha, NE 68198 USA; Eppley Canc Ctr, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Wahl, JK (corresponding author), Univ Nebraska, Med Ctr, Coll Dent, 987696 Nebraska Med Ctr, Omaha, NE 68198 USA.		Cullen, John M/I-2051-2019		NIDCR NIH HHS [DE12308] Funding Source: Medline; NIGMS NIH HHS [GM51188] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012308] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Chen HY, 1997, J CELL SCI, V110, P345; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Finnemann S, 1997, J BIOL CHEM, V272, P11856, DOI 10.1074/jbc.272.18.11856; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Mary S, 2002, MOL BIOL CELL, V13, P285, DOI 10.1091/mbc.01-07-0337; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nieset JE, 1997, J CELL SCI, V110, P1013; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ozawa M, 2002, J BIOL CHEM, V277, P19600, DOI 10.1074/jbc.M202029200; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; Pokutta S, 2000, MOL CELL, V5, P533, DOI 10.1016/S1097-2765(00)80447-5; Posthaus H, 1998, FEBS LETT, V438, P306, DOI 10.1016/S0014-5793(98)01330-1; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Wahl JK, 2002, HYBRIDOMA HYBRIDOM, V21, P37, DOI 10.1089/15368590252917629; Wheelock MJ, 1996, CURR TOP MEMBR, V43, P169; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; Yagi T, 2000, GENE DEV, V14, P1169; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	37	95	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17269	17276		10.1074/jbc.M211452200	http://dx.doi.org/10.1074/jbc.M211452200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604612	hybrid			2022-12-27	WOS:000182818600110
J	Gil-Henn, H; Elson, A				Gil-Henn, H; Elson, A			Tyrosine phosphatase-epsilon activates Src and supports the transformed phenotype of Neu-induced mammary tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY KINASES; BREAST-CANCER; C-SRC; DOWN-REGULATION; PTP-EPSILON; RPTP-ALPHA; GROWTH; SIGNAL; PHOSPHORYLATION; EXPRESSION	Few tyrosine phosphatases support, rather than inhibit, survival of tumor cells. We present genetic evidence that receptor-type protein-tyrosine phosphatase (RPTP)-epsilon performs such a function, as cells from mammary epithelial tumors induced by activated Neu in mice genetically lacking RPTPLepsilon appeared morphologically less transformed and exhibited reduced proliferation. We show that at the molecular level, RPTPepsilon activates Src, a known collaborator of Neu in mammary tumorigenesis. Lack of RPTPepsilon reduced Src activity and altered Src phosphorylation in tumor cells; RPTPepsilon dephosphorylated and activated Src; and Src bound a substrate-trapping mutant of RPTPepsilon. The altered morphology of tumor cells lacking RPTPepsilon was corrected by exogenous Src and exogenous RPTPepsilon or RPTPalpha; exogenous activated Src corrected also the growth rate phenotype. Together, these results suggest that the altered morphology of RPTPepsilon-deficient tumor cells is caused by reduced Src activity, caused, in turn, by lack of RPTPepsilon. Unexpectedly, the phenotype of RPTPepsilon-deficient tumor cells occurs despite expression of the related RPTPalpha, indicating that endogenous RPTPalpha does not compensate for the absence of RPTPepsilon in this case. We conclude that RPTPepsilon is a physiological activator of Src in Neuinduced mammary tumors and suggest that pharmacological inhibition of phosphatases that activate Src may be useful to augment direct pharmacological inhibition of Src.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Herzl St, IL-76100 Rehovot, Israel.	ari.elson@weizmann.ac.il		Elson, Ari/0000-0001-9808-9135				Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Andersen JN, 2001, BIOCHEM J, V354, P581, DOI 10.1042/0264-6021:3540581; Andrechek ER, 2000, BREAST CANCER RES, V2, P211, DOI 10.1186/bcr56; Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; DAUM G, 1994, J BIOL CHEM, V269, P10524; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gil-Henn H, 2000, ONCOGENE, V19, P4375, DOI 10.1038/sj.onc.1203790; Gil-Henn H, 2001, J BIOL CHEM, V276, P31772, DOI 10.1074/jbc.M103395200; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Meinhold-Heerlein I, 2001, AM J PATHOL, V158, P1335, DOI 10.1016/S0002-9440(10)64084-9; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Nakamura K, 1996, BIOCHEM BIOPH RES CO, V218, P726, DOI 10.1006/bbrc.1996.0129; Peretz A, 2000, EMBO J, V19, P4036, DOI 10.1093/emboj/19.15.4036; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Shin DY, 1997, ONCOGENE, V14, P2633, DOI 10.1038/sj.onc.1201106; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Sully V, 2001, BIOCHEM BIOPH RES CO, V286, P184, DOI 10.1006/bbrc.2001.5360; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; Tanuma N, 2001, BLOOD, V98, P3030, DOI 10.1182/blood.V98.10.3030; Tanuma N, 2000, J BIOL CHEM, V275, P28216; Thompson LJ, 2001, AM J PHYSIOL-HEART C, V281, pH396, DOI 10.1152/ajpheart.2001.281.1.H396; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	53	77	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15579	15586		10.1074/jbc.M210273200	http://dx.doi.org/10.1074/jbc.M210273200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598528	hybrid			2022-12-27	WOS:000182680000017
J	Wilsie, LC; Orlando, RA				Wilsie, LC; Orlando, RA			The low density lipoprotein receptor-related protein complexes with cell surface heparan sulfate proteoglycans to regulate proteoglycan-mediated lipoprotein catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; CHYLOMICRON REMNANT UPTAKE; APOLIPOPROTEIN-E; LDL RECEPTOR; BETA-VLDL; IN-VITRO; ALPHA(2)-MACROGLOBULIN RECEPTOR; HEYMANN NEPHRITIS; CULTURED-CELLS	It has been proposed that clearance of cholesterol-enriched very low density lipoprotein (VLDL) particles occurs through a multistep process beginning with their initial binding to cell-surface heparan sulfate proteoglycans (HSPG), followed by their uptake into cells by a receptor-mediated process that utilizes members of the low density lipoprotein receptor (LDLR) family, including the low density lipoprotein receptor-related protein (LRP). We have further explored the relationship between HSPG binding of VLDL and its subsequent internalization by focusing on the LRP pathway using a cell line deficient in LDLR. In this study, we show that LRP and HSPG are part of a co-immunoprecipitable complex at the cell surface demonstrating a novel association for these two cell surface receptors. Cell surface binding assays show that this complex can be disrupted by an LRP-specific ligand binding antagonist, which in turn leads to increased VLDL binding and degradation. The increase in VLDL binding results from an increase in the availability of HSPG sites as treatment with heparinase or competitors of glycosaminoglycan chain addition eliminated the augmented binding. From these results we propose a model whereby LRP regulates the availability of VLDL binding sites at the cell surface by complexing with HSPG. Once HSPG dissociates from LRP, it is then able to bind and internalize VLDL independent of LRP endocytic activity. We conclude that HSPG and LRP together participate in VLDL clearance by means of a synergistic relationship.	Univ New Mexico, Hlth Sci Ctr, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center	Orlando, RA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Biochem & Mol Biol, MSC08-4670, Albuquerque, NM 87131 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063291] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 63291] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1993, ARTERIOSCLER THROMB, V13, P618, DOI 10.1161/01.ATV.13.4.618; Baeg GH, 2000, CURR OPIN CELL BIOL, V12, P575, DOI 10.1016/S0955-0674(00)00134-4; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BEMFIELD M, 1992, ANN REV CELL BIOL, V8, P365; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; Bu GJ, 1997, J CELL SCI, V110, P65; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; Chappell DA, 1998, PROG LIPID RES, V37, P393, DOI 10.1016/S0163-7827(98)00017-4; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHAPPELL DA, 1993, J BIOL CHEM, V268, P25487; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; CZEKAY RP, 1995, J CELL SCI, V108, P1433; Czekay RP, 1997, MOL BIOL CELL, V8, P517, DOI 10.1091/mbc.8.3.517; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; de Beer F, 1999, ARTERIOSCL THROM VAS, V19, P633, DOI 10.1161/01.ATV.19.3.633; Field PA, 2000, METABOLISM, V49, P492, DOI 10.1016/S0026-0495(00)80014-1; Fitzgerald ML, 2000, J CELL BIOL, V148, P811, DOI 10.1083/jcb.148.4.811; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Havel Richard J., 1994, Current Opinion in Lipidology, V5, P102, DOI 10.1097/00041433-199404000-00006; HAVEL RJ, 1989, ARTERIOSCLEROSIS, V9, pI33; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Huang YD, 1998, J BIOL CHEM, V273, P17483, DOI 10.1074/jbc.273.28.17483; Huff MW, 1997, J LIPID RES, V38, P1318; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JAAKKOLA O, 1989, ATHEROSCLEROSIS, V79, P173, DOI 10.1016/0021-9150(89)90122-6; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1995, J LIPID RES, V36, P583; Karpe F, 1999, J INTERN MED, V246, P341, DOI 10.1046/j.1365-2796.1999.00548.x; Kerjaschki D, 1997, J CLIN INVEST, V100, P2303, DOI 10.1172/JCI119768; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Libeu CP, 2001, J BIOL CHEM, V276, P39138, DOI 10.1074/jbc.M104746200; Lugemwa FN, 1996, J BIOL CHEM, V271, P19159, DOI 10.1074/jbc.271.32.19159; LUNDSTROM M, 1993, AM J PATHOL, V143, P1423; MacPhee CE, 2000, BIOCHEMISTRY-US, V39, P3433, DOI 10.1021/bi992523t; MAHLEY RW, 1994, ANN NY ACAD SCI, V737, P39, DOI 10.1111/j.1749-6632.1994.tb44300.x; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCKEONE BJ, 1988, BIOCHEMISTRY-US, V27, P4500, DOI 10.1021/bi00412a042; MEDH JD, 1995, J BIOL CHEM, V270, P536, DOI 10.1074/jbc.270.2.536; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; MULDER M, 1993, J BIOL CHEM, V268, P9369; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Olivecrona G, 1997, ARTERIOSCL THROM VAS, V17, P1545, DOI 10.1161/01.ATV.17.8.1545; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Rinninger F, 1998, J LIPID RES, V39, P1335; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; ROSKAMS T, 1995, HEPATOLOGY, V21, P950, DOI 10.1016/0270-9139(95)90239-2; Seo T, 1997, J LIPID RES, V38, P765; SHAFI S, 1994, J LIPID RES, V35, P709; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Taylor WH, 1998, J BIOL CHEM, V273, P22260, DOI 10.1074/jbc.273.35.22260; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; van der Voort R, 2000, J EXP MED, V192, P1115, DOI 10.1084/jem.192.8.1115; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; Vlodavsky I, 1996, CANCER METAST REV, V15, P177, DOI 10.1007/BF00437470; Weaver AM, 1997, J LIPID RES, V38, P1841; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; Willnow TE, 1998, BIOL CHEM, V379, P1025; WILLNOW TE, 1994, SCIENCE, V264, P1471, DOI 10.1126/science.7515194; Yu KCW, 2001, FRONT BIOSCI-LANDMRK, V6, pD332, DOI 10.2741/Yu; Zeng BJ, 1998, J LIPID RES, V39, P845; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	79	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15758	15764		10.1074/jbc.M208786200	http://dx.doi.org/10.1074/jbc.M208786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598530	hybrid			2022-12-27	WOS:000182680000039
J	Blencke, S; Ullrich, A; Daub, H				Blencke, S; Ullrich, A; Daub, H			Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLINICAL RESISTANCE; SIGNAL-TRANSDUCTION; PROTEIN; DRUG; EGF; PHOSPHORYLATION; FAMILY; TARGET; DOMAIN; STI571	Small molecule inhibitors of protein tyrosine kinases such as STI571 represent a major new class of therapeutics for target-selective treatment of human cancer. Clinical resistance formation to the BCR-ABL inhibitor STI571 has been observed in patients with advanced chronic myeloid leukemia and was frequently caused by a C to T single nucleotide change in the Abl kinase domain, which substituted Thr-315 with isoleucine and rendered BCR-ABL resistant to STI571 inhibition. The corresponding mutation in the epidermal growth factor receptor (EGFR) tyrosine kinase replaced Thr-766 of the EGFR by methionine and dramatically reduced the sensitivity of EGFR to inhibition by selective 4-anilino-quinazoline inhibitors such as PD153035. Inhibitor-resistant EGFR exhibited the same signaling capacity as wild-type receptor in vivo and provides a useful tool for analyzing EGFR-mediated signal transduction. Our data identify Thr-766 of the EGFR as a structural determinant that bears the potential to become a relevant feature in resistance formation during cancer therapy with EGFR-specific 4-anilinoquinazoline inhibitors.	Axxima Pharmaceut AG, D-81377 Munich, Germany; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Daub, H (corresponding author), Axxima Pharmaceut AG, Max Lebsche Pl 32, D-81377 Munich, Germany.	daub@axxima.com						Bishop AC, 1998, CURR BIOL, V8, P257, DOI 10.1016/S0960-9822(98)70198-8; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; de Bono JS, 2002, TRENDS MOL MED, V8, pS19, DOI 10.1016/S1471-4914(02)02306-7; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Kubota Y, 1998, CELL GROWTH DIFFER, V9, P247; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; McCormick F, 2001, NATURE, V412, P281, DOI 10.1038/35085665; NAPIER MA, 1987, ARCH BIOCHEM BIOPHYS, V259, P296, DOI 10.1016/0003-9861(87)90496-6; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; Zwick E, 2001, ENDOCR-RELAT CANCER, V8, P161, DOI 10.1677/erc.0.0080161	28	100	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15435	15440		10.1074/jbc.M211158200	http://dx.doi.org/10.1074/jbc.M211158200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594213	hybrid			2022-12-27	WOS:000182516100110
J	Su, L; Hattori, M; Moriyama, M; Murata, N; Harazaki, M; Kaibuchi, K; Minato, N				Su, L; Hattori, M; Moriyama, M; Murata, N; Harazaki, M; Kaibuchi, K; Minato, N			AF-6 controls integrin-mediated cell adhesion by regulating Rap1 activation through the specific recruitment of Rap1GTP and SPA-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ DOMAINS; PROTEIN; GTPASE; RAS; TARGET; DEGRADATION; DISTINCT; PARTNER; PATHWAY; COMPLEX	In the present study, we showed that SPA-1, a Rap1 GTPase-activating protein (GAP), was bound to a cytoskeleton-anchoring protein AF-6. SPA-1 and AF-6 were co-immunoprecipitated in the 293T cells transfected with both cDNAs as well as in normal thymocytes. In vitro binding studies using truncated fragments and their mutants suggested that SPA-1 was bound to the PDZ domain of AF-6 via probable internal PDZ ligand motif within the GAP-related domain. The motif was conserved among Rap1 GAPs, and it was shown that rapGAP I was bound to AF-6 comparably with SPA-1. RapV12 was also bound to AF-6 via the N-terminal domain, and SPA-1 and RapV12 were co-immunoprecipitated only in the presence of AF-6, indicating that they could be brought into close proximity via AF-6 in cells. Immunostaining analysis revealed that SPA-1 and RapV12 were co-localized with AF-6 at the cell attachment sites. In HeLa cells expressing SPA-1 in a tetracycline-regulatory manner, expression of AF-6 inhibited endogenous Rap1GTP and beta(1) integrin-mediated cell adhesion to fibronectin in SPA-1-induced conditions, whereas it affected neither of them in SPA-1-repressed conditions. These results suggested that AF-6 could control integrin-mediated cell adhesion by regulating Rap1 activation through the recruitment of both SPA-1 and Rap1GTP via distinct domains.	Kyoto Univ, Dept Immunol & Cell Biol, Grad Sch Med, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan; Nagoya Univ, Grad Sch Med, Dept Cell Pharmacol, Nagoya, Aichi 4668550, Japan	Kyoto University; Kyoto University; Nagoya University	Minato, N (corresponding author), Kyoto Univ, Dept Immunol & Cell Biol, Grad Sch Med, Kyoto 6068501, Japan.							Abbitt KB, 2000, J IMMUNOL METHODS, V239, P109, DOI 10.1016/S0022-1759(00)00189-7; Ahmadian MR, 1997, FEBS LETT, V408, P315, DOI 10.1016/S0014-5793(97)00422-5; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; Flaishon L, 2001, J BIOL CHEM, V276, P46701, DOI 10.1074/jbc.M103484200; Gao QS, 2002, CANCER RES, V62, P3315; Gao QS, 1999, MOL CELL BIOL, V19, P733; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hock B, 1998, P NATL ACAD SCI USA, V95, P9779, DOI 10.1073/pnas.95.17.9779; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Pak DTS, 2001, NEURON, V31, P289, DOI 10.1016/S0896-6273(01)00355-5; PRASAD R, 1993, CANCER RES, V53, P5624; Roy BC, 2002, GENES CELLS, V7, P607; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sims TN, 2002, IMMUNOL REV, V186, P100, DOI 10.1034/j.1600-065X.2002.18610.x; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Suga K, 2001, FEBS LETT, V489, P249, DOI 10.1016/S0014-5793(00)02222-5; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Yamamoto T, 1999, BIOCHEM BIOPH RES CO, V259, P103, DOI 10.1006/bbrc.1999.0731; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785	30	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15232	15238		10.1074/jbc.M211888200	http://dx.doi.org/10.1074/jbc.M211888200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590145	hybrid, Green Submitted			2022-12-27	WOS:000182516100084
J	Barbier, O; Villeneuve, L; Bocher, V; Fontaine, C; Torra, IP; Duhem, C; Kosykh, V; Fruchart, JC; Guillemette, C; Staels, B				Barbier, O; Villeneuve, L; Bocher, V; Fontaine, C; Torra, IP; Duhem, C; Kosykh, V; Fruchart, JC; Guillemette, C; Staels, B			The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIVER; PPAR-ALPHA; CLINICAL PHARMACOKINETICS; IN-VITRO; METABOLISM; EXPRESSION; GLUCURONIDATION; ACID; IDENTIFICATION; RAT	Peroxisome proliferator-activated receptor (PPAR) alpha and gamma are ligand-activated transcription factors belonging to the nuclear receptor family. PPARa mediates the hypolipidemic action of the fibrates, whereas PPARgamma is a receptor for the antidiabetic glitazones. In the present study, the UDP-glucuronosyltransferase (UGT) 1A9 enzyme is identified as a PPARalpha and PPARgamma target gene. UGTs catalyze the glucuronidation reaction, which is a major pathway in the catabolism and elimination of numerous endo- and xenobiotics. Among the UGT1A family enzymes, UGT1A9 metabolizes endogenous compounds, including catecholestrogens, and xenobiotics, such as fibrates and to a lesser extent troglitazone. Treatment of human hepatocytes and macrophages and murine adipocytes with activators of PPARalpha or PPARgamma resulted in an enhanced UGT1A9 expression and activity. In addition, disruption of the PPARalpha gene in mice completely abolished the PPARalpha agonist-induced UGT1A9 mRNA and activity levels. A PPAR response element was identified in the promoter of UGT1A9 at positions -719 to -706 bp by transient transfection and electromobility shift assays. Considering the role of UGT1A9 in catecholestrogen metabolism, PPARalpha and PPARgamma activation may contribute to the protection against genotoxic catecholestrogens by stimulating their inactivation in glucuronide derivatives. Furthermore, since UGT1A9 is involved in the catabolism of fibrates, these results suggest that PPARalpha and PPARgamma may control the intracellular level of active fibrates.	Inst Pasteur, INSERM, U545, Dept Atherosclerose, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59019 Lille, France; CHUL, Res Ctr, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Pharm, Quebec City, PQ G1V 4G2, Canada; Inst Expt Cardiol, Moscow 121552, Russia	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Laval University; Laval University; National Medical Research Center of Cardiology	Staels, B (corresponding author), Inst Pasteur, INSERM, U545, Dept Atherosclerose, 1 Rue Pr Calmette,BP 245, F-59019 Lille, France.	bart.staels@pasteur-lille.fr	Guillemette, Chantal/J-6463-2012; Fontaine, Coralie/N-3814-2017; Guillemette, Chantal/AAT-6246-2020; Staels, Bart/N-9497-2016	Guillemette, Chantal/0000-0002-1113-1212; Staels, Bart/0000-0002-3784-1503; Pineda Torra, Ines/0000-0002-7349-2208; Barbier, Olivier/0000-0002-3067-1134; Duhem, Christian/0000-0003-0931-3815; Fontaine, Coralie/0000-0002-7253-922X				Albert C, 1999, ENDOCRINOLOGY, V140, P3292, DOI 10.1210/en.140.7.3292; Barbier O, 2002, ARTERIOSCL THROM VAS, V22, P717, DOI 10.1161/01.ATV.0000015598.86369.04; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; Bock KW, 1999, DRUG METAB REV, V31, P411, DOI 10.1081/DMR-100101927; BODE BP, 1995, HEPATOLOGY, V21, P511; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claudel T, 2002, J CLIN INVEST, V109, P961; Congiu M, 2002, DRUG METAB DISPOS, V30, P129, DOI 10.1124/dmd.30.2.129; Cox PJ, 2000, DRUG METAB DISPOS, V28, P772; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Dutton G.F., 1980, GLUCURONIDATION DRUG; EBNER T, 1993, DRUG METAB DISPOS, V21, P50; Findlay KAB, 2000, J CLIN ENDOCR METAB, V85, P2879, DOI 10.1210/jc.85.8.2879; Goodman MT, 2001, CANCER EPIDEM BIOMAR, V10, P209; HAUTANEN A, 1992, J STEROID BIOCHEM, V42, P433, DOI 10.1016/0960-0760(92)90149-D; Hedrick CC, 1999, ADV EXP MED BIOL, V469, P455; Huang LY, 2001, DRUG METAB DISPOS, V29, P634; Jemnitz K, 2000, DRUG METAB DISPOS, V28, P34; Jude AR, 2001, DRUG METAB DISPOS, V29, P652; Khan MA, 2002, DIABETES CARE, V25, P708, DOI 10.2337/diacare.25.4.708; King CD, 2000, CURR DRUG METAB, V1, P143, DOI 10.2174/1389200003339171; Kockx M, 1999, BLOOD, V93, P2991; Kok T, 2003, BIOCHEM J, V369, P539, DOI 10.1042/BJ20020981; Kozak KR, 2002, J BIOL CHEM, V277, P23278, DOI 10.1074/jbc.M201084200; KRIETER PA, 1994, DRUG METAB DISPOS, V22, P625; Lavigne JA, 1997, CANCER RES, V57, P5493; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Liehr JG, 1997, EUR J CANCER PREV, V6, P3, DOI 10.1097/00008469-199702000-00002; LIU HF, 1991, EUR J CLIN PHARMACOL, V41, P153; Loi CM, 1999, CLIN PHARMACOKINET, V37, P91, DOI 10.2165/00003088-199937020-00001; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; Miller DB, 1998, CLIN PHARMACOKINET, V34, P155, DOI 10.2165/00003088-199834020-00003; MOUNIE J, 1988, FUND CLIN PHARMACOL, V2, P259, DOI 10.1111/j.1472-8206.1988.tb00637.x; Natarajan R, 2001, ARTERIOSCL THROM VAS, V21, P1408, DOI 10.1161/hq0901.095278; Owens IS, 1996, J PHARMACOKINET BIOP, V24, P491, DOI 10.1007/BF02353476; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; Patricia MK, 1999, ARTERIOSCL THROM VAS, V19, P2615, DOI 10.1161/01.ATV.19.11.2615; Pless D, 1999, DRUG METAB DISPOS, V27, P588; Prueksaritanont T, 2002, J PHARMACOL EXP THER, V301, P1042, DOI 10.1124/jpet.301.3.1042; Prueksaritanont T, 2002, DRUG METAB DISPOS, V30, P1280, DOI 10.1124/dmd.30.11.1280; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Ritter JK, 2000, CHEM-BIOL INTERACT, V129, P171, DOI 10.1016/S0009-2797(00)00198-8; Rubin GL, 2002, ENDOCRINOLOGY, V143, P2863, DOI 10.1210/en.143.8.2863; Rubin GL, 2000, CANCER RES, V60, P1604; Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Smas CM, 1997, CRIT REV EUKAR GENE, V7, P281, DOI 10.1615/CritRevEukarGeneExpr.v7.i4.10; Strassburg CP, 1999, GASTROENTEROLOGY, V116, P149, DOI 10.1016/S0016-5085(99)70239-8; Strassburg CP, 1998, J BIOL CHEM, V273, P8719, DOI 10.1074/jbc.273.15.8719; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Torra IP, 2002, MOL ENDOCRINOL, V16, P1013; Torra IP, 2001, CURR OPIN LIPIDOL, V12, P245, DOI 10.1097/00041433-200106000-00002; Viita H, 1999, ANTIOXID REDOX SIGN, V1, P83, DOI 10.1089/ars.1999.1.1-83; Viollon-Abadie C, 2000, TOXICOL IN VITRO, V14, P505, DOI 10.1016/S0887-2333(00)00044-8; Watanabe Y, 2002, DRUG METAB DISPOS, V30, P1462, DOI 10.1124/dmd.30.12.1462; Wheelan P, 1999, J PHARMACOL EXP THER, V288, P326; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Yoshigae Yasushi, 2000, Journal of Toxicological Sciences, V25, P433; Zhu BT, 1998, CARCINOGENESIS, V19, P1, DOI 10.1093/carcin/19.1.1	66	105	109	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13975	13983		10.1074/jbc.M300749200	http://dx.doi.org/10.1074/jbc.M300749200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582161	hybrid			2022-12-27	WOS:000182405000054
J	Henrikson, CA; Xue, T; Dong, PH; Sang, DP; Marban, E; Li, RA				Henrikson, CA; Xue, T; Dong, PH; Sang, DP; Marban, E; Li, RA			Identification of a surface charged residue in the S3-S4 linker of the pacemaker (HCN) channel that influences activation gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; VOLTAGE-SENSING RESIDUES; CALF PURKINJE-FIBERS; PACE-MAKER CURRENT; POTASSIUM CHANNEL; ELECTROSTATIC INTERACTIONS; TRANSMEMBRANE SEGMENTS; ION CHANNELS; S4 REGION; SENSOR	it, encoded by the hyperpolarization-activated cyclic nucleotide-modulated (HCN) channel family, is a key player in cardiac and neuronal pacing. Although HCN channels structurally resemble voltage-gated K+ (Kv) channels, their structure-function correlation is much less clear. Here we probed the functional importance of the HCN1 S3-S4 linker by multiple substitutions of its residues. Neutralizing Glu(235), an acidic S3-S4 linker residue conserved in all hyperpolarization-activated channels, by Ala substitution produced a depolarizing activation shift (V-1/2 = -65.0 +/- 0.7 versus -70.6 +/- 0.7 mV for wild-type HCN1); the charge-reversed mutation E235R shifted activation even more positively (-56.2 +/- 0.5 mV). Increasing external Me, mimicked the progressive rightward shifts of E235A and E235R by gradually shifting activation (V-1/2 = 1 < 3 < 10 < 30 mM); DeltaV(1/2) induced by 30 mM me, was significantly attenuated for E235A (+7.9 +/- 1.2 versus +11.3 +/- 0.9 mV for wild-type HCN1) and E235R (+3.3 +/- 1.4 mV) channels, as if surface charges were already shielded. Consistent with an electrostatic role, the energetic changes associated with DeltaV(1/2) resulting from various Glu(235) substitutions (ie. Asp, Ala, Pro, His, Lys, and Arg) displayed a strong correlation with their charges (DeltaDeltaG = -2.1 +/- 0.3 kcal/mol/charge; r = 0.94). In contrast, D233E, D233A, D233G, and D233R did not alter activation gating. D233C (in C318S background) was also not externally accessible when probed with methanethiosulfonate ethylammonium (MTSEA). We conclude that the S3-S4 linker residue Glu(235) influences activation gating, probably by acting as a surface charge.	Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA	Johns Hopkins University	Li, RA (corresponding author), Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, 720 Rutland Ave,Ross 844, Baltimore, MD 21205 USA.		Marban, Eduardo/GWC-8514-2022; Li, Ronald/E-9833-2010; Xue, Tian/G-9009-2018		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007227, R01HL052768] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07227-26, R01 HL52768] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Azene EM, 2003, J PHYSIOL-LONDON, V547, P349, DOI 10.1113/jphysiol.2003.039768; BROWN HF, 1977, J PHYSIOL-LONDON, V271, P783, DOI 10.1113/jphysiol.1977.sp012026; Cha A, 1997, NEURON, V19, P1127, DOI 10.1016/S0896-6273(00)80403-1; Chen J, 2000, J BIOL CHEM, V275, P36465, DOI 10.1074/jbc.M007034200; Chen J, 2001, P NATL ACAD SCI USA, V98, P11277, DOI 10.1073/pnas.201250598; Chen SG, 2000, FACT RES INTERV GER, V1-2, P491; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P377, DOI 10.1113/jphysiol.1981.sp013714; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P359, DOI 10.1113/jphysiol.1981.sp013713; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Elinder F, 2001, J GEN PHYSIOL, V118, P1, DOI 10.1085/jgp.118.1.1; Gandhi CS, 2000, NEURON, V27, P585, DOI 10.1016/S0896-6273(00)00068-4; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Gonzalez C, 2000, J GEN PHYSIOL, V115, P193, DOI 10.1085/jgp.115.2.193; Gonzalez C, 2001, P NATL ACAD SCI USA, V98, P9617, DOI 10.1073/pnas.171306298; Henrikson CA, 2002, CIRCULATION, V106, P226; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Li-Smerin Y, 2001, J GEN PHYSIOL, V117, P205, DOI 10.1085/jgp.117.3.205; LIMAN ER, 1991, NATURE, V353, P752, DOI 10.1038/353752a0; LOGOTHETIS DE, 1993, NEURON, V10, P1121, DOI 10.1016/0896-6273(93)90060-5; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Mannikko R, 2002, NATURE, V419, P837, DOI 10.1038/nature01038; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; Mathur R, 1997, J GEN PHYSIOL, V109, P191, DOI 10.1085/jgp.109.2.191; NAKAI J, 1994, P NATL ACAD SCI USA, V91, P1014, DOI 10.1073/pnas.91.3.1014; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Sorensen JB, 2000, J GEN PHYSIOL, V115, P209, DOI 10.1085/jgp.115.2.209; TiwariWoodruff SK, 1997, BIOPHYS J, V72, P1489, DOI 10.1016/S0006-3495(97)78797-6; Vaca L, 2000, FEBS LETT, V479, P35, DOI 10.1016/S0014-5793(00)01837-8; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; Xue T, 2002, CIRC RES, V90, P1267, DOI 10.1161/01.RES.0000024390.97889.C6; Xue T, 2002, J BIOL CHEM, V277, P46233, DOI 10.1074/jbc.M204915200; YANAGIHARA K, 1980, PFLUG ARCH EUR J PHY, V388, P255, DOI 10.1007/BF00658491	42	30	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13647	13654		10.1074/jbc.M211025200	http://dx.doi.org/10.1074/jbc.M211025200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582169	hybrid			2022-12-27	WOS:000182405000013
J	Tabernero, L; Rodwell, VW; Stauffacher, CV				Tabernero, L; Rodwell, VW; Stauffacher, CV			Crystal structure of a statin bound to a class II hydroxymethylglutaryl-CoA reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; ISOPENTENYL DIPHOSPHATE BIOSYNTHESIS; PSEUDOMONAS-MEVALONII; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; CATALYSIS; CLONING; PROTEIN; PURIFICATION; ESSENTIALITY; EXPRESSION	Hydroxymethylglutaryl-CoA (HMG-CoA) reductase is the primary target in the current clinical treatment of hypercholesterolemias with specific inhibitors of the "statin" family. Statins are excellent inhibitors of the class I (human) enzyme but relatively poor inhibitors of the class II enzymes of important bacterial pathogens. To investigate the molecular basis for this difference we determined the x-ray structure of the class II Pseudomonas mevalonii HMG-CoA reductase in complex with the statin drug lovastatin. The structure shows lovastatin bound in the active site and its interactions with residues critically involved in catalysis and substrate binding. Binding of lovastatin also displaces the flap domain of the enzyme, which contains the catalytic residue His-381. Comparison with the structures of statins bound to the human enzyme revealed a similar mode of binding but marked differences in specific interactions that account for the observed differences in affinity. We suggest that these differences might be exploited to develop selective class II inhibitors for use as antibacterial agents against pathogenic microorganisms.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	University of Manchester; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Tabernero, L (corresponding author), Univ Manchester, Sch Biol Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.		Tabernero, Lydia/F-3795-2018	Tabernero, Lydia/0000-0001-8867-455X	NHLBI NIH HHS [HL 52115] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052115] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; Bischoff KM, 1996, J BACTERIOL, V178, P19, DOI 10.1128/jb.178.1.19-23.1996; Bochar DA, 1999, BIOCHEMISTRY-US, V38, P8879, DOI 10.1021/bi9902687; Bochar DA, 1999, MOL GENET METAB, V66, P122, DOI 10.1006/mgme.1998.2786; BRUNGER AT, 1992, XPLOR MANUAL VERSION; CORSINI A, 1995, PHARMACOL RES, V31, P9, DOI 10.1016/1043-6618(95)80042-5; Dairi T, 2000, MOL GEN GENET, V262, P957, DOI 10.1007/PL00008664; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FRIMPONG K, 1994, J BIOL CHEM, V269, P11478; Hedl M, 2002, J BACTERIOL, V184, P2116, DOI 10.1128/JB.184.8.2116-2122.2002; Istvan ES, 2000, EMBO J, V19, P819, DOI 10.1093/emboj/19.5.819; Istvan ES, 2001, CURR OPIN STRUC BIOL, V11, P746, DOI 10.1016/S0959-440X(01)00276-7; Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344; JORDANSTARCK TC, 1989, J BIOL CHEM, V264, P17913; Kim DY, 2000, PROTEIN SCI, V9, P1226, DOI 10.1110/ps.9.6.1226; Kuzuyama T, 2000, J BACTERIOL, V182, P891, DOI 10.1128/JB.182.4.891-897.2000; LAWRENCE CM, 1995, SCIENCE, V268, P1758, DOI 10.1126/science.7792601; LAWRENCE CM, 1995, ACTA CRYSTALLOGR D, V51, P386, DOI 10.1107/S0907444994009819; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAT; POPJAK G, 1979, J LIPID RES, V20, P716; Rodwell VW, 2000, METHOD ENZYMOL, V324, P259; Rohmer M., 1999, COMPR NAT PROD CHEM, V2, P45, DOI 10.1016/B978-0-08-091283-7.00036-9; SUDI J, 1976, BIOCHEM J, V153, P491, DOI 10.1042/bj1530491; Tabernero L, 1999, P NATL ACAD SCI USA, V96, P7167, DOI 10.1073/pnas.96.13.7167; Takahashi S, 1999, J BACTERIOL, V181, P1256, DOI 10.1128/JB.181.4.1256-1263.1999; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wilding EI, 2000, J BACTERIOL, V182, P4319, DOI 10.1128/JB.182.15.4319-4327.2000; Wilding EI, 2000, J BACTERIOL, V182, P5147, DOI 10.1128/JB.182.18.5147-5152.2000	29	39	43	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19933	19938		10.1074/jbc.M213006200	http://dx.doi.org/10.1074/jbc.M213006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12621048	hybrid			2022-12-27	WOS:000183078000048
J	Park, E; Na, M; Choi, JH; Kim, S; Lee, JR; Yoon, JY; Park, D; Sheng, M; Kim, E				Park, E; Na, M; Choi, JH; Kim, S; Lee, JR; Yoon, JY; Park, D; Sheng, M; Kim, E			The Shank family of postsynaptic density proteins interacts with and promotes synaptic accumulation of the beta PIX guanine nucleotide exchange factor for Rac1 and Cdc42	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENDRITIC SPINE MORPHOLOGY; PDZ-DOMAIN; SCAFFOLDING PROTEINS; BINDING-PROTEIN; SMALL GTPASES; RAT-BRAIN; RECEPTOR; RHO; ACTIN; LOCALIZATION	The Shank/ProSAP family of multidomain proteins is known to play an important role in organizing synaptic multiprotein complexes. Here we report a novel interaction between Shank and betaPIX, a guanine nucleotide exchange factor for the Rac1 and Cdc42 small GTPases. This interaction is mediated by the PDZ domain of Shank and the C-terminal leucine zipper domain and the PDZ domain-binding motif at the extreme C terminus of betaPIX. Shank colocalizes with betaPIX at excitatory synaptic sites in cultured neurons. In brain, Shank forms a complex with betaPIX and betaPIX-associated signaling molecules including p21-associated kinase (PAK), an effector kinase of Rac1/Cdc42. Importantly, overexpression of Shank in cultured neurons promotes synaptic accumulation of betaPIX and PAK. Considering the involvement of Rac1 and PAK in spine dynamics, these results suggest that Shank recruits betaPIX and PAK to spines for the regulation of postsynaptic structure.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, RIKEN MIT Neurosci Res Ctr, Picower Ctr Learning & Memory, Cambridge, MA 02139 USA	Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); RIKEN	Kim, E (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	kime@mail.kaist.ac.kr	Kim, Eunjoon/C-1566-2011	Sheng, Morgan/0000-0002-8703-5366				Allison DW, 1998, J NEUROSCI, V18, P2423; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Banker G., 1991, CULTURING NERVE CELL; Bockers TM, 2001, J BIOL CHEM, V276, P40104, DOI 10.1074/jbc.M102454200; Bockmann J, 2002, J NEUROCHEM, V83, P1013, DOI 10.1046/j.1471-4159.2002.01204.x; Boeckers TM, 1999, J NEUROSCI, V19, P6506; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Du YR, 1998, MOL CELL BIOL, V18, P5838, DOI 10.1128/MCB.18.10.5838; Ehlers MD, 2002, TRENDS NEUROSCI, V25, P64, DOI 10.1016/S0166-2236(02)02061-1; Feng W, 2002, J BIOL CHEM, V277, P41140, DOI 10.1074/jbc.M207206200; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Im YJ, 2003, J BIOL CHEM, V278, P8501, DOI 10.1074/jbc.M212263200; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kim CH, 1999, J NEUROSCI, V19, P4314; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim S, 2000, BIOCHEM BIOPH RES CO, V272, P721, DOI 10.1006/bbrc.2000.2845; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Ko J, 2003, J NEUROSCI, V23, P1667; Koh CG, 2001, J CELL SCI, V114, P4239; Kreienkamp HJ, 2000, J BIOL CHEM, V275, P32387, DOI 10.1074/jbc.C000490200; Krucker T, 2000, P NATL ACAD SCI USA, V97, P6856, DOI 10.1073/pnas.100139797; Lim S, 2001, MOL CELL NEUROSCI, V17, P385, DOI 10.1006/mcne.2000.0940; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Matus A, 2000, SCIENCE, V290, P754, DOI 10.1126/science.290.5492.754; Mok H, 2002, J NEUROSCI, V22, P5253; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; Okamoto PM, 2001, J BIOL CHEM, V276, P48458, DOI 10.1074/jbc.M104927200; Park SH, 2002, ACTA CRYSTALLOGR D, V58, P1353, DOI 10.1107/S0907444902009162; Parnas D, 2001, NEURON, V32, P415, DOI 10.1016/S0896-6273(01)00485-8; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; Penzes P, 2001, J NEUROSCI, V21, P8426, DOI 10.1523/JNEUROSCI.21-21-08426.2001; Penzes P, 2000, J BIOL CHEM, V275, P6395, DOI 10.1074/jbc.275.9.6395; Penzes P, 2003, NEURON, V37, P263, DOI 10.1016/S0896-6273(02)01168-6; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sheng M, 2000, J CELL SCI, V113, P1851; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Soltau M, 2002, MOL CELL NEUROSCI, V21, P575, DOI 10.1006/mcne.2002.1201; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tashiro A, 2000, CEREB CORTEX, V10, P927, DOI 10.1093/cercor/10.10.927; Tobaben S, 2000, J BIOL CHEM, V275, P36204, DOI 10.1074/jbc.M006448200; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Werner LA, 1997, GENE, V187, P107, DOI 10.1016/S0378-1119(96)00732-9; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Yao I, 1999, J BIOL CHEM, V274, P27463, DOI 10.1074/jbc.274.39.27463; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8; Zitzer H, 1999, J BIOL CHEM, V274, P18153, DOI 10.1074/jbc.274.26.18153; Zitzer H, 1999, J BIOL CHEM, V274, P32997, DOI 10.1074/jbc.274.46.32997	62	125	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19220	19229		10.1074/jbc.M301052200	http://dx.doi.org/10.1074/jbc.M301052200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626503	hybrid			2022-12-27	WOS:000182932200066
J	Yahiro, K; Wada, A; Nakayama, M; Kimura, T; Ogushi, K; Niidome, T; Aoyagi, H; Yoshino, K; Yonezawa, K; Moss, J; Hirayama, T				Yahiro, K; Wada, A; Nakayama, M; Kimura, T; Ogushi, K; Niidome, T; Aoyagi, H; Yoshino, K; Yonezawa, K; Moss, J; Hirayama, T			Protein-tyrosine phosphatase alpha, RPTP alpha, is a Helicobacter pylori VacA receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLATING CYTOTOXIN; GASTRIC CELLS; TOXIN; BINDING; BETA; SENSITIVITY; INDUCTION; INFECTION; CLONING; DISEASE	Helicobacter pylori vacuolating cytotoxin, VacA, induces vacuolation, mitochondrial damage, cytochrome c release, and apoptosis of gastric epithelial cells. To detect gastric proteins that serve as VacA receptors, we used VacA co-immunoprecipitation techniques following biotinylation of the cell surface and identified p250, a receptor-like protein-tyrosine phosphatase beta (RPTPbeta) as a VacA-binding protein (Yahiro, K., Niidome, T., Kimura, M., Hatakeyama, T., Aoyagi, H., Kurazono, H., Imagawa, K., Wada, A., Moss, J., and Hirayama, T. (1999) J. Biol. Chem. 274, 36693-36699). VacA causes vacuolation of G401 cells, a human kidney tumor cell line, although they do not express RPTPbeta. By co-immunoprecipitation with VacA, we identified p140 as a potential receptor in those cells. p140 purified by chromatography on a peanut agglutinin affinity matrix contained internal amino acid sequences of RGEENTDYVNASFIDGYRQK and AEGILDVFQTVK, which are identical to those in RPTPalpha. The peptide mass fingerprinting of p140 by time of flight-MS analysis also supported this identification. Treatment of G401 cells with RPTPalpha-morpholino antisense oligonucleotide before exposure to toxin inhibited vacuolation. These data suggest that RPTPbeta acts as a receptor for VacA in G401 cells. Thus, two receptor tyrosine phosphatases, RPTPalpha and RPTPbeta, serve as VacA receptors.	Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan; Japan Sci & Technol Corp, PRESTO, Saitama, Japan; Nagasaki Univ, Fac Engn, Dept Appl Chem, Nagasaki 8528521, Japan; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Nagasaki University; Japan Science & Technology Agency (JST); Nagasaki University; Kobe University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Hirayama, T (corresponding author), Nagasaki Univ, Inst Trop Med, Dept Bacteriol, Nagasaki 8528523, Japan.	hirayama@net.nagasaki-u.ac.jp	Niidome, Takuro/F-1508-2010	Niidome, Takuro/0000-0002-8070-8708; Yahiro, Kinnosuke/0000-0002-9813-0780	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Czajkowsky DM, 1999, P NATL ACAD SCI USA, V96, P2001, DOI 10.1073/pnas.96.5.2001; Del Giudice G, 2001, ANNU REV IMMUNOL, V19, P523, DOI 10.1146/annurev.immunol.19.1.523; Eaton KA, 1997, INFECT IMMUN, V65, P3462, DOI 10.1128/IAI.65.8.3462-3464.1997; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Garner JA, 1996, INFECT IMMUN, V64, P4197, DOI 10.1128/IAI.64.10.4197-4203.1996; GHIRA P, 1995, INFECT IMMUN, V63, P4154, DOI 10.1128/IAI.63.10.4154-4160.1995; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; Kimura M, 1999, MICROB PATHOGENESIS, V26, P45, DOI 10.1006/mpat.1998.0241; Kuck D, 2001, INFECT IMMUN, V69, P5080, DOI 10.1128/IAI.69.8.5080-5087.2001; LEUNK RD, 1988, J MED MICROBIOL, V26, P93, DOI 10.1099/00222615-26-2-93; MANETTI R, 1995, INFECT IMMUN, V63, P4476, DOI 10.1128/IAI.63.11.4476-4480.1995; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; Massari P, 1998, INFECT IMMUN, V66, P3981, DOI 10.1128/IAI.66.8.3981-3984.1998; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Nakajima S, 1997, GASTROENTEROLOGY, V113, P746, DOI 10.1016/S0016-5085(97)70167-7; Padilla PI, 2000, J BIOL CHEM, V275, P15200, DOI 10.1074/jbc.275.20.15200; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peles E, 1998, TRENDS BIOCHEM SCI, V23, P121, DOI 10.1016/S0968-0004(98)01195-5; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; Ricci V, 2000, MOL BIOL CELL, V11, P3897, DOI 10.1091/mbc.11.11.3897; Ricci V, 1997, J PATHOL, V183, P453; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SOUTHERN JA, 1991, J GEN VIROL, V72, P1551, DOI 10.1099/0022-1317-72-7-1551; Supajatura V, 2002, J IMMUNOL, V168, P2603, DOI 10.4049/jimmunol.168.6.2603; Suzuki J, 2001, J CLIN INVEST, V107, P363, DOI 10.1172/JCI10254; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Yahiro K, 1997, BIOCHEM BIOPH RES CO, V238, P629, DOI 10.1006/bbrc.1997.7345; Yahiro K, 1999, J BIOL CHEM, V274, P36693, DOI 10.1074/jbc.274.51.36693	32	99	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19183	19189		10.1074/jbc.M300117200	http://dx.doi.org/10.1074/jbc.M300117200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626515	hybrid			2022-12-27	WOS:000182932200062
J	Rosenfeld, SS; Fordyce, PM; Jefferson, GM; King, PH; Block, SM				Rosenfeld, SS; Fordyce, PM; Jefferson, GM; King, PH; Block, SM			Stepping and stretching - How kinesin uses internal strain to walk processively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP HYDROLYSIS; KINETIC MECHANISM; LOADING DIRECTION; DIMERIC KINESIN; MOLECULAR MOTOR; FORCE CLAMP; MYOSIN-V; RELEASE; PATHWAY; MOTILITY	The ability of kinesin to travel long distances on its microtubule track without dissociating has led to a variety of models to explain how this remarkable degree of processivity is maintained. All of these require that the two motor domains remain enzymatically "out of phase," a behavior that would ensure that, at any given time, one motor is strongly attached to the microtubule. The maintenance of this coordination over many mechanochemical cycles has never been explained, because key steps in the cycle could not be directly observed. We have addressed this issue by applying several novel spectroscopic approaches to monitor motor dissociation, phosphate release, and nucleotide binding during processive movement by a dimeric kinesin construct. Our data argue that the major effect of the internal strain generated when both motor domains of kinesin bind the microtubule is to block ATP from binding to the leading motor. This effect guarantees the two motor domains remain out of phase for many mechanochemical cycles and provides an efficient and adaptable mechanism for the maintenance of processive movement.	Univ Alabama, Dept Neurol, MEB 510, Birmingham, AL 35294 USA; Dept Vet Affairs Med Ctr, Neurol Serv, Birmingham, AL 35294 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	University of Alabama System; University of Alabama Birmingham; Stanford University; Stanford University; Stanford University	Rosenfeld, SS (corresponding author), Univ Alabama, Dept Neurol, MEB 510, 1813 6th Ave S, Birmingham, AL 35294 USA.	stevensr@uab.edu	Fordyce, Polly/AAY-6365-2020	Fordyce, Polly/0000-0002-9505-0638; King, Peter/0000-0001-9391-7464	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051453] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051453] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Block SM, 2003, P NATL ACAD SCI USA, V100, P2351, DOI 10.1073/pnas.0436709100; Brendza KM, 2000, J BIOL CHEM, V275, P22187, DOI 10.1074/jbc.M001124200; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Crevel I, 1999, EMBO J, V18, P5863, DOI 10.1093/emboj/18.21.5863; Cross RA, 2000, PHILOS T ROY SOC B, V355, P459, DOI 10.1098/rstb.2000.0587; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; Derenyi I, 1996, P NATL ACAD SCI USA, V93, P6775, DOI 10.1073/pnas.93.13.6775; Farrell CM, 2002, J BIOL CHEM, V277, P17079, DOI 10.1074/jbc.M108793200; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hackney DD, 2002, BIOCHEMISTRY-US, V41, P4437, DOI 10.1021/bi0159229; Hancock WO, 1999, P NATL ACAD SCI USA, V96, P13147, DOI 10.1073/pnas.96.23.13147; Hua W, 2002, SCIENCE, V295, P844, DOI 10.1126/science.1063089; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; Kawaguchi K, 2001, SCIENCE, V291, P667, DOI 10.1126/science.291.5504.667; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Rosenfeld SS, 2002, J BIOL CHEM, V277, P36731, DOI 10.1074/jbc.M205261200; Rosenfeld SS, 2001, J BIOL CHEM, V276, P40167, DOI 10.1074/jbc.M103899200; Schief WR, 2001, CURR OPIN CELL BIOL, V13, P19, DOI 10.1016/S0955-0674(00)00169-1; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Uemura S, 2003, NAT STRUCT BIOL, V10, P308, DOI 10.1038/nsb911; Uemura S, 2002, P NATL ACAD SCI USA, V99, P5977, DOI 10.1073/pnas.092546199; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200; Young EC, 1998, BIOCHEMISTRY-US, V37, P3467, DOI 10.1021/bi972172n	38	149	153	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18550	18556		10.1074/jbc.M300849200	http://dx.doi.org/10.1074/jbc.M300849200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626516	Green Accepted, hybrid			2022-12-27	WOS:000182838300126
J	Nogami, K; Wakabayashi, H; Fay, PJ				Nogami, K; Wakabayashi, H; Fay, PJ			Mechanisms of factor Xa-catalyzed cleavage of the factor VIIIa A1 subunit resulting in cofactor inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; A2 SUBUNIT; PROCOAGULANT ACTIVITY; A1/A3-C1-C2 DIMER; INTERACTIVE SITE; HEAVY-CHAIN; FACTOR-IXA; FACTOR VA; BINDING; IDENTIFICATION	Activation of factor VIII by factor Xa is followed by proteolytic inactivation resulting from cleavage within the A1 subunit (residues 1-372) of factor VIIIa. Factor Xa attacks two sites in A1, Arg(336), which precedes the highly acidic C-terminal region, and a recently identified site at Lys(36). By using isolated A1 subunit as substrate for proteolysis, production of the terminal fragment, A1(37-336), was shown to proceed via two pathways identified by the intermediates A1(1-336) and A1(37-372) and generated by initial cleavage at Arg(336) and Lys(36), respectively. Appearance of the terminal product by the former pathway was 7-8-fold slower than the product obtained by the latter pathway. The isolated A1 subunit was cleaved slowly, independent of the presence of phospholipid. The A1/A3-C1-C2 dimer demonstrated an similar to3-fold increased cleavage rate constant, and inclusion of phospholipid further enhanced this value by similar to2-fold. Although association of A1 or A1(37-372) with A3-C1-C2 enhanced the rate of cleavage at Arg(336), inclusion of A3-C1-C2 did not affect the cleavage at Lys(36) in A1(1-336). A synthetic peptide 337-372 blocked the cleavage at Lys(36) (IC50=230 muM) while showing little if any effect on cleavage at Arg(336). Proteolysis at Lys(36), and to a lesser extent Arg(336), was inhibited in a dose-dependent manner by heparin. These results suggest that inactivating cleavages catalyzed by factor Xa at Lys(36) and Arg(336) are regulated in part by the A3-C1-C2 subunit. Furthermore, cleavage at Lys36 appears to be selectively modulated by the C-terminal acidic region of A1, a region that may interact with factor Xa via its heparin-binding exosite.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Biochem & Biophys, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.	Philip_Fay@urmc.rochester.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616, R01HL038199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38199, HL 30616] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1993, J BIOL CHEM, V268, P17861; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; Fay PJ, 2001, J BIOL CHEM, V276, P12434, DOI 10.1074/jbc.M009539200; Fay PJ, 1999, J BIOL CHEM, V274, P15401, DOI 10.1074/jbc.274.22.15401; FOSTER PA, 1988, J CLIN INVEST, V82, P123, DOI 10.1172/JCI113559; Kalafatis M, 2002, BIOCHEMISTRY-US, V41, P12715, DOI 10.1021/bi026208+; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lapan KA, 1998, THROMB HAEMOSTASIS, V80, P418, DOI 10.1055/s-0037-1615223; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; MANN KG, 1990, BLOOD, V76, P1; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Nogami K, 2003, J BIOL CHEM, V278, P1634, DOI 10.1074/jbc.M209811200; Nogami K, 1999, J BIOL CHEM, V274, P31000, DOI 10.1074/jbc.274.43.31000; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; Parker ET, 1997, BIOCHEMISTRY-US, V36, P9365, DOI 10.1021/bi970599o; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Regan LM, 1996, J BIOL CHEM, V271, P3982; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; Rosenblum MEK, 2002, J BIOL CHEM, V277, P11664, DOI 10.1074/jbc.M200037200; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0	36	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16502	16509		10.1074/jbc.M213044200	http://dx.doi.org/10.1074/jbc.M213044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606556	hybrid			2022-12-27	WOS:000182818600010
J	Pestryakov, PE; Weisshart, K; Schlott, B; Khodyreva, SN; Kremmer, E; Grosse, F; Lavrik, OI; Nasheuer, HP				Pestryakov, PE; Weisshart, K; Schlott, B; Khodyreva, SN; Kremmer, E; Grosse, F; Lavrik, OI; Nasheuer, HP			Human replication protein A - The C-terminal RPA70 and the central RPA32 domains are involved in the interactions with the 3 '-end of a primer-template DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; BINDING DOMAIN; SUBUNIT; PURIFICATION; MECHANISM; POLARITY	Although the mechanical aspects of the single-stranded DNA (ssDNA) binding activity of human replication protein A (RPA) have been extensively studied, only limited information is available about its interaction with other physiologically relevant DNA structures. RPA interacts with partial DNA duplexes that resemble DNA intermediates found in the processes of DNA replication and DNA repair. Limited proteolysis of RPA showed that RPA associated with ssDNA is less protected against proteases than RPA bound to a partial duplex DNA containing a 5'-protruding tail that had the same length as the ssDNA. Modification of both the 70- and 32-kDa subunits, RPA70 and RPA32, respectively, by photoaffinity labeling indicates that RPA can bind the primer-template junction of partial duplex DNAs by interacting with the 3'-end of the primer. The identification of the protein domains modified by the photoreactive 3'-end of the primer showed that domains located in the central part of the RPA32 subunit (amino acids 39 180) and the C-terminal part of the RPA70 subunit (amino acids 432-616) are involved in these interactions.	Inst Mol Biotechnol, Biochem Abt, D-07745 Jena, Germany; Russian Acad Sci, Siberian Div, Novosibirsk Bioorgan Chem Inst, Novosibirsk 630090, Russia; GSF Munich, Inst Mol Immunol, D-81377 Munich, Germany; Natl Univ Ireland Univ Coll Galway, Dept Biochem, Cell Cycle Control Lab, Galway, Ireland	Institute of Chemical Biology & Fundamental Medicine, Siberian Branch of the RAS; Russian Academy of Sciences; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Ollscoil na Gaillimhe-University of Galway	Nasheuer, HP (corresponding author), Natl Univ Ireland Univ Coll Galway, Dept Biochem, Cell Cycle Control Lab, Galway, Ireland.	h.nasheuer@nuigalway.ie	Khodyreva, Svetlana N/G-4659-2013; Nasheuer, Heinz P./B-9025-2008; Lavrik, Olga I/G-4641-2013; Pestryakov, Pavel/AAH-2022-2020	Pestryakov, Pavel/0000-0003-3277-5321; Nasheuer, Heinz Peter/0000-0002-9218-9079				Bastin-Shanower SA, 2001, J BIOL CHEM, V276, P36446, DOI 10.1074/jbc.M104386200; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Blackwell LJ, 1996, MOL CELL BIOL, V16, P4798; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 2001, EMBO J, V20, P612, DOI 10.1093/emboj/20.3.612; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Bochkareva E, 1998, J BIOL CHEM, V273, P3932, DOI 10.1074/jbc.273.7.3932; Brill SJ, 1998, MOL CELL BIOL, V18, P7225, DOI 10.1128/MCB.18.12.7225; CARTY MP, 1992, MUTAT RES, V274, P29, DOI 10.1016/0921-8777(92)90041-Z; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P5586, DOI 10.1021/bi9526995; Harlow E., 1988, ANTIBODIES LAB MANUA; Hennig L, 1999, BIOTECHNIQUES, V26, P1170, DOI 10.2144/99266bc02; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; KENNY MK, 1990, J BIOL CHEM, V265, P769; KIM C, 1995, BIOCHEMISTRY-US, V34, P2058, DOI 10.1021/bi00006a028; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; Kolpashchikov DM, 2001, NUCLEIC ACIDS RES, V29, P373, DOI 10.1093/nar/29.2.373; Kolpashchikov DM, 1999, FEBS LETT, V450, P131, DOI 10.1016/S0014-5793(99)00484-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lao Y, 1999, BIOCHEMISTRY-US, V38, P3974, DOI 10.1021/bi982371m; Lavrik OI, 1998, FEBS LETT, V441, P186, DOI 10.1016/S0014-5793(98)01544-0; Lavrik OI, 1999, NUCLEIC ACIDS RES, V27, P4235, DOI 10.1093/nar/27.21.4235; Maga G, 2001, J BIOL CHEM, V276, P18235, DOI 10.1074/jbc.M009599200; Mass G, 1998, MOL CELL BIOL, V18, P6399, DOI 10.1128/MCB.18.11.6399; Mass G, 2001, NUCLEIC ACIDS RES, V29, P3892, DOI 10.1093/nar/29.18.3892; NASHEUER HP, 1992, CHROMOSOMA, V102, pS52, DOI 10.1007/BF02451786; Nasheuer HP, 2002, PROG NUCLEIC ACID RE, V72, P41, DOI 10.1016/S0079-6603(02)72067-9; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; Patrick SM, 2001, J BIOL CHEM, V276, P22630, DOI 10.1074/jbc.M010314200; SWAIN M, 1995, ELECTROPHORESIS, V16, P948, DOI 10.1002/elps.11501601159; Walther AP, 1999, BIOCHEMISTRY-US, V38, P3963, DOI 10.1021/bi982370u; WLASSOFF WA, 1995, BIOCONJUGATE CHEM, V6, P352, DOI 10.1021/bc00034a003; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wong JMS, 2003, ONCOGENE, V22, P28, DOI 10.1038/sj.onc.1206071	39	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17515	17524		10.1074/jbc.M301265200	http://dx.doi.org/10.1074/jbc.M301265200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600993	hybrid			2022-12-27	WOS:000182818600140
J	Rick, PD; Barr, K; Sankaran, K; Kajimura, J; Rush, JS; Waechter, CJ				Rick, PD; Barr, K; Sankaran, K; Kajimura, J; Rush, JS; Waechter, CJ			Evidence that the wzxE gene of Escherichia coli K-12 encodes a protein involved in the transbilayer movement of a trisaccharide-lipid intermediate in the assembly of enterobacterial common antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID TRANSMEMBRANE MOVEMENT; WATER-SOLUBLE ANALOG; IN-VITRO SYNTHESIS; GLC-P-DOLICHOL; O-ANTIGEN; ENDOPLASMIC-RETICULUM; RFE-GENE; MEMBRANE-VESICLES; CHAIN GROWTH; PIG BRAIN	The assembly of many bacterial cell surface polysaccharides requires the transbilayer movement of polyisoprenoid-linked saccharide intermediates across the cytoplasmic membrane. It is generally believed that transverse diffusion of glycolipid intermediates is mediated by integral membrane proteins called translocases or "flippases." The bacterial genes proposed to encode these translocases have been collectively designated wzx genes. The wzxE gene of Escherichia coli K-12 has been implicated in the transbilayer movement of Fuc4NAc-ManNAcA-GlcNAc-P-P-undecaprenol (lipid III), the donor of the trisaccharide repeat unit in the biosynthesis of enterobacterial common antigen (ECA). Previous studies (Feldman, M.F., Marolda, C.L., Monteiro, M. A., Perry, M.B., Parodi, A.J., and Valvano, M. (1999) J. Biol. Chem. 274, 35129-35138) provided indirect evidence that the wzx(016) gene product of E. coli K-12 encoded a translocase capable of mediating the transbilayer movement of N-acetylglucosaminylpyrophosphorylundecaprenol (GlcNAc-P-P-Und), an early intermediate in the synthesis of ECA and many lipopolysaccharide O antigens. Therefore, genetic and biochemical studies were conducted to determine if the putative Wzx(O16) translocase was capable of mediating the transport of N-acetylglucosaminylpyrophosphorylnerol (GlcNAc-P-P-Ner), a water-soluble analogue of GlcNAc-P-P-Und. [H-3] GlcNAc-P-P-Ner was transported into sealed, everted cytoplasmic membrane vesicles of E. coli K-12 as well as a deletion mutant lacking both the wzx016 and wzxC genes. In contrast, [H-3] GlcNAc-P-P-Ner was not transported into membrane vesicles prepared from a wzxE-null mutant, and metabolic radiolabeling experiments revealed the accumulation of lipid III in this mutant. The WzxE transport system exhibited substrate specificity by recognizing both a pyrophosphoryl-linked saccharide and an unsaturated alpha-isoprene unit in the carrier lipid. These results support the conclusion that the wzxE gene encodes a membrane protein involved in the transbilayer movement of lipid III in E. coli.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA; Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	Uniformed Services University of the Health Sciences - USA; University of Kentucky	Rick, PD (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	rickp@usuhs.mil			NIGMS NIH HHS [GM52882, GM36365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ALEXANDER DC, 1994, J BACTERIOL, V176, P7079, DOI 10.1128/JB.176.22.7079-7084.1994; AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; Anand M, 2001, MOL BIOL CELL, V12, P487, DOI 10.1091/mbc.12.2.487; BARR K, 1989, J BACTERIOL, V171, P1326, DOI 10.1128/jb.171.3.1326-1332.1989; BARR K, 1987, J BIOL CHEM, V262, P7142; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRAY D, 1967, BIOCHEM BIOPH RES CO, V28, P334, DOI 10.1016/0006-291X(67)90314-2; DANILOV LL, 1989, CHEM PHYS LIPIDS, V51, P191, DOI 10.1016/0009-3084(89)90006-6; DANILOV LL, 1981, FEBS LETT, V131, P310, DOI 10.1016/0014-5793(81)80392-4; DITTMER JC, 1964, J LIPID RES, V5, P126; DUNPHY PJ, 1967, BIOCHIM BIOPHYS ACTA, V136, P136, DOI 10.1016/0304-4165(67)90329-7; Feldman MF, 1999, J BIOL CHEM, V274, P35129, DOI 10.1074/jbc.274.49.35129; FUTAI M, 1974, J MEMBRANE BIOL, V15, P15, DOI 10.1007/BF01870079; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANOVER JA, 1979, J BIOL CHEM, V254, P9237; Helenius J, 2002, NATURE, V415, P447, DOI 10.1038/415447a; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hrafnsdottir S, 1997, BIOCHEMISTRY-US, V36, P4969, DOI 10.1021/bi962513h; Huijbregts RPH, 1996, BBA-BIOMEMBRANES, V1280, P41, DOI 10.1016/0005-2736(95)00272-3; Keenleyside WJ, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P331; Kol MA, 2002, SEMIN CELL DEV BIOL, V13, P163, DOI 10.1016/S1084-9521(02)00044-7; Kubelt J, 2002, BIOCHEMISTRY-US, V41, P5605, DOI 10.1021/bi0118714; KUHN HM, 1983, INFECT IMMUN, V40, P696, DOI 10.1128/IAI.40.2.696-700.1983; Lannert H, 1998, J BIOL CHEM, V273, P2939, DOI 10.1074/jbc.273.5.2939; LENNARZ WJ, 1987, BIOCHEMISTRY-US, V26, P7205, DOI 10.1021/bi00397a001; Liu D, 1996, J BACTERIOL, V178, P2102, DOI 10.1128/jb.178.7.2102-2107.1996; LUGOWSKI C, 1983, CARBOHYD RES, V118, P173, DOI 10.1016/0008-6215(83)88045-8; MACPHERSON DF, 1995, GENE, V155, P9, DOI 10.1016/0378-1119(94)00918-I; MCCLOSKEY MA, 1980, BIOCHEMISTRY-US, V19, P2061, DOI 10.1021/bi00551a009; MCGRATH BC, 1991, J BACTERIOL, V173, P649, DOI 10.1128/jb.173.2.649-654.1991; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MEIERDIETER U, 1992, J BIOL CHEM, V267, P746; MENON A, 1995, TRENDS CELL BIOL, V5, P355, DOI 10.1016/S0962-8924(00)89069-8; Menon AK, 2000, CURR BIOL, V10, P241, DOI 10.1016/S0960-9822(00)00356-0; Menon AK, 2002, SEMIN CELL DEV BIOL, V13, P159, DOI 10.1016/S1084-9521(02)00043-5; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NEUHARD J, 1976, J BACTERIOL, V126, P999, DOI 10.1128/JB.126.2.999-1001.1976; PERLIN DS, 1986, ARCH BIOCHEM BIOPHYS, V248, P53, DOI 10.1016/0003-9861(86)90400-5; REENSTRA WW, 1980, BIOCHEMISTRY-US, V19, P1, DOI 10.1021/bi00542a001; REEVES PR, 1994, NEW COMPR BIOCH, V27, P281; Rick P, 1996, ESCHERICHIA COLI SAL, P104; Rick PD, 1998, GLYCOBIOLOGY, V8, P557, DOI 10.1093/glycob/8.6.557; RICK PD, 1994, J BACTERIOL, V176, P2877, DOI 10.1128/JB.176.10.2877-2884.1994; RICK PD, 1985, J BACTERIOL, V162, P494, DOI 10.1128/JB.162.2.494-503.1985; ROBBINS PW, 1967, SCIENCE, V158, P1536, DOI 10.1126/science.158.3808.1536; ROTHFIELD L, 1964, J BIOL CHEM, V239, P2788; ROTHMAN JE, 1977, P NATL ACAD SCI USA, V74, P1821, DOI 10.1073/pnas.74.5.1821; RUSH JS, 1993, J BIOL CHEM, V268, P13110; RUSH JS, 1995, J CELL BIOL, V130, P529, DOI 10.1083/jcb.130.3.529; Rush JS, 1997, GLYCOBIOLOGY, V7, P315, DOI 10.1093/glycob/7.2.315; Rush JS, 1998, GLYCOBIOLOGY, V8, P1207, DOI 10.1093/glycob/8.12.1207; Rush JS, 1998, GLYCOBIOLOGY, V8, P1195, DOI 10.1093/glycob/8.12.1195; Schenk B, 2001, GLYCOBIOLOGY, V11, p61R, DOI 10.1093/glycob/11.5.61R; SILHAVY TJ, 1984, EXPT GENE FUSIONS, P104; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; YAMAGUCHI A, 1991, FEBS LETT, V282, P415, DOI 10.1016/0014-5793(91)80527-A; YAO ZJ, 1994, J BACTERIOL, V176, P4133, DOI 10.1128/JB.176.13.4133-4143.1994; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; ZACHOWSKI A, 1990, EXPERIENTIA, V46, P644, DOI 10.1007/BF01939703; ZHU XY, 1992, J BIOL CHEM, V267, P8895	67	87	92	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16534	16542		10.1074/jbc.M301750200	http://dx.doi.org/10.1074/jbc.M301750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621029	hybrid			2022-12-27	WOS:000182818600014
J	Rudrabhatla, P; Rajasekharan, R				Rudrabhatla, P; Rajasekharan, R			Mutational analysis of stress-responsive peanut dual specificity protein kinase - Identification of tyrosine residues involved in regulation of protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION SITES; MAP KINASE; SCHIZOSACCHAROMYCES-POMBE; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; C-THETA; ACTIVATION; DOMAIN; AUTOPHOSPHORYLATION; PP60C-SRC	We recently reported that Arachis hypogaea serine/threonine/tyrosine (STY) protein kinase is developmentally regulated and is induced by abiotic stresses (Rudrabhatla, P., and Rajasekharan, R. (2002) Plant Physiol. 130, 380-390). Other than MAPKs, the site of tyrosine phosphorylation has not been documented for any plant kinases. To study the role of tyrosines in the phosphorylation of STY protein kinase, four conserved tyrosine residues were sequentially substituted with phenylalanine and expressed as histidine fusion proteins. Mass spectrometry experiments showed that STY protein kinase autophosphorylated within the predicted kinase ATP-binding motif, activation loop, and an additional site in the C terminus. The protein kinase activity was abolished by substitution of Tyr(297) with Phe in the activation loop between subdomains VII and VIII. In addition, replacing Tyr(148) in the ATP-binding motif and Tyr(317) in the C-terminal domain with Phe not only obliterated the ability of the STY protein kinase protein to be phosphorylated, but also inhibited histone phosphorylation, suggesting that STY protein kinase is phosphorylated at multiple sites. Replacing Tyr(213) in the Thr-Glu-Tyr sequence motif with Phe resulted in a 4-fold increase in autophosphorylation and 2.8-fold increase in substrate phosphorylation activities. Mutants Y148F, Y297F, and Y317F displayed dramatically lower phosphorylation efficiency (k(cat)/K-m) with ATP and histone, whereas mutant Y213F showed increased phosphorylation. Our results suggest that autophosphorylation of Tyr(148), Tyr(213), Tyr(297), and Tyr(317) is important for the regulation of STY protein kinase activity. Our study reveals the first example of Thr-Glu-Tyr domain-mediated autoinhibition of kinases.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rajasekharan, R (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	lipid@biochem.iisc.ernet.in	Rajasekharan, Ram/R-2257-2019; R, Rajasekharan/D-3420-2009	Rajasekharan, Ram/0000-0002-2124-6013; Rudrabhatla, Parvathi/0000-0002-7537-3130; Ram, Rajasekharan/0000-0002-4114-0654				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALI N, 1994, J BIOL CHEM, V269, P31626; Barizza E, 1999, FEBS LETT, V447, P191, DOI 10.1016/S0014-5793(99)00272-0; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; Crosby D, 2002, J BIOL CHEM, V277, P9958, DOI 10.1074/jbc.M108965200; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FENG XH, 1993, BIOCHIM BIOPHYS ACTA, V1172, P200, DOI 10.1016/0167-4781(93)90295-O; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HEIERHORST J, 1994, J BIOL CHEM, V269, P21086; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kawakami Y, 2000, P NATL ACAD SCI USA, V97, P7423, DOI 10.1073/pnas.120175097; KAZUHISA K, 2000, NATURE, V407, P37; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI JY, 1994, J BIOL CHEM, V269, P21078; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; MUNOZ G, 1990, ANAL BIOCHEM, V190, P233, DOI 10.1016/0003-2697(90)90185-C; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RIEDEL H, 1987, SCIENCE, V236, P197, DOI 10.1126/science.3494307; Rudrabhatla P, 2002, PLANT PHYSIOL, V130, P380, DOI 10.1104/pp.005173; Sambrook J, 1989, MOL CLONING LABORATO, p1 25; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sessa G, 2000, EMBO J, V19, P2257, DOI 10.1093/emboj/19.10.2257; Shah K, 2001, J BIOL CHEM, V276, P41263, DOI 10.1074/jbc.M102381200; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI K, 1995, PLANT CELL, V7, P639, DOI 10.1105/tpc.7.5.639; Tregear JW, 1996, PLANT SCI, V117, P107, DOI 10.1016/0168-9452(96)04400-7; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Weijland A, 1997, P NATL ACAD SCI USA, V94, P3590, DOI 10.1073/pnas.94.8.3590; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Zhang H, 2001, J BIOL CHEM, V276, P45598, DOI 10.1074/jbc.M107176200; Zhang SQ, 2001, TRENDS PLANT SCI, V6, P520, DOI 10.1016/S1360-1385(01)02103-3; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	52	18	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17328	17335		10.1074/jbc.M300024200	http://dx.doi.org/10.1074/jbc.M300024200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624102	hybrid			2022-12-27	WOS:000182818600118
J	Borjigin, J; Deng, J; Sun, X; De Jesus, M; Liu, TC; Wang, MM				Borjigin, J; Deng, J; Sun, X; De Jesus, M; Liu, TC; Wang, MM			Diurnal pineal 3-O-sulphotransferase 2 expression controlled by beta-adrenergic repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; GLAND; STIMULATION; MELATONIN; GENE	The 3-O-sulfotransferases (3OSTs) catalyze the addition of sulfate groups at the 3-OH site of glucosamine in heparan sulfate proteoglycans, which serve as critical mediators of various biological functions. We demonstrate that the 3OST2 isoform is expressed at high levels in the rat pineal specifically during the daylight hours. The dramatic diurnal rhythm of 3OST2 is regulated by central clock-controlled activities of the superior cervical ganglion, persists in constant darkness, and is inducible by light at nighttime. Importantly, 3OST2 transcription is blocked by beta-adrenergic agonists that activate the pineal melatonin formation and is induced by beta-adrenergic antagonists, which block melatonin production in vivo. Because of the inverse expression and regulation patterns of 3OST2 with serotortin N-acetyltransferase, the enzyme controlling the melatonin rhythm in the pineal, we tested the effects of forced expression of 3OST2 in the night pineals on N-acetyltransferase gene expression and melatonin production and found that, surprisingly, 3OST2 expression at night fails to interfere with melatonin synthesis. These data suggest 3OST2 may serve a unique function in the pineal that may be independent of melatonin formation.	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA	Carnegie Institution for Science; University of Pennsylvania; Johns Hopkins University	Borjigin, J (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.		Borjigin, Jimo/GXA-3484-2022					Arendt J., 1995, MELATONIN MAMMALIAN; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; Borjigin J, 1999, ANNU REV PHARMACOL, V39, P53, DOI 10.1146/annurev.pharmtox.39.1.53; Borjigin J, 1999, J NEUROSCI, V19, P1018; Borjigin J, 1999, J BIOL CHEM, V274, P35012, DOI 10.1074/jbc.274.49.35012; DRIJFHOUT WJ, 1993, J NEUROCHEM, V61, P936, DOI 10.1111/j.1471-4159.1993.tb03605.x; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; ROSENBERG RD, 1997, J CLIN INVEST, V100, P67; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; STEHLE JH, 1995, MOL ENDOCRINOL, V9, P706, DOI 10.1210/me.9.6.706; Sun X, 2002, P NATL ACAD SCI USA, V99, P4686, DOI 10.1073/pnas.062585499; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505	18	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16315	16319		10.1074/jbc.M300828200	http://dx.doi.org/10.1074/jbc.M300828200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601002	hybrid			2022-12-27	WOS:000182680000109
J	Bosserhoff, AK; Moser, M; Scholmerich, J; Buettner, R; Hellerbrand, C				Bosserhoff, AK; Moser, M; Scholmerich, J; Buettner, R; Hellerbrand, C			Specific expression and regulation of the new melanoma inhibitory activity-related gene MIA2 in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS IN-VIVO; MALIGNANT-MELANOMA; INTERLEUKIN-6-DEFICIENT MICE; TRANSCRIPTION FACTORS; RETINOIC ACID; LIVER-INJURY; TGF-BETA; PROTEIN; DIFFERENTIATION; ENDOTOXIN	The novel human gene MIA2 encoding a melanoma inhibitory activity (MIA) homologous protein was identified by a GenBank(TM) search. MIA2, together with MIA, OTOR, and TANGO, belongs to the novel MIA gene family sharing important structural features, significant homology at both the nucleotide and protein levels, and similar genomic organization. In situ hybridization, reverse transcriptase-PCR, and Northern blots presented a highly tissue-specific MIA2 expression pattern in the liver. Promoter studies analyzing transcriptional regulation of MIA2 revealed an HNF-1-binding site at position -236 controlling hepatocyte-specific expression. Mutation of the site led to a complete loss of promoter activity in HepG2 cell. Further sites detected in the MIA,2 promoter were consensus binding sites for SMAD and STAT3, Consistently, stimulation of MIA2 mRNA expression occurred by treatment with interleukin-6, transforming growth factor-beta, and conditioned medium from activated hepatic stellate cells. In accordance with these results, MIA2 mRNA was found to be increased in liver tissue of patients with chronic hepatitis C infection compared with controls. MIA2 mRNA levels were significantly higher in patients with severe fibrosis or inflammation than in patients with less severe fibrosis or inflammation. In summary our data indicate that MIA2 represents a potential novel acute phase protein and MIA2 expression responds to liver damage. The increased transcription in more severe chronic liver disease suggests that MIA2 may serve as a marker of hepatic disease activity and severity.	Univ Regensburg, Inst Pathol, D-93042 Regensburg, Germany; Univ Regensburg, Dept Internal Med 1, D-93042 Regensburg, Germany; Univ Bonn, Inst Pathol, D-52127 Bonn, Germany; Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany	University of Regensburg; University of Regensburg; University of Bonn; Max Planck Society	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.		Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				BLESCH A, 1994, CANCER RES, V54, P5695; BOGDAHN U, 1989, CANCER RES, V49, P5358; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Bosserhoff AK, 2001, MELANOMA RES, V11, P417, DOI 10.1097/00008390-200108000-00013; Bosserhoff AK, 1997, DEV DYNAM, V208, P516, DOI 10.1002/(SICI)1097-0177(199704)208:4<516::AID-AJA7>3.0.CO;2-L; Burke PA, 1996, SURGERY, V120, P374, DOI 10.1016/S0039-6060(96)80312-6; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; Cohen-Salmon M, 2000, J BIOL CHEM, V275, P40036, DOI 10.1074/jbc.M002876200; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; Dietz UH, 1996, J BIOL CHEM, V271, P3311, DOI 10.1074/jbc.271.6.3311; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner; Guba M, 2000, BRIT J CANCER, V83, P1216, DOI 10.1054/bjoc.2000.1424; Hellerbrand C, 1996, HEPATOLOGY, V24, P670; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; JACOB K, 1995, INT J CANCER, V60, P668, DOI 10.1002/ijc.2910600517; Koehler MR, 1996, GENOMICS, V35, P265, DOI 10.1006/geno.1996.0352; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; Leu JI, 2001, MOL CELL BIOL, V21, P414, DOI 10.1128/MCB.21.2.414-424.2001; Lougheed JC, 2001, P NATL ACAD SCI USA, V98, P5515, DOI 10.1073/pnas.091601698; Memon RA, 1999, BBA-MOL CELL BIOL L, V1440, P118, DOI 10.1016/S1388-1981(99)00120-1; Navasa M, 1998, J LIPID RES, V39, P1220; Ninomiya T, 1996, J HEPATOL, V25, P445, DOI 10.1016/S0168-8278(96)80203-0; Rendtorff ND, 2001, GENOMICS, V71, P40, DOI 10.1006/geno.2000.6409; Robertson NG, 2000, GENOMICS, V66, P242, DOI 10.1006/geno.2000.6224; Schlott T, 2002, ANTICANCER RES, V22, P1545; Stoll R, 2001, EMBO J, V20, P340, DOI 10.1093/emboj/20.3.340; Streetz KL, 2001, CELL MOL BIOL, V47, P661; Trauner M, 1998, J CLIN INVEST, V101, P2092, DOI 10.1172/JCI1680; Wach F, 1998, SKIN PHARMACOL APPL, V11, P43, DOI 10.1159/000029807; Wheeler MD, 2001, J LEUKOCYTE BIOL, V69, P622; Yamamoto T, 2001, FEBS LETT, V492, P247, DOI 10.1016/S0014-5793(01)02258-X	33	40	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15225	15231		10.1074/jbc.M212639200	http://dx.doi.org/10.1074/jbc.M212639200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586826	hybrid			2022-12-27	WOS:000182516100083
J	Kim, J; Ogata, Y; Feldman, RA				Kim, J; Ogata, Y; Feldman, RA			Fes tyrosine kinase promotes survival and terminal granulocyte differentiation of factor-dependent myeloid progenitors (32D) and activates lineage-specific transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; BINDING PROTEIN-ALPHA; SRC FAMILY KINASES; C/EBP-ALPHA; CELL-LINE; HEMATOPOIETIC-CELLS; MACROPHAGE DIFFERENTIATION; INTERLEUKIN-3 DEPENDENCE; SIGNALING PATHWAYS; GENE-EXPRESSION	The c-fps/fes proto-oncogene encodes a 92-kDa protein-tyrosine kinase that is involved in myeloid cell development and function. We have recently shown that expression of an activated allele of Fes (Fes(act)) in monocyte precursors resulted in their differentiation into functional macrophages through the activation of lineage-specific transcription factors. We now report that this kinase also plays a role in the survival and terminal differentiation of granulocyte progenitors. The expression of Fes(act) in factor-dependent 32D cells prevented their apoptotic death after interleukin-3 removal, but Fes(act)-expressing cells remained factor-dependent for proliferation. Removal of interleukin-3 from the Fes(act)-expressing cells was followed by granulocytic differentiation in the absence of granulocyte colony-stimulating factor within 4-8 days. The differentiated cells had distinctive granulocyte morphology and there was up-regulation of CD11b, Gr-1, and late differentiation markers such as lactoferrin, suggesting that this kinase induced terminal granulocytic differentiation. Concomitantly, Fes(act) down-regulated the macrophage marker F4/80, suggesting that the biological activity of Fes was coordinated in a lineage-specific manner. Further analysis showed that Fes(act) caused activation of CCAAT/enhancer-binding protein-alpha and STAT3, two transcription factors that are involved in granulocyte differentiation. Our results provide evidence that Fes may be a key component of the granulocyte differentiation machinery, and suggest a potential mechanism by which this kinase may regulate granulocyte-specific gene expression.	Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Feldman, RA (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.			Feldman, Ricardo A./0000-0001-6090-0439	NATIONAL CANCER INSTITUTE [R29CA055293, R01CA055293] Funding Source: NIH RePORTER; NCI NIH HHS [CA55293] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; Choi BH, 1999, J BIOL CHEM, V274, P2858, DOI 10.1074/jbc.274.5.2858; Clarke S, 1998, J LEUKOCYTE BIOL, V63, P153, DOI 10.1002/jlb.63.2.153; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Craig AWB, 2002, MOL CELL BIOL, V22, P6363, DOI 10.1128/MCB.22.18.6363-6374.2002; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FELDMAN RA, 1986, MOL CELL BIOL, V6, P1065, DOI 10.1128/MCB.6.4.1065; FRIEDMAN AD, 1991, BLOOD, V78, P2426; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; HACKEN MI, 2002, DEV BIOL, V245, P255; Hackenmiller R, 2000, IMMUNITY, V13, P397, DOI 10.1016/S1074-7613(00)00039-X; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; Jucker M, 1997, J BIOL CHEM, V272, P2104; Kim J, 2002, MOL CELL BIOL, V22, P1903, DOI 10.1128/MCB.22.6.1903-1918.2002; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; KRUGER A, 1991, ONCOGENE, V6, P245; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Mocsai A, 1999, J IMMUNOL, V162, P1120; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Park WY, 1998, CANCER LETT, V129, P29, DOI 10.1016/S0304-3835(98)00077-9; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pereira S, 2001, J IMMUNOL, V166, P4115, DOI 10.4049/jimmunol.166.6.4115; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; ROVERA G, 1987, ONCOGENE, V1, P29; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; Shimoda K, 1997, BLOOD, V90, P597, DOI 10.1182/blood.V90.2.597.597_597_604; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; YU G, 1989, J BIOL CHEM, V264, P10276; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173; Zhang P, 2002, BLOOD, V99, P4406, DOI 10.1182/blood.V99.12.4406; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zirngibl RA, 2002, MOL CELL BIOL, V22, P2472, DOI 10.1128/MCB.22.8.2472-2486.2002	48	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14978	14984		10.1074/jbc.M212118200	http://dx.doi.org/10.1074/jbc.M212118200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584192	hybrid			2022-12-27	WOS:000182516100053
J	Shi, CS; Kehrl, JH				Shi, CS; Kehrl, JH			Tumor necrosis factor (TNF)-induced germinal center kinase-related (GCKR) and stress-activated protein-kinase (SAPK) activation depends upon the E2/E3 complex Ubc13-Uev1A/TNF receptor-associated factor 2 (TRAF2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; KAPPA-B; TNF; APOPTOSIS; ASK1; JNK; INHIBITOR; INDUCTION; REQUIRES; PATHWAY	Tumor necrosis factor (TNF)-induced activation of apoptosis signal-regulating kinase 1 (ASK1.) and germinal center kinases (GCKs) and the subsequent activation of stress-activated protein kinases (SAPKs and c-Jun NH2-terminal kinases) requires TNF receptor-associated factor 2 (TRAF2). Although the TRAF2 TRAF domain binds ASK1, GCK, and the highly related kinase GCKR, the RING finger domain is needed for their activation. Here, we report that TNF activates GCKR and the SAPK pathway in a manner that depends upon TRAF2 and Ubc13, a member along with Uev1A of a dimeric ubiquitin-conjugating enzyme complex. Interference with LTbc13 function or expression inhibits both TNF- and TRAF2-mediated GCKR and SAPK activation, but has a minimal effect on ASK1. activation. TNF signaling leads to TRAF2 polyubiquitination and oligomerization and to the oligomerization, ubiquitination, and activation of GCKR, all of which are sensitive to the disruption of Ubc13 function. These results indicate that the assembly of a TRAF2 lysine 63-linked polyubiquitin chain by LTbc13/Uev1A is required for TNF-mediated GCKR and SAPK activation, but may not be required for ASK1 activation.	NIAID, Cell Immunol Sect B, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kehrl, JH (corresponding author), NIAID, Cell Immunol Sect B, NIH, Bldg 10,RmB-08,10 Ctr Dr,MSC 1876, Bethesda, MD 20892 USA.	Jkehrl@niaid.nih.gov	Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000739, ZIAAI000739] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Chadee DN, 2002, MOL CELL BIOL, V22, P737, DOI 10.1128/MCB.22.3.737-749.2002; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Kyriakis JM, 2000, FR MOLEC B, V29, P40; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shi CS, 1999, J IMMUNOL, V163, P3279; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681	21	152	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15429	15434		10.1074/jbc.M211796200	http://dx.doi.org/10.1074/jbc.M211796200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12591926	hybrid			2022-12-27	WOS:000182516100109
J	Yabuta, Y; Subbian, E; Oiry, C; Shinde, U				Yabuta, Y; Subbian, E; Oiry, C; Shinde, U			Folding pathway mediated by an intramolecular chaperone - A functional peptide chaperone designed using sequence databases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-LYTIC PROTEASE; PRO-SEQUENCE; SUBTILISIN-E; PROPEPTIDE; ACTIVATION; NUCLEOTIDE; COMPLEX; RATES	Catalytic domains of several prokaryotic and eukaryotic protease families require dedicated N-terminal propeptide domains or "intramolecular chaperones" to facilitate correct folding. Amino acid sequence analysis of these families establishes three important characteristics: (i) propeptides are almost always less conserved than their cognate catalytic domains, (ii) they contain a large number of charged amino acids, and (iii) propeptides within different protease families display insignificant sequence similarity. The implications of these findings are, however, unclear. In this study, we have used subtilisin as our model to redesign a peptide chaperone using information databases. Our goal was to establish the minimum sequence requirements for a functional subtilisin propeptide, because such information could facilitate subsequent design of tailor-made chaperones. A decision-based computer algorithm that maintained conserved residues but varied all non-conserved residues from a multiple protein sequence alignment was developed and utilized to design a novel peptide sequence (ProD). Interestingly, despite a difference of 5 pH units between their isoelectric points and despite displaying only 16% sequence identity with the wildtype propeptide (ProWT), ProD chaperones folding and functions as a potent subtilisin inhibitor. The computed secondary structures and hydrophobic patterns within these two propeptides are similar. However, unlike ProWT, ProD adopts a well defined alpha-beta conformation as an isolated peptide and forms a stoichiometric complex with mature subtilisin. The CD spectra of this complex is similar to ProWT-subtilisin. Our results establish that despite low sequence identity and dramatically different charge distribution, both propeptides adopt similar structural scaffolds. Hence, conserved scaffolds and hydrophobic patterns, but not absolute charge, dictate propeptide function.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Shinde, U (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; Baker D, 1998, NAT STRUCT BIOL, V5, P1021, DOI 10.1038/4130; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659; BIGELOW CC, 1967, J THEOR BIOL, V16, P187, DOI 10.1016/0022-5193(67)90004-5; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; Buevich AV, 2001, J BIOMOL NMR, V20, P233, DOI 10.1023/A:1011243116136; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; Fu X, 2000, J BIOL CHEM, V275, P16871, DOI 10.1074/jbc.275.22.16871; *GEN COMP GROUP, PROGR MAN WISC PACK; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; Jaswal SS, 2002, NATURE, V415, P343, DOI 10.1038/415343a; Li W. H., 1985, MOL EVOLUTIONARY GEN, P1; LI WH, 1985, MOL BIOL EVOL, V2, P150; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; Marie-Claire C, 2001, J MOL BIOL, V305, P151, DOI 10.1006/jmbi.2000.4233; MIYATA T, 1980, J MOL EVOL, V16, P23, DOI 10.1007/BF01732067; Muller L, 2000, J BIOL CHEM, V275, P39213, DOI 10.1074/jbc.M003547200; Rost B, 1996, METHOD ENZYMOL, V266, P525; Ruan B, 1999, BIOCHEMISTRY-US, V38, P8562, DOI 10.1021/bi990362n; Shinde U, 1999, J BIOL CHEM, V274, P15615, DOI 10.1074/jbc.274.22.15615; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; Shinde U, 2000, SEMIN CELL DEV BIOL, V11, P35, DOI 10.1006/scdb.1999.0349; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SILEN JL, 1989, NATURE, V341, P362; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; WONG SL, 1986, J BIOL CHEM, V261, P176; Yabuta Y, 2001, J BIOL CHEM, V276, P44427, DOI 10.1074/jbc.M107573200; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	34	26	27	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15246	15251		10.1074/jbc.M212003200	http://dx.doi.org/10.1074/jbc.M212003200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12582173	hybrid			2022-12-27	WOS:000182516100086
J	Johnson, KA; van Etten, D; Nanda, N; Graham, RM; Terkeltaub, RA				Johnson, KA; van Etten, D; Nanda, N; Graham, RM; Terkeltaub, RA			Distinct transglutaminase 2-independent and transglutaminase 2-dependent pathways mediate articular chondrocyte hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MEMBRANE GLYCOPROTEIN-1; X COLLAGEN-SYNTHESIS; TISSUE TRANSGLUTAMINASE; RETINOIC ACID; BONE-FORMATION; DIFFERENTIAL REGULATION; NATRIURETIC PEPTIDE; THYROID-HORMONES; GENE-EXPRESSION; FACTOR XIIIA	Altered chondrocyte differentiation, including development of chondrocyte hypertrophy, mediates osteoarthritis and pathologic articular cartilage matrix calcification. Similar changes in endochondral chondrocyte differentiation are essential for physiologic growth plate mineralization. In both articular and growth plate cartilages, chondrocyte hypertrophy is associated with up-regulated expression of certain protein-crosslinking enzymes ( transglutaminases (TGs)) including the unique dual-functioning TG and GTPase TG2. Here, we tested if TG2 directly mediates the development of chondrocyte hypertrophic differentiation. To do so, we employed normal bovine chondrocytes and mouse knee chondrocytes from recently described TG2 knockout mice, which are phenotypically normal. We treated chondrocytes with the osteoarthritis mediator IL-1beta, with the all-trans form of retinoic acid ( ATRA), which promotes endochondral chondrocyte hypertrophy and pathologic calcification, and with C-type natriuretic peptide, an essential factor in endochondral development. IL-1beta and ATRA induced TG transamidation activity and calcification in wild-type but not in TG2 (-/-) mouse knee chondrocytes. In addition, ATRA induced multiple features of hypertrophic differentiation ( including type X collagen, alkaline phosphatase, and MMP-13), and these effects required TG2. Significantly, TG2 (-/-) chondrocytes lost the capacity for ATRA-induced expression of Cbfa1, a transcription factor necessary for ATRA-induced chondrocyte hypertrophy. Finally, C-type natriuretic peptide, which did not modulate TG activity, comparably promoted Cbfa1 expression and hypertrophy ( without associated calcification) in TG2 (+/+) and TG2 (-/-) chondrocytes. Thus, distinct TG2-independent and TG2-dependent mechanisms promote Cbfa1 expression, articular chondrocyte hypertrophy, and calcification. TG2 is a potential site for intervention in pathologic calcification promoted by IL-1beta and ATRA.	Univ Calif San Diego, Vet Affairs Med Ctr, La Jolla, CA 92161 USA; Univ New S Wales, Sch Biochem & Mol Genet, Victor Chang Cardiac Res Inst, Mol Cardiol Unit, Kensington, NSW 2010, Australia	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New South Wales Sydney; Victor Chang Cardiac Research Institute	Terkeltaub, RA (corresponding author), Univ Calif San Diego, Vet Affairs Med Ctr, 3350 La Jolla Village Dr, La Jolla, CA 92161 USA.				NATIONAL INSTITUTE ON AGING [P01AG007996] Funding Source: NIH RePORTER; NIA NIH HHS [P01AGO7996] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; ALINI M, 1994, J BONE MINER RES, V9, P1077; Alini M, 1996, J BONE MINER RES, V11, P105; Anwar R, 1998, BLOOD, V91, P149, DOI 10.1182/blood.V91.1.149.149_149_153; Attur MG, 1998, P ASSOC AM PHYSICIAN, V110, P65; Boskey Adele L, 2002, Curr Rheumatol Rep, V4, P245, DOI 10.1007/s11926-002-0072-3; Candi E, 2001, J BIOL CHEM, V276, P35014, DOI 10.1074/jbc.M010157200; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; CUNY JF, 1989, ANN DERMATOL VENER, V116, P95; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Dogan S, 2002, BIOL REPROD, V66, P596, DOI 10.1095/biolreprod66.3.596; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Egea PF, 2001, J MOL BIOL, V307, P557, DOI 10.1006/jmbi.2000.4409; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Gerstenfeld LC, 1996, J CELL BIOCHEM, V62, P1; Gionti E, 1999, CELL BIOL INT, V23, P41, DOI 10.1006/cbir.1998.0316; Goldring MB, 2000, ARTHRITIS RHEUM-US, V43, P1916, DOI 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Haroon ZA, 1999, FASEB J, V13, P1787, DOI 10.1096/fasebj.13.13.1787; Hashimoto S, 1998, P NATL ACAD SCI USA, V95, P3094, DOI 10.1073/pnas.95.6.3094; Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399; ISHIKAWA K, 1989, J BONE JOINT SURG AM, V71A, P875, DOI 10.2106/00004623-198971060-00012; IWAMOTO M, 1994, MICROSC RES TECHNIQ, V28, P483, DOI 10.1002/jemt.1070280604; Iwamoto M, 2003, OSTEOARTHR CARTILAGE, V11, P6, DOI 10.1053/joca.2002.0860; Jimenez MJG, 2001, J CELL BIOL, V155, P1333, DOI 10.1083/jcb.200106147; Johnson K, 1999, ARTHRITIS RHEUM-US, V42, P1986, DOI 10.1002/1529-0131(199909)42:9<1986::AID-ANR26>3.0.CO;2-O; Johnson K, 2001, AM J PATHOL, V159, P149, DOI 10.1016/S0002-9440(10)61682-3; JOHNSON K, 2003, IN PRESS ARTHRITIS R; Kaartinen MT, 2002, J BONE MINER RES, V17, P2161, DOI 10.1359/jbmr.2002.17.12.2161; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Koyama E, 1999, DEV BIOL, V208, P375, DOI 10.1006/dbio.1999.9207; Krane SM, 2001, J CLIN INVEST, V107, P31, DOI 10.1172/JCI11892; Linsenmayer TF, 1998, PROG NUCLEIC ACID RE, V60, P79, DOI 10.1016/S0079-6603(08)60890-9; McCarthy G M, 1999, Curr Rheumatol Rep, V1, P101, DOI 10.1007/s11926-999-0005-5; Merz D, 2002, ARTHRITIS RHEUM-US, V46, pS221; Miyazawa T, 2002, ENDOCRINOLOGY, V143, P3604, DOI 10.1210/en.2002-220307; MORK NJ, 1992, ACTA DERM-VENEREOL, V72, P445; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Nurminskaya M, 1998, J CELL BIOL, V142, P1135, DOI 10.1083/jcb.142.4.1135; Nurminskaya M, 1996, DEV DYNAM, V206, P260, DOI 10.1002/(SICI)1097-0177(199607)206:3<260::AID-AJA4>3.0.CO;2-G; PACIFICI M, 1991, EXP CELL RES, V195, P38, DOI 10.1016/0014-4827(91)90497-I; POOLE AR, 1989, ANAT REC, V224, P167; Rosenthal AK, 1997, ARTHRITIS RHEUM, V40, P966, DOI 10.1002/art.1780400526; Rosenthal AK, 1999, J RHEUMATOL, V26, P395; Rosenthal AK, 1996, CALCIFIED TISSUE INT, V59, P128, DOI 10.1007/s002239900099; Shimizu T, 2000, CANCER RES, V60, P4544; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; Sohn J, 2003, J CLIN INVEST, V111, P121, DOI 10.1172/JCI200315937; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Terkeltaub RA, 2002, J RHEUMATOL, V29, P411; VIGNON E, 1983, ANN RHEUM DIS, V42, P82, DOI 10.1136/ard.42.1.82; Vincan E, 1996, MOL CELL BIOCHEM, V157, P107; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; Wang DS, 2001, J BIOL CHEM, V276, P33995, DOI 10.1074/jbc.M007757200	58	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18824	18832		10.1074/jbc.M301055200	http://dx.doi.org/10.1074/jbc.M301055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12606540	hybrid			2022-12-27	WOS:000182932200017
J	Arinze, IJ; Kawai, Y				Arinze, IJ; Kawai, Y			Sp family of transcription factors is involved in valproic acid-induced expression of G alpha(i2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 1; HISTONE DEACETYLASE; SODIUM-BUTYRATE; GENE PROMOTER; IN-VITRO; MOOD STABILIZER; ALPHA-SUBUNIT; RECEPTOR GENE; OKADAIC ACID; CALYCULIN-A	Valproic acid-induced gene expression has been attributed to the DNA-binding activity of the transcription factor activator protein 1 (AP-1). Using K562 cells, we have studied valproic acid-induced transcription from the human Galpha(i2) gene promoter, which lacks AP-1-binding motifs. We find that valproic acid-induced expression of Galpha(i2) is inhibited by mithramycin A, a compound that interferes with Sp1 binding to GC boxes in DNA. Three Sp1-binding sequences, located at +68/+75, +50/+36, and +92/+85 in the promoter, accounted for about 60% of this transcriptional effect, as judged by transient transfection assays. Electrophoretic mobility shift assays indicated that these sites bind members of the Sp family of transcription factors. Binding to DNA was inhibited by mithramycin A and was greater in nuclear extracts from cells treated with valproic acid than in control cells. Okadaic acid, calyculin A, and fostriecin, which are potent inhibitors of protein phosphatase, suppressed the transcriptional response to valproic acid. This inhibitory effect was not observed when promoter constructs containing mutations in the referenced Sp1-binding sites were used for transfections. In nuclear extracts from cells cultured in the presence of these inhibitors, the binding of Sp1/Sp3 to DNA probes was much less than in control cells. Alkaline phosphatase treatment of nuclear extracts resulted in enhanced binding of Sp proteins to the DNA probes. These results are consistent with the idea that dephosphorylating conditions enhanced Sp binding to the DNA probes as well as Sp-mediated transcription induced by valproic acid. This study demonstrates that the gene expression-inducing effect of valproic acid occurs, in part, through the Sp family of transcription factors.	Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA	Meharry Medical College	Arinze, IJ (corresponding author), Meharry Med Coll, Dept Biochem, 1005 Dr David B Todd Jr Blvd, Nashville, TN 37208 USA.	iarinze@mail.mmc.edu						Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; ARDINGER HH, 1988, AM J MED GENET, V29, P171, DOI 10.1002/ajmg.1320290123; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Chen G, 1998, J NEUROCHEM, V70, P1768; Chen G, 1999, MOL BRAIN RES, V64, P52, DOI 10.1016/S0169-328X(98)00303-9; Cuisset L, 1997, J BIOL CHEM, V272, P24148, DOI 10.1074/jbc.272.39.24148; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Davis MG, 2000, BIOCHEM J, V346, P455, DOI 10.1042/0264-6021:3460455; DILIBERTI JH, 1984, AM J MED GENET, V19, P473, DOI 10.1002/ajmg.1320190308; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Garcia A, 2000, J BIOL CHEM, V275, P9385, DOI 10.1074/jbc.275.13.9385; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Hinnebusch BF, 2002, J NUTR, V132, P1012, DOI 10.1093/jn/132.5.1012; HOUT C, 1987, CAN J NEUROL SCI, V14, P290; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JOFFE RT, 1993, CAN J PSYCHIAT, V38, pS46; Johannessen CU, 2000, NEUROCHEM INT, V37, P103, DOI 10.1016/S0197-0186(00)00013-9; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Lacroix I, 2002, J BIOL CHEM, V277, P9598, DOI 10.1074/jbc.M111444200; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; Li JH, 2002, J BIOL CHEM, V277, P39967, DOI 10.1074/jbc.M200840200; Manji HK, 2001, BRIT J PSYCHIAT, V178, pS107, DOI 10.1192/bjp.178.41.s107; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MARTINEZFRIAS ML, 1990, AM J MED GENET, V37, P277, DOI 10.1002/ajmg.1320370224; Mitchell PB, 1999, AUST NZ J PSYCHIAT, V33, pS99, DOI 10.1111/j.1440-1614.1999.00672.x; NAU H, 1991, PHARMACOL TOXICOL, V69, P310, DOI 10.1111/j.1600-0773.1991.tb01303.x; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROBERT E, 1982, LANCET, V2, P937, DOI 10.1016/s0140-6736(82)90908-4; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; SADOCK BJ, 2000, COMPREHENSIVE TXB PS, P1284; Sands SA, 2000, NEUROPSYCHOPHARMACOL, V22, P27, DOI 10.1016/S0893-133X(99)00072-X; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Taniura S, 2002, J BIOL CHEM, V277, P16823, DOI 10.1074/jbc.M200527200; Tunnicliff G, 1999, J PHYSIOL PHARMACOL, V50, P347; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WEINSTEIN LS, 1990, MOL ENDOCRINOL, V4, P958, DOI 10.1210/mend-4-7-958; Werling U, 2001, MOL PHARMACOL, V59, P1269, DOI 10.1124/mol.59.5.1269; Wlodarczyk BC, 1996, TERATOLOGY, V54, P284, DOI 10.1002/(SICI)1096-9926(199612)54:6<284::AID-TERA3>3.3.CO;2-J; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; Yoo J, 2002, J BIOL CHEM, V277, P11904, DOI 10.1074/jbc.M111788200; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Yuan PX, 1999, J NEUROCHEM, V73, P2299, DOI 10.1046/j.1471-4159.1999.0732299.x; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200	56	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17785	17791		10.1074/jbc.M209430200	http://dx.doi.org/10.1074/jbc.M209430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624107	hybrid			2022-12-27	WOS:000182838300026
J	Chicka, MC; Strehler, EE				Chicka, MC; Strehler, EE			Alternative splicing of the first intracellular loop of plasma membrane Ca2+-ATPase isoform 2 alters its membrane targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CALCIUM-PUMP; CA2+ PUMP; PROTEIN; ATPASE; EXPRESSION; CALMODULIN; EXCHANGER; DOMAINS; NEURONS	Plasma membrane Ca2+-ATPases (PMCAs) are involved in local Ca2+ signaling and in the spatial control of Ca2+ extrusion, but how different PMCA isoforms are targeted to specific membrane domains is unknown. In polarized MDCK epithelial cells, a green fluorescent protein-tagged PMCA4b construct was targeted to the basolateral membrane, whereas a green fluorescent protein-tagged PMCA2b construct was localized to both the apical and basolateral domain. The PDZ protein-binding COOH-terminal tail of PMCA2b was not responsible for its apical membrane localization, as a chimeric pump made of an NH2-terminal portion from PMCA4 and a COOH-terminal tail from PMCA2b was targeted to the basolateral domain. Deletion of the last six residues of the COOH terminus of either PMCA2b or PMCA4b did not alter their membrane targeting, suggesting that PDZ protein interactions are not essential for proper membrane localization of the pumps. Instead, we found that alternative splicing affecting the first cytosolic loop determined apical membrane targeting of PMCA2. Only the "w" form, which contains a 45-amino acid residue insertion, showed prominent apical membrane localization. By contrast, the x and z splice variants containing insertions of 14 and 0 residues, respectively, localized to the basolateral membrane. The w splice insert was the crucial determinant of apical PMCA2 localization, and this was independent of the splice configuration at the COOH-terminal end of the pump; both PMCA2w/b and PMCA2w/a showed prominent apical targeting, whereas PMCA2x/b, PMCA2z/b, and PMCA2z/a were confined to the basolateral membrane. These data report the first differential effect of alternative splicing within the first cytosolic loop of PMCA2 and help explain the selective enrichment of specific PMCA2 isoforms in specialized membrane compartments such as stereocilia of auditory hair cells.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Strehler, EE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	strehler.emanuel@mayo.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058710] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-58710] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Bootman MD, 2001, J CELL SCI, V114, P2213; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; Bruce JIE, 2002, J BIOL CHEM, V277, P48172, DOI 10.1074/jbc.M208393200; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Caride AJ, 2001, J BIOL CHEM, V276, P39797, DOI 10.1074/jbc.M104380200; DeMarco SJ, 2002, J BIOL CHEM, V277, P10506, DOI 10.1074/jbc.M111616200; DeMarco SJ, 2001, J BIOL CHEM, V276, P21594, DOI 10.1074/jbc.M101448200; Dumont RA, 2001, J NEUROSCI, V21, P5066, DOI 10.1523/JNEUROSCI.21-14-05066.2001; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kim E, 1998, J BIOL CHEM, V273, P1591, DOI 10.1074/jbc.273.3.1591; Kip SN, 2003, AM J PHYSIOL-RENAL, V284, pF122, DOI 10.1152/ajprenal.00161.2002; Krizaj D, 2002, J COMP NEUROL, V451, P1, DOI 10.1002/cne.10281; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; Reinhardt TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1595, DOI 10.1152/ajpcell.2000.279.5.C1595; Reinhardt TA, 1999, AM J PHYSIOL-CELL PH, V276, pC796, DOI 10.1152/ajpcell.1999.276.4.C796; Rogers MS, 2001, J BIOL CHEM, V276, P12182, DOI 10.1074/jbc.M010056200; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Schuh K, 2001, J CELL BIOL, V155, P201, DOI 10.1083/jcb.200104131; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Usachev YM, 2002, NEURON, V33, P113, DOI 10.1016/S0896-6273(01)00557-8; Usachev YM, 2001, J NEUROCHEM, V76, P1756, DOI 10.1046/j.1471-4159.2001.00169.x; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Zacharias DA, 1996, CURR BIOL, V6, P1642, DOI 10.1016/S0960-9822(02)70788-4; Zhong N, 2001, J NEUROSCI, V21, P9598, DOI 10.1523/JNEUROSCI.21-24-09598.2001	38	85	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18464	18470		10.1074/jbc.M301482200	http://dx.doi.org/10.1074/jbc.M301482200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624087	hybrid			2022-12-27	WOS:000182838300114
J	Chou, KM; Cheng, YC				Chou, KM; Cheng, YC			The exonuclease activity of human apurinic/apyrimidinic endonuclease (APE1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR ENZYME; BASE EXCISION-REPAIR; HUMAN APURINIC ENDONUCLEASE; POLYMERASE-BETA; 3'-TO-5' EXONUCLEASE; NUCLEOSIDE ANALOG; BINDING ACTIVITY; L-CONFIGURATION; HAP1; REF-1	Human DNA apurinic/apyrimidinic endonuclease (APE1) plays a key role in the DNA base excision repair process. In this study, we further characterized the exonuclease activity of APE1. The magnesium requirement and pH dependence of the exonuclease and endonuclease activities of APE1 are significantly different. APE1 showed a similar K-m value for matched, 3' mispaired, or nucleoside analog beta-L-dioxolane-cytidine terminated nicked DNA as well as for DNA containing a tetrahydrofuran, an abasic site analog. The k(cat) for exonuclease activity on matched, 3' mispaired, and beta-L-dioxolanecytidine nicked DNA are 2.3, 61.2, and 98.8 min(-1), respectively, and 787.5 min(-1) for APE1 endonuclease. Site- directed APE1 mutant proteins ( E96A, E96Q, D210E, D210N, and H309N), which target amino acid residues in the endonuclease active site, also showed significant decrease in exonuclease activity. Gp(4)G was the only potent inhibitor to compete against the substrates of endonuclease and exonuclease activities among all tested naturally occurring ribo-, deoxyribonucleoside/nucleotides, NAD(+), NADP(+), and Ap(4)A. The K-i values of Gp(4)G for the endonuclease and exonuclease activities of APE1 are 10 +/- 0.6 and 1 +/- 0.2 muM, respectively. Given the relative concentrations of Gp(4)G, 3' mispaired, and abasic DNA, Gp(4)G may play an important role in regulating APE1 activity in cells. The data presented here suggest that the APE1 exonuclease and AP endonuclease are two distinct activities. APE1 may exist in two different conformations, and each conformation has a preference for a substrate. The different conformations can be affected by MgCl2 or salt concentrations.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Cheng, YC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,SHM B315, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038204] Funding Source: NIH RePORTER; NCI NIH HHS [CA 73477] Funding Source: Medline; NIAID NIH HHS [AI 38204] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; Beernink PT, 2001, J MOL BIOL, V307, P1023, DOI 10.1006/jmbi.2001.4529; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Chou KM, 2000, J BIOL CHEM, V275, P31009, DOI 10.1074/jbc.M004082200; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; COSTE H, 1987, J BIOL CHEM, V262, P12096; DERSE D, 1981, J BIOL CHEM, V256, P8525; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Giles FJ, 2002, J CLIN ONCOL, V20, P656, DOI 10.1200/JCO.20.3.656; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; GRAU PP, 1988, FEBS LETT, V236, P291, DOI 10.1016/0014-5793(88)80040-1; GRAU VP, 1982, J BIOL CHEM, V257, P1848; Grove KL, 1996, CANCER RES, V56, P4187; GROVE KL, 1995, CANCER RES, V55, P3008; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LIU JJ, 1994, J BIOL CHEM, V269, P11787; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; McLennan AG, 2000, PHARMACOL THERAPEUT, V87, P73, DOI 10.1016/S0163-7258(00)00041-3; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Pelicano H, 2000, MOL PHARMACOL, V57, P1051; RENART MF, 1976, BIOCHEMISTRY-US, V15, P4962, DOI 10.1021/bi00668a003; Rothwell DG, 2000, NUCLEIC ACIDS RES, V28, P2207, DOI 10.1093/nar/28.11.2207; RUTH JL, 1981, MOL PHARMACOL, V20, P415; Schluter H, 1998, J CLIN INVEST, V101, P682, DOI 10.1172/JCI119882; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SMITH RE, 1982, J BIOL CHEM, V257, P485; Sokhansanj BA, 2002, NUCLEIC ACIDS RES, V30, P1817, DOI 10.1093/nar/30.8.1817; SPECTOR T, 1979, J BIOL CHEM, V254, P2308; TSURUMI T, 1992, VIROLOGY, V189, P803, DOI 10.1016/0042-6822(92)90611-R; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; WARNER AH, 1968, DEV BIOL, V18, P278, DOI 10.1016/0012-1606(68)90036-5; Wilson DM, 2001, MUTAT RES-DNA REPAIR, V485, P283, DOI 10.1016/S0921-8777(01)00063-5; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YAMAKAWA M, 1982, P NATL ACAD SCI-BIOL, V79, P6142, DOI 10.1073/pnas.79.20.6142	44	93	98	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18289	18296		10.1074/jbc.M212143200	http://dx.doi.org/10.1074/jbc.M212143200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624104	hybrid			2022-12-27	WOS:000182838300092
J	Erdtmann, L; Franck, N; Lerat, H; Le Seyec, J; Gilot, D; Cannie, I; Gripon, P; Hibner, U; Guguen-Guillouzo, C				Erdtmann, L; Franck, N; Lerat, H; Le Seyec, J; Gilot, D; Cannie, I; Gripon, P; Hibner, U; Guguen-Guillouzo, C			The hepatitis C virus NS2 protein is an inhibitor of CIDE-B-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; CASPASE-ACTIVATED DNASE; CORE PROTEIN; CYTOCHROME-C; KINASE PKR; HIV-1 NEF; PATHWAY; FRAGMENTATION; REPLICATION; INTERACTS	Chronic hepatitis C virus (HCV) infection frequently leads to liver cancer. To determine the viral factor(s) potentially involved in viral persistence, we focused our work on NS2, a viral protein of unknown function. To assign a role for NS2, we searched for cellular proteins that interact with NS2. Performing a two-hybrid screen on a human liver cDNA library, we found that NS2 interacted with the liver-specific pro-apoptotic CIDE-B protein. Binding specificity of NS2 for CIDE-B was confirmed by cell-free assays associated with colocalization studies and coprecipitation experiments on human endogenous CIDE-B. CIDE-B, a member of the novel CIDE family of apoptosis-inducing factors, has been reported to show strong cell death-inducing activity in its C-terminal domain. We show that this CIDE-B killing domain is involved in the NS2 interaction. NS2 binding was sufficient to inhibit CIDE-B-induced apoptosis because an NS2 deletion mutant unable to interact with CIDE-B in vitro lost its capacity to interfere with CIDE-B cell death activity. Although it has been reported that CIDE-B-induced apoptosis is characterized by mitochondrial localization, the precise apoptotic mechanism remained unknown. Here, we show that CIDE-B induced cell death in a caspase-dependent manner through cytochrome c release from mitochondria. Furthermore, we found that NS2 counteracted the cytochrome c release induced by CIDE-B. In vivo, the CIDE-B protein level was extremely low in adenovirus-infected transgenic mice expressing the HCV polyprotein compared with that in wild-type mice. We suggest that NS2 interferes with the CIDE-B-induced death pathway and participates in HCV strategies to subvert host cell defense.	Hop Pontchaillou, INSERM, U522, F-35033 Rennes, France; CNRS, Inst Genet Mol, UMR 5535, F-34293 Montpellier 5, France	CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Erdtmann, L (corresponding author), Hop Pontchaillou, INSERM, U522, 2 Rue Henri Guilloux, F-35033 Rennes, France.	lars.erdtmann@univ-rennes1.fr	Le Seyec, Jacques/J-5680-2015; LERAT, Hervé/D-4331-2019; GRIPON, Philippe/J-6068-2015	LERAT, Hervé/0000-0002-8505-378X; Le Seyec, Jacques/0000-0002-1118-3311; Hibner, Urszula/0000-0002-5520-7311				Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bukh J, 2002, P NATL ACAD SCI USA, V99, P14416, DOI 10.1073/pnas.212532699; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Chen ZM, 2000, J BIOL CHEM, V275, P22619, DOI 10.1074/jbc.C000207200; Dumoulin FL, 1999, EUR J CLIN INVEST, V29, P940; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Erdtmann L, 2000, TRAFFIC, V1, P871, DOI 10.1034/j.1600-0854.2000.011106.x; Everett H, 1999, TRENDS MICROBIOL, V7, P160, DOI 10.1016/S0966-842X(99)01487-0; Flajolet M, 2000, GENE, V242, P369, DOI 10.1016/S0378-1119(99)00511-9; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Grakoui A, 2001, HEPATOLOGY, V33, P489, DOI 10.1053/jhep.2001.23041; Hahn CS, 2000, VIROLOGY, V276, P127, DOI 10.1006/viro.2000.0541; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; Honda A, 1999, J MED VIROL, V59, P281, DOI 10.1002/(SICI)1096-9071(199911)59:3<281::AID-JMV4>3.0.CO;2-S; Honda A, 2000, J HEPATOL, V33, P440, DOI 10.1016/S0168-8278(00)80280-9; INCHAUSPE G, 1991, P NATL ACAD SCI USA, V88, P10292, DOI 10.1073/pnas.88.22.10292; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Kalkeri G, 2001, VIROLOGY, V282, P26, DOI 10.1006/viro.2000.0835; Kim JE, 1999, ARCH VIROL, V144, P329, DOI 10.1007/s007050050507; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; Klonjkowski B, 1997, HUM GENE THER, V8, P2103, DOI 10.1089/hum.1997.8.17-2103; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu LX, 1997, J BIOL CHEM, V272, P13779, DOI 10.1074/jbc.272.21.13779; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1996, J HEPATOL, V24, P11; Lugovskoy AA, 1999, CELL, V99, P747, DOI 10.1016/S0092-8674(00)81672-4; Machida K, 2001, J BIOL CHEM, V276, P12140, DOI 10.1074/jbc.M010137200; Mak P, 2001, FEBS LETT, V503, P13, DOI 10.1016/S0014-5793(01)02678-3; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833; Pallaoro M, 2001, J VIROL, V75, P9939, DOI 10.1128/JVI.75.20.9939-9946.2001; Pavio N, 2002, J VIROL, V76, P1265, DOI 10.1128/JVI.76.3.1265-1272.2002; Pieroni L, 1997, J VIROL, V71, P6373, DOI 10.1128/JVI.71.9.6373-6380.1997; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; Sakahira H, 2001, ARCH BIOCHEM BIOPHYS, V388, P91, DOI 10.1006/abbi.2000.2266; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; SANTOLINI E, 1995, J VIROL, V69, P7461, DOI 10.1128/JVI.69.12.7461-7471.1995; Seino KI, 1997, GASTROENTEROLOGY, V113, P1315, DOI 10.1053/gast.1997.v113.pm9322527; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; Wang XD, 2001, GENE DEV, V15, P2922; Yamaga AK, 2002, J BIOL CHEM, V277, P33228, DOI 10.1074/jbc.M202304200; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	57	97	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18256	18264		10.1074/jbc.M209732200	http://dx.doi.org/10.1074/jbc.M209732200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12595532	Green Published, hybrid			2022-12-27	WOS:000182838300088
J	Cheung-Flynn, J; Roberts, PJ; Riggs, DL; Smith, DF				Cheung-Flynn, J; Roberts, PJ; Riggs, DL; Smith, DF			C-terminal sequences outside the tetratricopeptide repeat domain of FKBP51 and FKBP52 cause differential binding to hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; GLUCOCORTICOID RECEPTOR; FK506-BINDING IMMUNOPHILIN; PROGESTERONE-RECEPTOR; STEROID-RECEPTORS; MOLECULAR-CLONING; SQUIRREL-MONKEY; TPR DOMAINS; COMPLEXES; PHOSPHATASE-5	Hsp90 assembles with steroid receptors and other client proteins in association with one or more Hsp90-binding cochaperones, some of which contain a common tetratricopeptide repeat (TPR) domain. Included in the TPR cochaperones are the Hsp70-Hsp90-organizing protein Hop, the FK506-binding immunophilins FKBP52 and FKBP51, the cyclosporin A-binding immunophilin CyP40, and protein phosphatase PP5. The TPR domains from these proteins have similar x-ray crystallographic structures and target cochaperone binding to the MEEVD sequence that terminates Hsp90. However, despite these similarities, the TPR cochaperones have distinctive properties for binding Hsp90 and assembling with Hsp90.steroid receptor complexes. To identify structural features that differentiate binding of FKBP51 and FKBP52 to Hsp90, we generated an assortment of truncation mutants and chimeras that were compared for coimmunoprecipitation with Hsp90. Although the core TPR domain (approximately amino acids 260-400) of FKBP51 and FKBP52 is required for Hsp90 binding, the C-terminal 60 amino acids (similar to400-end) also influence Hsp90 binding. More specifically, we find that amino acids 400-420 play a critical role for Hsp90 binding by either FKBP. Within this 20-amino acid region, we have identified a consensus sequence motif that is also present in some other TPR cochaperones. Additionally, the final 30 amino acids of FKBP51 enhance binding to Hsp90, whereas the corresponding region of FKBP52 moderates binding to Hsp90. Taking into account the x-ray crystal structure for FKBP51, we conclude that the C-terminal regions of FKBP51 and FKBP52 outside the core TPR domains are likely to assume alternative conformations that significantly impact Hsp90 binding.	Mayo Clin Scottsdale, Dept Biochem & Mol Biol, SC Johnson Res Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Smith, DF (corresponding author), Mayo Clin Scottsdale, Dept Biochem & Mol Biol, SC Johnson Res Ctr, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048218] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48218] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; BAUGHMAN G, 1995, MOL CELL BIOL, V15, P4395; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; HONORE B, 1992, J BIOL CHEM, V267, P8485; Kumar A, 2001, J MOL BIOL, V307, P271, DOI 10.1006/jmbi.2000.4465; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meng X, 1998, GENOMICS, V52, P130, DOI 10.1006/geno.1998.5412; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Riggs DL, 2003, EMBO J, V22, P1158, DOI 10.1093/emboj/cdg108; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scammell JG, 2001, GEN COMP ENDOCR, V124, P152, DOI 10.1006/gcen.2001.7696; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Sinars CR, 2003, P NATL ACAD SCI USA, V100, P868, DOI 10.1073/pnas.0231020100; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7	37	70	73	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17388	17394		10.1074/jbc.M300955200	http://dx.doi.org/10.1074/jbc.M300955200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611898	hybrid			2022-12-27	WOS:000182818600125
J	Hall, MC; Torres, MP; Schroeder, GK; Borchers, CH				Hall, MC; Torres, MP; Schroeder, GK; Borchers, CH			Mnd2 and Swm1 are core subunits of the Saccharomyces cerevisiae anaphase-promoting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; IDENTIFICATION; PROTEIN; APC11; PROTEOLYSIS; MEIOSIS; SPORULATION; CHECKPOINT; MITOSIS; SCREEN	The anaphase-promoting complex (APC) is a multi-subunit E3 ubiquitin ligase that regulates the metaphase-anaphase transition and exit from mitosis in eukaryotic cells. Eleven subunits have been previously identified in APC from budding yeast. We have identified two additional subunits, Mnd2 and Swm1, by mass spectrometry. Both Mnd2 and Swm1 were found specifically associated with a highly purified preparation of APC from haploid yeast whole cell extract. Moreover, the APC co-purified with epitope-tagged Mnd2 and Swm1. Both proteins were present in APC preparations from haploid cells arrested in G(1), S, and M phases and from meiotic diploid cells, indicating that they are constitutive components of the complex throughout the yeast cell cycle. Mnd2 interacted strongly with Cdc23, Apc5, and Apc1 when coexpressed in an in vitro transcription/translation reaction. Swm1 also interacted with Cdc23 and Apc5 in this system. Previous studies described meiotic defects for mutations in MND2 and SWM1. Here, we show that mnd2Delta and swm1Delta haploid strains exhibit slow growth and accumulation of G(2)/M cells comparable with that seen in apc9Delta or apc10Delta strains and consistent with an APC defect. Taken together, these results demonstrate that Swm1 and Mnd2 are functional components of the yeast APC.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Borchers, CH (corresponding author), Univ N Carolina, Dept Biochem & Biophys, CB 7260 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.		, UNC Flow Cytometry Core/AGU-9839-2022; Hall, Mark C./D-1698-2011; BORCHERS, Christoph/U-5964-2019	Hall, Mark/0000-0001-6429-2506; Torres, Matthew/0000-0001-7296-4536				Blanco MA, 2001, J CELL SCI, V114, P2135; Bolte M, 2002, P NATL ACAD SCI USA, V99, P4385, DOI 10.1073/pnas.072385099; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cooper KF, 2000, P NATL ACAD SCI USA, V97, P14548, DOI 10.1073/pnas.250351297; Foiani M, 2000, MUTAT RES-FUND MOL M, V451, P187, DOI 10.1016/S0027-5107(00)00049-X; Gelbart ME, 2001, MOL CELL BIOL, V21, P2098, DOI 10.1128/MCB.21.6.2098-2106.2001; Gmachl M, 2000, P NATL ACAD SCI USA, V97, P8973, DOI 10.1073/pnas.97.16.8973; Grossberger R, 1999, J BIOL CHEM, V274, P14500, DOI 10.1074/jbc.274.20.14500; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Primig M, 2000, NAT GENET, V26, P415, DOI 10.1038/82539; Rabitsch KP, 2001, CURR BIOL, V11, P1001, DOI 10.1016/S0960-9822(01)00274-3; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Ufano S, 1999, MOL CELL BIOL, V19, P2118; Yoon HJ, 2002, CURR BIOL, V12, P2048, DOI 10.1016/S0960-9822(02)01331-3; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4	25	50	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16698	16705		10.1074/jbc.M213109200	http://dx.doi.org/10.1074/jbc.M213109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609981	hybrid, Green Published			2022-12-27	WOS:000182818600034
J	Maggi, LB; Moran, JM; Buller, RML; Corbett, JA				Maggi, LB; Moran, JM; Buller, RML; Corbett, JA			ERK activation is required for double-stranded RNA- and virus-induced interleukin-1 expression by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; DEPENDENT PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; TARGETED DELETION; ENDOTHELIAL-CELLS; INTERFERON-GAMMA; VIRAL-INFECTION; POTENTIAL ROLE; TNF-ALPHA	Double-stranded (ds) RNA, which accumulates during viral replication, activates the antiviral response of infected cells. In this study, we have identified a requirement for extracellular signal-regulated kinase (ERK) in the regulation of interleukin 1 (IL-1) expression by macrophages in response to dsRNA and viral infection. Treatment of RAW 264.7 cells or mouse macrophages with dsRNA stimulates ERK phosphorylation that is first apparent following a 15-min incubation and persists for up to 60 min, the accumulation of iNOS and IL-1 mRNA following a 6-h incubation, and the expression of iNOS and IL-1 at the protein level following a 24-h incubation. Inhibitors of ERK activation prevent dsRNA-induced ERK phosphorylation and IL-1 expression by macrophages. The regulation of macrophage activation by ERK appears to be selective for IL-1, as ERK inhibition does not attenuate dsRNA-induced iNOS expression by macrophages. dsRNA stimulates both ERK activation and IL-1 expression by macrophages isolated from dsRNA-dependent protein kinase (PKR)-deficient mice, indicating that PKR does not participate in this antiviral response. These findings support a novel PKR-independent role for ERK in the regulation of the antiviral response of IL-1 expression and release by macrophages.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Corbett, JA (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	corbettj@slu.edu	Maggi, Leonard/L-5217-2019	Maggi, Leonard/0000-0003-0138-0984	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044458] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052194] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-44458] Funding Source: Medline; NIDDK NIH HHS [DK-52194] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arnush M, 1998, J IMMUNOL, V160, P2684; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Baltzis D, 2002, J BIOL CHEM, V277, P38364, DOI 10.1074/jbc.M203564200; Bandyopadhyay SK, 2000, J IMMUNOL, V164, P2077, DOI 10.4049/jimmunol.164.4.2077; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; Blair LA, 2001, DIABETES, V50, P283, DOI 10.2337/diabetes.50.2.283; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; Chan ED, 1999, J IMMUNOL, V162, P415; Chan ED, 2001, INFECT IMMUN, V69, P2001, DOI 10.1128/IAI.69.4.2001-2010.2001; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Flodstrom M, 2001, VIROLOGY, V281, P205, DOI 10.1006/viro.2000.0801; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; GODAMBE SA, 1993, CYTOKINE, V5, P327, DOI 10.1016/1043-4666(93)90064-C; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Harcourt JL, 2001, EUR J BIOCHEM, V268, P1373, DOI 10.1046/j.1432-1327.2001.02003.x; Heitmeier MR, 1998, J BIOL CHEM, V273, P15301, DOI 10.1074/jbc.273.24.15301; HIBBS JB, 1990, INT CONGR SER, V897, P189; Hill JR, 1996, ANAL BIOCHEM, V236, P14, DOI 10.1006/abio.1996.0125; Hirasawa K, 1999, J VIROL, V73, P8541, DOI 10.1128/JVI.73.10.8541-8548.1999; HOVANESSIAN AG, 1993, TRANSLATIONAL REGULA, P163; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KOROMILAS AE, 1995, J BIOL CHEM, V270, P25426, DOI 10.1074/jbc.270.43.25426; Kreil TR, 1996, VIROLOGY, V219, P304, DOI 10.1006/viro.1996.0252; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Maggi LB, 2002, J BIOL CHEM, V277, P38449, DOI 10.1074/jbc.M206247200; Maggi LB, 2000, EMBO J, V19, P3630, DOI 10.1093/emboj/19.14.3630; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; MILHAUD PG, 1991, J INTERFERON RES, V11, P261, DOI 10.1089/jir.1991.11.261; Nath A, 1999, J BIOL CHEM, V274, P17098, DOI 10.1074/jbc.274.24.17098; OFFERMANN MK, 1995, EUR J BIOCHEM, V232, P28, DOI 10.1111/j.1432-1033.1995.tb20777.x; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Reiss CS, 1998, J VIROL, V72, P4547, DOI 10.1128/JVI.72.6.4547-4551.1998; Samuel CE, 1997, INT J HEMATOL, V65, P227; Scarim AL, 2001, AM J PATHOL, V159, P273, DOI 10.1016/S0002-9440(10)61693-8; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zaragoza C, 1999, J IMMUNOL, V163, P5497	50	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16683	16689		10.1074/jbc.M211744200	http://dx.doi.org/10.1074/jbc.M211744200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609986	hybrid			2022-12-27	WOS:000182818600032
J	Maglich, JM; Parks, DJ; Moore, LB; Collins, JL; Goodwin, B; Billin, AN; Stoltz, CA; Kliewer, SA; Lambert, MH; Willson, TM; Moore, JT				Maglich, JM; Parks, DJ; Moore, LB; Collins, JL; Goodwin, B; Billin, AN; Stoltz, CA; Kliewer, SA; Lambert, MH; Willson, TM; Moore, JT			Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREGNANE-X-RECEPTOR; RESPONSIVE NUCLEAR TRANSLOCATION; HEPATIC DRUG-METABOLISM; HUMAN CYP2B6 GENE; XENOBIOTIC RECEPTOR; ENHANCER MODULE; TRANSCRIPTIONAL ACTIVATION; CYP3A4 GENE; BILE-ACIDS; PXR	The orphan nuclear constitutive androstane receptor (CAR) is proposed to play a central role in the response to xenochemical stress. Identification of CAR target genes in humans has been limited by the lack of a selective CAR agonist. We report the identification of 6-(4-chlorophenyl) imidazo[2,1-b][1,3] thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl) oxime (CITCO) as a novel human CAR agonist with the following characteristics: (a) potent activity in an in vitro fluorescence-based CAR activation assay; (b) selectivity for CAR over other nuclear receptors, including the xenobiotic pregnane X receptor (PXR); (c) the ability to induce human CAR nuclear translocation; and (d) the ability to induce the prototypical CAR target gene CYP2B6 in primary human hepatocytes. Using primary cultures of human hepatocytes, the effects of CITCO on gene expression were compared with those of the PXR ligand rifampicin. The relative expression of a number of genes encoding proteins involved in various aspects of steroid and xenobiotic metabolism was analyzed. Notably, CAR and PXR activators differentially regulated the expression of several genes, demonstrating that these two nuclear receptors subserve overlapping but distinct biological functions in human hepatocytes.	GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Moore, JT (corresponding author), GlaxoSmithKline, Nucl Receptor Discovery Res, 5 Moore Dr,V-116B, Res Triangle Pk, NC 27709 USA.		feinstein, doug/M-9414-2019	Billin, Andrew/0000-0001-7752-0934				Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Code EL, 1997, DRUG METAB DISPOS, V25, P985; David G B, 1975, Prog Histochem Cytochem, V7, P1; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Gibson GG, 2002, XENOBIOTICA, V32, P165, DOI 10.1080/00498250110102674; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Goodwin B, 2002, MOL PHARMACOL, V62, P359, DOI 10.1124/mol.62.2.359; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Iwata H, 2002, COMP BIOCHEM PHYS C, V131, P501, DOI 10.1016/S1532-0456(02)00038-8; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; Kalow W, 2001, Pharmacogenomics J, V1, P234; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038; Lamba JK, 2002, PHARMACOGENETICS, V12, P121, DOI 10.1097/00008571-200203000-00006; LAMBERT MH, 1997, PRACTICAL APPL COMPU, P243; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Liddle C, 2002, SEMIN LIVER DIS, V22, P115, DOI 10.1055/s-2002-30098; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; Moore JT, 2000, TOXICOLOGY, V153, P1, DOI 10.1016/S0300-483X(00)00300-0; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Smirlis D, 2001, J BIOL CHEM, V276, P12822, DOI 10.1074/jbc.M005930200; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tyndale R, 1999, NICOTINE TOB RES, V1, P63; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Tzameli I, 2001, TRENDS ENDOCRIN MET, V12, P7, DOI 10.1016/S1043-2760(00)00332-5; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; WATKINS PB, 1995, HEPATOLOGY, V22, P994, DOI 10.1016/0270-9139(95)90325-9; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; Wei P., 2002, Pharmacogenomics Journal, V2, P117, DOI 10.1038/sj.tpj.6500087; Westlind A, 1999, BIOCHEM BIOPH RES CO, V259, P201, DOI 10.1006/bbrc.1999.0752; Xie HG, 2001, ANNU REV PHARMACOL, V41, P815, DOI 10.1146/annurev.pharmtox.41.1.815; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398	41	341	358	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17277	17283		10.1074/jbc.M300138200	http://dx.doi.org/10.1074/jbc.M300138200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611900	hybrid			2022-12-27	WOS:000182818600111
J	Mongiat, M; Fu, J; Oldershaw, R; Greenhalgh, R; Gown, AM; Iozzo, RV				Mongiat, M; Fu, J; Oldershaw, R; Greenhalgh, R; Gown, AM; Iozzo, RV			Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; FIBROBLAST GROWTH-FACTOR; DENSITY-LIPOPROTEIN-RECEPTOR; TERMINAL GLOBULAR DOMAIN; SILVERMAN-HANDMAKER TYPE; CELL-ADHESION MOLECULES; BASEMENT-MEMBRANE; STRUCTURAL BASIS; DYSSEGMENTAL DYSPLASIA; CHONDROGENIC ACTIVITY	The goal of this study was to discover novel partners for perlecan, a major heparan sulfate proteoglycan of basement membranes, and to examine new interactions through which perlecan may influence cell behavior. We employed the yeast two-hybrid system and used perlecan domain V as bait to screen a human keratinocyte cDNA library. Among the strongest interacting clones, we isolated a similar to1.6-kb cDNA insert that encoded extracellular matrix protein 1 (ECM1), a secreted glycoprotein involved in bone formation and angiogenesis. The sequencing of the clone revealed the existence of a novel splice variant that we name ECM1c. The interaction was validated by co-immunoprecipitation studies, using both cell-free systems and mammalian cells, and the specific binding site within each molecule was identified employing various deletion mutants. The C terminus of ECM1 interacted specifically with the epidermal growth factor-like modules flanking the LG2 subdomain of perlecan domain V. Perlecan and ECM1 were also co-expressed by a variety of normal and transformed cells, and immunohistochemical studies showed a partial expression overlap, particularly around dermal blood vessels and adnexal epithelia. ECM1 has been shown to regulate endochondral bone formation, stimulate the proliferation of endothelial cells, and induce angiogenesis. Similarly, perlecan plays an important role in chondrogenesis and skeletal development, as well as harboring pro- and anti-angiogenic activities. Thus, a physiological interaction could also occur in vivo during development and in pathological events, including tissue remodeling and tumor progression.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Signaling Program, Philadelphia, PA 19107 USA; Phenopath Labs, Seattle, WA 98103 USA	Jefferson University; Jefferson University; PhenoPath Laboratories	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 249 Jefferson Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.		Mongiat, Maurizio/H-8297-2018; Iozzo, Renato/AAS-1980-2020	Mongiat, Maurizio/0000-0001-6509-0068; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aho S, 1998, MATRIX BIOL, V17, P401, DOI 10.1016/S0945-053X(98)90100-7; Arikawa-Hirasawa E, 2001, AM J MED GENET, V106, P254, DOI 10.1002/ajmg.10229.abs; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; Arikawa-Hirasawa E, 2001, NAT GENET, V27, P431, DOI 10.1038/86941; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BATTAGLIA C, 1993, EUR J CELL BIOL, V61, P92; BHALERAO J, 1995, J BIOL CHEM, V270, P16385, DOI 10.1074/jbc.270.27.16385; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brown JC, 1997, EUR J BIOCHEM, V250, P39, DOI 10.1111/j.1432-1033.1997.t01-1-00039.x; BROWN JR, 1976, FED PROC, V35, P2141; CARSON DD, 1993, DEV BIOL, V155, P97, DOI 10.1006/dbio.1993.1010; CHAKRAVARTI S, 1995, J BIOL CHEM, V270, P404, DOI 10.1074/jbc.270.1.404; COHEN IR, 1994, CANCER RES, V54, P5771; Costell M, 2002, CIRC RES, V91, P158, DOI 10.1161/01.RES.0000026056.81424.DA; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; COUCHMAN JR, 1989, MATRIX, V9, P311, DOI 10.1016/S0934-8832(89)80007-1; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; COUCHMAN JR, 1995, J HISTOCHEM CYTOCHEM, V43, P955, DOI 10.1177/43.9.7543915; Deckers MML, 2001, BONE, V28, P14, DOI 10.1016/S8756-3282(00)00428-2; Dhanabal M, 2002, CANCER RES, V62, P3834; DUNLEVY JR, 2000, PROTEOGLYCANS STRUCT, P275; DZIADEK M, 1985, EMBO J, V4, P905, DOI 10.1002/j.1460-2075.1985.tb03717.x; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Ettner N, 1998, FEBS LETT, V430, P217, DOI 10.1016/S0014-5793(98)00601-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; French MM, 1999, J CELL BIOL, V145, P1103, DOI 10.1083/jcb.145.5.1103; French MM, 2002, J BONE MINER RES, V17, P48, DOI 10.1359/jbmr.2002.17.1.48; Friedrich MVK, 1999, J MOL BIOL, V294, P259, DOI 10.1006/jmbi.1999.3259; Friedrich MVK, 2000, EUR J BIOCHEM, V267, P3149, DOI 10.1046/j.1432-1327.2000.01337.x; Godin RE, 1996, DEV BIOL, V179, P148, DOI 10.1006/dbio.1996.0247; Gohring W, 1998, EUR J BIOCHEM, V255, P60, DOI 10.1046/j.1432-1327.1998.2550060.x; Hamada T, 2002, HUM MOL GENET, V11, P833, DOI 10.1093/hmg/11.7.833; Han ZQ, 2001, FASEB J, V15, P988, DOI 10.1096/fj.99-0934com; Handler M, 1997, DEV DYNAM, V210, P130, DOI 10.1002/(SICI)1097-0177(199710)210:2<130::AID-AJA6>3.0.CO;2-H; HASSELL JR, 1980, P NATL ACAD SCI-BIOL, V77, P4494, DOI 10.1073/pnas.77.8.4494; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; Hopf M, 1999, EUR J BIOCHEM, V259, P917, DOI 10.1046/j.1432-1327.1999.00127.x; IOZZO RV, 1994, BIOCHEM J, V302, P625, DOI 10.1042/bj3020625; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; IOZZO RV, 1994, MATRIX BIOL, V14, P203, DOI 10.1016/0945-053X(94)90183-X; IOZZO RV, 1984, J CELL BIOL, V99, P403, DOI 10.1083/jcb.99.2.403; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; Joseph SJ, 1996, DEVELOPMENT, V122, P3443; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; MATHIEU E, 1994, J BONE MINER RES, V9, P903; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mongiat M, 2000, J BIOL CHEM, V275, P25471, DOI 10.1074/jbc.M001426200; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Mongiat M, 2000, J BIOL CHEM, V275, P7095, DOI 10.1074/jbc.275.10.7095; MURDOCH AD, 1994, J HISTOCHEM CYTOCHEM, V42, P239, DOI 10.1177/42.2.7507142; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; Nugent MA, 2000, P NATL ACAD SCI USA, V97, P6722, DOI 10.1073/pnas.97.12.6722; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; Sasaki T, 2000, J MOL BIOL, V301, P1179, DOI 10.1006/jmbi.2000.3996; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; Smits P, 1999, GENE, V226, P253, DOI 10.1016/S0378-1119(98)00558-7; Smits P, 1997, GENOMICS, V45, P487, DOI 10.1006/geno.1997.4918; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; VIGNY M, 1988, J CELL PHYSIOL, V137, P321, DOI 10.1002/jcp.1041370216; Villar MJ, 1999, J CELL BIOCHEM, V75, P665, DOI 10.1002/(SICI)1097-4644(19991215)75:4<665::AID-JCB12>3.0.CO;2-S; Whitelock JM, 1999, MATRIX BIOL, V18, P163, DOI 10.1016/S0945-053X(99)00014-1; YURCHENCO PD, 1987, J BIOL CHEM, V262, P17668	75	129	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17491	17499		10.1074/jbc.M210529200	http://dx.doi.org/10.1074/jbc.M210529200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604605	hybrid			2022-12-27	WOS:000182818600137
J	Pauwels, F; Vergauwen, B; Vanrobaeys, F; Devreese, B; Van Beeumen, JJ				Pauwels, F; Vergauwen, B; Vanrobaeys, F; Devreese, B; Van Beeumen, JJ			Purification and characterization of a chimeric enzyme from Haemophilus influenzae Rd that exhibits glutathione-dependent peroxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; THIOREDOXIN; IDENTIFICATION; REDUCTASE; PROTEINS; PEROXIREDOXINS; GLUTAREDOXIN; ANTIOXIDANT	While belonging to the same family of antioxidant enzymes, members of the peroxiredoxins do not necessarily employ one and the same method for their reduction. Most representatives become reduced with the aid of thioredoxin, whereas some members use AhpF, tryparedoxin, or cyclophilin A. Recent research on a new peroxiredoxin isoform (type C) from Populus trichocarpa has shown that these particular types may also use glutaredoxin instead of thioredoxin. This finding is supported by the occurrence of chimeric proteins composed of a peroxiredoxin and glutaredoxin region. A gene encoding such a fusion protein is enclosed in the Haemophilus influenzae Rd genome. We expressed the H. influenzae protein, denoted here as PGdx, in Escherichia coli and purified the recombinant enzyme. In vitro assays demonstrate that PGdx, in the presence of dithiothreitol or glutathione, is able to protect super-coiled DNA against the metal ion-catalyzed oxidation-system. Enzymatic assays did, indeed, characterize PGdx as a peroxidase, requiring the glutathione redox cycle for the reduction of hydrogen peroxide (k(cat)/K-m 5.01 x 10(6) s(-1) M-1) as well as the small organic hydroperoxide tert-butylhydroperoxide (k(cat)/K-m 5.67 x 10(4) s(-1) M-1). Enzymatic activity as function of the glutathione concentration deviated from normal Michaelis-Menten kinetics, giving a sigmoidal pattern with an apparent Hill coefficient of 2.9. Besides the formation of a disulfide-linked PGdx dimer, it was also shown by mass spectrometric analysis that cysteine 49, which is equivalent to the active site cysteine of the peroxiredoxins, undergoes glutathionylation during purification under nonreducing conditions. Based on these results, we propose a model for the catalytic mechanism.	Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium	Ghent University	Van Beeumen, JJ (corresponding author), Univ Ghent, Lab Prot Biochem & Prot Engn, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	Jozef.vanbeeumen@rug.ac.be	Devreese, Bart/B-2011-2009; Devreese, Bart/K-2841-2019	Devreese, Bart/0000-0002-9764-2581; Devreese, Bart/0000-0002-9764-2581				ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BARCAK GJ, 1991, METHOD ENZYMOL, V204, P321; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BISHAI WR, 1994, INFECT IMMUN, V62, P4855, DOI 10.1128/IAI.62.11.4855-4860.1994; BISHAI WR, 1994, J BACTERIOL, V176, P2914, DOI 10.1128/JB.176.10.2914-2921.1994; Calzi ML, 1997, BIOCHEMISTRY-US, V36, P13357, DOI 10.1021/bi9713660; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Copeland R. A., 2000, ENZYMES PRACTICAL IN, P367; Craig JE, 2001, FEMS MICROBIOL LETT, V203, P55, DOI 10.1016/S0378-1097(01)00328-7; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Goyer A, 1999, FEBS LETT, V444, P165, DOI 10.1016/S0014-5793(99)00051-4; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Harris JR, 2001, BBA-PROTEIN STRUCT M, V1547, P221, DOI 10.1016/S0167-4838(01)00184-4; HOLLANDER R, 1976, A VAN LEEUW J MICROB, V42, P429, DOI 10.1007/BF00410174; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lind C, 2002, ARCH BIOCHEM BIOPHYS, V406, P229, DOI 10.1016/S0003-9861(02)00468-X; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Pericone CD, 2000, INFECT IMMUN, V68, P3990, DOI 10.1128/IAI.68.7.3990-3997.2000; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Rouhier N, 2002, J BIOL CHEM, V277, P13609, DOI 10.1074/jbc.M111489200; Rouhier N, 2001, PLANT PHYSIOL, V127, P1299, DOI 10.1104/pp.010586; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; SEGEL IH, 1975, ENZYME KINETICS, P347; Shenton D, 2002, J BIOL CHEM, V277, P16853, DOI 10.1074/jbc.M200559200; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Vergauwen B, 2003, J BACTERIOL, V185, P1572, DOI 10.1128/JB.185.5.1572-1581.2003; Vergauwen B, 2001, J BIOL CHEM, V276, P20890, DOI 10.1074/jbc.M102026200; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m	37	47	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16658	16666		10.1074/jbc.M300157200	http://dx.doi.org/10.1074/jbc.M300157200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606554	hybrid			2022-12-27	WOS:000182818600029
J	Seeger, M; Hartmann-Petersen, R; Wilkinson, CRM; Wallace, M; Samejima, I; Taylor, MS; Gordon, C				Seeger, M; Hartmann-Petersen, R; Wilkinson, CRM; Wallace, M; Samejima, I; Taylor, MS; Gordon, C			Interaction of the anaphase-promoting complex/cyclosome and proteasome protein complexes with multiubiquitin chain-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-ATPASE SUBUNIT; FISSION YEAST; 26S PROTEASOME; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; REGULATORY COMPLEX; DNA-REPAIR; UBIQUITIN; DEGRADATION; DOMAIN	Fission yeast Rhp23 and Pus1 represent two families of multiubiquitin chain-binding proteins that associate with the proteasome. We show that both proteins bind to different regions of the proteasome subunit Mts4. The binding site for Pus1 was mapped to a cluster of repetitive sequences also found in the proteasome subunit SpRpn2 and the anaphase-promoting complex/cyclosome (APC/C) subunit Cut4. The putative role of Pus1 as a factor involved in allocation of ubiquitinylated substrates for the proteasome is discussed.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Gordon, C (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	Colin.Gordon@hgu.mrc.ac.uk	Hartmann-Petersen, Rasmus/K-4434-2014; Taylor, Martin S/C-3825-2009	Hartmann-Petersen, Rasmus/0000-0002-4155-7791; Taylor, Martin S/0000-0001-7656-330X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HARACSKA L, 1995, EUR J BIOCHEM, V231, P720, DOI 10.1111/j.1432-1033.1995.0720d.x; Haracska L, 1997, FEBS LETT, V412, P331, DOI 10.1016/S0014-5793(97)00808-9; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lambertson D, 1999, GENETICS, V153, P69; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Wilkinson CRM, 1997, J BIOL CHEM, V272, P25768, DOI 10.1074/jbc.272.41.25768; Wilkinson CRM, 2000, J BIOL CHEM, V275, P15182, DOI 10.1074/jbc.275.20.15182; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	41	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16791	16796		10.1074/jbc.M208281200	http://dx.doi.org/10.1074/jbc.M208281200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615927	hybrid			2022-12-27	WOS:000182818600047
J	Yang, JH; Hu, GH; Wang, SW; Li, YC; Martin, R; Li, K; Yao, ZB				Yang, JH; Hu, GH; Wang, SW; Li, YC; Martin, R; Li, K; Yao, ZB			Calcineurin/nuclear factors of activated T cells (NFAT)-activating and immunoreceptor tyrosine-based activation motif (ITAM)-containing protein (CNAIP), a novel ITAM-containing protein that activates the calcineurin/NFAT-signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; DEPENDENT PATHWAY; GENE-EXPRESSION; NUCLEAR FACTORS; DEFICIENT MICE; NFAT; ANTIGEN; TRANSCRIPTION; PREDICTION; KINASE	We report in this study the identification and characterization of a novel protein that we designated as calcineurin/NFAT- activating and immunoreceptor tyrosine-based activation motif (ITAM)-containing protein (CNAIP). The predicted 270-amino acid sequence contains an N-terminal signal peptide, an immunoglobin domain in the extracellular region, a transmembrane domain and an ITAM in the cytoplasmic tail. Quantitative reverse transcription-PCR showed that CNAIP was preferentially expressed in neutrophils, monocytes, mast cells, and other immune-related cells. Co-transfection of CNAIP expression constructs with luciferase reporter plasmids in HMC-1 cells resulted in activation of interleukin-13 and tumor necrosis factor-alpha promoters, which was mediated through the calcineurin/NFAT-signaling pathway. Mutation of either or both tyrosines in the ITAM abolished transcriptional activation induced by CNAIP, indicating that the ITAM is indispensable for CNAIP function in activating cytokine gene promoters. Thus, it is concluded that CNAIP is a novel ITAM-containing protein that activates the calcineurin/NFAT-signaling pathway and the downstream cytokine gene promoters.	Tanox Biosyst Inc, Dept Exploratory Biol, Houston, TX 77025 USA		Li, K (corresponding author), Tanox Biosyst Inc, Dept Exploratory Biol, Houston, TX 77025 USA.	kli@tanox.com; byao@tanox.com						Ali H, 2000, J IMMUNOL, V165, P7215, DOI 10.4049/jimmunol.165.12.7215; ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; Berland R, 2000, CURR TOP MICROBIOL, V252, P131; Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991; Bouchon A, 2001, NATURE, V410, P1103, DOI 10.1038/35074114; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P9398, DOI 10.1073/pnas.152665399; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Fischer D, 1999, PROTEINS, P209; Furuke K, 1999, J IMMUNOL, V162, P1988; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; Isakov N, 1997, J LEUKOCYTE BIOL, V61, P6, DOI 10.1002/jlb.61.1.6; Isakov N, 1997, IMMUNOL RES, V16, P85, DOI 10.1007/BF02786325; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Khan WN, 2001, IMMUNOL RES, V23, P147, DOI 10.1385/IR:23:2-3:147; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Kiani A, 2001, BLOOD, V98, P1480, DOI 10.1182/blood.V98.5.1480; Lanier LL, 2001, NAT IMMUNOL, V2, P23, DOI 10.1038/83130; Love PE, 2000, IMMUNITY, V12, P591, DOI 10.1016/S1074-7613(00)80210-1; Luo C, 1996, MOL CELL BIOL, V16, P3955; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Marone G, 1997, INT ARCH ALLERGY IMM, V114, P207, DOI 10.1159/000237670; Masuda ES, 1998, CELL SIGNAL, V10, P599, DOI 10.1016/S0898-6568(98)00019-9; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Palanki MSS, 2002, CURR MED CHEM, V9, P219, DOI 10.2174/0929867023371265; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Perkins D, 1996, J IMMUNOL, V156, P4154; Qian DP, 1996, J EXP MED, V183, P611, DOI 10.1084/jem.183.2.611; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Stranick KS, 1997, J BIOL CHEM, V272, P16453, DOI 10.1074/jbc.272.26.16453; TING AT, 1991, J IMMUNOL, V147, P3122	42	13	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16797	16801		10.1074/jbc.M211060200	http://dx.doi.org/10.1074/jbc.M211060200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615919	hybrid			2022-12-27	WOS:000182818600048
J	Bitard, J; Daburon, S; Duplomb, L; Blanchard, F; Vuisio, P; Jacques, Y; Godard, A; Heath, JK; Moreau, JF; Taupin, JL				Bitard, J; Daburon, S; Duplomb, L; Blanchard, F; Vuisio, P; Jacques, Y; Godard, A; Heath, JK; Moreau, JF; Taupin, JL			Mutations in the immunoglobulin-like domain of gp190, the leukemia inhibitory factor (LIF) receptor, increase or decrease its affinity for LIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING FACTOR-RECEPTOR; CYTOKINE-BINDING DOMAINS; FACTOR-II RECEPTOR; ONCOSTATIN-M; SIGNAL-TRANSDUCTION; HUMAN INTERLEUKIN; CRYSTAL-STRUCTURE; LIGAND-BINDING; GP130; COMPLEX	The leukemia inhibitory factor (LIF) receptor comprises the low affinity binding chain gp190 and the high affinity converter gp130. The ectodomain of gp190 is among the most complex in the hematopoietin receptor family, because it contains two typical cytokine receptor homology domains separated by an immunoglobulin-like (Ig-like) domain. Human and murine gp190 proteins share 76% homology, but murine gp190 binds human LIF with a much higher affinity, a property attributed to the Ig-like domain. Using alanine-scanning mutagenesis of the Ig-like domain, we mapped a LIF binding site at its carboxyl terminus, mainly involving residue Phe-328. Mutation of selected residues into their orthologs in the murine receptor (Q251E and N321D) significantly increased the affinity for human LIF. Interestingly, these residues, although localized at both the amino and carboxyl terminus, make a spatially unique LIF binding site in a structural model of the Ig-like module. These results demonstrate definitively the role of the Ig-like domain in LIF binding and the potential to modulate receptor affinity in this family with very limited amino acid changes.	Univ Bordeaux 2, CNRS, UMR 5540, F-33076 Bordeaux, France; IFR 66, F-33076 Bordeaux, France; INSERM, U463, F-44035 Nantes, France; IFR 26, F-44035 Nantes, France; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Birmingham	Taupin, JL (corresponding author), Univ Bordeaux 2, CNRS, UMR 5540, 146 Rue Leo Saignat, F-33076 Bordeaux, France.		Blanchard, Frederic/K-8018-2015; Blanchard, Frederic/AAS-1930-2021	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573; Heath, John/0000-0003-4886-4070; BITARD, Juliette/0000-0001-6626-3522; Duplomb, Laurence/0000-0002-5715-3759				Barton VA, 1999, J BIOL CHEM, V274, P5755, DOI 10.1074/jbc.274.9.5755; Blanchard F, 1999, J BIOL CHEM, V274, P24685, DOI 10.1074/jbc.274.35.24685; Blanchard F, 2001, J BIOL CHEM, V276, P47038, DOI 10.1074/jbc.M107971200; Blanchard F, 1998, J BIOL CHEM, V273, P20886, DOI 10.1074/jbc.273.33.20886; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Cabibbo A, 1995, GENE, V167, P41, DOI 10.1016/0378-1119(95)00632-X; Chevalier S, 1996, J BIOL CHEM, V271, P14764, DOI 10.1074/jbc.271.25.14764; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Chow DC, 2001, BIOCHEMISTRY-US, V40, P7593, DOI 10.1021/bi010192q; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Deller MC, 2000, STRUCT FOLD DES, V8, P863, DOI 10.1016/S0969-2126(00)00176-3; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GODARD A, 1992, J BIOL CHEM, V267, P3214; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; Huang X, 1991, ADV APPL MATH, V12, P373; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; Layton JE, 2001, J BIOL CHEM, V276, P36779, DOI 10.1074/jbc.M104787200; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LAYTON MJ, 1994, J BIOL CHEM, V269, P17048; Owczarek CM, 1997, J BIOL CHEM, V272, P23976, DOI 10.1074/jbc.272.38.23976; OWCZAREK CM, 1993, EMBO J, V12, P3487, DOI 10.1002/j.1460-2075.1993.tb06023.x; Pitard V, 1997, J IMMUNOL METHODS, V205, P177, DOI 10.1016/S0022-1759(97)00074-4; Pitard V, 1998, EUR CYTOKINE NETW, V9, P599; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; Staunton D, 1998, PROTEIN ENG, V11, P1093, DOI 10.1093/protein/11.11.1093; Taupin JL, 1999, J BIOL CHEM, V274, P14482, DOI 10.1074/jbc.274.20.14482; Taupin JL, 2001, J BIOL CHEM, V276, P47975, DOI 10.1074/jbc.M105476200; TAUPIN JL, 1993, SCAND J IMMUNOL, V38, P293, DOI 10.1111/j.1365-3083.1993.tb01728.x; Taupin JL, 1997, CYTOKINE, V9, P112, DOI 10.1006/cyto.1996.0144; Tomida M, 1996, J BIOCHEM-TOKYO, V120, P201; Vernallis AB, 1997, J BIOL CHEM, V272, P26947, DOI 10.1074/jbc.272.43.26947; Voisin MB, 2002, J BIOL CHEM, V277, P13682, DOI 10.1074/jbc.M111624200; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	37	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16253	16261		10.1074/jbc.M207193200	http://dx.doi.org/10.1074/jbc.M207193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601009	hybrid			2022-12-27	WOS:000182680000101
J	Dhani, SU; Mohammad-Panah, R; Ahmed, N; Ackerley, C; Ramjeesingh, M; Bear, CE				Dhani, SU; Mohammad-Panah, R; Ahmed, N; Ackerley, C; Ramjeesingh, M; Bear, CE			Evidence for a functional interaction between the CIC-2 chloride channel and the retrograde motor dynein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CL CURRENT; CYTOPLASMIC DYNEIN; POTENTIAL MECHANISM; EPITHELIAL-CELLS; DYNACTIN COMPLEX; DENTS-DISEASE; CLC-2; SUBUNIT; PHOSPHORYLATION; ORGANIZATION	The ClC-2 chloride channel has been implicated in essential physiological functions. Analyses of ClC-2 knock-out mice suggest that ClC-2 expression in retinal pigment epithelia and Sertoli cells normally supports the viability of photoreceptor cells and male germ cells, respectively. Further, other studies suggest that ClC-2 expression in neurons may modify inhibitory synaptic transmission via the gamma-aminobutyric acid, type A receptor. However, complete understanding of the physiological functions of ClC-2 requires elucidation of the molecular basis for its regulation. Using cell imaging and biochemical and electrophysiological techniques, we show that expression of ClC-2 at the cell surface may be regulated via an interaction with the dynein motor complex. Mass spectrometry and Western blot analysis of eluate from a ClC-2 affinity matrix showed that heavy and intermediate chains of dynein bind ClC-2 in vitro. The dynein intermediate chain co-immunoprecipitates with ClC-2 from hippocampal membranes suggesting that they also interact in vivo. Disruption of dynein motor function perturbs ClC-2 localization and increases the functional expression of ClC-2 in the plasma membranes of COS7 cells. Thus, cell surface expression of ClC-2 may be regulated by dynein motor activity. This work is the first to demonstrate an in vivo interaction between an ion channel and the dynein motor complex.	Hosp Sick Children, Res Inst, Programme Struct Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Pathol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Bear, CE (corresponding author), Hosp Sick Children, Res Inst, Programme Struct Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.				NIDDK NIH HHS [DK 49096] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049096] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bali MZ, 2001, AM J PHYSIOL-CELL PH, V280, pC1588, DOI 10.1152/ajpcell.2001.280.6.C1588; Blaisdell CJ, 1999, AM J RESP CELL MOL, V20, P842, DOI 10.1165/ajrcmb.20.4.3431; Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; DUNN WA, 1980, J BIOL CHEM, V255, P5971; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Eckley DM, 1999, J CELL BIOL, V147, P307, DOI 10.1083/jcb.147.2.307; EKSTROM P, 1984, J NEUROCHEM, V43, P1342, DOI 10.1111/j.1471-4159.1984.tb05392.x; Fritsch J, 1996, J PHYSIOL-LONDON, V490, P115, DOI 10.1113/jphysiol.1996.sp021130; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Gyomorey K, 2000, AM J PHYSIOL-CELL PH, V279, pC1787, DOI 10.1152/ajpcell.2000.279.6.C1787; Holleran EA, 2001, J BIOL CHEM, V276, P36598, DOI 10.1074/jbc.M104838200; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Huang J, 2001, P NATL ACAD SCI USA, V98, P13084, DOI 10.1073/pnas.241368698; JANEVSKI J, 1995, EXP CELL RES, V217, P227, DOI 10.1006/excr.1995.1082; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; King SJ, 2002, PROTEIN SCI, V11, P1239, DOI 10.1110/ps.2520102; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Marples D, 1996, J PHYSIOL-LONDON, V490, P767, DOI 10.1113/jphysiol.1996.sp021184; Martou G, 2000, EXP CELL RES, V256, P131, DOI 10.1006/excr.1999.4793; Mohammad-Panah R, 2001, J BIOL CHEM, V276, P8306, DOI 10.1074/jbc.M006764200; Molero JC, 2001, J BIOL CHEM, V276, P43829, DOI 10.1074/jbc.M105452200; Muresan V, 2001, MOL CELL, V7, P173, DOI 10.1016/S1097-2765(01)00165-4; Murray CB, 1996, AM J PHYSIOL-LUNG C, V271, pL829, DOI 10.1152/ajplung.1996.271.5.L829; Nehrke K, 2002, J BIOL CHEM, V277, P23604, DOI 10.1074/jbc.M202900200; Piwon N, 2000, NATURE, V408, P369, DOI 10.1038/35042597; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Ramjeesingh M, 2000, BIOCHEMISTRY-US, V39, P13838, DOI 10.1021/bi001282i; Rutledge E, 2001, CURR BIOL, V11, P161, DOI 10.1016/S0960-9822(01)00051-3; SCHROER TA, 1994, CURR OPIN CELL BIOL, V6, P69, DOI 10.1016/0955-0674(94)90118-X; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P3879, DOI 10.1073/pnas.95.7.3879; Sik A, 2000, NEUROSCIENCE, V101, P51, DOI 10.1016/S0306-4522(00)00360-2; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; VANDEURS B, 1987, EXP CELL RES, V171, P137, DOI 10.1016/0014-4827(87)90257-6; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Wan Q, 1997, J NEUROSCI, V17, P5062; Zheng YJ, 2002, J BIOL CHEM, V277, P32268, DOI 10.1074/jbc.M202105200	45	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16262	16270		10.1074/jbc.M209828200	http://dx.doi.org/10.1074/jbc.M209828200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601004	hybrid			2022-12-27	WOS:000182680000102
J	Koerner, C; Guan, T; Gerace, L; Cingolani, G				Koerner, C; Guan, T; Gerace, L; Cingolani, G			Synergy of silent and hot spot mutations in importin beta reveals a dynamic mechanism for recognition of a nuclear localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; ELECTRON-DENSITY MAPS; PROTEIN IMPORT; CRYSTALLOGRAPHIC ANALYSIS; KARYOPHERIN-ALPHA; PORE COMPLEX; TRANSPORT; RAN; RECEPTOR; BIOLOGY	Molecular recognition of the importin beta-binding (IBB) domain of importin a by importin 6 is critical for the nuclear import of protein cargoes containing a classical nuclear localization signal. We have studied the function of four conserved tryptophans of importin beta (Trp-342, Trp-430, Trp-472, and Trp-864) located at the binding interface with the IBB domain by systematic alanine substitution mutagenesis. We found that Trp-864 is a mutational hot spot that significantly affects IBB-binding and import activity, whereas residues Trp-342, Trp-430, and Trp-472 are mutationally silent when analyzed individually. Interestingly, the combination of the hot spot at residue Trp-864 with mutations in the other three tryptophans gives rise to a striking synergy that diminishes IBB domain binding by up to similar to 1000-fold and, in turn, abolishes import activity. We propose that importin beta uses the tryptophans to select and stabilize a helical conformation of the IBB domain, which, in turn, conveys specific, high affinity binding.	Scripps Res Inst, Dept Cell & Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Gerace, L (corresponding author), Scripps Res Inst, Dept Cell & Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Körner, Carolin/AAT-7799-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041955] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41955] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1992, METHOD ENZYMOL, V219, P97; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; Cingolani G, 2000, FEBS LETT, V484, P291, DOI 10.1016/S0014-5793(00)02154-2; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Delphin C, 1997, MOL BIOL CELL, V8, P2379, DOI 10.1091/mbc.8.12.2379; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Frosst P, 2002, J CELL BIOL, V156, P617, DOI 10.1083/jcb.200106046; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Kumar S, 2000, PROTEIN SCI, V9, P10; Lyman SK, 2002, J CELL BIOL, V159, P55, DOI 10.1083/jcb.200204163; Ma BY, 2002, PROTEIN SCI, V11, P184, DOI 10.1110/ps.21302; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Malik HS, 1997, P NATL ACAD SCI USA, V94, P13738, DOI 10.1073/pnas.94.25.13738; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Melchior F, 1998, METH MOL B, V88, P265; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nachury MV, 1999, P NATL ACAD SCI USA, V96, P9622, DOI 10.1073/pnas.96.17.9622; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Ye XM, 1999, CHEM BIOL, V6, P657, DOI 10.1016/S1074-5521(99)80117-3	36	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16216	16221		10.1074/jbc.M301137200	http://dx.doi.org/10.1074/jbc.M301137200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594203	hybrid			2022-12-27	WOS:000182680000096
J	Kouklis, P; Konstantoulaki, M; Malik, AB				Kouklis, P; Konstantoulaki, M; Malik, AB			VE-cadherin-induced Cdc42 signaling regulates formation of membrane protrusions in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-CADHERIN; MOLECULAR-ORGANIZATION; FUNCTIONAL-ROLE; ALPHA-CATENIN; BETA-CATENIN; ADHESION; JUNCTIONS; COMPLEX; DOMAIN; RHO	The cytoplasmic domain of cadherins and the associated catenins link the cytoskeleton with signal transduction pathways. To study the signaling function of non-junctional VE-cadherin, which can form during the loss VE-cadherin homotypic adhesion, wild type VE-cadherin or VE-cadherin cytoplasmic domain (DeltaEXD) was expressed in sub-confluent endothelial cells. We observed that Cdc42 was activated in transfected cells and that these cells also developed Cdc42-dependent >70-mum-long plasma membrane protrusions. The formation of these structures required actin polymerization, and they developed specifically in endothelial cells as compared with epithelial cells. Expression of the VE-cadherin cytoplasmic domain lacking the beta-catenin binding site also induced Cdc42 activation; thus, its activation cannot be ascribed to beta-catenin binding. However, these cells were not able to form the protrusions. These results suggest that the cytoplasmic domain of non-junctional VE-cadherin can serve as a scaffold involved in Cdc42 activation at the endothelial plasma membrane. beta-Catenin and the associated alpha-catenin may serve as support sites for actin polymerization, leading to formation of long plasma membrane protrusions. Thus, non-junctional VE-cadherin actively participates in inside-out signaling at the plasma membrane, leading to the development of endothelial membrane protrusions.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kouklis, P (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,M-C 868, Chicago, IL 60612 USA.	pkouklis@uic.edu		Malik, Asrar/0000-0002-8205-7128; Kouklis, Panos/0000-0003-0378-5619				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Allport JR, 2000, J CELL BIOL, V148, P203, DOI 10.1083/jcb.148.1.203; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Ben-Ze'Ev A, 1999, ANN NY ACAD SCI, V886, P37, DOI 10.1111/j.1749-6632.1999.tb09398.x; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Dejana E, 2000, INT J DEV BIOL, V44, P743; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; DUFOUR S, 1994, J CELL BIOL, V127, P521, DOI 10.1083/jcb.127.2.521; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; Gotsch U, 1997, J CELL SCI, V110, P583; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hertig CM, 1996, J CELL SCI, V109, P1; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Luscinskas FW, 2002, IMMUNOL REV, V186, P57, DOI 10.1034/j.1600-065X.2002.18606.x; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nieman MT, 1999, J CELL SCI, V112, P1621; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Radice GL, 1997, J CELL BIOL, V139, P1025, DOI 10.1083/jcb.139.4.1025; Radice GL, 1997, DEV BIOL, V181, P64, DOI 10.1006/dbio.1996.8443; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; STAPPENBECK TS, 1993, J CELL BIOL, V123, P691, DOI 10.1083/jcb.123.3.691; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Venkiteswaran K, 2002, AM J PHYSIOL-CELL PH, V283, pC811, DOI 10.1152/ajpcell.00417.2001; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Zhu AJ, 1996, J CELL SCI, V109, P3013	42	47	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16230	16236		10.1074/jbc.M212591200	http://dx.doi.org/10.1074/jbc.M212591200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595527	hybrid			2022-12-27	WOS:000182680000098
J	Lusetti, SL; Shaw, JJ; Cox, MM				Lusetti, SL; Shaw, JJ; Cox, MM			Magnesium ion-dependent activation of the RecA protein involves the C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-RECA; SINGLE-STRANDED-DNA; ATP-GAMMA-S; BINDING-PROTEIN; CONFORMATIONAL-CHANGES; STABLE COMPLEXES; INACTIVE FORMS; GENE-PRODUCT; SOS RESPONSE; SSB PROTEIN	Optimal conditions for RecA protein-mediated DNA strand exchange include 6-8 mm.Mg2+ in excess of that required to form complexes with ATP. We provide evidence that the free magnesium ion is required to mediate a conformational change in the RecA protein C terminus that activates RecA-mediated DNA strand exchange. In particular, a "closed" (low Mg2+) conformation of a RecA nucleoprotein filament restricts DNA pairing by incoming duplex DNA, although single-stranded overhangs at the ends of a duplex allow limited DNA pairing to occur. The addition of excess Mg2+ results in an "open" conformation, which can promote efficient DNA pairing and strand exchange regardless of DNA end structure. The removal of 17 amino acid residues at the Escherichia coli RecA C terminus eliminates a measurable requirement for excess Mg2+ and permits efficient DNA pairing and exchange similar to that seen with the wild-type protein at high Mg2+ levels. Thus, the RecA C terminus imposes the need for the high magnesium. ion concentrations requisite in RecA reactions in vitro. We propose that the C terminus acts as a regulatory switch, modulating the access of double-stranded DNA to the presynaptic filament and thereby inhibiting homologous DNA pairing and strand exchange at low magnesium ion concentrations.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; COX MM, 1983, J BIOL CHEM, V258, P2577; COX MM, 1982, J BIOL CHEM, V257, P8523; COX MM, 1999, PROG NUCL ACID RES M, V63, P310; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Datta S, 2000, NUCLEIC ACIDS RES, V28, P4964, DOI 10.1093/nar/28.24.4964; DAVIS RW, 1980, ADV BACTERIAL GENET, P70; EGELMAN EH, 1988, J MOL BIOL, V200, P329, DOI 10.1016/0022-2836(88)90245-8; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; FLORY SS, 1984, COLD SPRING HARB SYM, V49, P513, DOI 10.1101/SQB.1984.049.01.058; HONIGBERG SM, 1985, J BIOL CHEM, V260, P1845; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KUHN A, 1985, J BACTERIOL, V163, P906, DOI 10.1128/JB.163.3.906-912.1985; KUHN AHU, 1983, J VIROL, V47, P540, DOI 10.1128/JVI.47.3.540-552.1983; Kurumizaka H, 1999, ARCH BIOCHEM BIOPHYS, V365, P83, DOI 10.1006/abbi.1999.1166; Kurumizaka H, 2000, FEBS LETT, V477, P129, DOI 10.1016/S0014-5793(00)01781-6; Kurumizaka H, 1996, J BIOL CHEM, V271, P33515, DOI 10.1074/jbc.271.52.33515; LARMINAT F, 1989, MOL GEN GENET, V216, P106, DOI 10.1007/BF00332237; LAVERY PE, 1992, J BIOL CHEM, V267, P9307; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; LUSK JE, 1968, J BIOL CHEM, V243, P2618; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PHILLIPS RC, 1966, J AM CHEM SOC, V88, P2631, DOI 10.1021/ja00964a002; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; ROBERTS JW, 1978, P NATL ACAD SCI USA, V75, P4714, DOI 10.1073/pnas.75.10.4714; ROMAN LJ, 1986, BIOCHEMISTRY-US, V25, P7375, DOI 10.1021/bi00371a020; RUSCHE JR, 1985, J BIOL CHEM, V260, P949; Saecker RM, 2002, CURR OPIN STRUC BIOL, V12, P311, DOI 10.1016/S0959-440X(02)00326-3; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; Shinagawa H, 1996, EXS, V77, P221; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; WEDEKIND JE, 1994, BIOCHEMISTRY-US, V33, P9333, DOI 10.1021/bi00197a038; YARRANTON GT, 1982, MOL GEN GENET, V185, P99, DOI 10.1007/BF00333797; YU X, 1992, J MOL BIOL, V225, P193, DOI 10.1016/0022-2836(92)91036-O; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L; YU X, 1991, J STRUCT BIOL, V106, P243, DOI 10.1016/1047-8477(91)90074-7; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	54	65	78	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16381	16388		10.1074/jbc.M212916200	http://dx.doi.org/10.1074/jbc.M212916200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595538	hybrid			2022-12-27	WOS:000182680000117
J	Qiao, DH; Meyer, K; Mundhenke, C; Drew, SA; Friedl, A				Qiao, DH; Meyer, K; Mundhenke, C; Drew, SA; Friedl, A			Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LUNG FIBROBLASTS; MOLECULAR-CLONING; FACTOR RECEPTOR-1; CARCINOMA CELLS; FGF RECEPTORS; TUMOR-GROWTH; IN-SITU; BINDING; ANGIOGENESIS; EXPRESSION	Fibroblast growth factor-2 (FGF2) is a potent angiogenic factor in gliomas. Heparan sulfate promotes ligand binding to receptor tyrosine kinase and regulates signaling. The goal of this study was to examine the contribution of heparan sulfate proteoglycans (HSPGs) to glioma angiogenesis. Here we show that all brain endothelial cell HSPGs carry heparan sulfate chains similarly capable of forming a ternary complex with FGF2 and fibroblast growth factor receptor-1c and of promoting a mitogenic. signal. Immunohistochemical analysis revealed that glypican-1 was overexpressed in glioma vessel endothelial cells, whereas this cell-surface HSPG was consistently undetectable in normal brain vessels. To determine the effect of increased glypican-1 expression on FGF2 signaling, we transfected normal brain endothelial cells, which express low base-line levels of glypican-1, with this proteoglycan. Glypican-1 expression enhanced growth of brain endothelial cells and sensitized them to FGF2-induced mitogenesis despite the fact that glypican-1 remained a minor proteoglycan. In contrast, overexpression of syndecan-1 had no effect on growth or FGF2 sensitivity. We conclude that the glypican-1 core protein has a specific role in FGF2 signaling. Glypican-1 overexpression may contribute to angiogenesis and the radiation resistance characteristic of this malignancy.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53562 USA	University of Wisconsin System; University of Wisconsin Madison	Friedl, A (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Clin Sci Ctr K4-850, Madison, WI 53562 USA.		Mundhenke, Christoph/D-2593-2010	Mundhenke, Christoph/0000-0002-6989-6250				ALBY L, 1984, P NATL ACAD SCI-BIOL, V81, P5739, DOI 10.1073/pnas.81.18.5739; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Chang Z, 2000, FASEB J, V14, P137, DOI 10.1096/fasebj.14.1.137; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Friedl A, 2001, Methods Mol Biol, V171, P535; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; GOTO F, 1993, LAB INVEST, V69, P508; Gualandris A, 1997, MICROVASC RES, V53, P254, DOI 10.1006/mvre.1996.1998; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Huber R, 1999, P NATL ACAD SCI USA, V96, P616, DOI 10.1073/pnas.96.2.616; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Jaakkola P, 1997, MOL CELL BIOL, V17, P3210, DOI 10.1128/MCB.17.6.3210; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; KITADAI Y, 1995, AM J PATHOL, V147, P1238; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Knox S, 2002, J BIOL CHEM, V277, P14657, DOI 10.1074/jbc.M111826200; Kohl R, 2002, J BIOL CHEM, V277, P32760, DOI 10.1074/jbc.M204661200; Kumar R, 1998, ONCOL RES, V10, P301; Liu DF, 2002, P NATL ACAD SCI USA, V99, P568, DOI 10.1073/pnas.012578299; LORIES V, 1992, J BIOL CHEM, V267, P1116; LORIES V, 1989, J BIOL CHEM, V264, P7009; Matsuda K, 2001, CANCER RES, V61, P5562; McFall AJ, 1998, J BIOL CHEM, V273, P28270, DOI 10.1074/jbc.273.43.28270; Mundhenke C, 2002, AM J PATHOL, V160, P185, DOI 10.1016/S0002-9440(10)64362-3; Nugent MA, 2000, P NATL ACAD SCI USA, V97, P6722, DOI 10.1073/pnas.97.12.6722; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 2001, GENOME BIOL; Padera R, 1999, FASEB J, V13, P1677, DOI 10.1096/fasebj.13.13.1677; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; PRESTA M, 1989, J CELL BIOL, V109, P1877, DOI 10.1083/jcb.109.4.1877; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; Volk R, 1999, J BIOL CHEM, V274, P24417, DOI 10.1074/jbc.274.34.24417; Wu XC, 2001, CANCER RES, V61, P5295; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279	42	90	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16045	16053		10.1074/jbc.M211259200	http://dx.doi.org/10.1074/jbc.M211259200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591930	hybrid			2022-12-27	WOS:000182680000076
J	Bakovic, M; Waite, K; Vance, DE				Bakovic, M; Waite, K; Vance, DE			Oncogenic Ha-Ras transformation modulates the transcription of the CTP : Phosphocholine cytidylyltransferase alpha gene via p42/44(MAPK) and transcription factor Sp3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); PRO-INFLAMMATORY CYTOKINES; MESSENGER-RNA STABILITY; MAP-KINASE CASCADE; PHOSPHATIDYLCHOLINE METABOLISM; PHOSPHORYLATION SITES; CELL-CYCLE; PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE-2; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; CHOLINEPHOSPHATE CYTIDYLYLTRANSFERASE	We have shown previously that expression of the murine CTP:phosphocholine cytidylyltransferase (CT) a gene is regulated during cell proliferation (Golfman, L. S., Bakovic, M., and Vance, D. E. (2001) J. Biol. Chem. 276, 43688-43692). We have now characterized the role of Ha-Ras in the transcriptional regulation of the CTalpha gene. The expression of CTalpha and CTbeta2 proteins and mRNAs was stimulated in C3H10T1/2 murine fibroblasts expressing oncogenic Ha-Ras. Incubation of cells with the specific inhibitor (PD98059) of p42/44 (MAPK) decreased the expression of both CT isoforms. Transfection of fibroblasts with CTalpha promoter-luciferase constructs resulted in an similar to2-fold enhanced luciferase expression in Ha-Ras-transformed, compared with nontransformed, fibroblasts. Electromobility shift assays indicated enhanced binding of the Sp3 transcription factor to the CTalpha promoter in Ha-Ras-transformed cells. Expression of several forms of Sp3 was increased in nuclear extracts of Ha-Ras-transformed fibroblasts compared with nontransformed cells. Tyrosine phosphorylation of one Sp3 form was decreased, whereas phosphorylation of two other forms of Sp3 was increased in nuclear extracts of Ha-Ras-transformed cells. When control fibroblasts were transfected with a Sp3-expressing plasmid, an enhanced expression of CTa and CTP was observed. However, the expression of CTalpha or CTbeta was not increased in Ha-Ras-transformed cells transfected with a Sp3 plasmid presumably because expression was already maximally enhanced. The results suggest that Sp3 is a downstream effector of a Ras/p42/44(MAPK) signaling pathway which increases CTalpha gene transcription.	Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arnold RS, 1996, BIOCHEMISTRY-US, V35, P9917, DOI 10.1021/bi960397c; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; Bakovic M, 2000, J LIPID RES, V41, P583; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; Choi SB, 1997, MOL CELLS, V7, P58; Clement JM, 1999, BIOCHEM BIOPH RES CO, V257, P643, DOI 10.1006/bbrc.1999.0512; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Dhawan P, 1999, J LIPID RES, V40, P1911; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Geilen CC, 1996, BBA-LIPID LIPID MET, V1299, P299, DOI 10.1016/0005-2760(95)00221-9; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hamilton M, 1998, J BIOL CHEM, V273, P28155, DOI 10.1074/jbc.273.43.28155; Hogan M, 1996, BIOCHEM J, V314, P799, DOI 10.1042/bj3140799; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; HOUWELING M, 1993, EUR J BIOCHEM, V214, P927, DOI 10.1111/j.1432-1033.1993.tb17996.x; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; KALMAR GB, 1994, BBA-GENE STRUCT EXPR, V1219, P328, DOI 10.1016/0167-4781(94)90056-6; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Kast HR, 2001, J LIPID RES, V42, P1266; KENNEDY EP, 1989, PHOSPHATIDYLCHOLINE, P1; Kennett SB, 2002, J BIOL CHEM, V277, P9780, DOI 10.1074/jbc.M108661200; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KISS Z, 1995, FEBS LETT, V357, P279, DOI 10.1016/0014-5793(94)01371-7; Kotzka J, 2000, J LIPID RES, V41, P99; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LACAL JC, 1994, ONCOL REP, V1, P677; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; Lagace TK, 2000, J BIOL CHEM, V275, P14367, DOI 10.1074/jbc.275.19.14367; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lykidis A, 1998, J BIOL CHEM, V273, P14022, DOI 10.1074/jbc.273.22.14022; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; Marinovic AC, 2002, J BIOL CHEM, V277, P16673, DOI 10.1074/jbc.M200501200; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Momchilova A, 1999, CELL BIOL INT, V23, P603, DOI 10.1006/cbir.1999.0430; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; Nishida I, 1996, PLANT MOL BIOL, V31, P205, DOI 10.1007/BF00021784; Northwood IC, 1999, J BIOL CHEM, V274, P26240, DOI 10.1074/jbc.274.37.26240; Noti JD, 1997, J BIOL CHEM, V272, P24038, DOI 10.1074/jbc.272.38.24038; PERSENGIEV SP, 1995, P NATL ACAD SCI USA, V92, P9107, DOI 10.1073/pnas.92.20.9107; PREISS J, 1986, J BIOL CHEM, V261, P8597; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Reddy S, 1999, J BIOL CHEM, V274, P33050, DOI 10.1074/jbc.274.46.33050; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RUTHERFORD MS, 1993, GENOMICS, V18, P698, DOI 10.1016/S0888-7543(05)80377-5; Ryan AJ, 2000, J LIPID RES, V41, P1268; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sesca E, 1996, BIOCHEM BIOPH RES CO, V229, P158, DOI 10.1006/bbrc.1996.1773; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Sugimoto H, 2001, J BIOL CHEM, V276, P12338, DOI 10.1074/jbc.M100090200; SUGUIRA N, 2000, BIOCHEM J, V347, P155; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Trevisi L, 2002, BIOCHEM PHARMACOL, V64, P425, DOI 10.1016/S0006-2952(02)01066-3; Tseu I, 2002, AM J RESP CELL MOL, V26, P506, DOI 10.1165/ajrcmb.26.4.4702; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; van Rossum GSAT, 2001, J BIOL CHEM, V276, P28976, DOI 10.1074/jbc.M101361200; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P33; VISCARDI RM, 1994, LIFE SCI, V54, P1411, DOI 10.1016/0024-3205(94)00596-6; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1995, J BIOL CHEM, V270, P354, DOI 10.1074/jbc.270.1.354; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WIEPRECHT M, 1994, FEBS LETT, V353, P221, DOI 10.1016/0014-5793(94)01040-4; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; Zheng XL, 2001, J BIOL CHEM, V276, P13822, DOI 10.1074/jbc.M011031200	88	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14753	14761		10.1074/jbc.M300162200	http://dx.doi.org/10.1074/jbc.M300162200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584202	hybrid			2022-12-27	WOS:000182516100023
J	Gardner, AM; Olah, ME				Gardner, AM; Olah, ME			Distinct protein kinase C isoforms mediate regulation of vascular endothelial growth factor expression by A(2A) adenosine receptor activation and phorbol esters in pheochromocytoma PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GLIOMA-CELLS; IN-VITRO; PERMEABILITY FACTOR; DOWN-REGULATION; INDUCED DIFFERENTIATION; HUMAN KERATINOCYTES; NERVE-TERMINALS; GENE-EXPRESSION; PKC-ZETA; ANGIOGENESIS	Vascular endothelial growth factor (VEGF) stimulates angiogenesis during development and in disease. In pheochromocytoma. (PC12) cells, VEGF expression is regulated by A(2A) adenosine receptor (A(2A)AR) activation. The present work examines the underlying signaling pathway. The adenylyl cyclase-protein kinase A cascade has no role in the down-regulation of VEGF mRNA induced by the A(2)AAR agonist, 2-[4-[(2-carboxyethyl)phenyllethyl-amino]-5'-N-ethylcarboxamidoadenosine (CGS21680). Conversely, 6-h exposure of cells to either phorbol 12-myristate 13-acetate (PMA) or protein kinase C (PKC) inhibitors mimicked the CGS21680-induced down-regulation. PMA activated PKCalpha, PKCepsilon, and PKCzeta, and CGS21680 activated PKCepsilon and PKCzeta as assessed by cellular translocation. By 6 h, PMA but not CGS21680 decreased PKCalpha and PKCepsilon expression. Neither compound affected PKCzeta levels. Following prolonged PMA treatment to down-regulate susceptible PKC isoforms, CGS21680 but not PMA inhibited the cobalt chloride induction of VEGF. mRNA. The proteasome inhibitor, MG-132, abolished PMA- but not CGS21680-induced downregulation of VEGF mRNA. Phorbol 12,13-diacetate reduced VEGF mRNA levels while down-regulating PKCepsilon but not PKCalpha expression. In cells expressing a dominant negative PKCC construct, CGS21680 was unable to reduce VEGF mRNA. Together, the findings suggest that phorbol ester-induced down-regulation of VEGF mRNA occurs as a result of a reduction of PKCepsilon activity, whereas that mediated by the A(2)AAR occurs following deactivation of PKC.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Olah, ME (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA.				NCI NIH HHS [R01 CA79531] Funding Source: Medline; NHLBI NIH HHS [5T32 HL07382] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079531] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007382] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIN JG, 1990, J NEUROCHEM, V54, P1666, DOI 10.1111/j.1471-4159.1990.tb01220.x; Arslan G, 1999, N-S ARCH PHARMACOL, V359, P28, DOI 10.1007/PL00005319; Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; Braz JC, 2002, J CELL BIOL, V156, P905, DOI 10.1083/jcb.200108062; BROWN LF, 1993, AM J PATHOL, V143, P1255; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Cunha RA, 2000, NEUROSCI LETT, V289, P127, DOI 10.1016/S0304-3940(00)01295-7; Cunha RA, 2000, NEUROPHARMACOLOGY, V39, P1156, DOI 10.1016/S0028-3908(99)00237-3; Deindl E, 1998, MOL CELL BIOCHEM, V186, P43, DOI 10.1023/A:1006853432678; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Feoktistov I, 2002, CIRC RES, V90, P531, DOI 10.1161/01.RES.0000012203.21416.14; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gille J, 2001, J INVEST DERMATOL, V117, P1581, DOI 10.1046/j.0022-202x.2001.01573.x; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Grant MB, 1999, CIRC RES, V85, P699, DOI 10.1161/01.RES.85.8.699; Gubitz AK, 1996, J NEUROCHEM, V67, P374; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; Huang HM, 1999, J NEUROSCI RES, V56, P668, DOI 10.1002/(SICI)1097-4547(19990615)56:6<668::AID-JNR13>3.3.CO;2-I; Huang NK, 2001, J BIOL CHEM, V276, P13838, DOI 10.1074/jbc.M008589200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawata H, 2001, CIRC RES, V88, P696, DOI 10.1161/hh0701.088842; Kim MS, 2001, CANCER LETT, V171, P79, DOI 10.1016/S0304-3835(01)00505-5; Kobayashi S, 1999, J BIOL CHEM, V274, P20358, DOI 10.1074/jbc.274.29.20358; Kotsonis P, 2001, BRIT J PHARMACOL, V132, P489, DOI 10.1038/sj.bjp.0703813; Lee HW, 1997, MOL PHARMACOL, V51, P439; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Lohrer P, 2001, NEUROENDOCRINOLOGY, V74, P95, DOI 10.1159/000054675; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Martelli AM, 1999, J CELL BIOCHEM, V74, P499, DOI 10.1002/(SICI)1097-4644(19990915)74:4<499::AID-JCB1>3.0.CO;2-X; Mentlein R, 2001, INT J CANCER, V92, P545, DOI 10.1002/ijc.1223; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINCHENKO A, 1994, LAB INVEST, V71, P374; Nagashima M, 2000, RHEUMATOLOGY, V39, P1255, DOI 10.1093/rheumatology/39.11.1255; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OHMICHI M, 1993, BIOCHEM J, V295, P767, DOI 10.1042/bj2950767; OLAH ME, 1992, ANNU REV PHYSIOL, V54, P211, DOI 10.1146/annurev.physiol.54.1.211; Olah ME, 2000, J PHARMACOL EXP THER, V293, P779; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; Pedram A, 2001, ENDOCRINOLOGY, V142, P1578, DOI 10.1210/en.142.4.1578; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; Redondo P, 2000, ARCH DERMATOL RES, V292, P621, DOI 10.1007/s004030000187; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; Shizukuda Y, 1999, CIRC RES, V85, P247, DOI 10.1161/01.RES.85.3.247; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199; Smith SK, 2001, TRENDS ENDOCRIN MET, V12, P147, DOI 10.1016/S1043-2760(01)00379-4; Sowter HM, 1997, LAB INVEST, V77, P607; Sparatore B, 2000, BIOCHEM BIOPH RES CO, V275, P149, DOI 10.1006/bbrc.2000.3258; Suzuma I, 2002, J BIOL CHEM, V277, P1047, DOI 10.1074/jbc.M105336200; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; Volm M, 1997, ANTICANCER RES, V17, P99; Wakai A, 2001, SHOCK, V15, P297, DOI 10.1097/00024382-200115040-00008; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; Wilkinson-Berka JL, 2001, J VASC RES, V38, P527, DOI 10.1159/000051088; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395	70	15	18	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15421	15428		10.1074/jbc.M208366200	http://dx.doi.org/10.1074/jbc.M208366200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590138	hybrid			2022-12-27	WOS:000182516100108
J	Yu, SW; Girotto, S; Lee, C; Magliozzo, RS				Yu, SW; Girotto, S; Lee, C; Magliozzo, RS			Reduced afflinity for isoniazid in the S315T mutant of Mycobacterium tuberculosis KatG is a key factor in antibiotic resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALASE-PEROXIDASE KATG; SITE-DIRECTED MUTAGENESIS; DRUG-RESISTANCE; HALOARCULA-MARISMORTUI; MOLECULAR MECHANISMS; PURIFICATION; MUTATIONS; GENE; KATG(S315T); ACTIVATION	Catalase-peroxidase (KatG) from Mycobacterium tuberculosis is responsible for the activation of the antitubercular drug isonicotinic acid hydrazide (INH) and is important for survival of M. tuberculosis in macrophages. Characterization of the structure and catalytic mechanism of KatG is being pursued to provide insights into drug (INH) resistance in M. tuberculosis. Site-directed mutagenesis was used to prepare the INH-resistant mutant KatG[S315T], and the overexpressed enzyme was characterized and compared with wild-type KatG. KatG[S315T] exhibits a reduced tendency to form six-coordinate heme, because of coordination of water to iron during purification and storage, and also forms a highly unstable Compound III (oxyferrous enzyme). Catalase activity and peroxidase activity measured using, t-butylhydroperoxide and o-dianisidine were moderately reduced in the mutant compared with wild-type KatG. Stopped-flow spectrophotometric experiments revealed a rate of Compound I formation similar to wildtype KatG using peroxyacetic acid to initiate the catalytic cycle, but no Compound I was detected when bulkier peroxides (chloroperoxybenzoic acid, t-butylhydroperoxide) were used. The affinity of resting (ferric) KatG[S315T] for INH, measured using isothermal titration calorimetry, was greatly reduced compared with wild-type KatG, as were rates of reaction of Compound I with the drug. These observations reveal that although KatG[S315T] maintains reasonably good steady state catalytic rates, poor binding of the drug to the enzyme limits drug activation and brings about INH resistance.	CUNY Brooklyn Coll, Dept Chem, Brooklyn, NY 11210 USA; CUNY, Grad Ctr, Brooklyn, NY 11210 USA	City University of New York (CUNY) System; Brooklyn College (CUNY); City University of New York (CUNY) System	Magliozzo, RS (corresponding author), CUNY Brooklyn Coll, Dept Chem, 2900 Bedford Ave, Brooklyn, NY 11210 USA.		Girotto, Stefania/F-5997-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043582] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-43582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CENDRIN F, 1994, BBA-PROTEIN STRUCT M, V1209, P1, DOI 10.1016/0167-4838(94)90129-5; Chouchane S, 2003, J BIOL CHEM, V278, P8154, DOI 10.1074/jbc.M208256200; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; COCKERILL FR, 1995, J INFECT DIS, V171, P240, DOI 10.1093/infdis/171.1.240; Fraaije MW, 1996, EUR J BIOCHEM, V235, P192, DOI 10.1111/j.1432-1033.1996.00192.x; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1992, RES MICROBIOL, V143, P721, DOI 10.1016/0923-2508(92)90067-X; HICKS DB, 1995, BBA-BIOENERGETICS, V1229, P347, DOI 10.1016/0005-2728(95)00016-C; HOCHMAN A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P299, DOI 10.1016/0167-4838(91)90544-A; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; LOEWEN PC, 1990, BIOCHEM CELL BIOL, V68, P1037, DOI 10.1139/o90-153; Lukat-Rodgers GS, 2000, BIOCHEMISTRY-US, V39, P9984, DOI 10.1021/bi0006870; Magliozzo RS, 1996, J AM CHEM SOC, V118, P11303, DOI 10.1021/ja962047j; MARCINKEVICIENE JA, 1995, J BIOL CHEM, V270, P22290, DOI 10.1074/jbc.270.38.22290; Marttila HJ, 1998, ANTIMICROB AGENTS CH, V42, P2443, DOI 10.1128/AAC.42.9.2443; Marttila HJ, 1996, ANTIMICROB AGENTS CH, V40, P2187, DOI 10.1128/AAC.40.9.2187; MORRIS S, 1995, J INFECT DIS, V171, P954, DOI 10.1093/infdis/171.4.954; Musser JM, 1996, EMERG INFECT DIS, V2, P1, DOI 10.3201/eid0201.960101; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; NAKAJIMA R, 1987, J BIOL CHEM, V262, P2576; Pym AS, 2002, INFECT IMMUN, V70, P4955, DOI 10.1128/IAI.70.9.4955-4960.2002; Ramaswamy S., 1998, Tubercle and Lung Disease, V79, P3, DOI 10.1054/tuld.1998.0002; ROBITZEK EH, 1952, AM REV TUBERC PULM, V65, P402; RodriguezLopez JN, 1997, J BIOL CHEM, V272, P5469, DOI 10.1074/jbc.272.9.5469; ROUSE DA, 1995, ANTIMICROB AGENTS CH, V39, P2472, DOI 10.1128/AAC.39.11.2472; Rouse DA, 1996, MOL MICROBIOL, V22, P583, DOI 10.1046/j.1365-2958.1996.00133.x; ROUSE DA, 1995, INFECT IMMUN, V63, P1427, DOI 10.1128/IAI.63.4.1427-1433.1995; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Saint-Joanis B, 1999, BIOCHEM J, V338, P753, DOI 10.1042/0264-6021:3380753; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Todorovic S, 1999, J AM CHEM SOC, V121, P10962, DOI 10.1021/ja9918674; van Soolingen D, 2000, J INFECT DIS, V182, P1788, DOI 10.1086/317598; Victor TC, 1996, ANTIMICROB AGENTS CH, V40, P1572, DOI 10.1128/AAC.40.6.1572; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; Wengenack NL, 1997, J INFECT DIS, V176, P722, DOI 10.1086/514096; Wengenack NL, 1998, BIOCHEMISTRY-US, V37, P15825, DOI 10.1021/bi982023k; Wengenack NL, 1999, J AM CHEM SOC, V121, P9748, DOI 10.1021/ja992590a; Wengenack NL, 2001, BIOCHEMISTRY-US, V40, P8990, DOI 10.1021/bi002614m; *WHO, 2002, 104 WHO; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834; Yu SW, 2002, PROTEIN SCI, V11, P58, DOI 10.1110/ps.ps.09902; YUMOTO I, 1990, J BIOCHEM, V108, P583, DOI 10.1093/oxfordjournals.jbchem.a123246; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x	47	71	76	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14769	14775		10.1074/jbc.M300326200	http://dx.doi.org/10.1074/jbc.M300326200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586821	hybrid			2022-12-27	WOS:000182516100025
J	Fayos, R; Melacini, G; Newlon, MG; Burns, L; Scott, JD; Jennings, PA				Fayos, R; Melacini, G; Newlon, MG; Burns, L; Scott, JD; Jennings, PA			Induction of flexibility through protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-15 NMR RELAXATION; GROUP HYDROGEN-EXCHANGE; REGULATORY SUBUNIT RII; AMIDE PROTON-EXCHANGE; BACKBONE DYNAMICS; A-KINASE; LIGAND-BINDING; ANCHORING PROTEINS; ROTATIONAL DIFFUSION; DOMAIN	The (d) under bar imerization/(d) under bar ocking (D/D) domain of the cyclic AMP-dependent protein kinase (PKA) holoenzyme mediates important protein-protein interactions that direct the subcellular localization of the enzyme. (A) under bar (k) under bar inase (a) under bar nchoring (p) under bar roteins (AKAPs) provide the molecular scaffold for the localization of PKA. The recent solution structures of two D/D AKAP complexes revealed that the AKAP binds to a surface-exposed, hydrophobic groove on the D/D. In the present study, we present an analysis of the changes in hydrogen/deuterium exchange protection and internal motions of the backbone of the D/D when free and bound to the prototype anchoring protein, Ht31(pep). We observe that formation of the complex results in significant, but small, increases in H/D exchange protection factors as well as increases in backbone flexibility, throughout the D/D, and in particular, in the hydrophobic binding groove. This unusual observation of increased backbone flexibility and marginal H/D exchange protection, despite high affinity protein-ligand interactions, may be a general effect observed for the stabilization of hydrophobic ligand/hydrophobic pocket interactions.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97201 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; Oregon Health & Science University	Jennings, PA (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKKE M, 1993, BIOCHEMISTRY-US, V32, P9832, DOI 10.1021/bi00088a039; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Baxter NJ, 1998, J MOL BIOL, V284, P1625, DOI 10.1006/jmbi.1998.2265; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CARR DW, 1991, J BIOL CHEM, V266, P14188; Cavanagh J, 2000, NAT STRUCT BIOL, V7, P11, DOI 10.1038/71202; CLARKE J, 1993, P NATL ACAD SCI USA, V90, P9837, DOI 10.1073/pnas.90.21.9837; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Diviani D, 2000, CURR BIOL, V10, P417, DOI 10.1016/S0960-9822(00)00422-X; Dyson HJ, 2001, METHOD ENZYMOL, V339, P258; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Favier A, 2002, J MOL BIOL, V317, P131, DOI 10.1006/jmbi.2002.5397; Fischer MWF, 1998, PROG NUCL MAG RES SP, V33, P207, DOI 10.1016/S0079-6565(98)00023-5; Forman-Kay JD, 1999, NAT STRUCT BIOL, V6, P1086, DOI 10.1038/70008; Ghaemmaghami S, 2000, P NATL ACAD SCI USA, V97, P8296, DOI 10.1073/pnas.140111397; Glover KJ, 2001, BIOCHEMISTRY-US, V40, P13137, DOI 10.1021/bi011485m; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HERZBERG O, 1994, CURR OPIN STRUC BIOL, V4, P814, DOI 10.1016/0959-440X(94)90262-3; Hilser VJ, 1998, P NATL ACAD SCI USA, V95, P9903, DOI 10.1073/pnas.95.17.9903; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Huster D, 1999, J AM CHEM SOC, V121, P1992, DOI 10.1021/ja9838413; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Krishnan VV, 2000, BIOCHEMISTRY-US, V39, P9119, DOI 10.1021/bi000296l; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Li F, 2002, J MOL BIOL, V315, P459, DOI 10.1006/jmbi.2001.5256; Lillemoen J, 1997, J MOL BIOL, V268, P482, DOI 10.1006/jmbi.1997.0982; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Lu JY, 1999, J MOL BIOL, V286, P1179, DOI 10.1006/jmbi.1999.2544; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MARKLEY JL, 1971, J CHEM PHYS, V55, P3604, DOI 10.1063/1.1676626; MOLDAY RS, 1972, BIOCHEMISTRY-US, V11, P150, DOI 10.1021/bi00752a003; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MORTON A, 1995, BIOCHEMISTRY-US, V34, P8576, DOI 10.1021/bi00027a007; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Newlon MG, 1997, J BIOL CHEM, V272, P23637, DOI 10.1074/jbc.272.38.23637; Newlon MG, 2001, EMBO J, V20, P1651, DOI 10.1093/emboj/20.7.1651; OHKI S, 1991, J BIOCHEM-TOKYO, V109, P234; Osborne MJ, 2001, BIOCHEMISTRY-US, V40, P9846, DOI 10.1021/bi010621k; Pan H, 2000, P NATL ACAD SCI USA, V97, P12020, DOI 10.1073/pnas.220240297; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Powell KD, 2002, J AM CHEM SOC, V124, P10256, DOI 10.1021/ja026574g; SCHURR JM, 1994, J MAGN RESON SER B, V105, P211, DOI 10.1006/jmrb.1994.1127; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; Stivers JT, 1996, BIOCHEMISTRY-US, V35, P16036, DOI 10.1021/bi961834q; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Vijayaraghavan S, 1999, MOL ENDOCRINOL, V13, P705, DOI 10.1210/me.13.5.705; Wang GS, 2000, J BIOL CHEM, V275, P16401, DOI 10.1074/jbc.C000167200; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Yu LP, 1996, BIOCHEMISTRY-US, V35, P9661, DOI 10.1021/bi960507f; Yun SG, 2001, BIOCHEMISTRY-US, V40, P3967, DOI 10.1021/bi0023192; Zidek L, 1999, NAT STRUCT BIOL, V6, P1118	59	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18581	18587		10.1074/jbc.M300866200	http://dx.doi.org/10.1074/jbc.M300866200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12604595	hybrid			2022-12-27	WOS:000182838300130
J	Stephens, AN; Khan, MA; Roucou, X; Nagley, P; Devenish, RJ				Stephens, AN; Khan, MA; Roucou, X; Nagley, P; Devenish, RJ			The molecular neighborhood of subunit 8 of yeast mitochondrial F1F0-ATP synthase probed by cysteine scanning mutagenesis and chemical modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL HYDROPHOBIC DOMAIN; ATP SYNTHASE; SACCHAROMYCES-CEREVISIAE; ENZYME COMPLEX; ROTARY MOTOR; F0 SECTOR; H+-ATPASE; 2ND STALK; MEMBRANE; ROTATION	The detailed membrane topography and neighboring polypeptides of subunit 8 in yeast mitochondrial ATP synthase have been determined using a combination of cysteine scanning mutagenesis and chemical modification. 46 single cysteine substitution mutants encompassing the length of the subunit 8 protein were constructed by site-directed mutagenesis. Expression of each cysteine variant in yeast lacking endogenous subunit 8 restored respiratory phenotype to cells and had little measurable effect on ATP hydrolase function. The exposure of each introduced cysteine residue to the aqueous environment was assessed in isolated mitochondria using the fluorescent thiol-modifying probe fluorescein 5-maleimide. The first 14 and last 13 amino acids of subunit 8 were accessible to fluorescein 5-maleimide in osmotically lysed mitochondria and are thus extrinsic to the lipid bilayer, indicating a 21-amino acid transmembrane span. The C-terminal region of subunit 8 was partially occluded by other ATP synthase subunits, especially in a small region surrounding Val-40 that was demonstrated to play an important role in maintaining the stability of the F-1-F-0 interaction. Cross-linking using heterobifunctional reagents revealed the proximity of subunit 8 to subunits b, d, and f in the matrix and to subunits b, f, and 6 in the intermembrane space. A disulfide bridge was also formed between subunit 8(F7C) or (M10C) and residue Cys-23 of subunit 6, demonstrating a close interaction between these two hydrophobic membrane subunits and confirming the location of the N termini of each in the intermembrane space. We conclude that subunit 8 is an integral component of the stator stalk of yeast mitochondrial F1F0-ATP synthase.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Monash University	Devenish, RJ (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton Campus, Clayton, Vic 3800, Australia.		Stephens, Andrew/G-5161-2013					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1999, J BIOL CHEM, V274, P36, DOI 10.1074/jbc.274.1.36; Bateson M, 1999, J BIOL CHEM, V274, P7462, DOI 10.1074/jbc.274.11.7462; Bottcher B, 2000, BBA-BIOENERGETICS, V1458, P404, DOI 10.1016/S0005-2728(00)00090-6; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; DEVENISH RJ, 1992, ANN NY ACAD SCI, V671, P403, DOI 10.1111/j.1749-6632.1992.tb43814.x; Devenish RJ, 2000, BBA-BIOENERGETICS, V1458, P428, DOI 10.1016/S0005-2728(00)00092-X; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GALANIS M, 1990, BIOCHEM INT, V22, P1059; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GRASSO DG, 1991, EUR J BIOCHEM, V199, P203, DOI 10.1111/j.1432-1033.1991.tb16110.x; HADIKUSUMO RG, 1984, BIOCHIM BIOPHYS ACTA, V765, P258, DOI 10.1016/0005-2728(84)90164-6; Hasler K, 1998, FEBS LETT, V426, P301, DOI 10.1016/S0014-5793(98)00358-5; Joseph-Liauzun E, 1998, J BIOL CHEM, V273, P2146, DOI 10.1074/jbc.273.4.2146; Kaim G, 2002, FEBS LETT, V525, P156, DOI 10.1016/S0014-5793(02)03097-1; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; LAW RHP, 1988, FEBS LETT, V236, P501, DOI 10.1016/0014-5793(88)80086-3; MACREADIE IG, 1983, NUCLEIC ACIDS RES, V11, P4435, DOI 10.1093/nar/11.13.4435; MARZUKI S, 1989, BIOCHIM BIOPHYS ACTA, V975, P222, DOI 10.1016/S0005-2728(89)80252-X; MCENERY MW, 1989, J BIOL CHEM, V264, P12029; MICHON T, 1988, EUR J BIOCHEM, V172, P621, DOI 10.1111/j.1432-1033.1988.tb13934.x; NAGLEY P, 1988, TRENDS GENET, V4, P46, DOI 10.1016/0168-9525(88)90066-2; NAGLEY P, 1990, BIOENERGETICS, P305; NAGLEY P, 1989, TRENDS BIOCHEM SCI, V14, P31, DOI 10.1016/0968-0004(89)90087-X; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; NORAIS N, 1991, J BIOL CHEM, V266, P16541; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Papakonstantinou T, 1996, CURR GENET, V30, P12, DOI 10.1007/s002940050094; PAPAKONSTANTINOU T, 1995, EUR J BIOCHEM, V227, P745, DOI 10.1111/j.1432-1033.1995.tb20197.x; PAPAKONSTANTINOU T, 1993, BIOCHIM BIOPHYS ACTA, V1144, P22, DOI 10.1016/0005-2728(93)90026-C; Papakonstantinou T, 1996, BIOCHEM MOL BIOL INT, V39, P253; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paumard P, 2002, BIOCHEMISTRY-US, V41, P10390, DOI 10.1021/bi025923g; Paumard P, 2000, BIOCHEMISTRY-US, V39, P4199, DOI 10.1021/bi992438l; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Roucou X, 1999, EUR J BIOCHEM, V261, P444, DOI 10.1046/j.1432-1327.1999.00289.x; Roudeau S, 1999, J BIOENERG BIOMEMBR, V31, P85, DOI 10.1023/A:1005407525915; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Soubannier V, 1999, BIOCHEMISTRY-US, V38, P15017, DOI 10.1021/bi9916067; Soubannier V, 2002, J BIOL CHEM, V277, P10739, DOI 10.1074/jbc.M111882200; Spannagel C, 1998, BIOCHEMISTRY-US, V37, P615, DOI 10.1021/bi9714971; Spannagel C, 1997, EUR J BIOCHEM, V247, P1111, DOI 10.1111/j.1432-1033.1997.01111.x; Spannagel C, 1998, BBA-BIOMEMBRANES, V1414, P260, DOI 10.1016/S0005-2736(98)00174-6; Steiner-Mordoch S., 1999, J BIOL CHEM, V274, P19480; Stephens AN, 2000, EUR J BIOCHEM, V267, P6443, DOI 10.1046/j.1432-1327.2000.01733.x; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; STRAFFON AFL, 1994, BIOCHEM BIOPH RES CO, V203, P1567, DOI 10.1006/bbrc.1994.2365; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VELOURS J, 1986, BIOCHEM BIOPH RES CO, V138, P78, DOI 10.1016/0006-291X(86)90249-4; VELOURS J, 1984, EMBO J, V3, P207, DOI 10.1002/j.1460-2075.1984.tb01785.x; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910	63	33	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17867	17875		10.1074/jbc.M300967200	http://dx.doi.org/10.1074/jbc.M300967200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626501	hybrid			2022-12-27	WOS:000182838300036
J	Wang, BE; Shou, JY; Ross, S; Koeppen, H; de Sauvage, FJ; Gao, WQ				Wang, BE; Shou, JY; Ross, S; Koeppen, H; de Sauvage, FJ; Gao, WQ			Inhibition of epithelial ductal branching in the prostate by sonic hedgehog is indirectly mediated by stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN HOMOLOG; GROWTH; MORPHOGENESIS; EXPRESSION; GENE; PROLIFERATION; INDUCTION; RECEPTOR; PROTEIN; DIFFERENTIATION	Sonic hedgehog (Shh), a vertebrate homologue of the Drosophila segment-polarity gene hedgehog, has been reported to play an important role during normal development of various tissues. Abnormal activities of Shh signaling pathway have been implicated in tumorigenesis such as basal cell carcinomas and medulloblastomas. Here we show that Shh signaling negatively regulates prostatic epithelial ductal morphogenesis. In organo-typic cultures of developing rat prostates, Shh inhibited cell proliferation and promoted differentiation of luminal epithelial cells. The expression pattern of Shh and its receptors suggests a paracrine mechanism of action. The Shh receptors Ptc1 ((P) under bara (t) under bar ched (1) under bar) and Ptc2 were found to be expressed in prostatic stromal cells adjacent to the epithelium, where Shh itself was produced. This paracrine model was confirmed by co-culturing the developing prostate in the presence of stromal cells transfected with a vector expressing a constitutively active form of Smoothened, the real effector of the Shh signaling pathway. Furthermore, expression of activin A and TGF-beta1 that were shown previously to inhibit prostatic epithelial branching was up-regulated following Shh treatment in the organotypic cultures. Taken together, these results suggest that Shh negatively regulates prostatic ductal branching indirectly by acting on the surrounding stromal cells, at least partly via up-regulating expression of activin A and TGF-beta1.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Gao, WQ (corresponding author), Genentech Inc, Dept Mol Oncol, MS 72,1 DNA Way, San Francisco, CA 94080 USA.	gao@gene.com	de Sauvage, Frederic/ABE-8400-2020; Gao, Wei/GXH-0380-2022	de Sauvage, Frederic/0000-0002-5275-2584; Shou, Jianyong/0000-0002-3752-7215				Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Alcedo J, 2000, MOL CELL, V6, P457, DOI 10.1016/S1097-2765(00)00044-7; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Alvarez J, 2002, DEVELOPMENT, V129, P1913; Ball EMA, 2001, DEV BIOL, V238, P1, DOI 10.1006/dbio.2001.0399; Bellusci S, 1997, DEVELOPMENT, V124, P53; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Cancilla B, 2001, DEV BIOL, V237, P145, DOI 10.1006/dbio.2001.0364; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1998, DEVELOPMENT, V125, P4943; CHUNG LWK, 1995, CANCER SURV, V23, P33; CHUNG LWK, 1983, PROSTATE, V4, P503, DOI 10.1002/pros.2990040509; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Cunha G R, 1989, Cancer Treat Res, V46, P159; CUNHA GR, 1980, BIOL REPROD, V22, P19, DOI 10.1095/biolreprod22.1.19; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; GOODRICH L, 1991, SCIENCE, V277, P1109; Grapin-Botton A, 2001, GENE DEV, V15, P444, DOI 10.1101/gad.846001; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hayward SW, 1996, ACTA ANAT, V155, P81; Hayward SW, 1996, ANN NY ACAD SCI, V784, P50, DOI 10.1111/j.1749-6632.1996.tb16227.x; Hayward SW, 1997, BRIT J UROL, V79, P18, DOI 10.1111/j.1464-410X.1997.tb16917.x; Hayward SW, 2001, CANCER RES, V61, P8135; Hebrok M, 2000, DEVELOPMENT, V127, P4905; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Ingham PW, 2000, CURR BIOL, V10, P1315, DOI 10.1016/S0960-9822(00)00755-7; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Johnson RL, 2000, MOL CELL, V6, P467, DOI 10.1016/S1097-2765(00)00045-9; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kalderon D, 2000, CELL, V103, P371, DOI 10.1016/S0092-8674(00)00129-X; Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215; Kim IY, 1996, CLIN CANCER RES, V2, P1255; KOOISTRA A, 1995, PROSTATE, V26, P123, DOI 10.1002/pros.2990260304; Lamm MLG, 2002, DEV BIOL, V249, P349, DOI 10.1006/dbio.2002.0774; Lamm MLG, 2001, DEV BIOL, V232, P301, DOI 10.1006/dbio.2001.0187; Lipschutz JH, 1997, PROSTATE, V32, P35; LU LH, 1994, CELL VISION, V1, P169; Machold R, 2002, TRENDS NEUROSCI, V25, P10, DOI 10.1016/S0166-2236(00)01982-2; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Morgan BA, 1998, DEV BIOL, V201, P1, DOI 10.1006/dbio.1998.8969; Olumi AF, 1999, CANCER RES, V59, P5002; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Podlasek CA, 1999, DEV BIOL, V209, P28, DOI 10.1006/dbio.1999.9229; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; Robinson EJ, 1998, PROSTATE, V37, P149, DOI 10.1002/(SICI)1097-0045(19981101)37:3<149::AID-PROS4>3.0.CO;2-E; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SHANNON JM, 1984, BIOL REPROD, V31, P175, DOI 10.1095/biolreprod31.1.175; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Shou JY, 2001, CANCER RES, V61, P7291; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; SUGIMURA Y, 1986, BIOL REPROD, V34, P961, DOI 10.1095/biolreprod34.5.961; Sung SY, 2002, DIFFERENTIATION, V70, P506, DOI 10.1046/j.1432-0436.2002.700905.x; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; TIMMS BG, 1994, J UROLOGY, V151, P1427, DOI 10.1016/S0022-5347(17)35273-4; van den Brink GR, 2001, GASTROENTEROLOGY, V121, P317, DOI 10.1053/gast.2001.26261; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Williams RH, 1996, CLIN CANCER RES, V2, P635; Wolk A, 1998, J NATL CANCER I, V90, P911, DOI 10.1093/jnci/90.12.911; Wong YC, 2002, DIFFERENTIATION, V70, P633, DOI 10.1046/j.1432-0436.2002.700916.x; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yu J, 2002, DEVELOPMENT, V129, P5301; Zhang J, 2001, DEV BIOL, V229, P188, DOI 10.1006/dbio.2000.9953; Zhao H, 2002, BIOCHEM BIOPH RES CO, V294, P464, DOI 10.1016/S0006-291X(02)00484-9; Zheng JL, 2000, NAT NEUROSCI, V3, P580, DOI 10.1038/75753; Zheng JL, 2000, DEVELOPMENT, V127, P4551; Zhou L, 1996, DEV BIOL, V175, P227, DOI 10.1006/dbio.1996.0110	80	71	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18506	18513		10.1074/jbc.M300968200	http://dx.doi.org/10.1074/jbc.M300968200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626524	hybrid			2022-12-27	WOS:000182838300120
J	Filee, P; Vreuls, C; Herman, R; Thamm, I; Aerts, T; De Deyn, PP; Frere, JM; Joris, B				Filee, P; Vreuls, C; Herman, R; Thamm, I; Aerts, T; De Deyn, PP; Frere, JM; Joris, B			Dimerization and DNA binding properties of the Bacillus licheniformis 749/I BlaI repressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAMASE SYNTHESIS; STAPHYLOCOCCUS-AUREUS; PROTEIN; INDUCTION; TRANSDUCER; SYSTEM; DIMER; GENES; FATE	In the absence of penicillin, the beta-lactamase encoding gene blaP of Bacillus licheniformis 749/I is negatively regulated by the transcriptional repressor BlaI. Three palindromic operator regions are recognized by BlaI: two in the blaP promoter (OP1 and OP2) and one (OP3) in the promoter of the blaI-blaR1 operon. In this study, the dissociation constant of the purified BlaI dimer was estimated at 25 muM by equilibrium ultracentrifugation. Quantitative Western blot analysis indicates that the intracellular concentrations of BlaI in B. licheniformis 749/I and Bacillus subtilis transformed by a multicopy plasmid harboring the beta-lactamase locus (blaP-blaI-blaR1) were lower than (1.9 muM) or in the same range as (75 muM) the dissociation constant, respectively. This suggests that BlaI is partially dimeric in the cytoplasm of these strains and interacts in vivo with its operators as a preformed dimer. This hypothesis is supported by band shift assays on an operator containing a randomized half-operator sequence. The global dissociation constants of the operator-BlaI dimer complexes were measured by band shift assays and estimated as K-dOP1=1.7+/-0.5 10(-15) M-2, K-dOP2=3.3+/-0.9 10(-15) M-2, and K-dOP3=10.5+/-2.5 10(-15) M-2. The role of the DNA binding properties of BlaI on the beta-lactamase regulation is discussed.	Univ Liege, Inst Chim B6A, Ctr Ingn Prot, B-4000 Liege, Belgium; Univ Liege, Inst Phys B5, Lab Phys Biomed, B-4000 Liege, Belgium; Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium	University of Liege; University of Liege; University of Antwerp	Joris, B (corresponding author), Univ Liege, Inst Chim B6A, Ctr Ingn Prot, B-4000 Liege, Belgium.	bjoris@ulg.ac.be						Abril AM, 1997, BIOCHEMISTRY-US, V36, P11901, DOI 10.1021/bi970994e; Clarke SR, 2001, MICROBIOL-UK, V147, P803, DOI 10.1099/00221287-147-4-803; Dyke JW, 1979, BETA LACTAMASES, V291-310; Filee P, 2002, MOL MICROBIOL, V44, P685, DOI 10.1046/j.1365-2958.2002.02888.x; Filee P, 2001, BIOTECHNIQUES, V30, P1044, DOI 10.2144/01305rr03; Gabelica V, 2002, RAPID COMMUN MASS SP, V16, P1723, DOI 10.1002/rcm.776; Gregory PD, 1997, MOL MICROBIOL, V24, P1025, DOI 10.1046/j.1365-2958.1997.4051770.x; Hardt K, 1997, MOL MICROBIOL, V23, P935, DOI 10.1046/j.1365-2958.1997.2761642.x; HOLLADAY LA, 1974, ANAL BIOCHEM, V57, P506, DOI 10.1016/0003-2697(74)90106-7; JORIS B, 1990, FEMS MICROBIOL LETT, V70, P107, DOI 10.1016/0378-1097(90)90111-3; JORIS B, 1994, N COMP BIOC, V27, P505; KELLY L, 1990, BIOCHEMISTRY-US, V29, P5062, DOI 10.1021/bi00473a010; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; KOBAYASHI T, 1987, J BACTERIOL, V169, P3873, DOI 10.1128/jb.169.9.3873-3878.1987; Kohler JJ, 1999, P NATL ACAD SCI USA, V96, P11735, DOI 10.1073/pnas.96.21.11735; Lewis RA, 1999, FEMS MICROBIOL LETT, V178, P271, DOI 10.1016/S0378-1097(99)00366-3; Mohana-Borges R, 2000, J BIOL CHEM, V275, P4708, DOI 10.1074/jbc.275.7.4708; NICHOLLS NJ, 1987, FEBS LETT, V221, P179, DOI 10.1016/0014-5793(87)80375-7; Orth P, 2000, NAT STRUCT BIOL, V7, P215; RYFFEL C, 1990, GENE, V94, P137, DOI 10.1016/0378-1119(90)90481-6; SHERRATT DJ, 1973, J GEN MICROBIOL, V76, P217, DOI 10.1099/00221287-76-1-217; Steinmetzer K, 1998, J MOL BIOL, V283, P595, DOI 10.1006/jmbi.1998.2122; Strausak D, 1997, J BIOL CHEM, V272, P8932; SULLIVAN MA, 1984, GENE, V29, P21, DOI 10.1016/0378-1119(84)90161-6; WITTMAN V, 1988, J BACTERIOL, V170, P3206, DOI 10.1128/jb.170.7.3206-3212.1988; WITTMAN V, 1993, J BACTERIOL, V175, P7383, DOI 10.1128/JB.175.22.7383-7390.1993; Zhang HZ, 2001, SCIENCE, V291, P1962, DOI 10.1126/science.1055144; ZHU YF, 1992, J BACTERIOL, V174, P6171, DOI 10.1128/JB.174.19.6171-6178.1992	28	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16482	16487		10.1074/jbc.M210887200	http://dx.doi.org/10.1074/jbc.M210887200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615920	hybrid			2022-12-27	WOS:000182818600007
J	Gentle, A; Liu, YY; Martin, JE; Conti, GL; McBrien, NA				Gentle, A; Liu, YY; Martin, JE; Conti, GL; McBrien, NA			Collagen gene expression and the altered accumulation of scleral collagen during the development of high myopia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORM-DEPRIVATION MYOPIA; TREE SHREW SCLERA; FIBRIL DIAMETER; EYE ENLARGEMENT; VIII COLLAGEN; HUMAN CORNEAL; AXIAL MYOPIA; RECOVERY; TURNOVER; PROLINE	The development of high myopia is associated with reduced scleral collagen accumulation, scleral thinning, and loss of scleral tissue, in both humans and animal models. Reduced collagen fibril diameter is also observed in the sclera of eyes with high myopia. The present study investigated aspects of scleral collagen synthesis and degradation, in a mammalian model of high myopia, to elucidate the factors underlying scleral changes. General synthesis and degradation of scleral collagen was investigated in monocularly deprived tree shrews, through the in vivo administration of [H-3] proline and subsequent assay of scleral tissue for [H-3] collagen. In addition, PCR enriched cDNA, produced from tree shrew scleral mRNA, was used to synthesize probes for hybridization to custom gene arrays consisting of partial sequences for 11 collagen subtypes. Finally, real-time reverse transcriptase-PCR was employed to investigate collagen type I, III, and V mRNA expression in the sclera of myopic, contralateral control, and normal tree shrew eyes. Scleral [H-3] proline incorporation was reduced at the posterior pole of myopic eyes following 5 days of monocular deprivation (-36+/-4%), whereas [H-3] proline content was similar in treated and control eyes before myopia induction (-1+/-8%) but was reduced in myopic eyes following 5 (-8+/-2%), 12 (-15+/-4%), and 24 (-10+/-4%) days of myopia induction. The majority of the collagens investigated were found to be expressed in the sclera, with 11 subtypes being identified. Collagen type I mRNA expression was reduced in the sclera of myopic eyes (-20+/-7%), however, collagen type III (+2+/-9%) and type V (-1+/-6%) expression was unchanged relative to control, resulting in a net increase in the ratio of expression of collagen type III/type I and collagen type V/type I (22 and 25%, respectively). These results show that reduced scleral collagen accumulation in myopic eyes is a result of both decreased collagen synthesis and accelerated collagen degradation. Furthermore, changes in collagen synthesis are driven by reduced type I collagen production. Short term increases in the ratio of newly synthesized collagen type III/type I and type V/type I are likely to be important in the increasing frequency of small diameter scleral collagen fibrils observed in high myopia and may be important in the subsequent development of posterior staphyloma in humans with pathological myopia.	Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia	University of Melbourne	McBrien, NA (corresponding author), Univ Melbourne, Dept Optometry & Vis Sci, Parkville, Vic 3010, Australia.							Arokoski JPA, 1999, J BIOMED MATER RES, V48, P99; AVETISOV ES, 1984, METAB PEDIATR SYST O, V7, P183; Birk DE, 1997, EUR J CELL BIOL, V72, P352; BIRK DE, 1990, J CELL SCI, V95, P649; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURCIO CA, 1987, SCIENCE, V236, P579, DOI 10.1126/science.3576186; Curtin B J, 1977, Trans Am Ophthalmol Soc, V75, P67; CURTIN BJ, 1979, ARCH OPHTHALMOL-CHIC, V97, P912, DOI 10.1001/archopht.1979.01020010470017; CURTIN BJ, 1957, T AM ACAD OPHTHALMOL, V62, P777; CURTIN BJ, 1985, MYOPIAS BASIC SCI CL; Fitzgerald J, 2001, FEBS LETT, V505, P275, DOI 10.1016/S0014-5793(01)02754-5; FUNATA M, 1990, GRAEF ARCH CLIN EXP, V228, P174, DOI 10.1007/BF02764314; Gentle A, 1999, EXP EYE RES, V68, P155, DOI 10.1006/exer.1998.0587; Gentle A, 2002, CYTOKINE, V18, P344, DOI 10.1006/cyto.2002.1046; Gentle A, 2001, BIOTECHNIQUES, V31, P502, DOI 10.2144/01313st03; GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009; Guggenheim JA, 1996, INVEST OPHTH VIS SCI, V37, P1380; Ihanamaki T, 2001, EXP EYE RES, V72, P423, DOI 10.1006/exer.2000.0972; JACKSON SH, 1975, BIOCHIM BIOPHYS ACTA, V381, P359, DOI 10.1016/0304-4165(75)90241-X; KITTELBERGER R, 1990, CONNECT TISSUE RES, V24, P303, DOI 10.3109/03008209009152157; Koyano Y, 1997, BIOTECHNIQUES, V22, P706; LAURENT GJ, 1982, BIOCHEM J, V206, P535, DOI 10.1042/bj2060535; LAURENT GJ, 1978, BIOCHEM J, V176, P393, DOI 10.1042/bj1760393; LEE RE, 1981, EXP EYE RES, V32, P737, DOI 10.1016/0014-4835(81)90023-3; MARSHALL GE, 1993, CURR EYE RES, V12, P143, DOI 10.3109/02713689308999482; McBrien NA, 2000, INVEST OPHTH VIS SCI, V41, P3713; MCBRIEN NA, 1993, INVEST OPHTH VIS SCI, V34, P205; MCBRIEN NA, 1992, VISION RES, V32, P843, DOI 10.1016/0042-6989(92)90027-G; McBrien NA, 2001, INVEST OPHTH VIS SCI, V42, P2179; MULLER B, 1989, J COMP NEUROL, V282, P581, DOI 10.1002/cne.902820409; NEWSOME DA, 1982, INVEST OPHTH VIS SCI, V22, P376; NORTON TT, 1995, INVEST OPHTH VIS SCI, V36, pS760; NORTON TT, 1995, VISION RES, V35, P1271, DOI 10.1016/0042-6989(94)00243-F; PHILLIPS JR, 1995, OPHTHAL PHYSL OPT, V15, P357, DOI 10.1016/0275-5408(95)00062-I; Rada JA, 2000, INVEST OPHTH VIS SCI, V41, P2050; Reddy GK, 1996, CLIN BIOCHEM, V29, P225, DOI 10.1016/0009-9120(96)00003-6; Sandberg-Lall M, 2000, EXP EYE RES, V70, P401, DOI 10.1006/exer.1998.0826; Siegwart JT, 1999, VISION RES, V39, P387, DOI 10.1016/S0042-6989(98)00150-3; Siegwart JT, 1998, VISION RES, V38, P3505, DOI 10.1016/S0042-6989(98)00053-4; Siegwart JT, 2001, INVEST OPHTH VIS SCI, V42, P1153; SIEGWART JT, 1994, LAB ANIM SCI, V44, P213; Sorsby A, 1969, MED RES COUNC SPEC R, V309, P1; TAMURA Y, 1991, INVEST OPHTH VIS SCI, V32, P2636; Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200; Wessel H, 1997, INVEST OPHTH VIS SCI, V38, P2408; WIESEL TN, 1977, NATURE, V266, P66, DOI 10.1038/266066a0; ZORN N, 1992, INVEST OPHTH VIS SCI, V33, pS1053	47	141	162	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16587	16594		10.1074/jbc.M300970200	http://dx.doi.org/10.1074/jbc.M300970200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606541	hybrid			2022-12-27	WOS:000182818600020
J	Leitinger, B				Leitinger, B			Molecular analysis of collagen binding by the human discoidin domain receptors, DDR1 and DDR2 - Identification of collagen binding sites in DDR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; TYROSINE KINASE; CRYSTAL-STRUCTURE; MEMBRANE-BINDING; C2 DOMAIN; FACTOR V; CANCER; PROLIFERATION; EXPRESSION; PROTEIN	The widely expressed mammalian discoidin domain receptors (DDRs), DDR1 and DDR2, are unique among receptor tyrosine kinases in that they are activated by the extracellular matrix protein collagen. Various collagen types bind to and activate the DDRs, but the molecular details of collagen recognition have not been well defined. In this study, recombinant extracellular domains of DDR1 and DDR2 were produced to explore DDR-collagen binding in detail. In solid phase assays, both DDRs bound collagen I with high affinity. DDR1 recognized collagen I only as a dimeric and not as a monomeric construct, indicating a requirement for receptor dimerization in the DDR1-collagen interaction. The DDRs contain a discoidin homology domain in their extracellular domains, and the isolated discoidin domain of DDR2 bound collagen I with high affinity. Furthermore, the discoidin domain of DDR2, but not of DDR1, was sufficient for transmembrane receptor signaling. To map the collagen binding site within the discoidin domain of DDR2, mutant constructs were created, in which potential surface-exposed loops in DDR2 were exchanged for the corresponding loops of functionally unrelated discoidin domains. Three spatially adjacent surface loops within the DDR2 discoidin domain were found to be critically involved in collagen binding of the isolated DDR2 extracellular domain. In addition, the same loops were required for collagen-dependent receptor activation. It is concluded that the loop region opposite to the polypeptide chain termini of the DDR2 discoidin domain constitutes the collagen recognition site.	UCL, Sackler Inst Muscular Skeletal Res, Dept Med, London WC1E 6JJ, England	University of London; University College London	Leitinger, B (corresponding author), UCL, Sackler Inst Muscular Skeletal Res, Dept Med, 5 Univ St, London WC1E 6JJ, England.	b.leitinger@ucl.ac.uk						Agarwal G, 2002, BIOCHEMISTRY-US, V41, P11091, DOI 10.1021/bi020087w; ALVES F, 1995, ONCOGENE, V10, P609; BARKER KT, 1995, ONCOGENE, V10, P569; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; Bhatt RS, 2000, GENE DEV, V14, P2216, DOI 10.1101/gad.821600; Curat CA, 2001, J BIOL CHEM, V276, P45952, DOI 10.1074/jbc.M104360200; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; Gilbert GE, 2002, J BIOL CHEM, V277, P6374, DOI 10.1074/jbc.M104732200; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Hou GP, 2001, J CLIN INVEST, V107, P727, DOI 10.1172/JCI10720; Jansson M, 2001, J CELL SCI, V114, P2043; Kim SW, 2000, BIOCHEMISTRY-US, V39, P1951, DOI 10.1021/bi992256r; Kohfeldt E, 1998, J MOL BIOL, V282, P99, DOI 10.1006/jmbi.1998.2004; L'hote CGML, 2001, FASEB J, V15, P234, DOI 10.1096/fj.01-0414fje; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Lee CC, 2003, STRUCTURE, V11, P99, DOI 10.1016/S0969-2126(02)00941-3; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; Perez JL, 1996, ONCOGENE, V12, P1469; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Romijn RAP, 2001, J BIOL CHEM, V276, P9985, DOI 10.1074/jbc.M006548200; Sasaki T, 1998, EMBO J, V17, P1625, DOI 10.1093/emboj/17.6.1625; Sasaki T, 2000, FASEB J, V14, P761, DOI 10.1096/fasebj.14.5.761; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Symersky J, 1997, NAT STRUCT BIOL, V4, P833, DOI 10.1038/nsb1097-833; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; Weiner HL, 2000, NEUROSURGERY, V47, P1400, DOI 10.1097/00006123-200012000-00028	35	153	160	3	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16761	16769		10.1074/jbc.M301370200	http://dx.doi.org/10.1074/jbc.M301370200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611880	hybrid			2022-12-27	WOS:000182818600043
J	Pezza, JA; Choi, KH; Berardini, TZ; Beernink, PT; Allen, KN; Tolan, DR				Pezza, JA; Choi, KH; Berardini, TZ; Beernink, PT; Allen, KN; Tolan, DR			Spatial clustering of isozyme-specific residues reveals unlikely determinants of isozyme specificity in fructose-1,6-bisphosphate aldolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NUCLEOTIDE-SEQUENCE; MUSCLE ALDOLASE; MESSENGER-RNA; ESCHERICHIA-COLI; TERMINAL REGION; F-ACTIN; BINDING; IDENTIFICATION; EXPRESSION	Vertebrate fructose-1,6-bisphosphate aldolase exists as three isozymes (A, B, and C) that demonstrate kinetic properties that are consistent with their physiological role and tissue-specific expression. The isozymes demonstrate specific substrate cleavage efficiencies along with differences in the ability to interact with other proteins; however, it is unknown how these differences are conferred. An alignment of 21 known vertebrate aldolase sequences was used to identify all of the amino acids that are specific to each isozyme, or isozyme-specific residues (ISRs). The location of ISRs on the tertiary and quaternary structures of aldolase reveals that ISRs are found largely on the surface (24 out of 27) and are all outside of hydrogen bonding distance to any active site residue. Moreover, ISRs cluster into two patches on the surface of aldolase with one of these patches, the terminal surface patch, overlapping with the actin-binding site of aldolase A and overlapping an area of higher than average temperature factors derived from the x-ray crystal structures of the isozymes. The other patch, the distal surface patch, comprises an area with a different electrostatic surface potential when comparing isozymes. Despite their location distal to the active site, swapping ISRs between aldolase A and B by multiple site mutagenesis on recombinant expression plasmids is sufficient to convert the kinetic properties of aldolase A to those of aldolase B. This implies that ISRs influence catalysis via changes that alter the structure of the active site from a distance or via changes that alter the interaction of the mobile C-terminal portion with the active site. The methods used in the identification and analysis of ISRs discussed here can be applied to other protein families to reveal functionally relevant residue clusters not accessible by conventional primary sequence alignment methods.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA; Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University; Boston University	Allen, KN (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, 715 Albany st, Boston, MA 02118 USA.		Allen, Karen N./J-7045-2019	Allen, Karen N./0000-0001-7296-0551; Berardini, Tanya/0000-0002-3837-8864; Tolan, Dean/0000-0002-0598-7241	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060616] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60616] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agius L, 1996, BIOCHEM J, V315, P651, DOI 10.1042/bj3150651; AHN AH, 1994, DEVELOPMENT, V120, P2081; Baron CB, 1999, BIOCHEM J, V341, P805, DOI 10.1042/0264-6021:3410805; BEERNINK PT, 1994, PROTEIN SCI, V3, P1383, DOI 10.1002/pro.5560030904; BEERNINK PT, 1992, PROTEIN EXPRES PURIF, V3, P332, DOI 10.1016/1046-5928(92)90009-L; Berardini TZ, 1999, COMP BIOCHEM PHYS B, V122, P53, DOI 10.1016/S0305-0491(98)10140-2; Berardini TZ, 1997, COMP BIOCHEM PHYS A, V117, P471, DOI 10.1016/S0300-9629(96)00396-9; BERTHIAUME L, 1993, J BIOL CHEM, V268, P10826; BERTHIAUME L, 1991, J BIOL CHEM, V266, P17099; Blom N, 1997, NAT STRUCT BIOL, V4, P36, DOI 10.1038/nsb0197-36; CASARI G, 1995, NAT STRUCT BIOL, V2, P171, DOI 10.1038/nsb0295-171; Choi KH, 2001, BIOCHEMISTRY-US, V40, P13868, DOI 10.1021/bi0114877; Dalby AR, 2001, ACTA CRYSTALLOGR D, V57, P1526, DOI 10.1107/S0907444901012719; FUNARI VA, 2001, THESIS BOSTON U; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HERS HG, 1953, BIOCHIM BIOPHYS ACTA, V11, P427, DOI 10.1016/0006-3002(53)90062-6; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hikasa H, 1997, BBA-GENE STRUCT EXPR, V1354, P189, DOI 10.1016/S0167-4781(97)00086-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holland LZ, 1997, BIOCHEMISTRY-US, V36, P3207, DOI 10.1021/bi962664k; Horecker B. L, 1972, ENZYMES, P213, DOI DOI 10.1016/S1874-6047(08)60450-3; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; JOH K, 1985, GENE, V39, P17; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSAKABE T, 1994, J BIOCHEM-TOKYO, V115, P1172, DOI 10.1093/oxfordjournals.jbchem.a124475; Kusakabe T, 1997, ARCH BIOCHEM BIOPHYS, V344, P184, DOI 10.1006/abbi.1997.0204; Landgraf R, 2001, J MOL BIOL, V307, P1487, DOI 10.1006/jmbi.2001.4540; LEBHERZ HG, 1969, BIOCHEMISTRY-US, V8, P109, DOI 10.1021/bi00829a016; LEBIODA L, 1991, INT J BIOL MACROMOL, V13, P97, DOI 10.1016/0141-8130(91)90055-Y; Lichtarge O, 1997, J MOL BIOL, V274, P325, DOI 10.1006/jmbi.1997.1395; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; Llewellyn L, 1998, BBA-GENE STRUCT EXPR, V1443, P375, DOI 10.1016/S0167-4781(98)00229-2; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MORRIS AJ, 1993, J BIOL CHEM, V268, P1095; MOTOKI K, 1993, J BIOL CHEM, V268, P1677; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OREILLY G, 1993, FEBS LETT, V321, P69, DOI 10.1016/0014-5793(93)80623-3; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PENHOET EE, 1969, BIOCHEMISTRY-US, V8, P4391, DOI 10.1021/bi00839a025; PENHOET EE, 1971, J BIOL CHEM, V246, P318; PENHOET EE, 1968, THESIS U WASHINGTON; RACKER E, 1952, J BIOL CHEM, V196, P347; Rellos P, 2000, J BIOL CHEM, V275, P1145, DOI 10.1074/jbc.275.2.1145; ROTTMANN WH, 1987, BIOCHIMIE, V69, P137, DOI 10.1016/0300-9084(87)90246-X; ROTTMANN WH, 1984, P NATL ACAD SCI USA, V81, P2734; SAKAKIBARA M, 1985, BIOCHEM BIOPH RES CO, V131, P413, DOI 10.1016/0006-291X(85)91818-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P10; STAUFFER JK, 1992, NUCLEIC ACIDS RES, V20, P327, DOI 10.1093/nar/20.2.327; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TOLAN DR, 1987, AM J HUM GENET, V41, P907; TOLAN DR, 1984, J BIOL CHEM, V259, P1127; Wang JA, 1996, J BIOL CHEM, V271, P6861, DOI 10.1074/jbc.271.12.6861; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	58	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17307	17313		10.1074/jbc.M209185200	http://dx.doi.org/10.1074/jbc.M209185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611890	hybrid			2022-12-27	WOS:000182818600115
J	Reigstad, LJ; Sande, HM; Fluge, O; Bruland, O; Muga, A; Varhaug, JE; Martinez, A; Lillehaug, JR				Reigstad, LJ; Sande, HM; Fluge, O; Bruland, O; Muga, A; Varhaug, JE; Martinez, A; Lillehaug, JR			Platelet-derived growth factor (PDGF)-C, a PDGF family member with a vascular endothelial growth factor-like structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ELECTROPHORETIC TRANSFER; INFRARED-SPECTROSCOPY; POLYACRYLAMIDE GELS; DISULFIDE LINKAGES; RECEPTOR-BINDING; ALPHA-RECEPTOR; BETA-RECEPTOR; TUMOR-CELLS; FACTOR-BB	Platelet-derived growth factor (PDGF)-C is a novel member of the PDGF family that binds to PDGF alphaalpha and alphabeta receptors. The growth factor domain of PDGF-C (GFD-PDGF-C) was expressed in high yields in Escherichia coli and was purified and refolded from inclusion bodies obtaining a biologically active growth factor with dimeric structure. The GFD-PDGF-C contains 12 cysteine residues, and Ellman assay analysis indicates that it contains three intramonomeric disulfide bonds, which is in accordance with GFD-PDGF-C being a member of the cystine knot superfamily of growth factors. The recombinant GFD-PDGF-C was characterized by CD, fluorescence, NMR, and infrared spectroscopy. Together, our data indicate that GFD-PDGF-C is a highly thermostable protein that contains mostly beta-sheet secondary structure and some (6%) alpha-helix structure. The structural model of PDGF-C, obtained by homology-based molecular modeling using the structural representatives of this family of growth factors, shows that GFD-PDGF-C has a higher structural homology to the vascular endothelial growth factor than to PDGF-B. The modeled structure can give further insights into the function and specificity of this molecule.	Univ Bergen, Dept Mol Biol, N-5009 Bergen, Norway; Univ Bergen, Dept Pediat, N-5009 Bergen, Norway; Univ Bergen, Dept Surg, N-5009 Bergen, Norway; Univ Bergen, Dept Biochem & Mol Biol, N-5009 Bergen, Norway; Univ Basque Country, CSIC UPV EHU, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim & Biol Mol, E-48080 Bilbao, Spain	University of Bergen; University of Bergen; University of Bergen; University of Bergen; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country	Lillehaug, JR (corresponding author), Univ Bergen, HIB, Dept Mol Biol, Thormohlensgate 55, N-5020 Bergen, Norway.	johan.lillehaug@mbi.uib.no	Muga, Arturo/N-1174-2014; Martinez, Aurora/M-3088-2019	Muga, Arturo/0000-0003-0345-6882; Martinez, Aurora/0000-0003-1643-6506				ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BORK P, 1991, FEBS LETT, V282, P9, DOI 10.1016/0014-5793(91)80433-4; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cao RH, 2002, FASEB J, V16, P1575, DOI 10.1096/fj.02-0319com; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chehin R, 1999, BIOCHEMISTRY-US, V38, P1525, DOI 10.1021/bi981567j; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; Dijkmans J, 2002, INT J BIOCHEM CELL B, V34, P414, DOI 10.1016/S1357-2725(01)00124-8; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FLUGE O, 2000, P AM ASSOC CANC RES, V41, P862; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; GOODMAN SL, 1985, EMBO J, V4, P2769, DOI 10.1002/j.1460-2075.1985.tb04002.x; Gros E., 1967, METHOD ENZYMOL, V11, P238; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HANIU M, 1993, BIOCHEMISTRY-US, V32, P2431, DOI 10.1021/bi00060a039; HANIU M, 1994, ARCH BIOCHEM BIOPHYS, V310, P433, DOI 10.1006/abbi.1994.1189; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; Iyer S, 2002, TRENDS CARDIOVAS MED, V12, P128, DOI 10.1016/S1050-1738(01)00164-5; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; JANATOVA J, 1968, J BIOL CHEM, V243, P3612; Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H; Khurana R, 2000, BIOPHYS J, V78, P994, DOI 10.1016/S0006-3495(00)76657-4; KINI RM, 1995, BIOCHEM BIOPH RES CO, V212, P1115, DOI 10.1006/bbrc.1995.2084; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Larrivee B, 2000, INT J MOL MED, V5, P447; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Liu ML, 1998, J MAGN RESON, V132, P125, DOI 10.1006/jmre.1998.1405; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; MALE R, 1985, CARCINOGENESIS, V6, P1367, DOI 10.1093/carcin/6.9.1367; MARTINEZ A, 1995, BIOCHEM J, V306, P589, DOI 10.1042/bj3060589; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; MUGA A, 1994, BIOCHEMISTRY-US, V33, P4444, DOI 10.1021/bi00181a002; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Starovasnik MA, 1999, J MOL BIOL, V293, P531, DOI 10.1006/jmbi.1999.3134; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VASSBOTN FS, 1994, J CELL PHYSIOL, V158, P381, DOI 10.1002/jcp.1041580221; Wiesmann C, 2000, J MOL MED, V78, P247, DOI 10.1007/s001090000082; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; WOODY RW, 1996, CIRCULAR DICHROISM C, P112; Zwerner JP, 2002, ONCOGENE, V21, P3847, DOI 10.1038/sj.onc.1205486	48	27	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17114	17120		10.1074/jbc.M301728200	http://dx.doi.org/10.1074/jbc.M301728200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12598536	hybrid			2022-12-27	WOS:000182818600090
J	Tomari, Y; Hino, N; Nagaike, T; Suzuki, T; Ueda, T				Tomari, Y; Hino, N; Nagaike, T; Suzuki, T; Ueda, T			Decreased CCA-addition in human mitochondrial tRNAs bearing a pathogenic A4317G or A10044G mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICODON WOBBLE NUCLEOTIDE; MODIFICATION DEFECT; ESCHERICHIA-COLI; NUCLEOTIDYLTRANSFERASES; SUBSTITUTIONS; SEQUENCE; LOOP	Pathogenic point mutations in mitochondrial tRNA genes are known to cause a variety of human mitochondrial diseases. Reports have associated an A4317G mutation in the mitochondrial tRNAIle gene with fatal infantile cardiomyopathy and an A10044G mutation in the mitochondrial tRNAGly gene with sudden infant death syndrome. Here we demonstrate that both mutations inhibit in vitro CCA-addition to the respective tRNA by the human mitochondrial CCA-adding enzyme. Structures of these two mutant tRNAs were examined by nuclease probing. In the case of the A4317G tRNAIle mutant, structural rearrangement of the T-arm region, conferring an aberrantly stable T-arm structure and an increased T-m value, was clearly observed. In the case of the A10044G tRNAGly mutant, high nuclease sensitivity in both the T- and D-loops suggested a weakened interaction between the loops. These are the first reported instances of inefficient CCA-addition being one of the apparent molecular pathogeneses caused by pathogenic point mutations in human mitochondrial tRNA genes.	Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Kashiwa, Chiba 2778562, Japan	University of Tokyo	Suzuki, T (corresponding author), Univ Tokyo, Dept Integrated Biosci, Grad Sch Frontier Sci, Bldg FSB-301,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.	t-suzuki@k.u-tokyo.ac.jp	Tomari, Yukihide/A-8009-2009; Ueda, Takuya/K-5217-2014; Suzuki, Tsutomu/J-1776-2015	Tomari, Yukihide/0000-0001-8442-0851; Ueda, Takuya/0000-0002-7760-8271; Suzuki, Tsutomu/0000-0002-9731-1731				Degoul F, 1998, HUM MOL GENET, V7, P347, DOI 10.1093/hmg/7.3.347; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111; HEGG LA, 1990, NUCLEIC ACIDS RES, V18, P5975, DOI 10.1093/nar/18.20.5975; Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047; Kelley SO, 2001, J BIOL CHEM, V276, P10607, DOI 10.1074/jbc.M008320200; Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112; Levinger L, 1998, J BIOL CHEM, V273, P1015, DOI 10.1074/jbc.273.2.1015; Li ZL, 1996, BIOCHEM J, V314, P49, DOI 10.1042/bj3140049; LOCKARD RE, 1981, NUCLEIC ACIDS RES, V9, P5125, DOI 10.1093/nar/9.19.5125; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Nagaike T, 2001, J BIOL CHEM, V276, P40041, DOI 10.1074/jbc.M106202200; Reichert AS, 2000, NUCLEIC ACIDS RES, V28, P2043, DOI 10.1093/nar/28.10.2043; ROSSMANITH W, 1995, J BIOL CHEM, V270, P12885, DOI 10.1074/jbc.270.21.12885; Santorelli FM, 1996, PEDIATR NEUROL, V15, P145, DOI 10.1016/0887-8994(96)00163-4; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; SPACCIAPOLI P, 1989, J BIOL CHEM, V264, P3799; Spacciapoli P, 1990, J Mol Recognit, V3, P149, DOI 10.1002/jmr.300030403; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656; TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I; Yasukawa T, 2000, NUCLEIC ACIDS RES, V28, P3779, DOI 10.1093/nar/28.19.3779; Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251; Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5; Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794	26	29	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16828	16833		10.1074/jbc.M213216200	http://dx.doi.org/10.1074/jbc.M213216200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621050	hybrid			2022-12-27	WOS:000182818600052
J	Yi, XL; Yin, XM; Dong, Z				Yi, XL; Yin, XM; Dong, Z			Inhibition of Bid-induced apoptosis by Bcl-2 - tBid insertion, Bax translocation, and Bax/Bak oligomerization suppressed	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; OUTER MITOCHONDRIAL-MEMBRANE; BH3 DOMAIN; CONFORMATIONAL CHANGE; FAMILY PROTEINS; CELL-SURVIVAL; DEATH; HYPOXIA; HETERODIMERIZATION; REOXYGENATION	Bcl-2 family proteins are important regulators of apoptosis. They can be pro-apoptotic (e.g. Bid, Bax, and Bak) or anti-apoptotic (e.g. Bcl-2 and Bcl-x(L)). The current study examined Bid-induced apoptosis and its inhibition by Bcl-2. Transfection of Bid led to apoptosis in HeLa cells. In these cells, Bid was processed into active forms of truncated Bid or tBid. Following processing, tBid translocated to the membrane-bound organellar fraction. Bcl-2 co-transfection inhibited Bid-induced apoptosis but did not prevent Bid processing or tBid translocation. On the other hand, Bcl-2 blocked the release of mitochondrial cytochrome c in Bid-transfected cells, suggesting actions at the mitochondrial level. Alkaline treatment stripped off tBid from the membrane-bound organellar fraction of Bid plus Bcl-2-co-transfected cells, but not from cells transfected with only Bid, suggesting inhibition of tBid insertion into mitochondrial membranes by Bcl-2. Bcl-2 also prevented Bid-induced Bax translocation from cytosol to the membrane-bound organellar fraction. Finally, Bcl-2 diminished Bid-induced oligomerization of Bax and Bak within the membrane-bound organellar fraction, shown by cross-linking experiments. In conclusion, Bcl-2 inhibited Bid-induced apoptosis at the mitochondrial level by blocking cytochrome c release, without suppressing Bid processing or activation. Critical steps blocked by Bcl-2 included tBid insertion, Bax translocation, and Bax/Bak oligomerization in the mitochondrial membranes.	Med Coll Georgia, Dept Anat & Cell Biol, Augusta, GA 30912 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA	University System of Georgia; Augusta University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Dong, Z (corresponding author), Med Coll Georgia, Dept Cellular Biol & Anat, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.				NATIONAL CANCER INSTITUTE [K01CA074885, R01CA083817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058831] Funding Source: NIH RePORTER; NCI NIH HHS [CA83817, CA74885] Funding Source: Medline; NIDDK NIH HHS [DK58831] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dong Z, 2000, BIOCHEM J, V347, P669, DOI 10.1042/0264-6021:3470669; Dong Z, 2001, J BIOL CHEM, V276, P18702, DOI 10.1074/jbc.M011774200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Esposti MD, 2002, APOPTOSIS, V7, P433, DOI 10.1023/A:1020035124855; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li SC, 2002, J BIOL CHEM, V277, P26912, DOI 10.1074/jbc.M200726200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Tafani M, 2002, J BIOL CHEM, V277, P49569, DOI 10.1074/jbc.M208915200; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	49	104	121	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16992	16999		10.1074/jbc.M300039200	http://dx.doi.org/10.1074/jbc.M300039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624108	hybrid			2022-12-27	WOS:000182818600074
J	Dunckley, T; Lukas, RJ				Dunckley, T; Lukas, RJ			Nicotine modulates the expression of a diverse set of genes in the neuronal SH-SY5Y cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PATHWAY INHIBITOR-2; PROTEIN-KINASE PATHWAY; ACETYLCHOLINE-RECEPTOR; INDUCED CONVULSIONS; CONTACTIN FORM; COMPLEX; IDENTIFICATION; INVASIVENESS; ACTIVATION; MOLECULES	Nicotine exposure can have long lasting effects on nervous system function, some of which must contribute to nicotine dependence. Up-regulation, an increase in numbers of radioligand-binding nicotinic acetylcholine receptors (nAChR), occurs on exposure to nicotine at high concentrations. To determine whether altered gene expression might account for long term changes and up-regulation following nicotine exposure, we assessed effects of 1 h of 1 mm nicotine exposure on alteration of gene expression in the neuron-like SH-SY5Y neuroblastoma clonal line. Repeat and cross-controlled microarray analyses yielded a list of 17 genes from the initially screened similar to5,000 whose expression was consistently altered following nicotine treatment. Subsequent quantitative, real time reverse transcriptase PCR analyses confirmed altered expression in 14 of 16 genes tested. Further, the general nAChR antagonist, d-tubocurarine, blocked all but two of the observed changes in gene expression, indicating that these changes are dependent on nAChR activation. Use of other antagonists revealed that nAChR subtypes can differentially affect gene expression. The genes affected code for proteins that may be broadly categorized into four groups: transcription factors, protein processing factors, RNA-binding proteins, and plasma membrane-associated proteins. Our results suggest that nicotinic activation of nAChR may have a broad role in affecting cellular physiology through modulating gene expression.	Barrow Neurol Inst, Div Neurobiol, Phoenix, AZ 85013 USA	Barrow Neurological Institute	Lukas, RJ (corresponding author), Barrow Neurol Inst, Div Neurobiol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	rlukas@chw.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040417] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 40417] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKER WW, 1967, P SOC EXP BIOL MED, V124, P607; BELESLIN DB, 1986, PHARMACOL BIOCHEM BE, V24, P1509, DOI 10.1016/0091-3057(86)90476-4; CARR LA, 1989, NEUROCHEM RES, V14, P511, DOI 10.1007/BF00964911; CAULFIELD MP, 1983, NEUROPHARMACOLOGY, V22, P347, DOI 10.1016/0028-3908(83)90251-4; Dajas-Bailador FA, 2002, J NEUROCHEM, V80, P520, DOI 10.1046/j.0022-3042.2001.00725.x; Donnelly-Roberts DL, 1999, NEURONAL NICOTINIC R, P337; FONTANA A, 1978, BIOCH MYASTHENIA GRA; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Harlan RE, 1998, MOL NEUROBIOL, V16, P221, DOI 10.1007/BF02741385; Heidebrecht HJ, 2000, GENOMICS, V68, P348, DOI 10.1006/geno.2000.6301; Heusch WL, 1998, CARCINOGENESIS, V19, P551, DOI 10.1093/carcin/19.4.551; Ichino N, 2002, J NEURAL TRANSM, V109, P1015, DOI 10.1007/s007020200084; Ji D, 2001, NEURON, V31, P131, DOI 10.1016/S0896-6273(01)00332-4; Kane JK, 2000, ENDOCRINOLOGY, V141, P3623, DOI 10.1210/en.141.10.3623; Kazarinova-Noyes K, 2001, J NEUROSCI, V21, P7517, DOI 10.1523/JNEUROSCI.21-19-07517.2001; Ke L, 1998, J PHARMACOL EXP THER, V286, P825; Kleines M, 2001, GENE, V275, P157, DOI 10.1016/S0378-1119(01)00620-5; Konduri SD, 2001, INT J ONCOL, V18, P127; Kramer EM, 1999, J BIOL CHEM, V274, P29042, DOI 10.1074/jbc.274.41.29042; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; Levin ED, 1998, PSYCHOPHARMACOLOGY, V138, P217, DOI 10.1007/s002130050667; Li MD, 2000, BRAIN RES, V867, P157, DOI 10.1016/S0006-8993(00)02283-6; Liu CJ, 2001, J BIOL CHEM, V276, P46553, DOI 10.1074/jbc.M108699200; LUKAS RJ, 1993, MOL CELL NEUROSCI, V4, P1, DOI 10.1006/mcne.1993.1001; Meagher MJ, 2001, MOL CELL BIOL, V21, P2880, DOI 10.1128/MCB.21.8.2880-2890.2001; MINER LL, 1985, LIFE SCI, V37, P75, DOI 10.1016/0024-3205(85)90628-9; Mirnics K, 2001, TRENDS NEUROSCI, V24, P479, DOI 10.1016/S0166-2236(00)01862-2; Nakayama H, 2001, J NEUROCHEM, V79, P489, DOI 10.1046/j.1471-4159.2001.00602.x; Neaud V, 2000, J BIOL CHEM, V275, P35565, DOI 10.1074/jbc.M006101200; Nisell M, 1997, NEUROPSYCHOPHARMACOL, V17, P151, DOI 10.1016/S0893-133X(97)00040-7; Papke RL, 2001, J PHARMACOL EXP THER, V297, P646; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; PENG X, 1994, MOL PHARMACOL, V45, P546; Pich EM, 1997, SCIENCE, V275, P83; Rao CN, 2001, CLIN CANCER RES, V7, P570; Rasmussen R., 1998, BIOCHIMICA, V2, P8; Rios JC, 2000, J NEUROSCI, V20, P8354, DOI 10.1523/JNEUROSCI.20-22-08354.2000; *ROCH BIOCH, 2000, LIGHTC OP MAN VERS 3; Schinzel A, 2001, AM J MED GENET, V106, P119, DOI 10.1002/ajmg.1576; Shim IS, 2000, J ETHNOPHARMACOL, V70, P161, DOI 10.1016/S0378-8741(99)00166-X; SILVETTE H, 1962, PHARMACOL REV, V14, P137; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tang KC, 1998, MOL PHARMACOL, V54, P59, DOI 10.1124/mol.54.1.59; Thomaidou D, 2001, J NEUROCHEM, V78, P767, DOI 10.1046/j.1471-4159.2001.00454.x; Torres G, 1999, PSYCHOSOM MED, V61, P630, DOI 10.1097/00006842-199909000-00007; Wang J, 2001, ACTA PHARMACOL SIN, V22, P685; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zhang SL, 2001, PHYSIOL GENOMICS, V5, P187, DOI 10.1152/physiolgenomics.2001.5.4.187; Zhang Z, 2001, CELL, V106, P465, DOI 10.1016/S0092-8674(01)00466-4	51	61	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15633	15640		10.1074/jbc.M210389200	http://dx.doi.org/10.1074/jbc.M210389200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12588870	hybrid			2022-12-27	WOS:000182680000024
J	Richardson, RM; Tokunaga, K; Marjoram, R; Sata, T; Snyderman, R				Richardson, RM; Tokunaga, K; Marjoram, R; Sata, T; Snyderman, R			Interleukin-8-mediated heterologous receptor internalization provides resistance to HIV-1 infectivity - Role of signal strength and receptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTORS; PHOSPHORYLATION SITES; CROSS-REGULATION; T-LYMPHOCYTES; EXPRESSION; CCR5; BINDING; ENTRY; IDENTIFICATION; MONOCYTES	Human immunodeficiency virus type 1 (HIV-1) entry into CD4(+) cells requires the chemokine receptors CCR5 or CXCR4 as co-fusion receptors. We have previously demonstrated that chemokine receptors are capable of cross-regulating the functions of each other and, thus, affecting cellular responsiveness at the site of infection. To investigate the effects of chemokine receptor cross-regulation in HIV-1 infection, monocytes and MAGIC5 and rat basophilic leukemia (RBL-2H3) cell lines co-expressing the interleukin-8 (IL-8 or CXCLS) receptor CXCR1 and either CCR5 (ACCR5) or CXCR4 (ACXCR4) were generated. IL-8 activation of CXCR1, but not the IL-8 receptor CXCR2, cross-phosphorylated CCR5 and CXCR4 and cross-desensitized their responsiveness to RANTES (regulated on activation normal T cell expressed and secreted) (CCL5) and stromal derived factor (SDF-1 or CXCL12), respectively. CXCR1 activation internalized CCR5 but not CXCR4 despite cross-phosphorylation of both. IL-8 pretreatment also inhibited CCR5- but not CXCR4-mediated virus entry into MAGIC5 cells. A tail-deleted mutant of CXCR1, DeltaCXCR1, produced greater signals upon activation (Ca2+ mobilization and phosphoinositide hydrolysis) and cross-internalized CXCR4, inhibiting HIV-1 entry. The protein kinase C inhibitor staurosporine prevented phosphorylation and internalization of the receptors by CXCR1 activation. Taken together, these results indicate that chemokine receptor-mediated HIV-1 cell infection is blocked by receptor internalization but not desensitization alone. Thus, activation of chemokine receptors unrelated to CCR5 and CXCR4 may play a cross-regulatory role in the infection and propagation of HIV-1. Since DeltaCXCR1, but not CXCR1, cross-internalized and cross-inhibited HIV-1 infection to CXCR4, the data indicate the importance of the signal strength of a receptor and, as a consequence, protein kinase C activation in the suppression of HIV-1 infection by cross-receptor-mediated internalization.	Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA; Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Natl Inst Infect Dis, Dept Pathol, Tokyo 1628640, Japan; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Meharry Medical College; Vanderbilt University; National Institute of Infectious Diseases (NIID); Duke University	Richardson, RM (corresponding author), Meharry Med Coll, Dept Biochem, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA.	mrrichardson@mmc.edu	Tokunaga, Kenzo/Q-9914-2018	Tokunaga, Kenzo/0000-0002-2625-5322	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038910, R01AI038910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE003738] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 38910] Funding Source: Medline; NIDCR NIH HHS [DE 03738] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; BACON KB, 1995, J IMMUNOL, V154, P3654; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Deng XY, 1999, BLOOD, V94, P1165, DOI 10.1182/blood.V94.4.1165.416k23_1165_1173; Dimitrov DS, 1998, J MEMBRANE BIOL, V166, P75, DOI 10.1007/s002329900450; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Fouchier RAM, 1997, EMBO J, V16, P4531, DOI 10.1093/emboj/16.15.4531; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; Huttenrauch F, 2002, J BIOL CHEM, V277, P30769, DOI 10.1074/jbc.M204033200; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; MALIM MH, 1988, NATURE, V335, P181, DOI 10.1038/335181a0; Mantovani A, 1999, IMMUNOL TODAY, V20, P254, DOI 10.1016/S0167-5699(99)01469-3; Mochizuki N, 1999, AIDS RES HUM RETROV, V15, P1321, DOI 10.1089/088922299310223; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2000, PHARMACOL REV, V52, P145; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Qin SX, 1996, EUR J IMMUNOL, V26, P640, DOI 10.1002/eji.1830260320; Richardson RM, 2000, J BIOL CHEM, V275, P9201, DOI 10.1074/jbc.275.13.9201; Richardson RM, 1998, J BIOL CHEM, V273, P23830, DOI 10.1074/jbc.273.37.23830; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; RICHARDSON RM, 2001, CHEMOKINE RECEPTORS, P31; Shen WP, 2000, BIOCHEM BIOPH RES CO, V272, P276, DOI 10.1006/bbrc.2000.2770; Tani K, 1998, EUR J IMMUNOL, V28, P502, DOI 10.1002/(SICI)1521-4141(199802)28:02<502::AID-IMMU502>3.0.CO;2-5; Tokunaga K, 2001, J VIROL, V75, P6776, DOI 10.1128/JVI.75.15.6776-6785.2001; TOMHAVE ED, 1994, J IMMUNOL, V153, P3267; Utsunomiya I, 1997, EUR J IMMUNOL, V27, P1406, DOI 10.1002/eji.1830270617; Wang Ji Ming, 1996, Methods (Orlando), V10, P135, DOI 10.1006/meth.1996.0087; Wuyts Anja, 1998, P271; XU LL, 1995, EUR J IMMUNOL, V25, P2612, DOI 10.1002/eji.1830250931; XU LL, 1995, J LEUKOCYTE BIOL, V57, P335, DOI 10.1002/jlb.57.2.335; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	40	48	51	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15867	15873		10.1074/jbc.M211745200	http://dx.doi.org/10.1074/jbc.M211745200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594210	hybrid			2022-12-27	WOS:000182680000053
J	Kim, TY; Lee, KH; Chang, S; Chung, C; Lee, HW; Yim, J; Kim, TK				Kim, TY; Lee, KH; Chang, S; Chung, C; Lee, HW; Yim, J; Kim, TK			Oncogenic potential of a dominant negative mutant of interferon regulatory factor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; VIRUS-INFECTION; TUMOR-ANTIGEN; TRANSCRIPTION; IRF-3; ACTIVATION; PROTEIN; RAS; TRANSFORMATION; APOPTOSIS	Interferon regulatory factor 3 (IRF3) is activated in response to various environmental stresses including viral infection and DNA-damaging agents. However, the biological function of IRF3 in cell growth is not well understood. We demonstrated that IRF3 markedly inhibited growth and colony formation of cells. IRF3 blocked DNA synthesis and induced apoptosis. Based on this negative control of cell growth by IRF3, we examined whether functional loss of IRF3 may contribute to oncogenic transformation. IRF3 activity was specifically inhibited by expression of its dominant negative mutant. This mutant lacks a portion of the DNA binding domain like IRF3a, an alternative splice form of IRF3 in the cells. This dominant negative inhibition blocked expression of specific IRF3 target genes. Mutant IRF3 efficiently transformed NIH3T3 cells, as demonstrated by anchorage-independent growth in soft agar and tumorigenicity in. nude mice. These results imply that IRF3 may function as a tumor suppressor and suggest a possible role for the relative levels of IRF3 and its dominant negative mutant in tumorigenesis.	Korea Adv Inst Sci & Technol, Dept Sci Biol, Taejon 305701, South Korea; Seoul Natl Univ, Dept Microbiol, Seoul 151742, South Korea; Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Suwon 440746, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Natl Creat Res Initiat Ctr Genet Reprogramming, Seoul 151742, South Korea; Harvard Univ, Sch Med, Inst Chem & Cell Biol, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU); Sungkyunkwan University (SKKU); Seoul National University (SNU); Harvard University; Harvard Medical School	Kim, TK (corresponding author), Korea Adv Inst Sci & Technol, Dept Sci Biol, Taejon 305701, South Korea.	tkkim@mail.kaist.ac.kr						BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Duguay D, 2002, CANCER RES, V62, P5148; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Karpova AY, 2002, P NATL ACAD SCI USA, V99, P2818, DOI 10.1073/pnas.052713899; Karpova AY, 2001, MOL CELL BIOL, V21, P4169, DOI 10.1128/MCB.21.13.4169-4176.2001; Karpova AY, 2000, GENE DEV, V14, P2813, DOI 10.1101/gad.813800; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; Kim T, 2000, J BIOL CHEM, V275, P16910, DOI 10.1074/jbc.M000524200; Kim TK, 2000, CANCER RES, V60, P1153; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2001, ONCOGENE, V20, P800, DOI 10.1038/sj.onc.1204163; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Navarro L, 1998, MOL CELL BIOL, V18, P3796, DOI 10.1128/MCB.18.7.3796; OIJEN M, 2000, CLIN CANCER RES, V6, P2138; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weaver BK, 2001, FASEB J, V15, P501, DOI 10.1096/fj.00-0222com; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952	36	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15272	15278		10.1074/jbc.M205792200	http://dx.doi.org/10.1074/jbc.M205792200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12582166	hybrid			2022-12-27	WOS:000182516100089
J	Saito, H; Dhanasekaran, P; Nguyen, D; Baldwin, F; Weisgraber, KH; Wehrli, S; Phillips, MC; Lund-Katz, S				Saito, H; Dhanasekaran, P; Nguyen, D; Baldwin, F; Weisgraber, KH; Wehrli, S; Phillips, MC; Lund-Katz, S			Characterization of the heparin binding sites in human apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; SULFATE PROTEOGLYCAN-BINDING; AMPHIPATHIC ALPHA-HELIX; N-TERMINAL DOMAIN; ALZHEIMERS-DISEASE; III HYPERLIPOPROTEINEMIA; E ISOFORMS; EXTRACELLULAR-MATRIX; TRANSPORT PROTEIN; E FRAGMENTS	Apolipoprotein (apo) E mediates lipoprotein remnant clearance via interaction with cell-surface heparan sulfate proteoglycans. Both the 22-kDa N-terminal domain and 10-kDa C-terminal domain of apoE contain a heparin binding site; the N-terminal site overlaps with the low density lipoprotein receptor binding region and the G terminal site is undefined. To understand the molecular details of the apoE-heparin interaction, we defined the microenvironments of all 12 lysine residues in intact apoE3 and examined their relative contributions to heparin binding. Nuclear magnetic resonance measurements showed that, in apoE3-dimyristoyl phosphatidylcholine discs, Lys-143 and -146 in the N-terminal domain and Lys-233 in the C-terminal domain have unusually low pK(a) values, indicating high positive electrostatic potential around these residues. Binding experiments using heparin-Sepharose gel demonstrated that the lipid-free 10-kDa fragment interacted strongly with heparin and a point mutation K233Q largely abolished the binding, indicating that Lys-233 is involved in heparin binding and that an unusually basic lysine microenvironment is critical for the interaction with heparin. With lipidated apoE3, it is confirmed that the Lys-233 site is completely masked and the N-terminal site mediates heparin binding. In addition, mutations of the two heparin binding sites in intact apoE3 demonstrated the dominant role of the N-teriminal site in the heparin binding of apoE even in the lipid-free state. These results suggest that apoE interacts predominately with cell-surface heparan sulfate proteoglycans through the N-terminal binding site. However, Lys-233 may be involved in the binding of apoE to certain cell-surface sites, such as the protein core of biglycan.	Univ Penn, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Sch Med, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Lund-Katz, S (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Sch Med, Abramson Res Bldg,Suite 302,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	katzs@email.chop.edu		Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL56083, HL41633] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633, R01HL056083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; Aizawa Y, 1997, BRAIN RES, V768, P208, DOI 10.1016/S0006-8993(97)00640-9; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Burgess JW, 1998, J BIOL CHEM, V273, P5645, DOI 10.1074/jbc.273.10.5645; Cardin A D, 1988, Adv Exp Med Biol, V243, P157; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; CARDIN AD, 1991, METHOD ENZYMOL, V203, P556; CASTANO EM, 1995, J BIOL CHEM, V270, P17610, DOI 10.1074/jbc.270.29.17610; Cooper AD, 1997, J LIPID RES, V38, P2173; Dong J, 2000, J LIPID RES, V41, P1783; Dong J, 2001, BIOCHEMISTRY-US, V40, P2826, DOI 10.1021/bi002417n; DYER CA, 1991, J BIOL CHEM, V266, P15009; Fisher CA, 1999, J LIPID RES, V40, P93; Fisher CA, 2000, J BIOL CHEM, V275, P33601, DOI 10.1074/jbc.M002643200; FUNAHASHI T, 1989, J BIOCHEM-TOKYO, V105, P582, DOI 10.1093/oxfordjournals.jbchem.a122708; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; Ji ZS, 1998, J BIOL CHEM, V273, P13452, DOI 10.1074/jbc.273.22.13452; Klezovitch O, 2000, J BIOL CHEM, V275, P18913, DOI 10.1074/jbc.M909644199; Libeu CP, 2001, J BIOL CHEM, V276, P39138, DOI 10.1074/jbc.M104746200; Lin CY, 2001, J LIPID RES, V42, P1125; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu B, 2000, J BIOL CHEM, V275, P20775, DOI 10.1074/jbc.M003508200; Lucas M, 1996, J BIOL CHEM, V271, P13454, DOI 10.1074/jbc.271.23.13454; Lund-Katz S, 2000, J BIOL CHEM, V275, P34459, DOI 10.1074/jbc.M005265200; Lund-Katz S, 2001, J LIPID RES, V42, P894; LUNDKATZ S, 1988, J BIOL CHEM, V263, P13831; LUNDKATZ S, 1993, J BIOL CHEM, V268, P23008; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; Mahley RW, 2000, ANNU REV GENOM HUM G, V1, P507, DOI 10.1146/annurev.genom.1.1.507; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MANN WA, 1995, J LIPID RES, V36, P517; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Narayanaswami V, 2001, J BIOL CHEM, V276, P37853; O'Brien KD, 1998, CIRCULATION, V98, P519, DOI 10.1161/01.CIR.98.6.519; Olin KL, 2001, ARTERIOSCL THROM VAS, V21, P129, DOI 10.1161/01.ATV.21.1.129; Saito H, 2001, J BIOL CHEM, V276, P40949, DOI 10.1074/jbc.M106337200; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SEGREST JP, 1992, J LIPID RES, V33, P141; Shuvaev VV, 1999, FEBS LETT, V459, P353, DOI 10.1016/S0014-5793(99)01285-5; Shuvaev VV, 2000, NEUROSCI LETT, V280, P131, DOI 10.1016/S0304-3940(00)00764-3; Swertfeger DK, 2001, J BIOL CHEM, V276, P25043, DOI 10.1074/jbc.M102357200; Verrecchio A, 2000, J BIOL CHEM, V275, P7701, DOI 10.1074/jbc.275.11.7701; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; Weisgraber KH, 1996, FASEB J, V10, P1485, DOI 10.1096/fasebj.10.13.8940294; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Zaiou M, 2000, J LIPID RES, V41, P1087	54	66	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14782	14787		10.1074/jbc.M213207200	http://dx.doi.org/10.1074/jbc.M213207200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588864	hybrid			2022-12-27	WOS:000182516100027
J	Szabadkai, G; Simoni, AM; Rizzuto, R				Szabadkai, G; Simoni, AM; Rizzuto, R			Mitochondrial Ca2+ uptake requires sustained Ca2+ release from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYTOPLASMIC CA2+; CALCIUM; ENTRY; CELL; OSCILLATIONS; HOMEOSTASIS; PHOSPHORYLATION; OVEREXPRESSION; MICRODOMAINS	We analyzed the role of inositol 1,4,5-trisphosphate-induced Ca2+ release from the endoplasmic reticulum (ER) (i) in powering mitochondrial Ca2+ uptake and (ii) in maintaining a sustained elevation of cytosolic Ca2+ concentration ([Ca2+](c)). For this purpose, we expressed in HeLa cells aequorin-based Ca2+-sensitive probes targeted to different intracellular compartments and studied the effect of two agonists: histamine, acting on endogenous H-1 receptors, and glutamate, acting on co-transfected metabotropic glutamate receptor (mGluR1a), which rapidly inactivates through protein kinase C-dependent phosphorylation and thus causes transient inositol 1,4,5-trisphosphate production. Glutamate induced a transient [Ca2+](c) rise and drop in ER luminal [Ca2+] ([Ca2+](er)), and then the ER refilled with [Ca2+](c) at resting values. With histamine, [Ca2+](c) after the initial peak stabilized at a sustained plateau, and [Ca2+](er) decreased to a low steady-state value. In mitochondria, histamine evoked a much larger mitochondrial Ca2+ response than glutamate (similar to15 versus similar to65 muM). Protein kinase C inhibition, partly relieving mGluR1a desensitization, reestablished both the [Ca2+](c) plateau and the sustained ER Ca2+ release and markedly increased the mitochondrial Ca2+ response. Conversely, mitochondrial Ca2+ uptake evoked by histamine was drastically reduced by very transient (similar to2-s) agonist applications. These data indicate that efficient mitochondrial Ca2+ uptake depends on the preservation of high Ca2+ microdomains at the mouth of ER Ca2+ release sites close to mitochondria. This in turn depends on continuous Ca2+ release balanced by Ca2+ reuptake into the ER and maintained by Ca2+ influx from the extracellular space.	Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Ferrara, Interdisciplinary Ctr Study Inflammat, I-44100 Ferrara, Italy	University of Ferrara; University of Ferrara	Rizzuto, R (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, Via Borsari 46, I-44100 Ferrara, Italy.	r.rizzuto@unife.it	Rizzuto, Rosario/B-6312-2008	Rizzuto, Rosario/0000-0001-7044-5097; Szabadkai, Gyorgy/0000-0002-3006-3577	Telethon [1285] Funding Source: Medline	Telethon(Fondazione Telethon)		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BLAUSTEIN MP, 1988, TRENDS NEUROSCI, V11, P438, DOI 10.1016/0166-2236(88)90195-6; Blaustein MR, 2001, TRENDS NEUROSCI, V24, P602, DOI 10.1016/S0166-2236(00)01891-9; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; Camello P, 1996, J PHYSIOL-LONDON, V490, P585, DOI 10.1113/jphysiol.1996.sp021169; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; Daub B, 2000, CELL CALCIUM, V27, P3, DOI 10.1054/ceca.1999.0084; Drummond RM, 2000, J PHYSIOL-LONDON, V522, P375, DOI 10.1111/j.1469-7793.2000.t01-2-00375.x; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fierro L, 1996, J PHYSIOL-LONDON, V496, P617, DOI 10.1113/jphysiol.1996.sp021713; Francesconi A, 2000, P NATL ACAD SCI USA, V97, P6185, DOI 10.1073/pnas.97.11.6185; GABELLINI N, 1993, NEUROREPORT, V4, P531, DOI 10.1097/00001756-199305000-00017; Gerencser AA, 2001, CELL CALCIUM, V30, P311, DOI 10.1054/ceca.2001.0238; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hermans E, 2001, BIOCHEM J, V359, P465, DOI 10.1042/0264-6021:3590465; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; Janssen LJ, 1999, AM J PHYSIOL-LUNG C, V276, pL744, DOI 10.1152/ajplung.1999.276.5.L744; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Mignen O, 2001, J BIOL CHEM, V276, P35676, DOI 10.1074/jbc.M105626200; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; Moccia F, 2002, BIOCHEM J, V364, P235, DOI 10.1042/bj3640235; Mogami H, 1999, J PHYSIOL-LONDON, V518, P463, DOI 10.1111/j.1469-7793.1999.0463p.x; Montero M, 2002, FASEB J, V16, P1955, DOI 10.1096/fj.02-0553fje; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; Petersen OH, 1999, BIOESSAYS, V21, P851, DOI 10.1002/(SICI)1521-1878(199910)21:10<851::AID-BIES7>3.3.CO;2-6; Petersen OH, 1999, EUR J CELL BIOL, V78, P221, DOI 10.1016/S0171-9335(99)80054-5; Petersen OH, 2001, TRENDS NEUROSCI, V24, P271, DOI 10.1016/S0166-2236(00)01787-2; Putney JW, 2001, J CELL SCI, V114, P2223; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rohacs T, 1997, BIOCHEM J, V322, P785, DOI 10.1042/bj3220785; Rutter GA, 2000, TRENDS BIOCHEM SCI, V25, P215, DOI 10.1016/S0968-0004(00)01585-1; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Shuttleworth TJ, 1996, BIOCHEM J, V313, P815, DOI 10.1042/bj3130815; Szabadkai G, 2001, PFLUG ARCH EUR J PHY, V441, P678, DOI 10.1007/s004240000466; TILLY BC, 1990, BIOCHEM J, V266, P235, DOI 10.1042/bj2660235; Vandecasteele G, 2001, IUBMB LIFE, V52, P213, DOI 10.1080/15216540152846028; Verkhratsky A, 2002, EUR J PHARMACOL, V447, P141, DOI 10.1016/S0014-2999(02)01838-1; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245, DOI 10.1113/jphysiol.1993.sp019813	50	72	73	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15153	15161		10.1074/jbc.M300180200	http://dx.doi.org/10.1074/jbc.M300180200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586823	hybrid			2022-12-27	WOS:000182516100074
J	Yamazaki, K; Aso, T; Ohnishi, Y; Ohno, M; Tamura, K; Shuin, T; Kitajima, S; Nakabeppu, Y				Yamazaki, K; Aso, T; Ohnishi, Y; Ohno, M; Tamura, K; Shuin, T; Kitajima, S; Nakabeppu, Y			Mammalian elongin A is not essential for cell viability but is required for proper cell cycle progression with limited alteration of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION ELONGATION-FACTOR; TUMOR-SUPPRESSOR PROTEIN; FACTOR-SIII; STEM-CELLS; IDENTIFICATION; BINDING; ACTIVATION; DISRUPTION; MUTATIONS	Elongin A is a transcription elongation factor that increases the overall rate of mRNA chain elongation by RNA polymerase II To investigate the function of Elongin A in vivo, the two alleles of the Elongin A gene have been disrupted by homologous recombination in murine embryonic stem (ES) cells. The Elongin A-deficient ES cells are viable, but show a slow growth phenotype because they undergo a delayed mitosis. The cDNA microarray and RNase protection assay using the wildtype and Elongin A-deficient ES cells indicate that the expression of only a small subset of genes is affected in the mutant cells. Taken together, our results suggest that Elongin A regulates transcription of a subset but not all of genes and reveal a linkage between Elongin A function and cell cycle progression.	Kochi Med Sch, Fac Med, Dept Chem, Nanko Ku, Kochi 7838505, Japan; Kochi Med Sch, Fac Med, Dept Urol, Nanko Ku, Kochi 7838505, Japan; Japan Sci & Technol Corp, CREST, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol, CREST, Higashi Ku, Fukuoka 8128582, Japan; Tokyo Med & Dent Univ, Dept Biochem Genet, Inst Med Res, Bunkyo Ku, Tokyo 1138510, Japan	Kochi University; Kochi University; Japan Science & Technology Agency (JST); Kyushu University; Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU)	Aso, T (corresponding author), Kochi Med Sch, Fac Med, Dept Chem, Nanko Ku, Oko Cho, Kochi 7838505, Japan.		Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X				Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Aso T, 1996, EMBO J, V15, P5557, DOI 10.1002/j.1460-2075.1996.tb00940.x; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Aso T, 2000, J BIOL CHEM, V275, P6546, DOI 10.1074/jbc.275.9.6546; Aso T, 1999, CYTOGENET CELL GENET, V86, P259, DOI 10.1159/000015355; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; Chavez S, 2000, EMBO J, V19, P5824, DOI 10.1093/emboj/19.21.5824; Chavez S, 1997, GENE DEV, V11, P3459, DOI 10.1101/gad.11.24.3459; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Joyner AL, 1993, GENE TARGETING PRACT; Kamura T, 2001, J BIOL CHEM, V276, P29748, DOI 10.1074/jbc.M103093200; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KISHIDA T, 1995, CANCER RES, V55, P4544; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Martin J, 1999, MOL CELL BIOL, V19, P5548; ODA S, 1995, ONCOGENE, V10, P1343; Piruat JI, 1998, EMBO J, V17, P4859, DOI 10.1093/emboj/17.16.4859; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; Reines D, 1996, TRENDS BIOCHEM SCI, V21, P351, DOI 10.1016/0968-0004(96)10045-1; Robertson E. J., 1987, TERATOCARCINOMAS EMB; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Selby CP, 1997, P NATL ACAD SCI USA, V94, P11205, DOI 10.1073/pnas.94.21.11205; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; Um M, 2001, MOL CELL BIOL, V21, P2435, DOI 10.1128/MCB.21.7.2435-2448.2001; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; Yamazaki K, 2002, J BIOL CHEM, V277, P26444, DOI 10.1074/jbc.M202859200	34	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 11	2003	278	15					13585	13589		10.1074/jbc.C300047200	http://dx.doi.org/10.1074/jbc.C300047200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	666RD	12604609	hybrid			2022-12-27	WOS:000182189500124
J	Burnay, M; Crambert, G; Kharoubi-Hess, S; Geering, K; Horisberger, JD				Burnay, M; Crambert, G; Kharoubi-Hess, S; Geering, K; Horisberger, JD			Electrogenicity of Na,K- and H,K-ATPase activity and presence of a positively charged amino acid in the fifth transmembrane segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC H+,K+-ATPASE ACTIVITY; NA,K-ATPASE ALPHA-SUBUNIT; NA+-K+ PUMP; FUNCTIONAL EXPRESSION; BETA-SUBUNIT; SARCOPLASMIC-RETICULUM; SCANNING MUTAGENESIS; PRIMARY SEQUENCE; XENOPUS OOCYTES; CALCIUM-PUMP	The transport activity of the Na, K-ATPase (a 3 Na+ for 2 K+ ion exchange) is electrogenic, whereas the closely related gastric and non-gastric H,K-ATPases perform electroneutral cation exchange. We have studied the role of a highly conserved serine residue in the fifth transmembrane segment of the Na,K-ATPase, which is replaced with a lysine in all known H,K-ATPases. Ouabain-sensitive Rb-86 uptake and K+-activated currents were measured in Xenopus oocytes expressing the Bufo bladder H,K-ATPase or the Bufo Na,K-ATPase in which these residues, Lys(800) and Ser(782), respectively, were mutated. Mutants K800A and K800E of the H,K-ATPase showed K+-stimulated and ouabain-sensitive electrogenic transport. In contrast, when the positive charge was conserved (K800R), no K+-induced outward current could be measured, even though rubidium transport activity was present. Conversely, the S782R mutant of the Na,K-ATPase had non-electrogenic transport activity, whereas the S782A mutant was electrogenic. The K800S mutant of the H,K-ATPase had a more complex behavior, with electrogenic transport only in the absence of extracellular Na+. Thus, a single positively charged residue in the fifth transmembrane segment of the alpha-subunit can determine the electrogenicity and therefore the stoichiometry of cation transport by these ATPases.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Horisberger, JD (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Bugnon 27, CH-1005 Lausanne, Switzerland.	Jean-Daniel.Horisberger@ipharm.unil.ch	Horisberger, Jean-Daniel/A-2538-2009	Crambert, Gilles/0000-0001-7065-9124				APELL HJ, 1989, J MEMBRANE BIOL, V110, P103, DOI 10.1007/BF01869466; Arguello JM, 1999, ARCH BIOCHEM BIOPHYS, V367, P341, DOI 10.1006/abbi.1999.1278; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; Burnay M, 2001, AM J PHYSIOL-RENAL, V281, pF869, DOI 10.1152/ajprenal.2001.281.5.F869; Cougnon M, 1998, P NATL ACAD SCI USA, V95, P6516, DOI 10.1073/pnas.95.11.6516; DEWEER P, 1985, KIDNEY PHYSL PATHOPH, P31; EFTHYMIADIS A, 1993, CELL BIOL INT, V17, P1107, DOI 10.1006/cbir.1993.1043; Favre I, 1996, BIOPHYS J, V71, P3110, DOI 10.1016/S0006-3495(96)79505-X; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; Grishin AV, 1998, J BIOL CHEM, V273, P27772, DOI 10.1074/jbc.273.43.27772; Guennoun S, 2000, FEBS LETT, V482, P144, DOI 10.1016/S0014-5793(00)02050-0; Hermsen HPH, 2000, BIOCHEMISTRY-US, V39, P1330, DOI 10.1021/bi991396y; Horisberger JD, 2002, J PHYSIOL-LONDON, V539, P669, DOI 10.1113/jphysiol.2001.013201; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAISSER F, 1993, PFLUG ARCH EUR J PHY, V425, P446, DOI 10.1007/BF00374871; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; JAUNIN P, 1992, J BIOL CHEM, V267, P577; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Peluffo RD, 2000, J GEN PHYSIOL, V116, P47, DOI 10.1085/jgp.116.1.47; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Swarts HGP, 2001, J BIOL CHEM, V276, P36909, DOI 10.1074/jbc.M103945200; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vagin O, 2001, BIOCHEMISTRY-US, V40, P7480, DOI 10.1021/bi0105328; Vilsen B, 1999, BIOCHEMISTRY-US, V38, P11389, DOI 10.1021/bi990951t; WANG X, 1995, AM J PHYSIOL, V37, pC590; Wang XY, 1996, J PHYSIOL-LONDON, V491, P579, DOI 10.1113/jphysiol.1996.sp021241; Zillikens S, 2000, BBA-BIOMEMBRANES, V1509, P155, DOI 10.1016/S0005-2736(00)00289-3	38	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19237	19244		10.1074/jbc.M300946200	http://dx.doi.org/10.1074/jbc.M300946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637496	hybrid			2022-12-27	WOS:000182932200068
J	Kelly, A; Vereker, E; Nolan, Y; Brady, M; Barry, C; Loscher, CE; Mills, KHG; Lynch, MA				Kelly, A; Vereker, E; Nolan, Y; Brady, M; Barry, C; Loscher, CE; Mills, KHG; Lynch, MA			Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 beta on long term potentiation in rat dentate gyrus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; PROTECTS HIPPOCAMPAL-NEURONS; AGE-RELATED-CHANGES; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; DIETARY SUPPLEMENTATION; NUCLEAR TRANSLOCATION; ENTORHINAL CORTEX; GLUTAMATE RELEASE; ARACHIDONIC-ACID	Lipopolysaccharide (LPS), a component of the cell wall of Gram-negative bacteria, has been shown to induce profound changes both peripherally and centrally. It has recently been reported that intraperitoneal injection of LPS inhibited long term potentiation (LTP) in perforant path-granule cell synapses and that this effect was coupled with an increase in the concentration of the proinflammatory cytokine, interleukin-1beta (IL-1beta). The LPS-induced effects were abrogated by inhibition of caspase-1, suggesting that IL-1beta may mediate the effects of LPS. Here we report that the inhibition of LTP induced by LPS and IL-1beta was coupled with stimulation of the stress-activated protein kinase p38 in hippocampus and entorhinal cortex and that this effect was abrogated by the p38 inhibitor SB203580, while the effect of LPS was markedly attenuated in C57BL/6 IL-1RI(-/-) mice. The data also indicate that activation of the transcription factor, nuclear factor kappaB (NFkappaB), may play a role, since the inhibitory effect of LPS and IL-1beta on LTP was attenuated by the NFkappaB inhibitor, SN50; consistently, LPS and IL-1beta led to activation of NFkappaB in entorhinal cortex. We suggest that one consequence of these LPS- and IL-1beta-induced changes is a compromise in glutamate release in dentate gyrus, which was coupled with the inhibition of LTP. The evidence is consistent with the idea that the LPS- induced impairment in LTP is mediated by IL-1beta and is a consequence of activation of p38.	Univ Dublin Trinity Coll, Inst Neurosci, Dept Physiol, Dublin 2, Ireland; Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin	Kelly, A (corresponding author), Univ Dublin Trinity Coll, Inst Neurosci, Dept Physiol, Dublin 2, Ireland.	aikelly@tcd.ie	Mills, Kingston H/F-5684-2013	Mills, Kingston H/0000-0003-3646-8222; Nolan, Yvonne/0000-0003-2426-234X; Lynch, Marina/0000-0002-4631-0499; Kelly, Aine/0000-0002-9255-0848				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V14, P649; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; BENVENISTE EN, 1997, IMMUNOLOGY NERVOUS S, P419; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANEVARI L, 1994, BRAIN RES, V667, P115, DOI 10.1016/0006-8993(94)91720-5; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Clemens JA, 1997, MOL BRAIN RES, V48, P187, DOI 10.1016/S0169-328X(97)00092-2; Coogan A, 1997, NEUROREPORT, V8, P2107, DOI 10.1097/00001756-199707070-00004; Coogan AN, 1999, NEUROSCIENCE, V93, P57, DOI 10.1016/S0306-4522(99)00100-1; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Guay J, 1997, J CELL SCI, V110, P357; HAAN EA, 1981, J NEUROCHEM, V37, P243, DOI 10.1111/j.1471-4159.1981.tb05315.x; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Junger WG, 1997, J TRAUMA, V42, P437, DOI 10.1097/00005373-199703000-00011; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Kelly A, 2000, HIPPOCAMPUS, V10, P431, DOI 10.1002/1098-1063(2000)10:4<431::AID-HIPO9>3.0.CO;2-Z; Lee M, 2000, INT J IMMUNOPHARMACO, V22, P615, DOI 10.1016/S0192-0561(00)00024-2; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Lynch MA, 1999, MOL PSYCHIATR, V4, P15, DOI 10.1038/sj.mp.4000438; Lynch MA, 1998, PROG NEUROBIOL, V56, P571, DOI 10.1016/S0301-0082(98)00054-9; Maroney AC, 1998, J NEUROSCI, V18, P104; Matsuoka Y, 1999, EXP BRAIN RES, V124, P215, DOI 10.1007/s002210050616; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2; McGahon B, 1996, NEUROSCIENCE, V72, P847, DOI 10.1016/0306-4522(95)00579-X; McGahon B, 1997, NEUROSCIENCE, V81, P9, DOI 10.1016/S0306-4522(97)00116-4; McGahon BM, 1999, NEUROBIOL AGING, V20, P643, DOI 10.1016/S0197-4580(99)00027-5; McGahon BM, 1999, NEUROSCIENCE, V94, P305, DOI 10.1016/S0306-4522(99)00219-5; Meberg PJ, 1996, MOL BRAIN RES, V38, P179, DOI 10.1016/0169-328X(95)00229-L; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mielke K, 1999, NEUROSCIENCE, V91, P471, DOI 10.1016/S0306-4522(98)00667-8; Mullany P, 1997, NEUROPHARMACOLOGY, V36, P973, DOI 10.1016/S0028-3908(97)00073-7; Murray CA, 1998, J BIOL CHEM, V273, P12161, DOI 10.1074/jbc.273.20.12161; Murray CA, 1997, NEUROBIOL AGING, V18, P343, DOI 10.1016/S0197-4580(97)80317-X; Murray CA, 1998, J NEUROSCI, V18, P2974; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Nick JA, 1996, J IMMUNOL, V156, P4867; O'Donnell E, 2000, EUR J NEUROSCI, V12, P345, DOI 10.1046/j.1460-9568.2000.00900.x; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; ORDRONNEAU P, 1991, J IMMUNOL METHODS, V142, P169, DOI 10.1016/0022-1759(91)90103-M; Ozawa H, 1999, NEUROSCI LETT, V262, P57, DOI 10.1016/S0304-3940(99)00034-8; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; Qin ZH, 1999, J NEUROSCI, V19, P4023; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; RADA P, 1991, BRAIN RES, V550, P287, DOI 10.1016/0006-8993(91)91330-4; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rong YQ, 1996, J NEUROCHEM, V67, P662; SALMINEN A, 1995, BIOCHEM BIOPH RES CO, V212, P939, DOI 10.1006/bbrc.1995.2060; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; Takagi Y, 2000, NEUROSCI LETT, V294, P117, DOI 10.1016/S0304-3940(00)01552-4; Tamatani M, 2000, J NEUROCHEM, V75, P683, DOI 10.1046/j.1471-4159.2000.0750683.x; Terai K, 1997, BRAIN RES, V769, P385, DOI 10.1016/S0006-8993(97)00849-4; ToliverKinsky T, 1997, J NEUROSCI RES, V48, P580, DOI 10.1002/(SICI)1097-4547(19970615)48:6<580::AID-JNR11>3.0.CO;2-Z; Uciechowski P, 1996, FEBS LETT, V394, P273, DOI 10.1016/0014-5793(96)00967-2; Vereker E, 2000, J NEUROSCI, V20, P6811, DOI 10.1523/JNEUROSCI.20-18-06811.2000; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999; Zhang SJ, 1998, MOL BRAIN RES, V63, P121, DOI 10.1016/S0169-328X(98)00267-8	67	135	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19453	19462		10.1074/jbc.M301938200	http://dx.doi.org/10.1074/jbc.M301938200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12609991	hybrid, Green Published			2022-12-27	WOS:000182932200095
J	Sogabe, S; Yoshizumi, A; Fukami, TA; Shiratori, Y; Shimizu, S; Takagi, H; Nakamori, S; Wada, M				Sogabe, S; Yoshizumi, A; Fukami, TA; Shiratori, Y; Shimizu, S; Takagi, H; Nakamori, S; Wada, M			The crystal structure and stereospecificity of levodione reductase from Corynebacterium aquaticum M-13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; TROPINONE REDUCTASE; ANGSTROM RESOLUTION; SUBSTRATE-BINDING; ACTIVE-SITE; PURIFICATION; MECHANISM; RESIDUES; COMPLEX; PSEUDOTROPINE	The (6R)-2,2,6-trimethyl-1,4-cyclohexanedione ( levodione) reductase (LVR) of the soil isolate bacterium Corynebacterium aquaticum M-13 is a NAD(H)-linked enzyme that catalyzes reversible oxidoreduction between (4R)-hydroxy-(6R)-2,2,6-trimethylcyclohexanone (actinol) and levodione. Here the crystal structure of a ternary complex of LVR with NADH and its inhibitor 2-methyl-2,4-pentanediol has been determined by molecular replacement and refined at 1.6-Angstrom resolution with a crystallographic R factor of 0.199. The overall structure is similar to those of other short-chain alcohol dehydrogenase/ reductase enzymes. The positions of NADH and 2-methyl-2,4-pentanediol indicate the binding site of the substrate and identify residues that are likely to be important in the catalytic reaction. Modeling of the substrate binding in the active site suggests that the specificity of LVR is determined by electrostatic interactions between the negatively charged surface of Glu-103 of LVR and the positively charged surface on the re side of levodione. Mutant LVR enzymes in which Glu-103 is substituted with alanine (E103A), glutamine (E103Q), asparagines (E103N), or aspartic acid (E103D) show a 2-6-fold increase in K-m values as compared with wild-type LVR and a much lower enantiomeric excess of the reaction products (60%) than the wild-type enzyme (95%). Together, these data indicate that Glu-103 has an important role in determining the stereospecificity of LVR.	Fukui Prefectural Univ, Dept Biosci, Matsuoka, Fukui 9101195, Japan; Nippon Roche Res Ctr, Kanagawa 2478530, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan	Fukui Prefectural University; Roche Holding; Kyoto University	Wada, M (corresponding author), Fukui Prefectural Univ, Dept Biosci, 4-1-1 Kenjyojima, Matsuoka, Fukui 9101195, Japan.	masaru@fpu.ac.jp	Wada, Masaru/B-7775-2012; Wada, Masaru/AAX-1401-2021	Takagi, Hiroshi/0000-0002-1786-3174				Andersson A, 1997, FEBS LETT, V400, P173, DOI 10.1016/S0014-5793(96)01382-8; Andersson A, 1996, STRUCTURE, V4, P1161, DOI 10.1016/S0969-2126(96)00124-4; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; BURDEN RS, 1970, TETRAHEDRON LETT, P4071; Dinger MB, 1999, CHEM COMMUN, P2525, DOI 10.1039/a907476g; DRAGER B, 1988, AGR BIOL CHEM TOKYO, V52, P2663; GERBER PR, 1992, BIOPOLYMERS, V32, P1003, DOI 10.1002/bip.360320811; GHOSH D, 1994, STRUCTURE, V2, P973, DOI 10.1016/S0969-2126(94)00099-9; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; HASHIMOTO T, 1992, PLANT PHYSIOL, V100, P836, DOI 10.1104/pp.100.2.836; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KOELEN KJ, 1982, PLANTA MED, V44, P227, DOI 10.1055/s-2007-971454; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, P50; LEUENBERGER HGW, 1976, HELV CHIM ACTA, V59, P1832, DOI 10.1002/hlca.19760590541; Liao DI, 2001, STRUCTURE, V9, P19, DOI 10.1016/S0969-2126(00)00548-7; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nakajima K, 1999, J BIOL CHEM, V274, P16563, DOI 10.1074/jbc.274.23.16563; Nakajima K, 1998, P NATL ACAD SCI USA, V95, P4876, DOI 10.1073/pnas.95.9.4876; ORR GA, 1984, ANAL BIOCHEM, V142, P232, DOI 10.1016/0003-2697(84)90544-X; Otagiri M, 2001, J BIOCHEM, V129, P205, DOI 10.1093/oxfordjournals.jbchem.a002845; Parikh S, 1999, BIOCHEMISTRY-US, V38, P13623, DOI 10.1021/bi990529c; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; VIOLA RE, 1979, ANAL BIOCHEM, V96, P334, DOI 10.1016/0003-2697(79)90590-6; Wada M, 1999, APPL ENVIRON MICROB, V65, P4399; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Yamamoto K, 2001, J BIOCHEM, V129, P303, DOI 10.1093/oxfordjournals.jbchem.a002858; Yamashita A, 1999, BIOCHEMISTRY-US, V38, P7630, DOI 10.1021/bi9825044; Yoshisumi A, 2001, BIOSCI BIOTECH BIOCH, V65, P830, DOI 10.1271/bbb.65.830	35	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19387	19395		10.1074/jbc.M208146200	http://dx.doi.org/10.1074/jbc.M208146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12621044	hybrid			2022-12-27	WOS:000182932200087
J	Deregibus, MC; Buttiglieri, S; Russo, S; Bussolati, B; Camussi, G				Deregibus, MC; Buttiglieri, S; Russo, S; Bussolati, B; Camussi, G			CD40-dependent activation of phosphatidylinositol 3-kinase/Akt pathway mediates endothelial cell survival and in vitro angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CD40 LIGAND; GROWTH-FACTOR; SMOOTH-MUSCLE; EXPRESSION; CD154; INHIBITION; LIGATION; FAMILY; ATHEROSCLEROSIS	CD40 has been involved in tumor and inflammatory neoangiogenesis. In this study we determined that stimulation of endothelial CD40 with sCD154 induced resistance to apoptosis and in vitro vessel-like formation by human microvascular endothelial cells (HMEC). These effects were determined to be mediated by CD40-dependent signaling because they were inhibited by a soluble CD40-muIg fusion protein. Moreover, apoptosis of HMEC was associated with an impairment of Akt phosphorylation, which was restored by stimulation with sCD154. The anti-apoptotic effect as well as in vitro vessel-like formation and Akt phosphorylation were inhibited by treatment of HMEC with two unrelated pharmacological inhibitors of phosphatidylinositol 3-kinase (PI3K), wortmannin and LY294002. CD40 stimulation induced a rapid increase in Akt enzymatic activity that was not prevented by cycloheximide, an inhibitor of protein synthesis. The enhanced Akt activity induced by stimulation of endothelial CD40 was temporarily correlated with the association of CD40 with TRAF6, c-Cbl, and the p85 subunit of PI3K. Expression of negative-dominant Akt inhibited the activation of endogenous Akt through CD40 stimulation, despite the observation that association of CD40 with TRAF6, c-Cbl, and PI3K was intact. The defective activation of Akt abrogated not only the anti-apoptotic effect of CD40 stimulation but also the proliferative response, the enhanced motility, and the in vitro formation of vessel-like tubular structures by CD40-stimulated HMEC. In conclusion, these results suggest that endothelial CD40, through activation of the PI3K/Akt signaling pathway, regulates cell survival, proliferation, migration, and vessel-like structure formation, all steps considered critical for angiogenesis.	Univ Turin, Dipartimento Med Interna, Cattedra Nefrol, I-10126 Turin, Italy; CeRMS, I-10126 Turin, Italy	University of Turin	Camussi, G (corresponding author), Osped Maggiore S Giovanni Battista, Dipartimento Med Interna, Cattedra Nefrol, Corso Dogliotti 14, I-10126 Turin, Italy.	giovanni.camussi@unito.it	Bussolati, Benedetta/AAA-9058-2022; buttiglieri, stefano/L-3005-2013; Camussi, Giovanni/J-7624-2016	Bussolati, Benedetta/0000-0002-3663-5134; Camussi, Giovanni/0000-0003-2795-232X				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Biancone L, 1999, INT J MOL MED, V3, P343; Biancone L, 1999, J IMMUNOL, V163, P6201; Bussolati B, 2002, INT J CANCER, V100, P654, DOI 10.1002/ijc.10545; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; Conaldi PG, 1997, J INFECT DIS, V175, P693, DOI 10.1093/infdis/175.3.693; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dechanet J, 1997, J IMMUNOL, V159, P5640; DEL PL, 1997, SCIENCE, V278, P687; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Henn V, 1998, NATURE, V391, P591, DOI 10.1038/35393; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kluth B, 1997, CANCER RES, V57, P891; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; Lutgens E, 2002, TRENDS CARDIOVAS MED, V12, P27, DOI 10.1016/S1050-1738(01)00142-6; Mach F, 1998, NATURE, V394, P200, DOI 10.1038/28204; Mach F, 1997, P NATL ACAD SCI USA, V94, P1931, DOI 10.1073/pnas.94.5.1931; Mach F, 1999, AM J PATHOL, V154, P229, DOI 10.1016/S0002-9440(10)65269-8; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Melter M, 2000, BLOOD, V96, P3801, DOI 10.1182/blood.V96.12.3801.h8003801_3801_3808; Montesano R, 1997, J CELL PHYSIOL, V173, P152, DOI 10.1002/(SICI)1097-4652(199711)173:2<152::AID-JCP14>3.0.CO;2-I; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; Reul RM, 1997, TRANSPLANTATION, V64, P1765, DOI 10.1097/00007890-199712270-00025; Schonbeck U, 2000, P NATL ACAD SCI USA, V97, P7458, DOI 10.1073/pnas.97.13.7458; Schonbeck U, 2001, CIRC RES, V89, P1092, DOI 10.1161/hh2401.101272; Schonbeck U, 1997, J BIOL CHEM, V272, P19569, DOI 10.1074/jbc.272.31.19569; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Slupsky JR, 1998, THROMB HAEMOSTASIS, V80, P1008; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Talapatra S, 2001, J PHARMACOL EXP THER, V298, P873; Thienel U, 1999, CELL IMMUNOL, V198, P87, DOI 10.1006/cimm.1999.1583; Urbich C, 2001, J CLIN INVEST, V108, P1451, DOI 10.1172/JCI200113620; WEIHUA W, 2000, J BIOL CHEM, V275, P40113; Werneburg BG, 2001, J BIOL CHEM, V276, P43334, DOI 10.1074/jbc.M104994200; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Young LS, 1998, IMMUNOL TODAY, V19, P502, DOI 10.1016/S0167-5699(98)01340-1; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	52	86	87	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18008	18014		10.1074/jbc.M300711200	http://dx.doi.org/10.1074/jbc.M300711200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637493	hybrid			2022-12-27	WOS:000182838300054
J	Di Venere, A; Salucci, ML; van Zadelhoff, G; Veldink, G; Mei, G; Rosato, N; Finazzi-Agro, A; Maccarrone, M				Di Venere, A; Salucci, ML; van Zadelhoff, G; Veldink, G; Mei, G; Rosato, N; Finazzi-Agro, A; Maccarrone, M			Structure-to-function relationship of mini-lipoxygenase, a 60-kDa fragment of soybean lipoxygenase-1 with lower stability but higher enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ACID-BINDING PROTEIN; MOLTEN GLOBULE STATE; N-TERMINAL DOMAIN; INTERNAL CAVITIES; ORGANELLE DEGRADATION; MEMBRANE-BINDING; VOLUME CHANGES; BURIED WATERS; 5-LIPOXYGENASE	Lipoxygenase-1 (Lox-1) is a member of the lipoxygenase family, a class of dioxygenases that take part in the metabolism of polyunsatured fatty acids in eukaryotes. Tryptic digestion of soybean Lox-1 is known to produce a 60 kDa fragment, termed "mini-Lox," which shows enhanced catalytic efficiency and higher membrane-binding ability than the native enzyme (Maccarrone, M., Salucci, M. L., van Zadelhoff, G., Malatesta, F., Veldink, G. Vliegenthart, J. F. G., and Finazzi-Agro, A. (2001) Biochemistry 40, 6819-6827). In this study, we have investigated the stability of mini-Lox in guanidinium hydrochloride and under high pressure by fluorescence and circular dichroism spectroscopy. Only a partial unfolding could be obtained at high pressure in the range 1-3000 bar at variance with guanidinium hydrochloride. However, in both cases a reversible denaturation was observed. The denaturation experiments demonstrate that mini-Lox is a rather unstable molecule, which undergoes a two-step unfolding transition at moderately low guanidinium hydrochloride concentration (0-4.5 M). Both chemical- and physical-induced denaturation suggest that mini-Lox is more hydrated than Lox-1, an observation also confirmed by 1-anilino-8-naphthalenesulfonate (ANS) binding studies. We have also investigated the occurrence of substrate-induced changes in the protein tertiary structure by dynamic fluorescence techniques. In particular, eicosatetraynoic acid, an irreversible inhibitor of lipoxygenase, has been used to mimic the effect of substrate binding. We demonstrated that mini-Lox is indeed characterized by much larger conformational changes than those occurring in the native Lox-1 upon binding of eicosatetraynoic acid. Finally, by both activity and fluorescence measurements we have found that 1-anilino-8-naphthalenesulfonate has access to the active site of mini-Lox but not to that of intact Lox-1. These findings strongly support the hypothesis that the larger hydration of mini-Lox renders this molecule more flexible, and therefore less stable.	Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; INFM, I-16152 Genoa, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Aquila, Dept Pure & Appl Biol, I-67100 Laquila, Italy; Univ Utrecht, Dept Bioorgan Chem, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands; Osped San Giovanni Calibita, Div Neurol, CRCCS, AFaR, I-00100 Rome, Italy	University of Teramo; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Rome Tor Vergata; University of L'Aquila; Utrecht University	Maccarrone, M (corresponding author), Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy.	Maccarrone@vet.unite.it	van Zadelhoff, Guus/F-2260-2010	Di Venere, Almerinda/0000-0002-9493-0270				AGRO AF, 1975, FEBS LETT, V52, P73; Arighi CN, 1998, BIOCHEMISTRY-US, V37, P16802, DOI 10.1021/bi981827x; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P849; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Carlile AJ, 2000, MOL PLANT MICROBE IN, V13, P538, DOI 10.1094/MPMI.2000.13.5.538; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Di Venere A, 1998, EUR J BIOCHEM, V257, P337, DOI 10.1046/j.1432-1327.1998.2570337.x; Di Venere A, 2000, J BIOL CHEM, V275, P3915, DOI 10.1074/jbc.275.6.3915; FINAZZIAGRO A, 1973, BIOCHIM BIOPHYS ACTA, V326, P462, DOI 10.1016/0005-2760(73)90146-X; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; Frye KJ, 1998, PROTEIN SCI, V7, P2217, DOI 10.1002/pro.5560071020; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; GRATTON E, 1983, BIOPHYS J, V44, P315, DOI 10.1016/S0006-3495(83)84305-7; Grechkin A, 1998, PROG LIPID RES, V37, P317, DOI 10.1016/S0163-7827(98)00014-9; Grullich C, 2001, FEBS LETT, V489, P51, DOI 10.1016/S0014-5793(01)02080-4; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; Hemak J, 2002, J MOL MODEL, V8, P102, DOI 10.1007/s00894-002-0076-y; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; Inoue K, 2000, NAT STRUCT BIOL, V7, P547; Jenkins AE, 2002, BIOCHEMISTRY-US, V41, P2022, DOI 10.1021/bi015769i; Jones SM, 2002, J BIOL CHEM, V277, P38550, DOI 10.1074/jbc.M206070200; KLEIN BP, 1985, PHYTOCHEMISTRY, V24, P1903, DOI 10.1016/S0031-9422(00)83089-7; Kobashigawa Y, 1999, PROTEIN SCI, V8, P2765; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Maccarrone M, 2000, EUR J BIOCHEM, V267, P5078, DOI 10.1046/j.1432-1327.2000.01564.x; Maccarrone M, 2001, CELL DEATH DIFFER, V8, P776, DOI 10.1038/sj.cdd.4400908; Maccarrone M, 2001, BIOCHEMISTRY-US, V40, P6819, DOI 10.1021/bi010187m; Maccarrone M, 1999, J AM SOC NEPHROL, V10, P1991; Malvezzi-Campeggi F, 2001, BIOCHEM BIOPH RES CO, V289, P1295, DOI 10.1006/bbrc.2001.6109; MEI G, 1994, J MOL BIOL, V242, P559, DOI 10.1006/jmbi.1994.1600; Millar DP, 1996, CURR OPIN STRUC BIOL, V6, P637, DOI 10.1016/S0959-440X(96)80030-3; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; PRYSE KM, 1992, BIOCHEMISTRY-US, V31, P5127, DOI 10.1021/bi00137a006; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RAMACHANDRAN S, 1992, BIOCHEMISTRY-US, V31, P7700, DOI 10.1021/bi00148a034; RASHIN AA, 1986, BIOCHEMISTRY-US, V25, P3619, DOI 10.1021/bi00360a021; Royer CA, 2002, BBA-PROTEIN STRUCT M, V1595, P201, DOI 10.1016/S0167-4838(01)00344-2; Rusterucci C, 1999, J BIOL CHEM, V274, P36446, DOI 10.1074/jbc.274.51.36446; SCHILSTRA MJ, 1994, BIOCHEMISTRY-US, V33, P3974, DOI 10.1021/bi00179a025; Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1; Srinivasulu S, 1996, BBA-PROTEIN STRUCT M, V1294, P115, DOI 10.1016/0167-4838(95)00263-4; Sudharshan E, 1997, FEBS LETT, V406, P184, DOI 10.1016/S0014-5793(97)00268-8; Sudharshan E, 1999, J BIOL CHEM, V274, P35351, DOI 10.1074/jbc.274.50.35351; Sudharshan E, 2000, BBA-PROTEIN STRUCT M, V1480, P13, DOI 10.1016/S0167-4838(00)00099-6; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Vidugiris GJA, 1998, BIOPHYS J, V75, P463, DOI 10.1016/S0006-3495(98)77534-4; Walther M, 2002, J BIOL CHEM, V277, P27360, DOI 10.1074/jbc.M203234200; WASYLEWSKI Z, 1992, EUR J BIOCHEM, V206, P235, DOI 10.1111/j.1432-1033.1992.tb16921.x; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808	55	23	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18281	18288		10.1074/jbc.M212122200	http://dx.doi.org/10.1074/jbc.M212122200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626522	Green Published, hybrid			2022-12-27	WOS:000182838300091
J	Kozel, BA; Wachi, H; Davis, EC; Mecham, RP				Kozel, BA; Wachi, H; Davis, EC; Mecham, RP			Domains in tropoelastin that mediate elastin deposition in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPRAVALVULAR AORTIC-STENOSIS; CARBOXY-TERMINUS; TRANSGENIC MICE; POINT MUTATIONS; BANDED FIBERS; CUTIS LAXA; GENE; PROTEINS; FIBRILLIN-1; EXPRESSION	Elastic fiber assembly is a complicated process involving multiple different proteins and enzyme activities. However, the specific protein-protein interactions that facilitate elastin polymerization have not been defined. To identify domains in the tropoelastin molecule important for the assembly process, we utilized an in vitro assembly model to map sequences within tropoelastin that facilitate its association with fibrillin-containing microfibrils in the extracellular matrix. Our results show that an essential assembly domain is located in the C-terminal region of the molecule, encoded by exons 29-36. Fine mapping studies using an exon deletion strategy and synthetic peptides identified the hydrophobic sequence in exon 30 as a major functional element in this region and suggested that the assembly process is driven by the propensity of this sequence to form beta-sheet structure. Tropoelastin molecules lacking the C-terminal assembly domain expressed as transgenes in mice did not assemble nor did they interfere with assembly of full-length normal mouse elastin. In addition to providing important information about elastin assembly in general, the results of this study suggest how removal or alteration of the C terminus through stop or frameshift mutations might contribute to the elastin-related diseases supravalvular aortic stenosis and cutis laxa.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Hoshi Univ, Sch Pharm, Dept Clin Chem, Tokyo 142850, Japan; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	Washington University (WUSTL); Hoshi University; McGill University	Mecham, RP (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.		Kozel, Beth/AAP-9177-2020; Davis, Elaine/F-3449-2012	Kozel, Beth/0000-0002-9757-7118; 	NHLBI NIH HHS [HL53325, HL61006, HL62295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL053325, R01HL062295, P50HL061006, R01HL053325] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baskar JF, 1996, J VIROL, V70, P3215, DOI 10.1128/JVI.70.5.3215-3226.1996; Baskar JF, 1996, J VIROL, V70, P3207, DOI 10.1128/JVI.70.5.3207-3214.1996; Bochicchio B, 2001, MATRIX BIOL, V20, P243, DOI 10.1016/S0945-053X(01)00139-1; BRESSAN GM, 1986, J ULTRA MOL STRUCT R, V94, P209, DOI 10.1016/0889-1605(86)90068-6; BRESSAN GM, 1983, J ULTRA MOL STRUCT R, V82, P335, DOI 10.1016/S0022-5320(83)80021-5; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; CAPUTO CB, 1992, ARCH BIOCHEM BIOPHYS, V292, P199, DOI 10.1016/0003-9861(92)90068-8; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; COCAPRADOS M, 1986, P NATL ACAD SCI USA, V83, P8754, DOI 10.1073/pnas.83.22.8754; COX BA, 1974, J BIOL CHEM, V249, P997; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; EWART AK, 1994, J CLIN INVEST, V93, P1071, DOI 10.1172/JCI117057; Gosline J, 2002, PHILOS T R SOC B, V357, P121, DOI 10.1098/rstb.2001.1022; GROSSO LE, 1993, BIOCHEMISTRY-US, V32, P13369, DOI 10.1021/bi00211a052; HAMODRAKAS SJ, 1985, J MOL BIOL, V186, P583, DOI 10.1016/0022-2836(85)90132-9; HAMODRAKAS SJ, 1988, PROTEIN ENG, V2, P201, DOI 10.1093/protein/2.3.201; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; HINEK A, 1993, J BIOL CHEM, V268, P1405; Hsiao H, 1999, CONNECT TISSUE RES, V40, P83, DOI 10.3109/03008209909029104; INDIK Z, 1989, AM J MED GENET, V34, P81, DOI 10.1002/ajmg.1320340115; Jensen SA, 2000, J BIOL CHEM, V275, P28449, DOI 10.1074/jbc.M004265200; Keene DR, 1997, J HISTOCHEM CYTOCHEM, V45, P1069, DOI 10.1177/002215549704500805; KOEDOOD M, 1995, J VIROL, V69, P2194, DOI 10.1128/JVI.69.4.2194-2207.1995; Li DY, 1997, HUM MOL GENET, V6, P1021, DOI 10.1093/hmg/6.7.1021; Mecham R, 1977, Adv Exp Med Biol, V79, P209; MECHAM RP, 1977, BIOCHEMISTRY-US, V16, P3825, DOI 10.1021/bi00636a017; Metcalfe K, 2000, EUR J HUM GENET, V8, P955, DOI 10.1038/sj.ejhg.5200564; Milewicz DM, 2000, MATRIX BIOL, V19, P471, DOI 10.1016/S0945-053X(00)00099-8; Ritty TM, 1999, J BIOL CHEM, V274, P8933, DOI 10.1074/jbc.274.13.8933; Robb BW, 1999, MOL BIOL CELL, V10, P3595, DOI 10.1091/mbc.10.11.3595; Robson P, 2000, MOL BIOL EVOL, V17, P1739, DOI 10.1093/oxfordjournals.molbev.a026272; ROBSON P, 1993, J BIOL CHEM, V268, P1440; ROSS R, 1969, J CELL BIOL, V40, P366, DOI 10.1083/jcb.40.2.366; Sechler JL, 1995, CIBA F SYMP, V192, P148; Tassabehji M, 1997, HUM MOL GENET, V6, P1029, DOI 10.1093/hmg/6.7.1029; Tassabehji M, 1998, HUM MOL GENET, V7, P1021, DOI 10.1093/hmg/7.6.1021; Trask TM, 2000, J BIOL CHEM, V275, P24400, DOI 10.1074/jbc.M003665200; Urban Z, 1999, HUM GENET, V104, P135, DOI 10.1007/s004390050926; Urban Z, 2000, HUM GENET, V106, P577, DOI 10.1007/s004390050028; Urban Z, 2001, HUM GENET, V109, P512, DOI 10.1007/s00439-001-0608-z; van Beek JD, 2002, P NATL ACAD SCI USA, V99, P10266, DOI 10.1073/pnas.152162299; WIRTSCHAFTER ZT, 1967, J CELL BIOL, V33, P481, DOI 10.1083/jcb.33.3.481; Zhang MC, 1999, J BIOL CHEM, V274, P981, DOI 10.1074/jbc.274.2.981	44	105	105	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18491	18498		10.1074/jbc.M212715200	http://dx.doi.org/10.1074/jbc.M212715200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626514	hybrid			2022-12-27	WOS:000182838300118
J	Qiao, ZS; Min, CY; Hua, QX; Weiss, MA; Feng, YM				Qiao, ZS; Min, CY; Hua, QX; Weiss, MA; Feng, YM			In vitro refolding of human proinsulin - Kinetic intermediates, putative disulfide-forming pathway, folding initiation site, and potential role of C-peptide in folding process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PANCREATIC TRYPSIN-INHIBITOR; ENGINEERED INSULIN MONOMER; STRUCTURAL INFORMATION; MASS-SPECTROMETRY; NATIVE MOLECULE; RIBONUCLEASE-A; SMALL PROTEINS; IGF-I; BPTI	Human insulin is a double-chain peptide that is synthesized in vivo as a single-chain human proinsulin (HPI). We have investigated the disulfide-forming pathway of a single-chain porcine insulin precursor (PIP). Here we further studied the folding pathway of HPI in vitro. While the oxidized refolding process of HPI was quenched, four obvious intermediates (namely P1, P2, P3, and P4, respectively) with three disulfide bridges were isolated and characterized. Contrary to the folding pathway of PIP, no intermediates with one- or two-disulfide bonds could be captured under different refolding conditions. CD analysis showed that P1, P2, and P3 retained partially structural conformations, whereas P4 contained little secondary structure. Based on the time-dependent distribution, disulfide pair analysis, and disulfide-reshuffling process of the intermediates, we have proposed that the folding pathway of HPI is significantly different from that of PIP. These differences reveal that the C-peptide not only facilitates the folding of HPI but also governs its kinetic folding pathway of HPI. Detailed analysis of the molecular folding process reveals that there are some similar folding mechanisms between PIP and HPI. These similarities imply that the initiation site for the folding of PIP/HPI may reside in the central alpha-helix of the B-chain. The formation of disulfide A20-B19 may guide the transfer of the folding information from the B-chain template to the unstructured A-chain. Furthermore, the implications of this in vitro refolding study on the in vivo folding process of HPI have been discussed.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44016 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Case Western Reserve University	Feng, YM (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	fengym@sunm.shcnc.ac.cn						Alm E, 1999, CURR OPIN STRUC BIOL, V9, P189, DOI 10.1016/S0959-440X(99)80027-X; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Baker D, 2000, NATURE, V405, P39, DOI 10.1038/35011000; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BALDWIN RL, 1989, TRENDS BIOCHEM SCI, V14, P291, DOI 10.1016/0968-0004(89)90067-4; BEDARKAR S, 1977, NATURE, V270, P449, DOI 10.1038/270449a0; Bulaj G, 1999, PROTEIN SCI, V8, P1825, DOI 10.1110/ps.8.9.1825; Bullesbach EE, 1997, BIOCHEMISTRY-US, V36, P10735, DOI 10.1021/bi970393n; CHAN SJ, 1990, P NATL ACAD SCI USA, V87, P9319, DOI 10.1073/pnas.87.23.9319; CHANG JY, 1995, J BIOL CHEM, V270, P9207, DOI 10.1074/jbc.270.16.9207; CHANG JY, 1994, J BIOL CHEM, V269, P22087; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; Chen LM, 2002, J BIOCHEM, V131, P855, DOI 10.1093/oxfordjournals.jbchem.a003175; Creighton T E, 1986, Methods Enzymol, V131, P83; Creighton TE, 1997, BIOL CHEM, V378, P731; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; DARBY NJ, 1995, J MOL BIOL, V249, P463, DOI 10.1006/jmbi.1995.0309; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; FRANK BH, 1972, BIOCHEMISTRY-US, V11, P4926, DOI 10.1021/bi00776a008; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P1556, DOI 10.1021/bi011166v; Guo ZY, 2001, BIOL CHEM, V382, P443, DOI 10.1515/BC.2001.054; HIROMICHI NS, 1980, SCI SINICA, V23, P1053; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; Hua QX, 1996, J MOL BIOL, V259, P297, DOI 10.1006/jmbi.1996.0320; HUA QX, 1995, NAT STRUCT BIOL, V2, P129, DOI 10.1038/nsb0295-129; Hua QX, 2002, BIOCHEMISTRY-US, V41, P14700, DOI 10.1021/bi0202981; Hua QX, 2002, J BIOL CHEM, V277, P43443, DOI 10.1074/jbc.M206107200; Hua QX, 1996, J MOL BIOL, V264, P390, DOI 10.1006/jmbi.1996.0648; Hua QX, 2001, BIOCHEMISTRY-US, V40, P12299, DOI 10.1021/bi011021o; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; LOW BW, 1974, NATURE, V248, P339, DOI 10.1038/248339a0; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; Milner SJ, 1999, BIOTECHNOL BIOENG, V62, P693; Olsen HB, 1996, BIOCHEMISTRY-US, V35, P8836, DOI 10.1021/bi960292+; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; RINDERKNECHT E, 1978, FEBS LETT, V89, P283, DOI 10.1016/0014-5793(78)80237-3; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; Rosenfeld RD, 1997, ARCH BIOCHEM BIOPHYS, V342, P298, DOI 10.1006/abbi.1997.9996; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2671, DOI 10.1021/bi00061a027; ROY M, 1990, J BIOL CHEM, V265, P5448; SMIT AB, 1988, NATURE, V331, P535, DOI 10.1038/331535a0; SNELL CR, 1975, J BIOL CHEM, V250, P6291; STEINER DF, 1978, DIABETES, V27, P145, DOI 10.2337/diab.27.1.S145; STEINER DF, 1967, SCIENCE, V157, P697, DOI 10.1126/science.157.3789.697; STEINER DF, 1971, J BIOL CHEM, V246, P1365; STEINER DF, 1973, NATURE, V243, P528, DOI 10.1038/243528a0; STEINER DF, 1988, HORM METAB RES, V20, P443, DOI 10.1055/s-2007-1010855; STEINER DF, 1967, T NEW YORK ACAD SCI, V30, P60, DOI 10.1111/j.2164-0947.1967.tb02452.x; STEINER DF, 1968, P NATL ACAD SCI USA, V60, P622, DOI 10.1073/pnas.60.2.622; TANG JG, 1990, BIOCHEM J, V268, P429, DOI 10.1042/bj2680429; WANG CC, 1991, TRENDS BIOCHEM SCI, V16, P279, DOI 10.1016/0968-0004(91)90114-B; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8389, DOI 10.1021/bi00488a028; Weiss MA, 2000, BIOCHEMISTRY-US, V39, P15429, DOI 10.1021/bi001905s; WEISS MA, 1991, BIOCHEMISTRY-US, V30, P7373, DOI 10.1021/bi00244a004; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1992, CELL, V71, P841, DOI 10.1016/0092-8674(92)90559-U; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Winter J, 2002, J BIOL CHEM, V277, P310, DOI 10.1074/jbc.M107832200; Wu J, 1998, PROTEIN SCI, V7, P1017; Xu XB, 1996, BIOCHEMISTRY-US, V35, P6406, DOI 10.1021/bi960090d; Yan H, 2003, PROTEIN SCI, V12, P768, DOI 10.1110/ps.0237203; Yang Y, 1999, J BIOL CHEM, V274, P37598, DOI 10.1074/jbc.274.53.37598	70	70	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17800	17809		10.1074/jbc.M300906200	http://dx.doi.org/10.1074/jbc.M300906200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624089	hybrid			2022-12-27	WOS:000182838300028
J	Barnham, KJ; McKinstry, WJ; Multhaup, G; Galatis, D; Morton, CJ; Curtain, CC; Williamson, NA; White, AR; Hinds, MG; Norton, RS; Beyreuther, K; Masters, CL; Parker, MW; Cappai, R				Barnham, KJ; McKinstry, WJ; Multhaup, G; Galatis, D; Morton, CJ; Curtain, CC; Williamson, NA; White, AR; Hinds, MG; Norton, RS; Beyreuther, K; Masters, CL; Parker, MW; Cappai, R			Structure of the Alzheimer's disease amyloid precursor protein copper binding domain - A regulator of neuronal copper homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; A-BETA; NEURODEGENERATIVE DISEASE; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; CRYSTAL-STRUCTURE; PICHIA-PASTORIS; REDUCTION; METALS; ZINC	A major source of free radical production in the brain derives from copper. To prevent metal-mediated oxidative stress, cells have evolved complex metal transport systems. The Alzheimer's disease amyloid precursor protein (APP) is a major regulator of neuronal copper homeostasis. APP knockout mice have elevated copper levels in the cerebral cortex, whereas APP-overexpressing transgenic mice have reduced brain copper levels. Importantly, copper binding to APP can greatly reduce amyloid beta production in vitro. To understand this interaction at the molecular level we solved the structure of the APP copper binding domain (CuBD) and found that it contains a novel copper binding site that favors Cu(I) coordination. The surface location of this site, structural homology of CuBD to copper chaperones, and the role of APP in neuronal copper homeostasis are consistent with the CuBD acting as a neuronal metallotransporter.	Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; Mental Hlth Res Inst, Parkville, Vic 3052, Australia; St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia; Free Univ Berlin, Inst Biochem Chem, D-14195 Berlin, Germany; Monash Univ, Sch Phys & Mat Engn, Clayton, Vic 3168, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Heidelberg, Ctr Mol Biol, D-69120 Heidelberg, Germany	University of Melbourne; Florey Institute of Neuroscience & Mental Health; St. Vincent's Institute of Medical Research; Free University of Berlin; Monash University; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Ruprecht Karls University Heidelberg	Parker, MW (corresponding author), St Vincents Inst Med Res, Biota Struct Biol Lab, 9 Princes St, Fitzroy, Vic 3065, Australia.		Williamson, Nicholas A/O-9812-2016; Parker, Michael W/F-9069-2013; Morton, Craig/GON-8638-2022; McKinstry, William J/D-2612-2013; Hinds, Mark Gavin/AAD-3653-2020; Cappai, Roberto/B-3347-2010; White, Anthony/P-5596-2016	Williamson, Nicholas A/0000-0002-2173-3452; Parker, Michael W/0000-0002-3101-1138; Morton, Craig/0000-0001-5452-5193; McKinstry, William J/0000-0001-9668-9364; Hinds, Mark Gavin/0000-0002-2856-5375; Cappai, Roberto/0000-0002-9505-8496; White, Anthony/0000-0003-1802-9891; Curtain, Cyril/0000-0001-6955-320X; Norton, Raymond/0000-0001-8893-0584				ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; Andrews NC, 2001, P NATL ACAD SCI USA, V98, P6543, DOI 10.1073/pnas.131192498; Atwood CS, 1998, J BIOL CHEM, V273, P12817, DOI 10.1074/jbc.273.21.12817; Borchardt T, 2000, CELL MOL BIOL, V46, P785; Borchardt T, 1999, BIOCHEM J, V344, P461, DOI 10.1042/0264-6021:3440461; Brown DR, 2002, MOL BIOTECHNOL, V22, P165, DOI 10.1385/MB:22:2:165; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Carri MT, 2001, FUNCT NEUROL, V16, P181; Casella L., 1993, BIOINORGANIC CHEM CO, P292; Cherny RA, 2001, NEURON, V30, P665, DOI 10.1016/S0896-6273(01)00317-8; Cherny RA, 1999, J BIOL CHEM, V274, P23223, DOI 10.1074/jbc.274.33.23223; Cobine PA, 2002, BIOCHEMISTRY-US, V41, P5822, DOI 10.1021/bi025515c; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Day CL, 1999, CELL DEATH DIFFER, V6, P1125, DOI 10.1038/sj.cdd.4400584; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hart PJ, 1996, PROTEIN SCI, V5, P2175, DOI 10.1002/pro.5560051104; Henry A, 1997, PROTEIN EXPRES PURIF, V10, P283, DOI 10.1006/prep.1997.0748; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Kim YJ, 2001, INORG CHEM, V40, P4481, DOI 10.1021/ic001396i; KLAUS W, 1993, J MOL BIOL, V232, P897, DOI 10.1006/jmbi.1993.1438; LAROCHE Y, 1994, BIO-TECHNOL, V12, P1119, DOI 10.1038/nbt1194-1119; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MARTINS RN, 1986, J NEUROCHEM, V46, P1042, DOI 10.1111/j.1471-4159.1986.tb00615.x; MASTERS CL, 2002, 7 INT GEN SPRINGF AL; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Multhaup G, 1998, BIOCHEMISTRY-US, V37, P7224, DOI 10.1021/bi980022m; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; PEISACH J, 1974, ARCH BIOCHEM BIOPHYS, V165, P691, DOI 10.1016/0003-9861(74)90298-7; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Poulos TL, 1999, NAT STRUCT BIOL, V6, P709, DOI 10.1038/11464; Prigge ST, 1997, SCIENCE, V278, P1300, DOI 10.1126/science.278.5341.1300; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Sayre LM, 1999, CURR OPIN CHEM BIOL, V3, P220, DOI 10.1016/S1367-5931(99)80035-0; Sayre LM, 2000, J NEUROCHEM, V74, P270, DOI 10.1046/j.1471-4159.2000.0740270.x; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Smith MA, 1997, J NEUROSCI, V17, P2653; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250; White AR, 1999, J NEUROSCI, V19, P9170; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; White AR, 2002, J NEUROSCI, V22, P365, DOI 10.1523/JNEUROSCI.22-02-00365.2002	49	231	242	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17401	17407		10.1074/jbc.M300629200	http://dx.doi.org/10.1074/jbc.M300629200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611883	hybrid			2022-12-27	WOS:000182818600127
J	Brannstrom, K; Segerman, B; Gullberg, M				Brannstrom, K; Segerman, B; Gullberg, M			Molecular dissection of GTP exchange and hydrolysis within the ternary complex of tubulin heterodimers and Op18/stathmin family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATHMIN; PROTEIN; BINDING; DISSOCIATION; ENCODES; MODEL	The ubiquitous Op18 and the neural RB3 and SCG10 proteins are members of the oncoprotein18/stathmin family of microtubule regulators. These proteins bind two tubulin heterodimers via two imperfect helical repeats to form a complex of heterodimers aligned head-to-tail. Here we have analyzed GTP exchange and GTP hydrolysis at the exchangeable GTP-binding site (E-site) of tubulin heterodimers in complex with Op18, RB3, or SCG10. These proteins stimulate a low and indistinguishable rate of GTP hydrolysis, and our results show that GTP exchange is blocked at both E-sites of the ternary complex, whereas GTP hydrolysis only occurs at one of the two E-sites. Results from mutational analysis of clusters of hydrophobic residues within the first helical repeat of Op18 suggest that GTP is hydrolyzed at the E-site that is interfaced between the head-to-tail arranged heterodimers, which is consistent with predicted GTPase productive interactions between the two tubulin heterodimers. Our mutational analysis has also indicated that Op18/stathmin family members actively restrain the otherwise potent GTPase productive interactions that are generated by longitudinal interactions within protofilaments. We conclude that tubulin heterodimers in complex with Op18/stathmin family members are subject to allosteric effects that prevent futile cycles of GTP hydrolysis.	Umea Univ, Dept Biol Mol, SE-90187 Umea, Sweden	Umea University	Gullberg, M (corresponding author), Umea Univ, Dept Biol Mol, SE-90187 Umea, Sweden.	Martin.Gullberg@molbiol.umu.se	Brännström, Kristoffer/D-3648-2009; Brännström, Kristoffer/AAC-1204-2020	Gullberg, Martin/0000-0002-3984-4572				Amayed P, 2000, BIOCHEMISTRY-US, V39, P12295, DOI 10.1021/bi000279w; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Charbaut E, 2001, J BIOL CHEM, V276, P16146, DOI 10.1074/jbc.M010637200; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DOYE V, 1989, J BIOL CHEM, V264, P12134; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; Holmfeldt P, 2002, CURR BIOL, V12, P1034, DOI 10.1016/S0960-9822(02)00897-7; Holmfeldt P, 2001, MOL BIOL CELL, V12, P73, DOI 10.1091/mbc.12.1.73; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Larsson NL, 1999, MOL CELL BIOL, V19, P2242; Mejillano MR, 1996, ARCH BIOCHEM BIOPHYS, V336, P130, DOI 10.1006/abbi.1996.0540; Mori N, 2002, J NEUROSCI RES, V70, P264, DOI 10.1002/jnr.10353; Muller DR, 2001, ANAL CHEM, V73, P1927, DOI 10.1021/ac001379a; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; SECKLER R, 1990, J BIOL CHEM, V265, P7655; Segerman B, 2000, J BIOL CHEM, V275, P35759, DOI 10.1074/jbc.M005875200; Segerman B, 2003, J CELL SCI, V116, P197, DOI 10.1242/jcs.00205; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Wallon G, 2000, EMBO J, V19, P213, DOI 10.1093/emboj/19.2.213	24	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16651	16657		10.1074/jbc.M300131200	http://dx.doi.org/10.1074/jbc.M300131200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606544	hybrid			2022-12-27	WOS:000182818600028
J	Cunha, CA; Macieira, S; Dias, JM; Almeida, G; Goncalves, LL; Costa, C; Lampreia, J; Huber, R; Moura, JJG; Moura, I; Romao, MJ				Cunha, CA; Macieira, S; Dias, JM; Almeida, G; Goncalves, LL; Costa, C; Lampreia, J; Huber, R; Moura, JJG; Moura, I; Romao, MJ			Cytochrome c nitrite reductase from Desulfovibrio desulfuricans ATCC 27774 - The relevance of the two calcium sites in the structure of the catalytic subunit (NrfA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORSERADISH-PEROXIDASE C; CRYSTAL-STRUCTURE; WOLINELLA-SUCCINOGENES; ANGSTROM RESOLUTION; LIGNIN PEROXIDASE; IDENTIFICATION; ENVIRONMENT; REFINEMENT; MEMBRANE; CLEAVAGE	The gene encoding cytochrome c nitrite reductase (NrfA) from Desulfovibrio desulfuricans ATCC 27774 was sequenced and the crystal structure of the enzyme was determined to 2.3-Angstrom resolution. In comparison with homologous structures, it presents structural differences mainly located at the regions surrounding the putative substrate inlet and product outlet, and includes a well defined second calcium site with octahedral geometry, coordinated to propionates of hemes 3 and 4, and caged by a loop non-existent in the previous structures. The highly negative electrostatic potential in the environment around hemes 3 and 4 suggests that the main role of this calcium ion may not be electrostatic but structural, namely in the stabilization of the conformation of the additional loop that cages it and influences the solvent accessibility of heme 4. The NrfA active site is similar to that of peroxidases with a nearby calcium site at the heme distal side nearly in the same location as occurs in the class II and class III peroxidases. This fact suggests that the calcium ion at the distal side of the active site in the NrfA enzymes may have a similar physiological role to that reported for the peroxidases.	Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, REQUIMTE CQFB, P-2829516 Caparica, Portugal; Inst Super Ciencias Saude Sul, P-2825511 Caparica, Portugal; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany	Universidade Nova de Lisboa; Max Planck Society	Romao, MJ (corresponding author), Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, REQUIMTE CQFB, P-2829516 Caparica, Portugal.	mromao@dq.fct.unl.pt	Gonçalves, Luisa/A-4120-2016; Almeida, Gabriela/GXV-3687-2022; Almeida, Maria Gabriela/D-8265-2013; Romao, Maria J/A-4115-2013; Costa, Cristina/A-9966-2012; Lampreia, Jorge/A-9927-2012; Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013; UCIBIO, U Cienc Biom Apl/F-7948-2017	Gonçalves, Luisa/0000-0002-3654-8612; Almeida, Maria Gabriela/0000-0002-4508-7379; Romao, Maria J/0000-0002-3004-0543; Costa, Cristina/0000-0002-8611-9023; Lampreia, Jorge/0000-0001-8846-0041; Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388; UCIBIO, U Cienc Biom Apl/0000-0002-3004-0543; Goncalves, Luisa/0000-0002-2385-7395				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Angove HC, 2002, J BIOL CHEM, V277, P23374, DOI 10.1074/jbc.M200495200; Aubert C, 1997, J BIOL CHEM, V272, P15128, DOI 10.1074/jbc.272.24.15128; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bamford VA, 2002, BIOCHEMISTRY-US, V41, P2921, DOI 10.1021/bi015765d; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; COSTA C, 1990, FEBS LETT, V276, P67, DOI 10.1016/0014-5793(90)80508-G; Costa C, 1996, J BIOL CHEM, V271, P23191, DOI 10.1074/jbc.271.38.23191; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; Dias JM, 2000, ACTA CRYSTALLOGR D, V56, P215, DOI 10.1107/S0907444999016066; Einsle O, 2000, J BIOL CHEM, V275, P39608, DOI 10.1074/jbc.M006188200; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; Einsle O, 2002, J AM CHEM SOC, V124, P11737, DOI 10.1021/ja0206487; Ferguson SJ, 1998, CURR OPIN CHEM BIOL, V2, P182, DOI 10.1016/S1367-5931(98)80059-8; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; George SJ, 1999, BIOCHEM J, V344, P237, DOI 10.1042/0264-6021:3440237; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; Henriksen A, 1999, J BIOL CHEM, V274, P35005, DOI 10.1074/jbc.274.49.35005; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASSNER RJ, 1973, J AM CHEM SOC, V95, P2674, DOI 10.1021/ja00789a044; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU MC, 1994, METHOD ENZYMOL, V243, P303; LIU MC, 1981, J BIOL CHEM, V256, P3159; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moura I, 1997, ANAEROBE, V3, P279, DOI 10.1006/anae.1997.0093; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; POULOS TL, 1980, J BIOL CHEM, V255, P575; POULOS TL, 1993, J BIOL CHEM, V268, P4429; RAFFERTY SP, 1990, BIOCHEMISTRY-US, V29, P9365, DOI 10.1021/bi00492a009; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; SCHRODER I, 1985, ARCH MICROBIOL, V140, P380, DOI 10.1007/BF00446982; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; Simon J, 2000, MOL MICROBIOL, V35, P686, DOI 10.1046/j.1365-2958.2000.01742.x; Simon J, 2002, FEMS MICROBIOL REV, V26, P285, DOI 10.1111/j.1574-6976.2002.tb00616.x; Simon J, 2001, EUR J BIOCHEM, V268, P5776, DOI 10.1046/j.0014-2956.2001.02520.x; Stach P, 2000, J INORG BIOCHEM, V79, P381, DOI 10.1016/S0162-0134(99)00248-2; STEENKAMP DJ, 1981, J BIOL CHEM, V256, P5450; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; Sutherland GRJ, 1997, BIOCHEMISTRY-US, V36, P3654, DOI 10.1021/bi962195m; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036	53	81	83	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17455	17465		10.1074/jbc.M211777200	http://dx.doi.org/10.1074/jbc.M211777200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618432	Green Published, hybrid			2022-12-27	WOS:000182818600133
J	Johansson, CC; Dahle, MK; Blomqvist, SR; Gronning, LM; Aandahl, EM; Enerback, S; Tasken, K				Johansson, CC; Dahle, MK; Blomqvist, SR; Gronning, LM; Aandahl, EM; Enerback, S; Tasken, K			A winged helix forkhead (FOXD2) tunes sensitivity to cAMP in T lymphocytes through regulation of cAMP-dependent protein kinase RI alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SIGNALING PATHWAYS; BINDING-SITES; B ACTIVATION; SUBUNIT; GENE; EXPRESSION; CELLS; SPECIFICITY; MECHANISMS	Forkhead/winged helix ( FOX) transcription factors are essential for control of the cell cycle and metabolism. Here, we show that spleens from Mf2-/- (FOXD2-/-) mice have reduced mRNA (50%) and protein (35%) levels of the RIalpha subunit of the cAMP-dependent protein kinase. In T cells from Mf2-/- mice, reduced levels of RIalpha translates functionally into similar to2-fold less sensitivity to cAMP-mediated inhibition of proliferation triggered through the T cell receptor-CD3 complex. In Jurkat T cells, FOXD2 overexpression increased the endogenous levels of RIalpha through induction of the RIalpha1b promoter. FOXD2 overexpression also increased the sensitivity of the promoter to cAMP. Finally, co-expression experiments demonstrated that protein kinase Balpha/Akt1 work together with FOXD2 to induce the RIalpha1b promoter (10-fold) and increase endogenous RIalpha protein levels further. Taken together, our data indicate that FOXD2 is a physiological regulator of the RIalpha1b promoter in vivo working synergistically with protein kinase B to induce cAMP-dependent protein kinase RIalpha expression, which increases cAMP sensitivity and sets the threshold for cAMP-mediated negative modulation of T cell activation.	Univ Oslo, Inst Basic Med Sci, Dept Biochem Med, N-0317 Oslo, Norway; Univ Gothenburg, Dept Biochem Med, SE-40530 Gothenburg, Sweden	University of Oslo; University of Gothenburg	Tasken, K (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Biochem Med, N-0317 Oslo, Norway.		Dahle, Maria K/AAK-5130-2021	Dahle, Maria K/0000-0003-0380-084X; Aandahl, Einar Martin/0000-0002-0115-8382; Tasken, Kjetil/0000-0003-2841-4697				Aandahl EM, 1998, FASEB J, V12, P855, DOI 10.1096/fasebj.12.10.855; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Aukrust P, 1999, J IMMUNOL, V162, P1178; Barradeau S, 2000, FEBS LETT, V476, P272, DOI 10.1016/S0014-5793(00)01653-7; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Dahle MK, 2002, J BIOL CHEM, V277, P22902, DOI 10.1074/jbc.M200131200; Dahle MK, 2001, EUR J BIOCHEM, V268, P5920, DOI 10.1046/j.0014-2956.2001.02542.x; Dahle MK, 2001, MOL REPROD DEV, V59, P11, DOI 10.1002/mrd.1001; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; Ernstsson S, 1997, GENOMICS, V46, P78, DOI 10.1006/geno.1997.4986; Ernstsson S, 1996, J BIOL CHEM, V271, P21094, DOI 10.1074/jbc.271.35.21094; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Herberg FW, 2000, J MOL BIOL, V298, P329, DOI 10.1006/jmbi.2000.3662; Hoover F, 2002, MOL CELL NEUROSCI, V19, P125, DOI 10.1006/mcne.2001.1053; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Kops GJPL, 2000, J ANAT, V197, P571, DOI 10.1046/j.1469-7580.2000.19740571.x; Kume T, 2000, MOL CELL BIOL, V20, P1419, DOI 10.1128/MCB.20.4.1419-1425.2000; Laxminarayana D, 1999, J IMMUNOL, V162, P5639; OGREID D, 1989, EUR J BIOCHEM, V181, P19; ORELLANA SA, 1990, J BIOL CHEM, V265, P3048; OYEN O, 1987, BIOL REPROD, V37, P947, DOI 10.1095/biolreprod37.4.947; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; Reif K, 1997, J BIOL CHEM, V272, P14426, DOI 10.1074/jbc.272.22.14426; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; Solberg R, 1997, ENDOCRINOLOGY, V138, P169, DOI 10.1210/en.138.1.169; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497	32	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17573	17579		10.1074/jbc.M300311200	http://dx.doi.org/10.1074/jbc.M300311200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621056	hybrid			2022-12-27	WOS:000182818600147
J	Montalvetti, A; Fernandez, A; Sanders, JM; Ghosh, S; Van Brussel, E; Oldfield, E; Docampo, R				Montalvetti, A; Fernandez, A; Sanders, JM; Ghosh, S; Van Brussel, E; Oldfield, E; Docampo, R			Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei - In vitro RNA interference and in vivo inhibition studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN-CONTAINING BISPHOSPHONATES; LEISHMANIA-DONOVANI; GENE-EXPRESSION; GROWTH; ALENDRONATE; SEQUENCE; PROTEIN; TARGET; LENGTH; DRUGS	We report the cloning and sequencing of a gene encoding the farnesyl pyrophosphate synthase (FPPS) of Trypanosoma brucei. The protein (TbFPPS) is an attractive target for drug development because the growth of T. brucei has been shown to be inhibited by analogs of its substrates, the nitrogen containing bisphosphonates currently in use in bone resorption therapy. The protein predicted from the nucleotide sequence of the gene has 367 amino acids and a molecular mass of 42 kDa. Several sequence motifs found in other FPPSs are present in TbFPPS, including an 11-mer peptide insertion present also in the Trypanosoma cruzi FPPS. Heterologous expression of TbFPPS in Escherichia coli produced a functional enzyme that was inhibited by several nitrogen-containing bisphosphonates, such as pamidronate and risedronate. Risedronate was active in vivo against T. brucei infection in mice (giving a 60% survival rate), but pamidronate was not effective. The essential nature of TbFPPS was studied using RNA interference (RNAi) to inhibit the expression of the gene. Expression of TbFPPS double-stranded RNA in procyclic trypomastigotes caused specific degradation of mRNA. After 4 days of RNAi, the parasite growth rate declined and the cells subsequently died. Similar results were obtained with bloodstream form trypomastigotes, except that the RNAi system in this case was leaky and mRNA levels and parasites recovered with time. Molecular modeling and structure-activity investigations of enzyme and in vitro growth inhibition data resulted in similar pharmacophores, further validating TbFPPS as the target for bisphosphonates. These results establish that FPPS is essential for parasite viability and validate this enzyme as a target for drug development.	Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Coll Vet Med, Ctr Zoonoses Res, Urbana, IL 61802 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Av, Urbana, IL 61802 USA.	rodoc@uiuc.edu	ghosh, subhash/C-3907-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065307] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-65307] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		*ACC INC, 2002, INS 2 PROGR 2000 1; Barrett MP, 1999, LANCET, V353, P1113, DOI 10.1016/S0140-6736(98)00416-4; BELMANT C, 2000, Patent No. 2782721; Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DL, 1999, J CLIN PHARMACOL, V39, P651, DOI 10.1177/00912709922008272; Cromartie TH, 1999, PESTIC BIOCHEM PHYS, V63, P114, DOI 10.1006/pest.1999.2397; Das H, 2001, BLOOD, V98, P1616, DOI 10.1182/blood.V98.5.1616; DING VDH, 1991, BIOCHEM J, V275, P61, DOI 10.1042/bj2750061; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; Docampo Roberto, 2001, Current Drug Targets - Infectious Disorders, V1, P51, DOI 10.2174/1568005013343191; DUMAS M, 2000, B WORLD HEALTH ORGAN, V78, P9; Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235; EUBANK WB, 1982, J PARASITOL, V68, P599, DOI 10.2307/3280916; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Frisch M.J., 2016, GAUSSIAN 16 REVISION; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Grove JE, 2000, J BONE MINER RES, V15, P971, DOI 10.1359/jbmr.2000.15.5.971; Hill JE, 2000, BIOCHEM J, V351, P281, DOI 10.1042/0264-6021:3510281; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Inc Accelrys, 2000, CAT 4 6 PROGR; Keller RK, 1999, BIOCHEM BIOPH RES CO, V266, P560, DOI 10.1006/bbrc.1999.1849; Koyama T, 1999, BIOSCI BIOTECH BIOCH, V63, P1671, DOI 10.1271/bbb.63.1671; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Martin MB, 1999, BIOCHEM BIOPH RES CO, V263, P754, DOI 10.1006/bbrc.1999.1404; Martin MB, 2002, J MED CHEM, V45, P2904, DOI 10.1021/jm0102809; Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578; Montalvetti A, 2001, J BIOL CHEM, V276, P33930, DOI 10.1074/jbc.M103950200; Morris JC, 2001, MOL BIOCHEM PARASIT, V117, P111, DOI 10.1016/S0166-6851(01)00334-6; Reilly JF, 2002, BIOCHEM J, V366, P501, DOI 10.1042/BJ20020560; Rodan GA, 1998, ANNU REV PHARMACOL, V38, P375, DOI 10.1146/annurev.pharmtox.38.1.375; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Rodriguez N, 2002, J INFECT DIS, V186, P138, DOI 10.1086/341074; Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; SHINODA H, 1983, CALCIFIED TISSUE INT, V35, P87, DOI 10.1007/BF02405012; Sicard H, 2001, MOL MED, V7, P711, DOI 10.1007/BF03401961; SUNBERG RJ, 1991, CHEMTECH, V21, P304; Szajnman SH, 2001, BIOORG MED CHEM LETT, V11, P789, DOI 10.1016/S0960-894X(01)00057-9; Takeuchi M, 1998, CHEM PHARM BULL, V46, P1703; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499; van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224; Wang CC, 1997, PARASITOLOGY, V114, pS31; Wang LS, 2001, J CLIN INVEST, V108, P1349, DOI 10.1172/JCI13584; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; Yardley V, 2002, ANTIMICROB AGENTS CH, V46, P929, DOI 10.1128/AAC.46.3.929-931.2002	52	80	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17075	17083		10.1074/jbc.M210467200	http://dx.doi.org/10.1074/jbc.M210467200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618430	hybrid			2022-12-27	WOS:000182818600085
J	Shogren-Knaak, MA; Fry, CJ; Peterson, CL				Shogren-Knaak, MA; Fry, CJ; Peterson, CL			A native peptide Ligation strategy for deciphering nucleosomal histone modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SWI/SNF COMPLEX; PHOSPHORYLATION; ACETYLATION; ARRAYS; H3; ACETYLTRANSFERASE; PURIFICATION; MODEL; GCN5P	Post-translational modifications of histones influence both chromatin structure and the binding and function of chromatin-associated proteins. A major limitation to understanding these effects has been the inability to construct nucleosomes in vitro that harbor homogeneous and site-specific histone modifications. Here, we describe a native peptide ligation strategy for generating nucleosomal arrays that can harbor a wide range of desired histone modifications. As a first test of this method, we engineered model nucleosomal arrays in which each histone H3 contains a phosphorylated serine at position 10 and performed kinetic analyses of Gcn5-dependent histone acetyltransferase activities. Recombinant Gcn5 shows increased histone acetyltransferase activity on nucleosomal arrays harboring phosphorylated H3 serine 10 and is consistent with peptide studies. However, in contrast to analyses using peptide substrates, we find that the histone acetyltransferase activity of the Gcn5-containing SAGA complex is not stimulated by H3 phosphorylation in the context of nucleosomal arrays. This difference between peptide and array substrates suggests that the ability to generate specifically modified nucleosomal arrays should provide a powerful tool for understanding the effects of post-translational histone modifications.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Peterson, CL (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, 373 Plantat St,Biotech 2,Suite 210, Worcester, MA 01605 USA.				NATIONAL CANCER INSTITUTE [P01CA082834] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049650, R37GM049650, R01GM054096] Funding Source: NIH RePORTER; NCI NIH HHS [CA 82834] Funding Source: Medline; NIAID NIH HHS [F32 AI 10611] Funding Source: Medline; NIGMS NIH HHS [R01 GM054096, GM 49650] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENZ H, 1994, SYNTHESIS-STUTTGART, P337; Blaschke UK, 2000, METHOD ENZYMOL, V328, P478, DOI 10.1016/S0076-6879(00)28414-0; Boyer LA, 2002, MOL CELL, V10, P935, DOI 10.1016/S1097-2765(02)00634-2; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Dawson PE, 1997, J AM CHEM SOC, V119, P4325, DOI 10.1021/ja962656r; Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; Futaki S, 1997, TETRAHEDRON LETT, V38, P6237, DOI 10.1016/S0040-4039(97)01434-2; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Labrador M, 2003, GENE DEV, V17, P43, DOI 10.1101/gad.1021403; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Logie C, 1999, METHOD ENZYMOL, V304, P726; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1999, METH MOL B, V119, P1; MUSZYNSKA G, 1992, J CHROMATOGR, V604, P19, DOI 10.1016/0021-9673(92)85524-W; Sendra R, 2000, J BIOL CHEM, V275, P24928, DOI 10.1074/jbc.M003783200; Smith CL, 2003, NAT STRUCT BIOL, V10, P141, DOI 10.1038/nsb888; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Tse C, 1998, J BIOL CHEM, V273, P32388, DOI 10.1074/jbc.273.49.32388; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200	23	92	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15744	15748		10.1074/jbc.M301445200	http://dx.doi.org/10.1074/jbc.M301445200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595522	hybrid			2022-12-27	WOS:000182680000037
J	Tanahashi-Hori, T; Tanahashi, N; Tanaka, K; Chiba, T				Tanahashi-Hori, T; Tanahashi, N; Tanaka, K; Chiba, T			Conditional knockdown of proteasomes results in cell-cycle arrest and enhanced expression of molecular chaperones Hsp70 and Hsp40 in chicken DT40 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							20S PROTEASOME; SACCHAROMYCES-CEREVISIAE; PROTEINS; SUBUNIT; INHIBITORS; RESOLUTION; THREONINE; COMPLEXES; HOMOLOG; KINASE	The 26 S proteasome is an evolutionarily conserved ATP-dependent protease complex that degrades poly-ubiquitinated proteins' and plays essential roles in a critical part of cellular regulation. In vertebrates, the roles of the proteasome have been widely studied by use of specific inhibitors, but not genetically. Here, we generated a cell line Z(-/-/-)/Z-HA, in which the expression of the catalytic subunit of the proteasome, Z (beta2) could be manipulated. This cell line expresses exogenous Z protein under the control of a tetracycline-repressible promoter in a Z-nullizygous genetic background. Treatment of these cells with doxycycline inhibited Z expression and, hence, the function of the proteasome. The latter resulted in accumulation of poly-ubiquitinated proteins and concomitant induction of molecular chaperones Hsp70 and Hsp40. These results suggest a synergistic role for the proteasome with these molecular chaperones to eliminate misfolded or damaged proteins in vivo. Furthermore, knockdown of the proteasome induced apoptotic cell death following cell-cycle arrest at G(2)/M phase. Our Z(-/-/-)/Z-HA cell line would be useful for evaluating proteolytic processes catalyzed by the proteasome in many biological events in vertebrate cells.	Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan; Sumitomo Elect Ind Ltd, Osaka R&D Labs, EPM Project Grps, Sakae Ku, Yokohama, Kanagawa 2448588, Japan; New Energy & Ind Technol Dev Org, Sakae Ku, Yokohama, Kanagawa 2448588, Japan	Tokyo Metropolitan Institute of Medical Science; Sumitomo Electric Industries	Chiba, T (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.							Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Kim KB, 1999, BIOORG MED CHEM LETT, V9, P3335, DOI 10.1016/S0960-894X(99)00612-5; KOMINAMI K, 1995, EMBO J, V14, P3105, DOI 10.1002/j.1460-2075.1995.tb07313.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Schmidtke G, 1997, J MOL BIOL, V268, P95, DOI 10.1006/jmbi.1997.0947; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; TANAKA K, 1988, J BIOL CHEM, V263, P16209; Unno M, 2002, STRUCTURE, V10, P609, DOI 10.1016/S0969-2126(02)00748-7; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563	29	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16237	16243		10.1074/jbc.M301331200	http://dx.doi.org/10.1074/jbc.M301331200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594202	hybrid			2022-12-27	WOS:000182680000099
J	Wang, J; Liu, XJ				Wang, J; Liu, XJ			A G protein-coupled receptor kinase induces Xenopus oocyte maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; BETA-GAMMA-SUBUNITS; G(BETA-GAMMA) SUBUNITS; ADENYLATE-CYCLASE; LAEVIS OOCYTES; CELL-CYCLE; INHIBITION; ACTIVATION; INSULIN; STIMULATION	Several recent studies have suggested that resumption of oocyte meiosis, indicated by germinal vesicle breakdown or GVBD, involves inhibition of endogenous heterotrimeric G proteins in both frogs and mice. These studies imply that a heterotrimeric G protein(s), and hence its upstream activator (a G protein-coupled receptor or GpCR), is activated in prophase oocytes and is responsible for maintaining meiosis arrest. To test the existence and function of this putative GpCR, we utilized a mammalian G-protein-coupled receptor kinase (GRK3) and. beta-arrestin-2, which together are known to cause GpCR desensitization. Injection of mRNA for rat GRK3 caused hormone-independent GVBD. The kinase activity of GRK3 was essential for GVBD induction as its kinase-dead mutant (GRK3-K220R) was completely ineffective. Another GRK3 mutant (GRK3-DeltaC), which lacked the C-terminal G(betagamma)-binding domain and which was not associated with oocyte membranes, also failed to induce GVBD. Furthermore, injection of rat beta-arrestin-2 mRNA also induced hormone-independent GVBD. Several inhibitors of clathrin-mediated receptor endocytosis (the clathrin-binding domain of beta-arrestin-2, concanavalin A, and monodansyl cadaverine) significantly reduced the abilities of GRK3/beta-arrestin-2 to induce GVBD. These results support the central role of a yet-unidentified GpCR in maintaining prophase arrest in frog oocytes and provide a potential means for its molecular identification.	Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Dept Obstet & Gynaecol, Ottawa, ON K1N 6N5, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Liu, XJ (corresponding author), Ottawa Hlth Res Inst, 725 Parkdale Ave,Ottawa Hosp Civ Campus, Ottawa, ON K1Y 4E9, Canada.	jliu@ohri.ca		Liu, X. Johne/0000-0003-3381-5030; Wang, Jing/0000-0003-2410-4771				ARRIZA JL, 1992, J NEUROSCI, V12, P4045; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Bayaa M, 2000, P NATL ACAD SCI USA, V97, P12607, DOI 10.1073/pnas.220302597; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; Booth RA, 2002, J BIOL CHEM, V277, P6719, DOI 10.1074/jbc.M108033200; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Dupre A, 2002, ONCOGENE, V21, P6425, DOI 10.1038/sj.onc.1205827; FINIDORILEPICARD J, 1981, NATURE, V292, P255, DOI 10.1038/292255a0; GALLO CJ, 1995, J CELL BIOL, V130, P275, DOI 10.1083/jcb.130.2.275; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; HARIBABU B, 1993, P NATL ACAD SCI USA, V90, P9398, DOI 10.1073/pnas.90.20.9398; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; Karoor V, 1996, J BIOL CHEM, V271, P29347, DOI 10.1074/jbc.271.46.29347; Keummerle JF, 2001, J BIOL CHEM, V276, P7187, DOI 10.1074/jbc.M011145200; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Lou XJ, 2001, MOL BIOL CELL, V12, P615, DOI 10.1091/mbc.12.3.615; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Lutz LB, 2000, J BIOL CHEM, V275, P41512, DOI 10.1074/jbc.M006757200; MASUI Y, 1967, J EXP ZOOL, V166, P365, DOI 10.1002/jez.1401660309; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Mehlmann LM, 2002, SCIENCE, V297, P1343, DOI 10.1126/science.1073978; NANDI PK, 1981, BIOCHEMISTRY-US, V20, P6706, DOI 10.1021/bi00526a028; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SADLER SE, 1987, J BIOL CHEM, V262, P10644; SADLER SE, 1984, MOL PHARMACOL, V26, P526; SADLER SE, 1981, J BIOL CHEM, V256, P6368; SALISBURY JL, 1981, COLD SPRING HARB SYM, V46, P733; SCHORDERETSLATKINE S, 1982, ENDOCRINOLOGY, V111, P1385, DOI 10.1210/endo-111-4-1385; Sheng YL, 2001, CURR BIOL, V11, P405, DOI 10.1016/S0960-9822(01)00123-3; SMITH LD, 1989, DEVELOPMENT, V107, P685; Tian JD, 2000, P NATL ACAD SCI USA, V97, P14358, DOI 10.1073/pnas.250492197; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723	41	15	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15809	15814		10.1074/jbc.M300320200	http://dx.doi.org/10.1074/jbc.M300320200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600992	hybrid			2022-12-27	WOS:000182680000046
J	Corvaisier, S; Bordeau, V; Felden, B				Corvaisier, S; Bordeau, V; Felden, B			Inhibition of transfer messenger RNA aminoacylation and trans-translation by aminoglycoside antibiotics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; HAMMERHEAD RIBOZYME; RIBOSOME RESCUE; METAL-IONS; 10SA RNA; TMRNA; BINDING; PROTEIN; SMPB; MOLECULES	Transfer messenger RNA (tmRNA) directs the modification of proteins of which the biosynthesis has stalled or has been interrupted. Here, we report that aminoglycosides can interfere with this quality control system in bacteria, termed trans-translation. Neomycin B is the strongest inhibitor of tmRNA aminoacylation with alanine (K-i value of similar to35 muM), an essential step during transtranslation. The binding sites of neomycin B do not overlap with the identity determinants for alanylation, but the aminoglycoside perturbs the conformation of the acceptor stem that contains the aminoacylation signals. Aminoglycosides reduce the conformational freedom of the transfer RNA-like domain of tmRNA. Additional contacts between aminoglycosides and tmRNA are within the tag reading frame, probably also disturbing reprogramming of the stalled ribosomes prior protein tagging. Aminoglycosides impair tmRNA aminoacylation in the presence of all of the transfer RNAs from Escherichia coli, small protein B, and elongation factor Tu, but when both proteins are present, the inhibition constant is 1 order of magnitude higher. SmpB and elongation factor Tu have RNA chaperone activities, ensuring that tmRNA adopts an optimal conformation during aminoacylation.	Univ Rennes 2, UPRES, Fac Pharm, Lab Biochim Pharmaceut, F-35043 Rennes, France	Universite de Rennes; Universite Rennes 2	Felden, B (corresponding author), Univ Rennes 2, UPRES, Fac Pharm, Lab Biochim Pharmaceut, Jeuna Equipe 2311,2 Ave Prof Leon Bernard, F-35043 Rennes, France.		felden, brice/L-4825-2015; Bordeau, Valérie/L-1992-2015	BORDEAU, VALERIE/0000-0003-1137-1053				Barends S, 2001, J MOL BIOL, V314, P9, DOI 10.1006/jmbi.2001.5114; Dong HJ, 1996, J MOL BIOL, V260, P649, DOI 10.1006/jmbi.1996.0428; Earnshaw DJ, 1998, NUCLEIC ACIDS RES, V26, P5551, DOI 10.1093/nar/26.24.5551; Felden B, 1997, RNA, V3, P89; FELDEN B, 2003, LANDES BIOSCIENCES; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; GALE EF, 1981, MOL BASIS ANTIBIOTIC, P419; Gillet R, 2001, MOL MICROBIOL, V42, P879, DOI 10.1046/j.1365-2958.2001.02701.x; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Hanawa-Suetsugu K, 2002, NUCLEIC ACIDS RES, V30, P1620, DOI 10.1093/nar/30.7.1620; Hermann T, 1998, J MOL BIOL, V276, P903, DOI 10.1006/jmbi.1997.1590; Hickerson RP, 1998, J MOL BIOL, V279, P577, DOI 10.1006/jmbi.1998.1813; Hoch I, 1998, J MOL BIOL, V282, P557, DOI 10.1006/jmbi.1998.2035; Huang CH, 2000, EMBO J, V19, P1098, DOI 10.1093/emboj/19.5.1098; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; LEE SY, 1978, J BACTERIOL, V133, P1015, DOI 10.1128/JB.133.2.1015-1023.1978; Mikkelsen NE, 1999, P NATL ACAD SCI USA, V96, P6155, DOI 10.1073/pnas.96.11.6155; Mikkelsen NE, 2001, NAT STRUCT BIOL, V8, P510, DOI 10.1038/88569; Nameki N, 1999, J MOL BIOL, V289, P1, DOI 10.1006/jmbi.1999.2754; Rogers J, 1996, J MOL BIOL, V259, P916, DOI 10.1006/jmbi.1996.0369; RUDINGERTHIRION J, 1999, RNA, V5, P1; Ryu DH, 2001, BIOORGAN MED CHEM, V9, P2601; Schroeder R, 2000, EMBO J, V19, P1, DOI 10.1093/emboj/19.1.1; Shimizu Y, 2002, FEBS LETT, V514, P74, DOI 10.1016/S0014-5793(02)02333-5; STAGE TK, 1995, RNA, V1, P95; Tok JBH, 1999, BIOCHEMISTRY-US, V38, P199, DOI 10.1021/bi9819428; USHIDA C, 1994, NUCLEIC ACIDS RES, V22, P3392, DOI 10.1093/nar/22.16.3392; Vicens Q, 2001, STRUCTURE, V9, P647, DOI 10.1016/S0969-2126(01)00629-3; Walter F, 1999, CURR OPIN CHEM BIOL, V3, P694, DOI 10.1016/S1367-5931(99)00028-9; Walter F, 2002, EMBO J, V21, P760, DOI 10.1093/emboj/21.4.760; Williams KP, 2002, NUCLEIC ACIDS RES, V30, P179, DOI 10.1093/nar/30.1.179; Withey JH, 2002, CURR OPIN MICROBIOL, V5, P154, DOI 10.1016/S1369-5274(02)00299-0; ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B; Zvereva MI, 2001, J BIOL CHEM, V276, P47702, DOI 10.1074/jbc.M106786200	36	26	28	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14788	14797		10.1074/jbc.M212830200	http://dx.doi.org/10.1074/jbc.M212830200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588865	hybrid			2022-12-27	WOS:000182516100028
J	Clifton, IJ; Doan, LX; Sleeman, MC; Topf, M; Suzuki, H; Wilmouth, RC; Schofield, CJ				Clifton, IJ; Doan, LX; Sleeman, MC; Topf, M; Suzuki, H; Wilmouth, RC; Schofield, CJ			Crystal structure of carbapenem synthase (CarC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM SYNTHETASE; KETOGLUTARATE DIOXYGENASE; ANTIBIOTIC PRODUCTION; CLAVAMINATE SYNTHASE; ERWINIA-CAROTOVORA; GENE-CLUSTER; SERRATIA; ACID; BIOSYNTHESIS; DYNAMICS	The proposed biosynthetic pathway to the carbapenem antibiotics proceeds via epimerization/desaturation of a carbapenam in an unusual process catalyzed by an iron- and 2-oxoglutarate-dependent oxygenase, CarC. Crystal structures of CarC complexed with Fe(II) and 2-oxoglutarate reveal it to be hexameric (space group C2221), consistent with solution studies. CarC monomers contain a double-stranded beta-helix core that supports ligands binding a single Fe(II) to which 2-oxoglutarate complexes in a bi-dentate manner. A structure was obtained with L-N-acetylproline acting as a substrate analogue. Quantum mechanical/molecular mechanical modeling studies with stereoisomers of carbapenams and carbapenems were used to investigate substrate binding. The combined work will stimulate further mechanistic studies and aid in the engineering of carbapenem biosynthesis.	Oxford Ctr Mol Sci, Oxford OX1 3QZ, England; Dyson Perrins Lab, Oxford OX1 3QZ, England; Phys & Theoret Chem Lab, Oxford OX1 3QZ, England; Nanyang Technol Univ, Sch Biol Sci, Singapore 637616, Singapore	University of Oxford; University of Oxford; University of Oxford; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Wilmouth, RC (corresponding author), Oxford Ctr Mol Sci, S Parks Rd, Oxford OX1 3QZ, England.	RCWilmouth@ntu.edu.sg; christopher.schofield@chem.ox.ac.uk		Schofield, Christopher/0000-0002-0290-6565; Topf, Maya/0000-0002-8185-1215				*ACC INC, 1997, QUANTA; Bachmann BO, 1998, P NATL ACAD SCI USA, V95, P9082, DOI 10.1073/pnas.95.16.9082; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BESLER BH, 1990, J COMPUT CHEM, V11, P431, DOI 10.1002/jcc.540110404; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Burzlaff NI, 1999, NATURE, V401, P721, DOI 10.1038/44400; Bycroft BW, 2003, TETRAHEDRON LETT, V44, P973, DOI 10.1016/S0040-4039(02)02731-4; BYCROFT BW, 1987, J CHEM SOC CHEM COMM, P1623, DOI 10.1039/c39870001623; BYCROFT BW, 1989, J CHEM SOC CHEM COMM, P423, DOI 10.1039/c39890000423; Clifton IJ, 2001, EUR J BIOCHEM, V268, P6625, DOI 10.1046/j.0014-2956.2001.02617.x; Cox ARJ, 1998, MICROBIOL-UK, V144, P201, DOI 10.1099/00221287-144-1-201; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; Elkins JM, 2002, BIOCHEMISTRY-US, V41, P5185, DOI 10.1021/bi016014e; FIELD MJ, 1990, J COMPUT CHEM, V11, P700, DOI 10.1002/jcc.540110605; Frisch M. J., 1998, GAUSSIAN98; Fusetti F, 2002, STRUCTURE, V10, P259, DOI 10.1016/S0969-2126(02)00704-9; Hogan DA, 1999, J BACTERIOL, V181, P5876, DOI 10.1128/JB.181.18.5876-5879.1999; Ishibashi H, 2002, SYNTHESIS-STUTTGART, P695, DOI 10.1055/s-2002-25759; Iwata-Reuyl D, 1999, J AM CHEM SOC, V121, P11356, DOI 10.1021/ja992649d; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAHAN JS, 1979, J ANTIBIOT, V32, P1; Kanno O, 2000, J ANTIBIOT, V53, P404, DOI 10.7164/antibiotics.53.404; Kershaw NJ, 2002, EUR J BIOCHEM, V269, P2052, DOI 10.1046/j.1432-1033.2002.02853.x; Li RF, 2000, J AM CHEM SOC, V122, P9296, DOI 10.1021/ja001723l; Livermore DM, 2000, CURR OPIN MICROBIOL, V3, P489, DOI 10.1016/S1369-5274(00)00128-4; Lloyd MD, 1999, TETRAHEDRON, V55, P10201, DOI 10.1016/S0040-4020(99)00547-5; Lloyd MD, 1999, J MOL BIOL, V287, P943, DOI 10.1006/jmbi.1999.2594; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MCGOWAN S, 1995, MICROBIOL-SGM, V141, P541, DOI 10.1099/13500872-141-3-541; McGowan SJ, 1999, ANTON LEEUW INT J G, V75, P135, DOI 10.1023/A:1001768428383; McGowan SJ, 1996, MOL MICROBIOL, V22, P415, DOI 10.1046/j.1365-2958.1996.00125.x; McGowan SJ, 1997, MOL MICROBIOL, V26, P545, DOI 10.1046/j.1365-2958.1997.6001974.x; McGowan SJ, 1998, TRENDS MICROBIOL, V6, P203, DOI 10.1016/S0966-842X(98)01251-7; McNaughton HJ, 1998, CHEM COMMUN, P2325, DOI 10.1039/a806713i; Miller MT, 2001, NAT STRUCT BIOL, V8, P684, DOI 10.1038/90394; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICOLAOU KC, 1996, CLASSICS TOTAL SYNTH, P249; PARKER WL, 1982, J ANTIBIOT, V35, P653, DOI 10.7164/antibiotics.35.653; Que L, 2000, NAT STRUCT BIOL, V7, P182, DOI 10.1038/73270; STEINBACH PJ, 1994, J COMPUT CHEM, V15, P667, DOI 10.1002/jcc.540150702; Stubbe J, 2000, CURR OPIN STRUC BIOL, V10, P731, DOI 10.1016/S0959-440X(00)00153-6; Tanaka H, 2002, TETRAHEDRON LETT, V43, P93, DOI 10.1016/S0040-4039(01)02073-1; TANNER DD, 1979, J ORG CHEM, V44, P1674, DOI 10.1021/jo01324a020; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thomson NR, 2000, MOL MICROBIOL, V36, P539, DOI 10.1046/j.1365-2958.2000.01872.x; WARSHEL A, 1976, J MOL BIOL, V103, P227, DOI 10.1016/0022-2836(76)90311-9; WILLIAMSON JM, 1986, CRIT REV BIOTECHNOL, V4, P111, DOI 10.3109/07388558609150792; Zhang ZH, 2002, FEBS LETT, V517, P7, DOI 10.1016/S0014-5793(02)02520-6; Zhang ZH, 2000, NAT STRUCT BIOL, V7, P127	51	81	83	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20843	20850		10.1074/jbc.M213054200	http://dx.doi.org/10.1074/jbc.M213054200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12611886	hybrid			2022-12-27	WOS:000183230500053
J	Scott, PG; Grossmann, JG; Dodd, CM; Sheehan, JK; Bishop, PN				Scott, PG; Grossmann, JG; Dodd, CM; Sheehan, JK; Bishop, PN			Light and X-ray scattering show decorin to be a dimer in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN PROTEODERMATAN SULFATE; LEUCINE-RICH REPEAT; GROWTH-FACTOR-BETA; DERMATAN SULFATE; SELF-ASSOCIATION; EXTRACELLULAR-MATRIX; PROTEOGLYCAN-II; CORE PROTEIN; COLLAGEN; ACID	Decorin is a widely distributed member of the extracellular matrix small leucine-rich repeat glycoprotein/proteoglycan family. For investigation of its physical properties, decorin from two sources (young steer skin and a recombinant adenovirus) was used. The first sample was extracted into 7 M urea and purified, while the second was isolated from medium conditioned by 293A cells infected with adenovirus and purified without chaotropes. The only chemical differences detected between these materials were a slightly shorter glycosaminoglycan chain and the retention of the propeptide on the latter. Circular dichroism spectra of the two samples were virtually identical, showing a high proportion of beta-sheet and beta-turn and little alpha-helix. The protein cores were completely denatured in 2.25 M guanidine HCl (GdnHCl) but recovered their secondary structure on removal of chaotrope. Light scattering of material eluted from gel-filtration columns in Tris-buffered saline, pH 7.0, gave molecular mass values of 165 +/- 1 kDa and 84.6 +/- 4 kDa for intact decorin and the glycoprotein core produced by digestion with chondroitin ABC lyase, respectively. Intact recombinant prodecorin had a mass of 148 +/- 18 kDa. These values, which are double those estimated from SDS gel electrophoresis or from the known sequences and compositions, were halved in 2.5 M GdnHCl. Data from solution x-ray scattering of intact decorin and its core in Tris-buffered saline are consistent with a dimeric particle whose protein component has a radius of gyration of 31.6 +/- 0.4 Angstrom, a maximum diameter of 98 +/- 5 Angstrom, and approximates two intertwined C shapes.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Res Councils Daresbury Lab, Cent Lab, Synchrotron Radiat Dept, Mol Biophys Grp, Warrington WA4 4AD, Cheshire, England; Univ Manchester, Sch Med, Res Grp Eye & Vis Sci, Manchester M13 9PL, Lancs, England; Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PL, Lancs, England	University of Alberta; STFC Daresbury Laboratory; University of Manchester; University of Manchester	Scott, PG (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.			Bishop, Paul/0000-0001-7937-7932				Blaschke UK, 1996, J BIOL CHEM, V271, P30347, DOI 10.1074/jbc.271.48.30347; CHOPRA RK, 1985, BIOCHEM J, V232, P277, DOI 10.1042/bj2320277; COSTER L, 1981, BIOCHEM J, V197, P483; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; Evdokimov AG, 2001, J MOL BIOL, V312, P807, DOI 10.1006/jmbi.2001.4973; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; Feigin L.A., 1987, STRUCTURE ANAL SMALL; FRANSSON LA, 1979, BIOCHIM BIOPHYS ACTA, V586, P179, DOI 10.1016/0304-4165(79)90416-1; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; Grossmann JG, 2001, BIOCHEMISTRY-US, V40, P6267, DOI 10.1021/bi0028946; Hakkinen L, 2000, LAB INVEST, V80, P1869, DOI 10.1038/labinvest.3780197; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LIU J, 1994, J BIOL CHEM, V269, P28366; MECHANIC G, 1979, SKELETAL RES EXPT AP, P227; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; PEARSON CH, 1983, J BIOL CHEM, V258, P5101; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; SCOTT JE, 1985, BIOSCIENCE REP, V5, P71, DOI 10.1007/BF01117443; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SCOTT PG, 1986, BIOCHEM BIOPH RES CO, V138, P1348, DOI 10.1016/S0006-291X(86)80431-4; SCOTT PG, 1993, J BIOL CHEM, V268, P11558; SCOTT PG, 1990, CONNECT TISSUE RES, V24, P225, DOI 10.3109/03008209009152151; Scott PG, 1997, BBA-GEN SUBJECTS, V1336, P254, DOI 10.1016/S0304-4165(97)00040-8; SCOTT PG, 1993, DERMATAN SULPHATE PR, P81; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZANGRANDO D, 1989, BIOPOLYMERS, V28, P1295, DOI 10.1002/bip.360280710	39	44	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18353	18359		10.1074/jbc.M211936200	http://dx.doi.org/10.1074/jbc.M211936200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12601001	hybrid			2022-12-27	WOS:000182838300100
J	Stromer, T; Ehrnsperger, M; Gaestel, M; Buchner, J				Stromer, T; Ehrnsperger, M; Gaestel, M; Buchner, J			Analysis of the interaction of small heat shock proteins with unfolding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-B-CRYSTALLIN; EHRLICH ASCITES TUMOR; MOLECULAR CHAPERONES; QUATERNARY STRUCTURE; THERMAL PROTECTION; ESCHERICHIA-COLI; OVER-EXPRESSION; A-CRYSTALLIN; HSP25; STRESS	The ubiquitous small heat shock proteins (sHsps) are efficient molecular chaperones that interact with nonnative proteins, prevent their aggregation, and support subsequent refolding. No obvious substrate specificity has been detected so far. A striking feature of sHsps is that they form large complexes with nonnative proteins. Here, we used several well established model chaperone substrates, including citrate synthase, alpha-glucosidase, rhodanese, and insulin, and analyzed their interaction with murine Hsp25 and yeast Hsp26 upon thermal unfolding. The two sHsps differ in their modes of activation. In contrast to Hsp25, Hsp26 undergoes a temperature-dependent dissociation that is required for efficient substrate binding. Our analysis shows that Hsp25 and Hsp26 reacted in a similar manner with the nonnative proteins. For all substrates investigated, complexes of defined size and shape were formed. Interestingly, several different nonnative proteins could be incorporated into defined sHsp-substrate complexes. The first substrate protein bound seems to determine the complex morphology. Thus, despite the differences in quaternary structure and mode of activation, the formation of large uniform sHsp-substrate complexes seems to be a general feature of sHsps, and this unique chaperone mechanism is conserved from yeast to mammals.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany; Hannover Med Sch, Inst Biochem, D-30625 Hannover, Germany	Technical University of Munich; Hannover Medical School	Buchner, J (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Gaestel, Matthias/A-6560-2013; Buchner, Johannes/A-2651-2010	Gaestel, Matthias/0000-0002-4944-4652; Buchner, Johannes/0000-0003-1282-7737				Andreasi B F, 1995, BIOPHYS J, V69, P2720; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Bova MP, 2002, J BIOL CHEM, V277, P38468, DOI 10.1074/jbc.M205594200; Buchner J, 1998, METHOD ENZYMOL, V290, P339, DOI 10.1016/S0076-6879(98)90030-1; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1998, ANAL BIOCHEM, V259, P218, DOI 10.1006/abio.1998.2630; Ehrnsperger M, 2000, METH MOL B, V99, P421; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Ehrnsperger M., 1998, STRUCTURE FUNCTION S, P533; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; Giese KC, 2002, J BIOL CHEM, V277, P46310, DOI 10.1074/jbc.M208926200; Haley DA, 1998, J MOL BIOL, V277, P27, DOI 10.1006/jmbi.1997.1611; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck M, 2002, CELL MOL LIFE SCI, V59, P1649, DOI 10.1007/PL00012492; Haslbeck Martin, 2002, Prog Mol Subcell Biol, V28, P37; HOLLNEUGEBAUER B, 1991, BIOCHEMISTRY-US, V30, P11609; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JAENICKE R, 1993, CURR BIOL, V3, P234, DOI 10.1016/0960-9822(93)90342-L; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; KNAUF U, 1992, FEBS LETT, V309, P297, DOI 10.1016/0014-5793(92)80793-G; KOPETZKI E, 1989, YEAST, V5, P11, DOI 10.1002/yea.320050104; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; MENDOZA JA, 1992, J BIOL CHEM, V267, P17631; Nakamoto H, 2000, FEBS LETT, V483, P169, DOI 10.1016/S0014-5793(00)02097-4; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; SANGER F, 1949, BIOCHEM J, V45, P563, DOI 10.1042/bj0450563; SPECTOR A, 1971, BIOCHEM J, V124, P337, DOI 10.1042/bj1240337; Studer S, 2000, J BIOL CHEM, V275, P37212, DOI 10.1074/jbc.M004701200; Sun WN, 2002, BBA-GENE STRUCT EXPR, V1577, P1, DOI 10.1016/S0167-4781(02)00417-7; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; WANG KY, 1995, INVEST OPHTH VIS SCI, V36, P311	50	135	145	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18015	18021		10.1074/jbc.M301640200	http://dx.doi.org/10.1074/jbc.M301640200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637495	hybrid			2022-12-27	WOS:000182838300055
J	Bedogni, B; Pani, G; Colavitti, R; Riccio, A; Borrello, S; Murphy, M; Smith, R; Eboli, ML; Galeotti, T				Bedogni, B; Pani, G; Colavitti, R; Riccio, A; Borrello, S; Murphy, M; Smith, R; Eboli, ML; Galeotti, T			Redox regulation of cAMP-responsive element-binding protein and induction of manganous superoxide dismutase in nerve growth factor-dependent cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; CORTICAL-NEURONS; OXIDATIVE STRESS; OXYGEN RADICALS; APOPTOSIS; KINASE; SYSTEM; PHOSPHORYLATION	Reactive oxygen species (ROS) act as both signaling molecules and mediators of cell damage in the nervous system and are implicated in the pathogenesis of neurodegenerative diseases. Neurotrophic factors such as the nerve-derived growth factor (NGF) support neuronal survival during development and promote regeneration after neuronal injury through the activation of intracellular signals whose molecular effectors and downstream targets are still largely unknown. Here we present evidence that early oxidative signals initiated by NGF in PC12 cells, an NGF-responsive cell line, play a critical role in preventing apoptosis induced by serum deprivation. This redox-signaling cascade involves phosphatidylinositol 3-kinase, the small GTPase Rac-1, and the transcription factor cAMP-responsive element-binding protein ( CREB), a molecule essential to promote NGF-dependent survival. We found that ROS are necessary for NGF-dependent phosphorylation of CREB, an event directly correlated with CREB activity, whereas hydrogen peroxide induces a robust CREB phosphorylation. Cells exposed to NGF show a late decrease in the intracellular content of ROS when compared with untreated cells and increased expression of the mitochondrial antioxidant enzyme manganese superoxide dismutase, a general inhibitor of cell death. Accordingly, serum deprivatio-induced apoptosis was selectively inhibited by low concentrations of the mitochondrially targeted antioxidant Mito Q (mitoquinol/mitoquinone). Taken together, these data demonstrate that the oxidant-dependent activation of CREB is a component of NGF survival signaling in PC12 cells and outline an intriguing circuitry by which a cytosolic redox cascade promotes cell survival at least in part by increasing mitochondrial resistance to oxidative stress.	Univ Sacred Heart, Sch Med, Inst Gen Pathol, I-00168 Rome, Italy; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Otago, Dept Chem, Dunedin, New Zealand	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Johns Hopkins University; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Otago	Galeotti, T (corresponding author), Univ Sacred Heart, Sch Med, Inst Gen Pathol, Largo F Vito 1, I-00168 Rome, Italy.		Pani, Giovambattista/AAB-1446-2019; Murphy, Michael P/C-2120-2009	Murphy, Michael P/0000-0003-1115-9618; Pani, Giovambattista/0000-0001-7133-8728				Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Du KY, 2000, MOL CELL BIOL, V20, P4320, DOI 10.1128/MCB.20.12.4320-4327.2000; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P4086, DOI 10.1073/pnas.94.8.4086; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; JACKSON GR, 1994, DEV NEUROSCI-BASEL, V16, P285, DOI 10.1159/000112121; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kim HP, 1999, J BIOL CHEM, V274, P37455, DOI 10.1074/jbc.274.52.37455; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; Maehara K, 2001, FASEB J, V15, P2025, DOI 10.1096/fj.00-0909fje; Maher P, 2000, CELL MOL LIFE SCI, V57, P1287, DOI 10.1007/PL00000766; Mai L, 2002, J NEUROCHEM, V82, P75, DOI 10.1046/j.1471-4159.2002.00939.x; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Merad-Boudia M, 1998, BIOCHEM PHARMACOL, V56, P645, DOI 10.1016/S0006-2952(97)00647-3; Mills EM, 1998, J BIOL CHEM, V273, P22165, DOI 10.1074/jbc.273.35.22165; Moldovan L, 1999, ANTIOXID REDOX SIGN, V1, P29, DOI 10.1089/ars.1999.1.1-29; Ozdinler PH, 2001, J COMP NEUROL, V438, P377; Palazzotti B, 1999, INT J CANCER, V82, P145, DOI 10.1002/(SICI)1097-0215(19990702)82:1<145::AID-IJC24>3.3.CO;2-2; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; Pani G, 2000, BIOCHEM J, V347, P173, DOI 10.1042/0264-6021:3470173; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rhee S.G., 2000, SCI STKE; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Teixeira HD, 1998, P NATL ACAD SCI USA, V95, P7872, DOI 10.1073/pnas.95.14.7872; Warner BB, 1996, AM J PHYSIOL-LUNG C, V271, pL150, DOI 10.1152/ajplung.1996.271.1.L150; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	56	120	120	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16510	16519		10.1074/jbc.M301089200	http://dx.doi.org/10.1074/jbc.M301089200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609977	hybrid			2022-12-27	WOS:000182818600011
J	Collins, BM; Cubeddu, L; Naidoo, N; Harrop, SJ; Kornfeld, GD; Dawes, IW; Curmi, PMG; Mabbutt, BC				Collins, BM; Cubeddu, L; Naidoo, N; Harrop, SJ; Kornfeld, GD; Dawes, IW; Curmi, PMG; Mabbutt, BC			Homomeric ring assemblies of eukaryotic Sm proteins have affinity for both RNA and DNA - Crystal structure of an oligomeric complex of yeast SmF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNRNP CORE; ELECTRON-MICROSCOPY; FUNCTIONAL-ANALYSIS; U6 SNRNA; BINDING; DOMAIN; MODEL; HFQ; IDENTIFICATION; HETEROMER	Sm and Sm-like proteins are key components of small ribonucleoproteins involved in many RNA and DNA processing pathways. In eukaryotes, these complexes contain seven unique Sm or Sm-like (Lsm) proteins assembled as hetero-heptameric rings, whereas in Archaea and bacteria six or seven-membered rings are made from only a single polypeptide chain. Here we show that single Sm and Lsm proteins from yeast also have the capacity to assemble into homo-oligomeric rings. Formation of homo-oligomers by the spliceosomal small nuclear ribonucleoprotein components SmE and SmF preclude hetero-interactions vital to formation of functional small nuclear RNP complexes in vivo. To better understand these unusual complexes, we have determined the crystal structure of the homomeric assembly of the spliceosomal protein SmF. Like its archaeal/bacterial homologs, the SmF complex forms a homomeric ring but in an entirely novel arrangement whereby two heptameric rings form a co-axially stacked dimer via interactions mediated by the variable loops of the individual SmF protein chains. Furthermore, we demonstrate that the homomeric assemblies of yeast Sm and Lsm proteins are capable of binding not only to oligo(U) RNA but, in the case of SmF, also to oligo(dT) single-stranded DNA.	Macquarie Univ, Dept Chem, Sydney, NSW 2109, Australia; Univ Cambridge, Dept Clin Biochem, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; St Vincents Hosp, Ctr Immunol, Darlinghurst, NSW 2010, Australia; Univ New S Wales, Sch Phys, Sydney, NSW 2052, Australia	Macquarie University; University of Cambridge; University of New South Wales Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney	Mabbutt, BC (corresponding author), Macquarie Univ, Dept Chem, Sydney, NSW 2109, Australia.	bridget.mabbutt@mq.edu.au	Curmi, Paul/G-7185-2011; Collins, Brett/J-1563-2014	Curmi, Paul/0000-0001-5762-7638; Collins, Brett/0000-0002-6070-3774				Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; Achsel T, 2001, P NATL ACAD SCI USA, V98, P3685, DOI 10.1073/pnas.071033998; Anantharaman V, 2002, NUCLEIC ACIDS RES, V30, P1427, DOI 10.1093/nar/30.7.1427; BLUMENTHAL T, 1995, TRENDS GENET, V11, P132, DOI 10.1016/S0168-9525(00)89026-5; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burge CB, 1999, RNA WORLD, P525; Camasses A, 1998, MOL CELL BIOL, V18, P1956, DOI 10.1128/MCB.18.4.1956; CATHALA G, 1990, NUCLEIC ACIDS RES, V18, P201, DOI 10.1093/nar/18.1.201; Collins BM, 2001, J MOL BIOL, V309, P915, DOI 10.1006/jmbi.2001.4693; COOPER M, 1995, EMBO J, V14, P2066, DOI 10.1002/j.1460-2075.1995.tb07198.x; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; Fury MG, 1997, EXP CELL RES, V237, P63, DOI 10.1006/excr.1997.3750; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; KASTNER B, 1990, P NATL ACAD SCI USA, V87, P1710, DOI 10.1073/pnas.87.5.1710; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; LESLIE AGW, 1992, JOINT CCP PLUS ESF E, V26; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; MacKenzie AE, 2001, NAT STRUCT BIOL, V8, P13, DOI 10.1038/82983; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Moller T, 2002, MOL CELL, V9, P23, DOI 10.1016/S1097-2765(01)00436-1; Mura C, 2001, P NATL ACAD SCI USA, V98, P5532, DOI 10.1073/pnas.091102298; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neylon C, 2000, BIOCHEMISTRY-US, V39, P11989, DOI 10.1021/bi001174w; Palfi Z, 2000, P NATL ACAD SCI USA, V97, P8967, DOI 10.1073/pnas.150236097; Plessel G, 1997, J MOL BIOL, V265, P87, DOI 10.1006/jmbi.1996.0713; Raker VA, 1999, MOL CELL BIOL, V19, P6554; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schumacher MA, 2002, EMBO J, V21, P3546, DOI 10.1093/emboj/cdf322; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; Seto AG, 1999, NATURE, V401, P177, DOI 10.1038/43694; Stark H, 2001, NATURE, V409, P539, DOI 10.1038/35054102; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Thore S, 2003, J BIOL CHEM, V278, P1239, DOI 10.1074/jbc.M207685200; Toro I, 2002, J MOL BIOL, V320, P129, DOI 10.1016/S0022-2836(02)00406-0; Toro I, 2001, EMBO J, V20, P2293, DOI 10.1093/emboj/20.9.2293; Urlaub H, 2001, EMBO J, V20, P187, DOI 10.1093/emboj/20.1.187; Walke S, 2001, J MOL BIOL, V308, P49, DOI 10.1006/jmbi.2001.4549; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3	49	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17291	17298		10.1074/jbc.M211826200	http://dx.doi.org/10.1074/jbc.M211826200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618433	hybrid			2022-12-27	WOS:000182818600113
J	Ikeyama, S; Wang, XT; Li, J; Podlutsky, A; Martindale, JL; Kokkonen, G; van Huizen, R; Gorospe, M; Holbrook, NJ				Ikeyama, S; Wang, XT; Li, J; Podlutsky, A; Martindale, JL; Kokkonen, G; van Huizen, R; Gorospe, M; Holbrook, NJ			Expression of the pro-apoptotic gene gadd153/chop is elevated in liver with aging and sensitizes cells to oxidant injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EXTENDED LIFE-SPAN; OXIDATIVE STRESS; CAENORHABDITIS-ELEGANS; ENDOPLASMIC-RETICULUM; CALORIC RESTRICTION; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; CELLULAR-RESPONSE; GROWTH	Aging is generally accompanied by reduced tolerance to oxidative stress and altered responsiveness to proliferative signals. We have shown that hepatocytes derived from aged rats (24-26 months) exhibit greater sensitivity to H2O2 treatment and reduced proliferation following epidermal growth factor (EGF) treatment than cells of young adult rats (5-6 months). Here we examined the effects of aging and calorie restriction (CR) on expression of the oxidative stress-inducible and pro-apoptotic gene gadd153 (chop) in these hepatocytes, and we investigated its influence on sensitivity to oxidants. We show that aging was associated with elevated expression of gadd153, both basally and in response to H2O2 treatment. CR, which attenuates age-associated declines in stress tolerance, prevented the age-related increase in gadd153 expression. EGF treatment also resulted in gadd153 induction in old cells. This effect was absent in young cells and in old cells of CR rats. gadd153 induction by EGF was reactive oxygen species-dependent and correlated with heightened sensitivity to subsequent H2O2 treatment, suggesting that elevated Gadd153 contributes to the greater sensitivity of EGF-pretreated old cells to oxidative stress. Additional support for this hypothesis was provided by experiments with Rat1 fibroblasts in which conditional expression of Gadd153 conferred increased sensitivity to H2O2. We propose a model whereby the diminished ability of old hepatocytes to overcome an EGF-triggered reactive oxygen species load leads to induction of the proapoptotic gene gadd153, which, in turn, sensitizes the cells to oxidant injury. Our findings point to gadd153 expression levels as an important factor in liver aging.	Yale Univ, Sch Med, Sect Geriatr, New Haven, CT 06520 USA; NIA, Biol Cellulaire & Mol Lab, IRP, Baltimore, MD 21224 USA	Yale University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Holbrook, NJ (corresponding author), Yale Univ, Sch Med, Sect Geriatr, Dept Internal Med, POB 208025, New Haven, CT 06511 USA.	nikki-holbrook@yale.edu	Podlutsky, Andrej/F-5421-2015; Martindale, Jennifer Luethy/AAD-1963-2022	Martindale, Jennifer Luethy/0000-0002-3234-6861	NATIONAL INSTITUTE ON AGING [ZIAAG000511, P30AG021342, Z01AG000511] Funding Source: NIH RePORTER; NIA NIH HHS [T30AG21342] Funding Source: Medline; PHS HHS [T30-3489] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Anantharaju A, 2002, GERONTOLOGY, V48, P343, DOI 10.1159/000065506; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Chen CH, 1996, ONCOGENE, V13, P1659; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; GOOD RA, 1992, INT J IMMUNOPHARMACO, V14, P361, DOI 10.1016/0192-0561(92)90165-H; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hall DM, 2000, FASEB J, V14, P78, DOI 10.1096/fasebj.14.1.78; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Holbrook NJ, 2002, BIOCHEM PHARMACOL, V64, P999, DOI 10.1016/S0006-2952(02)01169-3; HORNSBY PJ, 2001, HDB BIOL AGING, P207; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; IKEYAMA S, 2003, IN PRESS EXP GERONTO; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; LIU Y, 2002, HDB BIOL AGING, P179; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; MASORO EJ, 2001, HDB BIOL AGING, P396; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Murakami S, 1996, GENETICS, V143, P1207; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; PARNHAM MJ, 1984, BIOCHEM PHARMACOL, V33, P3247, DOI 10.1016/0006-2952(84)90085-6; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SOBAL RS, 2002, FREE RADIC BIOL MED, V33, P37; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; WANG JF, 1992, HEPATOLOGY, V15, P1112, DOI 10.1002/hep.1840150623; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Zanella CL, 1996, CANCER RES, V56, P5334; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	50	65	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16726	16731		10.1074/jbc.M300677200	http://dx.doi.org/10.1074/jbc.M300677200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609979	hybrid			2022-12-27	WOS:000182818600038
J	Moore, ML; Park, EA; McMillin, JB				Moore, ML; Park, EA; McMillin, JB			Upstream stimulatory factor represses the induction of carnitine palmitoyltransferase-I beta expression by PGC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; TRANSCRIPTIONAL COACTIVATOR PGC-1; MITOCHONDRIAL CREATINE-KINASE; NEONATAL CARDIAC MYOCYTES; PPAR-GAMMA COACTIVATOR-1; HEAVY-CHAIN GENE; E-BOX; SKELETAL-MUSCLE; TRANSGENIC MICE; FACTOR USF	Transcriptional regulation of carnitine palmitoyltransferase-1beta (CPT-1beta) is coordinated with contractile gene expression through cardiac-enriched transcription factors, GATA4 and SRF. Metabolic modulation of CPT-1beta promoter activity has been described with the stimulation of gene expression by oleate that is mediated through the peroxisome proliferator-activated receptor (PPAR) pathway. The coactivator, peroxisomal proliferator-activated receptor gamma coactivator (PGC-1), enhances gene expression through interactions with nuclear hormone receptors and the myocyte enhancer factor 2 (MEF2) family. PGC-1 and MEF2A synergistically activate CPT-1beta promoter activity. This stimulation is enhanced by mutation of the E-box sequences that flank the MEF2A binding site. These elements bind the upstream stimulatory factors (USF1 and USF2), which activate transcription in CV-1 fibroblasts. However, overexpression of the USF proteins in myocytes depresses CPT-1beta activity and significantly reduces MEF2A and PGC-1 synergy. Co-immunoprecipitation studies demonstrate that PGC-1 and USF2 proteins can physically interact. Our studies demonstrate that PGC-1 stimulates CPT-1beta gene expression through MEF2A. USF proteins have a novel role in repressing the expression of the CPT-1beta gene and modulating the induction by the coactivator, PGC-1.	Univ Texas, Sch Med, Dept Pathol & Lab Med, Hlth Sci Ctr, Houston, TX 77030 USA; Texas Med Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA; Univ Tennessee, Dept Pharmacol, Memphis, TN 38163 USA	University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Texas System; University of Texas Health Science Center Houston; University of Tennessee System; University of Tennessee Health Science Center	McMillin, JB (corresponding author), Univ Texas, Sch Med, Dept Pathol & Lab Med, Hlth Sci Ctr, 6431 Fannin, Houston, TX 77030 USA.				NHLBI NIH HHS [R01 HL38863] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038863] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Christensen TH, 1999, GENE EXPRESSION, V8, P247; Cook GA, 2001, J MOL CELL CARDIOL, V33, P317, DOI 10.1006/jmcc.2000.1304; GOPALSRIVASTAVA R, 1995, MOL CELL BIOL, V15, P7081; Han SY, 2001, FEBS LETT, V505, P57, DOI 10.1016/S0014-5793(01)02777-6; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; Lehman JJ, 2002, CLIN EXP PHARMACOL P, V29, P339, DOI 10.1046/j.1440-1681.2002.03655.x; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lenka N, 1998, PROG NUCLEIC ACID RE, V61, P309, DOI 10.1016/S0079-6603(08)60830-2; Luo X, 1996, MOL CELL BIOL, V16, P1367; Mably JD, 1996, CIRC RES, V79, P4, DOI 10.1161/01.RES.79.1.4; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MCMILLIN JB, 1993, METHODS TOXICOL, V2, P301; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; MOSS JB, 1994, J BIOL CHEM, V269, P12731; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; Nicholas SB, 1999, AM J PHYSIOL-HEART C, V277, pH324, DOI 10.1152/ajpheart.1999.277.1.H324; Oberkofler H, 2002, J BIOL CHEM, V277, P16750, DOI 10.1074/jbc.M200475200; Ojamaa K, 1995, J BIOL CHEM, V270, P31276, DOI 10.1074/jbc.270.52.31276; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Qin WN, 1999, HISTOCHEM J, V31, P357, DOI 10.1023/A:1003748108062; Qin WN, 1997, J BIOL CHEM, V272, P25210, DOI 10.1074/jbc.272.40.25210; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Shield MA, 1996, MOL CELL BIOL, V16, P5058; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; van der Lee KAJM, 2000, J LIPID RES, V41, P41; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang DC, 1998, GENOMICS, V48, P314, DOI 10.1006/geno.1997.5184; Wang GL, 2002, BIOCHEM J, V362, P609, DOI 10.1042/0264-6021:3620609; Wu PF, 1999, DIABETES, V48, P1593, DOI 10.2337/diabetes.48.8.1593; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xia Y, 1996, J BIOL CHEM, V271, P12082, DOI 10.1074/jbc.271.20.12082; Xiao QX, 2002, AM J PHYSIOL-HEART C, V283, pH213, DOI 10.1152/ajpheart.01085.2001; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; YUTZEY KE, 1992, NUCLEIC ACIDS RES, V20, P5105, DOI 10.1093/nar/20.19.5105	48	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17263	17268		10.1074/jbc.M210486200	http://dx.doi.org/10.1074/jbc.M210486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611894	hybrid			2022-12-27	WOS:000182818600109
J	Uchida, K; Miyauchi, H; Furuichi, T; Michikawa, T; Mikoshiba, K				Uchida, K; Miyauchi, H; Furuichi, T; Michikawa, T; Mikoshiba, K			Critical regions for activation gating of the inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITE; CALCIUM-RELEASE; TRISPHOSPHATE RECEPTORS; CONFORMATIONAL-CHANGES; SIGNAL-TRANSDUCTION; COMPLEX-FORMATION; MOUSE CEREBELLUM; INSP3 RECEPTOR; PURKINJE-CELL; CHANNEL	To understand the molecular mechanism of ligand-induced gating of the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R)/Ca2+ release channel, we analyzed the channel properties of deletion mutants retaining both the IP3-binding and channel-forming domains of IP(3)R1. Using intrinsically IP3R-deficient cells as the host cells for receptor expression, we determined that six of the mutants, those lacking residues 1-223, 651-1130, 1267-2110, 1845-2042, 1845-2216, and 2610-2748, did not exhibit any measurable Ca2+ release activity, whereas the mutants lacking residues 1131-1379 and 2736-2749 retained the activity. Limited trypsin digestion showed that not only the IP3-gated Ca2+-permeable mutants lacking residues 1131-1379 and 2736-2749, but also two nonfunctional mutants lacking residues 1-223 and 651-1130, retained the normal folding structure of at least the C-terminal channel-forming domain. These results indicate that two regions of IP(3)R1, viz. residues 1-223 and 651-1130, are critical for IP3-induced gating. We also identified a highly conserved cysteine residue at position 2613, which is located within the C-terminal tail, as being essential for channel opening. Based on these results, we propose a novel five-domain structure model in which both N-terminal and internal coupling domains transduce ligand-binding signals to the C-terminal tail, which acts as a gatekeeper that triggers opening of the activation gate of IP(3)R1 following IP3 binding.	Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan; Keio Univ, Sch Med, Dept Pediat, Shinjuku Ku, Tokyo 1608582, Japan; Japanese Red Cross Med Ctr, Dept Neurosurg, Shibuya Ku, Tokyo 1508935, Japan; Univ Tokyo, Dept Neurosurg, Bunkyo Ku, Tokyo 1138655, Japan; RIKEN, Brain Sci Inst, Lab Mol Neurogenesis, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, Int Cooperat Res Project, Calcium Oscillat Project, Minato Ku, Tokyo 1080071, Japan	University of Tokyo; Keio University; Japanese Red Cross Medical Center; University of Tokyo; RIKEN; RIKEN; Japan Science & Technology Agency (JST)	Mikoshiba, K (corresponding author), Univ Tokyo, Inst Med Sci, Dept Basic Med Sci, Div Mol Neurobiol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Furuichi, Teiichi/B-5086-2014; Mikoshiba, Katsuhiko/N-7943-2015	Furuichi, Teiichi/0000-0002-9676-1888; 				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Boehning D, 2001, BIOPHYS J, V81, P117, DOI 10.1016/S0006-3495(01)75685-8; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; Bosanac I, 2002, NATURE, V420, P696, DOI 10.1038/nature01268; Broillet MC, 2000, J BIOL CHEM, V275, P15135, DOI 10.1074/jbc.275.20.15135; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DeSmedt H, 1997, BIOCHEM J, V322, P575; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Gordon SE, 1997, NEURON, V19, P431, DOI 10.1016/S0896-6273(00)80951-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; Hamada K, 2002, J BIOL CHEM, V277, P21115, DOI 10.1074/jbc.C200244200; HIROTA J, 1995, J BIOL CHEM, V270, P19046, DOI 10.1074/jbc.270.32.19046; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MAEDA N, 1988, J NEUROCHEM, V51, P1724, DOI 10.1111/j.1471-4159.1988.tb01151.x; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MIYAWAKI A, 1990, NEURON, V5, P11, DOI 10.1016/0896-6273(90)90029-F; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKADE S, 1991, BIOCHEM J, V277, P125, DOI 10.1042/bj2770125; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NUCIFORA FC, 1995, MOL BRAIN RES, V32, P291, DOI 10.1016/0169-328X(95)00089-B; PRICE NC, 1989, PROTEOLYTIC ENZYMES, P163; Rosenbaum T, 2002, NEURON, V33, P703, DOI 10.1016/S0896-6273(02)00599-8; Sayers LG, 1997, BIOCHEM J, V323, P273, DOI 10.1042/bj3230273; Schulte U, 1998, J BIOL CHEM, V273, P34575, DOI 10.1074/jbc.273.51.34575; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Sienaert I, 2002, BIOCHEM J, V365, P269, DOI 10.1042/BJ20020144; Sienaert I, 1997, J BIOL CHEM, V272, P25899, DOI 10.1074/jbc.272.41.25899; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591; Yoshikawa F, 1999, J BIOL CHEM, V274, P328, DOI 10.1074/jbc.274.1.328; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498; Zhang SB, 2003, J BIOL CHEM, V278, P4048, DOI 10.1074/jbc.M209960200	59	114	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16551	16560		10.1074/jbc.M300646200	http://dx.doi.org/10.1074/jbc.M300646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621039	Green Submitted, hybrid			2022-12-27	WOS:000182818600016
J	Williams, ME; Strickland, P; Watanabe, K; Hinck, L				Williams, ME; Strickland, P; Watanabe, K; Hinck, L			UNC5H1 induces apoptosis via its juxtamembrane region through an interaction with NRAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P75 NEUROTROPHIN RECEPTOR; CELL-CYCLE PROGRESSION; DEATH DOMAIN; C-ELEGANS; NETRIN RECEPTOR; TNF RECEPTOR; PROTEIN; GROWTH; UNC-5; DCC	The UNC5Hs are axon guidance receptors that mediate netrin-1-dependent chemorepulsion, and dependence receptors that mediate netrin-1-independent apoptosis. Here, we report an interaction between UNC5H1 and NRAGE. Our experiments show that this interaction is responsible for apoptosis induced by UNC5H1, and this level of apoptosis is greater than the amount induced by either UNC5H2 or UNC5H3. We mapped the NRAGE binding domain of UNC5H1 to its ZU-5 domain and show that this region, in addition to an adjacent PEST sequence, is required for UNC5H1-mediated apoptosis. Chimeric UNC5H2 and UNC5H3 receptors, containing the NRAGE binding domain and PEST sequence of UNC5H1, bind NRAGE and cause increased levels of apoptosis. UNC5H1 expression does not induce apoptosis in differentiated PC12 cells, which down-regulate NRAGE, but induces apoptosis in native PC12 cells that endogenously express high levels of NRAGE and in differentiated PC12 cells when NRAGE is overexpressed. Together, these results demonstrate a mechanism for UNC5H1-mediated apoptosis that requires an interaction with the MAGE protein NRAGE.	Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan	University of California System; University of California Santa Cruz	Hinck, L (corresponding author), Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA.		Watanabe, Ken/I-3960-2013	Watanabe, Ken/0000-0003-0664-3915; Williams, Megan/0000-0002-5461-4126; Hinck, Lindsay/0000-0002-4009-3913	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039572] Funding Source: NIH RePORTER; NIMH NIH HHS [MH12813-02] Funding Source: Medline; NINDS NIH HHS [NS39572-01, R01 NS039572] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barker PA, 2002, J NEUROSCI RES, V67, P705, DOI 10.1002/jnr.10160; Barrett C, 2001, MECH DEVELOP, V106, P163, DOI 10.1016/S0925-4773(01)00415-4; Coulson EJ, 2000, J BIOL CHEM, V275, P30537, DOI 10.1074/jbc.M005214200; Coulson EJ, 1999, J BIOL CHEM, V274, P16387, DOI 10.1074/jbc.274.23.16387; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Finger JH, 2002, J NEUROSCI, V22, P10346; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HAYASHI Y, 1995, BIOCHEM BIOPH RES CO, V213, P317, DOI 10.1006/bbrc.1995.2132; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Jordan BWM, 2001, J BIOL CHEM, V276, P39985, DOI 10.1074/jbc.C100171200; Keleman K, 2001, NEURON, V32, P605, DOI 10.1016/S0896-6273(01)00505-0; Kendall SE, 2002, MECH DEVELOP, V117, P187, DOI 10.1016/S0925-4773(02)00204-6; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Masuda Y, 2001, J BIOL CHEM, V276, P5331, DOI 10.1074/jbc.M008590200; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Nijhawan D, 2000, ANNU REV NEUROSCI, V23, P73, DOI 10.1146/annurev.neuro.23.1.73; Przyborski SA, 1998, DEVELOPMENT, V125, P41; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Salehi AH, 2002, J BIOL CHEM, V277, P48043, DOI 10.1074/jbc.M205324200; Sasaki A, 2002, J BIOL CHEM, V277, P22541, DOI 10.1074/jbc.M109728200; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shiras Anjali, 2001, Molecular Cell Biology Research Communications, V4, P313, DOI 10.1006/mcbr.2001.0298; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	35	88	97	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17483	17490		10.1074/jbc.M300415200	http://dx.doi.org/10.1074/jbc.M300415200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12598531	hybrid			2022-12-27	WOS:000182818600136
J	Chen, L; Esteve, E; Sabatier, JM; Ronjat, M; De Waard, M; Allen, PD; Pessah, IN				Chen, L; Esteve, E; Sabatier, JM; Ronjat, M; De Waard, M; Allen, PD; Pessah, IN			Maurocalcine and peptide A stabilize distinct subconductance states of ryanodine receptor type 1, revealing a proportional gating mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-III-LOOP; CALCIUM-RELEASE CHANNEL; MUSCLE DIHYDROPYRIDINE RECEPTOR; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; IMPERATOXIN-A; CA2+ RELEASE; CARDIAC-MUSCLE; CONTRACTION; ACTIVATION	Maurocalcine (MCa) isolated from Scorpio maurus palmatus venom shares 82% sequence identity with imperatoxin A. Both scorpion toxins are putative mimics of the II-III loop peptide (termed peptide A (pA)) of alpha(1s)-dihydropyridine receptor and are thought to act at a common site on ryanodine receptor type 1 (RyR1) important for skeletal muscle EC coupling. The relationship between the actions of synthetic MCa (sMCa) and pA on RyR1 were examined. sMCa released Ca2+ from SR vesicles (EC50 = 17.5 nm) in a manner inhibited by micromolar ryanodine or ruthenium red. pA (0.5-40 mum) failed to induce SR Ca2+ release. Rather, pA enhanced Ca2+ loading into SR and fully inhibited Ca2+-, caffeine-, and sMCa-induced Ca2+ release. The two peptides modified single channel gating behavior in distinct ways. With Cs+-carrying current, 10 nm to 1 mum sMCa induced long lived subconductances having 48% of the characteristic full open state and occasional transitions to 29% at either positive or negative holding potentials. In contrast, pA stabilized long lived channel closures with occasional burst transitions to 65% (s1) and 86% (s2) of the full conductance. The actions of pA and sMCa were observed in tandem. sMCa stabilized additional subconductance states proportional to pA-induced subconductances (i.e. 43% of pA-modified s1 and s2 substates), revealing a proportional gating mechanism. [H-3]Ryanodine binding and surface plasmon resonance analyses indicated that the peptides did not interact by simple competition for a single class of mutually exclusive sites on RyR1 to produce proportional gating. The actions of sMCa were also observed with ryanodine-modified channels and channels deficient in immunophilin 12-kDa FK506-binding protein. These results provide evidence that sMCa and pA stabilize distinct RyR1 channel states through distinct mechanisms that allosterically stabilize gating states having proportional conductance.	Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Grad Program Neurosci, Davis, CA 95616 USA; UJF, CEA, INSERM, EMI 9931,Lab Canaux Ion & Signalisat, F-38054 Grenoble, France; Fac Med Nord, CNRS, UMR 6560, F-13916 Marseille 20, France; Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02115 USA	University of California System; University of California Davis; University of California System; University of California Davis; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Harvard University; Brigham & Women's Hospital	Pessah, IN (corresponding author), Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA.		ESTEVE, Eric/M-7490-2014; Pessah, Isaac N/K-7985-2017; De Waard, Michel/G-7406-2014	Pessah, Isaac N/0000-0002-8149-588X; De Waard, Michel/0000-0002-2782-9615; ESTEVE, Eric/0000-0002-4548-9140; SABATIER, Jean-Marc/0000-0002-9040-5647; Ronjat, Michel/0000-0002-9728-6425	NIAMS NIH HHS [2P01 AR 17605] Funding Source: Medline; NIEHS NIH HHS [1P01 ES 11269] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011269] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEELER GW, 1970, J PHYSIOL-LONDON, V207, P211, DOI 10.1113/jphysiol.1970.sp009057; BUCK E, 1992, J BIOL CHEM, V267, P23560; Chen L, 1999, J BIOL CHEM, V274, P32603, DOI 10.1074/jbc.274.46.32603; Dulhunty AF, 1999, BIOPHYS J, V77, P189, DOI 10.1016/S0006-3495(99)76881-5; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; ELHAYEK R, 1995, J BIOL CHEM, V270, P22116, DOI 10.1074/jbc.270.38.22116; Fajloun Z, 2000, FEBS LETT, V469, P179, DOI 10.1016/S0014-5793(00)01239-4; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; HORACKOVA M, 1976, J PHYSIOL-LONDON, V259, P597, DOI 10.1113/jphysiol.1976.sp011485; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU XY, 1994, J BIOL CHEM, V269, P6511; MACK MM, 1992, J PHARMACOL EXP THER, V262, P1028; Mead F, 2002, BIOPHYS J, V82, P1953, DOI 10.1016/S0006-3495(02)75544-6; MELZER W, 1995, BBA-REV BIOMEMBRANES, V1241, P59, DOI 10.1016/0304-4157(94)00014-5; MOSBAH A, 1998, 6 REC TAX AUG 1 4 19; NABAUER M, 1989, AM J PHYSIOL, V256, pH916, DOI 10.1152/ajpheart.1989.256.3.H916; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; Nabhani T, 2002, BIOPHYS J, V82, P1319, DOI 10.1016/S0006-3495(02)75487-8; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P24983, DOI 10.1074/jbc.273.39.24983; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; PALADE P, 1987, J BIOL CHEM, V262, P6142; Pessah IN, 1997, AM J PHYSIOL-CELL PH, V272, pC601, DOI 10.1152/ajpcell.1997.272.2.C601; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1986, J BIOL CHEM, V261, P8643; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; Proenza C, 2000, J BIOL CHEM, V275, P29935, DOI 10.1074/jbc.C000464200; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; RIOS E, 1991, J MUSCLE RES CELL M, V12, P127, DOI 10.1007/BF01774031; ROUSSEAU E, 1987, AM J PHYSIOL, V253, P364; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; Samso M, 1999, J CELL BIOL, V146, P493, DOI 10.1083/jcb.146.2.493; SCHNEIDER MF, 1994, ANNU REV PHYSIOL, V56, P463, DOI 10.1146/annurev.ph.56.030194.002335; Serysheva II, 1999, BIOPHYS J, V77, P1936, DOI 10.1016/S0006-3495(99)77035-9; Shtifman A, 2000, BIOPHYS J, V79, P814, DOI 10.1016/S0006-3495(00)76338-7; Stange M, 2001, BIOPHYS J, V81, P1419, DOI 10.1016/S0006-3495(01)75797-9; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; Tripathy A, 1998, J GEN PHYSIOL, V111, P679, DOI 10.1085/jgp.111.5.679; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; Wilkens CM, 2001, P NATL ACAD SCI USA, V98, P5892, DOI 10.1073/pnas.101618098	47	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16095	16106		10.1074/jbc.M209501200	http://dx.doi.org/10.1074/jbc.M209501200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12586831	hybrid			2022-12-27	WOS:000182680000082
J	Jourd'heuil, D; Jourd'heuil, FL; Feelisch, M				Jourd'heuil, D; Jourd'heuil, FL; Feelisch, M			Oxidation and nitrosation of thiols at low micromolar exposure to nitric oxide - Evidence for a free radical mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROGLUTATHIONE; SERUM-ALBUMIN; PEROXYNITRITE; KINETICS; NO; GLUTATHIONE; FATE; NITROSOTHIOLS; NITROSYLATION	Although the nitric oxide ((NO)-N-.)-mediated nitrosation of thiol-containing molecules is increasingly recognized as an important post-translational modification in cell signaling and pathology, little is known about the factors that govern this process in vivo. In the present study, we examined the chemical pathways of nitrosothiol (RSNO) production at low micromolar concentrations of (NO)-N-.. Our results indicate that, in addition to nitrosation by the (NO)-N-. derivative dinitrogen trioxide (N2O3), RSNOs may be formed via intermediate one-electron oxidation of thiols, possibly mediated by nitrogen dioxide ((NO2)-N-.), and the subsequent reaction of thiyl radicals with (NO)-N-.. In vitro, the formation of S-nitrosoglutathione (GSNO) from (NO)-N-. and excess glutathione (GSH) was accompanied by the formation of glutathione disulfide, which could not be ascribed to the secondary reaction of GSH with GSNO. Superoxide dismutase significantly increased GSNO yields and the thiyl radical trap, 5,5-dimethyl-1-pyrroline N-oxide (DMPO), inhibited by 45 and 98% the formation of GSNO and GSSG, respectively. Maximum nitrosation yields were obtained at an oxygen concentration of 3%, whereas higher oxygen tensions decreased GSNO and increased GSSG formation. When murine fibroblasts were exposed to exogenous WO, RSNO formation was sensitive to DMPO and oxygen tension in a manner similar to that observed with GSH alone. Our data indicate that RSNO formation is favored at oxygen concentrations that typically occur in tissues. Nitrosothiol formation in vivo depends not only on the availability of (NO)-N-. and O-2 but also on the degree of oxidative stress by affecting the steady-state concentration of thiyl radicals.	Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA	Albany Medical College; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Jourd'heuil, D (corresponding author), Albany Med Coll, Ctr Cardiovasc Sci, 47 New Scotland Ave MC8, Albany, NY 12208 USA.	jourdhd@mail.ame.edu	Feelisch, Martin/C-3042-2008	Feelisch, Martin/0000-0003-2320-1158; Jourd'heuil, David/0000-0002-6555-5061	NCI NIH HHS [CA 89366] Funding Source: Medline; NHLBI NIH HHS [HL 69029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089366] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Archer Stephen L., 1995, Methods (Orlando), V7, P21, DOI 10.1006/meth.1995.1004; Balazy M, 1998, J BIOL CHEM, V273, P32009, DOI 10.1074/jbc.273.48.32009; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; Espey MG, 2001, J BIOL CHEM, V276, P30085, DOI 10.1074/jbc.M101723200; Espey MG, 2002, ANN NY ACAD SCI, V962, P195, DOI 10.1111/j.1749-6632.2002.tb04068.x; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006; Ford E, 2002, FREE RADICAL BIO MED, V32, P1314, DOI 10.1016/S0891-5849(02)00850-X; Goldstein S, 1996, J AM CHEM SOC, V118, P3419, DOI 10.1021/ja9536680; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; HUIE RE, 1994, TOXICOLOGY, V89, P193, DOI 10.1016/0300-483X(94)90098-1; JONES DP, 1986, AM J PHYSIOL, V250, pC663, DOI 10.1152/ajpcell.1986.250.5.C663; Keshive M, 1996, CHEM RES TOXICOL, V9, P988, DOI 10.1021/tx960036y; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Mannick JB, 2002, ARCH BIOCHEM BIOPHYS, V408, P1, DOI 10.1016/S0003-9861(02)00490-3; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MORO MA, 1994, P NATL ACAD SCI USA, V91, P6702, DOI 10.1073/pnas.91.14.6702; Pou S, 1998, J CHEM SOC PERK T 2, P1507, DOI 10.1039/a707662b; Rafikova O, 2002, P NATL ACAD SCI USA, V99, P5913, DOI 10.1073/pnas.092048999; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stubauer G, 1999, J BIOL CHEM, V274, P28128, DOI 10.1074/jbc.274.40.28128; Tsikas D, 2001, J CHROMATOGR A, V915, P107, DOI 10.1016/S0021-9673(01)00634-3; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; WARDMAN P, 1995, METHOD ENZYMOL, V251, P31, DOI 10.1016/0076-6879(95)51108-3; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003	28	158	161	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15720	15726		10.1074/jbc.M300203200	http://dx.doi.org/10.1074/jbc.M300203200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595536	hybrid			2022-12-27	WOS:000182680000034
J	Litvin, TN; Kamenetsky, M; Zarifyan, A; Buck, J; Levin, LR				Litvin, TN; Kamenetsky, M; Zarifyan, A; Buck, J; Levin, LR			Kinetic properties of "soluble" adenylyl cyclase - Synergism between calcium and bicarbonate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; ACROSOME REACTION; DIVALENT-CATIONS; SPERM; CALMODULIN; SPERMATOZOA; MOTILITY; PHOSPHORYLATION; PURIFICATION; CAPACITATION	"Soluble" adenylyl cyclase (sAC) is a widely expressed source of cAMP in mammalian cells that is evolutionarily, structurally, and biochemically distinct from the G protein-responsive transmembrane adenylyl cyclases. In contrast to transmembrane adenylyl cyclases, sAC is insensitive to heterotrimeric G protein regulation and forskolin stimulation and is uniquely modulated by bicarbonate ions. Here we present the first report detailing kinetic analysis and biochemical properties of purified recombinant sAC. We confirm that bicarbonate regulation is conserved among mammalian sAC orthologs and demonstrate that bicarbonate stimulation is consistent with an increase in the V-max of the enzyme with little effect on the apparent K-m for substrate, ATP-Mg2+. Bicarbonate can further increase sAC activity by relieving substrate inhibition. We also identify calcium as a direct modulator of sAC activity. In contrast to bicarbonate, calcium stimulates sAC activity by decreasing its apparent K-m for ATP-Mg2+. Because of their different mechanisms, calcium and bicarbonate synergistically activate sAC therefore, small changes of either calcium or bicarbonate will lead to significant changes in cellular cAMP levels.	Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA	Cornell University	Buck, J (corresponding author), Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA.	jobuck@med.cornell.edu		Levin, Lonny/0000-0002-5204-6356	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062328] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 42060, HD 38722] Funding Source: Medline; NIDA NIH HHS [DA 07274] Funding Source: Medline; NIGMS NIH HHS [GM 62328] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAUN T, 1975, J CYCLIC NUCL PROT, V1, P271; BRAUN T, 1991, METHOD ENZYMOL, V195, P130; BRAUN T, 1975, P NATL ACAD SCI USA, V72, P1097, DOI 10.1073/pnas.72.3.1097; Breitbart H, 2002, MOL CELL ENDOCRINOL, V187, P139, DOI 10.1016/S0303-7207(01)00704-3; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Buck J, 2002, METHOD ENZYMOL, V345, P95; CALI JJ, 1994, J BIOL CHEM, V269, P12190; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; Cooper Dermot M.F., 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P23; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; GARBERS DL, 1982, J BIOL CHEM, V257, P8980; GORDELADZE JO, 1981, J CLIN ENDOCR METAB, V53, P465, DOI 10.1210/jcem-53-3-465; Hurley JH, 1999, J BIOL CHEM, V274, P7599, DOI 10.1074/jbc.274.12.7599; HYNE RV, 1979, BIOL REPROD, V21, P1135, DOI 10.1095/biolreprod21.5.1135; Kulanand J, 2001, ANDROLOGIA, V33, P95, DOI 10.1046/j.1439-0272.2001.00410.x; LEE MA, 1986, BIOL REPROD, V34, P349, DOI 10.1095/biolreprod34.2.349; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; LEVINE N, 1971, J PHYSIOL-LONDON, V213, P557, DOI 10.1113/jphysiol.1971.sp009400; MAGNUS O, 1990, ARCH ANDROLOGY, V24, P159, DOI 10.3109/01485019008986875; OKAMURA N, 1985, J BIOL CHEM, V260, P9699; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; RODRIGUEZMARTINEZ H, 1990, INT J ANDROL, V13, P238, DOI 10.1111/j.1365-2605.1990.tb00982.x; ROJAS FJ, 1993, ENDOCRINOLOGY, V133, P3030, DOI 10.1210/en.133.6.3030; Sinclair ML, 2000, MOL REPROD DEV, V56, P6, DOI 10.1002/(SICI)1098-2795(200005)56:1&lt;6::AID-MRD2&gt;3.0.CO;2-M; STENGEL D, 1984, ANN NY ACAD SCI, V438, P18, DOI 10.1111/j.1749-6632.1984.tb38272.x; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Visconti PE, 2002, J REPROD IMMUNOL, V53, P133, DOI 10.1016/S0165-0378(01)00103-6; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Wuttke M S, 2001, JOP, V2, P154; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650; Zippin JH, 2002, FASEB J, V16, P82, DOI 10.1096/fj.02-0598fje; Zippin JH, 2001, TRENDS ENDOCRIN MET, V12, P366, DOI 10.1016/S1043-2760(01)00454-4	39	261	272	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15922	15926		10.1074/jbc.M212475200	http://dx.doi.org/10.1074/jbc.M212475200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12609998	hybrid			2022-12-27	WOS:000182680000060
J	Wojnar, P; Lechner, M; Redl, B				Wojnar, P; Lechner, M; Redl, B			Antisense down-regulation of lipocalin-interacting membrane receptor expression inhibits cellular internalization of lipocalin-1 in human NT2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING-PROTEIN; HUMAN TEAR LIPOCALIN; GENE FAMILY; LIPOPROTEIN; MEGALIN; CLONING; MOUSE; IDENTIFICATION; SUPERFAMILY; SCAVENGER	There is increasing experimental evidence demonstrating that many lipocalins bind to specific cell surface receptors. However, whereas the binding of lipocalins to their lipophilic ligands has now been characterized in much detail, there is a lack of knowledge about the nature of lipocalin receptors, the physiological role of receptor binding, and the molecular mechanism of ligand delivery. We previously identified a novel human membrane protein (lipocalin-l-interacting membrane receptor (LIMR)),which interacts with lipocalin-1 (Wojnar, P., Lechner, M., Merschak, P., and Redl, B. (2001) J. Biol. Chem. 276, 20206-20212). In the present study, we investigated the physiological role of LIMR and found this protein to be essential for mediating internalization of lipocalin-1 (Lcn-1) in NT2 cells, leading to its degradation. Whereas control NT2 cells rapidly internalized (125)I-Lcn-1 or fluorescein isothiocyanate-labeled Lcn-1, NT2 cells that were made LIMR deficient by cDNA antisense expression greatly accumulated Lcn-1 in the culture medium but did not internalize it. Because sequence and structure analysis indicated that proteins similar to LIMR are present in several organisms and at least two closely related orthologues are found in human and mouse, we suggest LIMR to be the prototype of a new family of endocytic receptors, which are topographically characterized by nine putative transmembrane domains and a characteristic large central cytoplasmic loop.	Univ Innsbruck, Dept Biol Mol, A-6020 Innsbruck, Austria	University of Innsbruck	Redl, B (corresponding author), Univ Innsbruck, Dept Biol Mol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	bernhard.redl@uibk.ac.at						Akerstrom B, 2000, BBA-PROTEIN STRUCT M, V1482, P1, DOI 10.1016/S0167-4838(00)00137-0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andersen UO, 1996, J MOL RECOGNIT, V9, P364, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<364::AID-JMR266>3.0.CO;2-6; BAVIK CO, 1991, J BIOL CHEM, V266, P14978; BISHOP RE, 1995, J BIOL CHEM, V270, P23097, DOI 10.1074/jbc.270.39.23097; Boudjelal M, 1996, BIOCHEM J, V317, P23, DOI 10.1042/bj3170023; Bratt T, 2000, BBA-PROTEIN STRUCT M, V1482, P318, DOI 10.1016/S0167-4838(00)00154-0; Bugos RC, 1998, J BIOL CHEM, V273, P15321, DOI 10.1074/jbc.273.25.15321; Cavaggioni A, 2000, BBA-PROTEIN STRUCT M, V1482, P218, DOI 10.1016/S0167-4838(00)00149-7; CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; CHEN CC, 1977, J BIOL CHEM, V252, P5216; Christensen EI, 1999, J AM SOC NEPHROL, V10, P685; Clark RM, 2000, GENOMICS, V67, P19, DOI 10.1006/geno.2000.6225; Clark RM, 2001, GENETICS, V159, P715; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; FERNANDEZLUNA JL, 1988, FEBS LETT, V236, P471, DOI 10.1016/0014-5793(88)80079-6; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P327, DOI 10.1016/S0167-4838(00)00169-2; Flower DR, 1996, BIOCHEM J, V318, P1; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; GLASGOW BJ, 1995, CURR EYE RES, V14, P363, DOI 10.3109/02713689508999934; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Kang Y, 1997, BBA-BIOMEMBRANES, V1324, P285, DOI 10.1016/S0005-2736(96)00235-0; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lacazette E, 2000, HUM MOL GENET, V9, P289, DOI 10.1093/hmg/9.2.289; Lechner M, 2001, BIOCHEM J, V356, P129, DOI 10.1042/0264-6021:3560129; Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002-9440(10)65238-8; Lettice LA, 2002, P NATL ACAD SCI USA, V99, P7548, DOI 10.1073/pnas.112212199; Logdberg L, 2000, BBA-PROTEIN STRUCT M, V1482, P284, DOI 10.1016/S0167-4838(00)00164-3; MALABA L, 1995, J BIOL CHEM, V270, P15686, DOI 10.1074/jbc.270.26.15686; Mansouri A, 1997, BBA-MOL CELL RES, V1357, P107, DOI 10.1016/S0167-4889(97)00018-9; Mansouri A, 1998, BIOFACTORS, V7, P287, DOI 10.1002/biof.5520070401; Miller RE, 1998, FEBS LETT, V436, P455, DOI 10.1016/S0014-5793(98)01184-3; MU JZ, 1994, BBA-MOL CELL RES, V1222, P483, DOI 10.1016/0167-4889(94)90058-2; NOY N, 1991, BIOCHEMISTRY-US, V30, P6380, DOI 10.1021/bi00240a005; REDL B, 1992, J BIOL CHEM, V267, P20282; Redl B, 2000, BBA-PROTEIN STRUCT M, V1482, P241, DOI 10.1016/S0167-4838(00)00142-4; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SENOO H, 1990, J LIPID RES, V31, P1229; SIVAPRASADARAO A, 1994, BIOCHEM J, V302, P245, DOI 10.1042/bj3020245; Sundaram M, 1998, J BIOL CHEM, V273, P3336, DOI 10.1074/jbc.273.6.3336; Wester L, 1998, SCAND J IMMUNOL, V48, P1; Wojnar P, 2001, J BIOL CHEM, V276, P20206, DOI 10.1074/jbc.M101762200	48	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16209	16215		10.1074/jbc.M210922200	http://dx.doi.org/10.1074/jbc.M210922200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591932	hybrid			2022-12-27	WOS:000182680000095
J	van der Wijk, T; Blanchetot, C; Overvoorde, J; den Hertog, J				van der Wijk, T; Blanchetot, C; Overvoorde, J; den Hertog, J			Redox-regulated rotational coupling of receptor protein-tyrosine phosphatase alpha dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSIBLE INACTIVATION; NEGATIVE REGULATION; LIGAND; DIMERIZATION; DOMAINS; CD45; PHOSPHORYLATION; ASSOCIATION; SPECIFICITY; INHIBITION	Receptor protein-tyrosine phosphatase a (RPTPalpha) constitutively forms dimers in the membrane, and activity studies with forced dimer mutants of RPTPalpha revealed that rotational coupling of the dimer defines its activity. The hemagglutinin (HA) tag of wild type RPTPalpha and of constitutively dimeric, active RPTPalpha-F135C with a disulfide bond in the extracellular domain was not accessible for antibody, whereas the HA tag of constitutively dimeric, inactive RPTPalpha-P137C was. All three proteins were expressed on the plasma membrane to a similar extent, and the accessibility of their extracellular domains did not differ as determined by biotinylation studies. Dimerization was required for masking the RA tag, and we identified a region in the N terminus of RPTPalpha that was essential for the effect. Oxidative stress has been shown to induce a conformational change of the membrane distal PTP domain (RPTPalpha-D2). Here we report that H2O2 treatment of cells induced a change in rotational coupling in RPTPa dimers as detected using accessibility of an HA tag in the extracellular domain as a read-out. The catalytic site Cys(723) in RPTPalpha-D2, which was required for the conformational change of RPTPalpha-D2 upon H2O2 treatment, was essential for the H2O2-induced increase in accessibility. These results show for the first time that a conformational change in the intracellular domain of RPTPalpha led to a change in conformation of the extracellular domains, indicating that RPTPs have the capacity for inside-out signaling.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	den Hertog, J (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	hertog@niob.knaw.nl						Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Andersen JN, 2001, BIOCHEM J, V354, P581, DOI 10.1042/0264-6021:3540581; Aricescu AR, 2002, MOL CELL BIOL, V22, P1881, DOI 10.1128/MCB.22.6.1881-1892.2002; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Blanchetot C, 2000, FEBS LETT, V484, P235, DOI 10.1016/S0014-5793(00)02165-7; Blanchetot C, 2002, J BIOL CHEM, V277, P47263, DOI 10.1074/jbc.M205810200; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; Blanchetot C, 2002, EMBO J, V21, P493, DOI 10.1093/emboj/21.4.493; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Dornan S, 2002, J BIOL CHEM, V277, P1912, DOI 10.1074/jbc.M108386200; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Gil-Henn H, 2001, J BIOL CHEM, V276, P31772, DOI 10.1074/jbc.M103395200; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sorby M, 2001, ONCOGENE, V20, P5219, DOI 10.1038/sj.onc.1204581; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; Tertoolen LGJ, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-8; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6; Xu Z, 2002, NAT IMMUNOL, V3, P764, DOI 10.1038/ni822; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707	39	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13968	13974		10.1074/jbc.M300632200	http://dx.doi.org/10.1074/jbc.M300632200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582170	hybrid			2022-12-27	WOS:000182405000053
J	Gong, XM; Agalarov, R; Brettel, K; Carmeli, C				Gong, XM; Agalarov, R; Brettel, K; Carmeli, C			Control of electron transport in photosystem I by the iron-sulfur cluster F-X in response to intra- and intersubunit interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCOCCUS-SP; ACCEPTOR COMPLEX; 4FE-4S CLUSTERS; CORE; CENTERS; PROTEIN; PSAC; A(1); IDENTIFICATION; RECONSTITUTION	Photosystem I (PS I) is a transmembraneal multisubunit complex that mediates light-induced electron transfer from plactocyanine to ferredoxin. The electron transfer proceeds from an excited chlorophyll a dimer (P700) through a chlorophyll a (A(0)), a phylloquinone (A(1)), and a [4Fe-4S] iron-sulfur cluster F-X, all located on the core subunits PsaA and PsaB, to iron-sulfur clusters F-A and F-B, located on subunit PsaC. Earlier, it was attempted to determine the function of F-X in the absence of F-A/B mainly by chemical dissociation of subunit PsaC. However, not all PsaC subunits could be removed from the PS I preparations by this procedure without partially damaging F-X. We therefore removed subunit PsaC by interruption of the psaC2 gene of PS I in the cyanobacterium Synechocystis sp. PCC 6803. Cells could not grow under photosynthetic conditions when subunit PsaC was deleted, yet the PsaC-deficient mutant cells grew under heterotrophic conditions and assembled the core subunits of PS I in which light-induced electron transfer from P700 to A(1) occurred. The photoreduction of F-X was largely inhibited, as seen from direct measurement of the extent of electron transfer from A(1) to F-X. From the crystal structure it can be seen that the removal of subunits PsaC, PsaD, and PsaE in the PsaC-deficient mutant resulted in the braking of salt bridges between these subunits and PsaB and PsaA and the formation of a net of two negative surface charges on PsaA/B. The potential induced on F-X by these surface charges is proposed to inhibit electron transport from the quinone. In the complete PS I complex, replacement of a cysteine ligand of F-X by serine in site-directed mutation C565S/D566E in subunit PsaB caused an similar to10-fold slow down of electron transfer from the quinone to F-X without much affecting the extent of this electron transfer compared with wild type. Based on these and other results, we propose that F-X might have a major role in controlling electron transfer through PS I.	Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel; CEA Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; CEA, Serv Bioenerget, F-91191 Gif Sur Yvette, France	Tel Aviv University; CEA; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay	Carmeli, C (corresponding author), Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel.	ccarmeli@post.tau.ac.il						ANDERSON SL, 1991, J BACTERIOL, V173, P2761, DOI 10.1128/JB.173.9.2761-2767.1991; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BERTINI I, 1995, EUR J BIOCHEM, V232, P192, DOI 10.1111/j.1432-1033.1995.tb20799.x; BRETTEL K, 1988, FEBS LETT, V239, P93, DOI 10.1016/0014-5793(88)80552-0; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; Brettel K, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P611; BRETTEL K, 1989, BIOCHIM BIOPHYS ACTA, V976, P246, DOI 10.1016/S0005-2728(89)80237-3; Brettel K, 1995, PHOTOSYNTH RES, V45, P183, DOI 10.1007/BF00015559; Brettel K, 1998, BBA-BIOENERGETICS, V1363, P175, DOI 10.1016/S0005-2728(98)00010-3; CHITNIS PR, 1991, PHOTOSYNTHETIC APPAR, P177; CROWDER MS, 1983, BIOCHIM BIOPHYS ACTA, V722, P23, DOI 10.1016/0005-2728(83)90153-6; EVANS MCW, 1974, FEBS LETT, V49, P111, DOI 10.1016/0014-5793(74)80644-7; EVANS MCW, 1980, BIOCHIM BIOPHYS ACTA, V590, P89, DOI 10.1016/0005-2728(80)90148-6; Faller P, 2001, P NATL ACAD SCI USA, V98, P14368, DOI 10.1073/pnas.251382598; FISH LE, 1986, J BIOL CHEM, V261, P8134; GOLBECK JH, 1988, FEBS LETT, V228, P268, DOI 10.1016/0014-5793(88)80013-9; GOLBECK JH, 1976, ANAL BIOCHEM, V73, P539, DOI 10.1016/0003-2697(76)90205-0; GOLBECK JH, 1977, ARCH BIOCHEM BIOPHYS, V178, P140, DOI 10.1016/0003-9861(77)90178-3; Golbeck JH, 1991, CURRENT TOPICS BIOEN; GONG XM, 2002, THESIS TEL AVIV U TE; Guergova-Kuras M, 2001, P NATL ACAD SCI USA, V98, P4437, DOI 10.1073/pnas.081078898; HERBERT SK, 1992, P NATL ACAD SCI USA, V89, P8716, DOI 10.1073/pnas.89.18.8716; HIYAMA T, 1971, ARCH BIOCHEM BIOPHYS, V147, P99, DOI 10.1016/0003-9861(71)90314-6; HIYAMA T, 1978, BIOCHIM BIOPHYS ACTA, V257, P160; Joliot P, 1999, BIOCHEMISTRY-US, V38, P11130, DOI 10.1021/bi990857c; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KING TE, 1967, METHOD ENZYMOL, V10, P634; Kurnikov IV, 2001, J PHYS CHEM B, V105, P5359, DOI 10.1021/jp002540o; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lanzilotta WN, 1997, BIOCHEMISTRY-US, V36, P12976, DOI 10.1021/bi9715371; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNEBERG J, 1994, FEBS LETT, V338, P197, DOI 10.1016/0014-5793(94)80364-1; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MATHIAS RT, 1992, NATO ADV SCI I C-MAT, V335, P473; MEHARI T, 1991, BIOCHIM BIOPHYS ACTA, V1056, P139, DOI 10.1016/S0005-2728(05)80280-4; MOENNELOCCOZ P, 1994, BIOCHEMISTRY-US, V33, P10037, DOI 10.1021/bi00199a030; NECHUSHTAI R, 1983, P NATL ACAD SCI-BIOL, V80, P1179, DOI 10.1073/pnas.80.5.1179; PARRETT KG, 1989, BIOCHIM BIOPHYS ACTA, V973, P324, DOI 10.1016/S0005-2728(89)80439-6; PARRETT KG, 1990, BIOCHIM BIOPHYS ACTA, V1015, P341, DOI 10.1016/0005-2728(90)90039-7; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Rabinowitz J, 1972, Methods Enzymol, V24, P431; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER K, 1978, BIOCHIM BIOPHYS ACTA, V503, P120, DOI 10.1016/0005-2728(78)90166-4; Schlodder E, 1998, BIOCHEMISTRY-US, V37, P9466, DOI 10.1021/bi973182r; SETIF P, 1989, BIOCHEMISTRY-US, V28, P2689, DOI 10.1021/bi00432a049; SETIF P, 1993, BIOCHEMISTRY-US, V32, P7846, DOI 10.1021/bi00082a002; Shen GZ, 2002, J BIOL CHEM, V277, P20355, DOI 10.1074/jbc.M201104200; SMART LB, 1993, P NATL ACAD SCI USA, V90, P1132, DOI 10.1073/pnas.90.3.1132; STEINMULLER K, 1992, PLANT MOL BIOL, V20, P997, DOI 10.1007/BF00027170; SUN ASK, 1971, BIOCHIM BIOPHYS ACTA, V234, P399, DOI 10.1016/0005-2728(71)90207-6; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; Tjus SE, 2001, PLANT PHYSIOL, V125, P2007, DOI 10.1104/pp.125.4.2007; VANDEREST A, 1994, BIOCHEMISTRY-US, V33, P11789, DOI 10.1021/bi00205a015; Vassiliev IR, 1997, BIOPHYS J, V72, P301, DOI 10.1016/S0006-3495(97)78669-7; WARREN PV, 1993, BIOCHEMISTRY-US, V32, P4411, DOI 10.1021/bi00067a034; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Yu JP, 1997, J BIOL CHEM, V272, P8032, DOI 10.1074/jbc.272.12.8032; YU JP, 1995, PLANT MOL BIOL, V29, P331, DOI 10.1007/BF00043656; Zeng MT, 2002, BBA-BIOENERGETICS, V1556, P254, DOI 10.1016/S0005-2728(02)00370-5; Zeng MT, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P643	64	20	22	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19141	19150		10.1074/jbc.M301808200	http://dx.doi.org/10.1074/jbc.M301808200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626505	hybrid			2022-12-27	WOS:000182932200056
J	Bagheri-Yarmand, R; Vadlamudi, RK; Kumar, R				Bagheri-Yarmand, R; Vadlamudi, RK; Kumar, R			Activating transcription factor 4 overexpression inhibits proliferation and differentiation of mammary epithelium resulting in impaired lactation and accelerated involution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLAND DEVELOPMENT; LEUCINE-ZIPPER; DNA-BINDING; CELL-DEATH; TRANSGENIC MICE; LOBULOALVEOLAR DEVELOPMENT; TARGETED EXPRESSION; RESPONSE ELEMENT; C/EBP-BETA; CYCLIN D1	The basic leucine zipper containing activating transcription factors (ATFs) modulates the expression of growth-regulating genes. In this study, we sought to determine specifically the consequences of ATF4 expression on mammary gland development in transgenic mice. Overexpression of ATF4 severely impaired normal development of the mammary gland, which was associated with reduced proliferation and differentiation of mammary alveolar epithelium and up-regulation of p21(WAF1) and p27(Kip1). In addition, there was also impaired lactation accompanied by decreased expression of alpha-lactoalbumin, whey acidic protein, and beta-casein, possibly because of the down-regulation of STAT5a tyrosine phosphorylation. Mammary gland involution in ATF4-transgenic mice was accelerated, compared with wild type littermates by whole mount analysis. In addition, day 18 of lactation in transgenic mice was phenotypically equivalent to day 3 of involution in wild type mice, as determined by the TUNEL assay and expression of Bax. The concentration of the proapoptotic molecule caspase-3 was increased during lactation in ATF4-transgenic animal. Mammary glands from ATF4-transgenic mice also showed significant nuclear translocation of activated STAT3 and up-regulation of one of its target genes, insulin-like growth factor-binding protein-5, which is thought to facilitate apoptosis by sequestering insulin-like growth factor. Together, these findings suggest that ATF4 may play a role during mammary gland development and that down-regulation of ATF4 may be important for the onset of involution in the mammary gland.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Bagheri-Yarmand, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,108, Houston, TX 77030 USA.			Bagheri-Yarmand, Rozita/0000-0001-5139-6381	NCI NIH HHS [CA16672, CA 90970] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA090970] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Butscher WG, 1998, J BIOL CHEM, V273, P552, DOI 10.1074/jbc.273.1.552; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Chapman RS, 2000, ONCOGENE, V19, P6386, DOI 10.1038/sj.onc.1204016; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Gachon F, 1998, J VIROL, V72, P8332, DOI 10.1128/JVI.72.10.8332-8337.1998; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gombart A. F., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P185; Hadsell DL, 1996, ENDOCRINOLOGY, V137, P321, DOI 10.1210/en.137.1.321; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; Jones FE, 1999, ONCOGENE, V18, P3481, DOI 10.1038/sj.onc.1202698; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; JUNGLING S, 1994, EUR J BIOCHEM, V226, P925, DOI 10.1111/j.1432-1033.1994.00925.x; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kato Y, 1999, MOL CELL ENDOCRINOL, V154, P151, DOI 10.1016/S0303-7207(99)00078-7; Krane IM, 1996, ONCOGENE, V12, P1781; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; Mielnicki LM, 1996, BIOCHEM BIOPH RES CO, V228, P586, DOI 10.1006/bbrc.1996.1702; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; NISHIZAWA M, 1992, FEBS LETT, V299, P36, DOI 10.1016/0014-5793(92)80094-W; Pati D, 1999, MOL CELL BIOL, V19, P5001; Philp JAC, 1996, FEBS LETT, V396, P77, DOI 10.1016/0014-5793(96)01069-1; PRODUST LM, 2001, J BIOL CHEM, V276, P505; Reddy TR, 1997, ONCOGENE, V14, P2785, DOI 10.1038/sj.onc.1201119; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; STRANGE R, 1992, DEVELOPMENT, V115, P49; TALAMANTES F, 1984, AM J PHYSIOL, V247, P126; Talukder AH, 2000, CANCER RES, V60, P276; Tanaka T, 1998, GENES CELLS, V3, P801, DOI 10.1046/j.1365-2443.1998.00230.x; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tonner E, 2002, DEVELOPMENT, V129, P4547; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; Travers MT, 1996, ENDOCRINOLOGY, V137, P1530, DOI 10.1210/en.137.5.1530; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543	57	33	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17421	17429		10.1074/jbc.M300761200	http://dx.doi.org/10.1074/jbc.M300761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611881	hybrid, Green Published			2022-12-27	WOS:000182818600129
J	Yu, ASL; Enck, AH; Lencer, WI; Schneeberger, EE				Yu, ASL; Enck, AH; Lencer, WI; Schneeberger, EE			Claudin-8 expression in Madin-Darby canine kidney cells augments the paracellular barrier to cation permeation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT JUNCTION STRANDS; EPITHELIAL-CELLS; MDCK CELLS; RABBIT GALLBLADDER; SELECTIVE CHANNELS; ADHESION MOLECULE; PROTEIN; OCCLUDIN; PERMEABILITY; MECHANISM	Claudins are a family of integral membrane proteins of the tight junction that are thought to participate in the permeation of solutes across epithelia via the paracellular pathway. Claudin-8 is expressed in the distal renal tubule, which has a characteristically low passive permeability to monovalent cations. To test the hypothesis that claudin-8 plays a role in forming a tight paracellular barrier to cations, stably transfected Madin-Darby canine kidney II cell lines with inducible expression of claudin-8 were generated. Induction of claudin-8 expression was associated with down-regulation of endogenous claudin-2 protein. Other tight junction proteins were expressed and targeted normally, and the number of junctional strands was minimally altered. By Ussing chamber and radiotracer flux studies, claudin-8 expression was found to reduce paracellular permeability to monovalent inorganic and organic cations and to divalent cations but not to anions or neutral solutes. The size selectivity, charge dependence, and activation energy of paracellular cation permeation were all unchanged. These observations are consistent with a model in which claudin-2 encodes a highly cation-permeable channel, whereas claudin-8 acts primarily as a cation barrier. When exogenous claudin-8 is expressed, it replaces endogenous claudin-2, inserting in its place into existing tight junction strands, thereby reducing the apparent number of functional cation pores. Our findings suggest that claudin-8 plays an important role in the paracellular cation barrier of the distal renal tubule.	Univ So Calif, Keck Sch Med, Div Nephrol, Dept Med, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Physiol & Biophys, Los Angeles, CA 90033 USA; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Harvard Digest Dis Ctr, Boston, MA 02115 USA	University of Southern California; University of Southern California; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Yu, ASL (corresponding author), Univ So Calif, Keck Sch Med, Div Nephrol, Dept Med, 2025 Zonal Ave,RMR 406, Los Angeles, CA 90033 USA.	alanyu@usc.edu	Yu, Alan/AID-7467-2022	Yu, Alan/0000-0002-1776-2533; Lencer, Wayne/0000-0001-7346-2730	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL25822] Funding Source: Medline; NIDDK NIH HHS [DK34854] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; BARRY PH, 1971, J MEMBRANE BIOL, V4, P358, DOI 10.1007/BF02431979; BARRY PH, 1970, J MEMBRANE BIOL, V3, P93, DOI [10.1007/BF01868022, 10.1007/BF01868023]; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; Colegio OR, 2002, AM J PHYSIOL-CELL PH, V283, pC142, DOI 10.1152/ajpcell.00038.2002; Cunningham SA, 2000, J BIOL CHEM, V275, P34750, DOI 10.1074/jbc.M002718200; DeCoursey TE, 1998, J GEN PHYSIOL, V112, P503, DOI 10.1085/jgp.112.4.503; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; DIAMOND JM, 1969, ANNU REV PHYSIOL, V31, P581, DOI 10.1146/annurev.ph.31.030169.003053; Dowland LK, 2000, J BIOL CHEM, V275, P37765, DOI 10.1074/jbc.M004840200; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; Fanning AS, 1999, J AM SOC NEPHROL, V10, P1337; FINKELST.A, 1970, BIOCHIM BIOPHYS ACTA, V205, P1, DOI 10.1016/0005-2728(70)90055-1; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Inai T, 1999, EUR J CELL BIOL, V78, P849, DOI 10.1016/S0171-9335(99)80086-7; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; KIMIZUKA H, 1964, J THEOR BIOL, V6, P290, DOI 10.1016/0022-5193(64)90035-9; Kiuchi-Saishin Y, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134875; Kobayashi J, 2002, HISTOCHEM CELL BIOL, V117, P29, DOI 10.1007/s00418-001-0359-x; LU Y, 2001, J AM SOC NEPHROL, V12, P756; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; McCarthy KM, 2000, J CELL SCI, V113, P3387; McCarthy KM, 1996, J CELL SCI, V109, P2287; McCleskey EW, 1999, J GEN PHYSIOL, V113, P765, DOI 10.1085/jgp.113.6.765; MISFELDT DS, 1976, P NATL ACAD SCI USA, V73, P1212, DOI 10.1073/pnas.73.4.1212; MORENO JH, 1975, J MEMBRANE BIOL, V21, P197, DOI 10.1007/BF01941070; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Nasdala I, 2002, J BIOL CHEM, V277, P16294, DOI 10.1074/jbc.M111999200; Rahner C, 2001, GASTROENTEROLOGY, V120, P411, DOI 10.1053/gast.2001.21736; Reyes JL, 2002, KIDNEY INT, V62, P476, DOI 10.1046/j.1523-1755.2002.00479.x; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13; Turksen K, 2002, DEVELOPMENT, V129, P1775; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; WEDNER HJ, 1969, J MEMBRANE BIOL, V1, P92, DOI 10.1007/BF01869776; WRIGHT EM, 1971, J MEMBRANE BIOL, V4, P331, DOI 10.1007/BF02431978; YU A, 2001, J AM SOC NEPHROL, V12, P45	42	226	236	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17350	17359		10.1074/jbc.M213286200	http://dx.doi.org/10.1074/jbc.M213286200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615928	Green Published, hybrid			2022-12-27	WOS:000182818600121
J	Bohula, EA; Salisbury, AJ; Sohail, M; Playford, MP; Riedemann, J; Southern, EM; Macaulay, VM				Bohula, EA; Salisbury, AJ; Sohail, M; Playford, MP; Riedemann, J; Southern, EM; Macaulay, VM			The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; CULTURED-MAMMALIAN-CELLS; DOUBLE-STRANDED-RNA; ANTISENSE OLIGONUCLEOTIDES; MELANOMA-CELLS; EXPRESSION; HYBRIDIZATION; CLEAVAGE; SIRNAS; CANCER	The type 1 insulin-like growth factor receptor (IGF1R) is often overexpressed by tumors and mediates growth and apoptosis protection. We previously showed that antisense reagents complementary to the IGF1R translation start site enhance radio- and chemosensitivity and impair Atm function. However these agents induce relatively modest IGF1R down-regulation and affect insulin receptor levels. To identify alternative sites for molecular targeting, we utilized scanning oligonucleotide arrays to probe the secondary structure of IGF1R mRNA. This strategy enabled selection of antisense oligonucleotides that generated high heteroduplex yield with IGF1R but not insulin receptor transcripts. Antisense oligonucleotides that hybridized strongly to IGF1R mRNA caused IGF1R down-regulation within intact tumor cells, whereas weakly hybridizing oligonucleotides were inactive. Furthermore, the ability of small interfering RNAs (siRNAs) to block IGF1R expression correlated with the accessibility of the target sequence within the transcript. Thus, siRNAs corresponding to weakly hybridizing oligonucleotides caused minor IGF1R down-regulation, whereas siRNAs homologous to accessible targets induced profound sequence-specific IGF1R gene silencing, blocked IGF signaling, and enhanced tumor cell radiosensitivity. This indicates that secondary structure in the target transcript has a major effect on siRNA efficacy. These findings have implications for siRNA design and suggest that IGF1R-targeting agents incorporating this mode of action have potential as anticancer therapy.	Weatherall Inst Mol Med, Canc Res UK Mol Oncol Labs, Oxford OX3 9DS, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford; University of Oxford	Macaulay, VM (corresponding author), Weatherall Inst Mol Med, Canc Res UK Mol Oncol Labs, Headley Way,Headington, Oxford OX3 9DS, England.		Bohula, Erin/AAW-7276-2020					DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; Dunbar PR, 2000, J IMMUNOL, V165, P6644, DOI 10.4049/jimmunol.165.11.6644; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hakam A, 1999, HUM PATHOL, V30, P1128, DOI 10.1016/S0046-8177(99)90027-8; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Harborth J, 2001, J CELL SCI, V114, P4557; Hellawell GO, 2003, BJU INT, V91, P271, DOI 10.1046/j.1464-410X.2003.04061.x; Hellawell GO, 2002, CANCER RES, V62, P2942; Holen T, 2002, NUCLEIC ACIDS RES, V30, P1757, DOI 10.1093/nar/30.8.1757; Kanter-Lewensohn L, 2000, GROWTH FACTORS, V17, P193, DOI 10.3109/08977190009001068; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Ligensa T, 2001, J BIOL CHEM, V276, P33419, DOI 10.1074/jbc.M104509200; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; RESNICOFF M, 1994, CANCER RES, V54, P4848; Sohail M, 2002, Adv Biochem Eng Biotechnol, V77, P43; Sohail M, 2001, NUCLEIC ACIDS RES, V29, P2041, DOI 10.1093/nar/29.10.2041; Sohail M, 1999, RNA, V5, P646, DOI 10.1017/S1355838299982195; Stein CA, 2001, J CLIN INVEST, V108, P641, DOI 10.1172/JCI13885; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Vickers TA, 2003, J BIOL CHEM, V278, P7108, DOI 10.1074/jbc.M210326200; Wraight CJ, 2000, NAT BIOTECHNOL, V18, P521, DOI 10.1038/75382	27	199	235	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15991	15997		10.1074/jbc.M300714200	http://dx.doi.org/10.1074/jbc.M300714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604614	hybrid			2022-12-27	WOS:000182680000069
J	Kim, SJ; Ding, W; Albrecht, B; Green, PL; Lairmore, MD				Kim, SJ; Ding, W; Albrecht, B; Green, PL; Lairmore, MD			A conserved calcineurin-binding motif in human T lymphotropic virus type 1 p12(I) functions to modulate nuclear factor of activated T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							READING FRAME-I; HTLV TYPE-I; ENDOPLASMIC-RETICULUM; NF-AT; PHOSPHATASE CALCINEURIN; INHIBITS CALCINEURIN; CYCLOPHILIN LIGAND; VIRAL INFECTIVITY; MESSENGER-RNAS; PX REGION	The PXIXIT calcineurin binding motif or highly related sequences are found in a variety of calcineurin-binding proteins in yeast, mammalian cells, and viruses. The accessory protein p12(I) encoded in the HTLV-1 pX ORF I promotes T cell activation during the early stages of HTLV-1 infection by activating nuclear factor of activated T cells (NFAT) through calcium release from the endoplasmic reticulum. We identified in p12(I), a conserved motif, which is highly homologous with the PXIXIT calcineurin-binding motif of NFAT. Both immunoprecipitation and calmodulin agarose bead pull-down assays indicated that wild type p12(I) and mutants of p12(I) that contained the motif-bound calcineurin. In addition, an alanine substitution p12(I) mutant (p12(I) AXAXAA) had greatly reduced binding affinity for calcineurin. We then tested whether p12(I) binding to calcineurin affected NFAT activity. p12(I) competed with NFAT for calcineurin binding in calmodulin bead pull-down experiments. Furthermore, the p12(I) AXAXAA mutant enhanced NFAT nuclear translocation compared with wild type p12(I) and increased NFAT transcriptional activity 2-fold greater than wild type p12(I). Similar to NFAT, endogenous calcineurin phosphatase activity was increased in Jurkat T cells expressing p12(I) independent of its calcineurin binding property. Thus, the reduced binding of p12(I) to calcineurin allows enhanced nuclear translocation and transcription mediated by NFAT. Herein, we are the first to identify a retroviral protein that binds calcineurin. Our data suggest that HTLV-1 p12(I) modulates NFAT activation to promote early virus infection of T lymphocytes, providing a novel mechanism for retrovirus-mediated cell activation.	Ohio State Univ, Ctr Retrovirus Res, Columbus, OH 43210 USA; Ohio State Univ, Dept Vet Biosci, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA; Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Lairmore, MD (corresponding author), Ohio State Univ, Ctr Retrovirus Res, 1925 Coffey Rd, Columbus, OH 43210 USA.				NCI NIH HHS [CA 92009, CA 70529] Funding Source: Medline; NCRR NIH HHS [RR 14324] Funding Source: Medline; NIAID NIH HHS [AI 01474] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092009] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR014324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI001474] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albrecht B, 2002, J VIROL, V76, P3493, DOI 10.1128/JVI.76.7.3493-3501.2002; Albrecht B, 2000, J VIROL, V74, P9828, DOI 10.1128/JVI.74.21.9828-9835.2000; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; Boustany LM, 2002, GENE DEV, V16, P608, DOI 10.1101/gad.967602; Cereseto A, 1997, LEUKEMIA, V11, P866, DOI 10.1038/sj.leu.2400665; CIMINALE V, 1992, J VIROL, V66, P1737, DOI 10.1128/JVI.66.3.1737-1745.1992; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; Collins ND, 1996, J VIROL, V70, P7241, DOI 10.1128/JVI.70.10.7241-7246.1996; Dekaban GA, 2000, VIROLOGY, V274, P86, DOI 10.1006/viro.2000.0406; Ding W, 2002, J VIROL, V76, P10374, DOI 10.1128/JVI.76.20.10374-10382.2002; Ding W, 2001, J VIROL, V75, P7672, DOI 10.1128/JVI.75.16.7672-7682.2001; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; FRANCHINI G, 1995, BLOOD, V86, P3619, DOI 10.1182/blood.V86.10.3619.bloodjournal86103619; FURUKAWA K, 1991, FEBS LETT, V295, P141, DOI 10.1016/0014-5793(91)81404-V; Garcia-Cozar FJ, 1998, J BIOL CHEM, V273, P23877, DOI 10.1074/jbc.273.37.23877; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Holloway MP, 1998, J BIOL CHEM, V273, P16346, DOI 10.1074/jbc.273.26.16346; Holloway MP, 1996, J BIOL CHEM, V271, P8549, DOI 10.1074/jbc.271.15.8549; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; KIMATA JT, 1994, VIROLOGY, V204, P656, DOI 10.1006/viro.1994.1581; KORALNIK IJ, 1993, J VIROL, V67, P2360, DOI 10.1128/JVI.67.4.2360-2366.1993; KORALNIK IJ, 1992, P NATL ACAD SCI USA, V89, P8813, DOI 10.1073/pnas.89.18.8813; KORALNIK IJ, 1995, J GEN VIROL, V76, P1909, DOI 10.1099/0022-1317-76-8-1909; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Lairmore MD, 2000, AIDS RES HUM RETROV, V16, P1757, DOI 10.1089/08892220050193272; Lefebvre L, 2002, J VIROL, V76, P7843, DOI 10.1128/JVI.76.15.7843-7854.2002; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Masuda ES, 1998, CELL SIGNAL, V10, P599, DOI 10.1016/S0898-6568(98)00019-9; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; Miskin JE, 2000, J VIROL, V74, P9412, DOI 10.1128/JVI.74.20.9412-9420.2000; Miskin JE, 1998, SCIENCE, V281, P562, DOI 10.1126/science.281.5376.562; Mulloy JC, 1996, J VIROL, V70, P3599, DOI 10.1128/JVI.70.6.3599-3605.1996; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; Pique C, 2000, J EXP MED, V191, P567, DOI 10.1084/jem.191.3.567; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Saksena NK, 1997, AIDS RES HUM RETROV, V13, P425, DOI 10.1089/aid.1997.13.425; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Srivastava RK, 1999, J EXP MED, V190, P253, DOI 10.1084/jem.190.2.253; Trovato R, 1999, J VIROL, V73, P6460, DOI 10.1128/JVI.73.8.6460-6467.1999; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	50	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15550	15557		10.1074/jbc.M210210200	http://dx.doi.org/10.1074/jbc.M210210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601010	hybrid			2022-12-27	WOS:000182680000013
J	Nojima, H; Tokunaga, C; Eguchi, S; Oshiro, N; Hidayat, S; Yoshino, K; Hara, K; Tanaka, N; Avruch, J; Yonezawa, K				Nojima, H; Tokunaga, C; Eguchi, S; Oshiro, N; Hidayat, S; Yoshino, K; Hara, K; Tanaka, N; Avruch, J; Yonezawa, K			The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-GROWTH; AMINO-ACID; PHAS-I; EIF-4E BP1; PHOSPHORYLATION; PATHWAY; IDENTIFICATION; TRANSLATION; INSULIN	The mammalian target of rapamycin (mTOR) controls multiple cellular functions in response to amino acids and growth factors, in part by regulating the phosphorylation of p70 S6 kinase (p70S6k) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Raptor (regulatory associated protein of mTOR) is a recently identified mTOR binding partner that also binds p70S6k and 4E-BP1 and is essential for TOR signaling in vivo. Herein we demonstrate that raptor binds to p70S6k and 4E-BP1 through their respective TOS (conserved TOR signaling) motifs to be required for amino acid- and mTOR-dependent regulation of these mTOR substrates in vivo. A point mutation of the TOS motif also eliminates all in vitro mTOR-catalyzed 4E-BP1 phosphorylation and abolishes the raptor-dependent component of mTOR-catalyzed p70S6k phosphorylation in vitro. Raptor appears to serve as an mTOR scaffold protein, the binding of which to the TOS motif of mTOR substrates is necessary for effective mTOR-catalyzed phosphorylation in vivo and perhaps for conferring their sensitivity to rapamycin and amino acid sufficiency.	Kobe Univ, Biosignal Res Ctr, Nada Ku, Kobe, Hyogo 6578501, Japan; Japan Sci & Technol Corp, CREST, Okayama 7000914, Japan; Okayama Univ, Grad Sch Med & Dent, Dept Gastroenterol Surg Transplant & Surg Oncol, Okayama 7000914, Japan; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Med Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA	Kobe University; Japan Science & Technology Agency (JST); Okayama University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Yonezawa, K (corresponding author), Kobe Univ, Biosignal Res Ctr, Nada Ku, 1-1 Rokkodai Cho, Kobe, Hyogo 6578501, Japan.				NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017776, R37DK017776] Funding Source: NIH RePORTER; NCI NIH HHS [CA 73818] Funding Source: Medline; NIDDK NIH HHS [DK 17776] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Fox HL, 1998, AM J PHYSIOL-CELL PH, V274, pC206, DOI 10.1152/ajpcell.1998.274.1.C206; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Nishiuma T, 1998, BIOCHEM BIOPH RES CO, V252, P440, DOI 10.1006/bbrc.1998.9671; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178	28	484	501	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15461	15464		10.1074/jbc.C200665200	http://dx.doi.org/10.1074/jbc.C200665200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604610	hybrid, Green Published, Green Submitted			2022-12-27	WOS:000182680000002
J	D'Angelo, G; Duplan, E; Vigne, P; Frelin, C				D'Angelo, G; Duplan, E; Vigne, P; Frelin, C			Cyclosporin A prevents the hypoxic adaptation by activating hypoxia-inducible factor-1 alpha Pro-564 hydroxylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; FACTOR 1-ALPHA; PROLYL HYDROXYLATION; GROWTH-FACTOR; HIF-ALPHA; PROTEIN; ERYTHROPOIETIN; INHIBITION; EXPRESSION; 4-HYDROXYLASE	The mechanism by which hypoxia induces gene transcription involves the inhibition of hypoxia-inducible factor (HIF)-1alpha prolyl hydroxylase activity, which prevents von Hippel-Lindau (vHL)-dependent targeting of HIF-1alpha to the ubiquitin-proteasome pathway. HIF-1alpha is stabilized, translocates to the nucleus, interacts with hypoxia-responsive elements, and promotes the activation of target genes. This report shows that cyclosporin A (CsA) interferes with the hypoxic signaling cascade in C6 glioma cells. CsA inhibits hypoxia-dependent gene transcription in a reporter gene assay and prevents the hypoxic accumulation of HIF-1alpha. Addition of the 530603 C-terminal oxygen-dependent degradation (ODD) domain of HIF-1alpha to the green fluorescent protein (GFP) destabilized the protein in an oxygen-dependent manner. CsA prevented the hypoxic stabilization of an ODD.GFP fusion protein. An assay for 2-oxoglutarate-dependent dioxygenases was developed using a light mitochondrial kidney fraction as a source of enzyme. It uses the capacity of specific peptides to stimulate the degradation of [C-14]2-oxoglutarate. CsA stimulated the enzymatic activity in the presence of a peptide that mimicked the 557-576 sequence of HIF-1alpha. The enzyme promoted [S-35]vHL binding to glutathione S-transferase (GST)-ODD fusion protein. This association increased in the presence of CsA. CsA effects were not observed when the proline residue corresponding to Pro-564 in the HIF-1a sequence was replaced by a hydroxyproline or an alanine residue. Finally, CsA increased vHL-ODD interaction during hypoxia. We conclude that CsA destabilizes HIF-1alpha by promoting hydroxylation of Pro-564 in the ODD domain. Such a mechanism may prevent bypoxic adaptation during CsA-induced nephrotoxicity and contribute to the adverse effects of this drug.	CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	D'Angelo, G (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.		Duplan, Eric/AAK-8224-2020	Duplan, Eric/0000-0002-1348-1507; D'ANGELO, Gisela/0000-0003-3150-2241				BAADER E, 1994, BIOCHEM J, V300, P525, DOI 10.1042/bj3000525; BLACKBURN MEC, 1992, INT J CARDIOL, V36, P263, DOI 10.1016/0167-5273(92)90294-D; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fischer G, 1998, FEBS LETT, V426, P17, DOI 10.1016/S0014-5793(98)00242-7; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kang DH, 2001, AM J PHYSIOL-RENAL, V280, pF727, DOI 10.1152/ajprenal.2001.280.4.F727; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; MARUYAMA K, 1992, NEPHRON, V62, P27, DOI 10.1159/000186990; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; VANNUCCHI AM, 1991, BLOOD, V78, P1615; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510	26	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15406	15411		10.1074/jbc.M211293200	http://dx.doi.org/10.1074/jbc.M211293200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586829	hybrid, Green Published			2022-12-27	WOS:000182516100106
J	Kitano, J; Yamazaki, Y; Kimura, K; Masukado, T; Nakajima, Y; Nakanishi, S				Kitano, J; Yamazaki, Y; Kimura, K; Masukado, T; Nakajima, Y; Nakanishi, S			Tamalin is a scaffold protein that interacts with multiple neuronal proteins in distinct modes of protein-protein association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE EXOCYTOSIS; NUCLEOTIDE-EXCHANGE FACTORS; ELEGANS VULVAR INDUCTION; NMDA RECEPTOR SUBUNITS; EPITHELIAL-CELLS; POSTSYNAPTIC DENSITY; PDZ DOMAINS; FAMILY; LOCALIZATION; COMPLEX	Tamalin is a scaffold protein that comprises multiple protein-interacting domains, including a 95-kDa postsynaptic density protein (PSD-95)/discs-large/ZO-1 (PDZ) domain, a leucine-zipper region, and a carboxyl-terminal PDZ binding motif. Tamalin forms a complex with metabotropic glutamate receptors and guanine nucleotide exchange factor cytohesins and promotes intracellular trafficking and cell surface expression of group 1 metabotropic glutamate receptors. In the present study, using several different approaches we have shown that tamalin interacts with multiple neuronal proteins through its distinct protein-binding domains. The PDZ domain of tamalin binds to the PDZ binding motifs of SAP90/PSD-95-associated protein and tamalin itself, whereas the PDZ binding motif of tamalin is capable of interacting with the PDZ domain of S-SCAM. In addition, tamalin forms a complex with PSD-95 and Mint2/X11beta/X11L by mechanisms different from the PDZ-mediated interaction. Tamalin has the ability to assemble with these proteins in vivo; their protein complex with tamalin was verified by coimmunoprecipitation of rat brain lysates. Interestingly, the distinct protein-interacting domains of tamalin are evolutionarily conserved, and mRNA expression is developmentally up-regulated at the postnatal period. The results indicate that tamalin exists as a key element that forms a protein complex with multiple postsynaptic and protein-trafficking scaffold proteins.	Kyoto Univ, Dept Biol Sci, Fac Med, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Biostudies, Dept Mol & Syst Biol, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Nakanishi, S (corresponding author), Kyoto Univ, Dept Biol Sci, Fac Med, Kyoto 6068501, Japan.		Kimura, Kouji/C-1847-2015					BAUDE A, 1993, NEURON, V11, P771, DOI 10.1016/0896-6273(93)90086-7; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DULCOS F, 1993, P NATL ACAD SCI USA, V90, P109; Fukaya M, 1999, NEUROSCI RES, V33, P111, DOI 10.1016/S0168-0102(98)00120-5; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hata Y, 1996, J NEUROSCI, V16, P2488; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; Jo K, 1999, J NEUROSCI, V19, P4189, DOI 10.1523/jneurosci.19-11-04189.1999; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kawashima N, 1997, FEBS LETT, V418, P301, DOI 10.1016/S0014-5793(97)01399-9; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kitano J, 2002, J NEUROSCI, V22, P1280, DOI 10.1523/JNEUROSCI.22-04-01280.2002; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Liu XB, 1998, J COMP NEUROL, V395, P450, DOI 10.1002/(SICI)1096-9861(19980615)395:4<450::AID-CNE3>3.0.CO;2-0; Maximov A, 2002, J NEUROSCI, V22, P6939; Nakajima Y, 1999, J BIOL CHEM, V274, P27573, DOI 10.1074/jbc.274.39.27573; Nevrivy DJ, 2000, J BIOL CHEM, V275, P16827, DOI 10.1074/jbc.275.22.16827; Niethammer M, 1996, J NEUROSCI, V16, P2157; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Rowe J, 2001, J CELL SCI, V114, P3323; Sambrook J, 1995, MOL CLONING LAB MANU; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087	41	59	60	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14762	14768		10.1074/jbc.M300184200	http://dx.doi.org/10.1074/jbc.M300184200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586822	hybrid			2022-12-27	WOS:000182516100024
J	Shimizu, K; Okada, M; Nagai, K; Fukada, Y				Shimizu, K; Okada, M; Nagai, K; Fukada, Y			Suprachiasmatic nucleus circadian oscillatory protein, a novel binding partner of K-Ras in the membrane rafts, negatively regulates MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; LEUCINE-RICH REPEATS; N-RAS; ADENYLATE-CYCLASE; KINASE ACTIVATION; PLASMA-MEMBRANE; LIPID RAFTS; H-RAS; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION	Suprachiasmatic nucleus circadian oscillatory protein (SCOP) is a member of the leucine-rich repeat (LRR)-containing protein family. In addition to circathan expression in the rat hypothalamic suprachiasmatic nucleus, SCOP is constitutively expressed in neurons throughout the rat brain. Here we found that a substantial amount of SCOP was localized in the brain membrane rafts, in which only K-Ras was abundant among Ras isoforms. SCOP interacted directly through its LRR domain with a subset of K-Ras in the guanine nucleotide-free form that was present in the raft fraction. This interaction interfered with the binding of added guanine nucleotide to K-Ras in vitro. A negative regulatory role of SCOP for K-Ras function was examined in PC12 cell lines stably overexpressing SCOP or its deletion mutants. Overexpression of full-length SCOP markedly down-regulated ERK1/ERK2 activation induced by depolarization or phorbol ester stimulation, and this inhibitory effect of overexpressed SCOP was dependent on its LRR domain. These results strongly suggest that SCOP negatively regulates K-Ras signaling in the membrane rafts, identifying a novel mechanism for regulation of the Ras-MAPK pathway.	Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Tokyo 1130032, Japan; Japan Sci & Technol Corp, CREST, Bunkyo Ku, Tokyo 1130033, Japan; Osaka Univ, Inst Prot Res, Div Prot Metab, Suita, Osaka 5650871, Japan	University of Tokyo; Japan Science & Technology Agency (JST); Osaka University	Fukada, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Bunkyo Ku, Bldg 3,Rm 218A,Yayoi 2-11-16, Tokyo 1130032, Japan.		Kimiko, Shimizu/ACS-9013-2022; 吉孝, 深田/G-5090-2014; Shimizu, Kimiko/G-4956-2014	Kimiko, Shimizu/0000-0003-4943-2552; Shimizu, Kimiko/0000-0003-4943-2552				BOS JL, 1989, CANCER RES, V49, P4682; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; HANEY SA, 1994, J BIOL CHEM, V269, P16541; Harada Y, 2000, J BIOL CHEM, V275, P37078, DOI 10.1074/jbc.M004706200; Hayashi Y, 2001, FEBS LETT, V491, P71, DOI 10.1016/S0014-5793(01)02153-6; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Li WQ, 2000, GENE DEV, V14, P895; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Obrietan K, 1998, NAT NEUROSCI, V1, P693, DOI 10.1038/3695; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sanada K, 2000, J NEUROSCI, V20, P986, DOI 10.1523/JNEUROSCI.20-03-00986.2000; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Shimizu K, 1999, FEBS LETT, V458, P363, DOI 10.1016/S0014-5793(99)01190-4; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang DS, 1995, BIOCHEM BIOPH RES CO, V217, P608, DOI 10.1006/bbrc.1995.2818; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	41	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14920	14925		10.1074/jbc.M213214200	http://dx.doi.org/10.1074/jbc.M213214200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594205	hybrid			2022-12-27	WOS:000182516100045
J	Shin, D; Cho, N; Heu, S; Ryu, S				Shin, D; Cho, N; Heu, S; Ryu, S			Selective regulation of ptsG expression by Fis - Formation of either activating or repressing nucleoprotein complex in response to glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP RECEPTOR PROTEIN; ESCHERICHIA-COLI; MAJOR GLUCOSE; PHOSPHOTRANSFERASE SYSTEM; TRANSCRIPTION ACTIVATION; TRANSPORTER GENE; MLC; PROMOTER; INDUCTION; REGULON	Transcription of ptsG encoding glucose-specific permease, enzyme IICBGlc, in Escherichia coli is initiated from two promoters, P1 and P2. ptsG transcription is repressed by Mlc, a glucose-inducible regulator of carbohydrate metabolism. The regulation of ptsG P1 transcription is also under positive control by cyclic AMP receptor protein and cyclic AMP complex (CRP-cAMP) as observed in other Mlc regulon. We report here that Fis, one of the nucleoid-associated proteins, plays a key role in glucose induction of Mlc regulon. ptsG transcription was induced when wild-type cells were grown in the presence of glucose. However, in a fts mutant, the basal level of ptsG transcription was higher but decreased when cells were grown in the presence of glucose, which implies the possibility of regulatory interactions among Fis, Mlc, and CRP-cAMP. Footprinting experiments with various probes and transcription assays revealed that Fis assists both Mlc repression and CRP-cAMP activation of ptsG P1 through the formation of Fis-CRP-Mlc or Fis-CRP nucleoprotein complexes at ptsG P1 promoter depending on the availability of glucose in the growth medium. ptsG P2 transcription was inhibited by Fis and Mlc. Tighter Mlc repression and enhanced CRP-cAMP activation of ptsG P1 by Fis enable cells to regulate Mlc regulon efficiently by selectively controlling the concentration of enzyme IICBGlc that modulates Mlc activity.	Seoul Natl Univ, Dept Food Sci & Technol, Sch Agr Biotechnol, Suwon 441744, South Korea; Seoul Natl Univ, Ctr Agr Biomat, Suwon 441744, South Korea; Natl Inst Agr Sci & Technol, Plant Pathol Div, Suwon 441707, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Ryu, S (corresponding author), Seoul Natl Univ, Dept Food Sci & Technol, Sch Agr Biotechnol, Suwon 441744, South Korea.	sangryu@snu.ac.kr						Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; BUHR A, 1994, J BIOL CHEM, V269, P23437; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Busby S, 1997, MOL MICROBIOL, V23, P853, DOI 10.1046/j.1365-2958.1997.2771641.x; Decker K, 1998, MOL MICROBIOL, V27, P381, DOI 10.1046/j.1365-2958.1998.00694.x; DUMITRU I, 1994, NUCLEIC ACIDS RES, V22, P1450; ERNI B, 1986, J BIOL CHEM, V261, P6398; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; Gonzalez-Gil G, 1998, EMBO J, V17, P2877, DOI 10.1093/emboj/17.10.2877; GonzalezGil G, 1996, MOL MICROBIOL, V22, P21, DOI 10.1111/j.1365-2958.1996.tb02652.x; Hengen PN, 1997, NUCLEIC ACIDS RES, V25, P4994, DOI 10.1093/nar/25.24.4994; ISHIZUKA H, 1993, MOL MICROBIOL, V10, P341, DOI 10.1111/j.1365-2958.1993.tb01960.x; Kim SY, 1999, J BIOL CHEM, V274, P25398, DOI 10.1074/jbc.274.36.25398; Kimata K, 1997, P NATL ACAD SCI USA, V94, P12914, DOI 10.1073/pnas.94.24.12914; Kimata K, 1998, MOL MICROBIOL, V29, P1509, DOI 10.1046/j.1365-2958.1998.01035.x; Kimata K, 2001, EMBO J, V20, P3587, DOI 10.1093/emboj/20.13.3587; KONBERG HL, 1972, BIOCHEM J, V128, P1339; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee SJ, 2000, EMBO J, V19, P5353, DOI 10.1093/emboj/19.20.5353; McLeod SM, 2000, J BACTERIOL, V182, P4180, DOI 10.1128/JB.182.15.4180-4187.2000; Nam TW, 2001, EMBO J, V20, P491, DOI 10.1093/emboj/20.3.491; Nasser W, 2001, J BIOL CHEM, V276, P17878, DOI 10.1074/jbc.M100632200; Pettijohn D.E., 1996, ESCHERICHIA COLI SAL, P158; Plumbridge J, 1999, MOL MICROBIOL, V33, P260, DOI 10.1046/j.1365-2958.1999.01462.x; Plumbridge J, 1998, MOL MICROBIOL, V29, P1053, DOI 10.1046/j.1365-2958.1998.00991.x; Plumbridge J, 1998, MOL MICROBIOL, V27, P369, DOI 10.1046/j.1365-2958.1998.00685.x; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; RYU S, 1994, J BIOL CHEM, V269, P4767; SAIER MH, 1976, J BIOL CHEM, V251, P883; Sambrook J., 2001, MOL CLONING LAB MANU; Shin D, 2001, J BIOL CHEM, V276, P25871, DOI 10.1074/jbc.M101757200; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; Tanaka Y, 1999, GENES CELLS, V4, P391, DOI 10.1046/j.1365-2443.1999.00268.x; Tanaka Y, 2000, EMBO J, V19, P5344, DOI 10.1093/emboj/19.20.5344; Weinstein-Fischer D, 2000, MOL MICROBIOL, V35, P1413, DOI 10.1046/j.1365-2958.2000.01805.x	36	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14776	14781		10.1074/jbc.M213248200	http://dx.doi.org/10.1074/jbc.M213248200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588863	hybrid			2022-12-27	WOS:000182516100026
J	Cicchillitti, L; Fasanaro, P; Biglioli, P; Capogrossi, MC; Martelli, F				Cicchillitti, L; Fasanaro, P; Biglioli, P; Capogrossi, MC; Martelli, F			Oxidative stress induces protein phosphatase 2A-dependent dephosphorylation of the pocket proteins pRb, p107, and p130	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; 2A SUBUNIT INTERACTION; RETINOBLASTOMA PROTEIN; IN-VITRO; SERINE/THREONINE PHOSPHATASE; CATALYTIC SUBUNIT; DNA-REPLICATION; OKADAIC ACID; PPP2R1B GENE; G(1) ARREST	Oxidative stress induces cell death and growth arrest. In this study, the regulation and the functional role of the retinoblastoma family proteins pRb, p107, and p130 in the cellular response to oxidative stress were investigated. Treatment of endothelial cells with H2O2 induced rapid hypophosphorylation of the retinoblastoma family proteins. This event did not require p53 or p21(Waf1/Cip1/Sdi1) and was not associated with cyclin/cyclin-dependent kinase down-modulation. Four lines of evidence indicate that H2O2-induced hypophosphorylation of pRb, p107, and p130 was because of the activity of protein phosphatase 2A (PP2A). First, cell treatment with two phosphatase inhibitors, okadaic acid and calyculin A, prevented the hypophosphorylation of the retinoblastoma family proteins, at concentrations that specifically inhibit PP2A. Second, SV40 small t, which binds and inhibits PP2A, when overexpressed prevented H2O2-induced dephosphorylation of the retinoblastoma family proteins, whereas a SV40 small t mutant unable to bind PP2A was totally inert. Third, PP2A core enzyme physically interacted with pRb and p107, both in H2O2-treated and untreated cells. Fourth, a PP2A phosphatase activity was co-immunoprecipitated with pRb, and the activity of pRb-associated PP2A was positively modulated by cell treatment with H2O2. Because DNA damaging agents inhibit DNA synthesis in a pRb-dependent manner, it was determined whether the PP2A-mediated dephosphorylation of the retinoblastoma family proteins played a role in this S-phase response. Indeed, it was found that inhibition of PP2A by SV40 small t overexpression prevented DNA synthesis inhibition induced by H2O2.	IRCCS, Ist Dermopat Immacolata, Lab Patol Vasc, I-00167 Rome, Italy; IRCCS, Ist Cardiol Fdn I Monzino, Lab Biol Vasc & Terapia Genica, Milan, Italy; IRCCS, Ist Cardiol Fdn I Monzino, Dipartimento Chirurg Cardiovasc, Milan, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Centro Cardiologico Monzino; IRCCS Centro Cardiologico Monzino	Martelli, F (corresponding author), IRCCS, Ist Dermopat Immacolata, Lab Patol Vasc, Via Monti di Creta 104, I-00167 Rome, Italy.	f.martelli@idi.it	Martelli, Fabio/AAL-3788-2020	Martelli, Fabio/0000-0002-8624-7738				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Barnouin K, 2002, J BIOL CHEM, V277, P13761, DOI 10.1074/jbc.M111123200; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Ben-Israel H, 2002, FRONT BIOSCI-LANDMRK, V7, pD1369, DOI 10.2741/ben; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Bochkov VN, 2002, BLOOD, V99, P199, DOI 10.1182/blood.V99.1.199; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Davies KJA, 2000, IUBMB LIFE, V50, P279, DOI 10.1080/15216540051081010; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Esposito F, 2000, FEBS LETT, V470, P211, DOI 10.1016/S0014-5793(00)01318-1; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Feschenko MS, 2002, J PHARMACOL EXP THER, V302, P111, DOI 10.1124/jpet.302.1.111; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FRISCHER H, 1977, J LAB CLIN MED, V89, P1080; Gaetano C, 2000, GENE THER, V7, P1624, DOI 10.1038/sj.gt.3301296; Gorospe M, 1999, GENE EXPRESSION, V7, P377; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; Mates J M, 1999, Front Biosci, V4, pD339; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Munger K, 2002, FRONT BIOSCI-LANDMRK, V7, pD641, DOI 10.2741/munger; MUNGRE S, 1994, J VIROL, V68, P1675, DOI 10.1128/JVI.68.3.1675-1681.1994; Myles T, 2001, BIOCHEM J, V357, P225, DOI 10.1042/0264-6021:3570225; Noda T, 2001, FASEB J, V15, P2131, DOI 10.1096/fj.01-0131com; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pennaneach V, 2001, MOL CELL, V7, P715, DOI 10.1016/S1097-2765(01)00217-9; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Resjo S, 1999, BIOCHEM J, V341, P839, DOI 10.1042/0264-6021:3410839; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; Rubin E, 2001, ONCOGENE, V20, P3776, DOI 10.1038/sj.onc.1204518; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Rundell K, 2001, SEMIN CANCER BIOL, V11, P5, DOI 10.1006/scbi.2000.0341; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Swanton C, 2001, INT J EXP PATHOL, V82, P3, DOI 10.1046/j.1365-2613.2001.00165.x; Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268; Tamrakar S, 2000, FRONT BIOSCI-LANDMRK, V5, pD121, DOI 10.2741/Tamrakar; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; Voorhoeve PM, 1999, ONCOGENE, V18, P679, DOI 10.1038/sj.onc.1202289; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	70	94	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19509	19517		10.1074/jbc.M300511200	http://dx.doi.org/10.1074/jbc.M300511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12621062	hybrid			2022-12-27	WOS:000182932200101
J	Guidotti, JE; Bregerie, O; Robert, A; Debey, P; Brechot, C; Desdouets, C				Guidotti, JE; Bregerie, O; Robert, A; Debey, P; Brechot, C; Desdouets, C			Liver cell polyploidization: A pivotal role for binuclear hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARTIAL-HEPATECTOMY; MITOTIC SPINDLE; CITRON KINASE; DNA-CONTENT; PROTEIN; PLOIDY; CYCLE; RAT; CENTROSOME; P53	Polyploidy is a general physiological process indicative of terminal differentiation. During liver growth, this process generates the appearance of tetraploid (4n) and octoploid (8n) hepatocytes with one or two nuclei. The onset of polyploidy in the liver has been recognized for quite some time; however, the cellular mechanisms that govern it remain unknown. In this report, we observed the sequential appearance during liver growth of binuclear diploid (2 x 2n) and mononuclear 4n hepatocytes from a diploid hepatocyte population. To identify the cell cycle modifications involved in hepatocyte polyploidization, mitosis was then monitored in primary cultures of rat hepatocytes. Twenty percent of mononuclear 2n hepatocytes failed to undergo cytokinesis with no observable contractile movement of the ring. This process led to the formation of binuclear 2 x 2n hepatocytes. This tetraploid condition following cleavage failure did not activate the p53-dependent checkpoint in G(1). In fact, binuclear hepatocytes were able to proceed through S phase, and the formation of a bipolar spindle during mitosis constituted the key step leading to the genesis of two mononuclear 4n hepatocytes. Finally, we studied the duplication and clustering of centrosomes in the binuclear hepatocyte. These cells exhibited two centrosomes in G1 that were duplicated during S phase and then clustered by pairs at opposite poles of the cell during metaphase. This event led only to mononuclear 4n progeny and maintained the tetraploidy status of hepatocytes.	CHU Necker, INSERM, U370, F-75015 Paris, France; Museum Natl Hist Nat, UMR 8646, CNRS, INSERM,U565, F-75005 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN)	Desdouets, C (corresponding author), CHU Necker, INSERM, U370, 156 Rue Vaugirard, F-75015 Paris, France.	desdouet@necker.fr	Desdouets, Chantal/M-3430-2017; Guidotti, Jacques-Emmanuel/M-9014-2018; robert, aude/F-9584-2015	robert, aude/0000-0003-3095-4190; guidotti, jacques-emmanuel/0000-0001-9285-8167				Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Chassoux D, 1999, ANAL QUANT CYTOL, V21, P489; Fujikawa K, 2002, P NATL ACAD SCI USA, V99, P4313, DOI 10.1073/pnas.052715699; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; GOMEZLECHON MJ, 1981, CELL MOL BIOL, V27, P695; Hirose K, 2001, J BIOL CHEM, V276, P5821, DOI 10.1074/jbc.M007252200; KUDRYAVTSEV BN, 1993, VIRCHOWS ARCH B, V64, P387, DOI 10.1007/BF02915139; Lange BMH, 2002, CURR OPIN CELL BIOL, V14, P35, DOI 10.1016/S0955-0674(01)00291-5; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Liu HF, 2003, J BIOL CHEM, V278, P2541, DOI 10.1074/jbc.M210391200; Mackay AM, 1998, J CELL BIOL, V140, P991, DOI 10.1083/jcb.140.5.991; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Martin NC, 2002, J CELL PHYSIOL, V191, P138, DOI 10.1002/jcp.10057; Martineau-Thuillier S, 1998, CHROMOSOMA, V107, P461, DOI 10.1007/s004120050330; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; McIntyre M, 1999, ONCOGENE, V18, P4577, DOI 10.1038/sj.onc.1202815; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Minamishima YA, 2002, CANCER RES, V62, P995; Mollinari C, 2002, J CELL BIOL, V157, P1175, DOI 10.1083/jcb.200111052; MOSSIN L, 1994, EXP CELL RES, V214, P551, DOI 10.1006/excr.1994.1293; NADAL C, 1967, EXP CELL RES, V48, P518, DOI 10.1016/0014-4827(67)90318-7; NISLOW C, 1992, NATURE, V359, P543, DOI 10.1038/359543a0; Nunez F, 2000, FASEB J, V14, P1073, DOI 10.1096/fasebj.14.9.1073; Ravid K, 2002, J CELL PHYSIOL, V190, P7, DOI 10.1002/jcp.10035; SAETER G, 1988, CARCINOGENESIS, V9, P939, DOI 10.1093/carcin/9.6.939; SCHWARZE PE, 1984, CARCINOGENESIS, V5, P1267, DOI 10.1093/carcin/5.10.1267; Seglen PO, 1997, CELL BIOL TOXICOL, V13, P301, DOI 10.1023/A:1007487425047; SIGAL SH, 1995, DIFFERENTIATION, V59, P35, DOI 10.1046/j.1432-0436.1995.5910035.x; Sigal SH, 1999, AM J PHYSIOL-GASTR L, V276, pG1260, DOI 10.1152/ajpgi.1999.276.5.G1260; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; WHEATLEY DN, 1972, EXP CELL RES, V74, P455, DOI 10.1016/0014-4827(72)90401-6; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Yin L, 1998, HEPATOLOGY, V27, P73, DOI 10.1002/hep.510270113	36	226	232	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19095	19101		10.1074/jbc.M300982200	http://dx.doi.org/10.1074/jbc.M300982200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626502	Green Published, hybrid			2022-12-27	WOS:000182932200050
J	Hinkley, CS; Hirsch, HA; Gu, LP; LaMere, B; Henry, RW				Hinkley, CS; Hirsch, HA; Gu, LP; LaMere, B; Henry, RW			The small nuclear RNA-activating protein 190 Myb DNA binding domain stimulates TATA box-binding protein-TATA box recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III TRANSCRIPTION; PROXIMAL SEQUENCE ELEMENT; SNRNA GENE-TRANSCRIPTION; OCT-1 POU DOMAIN; FACTOR-TFIIIB; COMPLEX SNAP(C); HUMAN U6; EUKARYOTIC TRANSCRIPTION; PROMOTER ELEMENTS; TBP	Human U6 small nuclear RNA (snRNA) gene transcription by RNA polymerase III requires cooperative promoter binding involving the snRNA-activating protein complex (SNAP(c)) and the TATA-box binding protein (TBP). To investigate the role of SNAP(c) for TBP function at U6 promoters, TBP recruitment assays were performed using full-length TBP and a mini-SNAP(c) containing SNAP43, SNAP50, and a truncated SNAP190. Mini-SNAP(c) efficiently recruits TBP to the U6 TATA box, and two SNAP(c) subunits, SNAP43 and SNAP190, directly interact with the TBP DNA binding domain. Truncated SNAP190 containing only the Myb DNA binding domain is sufficient for TBP recruitment to the TATA box. Therefore, the SNAP190 Myb domain functions both to specifically recognize the proximal sequence element present in the core promoters of human snRNA genes and to stimulate TBP recognition of the neighboring TATA box present in human U6 snRNA promoters. The SNAP190 Myb domain also stimulates complex assembly with TBP and Brf2, a subunit of a snRNA-specific TFIIIB complex. Thus, interactions between the DNA binding domains of SNAP190 and TBP at juxtaposed promoter elements define the assembly of a RNA polymerase III-specific preinitiation complex.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Biochem Res Training Program, E Lansing, MI 48824 USA; Michigan State Univ, Cell & Mol Biol Program, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Henry, RW (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, 409 Biochem Bldg,Wilson Rd, E Lansing, MI 48824 USA.	henryrw@pilot.msu.edu			NIGMS NIH HHS [R01 GM59805] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059805] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Bai L, 1996, MOL CELL BIOL, V16, P5419; BERNUES J, 1993, EMBO J, V12, P3573, DOI 10.1002/j.1460-2075.1993.tb06031.x; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; Cabart P, 2001, J BIOL CHEM, V276, P43056, DOI 10.1074/jbc.M108515200; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; Ford E, 1998, GENE DEV, V12, P3528, DOI 10.1101/gad.12.22.3528; GOOMER RS, 1992, NUCLEIC ACIDS RES, V20, P4903, DOI 10.1093/nar/20.18.4903; Hampsey M, 1997, CURR BIOL, V7, pR44, DOI 10.1016/S0960-9822(06)00018-2; Henry RW, 1998, COLD SPRING HARB SYM, V63, P111, DOI 10.1101/sqb.1998.63.111; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; Henry RW, 1996, EMBO J, V15, P7129, DOI 10.1002/j.1460-2075.1996.tb01104.x; Henry RW, 1998, GENE DEV, V12, P2664, DOI 10.1101/gad.12.17.2664; Hernandez N, 2001, J BIOL CHEM, V276, P26733, DOI 10.1074/jbc.R100032200; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; Hirsch HA, 2000, MOL CELL BIOL, V20, P9182, DOI 10.1128/MCB.20.24.9182-9191.2000; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; Ma B, 2001, J BIOL CHEM, V276, P5027, DOI 10.1074/jbc.M009301200; Ma BC, 2002, MOL CELL BIOL, V22, P8067, DOI 10.1128/MCB.22.22.8067-8078.2002; McCulloch V, 2000, EMBO J, V19, P4134, DOI 10.1093/emboj/19.15.4134; MEYERS RE, 1993, MOL CELL BIOL, V13, P7953, DOI 10.1128/MCB.13.12.7953; Mital R, 1996, MOL CELL BIOL, V16, P7031; Mittal V, 1999, GENE DEV, V13, P1807, DOI 10.1101/gad.13.14.1807; Mittal V, 1997, SCIENCE, V275, P1136, DOI 10.1126/science.275.5303.1136; Mittal V, 1996, MOL CELL BIOL, V16, P1955; MURPHY S, 1992, MOL CELL BIOL, V12, P3247, DOI 10.1128/MCB.12.7.3247; Parkhurst KM, 1999, J MOL BIOL, V289, P1327, DOI 10.1006/jmbi.1999.2835; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Roeder RG, 1996, METHOD ENZYMOL, V273, P165; Sadowski CL, 1996, P NATL ACAD SCI USA, V93, P4289, DOI 10.1073/pnas.93.9.4289; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; Stunkel W, 1997, MOL CELL BIOL, V17, P4397; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; Willis IM, 2002, GENE DEV, V16, P1337, DOI 10.1101/gad.998102; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; Wong MW, 1998, MOL CELL BIOL, V18, P368, DOI 10.1128/MCB.18.1.368; Yoon JB, 1996, MOL CELL BIOL, V16, P1; Zhao XM, 2002, CELL, V108, P615, DOI 10.1016/S0092-8674(02)00648-7; Zhao XY, 2001, MOL CELL, V7, P539, DOI 10.1016/S1097-2765(01)00201-5	52	21	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18649	18657		10.1074/jbc.M204247200	http://dx.doi.org/10.1074/jbc.M204247200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621023	hybrid			2022-12-27	WOS:000182838300137
J	Mao, HP; Li, FH; Ruchalski, K; Mosser, DD; Schwartz, JH; Wang, YH; Borkan, SC				Mao, HP; Li, FH; Ruchalski, K; Mosser, DD; Schwartz, JH; Wang, YH; Borkan, SC			hsp72 inhibits focal adhesion kinase degradation in ATP-depleted renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK-PROTEIN HSP70; SIGNAL-TRANSDUCTION; SUBLETHAL INJURY; TERMINAL DOMAIN; GROWTH-FACTOR; APOPTOSIS; FAK; INTEGRIN; CYTOSKELETAL; CASPASES	Prior heat stress (HS) or the selective overexpression of hsp72 prevents apoptosis caused by exposure to metabolic inhibitors by protecting the mitochondrial membrane and partially reducing caspase-3 activation. Focal adhesion kinase (FAK), a tyrosine kinase, exhibits antiapoptotic properties and is a potential target for degradation by caspase-3. This study tested the hypothesis that hsp72 interacts with FAK, preventing caspase-3-mediated degradation during ATP depletion. ATP depletion (5 mM NaCN and 5 mM 2-deoxy-D-glucose in the absence of medium glucose) caused FAK degradation within 15 min. FAK degradation was completely prevented by a caspase-3-specific inhibitor. HS induced the accumulation of hsp72, increased the interaction between hsp72 and FAK, and significantly inhibited FAK degradation during ATP depletion. Selective overexpression of wild-type hsp72 (but not hsp72DeltaEEVD) reproduced the protective effects of HS on FAK cleavage. Purified hsp72 prevented the degradation of FAK by caspase-3 in vitro in a dose-dependent manner without affecting caspase-3 activity. Interaction between hsp72 and FAK is critical because both exogenous ATP and deletion of the substrate-binding site decreased protection of FAK by hsp72. These data indicate that FAK is an early target of injury in cells exposed to metabolic inhibitors and demonstrate that hsp72 reduces caspase-3-mediated proteolysis of FAK, an anti-apoptotic protein.	Boston Univ, Boston Med Ctr, Dept Med, Renal Sect, Boston, MA 02118 USA; Zhongshan Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou 510080, Peoples R China; Tufts Univ, Dept Pathol, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	Boston Medical Center; Boston University; Sun Yat Sen University; Tufts University; Tufts Medical Center; University of Guelph	Borkan, SC (corresponding author), Evans Biomed Res Ctr, Renal Sect, Rm 547,650 Albany St, Boston, MA 02118 USA.	sborkan@bu.edu	Mosser, Dick D/A-7391-2008; Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681; Mosser, Richard/0000-0002-9183-2288; Mao, Haiping/0000-0002-3608-3851; Borkan, Steven/0000-0003-3062-9486	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053387, R01DK052898] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52898, DK-53387] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alahari SK, 2002, INT REV CYTOL, V220, P145; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bellas RE, 2002, AM J PHYSIOL-LUNG C, V282, pL1135, DOI 10.1152/ajplung.00174.2001; Bergin E, 2000, AM J PHYSIOL-RENAL, V278, pF758, DOI 10.1152/ajprenal.2000.278.5.F758; Borkan SC, 1997, AM J PHYSIOL-RENAL, V272, pF347, DOI 10.1152/ajprenal.1997.272.3.F347; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Feldenberg LR, 1999, AM J PHYSIOL-RENAL, V276, pF837, DOI 10.1152/ajprenal.1999.276.6.F837; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Grossmann J, 2001, GASTROENTEROLOGY, V120, P79, DOI 10.1053/gast.2001.20879; Harrington EO, 2001, AM J PHYSIOL-LUNG C, V280, pL342, DOI 10.1152/ajplung.2001.280.2.L342; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; ILLC D, 1995, NATURE, V377, P539; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jones G, 2001, CANCER RES, V61, P4978; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; KROSHIAN VM, 1994, AM J PHYSIOL, V266, pF21, DOI 10.1152/ajprenal.1994.266.1.F21; Kwon O, 1998, J CLIN INVEST, V101, P2054, DOI 10.1172/JCI772; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li F, 2002, AM J PHYSIOL-CELL PH, V283, pC917, DOI 10.1152/ajpcell.00517.2001; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Lieberthal W, 1997, J AM SOC NEPHROL, V8, P175; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315, DOI 10.1152/ajprenal.1998.274.2.F315; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; NOIRI E, 1994, KIDNEY INT, V46, P1050, DOI 10.1038/ki.1994.366; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ridyard MS, 2001, CELL BIOL INT, V25, P215, DOI 10.1006/cbir.2000.0634; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Sakurai S, 2002, BIOCHEM BIOPH RES CO, V293, P174, DOI 10.1016/S0006-291X(02)00192-4; Sasaki H, 2002, GYNECOL ONCOL, V85, P339, DOI 10.1006/gyno.2002.6632; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHUMER M, 1992, AM J PATHOL, V140, P831; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Stewart A, 2002, BIOCHEM BIOPH RES CO, V299, P62, DOI 10.1016/S0006-291X(02)02547-0; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; Wang YH, 1999, KIDNEY INT, V55, P2224, DOI 10.1046/j.1523-1755.1999.00476.x; Wang YH, 1996, AM J PHYSIOL-RENAL, V270, pF1057, DOI 10.1152/ajprenal.1996.270.6.F1057; Wang YH, 2002, CELL STRESS CHAPERON, V7, P137, DOI 10.1379/1466-1268(2002)007<0137:HEESIA>2.0.CO;2; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zuk A, 1998, AM J PHYSIOL-CELL PH, V275, pC711, DOI 10.1152/ajpcell.1998.275.3.C711	51	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18214	18220		10.1074/jbc.M300126200	http://dx.doi.org/10.1074/jbc.M300126200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12611892	hybrid			2022-12-27	WOS:000182838300082
J	Srisailam, S; Krishnaswamy, T; Kumar, TKS; Rajalingam, D; Kathir, KM; Sheu, HS; Jan, FJ; Chao, PC; Yu, C				Srisailam, S; Krishnaswamy, T; Kumar, TKS; Rajalingam, D; Kathir, KM; Sheu, HS; Jan, FJ; Chao, PC; Yu, C			Amyloid-like fibril formation in an all beta-barrel protein - Partially structured intermediate state(s) is a precursor for fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; ALPHA-SYNUCLEIN; GLOBULAR-PROTEIN; HUMAN LYSOZYME; AGGREGATION; PRION; INSULIN; BETA(2)-MICROGLOBULIN; CONFORMATION; INCLUSION	Acidic fibroblast growth factor from newt (Notopthalmus viridescens) is a similar to15-kDa, all beta-sheet protein devoid of disulfide bonds. In the present study, we investigate the effects of 2,2,2-trifluoroethanol (TFE) on the structure of newt acidic fibroblast growth factor (nFGF-1). The protein aggregates maximally in 10% (v/v) TFE. Congo red and thioflavin T binding experiments suggest that the aggregates induced by TFE have properties resembling the amyloid fibrils. Transmission electron microscopy and x-ray fiber diffraction data show that the fibrils (induced by TFE) are straight, unbranched, and have a cross-beta structure with an average diameter of 10-15 Angstrom. Preformed fibrils (induced by TFE) of nFGF-1 are observed to seed amyloid-like fibril formation in solutions containing the protein (nFGF-1) in the native beta-barrel conformation. Fluorescence, far-UV CD, anilino-8-napthalene sulfonate binding, multidimensional NMR, and Fourier transformed infrared spectroscopy data reveal that formation of a partially structured intermediate state(s) precedes the onset of the fibrillation process. The native beta-barrel structure of nFGF-1 appears to be disrupted in the partially structured intermediate state(s). The protein in the partially structured intermediate state(s) is found to be "sticky" with a solvent-exposed non-polar surface(s). Amyloid fibril formation appears to occur due to coalescence of the protein in the partially structured intermediate state(s) through solvent-exposed non-polar surfaces and intermolecular beta-sheet formation among the extended, linear beta-strands in the protein.	Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan; Synchrotron Radiat Res Ctr, Hsinchu 300, Taiwan; Natl Chung Hsing Univ, Reg Instrumentat Ctr, Taichung 40277, Taiwan	National Tsing Hua University; National Synchrotron Radiation Research Center; National Chung Hsing University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan.	cyu@mx.nthu.edu.tw	Kumar, Dr Suresh/HHZ-2615-2022; Kumar, Suresh Thallapuranam/R-5606-2016; KUMAR, P. SURESH/AAT-8951-2020; Jan, Fuh-Jyh/Y-1781-2019	Kumar, Dr Suresh/0000-0002-2539-6553; Kumar, Suresh Thallapuranam/0000-0001-7262-1373; KUMAR, P. SURESH/0000-0003-3222-2604; 				Arunkumar AI, 2000, J BIOMOL NMR, V17, P279, DOI 10.1023/A:1008339701691; Arunkumar AI, 2002, PROTEIN SCI, V11, P1050, DOI 10.1110/ps.2270102; ARUNKUMAR AI, 1997, BIOCHIM BIOPHYS ACTA, V1138, P69; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bouchard M, 2000, PROTEIN SCI, V9, P1960, DOI 10.1110/ps.9.10.1960; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Caughey B, 2001, PHILOS T ROY SOC B, V356, P197, DOI 10.1098/rstb.2000.0765; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; Chan W, 1996, FOLD DES, V1, P77, DOI 10.1016/S1359-0278(96)00017-X; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; COHBERG JA, 2002, BIOCHEMISTRY-US, V41, P1502; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DABORA JM, 1991, J BIOL CHEM, V266, P23637; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Finke JM, 2000, BIOCHEMISTRY-US, V39, P15633, DOI 10.1021/bi001307d; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; Hamada D, 2002, PROTEIN SCI, V11, P2417, DOI 10.1110/ps.0217702; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Inouye H, 2000, J STRUCT BIOL, V130, P123, DOI 10.1006/jsbi.2000.4258; JIANG X, 2001, P NATL ACAD SCI USA, V277, P1310; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; Kelly JW, 1998, P NATL ACAD SCI USA, V95, P930, DOI 10.1073/pnas.95.3.930; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; KLEIN J, 1995, APPL ENVIRON MICROB, V61, P1220, DOI 10.1128/AEM.61.4.1220-1225.1995; Krebs MRH, 2000, J MOL BIOL, V300, P541, DOI 10.1006/jmbi.2000.3862; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; MacPhee CE, 2000, J AM CHEM SOC, V122, P12707, DOI 10.1021/ja0029580; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Morozova-Roche LA, 2000, J STRUCT BIOL, V130, P339, DOI 10.1006/jsbi.2000.4264; MULLINS J, 1993, CRYSTALLIZATION; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Padrick SB, 2001, J MOL BIOL, V308, P783, DOI 10.1006/jmbi.2001.4608; Pertinhez TA, 2001, FEBS LETT, V495, P184, DOI 10.1016/S0014-5793(01)02384-5; Rajan R, 1996, INT J PEPT PROT RES, V48, P328; Samuel D, 2001, J BIOL CHEM, V276, P4134, DOI 10.1074/jbc.M005921200; Samuel D, 2000, J BIOL CHEM, V275, P34968, DOI 10.1074/jbc.M005147200; Schulman BA, 1997, NAT STRUCT BIOL, V4, P630, DOI 10.1038/nsb0897-630; Seshadri S, 1999, METHOD ENZYMOL, V309, P559; Shtilerman MD, 2002, BIOCHEMISTRY-US, V41, P3855, DOI 10.1021/bi0120906; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Srisailam S, 2002, J AM CHEM SOC, V124, P1884, DOI 10.1021/ja012070r; Srisailam S, 2002, J BIOL CHEM, V277, P19027, DOI 10.1074/jbc.M110762200; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Taddei N, 2001, J BIOL CHEM, V276, P37149, DOI 10.1074/jbc.M105720200; THOMAS PD, 1993, PROTEIN SCI, V2, P2050, DOI 10.1002/pro.5560021206; Tito P, 2000, J MOL BIOL, V303, P267, DOI 10.1006/jmbi.2000.4142; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Zurdo J, 2001, J MOL BIOL, V311, P325, DOI 10.1006/jmbi.2001.4858	53	60	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17701	17709		10.1074/jbc.M300336200	http://dx.doi.org/10.1074/jbc.M300336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12584201	Green Submitted, hybrid			2022-12-27	WOS:000182838300016
J	Wan, KF; Sambi, BS; Tate, R; Waters, C; Pyne, NJ				Wan, KF; Sambi, BS; Tate, R; Waters, C; Pyne, NJ			The inhibitory gamma subunit of the type 6 retinal cGMP phosphodiesterase functions to link c-Src and G-protein-coupled receptor kinase 2 in a signaling unit that regulates p42/p44 mitogen-activated protein kinase by epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANOSINE-MONOPHOSPHATE PHOSPHODIESTERASE; MEDIATED TYROSINE PHOSPHORYLATION; AIRWAY SMOOTH-MUSCLE; G(BETA-GAMMA) SUBUNITS; FACTOR STIMULATION; BETA-ARRESTIN; INSULIN; CELLS; INTERNALIZATION; REQUIRES	The inhibitory gamma subunit of the retinal photoreceptor type 6 cGMP phosphodiesterase (PDEgamma) is phosphorylated by G-protein-coupled receptor kinase 2 on threonine 62 and regulates the epidermal growth factor-dependent stimulation of p42/p44 mitogen-activated protein kinase in human embryonic kidney 293 cells. We report here that PDEgamma is in a pre-formed complex with c-Src and that stimulation of cells with epidermal growth factor promotes the association of GRK2 with this complex. c-Src has a critical role in the stimulation of the p42/p44 mitogen-activated protein kinase cascade by epidermal growth factor, because c-Src inhibitors block the activation of this kinase by the growth factor. Mutation of Thr-62 (to Ala) in PDEgamma produced a GRK2 phosphorylation-resistant mutant that was less effective in associating with GRK2 in response to epidermal growth factor and did not potentiate the stimulation of p42/p44 mitogen-activated protein kinase by this growth factor. The transcript for a short splice variant version of PDEgamma lacking the Thr-62 phosphorylation site is also expressed in certain mammalian cells and, in common with the Thr-62 mutant, failed to potentiate the stimulatory effect of epidermal growth factor on p42/p44 mitogen-activated protein kinase. The mutation of Thr-22 (to Ala) in PDEgamma, which is a site for phosphorylation by p42/p44 mitogen-activated protein kinase, resulted in a prolonged activation of p42/p44 mitogen-activated protein kinase by epidermal growth factor, suggesting a role for this phosphorylation event in the negative feedback control of PDEgamma.	Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland	University of Strathclyde	Pyne, NJ (corresponding author), Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Physiol & Pharmacol, 27 Taylor St, Glasgow G4 0NR, Lanark, Scotland.			Tate, Rothwelle/0000-0001-5857-4267; Pyne, Nigel/0000-0002-5657-4578				Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; Conway AM, 1999, BIOCHEM J, V337, P171, DOI 10.1042/0264-6021:3370171; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Fedorov YV, 1998, MOL CELL BIOL, V18, P5780, DOI 10.1128/MCB.18.10.5780; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; Lochhead A, 1997, J BIOL CHEM, V272, P18397, DOI 10.1074/jbc.272.29.18397; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Paglia MJ, 2002, J BIOL CHEM, V277, P5017, DOI 10.1074/jbc.M106328200; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Rakhit S, 2001, MOL PHARMACOL, V60, P63, DOI 10.1124/mol.60.1.63; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; STRYER L, 1991, J BIOL CHEM, V266, P10711; Tate RJ, 2002, GENOMICS, V79, P582, DOI 10.1006/geno.2002.6740; Tate Rothwelle J., 1998, Cell Biochemistry and Biophysics, V29, P133, DOI 10.1007/BF02737832; VAN BT, 1995, NATURE, V376, P781; Wan KF, 2001, J BIOL CHEM, V276, P37802; Wang HY, 2000, J BIOL CHEM, V275, P36086, DOI 10.1074/jbc.M004404200	24	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18658	18663		10.1074/jbc.M212103200	http://dx.doi.org/10.1074/jbc.M212103200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624098	hybrid			2022-12-27	WOS:000182838300138
J	Yin, SM; Ho, CK; Shuman, S				Yin, SM; Ho, CK; Shuman, S			Structure-function analysis of T4 RNA ligase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-DNA-LIGASE; RNA CAPPING ENZYME; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; ADENYLYLATION SITE; NICK RECOGNITION; CATALYSIS; COMPLEX; MOTIFS; IV	Bacteriophage T4 RNA ligase 2 (Rnl2) exemplifies a polynucleotide ligase family that includes the trypanosome RNA-editing ligases and putative RNA ligases encoded by eukaryotic viruses and archaea. Here we analyzed 12 individual amino acids of Rnl2 that were identified by alanine scanning as essential for strand joining. We determined structure-activity relationships via conservative substitutions and examined mutational effects on the isolated steps of ligase adenylylation and phosphodiester bond formation. The essential residues of Rnl2 are located within conserved motifs that define a superfamily of nucleotidyl transferases that act via enzyme-(lysyl-N)-NMP intermediates. Our mutagenesis results underscore a shared active site architecture in Rnl2-like ligases, DNA ligases, and mRNA capping enzymes. They also highlight two essential signature residues, Glu(34) and Asn(40), that flank the active site lysine nucleophile (Lys(35)) and are unique to the Rnl2-like ligase family.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Ho, KIong/GPP-6051-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063611] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63611] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMITSUR M, 1987, EMBO J, V6, P2499, DOI 10.1002/j.1460-2075.1987.tb02532.x; CRANSTON JW, 1974, J BIOL CHEM, V249, P7447; Doherty AJ, 2000, J MOL BIOL, V296, P43, DOI 10.1006/jmbi.1999.3423; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; Ho CK, 2002, P NATL ACAD SCI USA, V99, P12709, DOI 10.1073/pnas.192184699; Kaufmann G, 2000, TRENDS BIOCHEM SCI, V25, P70, DOI 10.1016/S0968-0004(99)01525-X; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; McManus MT, 2001, RNA, V7, P167, DOI 10.1017/S1355838201002072; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Rusche LN, 2001, MOL CELL BIOL, V21, P979, DOI 10.1128/MCB.21.4.979-989.2001; Schnaufer A, 2001, SCIENCE, V291, P2159, DOI 10.1126/science.1058655; Sekiguchi J, 1997, J VIROL, V71, P9679, DOI 10.1128/JVI.71.12.9679-9684.1997; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1995, VIROLOGY, V211, P73, DOI 10.1006/viro.1995.1380; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; Shuman S, 2001, COLD SPRING HARB SYM, V66, P301, DOI 10.1101/sqb.2001.66.301; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SILBER R, 1972, P NATL ACAD SCI USA, V69, P3009, DOI 10.1073/pnas.69.10.3009; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P525, DOI 10.1093/nar/26.2.525; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P4618, DOI 10.1093/nar/26.20.4618; Sriskanda V, 2000, NUCLEIC ACIDS RES, V28, P2221, DOI 10.1093/nar/28.11.2221; Sriskanda V, 2002, J BIOL CHEM, V277, P9661, DOI 10.1074/jbc.M110613200; Sriskanda V, 2002, NUCLEIC ACIDS RES, V30, P903, DOI 10.1093/nar/30.4.903; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; SUGINO A, 1977, J BIOL CHEM, V252, P1732; THOGERSEN HC, 1985, EUR J BIOCHEM, V147, P325, DOI 10.1111/j.1432-1033.1985.tb08753.x; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573	30	57	63	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17601	17608		10.1074/jbc.M300817200	http://dx.doi.org/10.1074/jbc.M300817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12611899	hybrid			2022-12-27	WOS:000182838300005
J	Engblom, AC; Johansen, FF; Kristiansen, U				Engblom, AC; Johansen, FF; Kristiansen, U			Actions and interactions of extracellular potassium and kainate on expression of 13 gamma-aminobutyric acid type A receptor subunits in cultured mouse cerebellar granule neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL RT-PCR; GABA(A) RECEPTOR; A RECEPTOR; MESSENGER-RNAS; DELTA-SUBUNIT; RAT-BRAIN; POSTNATAL-DEVELOPMENT; CORTICAL-NEURONS; ALPHA-SUBUNITS; PATCH-CLAMP	Cerebellar granule neurons in culture are a popular model for studying neuronal signaling and development. Depolarizing concentrations of K+ are routinely used to enhance cell survival, and kainate is sometimes added to eliminate GABAergic neurons. We have investigated the effect of these measures on expression of mRNA for gamma-aminobutyric acid type A (GABA(A)) receptor alpha1-6, beta1-3, gamma1-3, and delta subunits in cultures of mouse cerebellar granule neurons grown for 7 or 12 days in vitro (DIV) using semi-quantitative reverse transcription-PCR. We detected mRNA for the alpha1, alpha2, alpha5, alpha6, beta2, beta3, beta2, and delta subunits in all the cell cultures, but the expression levels of the alpha5-, alpha6-, and beta2-subunit mRNAs were significantly dependent on the composition of the culture medium. Both an increase of the extracellular K+ concentration from 5 to 25 mM and the addition of 50 muM kainate immediately depolarized the neurons but prolonged exposure (7-8 DIV)-induced compensatory hyperpolarization. 25 mM K+ caused a shift from alpha6 to alpha5 expression measured at 7 and 12 DIV, which was mimicked by kainate in 12 DIV cultures. The expression of beta2 was decreased by 25 mM K+ in 7 DIV cultures and by kainate in 12 DIV cultures. The effects on beta2 expression could not be ascribed to depolarization. Alterations of alpha6 mRNA expression were reflected in altered sensitivity to GABA and furosemide of the resulting receptors. Our study has shown that a depolarizing K+ concentration as well as kainate in the culture medium significantly disturbs maturation of GABA(A) receptor subunit expression.	Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Neuropathol Lab, DK-2100 Copenhagen, Denmark	Royal Danish School of Pharmacy; University of Copenhagen	Kristiansen, U (corresponding author), Royal Danish Sch Pharm, Dept Pharmacol, 2 Univ Pk, DK-2100 Copenhagen, Denmark.							Alsbo CW, 2001, EUR J NEUROSCI, V13, P1673, DOI 10.1046/j.0953-816x.2001.01539.x; Barnard EA, 1998, PHARMACOL REV, V50, P291; BESSHO Y, 1994, NEURON, V12, P87, DOI 10.1016/0896-6273(94)90154-6; Bhave SV, 1999, J NEUROSCI, V19, P3277, DOI 10.1523/jneurosci.19-09-03277.1999; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Brooks-Kayal AR, 2001, J NEUROCHEM, V77, P1266, DOI 10.1046/j.1471-4159.2001.00329.x; CARUNCHO HJ, 1995, NEUROSCIENCE, V67, P583, DOI 10.1016/0306-4522(95)00065-Q; CONDORELLI DF, 1993, J NEUROCHEM, V61, P2133, DOI 10.1111/j.1471-4159.1993.tb07451.x; Courtney MJ, 1997, J NEUROSCI, V17, P4201; DARLISON MG, 1995, SEMIN NEUROSCI, V7, P115, DOI 10.1006/smns.1995.0013; Dingledine R, 1999, PHARMACOL REV, V51, P7; GALLO V, 1987, J NEUROSCI, V7, P2203; Gault LM, 1997, J NEUROSCI, V17, P2391; Gault LM, 1998, J NEUROCHEM, V70, P1907; HACK NJ, 1995, DEV BRAIN RES, V87, P55, DOI 10.1016/0165-3806(95)00054-H; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hansen SL, 2001, BRIT J PHARMACOL, V133, P539, DOI 10.1038/sj.bjp.0704121; HARRIS BT, 1995, MOL BRAIN RES, V28, P338, DOI 10.1016/0169-328X(94)00240-F; Jechlinger M, 1998, J NEUROSCI, V18, P2449; Jensen JB, 1998, NEUROCHEM INT, V32, P505, DOI 10.1016/S0197-0186(97)00130-7; JOHANSEN FF, 1995, NEUROCHEM INT, V26, P239, DOI 10.1016/0197-0186(94)00129-I; Jones A, 1997, J NEUROSCI, V17, P1350; Koester J., 1991, PRINCIPLES NEURAL SC, V3, P81; KORPI ER, 1995, MOL PHARMACOL, V47, P283; Korpi ER, 2002, PROG NEUROBIOL, V67, P113, DOI 10.1016/S0301-0082(02)00013-8; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; Lee YH, 2000, J NEUROCHEM, V74, P2401, DOI 10.1046/j.1471-4159.2000.0742401.x; MATHEWS GC, 1994, NEURON, V13, P149, DOI 10.1016/0896-6273(94)90465-0; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Mellor JR, 1998, J NEUROSCI, V18, P2822; MOGENSEN HS, 1994, INT J DEV NEUROSCI, V12, P451, DOI 10.1016/0736-5748(94)90029-9; Montpied P, 1998, DEV NEUROSCI-BASEL, V20, P74, DOI 10.1159/000017301; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; Nusser Z, 1999, EUR J NEUROSCI, V11, P1685, DOI 10.1046/j.1460-9568.1999.00581.x; Pirker S, 2000, NEUROSCIENCE, V101, P815, DOI 10.1016/S0306-4522(00)00442-5; POLLARD S, 1995, J BIOL CHEM, V270, P21285, DOI 10.1074/jbc.270.36.21285; POULTER MO, 1992, J NEUROSCI, V12, P2888, DOI 10.1523/JNEUROSCI.12-08-02888.1992; QUIRK K, 1994, J BIOL CHEM, V269, P16020; Rudolph U, 2001, TRENDS PHARMACOL SCI, V22, P188, DOI 10.1016/S0165-6147(00)01646-1; Saxena NC, 1996, MOL PHARMACOL, V49, P567; Schousboe A., 1989, DISSECTION TISSUE CU, P203; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Sigel E, 2000, J NEUROCHEM, V74, P2590, DOI 10.1046/j.1471-4159.2000.0742590.x; Sinkkonen ST, 2000, J NEUROSCI, V20, P3588, DOI 10.1523/JNEUROSCI.20-10-03588.2000; THOMPSON CL, 1994, J NEUROCHEM, V62, P2037; Vallano ML, 1996, J NEUROSCI, V16, P631; VERDOORN TA, 1994, MOL PHARMACOL, V45, P475; Wisden W, 1996, NEUROPHARMACOLOGY, V35, P1139, DOI 10.1016/S0028-3908(96)00076-7; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; ZHENG TM, 1994, P NATL ACAD SCI USA, V91, P10952, DOI 10.1073/pnas.91.23.10952	52	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16543	16550		10.1074/jbc.M300548200	http://dx.doi.org/10.1074/jbc.M300548200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621038	hybrid			2022-12-27	WOS:000182818600015
J	Jirawatnotai, S; Moons, DS; Stocco, CO; Franks, R; Hales, DB; Gibori, G; Kiyokawa, H				Jirawatnotai, S; Moons, DS; Stocco, CO; Franks, R; Hales, DB; Gibori, G; Kiyokawa, H			The cyclin-dependent kinase inhibitors p27(Kip1) and p21(Cip1) cooperate to restrict proliferative life span in differentiating ovarian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE FIBROBLASTS LACKING; CDK INHIBITORS; MICE LACKING; GRANULOSA-CELLS; ONCOGENIC RAS; SENESCENCE; G1; P16(INK4A); CULTURE; CANCER	The timing of cellular exit from the cell cycle during differentiation is specific for each cell type or lineage. Granulosa cells in the ovary establish quiescence within several hours after the ovulation-inducing luteinizing hormone surge, whereas they undergo differentiation into corpora lutea. The expression of Cdk inhibitors p21(Cip1/Waf1) and p27(Kip1) is up-regulated during this process, suggesting that these cell cycle inhibitors are involved in restricting proliferative capacity of differentiating granulosa cells. Here we demonstrate that the lack of p27(Kip1) and p21(Cip1) synergistically renders granulosa cells extended an proliferative life span. Immunohistochemical analyses demonstrated that corpora lutea of p27(Kip1), p21(Cip1) double-null mice showed large numbers of cells with bromodeoxyuridine incorporation and high proliferative cell nuclear antigen expression, which were more remarkable than those in p27(Kip1) single-deficient mice showing modest hyperproliferation. In contrast, differentiating granulosa cells in p21(Cip1-)deficient mice ceased proliferation similarly to those in wild-type mice. Interestingly, granulosa cells isolated from p27(Kip1), p21(Cip1) double-null mice exhibited markedly prolonged proliferative life span in culture, unlike cells with other genotypes. Cultured p27(Kip1), p21(Cip1) double-null granulosa cells maintained expression of steroidogenic enzymes and gonadotropin receptors through 8-10 passages and could undergo further differentiation in responses to cAMP accumulation. Thus, the cooperation of p27(Kip1) and p21(Cip1) is critical for withdrawal of granulosa cells from the cell cycle, in concert with luteal differentiation and possibly culture-induced senescence.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Dept Physiol & Biophys, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Res Resources Ctr, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kiyokawa, H (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, 900 S Ashland Ave,M-C 669, Chicago, IL 60607 USA.	kiyokawa@uic.edu		Kiyokawa, Hiroaki/0000-0002-7942-6455	NICHD NIH HHS [HD38085] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038085] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Campisi J, 1996, EXP GERONTOL, V31, P7, DOI 10.1016/0531-5565(95)02024-1; Campisi J, 2001, EXP GERONTOL, V36, P607, DOI 10.1016/S0531-5565(00)00230-8; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; HALES DB, 1989, ENDOCRINOLOGY, V124, P2099, DOI 10.1210/endo-124-5-2099; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HIRSHFIELD AN, 1991, INT REV CYTOL, V124, P43; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyokawa H, 1998, CURR TOP MICROBIOL, V227, P105; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kwon YH, 2002, J BIOL CHEM, V277, P41417, DOI 10.1074/jbc.M203388200; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Moons DS, 2002, ENDOCRINOLOGY, V143, P3001, DOI 10.1210/en.143.8.3001; Moons DS, 2002, ENDOCRINOLOGY, V143, P647, DOI 10.1210/en.143.2.647; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; ORLY J, 1980, CELL, V20, P817, DOI 10.1016/0092-8674(80)90328-1; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RAO MC, 1978, CELL, V14, P71, DOI 10.1016/0092-8674(78)90302-1; Reed SI, 1997, CANCER SURV, V29, P7; Robker RL, 1998, BIOL REPROD, V59, P476, DOI 10.1095/biolreprod59.3.476; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sugimoto M, 2002, ONCOGENE, V21, P8067, DOI 10.1038/sj.onc.1206019; Tong W, 1998, CELL GROWTH DIFFER, V9, P787; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zindy F, 2001, MOL CELL BIOL, V21, P3244, DOI 10.1128/MCB.21.9.3244-3255.2001; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	43	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17021	17027		10.1074/jbc.M301206200	http://dx.doi.org/10.1074/jbc.M301206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609976	hybrid			2022-12-27	WOS:000182818600078
J	Kilkenny, DM; Rocheleau, JV; Price, J; Reich, MB; Miller, GG				Kilkenny, DM; Rocheleau, JV; Price, J; Reich, MB; Miller, GG			c-Src regulation of fibroblast growth factor-induced proliferation in murine embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; FAMILY KINASES; CELL-PROLIFERATION; FACTOR RECEPTOR-1; PROTEIN; ASSOCIATION; REQUIREMENT; ACTIVATION	Activated fibroblast growth factor receptor 1 (FGFR1) propagates FGF signals through multiple intracellular pathways via intermediates FRS2, PLCgamma, and Ras. Conflicting reports exist concerning the interaction between FGFR1 and Src family kinases. To address the role of c-Src in FGFR1 signaling, we compared proliferative responses of murine embryonic fibroblasts (MEF) deficient in c-Src, Yes, and Fyn to MEF expressing either endogenous levels or overexpressing c-Src. MEF with endogenous c-Src had significantly greater FGF-induced DNA synthesis and proliferation than cells lacking or overexpressing c-Src. This was related directly to c-Src expression by analysis of c-Src-deficient cells transfected with and sorted for varying levels of a c-Src expression vector. This suggests an "optimal" quantity of c-Src expression for FGF-induced proliferation. To determine if this was a general phenomenon for growth factor signaling pathways utilizing c-Src, responses to epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and lysophosphatidic acid (LPA) were examined. As for FGF, responses to EGF were clearly inhibited when c-Src was absent or overexpressed. In contrast, varying levels of c-Src had little effect on responses to PDGF or LPA. The data show that mitogenic pathways activated by FGF-1 and EGF are regulated by c-Src protein levels and appear to differ significantly from those activated by PDGF and LPA.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Vet Affairs Med Ctr, Flow Cytometry Pathol Lab, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Miller, GG (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, A3310 Med Ctr N, Nashville, TN 37232 USA.	Geraldine.Miller@vanderbilt.edu		Rocheleau, Jonathan/0000-0002-1760-2564	NCI NIH HHS [P30CA68485] Funding Source: Medline; NHLBI NIH HHS [T32-HL69765-01, HL53771] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053771, T32HL069765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Bevan P, 2001, J CELL SCI, V114, P1429; Broome MA, 2000, ONCOGENE, V19, P2867, DOI 10.1038/sj.onc.1203608; CHACKALAPARAMPI.I, 1998, CELL, V52, P801; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; Dikov MM, 1998, J BIOL CHEM, V273, P15811, DOI 10.1074/jbc.273.25.15811; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LANDGREN E, 1995, ONCOGENE, V10, P2027; Landgren E, 1998, ONCOGENE, V17, P283, DOI 10.1038/sj.onc.1201936; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Miller GG, 1999, CIRCULATION, V100, P2396, DOI 10.1161/01.CIR.100.24.2396; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Tartaglia M, 2001, DNA CELL BIOL, V20, P367, DOI 10.1089/10445490152122488; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHAO XM, 1994, J CLIN INVEST, V94, P992, DOI 10.1172/JCI117466	33	33	40	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17448	17454		10.1074/jbc.M209698200	http://dx.doi.org/10.1074/jbc.M209698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621028	hybrid			2022-12-27	WOS:000182818600132
J	Lovato, P; Brender, C; Agnholt, J; Kelsen, J; Kaltoft, K; Svejgaard, A; Eriksen, KW; Woetmann, A; Odum, N				Lovato, P; Brender, C; Agnholt, J; Kelsen, J; Kaltoft, K; Svejgaard, A; Eriksen, KW; Woetmann, A; Odum, N			Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; IFN-GAMMA; PATHWAY; GROWTH; INTERLEUKIN-12; EXPRESSION; RESPONSES; LYMPHOMA; PROTEINS; SIGNALS	Via cytoplasmic signal transduction pathways, cytokines induce a variety of biological responses and modulate the outcome of inflammatory diseases and malignancies. Crohn's disease is a chronic inflammatory bowel disease of unknown etiology. Perturbation of the intestinal cytokine homeostasis is believed to play a pivotal role, but the pathogenesis of Crohn's disease is not fully understood. Here, we study intestinal T cells from Crohn's disease and healthy volunteers. We show that STAT3 and STAT4 are constitutively activated in Crohn's patients but not in healthy volunteers. The activation is specific, because other STAT proteins are not constitutively activated. Furthermore, the STAT3 regulated protein, SOCS3, is also constitutively expressed in Crohn's patients but not in healthy volunteers. Taken together, these data provide evidence of abnormal STAT/SOCS signaling in Crohn's disease. This aberrant activation, so far noted only in malignant cells, establish a new critical approach for better understanding the immunopathogenesis of Crohn's disease.	Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Biol, DK-2200 Copenhagen, Denmark; Aarhus Univ Hosp, Dept Med V, DK-8000 Aarhus, Denmark; Aarhus Univ, Inst Human Genet, DK-8000 Aarhus C, Denmark; Natl Univ Hosp, Tissue Typing Lab, Dept Clin Immunol, DK-2200 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Aarhus University; Aarhus University	Odum, N (corresponding author), Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, Panum 22-5,Blegdamsvej 3C, DK-2200 Copenhagen, Denmark.		Woetmann, Anders/AAJ-3171-2020	Woetmann, Anders/0000-0002-3008-735X; Lovato, Paola/0000-0002-4097-9634; Agnholt, Jorgen/0000-0003-2822-6442				Brender C, 2001, BLOOD, V97, P1056, DOI 10.1182/blood.V97.4.1056; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; KALTOFT K, 1992, IN VITRO CELL DEV-AN, V28A, P161; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Monteleone G, 1997, GASTROENTEROLOGY, V112, P1169, DOI 10.1016/S0016-5085(97)70128-8; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; NIELSEN M, 1994, EXP CLIN IMMUNOGENET, V11, P23; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Simpson SJ, 1998, J EXP MED, V187, P1225, DOI 10.1084/jem.187.8.1225; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Wirtz S, 1999, J IMMUNOL, V162, P1884; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zushi SI, 1998, INT J CANCER, V78, P326, DOI 10.1002/(SICI)1097-0215(19981029)78:3<326::AID-IJC12>3.0.CO;2-4	26	150	173	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16777	16781		10.1074/jbc.M207999200	http://dx.doi.org/10.1074/jbc.M207999200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615922	hybrid			2022-12-27	WOS:000182818600045
J	Sakai, N; Maruyama, T; Sakurai, R; Masuda, H; Yamamoto, Y; Shimizu, A; Kishi, I; Asada, H; Yamagoe, S; Yoshimura, Y				Sakai, N; Maruyama, T; Sakurai, R; Masuda, H; Yamamoto, Y; Shimizu, A; Kishi, I; Asada, H; Yamagoe, S; Yoshimura, Y			Involvement of histone acetylation in ovarian steroid-induced decidualization of human endometrial stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO DECIDUALIZATION; FACTOR BINDING PROTEIN-1; PROGESTERONE-RECEPTOR; PROLACTIN EXPRESSION; SIGNAL TRANSDUCER; MENSTRUAL-CYCLE; TRICHOSTATIN-A; GENE PROMOTER; GROWTH; TRANSCRIPTION	Histone acetyltransferases and histone deacetylases (HDACs) determine the acetylation status of histones, regulating gene transcription. Decidualization is the progestin-induced differentiation of estrogen-primed endometrial stromal cells (ESCs), which is crucial for implantation and maintenance of pregnancy. We here show that trichostatin A (TSA), a specific HDAC inhibitor, enhances the up-regulation of decidualization markers such as insulin-like growth factor binding protein-1 (IGFBP-1) and prolactin in a dose-dependent manner that is directed by 17beta-estradiol (E-2) plus progesterone (P-4) in cultured ESCs, but not glandular cells, both isolated from human endometrium. Morphological changes resembling decidual transformation were also augmented by co-addition of TSA. Acid urea triton gel analysis and immunoblot using acetylated histone type-specific antibodies demonstrated that treatment with E-2 plus P-4 significantly increased the levels of acetylated H3 and H4 whose increment was augmented by co-treatment with TSA. Chromatin immunoprecipitation assay revealed that treatment with E-2 plus P-4 increased the amount of proximal progesterone-responsive region of IGFBP-1 promoter associated with acetylated H4, which was dramatically enhanced by co-addition of TSA. Taken together, our results suggest that histone acetylation is deeply involved in differentiation of human ESCs and that TSA has a potential as an enhancer of decidualization through promotion of progesterone action.	Keio Univ, Dept Obstet & Gynecol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan; Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo 1628640, Japan	Keio University; National Institute of Infectious Diseases (NIID)	Maruyama, T (corresponding author), Keio Univ, Dept Obstet & Gynecol, Sch Med, Shinjuku Ku, Shinanomach 35, Tokyo 1608582, Japan.							Brar AK, 2001, PHYSIOL GENOMICS, V7, P135, DOI 10.1152/physiolgenomics.00061.2001; Brar AK, 1997, ENDOCRINE, V6, P301, DOI 10.1007/BF02820507; Brosens JJ, 1999, ENDOCRINOLOGY, V140, P4809, DOI 10.1210/en.140.10.4809; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gao JG, 1999, MOL CELL ENDOCRINOL, V153, P11, DOI 10.1016/S0303-7207(99)00096-9; GAO JG, 1994, DNA CELL BIOL, V13, P829, DOI 10.1089/dna.1994.13.829; Gao JG, 2000, MOL ENDOCRINOL, V14, P1954, DOI 10.1210/me.14.12.1954; Gao JG, 1996, MOL ENDOCRINOL, V10, P613, DOI 10.1210/me.10.6.613; GIUDICE LC, 1994, FERTIL STERIL, V61, P1; Gregory CW, 2002, J CLIN ENDOCR METAB, V87, P2960, DOI 10.1210/jc.87.6.2960; GURPIDE E, 1992, HORMONES IN GYNECOLOGICAL ENDOCRINOLOGY, P717; HUANG JR, 1987, ENDOCRINOLOGY, V121, P2011; IRWIN JC, 1989, FERTIL STERIL, V52, P761; Jabbour HN, 1998, J CLIN ENDOCR METAB, V83, P2545, DOI 10.1210/jc.83.7.2545; JIN CF, 1994, PCR METH APPL, V3, P252; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lockwood CJ, 1998, ENDOCRINOLOGY, V139, P4607, DOI 10.1210/en.139.11.4607; Mak IYH, 2002, J CLIN ENDOCR METAB, V87, P2581, DOI 10.1210/jc.87.6.2581; Maruyama T, 1999, ENDOCRINOLOGY, V140, P2632, DOI 10.1210/en.140.6.2632; Maruyama T, 1997, MOL HUM REPROD, V3, P989, DOI 10.1093/molehr/3.11.989; Maruyama T, 1999, ENDOCRINOLOGY, V140, P365, DOI 10.1210/en.140.1.365; Maruyama T, 1999, ENDOCRINOLOGY, V140, P5982, DOI 10.1210/endo.140.12.7184; NOYES RW, 1950, FERTIL STERIL, V1, P3, DOI 10.1016/s0015-0282(16)30062-0; Popovici RM, 2000, ENDOCRINOLOGY, V141, P3510, DOI 10.1210/en.141.9.3510; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SERRA MJ, 1979, BIOL REPROD, V20, P214, DOI 10.1095/biolreprod20.2.214; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; TABIBZADEH S, 1991, ENDOCR REV, V12, P272, DOI 10.1210/edrv-12-3-272; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; TANG BQ, 1993, ENDOCRINOLOGY, V133, P2197, DOI 10.1210/en.133.5.2197; Tazuke SI, 1998, P NATL ACAD SCI USA, V95, P10188, DOI 10.1073/pnas.95.17.10188; Telgmann R, 1997, ENDOCRINOLOGY, V138, P929, DOI 10.1210/en.138.3.929; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; Wieser F, 2002, MOL HUM REPROD, V8, P644, DOI 10.1093/molehr/8.7.644; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yamamoto Y, 2002, MOL HUM REPROD, V8, P1117, DOI 10.1093/molehr/8.12.1117; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	43	60	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16675	16682		10.1074/jbc.M211715200	http://dx.doi.org/10.1074/jbc.M211715200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609987	hybrid			2022-12-27	WOS:000182818600031
J	Yin, HY; Havrilla, CM; Gao, L; Morrow, JD; Porter, NA				Yin, HY; Havrilla, CM; Gao, L; Morrow, JD; Porter, NA			Mechanisms for the formation of isoprostane endoperoxides from arachidonic acid - "Dioxetane" intermediate versus beta-fragmentation of peroxyl radicals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONCYCLOOXYGENASE; HYDROPEROXIDES; PROSTAGLANDINS; CHROMATOGRAPHY; SPECTROMETRY; OXYGENATION; DERIVATIVES; CYCLIZATION; PRODUCTS; SERIES	The isoprostanes are a class of autoxidation products generated from arachidonic acid (or its esters) by a free radical initiated process. The potent biological activity of these compounds has been attracting intense research interest since they were detected in humans as well as animal models in the early 1990s. The measurement of these compounds has been regarded as one of the most useful non-invasive biomarkers for oxidative stress status. Two mechanisms for the formation of these compounds have been proposed. In the first mechanism, a peroxyl radical undergoes successive 5-exo cyclizations analogous to the enzymatic mechanism proposed for prostaglandin biosynthesis. The second mechanism starts with a 4-exo cyclization of a peroxyl radical leading to an intermediate dioxetane, a mechanism that has also been proposed for prostaglandin biosynthesis as well as for the formation of 4-hydroxy nonenal (HNE). Autoxidation of cholesteryl-15-HpETE under free radical conditions provides Type IV isoprostanes. The "dioxetane" mechanism for isoprostane generation from 15-HpETE requires that optically pure products are formed from an optically pure reactant, whereas an alternate mechanism for the process involving beta-fragmentation of the 15-peroxyl would give racemic isoprostane products. We have carried out a test of the mechanism based upon these stereochemical requirements. The results of analysis of the product mixture derived from autoxidation of optically pure Ch-15-HpETE by atmospheric pressure chemical ionization-mass spectrometry coupled with chiral high performance liquid chromatography indicate that the major isoprostane diastereomers are formed as a racemic mixture. These experimental results are consistent with a mechanism for isoprostane formation involving beta-fragmentation of the 15-peroxyl radical followed by re-addition of oxygen to form the 11-HPETE peroxyl, and they exclude a mechanism proceeding through the formation of a dioxetane intermediate.	Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA; Vanderbilt Univ, Dept Pharmacol, Ctr Mol Toxicol, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University	Porter, NA (corresponding author), Vanderbilt Univ, Dept Chem, Box 1822,Stn B, Nashville, TN 37235 USA.	n.porter@vanderbilt.edu		yin, hui yong/0000-0001-7049-1560	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017921, R37HL017921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL17921] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVERY MA, 1990, TETRAHEDRON LETT, V31, P1799, DOI 10.1016/S0040-4039(00)98789-6; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Colombani D, 1996, PROG POLYM SCI, V21, P439, DOI 10.1016/0079-6700(95)00024-0; COREY EJ, 1994, TETRAHEDRON LETT, V35, P539, DOI 10.1016/S0040-4039(00)75832-1; Cyrus T, 2001, CIRCULATION, V103, P2277; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Esterbauer H., 1991, MEMBRANE LIPID OXIDA; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GARDNER HW, 1993, J BIOL CHEM, V268, P6971; Gardner HW, 1998, PLANT PHYSIOL, V116, P1359, DOI 10.1104/pp.116.4.1359; Havrilla CM, 2000, J AM CHEM SOC, V122, P8042, DOI 10.1021/ja001180f; HAYNES RK, 1990, J CHEM SOC CHEM COMM, P449, DOI 10.1039/c39900000449; HAYNES RK, 1990, J CHEM SOC CHEM COMM, P451, DOI 10.1039/c39900000451; Kaur K, 1997, CHEM RES TOXICOL, V10, P1387, DOI 10.1021/tx970112c; KIEFER H, 1966, TETRAHEDRON LETT, P6163; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; MENDENHALL GD, 1983, TETRAHEDRON LETT, V24, P451; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1990, ANAL BIOCHEM, V184, P1, DOI 10.1016/0003-2697(90)90002-Q; Mueller MJ, 1998, CHEM BIOL, V5, pR323, DOI 10.1016/S1074-5521(98)90660-3; Murphy RC, 2001, CHEM REV, V101, P479, DOI 10.1021/cr9900883; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; PORTER NA, 1995, LIPIDS, V30, P277, DOI 10.1007/BF02536034; PORTER NA, 1980, FREE RADICALS BIOL, V4, P261; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; PRYOR WA, 1990, FREE RADICAL BIO MED, V8, P541, DOI 10.1016/0891-5849(90)90153-A; Pudukulathan Z, 1998, J AM CHEM SOC, V120, P11953, DOI 10.1021/ja982596k; Roberts LJ, 2002, CELL MOL LIFE SCI, V59, P808, DOI 10.1007/s00018-002-8469-8; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Rocca B, 2002, INT IMMUNOPHARMACOL, V2, P603, DOI 10.1016/S1567-5769(01)00204-1; Rokach J, 1998, SYNTHESIS-STUTTGART, P569; Rokach J, 1997, PROSTAG OTH LIPID M, V54, P823, DOI 10.1016/S0090-6980(97)00183-4; Schneider C, 2000, ANAL BIOCHEM, V287, P186, DOI 10.1006/abio.2000.4847; Schneider C, 2001, J BIOL CHEM, V276, P20831, DOI 10.1074/jbc.M101821200; Singh G, 2000, ANAL CHEM, V72, P3007, DOI 10.1021/ac000374a; Thomas MJ, 2001, FREE RADICAL BIO MED, V30, P1337, DOI 10.1016/S0891-5849(01)00527-5; Timmins GS, 1997, CHEM RES TOXICOL, V10, P1090, DOI 10.1021/tx970075p; VONWILLER SC, 1995, J AM CHEM SOC, V117, P11098, DOI 10.1021/ja00150a009; YIN H, 2002, THESIS VANDERBILT U; Yin HY, 2002, J AM CHEM SOC, V124, P7745, DOI 10.1021/ja0201092	41	50	52	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16720	16725		10.1074/jbc.M300604200	http://dx.doi.org/10.1074/jbc.M300604200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609993	hybrid			2022-12-27	WOS:000182818600037
J	Lu, Q; Hutchins, AE; Doyle, CM; Lundblad, JR; Kwok, RPS				Lu, Q; Hutchins, AE; Doyle, CM; Lundblad, JR; Kwok, RPS			Acetylation of cAMP-responsive element-binding protein (CREB) by CREB-binding protein enhances CREB-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; CYCLIC-AMP; IN-VIVO; PHOSPHORYLATED CREB; DNA-BINDING; COACTIVATOR CBP; GENE; ACTIVATION; DOMAIN; P300	The coactivator function of cAMP-responsive element-binding protein (CREB)-binding protein (CBP) is partly caused by its histone acetyltransferase activity. However, it has become increasingly clear that CBP acetylates both histones and non-histone proteins, many of which are transcription factors. Here we investigate the role of CBP acetylase activity in CREB-mediated gene expression. We show that CREB is acetylated within the cell and that in vitro, CREB is acetylated by CBP, but not by another acetylase, p300/CBP-associated factor. The acetylation sites within. CREB were mapped to three lysines within the CREB activation domain. Although inhibition of histone deacetylase activity results in an increase of CREB- or CBP-mediated gene expression, mutation of all three putative acetylation sites in the CREB activation domain markedly enhances the ability of CREB to activate a cAMP-responsive element-dependent reporter gene. Furthermore, these CREB lysine mutations do not increase interaction with the CRE or CBP. These data suggest that the transactivation potential of CREB may be modulated through acetylation by CBP. We propose that in addition to its functions as a bridging molecule and histone acetyltransferase, the ability of CBP to acetylate CREB may play a key role in modulating CREB-mediated gene expression.	Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Oregon Health & Science University; Oregon Health & Science University	Kwok, RPS (corresponding author), Univ Michigan, Dept Obstet & Gynecol, 6428 Med Sci Bldg 1,1301 E Catherine St, Ann Arbor, MI 48109 USA.	rkwok@umich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572, R01DK060133, R29DK051732] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 051732, DK 060133, 5P60 DK 20572] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; Bisotto S, 1996, J BIOL CHEM, V271, P17746, DOI 10.1074/jbc.271.30.17746; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Candau R, 1996, MOL CELL BIOL, V16, P593; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; Du KY, 2000, MOL CELL BIOL, V20, P4320, DOI 10.1128/MCB.20.12.4320-4327.2000; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HOEFFLER JP, 1990, MOL ENDOCRINOL, V4, P920, DOI 10.1210/mend-4-6-920; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kashanchi F, 1998, J BIOL CHEM, V273, P34646, DOI 10.1074/jbc.273.51.34646; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Liu L, 1999, MOL CELL BIOL, V19, P1202; Ludlam WH, 2002, MOL CELL BIOL, V22, P3832, DOI 10.1128/MCB.22.11.3832-3841.2002; Lundblad JR, 1998, J BIOL CHEM, V273, P19251, DOI 10.1074/jbc.273.30.19251; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shaywitz AJ, 2000, MOL CELL BIOL, V20, P9409, DOI 10.1128/MCB.20.24.9409-9422.2000; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Thompson PR, 2001, J BIOL CHEM, V276, P33721, DOI 10.1074/jbc.M104736200; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wolfl S, 1999, MOL ENDOCRINOL, V13, P659, DOI 10.1210/me.13.5.659; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	55	85	88	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15727	15734		10.1074/jbc.M300546200	http://dx.doi.org/10.1074/jbc.M300546200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595525	hybrid			2022-12-27	WOS:000182680000035
J	Meinhart, A; Silberzahn, T; Cramer, P				Meinhart, A; Silberzahn, T; Cramer, P			The mRNA transcription/processing factor Ssu72 is a potential tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; PHOSPHOTYROSYL PROTEIN PHOSPHATASE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; FUNCTIONAL INTERACTION; GENE-EXPRESSION; PHOSPHORYLATION; COMPLEX; TFIIB	Ssu72 is an essential and highly conserved protein involved in mRNA transcription and X-end processing. The biochemical function of Ssu72 was so far unknown. We report here evidence that Ssu72 is a phosphatase that resembles protein tyrosine phosphatases (PTPases). First, recombinant Ssu72 cleaves the phosphotyrosine analogue p-nitrophenylphosphate, and this catalytic activity is impaired by PTPase-inhibiting agents. Second, the Ssu72 sequence contains the CX5R signature motif of PTPases; mutation of the catalytic cysteine in this motif abolishes Ssu72 activity in vitro and has been shown to confer lethality in vivo. Third, secondary structure prediction and site-directed mu-tagenesis predict that Ssu72 adopts the fold of PTPases of the low molecular weight family. Distinguishing features, such as a short "aspartate loop" at the active site, suggest however that Ssu72 is the founding member of a new phosphatase subfamily. The novel Ssu72 activity may regulate coupling events during mRNA biogenesis.	Univ Munich, Inst Biochem, Gene Ctr, D-81377 Munich, Germany	University of Munich	Cramer, P (corresponding author), Univ Munich, Inst Biochem, Gene Ctr, Feodor Lynen Str 25, D-81377 Munich, Germany.		Meinhart, Anton/M-9647-2014					BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Barilla D, 2001, P NATL ACAD SCI USA, V98, P445, DOI 10.1073/pnas.021545298; Burke TR, 1998, BIOPOLYMERS, V47, P225, DOI 10.1002/(SICI)1097-0282(1998)47:3<225::AID-BIP3>3.0.CO;2-O; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DAVIS JP, 1994, J BIOL CHEM, V269, P8734; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Dichtl B, 2002, MOL CELL, V10, P1139, DOI 10.1016/S1097-2765(02)00707-4; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Kim JH, 2000, ARCH BIOCHEM BIOPHYS, V382, P72, DOI 10.1006/abbi.2000.1996; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; OSTANIN K, 1995, J BIOL CHEM, V270, P18491, DOI 10.1074/jbc.270.31.18491; Pappas DL, 2000, MOL CELL BIOL, V20, P8343, DOI 10.1128/MCB.20.22.8343-8351.2000; Prelich G, 2002, EUKARYOT CELL, V1, P153, DOI 10.1128/EC.1.2.153-162.2002; Ramponi G, 1997, INT J BIOCHEM CELL B, V29, P279, DOI 10.1016/S1357-2725(96)00109-4; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; Sun ZW, 1996, MOL CELL BIOL, V16, P1557; Sun ZW, 1996, NUCLEIC ACIDS RES, V24, P2560, DOI 10.1093/nar/24.13.2560; Wang SS, 2000, BIOCHEMISTRY-US, V39, P1903, DOI 10.1021/bi991348d; WEST ML, 1995, GENETICS, V140, P1223; WO YYP, 1992, J BIOL CHEM, V267, P10856; Wu WH, 1999, GENETICS, V153, P643; Yan D, 1999, P NATL ACAD SCI USA, V96, P14789, DOI 10.1073/pnas.96.26.14789; Zhang M, 1998, J BIOL CHEM, V273, P21714, DOI 10.1074/jbc.273.34.21714; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947	36	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15917	15921		10.1074/jbc.M301643200	http://dx.doi.org/10.1074/jbc.M301643200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12606538	hybrid			2022-12-27	WOS:000182680000059
J	Takemae, H; Ueda, R; Okubo, R; Nakato, H; Izumi, S; Saigo, K; Nishihara, S				Takemae, H; Ueda, R; Okubo, R; Nakato, H; Izumi, S; Saigo, K; Nishihara, S			Proteoglyean UDP-galactose :beta-xylose beta 1,4-galactosyltransferase I is essential for viability in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; PROTEIN LINKAGE REGION; CAENORHABDITIS-ELEGANS; RNA-INTERFERENCE; D-XYLOSYLTRANSFERASE; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; GENE; EXPRESSION; IDENTIFICATION	Heparan and chondroitin sulfates play essential roles in growth factor signaling during development and share a common linkage tetrasaccharide structure, GlcAbeta1,3Galbeta1,3Galbeta1,4Xylbeta1-O-Ser. In the present study, we identified the Drosophila proteoglycan UDP-galactose:beta-xylose beta1,4-galactosyltransferase I (dbeta4GalTI), and determined its substrate specificity. The enzyme transferred a Gal to the -beta-xylose (XyI) residue, confirming it to be the Drosophila ortholog of human proteoglycan UDP-galactose:beta-xylose 01,4-galactosyltransferase I. Then we established UAS-dbeta4GalTI-IR fly lines containing an inverted repeat of dbeta4GalTI ligated to the upstream activating sequence (UAS) promoter, a target of GAL4, and observed the Fi(1) generation of the cross between the UAS-dbeta4GalTI-IR fly and the Act5C-GAL4 fly. In the F, double-stranded RNA of dbeta4GalTI is expressed ubiquitously under the control of a cytoplasmic actin promoter to induce the silencing of the dbeta4GalTI gene. The expression of the target gene was disrupted specifically, and the degree of interference was correlated with phenotype. The lethality among the progeny proved that beta4GalTI is essential for viability. This study is the first to use reverse genetics, RNA interference, to study the Drosophila glycosyltransferase systematically.	Soka Univ, Div Cell Biol, Tokyo 1928577, Japan; Tokyo Metropolitan Univ, Dept Biol, Tokyo 1920397, Japan; Natl Inst Genet, Invertebrate Genet Lab, Shizuoka 4418540, Japan; Mitsubishi Kagaku Inst Life Sci, Genet Networks Res Grp, Tokyo 1948511, Japan; Japan Sci & Technol Corp, Core Res Evolutional Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Univ Arizona, Div Neurobiol, Tucson, AZ 85721 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan	Soka University; Tokyo Metropolitan University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Mitsubishi Kagaku Institute of Life Sciences (MITILS); Japan Science & Technology Agency (JST); University of Arizona; University of Arizona; University of Tokyo	Nishihara, S (corresponding author), Soka Univ, Div Cell Biol, Tokyo 1928577, Japan.		Takemae, Hitoshi/AEP-5503-2022	Nishihara, Shoko/0000-0002-1668-2603	NICHD NIH HHS [R01 HD042769] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD042769] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Giordano E, 2002, GENETICS, V160, P637; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kuhn J, 2001, J BIOL CHEM, V276, P4940, DOI 10.1074/jbc.M005111200; Lin XH, 2000, MATRIX BIOL, V19, P303, DOI 10.1016/S0945-053X(00)00073-1; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Nakamura Y, 2002, J BIOL CHEM, V277, P46280, DOI 10.1074/jbc.M203873200; Okada Y, 2002, J BIOL CHEM, V277, P42488, DOI 10.1074/jbc.M206510200; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Okajima T, 1999, J BIOL CHEM, V274, P28841, DOI 10.1074/jbc.274.41.28841; Pace KE, 2002, J BIOL CHEM, V277, P13091, DOI 10.1074/jbc.M112105200; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Ramakrishnan B, 2001, J BIOL CHEM, V276, P37665, DOI 10.1074/jbc.M102458200; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; Schwientek T, 2002, J BIOL CHEM, V277, P22623, DOI 10.1074/jbc.M202684200; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Ten Hagen KG, 2002, J BIOL CHEM, V277, P22616, DOI 10.1074/jbc.M201807200; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Ueda R, 2001, J NEUROGENET, V15, P193, DOI 10.3109/01677060109167376; Vadaie N, 2002, GLYCOBIOLOGY, V12, P589, DOI 10.1093/glycob/cwf074; Wilson IBH, 2002, J BIOL CHEM, V277, P21207, DOI 10.1074/jbc.M201634200	36	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15571	15578		10.1074/jbc.M301123200	http://dx.doi.org/10.1074/jbc.M301123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12590131	hybrid			2022-12-27	WOS:000182680000016
J	Vidricaire, G; Tardif, MR; Tremblay, MJ				Vidricaire, G; Tardif, MR; Tremblay, MJ			The low viral production in trophoblastic cells is due to a high endocytic internalization of the human immunodeficiency virus type 1 and can be overcome by the pro-inflammatory cytokines tumor necrosis factor-alpha and interleukin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; NF-KAPPA-B; HUMAN PLACENTA; HIV TYPE-1; IMMUNOHISTOCHEMICAL LOCALIZATION; HUMAN ENDOMETRIUM; PROVIRAL DNA; BREAST-MILK; TNF-ALPHA; INFECTION	Maternal-infant transmission of human immunodeficiency virus type-1 (HIV-1) is the primary cause of this retrovirus infection in neonates. Trophoblasts have been proposed to play a critical role in modulating virus spread to the fetus. This paper addresses the mechanism of HIV-1 biology in trophoblastic cells. The trophoblastic cell lines BeWo, JAR, and JEG-3 were infected with reporter HIV-1 particles pseudotyped with envelope glycoproteins from the vesicular stomatitis virus or various strains of HIV-1. We demonstrate that despite a high internalization process of HIV-1 and no block in viral production, HIV-1 established a limited infection of trophoblasts with the production of very few progeny viruses. The factor responsible for this restriction to virus replication in such a cellular microenvironment is that the intracellular p24 is concentrated predominantly in endosomal vesicles following HIV-1 entry. HIV-1 transcription and virus production of infectious particles were both augmented upon treatment of trophoblasts with tumor necrosis factor-alpha and interleukin-1. However, the amount of progeny virions released by trophoblasts infected with native HIV-1 virions was so low even in the presence of pro-inflammatory cytokines that a co-culture step with indicator cells was necessary to detect virus production. Collectively these data illustrate for the first time that the natural low permissiveness of trophoblasts to productive HIV-1 infection is because of a restriction in the mode of entry, and such a limitation can be overcome with physiologic doses of tumor necrosis factor-a and interleukin-1, which are both expressed by the placenta, in conjunction with cell-cell contact. Considering that there is a linear correlation between viral load and HIV-1 vertical transmission, the environment may thus contribute to the propagation of HIV-1 across the placenta.	CHU Quebec, Hop CHUL, Lab Immunoretrovirol Humaine, Ctr Rech Infectiol, St Foy, PQ G1V 4G2, Canada; Univ Laval, Dept Med Biol, Fac Med, St Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Tremblay, MJ (corresponding author), CHU Quebec, Hop CHUL, Lab Immunoretrovirol Humaine, Ctr Rech Infectiol, RC709,2705 Blvd Laurier, St Foy, PQ G1V 4G2, Canada.							Al-Harthi L, 2002, AIDS RES HUM RETROV, V18, P13, DOI 10.1089/088922202753394673; AZOCAR J, 1979, CANCER RES, V39, P3388; BACKE E, 1992, J CLIN PATHOL, V45, P871, DOI 10.1136/jcp.45.10.871; Bacsi A, 2001, J INTERF CYTOK RES, V21, P1079, DOI 10.1089/107999001317205213; Barbeau B, 1997, J BIOL CHEM, V272, P12968, DOI 10.1074/jbc.272.20.12968; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; Bounou S, 2002, J VIROL, V76, P1004, DOI 10.1128/JVI.76.3.1004-1014.2002; Canki M, 2001, J VIROL, V75, P7925, DOI 10.1128/JVI.75.17.7925-7933.2001; CHANDWANI S, 1991, J INFECT DIS, V163, P1134, DOI 10.1093/infdis/163.5.1134; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CHEN HL, 1991, AM J PATHOL, V139, P327; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DABS F, 1993, AIDS, V7, P1139; DAVID FJE, 1992, CLIN EXP IMMUNOL, V88, P10; DAVID FJE, 1995, VIROLOGY, V208, P784, DOI 10.1006/viro.1995.1212; DeAndreis C, 1996, AIDS, V10, P711, DOI 10.1097/00002030-199606001-00004; DOUGLAS GC, 1994, J REPROD IMMUNOL, V27, P49, DOI 10.1016/0165-0378(94)90014-0; El Kharroubi A, 1998, MOL CELL BIOL, V18, P2535, DOI 10.1128/MCB.18.5.2535; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; HU XL, 1992, J REPROD IMMUNOL, V22, P257, DOI 10.1016/0165-0378(92)90047-8; HUNT JS, 1992, BIOL REPROD, V47, P141, DOI 10.1095/biolreprod47.1.141; JAATTELA M, 1988, LAB INVEST, V58, P48; Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000; Knofler M, 2000, PLACENTA, V21, P525, DOI 10.1053/plac.1999.0501; Lagaye S, 2001, J VIROL, V75, P4780, DOI 10.1128/JVI.75.10.4780-4791.2001; LAHM HW, 1985, J CHROMATOGR, V326, P357, DOI 10.1016/S0021-9673(01)87461-6; Lee BN, 1997, J VIROL, V71, P3628, DOI 10.1128/JVI.71.5.3628-3635.1997; LEPAGE P, 1987, LANCET, V2, P400; LEWIS SH, 1990, LANCET, V335, P565, DOI 10.1016/0140-6736(90)90349-A; MANO H, 1991, AIDS RES HUM RETROV, V7, P83, DOI 10.1089/aid.1991.7.83; Marechal V, 1998, J VIROL, V72, P2208; MARTIN AW, 1992, HUM PATHOL, V23, P411, DOI 10.1016/0046-8177(92)90088-K; Menu E, 1999, J INFECT DIS, V179, P44, DOI 10.1086/314542; Miller SC, 1997, EXP CELL RES, V230, P9, DOI 10.1006/excr.1996.3397; Mognetti B, 2000, CLIN EXP IMMUNOL, V119, P486, DOI 10.1046/j.1365-2249.2000.01149.x; Norwitz ER, 2001, NEW ENGL J MED, V345, P1400, DOI 10.1056/NEJMra000763; Okada M, 2002, J VIROL, V76, P12564, DOI 10.1128/JVI.76.24.12564-12573.2002; OPSJON SL, 1993, AM J OBSTET GYNECOL, V169, P397, DOI 10.1016/0002-9378(93)90096-2; PAULESU L, 1991, LYMPHOKINE CYTOK RES, V10, P443; Phillips TA, 2001, PLACENTA, V22, P663, DOI 10.1053/plac.2001.0703; Pijnenborg R, 1998, PLACENTA, V19, P231, DOI 10.1016/S0143-4004(98)90054-6; Plaud-Valentin M, 1999, CELL MOL BIOL, V45, P423; Poli G, 1995, HUMAN CYTOKINES THEI, P421; Raghupathy R, 1997, IMMUNOL TODAY, V18, P478, DOI 10.1016/S0167-5699(97)01127-4; ROBERTSON SA, 1994, CRIT REV IMMUNOL, V14, P239, DOI 10.1615/CritRevImmunol.v14.i3-4.30; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; Saito S, 2000, J REPROD IMMUNOL, V47, P87, DOI 10.1016/S0165-0378(00)00060-7; Schaeffer E, 2001, J VIROL, V75, P2993, DOI 10.1128/JVI.75.6.2993-3000.2001; SOEIRO R, 1992, J INFECT DIS, V166, P699, DOI 10.1093/infdis/166.4.699; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; TABIBZADEH S, 1991, AM J REPROD IMMUNOL, V26, P1; THIRY L, 1985, LANCET, V2, P891; Tscherning-Casper C, 1999, J VIROL, V73, P9673, DOI 10.1128/JVI.73.11.9673-9678.1999; VIDRICAIRE G, 2003, IN PRESS MED SCI; VIDRICAIRE G, 2003, 10 C RETR OPP INF BO, P370; Willumsen JF, 2001, AIDS, V15, P1896, DOI 10.1097/00002030-200109280-00026; YANG YP, 1993, J IMMUNOL, V150, P5614; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; Yui J, 1996, BIOL REPROD, V55, P400, DOI 10.1095/biolreprod55.2.400; YUI J, 1994, PLACENTA, V15, P819, DOI 10.1016/S0143-4004(05)80184-5; ZACHAR V, 1991, J VIROL, V65, P2102, DOI 10.1128/JVI.65.4.2102-2107.1991; Zachar V, 2002, AIDS RES HUM RETROV, V18, P839, DOI 10.1089/08892220260190317; Zachar V, 1999, AIDS RES HUM RETROV, V15, P1673, DOI 10.1089/088922299309711; ZACHAR V, 1994, AIDS, V8, P129, DOI 10.1097/00002030-199401000-00020	67	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15832	15841		10.1074/jbc.M210470200	http://dx.doi.org/10.1074/jbc.M210470200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604606	hybrid			2022-12-27	WOS:000182680000049
J	Yu, LQ; York, J; von Bergmann, K; Lutjohann, D; Cohen, JC; Hobbs, HH				Yu, LQ; York, J; von Bergmann, K; Lutjohann, D; Cohen, JC; Hobbs, HH			Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANGIER-DISEASE; DIETARY-CHOLESTEROL; ACID SYNTHESIS; MICE LACKING; LXR-ALPHA; GENE; SITOSTEROLEMIA; XANTHOMATOSIS; ABSORPTION; MUTATIONS	Liver X receptor (LXR) is a nuclear receptor that plays a crucial role in orchestrating the trafficking of sterols between tissues. Treatment of mice with a potent and specific LXR agonist, T0901317, is associated with increased biliary cholesterol secretion, decreased fractional cholesterol absorption, and increased fecal neutral sterol excretion. Here we show that expression of two target genes of LXRalpha, the ATP-binding cassette (ABC) transporters Abcg5 and Abcg8, is required for both the increase in sterol excretion and the decrease in fractional cholesterol absorption associated with LXR agonist treatment. Mice expressing no ABCG5 and ABCG8 (G5G8(-/-) mice) and their littermate controls were treated for 7 days with T0901317. In wild type animals, treatment with the LXR agonist resulted in a 3-fold increase in biliary cholesterol concentrations, a 25% reduction in fractional cholesterol absorption, and a 4-fold elevation in fecal neutral sterol excretion. In contrast, the LXR agonist did not significantly affect biliary cholesterol levels, fractional cholesterol absorption, or neutral fecal sterol excretion in the G5G8(-/-) mice. Thus Abcg5 and Abcg8 are required for LXR agonist-associated changes in dietary and biliary sterol trafficking. These results establish a central role for ABCG5 and AECG8 in promoting cholesterol excretion in vivo.	Univ Texas, SW Med Ctr, Dept Mol Genet, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Bonn, Dept Clin Pharmacol, D-53105 Bonn, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Bonn	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, McDermott Ctr Human Growth & Dev, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NHLBI NIH HHS [HL 20948, HL 72304] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072304, P01HL020948, R37HL072304] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BHATTACHARYYA AK, 1974, J CLIN INVEST, V53, P1033, DOI 10.1172/JCI107640; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chen JY, 2002, J BIOL CHEM, V277, P42588, DOI 10.1074/jbc.M205117200; Costet P, 2000, J BIOL CHEM, V275, P28240; GOULD RG, 1969, METABOLIS, V18, P652, DOI 10.1016/0026-0495(69)90078-X; GREGG RE, 1986, J CLIN INVEST, V77, P1864, DOI 10.1172/JCI112513; Groen AK, 2001, J CLIN INVEST, V108, P843, DOI 10.1172/JCI12473; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; MIETTINEN TA, 1980, EUR J CLIN INVEST, V10, P27, DOI 10.1111/j.1365-2362.1980.tb00006.x; Mulligan JD, 2003, J BIOL CHEM, V278, P13356, DOI 10.1074/jbc.M212377200; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SALEN G, 1989, J LIPID RES, V30, P1319; SALEN G, 1970, J CLIN INVEST, V49, P952, DOI 10.1172/JCI106315; SALEN G, 1985, J LIPID RES, V26, P1126; Schoenheimer R, 1931, SCIENCE, V74, P579, DOI 10.1126/science.74.1928.579; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwarz M, 1998, J LIPID RES, V39, P1833; TURLEY SD, 1991, METABOLISM, V40, P1063, DOI 10.1016/0026-0495(91)90131-F; TURLEY SD, 1994, J LIPID RES, V35, P328; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	36	231	240	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15565	15570		10.1074/jbc.M301311200	http://dx.doi.org/10.1074/jbc.M301311200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601003	hybrid			2022-12-27	WOS:000182680000015
J	Chen, NF; Yu, JZ; Skiba, NP; Hamm, HE; Rasenick, MM				Chen, NF; Yu, JZ; Skiba, NP; Hamm, HE; Rasenick, MM			A specific domain of G(i)alpha required for the transactivation of G(i)alpha by tubulin is implicated in the organization of cellular microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL SIGNAL-TRANSDUCTION; GTP-BINDING PROTEINS; CYTOSKELETAL ELEMENTS; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; ACTIVATION; CELLS; MEMBRANE; PARTICIPATION; ASSOCIATION	G(s)x, G(i)alpha(1), and G(q)x subunits bind tubulin with high affinity, whereas transducin (Gtalpha) does not. The interaction between tubulin and Galpha, which also involves the direct transfer of GTP from tubulin to Got (transactivation), is not yet fully understood. This study, using chimeras of G(i)alpha and G(t)alpha, showed that the G(i)alpha (215-295) segment converted G(i)alpha to bind to tubulin and this chimera (chimera 1) could be transactivated by tubulin. Insertion of G(t)alpha (237-270) into chimera 1 to form chimera 2 resulted in a protein that, like G(t)alpha, did not bind tubulin. Thus, it was thought that the G(i)alpha (237-270) domain was essential to modulate the binding of G(i)alpha(1) to tubulin. Surprisingly, when domain (237-270) of G(i)alpha was replaced by G(t)alpha (237-270) to form chimera 3, the chimera bound to tubulin with a similar affinity (K-D congruent to120 nM) as wild-type G(i)alpha(1). However, even though chimera 3 displayed normal GTP binding, it was not transactivated by GTP-tubulin. Furthermore, when these chimeras were expressed in COS-1 cells, cellular processes in cells overexpressing G(i)alpha(1) or chimera 1 were more abundant and longer than those in native cells. Galpha was seen throughout the length of the process. Morphology of cells expressing chimera 2 was identical to controls. Consistent with the role of Chimera 3 as a "dominant negative" Galpha, cells transfected with chimera 3 had only few truncated processes. This study demonstrates that although G(i)alpha (237-270) is not obligatory for the binding of Galpha to tubulin, it is crucial for the transactivation of Galpha by tubulin. These results also suggest that the transactivation of Galpha by tubulin may play an important role in modulating microtubule organization and cell morphology.	Univ Illinois, Dept Physiol & Biophys, Coll Med, Chicago, IL 60612 USA; Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Vanderbilt University	Rasenick, MM (corresponding author), Univ Illinois, Dept Physiol & Biophys, Coll Med, M-C 901,835 Wolcott Ave, Chicago, IL 60612 USA.	raz@uic.edu	Hamm, Heidi E/G-2374-2014		NEI NIH HHS [EY 10291, EY06062] Funding Source: Medline; NIA NIH HHS [AG 15482] Funding Source: Medline; NIMH NIH HHS [MH 39595, MH 57391] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010291, R01EY006062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039595, R01MH057391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015482] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CARLIER MF, 1983, BIOCHEMISTRY-US, V22, P4814, DOI 10.1021/bi00289a031; Crouch MF, 2000, CELL SIGNAL, V12, P153, DOI 10.1016/S0898-6568(99)00080-7; HAGMANN J, 1980, J BIOL CHEM, V255, P2659; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; Lin Chi-Hung, 1994, Current Opinion in Neurobiology, V4, P640, DOI 10.1016/0959-4388(94)90004-3; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Panagiotou S, 1999, J CELL BIOCHEM, V73, P204, DOI 10.1002/(SICI)1097-4644(19990501)73:2<204::AID-JCB6>3.0.CO;2-V; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; Popova JS, 2000, J NEUROSCI, V20, P2774; Popova JS, 2002, J NEUROSCI, V22, P1668, DOI 10.1523/JNEUROSCI.22-05-01668.2002; POPOVA JS, 1994, J BIOL CHEM, V269, P21748; RASENICK MM, 1988, J NEUROCHEM, V51, P300, DOI 10.1111/j.1471-4159.1988.tb04870.x; RASENICK MM, 1981, NATURE, V294, P560, DOI 10.1038/294560a0; RASENICK MM, 1990, ADV SEC MESS PHOSPH, V24, P381; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; ROYCHOWDHURY S, 1993, BIOCHEMISTRY-US, V32, P4955, DOI 10.1021/bi00069a034; Roychowdhury S, 1999, J BIOL CHEM, V274, P13485, DOI 10.1074/jbc.274.19.13485; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; Sarma T, 2003, FASEB J, V17, P848, DOI 10.1096/fj.02-0730com; SARNDAHL E, 1993, P NATL ACAD SCI USA, V90, P6552, DOI 10.1073/pnas.90.14.6552; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; Thiyagarajan MM, 2002, BIOCHEMISTRY-US, V41, P9470, DOI 10.1021/bi025533u; WANG N, 1990, J BIOL CHEM, V265, P1239; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Willard FS, 2000, IMMUNOL CELL BIOL, V78, P387, DOI 10.1046/j.1440-1711.2000.00927.x; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; Yan K, 2001, J NEUROCHEM, V76, P182, DOI 10.1046/j.1471-4159.2001.00013.x; Yan K, 1996, J NEUROCHEM, V66, P1489; Yu JZ, 2002, MOL PHARMACOL, V61, P352, DOI 10.1124/mol.61.2.352	32	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15285	15290		10.1074/jbc.M300841200	http://dx.doi.org/10.1074/jbc.M300841200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12582171	hybrid			2022-12-27	WOS:000182516100091
J	Wang, HY; Maechler, P; Antinozzi, PA; Herrero, L; Hagenfeldt-Johansson, KA; Bjorklund, A; Wollheim, CB				Wang, HY; Maechler, P; Antinozzi, PA; Herrero, L; Hagenfeldt-Johansson, KA; Bjorklund, A; Wollheim, CB			The transcription factor SREBP-1c is instrumental in the development of beta-cell dysfunction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1; DIABETIC FATTY RATS; INSULIN-SECRETION; GENE-EXPRESSION; MITOCHONDRIAL ACTIVATION; UNCOUPLING PROTEIN-2; PANCREATIC-ISLETS; TRANSGENIC MICE; ACID SYNTHESIS; MESSENGER-RNA	Accumulation of lipids in non-adipose tissues is often associated with Type 2 diabetes and its complications. Elevated expression of the lipogenic transcription factor, sterol regulatory element binding protein-1c (SREBP-1c), has been demonstrated in islets and liver of diabetic animals. To elucidate the molecular mechanisms underlying SREBP-1c-induced beta-cell dysfunction, we employed the Tet-On inducible system to achieve tightly controlled and conditional expression of the nuclear active form of SREBP-1c (naSREBP-1c) in INS-1 cells. Controlled expression of naSREBP-1c induced massive accumulation of lipid droplets and blunted nutrient-stimulated insulin secretion in INS-1 cells. K+-evoked insulin exocytosis was unaltered. Quantification of the gene expression profile in this INS-1 stable clone revealed that naSREBP-1c induced beta-cell dysfunction by targeting multiple genes dedicated to carbohydrate metabolism, lipid biosynthesis, cell growth, and apoptosis. naSREBP-1c elicits cell growth-arrest and eventually apoptosis. We also found that the SREBP-1c processing in beta-cells was irresponsive to acute stimulation of glucose and insulin, which was distinct from that in lipogenic tissues. However, 2-day exposure to these agents promoted SREBP-1c processing. Therefore, the SREBP-1c maturation could be implicated in the pathogenesis of beta-cell glucolipotoxicity.	Ctr Med Univ Geneva, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Wang, HY (corresponding author), Ctr Med Univ Geneva, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland.	Haiyan.Wang@medicine.unige.ch	Herrero, Laura/D-4011-2014; Björklund, Anders/ABA-1326-2020	Herrero, Laura/0000-0003-4244-4673; Maechler, Pierre/0000-0002-2005-1433				Andreolas C, 2002, DIABETES, V51, P2536, DOI 10.2337/diabetes.51.8.2536; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Cavaghan MK, 2000, J CLIN INVEST, V106, P329, DOI 10.1172/JCI10761; Diomede L, 2001, EUR CYTOKINE NETW, V12, P625; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Friedman J, 2002, NATURE, V415, P268, DOI 10.1038/415268a; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Greenberg AS, 2002, EUR J CLIN INVEST, V32, P24, DOI 10.1046/j.1365-2362.32.s3.4.x; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harmon JS, 2001, DIABETES, V50, P2481, DOI 10.2337/diabetes.50.11.2481; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Hostens K, 1999, J CLIN INVEST, V104, P67, DOI 10.1172/JCI6438; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Kakuma T, 2000, P NATL ACAD SCI USA, V97, P8536, DOI 10.1073/pnas.97.15.8536; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kotzka J, 2000, J LIPID RES, V41, P99; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Lawler JF, 1998, J BIOL CHEM, V273, P5053, DOI 10.1074/jbc.273.9.5053; Lin HZ, 2000, NAT MED, V6, P998, DOI 10.1038/79697; Liu Y, 2002, ARTERIOSCL THROM VAS, V22, P76, DOI 10.1161/hq0102.101822; Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Muller-Wieland D, 2002, ANN NY ACAD SCI, V967, P19; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Roche E, 1998, DIABETES, V47, P1086, DOI 10.2337/diabetes.47.7.1086; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; Rubi B, 2001, J BIOL CHEM, V276, P36391, DOI 10.1074/jbc.M104999200; Saltiel AR, 2000, J CLIN INVEST, V106, P163, DOI 10.1172/JCI10533; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; Sun LJ, 2002, J BIOL CHEM, V277, P18919, DOI 10.1074/jbc.M110650200; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Tanaka Y, 2002, P NATL ACAD SCI USA, V99, P12363, DOI 10.1073/pnas.192445199; Tobe K, 2001, J BIOL CHEM, V276, P38337, DOI 10.1074/jbc.C100160200; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Unger RH, 2001, DIABETES, V50, pS118, DOI 10.2337/diabetes.50.2007.S118; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Wang MY, 1998, P NATL ACAD SCI USA, V95, P11921, DOI 10.1073/pnas.95.20.11921; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Ware TL, 2000, EMBO J, V19, P3119, DOI 10.1093/emboj/19.12.3119; WEIR GC, 1982, AM J MED, V73, P461, DOI 10.1016/0002-9343(82)90321-7; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; You M, 2002, J BIOL CHEM, V277, P29342, DOI 10.1074/jbc.M202411200; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zhou YT, 1998, DIABETES, V47, P1904, DOI 10.2337/diabetes.47.12.1904; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	73	78	82	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16622	16629		10.1074/jbc.M212488200	http://dx.doi.org/10.1074/jbc.M212488200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600983	hybrid			2022-12-27	WOS:000182818600025
J	Dubbs, JM; Tabita, FR				Dubbs, JM; Tabita, FR			Interactions of the cbb(II) promoter-operator region with CbbR and RegA (PrrA) regulators indicate distinct mechanisms to control expression of the two cbb operons of Rhodobacter sphaeroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE; CO2 FIXATION OPERON; PHOTOSYNTHESIS GENE-EXPRESSION; SIGNAL-TRANSDUCTION SYSTEM; CLONING VECTORS; NUCLEOTIDE-SEQUENCE; IN-VITRO; FORM-I; CAPSULATUS; OXYGENASE	In a previous study (Dubbs, J. M., Bird, T. H., Bauer, C. E., and Tabita, F. R. (2000) J. Biol. Chem 275,1922419230), it was demonstrated that the regulators CbbR and RegA (PrrA) interacted with both promoter proximal and promoter distal regions of the form I (ebb,) promoter operon specifying genes of the Calvin-Benson-Bassham cycle of Rhodobacter sphaeroides. To determine how these regulators interact with the form II (ebb,,) promoter, three cbbF(II:):lacZ translational fusion plasmids were constructed containing various lengths of sequence 5' to the cbb(II) operon of R. sphaeroides CAC. Expression of beta-galactosidase was monitored under a variety of growth conditions in both the parental strain and knock-out strains that contain mutations that affect synthesis of CbbR and RegA. The binding sites for both CbbR and RegA were determined by DNase I footprinting. A region of the cbb(II) promoter from +38 to -227 bp contained a CbbR binding site and conferred low level regulated cbb(II) expression. The region from -227 to -1025 bp contained six RegA binding sites and conferred enhanced cbb(II) expression under all growth conditions. Unlike the cbb(I) operon, the region between -227 and -545 bp that contains one RegA binding site, was responsible for the majority of the observed enhancement. Both RegA and CbbR were required for maximal cbb(II) expression. Two potentially novel and specific cbb(II) promoter-binding proteins that did not interact with the cbb(I) promoter region were detected in crude extracts of R. sphaeroides. These results, combined with the observation that chemoautotrophic expression of the cbb(I) operon is RegA independent, indicated that the mechanisms controlling cbb(I) and cbb(II) operon expression during chemoautotrophic growth are quite different.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Ohio State Univ, Plant Mol Biol Biotechnol Program, Columbus, OH 43210 USA	Ohio State University; Ohio State University	Tabita, FR (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12th Ave, Columbus, OH 43210 USA.				PHS HHS [G, 45404] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; Barber RD, 1998, J MOL BIOL, V280, P775, DOI 10.1006/jmbi.1998.1900; Bird TH, 1999, J BIOL CHEM, V274, P16343, DOI 10.1074/jbc.274.23.16343; CHEN JH, 1991, J BIOL CHEM, V266, P20447; Du SY, 1998, J BIOL CHEM, V273, P18509, DOI 10.1074/jbc.273.29.18509; Dubbs JM, 2000, J BIOL CHEM, V275, P19224, DOI 10.1074/jbc.M002125200; Dubbs JM, 1998, J BACTERIOL, V180, P4903, DOI 10.1128/JB.180.18.4903-4911.1998; Elsen S, 2000, J BACTERIOL, V182, P2831, DOI 10.1128/JB.182.10.2831-2837.2000; ERASO JM, 1995, J BACTERIOL, V177, P2695, DOI 10.1128/jb.177.10.2695-2706.1995; FALCONE DL, 1991, J BACTERIOL, V173, P2099, DOI 10.1128/jb.173.6.2099-2108.1991; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; GIBSON JL, 1993, J BACTERIOL, V175, P5778, DOI 10.1128/JB.175.18.5778-5784.1993; GIBSON JL, 1987, J BACTERIOL, V169, P3685, DOI 10.1128/jb.169.8.3685-3690.1987; GIBSON JL, 1991, J BIOL CHEM, V266, P14646; Gibson JL, 1996, ARCH MICROBIOL, V166, P141, DOI 10.1007/s002030050369; Gibson JL, 2002, J BACTERIOL, V184, P6654, DOI 10.1128/JB.184.23.6654-6664.2002; GIBSON JL, 1977, J BACTERIOL, V132, P818, DOI 10.1128/JB.132.3.818-823.1977; GIBSON JL, 1995, ANOXYGENIC PHOTOSYNT, P1107; HALLENBECK PL, 1990, J BACTERIOL, V172, P1749, DOI 10.1128/jb.172.4.1749-1761.1990; HALLENBECK PL, 1990, J BACTERIOL, V172, P1736, DOI 10.1128/jb.172.4.1736-1748.1990; INOUE K, 1995, BIOCHEMISTRY-US, V34, P391, DOI 10.1021/bi00002a002; Joshi HM, 1996, P NATL ACAD SCI USA, V93, P14515, DOI 10.1073/pnas.93.25.14515; JOUANNEAU Y, 1986, J BACTERIOL, V165, P620, DOI 10.1128/jb.165.2.620-624.1986; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; MOSLEY CS, 1994, J BACTERIOL, V176, P7566, DOI 10.1128/JB.176.24.7566-7573.1994; O'Gara JP, 1998, J BACTERIOL, V180, P4044; OMEROD JG, 1961, ARCH BIOCHEM BIOPHYS, V94, P449; Paoli GC, 1998, ARCH MICROBIOL, V170, P8, DOI 10.1007/s002030050609; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; QIAN Y, 1997, THESIS OHIO STATE U; Qian YL, 1998, J BACTERIOL, V180, P4644, DOI 10.1128/JB.180.17.4644-4649.1998; Qian YL, 1996, J BACTERIOL, V178, P12, DOI 10.1128/jb.178.1.12-18.1996; Swem LR, 2001, J MOL BIOL, V309, P121, DOI 10.1006/jmbi.2001.4652; Vichivanives P, 2000, J MOL BIOL, V300, P1079, DOI 10.1006/jmbi.2000.3914; XU HH, 1994, J BACTERIOL, V176, P7299, DOI 10.1128/JB.176.23.7299-7308.1994; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; [No title captured]	37	37	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16443	16450		10.1074/jbc.M211267200	http://dx.doi.org/10.1074/jbc.M211267200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601011	hybrid			2022-12-27	WOS:000182680000124
J	Espert, L; Degols, G; Gongora, C; Blondel, D; Williams, BR; Silverman, RH; Mechti, N				Espert, L; Degols, G; Gongora, C; Blondel, D; Williams, BR; Silverman, RH; Mechti, N			ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; VESICULAR STOMATITIS-VIRUS; BODY-ASSOCIATED PROTEIN; MOLECULAR-CLONING; TRANSGENIC MICE; MESSENGER-RNA; MX PROTEINS; 2-5A SYSTEM; CELLS; PKR	Interferons (IFNs) encode a family of secreted proteins that provide the front-line defense against viral infections. Their diverse biological actions are thought to be mediated by the products of specific but usually overlapping sets of cellular genes induced in the target cells. We have recently isolated a new human IFN-induced gene that we have termed ISG20, which codes for a 3' to 5' exonuclease with specificity for single-stranded RNA and, to a lesser extent, for DNA. In this report, we demonstrate that ISG20 is involved in the antiviral functions of IFN. In the absence of IFN treatment, ISG20-overexpressing HeLa cells showed resistance to infections by vesicular stomatitis vir-us (VSV), influenza virus, and encephalomyocarditis virus (three RNA genomic viruses) but not to the DNA genomic adenovirus. ISG20 specifically interfered with VSV mRNA synthesis and protein production while leaving the expression of cellular control genes unaffected. No antiviral effect was observed in cells overexpressing a mutated ISG20 protein defective in exonuclease activity, demonstrating that the antiviral effects were due to the exonuclease activity of ISG20. In addition, the inactive mutant ISG20 protein, which is able to inhibit ISG20 exonuclease activity in vitro, significantly reduced the ability of IFN to block VSV development. Taken together, these data suggested that the antiviral activity of IFN against VSV is partly mediated by ISG20. We thus show that, besides RNase L, ISG20 has an antiviral activity, supporting the idea that it might represent a novel antiviral pathway in the mechanism of IFN action.	CNRS, EFS, UMR 5094, F-34094 Montpellier 5, France; CNRS, UMR 2472, Lab Virol Mol & Struct, F-91198 Gif Sur Yvette, France; Lerner Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Universite Paris Saclay	Mechti, N (corresponding author), CNRS, EFS, UMR 5094, 240 Ave Emile Jeanbrau, F-34094 Montpellier 5, France.		Espert, Lucile/ABF-5614-2021; Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151; GONGORA, Celine/0000-0001-9034-4031				Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Arnheiter H, 1996, CURR TOP MICROBIOL, V206, P119; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; BLONDEL D, 1990, J VIROL, V64, P1716, DOI 10.1128/JVI.64.4.1716-1725.1990; BLONDEL D, 1988, J VIROL, V62, P277, DOI 10.1128/JVI.62.1.277-284.1988; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; DACQUISTO F, 2001, SCI STKE; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Durbin RK, 2002, VIRAL IMMUNOL, V15, P41, DOI 10.1089/088282402317340224; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; Fruh K, 1999, CURR OPIN IMMUNOL, V11, P76, DOI 10.1016/S0952-7915(99)80014-4; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Gongora C, 2000, NUCLEIC ACIDS RES, V28, P2333, DOI 10.1093/nar/28.12.2333; Gongora C, 1997, J BIOL CHEM, V272, P19457, DOI 10.1074/jbc.272.31.19457; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; Khabar KSA, 2000, J INTERF CYTOK RES, V20, P653, DOI 10.1089/107999000414835; Kumar M, 1998, MICROBIOL MOL BIOL R, V62, P1415, DOI 10.1128/MMBR.62.4.1415-1434.1998; Lee-Huang S, 1999, P NATL ACAD SCI USA, V96, P2678, DOI 10.1073/pnas.96.6.2678; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880; Mach B, 1996, ANNU REV IMMUNOL, V14, P301, DOI 10.1146/annurev.immunol.14.1.301; MAITRA RK, 1994, VIROLOGY, V204, P823, DOI 10.1006/viro.1994.1601; Mattei MG, 1997, CYTOGENET CELL GENET, V79, P286, DOI 10.1159/000134745; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5804; MILLHAUD PG, 1983, ANN VIROL E, V134, P405; Nau GJ, 2002, P NATL ACAD SCI USA, V99, P1503, DOI 10.1073/pnas.022649799; Nguyen LH, 2001, BIOCHEMISTRY-US, V40, P7174, DOI 10.1021/bi010141t; PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370; PAVLOVIC J, 1993, CIBA F SYMP, V176, P233; Player MR, 1998, PHARMACOL THERAPEUT, V78, P55, DOI 10.1016/S0163-7258(97)00167-8; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Scadden ADJ, 1997, EMBO J, V16, P2140, DOI 10.1093/emboj/16.8.2140; Scadden ADJ, 2001, EMBO J, V20, P4243, DOI 10.1093/emboj/20.15.4243; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Staege H, 2001, IMMUNOGENETICS, V53, P105, DOI 10.1007/s002510100306; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Varela N, 2001, J BIOL CHEM, V276, P17779, DOI 10.1074/jbc.M100815200; Vasandani VM, 1999, J INTERF CYTOK RES, V19, P447, DOI 10.1089/107999099313884; Williams B.R., 2001, SCI STKE, V2001, pre2; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zhou AM, 1999, VIROLOGY, V258, P435, DOI 10.1006/viro.1999.9738	53	164	176	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16151	16158		10.1074/jbc.M209628200	http://dx.doi.org/10.1074/jbc.M209628200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594219	hybrid, Green Published			2022-12-27	WOS:000182680000088
J	Gatei, M; Sloper, K; Sorensen, C; Syljuasen, R; Falck, J; Hobson, K; Savage, K; Lukas, J; Zhou, BB; Bartek, J; Khanna, KK				Gatei, M; Sloper, K; Sorensen, C; Syljuasen, R; Falck, J; Hobson, K; Savage, K; Lukas, J; Zhou, BB; Bartek, J; Khanna, KK			Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; PROTEIN-KINASE; S-PHASE; CHECKPOINT; DNA; DISRUPTION; MUTATIONS; PATHWAYS; LEADS; UV	In mammals, the ATM (ataxia-telangiectasia-mutated) and ATR (ATM and Rad3-related) protein kinases function as critical regulators of the cellular DNA damage response. The checkpoint functions of ATR and ATM are mediated, in part, by a pair of checkpoint effector kinases termed Chk1 and Chk2. In mammalian cells, evidence has been presented that Chk1 is devoted to the ATR signaling pathway and is modified by ATR in response to replication inhibition and UV-induced damage, whereas Chk2 functions primarily through ATM in response to ionizing radiation (IR), suggesting that Chk2 and Chk1 might have evolved to channel the DNA damage signal from ATM and ATR, respectively. We demonstrate here that the ATR-Chk1 and ATM-Chk2 pathways are not parallel branches of the DNA damage response pathway but instead show a high degree of cross-talk and connectivity. ATM does in fact signal to Chk1 in response to IR. Phosphorylation of Chk1 on Ser-317 in response to IR is ATM-dependent. We also show that functional NBS1 is required for phosphorylation of Chk1, indicating that NES1 might facilitate the access of Chk1 to ATM at the sites of DNA damage. Abrogation of Chk1 expression by RNA interference resulted in defects in IR-induced S and G2/M phase checkpoints; however, the overexpression of phosphorylation site mutant (S317A, S345A or S317A/S345A double mutant) Chk1 failed to interfere with these checkpoints. Surprisingly, the kinase-dead Chk1 (D130A) also failed to abrogate the S and G2 checkpoint through any obvious dominant negative effect toward endogenous Chk1. Therefore, further studies will be required to assess the contribution made by phosphorylation events to Chk1 regulation. Overall, the data presented in the study challenge the model in which Chk1 only functions downstream from ATR and indicate that ATM does signal to Chk1. In addition, this study also demonstrates that Chk1 is essential for IR-induced inhibition of DNA synthesis and the G2/M checkpoint.	Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Incyte Genom, Newark, DE 19714 USA	QIMR Berghofer Medical Research Institute; Danish Cancer Society; Incyte	Khanna, KK (corresponding author), Queensland Inst Med Res, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.	kumkumK@qimr.edu.au	Khanna, Kum Kum/I-1747-2013; Hobson, Keith/Q-9306-2019; Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; Sorensen, Claus/0000-0001-6022-9710; Khanna, Kum Kum/0000-0001-8650-5381; Savage, Kienan/0000-0002-4898-899X				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Brown EJ, 2000, GENE DEV, V14, P397; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Jackson JR, 2000, CANCER RES, V60, P566; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Liu QH, 2000, GENE DEV, V14, P1448; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; St Onge RP, 2001, J BIOL CHEM, V276, P41898, DOI 10.1074/jbc.M105152200; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Takai H, 2000, GENE DEV, V14, P1439; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	29	237	245	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14806	14811		10.1074/jbc.M210862200	http://dx.doi.org/10.1074/jbc.M210862200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588868	hybrid			2022-12-27	WOS:000182516100030
J	Koike, H; Okuda, D; Morita, T				Koike, H; Okuda, D; Morita, T			Mutations in autolytic loop-2 and at Asp(554) of human prothrombin that enhance protein C activation by meizothrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECHIS-CARINATUS VENOM; HUMAN ALPHA-THROMBIN; BOVINE PROTHROMBIN; BLOOD-COAGULATION; ANTITHROMBIN-III; MOLECULAR MECHANISMS; BINDING-SITE; FACTOR-X; THROMBOMODULIN; INTERMEDIATE	Thrombin acts on many protein substrates during the hemostatic process. Its specificity for these substrates is modulated through interactions at regions remote from the active site of the thrombin molecule, designated exosites. Exosite interactions can be with the substrate, cofactors such as thrombomodulin, or fragments from prothrombin. The relative activity of alpha-thrombin for fibrinogen is 10 times greater than that for protein C. However, the relative activity of meizothrombin for protein C is 14 times greater than that for fibrinogen. Modulation of thrombin specificity is linked to its Na+-binding site and residues in autolytic loop-2 that interact with the Na+-binding site. Recombinant prothrombins that yield recombinant meizothrombin (rMT) and rMT des-fragment 1 (rMT(desF1)) enable comparisons of the effects of mutations at the Na+-binding residue (Asp(554)) and deletion of loop-2 (Glu(466)-Thr(469)) on the relative activity of meizothrombin for several substrates. Hydrolysis of t-butoxycarbonyl-VPR-p-nitroanilide by alpha-thrombin, recombinant alpha-thrombin, or rMT(desF1) was almost identical, but that by rMT was only 40% of that by alpha-thrombin. Clotting of fibrinogen by rMT and rMT(desF1) was 12-16% of that by alpha-thrombin, as already known. Strikingly, however, although meizothrombins modified by substitution of Asp(554) with either Ala or Leu or by deletion of loop-2 had 6-8 and <1%, respectively, of the clotting activity of alpha-thrombin, the activity of these meizothrombins for protein C was increased to >10 times that of alpha-thrombin. It is proposed that interactions within thrombin that involve autolytic loop-2 and the Na+-binding site primarily enhance thrombin action on fibrinogen, but impair thrombin action on protein C.	Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan	Meiji Pharmaceutical University	Morita, T (corresponding author), Meiji Pharmaceut Univ, Dept Biochem, 2-522-1 Noshio, Tokyo 2048588, Japan.							BOVILL EG, 1995, ARTERIOSCL THROM VAS, V15, P754, DOI 10.1161/01.ATV.15.6.754; COTE HCF, 1994, J BIOL CHEM, V269, P11374; Cote HCF, 1997, J BIOL CHEM, V272, P6194, DOI 10.1074/jbc.272.10.6194; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Dang QD, 1997, J BIOL CHEM, V272, P19649, DOI 10.1074/jbc.272.32.19649; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; DOMBROSE FA, 1979, J BIOL CHEM, V254, P5027; DOULE MG, 1990, J BIOL CHEM, V265, P10693; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GITEL SN, 1973, P NATL ACAD SCI USA, V70, P1344, DOI 10.1073/pnas.70.5.1344; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KANE WH, 1988, BLOOD, V71, P539; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; MIYATA T, 1992, BIOCHEMISTRY-US, V31, P7457, DOI 10.1021/bi00148a005; MORITA T, 1981, METHOD ENZYMOL, V80, P303; MORITA T, 1976, J BIOCHEM, V79, P1089, DOI 10.1093/oxfordjournals.jbchem.a131150; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; Richardson JL, 2000, EMBO J, V19, P5650, DOI 10.1093/emboj/19.21.5650; Rose T, 2002, J BIOL CHEM, V277, P18875, DOI 10.1074/jbc.M110977200; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; Shi F, 1998, BIOPHYS CHEM, V75, P187, DOI 10.1016/S0301-4622(98)00205-1; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TANS G, 1991, J BIOL CHEM, V266, P21864; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALKER RK, 1994, J BIOL CHEM, V269, P27441; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; Yamada D, 1996, J BIOL CHEM, V271, P5200, DOI 10.1074/jbc.271.9.5200	40	2	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15015	15022		10.1074/jbc.M208220200	http://dx.doi.org/10.1074/jbc.M208220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588872				2022-12-27	WOS:000182516100058
J	Yang, TY; McNally, BA; Ferrone, S; Liu, Y; Zheng, P				Yang, TY; McNally, BA; Ferrone, S; Liu, Y; Zheng, P			A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSENSE-MEDIATED DECAY; DOWN-REGULATION; GENES; EXPRESSION; STABILITY; MOLECULES; MACHINERY; MECHANISM; CODONS; LMP2	Both viruses and tumors evade cytotoxic T lymphocyte-mediated host immunity by down-regulation of antigen presentation machineries. This can be achieved by either down-regulation of transcription of antigen presentation genes or posttranslational inactivation of proteins involved in antigen presentation. In this study, a major histocompatibility complex (MHC) class I-deficient melanoma cell line, SK-MEL-19, was found deficient in the expression of the transporter associated with antigen processing (TAP)-1 mRNA even after IFN-gamma stimulation, despite its active transcription of the TAP-1 gene. This abnormality was caused by a single-nucleotide deletion at position +1489 of the TAP-1 gene and was corrected by cycloheximide, which inhibits RNA degradation. Using an inducible Tet-Off system, we demonstrated that deletion of the nucleotide resulted in a >2-fold decrease in the half-life of TAP-1 mRNA. However, the decrease of the half-life of TAP-1 mRNA is not mediated by nonsense-mediated mRNA decay because deletions of two additional nucleotides in the region, which corrected the nonsense mutation, did not restore TAP-1 mRNA stability. To our knowledge, this is the first evidence that the degradation of mRNA of an antigen presentation gene is involved in HLA class I down-regulation in malignant cells.	Ohio State Univ, Med Ctr, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA	Ohio State University; James Cancer Hospital & Solove Research Institute; Ohio State University; Roswell Park Cancer Institute	Zheng, P (corresponding author), Ohio State Univ, Med Ctr, Dept Pathol, 129 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	zheng-1@medctr.osu.edu	Zheng, Pan/E-8691-2011	Zheng, Pan/0000-0003-2598-3544	NCI NIH HHS [CA82355, CA69091, CA58033] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082355, R01CA069091, R01CA058033] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; Brocke KS, 2002, HUM MOL GENET, V11, P331, DOI 10.1093/hmg/11.3.331; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; Dovhey SE, 2000, CANCER RES, V60, P5789; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Hicklin DJ, 1996, TISSUE ANTIGENS, V48, P38, DOI 10.1111/j.1399-0039.1996.tb02603.x; Kallfelz M, 1999, INT J CANCER, V81, P125, DOI 10.1002/(SICI)1097-0215(19990331)81:1<125::AID-IJC21>3.0.CO;2-2; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Liu HX, 2001, NAT GENET, V27, P55, DOI 10.1038/83762; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; Lykke-Andersen J, 2001, SCIENCE, V293, P1836, DOI 10.1126/science.1062786; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; MCCUTCHEON JA, 1995, J EXP MED, V181, P2085, DOI 10.1084/jem.181.6.2085; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; Rajavel KS, 2001, MOL CELL BIOL, V21, P5512, DOI 10.1128/MCB.21.16.5512-5519.2001; Romero P, 1998, J EXP MED, V188, P1641, DOI 10.1084/jem.188.9.1641; ROTEMYEHUDAR R, 1994, J EXP MED, V180, P477, DOI 10.1084/jem.180.2.477; RotemYehudar R, 1996, J EXP MED, V183, P499, DOI 10.1084/jem.183.2.499; ROTEMYEHUDAR R, 1994, GENE, V144, P265, DOI 10.1016/0378-1119(94)90388-3; SalazarOnfray F, 1997, J IMMUNOL, V159, P3195; Seliger B, 1998, EUR J IMMUNOL, V28, P122, DOI 10.1002/(SICI)1521-4141(199801)28:01<122::AID-IMMU122>3.0.CO;2-F; Seliger B, 2001, CANCER RES, V61, P8647; Singal DP, 1998, INT J CANCER, V75, P112, DOI 10.1002/(SICI)1097-0215(19980105)75:1<112::AID-IJC17>3.3.CO;2-I; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; Zhang J, 1998, MOL CELL BIOL, V18, P5272, DOI 10.1128/MCB.18.9.5272; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628; Zheng P, 1999, CANCER RES, V59, P3461; Zhou QM, 1998, MOL CELL BIOL, V18, P815, DOI 10.1128/MCB.18.2.815	34	43	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15291	15296		10.1074/jbc.M300954200	http://dx.doi.org/10.1074/jbc.M300954200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12582163	hybrid			2022-12-27	WOS:000182516100092
J	Kihara, A; Ikeda, M; Kariya, Y; Lee, EY; Lee, YM; Igarashi, Y				Kihara, A; Ikeda, M; Kariya, Y; Lee, EY; Lee, YM; Igarashi, Y			Sphingosine-1-phosphate lyase is involved in the differentiation of F9 embryonal carcinoma cells to primitive endoderm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERATOCARCINOMA STEM-CELLS; SPHINGOSINE KINASE; RETINOIC ACID; FUNCTIONAL EXPRESSION; CALCIUM MOBILIZATION; MOLECULAR-CLONING; PARIETAL ENDODERM; 2ND MESSENGER; 1-PHOSPHATE; GROWTH	Sphingosine I-phosphate (SIP) is a bioactive lipid molecule that acts both extracellularly and intracellularly. The SPL gene encodes a mammalian SIP lyase that degrades SIP. Here, we have disrupted the SPL gene in mouse F9 embryonal carcinoma cells by gene targeting. This is the first report of gene disruption of mammalian SIP lyase. The SPL-null cells exhibited no SIP lyase activity, and intracellular SIP was increased similar to2-fold, compared with wild-type cells. Treatment of F9 embryonal carcinoma cells with retinoic acid induces differentiation to primitive endoderm (PrE). An acceleration in this PrE differentiation was observed in the SPL-null cells. This effect was apparently caused by the accumulated S1P, since N,N-dimethylsphingosine, a S1P synthesis inhibitor, had an inhibitory effect on the PrE differentiation. Moreover, F9 cells stably expressing sphingosine kinase also exhibited an acceleration in the differentiation. Exogenous S1P had no effect on differentiation, indicating that intracellular but not extracellular S1P is involved. Moreover, we determined that expression of the SPL protein is up-regulated during the progression to PrE. We also showed that sphingosine kinase activity is increased in PrE-differentiated cells. These results suggest that intracellular S1P has a role in the PrE differentiation and that SPL may be involved in the regulation of intracellular S1P levels during this differentiation.	Hokkaido Univ, Dept Biomembrane & Biofunct Chem, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Chungbuk Natl Univ, Coll Pharm, Chonju 361763, South Korea	Hokkaido University; Chungbuk National University	Igarashi, Y (corresponding author), Hokkaido Univ, Dept Biomembrane & Biofunct Chem, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12 Jo,Nishi 6 Choume, Sapporo, Hokkaido 0600812, Japan.	yigarash@pharm.hokudai.ac.jp	KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788				Bjersing JL, 1997, J CELL BIOCHEM, V67, P378; Cho SY, 1999, MOL CELLS, V9, P179; Cho SY, 2000, BIOCHEM J, V352, P645, DOI 10.1042/0264-6021:3520645; Choi OH, 1996, NATURE, V380, P634; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DUPREY P, 1985, P NATL ACAD SCI USA, V82, P8535, DOI 10.1073/pnas.82.24.8535; Edsall LC, 1997, J NEUROSCI, V17, P6952; Gao P, 1996, J BIOL CHEM, V271, P30692, DOI 10.1074/jbc.271.48.30692; Gottlieb D, 1999, Mol Cell Biol Res Commun, V1, P66, DOI 10.1006/mcbr.1999.0109; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; Igarashi Y, 1997, J BIOCHEM-TOKYO, V122, P1080; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; Li GC, 2000, MICROBIOL-SGM, V146, P2219, DOI 10.1099/00221287-146-9-2219; Li GC, 2001, DEVELOPMENT, V128, P3473; Li Y, 1998, EXP CELL RES, V239, P320, DOI 10.1006/excr.1997.3904; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Min JK, 2002, ANAL BIOCHEM, V303, P167, DOI 10.1006/abio.2002.5579; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Murate T, 2001, J HISTOCHEM CYTOCHEM, V49, P845, DOI 10.1177/002215540104900705; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; Saba JD, 1997, J BIOL CHEM, V272, P26087, DOI 10.1074/jbc.272.42.26087; Skrzypek MS, 1999, J BACTERIOL, V181, P1134, DOI 10.1128/JB.181.4.1134-1140.1999; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Van Veldhoven PP, 2000, BBA-MOL CELL BIOL L, V1487, P128, DOI 10.1016/S1388-1981(00)00079-2; Van Veldhoven PP, 2000, METHOD ENZYMOL, V311, P244; Verheijen MHG, 1999, J BIOL CHEM, V274, P1487, DOI 10.1074/jbc.274.3.1487; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; Zhou JH, 1998, BIOCHEM BIOPH RES CO, V242, P502, DOI 10.1006/bbrc.1997.7993; ZUHERINGDORF DM, 1998, EMBO J, V17, P2830	45	70	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14578	14585		10.1074/jbc.M211416200	http://dx.doi.org/10.1074/jbc.M211416200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584204	hybrid			2022-12-27	WOS:000182405000126
J	Raja, SM; Chhablani, N; Swanson, R; Thompson, E; Laffan, M; Lane, DA; Olson, ST				Raja, SM; Chhablani, N; Swanson, R; Thompson, E; Laffan, M; Lane, DA; Olson, ST			Deletion of P1 arginine in a novel antithrombin variant (antithrombin london) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-SITE; FACTOR-XA; CONFORMATIONAL-CHANGE; KINETIC CHARACTERIZATION; BINDING; ACTIVATION; DEFICIENCY; SEQUENCE; PENTASACCHARIDE; SUBSTITUTION	A novel variant of antithrombin, the major serpin inhibitor of coagulation proteases, has been identified in a patient with early onset thrombosis and abnormal plasma antithrombin activity. Sequencing of the antithrombin genes of the patient revealed that one of the two alleles was abnormal due to an in-frame deletion of the codon for the P1 arginine residue. The abnormal antithrombin was separated from the normal inhibitor by complexing the latter with thrombin followed by heparin-agarose affinity chromatography. The purified variant, antithrombin London, was completely inactive as a thrombin or factor Xa inhibitor even after heparin activation. Surprisingly, the variant bound heparin with a K-D reflecting an similar to10-fold greater affinity than the normal inhibitor. Stopped-flow kinetic analysis showed that this was almost entirely due to a more favorable conformational activation of the variant than the normal inhibitor, as reflected by a decreased rate constant for reversal of the activation. Consistent with its higher than normal heparin affinity, the inactive antithrombin variant was a potent competitive antagonist of the heparin-catalyzed reaction of normal antithrombin with thrombin but did not affect the uncatalyzed reaction. These results suggest that deletion of the antithrombin P1 residue partially activates the serpin by inducing strain in the reactive center loop, which destabilizes the native loop-buried state and favors the activated loop-exposed state with high heparin affinity. The unusually severe thrombosis associated with the heterozygous mutation may be explained by the ability of antithrombin London to bind endogenous heparan sulfate or heparin molecules with high affinity and to thereby block activation of the normal inhibitor.	Univ Illinois, Ctr Mol Biol Oral Dis, Coll Dent, Chicago, IL 60612 USA; Univ London Imperial Coll Sci Technol & Med, Dept Hematol, Fac Med, London W12 0NN, England	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Imperial College London	Olson, ST (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, Coll Dent, Rm 530E Dent M-C 860,801 S Paulina St, Chicago, IL 60612 USA.			Laffan, Michael/0000-0002-8268-3268	NHLBI NIH HHS [R01-HL-39888] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039888] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bjork I, 1997, ADV EXP MED BIOL, V425, P17; BJORK I, 1982, J BIOL CHEM, V257, P2406; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CHOWDHURY V, 1993, BRIT J HAEMATOL, V84, P656, DOI 10.1111/j.1365-2141.1993.tb03142.x; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Chuang YJ, 2001, BIOCHEMISTRY-US, V40, P6670, DOI 10.1021/bi002933d; Desai UR, 1998, BIOCHEMISTRY-US, V37, P13033, DOI 10.1021/bi981426h; Desai UR, 1998, J BIOL CHEM, V273, P7478, DOI 10.1074/jbc.273.13.7478; ERDJUMENT H, 1988, J BIOL CHEM, V263, P5589; Futamura A, 2000, J BIOL CHEM, V275, P4092, DOI 10.1074/jbc.275.6.4092; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Ishiguro K, 2000, J CLIN INVEST, V106, P873, DOI 10.1172/JCI10489; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; JORDAN RE, 1980, J BIOL CHEM, V255, P81; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1992, J CLIN INVEST, V90, P2422, DOI 10.1172/JCI116133; LANE DA, 1989, J BIOL CHEM, V264, P10200; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MILETICH JP, 1981, METHOD ENZYMOL, V80, P221; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1995, J BIOL CHEM, V270, P9717, DOI 10.1074/jbc.270.17.9717; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; Rezaie AR, 2002, J BIOL CHEM, V277, P1235, DOI 10.1074/jbc.M108544200; SAS G, 1975, THROMB RES, V6, P87, DOI 10.1016/0049-3848(75)90153-X; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; van Boven HH, 1999, BLOOD, V94, P2590, DOI 10.1182/blood.V94.8.2590.420k40_2590_2594; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; vanBoven HH, 1997, SEMIN HEMATOL, V34, P188; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u	35	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13688	13695		10.1074/jbc.M300062200	http://dx.doi.org/10.1074/jbc.M300062200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12591924	hybrid			2022-12-27	WOS:000182405000018
J	Tomas, A; Moss, SE				Tomas, A; Moss, SE			Calcium- and cell cycle-dependent association of annexin 11 with the nuclear envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CA2+-DEPENDENT MANNER; TERMINAL DOMAIN; ALG-2 INTERACTS; BINDING-SITE; XI; CALCYCLIN; MEMBRANE; CAP-50; S100C	Annexin 11 is a widely expressed calcium- and phospholipid-binding protein that resides in the nucleoplasm in many cultured cell lines. This is in contrast to its most extensively characterized in vitro ligand, the small calcium- binding protein S100A6 ( calcyclin), which is concentrated in the nuclear envelope. Here we have examined the significance of the association of annexin 11 and S100A6 by asking whether circumstances exist in which the two proteins occupy the same subcellular localization. First, we show that in both A431 and vascular smooth muscle cells, elevation of intracellular Ca2+ leads to translocation of annexin 11 from the nucleus to the nuclear envelope where it co-localizes with S100A6. We also demonstrate, using fusions of annexin 11 with green fluorescent protein, that whereas the C-terminal core domain of annexin 11 is essential for Ca2+ sensitivity, the N-terminal domain is required for targeting to the nuclear envelope. Second, we show that annexin 11 relocalizes to the nuclear envelope as A431 cells transit from early to mid-prophase. In late prophase, at the time of nuclear envelope breakdown, annexin 11 and S100A6 become intensely localized with lamina-associated polypeptide 2 to folds in the nuclear envelope. From metaphase to telophase S100A6 is degraded, but in late telophase annexin 11 associates with the reforming nuclear envelope before resuming a nucleoplasmic location in interphase. These results show that co-localization of annexin 11 and S100A6 at the nuclear envelope may be regulated either by elevation of intracellular Ca2+ or by cell cycle progression and provide the first evidence that these proteins may associate in vivo.	Inst Ophthalmol, Div Cell Biol, London EC1V 9EL, England	University of London; University College London	Moss, SE (corresponding author), Inst Ophthalmol, Div Cell Biol, 11-43 Bath St, London EC1V 9EL, England.			Tomas, Alejandra/0000-0002-2290-8453				ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Badminton MN, 1998, CELL CALCIUM, V23, P79, DOI 10.1016/S0143-4160(98)90105-1; Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; CIAPA B, 1994, NATURE, V368, P875, DOI 10.1038/368875a0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; DORING V, 1995, J CELL SCI, V108, P2065; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; Furge LL, 1999, J BIOL CHEM, V274, P33504, DOI 10.1074/jbc.274.47.33504; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; Holmer L, 2001, CELL MOL LIFE SCI, V58, P1741, DOI 10.1007/PL00000813; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KINDY MS, 1991, J CELL BIOCHEM, V46, P345, DOI 10.1002/jcb.240460409; Kitaura Y, 2001, J BIOL CHEM, V276, P14053, DOI 10.1074/jbc.M008649200; Kubista H, 1999, CURR BIOL, V9, P1403, DOI 10.1016/S0960-9822(00)80085-8; Mailliard WS, 1996, J BIOL CHEM, V271, P719, DOI 10.1074/jbc.271.2.719; Merrifield CJ, 2001, CURR BIOL, V11, P1136, DOI 10.1016/S0960-9822(01)00321-9; MINAMI H, 1992, FEBS LETT, V305, P217, DOI 10.1016/0014-5793(92)80671-3; MIZUTANI A, 1993, J BIOL CHEM, V268, P15517; MIZUTANI A, 1995, ARCH BIOCHEM BIOPHYS, V318, P157, DOI 10.1006/abbi.1995.1216; NEAMATI N, 1995, J IMMUNOL, V154, P3788; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rety S, 2000, STRUCTURE, V8, P175, DOI 10.1016/S0969-2126(00)00093-9; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Satoh H, 2002, BBA-PROTEINS PROTEOM, V1600, P61, DOI 10.1016/S1570-9639(02)00445-4; Satoh H, 2002, BIOCHEM BIOPH RES CO, V291, P1166, DOI 10.1006/bbrc.2002.6600; Seemann J, 1997, FEBS LETT, V413, P185, DOI 10.1016/S0014-5793(97)00911-3; Stradal TB, 1999, J BIOL CHEM, V274, P31593, DOI 10.1074/jbc.274.44.31593; Sudo T, 1999, FEBS LETT, V444, P11, DOI 10.1016/S0014-5793(99)00014-9; TOKUMITSU H, 1993, ARCH BIOCHEM BIOPHYS, V303, P302, DOI 10.1006/abbi.1993.1287; Wilding M, 1996, J CELL BIOL, V135, P191, DOI 10.1083/jcb.135.1.191	33	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20210	20216		10.1074/jbc.M212669200	http://dx.doi.org/10.1074/jbc.M212669200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12601007	hybrid, Green Published			2022-12-27	WOS:000183078000082
J	Bunger, MK; Moran, SM; Glover, E; Thomae, TL; Lahvis, GP; Lin, BC; Bradfield, CA				Bunger, MK; Moran, SM; Glover, E; Thomae, TL; Lahvis, GP; Lin, BC; Bradfield, CA			Resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity and abnormal liver development in mice carrying a mutation in the nuclear localization sequence of the aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC AH RECEPTOR; DNA-BINDING; DEFICIENT MICE; IN-VIVO; RETINOBLASTOMA PROTEIN; SIGNALING PATHWAYS; KNOCKOUT MICE; CELL-CYCLE; C-SRC; DIOXIN	The Ah receptor (AHR) mediates the metabolic adaptation to a number of planar aromatic chemicals. Essential steps in this adaptive mechanism include AHR binding of ligand in the cytosol, translocation of the receptor to the nucleus, dimerization with the Ah receptor nuclear translocator, and binding of this heterodimeric transcription factor to dioxin-responsive elements (DREs) upstream of promoters that regulate the expression of genes involved in xenobiotic metabolism. The AHR is also involved in other aspects of mammalian biology, such as the toxicity of molecules like 2,3,7,8-tetrachlorodibenzo-p-dioxin as well as regulation of normal liver development. In an effort to test whether these additional AHR-mediated processes require a nuclear event, such as DRE binding, we used homologous recombination to generate mice with a mutation in the AHR nuclear localization/DRE binding domain. These Ahr(nls) mice were found to be resistant to all 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxic responses that we examined, including hepatomegaly, thymic involution, and cleft palate formation. Moreover, aberrations in liver development observed in these mice were identical to that observed in mice harboring a null allele at the Ahr locus. Taken in sum, these data support a model where most, if not all, of AHR-regulated biology requires nuclear localization.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Training Program Environm Toxicol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Bradfield, CA (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.			Lahvis, Garet/0000-0002-1986-8251	NCI NIH HHS [P01-CA22484, P01-CA14520, T32-CA09135, P01 CA022484, P30-CA07175] Funding Source: Medline; NIEHS NIH HHS [F32 ES005877-03, T32-ES07015, F32-ES05877] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135, P30CA007175, P01CA022484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005877, T32ES007015] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; Blankenship A, 1997, MOL PHARMACOL, V52, P667, DOI 10.1124/mol.52.4.667; BRADFIELD CA, 1988, MOL PHARMACOL, V34, P229; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; DEVORE J, 1986, STAT EXPLORATION ANA; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; Dong LQ, 1996, J BIOL CHEM, V271, P7942, DOI 10.1074/jbc.271.14.7942; Dunlap DY, 2002, TOXICOLOGY, V172, P125, DOI 10.1016/S0300-483X(02)00006-9; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; EMA M, 1994, J BIOL CHEM, V269, P27337; Enan E, 1996, BIOCHEM PHARMACOL, V52, P1599, DOI 10.1016/S0006-2952(96)00566-7; FernandezSalguero PM, 1997, VET PATHOL, V34, P605, DOI 10.1177/030098589703400609; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; Fukunaga BN, 1996, J BIOL CHEM, V271, P3743; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gonzalez FJ, 1998, DRUG METAB DISPOS, V26, P1194; Gradin K, 1996, MOL CELL BIOL, V16, P5221; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; JAIN S, 1994, J BIOL CHEM, V269, P31518; Klinge CM, 2000, ARCH BIOCHEM BIOPHYS, V373, P163, DOI 10.1006/abbi.1999.1552; Lahvis GP, 1998, BIOCHEM PHARMACOL, V56, P781, DOI 10.1016/S0006-2952(98)00134-8; Lahvis GP, 2000, P NATL ACAD SCI USA, V97, P10442, DOI 10.1073/pnas.190256997; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; McDonnell WM, 1996, SCIENCE, V271, P223; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OKEY AB, 1989, MOL PHARMACOL, V35, P823; Peters JM, 1999, TOXICOL SCI, V47, P86, DOI 10.1093/toxsci/47.1.86; Pisano MM, 2000, METH MOL B, V137, P267; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLAND A, 1986, J BIOL CHEM, V261, P6352; POLAND A, 1980, MOL PHARMACOL, V17, P86; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Reiners JJ, 1999, J BIOL CHEM, V274, P2502, DOI 10.1074/jbc.274.4.2502; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; SCHMIDT JV, 1993, J BIOL CHEM, V268, P22203; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Swanson HI, 1996, J BIOL CHEM, V271, P31657, DOI 10.1074/jbc.271.49.31657; Taya Y, 1999, DEVELOPMENT, V126, P3869; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; TORADO GJ, 1963, J CELL BIOL, V17, P299; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Whitlock JP, 1997, DRUG METAB REV, V29, P1107, DOI 10.3109/03602539709002245; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Zaher H, 1998, MOL PHARMACOL, V54, P313, DOI 10.1124/mol.54.2.313	49	157	163	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17767	17774		10.1074/jbc.M209594200	http://dx.doi.org/10.1074/jbc.M209594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621046	hybrid			2022-12-27	WOS:000182838300024
J	Horike, N; Takemori, H; Katoh, Y; Doi, J; Min, L; Asano, T; Sun, XJ; Yamamoto, H; Kasayama, S; Muraoka, M; Nonaka, Y; Okamoto, M				Horike, N; Takemori, H; Katoh, Y; Doi, J; Min, L; Asano, T; Sun, XJ; Yamamoto, H; Kasayama, S; Muraoka, M; Nonaka, Y; Okamoto, M			Adipose-specific expression, phosphorylation of Ser(794) in insulin receptor substrate-1, and activation in diabetic animals of salt-inducible kinase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENOCORTICAL TUMOR-CELLS; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; ADIPOCYTE DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; 3T3-L1 ADIPOCYTES; IRS PROTEINS; C/EBP-DELTA; FED RATS	Salt-inducible kinase (SIK), first cloned from the adrenal glands of rats fed a high salt diet, is a serine/threonine protein kinase belonging to an AMP-activated protein kinase family. Induced in Y1 cells at an early stage of ACTH stimulation, it regulated the initial steps of steroidogenesis. Here we report the identification of its isoform SIK2. When a green fluorescent protein-fused SIK2 was expressed in 3T3-L1 preadipocytes, it was mostly present in the cytoplasm. When coexpressed in cAMP-responsive element-reporter assay systems, SIK2 could repress the cAMP-responsive element-dependent transcription, although the degree of repression seemed weaker than that by SIK1. SIK2 was specifically expressed in adipose tissues. When 3T3-L1 cells were treated with the adipose differentiation mixture, SIK2 mRNA was induced within 1 h, the time of induction almost coinciding with that of c/EBPbeta mRNA. Coexpressed with human insulin receptor substrate-1 (IRS-1) in COS cells, SIK2 could phosphorylate Ser(794) of human IRS-1. Adenovirus-mediated overexpression of SIK2 in adipocytes elevated the level of phosphorylation at Ser(789), the mouse equivalent of human Ser(794). Moreover, the activity and content of SIK2 were elevated in white adipose tissues of db/db diabetic mice. These results suggest that highly expressed SIK2 in insulin-stimulated adipocytes phosphorylates Ser(794) of IRS-1 and, as a result, might modulate the efficiency of insulin signal transduction, eventually causing the insulin resistance in diabetic animals.	Osaka Univ, Grad Sch Med, Dept Biochem & Mol Biol H1, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Mol Med C4, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Labs Biomol Networks, Suita, Osaka 5650871, Japan; Kinran Coll, Dept Life Sci, Osaka 5650873, Japan; Univ Tokyo, Grad Sch Med, Dept Internal Med, Tokyo 1130033, Japan; Univ Vermont, Coll Med, Div Endocrinol, Burlington, VT 05405 USA; Prot Express Co Ltd, Chiba 2880041, Japan; Koshien Univ, Coll Nutr, Takarazuka, Hyogo 6650006, Japan	Osaka University; Osaka University; Osaka University; University of Tokyo; University of Vermont	Okamoto, M (corresponding author), Osaka Univ, Grad Sch Med H1, Dept Biochem & Mol Biol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Anai M, 1999, DIABETES, V48, P158, DOI 10.2337/diabetes.48.1.158; Belmonte N, 2001, MOL ENDOCRINOL, V15, P2037, DOI 10.1210/me.15.11.2037; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Doi J, 2002, J BIOL CHEM, V277, P15629, DOI 10.1074/jbc.M109365200; Doi J, 2001, J ENDOCRINOL, V168, P87, DOI 10.1677/joe.0.1680087; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Engelman JA, 2000, MOL ENDOCRINOL, V14, P1557, DOI 10.1210/me.14.10.1557; Greene MW, 2002, BIOCHEMISTRY-US, V41, P7082, DOI 10.1021/bi015992f; Halder SK, 1998, ENDOCRINOLOGY, V139, P3316, DOI 10.1210/en.139.7.3316; Hamilton SR, 2002, BIOCHEM BIOPH RES CO, V293, P892, DOI 10.1016/S0006-291X(02)00312-1; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Jakobsen SN, 2001, J BIOL CHEM, V276, P46912, DOI 10.1074/jbc.C100483200; Klemm DJ, 2001, J BIOL CHEM, V276, P28430, DOI 10.1074/jbc.M103382200; Kurebayashi S, 2001, ENDOCR J, V48, P249, DOI 10.1507/endocrj.48.249; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Lin XZ, 2001, MOL ENDOCRINOL, V15, P1264, DOI 10.1210/me.15.8.1264; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; Ogihara T, 2001, DIABETES, V50, P573, DOI 10.2337/diabetes.50.3.573; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Petersen KF, 2002, AM J CARDIOL, V90, p11G; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Reusch JEB, 2002, J BIOL CHEM, V277, P1426, DOI 10.1074/jbc.M107923200; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Sul HS, 1998, PROG NUCLEIC ACID RE, V60, P317, DOI 10.1016/S0079-6603(08)60896-X; Takemori H, 1998, J BIOL CHEM, V273, P2222, DOI 10.1074/jbc.273.4.2222; Takemori H, 2002, J BIOL CHEM, V277, P42334, DOI 10.1074/jbc.M204602200; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; Wang ZN, 1999, FEBS LETT, V453, P135, DOI 10.1016/S0014-5793(99)00708-5; White MF, 1998, CURR TOP MICROBIOL, V228, P179; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; WHITE MF, 1997, DIABETOLOGIA, V40, P2; Xiang XQ, 2002, MOL ENDOCRINOL, V16, P552, DOI 10.1210/me.16.3.552; Yamamoto H, 2002, J CELL SCI, V115, P3601, DOI 10.1242/jcs.00044; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	47	114	126	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18440	18447		10.1074/jbc.M211770200	http://dx.doi.org/10.1074/jbc.M211770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624099	hybrid			2022-12-27	WOS:000182838300111
J	Liu, L; Ben-Shlomo, H; Xu, YX; Stern, MZ; Goncharov, I; Zhang, YF; Michaeli, S				Liu, L; Ben-Shlomo, H; Xu, YX; Stern, MZ; Goncharov, I; Zhang, YF; Michaeli, S			The trypanosomatid signal recognition particle consists of two RNA molecules, a 7SL RNA homologue and a novel tRNA-like molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEPTOMONAS-COLLOSOMA; ELONGATION ARREST; BINDING-SITES; ALU DOMAIN; SPLICED LEADER; NUCLEAR EXPORT; SRP PROTEINS; IDENTIFICATION; LOCALIZATION; BRUCEI	Trypanosomatids are ancient eukaryotic parasites affecting humans and livestock. Here we report that the trypanosomatid signal recognition particle (SRP), unlike all other known SRPs in nature, contains, in addition to the 7SL RNA homologue, a short RNA molecule, termed sRNA-85. Using conventional chromatography, we discovered a small RNA molecule of 85 nucleotides co-migrating with the Leptomonas collosoma 7SL RNA. This RNA molecule was isolated, sequenced, and used to clone the corresponding gene. sRNA-85 was identified as a tRNA-like molecule that deviates from the canonical tRNA structure. The co-existence of these RNAs in a single complex was confirmed by affinity selection using an antisense oligonucleotide to sRNA-85. The two RNA molecules exist in a particle of similar to14 S that binds transiently to ribosomes. Mutations were introduced in sRNA-85 that disrupted its putative potential to interact with 7SL RNA by base pairing; such mutants were unable to bind to 7SL RNA and to ribosomes and were aberrantly distributed within the cell. We postulate that sRNA-85 may functionally replace the truncated Alu domain of 7SL RNA. The discovery of sRNA-85 raises the intriguing possibility that sRNA-85 functional homologues may exist in other lower eukaryotes and eubacteria that lack the Alu domain.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Bar Ilan University; Weizmann Institute of Science	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.	michaes@mail.biu.ac.il	Xu, Yu-Xin/G-4041-2010; Michaeli, Shulamit/AAC-8255-2022	Xu, Yu-Xin/0000-0002-0200-4633; Liu, Li/0000-0002-3733-6961				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ALTHOFF S, 1994, NUCLEIC ACIDS RES, V22, P1933, DOI 10.1093/nar/22.11.1933; ANDREWS DW, 1987, EMBO J, V6, P3471, DOI 10.1002/j.1460-2075.1987.tb02671.x; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; BEJA O, 1993, MOL BIOCHEM PARASIT, V57, P223, DOI 10.1016/0166-6851(93)90198-7; Ben-Shlomo H, 1997, NUCLEIC ACIDS RES, V25, P4977, DOI 10.1093/nar/25.24.4977; Ben-Shlomo H, 1999, J BIOL CHEM, V274, P25642, DOI 10.1074/jbc.274.36.25642; BJORK GR, 1987, ANNU REV BIOCHEM, V56, P263, DOI 10.1146/annurev.bi.56.070187.001403; Bovia F, 1996, J CELL SCI, V109, P2601; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; Bui N, 1999, BIOL CHEM, V380, P135, DOI 10.1515/BC.1999.021; Burkhardt N, 1998, CRIT REV BIOCHEM MOL, V33, P95, DOI 10.1080/10409239891204189; Chaves I, 1998, P NATL ACAD SCI USA, V95, P12328, DOI 10.1073/pnas.95.21.12328; Ciufo LF, 2000, CURR BIOL, V10, P1256, DOI 10.1016/S0960-9822(00)00743-0; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; England T E, 1980, Methods Enzymol, V65, P65; Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0; Goldring A, 1996, EXP PARASITOL, V84, P28, DOI 10.1006/expr.1996.0087; Grosshans H, 2001, J CELL BIOL, V153, P745, DOI 10.1083/jcb.153.4.745; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; Jacobson MR, 1998, P NATL ACAD SCI USA, V95, P7981, DOI 10.1073/pnas.95.14.7981; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Levitan A, 1998, NUCLEIC ACIDS RES, V26, P1775, DOI 10.1093/nar/26.7.1775; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; MANS RMW, 1991, EUR J BIOCHEM, V201, P303, DOI 10.1111/j.1432-1033.1991.tb16288.x; Mason N, 2000, EMBO J, V19, P4164, DOI 10.1093/emboj/19.15.4164; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MICHAELI S, 1992, MOL BIOCHEM PARASIT, V51, P55, DOI 10.1016/0166-6851(92)90200-4; Muto A, 1998, TRENDS BIOCHEM SCI, V23, P25, DOI 10.1016/S0968-0004(97)01159-6; NAKAAR V, 1995, PARASITOL TODAY, V11, P225, DOI 10.1016/0169-4758(95)80085-9; Nakamura K, 1999, J BIOL CHEM, V274, P13569, DOI 10.1074/jbc.274.19.13569; OGG SC, 1995, CELL, V81, P1075, DOI 10.1016/S0092-8674(05)80012-1; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; Pederson T, 1999, FASEB J, V13, pS238, DOI 10.1096/fasebj.13.9002.S238; RHEINBERGER HJ, 1986, J BIOL CHEM, V261, P9133; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Shi PY, 1998, RNA, V4, P276; SIEGEL V, 1988, CELL, V52, P39, DOI 10.1016/0092-8674(88)90529-6; SIEGEL V, 1988, TRENDS BIOCHEM SCI, V13, P314, DOI 10.1016/0968-0004(88)90127-2; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; Sinha R, 1999, J BIOL CHEM, V274, P30826, DOI 10.1074/jbc.274.43.30826; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; Strub K, 1999, RNA, V5, P1333, DOI 10.1017/S1355838299991045; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WATKINS KP, 1994, CELL, V76, P171, DOI 10.1016/0092-8674(94)90181-3; Weichenrieder O, 2000, NATURE, V408, P167, DOI 10.1038/35041507; Wild K, 2002, CURR OPIN STRUC BIOL, V12, P72, DOI 10.1016/S0959-440X(02)00292-0; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; Xu YX, 1997, P NATL ACAD SCI USA, V94, P8473, DOI 10.1073/pnas.94.16.8473	57	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18271	18280		10.1074/jbc.M209215200	http://dx.doi.org/10.1074/jbc.M209215200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12606550	hybrid			2022-12-27	WOS:000182838300090
J	Raffetseder, U; Frye, B; Rauen, T; Jurchott, K; Royer, HD; Jansen, PL; Mertens, PR				Raffetseder, U; Frye, B; Rauen, T; Jurchott, K; Royer, HD; Jansen, PL; Mertens, PR			Splicing factor SRp30c interaction with Y-box protein-1 confers nuclear YB-1 shuttling and alternative splice site selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEOPROTEIN PARTICLES; TRANSCRIPTION FACTOR YB-1; RNA-ASSOCIATED PROTEIN; MAJOR CORE PROTEIN; BINDING-PROTEIN; FUNCTIONAL INTERACTION; EXPRESSION; OVEREXPRESSION; IDENTIFICATION; TRANSLOCATION	The multifunctional DNA- and RNA-associated Y-box protein 1 (YB-1) specifically binds to splicing recognition motifs and regulates alternative splice site selection. Here, we identify the arginine/serine-rich SRp30c protein as an interacting protein of YB-1 by performing a two-hybrid screen against a human mesangial cell cDNA library. Co-immunoprecipitation studies confirm a direct interaction of tagged proteins YB-1 and SRp30c in the absence of RNA via two independent protein domains of YB-1. A high affinity interaction is conferred through the N-terminal region. We show that the subcellular YB-1 localization is dependent on the cellular SRp30c content. In proliferating cells, YB-1 localizes to the cytoplasm, whereas FLAG-SRp30c protein is detected in the nucleus. After overexpression of YB-1 and FLAG-SRp30c, both proteins are co-localized in the nucleus, and this requires the N-terminal region of YB-1. Heat shock treatment of cells, a condition under which SRp30c accumulates in stress-induced Sam68 nuclear bodies, abrogates the co-localization and YB-1 shuttles back to the cytoplasm. Finally, the functional relevance of the YB-1/SRp30c interaction for in vivo splicing is demonstrated in the E1A minigene model system. Here, changes in splice site selection are detected, that is, overexpression of YB-1 is accompanied by preferential 5' splicing site selection and formation of the 12 S isoform.	Univ Hosp Aachen, Div Nephrol & Clin Immunol, D-52057 Aachen, Germany; Humboldt Univ, Charite, Inst Pathol, D-10099 Berlin, Germany; Univ Dusseldorf, Inst Transplant Diagnost & Cell Therapy, D-40225 Dusseldorf, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Mertens, PR (corresponding author), Rhein Westfal TH Aachen, Med Klin 2, Pauwelsstr 30, D-52057 Aachen, Germany.	pmertens@ukaachen.de	Mertens, Peter/AAI-7310-2020; Royer, Hans-dieter/AAH-6293-2019	Raffetseder, Ute/0000-0002-7236-9793; Jurchott, Karsten/0000-0003-1589-0037				Banas B, 1999, J AM SOC NEPHROL, V10, P2314; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; BOUVET P, 1995, J BIOL CHEM, V270, P28297; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Capowski EE, 2001, J IMMUNOL, V167, P5970, DOI 10.4049/jimmunol.167.10.5970; Chansky HA, 2001, CANCER RES, V61, P3586; Chen CY, 2000, GENE DEV, V14, P1236; CHEN NN, 1995, J VIROL, V69, P5843, DOI 10.1128/JVI.69.9.5843-5848.1995; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Chernukhin IV, 2000, J BIOL CHEM, V275, P29915, DOI 10.1074/jbc.M001538200; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Holst B, 2001, J BIOL CHEM, V276, P19793, DOI 10.1074/jbc.M100621200; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Kohno K, 1997, Nihon Rinsho, V55, P1054; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; MINICH WB, 1989, FEBS LETT, V258, P227, DOI 10.1016/0014-5793(89)81659-X; MINICH WB, 1989, FEBS LETT, V257, P257, DOI 10.1016/0014-5793(89)81547-9; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Norman JT, 2001, J BIOL CHEM, V276, P29880, DOI 10.1074/jbc.M103145200; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; Stoss O, 1999, J BIOL CHEM, V274, P10951, DOI 10.1074/jbc.274.16.10951; Stoss O, 2001, J BIOL CHEM, V276, P8665, DOI 10.1074/jbc.M006851200; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; Woods R. A., 2001, METH MOL B, V177, P85; Young PJ, 2002, HUM MOL GENET, V11, P577, DOI 10.1093/hmg/11.5.577	44	100	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18241	18248		10.1074/jbc.M212518200	http://dx.doi.org/10.1074/jbc.M212518200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12604611	hybrid			2022-12-27	WOS:000182838300086
J	Westhoff, T; Jankowski, J; Schmidt, S; Luo, JK; Giebing, G; Schluter, H; Tepel, M; Zidek, W; van der Giet, M				Westhoff, T; Jankowski, J; Schmidt, S; Luo, JK; Giebing, G; Schluter, H; Tepel, M; Zidek, W; van der Giet, M			Identification and characterization of adenosine 5 '-tetraphosphate in human myocardial tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LASER DESORPTION IONIZATION; CARDIOVASCULAR-SYSTEM; CORONARY VASODILATATION; CHROMAFFIN GRANULES; MASS-SPECTROMETRY; P2X PURINOCEPTOR; RAT-HEART; ATP; RECEPTORS; TETRAPHOSPHATE	Endocrine functions of the human heart have been studied extensively. Only recently, nucleotidergic mechanisms have been studied in detail. Therefore, an isolation strategy was developed to isolate novel nucleotide compounds from human myocardium. The human myocardial tissue was fractionated by several chromatographic studies. A substance purified to homogeneity was identified as adenosine 5'-tetraphosphate (Ap(4)) by matrix-assisted laser desorption/ionization mass spectrometry (MALDI MS), post-source decay MALDI MS, and enzymatic cleavage analysis. Furthermore, Ap(4) was also identified in ventricular specific granules. In the isolated perfused rat heart, Ap(4) elicited dose-dependent vasodilations. Vasodilator responses were abolished in the presence of the P-2Y1 receptor antagonist MRS 2179 (1 muM) or the NO synthase inhibitor N-G-nitro-L-arginine methyl ester (50 muM). After removal of the endothelium by Triton X-100, Ap(4) induced dose-dependent vasoconstrictions. Inhibition of P-2X receptors by pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid (30 muM) or desensitization of P-2X receptors by alpha,beta-methylene ATP (alpha,beta-meATP, 1 muM) diminished these vasoconstrictor responses completely. In the present study Ap(4) has been isolated from human tissue. Ap(4) was shown to exist in human myocardial tissue and was identified in ventricular specific granules. In coronary vasculature the nucleotide exerted vasodilation via endothelial P-2Y1 receptors and vasoconstriction via P-2X receptors on vascular smooth muscle cells. Ap(4) acts as an endogenous extracellular mediator and might contribute to the regulation of coronary perfusion.	Free Univ Berlin, Klinikum Benjamin Franklin, Med Klin 4, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	van der Giet, M (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Med Klin 4, Hindenburgdamm 30, D-12200 Berlin, Germany.		Tepel, Martin/GRS-9581-2022; Schluter, Hartmut/D-1371-2015	Schluter, Hartmut/0000-0002-9358-7036; Westhoff, Timm H./0000-0001-5797-834X; Tepel, Martin/0000-0002-0086-0997; Luo, Jiankai/0000-0001-5169-3095; van der Giet, Markus/0000-0003-3590-5451				BARNES LD, 1985, ANAL BIOCHEM, V144, P296, DOI 10.1016/0003-2697(85)90120-4; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broad RM, 2001, HANDB EXP PHARM, V151, P3; CURRIE MG, 1984, SCIENCE, V223, P67, DOI 10.1126/science.6419347; DEBOLD AJ, 1973, CARDIOVASC RES, V7, P364; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; Flores NA, 1999, CARDIOVASC RES, V42, P15, DOI 10.1016/S0008-6363(99)00004-8; GarciaGuzman M, 1996, FEBS LETT, V388, P123, DOI 10.1016/0014-5793(96)00499-1; Giannella E, 1997, CIRC RES, V81, P415, DOI 10.1161/01.RES.81.3.415; Gualix J, 1996, FEBS LETT, V391, P195, DOI 10.1016/0014-5793(96)00732-6; HILLENKAMP F, 1990, METHOD ENZYMOL, V193, P280, DOI 10.1016/0076-6879(90)93420-P; HOPWOOD AM, 1987, EUR J PHARMACOL, V136, P49, DOI 10.1016/0014-2999(87)90777-1; KAUFMANN R, 1994, METHOD ENZYMOL, V193, P263; Lee CYG, 1995, J REPROD IMMUNOL, V29, P223, DOI 10.1016/0165-0378(95)00947-J; LIEBERMAN I, 1955, J AM CHEM SOC, V77, P3373, DOI 10.1021/ja01617a064; Luo J, 1999, FASEB J, V13, P695, DOI 10.1096/fasebj.13.6.695; MARRIAN DH, 1953, BIOCHIM BIOPHYS ACTA, V12, P492, DOI 10.1016/0006-3002(53)90176-0; NORDHOFF E, 1992, RAPID COMMUN MASS SP, V6, P771, DOI 10.1002/rcm.1290061212; Nori S, 1998, J VASC RES, V35, P179, DOI 10.1159/000025582; Pelleg A, 2001, HANDB EXP PHARM, V151, P73; Phillis JW, 1998, EUR J PHARMACOL, V356, P199, DOI 10.1016/S0014-2999(98)00512-3; Ralevic V, 1998, PHARMACOL REV, V50, P413; SMALL GD, 1966, BIOCHEMISTRY-US, V5, P26, DOI 10.1021/bi00865a004; Starling RC, 1998, MOL CELL BIOCHEM, V180, P171, DOI 10.1023/A:1006876031121; SULKOWSKI E, 1971, BIOCHIM BIOPHYS ACTA, V240, P443, DOI 10.1016/0005-2787(71)90538-7; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; van der Giet M, 2002, EUR J PHARMACOL, V448, P207, DOI 10.1016/S0014-2999(02)01986-6; VANDYKE K, 1977, PHARMACOLOGY, V15, P377, DOI 10.1159/000136714; ZISMAN LS, 1995, J CLIN INVEST, V96, P1490, DOI 10.1172/JCI118186	30	10	11	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17735	17740		10.1074/jbc.M300288200	http://dx.doi.org/10.1074/jbc.M300288200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12609994	hybrid			2022-12-27	WOS:000182838300020
J	Buu, LM; Chen, YC; Lee, FJS				Buu, LM; Chen, YC; Lee, FJS			Functional characterization and localization of acetyl-CoA hydrolase, Ach1p, in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A HYDROLASE; AMINO-ACID-SEQUENCE; RAT-LIVER; ACETATE UTILIZATION; FILAMENTOUS GROWTH; PROTEIN IMPORT; SHORT-CHAIN; YEAST; MITOCHONDRIA; GENE	Acetyl-CoA hydrolase (Ach1p), catalyzing the hydrolysis of acetyl-CoA, is presumably involved in regulating intracellular acetyl-CoA or CoASH pools; however, its intracellular functions and distribution remain to be established. Using site-directed mutagenesis analysis, we demonstrated that the enzymatic activity of Ach1p is dependent upon its putative acetyl-CoA binding sites. The ach1 mutant causes a growth defect in acetate but not in other non-fermentable carbon sources, suggesting that Ach1p is not involved in mitochondrial biogenesis. Overexpression of Ach1p, but not constructs containing acetyl-CoA binding site mutations, in ach1-1 complemented the defect of acetate utilization. By subcellular fractionation, most of the Ach1p in yeast was distributed with mitochondria and little Ach1p in the cytoplasm. By immunofluorescence microscopy, we show that Ach1p and acetyl-CoA binding site-mutated constructs, but not its N-terminal deleted construct, are localized in mitochondria. Moreover, the onset of pseudohyphal development in homozygote ach1-1 diploids was abolished. We infer that Ach1p may be involved in a novel acetyl-CoA biogenesis and/or acetate utilization in mitochondria and thereby indirectly affect pseudohyphal development in yeast.	Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Inst Mol Med, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Lee, FJS (corresponding author), Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Inst Mol Med, 7 Chung Shan S Rd, Taipei 100, Taiwan.		Chen, Yee-Chun/AGW-7535-2022	Chen, Yee-Chun/0000-0002-1816-9010; LEE, FANG-JEN/0000-0002-2167-2426				BERNSON VSM, 1976, EUR J BIOCHEM, V67, P403, DOI 10.1111/j.1432-1033.1976.tb10705.x; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; CONNERTON IF, 1992, J GEN MICROBIOL, V138, P1797, DOI 10.1099/00221287-138-9-1797; ELGERSMA Y, 1995, EMBO J, V14, P3472, DOI 10.1002/j.1460-2075.1995.tb07353.x; Flikweert MT, 1996, YEAST, V12, P247, DOI 10.1002/(SICI)1097-0061(19960315)12:3<247::AID-YEA911>3.0.CO;2-I; FUKAYA M, 1993, J FERMENT BIOENG, V76, P270, DOI 10.1016/0922-338X(93)90192-B; GERGELY J, 1952, J BIOL CHEM, V198, P323; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GRIGAT KP, 1979, BIOCHEM J, V177, P71, DOI 10.1042/bj1770071; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Huang CF, 1999, J BIOL CHEM, V274, P3819, DOI 10.1074/jbc.274.6.3819; Huang CF, 2002, J CELL SCI, V115, P275; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KNOWLES SE, 1974, BIOCHEM J, V142, P401, DOI 10.1042/bj1420401; LEE FJS, 1990, J BIOL CHEM, V265, P7413; LEE FJS, 1989, EUR J BIOCHEM, V184, P21, DOI 10.1111/j.1432-1033.1989.tb14985.x; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; Lee FJS, 1996, BBA-PROTEIN STRUCT M, V1297, P105, DOI 10.1016/0167-4838(96)00109-4; LEE FJS, 1988, J BIOL CHEM, V263, P14948; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; LOWE PN, 1988, BIOCHEM J, V250, P789, DOI 10.1042/bj2500789; MAHAN DE, 1975, BIOCHEM J, V145, P25, DOI 10.1042/bj1450025; MARATHE S, 1990, MOL CELL BIOL, V10, P2638, DOI 10.1128/MCB.10.6.2638; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NOBEL DD, 2001, YEAST, V18, P1413; Palecek SP, 2002, MICROBIOL-SGM, V148, P893, DOI 10.1099/00221287-148-4-893; PARALES RE, 1992, J BACTERIOL, V174, P4657, DOI 10.1128/JB.174.14.4657-4666.1992; PRASS RL, 1980, J BIOL CHEM, V255, P5215; Pronk JT, 1996, YEAST, V12, P1607, DOI 10.1002/(SICI)1097-0061(199612)12:16<1607::AID-YEA70>3.0.CO;2-4; ROBINSON JB, 1976, BIOCHEM BIOPH RES CO, V71, P959, DOI 10.1016/0006-291X(76)90748-8; Sambrook J., 2002, MOL CLONING LAB MANU; SANYAL A, 1995, J BIOL CHEM, V270, P11970, DOI 10.1074/jbc.270.20.11970; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; Sherman F., 1986, METHODS YEAST GENETI; Sohling B, 1996, J BACTERIOL, V178, P871; SOLING HD, 1985, EUR J BIOCHEM, V147, P111, DOI 10.1111/j.1432-1033.1985.tb08726.x; Suematsu N, 2001, EUR J BIOCHEM, V268, P2700, DOI 10.1046/j.1432-1327.2001.02162.x; Svensson LT, 1996, EUR J BIOCHEM, V239, P526, DOI 10.1111/j.1432-1033.1996.0526u.x; van den Berg MA, 1998, YEAST, V14, P1089, DOI 10.1002/(SICI)1097-0061(19980915)14:12<1089::AID-YEA312>3.3.CO;2-B; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Wilusz CJ, 2001, RNA, V7, P1416; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	45	41	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17203	17209		10.1074/jbc.M213268200	http://dx.doi.org/10.1074/jbc.M213268200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606555	hybrid			2022-12-27	WOS:000182818600102
J	Watson, LM; Chan, AKC; Berry, LR; Li, J; Sood, SK; Dickhout, JG; Xu, L; Werstuck, GH; Bajzar, L; Klamut, HJ; Austin, RC				Watson, LM; Chan, AKC; Berry, LR; Li, J; Sood, SK; Dickhout, JG; Xu, L; Werstuck, GH; Bajzar, L; Klamut, HJ; Austin, RC			Overexpression of the 78-kDa glucose-regulated protein/immunoglobulin-binding protein (GRP78/BiP) inhibits tissue factor procoagulant activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; ARTERIAL SMOOTH-MUSCLE; FACTOR EXPRESSION; FACTOR PATHWAY; ENDOTHELIAL-CELLS; MOLECULAR CHAPERONES; GENE-EXPRESSION; FACTOR ANTIGEN; GROWTH ARREST; OXIDIZED LDL	Previous studies have demonstrated that overexpression of GRP78/BiP, an endoplasmic reticulum (ER)-resident molecular chaperone, in mammalian cells inhibits the secretion of specific coagulation factors. However, the effects of GRP78/BiP on activation of the coagulation cascade leading to thrombin generation are not known. In this study, we examined whether GRP78/BiP overexpression mediates cell surface thrombin generation in a human bladder cancer cell line T24/83 having prothrombotic characteristics. We report here that cells overexpressing GRP78/BiP exhibited significant decreases in cell surface-mediated thrombin generation, prothrombin consumption and the formation of thrombin-inhibitor complexes, compared with wild-type or vector-transfected cells. This effect was attributed to the ability of GRP78/BiP to inhibit cell surface tissue factor (TF) procoagulant activity (PCA) because conversion of factor X to Xa and factor VII to VIIa were significantly lower on the surface of GRP78/ BiP-overexpressing cells. The additional findings that (i) cell surface factor Xa generation was inhibited in the absence of factor VIIa and (ii) TF PCA was inhibited by a neutralizing antibody to human TF suggests that thrombin generation is mediated exclusively by TF. GRP78/BiP overexpression did not decrease cell surface levels of TF, suggesting that the inhibition in TF PCA does not result from retention of TF in the ER by GRP78/BiP. The additional observations that both adenovirus-mediated and stable GRP78/BiP overexpression attenuated TF PCA stimulated by ionomycin or hydrogen peroxide suggest that GRP78/BiP indirectly alters TF PCA through a mechanism involving cellular Ca2+ and/or oxidative stress. Similar results were also observed in human aortic smooth muscle cells transfected with the GRP78/BiP adenovirus. Taken together, these findings demonstrate that overexpression of GRP78/BiP decreases thrombin generation by inhibiting cell surface TF PCA, thereby suppressing the prothrombotic potential of cells.	Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Pediat, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Med, Hamilton, ON L8V 1C3, Canada; Ontario Canc Inst, Div Expt Therapeut, Toronto, ON M5G 2M9, Canada	McMaster University; McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Austin, RC (corresponding author), Henderson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	raustin@thrombosis.hhscr.org	Dickhout, Jeffrey/R-2606-2019; Chan, Anthony K. C./AAR-8892-2021	Chan, Anthony K. C./0000-0003-1551-3995				[Anonymous], 1987, THROMB DIATH HAEMO; Aoki M, 2001, MOL BRAIN RES, V95, P117, DOI 10.1016/S0169-328X(01)00255-8; Ardissino D, 1997, LANCET, V349, P769, DOI 10.1016/S0140-6736(96)11189-2; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; Bach RR, 1997, BLOOD, V89, P3270, DOI 10.1182/blood.V89.9.3270; Badimon JJ, 1999, CIRCULATION, V99, P1780, DOI 10.1161/01.CIR.99.14.1780; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRAND K, 1994, ARTERIOSCLER THROMB, V14, P790, DOI 10.1161/01.ATV.14.5.790; BREIDER MA, 1994, VET PATHOL, V31, P55, DOI 10.1177/030098589403100107; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brown J, 2000, LAB INVEST, V80, P37, DOI 10.1038/labinvest.3780006; CALLANDER NS, 1992, CANCER-AM CANCER SOC, V70, P1194, DOI 10.1002/1097-0142(19920901)70:5<1194::AID-CNCR2820700528>3.0.CO;2-E; CARSON SD, 1994, BLOOD, V84, P526; Chan AKC, 1998, AM J PHYSIOL-LUNG C, V274, pL914, DOI 10.1152/ajplung.1998.274.6.L914; CONSONNI R, 1995, THROMB HAEMOSTASIS, V74, P904; CONWAY EM, 1989, THROMB RES, V53, P231, DOI 10.1016/0049-3848(89)90098-4; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; DRAKE TA, 1989, AM J PATHOL, V134, P1087; DRAKE TA, 1991, AM J PATHOL, V138, P601; FALANGA A, 1995, BLOOD, V86, P1072, DOI 10.1182/blood.V86.3.1072.bloodjournal8631072; FEI HH, 1993, ARTERIOSCLER THROMB, V13, P1711, DOI 10.1161/01.ATV.13.11.1711; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; Hansen CB, 1999, BLOOD, V94, P1657, DOI 10.1182/blood.V94.5.1657.417k30_1657_1664; Hatakeyama K, 1998, ATHEROSCLEROSIS, V139, P265, DOI 10.1016/S0021-9150(98)00077-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Khechai F, 1997, ARTERIOSCL THROM VAS, V17, P2885, DOI 10.1161/01.ATV.17.11.2885; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; Knarr G, 1999, J BIOL CHEM, V274, P29850, DOI 10.1074/jbc.274.42.29850; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; Kobayashi Y, 1998, TRANSPLANTATION, V66, P708, DOI 10.1097/00007890-199809270-00004; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Lievremont JP, 1997, J BIOL CHEM, V272, P30873, DOI 10.1074/jbc.272.49.30873; LING X, 1995, PEDIATR RES, V37, P373, DOI 10.1203/00006450-199503000-00020; Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; LopezPedrera C, 1997, AM J HEMATOL, V56, P71, DOI 10.1002/(SICI)1096-8652(199710)56:2<71::AID-AJH1>3.0.CO;2-Y; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; Meerovitch K, 1998, J BIOL CHEM, V273, P21025, DOI 10.1074/jbc.273.33.21025; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; NEMERSON Y, 1992, SEMIN HEMATOL, V29, P170; NEMERSON Y, 1988, BLOOD, V71, P1; Nishibe T, 2001, BLOOD, V97, P692, DOI 10.1182/blood.V97.3.692; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Paredes N, 2003, BRIT J HAEMATOL, V120, P315, DOI 10.1046/j.1365-2141.2003.03971.x; Penn MS, 2000, BLOOD, V96, P3056; Penn MS, 1999, CIRCULATION, V99, P1753, DOI 10.1161/01.CIR.99.13.1753; RAO LVM, 1992, CANCER METAST REV, V11, P249; RAPAPORT SI, 1995, THROMB HAEMOSTASIS, V74, P7; RICKLES FR, 1995, THROMB HAEMOSTASIS, V74, P391; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; Ruf W, 1996, Curr Opin Hematol, V3, P379; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; Schecter AD, 1997, J CLIN INVEST, V100, P2276, DOI 10.1172/JCI119765; Stephens RW, 1996, THROMB RES, V84, P453, DOI 10.1016/S0049-3848(96)00213-7; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; Toschi V, 1997, CIRCULATION, V95, P594, DOI 10.1161/01.CIR.95.3.594; vandePut FHMM, 1997, J BIOL CHEM, V272, P27764, DOI 10.1074/jbc.272.44.27764; Visseren FLJ, 2000, THROMB HAEMOSTASIS, V84, P319; Wang J, 2001, BRIT J HAEMATOL, V115, P382, DOI 10.1046/j.1365-2141.2001.03095.x; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; Wolberg AS, 2000, BIOCHEM BIOPH RES CO, V272, P332, DOI 10.1006/bbrc.2000.2783; Wolberg AS, 1999, BLOOD COAGUL FIBRIN, V10, P201, DOI 10.1097/00001721-199906000-00007; Xiao GQ, 1999, MOL BRAIN RES, V72, P121, DOI 10.1016/S0169-328X(99)00188-6; Xiao GQ, 1999, J NEUROSCI RES, V58, P652, DOI 10.1002/(SICI)1097-4547(19991201)58:5<652::AID-JNR6>3.0.CO;2-H	78	49	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17438	17447		10.1074/jbc.M301006200	http://dx.doi.org/10.1074/jbc.M301006200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621026	hybrid			2022-12-27	WOS:000182818600131
J	Zeng, WZ; Li, XJ; Hilgemann, DW; Huang, CL				Zeng, WZ; Li, XJ; Hilgemann, DW; Huang, CL			Protein kinase C inhibits ROMK1 channel activity via a phosphatidylinositol 4,5-bisphosphate-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; CORTICAL COLLECTING DUCT; K-ATP CHANNELS; PLASMA-MEMBRANE; ANIONIC PHOSPHOLIPIDS; RAT-KIDNEY; BETA-GAMMA; RECEPTOR; PIP2; ACTIVATION	The activity of apical K+ channels in cortical collecting duct (CCD) is stimulated and inhibited by protein kinase A (PKA) and C (PKC), respectively. Direct interaction between phosphatidylinositol 4,5-bisphosphate (PIP2) and the cloned CCD K+ channel, ROMK1, is critical for channel opening. We have found previously that phosphorylation of ROMK1 by PKA increases affinity of the channel for PIP2 and mutation of PKA sites reduces the affinity of ROMK1 for PIP2. In this study we investigate the molecular mechanism for PKC regulation of ROMK and report that mutants of ROMK1 with reduced PIP2 affinity exhibit an increased sensitivity to inhibition by phorbol myristate acetate (PMA). The effect of PMA can be prevented by pretreatment with calphostin-C. Activation of PKC by carbachol in Xenopus oocytes co-expressing M1 muscarinic receptors also causes inhibition of the channels. Calphostin-C prevents carbachol-induced inhibition, suggesting that activation of PKC is necessary for inhibition of the channels. PMA reduces open probability of the channel in cell-attached patch clamp recordings. After inhibition by PMA in cell-attached recordings, application of PIP2 to the cytoplasmic face of excised inside-out membranes restores channel activity. PMA reduces PIP2 content in oocyte membrane and calphostin-C prevents the reduction. These results suggest that reduction of membrane PIP2 content contributes to the inhibition of ROMK1 channels by PKC. This mechanism may underscore the inhibition of K+ secretion in CCD by hormones that activate PKC.	Univ Texas, SW Med Ctr, Dept Med, Div Nephrol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Huang, CL (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Nephrol, Rm J5-104A,5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054368] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-51323] Funding Source: Medline; NIDDK NIH HHS [DK-54368] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AnkorinaStark I, 1997, CELL CALCIUM, V22, P269, DOI 10.1016/S0143-4160(97)90065-8; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; BOON AM, 1985, BIOCHEM BIOPH RES CO, V129, P431, DOI 10.1016/0006-291X(85)90169-X; Breyer MD, 2000, AM J PHYSIOL-RENAL, V279, pF12, DOI 10.1152/ajprenal.2000.279.1.F12; CASSOLA AC, 1993, AM J PHYSIOL, V264, pF502, DOI 10.1152/ajprenal.1993.264.3.F502; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FIGUEROA CD, 1995, J HISTOCHEM CYTOCHEM, V43, P137, DOI 10.1177/43.2.7822771; Giebisch G, 2000, ACTA PHYSIOL SCAND, V170, P153, DOI 10.1046/j.1365-201x.2000.00770.x; Guan YF, 1998, J CLIN INVEST, V102, P194, DOI 10.1172/JCI2872; HALENDA SP, 1984, BIOCHEM BIOPH RES CO, V124, P507, DOI 10.1016/0006-291X(84)91583-3; HAYS SR, 1987, J CLIN INVEST, V80, P1561, DOI 10.1172/JCI113242; HEBERT SC, 1995, KIDNEY INT, V48, P1010, DOI 10.1038/ki.1995.383; Henry P, 1996, J PHYSIOL-LONDON, V495, P681, DOI 10.1113/jphysiol.1996.sp021625; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hill JJ, 2001, J BIOL CHEM, V276, P5505, DOI 10.1074/jbc.M008213200; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Karle CA, 2002, CIRCULATION, V106, P1493, DOI 10.1161/01.CIR.0000029747.53262.5C; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Leung YM, 2000, J BIOL CHEM, V275, P10182, DOI 10.1074/jbc.275.14.10182; Light PE, 2000, P NATL ACAD SCI USA, V97, P9058, DOI 10.1073/pnas.160068997; Liou HH, 1999, P NATL ACAD SCI USA, V96, P5820, DOI 10.1073/pnas.96.10.5820; MUTO S, 1991, AM J PHYSIOL, V260, pF163, DOI 10.1152/ajprenal.1991.260.2.F163; Nasuhoglu C, 2002, ANAL BIOCHEM, V301, P243, DOI 10.1006/abio.2001.5489; Nasuhoglu C, 2002, AM J PHYSIOL-CELL PH, V283, pC223, DOI 10.1152/ajpcell.00486.2001; Ooms LM, 2000, MOL CELL BIOL, V20, P9376, DOI 10.1128/MCB.20.24.9376-9390.2000; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; SUGIMOTO Y, 1994, AM J PHYSIOL, V266, pF823, DOI 10.1152/ajprenal.1994.266.5.F823; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; van Tiel CM, 2000, J BIOL CHEM, V275, P21532, DOI 10.1074/jbc.M002203200; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF599, DOI 10.1152/ajprenal.1994.267.4.F599; Wei YJ, 2002, J BIOL CHEM, V277, P46586, DOI 10.1074/jbc.M206860200; Wright FS, 1992, KIDNEY PHYSL PATHOPH, P2209; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Zeng WZ, 2002, AM J PHYSIOL-RENAL, V282, pF826, DOI 10.1152/ajprenal.00300.2001	38	58	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16852	16856		10.1074/jbc.M300619200	http://dx.doi.org/10.1074/jbc.M300619200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615924	hybrid			2022-12-27	WOS:000182818600055
J	Propsting, MJ; Jacob, R; Naim, HY				Propsting, MJ; Jacob, R; Naim, HY			A glutamine to proline exchange at amino acid residue 1098 in sucrase causes a temperature-sensitive arrest of sucrase-isomaltase in the endoplasmic reticulum and cis-Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTASE-PHLORHIZIN HYDROLASE; INTRACELLULAR-TRANSPORT; QUALITY-CONTROL; ENZYME COMPLEX; DEFICIENCY; PROTEIN; GLYCOSYLATION; BIOSYNTHESIS; EXPRESSION; MUTATIONS	A striking feature of phenotype II in congenital sucrase-isomaltase deficiency is the retention of the brush border protein sucrase-isomaltase (SI) in the cis-Golgi. This transport block is the consequence of a glutamine to proline substitution at amino acid residue 1098 of the sucrase subunit. Here we provide unequivocal biochemical and confocal data to show that the SIQ/P mutant reveals characteristics of a temperature-sensitive mutant. Thus, correct folding, competent intracellular transport, and full enzymatic activity can be partially restored by expression of the mutant SIQ/P at the permissive temperature of 20degreesC instead of 37degreesC. The acquisition of normal trafficking and function appears to utilize several cycles of anterograde and retrograde steps between the endoplasmic reticulum and the Golgi implicating the molecular chaperones calnexin and heavy chain-bindinig protein. The data presented in this communication are to our knowledge the first to implicate a temperature-sensitive mutation in an intestinal enzyme deficiency or an intestinal disorder.	Tierarztlichen Hsch Hannover, Dept Physiol Chem, D-30559 Hannover, Germany	University of Veterinary Medicine Hannover, Foundation	Naim, HY (corresponding author), Tierarztlichen Hsch Hannover, Dept Physiol Chem, Bunteweg 17, D-30559 Hannover, Germany.		Jacob, Ralf/B-8163-2011					CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAURI HP, 1985, P NATL ACAD SCI USA, V82, P4423, DOI 10.1073/pnas.82.13.4423; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HAURI HP, 1982, J BIOL CHEM, V257, P4522; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; JACOB R, 1995, J BIOL CHEM, V270, P18678, DOI 10.1074/jbc.270.31.18678; Jacob R, 2000, J BIOL CHEM, V275, P10630, DOI 10.1074/jbc.275.14.10630; Jacob R, 2002, J BIOL CHEM, V277, P32141, DOI 10.1074/jbc.M204116200; Jacob R, 2002, J BIOL CHEM, V277, P8217, DOI 10.1074/jbc.M111500200; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; JACOB R, 1994, J BIOL CHEM, V269, P2712; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Moolenaar CEC, 1997, J CELL SCI, V110, P557; NAIM HY, 1988, J CLIN INVEST, V82, P667, DOI 10.1172/JCI113646; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1991, J BIOL CHEM, V266, P12313; Ouwendijk J, 1996, J CLIN INVEST, V97, P633, DOI 10.1172/JCI118459; Stein MP, 2002, TRENDS CELL BIOL, V12, P374, DOI 10.1016/S0962-8924(02)02331-0	23	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16310	16314		10.1074/jbc.C300093200	http://dx.doi.org/10.1074/jbc.C300093200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12624106	hybrid			2022-12-27	WOS:000182680000108
J	Fukuda, A; Tokonabe, S; Hamada, M; Matsumoto, M; Tsukui, T; Nogi, Y; Hisatake, K				Fukuda, A; Tokonabe, S; Hamada, M; Matsumoto, M; Tsukui, T; Nogi, Y; Hisatake, K			Alleviation of PC4-mediated transcriptional repression by the ERCC3 helicase activity of general transcription factor TFIIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; COACTIVATOR PC4; MULTISUBUNIT COMPLEX; TERMINAL DOMAIN; BINDING PROTEIN; YEAST; DNA; ACTIVATION; PURIFICATION; COFACTORS	Positive cofactor 4 (PC4), originally identified as a transcriptional coactivator, possesses the ability to suppress promoter-driven as well as nonspecific transcription via its DNA binding activity. Previous studies showed that the repressive activity of PC4 on promoter-driven transcription is alleviated by transcription factor TFIIH, possibly through one of its enzymatic activities. Using recombinant TFIIH, we have analyzed the role of TFIIH for alleviating PC4-mediated transcriptional repression and determined that the excision repair cross complementing (ERCC3) helicase activity of TFIIH is the enzymatic activity that alleviates PC4-mediated repression via beta-gamma bond hydrolysis of ATP. In addition, the alleviation does not require either ERCC2 helicase or cyclin-dependent kinase 7 kinase activity. We also show that, as complexed within TFIIH, the cyclin-dependent kinase 7 kinase does not possess the activity to phosphorylate PC4. Thus, TFIIH appears to protect promoters from PC4-mediated repression by relieving the topological constraint imposed by PC4 through the ERCC3 helicase activity rather than by reducing the repressive activity of PC4 via its phosphorylation.	Saitama Med Sch, Dept Biol Mol, Moroyama, Saitama 3500495, Japan	Saitama Medical University	Hisatake, K (corresponding author), Saitama Med Sch, Dept Biol Mol, 38 Morohongo, Moroyama, Saitama 3500495, Japan.	kojihisa@saitama-med.ac.jp		Hisatake, Koji/0000-0002-5795-3115				Akoulitchev S, 2000, NATURE, V407, P102, DOI 10.1038/35024111; Bohm M, 1997, INT J CANCER, V74, P291; Borggrefe T, 2001, J BIOL CHEM, V276, P47150, DOI 10.1074/jbc.M109581200; Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Fondell JD, 1999, P NATL ACAD SCI USA, V96, P1959, DOI 10.1073/pnas.96.5.1959; Fukuda A, 2001, GENES CELLS, V6, P707, DOI 10.1046/j.1365-2443.2001.00456.x; FUKUDA A, 1999, P NATL ACAD SCI USA, V99, P1206; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Henry NL, 1996, J BIOL CHEM, V271, P21842, DOI 10.1074/jbc.271.36.21842; Holloway AF, 2000, J BIOL CHEM, V275, P21668, DOI 10.1074/jbc.M909058199; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; Kannan F, 1999, MOL CELL BIOL, V19, P899; Kershnar E, 1998, J BIOL CHEM, V273, P34444, DOI 10.1074/jbc.273.51.34444; Kimura M, 2001, EUR J BIOCHEM, V268, P612, DOI 10.1046/j.1432-1327.2001.01911.x; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LILLEY DMJ, 1988, TRENDS GENET, V4, P111, DOI 10.1016/0168-9525(88)90099-6; Liu JH, 2000, MOL CELL, V5, P331, DOI 10.1016/S1097-2765(00)80428-1; LOU Y, 1998, MOL CELL BIOL, V18, P3803; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MURCHIE AIH, 1992, BIOCHIM BIOPHYS ACTA, V1131, P1, DOI 10.1016/0167-4781(92)90091-D; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Wada T, 2000, MOL CELL, V5, P1067, DOI 10.1016/S1097-2765(00)80272-5; Werten S, 1999, J BIOL CHEM, V274, P3693, DOI 10.1074/jbc.274.6.3693; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Wieland I, 1996, ONCOGENE, V12, P97	36	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14827	14831		10.1074/jbc.M213172200	http://dx.doi.org/10.1074/jbc.M213172200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590132	hybrid			2022-12-27	WOS:000182516100033
J	Locke, D; Liu, CD; Peng, XH; Chen, H; Kahn, ML				Locke, D; Liu, CD; Peng, XH; Chen, H; Kahn, ML			Fc R gamma-independent signaling by the platelet collagen receptor glycoprotein VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; PHOSPHOLIPASE C-GAMMA-2; EPSILON-RI; CHAIN; ACTIVATION; SYK; ASSOCIATION; CALMODULIN	The platelet collagen receptor glycoprotein VI (GPVI) is structurally homologous to multisubunit immune receptors and signals through the immune receptor adaptor Fc Rgamma. Multisubunit receptors are composed of specialized subunits thought to be dedicated exclusively to ligand binding or signal transduction. However, recent studies of the intracellular region of GPVI, a ligand-binding subunit, have suggested the existence of protein-protein interactions that could regulate receptor signaling. In the present study we have investigated the signaling role of the GPVI intracellular domain by stably expressing GPVI mutants in RBL-2H3 cells, a model system that accurately reproduces the GPVI signaling events observed in platelets. Studies of mutant GPVI receptor protein-protein interaction and calcium signaling reveal the existence of discrete domains within the receptor's intracellular tail that mediate interaction with Fc Rgamma, calmodulin, and Src family tyrosine kinases. These receptor interactions are modular and mediated by non-overlapping regions of the receptor transmembrane and intracellular domains. GPVI signaling requires all three of these domains as receptor mutants able to couple to only two interacting proteins exhibited severe signaling defects despite normal surface expression. Our results demonstrate that the ligand-binding subunit of the GPVI-Fc Rgamma receptor participates directly in receptor signaling by interacting with downstream signaling molecules other than Fc Rgamma through an adaptor-like mechanism.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Kahn, ML (corresponding author), Univ Penn, Dept Med, 421 Cuie Blvd,BRB 2-3,Room 952, Philadelphia, PA 19104 USA.							ALBER G, 1991, J BIOL CHEM, V266, P22613; Andrews RK, 2002, BLOOD, V99, P4219, DOI 10.1182/blood-2001-11-0008; Andrews RK, 2001, BLOOD, V98, P681, DOI 10.1182/blood.V98.3.681; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Berlanga O, 2002, EUR J BIOCHEM, V269, P2951, DOI 10.1046/j.1432-1033.2002.02969.x; Chen H, 2002, J BIOL CHEM, V277, P3011, DOI 10.1074/jbc.M109714200; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Edberg JC, 1999, J BIOL CHEM, V274, P30328, DOI 10.1074/jbc.274.42.30328; Gessner JE, 1998, ANN HEMATOL, V76, P231, DOI 10.1007/s002770050396; Gross BS, 1999, J BIOL CHEM, V274, P5963, DOI 10.1074/jbc.274.9.5963; Holowka D, 2001, SEMIN IMMUNOL, V13, P99, DOI 10.1006/smim.2000.0301; Ichinohe T, 1997, J BIOL CHEM, V272, P63; Klaerke DA, 1997, BBA-PROTEIN STRUCT M, V1339, P203, DOI 10.1016/S0167-4838(96)00233-6; LANIER LL, 1991, J IMMUNOL, V146, P1571; Locke D, 2002, J BIOL CHEM, V277, P18801, DOI 10.1074/jbc.M111520200; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; SUGIYAMA T, 1987, BLOOD, V69, P1712; Suzuki-Inoue K, 2002, J BIOL CHEM, V277, P21561, DOI 10.1074/jbc.M201012200; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200	26	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15441	15448		10.1074/jbc.M212338200	http://dx.doi.org/10.1074/jbc.M212338200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594225	hybrid			2022-12-27	WOS:000182516100111
J	Nagamori, S; Vazquez-Ibar, JL; Weinglass, AB; Kaback, HR				Nagamori, S; Vazquez-Ibar, JL; Weinglass, AB; Kaback, HR			In vitro synthesis of lactose permease to probe the mechanism of membrane insertion and folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; LAC CARRIER PROTEIN; THIOL CROSS-LINKING; ESCHERICHIA-COLI; PROJECTION STRUCTURE; ANGSTROM RESOLUTION; TRANSPORT PROTEINS; SUBSTRATE-BINDING; HELIX PACKING; TRANSLOCATION	Insertion and folding of polytopic membrane proteins is an important unsolved biological problem. To study this issue, lactose permease, a membrane transport protein from Escherichia coli, is transcribed, translated, and inserted into inside-out membrane vesicles in vitro. The protein is in a native conformation as judged by sensitivity to protease, binding of a monoclonal antibody directed against a conformational epitope, and importantly, by functional assays. By exploiting this system it is possible to express the N-terminal six helices of the permease (N-6) and probe changes in conformation during insertion into the membrane. Specifically, when N-6 remains attached to the ribosome it is readily extracted from the membrane with urea, whereas after release from the ribosome or translation of additional helices, those polypeptides are not urea extractable. Furthermore, the accessibility of an engineered Factor Xa site to Xa protease is reduced significantly when N-6 is released from the ribosome or more helices are translated. Finally, spontaneous disulfide formation between Cys residues at positions 126 (Helix IV) and 144 (Helix V) is observed when N-6 is released from the ribosome and inserted into the membrane. Moreover, in contrast to full-length permease, N-6 is degraded by FtsH protease in vivo, and N-6 with a single Cys residue at position 148 does not react with N-ethylmaleimide. Taken together, the findings indicate that N-6 remains in a hydrophilic environment until it is released from the ribosome or additional helices are translated and continues to fold into a quasi-native conformation after insertion into the bilayer. Furthermore, there is synergism between N-6 and the C-terminal half of permease during assembly, as opposed to assembly of the two halves as independent domains.	Univ Calif Los Angeles, HHMI, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Physiol & Microbiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Mol Genet, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Kaback, HR (corresponding author), Univ Calif Los Angeles, HHMI, 5-748 Macdonald Res Labs,Box 951662, Los Angeles, CA 90095 USA.		Vazquez-Ibar, Jose-Luis/AAD-8827-2021; Nagamori, Shushi/P-4530-2018	Vazquez-Ibar, Jose-Luis/0000-0002-8314-3378; Nagamori, Shushi/0000-0003-0203-2754	NIDDK NIH HHS [DK51131:08] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051131] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHREM B, 1989, J CELL BIOL, V108, P1637, DOI 10.1083/jcb.108.5.1637; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Bernstein HD, 2000, CURR OPIN MICROBIOL, V3, P203, DOI 10.1016/S1369-5274(00)00076-X; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Bochkareva E, 1996, J BIOL CHEM, V271, P22256, DOI 10.1074/jbc.271.36.22256; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Bogdanov M, 1999, J BIOL CHEM, V274, P36827, DOI 10.1074/jbc.274.52.36827; Bogdanov M, 1998, EMBO J, V17, P5255, DOI 10.1093/emboj/17.18.5255; Borel AC, 1996, BIOCHEMISTRY-US, V35, P10587, DOI 10.1021/bi960950q; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1982, P NATL ACAD SCI-BIOL, V79, P6894, DOI 10.1073/pnas.79.22.6894; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; CONSLER TG, 1993, P NATL ACAD SCI USA, V90, P6934, DOI 10.1073/pnas.90.15.6934; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; Dalbey RE, 2000, CURR OPIN CELL BIOL, V12, P435, DOI 10.1016/S0955-0674(00)00113-7; de Gier JW, 2001, MOL MICROBIOL, V40, P314, DOI 10.1046/j.1365-2958.2001.02392.x; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; DUNTEN RL, 1993, BIOCHEMISTRY-US, V32, P3139, DOI 10.1021/bi00063a028; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRILLINGOS S, 1995, BIOCHEMISTRY-US, V34, P9368, DOI 10.1021/bi00029a012; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GOLDKORN T, 1983, P NATL ACAD SCI-BIOL, V80, P3322, DOI 10.1073/pnas.80.11.3322; Guan L, 2002, P NATL ACAD SCI USA, V99, P3475, DOI 10.1073/pnas.052703699; Guan L, 2002, P NATL ACAD SCI USA, V99, P6613, DOI 10.1073/pnas.102178299; Hacksell I, 2002, EMBO J, V21, P3569, DOI 10.1093/emboj/cdf378; Herskovits AA, 2002, J CELL BIOL, V159, P403, DOI 10.1083/jcb.200204144; Herskovits AA, 2000, MOL MICROBIOL, V38, P927, DOI 10.1046/j.1365-2958.2000.02198.x; Heymann JAW, 2001, EMBO J, V20, P4408, DOI 10.1093/emboj/20.16.4408; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; Kihara A, 1999, EMBO J, V18, P2970, DOI 10.1093/emboj/18.11.2970; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; KONINGS WN, 1996, HDB BIOL PHYSICS TRA; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Muller M, 2001, PROG NUCLEIC ACID RE, V66, P107; Nagamori S, 2000, J BIOCHEM-TOKYO, V128, P129, DOI 10.1093/oxfordjournals.jbchem.a022723; Nishiyama K, 2000, BIOSCI BIOTECH BIOCH, V64, P2121, DOI 10.1271/bbb.64.2121; Nouwen N, 2002, MOL MICROBIOL, V44, P1397, DOI 10.1046/j.1365-2958.2002.02972.x; Ogura T, 1999, MOL MICROBIOL, V31, P833, DOI 10.1046/j.1365-2958.1999.01221.x; Prinz WA, 1998, J BIOL CHEM, V273, P8419, DOI 10.1074/jbc.273.14.8419; Sahin-Toth M, 2002, BIOCHEMISTRY-US, V41, P13039, DOI 10.1021/bi0203076; Sahin-Toth M, 1999, BIOCHEMISTRY-US, V38, P813, DOI 10.1021/bi982200h; SahinToth M, 1996, BIOCHEMISTRY-US, V35, P2016, DOI 10.1021/bi952496g; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; SAHINTOTH M, 1995, BIOCHEMISTRY-US, V34, P1107, DOI 10.1021/bi00004a001; Saier MH, 2000, MOL MICROBIOL, V35, P699, DOI 10.1046/j.1365-2958.2000.01759.x; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SCHULDINER S, 1975, J BIOL CHEM, V250, P1361; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Seluanov A, 1997, J BIOL CHEM, V272, P2053; SHORT SA, 1974, P NATL ACAD SCI USA, V71, P1461, DOI 10.1073/pnas.71.4.1461; Sorgen PL, 2002, P NATL ACAD SCI USA, V99, P14037, DOI 10.1073/pnas.182552199; STOCHAJ U, 1987, EUR J BIOCHEM, V163, P653, DOI 10.1111/j.1432-1033.1987.tb10914.x; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P274, DOI 10.1021/bi962292f; Sun JZ, 1997, BIOCHEMISTRY-US, V36, P11959, DOI 10.1021/bi971172k; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; van Voorst F, 2000, BIOCHEM J, V347, P601, DOI 10.1042/bj3470601; Vazquez-Ibar JL, 2002, P NATL ACAD SCI USA, V99, P3487, DOI 10.1073/pnas.052703599; Venkatesan P, 1998, P NATL ACAD SCI USA, V95, P9802, DOI 10.1073/pnas.95.17.9802; VIITANEN P, 1984, P NATL ACAD SCI-BIOL, V81, P1629, DOI 10.1073/pnas.81.6.1629; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; Weinglass AB, 2000, P NATL ACAD SCI USA, V97, P8938, DOI 10.1073/pnas.140224497; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; WILLIAMS RW, 1986, METHOD ENZYMOL, V130, P311; Wolin CD, 2000, BIOCHEMISTRY-US, V39, P6130, DOI 10.1021/bi0001269; WRUBEL W, 1990, J BACTERIOL, V172, P5374, DOI 10.1128/jb.172.9.5374-5381.1990; Wu JH, 1996, P NATL ACAD SCI USA, V93, P14498, DOI 10.1073/pnas.93.25.14498; WU JH, 1995, P NATL ACAD SCI USA, V92, P9186, DOI 10.1073/pnas.92.20.9186; YAMADA H, 1989, J BIOL CHEM, V264, P1723; ZEN KH, 1994, BIOCHEMISTRY-US, V33, P8198, DOI 10.1021/bi00193a005; ZEN KH, 1995, BIOCHEMISTRY-US, V34, P3430, DOI 10.1021/bi00010a035; Zhao M, 1999, BIOCHEMISTRY-US, V38, P7407, DOI 10.1021/bi9906524	79	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14820	14826		10.1074/jbc.M300332200	http://dx.doi.org/10.1074/jbc.M300332200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590141	hybrid			2022-12-27	WOS:000182516100032
J	Takebayashi, T; Higashi, H; Sudo, H; Ozawa, H; Suzuki, E; Shirado, O; Katoh, H; Hatakeyama, M				Takebayashi, T; Higashi, H; Sudo, H; Ozawa, H; Suzuki, E; Shirado, O; Katoh, H; Hatakeyama, M			NF-kappa B-dependent induction of cyclin D1 by retinoblastoma protein (pRB) family proteins and tumor-derived pRB mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS E1A PROTEINS; CELL-CYCLE; GENE-PRODUCT; BREAST-CANCER; FUNCTIONAL INTERACTIONS; TRANSCRIPTION FACTOR; ECTOPIC EXPRESSION; SUPPRESSOR PROTEIN; CDK COMPLEXES; RB PROTEIN	The retinoblastoma protein (pRB) and its homologues, p107 and p130, prevent cell cycle progression from G(0)/G(1) to S phase by forming complexes with E2F transcription factors. Upon phosphorylation by G, cyclin-cyclin-dependent kinase (Cdk) complexes such as cyclin D1-Cdk4/6 and cyclin E-Cdk2, they lose the ability to bind E2F, and cells are thereby allowed to progress into S phase. Functional loss of one or more of the pRB family members, as a result of genetic mutation or deregulated phosphorylation, is considered to be an essential prerequisite for cellular transformation. In this study, we found that pRB family proteins have the ability to stimulate cyclin D1 transcription by activation of the NF-kappaB transcription factor. The cyclin D1-inducing activity of pRB is abolished by adenovirus E1A oncoprotein but not by the deletion of the A-box, the B-box, or the C-terminal region of the pocket, indicating that multiple pocket sequences are independently involved in cyclin D1 activation. Intriguingly, tumor-derived pRB pocket mutants retain the cyclin D1-inducing activity. Our results reveal a novel role of pRB family proteins as potential activators of NF-kappaB and inducers of G(1) cyclin. Certain pRB pocket mutants may give rise to a cellular situation in which deregulated E2F and cyclin D1 cooperatively promote abnormal cell proliferation.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Univ Tokyo, Fac Med, Dept Internal Med, Div Nephrol & Endocrinol, Tokyo 1138655, Japan; Hokkaido Univ, Grad Sch Med, Dept Surg Oncol, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Med, Dept Orthoped Surg, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; University of Tokyo; Hokkaido University; Hokkaido University	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0600815, Japan.		Sudo, Hideki/G-2748-2012; Higashi, Hideaki/F-6872-2012					ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; Ashizawa S, 2001, J BIOL CHEM, V276, P11362, DOI 10.1074/jbc.M007992200; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Charles A, 2001, J CELL BIOCHEM, V83, P414, DOI 10.1002/jcb.1239; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Coupland SE, 1998, BRIT J OPHTHALMOL, V82, P961, DOI 10.1136/bjo.82.8.961; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DELMER A, 1995, LEUKEMIA, V9, P1240; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fortunato EA, 1997, J VIROL, V71, P8176, DOI 10.1128/JVI.71.11.8176-8185.1997; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; Ibarra-Sanchez MD, 2001, ONCOGENE, V20, P4728, DOI 10.1038/sj.onc.1204648; Johnson-Pais T, 2001, P NATL ACAD SCI USA, V98, P2211, DOI 10.1073/pnas.051415898; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kondo T, 2001, J BIOL CHEM, V276, P17559, DOI 10.1074/jbc.M009911200; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Marhin WW, 1996, ONCOGENE, V12, P43; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAYOL X, 1993, ONCOGENE, V8, P2561; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Mizuguchi R, 1998, J BIOL CHEM, V273, P32297, DOI 10.1074/jbc.273.48.32297; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; NEVINS JR, 1992, SCIENCE, V258, P424; Nielsen NH, 1997, ONCOGENE, V14, P295, DOI 10.1038/sj.onc.1200833; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Ruas M, 1999, ONCOGENE, V18, P5423, DOI 10.1038/sj.onc.1202918; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SuzukiTakahashi I, 1997, BIOCHEM BIOPH RES CO, V234, P386, DOI 10.1006/bbrc.1997.6654; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAM SW, 1994, ONCOGENE, V9, P2663; Tamami M, 1996, J BIOL CHEM, V271, P24551, DOI 10.1074/jbc.271.40.24551; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Yamamoto H, 1999, CLIN CANCER RES, V5, P1805	76	32	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14897	14905		10.1074/jbc.M210849200	http://dx.doi.org/10.1074/jbc.M210849200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594215	hybrid			2022-12-27	WOS:000182516100042
J	Vanden Abeele, F; Roudbaraki, M; Shuba, Y; Skryma, R; Prevarskaya, N				Vanden Abeele, F; Roudbaraki, M; Shuba, Y; Skryma, R; Prevarskaya, N			Store-operated Ca2+ current in prostate cancer epithelial cells - Role of endogenous Ca2+ transporter type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; BASOPHILIC LEUKEMIA-CELLS; HUMAN EMBRYONIC KIDNEY; CURRENT I-CRAC; MAST-CELLS; ANTISENSE OLIGONUCLEOTIDES; PORE PROPERTIES; MIC CHANNELS; RELEASE; DEPLETION	Ca2+ influx via store-operated channels (SOCs) following stimulation of the plasma membrane receptors is the key event controlling numerous processes in nonexcitable cells. The human transient receptor potential vanilloid type 6 channel, originally termed Ca2+ transporter type 1 (CaT1) protein, is one of the promising candidates for the role of endogenous SOC, although investigations of its functions have generated considerable controversy. In order to assess the role of CaT1 in generating endogenous store-operated Ca2+ current (Is,c) in the lymph node carcinoma of the prostate (LN-CaP) human prostate cancer epithelial cell line, we manipulated its endogenous levels by means of antisense hybrid depletion or pharmacological up-regulation (antiandrogen treatment) combined with functional evaluation of Isoc. Antisense hybrid depletion of CaT1 decreased Isoc in LNCaP cells by similar to50%, whereas enhancement of CaT1 levels by 60% in response to Casodex treatment potentiated Isoc by 30%. The functional characteristics of Isoc in LNCaP cells were similar in many respects to those reported for heterologously expressed CaT1, although 2-aminoethoxydiphenyl borate sensitivity and lack of constitutive current highlighted notable departures. Our results suggest that CaT1 is definitely involved in Isoc, but it may constitute only a part of the endogenous SOC, which in general may be a heteromultimeric channel composed of homologous CaT1 and other transient receptor potential subunits.	Univ Sci & Tech Lille Flandres Artois, INSERM, EMI 0228, Lab Physiol Cellulaire, F-59655 Villeneuve Dascq, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille	Prevarskaya, N (corresponding author), Univ Sci & Tech Lille Flandres Artois, INSERM, EMI 0228, Lab Physiol Cellulaire, Batiment SN3, F-59655 Villeneuve Dascq, France.		Vanden Abeele, Fabien/O-6012-2017; Shuba, Yaroslav/AAT-6758-2021	Vanden Abeele, Fabien/0000-0001-7111-7220; Prevarskaya, natacha/0000-0003-0316-197X; Morad, Roudbaraki/0000-0001-5751-3323				BENNETT CF, 1994, J IMMUNOL, V152, P3530; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Bodding M, 2002, J BIOL CHEM, V277, P36656, DOI 10.1074/jbc.M202822200; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; CHOMCZYNSKY P, 1987, ANAL BIOCHEM, V172, P156; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cui J, 2002, J BIOL CHEM, V277, P47175, DOI 10.1074/jbc.M205870200; Fierro L, 1999, J PHYSIOL-LONDON, V520, P407, DOI 10.1111/j.1469-7793.1999.00407.x; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; Leung YM, 1999, JPN J PHARMACOL, V81, P253, DOI 10.1254/jjp.81.253; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; Nilius B, 2001, BRIT J PHARMACOL, V134, P453, DOI 10.1038/sj.bjp.0704272; Peng JB, 2001, BIOCHEM BIOPH RES CO, V282, P729, DOI 10.1006/bbrc.2001.4638; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2001, J CELL SCI, V114, P2223; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; SKRYMA RN, 2000, J PHYSL, V527, P73; Tsavaler L, 2001, CANCER RES, V61, P3760; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	42	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15381	15389		10.1074/jbc.M212106200	http://dx.doi.org/10.1074/jbc.M212106200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584203	hybrid			2022-12-27	WOS:000182516100103
J	Venema, R; Tjalsma, H; van Dijl, JM; de Jong, A; Leenhouts, K; Buist, G; Venema, G				Venema, R; Tjalsma, H; van Dijl, JM; de Jong, A; Leenhouts, K; Buist, G; Venema, G			Active lipoprotein precursors in the gram-positive eubacterium Lactococcus lactis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDASE-I; EXTRACELLULAR SERINE PROTEINASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; MYCOPLASMA-FERMENTANS; LIPID MODIFICATION; TRANSPORT-SYSTEM; CELL-ENVELOPE; ALPHA-AMYLASE; GENE	Lipid-modified proteins play important roles at the interface between eubacterial cells and their environment. The importance of lipoprotein processing by signal peptidase II (SPase II) is underscored by the fact that this enzyme is essential for viability of the Gram-negative eubacterium Escherichia coli. In contrast, SPase II is not essential for growth and viability of the Gram-positive eubacterium Bacillus subtilis. This could be due to alternative amino-terminal lipoprotein processing, which was shown previously to occur in SPase II mutants of B. subtilis. Alternatively, uncleaved lipoprotein precursors might be functional. To explore further the importance of lipoprotein processing in Gram-positive eubacteria, an SPase II mutant strain of Lactococcus lactis was constructed. Although some of the 39 (predicted) lactococcal lipoproteins, such as PrtM and OppA, are essential for growth in milk, the growth of SPase II mutant, L. lactis cells in this medium was not affected. Furthermore, the activity of the strictly PrtM-dependent extracellular protease PrtP, which is required for casein degradation, was not impaired in the absence of SPase II. Importantly, no alternative processing of pre-PrtM and pre-OppA was observed in cells lacking SPase II. Taken together, these findings show for the first time that authentic lipoprotein precursors retain biological activity.	Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Buist, G (corresponding author), Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Tjalsma, Harold/I-7146-2012; van Dijl, Jan Maarten/G-1205-2013					Antelmann H, 2001, GENOME RES, V11, P1484, DOI 10.1101/gr.182801; Beermann C, 2000, BIOCHEM BIOPH RES CO, V267, P897, DOI 10.1006/bbrc.1999.2057; Bengtsson J, 1999, J BACTERIOL, V181, P685, DOI 10.1128/JB.181.2.685-688.1999; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Calcutt MJ, 1999, INFECT IMMUN, V67, P760, DOI 10.1128/IAI.67.2.760-771.1999; Carlos J. L., 2001, ENZYMES, V22, P27; CHOMCZYNSKI P, 1984, BIOCHEM BIOPH RES CO, V122, P340, DOI 10.1016/0006-291X(84)90480-7; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636; DEVOS WM, 1989, GENE, V85, P169, DOI 10.1016/0378-1119(89)90477-0; GASSON MJ, 1983, J BACTERIOL, V154, P1; HAANDRIKMAN AJ, 1989, J BACTERIOL, V171, P2789, DOI 10.1128/jb.171.5.2789-2794.1989; HAANDRIKMAN AJ, 1991, J BACTERIOL, V173, P4517, DOI 10.1128/JB.173.14.4517-4525.1991; HAANDRIKMAN AJ, 1991, APPL ENVIRON MICROB, V57, P1899, DOI 10.1128/AEM.57.7.1899-1904.1991; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; INUKAI M, 1978, J ANTIBIOT, V31, P1203, DOI 10.7164/antibiotics.31.1203; Kempf B, 1997, J BACTERIOL, V179, P6213, DOI 10.1128/jb.179.20.6213-6220.1997; KONTINEN VP, 1993, MOL MICROBIOL, V8, P727, DOI 10.1111/j.1365-2958.1993.tb01616.x; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Leenhouts Kees, 1998, Methods in Cell Science, V20, P35, DOI 10.1023/A:1009862119114; LEENHOUTS KJ, 1990, APPL ENVIRON MICROB, V56, P2726, DOI 10.1128/AEM.56.9.2726-2735.1990; Leskela S, 1999, MOL MICROBIOL, V31, P1075, DOI 10.1046/j.1365-2958.1999.01247.x; MEIJER WJJ, 1995, MOL MICROBIOL, V17, P621, DOI 10.1111/j.1365-2958.1995.mmi_17040621.x; Mierau I, 1996, J BACTERIOL, V178, P2794, DOI 10.1128/jb.178.10.2794-2803.1996; MIERAU I, 1994, J BACTERIOL, V176, P2854, DOI 10.1128/JB.176.10.2854-2861.1994; Pragai Z, 1997, MICROBIOL-UK, V143, P1327, DOI 10.1099/00221287-143-4-1327; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Rawadi G, 1999, J BIOL CHEM, V274, P30794, DOI 10.1074/jbc.274.43.30794; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; SANKARAN K, 1994, SIGNAL PEPTIDASES, P17; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scragg IG, 2000, J BIOL CHEM, V275, P937, DOI 10.1074/jbc.275.2.937; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Siezen RJ, 1999, ANTON LEEUW INT J G, V76, P139, DOI 10.1023/A:1002036906922; Simon MM, 1999, ZBL BAKT-INT J MED M, V289, P690; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; Tjalsma H, 1999, J BIOL CHEM, V274, P28191, DOI 10.1074/jbc.274.40.28191; TJALSMA H, 2001, ENZYMES, V22, P3; TOKUNAGA M, 1982, J BIOL CHEM, V257, P9922; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7523, DOI 10.1128/JB.175.23.7523-7532.1993; van Roosmalen ML, 2001, J BIOL CHEM, V276, P25230, DOI 10.1074/jbc.M102099200; VANDEGUCHTE M, 1990, APPL ENVIRON MICROB, V56, P2606, DOI 10.1128/AEM.56.9.2606-2611.1990; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1988, MOL GEN GENET, V214, P55; VONHEIJNE G, 1989, PROTEIN ENG, V2, P531, DOI 10.1093/protein/2.7.531; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; YAMAGATA H, 1982, J BACTERIOL, V152, P1163; [No title captured]	58	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14739	14746		10.1074/jbc.M209857200	http://dx.doi.org/10.1074/jbc.M209857200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584195	Green Published, hybrid			2022-12-27	WOS:000182516100021
J	Dugan, TA; Yang, VWC; McQuillan, DJ; Hook, M				Dugan, TA; Yang, VWC; McQuillan, DJ; Hook, M			Decorin binds fibrinogen in a Zn2+-dependent interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; DERMATAN SULFATE PROTEOGLYCAN; COLLAGEN FIBRILLOGENESIS; CRYSTAL-STRUCTURE; MATRIX PROTEIN; SKIN FRAGILITY; CELL-MIGRATION; FRAGMENT-D; BIGLYCAN; EXPRESSION	We have previously shown that decorin, a member of the small leucine-rich proteoglycan family of extracellular matrix proteoglycans/glycoproteins is a Zn2+ metalloprotein at physiological Zn2+ concentrations (Yang, V. W-C., LaBrenz, S. R., Rosenberg, L. C., McQuillan, D., and Hook, M. (1999) J. Biol. Chem. 274,12454-12460). We now report that the decorin proteoglycan binds fibrinogen in the presence of Zn2+. The fibrinogen-binding site is located in the N-terminal domain of the decorin core protein and a 45-amino acid peptide representing this domain binds to the fibrinogen D fragment with an apparent K-D of 1.7 x 10(-6) m, as determined from fluorescence polarization data. Furthermore, we show that Zn2+ promotes the self-association of decorin. The N-terminal domain of the core protein also mediates this activity. The results of solid-phase binding assays and gel filtration chromatography suggest that the N-terminal domain of decorin, when present at low micromolar concentrations, forms an oligomer in a Zn2+-dependent manner. Thus, Zn2+ appears to play a pivotal role in the interactions and biological function of decorin.	Texas Med Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA; Tapei Med Univ, Grad Inst Biomed Mat, Taipei 110, Taiwan; LifeCell Corp, Somerville, NJ 08876 USA	Baylor College of Medicine; Taipei Municipal WanFang Hospital	Hook, M (corresponding author), Texas Med Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA.	mhook@ibt.tamu.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042919] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42919] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; Camper L, 1997, J CELL BIOL, V138, P1159, DOI 10.1083/jcb.138.5.1159; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CLARK RAF, 1982, J INVEST DERMATOL, V79, P264, DOI 10.1111/1523-1747.ep12500075; COLLEN D, 1975, J BIOL CHEM, V250, P5808; Corsi A, 2002, J BONE MINER RES, V17, P1180, DOI 10.1359/jbmr.2002.17.7.1180; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FRANKEL AD, 1987, P NATL ACAD SCI USA, V84, P4841, DOI 10.1073/pnas.84.14.4841; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; Henry SP, 2001, J BIOL CHEM, V276, P12212, DOI 10.1074/jbc.M011290200; Herrick S, 1999, INT J BIOCHEM CELL B, V31, P741, DOI 10.1016/S1357-2725(99)00032-1; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; Lishko VK, 2002, BIOCHEMISTRY-US, V41, P12942, DOI 10.1021/bi026324c; LIU J, 1994, J BIOL CHEM, V269, P28366; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; Marino M, 1999, MOL CELL, V4, P1063, DOI 10.1016/S1097-2765(00)80234-8; Merle B, 1999, J CELL BIOCHEM, V75, P538; Neame PJ, 2000, CELL MOL LIFE SCI, V57, P859, DOI 10.1007/s000180050048; O'Connell DP, 1998, J BIOL CHEM, V273, P6821, DOI 10.1074/jbc.273.12.6821; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; Takanosu M, 2001, INVEST OPHTH VIS SCI, V42, P2202; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VOSS B, 1986, J HISTOCHEM CYTOCHEM, V34, P1013, DOI 10.1177/34.8.2426331; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Wendel M, 1998, J CELL BIOL, V141, P839, DOI 10.1083/jcb.141.3.839; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; Yang VWC, 1999, J BIOL CHEM, V274, P12454, DOI 10.1074/jbc.274.18.12454; YANG VWC, 1999, THESIS U TEXAS HLTH	43	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13655	13662		10.1074/jbc.M300171200	http://dx.doi.org/10.1074/jbc.M300171200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582160	hybrid			2022-12-27	WOS:000182405000014
J	Hullin, R; Khan, IFY; Wirtz, S; Mohacsi, P; Varadi, G; Schwartz, A; Herzig, S				Hullin, R; Khan, IFY; Wirtz, S; Mohacsi, P; Varadi, G; Schwartz, A; Herzig, S			Cardiac L-type calcium channel beta-subunits expressed in human heart have differential effects on single channel characteristics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; ALPHA(1C) SUBUNIT; SMOOTH-MUSCLE; HUMAN VENTRICLE; MESSENGER-RNAS; CA2+ CHANNELS; MODULATION; CLONING; MYOCARDIUM; PROTEIN	L-Type calcium channels are multiprotein complexes composed of pore-forming ( Ca(V)1.2) and modulatory auxiliary alpha(2)delta- and beta-subunits. We demonstrate expression of two different isoforms for the beta(2)-subunit (beta(2a), beta(2b)) and the beta(3)-subunit (beta(3a), beta(3trunc)) in human non-failing and failing ischemic myocardium. Quantitatively, in the left ventricle expression of beta(2b) transcripts prevails in the order of > beta(3) >> beta(2a). The expressed cardiac full-length beta(3)-subunit is identical to the beta(3a)- isoform, and beta(3trunc) results from deletion of exon 6 ( 20 nn) entailing a reading frameshift and translation stop at nucleotide position 495. In failing ischemic myocardium beta(3trunc) expression increases whereas overall beta(3) expression remains unchanged. Heterologous coexpression studies demonstrated that beta(2) induced larger currents through rabbit and human cardiac Ca(V)1.2 pore subunits than beta(3) isoforms. All beta-subunits increased channel availability at single channel level, but beta(2) exerted an additional, marked stimulation of rapid gating ( open and closed times, first latency), leading to higher peak current values. We conclude that cardiac beta-subunit isoforms differentially modulate calcium inward currents because of regulatory effects within the channel protein complex. Moreover, differences in the various beta-subunit gene products present in human heart might account for altered single channel behavior found in human heart failure.	Univ Cologne, Dept Pharmacol, D-50931 Cologne, Germany; Univ Hosp, Swiss Cardiovasc Ctr Bern, CH-3010 Bern, Switzerland; Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA	University of Cologne; University of Bern; University Hospital of Bern; University System of Ohio; University of Cincinnati	Herzig, S (corresponding author), Univ Cologne, Dept Pharmacol, Gleueler Str 24, D-50931 Cologne, Germany.			Herzig, Stefan/0000-0001-8107-5204	NHLBI NIH HHS [P01 HL 22619] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; BOSSE E, 1992, EMBO J, V11, P2033, DOI 10.1002/j.1460-2075.1992.tb05260.x; BOUABOULA M, 1992, J BIOL CHEM, V267, P21830; Chen XW, 2002, CIRC RES, V91, P517, DOI 10.1161/01.RES.0000033988.13062.7C; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; COLLIN T, 1993, CIRC RES, V72, P1337, DOI 10.1161/01.RES.72.6.1337; COLLIN T, 1994, EUR J BIOCHEM, V220, P257, DOI 10.1111/j.1432-1033.1994.tb18621.x; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Erhardt JA, 1998, J BIOL CHEM, V273, P35222, DOI 10.1074/jbc.273.52.35222; Freise D, 1999, BIOL CHEM, V380, P897, DOI 10.1515/BC.1999.110; Haase H, 1996, J MOL MED-JMM, V74, P99; Handrock R, 1998, CARDIOVASC RES, V37, P445, DOI 10.1016/S0008-6363(97)00257-5; Handrock R, 1999, J PHYSIOL-LONDON, V521, P31, DOI 10.1111/j.1469-7793.1999.00031.x; Hasenfuss G, 1998, CARDIOVASC RES, V37, P279, DOI 10.1016/S0008-6363(97)00277-0; Hersel Joachim, 2002, Basic Research in Cardiology, V97; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; HORN R, 1991, BIOPHYS J, V60, P433, DOI 10.1016/S0006-3495(91)82069-0; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hullin R, 1999, CIRCULATION, V100, P155, DOI 10.1161/01.CIR.100.2.155; Iwashima Y, 2001, BIOCHEM BIOPH RES CO, V280, P923, DOI 10.1006/bbrc.2000.4122; Lauven M, 1999, N-S ARCH PHARMACOL, V360, P122, DOI 10.1007/s002109900059; MILNER RE, 1991, J BIOL CHEM, V266, P7155; Murakami M, 1996, EUR J BIOCHEM, V236, P138, DOI 10.1111/j.1432-1033.1996.t01-1-00138.x; Murphy AM, 2000, SCIENCE, V287, P488, DOI 10.1126/science.287.5452.488; Neely A, 1998, BIOPHYS J, V74, pA101; Richard S, 1998, CARDIOVASC RES, V37, P300, DOI 10.1016/S0008-6363(97)00273-3; Schroder F, 1998, CIRCULATION, V98, P969, DOI 10.1161/01.CIR.98.10.969; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; WAGNER JA, 1986, SCIENCE, V232, P515, DOI 10.1126/science.3008330; Wei S, 2000, CIRC RES, V86, P175, DOI 10.1161/01.RES.86.2.175; WELLING A, 1991, BLOOD VESSELS, V28, P154; WELLING A, 1993, CIRC RES, V73, P974, DOI 10.1161/01.RES.73.5.974; YAMADA Y, 1995, GENOMICS, V27, P312, DOI 10.1006/geno.1995.1048; Yamaguchi H, 1998, J BIOL CHEM, V273, P19348, DOI 10.1074/jbc.273.30.19348; Yamaguchi H, 2000, BIOCHEM BIOPH RES CO, V267, P156, DOI 10.1006/bbrc.1999.1926; Yang YB, 2000, J MOL CELL CARDIOL, V32, P973, DOI 10.1006/jmcc.2000.1138	37	86	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21623	21630		10.1074/jbc.M211164200	http://dx.doi.org/10.1074/jbc.M211164200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12606548	hybrid			2022-12-27	WOS:000183354200040
J	Lindzen, M; Aizman, R; Lifshitz, Y; Lubarski, I; Karlish, SJD; Garty, H				Lindzen, M; Aizman, R; Lifshitz, Y; Lubarski, I; Karlish, SJD; Garty, H			Structure-function relations of interactions between Na,K-ATPase, the gamma subunit, and corticosteroid hormone-induced factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA-K-ATPASE; IMMUNOCYTOCHEMICAL LOCALIZATION; RENAL NA,K-ATPASE; ALPHA-SUBUNIT; CHIF; EXPRESSION; REGULATOR; OCCLUSION; DISTINCT; TOPOLOGY	Corticosteroid hormone-induced factor (CHIF) and the gamma subunit of the Na,K-ATPase (gamma) are two members of the FXYD family whose function has been elucidated recently. CHIF and gamma interact with the Na+ pump and alter its kinetic properties, in different ways, which appear to serve their specific physiological roles. Although functional interactions with the Na, K-ATPase have been clearly demonstrated, it is not known which domains and which residues interact with the alpha and/or beta subunits and affect the pump kinetics. The current study provides the first systematic analysis of structure-function relations of CHIF and gamma. It is demonstrated that the stability of detergent-solubilized complexes of CHIF and gamma with alpha and/or beta subunits is determined by the trans-membrane segments, especially three residues that may be involved in hydrophobic interactions. The transmembrane segments also determine the opposite effects of CHIF and gamma on the Na+ affinity of the pump, but the amino acids involved in this functional effect are different from those responsible for stable interactions with alpha.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Garty, H (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Aizman, R. I./AAG-2952-2019	Aizman, R. I./0000-0002-7776-4768				Aizman R, 2002, AM J PHYSIOL-RENAL, V283, pF569, DOI 10.1152/ajprenal.00376.2001; Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; Capurro C, 1996, AM J PHYSIOL-CELL PH, V271, pC753, DOI 10.1152/ajpcell.1996.271.3.C753; Carradus M, 2000, INT CONGR SER, V1207, P301; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; GARTY H, 2003, IN PRESS ANN N Y ACA; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; LINDZEN M, 2003, IN PRESS ANN N Y ACA; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; PIHAKASKIEMAUNS.K, 2003, IN PRESS ANN N Y ACA; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Shi HK, 2001, AM J PHYSIOL-RENAL, V280, pF505, DOI 10.1152/ajprenal.2001.280.3.F505; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Wald H, 1996, AM J PHYSIOL-RENAL, V271, pF322, DOI 10.1152/ajprenal.1996.271.2.F322; Wald H, 1997, AM J PHYSIOL-RENAL, V272, pF617, DOI 10.1152/ajprenal.1997.272.5.F617; Wetzel RK, 2001, AM J PHYSIOL-RENAL, V281, pF531, DOI 10.1152/ajprenal.2001.281.3.F531	27	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18738	18743		10.1074/jbc.M213253200	http://dx.doi.org/10.1074/jbc.M213253200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626497	hybrid			2022-12-27	WOS:000182932200006
J	Cavet, ME; Lehoux, S; Berk, BC				Cavet, ME; Lehoux, S; Berk, BC			14-3-3 beta is a p90 ribosomal S6 kinase (RSK) isoform 1-binding protein that negatively regulates RSK kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/H+ EXCHANGER ISOFORM-1; RAF-1 KINASE; SUBCELLULAR-LOCALIZATION; SIGNAL-TRANSDUCTION; EXOENZYME-S; T-CELLS; IN-VIVO; IDENTIFICATION; ACTIVATION; BINDING	p90 ribosomal S6 kinase 1 (RSK1) is a serine/threonine kinase that is activated by extracellular signal-related kinases 1/2 and phosphoinositide-dependent protein kinase 1 upon mitogen stimulation. Under basal conditions, RSK1 is located in the cytosol and upon stimulation, RSK1 translocates to the plasma membrane where it is fully activated. The ability of RSK1 to bind the adapter protein 14-3-3beta was investigated because RSK1 contains several putative 14-3-3-binding motifs. We demonstrate that RSK1 specifically and directly binds 14-3-3beta. This interaction was dependent on phosphorylation of serine 154 within the motif RLSKEV of RSK1. Binding of RSK1 to 14-3-3beta was maximal under basal conditions and decreased significantly upon mitogen stimulation. After 5 min of serum stimulation, a portion of 14-3-3beta and RSK1 translocated to the membrane fraction, and immunofluorescence studies demonstrated colocalization of RSK1 and 14-3-3beta at the plasma membrane in vivo. Incubation of recombinant RSK1 with 14-3-3beta decreased RSK1 kinase activity by similar to50%. Mutation of RSK1 serine 154 increased both basal and serum-stimulated RSK activity. In addition, the epidermal growth factor response of RSK1S154A was enhanced compared with wild type RSK. The amount of RSK1S154A was significantly increased in the membrane fraction under basal conditions. Increased phosphorylation of two sites essential for RSK1 kinase activity (Ser(380) and Ser(363)) in RSK1S154A compared with RSK1 wild type, demonstrated that 14-3-3 interferes with RSK1 phosphorylation. These data suggest that 14-3-3beta binding negatively regulates RSK1 activity to maintain signal specificity and that association/dissociation of the 14-3-3-betaRSK1 complex is likely to be important for mitogen-mediated RSK1 activation.	Univ Rochester, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Rochester, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Berk, BC (corresponding author), Univ Rochester, Cardiovasc Res Ctr, 601 Elmwood Ave, Rochester, NY 14642 USA.			Berk, Bradford/0000-0002-2767-4115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044721] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL44721, HL07949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Couve A, 2001, MOL CELL NEUROSCI, V17, P317, DOI 10.1006/mcne.2000.0938; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Han DC, 2001, ONCOGENE, V20, P346, DOI 10.1038/sj.onc.1204068; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Lehoux S, 2001, J BIOL CHEM, V276, P15794, DOI 10.1074/jbc.M100410200; Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984-4996.2002; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; MattoYelin M, 1997, MOL BIOL CELL, V8, P1889, DOI 10.1091/mbc.8.10.1889; Meller N, 1996, MOL CELL BIOL, V16, P5782; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; NOMURA M, 2002, J BIOL CHEM, V7, P7; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Toshima JY, 2001, J BIOL CHEM, V276, P43471, DOI 10.1074/jbc.M104620200; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	39	37	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18376	18383		10.1074/jbc.M208475200	http://dx.doi.org/10.1074/jbc.M208475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12618428	hybrid			2022-12-27	WOS:000182838300103
J	Abram, CL; Seals, DF; Pass, I; Salinsky, D; Maurer, L; Roth, TM; Courtneidge, SA				Abram, CL; Seals, DF; Pass, I; Salinsky, D; Maurer, L; Roth, TM; Courtneidge, SA			The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; PX DOMAIN; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; SH3 DOMAIN; METALLOPROTEASE-DISINTEGRINS; INTRAMOLECULAR INTERACTION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAIN; CELLULAR INVASION	Fish is a scaffolding protein and Src substrate. It contains an amino-terminal Phox homology (PX) domain and five Src homology 3 (SH3) domains, as well as multiple motifs for binding both SH2 and SH3 domain-containing proteins. We have determined that the PX domain of Fish binds 3-phosphorylated phosphatidylinositols (including phosphatidylinositol 3-phosphate and phosphatidylinositol 3,4-bisphosphate). Consistent with this, a fusion protein of green fluorescent protein and the Fish PX domain localized to punctate structures similar to endosomes in normal fibroblasts. However, the full-length Fish protein was largely cytoplasmic, suggesting that its PX domain may not be able to make intermolecular interactions in unstimulated cells. In Src-transformed cells, we observed a dramatic re-localization of some Fish molecules to actin-rich structures called podosomes; the PX domain was both necessary and sufficient to effect this translocation. We used a phage display screen with the fifth SH3 domain of Fish and isolated ADAM19 as a binding partner. Subsequent analyses in mammalian cells demonstrated that Fish interacts with several members of the ADAMs family, including ADAMs 12, 15, and 19. In Src-transformed cells, ADAM12 co-localized with Fish in podosomes. Because members of the ADAMs family have been implicated in growth factor processing, as well as cell adhesion and motility, Fish could be acting as an adaptor molecule that allows Src to impinge on these processes.	Van Andel Res Inst, Grand Rapids, MI 49503 USA; SUGEN Inc, San Francisco, CA 94080 USA	Van Andel Institute; Pfizer	Courtneidge, SA (corresponding author), Van Andel Res Inst, 333 Bostwick NE, Grand Rapids, MI 49503 USA.	sara.courtneidge@vai.org		Maurer, Lisa/0000-0003-0492-9805				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; CRAMERI R, 1993, GENE, V137, P69, DOI 10.1016/0378-1119(93)90253-Y; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ellson CD, 2002, J CELL SCI, V115, P1099; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Evans JD, 2001, BIOESSAYS, V23, P62, DOI 10.1002/1521-1878(200101)23:1&lt;62::AID-BIES1008&gt;3.0.CO;2-7; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Hougaard S, 2000, BIOCHEM BIOPH RES CO, V275, P261, DOI 10.1006/bbrc.2000.3295; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kang Q, 2001, J BIOL CHEM, V276, P24466, DOI 10.1074/jbc.M101162200; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Lock P, 1998, EMBO J, V17, P4346, DOI 10.1093/emboj/17.15.4346; Mizutani K, 2002, CANCER RES, V62, P669; MONSKY WL, 1994, CANCER RES, V54, P5702; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; MUELLER SC, 1991, J CELL SCI, V99, P213; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Pfaff M, 2001, J CELL SCI, V114, P2775; Poghosyan Z, 2002, J BIOL CHEM, V277, P4999, DOI 10.1074/jbc.M107430200; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Schlondorff J, 1999, J CELL SCI, V112, P3603; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Suzuki A, 2000, ONCOGENE, V19, P5842, DOI 10.1038/sj.onc.1203986; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; TETI A, 1991, AM J PHYSIOL, V261, pC1, DOI 10.1152/ajpcell.1991.261.1.C1; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; Zozulya S, 1999, NAT BIOTECHNOL, V17, P1193, DOI 10.1038/70736	47	191	202	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16844	16851		10.1074/jbc.M300267200	http://dx.doi.org/10.1074/jbc.M300267200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615925	hybrid			2022-12-27	WOS:000182818600054
J	Kishimoto, H; Nakagawa, K; Watanabe, T; Kitagawa, D; Momose, H; Seo, J; Nishitai, G; Shimizu, N; Ohata, S; Tanemura, S; Asaka, S; Goto, T; Fukushi, H; Yoshida, H; Suzuki, A; Sasaki, T; Wada, T; Penninger, JM; Nishina, H; Katada, T				Kishimoto, H; Nakagawa, K; Watanabe, T; Kitagawa, D; Momose, H; Seo, J; Nishitai, G; Shimizu, N; Ohata, S; Tanemura, S; Asaka, S; Goto, T; Fukushi, H; Yoshida, H; Suzuki, A; Sasaki, T; Wada, T; Penninger, JM; Nishina, H; Katada, T			Different properties of SEK1 and MKK7 in dual phosphorylation of stress-induced activated protein kinase SAPK/JNK in embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNERGISTIC ACTIVATION; SIGNAL-TRANSDUCTION; SWITCH-LIKE; IN-VITRO; CASCADE; PROLIFERATION; APOPTOSIS; SEK1/MKK4; ISOFORMS; LACKING	Stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK), belonging to the mitogen-activated protein kinase family, plays an important role in stress signaling. SAPK/JNK activation requires the phosphorylation of both Thr and Tyr residues in its Thr-Pro-Tyr motif, and SEK1 and MKK7 have been identified as the dual specificity kinases. In this study, we generated mkk7(-/-) mouse embryonic stem (ES) cells in addition to sek1(-/-) cells and compared the two kinases in terms of the activation and phosphorylation of JNK. Although SAPK/JNK activation by various stress signals was markedly impaired in both sek1(-/-) and mkk7(-/-) ES cells, there were striking differences in the dual phosphorylation profile. The severe impairment observed in mkk7(-/-) cells was accompanied by a loss of the Thr phosphorylation of JNK without marked reduction in its Tyr-phosphorylated level. On the other hand, Thr phosphorylation of JNK in sek1(-/-) cells was also attenuated in addition to a decreased level of its Tyr phosphorylation. Analysis in human embryonic kidney 293T cells transfected with a kinase-dead SEK1 or a Thr-Pro-Phe mutant of JNK1 revealed that SEK1-induced Tyr phosphorylation of JNK1 was followed by additional Thr phosphorylation by MKK7. Furthermore, SEK1 but not MKK7 was capable of binding to JNK1 in 293T cells. These results indicate that the Tyr and Thr residues of SAPK/JNK are sequentially phosphorylated by SEK1 and MKK7, respectively, in the stress-stimulated ES cells.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1130033, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Immunol, Higashi Ku, Fukuoka 8128582, Japan; Akita Univ, Sch Med, Dept Biochem, Akita 0108543, Japan; Univ Toronto, Univ Hlth Network, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Univ Hlth Network, Dept Immunol, Toronto, ON M5G 2C1, Canada	University of Tokyo; Kyushu University; Akita University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Nishina, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Ohata, Shinya/S-2320-2018; Suzuki, Akira/GYD-6697-2022; Penninger, Josef M/I-6860-2013	Ohata, Shinya/0000-0003-4333-4433; Suzuki, Akira/0000-0002-5950-8808; Penninger, Josef M/0000-0002-8194-3777; Sasaki, Takehiko/0000-0003-1837-3748				Bagowski CP, 2001, CURR BIOL, V11, P1176, DOI 10.1016/S0960-9822(01)00330-X; Brown GC, 1997, TRENDS BIOCHEM SCI, V22, P288, DOI 10.1016/S0968-0004(97)82216-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ferrell JE, 1997, TRENDS BIOCHEM SCI, V22, P288, DOI 10.1016/S0968-0004(97)82217-7; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1997, J EXP MED, V186, P941, DOI 10.1084/jem.186.6.941; Nishina H, 1999, DEVELOPMENT, V126, P505; Sasaki T, 2001, J EXP MED, V194, P757, DOI 10.1084/jem.194.6.757; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Wada T, 2001, J BIOL CHEM, V276, P30892, DOI 10.1074/jbc.M011780200; Watanabe T, 2002, DEV BIOL, V250, P332, DOI 10.1006/dbio.2002.0781; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	19	62	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16595	16601		10.1074/jbc.M213182200	http://dx.doi.org/10.1074/jbc.M213182200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624093	hybrid			2022-12-27	WOS:000182818600021
J	Ma, YH; Yuan, J; Huang, M; Jove, R; Cress, WD				Ma, YH; Yuan, J; Huang, M; Jove, R; Cress, WD			Regulation of the cyclin D3 promoter by E2F1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F1; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; S-PHASE; CHROMATIN IMMUNOPRECIPITATION; MICROARRAY ANALYSIS; DNA-REPLICATION; MCL-1 PROMOTER; IN-VIVO	We have previously demonstrated that ectopic expression of E2F1 is sufficient to drive quiescent cells into S phase and that E2F1 expression can contribute to oncogenic transformation. Key target genes in this process include master regulators of the cell cycle, such as cyclin E, which regulates G(1) progression, and cyclin A, which is required for the initiation of DNA synthesis. In the present work, we present novel evidence that a second G(1) cyclin, cyclin D3, is also potently activated by E2F1. First, an estrogen receptor-E2F1 fusion protein ( ER-E2F1) potently activates the endogenous cyclin D3 mRNA upon treatment with 4-hydroxytamoxifen, which induces nuclear accumulation of the otherwise cytosolic fusion protein. Furthermore, trans-activation of cyclin D3 by ER-E2F1 occurs even in the presence of the protein synthesis inhibitor cycloheximide and thus appears direct. Second, all of the growth-stimulatory members of the E2F family ( E2F1, -2, and -3A) potently activate a cyclin D3 promoter reporter, whereas growth-restraining members of the family ( E2F4, -5, and -6) have little effect. Third, recombinant E2F1 binds with high affinity to the cyclin D3 promoter in vitro. Fourth, chromatin immunoprecipitation assays demonstrate that endogenous E2F1 is associated with the cyclin D3 promoter in vivo. Finally, mapping experiments localize the essential E2F regulatory element of the cyclin D3 promoter to a noncanonical E2F site in the promoter between nucleotides -143 and -135 relative to the initiating methionine codon. We conclude that in addition to cyclins E and A, E2F family members can also activate one member of the D-type cyclins, further contributing to the ability of the stimulatory E2F family members to drive cellular proliferation.	Univ S Florida, Coll Med, Program Mol Oncol, H Lee Moffit Comprehens Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cress, WD (corresponding author), Univ S Florida, Mol Oncol Program, H Lee Moffitt Canc Ctr, 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R29CA078214] Funding Source: NIH RePORTER; NCI NIH HHS [CA78214] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Cress WD, 1996, MOL CELL BIOL, V16, P2119; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Croxton R, 2002, ONCOGENE, V21, P1563, DOI 10.1038/sj.onc.1205232; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; He YW, 2002, J BIOL CHEM, V277, P23493, DOI 10.1074/jbc.M202629200; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Ma YH, 2003, MOL CANCER THER, V2, P73; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Payton M, 2002, INT J BIOCHEM CELL B, V34, P315, DOI 10.1016/S1357-2725(01)00137-6; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sherr CJ, 2000, CANCER RES, V60, P3689; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang AJ, 1999, NUCLEIC ACIDS RES, V27, P4609, DOI 10.1093/nar/27.23.4609; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang M, 1996, GENE, V181, P153, DOI 10.1016/S0378-1119(96)00499-4; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	55	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16770	16776		10.1074/jbc.M212702200	http://dx.doi.org/10.1074/jbc.M212702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611887	hybrid			2022-12-27	WOS:000182818600044
J	Neal, JW; Clipstone, NA				Neal, JW; Clipstone, NA			A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; GLYCOGEN-SYNTHASE KINASE-3; T-CELL-ACTIVATION; NUCLEAR FACTOR; GROWTH-FACTOR; NF-ATC; CYCLOSPORINE-A; ADIPOCYTE DIFFERENTIATION; MOLECULAR REGULATION; GENE-EXPRESSION	The calcineurin/nuclear factor of activated T cells (NFAT) signaling pathway is best known for its role in T lymphocyte activation. However, it has become increasingly apparent that this signaling pathway is also involved in the regulation of cell growth and development in a wide variety of different tissues and cell types. Here we have investigated the effects of sustained NFATc1 signaling on the growth and differentiation of the murine 3T3-L1 preadipocyte cell line. Remarkably, we find that expression of a constitutively active NFATc1 mutant (caNFATc1) in these immortalized cells inhibits their differentiation into mature adipocytes and causes them to adopt a transformed cell phenotype, including loss of contact-mediated growth inhibition, reduced serum growth requirements, protection from growth factor withdrawal-induced apoptosis, and formation of colonies in semisolid media. Furthermore, we find that caNFATc1-expressing cells acquire growth factor autonomy and are able to proliferate even in the complete absence of serum. We provide evidence that this growth factor independence is caused by the NFATc1-dependent production of a soluble heat-labile autocrine factor that is capable of promoting the growth and survival of wild type 3T3-L1 cells as well as potently inhibiting their differentiation into mature adipocytes. Finally, we demonstrate that cells expressing caNFATc1 form tumors in nude mice. Taken together, these results indicate that deregulated NFATc1 activity is able to induce the immortalized 3T3-L1 preadipocyte cell line to acquire the well established hallmarks of cellular transformation and thereby provide direct evidence for the oncogenic potential of the NFATc1 transcription factor.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Clipstone, NA (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.	nclipstone@northwestern.edu			NIGMS NIH HHS [R29 GM55292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Calvo S, 1999, MOL CELL BIOL, V19, P515; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Feske S, 2000, J IMMUNOL, V165, P297, DOI 10.4049/jimmunol.165.1.297; Gooch JL, 2001, J BIOL CHEM, V276, P42492, DOI 10.1074/jbc.M102994200; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; JANIK P, 1975, CANCER RES, V35, P3698; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Mulligan C, 2002, J BIOL CHEM, V277, P42480, DOI 10.1074/jbc.M206206200; Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Neal JW, 2002, J BIOL CHEM, V277, P49776, DOI 10.1074/jbc.M207913200; Polakis P, 2000, GENE DEV, V14, P1837; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Porter CM, 2002, J IMMUNOL, V168, P4936, DOI 10.4049/jimmunol.168.10.4936; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Schuh K, 1998, J EXP MED, V188, P1369, DOI 10.1084/jem.188.7.1369; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; SERRERO G, 1987, BIOCHEM BIOPH RES CO, V146, P194, DOI 10.1016/0006-291X(87)90710-8; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TRICOLI JV, 1986, CANCER RES, V46, P6169; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; VASSAUX G, 1994, J CELL PHYSIOL, V161, P249, DOI 10.1002/jcp.1041610209; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	57	118	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17246	17254		10.1074/jbc.M300528200	http://dx.doi.org/10.1074/jbc.M300528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12598522	hybrid			2022-12-27	WOS:000182818600107
J	Quevedo, C; Salinas, M; Alcazar, A				Quevedo, C; Salinas, M; Alcazar, A			Initiation factor 2B activity is regulated by protein phosphatase 1, which is activated by the mitogen-activated protein kinase-dependent pathway in insulin-like growth factor 1-stimulated neuronal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; GUANINE-NUCLEOTIDE-EXCHANGE; FACTOR EIF2B; TRANSLATION INITIATION; SKELETAL-MUSCLE; PC12 CELLS; PHOSPHORYLATION; STIMULATION; INHIBITION; MECHANISM	We have previously demonstrated that insulin-like growth factor 1 (IGF1) induces eukaryotic initiation factor 2B (eIF2B) activation in neuronal cells through the phosphatidylinositol 3 kinase/glycogen synthase kinase 3 pathway as well as by activation of the mitogen-activated protein kinase (MAPK)-activating kinase (MEK)/MAPK signaling pathway (Quevedo, C., Alcazar, A., and Salinas, M. (2000) J. Biol. Chem. 275, 19192-19197). This paper addresses the mechanism involved in IGF1-induced eIF2B activation via the MEK/MAPK cascade in cultured neurons treated with IGF1 and demonstrates that extracellular signal-regulated MAP kinase 1 and 2 (ERK1 and -2) immunoprecipitates of IGF1-treated neuronal cells promote this activation. This effect did not directly result from eIF2B phosphorylation by ERK immunoprecipitates. In addition, recombinant ERK1 and -2 neither activate eIF2B nor phosphorylate it. Endogenous protein phosphatase 1 and 2A catalytic subunits (PP1C and PP2AC, respectively) were co-immunoprecipitated with ERK1 and -2, and the association of ERK with PP1C was stimulated by IGF1 treatment, resulting in increased PP1 activity. ERK immunoprecipitates incubated with PP1 inhibitors did not activate eIF2B, indicating that PP1C activates eIF2B. In vitro experiments with phosphorylated eIF2B showed that recombinant PP1C (alpha isoform) dephosphorylates and activates eIF2B. Paralleling eIF2B activation, IGF1 treatment induced PP1 activation in a MEK/MAPK-dependent fashion. Moreover, the treatment of neurons with the PP1 inhibitor tautomycin inhibited PP1 activation and prevented IGF1-induced eIF2B activation. These findings strongly suggest that IGF1-induced eIF2B activation in neurons is effected by PP1, the activation of which is mediated by the MEK/MAPK signaling pathway.	Hosp Ramon y Cajal, Serv Bioquim Invest, E-28034 Madrid, Spain	Hospital Universitario Ramon y Cajal	Alcazar, A (corresponding author), Hosp Ramon y Cajal, Serv Bioquim Invest, Ctra Colmenar Km 9,1, E-28034 Madrid, Spain.							ALCAZAR A, 1995, J NEUROCHEM, V65, P754; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Clemens MJ, 2001, PROG MOLEC, V27, P57; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; COHEN P, 1988, METHOD ENZYMOL, V159, P390; Cohen PTW, 2002, J CELL SCI, V115, P241; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; Hershey JWB, 1996, TRANSLATIONAL CONTRO; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; KARINCH AM, 1993, AM J PHYSIOL, V264, pE101, DOI 10.1152/ajpendo.1993.264.1.E101; Kimball SR, 1999, INT J BIOCHEM CELL B, V31, P25, DOI 10.1016/S1357-2725(98)00128-9; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Kleijn M, 2000, FEBS LETT, V476, P262, DOI 10.1016/S0014-5793(00)01743-9; Kleijn M, 1998, J BIOL CHEM, V273, P5536, DOI 10.1074/jbc.273.10.5536; Liu J, 2000, J BIOL CHEM, V275, P15940, DOI 10.1074/jbc.M909303199; Manchester KL, 1997, BIOCHEM BIOPH RES CO, V239, P223, DOI 10.1006/bbrc.1997.7462; Miller TM, 1997, J BIOL CHEM, V272, P9847; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Price NE, 1999, CURR OPIN NEUROBIOL, V9, P336, DOI 10.1016/S0959-4388(99)80049-X; Proud C G, 2001, Prog Mol Subcell Biol, V26, P95; Proud CG, 1997, BIOCHEM J, V328, P329; Quevedo C, 2000, J BIOL CHEM, V275, P19192, DOI 10.1074/jbc.M000238200; Ragolia L, 1998, MOL CELL BIOCHEM, V182, P49, DOI 10.1023/A:1006827227162; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; Singh LP, 1996, BIOCHEMISTRY-US, V35, P3206, DOI 10.1021/bi9522099; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; VANLINT J, 1993, ANAL BIOCHEM, V208, P132, DOI 10.1006/abio.1993.1018; Wang XM, 2001, EMBO J, V20, P4349, DOI 10.1093/emboj/20.16.4349; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Williams DD, 2001, J BIOL CHEM, V276, P24697, DOI 10.1074/jbc.M011788200; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200	48	24	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16579	16586		10.1074/jbc.M212936200	http://dx.doi.org/10.1074/jbc.M212936200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624094	hybrid			2022-12-27	WOS:000182818600019
J	Watada, H; Scheel, DW; Leung, J; German, MS				Watada, H; Scheel, DW; Leung, J; German, MS			Distinct gene expression programs function in progenitor and mature islet cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX TRANSCRIPTION FACTOR; PANCREATIC BETA-CELLS; NUCLEAR FACTOR 3-BETA; MICE LACKING; ALPHA-CELLS; PDX-1 GENE; DIFFERENTIATION; PROTEIN; NKX2.2; NEUROGENIN3	Homeodomain transcription factor Nkx2.2 is required for the final differentiation of the beta-cells in the pancreas and for the production of insulin. Nkx2.2 is expressed in islet cell precursors during pancreatic development and persists in a subset of mature islet cells including all beta-cells. To understand the mechanisms regulating the expression of Nkx2.2 in these different cell populations, we outlined the structure of the mouse nkx2.2 gene and identified regions that direct cell type-specific expression. The nkx2.2 gene has two noncoding alternative first exons (exons 1a and 1b). In transgenic mice, sequences upstream from exon 1a directed expression predominantly in mature islet cells. Within this exon 1a promoter, cooperative interactions between HNF3 and basic helix-loop-helix factors neurogenin-3 or NeuroD1 binding to adjacent sites played key roles in its islet cell-specific expression. In contrast, sequences upstream from exon 1b restricted expression specifically to islet cell precursors. These studies reveal distinct mechanisms for directing the expression of a key differentiation factor in precursors versus mature islet cells.	Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	German, MS (corresponding author), Univ Calif San Francisco, Hormone Res Inst, 513 Parnassus Ave,HSW Rm 1090, San Francisco, CA 94143 USA.			Watada, Hirotaka/0000-0001-5961-1816	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021344, R56DK021344, R37DK021344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK21344, DK553401, R01 DK021344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Furuta H, 1998, DIABETES, V47, P1356, DOI 10.2337/diabetes.47.8.1356; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Harrison KA, 1999, NAT GENET, V23, P71, DOI 10.1038/12674; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Lee JC, 2001, DIABETES, V50, P928, DOI 10.2337/diabetes.50.5.928; Li H, 1999, NAT GENET, V23, P67; Marshak S, 2000, MOL CELL BIOL, V20, P7583, DOI 10.1128/MCB.20.20.7583-7590.2000; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PICTET R, 1972, HDB PHYSL ENDOCRINOL, V7, P25; QIAN XB, 1995, MOL CELL BIOL, V15, P1364; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Sander M, 2000, DEVELOPMENT, V127, P5533; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Sharma S, 1997, MOL CELL BIOL, V17, P2598, DOI 10.1128/MCB.17.5.2598; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SMITH RL, 1995, J VIROL, V69, P4593, DOI 10.1128/JVI.69.8.4593-4599.1995; Smith SB, 2000, J BIOL CHEM, V275, P36910, DOI 10.1074/jbc.M005202200; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sund NJ, 2001, GENE DEV, V15, P1706, DOI 10.1101/gad.901601; Sussel L, 1998, DEVELOPMENT, V125, P2213; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Watada H, 2000, J BIOL CHEM, V275, P34224, DOI 10.1074/jbc.M004981200; Watada H, 2000, P NATL ACAD SCI USA, V97, P9443, DOI 10.1073/pnas.97.17.9443; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Wilson ME, 2002, MECH DEVELOP, V115, P171, DOI 10.1016/S0925-4773(02)00118-1; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002	42	63	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17130	17140		10.1074/jbc.M213196200	http://dx.doi.org/10.1074/jbc.M213196200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604598	hybrid			2022-12-27	WOS:000182818600092
J	Zou, CG; Banerjee, R				Zou, CG; Banerjee, R			Tumor necrosis factor-alpha-induced targeted proteolysis of cystathionine beta-synthase modulates redox homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SUPEROXIDE ANION GENERATION; OXYGEN SPECIES PRODUCTION; SIGNAL-TRANSDUCTION; RAT-LIVER; HOMOCYSTEINE METABOLISM; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; GENE-EXPRESSION; HEME PROTEIN	Cystathionine beta-synthase (CBS) catalyzes the first of two steps in the transsulfuration pathway that converts homocysteine to cysteine, a precursor of glutathione, a major intracellular antioxidant. Tumor necrosis factor-alpha (TNFalpha), which is known to enhance production of reactive oxygen species, increased CBS activity and glutathione levels in HepG2 cells. Western blot analysis revealed that the higher CBS activity correlated with cleavage of the enzyme to a truncated form. This cleavage was suppressed by inhibitors of superoxide production or by transfection with an expression vector for manganese superoxide dismutase. The commonly used proteasome inhibitors, MG132 and lactacystin but not N-acetyl-Leu-Leu-norleucinal, suppressed the TNFalpha-induced response. Targeted proteolysis of CBS was also observed in livers of mice injected with lipopolysaccharide, which is known to induce TNFalpha. Together, these data reveal a novel and previously unknown mechanism of regulation for homocysteine-linked glutathione homeostasis in cells challenged by oxidative stress.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064959] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK64959] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUTISTA AP, 1990, AM J PHYSIOL, V259, pG907, DOI 10.1152/ajpgi.1990.259.6.G907; Beswick RA, 2001, HYPERTENSION, V38, P1107, DOI 10.1161/hy1101.093423; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Corda S, 2001, AM J RESP CELL MOL, V24, P762, DOI 10.1165/ajrcmb.24.6.4228; CZAJA MJ, 1994, AM J PHYSIOL, V266, pG737, DOI 10.1152/ajpgi.1994.266.4.G737; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Diehl AM, 2000, IMMUNOL REV, V174, P160, DOI 10.1034/j.1600-0528.2002.017411.x; Dinges MM, 2001, INFECT IMMUN, V69, P7169, DOI 10.1128/IAI.69.11.7169-7172.2001; Eto K, 2002, J NEUROSCI, V22, P3386; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Garcia-Nogales P, 1999, J NEUROCHEM, V72, P1750, DOI 10.1046/j.1471-4159.1999.721750.x; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; Hsu HY, 2002, J BIOL CHEM, V277, P22131, DOI 10.1074/jbc.M111883200; Ishibashi M, 1997, FREE RADICAL BIO MED, V22, P447, DOI 10.1016/S0891-5849(96)00338-3; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Janosik M, 2001, AM J HUM GENET, V68, P1506, DOI 10.1086/320597; KASHIWAMATA S, 1970, BIOCHIM BIOPHYS ACTA, V212, P488, DOI 10.1016/0005-2744(70)90255-X; Kery V, 1998, ARCH BIOCHEM BIOPHYS, V355, P222, DOI 10.1006/abbi.1998.0723; Kraus JP, 1999, HUM MUTAT, V13, P362; Li CQ, 2002, CHEM RES TOXICOL, V15, P527, DOI 10.1021/tx010171x; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Liu Y, 1999, J BIOL CHEM, V274, P24819, DOI 10.1074/jbc.274.35.24819; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Meier M, 2001, EMBO J, V20, P3910, DOI 10.1093/emboj/20.15.3910; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; Mosharov E, 2000, BIOCHEMISTRY-US, V39, P13005, DOI 10.1021/bi001088w; Ostrowska H, 2000, INT J BIOCHEM CELL B, V32, P747, DOI 10.1016/S1357-2725(00)00021-2; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; PHELPS DT, 1995, AM J PHYSIOL-LUNG C, V269, pL551, DOI 10.1152/ajplung.1995.269.4.L551; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Ratnam S, 2002, J BIOL CHEM, V277, P42912, DOI 10.1074/jbc.M206588200; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shan XY, 1998, NAT GENET, V19, P91, DOI 10.1038/ng0598-91; SKOVBY F, 1984, J BIOL CHEM, V259, P588; Sprong RC, 1998, AM J RESP CRIT CARE, V157, P1283; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Taoka S, 1999, BIOCHEMISTRY-US, V38, P13155, DOI 10.1021/bi990865t; Taoka S, 2002, BIOCHEMISTRY-US, V41, P10454, DOI 10.1021/bi026052d; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Vitvitsky V, 2003, REDOX REP, V8, P57, DOI 10.1179/135100003125001260; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Wu HM, 2002, FEBS LETT, V526, P101, DOI 10.1016/S0014-5793(02)03151-4; ZHU H, 1994, ARCH TOXICOL, V68, P582, DOI 10.1007/s002040050118; ZUROVSKY Y, 1995, AM J KIDNEY DIS, V25, P51, DOI 10.1016/0272-6386(95)90625-8	57	71	77	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16802	16808		10.1074/jbc.M212376200	http://dx.doi.org/10.1074/jbc.M212376200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615917	hybrid			2022-12-27	WOS:000182818600049
J	Bhullar, B; Zhang, Y; Junco, A; Oko, R; van der Hoorn, FA				Bhullar, B; Zhang, Y; Junco, A; Oko, R; van der Hoorn, FA			Association of kinesin light chain with outer dense fibers in a microtubule-independent fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNEIN SUPERFAMILY PROTEINS; DEVELOPMENTAL EXPRESSION; CYTOPLASMIC DYNEIN; MOLECULAR-CLONING; CANDIDATE MOTORS; SPERM PROTEIN; SEA-URCHIN; RAT; TESTIS; LOCALIZES	Conventional kinesin I motor molecules are heterotetramers consisting of two kinesin light chains (KLCs) and two kinesin heavy chains. The interaction between the heavy and light chains is mediated by the KLC heptad repeat (HR), a leucine zipper-like motif. Kinesins bind to microtubules and are involved in various cellular functions, including transport and cell division. We recently isolated a novel KLC gene, klc3. klc3 is the only known KLC expressed in post-meiotic male germ cells. A monoclonal anti-KLC3 antibody was developed that, in immunoelectron microscopy, detects KLC3 protein associated with outer dense fibers (ODFs), unique structural components of sperm tails. No significant binding of KLC3 with microtubules was observed with this monoclonal antibody. In vitro experiments showed that KLC3-ODF binding occurred in the absence of kinesin heavy chains or microtubules and required the KLC3 HR. ODF1, a major ODF protein, was identified as the KLC3 binding partner. The ODF1 leucine zipper and the KLC3 HR mediated the interaction. These results identify and characterize a novel interaction between a KLC and a non-microtubule macromolecular structure and suggest that KLC3 could play a microtubule-independent role during formation of sperm tails.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Queens Univ, Dept Cell Biol & Anat, Kingston, ON K7L 3N6, Canada	University of Calgary; Queens University - Canada	van der Hoorn, FA (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, 330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	fvdhoorn@ucalgary.ca			Canadian Institutes of Health Research [11361, 13680] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; BEUSHAUSEN S, 1993, DNA CELL BIOL, V12, P901, DOI 10.1089/dna.1993.12.901; Block SM, 1998, CELL, V93, P5, DOI 10.1016/S0092-8674(00)81138-1; Block SM, 1998, J CELL BIOL, V140, P1281, DOI 10.1083/jcb.140.6.1281; BRYAN JHD, 1977, CELL TISSUE RES, V180, P187, DOI 10.1007/BF00231951; CABEZAARVELAIZ Y, 1993, DNA CELL BIOL, V12, P881, DOI 10.1089/dna.1993.12.881; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Diefenbach RJ, 1998, BIOCHEMISTRY-US, V37, P16663, DOI 10.1021/bi981163r; Diez S, 2002, CURR BIOL, V12, pR203, DOI 10.1016/S0960-9822(02)00750-9; FAN J, 1994, J MOL BIOL, V240, P507, DOI 10.1006/jmbi.1994.1465; GAUGER AK, 1993, J BIOL CHEM, V268, P13657; Gindhart JG, 1998, J CELL BIOL, V141, P443, DOI 10.1083/jcb.141.2.443; Gindhart JG, 1996, TRENDS BIOCHEM SCI, V21, P52, DOI 10.1016/0968-0004(96)80865-6; Goldstein LSB, 2001, TRENDS CELL BIOL, V11, P477, DOI 10.1016/S0962-8924(01)02143-2; Gyoeva FK, 2000, J CELL SCI, V113, P2047; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; HALL ES, 1992, BIOL REPROD, V46, P817, DOI 10.1095/biolreprod46.5.817; Henson JH, 1997, CELL MOTIL CYTOSKEL, V38, P29, DOI 10.1002/(SICI)1097-0169(1997)38:1<29::AID-CM4>3.0.CO;2-C; HERMO L, 1991, ANAT REC, V229, P31, DOI 10.1002/ar.1092290106; HIGGY NA, 1994, BIOL REPROD, V50, P1357, DOI 10.1095/biolreprod50.6.1357; HIGGY NA, 1995, DEV GENET, V16, P190, DOI 10.1002/dvg.1020160211; Hirokawa N, 1998, CURR OPIN CELL BIOL, V10, P60, DOI 10.1016/S0955-0674(98)80087-2; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Johnson KJ, 1996, EUR J CELL BIOL, V69, P276; Junco A, 2001, BIOL REPROD, V64, P1320, DOI 10.1095/biolreprod64.5.1320; Kamal A, 2002, CURR OPIN CELL BIOL, V14, P63, DOI 10.1016/S0955-0674(01)00295-2; Karcher RL, 2002, TRENDS CELL BIOL, V12, P21, DOI 10.1016/S0962-8924(01)02184-5; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; Khodjakov A, 1998, MOL BIOL CELL, V9, P333, DOI 10.1091/mbc.9.2.333; Kierszenbaum AL, 2001, MOL REPROD DEV, V59, P347, DOI 10.1002/mrd.1040; Kierszenbaum AL, 2002, MOL REPROD DEV, V61, P1, DOI 10.1002/mrd.1124; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Miller MG, 1999, BIOL REPROD, V60, P1047, DOI 10.1095/biolreprod60.4.1047; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MORALES CR, 1994, MOL REPROD DEV, V37, P229, DOI 10.1002/mrd.1080370215; Nakajima T, 1997, ZOOL SCI, V14, P917, DOI 10.2108/zsj.14.917; Oko R, 1998, ANDROLOGIA, V30, P193; OKO R, 1988, BIOL REPROD, V39, P169, DOI 10.1095/biolreprod39.1.169; Oko RJ, 1996, BIOL REPROD, V54, P1141, DOI 10.1095/biolreprod54.5.1141; Rahman A, 1998, J BIOL CHEM, V273, P15395, DOI 10.1074/jbc.273.25.15395; Rahman A, 1999, J CELL BIOL, V146, P1277, DOI 10.1083/jcb.146.6.1277; Schalles U, 1998, DEV BIOL, V199, P250, DOI 10.1006/dbio.1998.8931; Shao XP, 1999, DEV BIOL, V211, P109, DOI 10.1006/dbio.1999.9297; Shao XP, 2001, MOL REPROD DEV, V59, P410, DOI 10.1002/mrd.1047; Shao XP, 1996, BIOL REPROD, V55, P1343, DOI 10.1095/biolreprod55.6.1343; Shao XP, 1997, J BIOL CHEM, V272, P6105, DOI 10.1074/jbc.272.10.6105; Sperry AO, 1996, MOL BIOL CELL, V7, P289, DOI 10.1091/mbc.7.2.289; Stenoien DL, 1997, MOL BIOL CELL, V8, P675, DOI 10.1091/mbc.8.4.675; VANDERHOORN FA, 1990, DEV BIOL, V142, P147, DOI 10.1016/0012-1606(90)90158-F; Verhey KJ, 1998, J CELL BIOL, V143, P1053, DOI 10.1083/jcb.143.4.1053; WEDAMAN KP, 1993, J MOL BIOL, V231, P155, DOI 10.1006/jmbi.1993.1267; Wilde A, 2001, NAT CELL BIOL, V3, P221, DOI 10.1038/35060000; Xue JP, 2002, MOL CELL BIOL, V22, P1993, DOI 10.1128/MCB.22.7.1993-1997.2002; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; Yang ZH, 2001, MOL CELL BIOL, V21, P5306, DOI 10.1128/MCB.21.16.5306-5311.2001; YU H, 1992, J BIOL CHEM, V267, P20457; Zarsky HA, 2003, BIOL REPROD, V68, P543, DOI [10.1095/BIOLREPROD.102.009076, 10.1095/biolreprod.102.009076]; Zou Y, 2002, BIOL REPROD, V66, P843, DOI 10.1095/biolreprod66.3.843	60	27	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16159	16168		10.1074/jbc.M213126200	http://dx.doi.org/10.1074/jbc.M213126200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594206	Green Accepted, hybrid			2022-12-27	WOS:000182680000089
J	Finney, N; Walther, F; Mantel, PY; Stauffer, D; Rovelli, G; Dev, KK				Finney, N; Walther, F; Mantel, PY; Stauffer, D; Rovelli, G; Dev, KK			The cellular protein level of parkin is regulated by its ubiquitin-like domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGASE ACTIVITY; JUVENILE PARKINSONISM; DISEASE; GENE; MUTATIONS; SYSTEM; STRESS; HHARI; UBCH7; BRAIN	Parkin is a ubiquitin-protein isopeptide ligase (E3) involved in ubiquitin/proteasome-mediated protein degradation. Mutations in the parkin gene cause a loss-of-function and/or alter protein levels of parkin. As a result, the toxic build-up of parkin substrates is thought to lead to autosomal recessive juvenile Parkinsonism. To identify a role for the ubiquitin-like domain (ULD) of parkin, we created a number of hemagglutinin (HA)tagged parkin constructs using mutational and structural information. Western blotting and immunocytochemistry showed a much stronger expression level for RA-parkin residues 77-465 (without ULD) than HA-par-kin full-length (with ULD). The deletion of ULD in Drosophila parkin also caused a sharp increase in expression of the truncated form, suggesting that the function of the ULD of parkin is conserved across species. By progressive deletion analysis of parkin ULD, we found that residues 1-6 of human parkin play a crucial role in controlling the expression levels of this gene. HA-parkin residues 77-465 showed ubiquitination in vivo, demonstrating that the ULD is not critical for parkin auto-ubiquitination; ubiquitination seemed to cluster on the central domain of parkin (residues 77-313). These effects were specific for the ULD of parkin and not transfection-, toxic-, epitope tag-, and/or vector-dependent. Taken together, these data suggest that the 76 most NH2-terminal residues (ULD) dramatically regulate the protein levels of parkin.	Novartis Pharma AG, Nervous Syst Res, CH-4002 Basel, Switzerland	Novartis	Dev, KK (corresponding author), Novartis Pharma AG, Nervous Syst Res, CH-4002 Basel, Switzerland.		Mantel, Pierre-Yves/N-3065-2015	Mantel, Pierre-Yves/0000-0001-9526-9309; Dev, Kumlesh/0000-0003-4274-9119				Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Ardley HC, 2001, J BIOL CHEM, V276, P19640, DOI 10.1074/jbc.M011028200; Choi P, 2000, NEUROREPORT, V11, P2635, DOI 10.1097/00001756-200008210-00006; CHOI P, 2000, SOC NEUR ABSTR, V26; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; DEV KK, 2003, IN PRESS NEUROPHARMA; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; Haass C, 2001, SCIENCE, V293, P224, DOI 10.1126/science.1063286; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hornykiewicz O, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.2_Suppl_2.S2; Huynh DP, 2000, ANN NEUROL, V48, P737, DOI 10.1002/1531-8249(200011)48:5<737::AID-ANA7>3.3.CO;2-4; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kahle PJ, 2000, TRENDS BIOCHEM SCI, V25, P524, DOI 10.1016/S0968-0004(00)01682-0; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kubo S, 2001, J NEUROCHEM, V78, P42, DOI 10.1046/j.1471-4159.2001.00364.x; Leroy E, 1998, HUM GENET, V103, P424, DOI 10.1007/s004390050845; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mengesdorf T, 2002, P NATL ACAD SCI USA, V99, P15042, DOI 10.1073/pnas.232588799; Mizuno Y, 1998, J NEUROCHEM, V71, P893; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	29	34	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16054	16058		10.1074/jbc.C300051200	http://dx.doi.org/10.1074/jbc.C300051200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12621021	Green Published, hybrid			2022-12-27	WOS:000182680000077
J	Gil-Parrado, S; Popp, O; Knoch, TA; Zahler, S; Bestvater, F; Felgentrager, M; Holloschi, A; Fernandez-Montalvan, A; Auerswald, EA; Fritz, H; Fuentes-Prior, P; Machleidt, W; Spiess, E				Gil-Parrado, S; Popp, O; Knoch, TA; Zahler, S; Bestvater, F; Felgentrager, M; Holloschi, A; Fernandez-Montalvan, A; Auerswald, EA; Fritz, H; Fuentes-Prior, P; Machleidt, W; Spiess, E			Subcellular localization and in vivo subunit interactions of ubiquitous mu-calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOFIBRILLAR PROTEIN-TURNOVER; CALCIUM-DEPENDENT PROTEASE; NUCLEAR-LOCALIZATION; CRYSTAL-STRUCTURE; NEUTRAL PROTEASE; THIOL PROTEASE; RAT CALPAIN; IN-VITRO; C-JUN; ACTIVATION	Ubiquitously expressed calpains are Ca2+-dependent, intracellular cysteine proteases comprising a large catalytic subunit (domains DI-DIV) and a noncovalently bound small regulatory subunit (domains DV and DVI). It is unclear whether Ca2+-induced calpain activation is followed by subunit dissociation or not. Here, we have applied advanced fluorescence microscopy techniques to study calpain subunit interactions in living cells using recombinant calpain subunits or domains fused to enhanced cyan and enhanced yellow fluorescent reporter proteins. All of the overexpressed variants of the catalytic subunit (DI-IV, DI-III, and DI-IIb) were active and Ca2+-dependent. The intact large subunit, but not its truncated variants, associates with the small subunit under resting and ionomycin-activated conditions. All of the variants were localized in cytoplasm and nuclei, except DI-IIb, which accumulates in the nucleus and in nucleoli as shown by microscopy and cell fractionation. Localization studies with mutated and chimeric variants indicate that nuclear targeting of the DI-IIb variant is conferred by the two N-terminal helices of DI. Only those variants that contain DIII migrated to membranes upon the addition of ionomycin, suggesting that DIII is essential for membrane targeting. We propose that intracellular localization and in particular membrane targeting of activated calpain, but not dissociation of its intact subunits, contribute to regulate its proteolytic activity in vivo.	Univ Munich Klinikum, Klin Chem & Klin Biochem Abt, Chirurg Klin Innenstadt, D-80336 Munich, Germany; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; Univ Munich, Inst Physiol, D-80336 Munich, Germany; Fachhsch Mannheim, Inst Mol Biol & Zellkulturtechn, D-68163 Mannheim, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Munich; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; Max Planck Society	Gil-Parrado, S (corresponding author), Univ Munich Klinikum, Klin Chem & Klin Biochem Abt, Chirurg Klin Innenstadt, Nussbaumstr 20, D-80336 Munich, Germany.	shirgilpa@web.de		Fuentes-Prior, Pablo/0000-0002-6618-3204; Zahler, Stefan/0000-0002-5140-7287; Fernandez-Montalvan, Amaury/0000-0001-9156-0000				Averna M, 1999, FEBS LETT, V450, P13, DOI 10.1016/S0014-5793(99)00461-5; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; Benetti R, 2001, EMBO J, V20, P2702, DOI 10.1093/emboj/20.11.2702; Bestvater F, 2002, BIOTECHNIQUES, V32, P844; Blanchard H, 1996, PROTEIN SCI, V5, P535; BRONK SF, 1993, AM J PHYSIOL, V264, pG744, DOI 10.1152/ajpgi.1993.264.4.G744; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen M, 2002, J BIOL CHEM, V277, P29181, DOI 10.1074/jbc.M204951200; Chen MZ, 1999, J VIROL, V73, P3236, DOI 10.1128/JVI.73.4.3236-3245.1999; Ciruela A, 2000, BIOCHEM J, V346, P587, DOI 10.1042/0264-6021:3460587; Cong M, 1998, J BIOL CHEM, V273, P660, DOI 10.1074/jbc.273.1.660; DAYTON WR, 1981, BIOCHIM BIOPHYS ACTA, V659, P48, DOI 10.1016/0005-2744(81)90270-9; Dutt P, 2000, BIOCHEM J, V348, P37, DOI 10.1042/0264-6021:3480037; Dutt P, 1998, FEBS LETT, V436, P367, DOI 10.1016/S0014-5793(98)01167-3; Elce JS, 1997, BIOCHEM J, V326, P31, DOI 10.1042/bj3260031; Gabrijelcic-Geiger D, 2001, BIOL CHEM, V382, P1733, DOI 10.1515/BC.2001.209; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; GRAHAMSIEGENTHALER K, 1994, J BIOL CHEM, V269, P30457; Guttmann RP, 1998, J BIOL CHEM, V273, P13331, DOI 10.1074/jbc.273.21.13331; Hata S, 2001, FEBS LETT, V501, P111, DOI 10.1016/S0014-5793(01)02611-4; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAVITA U, 1995, J BIOL CHEM, V270, P27758, DOI 10.1074/jbc.270.46.27758; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MELLGREN RL, 1994, BIOCHEM BIOPH RES CO, V204, P544, DOI 10.1006/bbrc.1994.2493; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; Moede T, 1999, FEBS LETT, V461, P229, DOI 10.1016/S0014-5793(99)01446-5; Moldoveanu T, 2002, CELL, V108, P649, DOI 10.1016/S0092-8674(02)00659-1; MURAKAMI T, 1981, J BIOCHEM-TOKYO, V90, P1809, DOI 10.1093/oxfordjournals.jbchem.a133659; MURAMATSU M, 1974, EXP CELL RES, V88, P345, DOI 10.1016/0014-4827(74)90250-X; Nakagawa K, 2001, J BIOCHEM-TOKYO, V130, P605, DOI 10.1093/oxfordjournals.jbchem.a003025; Norris FA, 1997, J BIOL CHEM, V272, P10987; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; Pal GP, 2001, J BIOL CHEM, V276, P47233, DOI 10.1074/jbc.M105149200; Pariat M, 2000, BIOCHEM J, V345, P129, DOI 10.1042/0264-6021:3450129; Piechaczyk M, 2000, METH MOL B, V144, P297; REVILLE WJ, 1976, J CELL BIOL, V70, P1, DOI 10.1083/jcb.70.1.1; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAKIHAMA T, 1985, P NATL ACAD SCI USA, V82, P6075, DOI 10.1073/pnas.82.18.6075; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P275, DOI 10.1093/oxfordjournals.jbchem.a133463; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279; YAMATO S, 1983, BIOCHEM BIOPH RES CO, V115, P715, DOI 10.1016/S0006-291X(83)80203-4; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y; YOSHIZAWA T, 1995, BIOCHEM BIOPH RES CO, V208, P376, DOI 10.1006/bbrc.1995.1348; Zhang WL, 1996, BIOCHEM BIOPH RES CO, V227, P890, DOI 10.1006/bbrc.1996.1601; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	63	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16336	16346		10.1074/jbc.M208657200	http://dx.doi.org/10.1074/jbc.M208657200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591934	Green Published, hybrid			2022-12-27	WOS:000182680000112
J	Gutman, N; Steiner-Mordoch, S; Schuldiner, S				Gutman, N; Steiner-Mordoch, S; Schuldiner, S			An amino acid cluster around the essential Glu-14 is part of the substrate- and proton-binding domain of EmrE, a multidrug transporter from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-TETRACYCLINE/H+ ANTIPORTER; SCANNING MUTAGENESIS; MEMBRANE-PROTEINS; H+; EFFLUX; SITE; MODEL; REVEALS; GENE	EmrE is a small multidrug transporter (110 amino acids long) from Escherichia coli that extrudes various drugs in exchange with protons, thereby rendering bacteria resistant to these compounds. Glu-14 is the only charged membrane-embedded residue in EmrE and is evolutionarily highly conserved. This residue has an unusually high pK and is an essential part of the binding domain, shared by substrates and protons. The occupancy of the binding domain is mutually exclusive, and, as such, this provides the molecular basis for the coupling between substrate and proton fluxes. Systematic cysteine-scanning mutagenesis of the residues in the transmembrane segment (TM1), where Glu-14 is located, reveals an amino acid cluster on the same face of TM1 as Glu-14 that is part of the substrate- and proton-binding domain. Substitutions at most of these positions yielded either inactive mutants or mutants with modified affinity to substrates. Substitutions at the Ala-10 position, one helix turn away from Glu-14, yielded mutants with modified affinity to protons and thereby impaired in the coupling of substrate and proton fluxes. Taken as a whole, the results strongly support the concept of a common binding site for substrate and protons and stress the importance of one face of TM1 in substrate recognition, binding, and H+-coupled transport.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	Shimon.Schuldiner@huji.ac.il	Schuldiner, Shimon/F-7628-2012	Schuldiner, Shimon/0000-0002-4874-6237	NINDS NIH HHS [NS 16708] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Chung Y J, 2001, Curr Opin Drug Discov Devel, V4, P237; Fillingame RH, 2002, BBA-BIOMEMBRANES, V1565, P232, DOI 10.1016/S0005-2736(02)00572-2; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Godsey MH, 2002, J BIOL CHEM, V277, P40169, DOI 10.1074/jbc.R200018200; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kimura T, 1997, J BIOL CHEM, V272, P580; Kimura T, 1998, J BIOL CHEM, V273, P5243, DOI 10.1074/jbc.273.9.5243; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Neyfakh AA, 2002, MOL MICROBIOL, V44, P1123, DOI 10.1046/j.1365-2958.2002.02965.x; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; NINIO S, 2003, IN PRESS J BIOL CHEM, V278; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Torres J, 2000, EUR J BIOCHEM, V267, P3422, DOI 10.1046/j.1432-1327.2000.01324.x; Van Bambeke F, 2000, BIOCHEM PHARMACOL, V60, P457, DOI 10.1016/S0006-2952(00)00291-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	30	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16082	16087		10.1074/jbc.M213120200	http://dx.doi.org/10.1074/jbc.M213120200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12590142	hybrid			2022-12-27	WOS:000182680000080
J	Koike, T; Yamagishi, H; Hatanaka, Y; Fukushima, A; Chang, JW; Xia, Y; Fields, M; Chandler, P; Iwashima, M				Koike, T; Yamagishi, H; Hatanaka, Y; Fukushima, A; Chang, JW; Xia, Y; Fields, M; Chandler, P; Iwashima, M			A novel ERK-dependent signaling process that regulates interleukin-2 expression in a late phase of T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NF-KAPPA-B; MIGRATION INHIBITORY FACTOR; ANTIGEN RECEPTOR; LYMPHOCYTE-PROLIFERATION; SH2 DOMAINS; IL-2 GENE; REL; THETA; TCR	Engagement of the T cell antigen receptor (TCR) rapidly induces multiple signal transduction pathways, including ERR activation. Here, we report a critical role for ERK at a late stage of T cell activation. Inhibition of the ERK pathway 2-6 h after the start of TCR stimulation significantly impaired interleukin-2 (IL-2) production, whereas the same treatment during the first 2 h had no effect. ERK inhibition significantly impaired nuclear translocation of c-Rel with a minimum reduction of NF-AT activity. Requirement for sustained ERK activation was also confirmed using primary T cells. To induce sustained activation of ERK, T cells required continuous engagement of TCR. Stimulation of T cells with soluble anti-TCR antibody resulted in activation of ERK lasting for 60 min, but failed to induce IL-2 production. In contrast, plate-bound anti-TCR antibody activated ERK over 4 h and induced IL-2. Furthermore, T cells treated with soluble anti-TCR antibody produced IL-2 when phorbol 12-myristate 13-acetate, which activates ERK, was present in the culture medium 2-6 h after the start of stimulation. Together, the data demonstrate the presence of a novel activation process following TCR stimulation that requires ERK-dependent regulation of c-Rel, a member of the NF-kappaB family.	Med Coll Georgia, Program Mol Immunol, Inst Mol Med & Genet, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Iwashima, M (corresponding author), Med Coll Georgia, Program Mol Immunol, Inst Mol Med & Genet, CA2004,1120 15th St, Augusta, GA 30912 USA.				NIAID NIH HHS [5R01 AI 47266] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047266] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman A, 2000, IMMUNOL TODAY, V21, P567, DOI 10.1016/S0167-5699(00)01749-7; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Ebinu JO, 2000, BLOOD, V95, P3199; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hogquist KA, 2001, CURR OPIN IMMUNOL, V13, P225, DOI 10.1016/S0952-7915(00)00208-9; Iwashima M, 2002, P NATL ACAD SCI USA, V99, P4544, DOI 10.1073/pnas.082647499; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZQUIERDO M, 1994, EUR J IMMUNOL, V24, P2462, DOI 10.1002/eji.1830241031; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Lanzavecchia A, 1997, J EXP MED, V185, P1717, DOI 10.1084/jem.185.10.1717; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Liou HC, 1999, INT IMMUNOL, V11, P361, DOI 10.1093/intimm/11.3.361; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; MEUER SC, 1986, J IMMUNOL, V136, P4106; MEUER SC, 1983, J EXP MED, V158, P988, DOI 10.1084/jem.158.3.988; MISHELL B, 1980, SELECTED METHODS CEL, P227; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Roose J, 2000, NAT IMMUNOL, V1, P275, DOI 10.1038/79713; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Venkataraman L, 1996, J IMMUNOL, V157, P1149; VENKATARAMAN L, 1995, J EXP MED, V181, P1091, DOI 10.1084/jem.181.3.1091; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; Yamasaki S, 1996, MOL CELL BIOL, V16, P7151; Zelenika D, 1998, J IMMUNOL, V161, P1868; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200	40	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15685	15692		10.1074/jbc.M210829200	http://dx.doi.org/10.1074/jbc.M210829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595531	hybrid			2022-12-27	WOS:000182680000030
J	Ning, Q; Lakatoo, S; Liu, MF; Yang, WM; Wang, ZM; Phillips, MJ; Levy, GA				Ning, Q; Lakatoo, S; Liu, MF; Yang, WM; Wang, ZM; Phillips, MJ; Levy, GA			Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; CORE PROTEIN; DNA-BINDING; C VIRUS; TRANSCRIPTION FACTORS; STRUCTURAL PROTEIN; GENE-EXPRESSION; RECEPTOR HNF-4; PROMOTER; PHOSPHORYLATION	Fibrinogen-like protein 2/fibroleukin (Fgl2) plays a pivotal role in the pathogenesis of both experimental and human fulminant hepatic failure. We have reported recently that the nucleocapsid (N) protein from strains of murine hepatitis virus (MHV-3, NLRV-A59), which cause massive hepatocellular necrosis but not from strains (MHV-JHM, MHV-2) which do not produce serious liver disease, induces transcription of fgl2. The purpose of the present study was to characterize both viral and host factor(s) necessary for viral induced transcription of fgl2. Mutation of residues Gly-12, Pro-38, Asn-40, Gln-41, and Asn-42 within domain 1 of the N protein of MHV-A59 to their corresponding residues found in MHV-2 abrogated. fgl2 transcription, whereas mutation of other N protein domains, including a protein expressed from an internal reading frame (1 protein), did not affect fgl2 gene transcription. We then examined the -372 to -306 sequence within the 1.3-kb fgl2 promoter region upstream from the transcription start site that was previously identified as necessary for N protein-induced gene transcription. We demonstrated that the -331/-325 HNF4 cis-element and its cognate transcription factor, HNF4alpha, are necessary for virus-induced fgl2 gene transcription. In uninfected macrophages and macrophages infected with MHV-2, an unidentified protein occupies the HNF4 cis-element. Following stimulation with AHW-A59, it was shown by electrophoretic mobility shift assay that HNF4alpha binds the HNF4 cis-element in the fgl2 promoter. We further report the unprecedented presence of HNF4alpha in peritoneal macrophages. Collectively, the results of this study define both viral and host factors necessary for induction of fgl2 prothrombinase gene transcription in MHV infection and may provide an explanation for the hepatotrophic nature of MHV-induced fulminant hepatic failure.	Univ Toronto, Toronto Gen Hosp, Multi Organ Transplant Program, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto Gen Hosp, Dept Pathol & Med, Toronto, ON M5G 2C4, Canada; Huazhong Univ Sci & Technol, Tongji Med Coll, Inst Immunol, Tongji Hosp,Dept Infect Dis, Wuhan 430030, Peoples R China	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Huazhong University of Science & Technology	Levy, GA (corresponding author), Univ Toronto, Toronto Gen Hosp, Multi Organ Transplant Program, 621 Univ Ave,NU 10-116, Toronto, ON M5G 2C4, Canada.	glfg12@attglobal.net						Attard FA, 2000, ARCH BIOCHEM BIOPHYS, V378, P57, DOI 10.1006/abbi.2000.1803; BARIC RS, 1988, J VIROL, V62, P4280, DOI 10.1128/JVI.62.11.4280-4287.1988; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; DECIMO D, 1993, ARCH VIROL, V130, P279, DOI 10.1007/BF01309660; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; DESIMONE V, 1992, BIOCHIM BIOPHYS ACTA, V1132, P119, DOI 10.1016/0167-4781(92)90001-G; Ding JW, 1997, J VIROL, V71, P9223, DOI 10.1128/JVI.71.12.9223-9230.1997; ERDMANN D, 1995, J BIOL CHEM, V270, P22988, DOI 10.1074/jbc.270.39.22988; Farsetti A, 1998, ENDOCRINOLOGY, V139, P4581, DOI 10.1210/en.139.11.4581; FernandezRachubinski FA, 1996, J BIOL CHEM, V271, P29502, DOI 10.1074/jbc.271.46.29502; Fischer F, 1997, J VIROL, V71, P996, DOI 10.1128/JVI.71.2.996-1003.1997; Fukai K, 1997, VIROLOGY, V236, P279, DOI 10.1006/viro.1997.8750; HU CH, 1995, J BIOL CHEM, V270, P28342; Jiang GQ, 1997, MOL CELL BIOL, V17, P6546, DOI 10.1128/MCB.17.11.6546; Jiang GQ, 1997, ARCH BIOCHEM BIOPHYS, V340, P1, DOI 10.1006/abbi.1997.9914; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; KUNITA S, 1993, VIROLOGY, V193, P520, DOI 10.1006/viro.1993.1158; LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; LAPPS W, 1987, VIROLOGY, V157, P47, DOI 10.1016/0042-6822(87)90312-6; Large MK, 1999, J IMMUNOL, V162, P931; LAVI E, 1990, LAB INVEST, V62, P570; LEVY GA, 1984, SEMIN LIVER DIS, V4, P59, DOI 10.1055/s-2008-1040646; LEVY GA, 1983, HEPATOLOGY, V3, P964; Levy GA, 2000, AM J PATHOL, V156, P1217, DOI 10.1016/S0002-9440(10)64992-9; LI C, 1992, J EXP MED, V176, P689, DOI 10.1084/jem.176.3.689; MASTERS PS, 1990, ADV EXP MED BIOL, V276, P239; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; MIAO CH, 1992, J BIOL CHEM, V267, P7395; Moldrup A, 1996, MOL ENDOCRINOL, V10, P661, DOI 10.1210/me.10.6.661; Naka H, 1996, BRIT J HAEMATOL, V92, P231, DOI 10.1046/j.1365-2141.1995.269804.x; NELSON GW, 1993, J GEN VIROL, V74, P1975, DOI 10.1099/0022-1317-74-9-1975; Ning Q, 1998, J IMMUNOL, V160, P3487; Ning Q, 1999, J BIOL CHEM, V274, P9930, DOI 10.1074/jbc.274.15.9930; Norris RA, 2001, J BIOL CHEM, V276, P26829, DOI 10.1074/jbc.M100239200; PARKER MM, 1990, VIROLOGY, V179, P463, DOI 10.1016/0042-6822(90)90316-J; PENG D, 1995, J VIROL, V69, P3449, DOI 10.1128/JVI.69.6.3449-3457.1995; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; Rasul I, 1999, HEPATOLOGY, V30, p594A; Reddy S, 1999, J BIOL CHEM, V274, P33050, DOI 10.1074/jbc.274.46.33050; Rouet P, 1998, BIOCHEM J, V334, P577, DOI 10.1042/bj3340577; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; Simpson KJ, 1997, J HEPATOL, V27, P1120, DOI 10.1016/S0168-8278(97)80160-2; SLADEK FM, 1993, RECEPTOR, V3, P223; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STOHLMAN SA, 1988, J VIROL, V62, P4288, DOI 10.1128/JVI.62.11.4288-4295.1988; Tahara SM, 1998, ADV EXP MED BIOL, V440, P313; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Webster G, 2000, BEST PRACT RES CL GA, V14, P229, DOI 10.1053/bega.1999.0072; Wurm T, 2001, J VIROL, V75, P9345, DOI 10.1128/JVI.75.19.9345-9356.2001; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yamada K, 1997, BIOCHEM J, V324, P917, DOI 10.1042/bj3240917; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871	56	38	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15541	15549		10.1074/jbc.M212806200	http://dx.doi.org/10.1074/jbc.M212806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594208	hybrid			2022-12-27	WOS:000182680000012
J	Fukuda, M				Fukuda, M			Slp4-a/granuphilin-a inhibits dense-core vesicle exocytosis through interaction with the GDP-bound form of Rab27A in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT OLIGOMERIZATION; SLP HOMOLOGY DOMAIN; TANDEM C2 DOMAINS; MYOSIN-VA; MELANOSOME TRANSPORT; SYNAPTOTAGMIN FAMILY; REGULATED SECRETION; GRISCELLI-SYNDROME; BINDING DOMAIN; ASHEN MICE	Slp4-a (synaptotagmin-like protein 4-a)/granuphilin-a is specifically localized on dense-core vesicles in PC12 cells and negatively controls dense-core vesicle exocytosis through specific interaction with Rab27A via the N-terminal Slp homology domain (SHD) (Fukuda, M., Kanno, E., Saegusa, C., Ogata, Y., and Kuroda, T. S. (2002) J. Biol. Chem. 277, 39673-39678). However, the mechanism of the inhibition by Slp4-a has never been elucidated at the molecular level and is still a matter of controversy. In this study, I discovered an unexpected biochemical property of Slp4-a, that Slp4-a, but not other Rab27 effectors reported thus far, is capable of interacting with both Rab27A(T23N), a dominant negative form that mimics the GDP-bound form, and Rab27A(Q78L), a dominant active form that mimics the GTP-bound form, whereas Slp4-a specifically recognizes the GTP-bound form of Rab3A and Rab8A and does not recognize their GDP-bound form. I show by deletion and mutation analyses that the TGDWFY sequence in SHD2 is essential for Rab27A(T23N) binding, whereas SHD1 is involved in Rab27A(Q78L) binding. I further show by immunoprecipitation and cotransfection assays that Aluncl.8-1, but not syntaxin IA, directly interacts with the C-terminal domain of Slp4-a in a Rab27A-independent manner. Expression of Slp4-a mutants that lack Rab27A(T23N) binding activity (i.e. specific binding to Rab27A(Q78L)) completely reverses the inhibitory effect of the wild-type Slp4-a on high KCl-dependent neuropeptide Y secretion in PC 12 cells. The results strongly indicate that interaction of Slp4-a with the GDP-bound form of Rab27A, not with syntaxin IA or Munc18-1, is the primary reason that Slp4-a expression inhibits dense core vesicle exocytosis in PC12 cells.	RIKEN, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	mnfukuda@brain.riken.go.jp	Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853				Bahadoran P, 2003, J BIOL CHEM, V278, P11386, DOI 10.1074/jbc.M211996200; Berkowitz JKM, 2001, J BIOL CHEM, V276, P18855, DOI 10.1074/jbc.M011167200; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Fukuda M, 2002, J BIOL CHEM, V277, P30351, DOI 10.1074/jbc.M204056200; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Fukuda M, 2002, J BIOL CHEM, V277, P40118, DOI 10.1074/jbc.M205765200; Fukuda M, 2002, J BIOL CHEM, V277, P39673, DOI 10.1074/jbc.M205349200; Fukuda M, 2002, J BIOL CHEM, V277, P43096, DOI 10.1074/jbc.M203862200; Fukuda M, 2002, BIOCHEM J, V366, P681, DOI 10.1042/BJ20020484; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; FUKUDA M, 2002, RRD NEUROCHEMISTRY, V5, P297; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Torii S, 2002, MOL CELL BIOL, V22, P5518, DOI 10.1128/MCB.22.15.5518-5526.2002; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Zhao SL, 2002, ENDOCRINOLOGY, V143, P1817, DOI 10.1210/en.143.5.1817	40	56	63	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15390	15396		10.1074/jbc.M213090200	http://dx.doi.org/10.1074/jbc.M213090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590134	hybrid			2022-12-27	WOS:000182516100104
J	Murray, J; Zhang, B; Taylor, SW; Oglesbee, D; Fahy, E; Marusich, MF; Ghosh, SS; Capaldi, RA				Murray, J; Zhang, B; Taylor, SW; Oglesbee, D; Fahy, E; Marusich, MF; Ghosh, SS; Capaldi, RA			The subunit composition of the human NADH dehydrogenase obtained by rapid one-step immunopurification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL COMPLEX-I; UBIQUINONE OXIDOREDUCTASE; RESPIRATORY-CHAIN; PROTEIN; IDENTIFICATION; LOCALIZATION; GRIM-19; MUSCLE	Defects of the NADH dehydrogenase complex are predominantly manifested in mitochondrial diseases and are significantly associated with the development of many late onset neurological disorders such as Parkinson's disease. Here we describe an immunocapture procedure for isolating this multisubunit membrane-bound complex from human tissue. Using small amounts of immunoisolated protein, one-dimensional and two-dimensional gel electrophoresis, matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) peptide mass finger printing (PMF), and nanoflow liquid chromatography mass spectrometry/mass spectrometry (LCMS/MS), we can resolve and identify the human homologues of 42 polypeptides detected so far in the more extensively studied beef heart complex 1. These polypeptides include the GRIM-19 protein, which is claimed to be involved in apoptosis, a polypeptide first identified by gene screening a's a neuronal protein, as well as a protein thought to be in differentiation linked processes. The concordance of data from human and bovine complex I isolated by different procedures adds to the certainty that these novel proteins of seemingly diverse function are a part of complex 1.	Univ Oregon, Dept Mol Biol, Eugene, OR 97403 USA; MitoKor, San Diego, CA 92121 USA	University of Oregon	Capaldi, RA (corresponding author), Univ Oregon, Dept Mol Biol, 13th St, Eugene, OR 97403 USA.	rcapaldi@oregon.uoregon.edu	Marusich, Michael/AAQ-3447-2020	Oglesbee, Devin/0000-0002-7147-5527				Aggeler R, 2002, J BIOL CHEM, V277, P33906, DOI 10.1074/jbc.M204538200; ALI ST, 1993, GENOMICS, V18, P435, DOI 10.1006/geno.1993.1493; Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; Arenas J, 1998, ANN NEUROL, V43, P397, DOI 10.1002/ana.410430321; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Dror N, 2002, MOL PSYCHIATR, V7, P995, DOI 10.1038/sj.mp.4001116; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; DUNCAN AMV, 1992, CYTOGENET CELL GENET, V60, P212, DOI 10.1159/000133340; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Hanson BJ, 2001, ELECTROPHORESIS, V22, P950, DOI 10.1002/1522-2683()22:5<950::AID-ELPS950>3.0.CO;2-D; Kim SH, 2001, LIFE SCI, V68, P2741, DOI 10.1016/S0024-3205(01)01074-8; Lenaz G, 2000, BBA-BIOENERGETICS, V1459, P397, DOI 10.1016/S0005-2728(00)00177-8; LIB M, 2003, IN PRESS ANAL BIOCH; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Skehel JM, 1998, FEBS LETT, V438, P301, DOI 10.1016/S0014-5793(98)01317-9; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Taylor SW, 2002, J PROTEOME RES, V1, P451, DOI 10.1021/pr025533g; Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397; Vielhaber S, 1999, J NEUROL SCI, V169, P133, DOI 10.1016/S0022-510X(99)00236-1; Vielhaber S, 2001, J NEUROPATH EXP NEUR, V60, P1032, DOI 10.1093/jnen/60.11.1032	27	83	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13619	13622		10.1074/jbc.C300064200	http://dx.doi.org/10.1074/jbc.C300064200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12611891	hybrid			2022-12-27	WOS:000182405000008
J	Trudeau, MC; Zagotta, WN				Trudeau, MC; Zagotta, WN			Calcium/calmodulin modulation of olfactory and rod cyclic nucleotide-gated ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GMP-ACTIVATED CONDUCTANCE; FUNCTIONAL EXPRESSION; CATION CHANNEL; BETA-SUBUNIT; CONE PHOTORECEPTORS; CALCIUM MODULATION; VERTEBRATE ROD; CNG CHANNEL; CALMODULIN; MECHANISM	Cyclic nucleotide-gated (CNG) ion channels mediate sensory transduction in olfactory sensory neurons and retinal photoreceptor cells. In these systems, internal calcium/calmodulin (Ca2+/CaM) inhibits CNG channels, thereby having a putative role in sensory adaptation. Functional differences in Ca2+/CaM-dependent inhibition depend on the different subunit composition of olfactory and rod CNG channels. Recent evidence shows that three subunit types (CNGA2, CNGA4, and CNGB1b) make up native olfactory CNG channels and account for the fast inhibition of native channels by Ca2+/CaM. In contrast, two subunit types (CNGA1 and CNGB1) appear sufficient to mirror the native properties of rod CNG channels, including the inhibition by Ca2+/CaM. Within CNG channel tetramers, specific subunit interactions also mediate Ca2+/CaM-dependent inhibition. In olfactory CNGA2 channels, Ca2+/CaM binds to an N-terminal region and disrupts an interaction between the N- and C-terminal regions, causing inhibition. Ca2+/CaM also binds the N-terminal region of CNGB1 subunits and disrupts an intersubunit, N- and C-terminal interaction between CNGB1 and CNGA1 subunits in rod channels. However, the precise N- and C-terminal regions that form these interactions in olfactory channels are different from those in rod channels. Here, we will review recent advances in understanding the subunit composition and the mechanisms and roles for Ca2+/CaM-dependent inhibition in olfactory and rod CNG channels.	Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Zagotta, WN (corresponding author), Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Box 357370, Seattle, WA 98195 USA.				NATIONAL EYE INSTITUTE [R01EY010329, T32EY007031] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY010329-10, T32 EY07031, R01 EY010329] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bauer PJ, 1996, J PHYSIOL-LONDON, V494, P675, DOI 10.1113/jphysiol.1996.sp021523; Baylor DA, 1998, EYE, V12, P521, DOI 10.1038/eye.1998.140; Bonigk W, 1999, J NEUROSCI, V19, P5332; Bonigk W, 1996, J NEUROSCI, V16, P7458; Bradley J, 2001, SCIENCE, V294, P2176, DOI 10.1126/science.1063415; Bradley J, 2001, SCIENCE, V294, P2095, DOI 10.1126/science.294.5549.2095; Burns ME, 2002, NEURON, V36, P81, DOI 10.1016/S0896-6273(02)00911-X; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHEN TY, 1994, P NATL ACAD SCI USA, V91, P11757, DOI 10.1073/pnas.91.24.11757; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Erickson MG, 2001, NEURON, V31, P973, DOI 10.1016/S0896-6273(01)00438-X; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Flynn GE, 2001, NAT REV NEUROSCI, V2, P643, DOI 10.1038/35090015; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; Gerstner A, 2000, J NEUROSCI, V20, P1324; GORDON SE, 1995, J PHYSIOL-LONDON, V486, P533, DOI 10.1113/jphysiol.1995.sp020832; GORDON SE, 1995, NEURON, V14, P177; GOULDING EH, 1994, NATURE, V372, P369, DOI 10.1038/372369a0; Grunwald ME, 1999, P NATL ACAD SCI USA, V96, P13444, DOI 10.1073/pnas.96.23.13444; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; Hackos DH, 1997, J GEN PHYSIOL, V110, P515, DOI 10.1085/jgp.110.5.515; HAYNES LW, 1992, J GEN PHYSIOL, V100, P783, DOI 10.1085/jgp.100.5.783; HAYNES LW, 1990, J PHYSIOL-LONDON, V429, P451, DOI 10.1113/jphysiol.1990.sp018267; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Kelliher KR, 2003, P NATL ACAD SCI USA, V100, P4299, DOI 10.1073/pnas.0736071100; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; KOUTALOS Y, 1995, J GEN PHYSIOL, V106, P891, DOI 10.1085/jgp.106.5.891; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; Kurahashi T, 1997, NATURE, V385, P725, DOI 10.1038/385725a0; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; MCLATCHIE LM, 1992, P ROY SOC B-BIOL SCI, V247, P113, DOI 10.1098/rspb.1992.0016; Menini A, 1999, CURR OPIN NEUROBIOL, V9, P419, DOI 10.1016/S0959-4388(99)80063-4; Muller F, 2001, J PHYSIOL-LONDON, V532, P399, DOI 10.1111/j.1469-7793.2001.0399f.x; Munger SD, 2001, SCIENCE, V294, P2172, DOI 10.1126/science.1063224; NAKATANI K, 1995, J PHYSIOL-LONDON, V484, P69, DOI 10.1113/jphysiol.1995.sp020648; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; QUANDT FN, 1991, NEUROSCIENCE, V42, P629, DOI 10.1016/0306-4522(91)90032-J; Rebrik TI, 1998, J GEN PHYSIOL, V112, P537, DOI 10.1085/jgp.112.5.537; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Richards MJ, 2000, BIOCHEMISTRY-US, V39, P14003, DOI 10.1021/bi001639i; Sautter A, 1998, P NATL ACAD SCI USA, V95, P4696, DOI 10.1073/pnas.95.8.4696; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; STERN JH, 1986, P NATL ACAD SCI USA, V83, P1163, DOI 10.1073/pnas.83.4.1163; Sunderman ER, 1999, J GEN PHYSIOL, V113, P601, DOI 10.1085/jgp.113.5.601; Takeuchi H, 2002, J PHYSIOL-LONDON, V541, P825, DOI 10.1113/jphysiol.2002.016600; TANAKA JC, 1989, BIOCHEMISTRY-US, V28, P2776, DOI 10.1021/bi00433a006; Trudeau MC, 2002, P NATL ACAD SCI USA, V99, P8424, DOI 10.1073/pnas.122015999; Trudeau MC, 2002, NEURON, V34, P197, DOI 10.1016/S0896-6273(02)00647-5; Varnum MD, 1996, BIOPHYS J, V70, P2667, DOI 10.1016/S0006-3495(96)79836-3; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; Weitz D, 2002, NEURON, V36, P881, DOI 10.1016/S0896-6273(02)01098-X; Weitz D, 1998, EMBO J, V17, P2273, DOI 10.1093/emboj/17.8.2273; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; Zheng J, 2002, NEURON, V36, P891, DOI 10.1016/S0896-6273(02)01099-1; Zhong HM, 2002, NATURE, V420, P193, DOI 10.1038/nature01201; Zimmerman AL, 2002, NEURON, V36, P997, DOI 10.1016/S0896-6273(02)01139-X; Zufall F, 2000, CHEM SENSES, V25, P473, DOI 10.1093/chemse/25.4.473; Zufall F, 2001, TRENDS NEUROSCI, V24, P191, DOI 10.1016/S0166-2236(00)01765-3	67	86	89	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18705	18708		10.1074/jbc.R300001200	http://dx.doi.org/10.1074/jbc.R300001200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626507	hybrid			2022-12-27	WOS:000182932200001
J	Xiao, KY; Allison, DF; Kottke, MD; Summers, S; Sorescu, GP; Faundez, V; Kowalczyk, AP				Xiao, KY; Allison, DF; Kottke, MD; Summers, S; Sorescu, GP; Faundez, V; Kowalczyk, AP			Mechanisms of VE-cadherin processing and degradation in microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; DESMOPLAKIN-CONTAINING JUNCTIONS; PROTEIN-KINASE-C; BETA-CATENIN; IN-VITRO; COMPLEXUS ADHAERENTES; CYTOPLASMIC DOMAIN; BARRIER FUNCTION; P120 CATENIN; N-CADHERIN	VE-cadherin is an endothelial-specific cadherin that plays important roles in vascular morphogenesis and growth control. To investigate the mechanisms by which endothelial cells regulate cadherin cell surface levels, a VE-cadherin mutant containing the non-adhesive interleukin-2 (IL-2) receptor extracellular domain and the VE-cadherin cytoplasmic tail (IL-2R-VE-cad(cyto)) was expressed in microvascular endothelial cells. Expression of the IL-2R-VE-cad(cyto) mutant resulted in the internalization of endogenous VE-cadherin and in a dramatic decrease in endogenous VE-cadherin levels. The internalized VE-cadherin co-localized with early endosomes, and the lysosomal inhibitor chloroquine dramatically inhibited the down-regulation of VE-cadherin in cells expressing the IL-2R-VE-cad(cyto) mutant. Chloroquine treatment also resulted in the accumulation of a VE-cadherin fragment lacking the beta-catenin binding domain of the VE-cadherin cytoplasmic tail. The formation of the VE-cadherin fragment could be prevented by treating endothelial cells with proteasome inhibitors. Furthermore, inhibition of the proteasome prevented VE-cadherin internalization and inhibited the disruption of endothelial intercellular junctions by the IL-2RVEcad(cyto) mutant. These results provide new insights into the mechanisms of VE-cadherin processing and degradation in microvascular endothelial cells.	Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Emory Skin Dis Res Ctr, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Kowalczyk, AP (corresponding author), Emory Univ, Sch Med, Dept Dermatol, Woodruff Mem Bldg,Rm 5007, Atlanta, GA 30322 USA.			Faundez, Victor/0000-0002-2114-5271	NIAMS NIH HHS [R01 AR048266, P30AR042687] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048266, P30AR042687] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERLE H, 1994, J CELL SCI, V107, P3655; Alexander JS, 1998, INFLAMMATION, V22, P419, DOI 10.1023/A:1022325017013; AMAGAI M, 1995, J INVEST DERMATOL, V104, P27, DOI 10.1111/1523-1747.ep12613462; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Angst BD, 2001, J CELL SCI, V114, P629; Bazzoni G, 2001, MICROCIRCULATION, V8, P143, DOI 10.1038/sj.mn.7800084; Benelli R, 1999, INT J BIOL MARKER, V14, P243, DOI 10.1177/172460089901400408; Bobryshev YV, 1999, CARDIOVASC RES, V43, P1003, DOI 10.1016/S0008-6363(99)00125-X; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Dejana E, 2001, THROMB HAEMOSTASIS, V86, P308; Frid MG, 2002, CIRC RES, V90, P1189, DOI 10.1161/01.RES.0000021432.70309.28; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gottardi CJ, 2001, CURR BIOL, V11, pR792, DOI 10.1016/S0960-9822(01)00473-0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1940, DOI 10.1152/ajpcell.2001.281.6.C1940; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kowalczyk AP, 1998, J CELL SCI, V111, P3045; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Miller JR, 1997, DEV BIOL, V192, P323, DOI 10.1006/dbio.1997.8740; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; Nieman MT, 1999, J CELL SCI, V112, P1621; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Norvell SM, 1998, J CELL SCI, V111, P1305; Pham CG, 2000, AM J PHYSIOL-HEART C, V279, pH2916, DOI 10.1152/ajpheart.2000.279.6.H2916; SCHMELZ M, 1994, DIFFERENTIATION, V57, P97, DOI 10.1046/j.1432-0436.1994.5720097.x; SCHMELZ M, 1993, EUR J CELL BIOL, V61, P274; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Stevens T, 2000, AM J PHYSIOL-LUNG C, V279, pL419, DOI 10.1152/ajplung.2000.279.3.L419; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Troxell ML, 1999, AM J PHYSIOL-CELL PH, V276, pC404, DOI 10.1152/ajpcell.1999.276.2.C404; Valiron O, 1996, J CELL SCI, V109, P2141; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; van Kerkhof P, 2001, BIOCHEM SOC T, V29, P488, DOI 10.1042/BST0290488; Venkiteswaran K, 2002, AM J PHYSIOL-CELL PH, V283, pC811, DOI 10.1152/ajpcell.00417.2001; Zhu AJ, 1996, J CELL SCI, V109, P3013	50	122	123	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19199	19208		10.1074/jbc.M211746200	http://dx.doi.org/10.1074/jbc.M211746200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626512	hybrid			2022-12-27	WOS:000182932200064
J	Buch-Pedersen, MJ; Palmgren, MG				Buch-Pedersen, MJ; Palmgren, MG			Conserved Asp(684) in transmembrane segment M6 of the plant plasma membrane P-type proton pump AHA2 is a molecular determinant of proton translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; H+-ATPASE; SARCOPLASMIC-RETICULUM; ALPHA-SUBUNIT; COORDINATING RESIDUES; RENAL NA,K-ATPASE; CALCIUM-PUMP; K+ IONS; BACTERIORHODOPSIN; TRANSPORT	The mechanism of proton pumping by P-type H+-ATPases is still unclear. In the plant P-type plasma membrane H+-ATPase AHA2, two charged residues, Arg(655) and Asp(684), are conserved in transmembrane segments M5 and M6, respectively, a region that has been shown be contribute to ion coordination in related P-type ATPases. Substitution of Arg(655) with either alanine or aspartate resulted in mutant enzymes exhibiting a significant shift in the P-type ATPase E1P-E2P conformational equilibrium. The mutant proteins accumulated in the E1P conformation, but were capable of conducting proton transport. This points to an important role of Arg(655) in the E1P-E2P conformational transition. The presence of a carboxylate moiety at position Asp(684) proved essential for coupling between initial proton binding and proton pumping. The finding that the carboxylate side chain of Asp(684) contributes to the proton-binding site and appears to function as an absolutely essential proton acceptor along the proton transport pathway is discussed in the context of a possible proton pumping mechanism of P-type H+-ATPases.	Royal Vet & Agr Univ, Dept Plant Biol, DK-1871 Frederiksberg C, Denmark; Univ Paris 06, CNRS, F-75252 Paris, France	University of Copenhagen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Palmgren, MG (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.	palmgren@biobase.dk	Palmgren, Michael/A-9808-2013	Palmgren, Michael/0000-0002-9982-6114				Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISKIN DP, 1992, J EXP BOT, V43, P269, DOI 10.1093/jxb/43.3.269; Buch-Pedersen MJ, 2000, J BIOL CHEM, V275, P39167, DOI 10.1074/jbc.M007537200; Bukrinsky JT, 2001, FEBS LETT, V494, P6, DOI 10.1016/S0014-5793(01)02301-8; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Fillingame RH, 2000, J EXP BIOL, V203, P9; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Gatto C, 1999, J BIOL CHEM, V274, P13737, DOI 10.1074/jbc.274.20.13737; Govindjee R, 1996, BIOPHYS J, V71, P1011, DOI 10.1016/S0006-3495(96)79302-5; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Lanfermeijer FC, 1998, PROTEIN EXPRES PURIF, V12, P29, DOI 10.1006/prep.1997.0788; Lanyi JK, 1997, J BIOL CHEM, V272, P31209, DOI 10.1074/jbc.272.50.31209; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; MOGI T, 1988, P NATL ACAD SCI USA, V85, P4148, DOI 10.1073/pnas.85.12.4148; MOLLER M, 1986, ADV PINEAL RES, V1, P51; Morsomme P, 2000, BBA-BIOMEMBRANES, V1465, P1, DOI 10.1016/S0005-2736(00)00128-0; MRABET NT, 1992, BIOCHEMISTRY-US, V31, P2239, DOI 10.1021/bi00123a005; Neutze R, 2002, BBA-BIOMEMBRANES, V1565, P144, DOI 10.1016/S0005-2736(02)00566-7; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Palmgren MG, 2001, ANNU REV PLANT PHYS, V52, P817, DOI 10.1146/annurev.arplant.52.1.817; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; SUBRAMANIAM S, 1990, P NATL ACAD SCI USA, V87, P1013, DOI 10.1073/pnas.87.3.1013; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VENEMA K, 1995, J BIOL CHEM, V270, P19659, DOI 10.1074/jbc.270.33.19659; VIK SB, 1994, J BIOL CHEM, V269, P30364; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	39	33	36	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17845	17851		10.1074/jbc.M212729200	http://dx.doi.org/10.1074/jbc.M212729200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626496	hybrid			2022-12-27	WOS:000182838300033
J	Flanagan, JJ; Chen, JC; Miao, YW; Shao, YL; Lin, JL; Bock, PE; Johnson, AE				Flanagan, JJ; Chen, JC; Miao, YW; Shao, YL; Lin, JL; Bock, PE; Johnson, AE			Signal recognition particle binds to ribosome-bound signal sequences with fluorescence-detected subnanomolar affinity that does not diminish as the nascent chain lengthens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; AMINOACYL-TRANSFER-RNA; ELONGATION-FACTOR-TU; PROTEIN TRANSLOCATION; MICROSOMAL-MEMBRANES; ER MEMBRANE; PRESECRETORY PROTEINS; BLOOD-COAGULATION; SECRETORY PROTEIN; ACTIVE-SITE	The binding of signal recognition particle (SRP) to ribosome-bound signal sequences has been characterized directly and quantitatively using fluorescence spectroscopy. A fluorescent probe was incorporated co-translationally into the signal sequence of a ribosome.nascent chain complex (RNC), and upon titration with SRP, a large and saturable increase in fluorescence intensity was observed. Spectral analyses of SRP and RNC association as a function of concentration allowed us to measure, at equilibrium, K-d values of 0.05-0.38 nM for SRP.RNC complexes with different signal sequences. Competitive binding experiments with nonfluorescent RNC species revealed that the nascent chain probe did not alter SRP affinity and that SRP has significant affinity for both nontranslating ribosomes (K-d = 71 nM) and RNCs that lack an exposed signal sequence (K-d = 8 nM). SRP can therefore distinguish between translating and nontranslating ribosomes. The very high signal sequence-dependent SRP.RNC affinity did not decrease as the nascent chain lengthened. Thus, the inhibition of SRP-dependent targeting of RNCs to the endoplasmic reticulum membrane observed with long nascent chains does not result from reduced SRP binding to the signal sequence, as widely thought, but rather from a subsequent step, presumably nascent chain interference of SRP.RNC association with the SRP receptor and/or translocon.	Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of Oklahoma System; University of Oklahoma Health Sciences Center; Vanderbilt University	Johnson, AE (corresponding author), TAMUS HSC, Coll Med, TAMU 1114, 116 Reynolds Med Bldg, College Stn, TX 77843 USA.		Johnson, Arthur E/G-3457-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038779, R01HL038779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494, T32GM008523] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38779] Funding Source: Medline; NIGMS NIH HHS [GM 26494, T32 GM08523] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON JK, 1985, BIOCHEMISTRY-US, V24, P692, DOI 10.1021/bi00324a023; Bock PE, 1997, J BIOL CHEM, V272, P19837, DOI 10.1074/jbc.272.32.19837; BOCK PE, 1983, J BIOL CHEM, V258, P5079; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; GAUT JR, 1993, J BIOL CHEM, V268, P7248; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JANIAK F, 1990, BIOCHEMISTRY-US, V29, P4268, DOI 10.1021/bi00470a002; JANIAK F, 1992, BIOCHEMISTRY-US, V31, P5830, DOI 10.1021/bi00140a019; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JOHNSON AE, 1976, BIOCHEMISTRY-US, V15, P569, DOI 10.1021/bi00648a018; JOHNSON AE, 1982, J MOL BIOL, V156, P113, DOI 10.1016/0022-2836(82)90462-4; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; OGG SC, 1995, CELL, V81, P1075, DOI 10.1016/S0092-8674(05)80012-1; SIEGEL V, 1988, EMBO J, V7, P1769, DOI 10.1002/j.1460-2075.1988.tb03007.x; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; SPERRAZZA JM, 1980, BIOCHEMISTRY-US, V19, P1053, DOI 10.1021/bi00547a001; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wild K, 2002, CURR OPIN STRUC BIOL, V12, P72, DOI 10.1016/S0959-440X(02)00292-0; WOLIN SL, 1993, J CELL BIOL, V121, P1211, DOI 10.1083/jcb.121.6.1211; YE J, 1991, J BIOL CHEM, V266, P23016	33	110	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18628	18637		10.1074/jbc.M300173200	http://dx.doi.org/10.1074/jbc.M300173200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621052	hybrid			2022-12-27	WOS:000182838300135
J	Kamikubo, Y; Takaori-Kondo, A; Uchiyama, T; Hori, T				Kamikubo, Y; Takaori-Kondo, A; Uchiyama, T; Hori, T			Inhibition of cell growth by conditional expression of kpm, a human homologue of Drosophila warts/lats tumor suppressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY KINASE; PROTEIN-KINASE; DAMAGE CHECKPOINT; FISSION YEAST; GENE; PHOSPHORYLATION; CYCLE; APOPTOSIS; ACTIVATION; SEQUENCE	kpm is a human serine/threonine kinase that is homologous to Drosophila tumor suppressor warts/lats and its mammalian homologue LATS1. In order to define the biological function of kpm, we generated stable transfectants of wild-type kpm (kpm-wt), a kinase-dead mutant of kpm (kpm-kd), and luciferase in HeLa Tet-Off cells under the tetracycline-responsive promoter. Western blot analysis showed that high levels of expression of kpm-wt as well as kpm-kd with an apparent mass of 150 kDa were induced after the removal of doxycycline. Induction of kpm-wt expression resulted in a marked decline in viable cell number measured by both trypan blue dye exclusion and MTT assay, whereas that of kpm-kd or luciferase had no effect. We then analyzed the cell cycle progression and apoptosis upon induction of kpm expression. 2-3 days after removal of doxycycline, cells underwent G(2)/M arrest, demonstrated by flow cytometric analysis of propidium iodide incorporation and MPM-2 reactivity. In vitro kinase assay showed that induction of kpm-wt led to down-regulation of kinase activity of the Cdc2-cyclin B complex, which was accompanied by an increase in the hyperphosphorylated form of Cdc2 and a change of phosphorylation status of Cdc25C. Furthermore, both DAPI staining and TUNEL assay showed that the proportion of apoptotic cells increased as kpm expression was induced. Taken together, these results indicate that kpm negatively regulates cell growth by inducing G(2)/M arrest and apoptotic cell death through its kinase activity.	Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Hori, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Hematol & Oncol, Sakyo Ku, 54 Shogoin Kawaracho, Kyoto 6068507, Japan.							CHOU CF, 1994, J CELL SCI, V107, P1833; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; GOLD R, 1994, LAB INVEST, V71, P219; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hori T, 2000, ONCOGENE, V19, P3101, DOI 10.1038/sj.onc.1203659; HULL HM, 1982, STAIN TECHNOL, V57, P273, DOI 10.3109/10520298209066723; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; KNEHR M, 1995, EXP CELL RES, V217, P546, DOI 10.1006/excr.1995.1121; KOEFFLER HP, 1980, BLOOD, V56, P265; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Morisaki T, 2002, FEBS LETT, V529, P319, DOI 10.1016/S0014-5793(02)03360-4; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; Ohashi A, 2001, BIOL REPROD, V65, P1195, DOI 10.1095/biolreprod65.4.1195; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rennel E, 2002, ANAL BIOCHEM, V309, P79, DOI 10.1016/S0003-2697(02)00250-6; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stebbins MJ, 2001, P NATL ACAD SCI USA, V98, P10775, DOI 10.1073/pnas.121186498; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Valverde P, 2000, BIOCHEM BIOPH RES CO, V276, P990, DOI 10.1006/bbrc.2000.3582; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x	37	60	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17609	17614		10.1074/jbc.M211974200	http://dx.doi.org/10.1074/jbc.M211974200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624101	Green Submitted, hybrid			2022-12-27	WOS:000182838300006
J	Del Valle, JM; Engel, P; Martin, M				Del Valle, JM; Engel, P; Martin, M			The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED LYMPHOPROLIFERATIVE-DISEASE; GENE-PRODUCT SAP; LYMPHOCYTIC ACTIVATION MOLECULE; SORTING SIGNALS; CUTTING EDGE; BREFELDIN-A; PROTEIN SAP; MOUSE LY-9; SLAM; RECOGNITION	CD229 (Ly9) is a cell surface receptor selectively expressed on T and B lymphocytes, and it belongs to the CD150 receptor family. Like other receptors of this family, CD229 interacts with SAP/SH2D1a protein, mutation of which is responsible for the fatal X-linked lymphoproliferative disease. Receptors of the CD150 family function as costimulatory molecules, regulating cytokine production and cytotoxicity. Thus, their signaling and regulation in lymphocytes may be critical to an understanding of the pathogenesis of the X-linked lymphoproliferative disease. Here we show that CD229 interacts with the mu(2) chain of the AP-2 adaptor complex that links transmembrane proteins to clathrin-coated pits. CD229 was the only member of the CD150 family associated with AP-2. We also show that the mu(2) chain interacts with the Y470EKL motif of CD229. The integrity of this site was necessary for CD229 internalization, but it was not involved in SAP recruitment. Moreover, CD229 binds to the AP-2 complex in T and B cell lines, and it is internalized rapidly from the cell surface on T cells after antibody ligation. In contrast, cross-linking of CD229 receptors with intact antibody inhibited CD229 internalization on B cells. However, when F(ab')(2) antibodies were used, CD229 internalization was similar on T and B cells, suggesting that Fcgamma receptors control CD229 cell surface expression. Furthermore, CD229 was regulated by T cell receptor and B cell receptor signaling because coligation with antibodies against anti-CD3 and anti-IgM increased the rate of CD229 endocytosis. These data suggest that CD229 cell surface expression on lymphocytes surface is strongly and differentially regulated within the CD150 family members.	Univ Barcelona, Sch Med, Inst Invest Biomed August Pi i Sunyer, Dept Cellular Biol & Pathol,Immunol Unit, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Martin, M (corresponding author), Fac Med, Dept Biol Celular, Unidad Inmunol, C Casanova 143, E-08036 Barcelona, Spain.		Engel, Pablo/R-5907-2019; Andorra, Margarita Martin/H-2025-2015; del Valle Mendoza, Juana/C-9805-2018	Engel, Pablo/0000-0001-8410-252X; Andorra, Margarita Martin/0000-0002-9245-4899; del Valle Mendoza, Juana/0000-0002-6011-5040				Arico M, 2001, BLOOD, V97, P1131, DOI 10.1182/blood.V97.4.1131; Aversa G, 1997, IMMUNOL CELL BIOL, V75, P202, DOI 10.1038/icb.1997.30; Bottino C, 2001, J EXP MED, V194, P235, DOI 10.1084/jem.194.3.235; Bremnes T, 1998, J BIOL CHEM, V273, P8638, DOI 10.1074/jbc.273.15.8638; Carballido JM, 1997, J IMMUNOL, V159, P4316; Castro AG, 1999, J IMMUNOL, V163, P5860; Cefai D, 1998, J IMMUNOL, V160, P2223; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; COOKS BG, 1995, NATURE, V376, P260; Crotty S, 2003, NATURE, V421, P282, DOI 10.1038/nature01318; de la Fuente MA, 2001, BLOOD, V97, P3513, DOI 10.1182/blood.V97.11.3513; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Kumaresan PR, 2002, MOL IMMUNOL, V39, P1, DOI 10.1016/S0161-5890(02)00094-9; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Liu HY, 2000, IMMUNITY, V13, P665, DOI 10.1016/S1074-7613(00)00066-2; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081; Martin M, 2001, J IMMUNOL, V167, P3668, DOI 10.4049/jimmunol.167.7.3668; Minskoff SA, 1998, J IMMUNOL, V161, P2079; Morra M, 2001, BLOOD, V98, P1321, DOI 10.1182/blood.V98.5.1321; Morra M, 2001, EMBO J, V20, P5840, DOI 10.1093/emboj/20.21.5840; Morra M, 2001, ANNU REV IMMUNOL, V19, P657, DOI 10.1146/annurev.immunol.19.1.657; Nakajima H, 1999, EUR J IMMUNOL, V29, P1676, DOI 10.1002/(SICI)1521-4141(199905)29:05<1676::AID-IMMU1676>3.0.CO;2-Y; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Peck SR, 2000, IMMUNOGENETICS, V52, P63, DOI 10.1007/s002510000252; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; SANDRIN MS, 1992, J IMMUNOL, V149, P1636; Sauter MM, 1996, J CELL BIOL, V132, P795, DOI 10.1083/jcb.132.5.795; Sayos J, 2001, BLOOD, V97, P3867, DOI 10.1182/blood.V97.12.3867; Sayos J, 2000, INT IMMUNOL, V12, P1749, DOI 10.1093/intimm/12.12.1749; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Shiratori T, 1997, IMMUNITY, V6, P583, DOI 10.1016/S1074-7613(00)80346-5; Sidorenko SP, 2003, NAT IMMUNOL, V4, P19, DOI 10.1038/ni0103-19; Tangye SG, 1999, J IMMUNOL, V162, P6981; Tovar V, 2000, IMMUNOGENETICS, V51, P788, DOI 10.1007/s002510000209; Tovar V, 2002, IMMUNOGENETICS, V54, P394, DOI 10.1007/s00251-002-0483-3; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VALIANTE NM, 1993, J EXP MED, V178, P1397, DOI 10.1084/jem.178.4.1397; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; Wu CB, 2001, NAT IMMUNOL, V2, P410, DOI 10.1038/87713	46	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17430	17437		10.1074/jbc.M301569200	http://dx.doi.org/10.1074/jbc.M301569200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621057	hybrid			2022-12-27	WOS:000182818600130
J	Gaille, C; Reimmann, C; Haas, D				Gaille, C; Reimmann, C; Haas, D			Isochorismate synthase (PchA), the first and rate-limiting enzyme in salicylate biosynthesis of Pseudomonas aeruginosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; L-PHENYLALANINE; IN-VITRO; PYOCHELIN; ACID; PURIFICATION; CHORISMATE; GENES; SYNTHETASE; OVEREXPRESSION	In Pseudomonas aeruginosa the extracellular metabolite and siderophore pyochelin is synthesized from two major precursors, chorismate and L-cysteine via salicylate as an intermediate. The regulatory role of isochorismate synthase, the first enzyme in the pyochelin biosynthetic pathway, was studied. This enzyme is encoded by pchA, the last gene in the pchDCBA operon. The PchA protein was purified to apparent electrophoretic homogeneity from a PchA-overexpressing P. aeruginosa strain. The native enzyme was a 52-kDa monomer in solution, and its activity strictly depended on Mg2+. At pH 7.0, the optimum, a K-m = 4.5 muM and a k(cat) = 43.1 min(-1) were determined for chorismate. No feedback inhibitors or other allosteric effectors were found. The intracellular PchA concentration critically determined the rate of salicylate formation both in vitro and in vivo. In cultures grown in iron-limiting media to high cell densities, overexpression of the pchA gene resulted in overproduction of salicylate as well as in enhanced pyochelin formation. From this work and earlier studies, it is proposed that one important factor influencing the flux through the pyochelin biosynthetic pathway is the PchA concentration, which is determined at a transcriptional level, with pyochelin acting as a positive signal and iron as a negative signal.	Univ Lausanne, Inst Microbiol Fondamentale, CH-1015 Lausanne, Switzerland	University of Lausanne	Haas, D (corresponding author), Univ Lausanne, Inst Microbiol Fondamentale, CH-1015 Lausanne, Switzerland.							ANKENBAUER RG, 1988, J BACTERIOL, V170, P5344, DOI 10.1128/jb.170.11.5344-5351.1988; Audenaert K, 2002, MOL PLANT MICROBE IN, V15, P1147, DOI 10.1094/MPMI.2002.15.11.1147; BARTON HA, 1996, MOL MICROBIOL, V21, P1005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brem D, 2001, MICROBIOL-SGM, V147, P1115, DOI 10.1099/00221287-147-5-1115; BRUNSCHWIG E, 1992, GENE, V111, P35, DOI 10.1016/0378-1119(92)90600-T; CALHOUN DH, 1973, MOL GEN GENET, V121, P117, DOI 10.1007/BF00277526; CALHOUN DH, 2001, GENOME BIOL, V2; CARMI R, 1994, J NAT PROD, V57, P1200, DOI 10.1021/np50111a002; COX CD, 1981, P NATL ACAD SCI-BIOL, V78, P4256, DOI 10.1073/pnas.78.7.4256; Dahm C, 1998, BBA-GEN SUBJECTS, V1425, P377, DOI 10.1016/S0304-4165(98)00089-0; Daruwala R, 1997, J BACTERIOL, V179, P3133, DOI 10.1128/jb.179.10.3133-3138.1997; Dosselaere F, 2001, CRIT REV MICROBIOL, V27, P75, DOI 10.1080/20014091096710; FISKE MJ, 1983, J BACTERIOL, V154, P623, DOI 10.1128/JB.154.2.623-631.1983; Gaille C, 2002, J BIOL CHEM, V277, P21768, DOI 10.1074/jbc.M202410200; Gehring AM, 1998, CHEM BIOL, V5, P573, DOI 10.1016/S1074-5521(98)90115-6; Gosset G, 2001, J BACTERIOL, V183, P4061, DOI 10.1128/JB.183.13.4061-4070.2001; Grisostomi C, 1997, BIOORG CHEM, V25, P297, DOI 10.1006/bioo.1997.1073; HAAS D, 1972, EUR J BIOCHEM, V31, P290, DOI 10.1111/j.1432-1033.1972.tb02531.x; HAAS D, 1975, EUR J BIOCHEM, V52, P377; HEINRICHS DE, 1993, J BACTERIOL, V175, P5882, DOI 10.1128/JB.175.18.5882-5889.1993; Kennedy J, 1996, MOL GEN GENET, V253, P189, DOI 10.1007/s004380050312; Khetan A, 1996, ANN NY ACAD SCI, V782, P17, DOI 10.1111/j.1749-6632.1996.tb40543.x; LAMMELI UK, 1973, J MOL BIOL, V80, P575; Lamont IL, 2002, P NATL ACAD SCI USA, V99, P7072, DOI 10.1073/pnas.092016999; LIU J, 1990, BIOCHEMISTRY-US, V29, P1417, DOI 10.1021/bi00458a012; Ludwig W, 1999, ASM NEWS, V65, P752; MADIGAN MT, 2000, BROCK BIOL MICROORGA, P212; McDonald M, 2001, J AM CHEM SOC, V123, P9459, DOI 10.1021/ja011243+; Park SM, 1997, J BACTERIOL, V179, P5309, DOI 10.1128/jb.179.17.5309-5317.1997; PATEL N, 1977, J BIOL CHEM, V252, P5839; Quadri LEN, 1999, BIOCHEMISTRY-US, V38, P14941, DOI 10.1021/bi991787c; Quadri LEN, 1998, CHEM BIOL, V5, P631, DOI 10.1016/S1074-5521(98)90291-5; Reimmann C, 1998, MICROBIOL-UK, V144, P3135, DOI 10.1099/00221287-144-11-3135; Reimmann C, 2001, J BACTERIOL, V183, P813, DOI 10.1128/JB.183.3.813-820.2001; SERINO L, 1995, MOL GEN GENET, V249, P217, DOI 10.1007/BF00290369; Serino L, 1997, J BACTERIOL, V179, P248, DOI 10.1128/jb.179.1.248-257.1997; STEELE BF, 1949, J BIOL CHEM, V177, P533; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIETZ D, 1987, ANAL BIOCHEM, V161, P395, DOI 10.1016/0003-2697(87)90468-4; Wang YL, 2000, NUCLEIC ACIDS RES, V28, P243, DOI 10.1093/nar/28.1.243; Wildermuth MC, 2001, NATURE, V414, P562, DOI 10.1038/35107108; Winkler ME, 1996, ESCHERICHIA COLI SAL, P485	43	74	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16893	16898		10.1074/jbc.M212324200	http://dx.doi.org/10.1074/jbc.M212324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624097	hybrid			2022-12-27	WOS:000182818600061
J	Hamilton, KL; Syme, CA; Devor, DC				Hamilton, KL; Syme, CA; Devor, DC			Molecular localization of the inhibitory arachidonic acid binding site to the pore of hIK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLORIDE SECRETORY RESPONSES; ACTIVATED POTASSIUM CHANNEL; COLONIC CELL-LINE; PROTEIN-KINASE-C; K+ CHANNEL; INTERMEDIATE-CONDUCTANCE; FATTY-ACIDS; EPITHELIAL-CELLS; PHOSPHOLIPASE A(2); ION CHANNELS	We previously demonstrated that the endogenously expressed human intermediate conductance, Ca2+-activated K+ channel (hIK1) was inhibited by arachidonic acid (AA) (Devor, D. C., and Frizzell, R. A. (1998) Am. J. Physiol. 274, C138-C148). Here we demonstrate, using the excised, inside-out patch-clamp technique, that hIK1, heterologously expressed in HEK293 cells, is inhibited 82 +/- 2% (n = 16) with 3 muM AA, being half-maximally inhibited (IC50) at 1.4 +/- 0.7 muM. In contrast, AA does not inhibit the Ca2+-dependent, small conductance K+ channel, rSK2, another member of the KCNN gene family. Therefore, we utilized chimeric hIK1/rSK2 channels to define the AA binding domain on hIK1 to the S5-Pore-S6 region of the channel. Subsequent site-directed mutagenesis revealed that mutation of Thr(250) to Ser (T250S) resulted in a channel with limited sensitivity to block by AA (8 +/- 2%, n = 8), demonstrating that Thr(250) is a key molecular determinant for the inhibition of hIK1 by AA. Likewise, when Val(275) in S6 was mutated to Ala (V275A) AA inhibited only 43 +/- 11% (n = 9) of current flow. The double mutation T250S/V275A eliminated the AA sensitivity of hIK1. Introducing the complimentary single amino acid substitutions into rSK2 (S359T and A384V) conferred partial AA sensitivity to rSK2, 21 +/- 3% and 31 +/- 3%, respectively. Further, introducing the double mutation S359T/A384V into rSK2 resulted in a 63 +/- 8% (n = 9) inhibition by AA, thereby demonstrating the ability to introduce this inhibitory AA binding site into another member of the KCNN gene family. These results demonstrate that AA interacts with the pore-lining amino acids, Thr(250) and Val(275) in hIK1, conferring inhibition of hIK1 by AA and that AA and clotrimazole share similar, if not identical, molecular sites of interaction.	Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Otago, Dept Physiol, Dunedin, New Zealand	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Otago	Devor, DC (corresponding author), Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, S312 BST,3500 Terrace St, Pittsburgh, PA 15261 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054941] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54941] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; ANDERSON MP, 1990, P NATL ACAD SCI USA, V87, P7334, DOI 10.1073/pnas.87.18.7334; Balestrieri ML, 1998, PROSTAG OTH LIPID M, V56, P363, DOI 10.1016/S0090-6980(98)00065-3; BARRETT KE, 1993, AM J PHYSIOL, V264, pC446, DOI 10.1152/ajpcell.1993.264.2.C446; BARRETT KE, 1995, CELL SIGNAL, V7, P225, DOI 10.1016/0898-6568(94)00087-R; Calabrese C, 2000, ALLERGY, V55, P27, DOI 10.1034/j.1398-9995.2000.00504.x; Clarke AL, 2002, AM J PHYSIOL-CELL PH, V283, pC1441, DOI 10.1152/ajpcell.00035.2002; DERUBERTIS FR, 1984, J CLIN INVEST, V74, P1614, DOI 10.1172/JCI111577; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL785, DOI 10.1152/ajplung.1996.271.5.L785; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; Devor DC, 1997, AM J PHYSIOL-CELL PH, V273, pC531, DOI 10.1152/ajpcell.1997.273.2.C531; DHARMSATHAPHORN K, 1989, AM J PHYSIOL, V256, pC1224, DOI 10.1152/ajpcell.1989.256.6.C1224; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gerlach AC, 2000, J BIOL CHEM, V275, P585, DOI 10.1074/jbc.275.1.585; Gerlach AC, 2001, J BIOL CHEM, V276, P10963, DOI 10.1074/jbc.M007716200; GUBITOSIKLUG RA, 1995, J BIOL CHEM, V270, P2885, DOI 10.1074/jbc.270.7.2885; Hamilton KL, 1999, PFLUG ARCH EUR J PHY, V439, P158, DOI 10.1007/s004240051140; Holmqvist MH, 2001, J NEUROSCI, V21, P4154, DOI 10.1523/JNEUROSCI.21-12-04154.2001; HONORE E, 1994, P NATL ACAD SCI USA, V91, P1937, DOI 10.1073/pnas.91.5.1937; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; KACHINTORN U, 1993, BRIT J PHARMACOL, V109, P510, DOI 10.1111/j.1476-5381.1993.tb13599.x; KACHINTORN U, 1993, AM J PHYSIOL, V264, pC671, DOI 10.1152/ajpcell.1993.264.3.C671; Kim Y, 2001, PFLUG ARCH EUR J PHY, V442, P952, DOI 10.1007/s004240100626; LAWSON LD, 1987, AM J PHYSIOL, V252, pG783, DOI 10.1152/ajpgi.1987.252.6.G783; LAZAROWSKI ER, 1994, AM J PHYSIOL, V266, P406; Lin WW, 1998, BRIT J PHARMACOL, V123, P1173, DOI 10.1038/sj.bjp.0701705; LINDEMAN RP, 1992, AM J PHYSIOL, V263, pC140, DOI 10.1152/ajpcell.1992.263.1.C140; Liu Y, 2001, MOL PHARMACOL, V59, P1061, DOI 10.1124/mol.59.5.1061; Macica CM, 1998, AM J PHYSIOL-RENAL, V274, pF175, DOI 10.1152/ajprenal.1998.274.1.F175; May LG, 1999, CELL SIGNAL, V11, P179, DOI 10.1016/S0898-6568(98)00053-9; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PACHECO S, 1987, CLIN SCI, V73, P361, DOI 10.1042/cs0730361; Rufo PA, 1996, J CLIN INVEST, V98, P2066, DOI 10.1172/JCI119012; Sansom SC, 1996, CLIN EXP PHARMACOL P, V23, P76; Siegel G, 2001, J BIOL CHEM, V276, P16986, DOI 10.1074/jbc.M101136200; Singh S, 2001, J PHARMACOL EXP THER, V296, P600; Stockand JD, 1998, AM J PHYSIOL-RENAL, V274, pF658, DOI 10.1152/ajprenal.1998.274.4.F658; TRAYNORKAPLAN AE, 1994, AM J PHYSIOL-CELL PH, V267, pC1224, DOI 10.1152/ajpcell.1994.267.5.C1224; VAANDRAGER AB, 1992, AM J PHYSIOL, V262, pG249, DOI 10.1152/ajpgi.1992.262.2.G249; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; Villarroel A, 1996, J NEUROSCI, V16, P2522; Visentin S, 1998, GLIA, V22, P1; WANG WH, 1992, AM J PHYSIOL, V262, pF554, DOI 10.1152/ajprenal.1992.262.4.F554; WARHURST G, 1991, AM J PHYSIOL, V261, pG220, DOI 10.1152/ajpgi.1991.261.2.G220; Warth R, 1999, PFLUG ARCH EUR J PHY, V438, P437, DOI 10.1007/s004240051059; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151; Wulff H, 2001, J BIOL CHEM, V276, P32040, DOI 10.1074/jbc.M105231200; Xing MZ, 1999, J BIOL CHEM, V274, P10035, DOI 10.1074/jbc.274.15.10035	52	45	46	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16690	16697		10.1074/jbc.M212959200	http://dx.doi.org/10.1074/jbc.M212959200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609997	hybrid			2022-12-27	WOS:000182818600033
J	Igbavboa, U; Pidcock, JM; Johnson, LNA; Malo, TM; Studniski, AE; Yu, S; Sun, GY; Wood, WG				Igbavboa, U; Pidcock, JM; Johnson, LNA; Malo, TM; Studniski, AE; Yu, S; Sun, GY; Wood, WG			Cholesterol distribution in the Golgi complex of DITNC1 astrocytes is differentially altered by fresh and aged amyloid beta-peptide-(1-42)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSOLUBLE MEMBRANE COMPARTMENT; APOLIPOPROTEIN-E; BETA-PEPTIDE; PRECURSOR PROTEIN; PHOSPHOLIPASE-D; SYNAPTOSOMAL MEMBRANES; BRAIN; DISEASE; DOMAINS; LOCALIZATION	The Golgi complex plays an important role in cholesterol trafficking in cells, and amyloid beta-peptides (Abetas) alter cholesterol trafficking. The hypothesis was tested that fresh and aged Abeta-(1-42) would differentially modify Golgi cholesterol content in DINTC1 astrocytes and that the effects of Abeta-(1-42) would be associated with the region of the Golgi complex. Two different methods were used to determine the effects of Abeta-(1-42) on Golgi complex cholesterol. Confocal microscopy showed that fresh Abeta-(1-42) significantly increased cholesterol and that aged Abeta-(1-42) significantly reduced cholesterol content in the Golgi complex. Isolation of the Golgi complex into two fractions using density gradient centrifugation showed effects of aged Abeta-(1-42) similar to those observed with confocal microscopy but revealed the novel finding that fresh Abeta-(1-42) had opposite effects on the two Golgi fractions suggesting a specificity of Abeta-(1-42) perturbation of the Golgi complex. Phosphatidylcholine-phospholipase D activity, cell membrane cholesterol, and apolipoprotein E levels were associated with effects of fresh Abeta-(1-42) on cholesterol distribution but not with effects of aged Abeta-(1-42), arguing against a common mechanism. Extracellular Abeta-(1-42) targets the Golgi complex and disrupts cell cholesterol homeostasis, and this action of Abeta-(1-42) could alter cell functions requiring optimal levels of cholesterol.	Univ Minnesota, Sch Med, Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Minneapolis, MN 55417 USA; Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55417 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA	Geriatric Research Education & Clinical Center; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Missouri System; University of Missouri Columbia	Wood, WG (corresponding author), Univ Minnesota, Sch Med, Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, 11G,1 Vet Dr, Minneapolis, MN 55417 USA.	Woodx002@umn.edu			NATIONAL INSTITUTE ON AGING [P01AG018357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010806] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-10806] Funding Source: Medline; NIA NIH HHS [1P0AG-18357] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDRES J, 1996, EXP PARASITOL, V83, P174; ATSHAVES BP, 2000, J BIOL CHEM, V275, P36582; AUERBACH BJ, 1990, J LIPID RES, V31, P738; Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Beffert U, 1998, J NEUROCHEM, V70, P1458; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chochina SV, 2001, J LIPID RES, V42, P1292; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Eckert GP, 2000, DEMENT GERIATR COGN, V11, P181, DOI 10.1159/000017234; Fang M, 1998, BBA-MOL CELL RES, V1404, P85, DOI 10.1016/S0167-4889(98)00049-4; Freyberg Z, 2002, MOL BIOL CELL, V13, P3930, DOI 10.1091/mbc.02-04-0059; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; Hayashi H, 2000, BBA-MOL CELL BIOL L, V1483, P81, DOI 10.1016/S1388-1981(99)00174-2; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kirsch C, 2002, AMYLOID, V9, P149, DOI 10.3109/13506120209114816; Koudinov AR, 2001, FASEB J, V15, P1858, DOI 10.1096/fj.00-0815fje; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LaDu MJ, 2000, J BIOL CHEM, V275, P33974, DOI 10.1074/jbc.M000602200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Liu YB, 1998, P NATL ACAD SCI USA, V95, P13266, DOI 10.1073/pnas.95.22.13266; Liu YB, 1999, PROG NEURO-PSYCHOPH, V23, P377, DOI 10.1016/S0278-5846(99)00003-2; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; Maekawa S, 1999, J BIOL CHEM, V274, P21369, DOI 10.1074/jbc.274.30.21369; Marsh BJ, 2002, NAT REV MOL CELL BIO, V3, P789, DOI 10.1038/nrm933; Mason RP, 1999, J BIOL CHEM, V274, P18801, DOI 10.1074/jbc.274.26.18801; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Mendez AJ, 1997, J LIPID RES, V38, P1807; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; Oshima N, 2001, AM J PATHOL, V158, P2209, DOI 10.1016/S0002-9440(10)64693-7; Papassotiropoulos A, 2002, J PSYCHIAT RES, V36, P27, DOI 10.1016/S0022-3956(01)00050-4; Pappolla MA, 2002, FREE RADICAL BIO MED, V33, P173, DOI 10.1016/S0891-5849(02)00841-9; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; RADANY EH, 1992, P NATL ACAD SCI USA, V89, P6467, DOI 10.1073/pnas.89.14.6467; RAO AM, 1993, NEUROCHEM INT, V23, P45; Runz H, 2002, J NEUROSCI, V22, P1679, DOI 10.1523/JNEUROSCI.22-05-01679.2002; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schroeder F, 2001, EXP BIOL MED, V226, P873, DOI 10.1177/153537020122601002; Siddhanta A, 2000, J BIOL CHEM, V275, P12023, DOI 10.1074/jbc.275.16.12023; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Singh IN, 1998, NEUROCHEM RES, V23, P1225, DOI 10.1023/A:1020731813973; Singh IN, 1998, BRAIN RES, V800, P275, DOI 10.1016/S0006-8993(98)00532-0; Sparks DL, 1997, ANN NY ACAD SCI, V826, P128, DOI 10.1111/j.1749-6632.1997.tb48466.x; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; Walter M, 1996, J CLIN INVEST, V98, P2315, DOI 10.1172/JCI119043; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wood WG, 1999, LIPIDS, V34, P225, DOI 10.1007/s11745-999-0357-9; WOOD WG, 1995, BRAIN RES, V683, P36; Wood WG, 2003, BBA-BIOMEMBRANES, V1610, P281, DOI 10.1016/S0005-2736(03)00025-7; Wood WG, 2002, NEUROBIOL AGING, V23, P685, DOI 10.1016/S0197-4580(02)00018-0; WOOD WG, 1993, ALCOHOL CLIN EXP RES, V17, P345, DOI 10.1111/j.1530-0277.1993.tb00773.x; Yanagisawa K, 2002, J NEUROSCI RES, V70, P361, DOI 10.1002/jnr.10348; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	61	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17150	17157		10.1074/jbc.M301150200	http://dx.doi.org/10.1074/jbc.M301150200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12584199	hybrid			2022-12-27	WOS:000182818600094
J	Krenz, M; Sanbe, A; Bouyer-Dalloz, F; Gulick, J; Klevitsky, R; Hewett, TE; Osinska, HE; Lorenz, JN; Brosseau, C; Federico, A; Alpert, NR; Warshaw, DM; Perryman, MB; Helmke, SM; Robbins, J				Krenz, M; Sanbe, A; Bouyer-Dalloz, F; Gulick, J; Klevitsky, R; Hewett, TE; Osinska, HE; Lorenz, JN; Brosseau, C; Federico, A; Alpert, NR; Warshaw, DM; Perryman, MB; Helmke, SM; Robbins, J			Analysis of myosin heavy chain functionality in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; IN-VITRO; KINETIC DIFFERENCES; ISOFORM EXPRESSION; SKELETAL-MUSCLE; MAMMALIAN HEART; SURFACE LOOPS; LIGHT-CHAIN; ACTIN; FIBERS	Comparison of mammalian cardiac alpha- and beta-myosin heavy chain isoforms reveals 93% identity. To date, genetic methodologies have effected only minor switches in the mammalian cardiac myosin isoforms. Using cardiac-specific transgenesis, we have now obtained major myosin isoform shifts and/or replacements. Clusters of non-identical amino acids are found in functionally important regions, i.e. the surface loops 1 and 2, suggesting that these structures may regulate isoform-specific characteristics. Loop 1 alters filament sliding velocity, whereas Loop 2 modulates actin-activated ATPase rate in Dictyostelium myosin, but this remains untested in mammalian cardiac myosins. alpha-->beta isoform switches were engineered into mouse hearts via transgenesis. To assess the structural basis of isoform diversity, chimeric myosins in which the sequences of either Loop 1+Loop 2 or Loop 2 of alpha-myosin were exchanged for those of beta-myosin were expressed in vivo. 2-fold differences in filament sliding velocity and ATPase activity were found between the two isoforms. Filament sliding velocity of the Loop 1+Loop 2 chimera and the ATPase activities of both loop chimeras were not significantly different compared with alpha-myosin. In mouse cardiac isoforms, myosin functionality does not depend on Loop 1 or Loop 2 sequences and must lie partially in other non-homologous residues.	Childrens Hosp Res Fdn, Cincinnati Childrens Hosp Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA; Univ Vermont, Coll Med, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Cardiol, Denver, CO 80262 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University of Vermont; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Robbins, J (corresponding author), Div Mol Cardiovasc Biol, MLC 7020,3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.robbins@echmc.org	Hewett, Timothy/G-1023-2011; Hewett, Timothy Edwin/GLT-1556-2022; Hewett, Timothy E/E-3241-2011	federico, antonio/0000-0002-5246-1621; Krenz, Maike/0000-0003-3784-287X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060546, P50HL052318, R01HL056370, R01HL066157] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52318, HL66157, HL60546, HL56370, HL69799] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alpert NR, 2002, AM J PHYSIOL-HEART C, V283, pH1446, DOI 10.1152/ajpheart.00274.2002; Blough ER, 1996, ANAL BIOCHEM, V233, P31, DOI 10.1006/abio.1996.0003; BOTTINELLI R, 1991, J PHYSIOL-LONDON, V437, P655, DOI 10.1113/jphysiol.1991.sp018617; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Fewell JG, 1998, J CLIN INVEST, V101, P2630, DOI 10.1172/JCI2825; Fitzsimons DP, 1998, J PHYSIOL-LONDON, V513, P171, DOI 10.1111/j.1469-7793.1998.171by.x; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Gulick J, 1997, CIRC RES, V80, P655, DOI 10.1161/01.RES.80.5.655; HARRIS DE, 1994, J MUSCLE RES CELL M, V15, P11, DOI 10.1007/BF00123828; Herron TJ, 2002, CIRC RES, V90, P1150, DOI 10.1161/01.RES.0000022879.57270.11; Hirayama Y, 2000, BIOCHEM BIOPH RES CO, V269, P237, DOI 10.1006/bbrc.2000.2273; IMAMURA SI, 1991, AM J PHYSIOL, V260, pH73, DOI 10.1152/ajpheart.1991.260.1.H73; James J, 1999, TRANSGENIC RES, V8, P9, DOI 10.1023/A:1008894507995; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; LITTEN RZ, 1982, CIRC RES, V50, P856, DOI 10.1161/01.RES.50.6.856; LOPES AC, 1993, J SUBMICR CYTOL PATH, V25, P263; Lorenz JN, 1997, AM J PHYSIOL-HEART C, V272, pH1137, DOI 10.1152/ajpheart.1997.272.3.H1137; MCAULIFFE JJ, 1990, CIRC RES, V66, P1204, DOI 10.1161/01.RES.66.5.1204; Metzger JM, 1999, CIRC RES, V84, P1310, DOI 10.1161/01.RES.84.11.1310; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; MORKIN E, 1993, CIRCULATION, V87, P1451, DOI 10.1161/01.CIR.87.5.1451; Murphy CT, 2000, J MUSCLE RES CELL M, V21, P139, DOI 10.1023/A:1005610007209; Murphy CT, 1998, BIOCHEMISTRY-US, V37, P6738, DOI 10.1021/bi972903j; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; Nguyen TTT, 1996, CIRC RES, V79, P222, DOI 10.1161/01.RES.79.2.222; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Palmiter KA, 1999, J PHYSIOL-LONDON, V519, P669, DOI 10.1111/j.1469-7793.1999.0669n.x; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Pereira JS, 2001, J BIOL CHEM, V276, P4409, DOI 10.1074/jbc.M006441200; POWERS FM, 1995, AM J PHYSIOL-CELL PH, V268, pC1348, DOI 10.1152/ajpcell.1995.268.6.C1348; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Reiser PJ, 1998, AM J PHYSIOL-HEART C, V274, pH1048, DOI 10.1152/ajpheart.1998.274.3.H1048; REISER PJ, 1985, J BIOL CHEM, V260, P9077; Reiser PJ, 2001, AM J PHYSIOL-HEART C, V280, pH1814, DOI 10.1152/ajpheart.2001.280.4.H1814; Rosen MR, 2001, LANCET, V357, P468, DOI 10.1016/S0140-6736(00)04020-4; Rouslin W, 1996, AM J PHYSIOL-CELL PH, V270, pC1271, DOI 10.1152/ajpcell.1996.270.5.C1271; Sanbe A, 2001, J BIOL CHEM, V276, P32682, DOI 10.1074/jbc.M009975200; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; Sugiura S, 1998, ADV EXP MED BIOL, V453, P125; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Tardiff JC, 2000, AM J PHYSIOL-HEART C, V278, pH412, DOI 10.1152/ajpheart.2000.278.2.H412; Tyska MJ, 2000, CIRC RES, V86, P737, DOI 10.1161/01.RES.86.7.737; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; Weiss A, 1999, J MOL BIOL, V290, P61, DOI 10.1006/jmbi.1999.2865	46	86	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17466	17474		10.1074/jbc.M210804200	http://dx.doi.org/10.1074/jbc.M210804200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12626511	hybrid			2022-12-27	WOS:000182818600134
J	Li, YX; Xie, MX; Song, XL; Gragen, S; Sachdeva, K; Wan, YS; Yan, BF				Li, YX; Xie, MX; Song, XL; Gragen, S; Sachdeva, K; Wan, YS; Yan, BF			DEC1 negatively regulates the expression of DEC2 through binding to the E-box in the proximal promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; TRANSCRIPTIONAL REPRESSION; MOLECULAR CHARACTERIZATION; INDUCED APOPTOSIS; GENE; ACTIVATION; STRA13; SPLIT; HAIRY; ENHANCER	Human DEC (differentially expressed in chondrocytes), mouse STRA (stimulated with retinoic acid), and rat SHARP (split and hairy related protein) proteins constitute a new and structurally distinct class of the basic helix-loop-helix proteins. In each species, two members are identified with a sequence identity of >90% in the basic helix-loop-helix region and similar to40% in the total proteins, respectively. Recently, we have reported that DEC1 is abundantly expressed in colon carcinomas but not in the adjacent normal tissues. The present study was undertaken to extend the expression study of DEC1 and to determine whether DEC1 and DEC2 had similar expression patterns among paired cancer-normal tissues from the colon, lung, and kidney. Without exceptions, DEC1 was markedly higher in the carcinomas, whereas the opposite was true with DEC2. In stable transfectants, tetracycline-induced expression of DEC1 caused proportional decreases in the expression of DEC2. Co-transfection with DEC1 repressed the activity of a DEC2 promoter reporter by as much as 90%. The repression was observed with wild type DEC1 but not its DNA binding-defective mutants. Studies with deletion and site-directed mutants located, in the proximal promoter, an E-box motif that supported the DEC1-mediated repression. Disruption of this E-box markedly abolished the ability of the reporter to respond to DEC1. Our findings assign for DEC1 the first target gene that is regulated through direct DNA binding. DEC/STRA/SHARP proteins are highly identical in the DNA binding domain but much more diverse in other areas. DEC1-mediated repression on the expression of DEC2 provides an important mechanism that these transcription factors regulate the cellular function not only by modulating the expression of their target genes but also the expression of members within the same class.	Univ Rhode Isl, Dept Biomed Sci, Kingston, RI 02881 USA; Providence Coll, Dept Biol, Providence, RI 02908 USA	University of Rhode Island; Providence College	Yan, BF (corresponding author), Univ Rhode Isl, Dept Biomed Sci, Kingston, RI 02881 USA.		Song, Xiulong/O-2814-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061988] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM61988] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Garriga-Canut M, 2001, J BIOL CHEM, V276, P14821, DOI 10.1074/jbc.M011619200; Giebel B, 1997, P NATL ACAD SCI USA, V94, P6250, DOI 10.1073/pnas.94.12.6250; Hirose K, 1996, MOL CELL BIOL, V16, P1706; Hojo M, 2000, DEVELOPMENT, V127, P2515; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Hu MW, 1999, ANAL BIOCHEM, V266, P233, DOI 10.1006/abio.1998.2954; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Katti MV, 2000, PROTEIN SCI, V9, P1203, DOI 10.1110/ps.9.6.1203; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Li YX, 2002, BIOCHEM J, V367, P413, DOI 10.1042/BJ20020514; Littlewood T.D., 1998, HELIX LOOP HELIX TRA, P1; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; Ohtsuka T, 2001, J BIOL CHEM, V276, P30467, DOI 10.1074/jbc.M102420200; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; Shen M, 2002, J BIOL CHEM, V277, P50112, DOI 10.1074/jbc.M206771200; SHEN M, 1997, ARCH BIOCHEM BIOPHYS, V336, P294; St-Pierre B, 2002, J BIOL CHEM, V277, P46544, DOI 10.1074/jbc.M111652200; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999; Zhang H, 1999, ARCH BIOCHEM BIOPHYS, V368, P14, DOI 10.1006/abbi.1999.1307; Zhu WZ, 2000, DRUG METAB DISPOS, V28, P186	34	105	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16899	16907		10.1074/jbc.M300596200	http://dx.doi.org/10.1074/jbc.M300596200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624110	Green Published, hybrid			2022-12-27	WOS:000182818600062
J	Philippar, K; Buchsenschutz, K; Abshagen, M; Fuchs, I; Geiger, D; Lacombe, B; Hedrich, R				Philippar, K; Buchsenschutz, K; Abshagen, M; Fuchs, I; Geiger, D; Lacombe, B; Hedrich, R			The K+ channel KZM1 mediates potassium uptake into the phloem and guard cells of the C-4 grass Zea mays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCROSE-EXPORT; BUNDLE-SHEATH; ARABIDOPSIS-THALIANA; PLASMA-MEMBRANE; MAIZE; EXPRESSION; LEAF; AKT1; PLASMODESMATA; SENSITIVITY	In search of K+ channel genes expressed in the leaf of the C-4 plant Zea mays, we isolated the cDNA of KZM1 (for K+ channel Zea mays 1). KZM1 showed highest similarity to the Arabidopsis K+ channels KAT1 and KAT2, which are localized in guard cells and phloem. When expressed in Xenopus oocytes, KZM1 exhibited the characteristic features of an inward-rectifying, potassium-selective channel. In contrast to KAT1- and KAT2-type K+ channels, however, KZM1 currents were insensitive to external pH changes. Northern blot analyses identified the leaf, nodes, and silks as sites of KZM1 expression. Following the separation of maize leaves into epidermal, mesophyll, and vascular fractions, quantitative real-time reverse transcriptase-PCR allowed us to localize KZM1 transcripts predominantly in vascular strands and the epidermis. Cell tissue separation and KZM1 localization were followed with marker genes such as the bundle sheath-specific ribulose-1,5-bisphosphate carboxylase, the phloem K+ channel ZMK2, and the putative sucrose transporter ZmSUT1. When expressed in Xenopus oocytes, ZmSUT1 mediated proton-coupled sucrose symport. Coexpression of ZmSUT1 with the phloem K+ channels KZM1 and ZMK2 revealed that ZMK2 is able to stabilize the membrane potential during phloem loading/unloading processes and KZM1 to mediate K+ uptake. During leaf development, sink-source transitions, and diurnal changes, KZM1 is constitutively expressed, pointing to a housekeeping function of this channel in K+ homeostasis of the maize leaf. Therefore, the voltage-dependent K+-uptake channel KZM1 seems to mediate K+ retrieval and K+ loading into the phloem as well as K+-dependent stomatal opening.	Univ Wurzburg, Lehrstuhl Mol Pflanzenphysiol & Biophys, Julius von Sachs Inst, D-97082 Wurzburg, Germany; Univ Kiel, Zentrum Biochem & Mol Biol, D-24098 Kiel, Germany	University of Wurzburg; University of Kiel	Hedrich, R (corresponding author), Univ Wurzburg, Lehrstuhl Mol Pflanzenphysiol & Biophys, Julius von Sachs Inst, Julius von Sachs Pl 2, D-97082 Wurzburg, Germany.	hedrich@botanik.uni-wuerzburg.de	Lacombe, Benoit/B-1202-2013; Hedrich, Rainer/G-8771-2011; Geiger, Dietmar/D-6914-2014; Philippar, Katrin/F-7942-2018; Geiger, Dietmar/AAH-8140-2019	Hedrich, Rainer/0000-0003-3224-1362; Geiger, Dietmar/0000-0003-0715-5710; Geiger, Dietmar/0000-0003-0715-5710; Philippar, Katrin/0000-0002-2140-4907; Lacombe, Benoit/0000-0001-9924-3093				Ache P, 2001, PLANT J, V27, P571, DOI 10.1046/j.1365-313X.2001.t01-1-01116.x; Ache P, 2000, FEBS LETT, V486, P93, DOI 10.1016/S0014-5793(00)02248-1; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Aoki N, 1999, PLANT CELL PHYSIOL, V40, P1072, DOI 10.1093/oxfordjournals.pcp.a029489; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Bauer CS, 2000, PLANT J, V24, P139, DOI 10.1046/j.1365-313X.2000.00844.x; Botha CEJ, 2000, PROTOPLASMA, V214, P65, DOI 10.1007/BF02524263; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; Deeken R, 2000, PLANT J, V23, P285, DOI 10.1046/j.1365-313x.2000.00791.x; Deeken R, 2002, PLANTA, V216, P334, DOI 10.1007/s00425-002-0895-1; Dennison KL, 2001, PLANT PHYSIOL, V127, P1012, DOI 10.1104/pp.010193; Ehrhardt T, 1997, FEBS LETT, V409, P166, DOI 10.1016/S0014-5793(97)00502-4; EVERT RF, 1978, PLANTA, V138, P279, DOI 10.1007/BF00386823; Evert RF, 1996, INT J PLANT SCI, V157, P247, DOI 10.1086/297344; FAIRLEYGRENOT KA, 1992, PLANTA, V186, P282, DOI 10.1007/BF00196258; FAIRLEYGRENOT KA, 1993, PLANTA, V189, P410, DOI 10.1007/BF00194439; FRITZ E, 1983, PLANTA, V159, P193, DOI 10.1007/BF00397525; FURBANK RT, 1985, PLANTA, V164, P172, DOI 10.1007/BF00396079; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; Gaymard F, 1998, CELL, V94, P647, DOI 10.1016/S0092-8674(00)81606-2; Geiger D, 2002, PLANT CELL, V14, P1859, DOI 10.1105/tpc.003244; HEDRICH R, 1995, EUR BIOPHYS J, V24, P107, DOI 10.1007/BF00211406; Hirsch RE, 1998, SCIENCE, V280, P918, DOI 10.1126/science.280.5365.918; Hoth S, 1997, P NATL ACAD SCI USA, V94, P4806, DOI 10.1073/pnas.94.9.4806; Hoth S, 1999, J BIOL CHEM, V274, P11599, DOI 10.1074/jbc.274.17.11599; Hoth S, 2001, PLANT CELL, V13, P943, DOI 10.1105/tpc.13.4.943; Ivashikina N, 2001, FEBS LETT, V508, P463, DOI 10.1016/S0014-5793(01)03114-3; KANAI R, 1973, PLANT PHYSIOL, V51, P1133, DOI 10.1104/pp.51.6.1133; Keunecke M, 1997, PLANT SOIL, V196, P239, DOI 10.1023/A:1004206208968; Keunecke M, 2000, PLANTA, V210, P792, DOI 10.1007/s004250050681; Kwak JM, 2001, PLANT PHYSIOL, V127, P473, DOI 10.1104/pp.010428; Lacombe B, 2000, FEBS LETT, V466, P351, DOI 10.1016/S0014-5793(00)01093-0; Lacombe B, 2000, PLANT CELL, V12, P837, DOI 10.1105/tpc.12.6.837; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Majore I, 2002, PLANT CELL PHYSIOL, V43, P844, DOI 10.1093/pcp/pcf104; Marten I, 1999, P NATL ACAD SCI USA, V96, P7581, DOI 10.1073/pnas.96.13.7581; Maser P, 2001, PLANT PHYSIOL, V126, P1646, DOI 10.1104/pp.126.4.1646; MATSUOKA M, 1994, PLANT J, V6, P311, DOI 10.1046/j.1365-313X.1994.06030311.x; Mouline K, 2002, GENE DEV, V16, P339, DOI 10.1101/gad.213902; Muller-Rober B, 1998, J EXP BOT, V49, P293, DOI 10.1093/jexbot/49.suppl_1.293; MULLERROBER B, 1995, EMBO J, V14, P2409, DOI 10.1002/j.1460-2075.1995.tb07238.x; NAKAMURA RL, 1995, PLANT PHYSIOL, V109, P371, DOI 10.1104/pp.109.2.371; NELSON T, 1992, ANNU REV PLANT PHYS, V43, P25, DOI 10.1146/annurev.pp.43.060192.000325; Neves-Piestun BG, 2001, PLANT PHYSIOL, V125, P1419, DOI 10.1104/pp.125.3.1419; Nicholas KB, 1997, EMBNEW NEWS, V4, P14; Outlaw WH, 2002, ARCH BIOCHEM BIOPHYS, V407, P63, DOI 10.1016/S0003-9861(02)00460-5; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Philippar K, 1999, P NATL ACAD SCI USA, V96, P12186, DOI 10.1073/pnas.96.21.12186; Pilot G, 2001, J BIOL CHEM, V276, P3215, DOI 10.1074/jbc.M007303200; Pratelli R, 2002, PLANT PHYSIOL, V128, P564, DOI [10.1104/pp.128.2.564, 10.1104/pp.010529]; PRIOUL JL, 1996, PHOTOASSIMILATE DIST, P549; Reintanz B, 2002, P NATL ACAD SCI USA, V99, P4079, DOI 10.1073/pnas.052677799; RUSSELL SH, 1985, PLANTA, V164, P448, DOI 10.1007/BF00395960; Russin WA, 1996, PLANT CELL, V8, P645, DOI 10.1105/tpc.8.4.645; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; Stitt M, 1996, PLANT CELL, V8, P565; Szyroki A, 2001, P NATL ACAD SCI USA, V98, P2917, DOI 10.1073/pnas.051616698; Tang XD, 2000, BIOPHYS J, V78, P1255, DOI 10.1016/S0006-3495(00)76682-3; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANBEL AJE, 1993, ANNU REV PLANT PHYS, V44, P253, DOI 10.1146/annurev.pp.44.060193.001345; Very AA, 2002, TRENDS PLANT SCI, V7, P168, DOI 10.1016/S1360-1385(02)02262-8	63	68	81	4	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16973	16981		10.1074/jbc.M212720200	http://dx.doi.org/10.1074/jbc.M212720200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611901	hybrid			2022-12-27	WOS:000182818600072
J	Yang, E; Lerner, L; Besser, D; Darnell, JE				Yang, E; Lerner, L; Besser, D; Darnell, JE			Independent and cooperative activation of chromosomal c-fos promoter by STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TERNARY COMPLEX-FORMATION; SERUM RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; PROTEIN-KINASES; 3T3 CELLS; STIMULATION	The c-fos gene was one of the earliest vertebrate genes shown to be transcriptionally induced by growth factors. Intensive study of the promoter of c-fos (-325 to -80) by transient or permanent transfections of synthetic DNA constructs has repeatedly shown the importance of several sequence elements and the resident nuclear proteins that bind them (e.g. ternary complex factor/ELK1; serum response factor, cAMP response element-binding protein/amino-terminal fragment/AP-1). However these studies have left unanswered numerous questions about the role of these proteins in the regulation of the native chromosomal gene. In particular, the role of a site in this enhancer that binds STATs has been controversial. We present evidence here that STAT3 and not STAT1 accumulates on the chromosomal c-fos promoter and provides a boost to transcription without the activation of resident nuclear proteins through serine kinases. Also, when resident nuclear proteins such as ELK1 are activated to varying extents by mitogen-activated protein kinase pathways, STAT3 activation provides a 2-fold boost regardless of the final level of activated transcription. Thus the several proteins that interact with the c-fos enhancer apparently can act either in a cooperative or independent manner to achieve very different levels of transcription.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA	Rockefeller University	Darnell, JE (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA.		Yang, Edward/Q-8175-2019; Besser, Daniel/A-8304-2012	Besser, Daniel/0000-0002-4958-9624	NCI NIH HHS [CA 09673] Funding Source: Medline; NIAID NIH HHS [AI 32489, AI 34420] Funding Source: Medline; NIGMS NIH HHS [GM 07739] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034420, R37AI034420, R01AI032489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; COFFER P, 1995, ONCOGENE, V10, P985; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Hirano Toshio, 1998, P197; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Leaman DW, 1996, MOL CELL BIOL, V16, P369; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yang E, 2002, J BIOL CHEM, V277, P13455, DOI 10.1074/jbc.M112038200; Yang E, 1999, MOL CELL BIOL, V19, P5106; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	38	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15794	15799		10.1074/jbc.M213073200	http://dx.doi.org/10.1074/jbc.M213073200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600988	hybrid			2022-12-27	WOS:000182680000044
J	Yang, HM; Lin, CH; Ma, G; Baffi, MO; Wathelet, MG				Yang, HM; Lin, CH; Ma, G; Baffi, MO; Wathelet, MG			Interferon regulatory factor-7 synergizes with other transcription factors through multiple interactions with p300/CBP coactivators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-INFECTION; POSITIVE FEEDBACK; GENE INDUCTION; ALPHA GENES; ACTIVATION; DISTINCT; IRF-3; BINDING; CBP/P300; DOMAINS	Interferon regulatory factor (IRF)-7 is activated in response to virus infection and stimulates the transcription of a set of cellular genes involved in host antiviral defense. The mechanism by which IRF-7 is activated and cooperates with other transcription factors is not fully elucidated. Activation of IRF-7 results from a conformational change triggered by the virus-dependent phosphorylation of its C terminus. This conformational change leads to dimerization, nuclear accumulation, DNA-binding, and transcriptional transactivation. Here we show that activation of IRF-7, like that of IRF-3, is dependent on modifications of two distinct sets of Ser/ Thr residues. Moreover, we show that different virus-inducible cis-acting elements display requirements for specific IRFs. In particular, the virus-responsive element of the ISG15 gene promoter can be activated by either IRF-3 or IRF-7 alone, whereas the P31 element of the interferon-beta gene is robustly activated only when IRF-3, IRF-7, and the p300/CBP coactivators are all present. Furthermore, we find that IRF-7 interacts with four distinct regions of p300/CBP. These interactions not only stimulate the intrinsic transcriptional activity of IRF-7, but they are also indispensable for its ability to strongly synergize with other transcription factors, including c-Jun and IRF-3.	Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45267 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	University System of Ohio; University of Cincinnati; Harvard University	Wathelet, MG (corresponding author), Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.				NIAID NIH HHS [AI 20642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020642, R01AI020642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Au WC, 2001, VIROLOGY, V280, P273, DOI 10.1006/viro.2000.0782; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P419, DOI 10.1016/S0952-7915(00)00111-4; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Harlow E., 1988, ANTIBODIES LAB MANUA; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Sambrook J., 2002, MOL CLONING LAB MANU; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stewart W, 1979, INTERFERON SYSTEM; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yang HM, 2002, EUR J BIOCHEM, V269, P6142, DOI 10.1046/j.1432-1033.2002.03330.x; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087	25	50	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15495	15504		10.1074/jbc.M212940200	http://dx.doi.org/10.1074/jbc.M212940200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604599	hybrid			2022-12-27	WOS:000182680000007
J	Berdiev, BK; Xia, JZ; McLean, LA; Markert, JM; Gillespie, GY; Mapstone, TB; Naren, AP; Jovov, B; Bubien, JK; Ji, HL; Fuller, CM; Kirk, KL; Benos, DJ				Berdiev, BK; Xia, JZ; McLean, LA; Markert, JM; Gillespie, GY; Mapstone, TB; Naren, AP; Jovov, B; Bubien, JK; Ji, HL; Fuller, CM; Kirk, KL; Benos, DJ			Acid-sensing ion channels in malignant gliomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONS CAUSING NEURODEGENERATION; EPITHELIAL SODIUM-CHANNELS; MAMMALIAN DEGENERIN MDEG; CFTR CHLORIDE CHANNELS; PLANAR LIPID BILAYERS; SENSITIVE NA+ CHANNEL; GATED CATION CHANNELS; CAENORHABDITIS-ELEGANS; CALCIUM CHANNELS; XENOPUS OOCYTES	High grade glioma cells derived from patient biopsies express an amiloride-sensitive sodium conductance that has properties attributed to the human brain sodium, channel family, also known as acid-sensing ion channels (ASICs). This amiloride-sensitive conductance was not detected in cells obtained from normal brain tissue or low grade or benign tumors. Differential gene profiling data showed that ASIC1 and ASIC2 mRNA were present in normal and low grade tumor cells. Although ASIC 1 was present in all of the high grade glial cells examined, ASIC2 mRNA was detected in less than half. The main purpose of our work was to ekamine the molecular mechanisms that may underlie the constitutively activated sodium currents present in high grade glioma cells. Our results show that 1) gain-of-function mutations of ASIC1 were not present in a number of freshly resected and cultured high grade,gliomas, 2) syntaxin 1A inhibited ASIC currents only when ASIC1 and ASIC2 were co-expressed, and 3) the inhibition of ASIC currents by syntaxin 1A had an absolute requirement for either gamma- or delta-hENaC. Transfection of cultured cells originally derived from high grade gliomas (U87-MG and SK-MG1) with ASIC2 abolished basal amiloride-sensitive sodium conductance; this inhibition was reversed by dialysis of the cell interior with Munc-18, a syntaxin-binding protein that typically blocks the interaction of syntaxin with other proteins. Thus, syntaxin 1A cannot inhibit Na+ permeability in the absence of adequate plasma membrane ASIC2 expression, accounting for the observed functional expression of amiloride-sensitive currents in high grade glioma cells.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama, Dept Surg, Birmingham, AL 35294 USA; Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Emory University	Benos, DJ (corresponding author), Univ Alabama, Dept Physiol & Biophys, 1918 Univ Blvd,MCLM 704, Birmingham, AL 35294 USA.		JI, HONGLONG/N-7822-2014; Fuller, Cathy/B-4046-2011	JI, HONGLONG/0000-0002-3228-7144; Gillespie, George/0000-0001-6436-9542	NCI NIH HHS [CA71933] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071933] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams CM, 1998, J BIOL CHEM, V273, P30204, DOI 10.1074/jbc.273.46.30204; Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Babinski K, 2000, J BIOL CHEM, V275, P28519, DOI 10.1074/jbc.M004114200; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Berdiev BK, 2002, J BIOL CHEM, V277, P45734, DOI 10.1074/jbc.M208995200; Berdiev BK, 2001, J BIOL CHEM, V276, P38755, DOI 10.1074/jbc.M107266200; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Biagini G, 2001, NEUROBIOL DIS, V8, P45, DOI 10.1006/nbdi.2000.0331; BRISMAR T, 1989, BRAIN RES, V480, P259, DOI 10.1016/0006-8993(89)90191-1; Bubien JK, 1999, AM J PHYSIOL-CELL PH, V276, pC1405, DOI 10.1152/ajpcell.1999.276.6.C1405; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Grunder S, 2001, EUR J HUM GENET, V9, P672, DOI 10.1038/sj.ejhg.5200699; Horimoto M, 2000, CANCER GENE THER, V7, P1341, DOI 10.1038/sj.cgt.0239; Ismailov II, 1997, J PHYSIOL-LONDON, V504, P287, DOI 10.1111/j.1469-7793.1997.287be.x; Ji HL, 1999, J BIOL CHEM, V274, P37693, DOI 10.1074/jbc.274.53.37693; Johnson MB, 2001, J CEREBR BLOOD F MET, V21, P734, DOI 10.1097/00004647-200106000-00011; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Markert JM, 2001, PHYSIOL GENOMICS, V5, P21, DOI 10.1152/physiolgenomics.2001.5.1.21; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Qi JJ, 1999, J BIOL CHEM, V274, P30345, DOI 10.1074/jbc.274.43.30345; Rettig J, 1997, J NEUROSCI, V17, P6647; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Ullrich N, 1996, AM J PHYSIOL-CELL PH, V270, pC1511; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; Zhang P, 2001, J GEN PHYSIOL, V117, P563, DOI 10.1085/jgp.117.6.563; Zhong HJ, 1999, NAT NEUROSCI, V2, P939, DOI 10.1038/14721	39	109	116	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15023	15034		10.1074/jbc.M300991200	http://dx.doi.org/10.1074/jbc.M300991200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584187	hybrid			2022-12-27	WOS:000182516100059
J	Chen, DL; Li, MY; Luo, JY; Gu, W				Chen, DL; Li, MY; Luo, JY; Gu, W			Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER DOMAIN; HYPOXIA; UBIQUITINATION; HIF-1; VHL; ACTIVATION; BINDING; FAMILY	The p53 tumor suppressor is maintained at low levels in normal cells by Mdm2-mediated degradation and strongly stabilized in response to various types of stress including hypoxia. Although hypoxia-inducible factor 1alpha (HIF-1alpha) has been implicated to be involved in p53 stabilization, the precise mechanism by which HIF-1alpha regulates p53-mediated function remains unknown. Here, we found that HIF-1alpha directly binds Mdm2 both in vitro and in vivo; in contrast, p53 fails to directly interact with HIF-1alpha in vitro. Interestingly, Mdm2 expression can significantly enhance the in vivo association between p53 and HIF-1alpha, indicating that Mdm2 may act as a bridge and mediate the indirect interaction between HIF-1alpha and p53 in cells. Furthermore, HIF-1alpha protects p53 degradation mediated by Mdm2, and leads to activation of p53-mediated transcription in cells. To elucidate the mechanism of HIF-1alpha-mediated effect, we also found that HIF-1alpha can significantly suppress Mdm2-mediated p53 ubiquitination in vitro and blocks Mdm2-mediated nuclear export of p53. These results have significant implications regarding the molecular mechanism by which p58 is activated by HIF-1alpha in response to hypoxia.	Columbia Univ, Inst Canc Genet, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Dept Pathol, Coll Phys & Surg, New York, NY 10032 USA	Columbia University; Columbia University	Gu, W (corresponding author), Columbia Univ, Inst Canc Genet, Coll Phys & Surg, Berrie Res Pavil,Rm 412C,1150 St Nicholas Ave, New York, NY 10032 USA.	wg8@columbia.edu	Luo, Jianyuan/ABI-7585-2020	Luo, Jianyuan/0000-0001-6057-2914				An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Blagosklonny MV, 2001, ONCOGENE, V20, P395, DOI 10.1038/sj.onc.1204055; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Prives C, 1999, J PATHOL, V187, P112; Ravi R, 2000, GENE DEV, V14, P34; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230	26	264	295	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13595	13598		10.1074/jbc.C200694200	http://dx.doi.org/10.1074/jbc.C200694200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12606552	hybrid			2022-12-27	WOS:000182405000002
J	Weber, J; Muharemagic, A; Wilke-Mounts, S; Senior, AE				Weber, J; Muharemagic, A; Wilke-Mounts, S; Senior, AE			F1F0-ATP synthase - Binding of delta subunit to a 22-residue peptide mimicking the N-terminal region of alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP SYNTHASE; F-1-ATPASE; STATOR; STALK; F1	The stator in F1F0-ATP synthase resists strain generated by rotor torque. In Escherichia coli the b(2)delta subunit complex comprises the stator, bound to subunit a in F-0 and to alpha(3)beta(3) hexagon of F-1. Proteolysis and cross-linking had suggested that N-terminal residues of a subunit are involved in binding delta. Here we demonstrate that a synthetic peptide consisting of the first 22 residues of a ("alphaN1-22") binds specifically to isolated wild-type delta subunit with high affinity (K-d = 130 nM), accounting for a major portion of the binding energy when delta-depleted F-1 and isolated delta bind together (K-d = 1.4 nM). Stoichiometry of binding of alphaN1-22 to delta at saturation was 1/1, showing that in intact F1F0-ATP synthase only one of the three a subunits is involved in delta binding. When alphaN1-22 was incubated with delta subunits containing mutations in helices I or 5 on the F-1-binding face of delta, peptide binding was impaired as was binding of delta-depleted F-2. Residues alpha6-18 are predicted to be helical, and a potential helix capping box occurs at residues alpha3-8. Circular dichroism measurements showed that alphaN1-22 had significant helical content. Hypothetically a helical region of residues alphaN1-22 packs with helices 1 and 5 on the F-1-binding face of delta, forming the alpha/delta interface.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.				NIGMS NIH HHS [GM25349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025349, R37GM025349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews MJI, 1999, TETRAHEDRON, V55, P11711, DOI 10.1016/S0040-4020(99)00678-X; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Beck-Sickinger A G, 1995, Pharm Acta Helv, V70, P33, DOI 10.1016/0031-6865(94)00049-2; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1980, J BIOL CHEM, V255, P6891; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Rubinstein JL, 2002, J MOL BIOL, V321, P613, DOI 10.1016/S0022-2836(02)00671-X; Weber J, 2003, J BIOL CHEM, V278, P13409, DOI 10.1074/jbc.M212037200; Weber J, 2002, J BIOL CHEM, V277, P18390, DOI 10.1074/jbc.M201047200; WEBER J, 2003, IN PRESS FEBS LETT; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381	20	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13623	13626		10.1074/jbc.C300061200	http://dx.doi.org/10.1074/jbc.C300061200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12595534	hybrid			2022-12-27	WOS:000182405000009
J	Kamei, D; Murakami, M; Nakatani, Y; Ishikawa, Y; Ishii, T; Kudo, I				Kamei, D; Murakami, M; Nakatani, Y; Ishikawa, Y; Ishii, T; Kudo, I			Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); APC(DELTA-716) KNOCKOUT MICE; COLON-CANCER CELLS; MAMMARY EPITHELIAL-CELLS; E-2 SYNTHASE; INTESTINAL POLYPOSIS; ENDOTHELIAL-CELLS; ANTIINFLAMMATORY AGENT; PROTEIN PHOSPHATASE; ACTIN CYTOSKELETON	Microsomal prostaglandin E-2 synthase-1 (mPGES-1) is a stimulus-inducible enzyme that functions downstream of cyclooxygenase ( COX)-2 in the PGE(2)-biosynthetic pathway. Given the accumulating evidence that COX-2-derived PGE(2) participates in the development of various tumors, including colorectal cancer, we herein examined the potential involvement of mPGES-1 in tumorigenesis. Immunohistochemical analyses demonstrated the expression of both COX-2 and mPGES-1 in human colon cancer tissues. HCA-7, a human colorectal adenocarcinoma cell line that displays COX-2- and PGE(2)-dependent proliferation, expressed both COX-2 and mPGES-1 constitutively. Treatment of HCA-7 cells with an mPGES-1 inhibitor or antisense oligonucleotide attenuated, whereas overexpression of mPGES-1 accelerated, PGE2 production and cell proliferation. Moreover, cotransfection of COX-2 and mPGES-1 into HEK293 cells resulted in cellular transformation manifested by colony formation in soft agar culture and tumor formation when implanted subcutaneously into nude mice. cDNA array analyses revealed that this mPGES-1-directed cellular transformation was accompanied by changes in the expression of a variety of genes related to proliferation, morphology, adhesion, and the cell cycle. These results collectively suggest that aberrant expression of mPGES-1 in combination with COX-2 can contribute to tumorigenesis.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Toho Univ, Sch Med, Dept Pathol, Ohta Ku, Tokyo 1438540, Japan	Showa University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.							BARKER HM, 1990, GENOMICS, V7, P159, DOI 10.1016/0888-7543(90)90536-4; Bianco NR, 2002, ONCOGENE, V21, P5233, DOI 10.1038/sj.onc.1205645; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; BROWN LF, 1993, CANCER RES, V53, P4727; Buckingham JC, 1996, BRIT J PHARMACOL, V118, P1; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Filion F, 2001, J BIOL CHEM, V276, P34323, DOI 10.1074/jbc.M103709200; FONAGY A, 1993, J CELL PHYSIOL, V154, P16, DOI 10.1002/jcp.1041540104; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Geiger B, 2002, CELL, V110, P139, DOI 10.1016/S0092-8674(02)00831-0; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Gullick WJ, 1996, CANCER SURV, V27, P339; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Heasley LE, 1997, J BIOL CHEM, V272, P14501, DOI 10.1074/jbc.272.23.14501; Hong KH, 2001, P NATL ACAD SCI USA, V98, P3935, DOI 10.1073/pnas.051635898; HORIKAWA I, 1995, EXP CELL RES, V220, P11, DOI 10.1006/excr.1995.1286; Howe LR, 1999, CANCER RES, V59, P1572; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Jabbour HN, 2001, BRIT J CANCER, V85, P1023; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; KAIPAINEN A, 1993, J EXP MED, V178, P2077, DOI 10.1084/jem.178.6.2077; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kim SW, 2001, J BIOL CHEM, V276, P15712, DOI 10.1074/jbc.M009905200; KONDOH N, 1992, CANCER RES, V52, P791; Lazarus M, 2002, ENDOCRINOLOGY, V143, P2410, DOI 10.1210/en.143.6.2410; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Mancini JA, 2001, J BIOL CHEM, V276, P4469, DOI 10.1074/jbc.M006865200; MARNETT LJ, 1992, CANCER RES, V52, P5575; Matsumoto H, 2002, J BIOL CHEM, V277, P29260, DOI 10.1074/jbc.M203996200; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Mutoh M, 2002, CANCER RES, V62, P28; Naora H, 1999, IMMUNOL CELL BIOL, V77, P197, DOI 10.1046/j.1440-1711.1999.00816.x; Naraba H, 2002, J BIOL CHEM, V277, P28601, DOI 10.1074/jbc.M203618200; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; RAO CV, 1995, CANCER RES, V55, P1464; REINHART WH, 1983, GASTROENTEROLOGY, V85, P1003; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; SAADAT M, 1995, CANCER LETT, V94, P165, DOI 10.1016/0304-3835(95)03846-O; Satoh K, 2000, NEUROSCI LETT, V283, P221, DOI 10.1016/S0304-3940(00)00926-5; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Tang DM, 1996, BIOCHEM CELL BIOL, V74, P419, DOI 10.1139/o96-046; Tanikawa N, 2002, BIOCHEM BIOPH RES CO, V291, P884, DOI 10.1006/bbrc.2002.6531; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Tarricone C, 2001, MOL CELL, V8, P657, DOI 10.1016/S1097-2765(01)00343-4; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Ueki T, 1997, HUM PATHOL, V28, P74, DOI 10.1016/S0046-8177(97)90282-3; Uematsu S, 2002, J IMMUNOL, V168, P5811, DOI 10.4049/jimmunol.168.11.5811; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Watanabe K, 1999, CANCER RES, V59, P5093; Wehrle-Haller B, 2002, TRENDS CELL BIOL, V12, P382, DOI 10.1016/S0962-8924(02)02321-8; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yamagata K, 2001, J NEUROSCI, V21, P2669, DOI 10.1523/JNEUROSCI.21-08-02669.2001; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P3971; Yoshimatsu K, 2001, CLIN CANCER RES, V7, P2669; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110	77	176	188	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19396	19405		10.1074/jbc.M213290200	http://dx.doi.org/10.1074/jbc.M213290200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626523	hybrid			2022-12-27	WOS:000182932200088
J	Lin, X; Liang, M; Liang, YY; Brunicardi, FC; Melchior, F; Feng, XH				Lin, X; Liang, M; Liang, YY; Brunicardi, FC; Melchior, F; Feng, XH			Activation of transforming growth factor-beta signaling by SUMO-1 modification of tumor suppressor Smad4/DPC4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; NUCLEAR-PORE COMPLEX; TGF-BETA; DEPENDENT DEGRADATION; SMAD2; IDENTIFICATION; TRANSCRIPTION; P15(INK4B); RANGAP1; ENZYME	Smads are important intracellular effectors in signaling pathways of the transforming growth factor-beta (TGF-beta) superfamily. Upon activation by TGF-beta, receptor-phosphorylated Smads form a complex with tumor suppressor Smad4/DPC4, and the Smad complexes then are imported into the nucleus. Although diverse pathways regulate the activity and expression of receptor-phosphorylated and inhibitory Smads, cellular factors modulating the activity of the common Smad4 remain unidentified. Here we describe the involvement of the small ubiquitin-like modifier-1 (SUMO-1) conjugation pathway in regulating the growth inhibitory and transcriptional responses of Smad4. The MH1 domain of Smad4 was shown to associate physically with Ubc9, the ubiquitin carrier protein (E2) conjugating enzyme in sumoylation. In cultured cells, Smad4 is modified by SUMO-1 at the endogenous level. The sumoylation sites were identified as two evolutionarily conserved lysine residues, Lys-113 and Lys-159, in the MH1 domain. We found that the mutations at Lys-113 and Lys-159 did not alter the ability of Smad4 to form a complex with Smad2 and FAST on the Mix. 2 promoter. Importantly, SUMO-1 overexpression enhanced TGF-beta-induced transcriptional responses. These findings identify sumoylation as a unique mechanism to modulate Smad4-dependent cellular responses.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Baylor College of Medicine; Baylor College of Medicine; Max Planck Society	Feng, XH (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,Rm 137D, Houston, TX 77030 USA.		Melchior, Frauke/E-2014-2014	Melchior, Frauke/0000-0001-9546-8797	NIGMS NIH HHS [R01 GM63773] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063773] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Muller S, 1999, J VIROL, V73, P5137; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Robertson G, 2001, UASGCP REP, V2001, P43; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Whitman M, 2001, SCI STKE; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	33	105	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18714	18719		10.1074/jbc.M302243200	http://dx.doi.org/10.1074/jbc.M302243200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12621041	hybrid			2022-12-27	WOS:000182932200003
J	Mellwig, C; Bottcher, B				Mellwig, C; Bottcher, B			A unique resting position of the ATP-synthase from chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; ALPHA-SUBUNIT; DELTA-SUBUNIT; PROTON TRANSLOCATION; DIMERIZATION DOMAIN; ANGSTROM RESOLUTION; CATALYTIC SITES; B-SUBUNITS; 2ND STALK; F-1	The chloroplast ATP-synthase catalyzes ATP synthesis coupled to transmembrane proton transport. The enzyme consists of two parts, a membrane-embedded F-0 part and an extrinsic F-1 part, which are linked by two connectors. One of these rotates during catalysis and the other remains static. Although the atomic structures of various sub-complexes and individual subunits have been reported, only limited structural information on the complex, as a whole, is available. In particular, information on the static connector is lacking. We contribute a three-dimensional map at about 20-Angstrom resolution, derived from electron cryomicroscopy of enzymes embedded in vitrified buffer followed by single particle image analysis. In the three-dimensional map both connectors, between the F-1 part and the F-0 part, are clearly visible. The static connector is tightly attached to an alpha subunit and faces the side of the neighboring beta subunit. The three-dimensional map provides a scaffold for fitting in the known atomic structures of various subunits and sub-complexes, and suggests that the oxidized, non-activated ATP-synthase from chloroplasts adopts a unique resting position.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Bottcher, B (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Bottcher, Bettina/E-9397-2010	Bottcher, Bettina/0000-0002-7962-4849				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; BELLARE JR, 1988, J ELECTRON MICR TECH, V10, P87, DOI 10.1002/jemt.1060100111; Bottcher B, 2000, J MOL BIOL, V296, P449, DOI 10.1006/jmbi.1999.3435; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Del Rizzo PA, 2002, BIOCHEMISTRY-US, V41, P6875, DOI 10.1021/bi025736i; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Domgall I, 2002, J BIOL CHEM, V277, P13115, DOI 10.1074/jbc.M112011200; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; Greie JC, 2000, EUR J BIOCHEM, V267, P3040, DOI 10.1046/j.1432-1327.2000.01327.x; Groth G, 2001, J BIOL CHEM, V276, P1345, DOI 10.1074/jbc.M008015200; HARAUZ G, 1986, OPTIK, V73, P146; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNESCH U, 1987, BIOCHIM BIOPHYS ACTA, V893, P275, DOI 10.1016/0005-2728(87)90049-1; JUNGE W, 1970, EUR J BIOCHEM, V14, P582, DOI 10.1111/j.1432-1033.1970.tb00327.x; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; Meier T, 2001, FEBS LETT, V505, P353, DOI 10.1016/S0014-5793(01)02837-X; Mellwig C, 2001, J STRUCT BIOL, V133, P214, DOI 10.1006/jsbi.2001.4340; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Possmayer FE, 2000, BBA-BIOENERGETICS, V1459, P202, DOI 10.1016/S0005-2728(00)00148-1; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	40	35	38	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18544	18549		10.1074/jbc.M212852200	http://dx.doi.org/10.1074/jbc.M212852200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624095	hybrid			2022-12-27	WOS:000182838300125
J	Shindo, M; Irie, K; Masuda, A; Ohigashi, H; Shirai, Y; Miyasaka, K; Saito, N				Shindo, M; Irie, K; Masuda, A; Ohigashi, H; Shirai, Y; Miyasaka, K; Saito, N			Synthesis and phorbol ester binding of the cysteine-rich domains of diacylglycerol kinase (DGK) isozymes - DGK gamma and DGK gamma are new targets of tumor-promoting phorbol esters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; SITE-DIRECTED MUTAGENESIS; PROTEIN-KINASE; MOLECULAR-CLONING; C-DELTA; EXPRESSION; ZINC; SPECIFICITY; ALPHA; IDENTIFICATION	Diacylglycerol kinase (DGK) and protein kinase C (PKC) are two distinct enzyme families associated with diacylglycerol. Both enzymes have cysteine-rich C1 domains (C1A, C1B, and C1C) in the regulatory region. Although most PKC C1 domains strongly bind phorbol esters, there has been no direct evidence that DGK C1 domains bind phorbol esters. We synthesized 11 cysteine-rich sequences of DGK C1 domains with good sequence homology to those of the PKC C1 domains. Among them, only DGKgamma-C1A and DGKbeta-C1A exhibited significant binding to phorbol 12,13-dibutyrate (PDBu). Scatchard analysis of rat-DGKgamma-C1A, human-DGKgamma-C1A, and human-DGKbeta-C1A gave K-d values of 3.6, 2.8, and 14.6 nM, respectively, suggesting that DGKgamma and DGKbeta are new targets of phorbol esters. An A12T mutation of human-GK beta-C1A enhanced the affinity to bind PDBu, indicating that the beta-hydroxyl group of Thr-12 significantly contributes to the binding. The K-d value for PDBu of FLAG-tagged whole rat-DGKgamma (4.4 nM) was nearly equal to that of rat-DGKgamma-C1A (3.6 nM). Moreover, 12-O-tetradecanoylphorbol 13-acetate induced the irreversible translocation of whole rat-DGKgamma and its C1B deletion mutant, not the C1A deletion mutant, from the cytoplasm to the plasma membrane of CHO-K1 cells. These results indicate that 12-O-tetradecanoylphorbol 13-acetate binds to C1A of DGKgamma to cause its translocation.	Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kyoto 6068502, Japan; Appl Biosyst Japan Ltd, Chuo Ku, Tokyo 1040032, Japan; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo 6578501, Japan	Kyoto University; Thermo Fisher Scientific; Applied Biosystems; Kobe University	Irie, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Sakyo Ku, Kitashiirakawa Oiwake Cho, Kyoto 6068502, Japan.		Shirai, Yasuhito/O-3255-2018; Irie, Kazuhiro/A-6121-2014	Irie, Kazuhiro/0000-0001-7109-8568				AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BLUMBERG PM, 1984, MECHANISMS TUMOR PRO, V3, P143; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Caricasole A, 2002, J BIOL CHEM, V277, P4790, DOI 10.1074/jbc.M110249200; CARPINO LA, 1993, J AM CHEM SOC, V115, P4397, DOI 10.1021/ja00063a082; Ding L, 1998, J BIOL CHEM, V273, P32746, DOI 10.1074/jbc.273.49.32746; ENDO Y, 1982, CHEM PHARM BULL, V30, P3457; FUJIKI H, 1985, P JPN ACAD B-PHYS, V61, P45, DOI 10.2183/pjab.61.45; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1992, MOL BRAIN RES, V16, P75, DOI 10.1016/0169-328X(92)90196-I; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; Houssa B, 1997, J BIOL CHEM, V272, P10422; Houssa B, 1998, BIOCHEM J, V331, P677; HUBBARD SR, 1991, SCIENCE, V254, P1776; Hurley JH, 1997, PROTEIN SCI, V6, P477; ICHIKAWA S, 1995, J BIOCHEM-TOKYO, V117, P566, DOI 10.1093/oxfordjournals.jbchem.a124745; Irie K, 1999, BIOORG MED CHEM LETT, V9, P2487, DOI 10.1016/S0960-894X(99)00413-8; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; IRIE K, 1984, AGR BIOL CHEM TOKYO, V48, P1269, DOI 10.1080/00021369.1984.10866289; JAMES HG, 1979, SAS USERS GUIDE, P357; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; Klauck TM, 1996, J BIOL CHEM, V271, P19781, DOI 10.1074/jbc.271.33.19781; MORI T, 1982, J BIOCHEM, V91, P427, DOI 10.1093/oxfordjournals.jbchem.a133714; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; Sakane F, 1996, BIOCHEM J, V318, P583, DOI 10.1042/bj3180583; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; SHARKEY NA, 1985, CANCER RES, V45, P19; Shindo M, 2001, BIOCHEM BIOPH RES CO, V289, P451, DOI 10.1006/bbrc.2001.5935; Shindo M, 2001, BIOORGAN MED CHEM, V9, P2073, DOI 10.1016/S0968-0896(01)00100-6; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; SORG B, 1982, Z NATURFORSCH B, V37, P748; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; van Blitterswijk WJ, 1999, CHEM PHYS LIPIDS, V98, P95, DOI 10.1016/S0009-3084(99)00022-5; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Wang QMJ, 1999, J BIOL CHEM, V274, P37233, DOI 10.1074/jbc.274.52.37233; Wang SM, 1996, J MED CHEM, V39, P2541, DOI 10.1021/jm950403n; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	45	56	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18448	18454		10.1074/jbc.M300400200	http://dx.doi.org/10.1074/jbc.M300400200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621060	hybrid			2022-12-27	WOS:000182838300112
J	Steinbacher, S; Kaiser, J; Eisenreich, W; Huber, R; Bacher, A; Rohdich, F				Steinbacher, S; Kaiser, J; Eisenreich, W; Huber, R; Bacher, A; Rohdich, F			Structural basis of fosmidomycin action revealed by the complex with 2-C-methyl-D-erythritol 4-phosphate synthase (IspC) - Implications for the catalytic mechanism and anti-malaria drug development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE; ISOPRENOID BIOSYNTHESIS; NONMEVALONATE PATHWAY; CRYSTAL-STRUCTURE; PHOSPHATE-PATHWAY; ESCHERICHIA-COLI; TERPENOIDS; SEQUENCE; ENZYME	2-C-Methyl-D-erythritol 4-phosphate synthase ( IspC) is the first enzyme committed to isoprenoid biosynthesis in the methylerythritol phosphate pathway, which represents an alternative route to the classical mevalonate pathway. As it is present in many pathogens and plants, but not in man, this pathway has attracted considerable interest as a target for novel antibiotics and herbicides. Fosmidomycin represents a specific high-affinity inhibitor of IspC. Very recently, its anti-malaria activity in man has been demonstrated in clinical trials. Here, we present the crystal structure of Escherichia coli IspC in complex with manganese and fosmidomycin at 2.5 Angstrom resolution. The (N-formyl-N-hydroxy) amino group provides two oxygen ligands to manganese that is present in a distorted octahedral coordination, whereas the phosphonate group is anchored in a specific pocket by numerous hydrogen bonds. Both sites are connected by a spacer of three methylene groups. The substrate molecule, 1-D-deoxyxylulose 5- phosphate, can be superimposed onto fosmidomycin, explaining the stereochemical course of the reaction.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-8046 Garching, Germany	Max Planck Society; Technical University of Munich	Steinbacher, S (corresponding author), CALTECH, Div Chem & Chem Engn, Mail Code 114-96, Pasadena, CA 91125 USA.	steinbac@caltech.edu	Eisenreich, Wolfgang/A-1258-2013; Kaiser, Johannes/F-7745-2013	Eisenreich, Wolfgang/0000-0002-9832-8279; Kaiser, Johannes/0000-0003-1949-4744				Arigoni D, 1997, P NATL ACAD SCI USA, V94, P10600, DOI 10.1073/pnas.94.20.10600; Arigoni D, 1999, CHEM COMMUN, P1127, DOI 10.1039/a902216c; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BROERS STJ, 1994, THESIS EIDGENOSSICHE; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dumas R, 2001, ACCOUNTS CHEM RES, V34, P399, DOI 10.1021/ar000082w; Duvold T, 1997, TETRAHEDRON LETT, V38, P4769, DOI 10.1016/S0040-4039(97)01045-9; Eisenreich W, 2001, TRENDS PLANT SCI, V6, P78, DOI 10.1016/S1360-1385(00)01812-4; Eisenreich W, 1996, P NATL ACAD SCI USA, V93, P6431, DOI 10.1073/pnas.93.13.6431; Eisenreich W, 1998, CHEM BIOL, V5, pR221, DOI 10.1016/S1074-5521(98)90002-3; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Frankish H, 2002, LANCET, V360, P1075, DOI 10.1016/S0140-6736(02)11179-2; Gardner MJ, 2002, NATURE, V419, P531, DOI 10.1038/nature01094; Hecht S, 2001, J ORG CHEM, V66, P7770, DOI 10.1021/jo015890v; Hoeffler JF, 2002, EUR J BIOCHEM, V269, P4446, DOI 10.1046/j.1432-1033.2002.03150.x; Hyman RW, 2002, NATURE, V419, P534, DOI 10.1038/nature01102; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Koppisch AT, 2002, BIOCHEMISTRY-US, V41, P236, DOI 10.1021/bi0118207; Kuzuyama T, 2000, J BIOL CHEM, V275, P19928, DOI 10.1074/jbc.M001820200; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P7913, DOI 10.1016/S0040-4039(98)01755-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Missinou MA, 2002, LANCET, V360, P1941, DOI 10.1016/S0140-6736(02)11860-5; OKUHARA M, 1980, J ANTIBIOT, V33, P13, DOI 10.7164/antibiotics.33.13; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellecchia M, 2002, J BIOMOL NMR, V22, P165, DOI 10.1023/A:1014256707875; Proteau PJ, 1999, ORG LETT, V1, P921, DOI 10.1021/ol990839n; Radykewicz T, 2000, FEBS LETT, V465, P157, DOI 10.1016/S0014-5793(99)01743-3; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Reuter K, 2002, J BIOL CHEM, V277, P5378, DOI 10.1074/jbc.M109500200; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; Rohmer M., 1999, COMPR NAT PROD CHEM, V2, P45, DOI 10.1016/B978-0-08-091283-7.00036-9; Rowsell S, 2002, J MOL BIOL, V319, P173, DOI 10.1016/S0022-2836(02)00262-0; Schwarz M, 1999, COMPREHENSIVE NATURA, V2, P367, DOI DOI 10.1016/B978-0-08-091283-7.00043-6; SCHWARZ MK, 1994, THESIS EIDGENOSSICHE; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; Trouiller P, 2002, LANCET, V359, P2188, DOI 10.1016/S0140-6736(02)09096-7; TURK D, 1992, THESIS TU MUNCHEN MU; Vial HJ, 2000, PARASITOL TODAY, V16, P140, DOI 10.1016/S0169-4758(00)01638-0; Wellems TE, 2002, SCIENCE, V298, P124, DOI 10.1126/science.1078167; Yajima S, 2002, J BIOCHEM, V131, P313, DOI 10.1093/oxfordjournals.jbchem.a003105; Zeidler J, 1998, Z NATURFORSCH C, V53, P980	41	147	157	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18401	18407		10.1074/jbc.M300993200	http://dx.doi.org/10.1074/jbc.M300993200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621040	Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000182838300106
J	Vitavska, O; Wieczorek, H; Merzendorfer, H				Vitavska, O; Wieczorek, H; Merzendorfer, H			A novel role for subunit C in mediating binding of the H+-V-ATPase to the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO HORNWORM MIDGUT; ANIMAL PLASMA-MEMBRANE; VACUOLAR-TYPE ATPASE; PROTON PUMP; TRANSPORTING EPITHELIA; ION-TRANSPORT; IN-VIVO; CLATHRIN; PURIFICATION; DISSOCIATION	Primary proton transport by V-ATPases is regulated via the reversible dissociation of the V1V0 holoenzyme into its V-1 and V-0 subcomplexes. Laser scanning microscopy of different tissues from the tobacco hornworm revealed co-localization of the holoenzyme and F-actin close to the apical membranes of the epithelial cells. In midgut goblet cells, no co-localization was observed under conditions where the V-1 complex detaches from the apical membrane. Binding studies, however, demonstrated that both the V-1 complex and the holoenzyme interact with F-actin, the latter with an apparently higher affinity. To identify F-actin binding subunits, we performed overlay blots that revealed two V-1 subunits as binding partners, namely subunit B, resembling the situation in the osteoclast V-ATPase (Holliday, L. S., Lu, M., Lee, B. S., Nelson, R. D., Solivan, S., Zhang, L., and Gluck, S. L. (2000) J. Biol. Chem. 275, 32331-32337), but, in addition, subunit C, which gets released during reversible dissociation of the holoenzyme. Overlay blots and co-pelleting assays showed that the recombinant subunit Calso binds to F-actin. When the V-1 complex was reconstituted with recombinant subunit C, enhanced binding to F-actin was observed. Thus, subunit C may function as an anchor protein regulating the linkage between V-ATPase and the actin-based cytoskeleton.	Univ Osnabruck, Dept Biol Chem, Div Anim Physiol, D-49069 Osnabruck, Germany	University Osnabruck	Merzendorfer, H (corresponding author), Univ Osnabruck, Dept Biol Chem, Div Anim Physiol, D-49069 Osnabruck, Germany.							ARNOLD H, 1970, EUR J BIOCHEM, V15, P360, DOI 10.1111/j.1432-1033.1970.tb01016.x; Baumann O, 2001, EXP CELL RES, V270, P176, DOI 10.1006/excr.2001.5343; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BONFANTI P, 1992, EUR J CELL BIOL, V57, P298; CIOFFI M, 1979, TISSUE CELL, V11, P467, DOI 10.1016/0040-8166(79)90057-0; Denker SP, 2002, CURR OPIN CELL BIOL, V14, P214, DOI 10.1016/S0955-0674(02)00304-6; Geyer M, 2002, J BIOL CHEM, V277, P28521, DOI 10.1074/jbc.M200522200; Geyer M, 2002, MOL BIOL CELL, V13, P2045, DOI 10.1091/mbc.02-02-0026; Graf R, 1996, J BIOL CHEM, V271, P20908, DOI 10.1074/jbc.271.34.20908; GRAF R, 1994, BBA-BIOMEMBRANES, V1190, P193, DOI 10.1016/0005-2736(94)90053-1; HO MN, 1993, J BIOL CHEM, V268, P221; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; HUSS M, 2001, STRUCTURE FUNCTION R; JUNGREIS AM, 1977, J INSECT PHYSIOL, V23, P503, DOI 10.1016/0022-1910(77)90261-X; KANE PM, 1995, J BIOL CHEM, V270, P17025; KLEIN U, 1992, J EXP BIOL, V172, P345; KLEIN U, 1991, J EXP BIOL, V161, P61; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; LIU Q, 1994, J BIOL CHEM, V269, P31592; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Mandic R, 2001, MOL BIOL CELL, V12, P463, DOI 10.1091/mbc.12.2.463; MARQUETANT R, 1986, ARCH BIOCHEM BIOPHYS, V245, P404, DOI 10.1016/0003-9861(86)90231-6; Merzendorfer H, 1997, FEBS LETT, V411, P239, DOI 10.1016/S0014-5793(97)00699-6; Merzendorfer H, 2000, BBA-BIOMEMBRANES, V1467, P369, DOI 10.1016/S0005-2736(00)00233-9; MYERS M, 1993, J BIOL CHEM, V268, P9184; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Price NC, 1996, ENZYMOLOGY LABFAX, P34; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Smardon AM, 2002, J BIOL CHEM, V277, P13831, DOI 10.1074/jbc.M200682200; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Svergun DI, 1998, BIOCHEMISTRY-US, V37, P17659, DOI 10.1021/bi982367a; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; WIECZOREK H, 1991, J BIOL CHEM, V266, P15340; Wieczorek H, 2000, J EXP BIOL, V203, P127; WIECZOREK H, 1990, METHOD ENZYMOL, V192, P608; Xu T, 2001, J BIOL CHEM, V276, P24855, DOI 10.1074/jbc.M100637200	42	121	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18499	18505		10.1074/jbc.M212844200	http://dx.doi.org/10.1074/jbc.M212844200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12606563	hybrid			2022-12-27	WOS:000182838300119
J	Whitlow, RD; Sacher, A; Loo, DDF; Nelson, N; Eskandari, S				Whitlow, RD; Sacher, A; Loo, DDF; Nelson, N; Eskandari, S			The anticonvulsant valproate increases the turnover rate of gamma-aminobutyric acid transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA UPTAKE INHIBITORS; NA+CL COTRANSPORT FUNCTION; OOCYTE MEMBRANE PATCHES; XENOPUS-LAEVIS OOCYTES; SODIUM VALPROATE; SUBSTANTIA-NIGRA; EXTRACELLULAR GABA; STEADY-STATE; NA+/GLUCOSE COTRANSPORTER; AMINOOXYACETIC ACID	Valproate is an important anticonvulsant currently in clinical use for the treatment of seizures. We used electrophysiological and tracer uptake methods to examine the effect of valproate on a gamma-aminobutyric acid (GABA) transporter (mouse GAT3) expressed in Xenopus laevis oocytes. In the absence of GABA, valproate (up to 50 mM) had no noticeable effect on the steady-state electrogenic properties of mGAT3. In the presence of GABA, however, valproate enhanced the GABA-evoked steady-state inward current in a dose-dependent manner with a half-maximal concentration of 4.6 +/- 0.5 mM. Maximal enhancement of the GABA-evoked current was 275 +/- 10%. Qualitatively similar observations were obtained for human GAT1 and mouse GAT4. The valproate enhancement did not alter the Na+ or Cl- dependence of the steady-state GABA-evoked currents. Uptake experiments under voltage clamp suggested that the valproate enhancement of the GABA-evoked current was matched by an enhancement in GABA uptake. Thus, despite the increase in GABA-evoked current, ion/GABA co-transport remained tightly coupled. Uptake experiments indicated that valproate is not transported by mouse GAT3 in the absence or presence of GABA. Valproate also enhanced the rate of the partial steps involved in transporter presteady-state charge movements. We propose that valproate increases the turnover rate of GABA transporters by an allosteric mechanism. The data suggest that at its therapeutic concentration, valproate may enhance the activity of neuronal and glial GABA transporters by up to 10%.	Calif State Polytech Univ Pomona, Dept Biol Sci, Pomona, CA 91768 USA; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	California State University System; California State Polytechnic University Pomona; Tel Aviv University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Eskandari, S (corresponding author), Calif State Polytech Univ Pomona, Dept Biol Sci, 3801 W Temple Ave, Pomona, CA 91768 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM053933] Funding Source: NIH RePORTER; NIGMS NIH HHS [S06 GM53933] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGGS CS, 1992, BRAIN RES, V594, P138, DOI 10.1016/0006-8993(92)91038-G; Borden LA, 1996, NEUROCHEM INT, V29, P335, DOI 10.1016/0197-0186(95)00158-1; CLARK JA, 1994, MOL PHARMACOL, V46, P550; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Dalby NO, 1997, EPILEPSY RES, V28, P51, DOI 10.1016/S0920-1211(97)00033-8; Dalby NO, 2000, NEUROPHARMACOLOGY, V39, P2399, DOI 10.1016/S0028-3908(00)00075-7; Eckstein-Ludwig U, 1999, BRIT J PHARMACOL, V128, P92, DOI 10.1038/sj.bjp.0702794; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FARRANT M, 1989, BRAIN RES, V504, P49, DOI 10.1016/0006-8993(89)91596-5; FINKJENSEN A, 1992, EUR J PHARMACOL, V220, P197, DOI 10.1016/0014-2999(92)90748-S; Fraser CM, 1999, EPILEPTIC DISORD, V1, P153; GODIN Y, 1969, J NEUROCHEM, V16, P869, DOI 10.1111/j.1471-4159.1969.tb08975.x; GRAM L, 1988, EPILEPSY RES, V2, P87, DOI 10.1016/0920-1211(88)90024-1; Green AR, 2000, NEUROPHARMACOLOGY, V39, P1483, DOI 10.1016/S0028-3908(99)00233-6; HACKMAN JC, 1981, BRAIN RES, V220, P269, DOI 10.1016/0006-8993(81)91217-8; Hirsch JR, 1996, J BIOL CHEM, V271, P14740, DOI 10.1074/jbc.271.25.14740; HYDEN H, 1984, NEUROPHARMACOLOGY, V23, P319, DOI 10.1016/0028-3908(84)90193-X; IADAROLA MJ, 1979, J NEUROCHEM, V33, P1119, DOI 10.1111/j.1471-4159.1979.tb05250.x; IADAROLA MJ, 1979, EUR J PHARMACOL, V59, P125, DOI 10.1016/0014-2999(79)90034-7; Johannessen CU, 2000, NEUROCHEM INT, V37, P103, DOI 10.1016/S0197-0186(00)00013-9; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; Kwan P, 2001, PHARMACOL THERAPEUT, V90, P21, DOI 10.1016/S0163-7258(01)00122-X; LARSSON OM, 1986, NEUROPHARMACOLOGY, V25, P617, DOI 10.1016/0028-3908(86)90214-5; Li M, 2000, J GEN PHYSIOL, V115, P491, DOI 10.1085/jgp.115.4.491; LIU QR, 1993, J BIOL CHEM, V268, P2106; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Loo DDF, 2000, J BIOL CHEM, V275, P37414, DOI 10.1074/jbc.M007241200; Loscher W, 1999, PROG NEUROBIOL, V58, P31, DOI 10.1016/S0301-0082(98)00075-6; LOSCHER W, 1980, J NEUROCHEM, V34, P1603, DOI 10.1111/j.1471-4159.1980.tb11250.x; LOSCHER W, 1984, LANCET, V2, P225; LOSCHER W, 1985, BIOCHEM PHARMACOL, V34, P1747, DOI 10.1016/0006-2952(85)90645-8; LOSCHER W, 1989, BRAIN RES, V501, P198, DOI 10.1016/0006-8993(89)91044-5; LOSCHER W, 1985, EPILEPSIA, V26, P314, DOI 10.1111/j.1528-1157.1985.tb05656.x; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; Lu CC, 1999, J GEN PHYSIOL, V114, P445, DOI 10.1085/jgp.114.3.445; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Matskevitch I, 1999, J BIOL CHEM, V274, P16709, DOI 10.1074/jbc.274.24.16709; Morimoto K, 1997, EPILEPSIA, V38, P966, DOI 10.1111/j.1528-1157.1997.tb01478.x; Nelson N, 1998, J NEUROCHEM, V71, P1785; NIELSEN EB, 1991, EUR J PHARMACOL, V196, P257, DOI 10.1016/0014-2999(91)90438-V; NILSSON M, 1992, NEUROCHEM RES, V17, P327, DOI 10.1007/BF00974573; Richards DA, 1996, NEUROCHEM RES, V21, P135, DOI 10.1007/BF02529130; Roettger V R, 1999, Adv Neurol, V79, P551; ROSS SM, 1981, J NEUROCHEM, V36, P1006, DOI 10.1111/j.1471-4159.1981.tb01693.x; Rowley HL, 1995, EUR J PHARMACOL, V294, P541, DOI 10.1016/0014-2999(95)00589-7; Sacher A, 2002, J MEMBRANE BIOL, V190, P57, DOI 10.1007/s00232-002-1024-6; SAYIN U, 1995, BRAIN RES, V669, P67, DOI 10.1016/0006-8993(94)01240-I; SUZDAK PD, 1992, EUR J PHARMACOL, V224, P189, DOI 10.1016/0014-2999(92)90804-D; SWINYARD EA, 1991, EPILEPSIA, V32, P569, DOI 10.1111/j.1528-1157.1991.tb04694.x; TAYLOR CP, 1992, EPILEPSY RES, V11, P103, DOI 10.1016/0920-1211(92)90044-T; VANDERLAAN JW, 1979, J NEUROCHEM, V32, P1769, DOI 10.1111/j.1471-4159.1979.tb02290.x; WOLF R, 1994, EPILEPSIA, V35, P226, DOI 10.1111/j.1528-1157.1994.tb02938.x; YUNGER LM, 1984, J PHARMACOL EXP THER, V228, P109; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507	57	23	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17716	17726		10.1074/jbc.M207582200	http://dx.doi.org/10.1074/jbc.M207582200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12595533	hybrid			2022-12-27	WOS:000182838300018
J	Chen, Y; Wen, RR; Yang, S; Shuman, J; Zhang, EE; Yi, TL; Feng, GS; Wang, DM				Chen, Y; Wen, RR; Yang, S; Shuman, J; Zhang, EE; Yi, TL; Feng, GS; Wang, DM			Identification of Shp-2 as a Stat5A phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; GROWTH-HORMONE; ERYTHROPOIETIN RECEPTOR; HEMATOPOIETIC-CELLS; NEGATIVE REGULATOR; PATHWAY; PROLACTIN; DEPHOSPHORYLATION	Stat5A, a member of the signal transducers and activators of transcription (Stat) family, is activated upon a single tyrosine phosphorylation. Although much is known about the activation process, the mechanism by which the tyrosine-phosphorylated Stat5A proteins are inactivated is largely unknown. In this report, we demonstrate that down-regulation of the tyrosine-phosphorylated Stat5A was via dephosphorylation. Using tyrosine-phosphorylated peptides derived from Stat5A, we were able to purify protein-tyrosine phosphatase Shp-2 from cell lysates. Shp-2, but not Shp-1, specifically interacted with Stat5A in vivo, and the interaction was tyrosine phosphorylation-dependent. Moreover, Shp-2 was able to accelerate Stat5A dephosphorylation, and dephosphorylation of Stat5A was dramatically delayed in Shp-2-deficient cells. Therefore, we conclude that Shp-2 is a Stat5A phosphatase, which down-regulates the active Stat5A in vivo.	Blood Ctr SE Wisconsin Inc, Blood Res Inst, Milwaukee, WI 53226 USA; Nanjing Univ, Inst Mol Med, Nanjing 210008, Peoples R China; Cleveland Clin Fdn, Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Burnham Inst, La Jolla, CA 92037 USA; Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Versiti Blood Center of Wisconsin; Nanjing University; Cleveland Clinic Foundation; Sanford Burnham Prebys Medical Discovery Institute; Medical College of Wisconsin	Wang, DM (corresponding author), Blood Ctr SE Wisconsin Inc, Blood Res Inst, 8727 Watertown Plank Rd, Milwaukee, WI 53226 USA.		Wang, Demin/AAX-4449-2020	Wang, Demin/0000-0001-5549-3795; Zhang, Eric/0000-0002-4472-7493	NCI NIH HHS [R01 CA78606, 1R01CA79891] Funding Source: Medline; NHLBI NIH HHS [R01 HL073284] Funding Source: Medline; NIAID NIH HHS [R01 AI52327-01] Funding Source: Medline; NIGMS NIH HHS [1R01GM58893, R01GM53660] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078606, R01CA079891] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052327] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058893, R01GM053660] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Aoki N, 2002, MOL ENDOCRINOL, V16, P58, DOI 10.1210/me.16.1.58; Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rolling C, 1996, FEBS LETT, V393, P53, DOI 10.1016/0014-5793(96)00835-6; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Yokoyama N, 2001, J INTERF CYTOK RES, V21, P369, DOI 10.1089/107999001750277844; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599	53	89	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16520	16527		10.1074/jbc.M210572200	http://dx.doi.org/10.1074/jbc.M210572200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615921	hybrid			2022-12-27	WOS:000182818600012
J	Chen, Y; Thai, P; Zhao, YH; Ho, YS; DeSouza, MM; Wu, R				Chen, Y; Thai, P; Zhao, YH; Ho, YS; DeSouza, MM; Wu, R			Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY EPITHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; NEUTROPHIL ELASTASE; MUCOCILIARY DIFFERENTIATION; MUCUS ACCUMULATION; PROTEIN EXPRESSION; TRANSGENIC MICE; MESSENGER-RNA; MUC5B MUCIN; IN-VIVO	Mucus hypersecretion and persistent airway inflammation are common features of various airway diseases, such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis. One key question is: does the associated airway inflammation in these diseases affect mucus production? If so, what is the underlying mechanism? It appears that increased mucus secretion results from increased mucin gene expression and is also frequently accompanied by an increased number of mucous cells (goblet cell hyperplasia/metaplasia) in the airway epithelium. Many studies on mucin gene expression have been directed toward Th2 cytokines such as interleukin (IL)-4, IL-9, and IL-13 because of their known pathophysiological role in allergic airway diseases such as asthma. However, the effect of these cytokines has not been definitely linked to their direct interaction with airway epithelial cells. In our study, we treated highly differentiated cultures of primary human tracheobronchial epithelial (TBE) cells with a panel of cytokines (interleukin-1alpha, 1beta, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 15, 16, 17, 18, and tumor necrosis factor alpha). We found that IL-6 and IL-17 could stimulate the mucin genes, MUC5B and MUC5AC. The Th2 cytokines IL-4, IL-9, and IL-13 did not stimulate MUC5AC or MUC5B in our experiments. A similar stimulation of MUC5B/Muc5b expression by IL-6 and IL-17 was demonstrated in primary monkey and mouse TBE cells. Further investigation of MUC5B expression demonstrated that IL-17's effect is at least partly mediated through IL-6 by a JAK2-dependent autocrine/paracrine loop. Finally, evidence is presented to show that both IL-6 and IL-17 mediate MUC5B expression through the ERK signaling pathway.	Univ Calif Davis, Ctr Comparat Resp Biol & Med, Davis, CA 95616 USA; Univ Calif Davis, Div Pulm & Crit Care Med, Davis, CA 95616 USA; Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI 48201 USA; GlaxoSmithKline, King Of Prussia, PA 19406 USA	University of California System; University of California Davis; University of California System; University of California Davis; Wayne State University; GlaxoSmithKline	Wu, R (corresponding author), Univ Calif Davis, Ctr Comparat Resp Biol & Med, Surge 1 Annex,Room 1121,1 Shields Ave, Davis, CA 95616 USA.	rwu@ucdavis.edu			NHLBI NIH HHS [HL35635] Funding Source: Medline; NIAID NIH HHS [AI50496] Funding Source: Medline; NIEHS NIH HHS [ES04699, ES00628, ES09701, ES05707, ES06230] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035635, R37HL035635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699, R01ES009701, R01ES006230] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Alimam MZ, 2000, AM J RESP CELL MOL, V22, P253, DOI 10.1165/ajrcmb.22.3.3768; Antonysamy MA, 1999, J IMMUNOL, V162, P577; Borchers MT, 1999, AM J PHYSIOL-LUNG C, V276, pL549, DOI 10.1152/ajplung.1999.276.4.L549; Burgel PR, 2001, J IMMUNOL, V167, P5948, DOI 10.4049/jimmunol.167.10.5948; Carroll N, 1996, EUR RESPIR J, V9, P709, DOI 10.1183/09031936.96.09040709; Chabaud M, 2001, ARTHRITIS RES, V3, P168, DOI 10.1186/ar294; Chen Y, 2001, AM J RESP CELL MOL, V25, P542, DOI 10.1165/ajrcmb.25.5.4298; Chen Y, 2001, AM J RESP CELL MOL, V25, P409, DOI 10.1165/ajrcmb.25.4.4413; Chen Y, 2001, AM J RESP CRIT CARE, V164, P1059, DOI 10.1164/ajrccm.164.6.2012114; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung KF, 2001, EUR RESPIR J, V18, p50S, DOI 10.1183/09031936.01.00229701; COHN LA, 1992, EXP LUNG RES, V18, P299, DOI 10.3109/01902149209031687; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Davies JR, 1999, BIOCHEM J, V344, P321, DOI 10.1042/0264-6021:3440321; Debailleul V, 1998, J BIOL CHEM, V273, P881, DOI 10.1074/jbc.273.2.881; DICOSMO BF, 1994, J CLIN INVEST, V94, P2028, DOI 10.1172/JCI117556; Fischer BM, 2002, AM J RESP CELL MOL, V26, P447, DOI 10.1165/ajrcmb.26.4.4473; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Hirano T, 1998, Int Rev Immunol, V16, P249; Hovenberg HW, 1996, BIOCHEM J, V318, P319, DOI 10.1042/bj3180319; Hovenberg HW, 1996, GLYCOCONJUGATE J, V13, P839, DOI 10.1007/BF00702348; Hsieh HG, 2002, CYTOKINE, V19, P159, DOI 10.1006/cyto.2002.1952; Jayawickreme SP, 1999, AM J PHYSIOL-LUNG C, V276, pL596, DOI 10.1152/ajplung.1999.276.4.L596; Jeffery PK, 2000, CHEST, V117, p251S, DOI 10.1378/chest.117.5_suppl_1.251S; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; KALINER M, 1986, AM REV RESPIR DIS, V134, P612; Kim CH, 2002, ACTA OTO-LARYNGOL, V122, P638, DOI 10.1080/000164802320396321; Kim YD, 2002, MOL PHARMACOL, V62, P1112, DOI 10.1124/mol.62.5.1112; KING M, 1980, FED PROC, V39, P3080; Kips JC, 2001, EUR RESPIR J, V18, p24S, DOI 10.1183/09031936.01.00229601; Kondo M, 2002, AM J RESP CELL MOL, V27, P536, DOI 10.1165/rcmb.4682; Koo JS, 2002, EXP LUNG RES, V28, P315, DOI 10.1080/01902140252964393; Laan M, 1999, J IMMUNOL, V162, P2347; Laoukili J, 2001, J CLIN INVEST, V108, P1817, DOI 10.1172/JCI13557; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; McKenzie RW, 2000, INVEST OPHTH VIS SCI, V41, P703; McMillan S, 2002, J EXP MED, V195, P51, DOI 10.1084/jem.20011732; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; MURRAY JF, 2000, TXB RESP MED, P443; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Ogata A, 1997, J IMMUNOL, V159, P2212; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Rose MC, 2000, J AEROSOL MED, V13, P245, DOI 10.1089/jam.2000.13.245; SCHNEEBERGER EE, 1978, J CELL SCI, V32, P307; Sheehan JK, 1999, BIOCHEM J, V338, P507, DOI 10.1042/0264-6021:3380507; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134, DOI 10.1152/ajplung.2001.280.1.L134; Singer M, 2002, AM J RESP CELL MOL, V26, P74, DOI 10.1165/ajrcmb.26.1.4618; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V259, P172, DOI 10.1006/bbrc.1999.0746; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V262, P14, DOI 10.1006/bbrc.1999.1156; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Temann UA, 1997, AM J RESP CELL MOL, V16, P471, DOI 10.1165/ajrcmb.16.4.9115759; Thornton DJ, 1997, J BIOL CHEM, V272, P9561; Thornton DJ, 1996, BIOCHEM J, V316, P967, DOI 10.1042/bj3160967; Thornton DJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1118, DOI 10.1152/ajplung.2000.278.6.L1118; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; Voynow JA, 1999, AM J PHYSIOL-LUNG C, V276, pL835; Voynow Judith A, 2002, Paediatr Respir Rev, V3, P98, DOI 10.1016/S1526-0550(02)00007-0; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Witowski J, 2000, J IMMUNOL, V165, P5814, DOI 10.4049/jimmunol.165.10.5814; Wu R, 1997, EUR RESPIR J, V10, P2398, DOI 10.1183/09031936.97.10102398; WU R, 1986, IN VITRO MODELS RESP, P1; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; YOO ZB, 1995, J IMMUNOL, V155, P5483; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Ziolkowska N, 2000, J IMMUNOL, V164, P2832, DOI 10.4049/jimmunol.164.5.2832	74	430	454	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17036	17043		10.1074/jbc.M210429200	http://dx.doi.org/10.1074/jbc.M210429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624114	hybrid			2022-12-27	WOS:000182818600080
J	Gu, ZL; Zhong, P; Yan, Z				Gu, ZL; Zhong, P; Yan, Z			Activation of muscarinic receptors inhibits beta-amyloid peptide-induced signaling in cortical slices	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LONG-TERM POTENTIATION; FOCAL ADHESION KINASE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; TRANSGENIC MICE; TYROSINE PHOSPHORYLATION; ACETYLCHOLINE-RECEPTOR; SYNAPTIC PLASTICITY; BASAL FOREBRAIN	Deposition of fibrillar aggregates of the beta-amyloid peptide (Abeta)is a key pathologic feature during the early stage of Alzheimer's disease. The initial neuronal responses to Abeta in cortical circuits and the regulation of Abeta-induced signaling remain unclear. In this study, we found that exposure of cortical slices to Abeta(1-42) or Abeta(25-35) induced a marked increase in the activation of protein kinase C (PKC) and Ca2+/calmodulin-dependent kinase II (CaMKII), two enzymes critically involved in a variety of cellular functions. Activation of M1 muscarinic receptors, but not nicotinic receptors, significantly inhibited the Abeta activation of PKC and CaMKII. Increasing inhibitory transmission mimicked the M1 effect on Abeta, whereas blocking GABA(A) receptors eliminated the M1 action. Moreover, electrophysiological evidence shows that application of Abeta to cortical slices induced action potential firing and enhanced excitatory postsynaptic currents, whereas muscarinic agonists potently increased inhibitory postsynaptic currents. These results suggest that Abeta activates PKC and CaMKII through enhancing excitatory activity in glutamatergic synaptic networks. Activation of M1 receptors inhibits Abeta signaling by enhancing the counteracting GABA(ergic) inhibitory transmission. Thus the muscarinic reversal of the Abeta-induced biochemical and physiological changes provides a potential mechanism for the treatment of Alzheimer's disease with cholinergic enhancers.	SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Yan, Z (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, 124 Sherman Hall, Buffalo, NY 14214 USA.				NIMH NIH HHS [MH63128] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063128] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adem A, 1997, LIFE SCI, V60, P1069, DOI 10.1016/S0024-3205(97)00049-0; Auld DS, 1998, TRENDS NEUROSCI, V21, P43, DOI 10.1016/S0166-2236(97)01144-2; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRORSON JR, 1995, J NEUROBIOL, V26, P325, DOI 10.1002/neu.480260305; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; Cai X, 2002, J PHYSIOL-LONDON, V540, P743; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Combs CK, 1999, J NEUROSCI, V19, P928; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DAVIDSON RM, 1994, BRAIN RES, V643, P324, DOI 10.1016/0006-8993(94)90041-8; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Feng J, 2001, J NEUROSCI, V21, P6502, DOI 10.1523/JNEUROSCI.21-17-06502.2001; Fisher A, 2000, ANN NY ACAD SCI, V920, P315; Fraser SP, 1997, TRENDS NEUROSCI, V20, P67, DOI 10.1016/S0166-2236(96)10079-5; FURUKAWA K, 1994, NEUROREPORT, V5, P2016, DOI 10.1097/00001756-199410270-00006; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HAASS C, 1992, NATURE, V359, P325; HAMMER R, 1980, NATURE, V283, P90, DOI 10.1038/283090a0; Hoshi M, 1997, J BIOL CHEM, V272, P2038, DOI 10.1074/jbc.272.4.2038; Hsiao K, 1998, PROG BRAIN RES, V117, P335; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Irizarry MC, 1997, J NEUROSCI, V17, P7053; Jhamandas JH, 2001, J NEUROPHYSIOL, V86, P1312, DOI 10.1152/jn.2001.86.3.1312; Jope RS, 1997, NEUROBIOL AGING, V18, P111, DOI 10.1016/S0197-4580(96)00205-9; Kar S, 1996, J NEUROSCI, V16, P1034; Kawaguchi Y, 1997, J NEUROPHYSIOL, V78, P1743, DOI 10.1152/jn.1997.78.3.1743; Kelly JF, 1996, P NATL ACAD SCI USA, V93, P6753, DOI 10.1073/pnas.93.13.6753; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; Kondo S, 2001, NEUROSCIENCE, V107, P551, DOI 10.1016/S0306-4522(01)00388-8; LEVEY AI, 1991, J NEUROSCI, V11, P3218; Lin L, 1999, P NATL ACAD SCI USA, V96, P12108, DOI 10.1073/pnas.96.21.12108; LUO YQ, 1995, BRAIN RES, V681, P65, DOI 10.1016/0006-8993(95)00282-U; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; McDonald DR, 1998, J NEUROSCI, V18, P4451; Messer William S. Jr., 2002, Current Topics in Medicinal Chemistry, V2, P353, DOI 10.2174/1568026024607553; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; Nayak AS, 1996, P NATL ACAD SCI USA, V93, P15451, DOI 10.1073/pnas.93.26.15451; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; Quinlan EM, 1996, J NEUROSCI, V16, P7627; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Serpell LC, 2000, BBA-MOL BASIS DIS, V1502, P16, DOI 10.1016/S0925-4439(00)00029-6; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SIMMONS MA, 1993, NEUROSCI LETT, V150, P133, DOI 10.1016/0304-3940(93)90519-Q; SITARAM N, 1978, SCIENCE, V201, P274, DOI 10.1126/science.351808; Small DH, 2001, NAT REV NEUROSCI, V2, P595, DOI 10.1038/35086072; Soderling TR, 2000, CURR OPIN NEUROBIOL, V10, P375, DOI 10.1016/S0959-4388(00)00090-8; Sommer B, 2002, CURR OPIN PHARMACOL, V2, P87, DOI 10.1016/S1471-4892(01)00126-6; Stewart AE, 1999, J NEUROPHYSIOL, V81, P72, DOI 10.1152/jn.1999.81.1.72; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Weinstock M, 1995, NEURODEGENERATION, V4, P349, DOI 10.1006/neur.1995.0042; WEISS JH, 1994, J NEUROCHEM, V62, P372; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; WHITEHOUSE PJ, 1981, ANN NEUROL, V10, P122, DOI 10.1002/ana.410100203; Williamson R, 2002, J NEUROSCI, V22, P10, DOI 10.1523/JNEUROSCI.22-01-00010.2002; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZHANG C, 1994, J BIOL CHEM, V269, P25247	71	43	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17546	17556		10.1074/jbc.M209892200	http://dx.doi.org/10.1074/jbc.M209892200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606559	hybrid			2022-12-27	WOS:000182818600144
J	Yang, L; Lin, HK; Altuwaijri, S; Xie, SZ; Wang, L; Chang, C				Yang, L; Lin, HK; Altuwaijri, S; Xie, SZ; Wang, L; Chang, C			APPL suppresses androgen receptor transactivation via potentiating Akt activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; INDUCED APOPTOSIS; C-AKT; SURVIVAL; COACTIVATOR; GROWTH; RAS	APPL may function as an adapter protein to modulate the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Although we have previously proven that the PI3K/Akt pathway can suppress androgen receptor (AR) transactivation, the potential linkage from APPL to the AR remains unclear. Here we demonstrated that APPL could suppress AR-mediated transactivation in a dose-dependent manner in LNCaP and PC-3 cells. This suppressive effect could be blocked by either dominant-negative Akt or dominant-negative PI3K or LY294002, suggesting that the APPL-mediated suppression of AR transactivation is dependent on the PI3K/Akt pathway. We also observed that APPL could further enhance the Akt-mediated suppression of AR transactivation and AR target gene using the reporter gene and Northern blot assay. APPL was able to enhance insulin-like growth factor (IGF-1)-mediated Akt activation. The abrogation of IGF-1-mediated Akt activation by the dominant-negative PI3K or LY294002 or antisense APPL suggests that APPL may function as an important adapter protein in controlling the IGF-1 --> Akt signal pathway. Co-immunoprecipitation and glutathione S-transferase pull-down assays suggest that APPL, Akt, and AR may exist in a complex and Akt may serve as an important bridge factor for the association of APPL with AR. Together, our data indicate that APPL may suppress AR transactivation via potentiating Akt activity.	Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.	chang@urmc.rochester.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905, R01DK060948] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60905, DK60948] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1993, ONCOGENE, V8, P745; BRESNICK EH, 1994, J BIOL CHEM, V269, P21110; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Coffer PJ, 1998, BIOCHEM J, V335, P1; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hsiao PW, 2000, MOL CELL BIOCHEM, V206, P169, DOI 10.1023/A:1007024726889; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Lin JQ, 1999, CANCER RES, V59, P2891; Manin M, 2002, BIOCHEM J, V366, P729, DOI 10.1042/BJ20020585; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; MULDERS TMT, 1990, EUR J SURG ONCOL, V16, P37; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; THOMPSON J, 2002, END SOC 84 ANN M SAN; Wen Y, 2000, CANCER RES, V60, P6841; Yeh Shuyuan, 1999, Keio Journal of Medicine, V48, P87; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	39	53	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16820	16827		10.1074/jbc.M213163200	http://dx.doi.org/10.1074/jbc.M213163200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621049	hybrid			2022-12-27	WOS:000182818600051
J	Jiang, TY; Qiu, Y				Jiang, TY; Qiu, Y			Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTORS; PH-DOMAIN; MECHANISM; TARGET; CELLS; ETK	Activation of Akt by growth factors is a multistep process. Here, we provide evidence that tyrosine kinase Src is directly associated with Akt through the interaction between its SH3 domain and a conserved proline-rich motif (PXXP) in the C-terminal regulatory region of Akt. Substitution of the proline residues Pro-424 and Pro-427 by alanines results in loss of Akt activity and phosphorylation induced by the epidermal growth factor (EGF), possibly because these mutations disrupt the interaction between Akt and the SH3 domain of Src. This possibility is corroborated by our observation that the Akt mutant lacking these two prolines fails to bind to Src both in vivo and in vitro. We also showed that phosphorylation of Tyr-315 in Akt induced by Src or EGF is dependent on the integrity of this proline-rich motif. Furthermore, the Akt mutant lacking this proline motif fails to block the transcription activity of Forkhead in 293 cells and poorly stimulates the proliferation of Madin-Darby canine kidney cells. Taken together, our data suggest that the interaction between the SH3 domain of Src family kinases and the proline-rich motif in the C-terminal regulatory region of Akt is required for tyrosine phosphorylation of Akt and its subsequent activation. It is noteworthy that this PXXP motif is conserved throughout several members of AGC kinase family, implying that association of this motif with the SH3 domain of an upstream regulator may represent a general mechanism applicable to these kinases as well.	Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Qiu, Y (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA.	yqiu@som.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA085380] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; CHAN TO, 2001, SCI STKE, pPE1; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DATTA K, 1995, MOL CELL BIOL, V15, P2304; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Galetic I, 1999, PHARMACOL THERAPEUT, V82, P409, DOI 10.1016/S0163-7258(98)00071-0; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; Kim O, 2002, J BIOL CHEM, V277, P30066, DOI 10.1074/jbc.M201713200; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; MARMYCONUS N, 2002, J BIOL CHEM; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Yang HB, 2002, J BIOL CHEM, V277, P30219, DOI 10.1074/jbc.M111933200; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200	19	142	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15789	15793		10.1074/jbc.M212525200	http://dx.doi.org/10.1074/jbc.M212525200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600984	hybrid			2022-12-27	WOS:000182680000043
J	Babnigg, G; Zagranichnaya, T; Wu, XY; Villereal, ML				Babnigg, G; Zagranichnaya, T; Wu, XY; Villereal, ML			Differential tyrosine phosphorylation of plasma membrane Ca2+-ATPase and regulation of calcium pump activity by carbachol and bradykinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA TRP; CA2+; ACTIVATION; CELLS; ENTRY; EXPRESSION; HOMOLOG; CLONING; INFLUX	We investigated the effects of thapsigargin (TG), bradykinin (BK), and carbachol (CCh) on Ca2+ entry via endogenous channels in human embryonic kidney BKR21 cells. After depletion of Ca2+ stores by either TG, BK, or CCh, the addition of Ca2+ gave a much larger rise in Ca2+ levels in CCh-treated and TG-treated cells than in cells treated with BK. However, in experiments performed with Ba2+, a cation not pumped by Ca2+-ATPases, only a modest difference between CCh- and BK-stimulated Ba2+ entry levels was observed, suggesting that the large difference in the Ca2+ response is mediated by a differential regulation of Ca2+ pump activity by CCh and BK. This hypothesis is supported by the finding that when Ca2+ is removed during the stable, CCh-induced Ca2+ plateau phase, the decline of cytosolic Ca2+ is much faster in the absence of CCh than in its presence. In addition, if Ca2+ is released from a caged Ca2+ compound after a UV pulse, the resulting Ca2+ peak is much larger in the presence of CCh than in its absence. Thus, the large increase in Ca2+ levels observed with CCh results from both the activation of Ca2+ entry pathways and the inhibition of Ca2+ pump activity. In contrast, BK has the opposite effect on Ca2+ pump activity. If Ca2+ is released from a caged Ca2+ compound, the resulting Ca2+ peak is much smaller in the presence of BK than in its absence. An investigation of tyrosine phosphorylation levels of the plasma membrane Ca2+-ATPase (PMCA) demonstrated that CCh stimulates an increase in tyrosine phosphorylation levels, which has been reported to inhibit Ca2+ pump activity, whereas in contrast, BK stimulates a reduction of PMCA tyrosine phosphorylation levels. Thus, BK and CCh have a differential effect both on Ca2+ pump activity and on tyrosine phosphorylation levels of the PMCA.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Argonne Natl Lab, Argonne, IL 60439 USA	University of Chicago; United States Department of Energy (DOE); Argonne National Laboratory	Villereal, ML (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Abbott 532,947 E 58th St, Chicago, IL 60637 USA.	mitch@drugs.bsd.uchicago.edu			NIGMS NIH HHS [GM-54500] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUMGARTEN LB, 1995, CELL CALCIUM, V17, P41, DOI 10.1016/0143-4160(95)90101-9; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Caride AJ, 1999, J BIOL CHEM, V274, P35227, DOI 10.1074/jbc.274.49.35227; Caride AJ, 2001, CELL CALCIUM, V30, P49, DOI 10.1054/ceca.2001.0212; Dean WL, 1997, J BIOL CHEM, V272, P15113, DOI 10.1074/jbc.272.24.15113; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; KWAN CY, 1990, J BIOL CHEM, V265, P678; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Rosado JA, 2000, J BIOL CHEM, V275, P19529, DOI 10.1074/jbc.M001319200; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Wu XY, 2002, J BIOL CHEM, V277, P13597, DOI 10.1074/jbc.M110881200; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	19	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14872	14882		10.1074/jbc.M210418200	http://dx.doi.org/10.1074/jbc.M210418200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594217	hybrid			2022-12-27	WOS:000182516100039
J	Eblen, ST; Kumar, NV; Shah, K; Henderson, MJ; Watts, CKW; Shokat, KM; Weber, MJ				Eblen, ST; Kumar, NV; Shah, K; Henderson, MJ; Watts, CKW; Shokat, KM; Weber, MJ			Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; UNNATURAL NUCLEOTIDE SPECIFICITY; NUCLEAR-PORE COMPLEX; MAP KINASE; SIGNAL-TRANSDUCTION; UBIQUITIN LIGASE; PLASMA-MEMBRANE; FAMILY PROTEIN; V-SRC; DOMAIN	The mitogen-activated protein kinases are key regulators of cellular organization and function. To understand the mechanisms(s) by which these ubiquitous kinases affect specific cellular changes, it is necessary to identify their diverse and numerous substrates in different cell contexts and compartments. As a first step in achieving this goal, we engineered a mutant ERK2 in which a bulky amino acid residue in the ATP binding site (glutamine 103) is changed to glycine, allowing this mutant to utilize an analog of ATP (cyclopentyl ATP) that cannot be used by wild-type ERK2 or other cellular kinases. The mutation did not inhibit ERK2 kinase activity or substrate specificity in vitro or in vivo. This method allowed us to detect only ERK2-specific phosphorylations within a mixture of proteins. Using this ERK2 mutant/analog pair to phosphorylate ERK2-associated proteins in COS-1 cells, we identified the ubiquitin ligase EDD (E3 identified by differential display) and the nucleoporin Tpr (translocated promoter region) as two novel substrates of ERK2, in addition to the known ERK2 substrate Rsk1. To further validate the method, we present data that confirm that ERK2 phosphorylates EDD in vitro and in vivo. These results not only identify two novel ERK2 substrates but also provide a framework for the future identification of numerous cellular targets of this important signaling cascade.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia	University of Virginia; University of Virginia; University of California System; University of California San Francisco; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Weber, MJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA.	mjw@virginia.edu	henderson, Michelle/G-6657-2012	Nandicoori, Vinay/0000-0002-5682-4178	NCI NIH HHS [CA40042, CA39076] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA039076, R01CA039076] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; Callaghan MJ, 1998, ONCOGENE, V17, P3479, DOI 10.1038/sj.onc.1202249; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chaudhary A, 2002, BIOCHEM BIOPH RES CO, V294, P293, DOI 10.1016/S0006-291X(02)00475-8; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; Eblen ST, 2001, MOL CELL BIOL, V21, P249, DOI 10.1128/MCB.21.1.249-259.2001; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Frosst P, 2002, J CELL BIOL, V156, P617, DOI 10.1083/jcb.200106046; Garcia J, 2002, EMBO J, V21, P5151, DOI 10.1093/emboj/cdf488; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Habelhah H, 2001, J BIOL CHEM, V276, P18090, DOI 10.1074/jbc.M011396200; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; Honda Y, 2002, J BIOL CHEM, V277, P3599, DOI 10.1074/jbc.M104347200; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liu Y, 1998, CHEM BIOL, V5, P91, DOI 10.1016/S1074-5521(98)90143-0; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Maekawa M, 2002, J BIOL CHEM, V277, P37783, DOI 10.1074/jbc.M204506200; MANNING BD, 2002, SCI STKE; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MIRANDA C, 1994, GENOMICS, V23, P714, DOI 10.1006/geno.1994.1566; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Vorum H, 1999, EXP CELL RES, V248, P473, DOI 10.1006/excr.1999.4431; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WEBER MJ, 1971, J BIOL CHEM, V246, P1828; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	38	96	101	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14926	14935		10.1074/jbc.M300485200	http://dx.doi.org/10.1074/jbc.M300485200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594221	hybrid			2022-12-27	WOS:000182516100046
J	Ohishi, K; Nagamune, K; Maeda, Y; Kinoshita, T				Ohishi, K; Nagamune, K; Maeda, Y; Kinoshita, T			Two Subunits of glycosylphosphatidylinositol transamidase, GPI8 and PIG-T, form a functionally important intermolecular disulfide bridge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; ENDOPLASMIC-RETICULUM PROTEINS; ANCHORED MEMBRANE-PROTEINS; CELL-FREE SYSTEM; TRYPANOSOMA-BRUCEI; IN-VITRO; A GENE; ATTACHMENT; BIOSYNTHESIS; PHOSPHATIDYLINOSITOL	Many eukaryotic proteins are tethered to the plasma membrane via glycosylphosphatidylinositol (GPI). GPI transamidase is localized in the endoplasmic reticulum and mediates post-translational transfer of preformed GPI to proteins bearing a carboxyl-terminal GPI attachment signal. Mammalian GPI transamidase is a multimeric complex consisting of at least five subunits. Here we report that two subunits of mammalian GPI transamidase, GP18 and PIG-T, form a functionally important disulfide bond between conserved cysteine residues. GP18 and PIG-T mutants in which relevant cysteines were replaced with serines were unable to fully restore the surface expression of GPI-anchored proteins upon transfection into their respective mutant cells. Microsomal membranes of these transfectants had markedly decreased activities in an in vitro transamidase assay. The formation of this disulfide bond is not essential but required for full transamidase activity. Antibodies against GPI8 and PIG-T revealed that endogenous as well as exogenous proteins formed a disulfide bond. Furthermore trypanosome GP18 forms a similar intermolecular disulfide bond via its conserved cysteine residue, suggesting that the trypanosome GPI transamidase is also a multimeric complex likely containing the orthologue of PIG-T. We also demonstrate that an inactive human GPI transamidase complex that consists of nonfunctional GP18 and four other components was co-purified with the proform of substrate proteins, indicating that these five components are sufficient to hold the substrate proteins.	Osaka Univ, Res Inst Microbial Dis, Dept Immunoregulat, Suita, Osaka 5650871, Japan	Osaka University	Kinoshita, T (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Immunoregulat, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.		Kinoshita, Taroh/C-7353-2009					ABE Y, 1993, J BIOL CHEM, V268, P3525; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; BIJLMAKERS MJJE, 1994, EMBO J, V13, P2699, DOI 10.1002/j.1460-2075.1994.tb06560.x; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Eisenhaber B, 2001, PROTEIN ENG, V14, P17, DOI 10.1093/protein/14.1.17; Ferguson MAJ, 2000, P NATL ACAD SCI USA, V97, P10673, DOI 10.1073/pnas.97.20.10673; Fraering P, 2001, MOL BIOL CELL, V12, P3295, DOI 10.1091/mbc.12.10.3295; Hilley JD, 2000, MOL BIOL CELL, V11, P1183, DOI 10.1091/mbc.11.4.1183; HONG Y, 2003, MOL BIOL CELL; Kang XD, 2002, J CELL SCI, V115, P2529; Kawagoe K, 1996, BLOOD, V87, P3600, DOI 10.1182/blood.V87.9.3600.bloodjournal8793600; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; KODUKULA K, 1991, J BIOL CHEM, V266, P4464; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; LILLICO S, 2003, MOL BIOL CELL; Locker JK, 1999, J CELL BIOL, V144, P267, DOI 10.1083/jcb.144.2.267; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; MORAN P, 1994, J CELL BIOL, V125, P333, DOI 10.1083/jcb.125.2.333; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Nozaki M, 1999, LAB INVEST, V79, P293; Ohishi K, 2000, MOL BIOL CELL, V11, P1523, DOI 10.1091/mbc.11.5.1523; Ohishi K, 2001, EMBO J, V20, P4088, DOI 10.1093/emboj/20.15.4088; PATNAIK PK, 1994, NUCLEIC ACIDS RES, V22, P4111, DOI 10.1093/nar/22.20.4111; Sharma DK, 2000, BIOCHEM J, V351, P717, DOI 10.1042/0264-6021:3510717; Sharma DK, 1999, J BIOL CHEM, V274, P16479, DOI 10.1074/jbc.274.23.16479; Spurway TD, 2001, J BIOL CHEM, V276, P15975, DOI 10.1074/jbc.M010128200; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; Vainauskas S, 2002, J BIOL CHEM, V277, P30535, DOI 10.1074/jbc.M205402200; VIDUGIRIENE J, 1995, EMBO J, V14, P4686, DOI 10.1002/j.1460-2075.1995.tb00150.x; Vidugiriene J, 2001, EUR J BIOCHEM, V268, P2290, DOI 10.1046/j.1432-1327.2001.02106.x; Yu JL, 1997, P NATL ACAD SCI USA, V94, P12580, DOI 10.1073/pnas.94.23.12580	34	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13959	13967		10.1074/jbc.M300586200	http://dx.doi.org/10.1074/jbc.M300586200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582175	hybrid			2022-12-27	WOS:000182405000052
J	Capote, KR; McCormack, FX; Possmayer, F				Capote, KR; McCormack, FX; Possmayer, F			Pulmonary surfactant protein-A (SP-A) restores the surface properties of surfactant after oxidation by a mechanism that requires the Cys(6) interchain disulfide bond and the phospholipid binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-LIKE REGION; IN-VITRO; AGGREGATION; INHIBITION; DIPALMITOYLPHOSPHATIDYLCHOLINE; CHOLESTEROL; MONOLAYERS; DEFICIENT; SECRETION; EXPOSURE	Reactive oxygen species produced by activated leukocytes in the alveolar epithelial lining fluid have been implicated in the inactivation of pulmonary surfactant and the impairment of lung function. Oxidation of bovine lipid extract surfactant (BLES), a therapeutic surfactant, with hypochlorous acid (H-BLES) or the Fenton reaction (F-BLES) led to temporary increases in conjugated dienes and formation of malondialdehyde and 4-hydroxy-2-nonenal. Electrospray ionization mass spectrometry revealed the appearance of lipid hydroperoxides, peroxides, lysophospholipids, and free fatty acids. Captive bubble tensiometer studies of H-BLES demonstrated prolonged adsorption times, film instability at low surface tensions during film compression, and reduced respreadability during film expansion. F-BLES exhibited prolonged adsorption times, a marked effect on increasing compressibility during compression, and a lesser effect on reducing respreadability on expansion. Addition of native bovine or rat surfactant-associated protein A (SP-A) reversed the effects of oxidation on surfactant biophysical properties. Studies using mutant recombinant rat SP-As indicated that an intact carbohydrate recognition domain and disulfide-dependent oligomeric assembly are critical for these effects, but the collagen-like region is not required. We conclude that SP-A can reverse the detrimental effects of surfactant oxidation on the biophysical properties of surfactant, by a mechanism that is dependent on interchain disulfide bond formation and the C-terminal domains of the protein.	Univ Western Ontario, London Hlth Sci Ctr, Dept Obstet & Gynecol, Canadian Inst Hlth Res Grp Fetal & Neonatal Hlth, London, ON N6A 5A5, Canada; Univ Western Ontario, Dept Biochem, Canadian Inst Hlth Res Grp Fetal & Neonatal Hlth, London, ON N6A 5A5, Canada; Inst Ciencias Basicas & Preclin Victoria Giron, Inst Super Ciencias Med Habana, Dept Bioquim, Havana, Cuba; Univ Cincinnati, Div Pulm & Crit Care Med, Dept Med, Cincinnati, OH 45267 USA	London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario); University System of Ohio; University of Cincinnati	Possmayer, F (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Dept Obstet & Gynecol, Canadian Inst Hlth Res Grp Fetal & Neonatal Hlth, 339 Windermere Rd, London, ON N6A 5A5, Canada.	fpossmay@uwo.ca	McCormack, Francis X./ABE-8398-2020; Rodriguez Capote, Karina/H-7400-2019	McCormack, Francis X./0000-0001-7168-9464; Rodriguez Capote, Karina/0000-0003-1766-4527	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068861] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68861] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amirkhanian JD, 1998, LUNG, V176, P63, DOI 10.1007/PL00007592; Andersson S, 1999, LUNG, V177, P179, DOI 10.1007/PL00007639; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bridges JP, 2000, J BIOL CHEM, V275, P38848, DOI 10.1074/jbc.M005322200; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Eberhardt M. K., 2000, REACTIVE OXYGEN META; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; Gunther A, 1996, AM J RESP CRIT CARE, V153, P176; Hawkins CL, 1999, BIOCHEM J, V340, P539, DOI 10.1042/0264-6021:3400539; Hohlfeld J, 1997, EUR RESPIR J, V10, P482, DOI 10.1183/09031936.97.10020482; HOLM BA, 1990, CHEM PHYS LIPIDS, V52, P243, DOI 10.1016/0009-3084(90)90120-G; Ikegami M, 2001, J BIOL CHEM, V276, P38542, DOI 10.1074/jbc.M102054200; KEOUGH KMW, 1998, MED INTELL UNIT, V5, P1; Lewis JE, 2003, ANNU REV PHYSIOL, V65, P613, DOI 10.1146/annurev.physiol.65.092101.142434; Mark L, 1999, AM J PHYSIOL-LUNG C, V276, pL491, DOI 10.1152/ajplung.1999.276.3.L491; Matthay MA, 1999, CRIT CARE MED, V27, P2028, DOI 10.1097/00003246-199909000-00055; McCormack F, 1997, CHEST, V111, pS114, DOI 10.1378/chest.111.6_Supplement.114S; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P8092, DOI 10.1021/bi970313f; McCormack FX, 1997, J BIOL CHEM, V272, P27971, DOI 10.1074/jbc.272.44.27971; McCormack FX, 1997, BIOCHEMISTRY-US, V36, P13963, DOI 10.1021/bi970745q; McCormack FX, 1998, BBA-MOL BASIS DIS, V1408, P109, DOI 10.1016/S0925-4439(98)00062-3; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; McCormack FX, 1999, J BIOL CHEM, V274, P3173, DOI 10.1074/jbc.274.5.3173; McCormack FX, 2001, PEDIATR PATHOL MOL M, V20, P293, DOI 10.1080/15513810109168823; MERRITT TA, 1993, BIOCHEM J, V295, P19, DOI 10.1042/bj2950019; Palaniyar N, 2001, COMP BIOCHEM PHYS A, V129, P109, DOI 10.1016/S1095-6433(01)00309-9; Palaniyar N, 1999, AM J PHYSIOL-LUNG C, V276, pL642, DOI 10.1152/ajplung.1999.276.4.L642; Possmayer F, 2001, COMP BIOCHEM PHYS A, V129, P209, DOI 10.1016/S1095-6433(01)00317-8; POSSMAYER F, 2003, IN PRESS FETAL NEONA; Postle AD, 2000, CLIN EXP ALLERGY, V30, P1201; Postle AD, 2001, COMP BIOCHEM PHYS A, V129, P65, DOI 10.1016/S1095-6433(01)00306-3; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; Putman E, 1997, LUNG, V175, P75, DOI 10.1007/PL00007561; Rodriguez-Capote K, 2001, AM J PHYSIOL-LUNG C, V281, pL231, DOI 10.1152/ajplung.2001.281.1.L231; RUSTOW B, 1994, BIOCHEM J, V302, P665; Schiller J, 2001, CHEM PHYS LIPIDS, V112, P67, DOI 10.1016/S0009-3084(01)00163-3; Schlame M, 1996, J LIPID RES, V37, P2608; SCHURCH S, 1989, J APPL PHYSIOL, V67, P2389, DOI 10.1152/jappl.1989.67.6.2389; Schurch S, 1998, BBA-MOL BASIS DIS, V1408, P180, DOI 10.1016/S0925-4439(98)00067-2; Schurch S, 2001, COMP BIOCHEM PHYS A, V129, P195, DOI 10.1016/S1095-6433(01)00316-6; SCHURCH S, 1995, BIOL NEONATE, V67, P61; Subbanagounder G, 2000, ARTERIOSCL THROM VAS, V20, P2248, DOI 10.1161/01.ATV.20.10.2248; Taneva SG, 2000, BIOPHYS J, V79, P2010, DOI 10.1016/S0006-3495(00)76449-6; Uhlson C, 2002, CHEM RES TOXICOL, V15, P896, DOI 10.1021/tx010183i; Veldhuizen R, 1998, BBA-MOL BASIS DIS, V1408, P90, DOI 10.1016/S0925-4439(98)00061-1; Veldhuizen RAW, 1996, BIOCHEM J, V313, P835, DOI 10.1042/bj3130835; VENKITARAMAN AR, 1990, CHEM PHYS LIPIDS, V56, P185, DOI 10.1016/0009-3084(90)90101-V; WARBURTON D, 1989, AM J PHYSIOL, V257, pL217, DOI 10.1152/ajplung.1989.257.4.L217; WATSON AD, 1937, J BIOL CHEM, V272, P13579; Wright SM, 2000, J APPL PHYSIOL, V89, P1283, DOI 10.1152/jappl.2000.89.4.1283; YU S, 1983, LIPIDS, V18, P522, DOI 10.1007/BF02535391; Yu SH, 1998, J LIPID RES, V39, P555; Yu SH, 1999, J LIPID RES, V40, P920	56	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20461	20474		10.1074/jbc.M212697200	http://dx.doi.org/10.1074/jbc.M212697200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12600986	hybrid			2022-12-27	WOS:000183230500005
J	Kuo, MR; Morbidoni, HR; Alland, D; Sneddon, SF; Gourlie, BB; Staveski, MM; Leonard, M; Gregory, JS; Janjigian, AD; Yee, C; Musser, JM; Kreiswirth, B; Iwamoto, H; Perozzo, R; Jacobs, WR; Sacchettini, JC; Fidock, DA				Kuo, MR; Morbidoni, HR; Alland, D; Sneddon, SF; Gourlie, BB; Staveski, MM; Leonard, M; Gregory, JS; Janjigian, AD; Yee, C; Musser, JM; Kreiswirth, B; Iwamoto, H; Perozzo, R; Jacobs, WR; Sacchettini, JC; Fidock, DA			Targeting tuberculosis and malaria through inhibition of enoyl reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER PROTEIN REDUCTASE; FATTY-ACID SYNTHESIS; PLASMODIUM-FALCIPARUM; ACP REDUCTASE; MYCOBACTERIUM-TUBERCULOSIS; TOXOPLASMA-GONDII; CRYSTAL-STRUCTURE; ISONIAZID TARGET; MOLECULAR-BASIS; TRICLOSAN	Tuberculosis and malaria together result in an estimated 5 million deaths annually. The spread of multidrug resistance in the most pathogenic causative agents, Mycobacterium tuberculosis and Plasmodium falciparum, underscores the need to identify active compounds with novel inhibitory properties. Although genetically unrelated, both organisms use a type II fatty-acid synthase system. Enoyl acyl carrier protein reductase (ENR), a key type II enzyme, has been repeatedly validated as an effective antimicrobial target. Using high throughput inhibitor screens with a combinatorial library, we have identified two novel classes of compounds with activity against the M. tuberculosis and P. falciparum enzyme (referred to as InhA and PfENR, respectively). The crystal structure of InhA complexed with NAD(+) and one of the inhibitors was determined to elucidate the mode of binding. Structural analysis of InhA with the broad spectrum antimicrobial triclosan revealed a unique stoichiometry where the enzyme contained either a single triclosan molecule, in a configuration typical of other bacterial ENR: triclosan structures, or harbored two triclosan molecules bound to the active site. Significantly, these compounds do not require activation and are effective against wild-type and drug-resistant strains of M. tuberculosis and P. falciparum. Moreover, they provide broader chemical diversity and elucidate key elements of inhibitor binding to InhA for subsequent chemical optimization.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Div Infect Dis, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Ctr Emerging Pathogens, Newark, NJ 07103 USA; Genzyme Corp, Genzyme Drug Discovery, Cambridge, MA 02139 USA; NIAID, Lab Human Bacterial Pathogenesis, Div Intramural Res, NIH,Rocky Mt Labs, Hamilton, MT 59840 USA; Publ Hlth Res Inst, TB Ctr, New York, NY 10016 USA	Texas A&M University System; Texas A&M University College Station; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Sanofi-Aventis; Genzyme Corporation; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, Biochem & Biophys Bldg,Rm 221, College Stn, TX 77843 USA.	sacchett@tamu.edu		Fidock, David/0000-0001-6753-8938; Jacobs, William/0000-0003-3321-3080	NIAID NIH HHS [AI43268] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043268, R21AI043268] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cooper RA, 2002, MOL PHARMACOL, V61, P35, DOI 10.1124/mol.61.1.35; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; Escalante P., 1998, Tubercle and Lung Disease, V79, P111, DOI 10.1054/tuld.1998.0013; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; Fidock DA, 1998, MOL PHARMACOL, V54, P1140, DOI 10.1124/mol.54.6.1140; GRASSBERGER MA, 1984, J MED CHEM, V27, P947, DOI 10.1021/jm00374a003; HAYASHI T, 1983, BIOCHEM BIOPH RES CO, V115, P1108, DOI 10.1016/S0006-291X(83)80050-3; Heath RJ, 1998, J BIOL CHEM, V273, P30316, DOI 10.1074/jbc.273.46.30316; Heath RJ, 2000, J BIOL CHEM, V275, P4654, DOI 10.1074/jbc.275.7.4654; Heath RJ, 1999, J BIOL CHEM, V274, P11110, DOI 10.1074/jbc.274.16.11110; Heerding DA, 2001, BIOORG MED CHEM LETT, V11, P2061, DOI 10.1016/S0960-894X(01)00404-8; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; Levy CW, 1999, NATURE, V398, P383, DOI 10.1038/18803; McFadden GI, 1997, BIOESSAYS, V19, P1033, DOI 10.1002/bies.950191114; McLeod R, 2001, INT J PARASITOL, V31, P109, DOI 10.1016/S0020-7519(01)00111-4; Miller WH, 2002, J MED CHEM, V45, P3246, DOI 10.1021/jm020050+; NISHIDA I, 1986, J BIOCHEM-TOKYO, V99, P1447, DOI 10.1093/oxfordjournals.jbchem.a135614; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palmer JD, 1996, P NATL ACAD SCI USA, V93, P7432, DOI 10.1073/pnas.93.15.7432; Parikh SL, 2000, BIOCHEMISTRY-US, V39, P7645, DOI 10.1021/bi0008940; Payne DJ, 2002, ANTIMICROB AGENTS CH, V46, P3118, DOI 10.1128/AAC.46.10.3118-3124.2002; Perozzo R, 2002, J BIOL CHEM, V277, P13106, DOI 10.1074/jbc.M112000200; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; Qiu XY, 1999, PROTEIN SCI, V8, P2529, DOI 10.1110/ps.8.11.2529; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; Rhee JT, 1999, J CLIN MICROBIOL, V37, P1764, DOI 10.1128/JCM.37.6.1764-1770.1999; Roujeinikova A, 1999, J MOL BIOL, V294, P527, DOI 10.1006/jmbi.1999.3240; Roujeinikova A, 1999, J BIOL CHEM, V274, P30811, DOI 10.1074/jbc.274.43.30811; Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Seefeld MA, 2001, BIOORG MED CHEM LETT, V11, P2241, DOI 10.1016/S0960-894X(01)00405-X; Stewart MJ, 1999, J MOL BIOL, V290, P859, DOI 10.1006/jmbi.1999.2907; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wang P, 1997, MOL MICROBIOL, V23, P979, DOI 10.1046/j.1365-2958.1997.2821646.x; Ward WHJ, 1999, BIOCHEMISTRY-US, V38, P12514, DOI 10.1021/bi9907779; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	46	226	241	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20851	20859		10.1074/jbc.M211968200	http://dx.doi.org/10.1074/jbc.M211968200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12606558	hybrid			2022-12-27	WOS:000183230500054
J	Sun, XM; Soutar, AK				Sun, XM; Soutar, AK			The transmembrane domain and PXXP motifs of ApoE receptor 2 exclude it from carrying out clathrin-mediated endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E RECEPTOR-2; DENSITY-LIPOPROTEIN RECEPTOR; MONOCLONAL-ANTIBODIES; SIGNALING MOLECULES; ACTIN CYTOSKELETON; CYTOPLASMIC DOMAIN; BINDING PROTEIN; KNOCKOUT MICE; MEMBRANE; EXPRESSION	The low density lipoprotein (LDL) receptor family comprises several proteins with similar structures including the LDL receptor and apoE receptor 2 (apoER2). The human brain expresses two major splice variants of apoER2 mRNA, one of which includes an additional exon that encodes 59 residues in the cytoplasmic domain. This exon is absent from the LDL receptor and contains three proline-rich (PXXP) motifs that may allow apoER2 to function as a signal transducer. To investigate the role of this insert, we took advantage of the well characterized low density lipoprotein receptor pathway. Chimeras comprising the ectodomain and transmembrane domain of the LDL receptor fused to the cytoplasmic domain of apoER2 lacking the PXXP-containing residues are able to mediate clathrin-dependent endocytosis of LDL as effectively as cells expressing the LDL receptor but not if the PXXP insert is present in the protein. Although expressed on the cell surface, the PXXP-containing chimeric receptor is excluded from clathrin vesicles as judged by its failure to co-localize with adaptor protein-2 possibly due to interaction with intracellular adaptors or scaffolding proteins. Chimeras with the transmembrane domain of apoER2, predicted to be longer than that of the LDL receptor by several residues, fail to mediate endocytosis of LDL or to co-localize with adaptor protein-2 regardless of the presence or absence of the PXXP insert. Thus features of apoER2 that distinguish it as a signaling receptor, rather than as an endocytosis receptor like the LDL receptor, reside in or near the transmembrane domain and in the proline-rich motifs.	Hammersmith Hosp, Imperial Coll Fac Med, MRC, Clin Sci Ctr,Lipoprot Grp, London W12 0NN, England	Imperial College London	Soutar, AK (corresponding author), Hammersmith Hosp, Imperial Coll Fac Med, MRC, Clin Sci Ctr,Lipoprot Grp, Ducane Rd, London W12 0NN, England.				Medical Research Council [MC_U120074271] Funding Source: Medline; MRC [MC_U120074271] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Barman S, 2000, J VIROL, V74, P6538, DOI 10.1128/JVI.74.14.6538-6545.2000; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; Bennett EM, 2001, TRAFFIC, V2, P851, DOI 10.1034/j.1600-0854.2001.21114.x; Bork P, 1997, TRENDS BIOCHEM SCI, V22, P296, DOI 10.1016/S0968-0004(97)01084-0; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Clatworthy AE, 1999, NEUROSCIENCE, V90, P903, DOI 10.1016/S0306-4522(98)00489-8; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1998, BIOESSAYS, V20, P235, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;235::AID-BIES7&gt;3.0.CO;2-Q; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Drakew A, 2002, EXP NEUROL, V176, P12, DOI 10.1006/exnr.2002.7918; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; Goldstein JL, 1995, METABOLIC MOL BASIS, VII, P1981; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Kim DH, 1997, J BIOL CHEM, V272, P8498, DOI 10.1074/jbc.272.13.8498; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KNIGHT BL, 1986, BIOCHEM J, V238, P405, DOI 10.1042/bj2380405; LaDu MJ, 2001, NEUROCHEM INT, V39, P427, DOI 10.1016/S0197-0186(01)00050-X; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Negri S, 2000, GENOMICS, V64, P324, DOI 10.1006/geno.2000.6129; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; PATEL DD, 1993, BIOCHEM J, V289, P569, DOI 10.1042/bj2890569; Riddell DR, 2001, J LIPID RES, V42, P998; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Schaffner-Reckinger E, 2001, THROMB HAEMOSTASIS, V85, P716, DOI 10.1055/s-0037-1615658; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Sun XM, 1999, EUR J BIOCHEM, V262, P230, DOI 10.1046/j.1432-1327.1999.00394.x; SUN XM, 1995, ARTERIOSCL THROM VAS, V15, P219, DOI 10.1161/01.ATV.15.2.219; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	41	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19926	19932		10.1074/jbc.M302047200	http://dx.doi.org/10.1074/jbc.M302047200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12621059	hybrid			2022-12-27	WOS:000183078000047
J	Chen, EI; Li, WZ; Godzik, A; Howard, EW; Smith, JW				Chen, EI; Li, WZ; Godzik, A; Howard, EW; Smith, JW			A residue in the S-2 subsite controls substrate selectivity of matrix metalloproteinase-2 and matrix metalloproteinase-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST COLLAGENASE; INHIBITOR MARIMASTAT; CATALYTIC DOMAIN; CYSTEINE SWITCH; MATRIX-METALLOPROTEINASE-9; MECHANISM; SPECIFICITY; ACTIVATION; CLEAVAGE	Matrix metalloproteinase (MMP)-2 and MMP-9 are closely related metalloproteinases that are implicated in angiogenesis. The two proteins have a similar domain structure and highly homologous catalytic domains, making them an excellent comparative model for understanding the structural basis of substrate recognition by the MMP family. Although the two MMPs exhibit some overlap in substrate recognition, our recent work showed that MMP-2 can cleave a set of peptide substrates that are only poorly recognized by MMP-9 (Chen, E.I., Kridel, S.J., Howard, E.W., Li, W., Godzik, A., and Smith, J.W. (2002) J. Biol. Chem. 277, 4485-4491). Mutations at the P-2 position of these peptide substrates dramatically reduced their selectivity for MMP-2. Inspection of the corresponding S-2 pocket of the substrate-binding cleft of the protease reveals that MMP-9 contains an Asp, whereas MMP-2 contains Glu. Here, we test the hypothesis that this conservative substitution has a role in substrate selectivity. Mutation of Glu(412) in MMP-2 to Asp significantly reduced the hydrolysis of selective substrates, with only a minor effect on hydrolysis of non-selective substrates. The predominant effect of the mutation is at the level of k(cat), or turnover rate, with reductions reaching as high as 37-fold. The residues that occupy this position in other MMPs are highly variable, providing a potential structural basis for substrate recognition across the MMP family.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA; Dept Pathol, Oklahoma City, OK 73104 USA	Sanford Burnham Prebys Medical Discovery Institute	Smith, JW (corresponding author), Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA.		Godzik, Adam/A-7279-2009; Godzik, Adam/AAW-1467-2020; Li, Weizhong/A-9735-2008	Godzik, Adam/0000-0002-2425-852X; Godzik, Adam/0000-0002-2425-852X; Li, Weizhong/0000-0003-1804-9403	NATIONAL CANCER INSTITUTE [R01CA069306, P30CA030199, P01CA082713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060049] Funding Source: NIH RePORTER; NCI NIH HHS [CA30199, CA82713, CA69306] Funding Source: Medline; NIAMS NIH HHS [AR42750] Funding Source: Medline; NIGMS NIH HHS [GM60049] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; Chen EI, 2002, J BIOL CHEM, V277, P4485, DOI 10.1074/jbc.M109469200; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; Fernandez-Patron C, 1999, THROMB HAEMOSTASIS, V82, P1730, DOI 10.1055/s-0037-1614906; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; GRAMS F, 1995, EUR J BIOCHEM, V228, P830, DOI 10.1111/j.1432-1033.1995.tb20329.x; GREENWALD RA, 1999, ANN NEW YORK ACAD SC; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; Millar AW, 1998, BRIT J CLIN PHARMACO, V45, P21, DOI 10.1046/j.1365-2125.1998.00639.x; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nemunaitis J, 1998, CLIN CANCER RES, V4, P1101; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; Parsons SL, 1997, EUR J SURG ONCOL, V23, P526, DOI 10.1016/S0748-7983(97)93077-8; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Sternlicht M., 1999, GUIDEBOOK EXTRACELLU, P503; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STOCKER W, 1995, PROTEIN SCI, V4, P823; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Yu Q, 2000, GENE DEV, V14, P163	28	43	45	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17158	17163		10.1074/jbc.M210324200	http://dx.doi.org/10.1074/jbc.M210324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12591933	hybrid			2022-12-27	WOS:000182818600095
J	El Yazidi-Belkoura, I; Adriaenssens, E; Dolle, L; Descamps, S; Hondermarck, H				El Yazidi-Belkoura, I; Adriaenssens, E; Dolle, L; Descamps, S; Hondermarck, H			Tumor necrosis factor receptor-associated death domain protein is involved in the neurotrophin receptor-mediated antiapoptotic activity of nerve growth factor in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAYS; P75 RECEPTOR; APOPTOSIS; DIFFERENTIATION; PROLIFERATION; EXPRESSION; ACTIVATION; P75(NTR); NUCLEAR; FAMILY	The common neurotrophin receptor p75(NTR) has been shown to initiate intracellular signaling that leads either to cell survival or to apoptosis depending on the cell type examined; however, the mechanism by which p75(NTR) initiates its intracellular transduction remains unclear. We show here that the tumor necrosis factor receptor-associated death domain protein (TRADD) interacts with p75(NTR) upon nerve growth factor (NGF) stimulation. TRADD could be immunodetected after p75(NTR) immunoprecipitation from MCF-7 breast cancer cells stimulated by nerve growth factor. In addition, confocal microscopy indicated that NGF stimulation induced the plasma membrane localization of TRADD. Using a dominant negative form of TRADD, we also show that interactions between p75(NTR) and TRADD are dependent on the death domain of TRADD, thus demonstrating its requirement for binding. Furthermore, the p75(NTR)-mediated activation of NF-kappaB was inhibited by transfection with a dominant negative TRADD, resulting in an inhibition of NGF antiapoptotic activity. These results thus demonstrate that TRADD is involved in the p75(NTR)-mediated antiapoptotic activity of NGF in breast cancer cells.	Univ Sci & Technol Lille, IFR 118, UPRES EA 1033, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille	Hondermarck, H (corresponding author), Univ Sci & Technol Lille, IFR 118, UPRES EA 1033, Batiment SN3, F-59655 Villeneuve Dascq, France.		Dollé, Laurent/H-4612-2014; El Yazidi-Belkoura, Ikram/AAE-8805-2022; Malwad, Govind V/F-4682-2010	EL YAZIDI-BELKOURA, IKRAM/0000-0002-5323-7509				ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Chiarenza A, 2001, CANCER RES, V61, P3002; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; Descamps S, 1998, J BIOL CHEM, V273, P16659, DOI 10.1074/jbc.273.27.16659; Descamps S, 2001, CANCER RES, V61, P4337; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; DJAKIEW D, 1991, CANCER RES, V51, P3304; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; Gentry JJ, 2000, J BIOL CHEM, V275, P7558, DOI 10.1074/jbc.275.11.7558; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; Hughes AL, 2001, J NEUROSCI RES, V63, P10, DOI 10.1002/1097-4547(20010101)63:1<10::AID-JNR2>3.0.CO;2-R; Jones EY, 2000, CURR OPIN STRUC BIOL, V10, P644, DOI 10.1016/S0959-440X(00)00149-4; Khursigara G, 2001, J NEUROSCI, V21, P5854, DOI 10.1523/JNEUROSCI.21-16-05854.2001; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Morgan M, 2002, J CELL BIOL, V157, P975, DOI 10.1083/jcb.200204039; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Pirianov G, 1999, CELL DEATH DIFFER, V6, P890, DOI 10.1038/sj.cdd.4400563; RABIZADEH S, 1993, SCIENCE, V261, P346; Sukits SF, 2001, J MOL BIOL, V310, P895, DOI 10.1006/jmbi.2001.4790; Tsao DHH, 2000, MOL CELL, V5, P1051, DOI 10.1016/S1097-2765(00)80270-1; Wang X, 2001, J BIOL CHEM, V276, P33812, DOI 10.1074/jbc.M010548200; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202	28	59	64	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16952	16956		10.1074/jbc.M300631200	http://dx.doi.org/10.1074/jbc.M300631200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604596	Green Published, hybrid			2022-12-27	WOS:000182818600069
J	Frick, IM; Akesson, P; Rasmussen, M; Schmidtchen, A; Bjorck, L				Frick, IM; Akesson, P; Rasmussen, M; Schmidtchen, A; Bjorck, L			SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-INHIBITING PROTEIN; DEFENSINS; BINDING; SEQUENCE; SURFACE; IDENTIFICATION; COMPONENTS; SELECTION; STRAINS	Some isolates of the significant human pathogen Streptococcus pyogenes, including virulent strains of the M1 serotype, secrete protein SIC. This molecule, secreted in large quantities, interferes with complement function. As a result of natural selection, SIC shows a high degree of variation. Here we provide a plausible explanation for this variation and the fact that strains of the M1 serotype are the most frequent cause of severe invasive S. pyogenes infections. Thus, protein SIC was found to inactivate human neutrophil alpha-defensin and LL-37, two major antibacterial peptides involved in bacterial clearance. This inactivation protected S. pyogenes against the antibacterial effect of the peptides. Moreover, SIC isolated from S. pyogenes of the M1 serotype was more powerful in this respect than SIC variants from strains of M serotypes 12 and 55, serotypes rarely connected with invasive infections.	Lund Univ, BMC, Dept Cell & Mol Biol, Sect Mol Pathogenesis, S-22184 Lund, Sweden; Univ Lund Hosp, Dept Med Microbiol Dermatol & Infect, S-22185 Lund, Sweden	Lund University; Lund University; Skane University Hospital	Frick, IM (corresponding author), Lund Univ, BMC, Dept Cell & Mol Biol, Sect Mol Pathogenesis, B14,Tornavagen 10, S-22184 Lund, Sweden.	Inga-Maria.Frick@medkem.lu.se	Schmidtchen, Artur/F-9507-2015	Rasmussen, Magnus/0000-0003-1588-5473				Akesson P, 1996, J BIOL CHEM, V271, P1081, DOI 10.1074/jbc.271.2.1081; AKESSON P, 1994, BIOCHEM J, V300, P877, DOI 10.1042/bj3000877; Ayabe T, 2002, J BIOL CHEM, V277, P5219, DOI 10.1074/jbc.M109410200; BERGE A, 1995, J BIOL CHEM, V270, P9862, DOI 10.1074/jbc.270.17.9862; Berge A, 1998, INFECT IMMUN, V66, P3449, DOI 10.1128/IAI.66.7.3449-3453.1998; Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; Brandt CM, 2001, J INFECT DIS, V183, P670, DOI 10.1086/318542; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Fernie-King BA, 2002, INFECT IMMUN, V70, P4908, DOI 10.1128/IAI.70.9.4908-4916.2002; Fernie-King BA, 2001, IMMUNOLOGY, V103, P390, DOI 10.1046/j.1365-2567.2001.01249.x; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; GOMI H, 1990, J IMMUNOL, V144, P4046; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HANSKI E, 1995, METHOD ENZYMOL, V253, P269; Hartas J, 1999, MICROB PATHOGENESIS, V26, P25, DOI 10.1006/mpat.1998.0244; HERWALD H, 1995, J BIOL CHEM, V270, P14634; Hoe NP, 1999, NAT MED, V5, P924, DOI 10.1038/11369; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Lukomski S, 2000, INFECT IMMUN, V68, P535, DOI 10.1128/IAI.68.2.535-542.2000; Musser JM, 1998, BIOMED RES REP, P185; Nagaoka I, 2000, INFLAMM RES, V49, P73, DOI 10.1007/s000110050561; NOWAK R, 1994, SCIENCE, V264, P1665, DOI 10.1126/science.8209244; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; Podbielski A, 1996, GENE, V177, P137, DOI 10.1016/0378-1119(96)84178-3; Rasmussen M, 1999, J BIOL CHEM, V274, P15336, DOI 10.1074/jbc.274.22.15336; Schroder JM, 1999, INT J BIOCHEM CELL B, V31, P645, DOI 10.1016/S1357-2725(99)00013-8; SELSTED ME, 1995, TRENDS CELL BIOL, V5, P114, DOI 10.1016/S0962-8924(00)88961-8; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; Stevens DL, 2000, ANNU REV MED, V51, P271, DOI 10.1146/annurev.med.51.1.271; Stockbauer KE, 1998, P NATL ACAD SCI USA, V95, P3128, DOI 10.1073/pnas.95.6.3128	32	134	138	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16561	16566		10.1074/jbc.M301995200	http://dx.doi.org/10.1074/jbc.M301995200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621031	hybrid			2022-12-27	WOS:000182818600017
J	Palacios, F; D'Souza-Schorey, C				Palacios, F; D'Souza-Schorey, C			Modulation of Rac1 and ARF6 activation during epithelial cell scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; ADP-RIBOSYLATION FACTOR-6; TYROSINE PHOSPHORYLATION; ADHERENS JUNCTIONS; BETA-CATENIN; RHO FAMILY; MDCK CELLS; CADHERIN; ADHESION; GTPASE	Epithelial cell scattering encompasses the dissolution of intercellular junctions, cell-cell dissociation, cell spreading, and motility. The Rac1 and ARF6 GTPases have been shown to regulate one or more of these aforementioned processes. In fact, activated Rac1 has been shown to promote cell-cell adhesion as well as to enhance cell motility, leading to conflicting reports on the effect of Rac1 activation on epithelial cell motility. In this study, we have examined the activation profiles of endogenous Rac1 and ARF6 during the sequential stages of epithelial cell scattering. Using Madin-Darby canine kidney cells treated with hepatocyte growth factor/scatter factor or cell lines stably expressing activated v-Src, we show that Rac1 and ARF6 exhibit distinct activation profiles during cell scattering. We have found that an initial ARF6-dependent decrease in the levels of Rac1-GTP is necessary to induce cell-cell dissociation. This is followed by a steady increase in Rac1 and ARF6 activation and cell migration. In sum, this study documents the progression of ARF6 and Rac1 activities during epithelial cell scattering.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Notre Dame, Walther Canc Inst, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame; Walther Cancer Institute	D'Souza-Schorey, C (corresponding author), Univ Notre Dame, Dept Biol Sci, Box 369,Calvin Life Sci Bldg, Notre Dame, IN 46556 USA.							BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Benard V, 2002, METHOD ENZYMOL, V345, P349; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; Birchmeier W, 1996, CURR TOP MICROBIOL, V213, P117; Boshans RL, 2000, MOL CELL BIOL, V20, P3685, DOI 10.1128/MCB.20.10.3685-3694.2000; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Fenteany G, 2000, CURR BIOL, V10, P831, DOI 10.1016/S0960-9822(00)00579-0; Gimond C, 1999, J CELL BIOL, V147, P1325, DOI 10.1083/jcb.147.6.1325; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Radhakrishna H, 1999, J CELL SCI, V112, P855; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Schmidt J W, 1993, Semin Cell Biol, V4, P161, DOI 10.1006/scel.1993.1020; Schweitzer JK, 2002, J BIOL CHEM, V277, P27210, DOI 10.1074/jbc.M201569200; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; THIERY JP, 1982, DEV BIOL, V93, P324, DOI 10.1016/0012-1606(82)90121-X; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	30	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17395	17400		10.1074/jbc.M300998200	http://dx.doi.org/10.1074/jbc.M300998200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609992	hybrid			2022-12-27	WOS:000182818600126
J	Sadtler, S; Laube, B; Lashub, A; Nicke, A; Betz, H; Schmalzing, G				Sadtler, S; Laube, B; Lashub, A; Nicke, A; Betz, H; Schmalzing, G			A basic cluster determines topology of the cytoplasmic M3-M4 loop of the glycine receptor alpha 1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN TOPOLOGY; CHARGED AMINO-ACIDS; GATED ION CHANNELS; TRANSMEMBRANE PROTEIN; FUNCTIONAL EXPRESSION; ENDOPLASMIC-RETICULUM; MICROSOMAL MEMBRANE; ESCHERICHIA-COLI; SIGNAL SEQUENCE; XENOPUS OOCYTES	The inhibitory glycine receptor is a member of the ligand-gated ion channel superfamily of neurotransmitter receptors, which are composed of homologous subunits with four transmembrane segments ( M1-M4), each. Here, we demonstrate that the correct topology of the glycine receptor alpha1 subunit depends critically on six positively charged residues within a basic cluster, RFR-RKRR, located in the large cytoplasmic loop (designated M3-M4 loop) following the C-terminal end of M3. Neutralization of one or more charges of this cluster, but not of other charged residues in the M3-M4 loop, led to an aberrant translocation into the endoplasmic reticulum lumen of the M3-M4 loop. However, when two of the three basic charges located in the ectodomain linking M2 and M3 were neutralized, in addition to two charges of the basic cluster, endoplasmic reticulum disposition of the M3-M4 loop was prevented. We conclude that a high density of basic residues C-terminal to M3 is required to compensate for the presence of positively charged residues in the M2-M3 ectodomain, which otherwise impair correct membrane integration of the M3 segment.	Rhein Westfal TH Aachen, Dept Mol Pharmacol, Sch Med, D-52074 Aachen, Germany; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	RWTH Aachen University; Max Planck Society	Schmalzing, G (corresponding author), Rhein Westfal TH Aachen, Dept Mol Pharmacol, Sch Med, Wendlingweg 2, D-52074 Aachen, Germany.			Nicke, Annette/0000-0001-6798-505X				AKAGI H, 1991, FEBS LETT, V281, P160, DOI 10.1016/0014-5793(91)80383-E; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; ANDERSSON H, 1992, J BIOL CHEM, V267, P1491; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; BELTZER JP, 1991, J BIOL CHEM, V266, P973; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Bogdanov M, 2002, EMBO J, V21, P2107, DOI 10.1093/emboj/21.9.2107; Buttner C, 2001, J BIOL CHEM, V276, P42978, DOI 10.1074/jbc.M102121200; GAFVELIN G, 1994, CELL, V77, P401, DOI 10.1016/0092-8674(94)90155-4; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GALLUSSER A, 1990, EMBO J, V9, P2723, DOI 10.1002/j.1460-2075.1990.tb07459.x; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Harley CA, 1996, J BIOL CHEM, V271, P24625, DOI 10.1074/jbc.271.40.24625; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Harvey RJ, 2000, HANDB EXP PHARM, V147, P479; Juretic D, 2002, J CHEM INF COMP SCI, V42, P620, DOI 10.1021/ci010263s; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; KUHSE J, 1993, NEURON, V11, P1049, DOI 10.1016/0896-6273(93)90218-G; KUHSE J, 1990, J BIOL CHEM, V265, P22317; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; LANGOSCH D, 1994, EMBO J, V13, P4223, DOI 10.1002/j.1460-2075.1994.tb06742.x; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Lewis TM, 1998, J PHYSIOL-LONDON, V507, P25, DOI 10.1111/j.1469-7793.1998.025bu.x; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nicke A, 1999, J RECEPT SIGNAL TR R, V19, P493, DOI 10.3109/10799899909036667; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; PFEIFFER F, 1981, BRAIN RES, V226, P273, DOI 10.1016/0006-8993(81)91099-4; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Sato M, 1999, J BIOL CHEM, V274, P24721, DOI 10.1074/jbc.274.35.24721; SATO T, 1990, EMBO J, V9, P2391, DOI 10.1002/j.1460-2075.1990.tb07414.x; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMALZING G, 1991, BIOCHEM J, V279, P329, DOI 10.1042/bj2790329; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; ZHANG JT, 1995, J BIOL CHEM, V270, P1742, DOI 10.1074/jbc.270.4.1742	43	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16782	16790		10.1074/jbc.M213077200	http://dx.doi.org/10.1074/jbc.M213077200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611885	hybrid			2022-12-27	WOS:000182818600046
J	Wu, ZLL; Zhang, LJ; Yabe, T; Kuberan, B; Beeler, DL; Love, A; Rosenberg, RD				Wu, ZLL; Zhang, LJ; Yabe, T; Kuberan, B; Beeler, DL; Love, A; Rosenberg, RD			The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; FGF RECEPTOR DIMERIZATION; MITOGENIC ACTIVITY; FACTOR-BINDING; CELL-SURFACE; HEPARIN/HEPARAN SULFATE; CRYSTAL-STRUCTURE; BASIC FGF; PROTEOGLYCANS; OLIGOSACCHARIDES	Fibroblast growth factor (FGF) signaling begins with the formation of a ternary complex of FGF, FGF receptor (FGFR), and heparan sulfate (HS). Multiple models have been proposed for the ternary complex. However, major discrepancies exist among those models, and none of these models have evaluated the functional importance of the interacting regions on the HS chains. To resolve the discrepancies, we measured the size and molar ratio of HS in the complex and showed that both FGF1 and FGFR1 simultaneously interact with HS; therefore, a model of 2:2:2 FGF1.HS.FGFR1 was shown to fit the data. Using genetic and biochemical methods, we generated HSs that were defective in FGF1 and/or FGFR1 binding but could form the signaling ternary complex. Both genetically and chemically modified HSs were subsequently assessed in a BaF3 cell mitogenic activity assay. The ability of HS to support the ternary complex formation was found to be required for FGF1-stimulated cell proliferation. Our data also proved that specific critical groups and sites on HS support complex formation. Furthermore, the molar ratio of HS, FGF1, and FGFR1 in the ternary complex was found to be independent of the size of HS, which indicates that the selected model can take place on the cell surface proteoglycans. Finally, a mechanism for the FGF.FGFR signaling complex formation on cell membrane was proposed, where FGF and FGFR have their own binding sites on HS and a distinct ternary complex formation site is directly responsible for mitogenic activity.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	Rosenberg, RD (corresponding author), MIT, Dept Biol, 31 Ames St,MIT Bldg 68-488, Cambridge, MA 02139 USA.		Yabe, Tomio/B-5900-2013	Yabe, Tomio/0000-0002-9295-8560; Wu, Zhengliang/0000-0002-0700-0906				Allen BL, 2001, J CELL BIOL, V155, P845, DOI 10.1083/jcb.200106075; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Berry D, 2001, FASEB J, V15, P1422, DOI 10.1096/fj.00-0661fje; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; DELEHEDDE M, 2002, BIOCHEM J, V9, P235; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; GAMBARINI AG, 1993, MOL CELL BIOCHEM, V124, P121, DOI 10.1007/BF00929204; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Ishihara M, 1997, J BIOCHEM-TOKYO, V121, P345; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; McKeehan WL, 1999, J BIOL CHEM, V274, P21511, DOI 10.1074/jbc.274.31.21511; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Naski M.C., 1998, FRONT BIOSCI-LANDMRK, V3, pd781, DOI [10.2741/a321, DOI 10.2741/A321]; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Powell AK, 2002, J BIOL CHEM, V277, P28554, DOI 10.1074/jbc.M111754200; Pye DA, 2000, GLYCOBIOLOGY, V10, P1183, DOI 10.1093/glycob/10.11.1183; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sleeman M, 2001, GENE, V271, P171, DOI 10.1016/S0378-1119(01)00518-2; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Wu ZLL, 2002, FASEB J, V16, P539, DOI 10.1096/fj.01-0807com; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zhang LJ, 2001, J BIOL CHEM, V276, P28806, DOI 10.1074/jbc.M100204200; Zhang Z, 2001, J BIOL CHEM, V276, P41921, DOI 10.1074/jbc.M106608200; Zhou FY, 1997, EUR J CELL BIOL, V73, P71	56	126	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17121	17129		10.1074/jbc.M212590200	http://dx.doi.org/10.1074/jbc.M212590200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604602	hybrid			2022-12-27	WOS:000182818600091
J	Malcolm, KC; Worthen, GS				Malcolm, KC; Worthen, GS			Lipopolysaccharide stimulates p38-dependent induction of antiviral genes in neutrophils independently of paracrine factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TOLL-LIKE RECEPTOR-4; DOUBLE-STRANDED-RNA; INTERFERON REGULATORY FACTOR-3; CELL-WALL COMPONENTS; N-TERMINAL KINASE; BACTERIAL LIPOPOLYSACCHARIDE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; HIV-1 INFECTION	Lipopolysaccharide (LPS) induces neutrophils to synthesize and secrete pro-inflammatory cytokines and chemokines, which are regulated at both the transcriptional and translational level. We reported previously that neutrophils stimulated with LPS induce expression of genes typically expressed in response to stimulation with antiviral type I interferons (IFN), such as myxovirus resistance-1 (MX1). However, we present evidence that this response of neutrophils to lipopolysaccharide occurs in the absence of interferon-dependent signaling. Lipopolysaccharide-stimulated neutrophils do not phosphorylate the interferon-associated transcription factors signal transducer and activator of transcription-1 and -3, and medium from lipopolysaccharide-stimulated cells was unable to induce MX1 gene expression, suggesting a soluble factor is not involved. Furthermore, LPS did not alter expression of IFNA and IFNB genes. In contrast to neutrophils, LPS-stimulated human monocyte-derived macrophages induced the expression of MX1, but IFNB was induced, and medium from LPS-stimulated monocyte-derived macrophages supported MX1 induction. An inhibitor of p38 kinase blocked induction of MX1 by lipopolysaccharide, but not IFNalpha, in neutrophils, and induction of MX1 was dependent on protein synthesis. LPS, but not IFNa, substantially activated p38. In contrast, the induction of MX1 by LPS in monocyte-derived macrophages was insensitive to p38 inhibition, although p38 is phosphorylated in LPS-stimulated but not IFNalpha-stimulated monocyte-derived macrophages. The expression of MX1 in neutrophils and monocyte-derived macrophages is mediated by TLR4 but not TLR2. The data presented here indicate that lipopolysaccharide activates novel interferon-independent signaling pathways in neutrophils and that induction of antiviral genes is a consequence of exposure of neutrophils to bacterial products.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80206 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Malcolm, KC (corresponding author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061407] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61407] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; AU WC, 1993, J BIOL CHEM, V268, P24032; BANDYOPADHYAY SK, 1995, J BIOL CHEM, V270, P19624, DOI 10.1074/jbc.270.33.19624; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Cassatella MA, 1997, ANN NY ACAD SCI, V832, P233, DOI 10.1111/j.1749-6632.1997.tb46251.x; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DAHER KA, 1986, J VIROL, V60, P1068, DOI 10.1128/JVI.60.3.1068-1074.1986; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Detmers PA, 1998, J IMMUNOL, V161, P1921; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Dziarski R, 2001, J IMMUNOL, V166, P1938, DOI 10.4049/jimmunol.166.3.1938; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fessler MB, 2002, J BIOL CHEM, V277, P31291, DOI 10.1074/jbc.M200755200; FOUDA SI, 1995, BIOCHEM J, V308, P815, DOI 10.1042/bj3080815; Franchin G, 2000, J IMMUNOL, V164, P2592, DOI 10.4049/jimmunol.164.5.2592; Gao JJ, 1998, J IMMUNOL, V161, P4803; GESSANI S, 1989, J VIROL, V63, P2785, DOI 10.1128/JVI.63.6.2785-2789.1989; GOETSCHY JF, 1989, J VIROL, V63, P2616, DOI 10.1128/JVI.63.6.2616-2622.1989; Grenier A, 1999, BLOOD, V93, P1413, DOI 10.1182/blood.V93.4.1413.404k06_1413_1421; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; HASLETT C, 1985, AM J PATHOL, V119, P101; HAYES MP, 1991, J LEUKOCYTE BIOL, V50, P176, DOI 10.1002/jlb.50.2.176; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Liverton NJ, 1999, J MED CHEM, V42, P2180, DOI 10.1021/jm9805236; MAEHARA N, 1977, INFECT IMMUN, V15, P78, DOI 10.1128/IAI.15.1.78-83.1977; Malcolm KC, 2003, AM J PHYSIOL-LUNG C, V284, pL663, DOI 10.1152/ajplung.00094.2002; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Mellado M, 2001, CELL MOL BIOL, V47, P575; MEMET S, 1991, J INTERFERON RES, V11, P131, DOI 10.1089/jir.1991.11.131; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; Nahas N, 1996, BIOCHEM J, V318, P247, DOI 10.1042/bj3180247; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535; Nick JA, 1996, J IMMUNOL, V156, P4867; Nick JA, 2000, J IMMUNOL, V164, P2151, DOI 10.4049/jimmunol.164.4.2151; Nick JA, 2002, J IMMUNOL, V169, P5260, DOI 10.4049/jimmunol.169.9.5260; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; Scherle PA, 1998, J IMMUNOL, V161, P5681; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Smith EJ, 2001, J BIOL CHEM, V276, P8951, DOI 10.1074/jbc.M008717200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; tenOever BR, 2002, J VIROL, V76, P3659, DOI 10.1128/JVI.76.8.3659-3669.2002; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Tumpey TM, 1996, J VIROL, V70, P898, DOI 10.1128/JVI.70.2.898-904.1996; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Verani A, 1997, J EXP MED, V185, P805, DOI 10.1084/jem.185.5.805; Wang S Z, 2000, Respirology, V5, P1, DOI 10.1046/j.1440-1843.2000.00219.x; WATHELET MG, 1992, EUR J BIOCHEM, V206, P901, DOI 10.1111/j.1432-1033.1992.tb16999.x; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weinmann AS, 2001, NAT IMMUNOL, V2, P51, DOI 10.1038/83168; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200; Zhu H, 1997, P NATL ACAD SCI USA, V94, P13985, DOI 10.1073/pnas.94.25.13985; Zu YL, 1998, J IMMUNOL, V160, P1982; Zybarth G, 1999, J IMMUNOL, V162, P400	83	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15693	15701		10.1074/jbc.M212033200	http://dx.doi.org/10.1074/jbc.M212033200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595530	hybrid			2022-12-27	WOS:000182680000031
J	Rybkin, II; Markham, DW; Yan, Z; Bassel-Duby, R; Williams, RS; Olson, EN				Rybkin, II; Markham, DW; Yan, Z; Bassel-Duby, R; Williams, RS; Olson, EN			Conditional expression of SV40 T-antigen in mouse cardiomyocytes facilitates an inducible switch from proliferation to differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CELL-LINE; IN-VITRO; VENTRICULAR MYOCYTES; CARDIAC-HYPERTROPHY; ADENOVIRAL VECTORS; TRANSGENIC MOUSE; MODEL SYSTEM; HEART; TRANSFORMATION; RECOMBINATION	Studies of cardiac muscle gene expression and signaling have been hampered by the lack of immortalized cardiomyocyte cell lines capable of proliferation and irreversible withdrawal from the cell cycle. With the goal of creating such cell lines, we generated transgenic mice using cardiac-specific cis-regulatory elements from the mouse Nkx2.5 gene to drive the expression of a simian virus 40 large T-antigen (TAg) gene flanked by sites for recombination by Cre recombinase. These transgenic mice developed tumors within the ventricular myocardium. Cells isolated from these tumors expressed cardiac markers and proliferated rapidly during serial passage in culture, without apparent senescence. However, they were unable to exit the cell cycle and failed to exhibit morphological features of terminal differentiation. Introduction of Cre recombinase to these cardiac cell lines by adenoviral delivery resulted in the elimination of TAg expression, accompanied by rapid cessation of cell division, and increase in cell size without an apparent induction of cellular differentiation. Incubation of cells lacking TAg in serum-deficient media with various pharmacological agents (norepinephrine, phenylephrine, or bone morphogenetic protein-2/4) or constitutively active calcium/calmodulin-dependent protein kinase I and/or calcineurin led to the formation of sarcomeres and up-regulation of cardiac genes involved in excitation-contraction coupling. The combination of TAg expression under the control of an early cardiac promoter and Cre-mediated recombination allowed us to derive an immortal cell line from the ventricular myocardium. that could be controllably withdrawn from the cell cycle. The conditional expression of TAg in this manner permits propagation and regulated growth termination of cell types that are otherwise unable to be maintained in cell culture and may have applications for cardiac repair technologies.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Duke Univ, Sch Med, Durham, NC 27710 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Duke University	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Eric.Olson@utsouthwestern.edu		Yan, Zhen/0000-0002-4826-9813; Rybkin, Igor/0000-0002-8434-1093				ANTON M, 1995, J VIROL, V69, P4600, DOI 10.1128/JVI.69.8.4600-4606.1995; Aoki K, 1999, MOL MED, V5, P224, DOI 10.1007/BF03402119; Brunskill EW, 2001, DEV BIOL, V235, P507, DOI 10.1006/dbio.2001.0313; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; CYRAN SE, 1992, J MOL CELL CARDIOL, V24, P1167, DOI 10.1016/0022-2828(92)93180-R; DEYOUNG MB, 1989, AM J PHYSIOL, V257, pC750, DOI 10.1152/ajpcell.1989.257.4.C750; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; Eisenberg CA, 1996, CIRC RES, V78, P205, DOI 10.1161/01.RES.78.2.205; ENGELMANN GL, 1993, J MOL CELL CARDIOL, V25, P197, DOI 10.1006/jmcc.1993.1022; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Jahn L, 1996, J CELL SCI, V109, P397; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Kawamoto S, 2000, FEBS LETT, V470, P263, DOI 10.1016/S0014-5793(00)01338-7; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; KLINE RP, 1993, J CARDIOVASC ELECTR, V4, P642, DOI 10.1111/j.1540-8167.1993.tb01251.x; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Lien CL, 1999, DEVELOPMENT, V126, P75; LINTS TJ, 1993, DEVELOPMENT, V119, P419; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MILLER C, 1994, MOL CELL BIOCHEM, V136, P29, DOI 10.1007/BF00931601; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; Mouly V, 1996, EXP CELL RES, V225, P268, DOI 10.1006/excr.1996.0176; Muller M, 2000, FASEB J, V14, P2540, DOI 10.1096/fj.00-0002com; Ng P, 1999, HUM GENE THER, V10, P2667, DOI 10.1089/10430349950016708; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; RUMYANTSEV PP, 1977, INT REV CYTOL, V51, P187; Soonpaa MH, 1997, AM J PHYSIOL-HEART C, V272, pH220, DOI 10.1152/ajpheart.1997.272.1.H220; STEINHELPER ME, 1990, AM J PHYSIOL, V259, pH1826, DOI 10.1152/ajpheart.1990.259.6.H1826; TEDESCO D, 1995, J VIROL, V69, P6947, DOI 10.1128/JVI.69.11.6947-6957.1995	35	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15927	15934		10.1074/jbc.M213102200	http://dx.doi.org/10.1074/jbc.M213102200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12590133	hybrid			2022-12-27	WOS:000182680000061
J	Wu, KJ; Jiang, SW; Couch, FJ				Wu, KJ; Jiang, SW; Couch, FJ			p53 mediates repression of the BRCA2 promoter and down-regulation of BRCA2 mRNA and protein levels in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUSCEPTIBILITY GENE BRCA2; TATA-BINDING PROTEIN; BREAST-CANCER CELLS; FACTOR-KAPPA-B; RADIATION HYPERSENSITIVITY; TRANSCRIPTION FACTOR; RAD51; REPAIR; EXPRESSION; IDENTIFICATION	Adriamycin and other DNA-damaging agents have been shown to reduce BRCA2 mRNA levels in breast cancer cell lines, but the mechanism by which this occurs is unknown. In this study, we show that adriamycin and mitomycin C, but not other DNA-damaging agents, repress BRCA2 promoter activity in a dose- and time-dependent manner. We demonstrate that the effect is dependent on wild type p53 and that adriamycin and p53 mediate repression of the BRCA2 promoter by inhibiting binding of an upstream stimulatory factor protein complex to the promoter. In addition, we present evidence indicating that adriamycin and other DNA-damaging agents reduce BRCA2 mRNA and protein levels by altering both BRCA2 mRNA stability and protein stability. Thus, BRCA2 levels in the cell are regulated by three independent mechanisms in a p53-dependent manner.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Endocrine Res Unit, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Couch, FJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, 200 1st St SW,1001 Guggenheim Bldg, Rochester, MN 55905 USA.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bertwistle D, 1997, CANCER RES, V57, P5485; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Blagosklonny MV, 1998, J CLIN ENDOCR METAB, V83, P2516, DOI 10.1210/jc.83.7.2516; Breen GAM, 1999, BBA-GEN SUBJECTS, V1428, P169, DOI 10.1016/S0304-4165(99)00061-6; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Cheung E, 1999, BIOCHEM J, V344, P145, DOI 10.1042/0264-6021:3440145; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Fan SJ, 1998, INT J CANCER, V77, P600, DOI 10.1002/(SICI)1097-0215(19980812)77:4<600::AID-IJC21>3.0.CO;2-8; Galibert MD, 1997, J IMMUNOL, V159, P6176; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Le Page F, 2000, CANCER RES, V60, P5548; LIU X, 1995, MOL CELL BIOL, V15, P6474; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MARTIN DW, 1993, BIOCHEM BIOPH RES CO, V195, P428, DOI 10.1006/bbrc.1993.2061; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Vaughn JP, 1996, CANCER RES, V56, P4590; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang SC, 2001, CANCER RES, V61, P2838; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu K, 2000, J BIOL CHEM, V275, P35548, DOI 10.1074/jbc.M004390200; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837	36	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15652	15660		10.1074/jbc.M211297200	http://dx.doi.org/10.1074/jbc.M211297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591928	hybrid			2022-12-27	WOS:000182680000026
J	Dey, A; Xhu, XR; Carroll, R; Turck, CW; Stein, J; Steiner, DF				Dey, A; Xhu, XR; Carroll, R; Turck, CW; Stein, J; Steiner, DF			Biological processing of the cocaine and amphetamine-regulated transcript precursors by prohormone convertases, PC2 and PC1/3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPROTEIN CONVERTASES; GEL-ELECTROPHORESIS; HYPOTHALAMIC CART; SEQUENCE-ANALYSIS; MESSENGER-RNAS; PEPTIDE; MICE; GENE; PITUITARY; PROTEINS	Cocaine and amphetamine-regulated transcript (CART), a neuroendocrine peptide influencing reward, feeding/appetite, and stress responses is derived from two peptide precursors of 129 and 116 amino acid (aa) residues that arise via alternative splicing from a single Cart gene in rats and mice. The signal peptide constitutes the first 27 aa resulting in pro-CART molecules of either 102 or 89 aa. In the present study, we have shown that pro-CART is a substrate for the neuroendocrine subtilisin/kexin-like prohormone convertases, PC2 (SPC2) and PC1/3 (SPC3). By using different neuroendocrine cell lines, with or without endogenous expression of either PC2 or PC1/3 or both enzymes, we have demonstrated through transient transfection studies that long pro-CART gives rise to an intermediate peptide, residues 33102, and the two major bioactive CART forms, residues 55-102 (1) and 62-102 (11), respectively. Likewise, short pro-CART also generates three peptides, an intermediate, residues 10-89, and the two identical bioactive CART forms. We have confirmed the identities of the bioactive and intermediate CART molecules by microsequencing and/or high performance liquid chromatography and mass spectrometry. We have shown that PC2 is more efficient in generating bioactive CART I compared with PC1/3, whereas the production of the smaller bioactive CART 11 is exclusively carried out by PC2. PC1/3 is predominantly responsible for generating the intermediate CART fragments, 33-102 and 10-89, from long and short pro-CART, respectively. To compare in vitro and in vivo processing of pro-CART, we have examined its processing in PC2, 7132, and PC1/3 knock-out mouse hypothalamic extracts and demonstrated that, as in vitro, PC2 is more potent than PC1/3 in generating bioactive CART I whereas bioactive CART II is solely generated by PC2. Also, in vivo, we have shown that PC1/3 is predominantly active in liberating the two intermediate CART fragments, 33-102 and 10-89. These findings confirm the key roles of PC2 and PC1/3 acting together or separately to carry out CART processing in selected sites in vivo.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of Chicago; Howard Hughes Medical Institute; University of Chicago; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Steiner, DF (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58Th St, Chicago, IL 60637 USA.	dfsteine@midway.uchicago.edu			NIDDK NIH HHS [DK13914, DK20595] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK013914, P60DK020595, R01DK013914, P30DK020595] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams LD, 1999, BRAIN RES, V848, P137, DOI 10.1016/S0006-8993(99)01907-1; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Berman Y, 2000, J NEUROCHEM, V75, P1763, DOI 10.1046/j.1471-4159.2000.0751763.x; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; Brischoux F, 2002, J NEUROBIOL, V52, P221, DOI 10.1002/neu.10077; Brunetti L, 2000, EUR J PHARMACOL, V409, P103, DOI 10.1016/S0014-2999(00)00783-4; Cameron A., 2001, ENZYMES, V22, P291; del Giudice EM, 2001, DIABETES, V50, P2157, DOI 10.2337/diabetes.50.9.2157; DICKERSON IM, 1990, ALFRED BENZON SYMP S, V29, P166; Douglass J, 1996, GENE, V169, P241, DOI 10.1016/0378-1119(96)88651-3; DOUGLASS J, 1995, J NEUROSCI, V15, P2471; Elias CF, 1998, NEURON, V21, P1375, DOI 10.1016/S0896-6273(00)80656-X; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; Furuta M, 1998, J BIOL CHEM, V273, P3431, DOI 10.1074/jbc.273.6.3431; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; GALANOPOULOU AS, 1995, BIOCHEM J, V311, P111, DOI 10.1042/bj3110111; Gautvik KM, 1996, P NATL ACAD SCI USA, V93, P8733, DOI 10.1073/pnas.93.16.8733; Gensberg K, 1998, SEMIN CELL DEV BIOL, V9, P11, DOI 10.1006/scdb.1997.0196; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Jensen PB, 1999, FEBS LETT, V447, P139, DOI 10.1016/S0014-5793(99)00291-4; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Koylu EO, 1997, J NEUROENDOCRINOL, V9, P823, DOI 10.1046/j.1365-2826.1997.00651.x; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Larsen PJ, 2000, OBES RES, V8, P590, DOI 10.1038/oby.2000.76; Laurent V, 2002, P NATL ACAD SCI USA, V99, P3087, DOI 10.1073/pnas.261715099; Ludvigsen S, 2001, BIOCHEMISTRY-US, V40, P9082, DOI 10.1021/bi010433u; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Molloy SS, 2002, ENZYMES, VXXII, P199; Muller L, 2000, PROG NUCLEIC ACID RE, V63, P69, DOI 10.1016/S0079-6603(08)60720-5; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; ROUILLE Y, 1995, J BIOL CHEM, V270, P26488, DOI 10.1074/jbc.270.44.26488; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Seidah NG, 1999, ANN NY ACAD SCI, V885, P57; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; Sohn EH, 2002, ENDOCRINOLOGY, V143, P954, DOI 10.1210/en.143.3.954; SPIESS J, 1981, BIOCHEMISTRY-US, V20, P1982, DOI 10.1021/bi00510a038; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STEINER DF, 1992, J BIOL CHEM, V267, P23435; Thim L, 1999, P NATL ACAD SCI USA, V96, P2722, DOI 10.1073/pnas.96.6.2722; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; Volkoff H, 2000, BRAIN RES, V887, P125, DOI 10.1016/S0006-8993(00)03001-8; Vrang N, 1999, BRAIN RES, V818, P499, DOI 10.1016/S0006-8993(98)01349-3; Vrang N., 1999, J NEUROSCI, V19, P1; WANG Z, 2000, END SOC M TOR JUN 21, P96; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; ZHOU A, 1993, J BIOL CHEM, V268, P1763; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10299, DOI 10.1073/pnas.162352799; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10293, DOI 10.1073/pnas.162352599	59	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15007	15014		10.1074/jbc.M212128200	http://dx.doi.org/10.1074/jbc.M212128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584191	hybrid			2022-12-27	WOS:000182516100057
J	Warke, VG; Nambiar, MP; Krishnan, S; Tenbrock, K; Geller, DA; Koritschoner, NP; Atkins, JL; Farber, DL; Tsokos, GC				Warke, VG; Nambiar, MP; Krishnan, S; Tenbrock, K; Geller, DA; Koritschoner, NP; Atkins, JL; Farber, DL; Tsokos, GC			Transcriptional activation of the human inducible nitric-oxide synthase promoter by Kruppel-like factor 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; RAT MESANGIAL CELLS; ZINC-FINGER PROTEIN; GENE-EXPRESSION; INOS GENE; BINDING PROTEIN; MURINE MELANOMA; PHOSPHORYLATION; SUPPRESSION; TUMORIGENICITY	Nitric oxide is a ubiquitous free radical that plays a key role in a broad spectrum of signaling pathways in physiological and pathophysiological processes. We have explored the transcriptional regulation of inducible nitric-oxide synthase (iNOS) by Kruppel-like factor 6 (KLF6), an Sp1-like zinc finger transcription factor. Study of serial deletion constructs of the iNOS promoter revealed that the proximal 0.63-kb region can support a 3-6-fold reporter activity similar to that of the full-length 16-kb promoter. Within the 0.63-kb region, we identified two CACCC sites (-164 to -168 and -261 to -265) that bound KLF6 in both electrophoretic mobility shift and chromatin immunoprecipitation assays. Mutation of both these sites abrogated the KLF6-induced enhancement of the 0.63-kb iNOS promoter activity. The binding of KLF6 to the iNOS promoter was significantly increased in Jurkat cells, primary T lymphocytes, and COS-7 cells subjected to NaCN-induced hypoxia, heat shock, serum. starvation, and phorbol 12-myristate 13-acetate/A23187 ionophore stimulation. Furthermore, in KLF6-transfected and NaCN-treated COS-7 cells, there was a 3-4-fold increase in the expression of the endogenous iNOS mRNA and protein that correlated with increased production of nitric oxide. These findings indicate that KLF6 is a potential transactivator of the human iNOS promoter in diverse pathophysiological conditions.	Walter Reed Army Inst Res, Dept Cellular Injury, Silver Spring, MD 20910 USA; Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA; Uniformed Serv Univ Hlth Sci, Dept Med, Bethesda, MD 20814 USA; Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA; Univ Nacl Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, RA-5000 Cordoba, Argentina	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University System of Maryland; University of Maryland College Park; Uniformed Services University of the Health Sciences - USA; University System of Maryland; University of Maryland Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National University of Cordoba	Tsokos, GC (corresponding author), Walter Reed Army Inst Res, Dept Cellular Injury, Bldg 503,Rm 1A32,Robert Grant Ave, Silver Spring, MD 20910 USA.	gtsokos@usa.net	tsokos, george C/O-3360-2013	tsokos, george C/0000-0001-9589-2360; Farber, Donna/0000-0001-8236-9183	PHS HHS [R01 49954] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Blanchon L, 2001, MECH DEVELOP, V105, P185, DOI 10.1016/S0925-4773(01)00391-4; Bouchie JL, 1998, ARTERIOSCL THROM VAS, V18, P1771, DOI 10.1161/01.ATV.18.11.1771; CONNOR JR, 1995, EUR J PHARMACOL, V273, P15, DOI 10.1016/0014-2999(94)00672-T; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Eberhardt W, 2000, KIDNEY INT, V57, P59, DOI 10.1046/j.1523-1755.2000.00808.x; Eberhardt W, 2000, J IMMUNOL, V165, P5788, DOI 10.4049/jimmunol.165.10.5788; Eberhardt W, 2002, KIDNEY INT, V61, P20, DOI 10.1046/j.1523-1755.2002.00087.x; Efron D T, 2000, Curr Opin Clin Nutr Metab Care, V3, P197, DOI 10.1097/00075197-200005000-00006; Efron DT, 1999, J GASTROINTEST SURG, V3, P592, DOI 10.1016/S1091-255X(99)80080-8; Fischer EA, 2001, J AM SOC NEPHROL, V12, P726, DOI 10.1681/ASN.V124726; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; Grisham MB, 2000, ALIMENT PHARM THERAP, V14, P3, DOI 10.1046/j.1365-2036.2000.014s1003.x; Hur GM, 1999, BIOCHEM BIOPH RES CO, V261, P917, DOI 10.1006/bbrc.1999.1143; Inuzuka H, 1999, BIOCHEM BIOPH RES CO, V265, P664, DOI 10.1006/bbrc.1999.1734; Jensen MS, 2000, TOXICOL SCI, V58, P127, DOI 10.1093/toxsci/58.1.127; Juang SH, 1998, HUM GENE THER, V9, P845, DOI 10.1089/hum.1998.9.6-845; Juang SH, 1997, CANCER BIOTHER RADIO, V12, P167, DOI 10.1089/cbr.1997.12.167; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kojima S, 2000, BLOOD, V95, P1309; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Li JR, 1999, CELL DEATH DIFFER, V6, P952, DOI 10.1038/sj.cdd.4400579; Liossis SNC, 1998, J CLIN INVEST, V101, P1448, DOI 10.1172/JCI1457; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Ouyang L, 1998, J BIOL CHEM, V273, P23019, DOI 10.1074/jbc.273.36.23019; Paulsen Stephen M., 1998, Wound Repair and Regeneration, V6, P142, DOI 10.1046/j.1524-475X.1998.60208.x; Pfeilschifter J, 2001, PFLUG ARCH EUR J PHY, V442, P479, DOI 10.1007/s004240100586; Ralston SH, 1996, BONE, V19, P29, DOI 10.1016/8756-3282(96)00101-9; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Slavin D, 1999, BIOL REPROD, V61, P1586, DOI 10.1095/biolreprod61.6.1586; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Taylor BS, 2000, SHOCK, V13, P413, DOI 10.1097/00024382-200006000-00001; Wang IJ, 2002, MOL VIS, V8, P94; Wang YN, 2002, ANN NY ACAD SCI, V962, P415, DOI 10.1111/j.1749-6632.2002.tb04085.x; XIE KP, 1995, J EXP MED, V181, P1333, DOI 10.1084/jem.181.4.1333; XIE QW, 1994, J BIOL CHEM, V269, P4705; Xu WM, 2001, FASEB J, V15, P213, DOI 10.1096/fj.01-0590fje; Yamasaki K, 1998, J CLIN INVEST, V101, P967, DOI 10.1172/JCI2067; Yang C W, 1996, J Biochem Toxicol, V11, P251, DOI 10.1002/(SICI)1522-7146(1996)11:5<251::AID-JBT6>3.0.CO;2-J; Zhao JL, 2000, J BIOL CHEM, V275, P8903, DOI 10.1074/jbc.275.12.8903	51	63	64	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14812	14819		10.1074/jbc.M300787200	http://dx.doi.org/10.1074/jbc.M300787200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590140	hybrid			2022-12-27	WOS:000182516100031
J	Zhao, YG; Xiao, AZ; Newcomer, RG; Park, HI; Kang, TB; Chung, LWK; Swanson, MG; Zhau, HE; Kurhanewicz, J; Sang, QXA				Zhao, YG; Xiao, AZ; Newcomer, RG; Park, HI; Kang, TB; Chung, LWK; Swanson, MG; Zhau, HE; Kurhanewicz, J; Sang, QXA			Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; MATRIX-METALLOPROTEINASE; TISSUE INHIBITOR; CYSTEINE-SWITCH; IV COLLAGENASE; MATRIX-METALLOPROTEINASE-9; PROGELATINASE; PROCOLLAGENASE; OVEREXPRESSION; FIBROBLASTS	This work has explored a putative biochemical mechanism by which endometase/matrilysin-2/matrix metalloproteinase-26 (MMP-26) may promote human prostate cancer cell invasion. Here, we showed that the levels of MMP-26 protein in human prostate carcinomas from multiple patients were significantly higher than those in prostatitis, benign prostate hyperplasia, and normal prostate glandular tissues. The role of MMP-26 in prostate cancer progression is unknown. MMP-26 was capable of activating pro-MMP-9 by cleavage at the Ala(93)-Met(94) site of the prepro-enzyme. This activation proceeded in a time- and dose-dependent manner, facilitating the efficient cleavage of fibronectin by MMP-9. The activated MMP-9 products generated by MMP-26 appeared more stable than those cleaved by MMP-7 under the conditions tested. To investigate the contribution of MMP-26 to cancer cell invasion via the activation of MMP-9, highly invasive and metastatic human prostate carcinoma cells, androgen-repressed prostate cancer (ARCaP) cells were selected as a working model. ARCaP cells express both MMP-26 and MMP-9. Specific anti-MMP-26 and anti-MMP-9 functional blocking antibodies both reduced the invasiveness of ARCaP cells across fibronectin or type IV collagen. Furthermore, the introduction of MMP-26 antisense cDNA into ARCaP cells significantly reduced the MMP-26 protein level in these cells and strongly suppressed the invasiveness of ARCaP cells. Double immunofluorescence staining and confocal laser scanning microscopic images revealed that MMP-26 and MMP-9 were co-localized in parental and MMP-26 sense-transfected ARCaP cells. Moreover, MMP-26 and MMP-9 proteins were both expressed in the same human prostate carcinoma tissue samples examined. These results indicate that MMP-26 may be a physiological and pathological activator of pro-MMP-9.	Florida State Univ, Dept Chem & Biochem, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; Emory Univ, Winship Canc Inst, Mol Urol & Therapeut Program, Atlanta, GA 30322 USA; Univ Calif San Francisco, Magnet Resonance Sci Ctr, San Francisco, CA 94143 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University; Emory University; University of California System; University of California San Francisco	Sang, QXA (corresponding author), Florida State Univ, Dept Chem & Biochem, Chem Res Bldg,Rm 203,203 DLC, Tallahassee, FL 32306 USA.	sang@chem.fsu.edu			NCI NIH HHS [CA76620, CA82739, CA78646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078646, R01CA082739, R01CA076620] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt M, 2002, CANCER RES, V62, P5543; de Coignac AB, 2000, EUR J BIOCHEM, V267, P3323; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; GOLDFARB RH, 1986, SEMIN THROMB HEMOST, V12, P294, DOI 10.1055/s-2007-1003570; Hrabec E, 2001, RESP MED, V95, P1, DOI 10.1053/rmed.2000.0923; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; Kang TB, 2002, J BIOL CHEM, V277, P25583, DOI 10.1074/jbc.M203532200; Li H, 1998, MOL CARCINOGEN, V22, P84; Li YW, 2002, CANCER LETT, V186, P157, DOI 10.1016/S0304-3835(02)00349-X; Marchenko GN, 2001, BIOCHEM J, V356, P705, DOI 10.1042/0264-6021:3560705; Marchenko ND, 2002, J BIOL CHEM, V277, P18967, DOI 10.1074/jbc.M201197200; Mase K, 2002, LUNG CANCER-J IASLC, V36, P271, DOI 10.1016/S0169-5002(02)00004-1; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Matsubara S, 2001, CANCER RES, V61, P6012; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; Nemeth JA, 2002, J NATL CANCER I, V94, P17; Nguyen M, 1998, J BIOL CHEM, V273, P5400, DOI 10.1074/jbc.273.9.5400; OKADA Y, 1992, J BIOL CHEM, V267, P21712; Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200; Park HI, 2002, J BIOL CHEM, V277, P35168, DOI 10.1074/jbc.M205071200; RAMOSDESIMONE N, 1993, HYBRIDOMA, V12, P349, DOI 10.1089/hyb.1993.12.349; Sakamoto Y, 2000, INT J ONCOL, V17, P237; SANG QX, 1995, BBA-PROTEIN STRUCT M, V1251, P99, DOI 10.1016/0167-4838(95)00086-A; Sang QXA, 2000, BIOCHEM BIOPH RES CO, V274, P780, DOI 10.1006/bbrc.2000.3212; Sang QXA, 1996, J PROTEIN CHEM, V15, P243, DOI 10.1007/BF01887112; Scorilas A, 2001, BRIT J CANCER, V84, P1488, DOI 10.1054/bjoc.2001.1810; Seftor REB, 2001, CANCER RES, V61, P6322; Shen KH, 2000, ANTICANCER RES, V20, P1307; Singer CF, 2002, BREAST CANCER RES TR, V72, P69, DOI 10.1023/A:1014918512569; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; TRIEBEL S, 1992, FEBS LETT, V298, P280, DOI 10.1016/0014-5793(92)80077-T; Tschesche H, 2001, EUR J BIOCHEM, V268, P1918, DOI 10.1046/j.1432-1327.2001.02066.x; Uria JA, 2000, CANCER RES, V60, P4745; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Zhang J, 2002, MOL HUM REPROD, V8, P659, DOI 10.1093/molehr/8.7.659; Zhao YG, 2002, MOL REPROD DEV, V62, P149, DOI 10.1002/mrd.10123; Zhao YG, 2001, BIOCHEM BIOPH RES CO, V289, P288, DOI 10.1006/bbrc.2001.5958; Zhau HYE, 1996, P NATL ACAD SCI USA, V93, P15152, DOI 10.1073/pnas.93.26.15152	40	105	119	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15056	15064		10.1074/jbc.M210975200	http://dx.doi.org/10.1074/jbc.M210975200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586837	hybrid			2022-12-27	WOS:000182516100063
J	Cortajarena, AL; Goni, FM; Ostolaza, H				Cortajarena, AL; Goni, FM; Ostolaza, H			A receptor-binding region in Escherichia coli alpha-haemolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE TOXIN; HUMAN TARGET-CELLS; PHOSPHOLIPID-VESICLES; LIPID-BILAYERS; RTX TOXINS; LEUKOTOXIN; INSERTION; MEMBRANE; PROTEIN; IDENTIFICATION	Escherichia coli alpha-hemolysin (HlyA) is a 107-kDa protein toxin with a wide range of mammalian target cells. Previous work has shown that glycophorin is a specific receptor for HlyA in red blood cells (Cortajarena, A. L., Goni, F. M., and Ostolaza, H. (2001) J. Biol. Chem. 276, 12513-12519). The present study was aimed at identifying the glycophorin-binding region in the toxin. Data in the literature pointed to a short amino acid sequence near the C terminus as a putative receptor-binding domain. Previous sequence analyses of several homologous toxins that belong, like HlyA, to the so-called RTX toxin family revealed a conserved region that corresponded to residues 914-936 of HlyA. We therefore prepared a deletion mutant lacking these residues (HlyADelta914-936) and found that its hemolytic activity was decreased by 10,000-fold with respect to the wild type. This deletion mutant was virtually unable to bind human and horse red blood cells or to bind pure glycophorin in an affinity column. The peptide Trp(914)-Arg(936) had no lytic activity of its own, but it could bind glycophorin reconstituted in lipid vesicles. Moreover, the peptide Trp(914)-Arg(936) protected red blood cells from hemolysis induced by wild type HlyA. It was concluded that amino acid residues 914-936 constitute a major receptor-binding region in alpha-hemolysin.	Univ Basque Country Euskal Herriko Unibertsitatea, CSIC, Unidad Biofis, Bilbao 48080, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country	Ostolaza, H (corresponding author), Univ Basque Country Euskal Herriko Unibertsitatea, CSIC, Unidad Biofis, Aptdo 644, Bilbao 48080, Spain.	gbzoseth@lg.ehu.es	Goni, Felix M/M-5425-2015; Cortajarena, Aitziber L/J-6202-2012	Goni, Felix M/0000-0001-6270-9216; Cortajarena, Aitziber L/0000-0002-5331-114X; OSTOLAZA ECHABE, ELENA AMAYA/0000-0003-2933-9975				Bakas L, 1998, BBA-BIOMEMBRANES, V1368, P225, DOI 10.1016/S0005-2736(97)00181-8; Bakas L, 1996, BIOPHYS J, V71, P1869, DOI 10.1016/S0006-3495(96)79386-4; Bauer ME, 1996, INFECT IMMUN, V64, P4665, DOI 10.1128/IAI.64.11.4665-4672.1996; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; Bejerano M, 1999, MOL MICROBIOL, V31, P381, DOI 10.1046/j.1365-2958.1999.01183.x; Chervaux C, 1996, J BACTERIOL, V178, P1232, DOI 10.1128/jb.178.4.1232-1236.1996; COOTE JG, 1996, REV MED MICROBIOL, V7, P53, DOI [10.1097/00013542-199601000-00006, DOI 10.1097/00013542-199601000-00006]; Cortajarena AL, 2001, J BIOL CHEM, V276, P12513, DOI 10.1074/jbc.M006792200; CRUZ WT, 1990, MOL MICROBIOL, V4, P1933, DOI 10.1111/j.1365-2958.1990.tb02042.x; Goni FM, 1998, BRAZ J MED BIOL RES, V31, P1019, DOI 10.1590/S0100-879X1998000800002; Hyland C, 2001, J BACTERIOL, V183, P5364, DOI 10.1128/JB.183.18.5364-5370.2001; IWAKI M, 1995, MOL MICROBIOL, V17, P1015, DOI 10.1111/j.1365-2958.1995.mmi_17061015.x; Lainson FA, 1996, MICROBIOL-UK, V142, P2499, DOI 10.1099/00221287-142-9-2499; LALLY ET, 1994, J BIOL CHEM, V269, P31289; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; Lim KB, 2000, J BIOL CHEM, V275, P36698, DOI 10.1074/jbc.C000544200; MACDONALD RI, 1975, J BIOL CHEM, V250, P9206; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; OSTOLAZA H, 1995, EUR J BIOCHEM, V228, P39, DOI 10.1111/j.1432-1033.1995.tb20225.x; OSTOLAZA H, 1991, FEBS LETT, V280, P195, DOI 10.1016/0014-5793(91)80291-A; PEREIRA FB, 1995, FEBS LETT, V362, P243, DOI 10.1016/0014-5793(95)00257-A; Schindel C, 2001, EUR J BIOCHEM, V268, P800, DOI 10.1046/j.1432-1327.2001.01937.x; Soloaga A, 1999, MOL MICROBIOL, V31, P1013, DOI 10.1046/j.1365-2958.1999.01225.x; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Sun YD, 1999, INFECT IMMUN, V67, P6264; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85; Young J, 1999, BBA-BIOMEMBRANES, V1461, P177, DOI 10.1016/S0005-2736(99)00158-3	28	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19159	19163		10.1074/jbc.M208552200	http://dx.doi.org/10.1074/jbc.M208552200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12582172	hybrid			2022-12-27	WOS:000182932200058
J	Longhi, S; Receveur-Brechot, V; Karlin, D; Johansson, K; Darbon, H; Bhella, D; Yeo, R; Finet, S; Canard, B				Longhi, S; Receveur-Brechot, V; Karlin, D; Johansson, K; Darbon, H; Bhella, D; Yeo, R; Finet, S; Canard, B			The C-terminal domain of the measles virus nucleoprotein is intrinsically disordered and folds upon binding to the C-terminal moiety of the phosphoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCAPSID-LIKE STRUCTURES; NATIVELY UNFOLDED PROTEINS; ANGLE NEUTRON-SCATTERING; X-RAY-SCATTERING; P-PROTEIN; UNSTRUCTURED PROTEINS; GENOME REPLICATION; ESCHERICHIA-COLI; RNA-SYNTHESIS; CONFORMATIONAL-CHANGES	The nucleoprotein of measles virus consists of an N-terminal moiety, N-CORE, resistant to proteolysis and a C-terminal moiety, N-TAIL, hypersensitive to proteolysis and not visible as a distinct domain by electron microscopy. We report the bacterial expression, purification, and characterization of measles virus N-TAIL. Using nuclear magnetic resonance, circular dichroism, gel filtration, dynamic light scattering, and small angle x-ray scattering, we show that N-TAIL is not structured in solution. Its sequence and spectroscopic and hydrodynamic properties indicate that N-TAIL belongs to the premolten globule subfamily within the class of intrinsically disordered proteins. The same epitopes are exposed in N-TAIL and within the nucleoprotein, which rules out dramatic conformational changes in the isolated N-TAIL domain compared with the full-length nucleoprotein. Most unstructured proteins undergo some degree of folding upon binding to their partners, a process termed "induced folding." We show that N-TAIL is able to bind its physiological partner, the phosphoprotein, and that it undergoes such an unstructured-to-structured transition upon binding to the C-terminal moiety of the phosphoprotein. The presence of flexible regions at the surface of the viral nucleocapsid would enable plastic interactions with several partners, whereas the gain of structure arising from induced folding would lead to modulation of these interactions. These results contribute to the study of the emerging field of natively unfolded proteins.	ESIL, CNRS, UMR 6098, F-13288 Marseille 09, France; Univ Aix Marseille 1, ESIL, F-13288 Marseille, France; Univ Aix Marseille 2, ESIL, F-13288 Marseille 09, France; Inst Virol, MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; University of Glasgow; European Synchrotron Radiation Facility (ESRF)	Longhi, S (corresponding author), ESIL, CNRS, UMR 6098, Case 925,163 Ave Luminy,Campus Luminy, F-13288 Marseille 09, France.		LONGHI, Sonia/M-5305-2014; Bhella, David/J-8514-2012	LONGHI, Sonia/0000-0002-6829-6771; Bhella, David/0000-0003-2096-8310; Receveur-Brechot, Veronique/0000-0002-7464-6192; Canard, Bruno/0000-0003-4924-1991	Medical Research Council [MC_U130115834] Funding Source: Medline; MRC [MC_U130115834] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bankamp B, 1996, VIROLOGY, V216, P272, DOI 10.1006/viro.1996.0060; Bergmann A, 2000, J APPL CRYSTALLOGR, V33, P1212, DOI 10.1107/S0021889800008372; Bhella D, 2002, J GEN VIROL, V83, P1831, DOI 10.1099/0022-1317-83-8-1831; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; Brown CJ, 2002, J MOL EVOL, V55, P104, DOI 10.1007/s00239-001-2309-6; BUCHHOLZ CJ, 1993, J VIROL, V67, P5803, DOI 10.1128/JVI.67.10.5803-5812.1993; BUCHHOLZ CJ, 1994, VIROLOGY, V204, P770, DOI 10.1006/viro.1994.1592; BUCKLAND R, 1989, J GEN VIROL, V70, P435, DOI 10.1099/0022-1317-70-2-435; Coronel EC, 2001, J VIROL, V75, P1117, DOI 10.1128/JVI.75.3.1117-1123.2001; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; CURRAN J, 1993, J VIROL, V67, P4358, DOI 10.1128/JVI.67.7.4358-4364.1993; Curran J, 1999, ADV VIRUS RES, V54, P403, DOI 10.1016/S0065-3527(08)60373-5; CURRAN J, 1995, J VIROL, V69, P849, DOI 10.1128/JVI.69.2.849-855.1995; Curran J, 1998, J VIROL, V72, P4274, DOI 10.1128/JVI.72.5.4274-4280.1998; Curran J, 1996, VIROLOGY, V221, P130, DOI 10.1006/viro.1996.0359; CURRAN J, 1994, VIROLOGY, V202, P875, DOI 10.1006/viro.1994.1409; CURRAN J, 1995, VIROLOGY, V214, P139, DOI 10.1006/viro.1995.9946; Daughdrill GW, 1998, BIOCHEMISTRY-US, V37, P1076, DOI 10.1021/bi971952t; De BP, 1999, MICROSC RES TECHNIQ, V47, P114, DOI 10.1002/(SICI)1097-0029(19991015)47:2<114::AID-JEMT4>3.3.CO;2-5; Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299; DESHPANDE KL, 1984, VIROLOGY, V139, P32, DOI 10.1016/0042-6822(84)90327-1; DIAMOND R, 1974, J MOL BIOL, V82, P371, DOI 10.1016/0022-2836(74)90598-1; Dunker AK, 2001, NAT BIOTECHNOL, V19, P805, DOI 10.1038/nbt0901-805; Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8; DUNKER AK, 1998, PAC S BIOCOMP, V3, P473; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; EGELMAN EH, 1989, J VIROL, V63, P2233, DOI 10.1128/JVI.63.5.2233-2243.1989; FINCH JT, 1970, J GEN VIROL, V6, P141, DOI 10.1099/0022-1317-6-1-141; FOOKS AR, 1993, J GEN VIROL, V74, P1439, DOI 10.1099/0022-1317-74-7-1439; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; GAST K, 1994, EUR BIOPHYS J BIOPHY, V23, P297, DOI 10.1007/BF00213579; GIRAUDON P, 1988, VIRUS RES, V10, P137, DOI 10.1016/0168-1702(88)90011-1; Glatter O., 1982, SMALL ANGLE XRAY SCA; Guinier A., 1955, SMALL ANGLE SCATTERI; HARTY RN, 1995, J GEN VIROL, V76, P2863, DOI 10.1099/0022-1317-76-11-2863; HEGGENESS MH, 1981, VIROLOGY, V114, P555, DOI 10.1016/0042-6822(81)90235-X; HEGGENESS MH, 1980, P NATL ACAD SCI-BIOL, V77, P2631, DOI 10.1073/pnas.77.5.2631; HORIKAMI SM, 1992, J VIROL, V66, P4901, DOI 10.1128/JVI.66.8.4901-4908.1992; Hua QX, 1998, BIOCHEMISTRY-US, V37, P5858, DOI 10.1021/bi9800808; HUBBARD SJ, 2001, PROTEOLYTIC ENZYMES, P233; HUBER M, 1991, VIROLOGY, V185, P299, DOI 10.1016/0042-6822(91)90777-9; Karlin D, 2002, VIROLOGY, V302, P420, DOI 10.1006/viro.2002.1634; Karlin D, 2002, VIROLOGY, V296, P251, DOI 10.1006/viro.2001.1296; Konno T, 1997, PROTEIN SCI, V6, P2242; LAMB R., 2001, FIELDS VIROLOGY, V1, P1305; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Liston P, 1997, ARCH VIROL, V142, P305, DOI 10.1007/s007050050078; LISTON P, 1995, VIRUS RES, V38, P241, DOI 10.1016/0168-1702(95)00067-Z; Liu JF, 2002, J MOL BIOL, V322, P53, DOI 10.1016/S0022-2836(02)00736-2; Marie JC, 2001, IMMUNITY, V14, P69, DOI 10.1016/S1074-7613(01)00090-5; Marion D, 2001, J BIOMOL NMR, V21, P75, DOI 10.1023/A:1011990021282; Morris MC, 1999, J PEPT SCI, V5, P263, DOI 10.1002/(SICI)1099-1387(199906)5:6<263::AID-PSC191>3.3.CO;2-1; MOYER SA, 1990, J GEN VIROL, V71, P775, DOI 10.1099/0022-1317-71-4-775; Myers TM, 1997, VIROLOGY, V229, P322, DOI 10.1006/viro.1996.8429; Myers TM, 1999, J GEN VIROL, V80, P1383, DOI 10.1099/0022-1317-80-6-1383; Narayanan T, 2001, NUCL INSTRUM METH A, V467, P1005, DOI 10.1016/S0168-9002(01)00553-8; Panick G, 1998, J MOL BIOL, V275, P389, DOI 10.1006/jmbi.1997.1454; Perez J, 2001, J MOL BIOL, V308, P721, DOI 10.1006/jmbi.2001.4611; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POTHIER P, 1997, MED MALADIES INFECT, V11, P592; Ravanel K, 1997, J EXP MED, V186, P269, DOI 10.1084/jem.186.2.269; Receveur V, 1998, FEBS LETT, V426, P57, DOI 10.1016/S0014-5793(98)00309-3; Russo D, 2001, BIOCHEMISTRY-US, V40, P3958, DOI 10.1021/bi002200t; RYAN KW, 1990, VIROLOGY, V174, P515, DOI 10.1016/0042-6822(90)90105-Z; RYAN KW, 1993, VIROLOGY, V193, P376, DOI 10.1006/viro.1993.1134; Schoehn G, 2001, J VIROL, V75, P490, DOI 10.1128/JVI.75.1.490-498.2001; Spehner D, 1997, VIROLOGY, V232, P260, DOI 10.1006/viro.1997.8568; SPEHNER D, 1991, J VIROL, V65, P6296, DOI 10.1128/JVI.65.11.6296-6300.1991; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Tarbouriech N, 2000, VIROLOGY, V266, P99, DOI 10.1006/viro.1999.0066; Tarbouriech N, 2000, NAT STRUCT BIOL, V7, P777; tenOever BR, 2002, J VIROL, V76, P3659, DOI 10.1128/JVI.76.8.3659-3669.2002; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Uversky VN, 2002, PROTEIN SCI, V11, P739, DOI 10.1110/ps.4210102; VANHOY M, 1993, CELL, V72, P587, DOI 10.1016/0092-8674(93)90077-4; WARNES A, 1995, GENE, V160, P173, DOI 10.1016/0378-1119(95)00227-W; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Zhang XS, 2002, J VIROL, V76, P8737, DOI 10.1128/JVI.76.17.8737-8746.2002	83	232	235	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18638	18648		10.1074/jbc.M300518200	http://dx.doi.org/10.1074/jbc.M300518200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621042	hybrid			2022-12-27	WOS:000182838300136
J	Kabotyanski, EB; Rosen, JM				Kabotyanski, EB; Rosen, JM			Signal transduction pathways regulated by prolactin and Src result in different conformations of activated Stat5b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; EPIDERMAL GROWTH-FACTOR; BETA-CASEIN GENE; COLONY-STIMULATING FACTOR; MAMMARY-GLAND DEVELOPMENT; RECEPTOR-ALPHA GENE; TRANSCRIPTION FACTOR; SERINE PHOSPHORYLATION; TYROSINE KINASES; EPITHELIAL-CELLS	Stat5 is activated by a broad spectrum of cytokines, as well as non-receptor tyrosine kinases, such as Src. In this study, the DNA binding properties of the two closely related Stat5 proteins, Stat5a and Stat5b, induced either by prolactin (Prl) or by Src were analyzed by electrophoretic mobility shift assays using several different Stat5 binding sites. Src-induced Stat5b-DNA binding complexes consistently displayed a slightly faster mobility than those induced by Prl, as well as differences in their ability to be supershifted by anti-Stat5 antibodies. IP-Westerns performed using specific antibodies directed at the N and C termini of Stat5b suggested that depending on the activating stimulus, Stat5b exhibited different conformations, which influenced antibody accessibility at its C terminus. These conformational differences may in part be due to differential effects of Prl and Src on Stat5b tyrosine phosphorylation, since Src induced several additional sites of tyrosine phosphorylation of Stat5b at residues other than Tyr-699, including Tyr-724 and Tyr-679. The latter Tyr-679 is conserved in all mammalian Stat5bs, but is not present in Stat5a. A Stat5bY679F mutant induced by Src kinase exhibited an altered pattern of nuclear localization as compared with wild-type Stat5b. Furthermore, this mutation inhibited v-Src-induced cyclin D1-luciferase reporter activity in transient transfection assays performed in Stat5a/b-deficient MEFs, suggesting that Tyr-679 phosphorylation may play a role in v-Src induced proliferation. Thus, depending on the signal transduction pathway responsible for activation, different conformations of activated Stat5 may result in selective biological responses.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.				NCI NIH HHS [CA16303] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; Ariyoshi K, 2000, J BIOL CHEM, V275, P24407, DOI 10.1074/jbc.M909771199; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Beuvink I, 2000, J BIOL CHEM, V275, P10247, DOI 10.1074/jbc.275.14.10247; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Boucheron C, 1998, J BIOL CHEM, V273, P33936, DOI 10.1074/jbc.273.51.33936; Bovolenta C, 1998, J BIOL CHEM, V273, P20779, DOI 10.1074/jbc.273.33.20779; BURDON TG, 1994, MOL ENDOCRINOL, V8, P1528, DOI 10.1210/me.8.11.1528; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Frank DA, 1996, LEUKEMIA, V10, P1724; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; John S, 1999, MOL CELL BIOL, V19, P1910; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Kloth MT, 2002, J BIOL CHEM, V277, P8693, DOI 10.1074/jbc.M111884200; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LI S, 1995, MOL CELL BIOL, V15, P2063; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Paukku K, 2000, BIOCHEM J, V345, P759, DOI 10.1042/0264-6021:3450759; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; PIERRE S, 1994, MOL ENDOCRINOL, V8, P1720, DOI 10.1210/me.8.12.1720; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Seyfert HM, 2000, J MOL EVOL, V50, P550, DOI 10.1007/s002390010058; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wyszomierski SL, 2001, MOL ENDOCRINOL, V15, P228, DOI 10.1210/me.15.2.228; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218	69	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17218	17227		10.1074/jbc.M301578200	http://dx.doi.org/10.1074/jbc.M301578200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621061	hybrid			2022-12-27	WOS:000182818600104
J	Koo, IC; Stephens, RS				Koo, IC; Stephens, RS			A developmentally regulated two-component signal transduction system in Chlamydia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; COMPLETE GENOME SEQUENCE; RNA-POLYMERASE; ACTIVATE TRANSCRIPTION; SIGMA(54) SIGMA(N); MYXOCOCCUS-XANTHUS; CENTRAL DOMAIN; TRACHOMATIS; NTRC; GENE	Two-component systems allow bacteria to adapt to changing environmental conditions and may induce developmental changes necessary for survival. Chlamydia trachomatis alternates between two distinct developmental forms, each optimized for survival in a separate niche. Transcriptional regulation of development is not understood. The C. trachomatis genome sequence revealed a single pair of genes (ctcB-ctcC) predicted to encode proteins with sequence conservation to bacterial two-component systems. Sequence analysis revealed that the sensor kinase, CtcB, possessed an energy-sensing PAS domain and phosphorylation site. The response regulator, CtcC, had homology to sigma(54) activators, possessing conserved receiver and ATPase domains and phosphorylation site, but lacked the C-terminal DNA-binding domain. ctcB and ctcC were expressed late in the developmental cycle, and both proteins were detected in EB lysates. Recombinant CtcB and CtcC were purified from denatured Escherichia coli inclusion bodies and refolded. CtcC was found to aggregate as dimers and tetramers in solution. In vitro phosphorylation assays showed that CtcB autophosphorylated in the presence of Mg2+, Mn2+, and Fe2+ and transferred the phosphoryl group in the presence of CtcC. Collectively, these results show that CtcB and CtcC function as a two-component system and are likely responsible for transcriptional regulation by sigma(54) holoenzyme during late-stage chlamydial development.	Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA; Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco	Stephens, RS (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, 140 Warren Hall, Berkeley, CA 94720 USA.				PHS HHS [AY42156] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAVOIL P, 1984, INFECT IMMUN, V44, P479, DOI 10.1128/IAI.44.2.479-485.1984; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; CONTRERAS A, 1988, NUCLEIC ACIDS RES, V16, P4025, DOI 10.1093/nar/16.9.4025; Cullen PJ, 1996, J BIOL CHEM, V271, P6530, DOI 10.1074/jbc.271.11.6530; Fehlner-Gardiner C, 2002, J BIOL CHEM, V277, P26893, DOI 10.1074/jbc.M203937200; FLASHNER Y, 1995, J MOL BIOL, V249, P700, DOI 10.1006/jmbi.1995.0330; HACKSTADT T, 1985, J BACTERIOL, V161, P25, DOI 10.1128/JB.161.1.25-31.1985; HATCH TP, 1986, J BACTERIOL, V165, P379, DOI 10.1128/jb.165.2.379-385.1986; HUALA E, 1989, J BACTERIOL, V171, P3354, DOI 10.1128/jb.171.6.3354-3365.1989; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; KAUL R, 1986, J BACTERIOL, V168, P722, DOI 10.1128/jb.168.2.722-727.1986; KLOSE KE, 1994, J MOL BIOL, V241, P233, DOI 10.1006/jmbi.1994.1492; KOEHLER JE, 1990, J BIOL CHEM, V265, P13206; KOSHIYAMA KY, 1998, P 9 INT S HUM CHLAM, P535; Kroos L, 1999, MOL MICROBIOL, V31, P1285, DOI 10.1046/j.1365-2958.1999.01214.x; Laskos L, 1998, GENE, V208, P95, DOI 10.1016/S0378-1119(97)00664-1; Li YH, 1996, J BACTERIOL, V178, P289, DOI 10.1128/jb.178.1.289-292.1996; Marques MDV, 1997, J BACTERIOL, V179, P5502, DOI 10.1128/jb.179.17.5502-5510.1997; Mathews SA, 2000, J BACTERIOL, V182, P6239, DOI 10.1128/JB.182.21.6239-6242.2000; MCCLEARY WR, 1990, J BACTERIOL, V172, P6661, DOI 10.1128/jb.172.12.6661-6668.1990; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; Moran NA, 1996, P NATL ACAD SCI USA, V93, P2873, DOI 10.1073/pnas.93.7.2873; MORETT E, 1988, NUCLEIC ACIDS RES, V16, P11469, DOI 10.1093/nar/16.24.11469; Neuwald AF, 1999, GENOME RES, V9, P27; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Shaw EI, 2000, MOL MICROBIOL, V37, P913, DOI 10.1046/j.1365-2958.2000.02057.x; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; STEPHENS RS, 2001, P 10 INT S HUM CHLAM, P3; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; Studholme DJ, 2000, FEMS MICROBIOL LETT, V186, P1; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Ward ME, 1988, MICOBIOLOGY CHLAMYDI, P71; WICHLAN DG, 1993, J BACTERIOL, V175, P2936, DOI 10.1128/JB.175.10.2936-2942.1993; WU SS, 1995, MOL MICROBIOL, V18, P547, DOI 10.1111/j.1365-2958.1995.mmi_18030547.x; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658	41	42	45	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17314	17319		10.1074/jbc.M212170200	http://dx.doi.org/10.1074/jbc.M212170200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600998	hybrid			2022-12-27	WOS:000182818600116
J	Morlon-Guyot, J; Helmy, M; Lombard-Frasca, S; Pignol, D; Pieroni, G; Beaumelle, B				Morlon-Guyot, J; Helmy, M; Lombard-Frasca, S; Pignol, D; Pieroni, G; Beaumelle, B			Identification of the ricin lipase site and implication in cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; A-CHAIN; ENDOPLASMIC-RETICULUM; INTERNALIZED RICIN; CRYSTAL-STRUCTURE; B-CHAIN; PROTEIN; TRANSLOCATION; CELLS; TOXIN	Ricin is a heterodimeric plant toxin and the prototype of type II ribosome-inactivating proteins. Its B-chain is a lectin that enables cell binding. After endocytosis, the A-chain translocates through the membrane of intracellular compartments to reach the cytosol where its N-glycosidase activity inactivates ribosomes, thereby arresting protein synthesis. We here show that ricin possesses a functional lipase active site at the interface between the two subunits. It involves residues from both chains. Mutation to alanine of catalytic serine 221 on the A-chain abolished ricin lipase activity. Moreover, this mutation slowed down the A-chain translocation rate and inhibited toxicity by 35%. Lipase activity is therefore required for efficient ricin A-chain translocation and cytotoxicity. This conclusion was further supported by structural examination of type II ribosome-inactivating proteins that showed that this lipase site is present in toxic (ricin and abrin) but is altered in nontoxic (ebulin 1 and mistletoe lectin I) members of this family.	Univ Montpellier 2, Dept Biol Sante, CNRS, UMR 5539, F-34095 Montpellier 05, France; Fac Med Marseille, INSERM, U476, F-13385 Marseille, France; CEA Cadarache, Dept Ecophysiol Vegetale & Microbiol, Lab Bioenerget Cellulaire, F-13107 St Paul Les Durance, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; CEA	Beaumelle, B (corresponding author), Univ Montpellier 2, Dept Biol Sante, CNRS, UMR 5539, Case 107, F-34095 Montpellier 05, France.			Beaumelle, Bruno/0000-0002-4912-9134; PIGNOL, David/0000-0002-8070-0319				Alami M, 1998, MOL BIOL CELL, V9, P387, DOI 10.1091/mbc.9.2.387; Beaumelle B, 1997, J BIOL CHEM, V272, P22097, DOI 10.1074/jbc.272.35.22097; BEAUMELLE B, 1993, J BIOL CHEM, V268, P23661; BILGE A, 1995, J BIOL CHEM, V270, P23720, DOI 10.1074/jbc.270.40.23720; CHADDOCK JA, 1993, PROTEIN ENG, V6, P425, DOI 10.1093/protein/6.4.425; Day PJ, 2002, BIOCHEMISTRY-US, V41, P2836, DOI 10.1021/bi012012i; Eschenburg S, 1998, BIOCHEM BIOPH RES CO, V247, P367, DOI 10.1006/bbrc.1998.8760; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; Frankel AE, 1997, LEUKEMIA, V11, P22, DOI 10.1038/sj.leu.2400517; GREGG EO, 1987, J IMMUNOL, V138, P4502; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; Helmy M, 1999, BIOCHEM BIOPH RES CO, V258, P252, DOI 10.1006/bbrc.1999.0618; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; Hussain MM, 2000, ATHEROSCLEROSIS, V148, P1; JAEGER KE, 1994, FEMS MICROBIOL REV, V15, P29, DOI 10.1016/0168-6445(94)90025-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kitaoka Y, 1998, EUR J BIOCHEM, V257, P255, DOI 10.1046/j.1432-1327.1998.2570255.x; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreitman RJ, 1999, CURR OPIN IMMUNOL, V11, P570, DOI 10.1016/S0952-7915(99)00005-9; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEWIS MS, 1986, J BIOL CHEM, V261, P1571; Lombard S, 2001, BIOCHEM J, V358, P773, DOI 10.1042/0264-6021:3580773; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; MLSNA D, 1993, PROTEIN SCI, V2, P429; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MOULIN A, 1994, P NATL ACAD SCI USA, V91, P11328, DOI 10.1073/pnas.91.24.11328; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; OLSNES S, 1976, J BIOL CHEM, V251, P3985; Pascal JM, 2001, PROTEINS, V43, P319, DOI 10.1002/prot.1043; Rohrer J, 2001, MOL BIOL CELL, V12, P1623, DOI 10.1091/mbc.12.6.1623; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; Schrag JD, 1997, STRUCTURE, V5, P187, DOI 10.1016/S0969-2126(97)00178-0; TAHIROV TH, 1995, J MOL BIOL, V250, P354, DOI 10.1006/jmbi.1995.0382; UTSUMI T, 1989, FEBS LETT, V242, P255, DOI 10.1016/0014-5793(89)80480-6; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1990, EUR J CELL BIOL, V51, P96; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; Wesche J, 1999, J BIOL CHEM, V274, P34443, DOI 10.1074/jbc.274.48.34443	40	32	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17006	17011		10.1074/jbc.M209516200	http://dx.doi.org/10.1074/jbc.M209516200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611897	Green Published, hybrid			2022-12-27	WOS:000182818600076
J	Stock, M; Schafer, H; Stricker, S; Gross, G; Mundlos, S; Otto, F				Stock, M; Schafer, H; Stricker, S; Gross, G; Mundlos, S; Otto, F			Expression of galectin-3 in skeletal tissues is controlled by Runx2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE-BINDING-FACTOR; OSTEOBLAST DIFFERENTIATION; BONE-FORMATION; CELL LINEAGES; GENE; PROTEIN; LECTINS; CBFA1; AML1; SECRETION	The beta-galatoside-specific lectin galectin-3 is expressed in vivo in osteoblasts as well as in epiphyseal cartilage. Here we show that in vitro, galectin-3 expression is upregulated in the preosteoblastic cell line MC3T3-E1 during the matrix maturation stage of the osteoblast developmental sequence. Expression persists into late differentiation stages when the mature osteoblastic phenotype is established. The skeletal expression pattern of galectin-3 overlaps at many sites with that of the transcription factor Runx2. Runx2 is a key regulator of osteoblast development and necessary for chondrocyte differentiation in the growth plate. Both human and mouse galectin-3 promoters contain putative Runx-binding sites. The constitutive or inducible forced expression of Runx2 is sufficient for the onset of galectin-3 transcription in the mesenchymal precursor cell line C3H10T1/2. Moreover, Runx2 is able to bind to at least two sites in the galectin-3 promoter region. The crucial role of Runx2 was confirmed in Runx2-deficient mice, which are devoid of galectin-3 expression in skeletal cells. The overlapping expression pattern of galectin-3 with the other two members of the Runt family of transcription factors (Runx1 and Runx3) points to a potential regulation of the galectin-3 gene (LGALS3) by these factors in hematopoietic, skin, and dorsal root ganglial cells.	Univ Freiburg, Med Ctr, Div Hematol Oncol, D-79106 Freiburg, Germany; Univ Freiburg, Inst Biol 1, D-79106 Freiburg, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Gesell Biotechnol Forsch mbH, D-38124 Braunschweig, Germany	University of Freiburg; University of Freiburg; Max Planck Society; Gesellschaft fur Biotechnologische Forschung mbH	Otto, F (corresponding author), Univ Freiburg, Med Ctr, Div Hematol Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.		Stock, Michael/B-9829-2009; Stricker, Sigmar/B-9169-2009; Mundlos, Stefan/ABH-9585-2020	Stricker, Sigmar/0000-0002-7174-5363; Mundlos, Stefan/0000-0002-9788-3166; Stock, Michael/0000-0002-3322-0961				AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; Aubin JE, 1996, J CELL PHYSIOL, V169, P468, DOI 10.1002/(SICI)1097-4652(199612)169:3<468::AID-JCP7>3.0.CO;2-M; BAO Q, 1995, J CELL SCI, V108, P2791; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Colnot C, 1999, CELL MOL BIOL, V45, P1191; Colnot C, 2001, DEV BIOL, V229, P203, DOI 10.1006/dbio.2000.9933; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; DEHNI G, 1995, MECH DEVELOP, V53, P369, DOI 10.1016/0925-4773(95)00452-1; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; Drissi H, 2000, J CELL PHYSIOL, V184, P341, DOI 10.1002/1097-4652(200009)184:3<341::AID-JCP8>3.0.CO;2-Z; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; FOWLIS D, 1995, DEV DYNAM, V203, P241, DOI 10.1002/aja.1002030211; GESSNER A, 1994, INFECT IMMUN, V62, P4112, DOI 10.1128/IAI.62.10.4112-4117.1994; Gotz W, 1997, DIFFERENTIATION, V62, P149, DOI 10.1046/j.1432-0436.1997.6230149.x; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Heilmann S, 2000, HISTOCHEM CELL BIOL, V113, P241, DOI 10.1007/s004180050444; HO MK, 1982, J IMMUNOL, V128, P1221; Kadrofske MM, 1998, ARCH BIOCHEM BIOPHYS, V349, P7, DOI 10.1006/abbi.1997.0447; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LIU FT, 1993, IMMUNOPHARMACOLOGY, V26, P187, DOI 10.1016/0162-3109(93)90034-N; LIU FT, 1993, IMMUNOL TODAY, V14, P486, DOI 10.1016/0167-5699(93)90263-K; Maniatis T., 1982, MOL CLONING LAB MANU; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Nishiyama J, 2000, AM J PATHOL, V157, P815, DOI 10.1016/S0002-9440(10)64595-6; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; Pesheva P, 2000, NEUROSCI LETT, V293, P37, DOI 10.1016/S0304-3940(00)01499-3; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; ROSENBERG IM, 1993, J BIOL CHEM, V268, P12393; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SATO S, 1994, J BIOL CHEM, V269, P4424; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(01)00271-9; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995	52	69	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17360	17367		10.1074/jbc.M207631200	http://dx.doi.org/10.1074/jbc.M207631200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604608	hybrid			2022-12-27	WOS:000182818600122
J	Takida, S; Wedegaertner, PB				Takida, S; Wedegaertner, PB			Heterotrimer formation, together with isoprenylation, is required for plasma membrane targeting of G beta gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL LIPID MODIFICATION; G-PROTEIN; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; CAAX MOTIF; G-ALPHA; LOCALIZATION; PRENYLATION; SUBUNIT; PALMITOYLATION	Nascent beta and gamma subunits of heterotrimeric G proteins need to be targeted to the cytoplasmic face of the plasma membrane (PM) in order to transmit signals. We show that beta(1)gamma(2) is poorly targeted to the PM and predominantly localized to endoplasmic reticulum (ER) membranes when expressed in HEK293 cells, but co-expression of a G protein alpha subunit allows strong PM localization of the beta(1)gamma(2). Furthermore, C-terminal isoprenylation of the gamma subunit is necessary but not sufficient for PM localization of beta(1)gamma(2). Isoprenylation of gamma(2) and localization of beta(1)gamma(2) to the ER occurs independently of alpha expression. Efficient PM localization of beta(1)gamma(2) in the absence of co-expressed alpha is observed when a site for palmitoylation, a putative second membrane targeting signal, is introduced into gamma(2). When a mutant of alpha(s) is targeted to mitochondria, beta(1)gamma(2) follows, consistent with an important role for alpha in promoting subcellular localization of betagamma. Furthermore, we directly demonstrate the requirement for alpha by showing that disruption of heterotrimer formation by the introduction of alpha binding mutations into beta(1) impedes PM targeting of beta(1)gamma(2). The results indicate that two membrane targeting signals, lipid modification and alpha binding, make concerted contributions to PM localization of betagamma.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Wedegaertner, PB (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, 233 S 10th St,839 BLSB, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM056444, R01GM056444, R56GM056444] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56444] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Evanko DS, 2001, J BIOL CHEM, V276, P23945, DOI 10.1074/jbc.M101154200; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; Gelb MH, 1998, CURR OPIN CHEM BIOL, V2, P40, DOI 10.1016/S1367-5931(98)80034-3; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Higgins JB, 1996, CELL SIGNAL, V8, P433, DOI 10.1016/S0898-6568(96)00071-X; Hirschman JE, 1999, MOL CELL BIOL, V19, P7705; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Manahan CL, 2000, MOL BIOL CELL, V11, P957, DOI 10.1091/mbc.11.3.957; Michaelson D, 2002, MOL BIOL CELL, V13, P3294, DOI 10.1091/mbc.E02-02-0095; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; Zhao LH, 2002, J BIOL CHEM, V277, P49352, DOI 10.1074/jbc.M209760200	33	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17284	17290		10.1074/jbc.M213239200	http://dx.doi.org/10.1074/jbc.M213239200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609996	hybrid			2022-12-27	WOS:000182818600112
J	Weihofen, A; Lemberg, MK; Friedmann, E; Rueeger, H; Schmitz, A; Paganetti, P; Rovelli, G; Martoglio, B				Weihofen, A; Lemberg, MK; Friedmann, E; Rueeger, H; Schmitz, A; Paganetti, P; Rovelli, G; Martoglio, B			Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; VIRUS CORE PROTEIN; INTRAMEMBRANE PROTEOLYSIS; INTRACELLULAR DOMAIN; THYMOCYTE DEVELOPMENT; BETA-SECRETASE; CLEAVAGE; APP; IDENTIFICATION	Presenilin is implicated in the pathogenesis of Alzheimer's disease. It is thought to constitute the catalytic subunit of the gamma-secretase complex that catalyzes intramembrane cleavage of beta-amyloid precursor protein, the last step in the generation of amyloidogenic Abeta peptides. The latter are major constituents of amyloid plaques in the brain of Alzheimer's disease patients. Inhibitors of gamma-secretase are considered potential therapeutics for the treatment of this disease because they prevent production of Abeta peptides. Recently, we discovered a family of presenilin-type aspartic proteases. The founding member, signal peptide peptidase, catalyzes intramembrane cleavage of distinct signal peptides in the endoplasmic reticulum membrane of animals. In humans, the protease plays a crucial role in the immune system. Moreover, it is exploited by the hepatitis C virus for the processing of the structural components of the virion and hence is an attractive target for anti-infective intervention. Signal peptide peptidase and presenilin share identical active site motifs and both catalyze intramembrane proteolysis. These common features let us speculate that gamma-secretase inhibitors directed against presenilin may also inhibit signal peptide peptidase. Here we demonstrate that some of the most potent known gamma-secretase inhibitors efficiently inhibit signal peptide peptidase. However, we found compounds that showed higher specificity for one or the other protease. Our findings highlight the possibility of developing selective inhibitors aimed at reducing Abeta generation without affecting other intramembrane-cleaving aspartic proteases.	ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland; Novartis Pharma AG, Nervous Syst Res, CH-4002 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Novartis	Martoglio, B (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland.	bruno.martoglio@bc.biol.ethz.ch	Paganetti, Paolo/AAF-8039-2020; Lemberg, Marius K/B-8881-2016; Weihofen, Andreas/A-1566-2011	Lemberg, Marius K/0000-0002-0996-1268; Weihofen, Andreas/0000-0001-6265-9087; Paganetti, Paolo/0000-0003-1896-6324				Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Grigorenko AP, 2002, BIOCHEMISTRY-MOSCOW+, V67, P826, DOI 10.1023/A:1016365227942; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Hegde RS, 2002, MOL CELL, V10, P697, DOI 10.1016/S1097-2765(02)00692-5; Hope RG, 2000, J GEN VIROL, V81, P1913, DOI 10.1099/0022-1317-81-8-1913; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Josien H, 2002, CURR OPIN DRUG DI DE, V5, P513; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Lemberg MK, 2001, J IMMUNOL, V167, P6441, DOI 10.4049/jimmunol.167.11.6441; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nadin A, 2001, TETRAHEDRON, V57, P1861, DOI 10.1016/S0040-4020(00)01167-4; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Radtke F, 2002, IMMUNOL REV, V187, P65, DOI 10.1034/j.1600-065X.2002.18706.x; SchraderFischer G, 1996, BRAIN RES, V716, P91, DOI 10.1016/0006-8993(96)00002-9; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Weihofen A, 2000, J BIOL CHEM, V275, P30951, DOI 10.1074/jbc.M005980200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844; Wolfe MS, 2001, J MED CHEM, V44, P2039, DOI 10.1021/jm0004897; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077	53	110	113	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16528	16533		10.1074/jbc.M301372200	http://dx.doi.org/10.1074/jbc.M301372200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621027	hybrid			2022-12-27	WOS:000182818600013
J	Atcha, FA; Munguia, JE; Li, TWH; Hovanes, K; Waterman, ML				Atcha, FA; Munguia, JE; Li, TWH; Hovanes, K; Waterman, ML			A new beta-catenin-dependent activation domain in T cell factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER FACTOR-I; COLORECTAL-CANCER; TRANSCRIPTIONAL REPRESSION; NUCLEAR-LOCALIZATION; SIGNALING PATHWAY; GENE-EXPRESSION; PROMOTER; PROTEIN; ISOFORMS; TCF-1	Transcription of the lymphoid enhancer factor-1 (LEF1) gene is aberrantly activated in sporadic colon cancer, whereas this gene is not expressed in the normal adult colon. We have shown previously that promoter I of the LEF1 gene is activated by T cell factor (TCF)-beta-catenin complexes in transient transfection assays, suggesting that LEF1 is a target of the Wnt pathway in colon cancer. To further explore the link between LEF1 expression and the Wnt pathway, we studied two response elements in the promoter. Surprisingly we found that the LEF1 promoter is selectively activated by specific isoforms of the LEF/TCF transcription factor family that contain an alternative C-terminal "E" tail. These isoforms, TCF-1E and TCF-4E, activate the promoter in a beta-catenin-dependent manner. We show that a complete E-tail domain is necessary for fall activity and delimits residues within two highly conserved peptide motifs within the tail that are required (KKCRARFG; WCXX-CRRKKKC). These peptide motifs are not only conserved among the TCF family members but are also found in two newly identified DNA-binding proteins named papillomavirus binding factor and GLUT4 enhancer factor. This study thus identifies a new and unique set of motifs used by the Wnt pathway for target gene regulation.	Univ Calif Irvine, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA	University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Waterman, ML (corresponding author), Univ Calif Irvine, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.				NCI NIH HHS [CA 83982, CA 09054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083982, T32CA009054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barker N, 2000, BIOESSAYS, V22, P961; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Boeckle S, 2002, VIROLOGY, V293, P103, DOI 10.1006/viro.2001.1231; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Duval A, 2000, CANCER RES, V60, P3872; EISENBERG SP, 1985, MOL CELL BIOL, V5, P1940, DOI 10.1128/MCB.5.8.1940; Galceran J, 1999, GENE DEV, V13, P709, DOI 10.1101/gad.13.6.709; Hecht A, 2003, J BIOL CHEM, V278, P3776, DOI 10.1074/jbc.M210081200; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hovanes K, 2000, NUCLEIC ACIDS RES, V28, P1994, DOI 10.1093/nar/28.9.1994; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; KABSCH W, 1984, P NATL ACAD SCI-BIOL, V81, P1075, DOI 10.1073/pnas.81.4.1075; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Lescher B, 1998, DEV DYNAM, V213, P440, DOI 10.1002/(SICI)1097-0177(199812)213:4<440::AID-AJA9>3.0.CO;2-6; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; Mayer K, 1997, INT J CANCER, V72, P625, DOI 10.1002/(SICI)1097-0215(19970807)72:4<625::AID-IJC13>3.0.CO;2-A; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Okamura RM, 1998, IMMUNITY, V8, P11, DOI 10.1016/S1074-7613(00)80454-9; Oshel KM, 2000, J BIOL CHEM, V275, P23666, DOI 10.1074/jbc.M001452200; Polakis P, 2000, GENE DEV, V14, P1837; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Prieve MG, 1996, J BIOL CHEM, V271, P7654, DOI 10.1074/jbc.271.13.7654; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Yu X, 1998, EMBO J, V17, P7021, DOI 10.1093/emboj/17.23.7021	37	68	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16169	16175		10.1074/jbc.M213218200	http://dx.doi.org/10.1074/jbc.M213218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12582159	hybrid			2022-12-27	WOS:000182680000090
J	Kargul, J; Nield, J; Barber, J				Kargul, J; Nield, J; Barber, J			Three-dimensional reconstruction of a light-harvesting complex I-photosystem I (LHCI-PSI) supercomplex from the green alga Chlamydomonas reinhardtii - Insights into light harvesting for PSI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-PARTICLE ANALYSIS; SYNECHOCOCCUS-ELONGATUS; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; STATE TRANSITIONS; MEMBRANE-PROTEIN; ANTENNA RING; SUBUNIT; CYANOBACTERIA; ORGANIZATION	A supercomplex containing the photosystem I (PSI) and chlorophyll a/b light-harvesting complex I (LHCI) has been isolated using a His-tagged mutant of Chlamydomonas reinhardtii. This LHCI-PSI supercomplex contained similar to215 chlorophyll molecules of which 175 were estimated to be chlorophyll a and 40 to be chlorophyll b, based on P700 oxidation and chlorophyll a/b ratio measurements. Its room temperature long wavelength absorption peak was at 680 nm, and it emitted chlorophyll fluorescence maximally at 715 nm (77 K). The LHCI was composed of four or more different types of Lhca polypeptides including Lhca3. No LHCII proteins or other phosphoproteins were detected in the LHCI-PSI supercomplexes suggesting that the cells from which they were isolated were in State 1. Electron microscopy of negatively stained samples followed by image analysis revealed the LHCI-PSI supercomplex to have maximal dimensions of 220 Angstrom by 180 Angstrom and to be similar to 105 Angstrom thick. An averaged top view was used to model in x-ray and electron crystallographic data for PSI and Lhca proteins respectively. We conclude that the supercomplex consists of a PSI reaction center monomer with 11 Lhca proteins arranged along the side where the PSI proteins, PsaK, PsaJ, PsaF, and PsaG are located. The estimated molecular mass for the complex is 700 kDa including the bound chlorophyll molecules. The assignment of 11 Lhca proteins is consistent with a total chlorophyll level of 215 assuming that the PSI reaction center core binds similar to100 chlorophylls and that each Lhca subunit binds 10 chlorophylls. There was no evidence for oligomerization of Chlamydomonas PSI in contrast to the trimerization of PSI in cyanobacteria.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wolfson Labs, London SW7 2AZ, England	Imperial College London	Barber, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wolfson Labs, S Kensington Campus, London SW7 2AZ, England.	j.barber@ic.ac.uk	Nield, Jon/C-5892-2013; Kargul, Joanna/AAN-4227-2021; Kargul, Joanna/AGD-9163-2022	Nield, Jon/0000-0001-9983-0239; Kargul, Joanna/0000-0003-1410-1905				Barber J, 2002, CURR OPIN STRUC BIOL, V12, P523, DOI 10.1016/S0959-440X(02)00357-3; BASSI R, 1992, J BIOL CHEM, V267, P25714; Bibby TS, 2001, NATURE, V413, P590, DOI 10.1038/35098153; Bibby TS, 2001, NATURE, V412, P743, DOI 10.1038/35089098; Bibby TS, 2001, J BIOL CHEM, V276, P43246, DOI 10.1074/jbc.M106541200; BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175; Boekema EJ, 2001, NATURE, V412, P745, DOI 10.1038/35089104; Boekema EJ, 2001, BIOCHEMISTRY-US, V40, P1029, DOI 10.1021/bi0015358; Buchel C, 2001, J MOL BIOL, V312, P371, DOI 10.1006/jmbi.2001.4951; Chitnis PR, 2001, ANNU REV PLANT PHYS, V52, P593, DOI 10.1146/annurev.arplant.52.1.593; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; Croce R, 1998, BIOCHEMISTRY-US, V37, P17355, DOI 10.1021/bi9813227; Croce R, 2002, BBA-BIOENERGETICS, V1556, P29, DOI 10.1016/S0005-2728(02)00304-3; DINER BA, 1980, EUR J BIOCHEM, V110, P521, DOI 10.1111/j.1432-1033.1980.tb04894.x; Fischer N, 1997, BIOCHEMISTRY-US, V36, P93, DOI 10.1021/bi962244v; Germano M, 2002, FEBS LETT, V525, P121, DOI 10.1016/S0014-5793(02)03100-9; GLAZER AN, 1994, PHOTOSYNTH RES, V40, P167, DOI 10.1007/BF00019333; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; Green BR, 1996, ANNU REV PLANT PHYS, V47, P685, DOI 10.1146/annurev.arplant.47.1.685; Haldrup A, 2001, TRENDS PLANT SCI, V6, P301, DOI 10.1016/S1360-1385(01)01953-7; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; Hippler M, 2001, PLANT J, V28, P595, DOI 10.1046/j.1365-313X.2001.01175.x; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Jensen PE, 2002, J BIOL CHEM, V277, P2798, DOI 10.1074/jbc.M110448200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KEREN N, 1998, MOL BIOL CHLOROPLAST, V7, P569; Knoetzel H, 2002, FEBS LETT, V510, P145, DOI 10.1016/S0014-5793(01)03253-7; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; MARSHO TV, 1971, METHOD ENZYMOL, V23, P515; Moseley JL, 2002, EMBO J, V21, P6709, DOI 10.1093/emboj/cdf666; Nield J, 2000, J BIOL CHEM, V275, P27940; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; Ruprecht J, 2001, PROG BIOPHYS MOL BIO, V75, P121, DOI 10.1016/S0079-6107(01)00004-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHATZ M, 1990, ULTRAMICROSCOPY, V32, P255, DOI 10.1016/0304-3991(90)90003-5; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Sugiura M, 1998, FEBS LETT, V426, P140, DOI 10.1016/S0014-5793(98)00328-7; van Heel M, 2000, Q REV BIOPHYS, V33, P307, DOI 10.1017/S0033583500003644; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; Zheleva D, 1996, BIOCHEMISTRY-US, V35, P15074, DOI 10.1021/bi961382h; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	44	101	107	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16135	16141		10.1074/jbc.M300262200	http://dx.doi.org/10.1074/jbc.M300262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12588873	hybrid			2022-12-27	WOS:000182680000086
J	Malygin, EG; Zinoviev, VV; Evdokimov, AA; Lindstrom, WM; Reich, NO; Hattman, S				Malygin, EG; Zinoviev, VV; Evdokimov, AA; Lindstrom, WM; Reich, NO; Hattman, S			DNA (cytosine-N-4-)- and -(adenine-N-6-)-methyltransferases have different kinetic mechanisms but the same reaction route - A comparison of M.BamHI and T4 Dam	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; CATALYTIC-PROPERTIES; PHAGE-T4 DAM; METHYLTRANSFERASE; METHYLATION; BAMHI; BINDING; OLIGONUCLEOTIDES; SPECIFICITY; ENZYME	We studied the kinetics of methyl group transfer by the BamHI DNA- (cytosine-N-4-)-methyltransferase (MTase) from Bacillus amyloliquefaciens to a 20-mer oligodeoxynucleotide duplex containing the palindromic recognition site GGATCC. Under steady state conditions the BamHI MTase displayed a simple kinetic behavior toward the 20-mer duplex. There was no apparent substrate inhibition at concentrations much higher than the K. for either DNA (100-fold higher) or S-adenosyl-L-methionine (AdoMet) (20-fold higher); this indicates that dead-end complexes did not form in the course of the methylation reaction. The DNA methylation rate was analyzed as a function of both substrate and product concentrations. It was found to exhibit product inhibition patterns consistent with a steady state random bi-bi mechanism in which the dominant order of substrate binding and product release (methylated DNA, DNA(Me), and S-adenosyl-L-homocysteine, AdoHcy) was Ado-Met down arrow DNA down arrow DNA(Me) up arrow AdoHcy up arrow. The M.BamHI kinetic scheme was compared with that for the T4 Dam (adenine-N-6-)-MTase. The two differed with respect to an effector action of substrates and in the rate-limiting step of the reaction (product inhibition patterns are the same for the both MTases). From this we conclude that the common chemical step in the methylation reaction, methyl transfer from AdoMet to a free exocyclic amino group, is not sufficient to dictate a common kinetic scheme even though both MTases follow the same reaction route.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA; State Res Ctr Virol & Biotechnol Vector, Inst Mol Biol, Koltsov 630559, Russia; Univ Calif Santa Barbara, Dept Chem & Biochem, Barbara, CA 93103 USA	University of Rochester; State Research Center of Virology & Biotechnology VECTOR; University of California System; University of California Santa Barbara	Hattman, S (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	modDNA@mail.rochester.edu	Ernst, Malygin/A-6741-2014; Evdokimov, Alexey/A-6485-2014		FIC NIH HHS [R03 TW 05755] Funding Source: Medline; NIGMS NIH HHS [GM 29227] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW005755] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Ahmad I, 1996, CRIT REV BIOCHEM MOL, V31, P361, DOI 10.3109/10409239609108722; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011; Berdis AJ, 1998, P NATL ACAD SCI USA, V95, P2874, DOI 10.1073/pnas.95.6.2874; Bhattacharya SK, 1999, J BIOL CHEM, V274, P14743, DOI 10.1074/jbc.274.21.14743; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORNISHBOWDEN A, 1976, PRINCIPLES ENZYME KI, P177; Evdokimov AA, 2002, J BIOL CHEM, V277, P279, DOI 10.1074/jbc.M108864200; Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609; Gowher H, 2000, J MOL BIOL, V303, P93, DOI 10.1006/jmbi.2000.4127; HATTMAN S, 1978, J MOL BIOL, V124, P701, DOI 10.1016/0022-2836(78)90178-X; Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967; JAENISCH R, 1999, GENOMIC IMPRINTING C, P118; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; Lindstrom WM, 2003, J MOL BIOL, V325, P711, DOI 10.1016/S0022-2836(02)01282-2; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Malygin EG, 1997, NUCLEIC ACIDS RES, V25, P4393, DOI 10.1093/nar/25.21.4393; Malygin EG, 2000, NUCLEIC ACIDS RES, V28, P4207, DOI 10.1093/nar/28.21.4207; MALYGIN EG, 1977, BIOFIZIKA+, V22, P15; Malygin EG, 2001, NUCLEIC ACIDS RES, V29, P2361, DOI 10.1093/nar/29.11.2361; Marinus M.G., 1996, E COLI SALMONELLA CE, P782; MCCLELLAND M, 1988, GENE, V74, P169, DOI 10.1016/0378-1119(88)90278-8; NARDONE G, 1986, J BIOL CHEM, V261, P2128; NARDONE G, 1984, J BIOL CHEM, V259, P357; RAO DN, 1989, J MOL BIOL, V209, P599, DOI 10.1016/0022-2836(89)90597-4; REICH NO, 1993, J BIOL CHEM, V268, P9191; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; SZILAK L, 1993, EUR J BIOCHEM, V218, P727, DOI 10.1111/j.1432-1033.1993.tb18427.x; Tuzikov FV, 1997, MOL BIOL+, V31, P73; VARFOLOMEEV SD, 1999, BIOKINETIKA PRAKTICH, P123; Vilkaitis G, 2001, J BIOL CHEM, V276, P20924, DOI 10.1074/jbc.M101429200; WU JC, 1987, J BIOL CHEM, V262, P4778; Zinoviev VV, 1998, BIOL CHEM, V379, P481, DOI 10.1515/bchm.1998.379.4-5.481	34	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15713	15719		10.1074/jbc.M213213200	http://dx.doi.org/10.1074/jbc.M213213200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598537	hybrid			2022-12-27	WOS:000182680000033
J	VanLeeuwen, D; Steffey, ME; Donahue, C; Ho, GY; MacKenzie, RG				VanLeeuwen, D; Steffey, ME; Donahue, C; Ho, GY; MacKenzie, RG			Cell surface expression of the melanocortin-4 receptor is dependent on a C-terminal di-isoleucine sequence at codons 316/317	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOPRESSIN V-2 RECEPTOR; EARLY-ONSET OBESITY; FRAMESHIFT MUTATION; DILEUCINE SEQUENCE; MORBID-OBESITY; GENE; AGONIST; HUMANS; MICE; DEFICIENCY	Loss-of-function mutations in the human melanocortin-4 receptor (MC4R) are associated with obesity. Previous work has implicated a C-terminal di-isoleucine motif at residues 316/317 in MC4R cell surface targeting. It was therefore of interest to examine function and cell surface expression of an MC4R mutation found in an obese proband in which one of these isoleucines was substituted by threonine (I317T). Single mutant (I316T or I317T) and double mutant (I316T,I317T) forms of MC4R were constructed by oligonucleotide-directed mutagenesis and tested for function and cell surface expression in transfected cells. Function was assessed using assays for agonist, [Nle(4)-D-Phe(7)]alpha-melanocyte-stimulating hormone (NDP-alpha-MSH) or forskolin-stimulated cAMP accumulation. Cell surface expression was determined by whole-cell binding of [I-125]NDP-alpha-MSH, fluorescence immunocytochemistry and fluorescence-activated cell sorting. Maximal cAMP generation of the single mutants was reduced by 40% of wild-type receptor; the double mutant further reduced function to 40% of control, effects that were mirrored by decreases in cell-surface expression. Quantitative RT-PCR showed that, relative to wild-type receptor, transcript levels for the mutated receptors were not reduced. The results further implicate the C-terminal di-isoleucines in cell surface expression of MC4R and suggest that mutations of residues 316 or 317 would predict MC4R hypofunction.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; Pfizer Global Res & Dev, Ann Arbor, MI 48105 USA	Wayne State University; Pfizer	MacKenzie, RG (corresponding author), Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, 510 E Canfield, Detroit, MI 48201 USA.							Alewijnse AE, 1997, FEBS LETT, V419, P171, DOI 10.1016/S0014-5793(97)01440-3; Benoit SC, 2000, J NEUROSCI, V20, P3442, DOI 10.1523/JNEUROSCI.20-09-03442.2000; Boutin P, 2001, BEST PRACT RES CL EN, V15, P391, DOI 10.1053/beem.2001.0153; Clement K, 2000, ANN ENDOCRINOL-PARIS, V61, P39; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cody JD, 1999, HUM GENET, V105, P424, DOI 10.1007/s004390051125; Cone RD, 2000, J CLIN INVEST, V106, P185, DOI 10.1172/JCI10628; Cone RD, 2001, INT J OBESITY, V25, pS63, DOI 10.1038/sj.ijo.0801913; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; Ho GY, 1999, J BIOL CHEM, V274, P35816, DOI 10.1074/jbc.274.50.35816; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Krause G, 2000, MOL PHARMACOL, V57, P232; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Nijenhuis WAJ, 2001, MOL ENDOCRINOL, V15, P164, DOI 10.1210/me.15.1.164; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; Yeo GSH, 2000, QJM-INT J MED, V93, P7, DOI 10.1093/qjmed/93.1.7; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404	25	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15935	15940		10.1074/jbc.M211546200	http://dx.doi.org/10.1074/jbc.M211546200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594226	hybrid			2022-12-27	WOS:000182680000062
J	Katoh, S; Hong, C; Tsunoda, Y; Murata, K; Takai, R; Minami, E; Yamazaki, T; Katoh, E				Katoh, S; Hong, C; Tsunoda, Y; Murata, K; Takai, R; Minami, E; Yamazaki, T; Katoh, E			High precision NMR structure and function of the RING-H2 finger domain of EL5, a rice protein whose expression is increased upon exposure to pathogen-derived oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLCHITOOLIGOSACCHARIDE ELICITOR; UBIQUITIN-CONJUGATING ENZYME; ARABIDOPSIS-THALIANA; REPRESSOR COMPLEX; LARGER PROTEINS; C-CBL; LIGASE; FAMILY; ZINC; IDENTIFICATION	EL5, a RING-H2 finger protein, is rapidly induced by N-acetylchitooligosaccharides in rice cell. We expressed the EL5 RING-H2 finger domain in Escherichia coli and determined its structure in solution by NAIR spectroscopy. The EL5 RING-H2 finger domain consists of two-stranded beta-sheets (beta1, Ala(147)-Phe(149); beta2, Gly(156)-HiS(158)), one a-helix (Cys(161)-Leu(166)), and two large N- and C-terminal loops. It is stabilized by two tetrahedrally coordinated zinc ions. This structure is similar to that of other RING finger domains of proteins of known function. From structural analogies, we inferred that the EL5 RING-H2 finger is a binding domain for ubiquitin-conjugating enzyme (E2). The binding site is probably formed by solvent-exposed hydrophobic residues of the N- and C-terminal loops and the a-helix. We demonstrated that the fusion protein with EL5-(96-181) and maltose-binding protein (AMP) was polyubiquitinated by incubation with ubiquitin, ubiquitin-activating enzyme (E1), and a rice E2 protein, OsUBC5b. This supported the idea that the EL5 RING finger domain is essential for ubiquitin-ligase activity of EL5. By NAIR titration experiments, we identified residues that are critical for the interaction between the EL5 RING-H2 finger and OsUBC5b. We conclude that the RING-H2 finger domain of EL5 is the E2 binding site of EL5.	Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300192, Japan	National Institute of Agrobiological Sciences - Japan; Nara Institute of Science & Technology	Katoh, E (corresponding author), Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan.							Albert TK, 2002, EMBO J, V21, P355, DOI 10.1093/emboj/21.3.355; ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BOLLER T, 1995, ANNU REV PLANT PHYS, V46, P189, DOI 10.1146/annurev.arplant.46.1.189; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Brunger A. T, 1993, XPLOR MANUAL VERSION; Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Hanzawa H, 2001, J BIOL CHEM, V276, P10185, DOI 10.1074/jbc.M009298200; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KOSAREV P, 2002, GENOME BIOL, V3; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIVE DH, 1984, J AM CHEM SOC, V106, P1934; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MartinezGarcia M, 1996, MOL GEN GENET, V252, P587, DOI 10.1007/s004380050266; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Salinas-Mondragon RE, 1999, PLANT MOL BIOL, V40, P579, DOI 10.1023/A:1006267201855; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Shibuya N, 2001, PHYSIOL MOL PLANT P, V59, P223, DOI 10.1006/pmpp.2001.0364; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SPERA S, 1991, J AM CHEM SOC, V111, P8317; Takai R, 2002, PLANT J, V30, P447, DOI 10.1046/j.1365-313X.2002.01299.x; Takai R, 2001, PLANT SCI, V160, P577, DOI 10.1016/S0168-9452(00)00390-3; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	40	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15341	15348		10.1074/jbc.M210531200	http://dx.doi.org/10.1074/jbc.M210531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588869	hybrid			2022-12-27	WOS:000182516100099
J	Wojtanik, KM; Liscum, L				Wojtanik, KM; Liscum, L			The transport of low density lipoprotein-derived cholesterol to the plasma membrane is defective in NPC1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PICK TYPE-C; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; PROTEIN; CYCLODEXTRINS; FIBROBLASTS; LYSOSOMES; TRAFFICKING; METABOLISM; MUTATIONS	Niemann-Pick disease type C (NPC) is characterized by lysosomal storage of cholesterol and gangliosides, which results from defects in intracellular lipid trafficking. Most studies of NPC1 have focused on its role in intracellular cholesterol movement. Our hypothesis is that NPC1 facilitates the egress of cholesterol from late endosomes, which are where active NPC1 is located. When NPC1 is defective, cholesterol does not exit late endosomes; instead, it is carried along to lysosomal storage bodies, where it accumulates. In this study, we addressed whether cholesterol is transported from endosomes to the plasma membrane before reaching NPC1-containing late endosomes. Our study was conducted in Chinese hamster ovary cell lines that display the classical NPC biochemical phenotype and belong to the NPC1 complementation group. We used three approaches to test whether low density lipoprotein (LDL)derived cholesterol en route to NPC1-containing organelles passes through the plasma membrane. First, we used cyclodextrins to measure the arrival of LDL cholesterol at the plasma membrane and found that the arrival of LDL cholesterol in a cyclodextrin-accessible pool was significantly delayed in NPC1 cells. Second, the movement of LDL cholesterol to NPC1-containing late endosomes was assessed and found to be normal in Chinese hamster ovary mutant 3-6, which exhibits defective movement of plasma membrane cholesterol to intracellular membranes. Third, we examined the movement of plasma membrane cholesterol to the endoplasmic reticulum and found that this pathway is intact in NPC1 cells, i.e. it does not pass through N-PC1-containing late endosomes. Our data suggest that in N-PC1 cells LDL cholesterol traffics directly through endosomes to lysosomes, bypassing the plasma membrane, and is trapped there because of dysfunctional NPC1.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Liscum, L (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.		Eckhardt, Erik/G-1567-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928, R01DK049564, T32DK007704] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07704, DK49564, P30 DK34928] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Christian AE, 1997, J LIPID RES, V38, P2264; Christian AE, 1999, J LIPID RES, V40, P1475; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; DAHL NK, 1992, J BIOL CHEM, V267, P4889; DAHL NK, 1994, J LIPID RES, V35, P1839; FAUST JR, 1977, J BIOL CHEM, V252, P4861; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Hao MM, 2002, J BIOL CHEM, V277, P609, DOI 10.1074/jbc.M108861200; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; Jacobs NL, 1997, J LIPID RES, V38, P1973; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lange Y, 2002, J LIPID RES, V43, P198; LANGE Y, 1993, J BIOL CHEM, V268, P13838; Liscum L, 2000, TRAFFIC, V1, P218, DOI 10.1034/j.1600-0854.2000.010304.x; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Ory DS, 2000, BBA-MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388-1981(00)00158-X; Patterson M. C., 2001, METABOLIC MOL BASES, VIII, P3611; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; RODRIGUEZLAFRASSE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P123, DOI 10.1016/0005-2760(90)90284-5; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; Watari H, 1999, J BIOL CHEM, V274, P21861, DOI 10.1074/jbc.274.31.21861; Xie CL, 2000, J LIPID RES, V41, P1278; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	32	120	122	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14850	14856		10.1074/jbc.M300488200	http://dx.doi.org/10.1074/jbc.M300488200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12591922	hybrid			2022-12-27	WOS:000182516100036
J	Noren, NK; Arthur, WT; Burridge, K				Noren, NK; Arthur, WT; Burridge, K			Cadherin engagement inhibits RhoA via p190RhoGAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; GTPASE-ACTIVATING PROTEIN; TYROSINE PHOSPHORYLATION; FAMILY GTPASES; C-SRC; V-SRC; ACTIN CYTOSKELETON; EPITHELIAL-CELLS; EXCHANGE FACTOR; P190 RHOGAP	Cadherins are transmembrane receptors that mediate cell-cell adhesion in epithelial cells. A number of changes occur during cadherin-mediated junction formation, one of which is a rearrangement of the actin cytoskeleton. Key regulators of actin cytoskeletal dynamics in cells are the Rho family of GTPases. We have demonstrated in previous studies that cadherin signaling suppresses RhoA activity and activates Rac1. The signaling events downstream of cadherins that modulate the activity of Rho family proteins remain unknown.. Here we have identified a pathway by which RhoA becomes inactivated by cadherins. To determine whether cadherins regulate RhoA through activation of a GTPase-activating protein (GAP) for RhoA, we used constitutively active RhoA to isolate activated GAPs. Using this assay, we have identified the RhoA-specific GAP, p190RhoGAP, downstream from engaged cadherins. We found that cadherin engagement induced tyrosine phosphorylation of p190RhoGAP and increased its binding to p120RasGAP. The increased precipitation of p190RhoGAP with 63LRhoA was blocked by addition of PP2 suggesting that Src family kinases are required downstream from cadherin signaling. The inhibition of RhoA activity by cadherins was antagonized by expression of a dominant negative p190RhoGAP. Taken, together, these data demonstrate that p190RhoGAP activity is critical for RhoA inactivation by cadherins.	Univ N Carolina, Dept Dev & Cell Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Noren, NK (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Noren Hooten, Nicole/J-5498-2019	Noren Hooten, Nicole/0000-0002-1683-3838	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE13079] Funding Source: Medline; NIGMS NIH HHS [GM29860] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Brouns MR, 2000, DEVELOPMENT, V127, P4891; Brouns MR, 2001, NAT CELL BIOL, V3, P361, DOI 10.1038/35070042; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHEN SY, 1994, ONCOGENE, V9, P2691; Fincham VJ, 1999, J CELL SCI, V112, P947; Frame MC, 2002, NAT REV MOL CELL BIO, V3, P233, DOI 10.1038/nrm779; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kinch M S, 1997, Cell Adhes Commun, V4, P425, DOI 10.3109/15419069709004459; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Kulkarni SV, 2000, J CELL BIOL, V149, P457, DOI 10.1083/jcb.149.2.457; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MICHALIDES R, 1994, CELL ADHES COMMUN, V2, P481, DOI 10.3109/15419069409014212; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; Nakagawa M, 2001, J CELL SCI, V114, P1829; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAPON N, 1997, CURR OPIN CELL BIOL, V9, P87; Tatsis N, 1998, J BIOL CHEM, V273, P34631, DOI 10.1074/jbc.273.51.34631; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VAN AL, 1997, GENE DEV, V11, P2295; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	40	136	138	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13615	13618		10.1074/jbc.C200657200	http://dx.doi.org/10.1074/jbc.C200657200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12606561	hybrid			2022-12-27	WOS:000182405000007
J	Weng, L; Van Bockstaele, DR; Wauters, J; Van Marck, E; Plum, J; Berneman, ZN; Merregaert, J				Weng, L; Van Bockstaele, DR; Wauters, J; Van Marck, E; Plum, J; Berneman, ZN; Merregaert, J			A novel alternative spliced chondrolectin isoform lacking the transmembrane domain is expressed during T cell maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTINS; ANIMAL LECTINS; PROTEIN; RECEPTOR; PHENOTYPE; BINDING; SEQUENCES; HOMOLOGY; ANTIGEN; LAYILIN	Chondrolectin (CHODL) is a novel type I transmembrane protein containing one carbohydrate recognition domain (CRD) of C-type lectins. Recently, data base searching revealed a variant of CHODL (AK022689) with a different 5' leader sequence derived from a new putative upstream alternative promoter (P-2). The P-2 promoter gives rise to at least three additional alternatively spliced isoforms, designated as CHODLf, CHODLfDeltaE, and CHODLDeltaE. Of all variants, the alternative exon E-splicing isoforms (CHODLfDeltaE/CHODLDeltaE) are expressed exclusively in the T lymphocyte lineage and are regulated during T lymphopoiesis. Peripheral T lymphocytes demonstrated a unique exon E-splicing pattern in comparison with end maturation stage thymocytes, suggesting its association with the post-thymic maturation of T cells. Since exon E encodes the transmembrane domain of CHODL, the exon E-skipping variant results in a non-transmembrane domain-containing isoform (CHODLfDeltaE/CHODLDeltaE) terminating in the QDEL sequence, thus suggesting different functional attributes of CHODL isoforms during the development of T cells. Double label immunofluoresence experiments demonstrated that the transmembrane-containing isoform (CHODLf) colocalizes with rBet1 to the endoplasmic reticulum-Golgi apparatus. In summary, this study describes the molecular characterization of novel members of the chondrolectin family associated with T cell maturation and a subcellular localization of CHODLf in the endoplasmic reticulum-Golgi apparatus.	Univ Antwerp, Univ Antwerp Hosp, Fac Med, Lab Expt Hematol, B-2650 Edegem, Belgium; Univ Antwerp, Univ Antwerp Hosp, Dept Biomed Sci, Lab Mol Biotechnol, B-2650 Edegem, Belgium; Univ Antwerp, Fac Med, Pathol Lab, B-2610 Wilrijk, Belgium; Univ Antwerp, Fac Med, Med Genet Lab, B-2610 Wilrijk, Belgium; State Univ Ghent, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium	University of Antwerp; University of Antwerp; University of Antwerp; University of Antwerp; Ghent University	Merregaert, J (corresponding author), Univ Antwerp, Dept Biomed Sci, Lab Mol Biotechnol, Univ Pl 1, B-2610 Wilrijk, Belgium.		Plum, Jean/A-4357-2008					ANDRES DA, 1991, J BIOL CHEM, V266, P14277; ARTHUR RP, 1986, J EXP MED, V163, P774, DOI 10.1084/jem.163.4.774; Bono P, 2001, MOL BIOL CELL, V12, P891, DOI 10.1091/mbc.12.4.891; Borowsky ML, 1998, J CELL BIOL, V143, P429, DOI 10.1083/jcb.143.2.429; BUHRING HJ, 1991, LEUKEMIA, V5, P854; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HOSSEINZADEH H, 1993, J IMMUNOL, V150, P1670; IKUTA K, 1987, P NATL ACAD SCI USA, V84, P819, DOI 10.1073/pnas.84.3.819; Kilpatrick DC, 2002, BBA-GEN SUBJECTS, V1572, P187, DOI 10.1016/S0304-4165(02)00308-2; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; McFarland RD, 2000, P NATL ACAD SCI USA, V97, P4215, DOI 10.1073/pnas.070061597; Protin U, 1999, J IMMUNOL, V163, P4917; SAMBROOK J, 1989, MOL CLONING, V2, P9; SPARSHOTT SM, 1991, EUR J IMMUNOL, V21, P993, DOI 10.1002/eji.1830210420; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Weng L, 2002, GENOMICS, V80, P62, DOI 10.1006/geno.2002.6806; WENG L, 2003, IN PRESS GENE AMST	22	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19164	19170		10.1074/jbc.M300653200	http://dx.doi.org/10.1074/jbc.M300653200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12621022	hybrid			2022-12-27	WOS:000182932200059
J	Bjornson, KP; Modrich, P				Bjornson, KP; Modrich, P			Differential and simultaneous adenosine di- and triphosphate binding by MutS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; RESISTANCE PROTEIN MRP1; ESCHERICHIA-COLI; HMUTS-ALPHA; TRANSLOCATION MECHANISM; MOLECULAR SWITCH; ATP HYDROLYSIS; SLIDING CLAMP; STRAND BREAK; ABC-ATPASE	The roles of ATP binding and hydrolysis in the function of MutS in mismatch repair are poorly understood. As one means of addressing this question, we have determined the affinities and number of adenosine di- and triphosphate binding sites within MutS. Nitrocellulose filter binding assay and equilibrium fluorescence anisotropy measurements have demonstrated that MutS has one high affinity binding site for ADP and one high affinity site for nonhydrolyzable ATP analogues per dimer equivalent. Low concentrations of 5'-adenylylimidodiphosphate (AMPPNP) promote ADP binding and a large excess of AMPPNP is required to displace ADP from the protein. Fluorescence energy transfer and filter binding assays indicate that ADP and nonhydrolyzable ATP analogues can bind simultaneously to adjacent subunits within the MutS oligomer with affinities in the low micromolar range. These findings suggest that the protein exists primarily as the ATP.MutS.ADP ternary complex in solution and that this may be the form of the protein that is involved in DNA encounters in vivo.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Modrich, P (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3711, Durham, NC 27710 USA.	modrich@biochem.duke.edu		Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023719, R01GM023719] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23719] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 1998, J BIOL CHEM, V273, P32049, DOI 10.1074/jbc.273.48.32049; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Blackwell LJ, 1998, J BIOL CHEM, V273, P32055, DOI 10.1074/jbc.273.48.32055; BRUNI R, 1988, NUCLEIC ACIDS RES, V16, P4875, DOI 10.1093/nar/16.11.4875; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CHI NW, 1994, J BIOL CHEM, V269, P29984; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Hess MT, 2002, J BIOL CHEM, V277, P25545, DOI 10.1074/jbc.M202282200; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Iaccarino I, 2000, J BIOL CHEM, V275, P2080, DOI 10.1074/jbc.275.3.2080; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Sixma TK, 2001, CURR OPIN STRUC BIOL, V11, P47, DOI 10.1016/S0959-440X(00)00169-X; SU SS, 1988, J BIOL CHEM, V263, P6829; Viswanathan M, 2001, J BIOL CHEM, V276, P31053, DOI 10.1074/jbc.M105481200; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Worth L, 1998, J BIOL CHEM, V273, P23176, DOI 10.1074/jbc.273.36.23176; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994	45	52	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18557	18562		10.1074/jbc.M301101200	http://dx.doi.org/10.1074/jbc.M301101200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624105	hybrid			2022-12-27	WOS:000182838300127
J	Park, Y; Kim, YJ; Dupriez, V; Adams, ME				Park, Y; Kim, YJ; Dupriez, V; Adams, ME			Two subtypes of ecdysis-triggering hormone receptor in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRUSTACEAN CARDIOACTIVE PEPTIDE; IDENTIFICATION; SEQUENCE; NEURONS	Insect ecdysis is a hormonally programmed physiological sequence that enables insects to escape their old cuticle at the end of each developmental stage. The immediate events leading to ecdysis, which are initiated upon release of ecdysis-triggering hormones (ETH) into the bloodstream, include respiratory inflation and sequential stereotypic behaviors that facilitate shedding of the cuticle. Here we report that the Drosophila gene CG5911 encodes two functionally distinct subtypes of G protein-coupled receptors through alternative splicing (CG5911a and CG5911b) that respond preferentially to ecdysis-triggering hormones of flies and moths. These subtypes show differences in ligand sensitivity and specificity, suggesting that they may play separate roles in ETH signaling. At significantly higher concentrations (> 100-fold), certain insect and vertebrate peptides also activate these receptors, providing evidence that CG5911 is evolutionarily related to the thyrotropin-releasing hormone and neuromedin U receptors. The ETH signaling system in insects is a vital system that provides opportunities for the construction of models for the molecular basis of stereotypic animal behavior as well as a target for the design of more sophisticated insect-selective pest control strategies.	Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; Euroscreen SA, B-6041 Gosselies, Belgium	University of California System; University of California Riverside; University of California System; University of California Riverside	Adams, ME (corresponding author), Univ Calif Riverside, Dept Cell Biol & Neurosci, 5429 Boyce Hall, Riverside, CA 92521 USA.	adams@mail.ucr.edu	Adams, Michael/ABF-6728-2020; Park, Yoonseong/J-5861-2013	Adams, Michael/0000-0003-0519-6113; Kim, Young-Joon/0000-0002-7990-754X; Park, Yoonseong/0000-0003-1191-7335	NIAID NIH HHS [AI-40555] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040555, R21AI040555] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Adams ME, 1997, BIOCHEM BIOPH RES CO, V230, P188, DOI 10.1006/bbrc.1996.5915; Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Ewer J, 1996, J COMP NEUROL, V370, P330; Gammie SC, 1999, J EXP BIOL, V202, P343; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; HUESMANN GR, 1995, FEBS LETT, V371, P311, DOI 10.1016/0014-5793(95)00929-4; Iversen A, 2002, BIOCHEM BIOPH RES CO, V299, P924, DOI 10.1016/S0006-291X(02)02798-5; Jespersen T, 2002, BIOTECHNIQUES, V32, P536, DOI 10.2144/02323st05; Le Poul E, 2002, J BIOMOL SCREEN, V7, P57, DOI 10.1089/108705702753520341; MATSUMOTO S, 1990, J INSECT PHYSIOL, V36, P427, DOI 10.1016/0022-1910(90)90060-S; McNabb SL, 1997, NEURON, V19, P813, DOI 10.1016/S0896-6273(00)80963-0; Meng XJ, 2002, MECH DEVELOP, V117, P5, DOI 10.1016/S0925-4773(02)00175-2; MORRIS HR, 1982, NATURE, V300, P643, DOI 10.1038/300643a0; O'Brien MA, 1998, J EXP BIOL, V201, P193; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Park Y, 1999, FEBS LETT, V463, P133, DOI 10.1016/S0014-5793(99)01622-1; Park Y, 2002, DEVELOPMENT, V129, P493; Park Y, 2002, P NATL ACAD SCI USA, V99, P11423, DOI 10.1073/pnas.162276199; RAINA AK, 1989, SCIENCE, V244, P796, DOI 10.1126/science.244.4906.796; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Truman JW, 1996, J EXP BIOL, V199, P749; Zitnan D, 2000, J EXP BIOL, V203, P1329; Zitnan D, 1999, NEURON, V23, P523, DOI 10.1016/S0896-6273(00)80805-3; Zitnan D, 1996, SCIENCE, V271, P88, DOI 10.1126/science.271.5245.88	25	67	71	1	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17710	17715		10.1074/jbc.M301119200	http://dx.doi.org/10.1074/jbc.M301119200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12586820	hybrid			2022-12-27	WOS:000182838300017
J	Barnes, BJ; Field, AE; Pitha-Rowe, PM				Barnes, BJ; Field, AE; Pitha-Rowe, PM			Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR-7; SEQUENCE-BINDING-PROTEIN; STIMULATED RESPONSE ELEMENT; ALPHA PROMOTER REGION; HISTONE H4 GENE; CELL-CYCLE; DIFFERENTIAL EXPRESSION; POSITIVE FEEDBACK; DNA-BINDING; INDUCTION	Transcription factors of the interferon regulatory factor (IRF) family have been identified as critical mediators of early inflammatory gene transcription in infected cells. We have shown previously that IRF-5, like IRF-3 and IRF-7, is a direct transducer of virus-mediated signaling and plays a role in the expression of multiple cytokines/chemokines. The present study is focused on the molecular mechanisms underlying the formation and function of IRF-5/IRF-7 heterodimers in infected cells. The interaction between IRF-5 and IRF-7 is not cooperative and results in a repression rather than enhancement of IFNA gene transcription. The formation of the IRF-5/IRF-7 heterodimer is dependent on IRF-7 phosphorylation, as shown by the glutathione S-transferase pull-down and immunoprecipitation assays. Mapping of the interaction domain revealed that formation of IRF-5/IRF-7 heterodimers occurs through the amino terminus resulting in a masking of the DNA binding domain, the consequent alteration of the composition of the enhanceosome complex binding to IFNA promoters in vivo, and modulation of the expression profile of IFNA subtypes. Thus, these results indicate that IRF-5 can act as both an activator and a repressor of IFN gene induction dependent on the IRF-interacting partner, and IRF-5 may be a part of the regulatory network that ensures timely expression of the immediate early inflammatory genes.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Barnes, BJ (corresponding author), Johns Hopkins Univ, Ctr Oncol, 1650 Orleans St, Baltimore, MD 21231 USA.				NIAID NIH HHS [R01AI/CA19737-19A1, R21AI19737-19] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019737, R21AI019737] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; AU WC, 1993, J BIOL CHEM, V268, P24032; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; Au WC, 2001, J BIOL CHEM, V276, P41629, DOI 10.1074/jbc.M105121200; Au WC, 2001, VIROLOGY, V280, P273, DOI 10.1006/viro.2000.0782; Aziz F, 1998, MOL BIOL REP, V25, P1, DOI 10.1023/A:1006888731301; Barnes B, 2002, J INTERF CYTOK RES, V22, P59, DOI 10.1089/107999002753452665; Barnes BJ, 2002, MOL CELL BIOL, V22, P5721, DOI 10.1128/MCB.22.16.5721-5740.2002; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Burysek L, 1999, J VIROL, V73, P7334; Burysek L, 1999, J HUMAN VIROL, V2, P19; Caillaud A, 2002, J BIOL CHEM, V277, P49417, DOI 10.1074/jbc.M207484200; CHEUNG SC, 1991, J IMMUNOL, V146, P121; Dent CL, 1996, EUR J BIOCHEM, V236, P895, DOI 10.1111/j.1432-1033.1996.t01-1-00895.x; Escalante CR, 1997, FEBS LETT, V414, P219, DOI 10.1016/S0014-5793(97)00996-4; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hiscott J, 1999, J INTERF CYTOK RES, V19, P1, DOI 10.1089/107999099314360; HISCOTT J, 1995, SEMIN VIROL, V6, P161, DOI 10.1006/smvy.1995.0021; HISCOTT J, 1984, NUCLEIC ACIDS RES, V12, P3727, DOI 10.1093/nar/12.9.3727; Island ML, 2002, MOL CELL BIOL, V22, P7120, DOI 10.1128/MCB.22.20.7120-7133.2002; Jesse TL, 1998, J CELL BIOL, V140, P1265, DOI 10.1083/jcb.140.5.1265; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P825, DOI 10.1093/nar/13.3.825; Kim YM, 1999, J IMMUNOL, V163, P2000; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Kuwata T, 2002, MOL CELL BIOL, V22, P7439, DOI 10.1128/MCB.22.21.7439-7448.2002; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; LUBYOVA B, 2002, J INTERFERON CYTOKIN, V22, P121; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marie I, 2000, MOL CELL BIOL, V20, P8803, DOI 10.1128/MCB.20.23.8803-8814.2000; MARIE I, 2002, J INTERFERON CYTOKIN, V22, P56; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEGYERI K, 1995, MOL CELL BIOL, V15, P2207; Meraro D, 2002, J IMMUNOL, V168, P6224, DOI 10.4049/jimmunol.168.12.6224; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Pitha PM, 1998, BIOCHIMIE, V80, P651, DOI 10.1016/S0300-9084(99)80018-2; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; SUHARA W, 2002, J INTERFERON CYTOKIN, V22, P131; TANIGUCHI T, 2002, J INTERFERON CYTOKIN, V22, P37; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yeow WS, 2001, J VIROL, V75, P3021, DOI 10.1128/JVI.75.6.3021-3027.2001; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748	67	98	100	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16630	16641		10.1074/jbc.M212609200	http://dx.doi.org/10.1074/jbc.M212609200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600985	hybrid			2022-12-27	WOS:000182818600026
J	Lilley, RMC; Wang, XQ; Krausz, E; Andrews, TJ				Lilley, RMC; Wang, XQ; Krausz, E; Andrews, TJ			Complete spectra of the far-red chemiluminescence of the oxygenase reaction of Mn2+-activated ribulose-bisphosphate carboxylase/oxygenase establish excited Mn2+ as the source	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSEBISPHOSPHATE CARBOXYLASE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; KINETIC-PROPERTIES; CRYSTAL-STRUCTURE; RUBISCO; TRANSITIONS; GENERATION; MUTATION; SUBUNIT; ENZYME	Chemiluminescence emitted by Mn(2+)activated ribulose-,5-bisphosphate carboxylase/oxygenase (rubisco) while catalyzing oxygenation was analyzed to clarify the source of the emission. Using dual detectors capturing radiation over a wide range of visible and infrared wavelengths, we tested for radiation from singlet O-2 decay and found it to be essentially absent (less than 0.1% of the total luminescence intensity). Spectra were determined between 647 and 885 nm with a very sensitive, charge-coupled detector-based spectrograph to detect differences in the emission spectra between rubiscos from bacterial and higher plant sources. All Mn2+-activated rubiscos emitted a broad, smooth spectrum of chemiluminescence, unchanging as the reaction progressed. The spectra from higher plant rubiscos (spinach and both the wild type and an L335V mutant from tobacco), all exhibited maxima at about 800 nm. However, Mn2+-activated rubisco from the bacterium, Rhodospirillum rubrum, emitted at shorter wavelengths (760 nm peak), demonstrating host ligand-field influences arising from aminoacyl residue differences and/or conformational changes caused by the absence of small subunits. The findings provide strong evidence that the chemiluminescence arises from an excited state of the active-site Mn2+ that is produced during oxygenation. We propose that the Mn2+ becomes excited by a one-electron exchange mechanism of oxygenation that is not available to Mg2+-activated rubisco.	Univ Wollongong, Dept Biol Sci, Wollongong, NSW 2522, Australia; Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia; Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 2601, Australia	University of Wollongong; Australian National University; Australian National University	Lilley, RMC (corresponding author), Univ Wollongong, Dept Biol Sci, Northfields Ave, Wollongong, NSW 2522, Australia.	rossl@uow.edu.au	Krausz, Elmars R/I-2885-2014; Lilley, Ross/B-8127-2008	Krausz, Elmars R/0000-0002-8536-6890; Lilley, Ross/0000-0002-4292-4629				Barnett NW, 2002, ANAL CHIM ACTA, V451, P181, DOI 10.1016/S0003-2670(01)01414-3; Blasse G., 1994, LUMINESCENT MAT, DOI [DOI 10.1007/978-3-642-79017-1_1, 10.1007/978-3-642-79017-1_1]; BUTZ ND, 1989, PLANT PHYSIOL, V89, P735, DOI 10.1104/pp.89.3.735; Chipman D, 1998, BBA-PROTEIN STRUCT M, V1385, P401, DOI 10.1016/S0167-4838(98)00083-1; CHRISTELLER JT, 1979, BIOCHEM J, V183, P747, DOI 10.1042/bj1830747; Cox SD, 1999, AUST J PLANT PHYSIOL, V26, P475, DOI 10.1071/PP99032; DURNER J, 1994, FEBS LETT, V354, P71, DOI 10.1016/0014-5793(94)01097-8; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1376, DOI 10.1104/pp.93.4.1376; FARQUHAR GD, 1980, PLANTA, V149, P78, DOI 10.1007/BF00386231; Frank J, 2000, PHYS CHEM CHEM PHYS, V2, P1301, DOI 10.1039/b000018n; GUTTERIDGE S, 1984, EMBO J, V3, P2737, DOI 10.1002/j.1460-2075.1984.tb02204.x; Horecker B. L., 1958, BIOCHEM PREP, V6, P83; JORDAN DB, 1983, ARCH BIOCHEM BIOPHYS, V227, P425, DOI 10.1016/0003-9861(83)90472-1; Kane HJ, 1998, PLANT PHYSIOL, V117, P1059, DOI 10.1104/pp.117.3.1059; Kanofsky JR, 2000, METHOD ENZYMOL, V319, P59; KANOFSKY JR, 1983, J BIOL CHEM, V258, P5991; KHAN AU, 1970, J AM CHEM SOC, V92, P3293, DOI 10.1021/ja00714a010; KHAN AU, 1984, J PHOTOCHEM, V25, P327, DOI 10.1016/0047-2670(84)87035-5; LILLEY RM, 1993, J BIOL CHEM, V268, P13877; LORIMER GH, 1973, BIOCHEMISTRY-US, V12, P18, DOI 10.1021/bi00725a004; MARTIN MN, 1981, FEBS LETT, V129, P39, DOI 10.1016/0014-5793(81)80750-8; Matsumoto M, 1999, LUMINESCENCE, V14, P345, DOI 10.1002/(SICI)1522-7243(199911/12)14:6<345::AID-BIO559>3.0.CO;2-T; MIZIORKO HM, 1980, BIOCHEMISTRY-US, V19, P1167, DOI 10.1021/bi00547a020; MIZIORKO HM, 1984, BIOCHEMISTRY-US, V23, P479, DOI 10.1021/bi00298a012; MOGEL SN, 1990, BIOCHEMISTRY-US, V29, P8333, DOI 10.1021/bi00488a019; MORELL MK, 1992, AUST J BOT, V40, P431, DOI 10.1071/BT9920431; Oelckers S, 1999, J PHOTOCH PHOTOBIO B, V53, P121, DOI 10.1016/S1011-1344(99)00137-2; PAUL K, 1993, PLANT PHYSIOL, V102, P1129, DOI 10.1104/pp.102.4.1129; Ruuska S, 1998, AUST J PLANT PHYSIOL, V25, P859, DOI 10.1071/PP98079; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; SERVAITES JC, 1985, ARCH BIOCHEM BIOPHYS, V238, P154, DOI 10.1016/0003-9861(85)90151-1; Taylor TC, 1996, NAT STRUCT BIOL, V3, P95, DOI 10.1038/nsb0196-95; Watanabe T, 2001, EUR J BIOCHEM, V268, P6114, DOI 10.1046/j.0014-2956.2001.02557.x; Whitney SM, 1999, PLANT PHYSIOL, V121, P579, DOI 10.1104/pp.121.2.579	34	14	14	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16488	16493		10.1074/jbc.M212402200	http://dx.doi.org/10.1074/jbc.M212402200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604603	hybrid			2022-12-27	WOS:000182818600008
J	Lotz, GP; Lin, HY; Harst, A; Obermann, WMJ				Lotz, GP; Lin, HY; Harst, A; Obermann, WMJ			Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; NITRIC-OXIDE SYNTHASE; STEROID-RECEPTOR; TYROSINE KINASE; IN-VIVO; CYCLE; HEAT-SHOCK-PROTEIN-90; IDENTIFICATION; DIMERIZATION; HYDROLYSIS	The ATP-dependent molecular chaperone Hsp90 is an essential and abundant stress protein in the eukaryotic cytosol that cooperates with a cohort of cofactors/cochaperones to fulfill its cellular tasks. We have identified Aha1 (activator of Hsp90 ATPase) and its relative Hch1 (high copy Hsp90 suppressor) as binding partners of Hsp90 in Saccharomyces cerevisiae. By using genetic and biochemical approaches, the middle domain of Hsp90 (amino acids 272-617) was found to mediate the interaction with Aha1 and Hch1. Data base searches revealed that homologues of Aha1 are conserved from yeast to man, whereas Hch1 was found to be restricted to lower eukaryotes like S. cerevisiae and Candida albicans. In experiments with purified proteins, Aha1 but not Hch1 stimulated the intrinsic ATPase activity of Hsp90 5-fold. To establish their cellular role further, we deleted the genes encoding Aha1 and Hch1 in S. cerevisiae. In vivo experiments demonstrated that Aha1 and Hch1 contributed to efficient activation of the heterologous Hsp90 client protein v-Src. Moreover, Aha1 and Hch1 became crucial for cell viability under non-optimal growth conditions when Hsp90 levels are limiting. Thus, our results identify a novel type of cofactor involved in the regulation of the molecular chaperone Hsp90.	Univ Bonn, Inst Genet, Prot Folding Grp, D-53117 Bonn, Germany	University of Bonn	Obermann, WMJ (corresponding author), Univ Bonn, Inst Genet, Prot Folding Grp, Romerstr 164, D-53117 Bonn, Germany.		Obermann, Wolfgang/AAN-3896-2020	Lotz, Gregor/0000-0002-0231-5503				ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Dey B, 1996, MOL BIOL CELL, V7, P91, DOI 10.1091/mbc.7.1.91; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Nathan DF, 1999, P NATL ACAD SCI USA, V96, P1409, DOI 10.1073/pnas.96.4.1409; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	44	166	177	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17228	17235		10.1074/jbc.M212761200	http://dx.doi.org/10.1074/jbc.M212761200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12604615	hybrid			2022-12-27	WOS:000182818600105
J	Dziennis, S; Habecker, BA				Dziennis, S; Habecker, BA			Cytokine suppression of dopamine-beta-hydroxylase by extracellular signal-regulated kinase-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; LEUKEMIA INHIBITORY FACTOR; NEUROTRANSMITTER BIOSYNTHETIC GENES; NEUROBLASTOMA CELL-LINE; TRANSCRIPTION FACTOR; HOMEODOMAIN PROTEIN; SYMPATHETIC NEURONS; ONCOSTATIN-M; GROWTH-FACTOR; RECEPTOR COMPONENTS	Cholinergic differentiation factors (CDFs) suppress no-radrenergic properties and induce cholinergic properties in sympathetic neurons. The CDFs leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF) bind to a LIFR.gp130 receptor complex to activate Jak/signal transducers and activators of transcription and Ras/mitogen-activated protein kinases signaling pathways. Little is known about how these differentiation factors suppress noradrenergic properties. We used sympathetic neurons and SK-N-BE(2)M17 neuroblastoma cells to investigate CDF down-regulation of the norepinephrine synthetic enzyme dopamine-beta-hydroxylase (DBH). LIF and CNTF activated extracellular signal-regulated kinases (ERKs) I and 2 but not p38 or Jun N-terminal kinases in both cell types. Preventing ERK activation with PD98059 blocked CNTF suppression of DBH protein in sympathetic neurons but did not prevent the loss of DBH mRNA. CNTF decreased transcription of a DBH promoter-luciferase reporter construct in SK-N-BE(2)M17 cells, and this was also ERK-independent. Cytokine inhibition of DBH promoter activity did not require a silencer element but was prevented by overexpression of the transcriptional activator Phox2a. Inhibiting ERK activation increased basal DBH transcription in SK-N-BE(2)M17 cells, and DBH mRNA in sympathetic neurons. Transfection of Phox2a into PD98059-treated M17 cells resulted in a synergistic increase in DBH promoter activity compared with Phox2a or PD98059 alone. These data suggest that CDFs down-regulate DBH protein via an ERK-dependent pathway but inhibit DBH gene expression through an ERK-independent pathway. They further suggest that ERK activity inhibits basal DBH gene expression.	Oregon Hlth Sci Univ, Dept Physiol Pharmacol, Portland, OR 97239 USA	Oregon Health & Science University	Habecker, BA (corresponding author), Oregon Hlth Sci Univ, Dept Physiol Pharmacol, L334,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.			Habecker, Beth/0000-0002-4658-8730	NHLBI NIH HHS [HL 68231, R01 HL068231] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068231] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi M, 2002, J BIOL CHEM, V277, P22915, DOI 10.1074/jbc.M201695200; Afar R, 1996, MOL BRAIN RES, V36, P79, DOI 10.1016/0169-328X(95)00247-P; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Brodski C, 2000, P NATL ACAD SCI USA, V97, P9683, DOI 10.1073/pnas.160080697; CERVINI R, 1994, NEUROREPORT, V5, P1346; Comer AM, 1999, BRAIN RES PROTOC, V4, P367, DOI 10.1016/S1385-299X(99)00042-2; CORCORAN JJ, 1990, AM J PHYSIOL, V259, pC161, DOI 10.1152/ajpcell.1990.259.1.C161; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; Eilers A, 1998, J NEUROSCI, V18, P1713; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Faris M, 1996, AIDS, V10, P369, DOI 10.1097/00002030-199604000-00004; GAGNON C, 1976, J NEUROCHEM, V27, P1083, DOI 10.1111/j.1471-4159.1976.tb00312.x; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Harrington AW, 2002, J NEUROSCI, V22, P156, DOI 10.1523/JNEUROSCI.22-01-00156.2002; Hawrot E, 1979, Methods Enzymol, V58, P574; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Ishiguro H, 1995, MOL BRAIN RES, V34, P251, DOI 10.1016/0169-328X(95)00170-W; JOHNSON JA, 1994, J BIOL CHEM, V269, P18856; Kim CH, 1999, J BIOL CHEM, V274, P6507, DOI 10.1074/jbc.274.10.6507; Kim HS, 1998, J NEUROSCI, V18, P8247; LANDIS SC, 1988, DEV BIOL, V126, P129, DOI 10.1016/0012-1606(88)90246-1; LANDIS SC, 1994, PROG BRAIN RES, V100, P19; Li WQ, 2001, J IMMUNOL, V166, P3491, DOI 10.4049/jimmunol.166.5.3491; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; RAO MS, 1990, DEV BIOL, V139, P65, DOI 10.1016/0012-1606(90)90279-R; Rosoff ML, 1999, CELL MOL NEUROBIOL, V19, P289, DOI 10.1023/A:1006937413310; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; SCHWARZSCHILD MA, 1994, J NEUROCHEM, V63, P1246; SHASKUS J, 1992, J BIOL CHEM, V267, P18821; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Swanson DJ, 1997, J BIOL CHEM, V272, P27382, DOI 10.1074/jbc.272.43.27382; Swanson DJ, 2000, J BIOL CHEM, V275, P2911, DOI 10.1074/jbc.275.4.2911; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; Symes A, 1997, J BIOL CHEM, V272, P9648; SYMES AJ, 1993, P NATL ACAD SCI USA, V90, P572, DOI 10.1073/pnas.90.2.572; TAGA T, 1995, CURR OPIN IMMUNOL, V7, P17, DOI 10.1016/0952-7915(95)80024-7; Tiveron MC, 1996, J NEUROSCI, V16, P7649; VIRDEE K, 1995, EUR J NEUROSCI, V7, P2159, DOI 10.1111/j.1460-9568.1995.tb00637.x; Yang CY, 1998, J NEUROCHEM, V71, P1813; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Zellmer E, 1995, J NEUROSCI, V15, P8109; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zigmond RE, 1996, PERSPECT DEV NEUROBI, V4, P75	57	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15897	15904		10.1074/jbc.M212480200	http://dx.doi.org/10.1074/jbc.M212480200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12609984	hybrid			2022-12-27	WOS:000182680000056
J	Yano, T; Sklar, J; Nakamaru-Ogiso, E; Takahashi, Y; Yagi, T; Ohnishi, T				Yano, T; Sklar, J; Nakamaru-Ogiso, E; Takahashi, Y; Yagi, T; Ohnishi, T			Characterization of cluster N5 as a fast-relaxing [4Fe-4S] cluster in the Nqo3 subunit of the proton-translocating NADH-ubiquinone oxidoreductase from Paracoccus denitrificans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; DEHYDROGENASE COMPLEX-I; IRON-SULFUR CLUSTERS; QUINONE OXIDOREDUCTASE; MITOCHONDRIAL NADH; CLOSTRIDIUM-PASTEURIANUM; 3-DIMENSIONAL STRUCTURE; EPR CHARACTERIZATION; YARROWIA-LIPOLYTICA; RESPIRATORY-CHAIN	The NADH-quinone oxidoreductase from Paracoccus denitrificans consists of 14 subunits (Nqol-14) and contains one FMN and eight iron-sulfur clusters. The Nqo3 subunit possesses fully conserved 11 Cys and 1 His in its N-terminal region and is considered to harbor three iron-sulfur clusters; however, only one binuclear (N1b) and one tetranuclear (N4) were previously identified. In this study, the Nqo3 subunit containing 1 x [2Fe-2S] and 2x[4Fe-4S] clusters was expressed in Escherichia coli. The second [4Fe-4S](1+) cluster is detected by EPR spectroscopy below 6 K, exhibiting very fast spin relaxation. The resolved EPR spectrum of this cluster is broad and nearly axial. The subunit exhibits an absorption-type EPR signal around g similar to 5 region below 6 K, most likely arising from an S = 3/2 ground state of the fast-relaxing [4Fe-4S](1+) species. The substitution of the conserved His(106) with Cys specifically affected the fast-relaxing [4Fe-4S](1+) cluster, suggesting that this cluster is coordinated by His(106). In the cholate-treated NDH-1-enriched P. denitrificans membranes, we observed EPR signals arising from a [4Fe-4S] cluster below 6 K exhibiting properties similar to those of cluster N5 detected in other complex I/NDH-1 and of the fast-relaxing [4Fe-4S](1+) cluster in the expressed Nqo3 subunit. Hence, we propose that the His-coordinated [4Fe-4S] cluster corresponds to cluster N5.	Univ Penn, Sch Med, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA; Scripps Res Inst, Div Biochem, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Osaka Univ, Dept Biol, Grad Sch Sci, Osaka 5600043, Japan	University of Pennsylvania; Scripps Research Institute; Osaka University	Yano, T (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA.		/AAD-2249-2020; Takahashi, Yasuhiro/F-1119-2011	Takahashi, Yasuhiro/0000-0002-0588-6045	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033712, R01GM030736] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 33712, R01 GM 30736] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ADAMS MWW, 1987, J BIOL CHEM, V262, P15054; Ahlers PM, 2000, J BIOL CHEM, V275, P23577, DOI 10.1074/jbc.M002074200; ALBRACHT SPJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P221, DOI 10.1016/0005-2728(93)90176-G; Beinert H, 1978, Methods Enzymol, V54, P435; BELOGRUDOV G, 1994, BIOCHEMISTRY-US, V33, P4571, DOI 10.1021/bi00181a018; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Dutton P L, 1978, Methods Enzymol, V54, P411; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; Friedrich T, 1997, J THEOR BIOL, V187, P529, DOI 10.1006/jtbi.1996.0387; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; FU W, 1993, BIOCHEMISTRY-US, V32, P4813, DOI 10.1021/bi00069a016; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Guenebaut V, 1997, J MOL BIOL, V265, P409, DOI 10.1006/jmbi.1996.0753; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Gutierrez-Correa J, 2001, FREE RADICAL RES, V34, P363, DOI 10.1080/10715760100300311; KERSCHER S, 2003, BIOCHIM BIOPHYS ACTA, V155, P83; LINDAHL PA, 1985, J BIOL CHEM, V260, P1160; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magnitsky S, 2002, J BIOENERG BIOMEMBR, V34, P193, DOI 10.1023/A:1016083419979; MEINHARDT SW, 1987, J BIOL CHEM, V262, P9147; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Ohnishi T, 1998, BBA-BIOENERGETICS, V1364, P186, DOI 10.1016/S0005-2728(98)00027-9; OHNISHI T, 1975, BIOCHIM BIOPHYS ACTA, V387, P475, DOI 10.1016/0005-2728(75)90087-0; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; PILKINGTON SJ, 1991, BIOCHEMISTRY-US, V30, P2166, DOI 10.1021/bi00222a021; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; RUNSWICK MJ, 1989, BIOCHEMISTRY-US, V28, P9452, DOI 10.1021/bi00450a031; RUPP H, 1978, BIOCHIM BIOPHYS ACTA, V537, P255, DOI 10.1016/0005-2795(78)90509-3; SLED VD, 1993, J BIOENERG BIOMEMBR, V25, P347, DOI 10.1007/BF00762460; Takano S, 1996, BIOCHEMISTRY-US, V35, P9120, DOI 10.1021/bi9605853; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VINOGRADOV AD, 1995, FEBS LETT, V370, P83, DOI 10.1016/0014-5793(95)00803-H; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; XU XM, 1992, ARCH BIOCHEM BIOPHYS, V296, P40, DOI 10.1016/0003-9861(92)90542-5; YAGI T, 1986, ARCH BIOCHEM BIOPHYS, V250, P302, DOI 10.1016/0003-9861(86)90731-9; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1; Yamaguchi M, 1998, J BIOL CHEM, V273, P8094, DOI 10.1074/jbc.273.14.8094; Yano T, 1996, J BIOL CHEM, V271, P5907, DOI 10.1074/jbc.271.10.5907; YANO T, 1995, J BIOL CHEM, V270, P18264, DOI 10.1074/jbc.270.31.18264; Yano T, 1999, J BIOL CHEM, V274, P28598, DOI 10.1074/jbc.274.40.28598; Yano T, 1997, J BIOL CHEM, V272, P4201, DOI 10.1074/jbc.272.7.4201; Yano T, 2001, J BIOENERG BIOMEMBR, V33, P213, DOI 10.1023/A:1010782903144; YANO T, 1994, BIOCHEMISTRY-US, V33, P494, DOI 10.1021/bi00168a014; Yano T, 2000, BBA-BIOENERGETICS, V1459, P299, DOI 10.1016/S0005-2728(00)00164-X; Yano T, 2002, MOL ASPECTS MED, V23, P345, DOI 10.1016/S0098-2997(02)00011-0; ZAMBRANO IC, 1989, J BIOL CHEM, V264, P20974; Zu YB, 2002, BIOCHEMISTRY-US, V41, P10056, DOI 10.1021/bi026026f	53	39	40	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15514	15522		10.1074/jbc.M212275200	http://dx.doi.org/10.1074/jbc.M212275200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600982	hybrid			2022-12-27	WOS:000182680000009
J	Charbonnel, P; Lamarque, M; Piard, JC; Gilbert, C; Juillard, V; Atlan, D				Charbonnel, P; Lamarque, M; Piard, JC; Gilbert, C; Juillard, V; Atlan, D			Diversity of oligopeptide transport specificity in Lactococcus lactis species - A tool to unravel the role of OppA in uptake specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN OPPA; STREPTOCOCCUS-LACTIS; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; PHEROMONE CCF10; BETA-CASEIN; SYSTEM; EXPRESSION; PERMEASE	The specific oligopeptide transport system Opp is essential for growth of Lactococcus lactis in milk. We examined the biodiversity of oligopeptide transport specificity in the L. lactis species. Six strains were tested for (i) consumption of peptides during growth in a chemically defined medium and (ii) their ability to transport these peptides. Each strain demonstrated some specific preferences for peptide utilization, which matched the specificity of peptide transport. Sequencing of the binding protein OppA in some strains revealed minor differences at the amino acid level. The differences in specificity were used as a tool to unravel the role of the binding protein in transport specificity. The genes encoding OppA in four strains were cloned and expressed in L. lactis MG1363 deleted for its oppA gene. The substrate specificity of these engineered strains was found to be similar to that of the L. lactis MG1363 parental strain, whichever oppA gene was expressed. In situ binding experiments demonstrated the ability of OppA to interact with non-transported peptides. Taken together, these results provide evidence for a new concept. Despite that fact that OppA is essential for peptide transport, it is not the (main) determinant of peptide transport specificity in L. lactis.	INRA, Unite Rech Laitieres & Genet Appliquee, F-78352 Jouy En Josas, France; Univ Lyon 1, CNRS, UMR 5122, Lab Microbiol & Genet, F-69622 Villeurbanne, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Juillard, V (corresponding author), INRA, Unite Rech Laitieres & Genet Appliquee, F-78352 Jouy En Josas, France.		Gilbert, Christophe/M-6005-2014	Gilbert, Christophe/0000-0003-3021-7350				Bensing BA, 1997, MOL MICROBIOL, V24, P285, DOI 10.1046/j.1365-2958.1997.3301710.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Bolotin A, 2001, GENOME RES, V11, P731, DOI 10.1101/gr.GR-1697R; Borezee E, 2000, INFECT IMMUN, V68, P7069, DOI 10.1128/IAI.68.12.7069-7077.2000; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Claverys JP, 2000, RES MICROBIOL, V151, P457, DOI 10.1016/S0923-2508(00)00169-8; Coulter SN, 1998, MOL MICROBIOL, V30, P393, DOI 10.1046/j.1365-2958.1998.01075.x; CUNDELL DR, 1995, INFECT IMMUN, V63, P2493, DOI 10.1128/IAI.63.7.2493-2498.1995; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Detmers FJM, 2000, P NATL ACAD SCI USA, V97, P12487, DOI 10.1073/pnas.220308797; Detmers FJM, 1998, BIOCHEMISTRY-US, V37, P16671, DOI 10.1021/bi981712t; Flambard B, 2000, APPL ENVIRON MICROB, V66, P5134, DOI 10.1128/AEM.66.12.5134-5140.2000; Garault P, 2002, J BIOL CHEM, V277, P32, DOI 10.1074/jbc.M107002200; GASSON MJ, 1983, J BACTERIOL, V154, P1; Gominet M, 2001, MOL MICROBIOL, V40, P963, DOI 10.1046/j.1365-2958.2001.02440.x; GOODELL EW, 1987, J BACTERIOL, V169, P3861, DOI 10.1128/jb.169.8.3861-3865.1987; Harlow E., 1988, ANTIBODIES LAB MANUA; JENKINSON HF, 1992, INFECT IMMUN, V60, P1225, DOI 10.1128/IAI.60.3.1225-1228.1992; Juillard V, 1998, APPL ENVIRON MICROB, V64, P1230; JUILLARD V, 1995, APPL ENVIRON MICROB, V61, P3024, DOI 10.1128/AEM.61.8.3024-3030.1995; KOIDE A, 1994, MOL MICROBIOL, V13, P417, DOI 10.1111/j.1365-2958.1994.tb00436.x; KUNJI ERS, 1995, J BIOL CHEM, V270, P1569, DOI 10.1074/jbc.270.4.1569; KUNJI ERS, 1993, J BACTERIOL, V175, P2052, DOI 10.1128/JB.175.7.2052-2059.1993; Kunji ERS, 1996, MOL MICROBIOL, V21, P123, DOI 10.1046/j.1365-2958.1996.6231339.x; LAAN H, 1991, APPL ENVIRON MICROB, V57, P2586, DOI 10.1128/AEM.57.9.2586-2590.1991; Lanfermeijer FC, 2000, EMBO J, V19, P3649, DOI 10.1093/emboj/19.14.3649; Lanfermeijer FC, 1999, BIOCHEMISTRY-US, V38, P14440, DOI 10.1021/bi9914715; Lazazzera BA, 1999, J BACTERIOL, V181, P5193, DOI 10.1128/JB.181.17.5193-5200.1999; Leonard BAB, 1996, P NATL ACAD SCI USA, V93, P260, DOI 10.1073/pnas.93.1.260; MAEDA S, 1986, J GEN MICROBIOL, V132, P331; PEREGO M, 1991, MOL MICROBIOL, V5, P173, DOI 10.1111/j.1365-2958.1991.tb01838.x; Picon A, 2000, J BACTERIOL, V182, P1600, DOI 10.1128/JB.182.6.1600-1608.2000; Podbielski A, 1996, MOL MICROBIOL, V21, P1087, DOI 10.1046/j.1365-2958.1996.661421.x; POOLMAN B, 1987, J BACTERIOL, V169, P2755, DOI 10.1128/jb.169.6.2755-2761.1987; POOLMAN B, 1988, J BACTERIOL, V170, P700, DOI 10.1128/jb.170.2.700-707.1988; Rostom AA, 2000, J MOL BIOL, V296, P269, DOI 10.1006/jmbi.1999.3431; Sambrook J., 2002, MOL CLONING LAB MANU; Sleigh SH, 1997, BIOCHEMISTRY-US, V36, P9747, DOI 10.1021/bi970457u; SOLOMON JM, 1995, GENE DEV, V9, P547, DOI 10.1101/gad.9.5.547; Tame JRH, 1995, STRUCTURE, V3, P1395, DOI 10.1016/S0969-2126(01)00276-3; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; TYNKKYNEN S, 1993, J BACTERIOL, V175, P7523, DOI 10.1128/JB.175.23.7523-7532.1993; Wells JM, 1996, ANTON LEEUW INT J G, V70, P317, DOI 10.1007/BF00395939; WELLS JM, 1993, J APPL BACTERIOL, V74, P629, DOI 10.1111/j.1365-2672.1993.tb05195.x; Yu WZ, 1996, PLASMID, V35, P145, DOI 10.1006/plas.1996.0017	45	28	28	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14832	14840		10.1074/jbc.M212454200	http://dx.doi.org/10.1074/jbc.M212454200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590143	hybrid			2022-12-27	WOS:000182516100034
J	Jin, C; Barrientos, A; Tzagoloff, A				Jin, C; Barrientos, A; Tzagoloff, A			Yeast dihydroxybutanone phosphate synthase, an enzyme of the riboflavin biosynthetic pathway, has a second unrelated function in expression of mitochondrial respiration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MEMBRANE SYSTEM; PROTEIN; VECTORS; CLONING; GENE; DNA; SITES	aE280/U1 is a pet mutant of Saccharomyces cerevisiae partially deficient in cytochromes a, a3, and cytochrome b. The ability of this mutant to respire is restored by RIB3, a gene previously shown to code for 3,4-dihydroxy2-butanone-4-phosphate synthase (DHBP synthase), an enzyme of the riboflavin biosynthetic pathway. The sequences of RIB3 from wild type and aE280/U1 indicated a single base change resulting in an A137T substitution. The alanine 137 is a conserved residue located in a cavity on the surface of the protein distant from the active site and from the subunit interaction domain involved in homodimer formation. The respiratory defect elicited by this mutation cannot be explained by a flavin insufficiency based on the following evidence: 1) growth of the aE280/U1 on respiratory substrates is not rescued by exogenous riboflavin; 2) the levels of flavin nucleotides are not significantly different in the mutant and wild type. We proposed that in addition to its known function in riboflavin synthesis, RIB3 also functions in expression of mitochondrial respiration. Restoration by riboflavin of growth of a rib3 deletion mutant on glucose but not glycerol/ethanol also supported this conclusion. An antibody against the N-terminal half of DHBP synthase was used to study its subcellular distribution. Most of the protein was localized in the cytosolic fraction, but a small fraction was detected in the mitochondrial intermembrane space.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Jin, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet2.bio.columbia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022174] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL022174, HL2274] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bacher A, 2000, ANNU REV NUTR, V20, P153, DOI 10.1146/annurev.nutr.20.1.153; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARCIARAMIREZ JJ, 1995, J BIOL CHEM, V270, P23801, DOI 10.1074/jbc.270.40.23801; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO DI, 2002, BIOCHEMISTRY-US, V41, P51806; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; TZAGOLOFF A, 1972, J BIOL CHEM, V247, P594; WU M, 1995, MOL CELL BIOL, V15, P264, DOI 10.1128/MCB.15.1.264; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	26	14	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14698	14703		10.1074/jbc.M300593200	http://dx.doi.org/10.1074/jbc.M300593200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12595523	hybrid			2022-12-27	WOS:000182516100016
J	Liu, M; Ramos-Castaneda, J; Arvan, P				Liu, M; Ramos-Castaneda, J; Arvan, P			Role of the connecting peptide in insulin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; ER STRESS; DISULFIDE BONDS; TRANSCRIPTION FACTOR; BIOLOGICAL-ACTIVITY; QUALITY-CONTROL; MESSENGER-RNA; ATF6; PROINSULIN	In single-chain insulins (SCIs), the C terminus of the insulin B-chain is contiguous with the N terminus of the A-chain, connected by a short bioengineered linker sequence. SCIs have been proposed to offer potential benefit for gene therapy of diabetes (Lee, H. C., Kim, S. J., Kim, K. S., Shin, H. C., and Yoon, J. W. (2000) Nature 408, 483-488) yet relatively little is known about their folding, intracellular transport, or secretion from mammalian cells. Because SCIs can be considered as mutant proinsulin (with selective shortening of the 35-amino acid connecting peptide that normally includes two sets of flanking dibasic residues), they offer insights into understanding the role of the connecting peptide in insulin biosynthesis. Herein we have explored the relationship of the linker sequence to SCI biosynthesis, folding, and intracellular transport in transiently transfected HEK293 or Chinese hamster ovary cells or in stably transfected AtT20 cells. Despite previous reports that direct linkage of B- and A-chains produces a structure isomorphous with authentic two-chain insulin, we find that constructs with short linkers tend to be synthesized at lower levels, with a significant fraction of molecules exhibiting improper disulfide bonding. Nevertheless, disulfide-mispaired isoforms from a number of different SCI constructs are secreted. While this suggests that a novel folded state goes unrecognized by secretory pathway quality control, we find that misfolded SCIs are detected at higher levels in Chinese hamster ovary cells with artificially activated unfolded protein response mediated by inducible overexpression of active ATF-6. Such a maneuver allows analysis of more seriously misfolded mutants with further foreshortening of the linker sequence or loss (by mutation) of the insulin interchain disulfide bonds.	Albert Einstein Coll Med, Div Endocrinol, Ctr Diabet Res & Training, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Arvan, P (corresponding author), Albert Einstein Coll Med, Div Endocrinol, Ctr Diabet Res & Training, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Ramos-Castañeda, jose/V-6678-2019	Liu, Ming/0000-0003-2665-4072	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048280] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48280] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Arvan P, 2002, TRAFFIC, V3, P771, DOI 10.1034/j.1600-0854.2002.31102.x; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Chou KC, 2000, ANAL BIOCHEM, V286, P1, DOI 10.1006/abio.2000.4757; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; Fassio A, 2002, HISTOCHEM CELL BIOL, V117, P151, DOI 10.1007/s00418-001-0364-0; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P1556, DOI 10.1021/bi011166v; Guo ZY, 2002, BIOCHEMISTRY-US, V41, P10585, DOI 10.1021/bi020165f; Guo ZY, 2001, BIOL CHEM, V382, P443, DOI 10.1515/BC.2001.054; HANG BY, 2002, J BIOL CHEM, V278, P3687; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hua QX, 1998, J MOL BIOL, V277, P103, DOI 10.1006/jmbi.1997.1574; HUA QX, 1995, NAT STRUCT BIOL, V2, P129, DOI 10.1038/nsb0295-129; Hua QX, 2002, J BIOL CHEM, V277, P43443, DOI 10.1074/jbc.M206107200; Hua QX, 2001, BIOCHEMISTRY-US, V40, P12299, DOI 10.1021/bi011021o; HUANG XF, 1995, J BIOL CHEM, V270, P20417, DOI 10.1074/jbc.270.35.20417; Kowarik M, 2002, MOL CELL, V10, P769, DOI 10.1016/S1097-2765(02)00685-8; Lee HC, 2000, NATURE, V408, P483, DOI 10.1038/35044106; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Lucocq J, 2001, EUR J CELL BIOL, V80, P508, DOI 10.1078/0171-9335-00186; NAKAGAWA SH, 1989, J BIOL CHEM, V264, P272; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; PERMUTT MA, 1981, ISLETS LANGERHANS BI, P75; POWELL SK, 1988, J CELL BIOL, V106, P1843, DOI 10.1083/jcb.106.6.1843; Qiao ZS, 2001, BIOCHEMISTRY-US, V40, P2662, DOI 10.1021/bi001613r; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEELE G, 1983, J BIOL CHEM, V258, P2005; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; SIEBER P, 1978, H-S Z PHYSIOL CHEM, V359, P113; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Steiner DF, 1997, SCIENCE, V277, P531, DOI 10.1126/science.277.5325.531; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; STEINER DF, 1972, HDB PHYSL 7, P175; TANG JG, 1990, BIOCHEM J, V268, P429, DOI 10.1042/bj2680429; Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Winter J, 2002, J BIOL CHEM, V277, P310, DOI 10.1074/jbc.M107832200; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000	42	41	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14798	14805		10.1074/jbc.M212070200	http://dx.doi.org/10.1074/jbc.M212070200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590147	hybrid			2022-12-27	WOS:000182516100029
J	Grabowska, D; Chelstowska, A				Grabowska, D; Chelstowska, A			The ALD6 gene product is indispensable for providing NADPH in yeast cells lacking glucose-6-phosphate dehydrogenase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL BETA-OXIDATION; SACCHAROMYCES-CEREVISIAE; ISOCITRATE DEHYDROGENASE; ENCODING GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; STRUCTURAL GENE; SHUTTLE VECTORS; FATTY-ACIDS; DISRUPTION; EXPRESSION; STRESS	Reducing equivalents in the form of NADPH are essential for many enzymatic steps involved in the biosynthesis of cellular macromolecules. An adequate level of NADPH is also required to protect cells against oxidative stress. The major enzymatic source of NADPH in the cell is the reaction catalyzed by glucose-6-phosphate dehydrogenase, the first enzyme in the pentose phosphate pathway. Disruption of the ZWF1 gene, encoding glucose-6-phosphate dehydrogenase in the yeast Saccharomyces cerevisiae, results in methionine auxotrophy and increased sensitivity to oxidizing agents. It is assumed that both phenotypes are due to an NADPH deficiency in the zwf1Delta strain. We used a Met(-) phenotype displayed by the zwf1Delta strain to look for multicopy suppressors of this deletion. We found that overexpression of the ALD6 gene coding for cytosolic acetaldehyde dehydrogenase, which utilizes NADP(+) as its cofactor, restores the Met(+) phenotype of the zwf1Delta strain. Another multicopy suppressor identified in our screen, the ZMS1 gene encoding a putative transcription factor, regulates the level of ALD6 expression. A strain bearing a double ZWF1 ALD6 gene disruption is not viable. Thus, our results indicate the reaction catalyzed by Ald6p as an important source of reducing equivalents in the yeast cells.	Polish Acad Sci, Inst Biochem & Biophys, Dept Genet, PL-02106 Warsaw, Poland	Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Chelstowska, A (corresponding author), Polish Acad Sci, Inst Biochem & Biophys, Dept Genet, Pawinskiego 5A, PL-02106 Warsaw, Poland.			Chelstowska, Anna/0000-0002-2431-7921				Adams A, 1997, METHODS YEAST GENETI; BEUTLER E, 1990, METABOLIC BASIS INHE; BILINSKI T, 1985, BIOCHEM BIOPH RES CO, V130, P533, DOI 10.1016/0006-291X(85)90449-8; Boles E, 1998, J BACTERIOL, V180, P2875, DOI 10.1128/JB.180.11.2875-2882.1998; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Boubekeur S, 2001, EUR J BIOCHEM, V268, P5057, DOI 10.1046/j.1432-1327.2001.02418.x; BRUNELLI JP, 1993, YEAST, V9, P1299, DOI 10.1002/yea.320091203; Draculic T, 2000, MOL MICROBIOL, V36, P1167, DOI 10.1046/j.1365-2958.2000.01948.x; FRAENKEL DG, 1968, J BACTERIOL, V95, P1267, DOI 10.1128/JB.95.4.1267-1271.1968; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; Henke B, 1998, J BIOL CHEM, V273, P3702, DOI 10.1074/jbc.273.6.3702; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Kucharczyk R, 1999, YEAST, V15, P987, DOI 10.1002/(SICI)1097-0061(199907)15:10B<987::AID-YEA403>3.0.CO;2-5; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; Meaden PG, 1997, YEAST, V13, P1319, DOI 10.1002/(SICI)1097-0061(199711)13:14<1319::AID-YEA183>3.0.CO;2-T; Minard KI, 1998, J BIOL CHEM, V273, P31486, DOI 10.1074/jbc.273.47.31486; Minard KI, 1999, J BIOL CHEM, V274, P3402, DOI 10.1074/jbc.274.6.3402; NOGAE I, 1990, GENE, V96, P161, DOI 10.1016/0378-1119(90)90248-P; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; RACKI W, 2002, THESIS CTR GENETIQUE; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Slekar KH, 1996, J BIOL CHEM, V271, P28831, DOI 10.1074/jbc.271.46.28831; Stryer L., 1989, BIOCHEMISTRY; THOMAS D, 1991, EMBO J, V10, P547, DOI 10.1002/j.1460-2075.1991.tb07981.x; van Roermund CWT, 1998, EMBO J, V17, P677, DOI 10.1093/emboj/17.3.677; VULLIAMY T, 1992, TRENDS GENET, V8, P138, DOI 10.1016/0168-9525(92)90372-B; Wang XP, 1998, J BACTERIOL, V180, P822, DOI 10.1128/JB.180.4.822-830.1998	32	95	101	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13984	13988		10.1074/jbc.M210076200	http://dx.doi.org/10.1074/jbc.M210076200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584194	hybrid			2022-12-27	WOS:000182405000055
J	Higashi, S; Miyazaki, K				Higashi, S; Miyazaki, K			Identification of a region of beta-amyloid precursor protein essential for its gelatinase a inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-DEGRADING METALLOPROTEINASE; 1.8-ANGSTROM CRYSTAL-STRUCTURE; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; ALZHEIMERS-DISEASE; IV COLLAGENASE; ACTIVATION; PURIFICATION; ANGIOGENESIS; ASSOCIATION	Because beta-amyloid precursor protein (APP) has the abilities both to interact with extracellular matrix and to inhibit gelatinase A activity, this molecule is assumed to play a regulatory role in the gelatinase A-catalyzed degradation of extracellular matrix. To determine a region of APP essential for the inhibitory activity, we prepared various derivatives of APP. Functional analyses of proteolytic fragments of soluble APP (sAPP) and glutathione S-transferase fusion proteins, which contain various COOH-terminal parts of sAPP, showed that a site containing residues 579-601 of APP(770) is essential for the inhibitory activity. Moreover, a synthetic decapeptide containing the 579-601 sequence corresponding to residues 586-595 of APP(770) had a gelatinase A inhibitory activity slightly higher than that of sAPP. Studies of deletion of the NH2- and COOH-terminal residues and alanine replacement of internal residues of the decapeptide further revealed that Tyr(588), Asp(591), and Leu(593) of APP mainly stabilize the interaction between gelatinase A and the inhibitor. We also found that the residues of Ile(586), Met(594), and Pro(595) modestly contribute to the inhibitory activity. The APP-derived decapeptide efficiently inhibited the activity of gelatinase A (IC50 = 30 nm), whereas its inhibitory activity toward membrane type 1 matrix metalloproteinase was much weaker (IC50 = 2 muM). The decapeptide had poor inhibitory activity toward gelatinase B, matrilysin, and stromelysin (IC50 > 10 muM). The APP-derived inhibitor formed a complex with active gelatinase A but not with progelatinase A, and the complex formation was prevented completely by a hydroxamate-based synthetic inhibitor. Therefore, the decapeptide region of APP is likely an active site-directed inhibitor that has high selectivity toward gelatinase A.	Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University	Higashi, S (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Maioka Cho 641-12, Yokohama, Kanagawa 2440813, Japan.	shigashi@yokohama-cu.ac.jp						Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; Betz M, 1997, EUR J BIOCHEM, V247, P356, DOI 10.1111/j.1432-1033.1997.00356.x; Brandstetter H, 2001, J BIOL CHEM, V276, P17405, DOI 10.1074/jbc.M007475200; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; Caceres J, 1997, J CELL BIOCHEM, V65, P145, DOI 10.1002/(SICI)1097-4644(199705)65:2<145::AID-JCB2>3.0.CO;2-U; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; DOCHERTY AJP, 1992, TRENDS BIOTECHNOL, V10, P200, DOI 10.1016/0167-7799(92)90214-G; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Finzel BC, 1998, PROTEIN SCI, V7, P2118, DOI 10.1002/pro.5560071008; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; IGARASHI K, 1992, BIOCHEM BIOPH RES CO, V185, P1000, DOI 10.1016/0006-291X(92)91726-7; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh T, 1998, CANCER RES, V58, P1048; Jia MC, 2000, ADV EXP MED BIOL, V476, P181; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; KIBBEY MC, 1993, P NATL ACAD SCI USA, V90, P10150, DOI 10.1073/pnas.90.21.10150; LIOTTA LA, 1986, CANCER RES, V46, P1; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohsawa I, 2001, J NEUROCHEM, V76, P1411, DOI 10.1046/j.1471-4159.2001.00144.x; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; RICE A, 1995, BIOCHEMISTRY-US, V34, P9249, DOI 10.1021/bi00028a038; Sambrook J., 1989, MOL CLONING, V2.9, P14; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Segel I. H., 1975, ENZYME KINETICS, P320; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SMALL DH, 1992, J NEUROSCI, V12, P4143; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; UMENISHI F, 1990, J BIOCHEM-TOKYO, V108, P537, DOI 10.1093/oxfordjournals.jbchem.a123238; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yana I, 2002, CLIN EXP METASTAS, V19, P209, DOI 10.1023/A:1015527220537; Zheng H, 1996, ANN NY ACAD SCI, V777, P421, DOI 10.1111/j.1749-6632.1996.tb34456.x	47	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14020	14028		10.1074/jbc.M212264200	http://dx.doi.org/10.1074/jbc.M212264200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12586836	hybrid			2022-12-27	WOS:000182405000060
J	Kim, JW; Lee, JE; Kim, MJ; Cho, EG; Cho, SG; Choi, EJ				Kim, JW; Lee, JE; Kim, MJ; Cho, EG; Cho, SG; Choi, EJ			Glycogen synthase kinase 3 beta is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; CELL-DEATH; INDUCED APOPTOSIS; BETA-CATENIN; MAP KINASES; AKT; PATHWAY; TRANSDUCTION; AXIN; JNK	Glycogen synthase kinase 3beta (GSK3beta) is implicated in many biological events, including embryonic development, cell differentiation, apoptosis, and insulin response. GSK3beta has now been shown to induce activation of the mitogen-activated protein kinase kinase kinase MEKK1 and thereby to promote signaling by the stress-activated protein kinase pathway. GSK3beta-binding protein blocked the activation of MEKK1 by GSK3beta in human embryonic kidney 293 (HEK293) cells. Furthermore, co-immunoprecipitation analysis revealed a physical association between endogenous GSK3beta and MEKK1 in HEK293 cells. Overexpression of axin1, a GSK3beta-regulated scaffolding protein, did not affect the physical interaction between GSK3beta and MEKK1 in transfected HEK293 cells. Exposure of cells to insulin inhibited the activation of MEKK1 by GSK3beta, and this inhibitory effect of insulin was abolished by the phosphatidylinositol 3-kinase inhibitor wortmannin. Furthermore, MEKK1 activity under either basal or UV- or tumor necrosis factor alpha-stimulated conditions was reduced in embryonic fibroblasts derived from GSK3beta knockout mice compared with that in such cells from wild-type mice. Ectopic expression of GSK3beta increased both basal and tumor necrosis factor alpha-stimulated activities of HEKK1. in GSK3beta(-/-) cells. Together, these observations suggest that GSK3beta functions as a natural activator of MEKK1.	Korea Univ, Grad Sch Life Sci & Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Seoul 136701, South Korea; Konkuk Univ, Dept Anim Sci, Seoul 143702, South Korea	Korea University; Konkuk University	Choi, EJ (corresponding author), Korea Univ, Grad Sch Life Sci & Biotechnol, Natl Creat Res Initiat Ctr Cell Death, Seoul 136701, South Korea.		KIM, JIN WOO/C-1655-2011	KIM, JIN WOO/0000-0003-0767-1918; Cho, Ssang-Goo/0000-0002-0968-7932				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Cerezo A, 1998, MOL BIOL CELL, V9, P3107, DOI 10.1091/mbc.9.11.3107; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hartigan JA, 2001, BIOCHEM BIOPH RES CO, V284, P485, DOI 10.1006/bbrc.2001.4986; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hetman M, 2000, J NEUROSCI, V20, P2567; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim JW, 2001, J BIOL CHEM, V276, P27064, DOI 10.1074/jbc.M009364200; Kim JW, 2001, J CELL BIOL, V153, P457, DOI 10.1083/jcb.153.3.457; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Levresse V, 2000, J NEUROSCI RES, V62, P799; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Oriente F, 2001, J BIOL CHEM, V276, P37109, DOI 10.1074/jbc.M104405200; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schlesinger TK, 1998, FRONT BIOSCI, V3, P1181; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WOODGETT JR, 2001, SCI STKE; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	51	75	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13995	14001		10.1074/jbc.M300253200	http://dx.doi.org/10.1074/jbc.M300253200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584189	hybrid			2022-12-27	WOS:000182405000057
J	Stiewe, T; Stanelle, J; Theseling, CC; Pollmeier, B; Beitzinger, M; Putzer, BM				Stiewe, T; Stanelle, J; Theseling, CC; Pollmeier, B; Beitzinger, M; Putzer, BM			Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER TISSUES; EXPRESSION; GENE; DELTA-NP73; PROTEIN; OVEREXPRESSION; NEUROBLASTOMA; TRANSCRIPTION; HOMOLOG; BINDING	The p53 family includes three members that share significant sequence homology, yet exhibit fundamentally different functions in tumorigenesis. Whereas p53 displays all characteristics of a classical tumor suppressor, its homologues p63 and p73 do not. We have previously shown, that NH2-terminally truncated isoforms of p73 (DeltaTA-p73), which act as dominant-negative inhibitors of p53 are frequently overexpressed in cancer cells. Here we provide evidence that DeltaTA-p73 isoforms also affect the retinoblastoma protein (RB) tumor suppressor pathway independent of p53. DeltaTA-p73 isoforms inactivate RB by increased phosphorylation, resulting in enhanced E2F activity and proliferation of fibroblasts. By inactivating the two major tumor suppressor pathways in human cells they act functionally analogous to several viral oncoproteins. These findings provide an explanation for the fundamentally different functions of p53 and p73 in tumorigenesis.	Univ Essen Gesamthsch, Ctr Canc Res & Canc Therapy, Inst Mol Biol, D-45122 Essen, Germany; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany	University of Duisburg Essen; University of Wurzburg	Putzer, BM (corresponding author), Univ Essen Gesamthsch, Ctr Canc Res & Canc Therapy, Inst Mol Biol, Hufelandstr 55, D-45122 Essen, Germany.	brigitte.puetzer@uni-essen.de		Stiewe, Thorsten/0000-0003-0134-7826				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Chen CL, 2000, CLIN CANCER RES, V6, P3910; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dominguez G, 2001, BREAST CANCER RES TR, V66, P183, DOI 10.1023/A:1010624717311; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishimoto O, 2002, CANCER RES, V62, P636; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; O'Nions J, 2001, BRIT J CANCER, V85, P1551, DOI 10.1054/bjoc.2001.2138; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Senoo M, 2001, BIOCHEM BIOPH RES CO, V286, P628, DOI 10.1006/bbrc.2001.5429; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Stiewe T, 2002, CANCER RES, V62, P3598; STIEWE T, 2002, CANCER RES, V277, P14177; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Thompson JB, 2000, PETROLOGY+, V8, P303; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	54	38	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14230	14236		10.1074/jbc.M300357200	http://dx.doi.org/10.1074/jbc.M300357200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584188	hybrid			2022-12-27	WOS:000182405000085
J	Im, H; Park, C; Feng, Q; Johnson, KD; Kiekhaefer, CM; Choi, K; Zhang, Y; Bresnick, EH				Im, H; Park, C; Feng, Q; Johnson, KD; Kiekhaefer, CM; Choi, K; Zhang, Y; Bresnick, EH			Dynamic regulation of histone H3 methylated at lysine 79 within a tissue-specific chromatin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NF-E2; LOCUS-CONTROL REGION; RNA-POLYMERASE-II; BETA-GLOBIN LOCUS; NUCLEOSOMAL DNA; ACTIVE GENES; IN-VITRO; HP1; ACETYLATION; EXPRESSION	Post-translational modifications of individual lysine residues of core histones can exert unique functional consequences. For example, methylation of histone H3 at lysine 79 (H3-meK79) has been implicated recently in gene silencing in Saccharomyces cerevisiae. However, the distribution and function of H3-meK79 in mammalian chromatin are not known. We found that H3-meK79 has a variable distribution within the murine beta-globin locus in adult erythroid cells, being preferentially enriched at the active betamajor gene. By contrast, acetylated H3 and H4 and H3 methylated at lysine 4 were enriched both at betamajor and at the upstream locus control region. H3-meK79 was also enriched at the active cad gene, whereas the transcriptionally inactive loci necdin and MyoD1 contained very little H3-meK79. As the pattern of H3-meK79 at the beta-globin locus differed between adult and embryonic erythroid cells, establishment and/or maintenance of H3-meK79 was developmentally dynamic. Genetic complementation analysis in null cells lacking the erythroid and megakaryocyte-specific transcription factor p45/NF-E2 showed that p45/NF-E2 preferentially establishes H3-meK79 at the betamajor promoter. These results support a model in which H3-meK79 is strongly enriched in mammalian chromatin at active genes but not uniformly throughout active chromatin domains. As H3-meK79 is highly regulated at the beta-globin locus, we propose that the murine ortholog of Disruptor of Telomeric Silencing-1-like (mDOT1L) methyltransferase, which synthesizes H3-meK79, regulates beta-globin transcription.	Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dev Biol Program, St Louis, MO 63110 USA; Univ N Carolina, Dept Biochem & Biophys, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill	Bresnick, EH (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, Mol & Cellular Pharmacol Program, 1300 Univ Ave,383 Med Sci Ctr, Madison, WI 53706 USA.			Zhang, Yi/0000-0002-2789-0811	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050107, R01DK055700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063067] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL07936] Funding Source: Medline; NIDDK NIH HHS [DK50107, DK55700] Funding Source: Medline; NIGMS NIH HHS [GM63067] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; BRESNICK EH, 1991, BIOCHEMISTRY-US, V30, P3490, DOI 10.1021/bi00228a020; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Im H, 2002, BIOCHEMISTRY-US, V41, P15152, DOI 10.1021/bi026786q; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Johnson KD, 2002, P NATL ACAD SCI USA, V99, P11760, DOI 10.1073/pnas.192285999; Johnson KD, 2001, MOL CELL, V8, P465, DOI 10.1016/S1097-2765(01)00309-4; Kabrun N, 1997, DEVELOPMENT, V124, P2039; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; Mosser EA, 1998, BIOCHEMISTRY-US, V37, P13686, DOI 10.1021/bi981310l; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; NUDEL U, 1977, P NATL ACAD SCI USA, V74, P1100, DOI 10.1073/pnas.74.3.1100; San-Segundo PA, 2000, MOL BIOL CELL, V11, P3601, DOI 10.1091/mbc.11.10.3601; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schubeler D, 2001, P NATL ACAD SCI USA, V98, P11432, DOI 10.1073/pnas.201394698; Singer MS, 1998, GENETICS, V150, P613; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200	45	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18346	18352		10.1074/jbc.M300890200	http://dx.doi.org/10.1074/jbc.M300890200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12604594	Green Published, hybrid			2022-12-27	WOS:000182838300099
J	Gu, Y; Xu, YC; Wu, RF; Nwariaku, FE; Souza, RF; Flores, SC; Terada, LS				Gu, Y; Xu, YC; Wu, RF; Nwariaku, FE; Souza, RF; Flores, SC; Terada, LS			p47(phox) participates in activation of RelA in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PHAGOCYTE NADPH OXIDASE; TUMOR-NECROSIS-FACTOR; AMINO-TERMINAL KINASE; TRANSCRIPTION FACTOR; SH3 DOMAIN; IL-1 RECEPTOR; P65 SUBUNIT; PHOSPHATIDYLINOSITOL 3-KINASE; DEPENDENT MECHANISM	Activation of endothelial cell NF-kappaB by interleukin (IL)-1 constitutes an event critical to the progression of the innate immune response. In this context, oxidants have been associated with NF-kappaB activation, although the molecular source and mechanism of targeting have remained obscure. We found that RelA, essential for NF-kappaB activation by IL-1, was associated with the NADPH oxidase adapter protein p47(phox) in yeast two-hybrid, coprecipitation, and in vitro binding studies. RelA and p47-GFP also colocalized in endothelial cells in focal submembranous dorsoventral protrusions. Overexpression of p47(phox) synergized with IL-1beta in the activation of an artificial kappaB-luciferase reporter and specifically augmented IL-1beta-induced RelA transactivation activity. p47(phox) overexpression also greatly increased IL-1beta-stimulated RelA phosphorylation, whereas it had no effect on I-kappaB degradation or on RelA nuclear translocation or kappaB binding. The tandem SH3 domains of p47(phox) were found to associate with a proline-rich mid-region of RelA (RelA-PR) located between the Rel homology and transactivation domains. The RelA-PR peptide blocked interaction of p47(phox) and RelA, and ectopic expression of RelA-PR abrogated IL-1beta-induced transactivation of the NF-kappaB-dependent E-selectin promoter. Further, suppression of NADPH oxidase function through the inhibitor diphenylene iodonium, the superoxide dismutase mimetic Mn(III) tetrakis(4-benzoic acid) porphyrin ( MnTBAP), or expression of a dominant interfering mutant of a separate NADPH oxidase subunit (p67(V204A)) decreased IL-1beta-induced E-selectin promoter activation, suggesting that p47(phox) facilitates NF-kappaB activation through linkage with the NADPH oxidase. IL-1beta rapidly increased tyrosine phosphorylation of IL-1 type I receptor-associated proteins, suggesting that oxidants may operate through inactivation of local protein-tyrosine phosphatases in the proximal IL-1beta signaling pathway leading to RelA activation.	Dallas Vet Affairs Med Ctr, Dallas, TX 75216 USA; Webb Waring Lung Inst, Denver, CO 80262 USA; Univ Texas SW, Dept Internal Med, Dallas, TX 75216 USA; Univ Texas SW, Dept Surg, Dallas, TX 75216 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Terada, LS (corresponding author), Dallas Vet Affairs Med Ctr, MC 151,4500 S Lancaster Rd, Dallas, TX 75216 USA.			Terada, Lance/0000-0001-7441-9734	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061897, R01HL067256] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL067256, R01-HL67256, R01 HL061897, R01-HL61897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abid MR, 2000, FEBS LETT, V486, P252, DOI 10.1016/S0014-5793(00)02305-X; Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Are AF, 2000, EXP CELL RES, V256, P533, DOI 10.1006/excr.2000.4830; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chintala SK, 1998, J BIOL CHEM, V273, P13545, DOI 10.1074/jbc.273.22.13545; Cota-Gomez A, 2002, J BIOL CHEM, V277, P14390, DOI 10.1074/jbc.M108591200; Dahan I, 2002, J BIOL CHEM, V277, P8421, DOI 10.1074/jbc.M109778200; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; Gu Y, 2002, EXP CELL RES, V272, P62, DOI 10.1006/excr.2001.5404; Gu Y, 2001, VIROLOGY, V286, P62, DOI 10.1006/viro.2001.0998; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Jefferies C, 2001, MOL CELL BIOL, V21, P4544, DOI 10.1128/MCB.21.14.4544-4552.2001; Jefferies CA, 2000, J BIOL CHEM, V275, P3114, DOI 10.1074/jbc.275.5.3114; Johnson JL, 1998, J BIOL CHEM, V273, P35147, DOI 10.1074/jbc.273.52.35147; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; Li JM, 2002, J BIOL CHEM, V277, P19952, DOI 10.1074/jbc.M110073200; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Marmiroli S, 1998, FEBS LETT, V438, P49, DOI 10.1016/S0014-5793(98)01270-8; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takehana K, 2002, BIOCHEM BIOPH RES CO, V293, P945, DOI 10.1016/S0006-291X(02)00322-4; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wei ZH, 1999, CIRC RES, V85, P682, DOI 10.1161/01.RES.85.8.682; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu YX, 2002, J BIOL CHEM, V277, P28051, DOI 10.1074/jbc.M202665200; Yoza BK, 1996, J BIOL CHEM, V271, P18306, DOI 10.1074/jbc.271.31.18306; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	54	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17210	17217		10.1074/jbc.M210314200	http://dx.doi.org/10.1074/jbc.M210314200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618429	hybrid			2022-12-27	WOS:000182818600103
J	Jiang, ZF; Zamanian-Daryoush, M; Nie, HQ; Silva, AM; Williams, BRG; Li, XX				Jiang, ZF; Zamanian-Daryoush, M; Nie, HQ; Silva, AM; Williams, BRG; Li, XX			Poly(dI center dot dC)-induced toll-like receptor 3 (TLR3)-mediated activation of NF kappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; INNATE IMMUNE-RESPONSE; IL-1 RECEPTOR; ADAPTER MOLECULE; GENE-EXPRESSION; DROSOPHILA TOLL; PROTEIN; TAK1; ALPHA; IRAK	Recent studies show that a member of the interleukin-1 (IL-1)/Toll receptor superfamily, Toll-like receptor 3 (TLR3), recognizes double-stranded RNA (dsRNA). Because of the similarity in their cytoplasmic domains, IL-1/Toll receptors share signaling components that associate with the IL-1 receptor, including IL-1 receptor-associated kinase (IRAK), MyD88, and TRAF6. However, we find that, in response to dsRNA, TLR3 can mediate the activation of both NFkappaB and mitogen-activated protein (MAP) kinases in IL-1-unresponsive mutant cell lines, including IRAK-deficient I1A and I3A cells, which are defective in a component that is downstream of IL-1R but upstream of IRAK. These results clearly indicate that TLR3 does not simply share the signaling components employed by the IL-1 receptor. Through biochemical analyses we have identified an IRAK-independent TLR3-mediated pathway. Upon binding of dsRNA to TLR3, TRAF6, TAK1, and TAB2 are recruited to the receptor to form a complex, which then translocates to the cytosol where TAK1 is phosphorylated and activated. The dsRNA-dependent protein kinase (PKR) is also detected in this signal-induced TAK1 complex. Kinase inactive mutants of TAK1 (TAK1DN) and PKR (PKRDN) inhibit poly(dI.dC)-induced TLR3-mediated NFkappaB activation, suggesting that both of these kinases play important roles in this pathway.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Li, XX (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151; Silva, Aristobolo/0000-0001-7473-7433	NIGMS NIH HHS [GM 600020] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; LORD KA, 1990, ONCOGENE, V5, P1095; Lovenberg TW, 1996, J NEUROIMMUNOL, V70, P113, DOI 10.1016/S0165-5728(96)00047-1; Majumder S, 1998, J NEUROSCI RES, V54, P169, DOI 10.1002/(SICI)1097-4547(19981015)54:2<169::AID-JNR5>3.0.CO;2-C; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Parnet P, 1996, J BIOL CHEM, V271, P3967; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thomassen E, 1999, CYTOKINE, V11, P389, DOI 10.1006/cyto.1998.0452; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	55	249	259	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16713	16719		10.1074/jbc.M300562200	http://dx.doi.org/10.1074/jbc.M300562200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609980	hybrid			2022-12-27	WOS:000182818600036
J	Gorlatova, NV; Elokdah, H; Fan, K; Crandall, DL; Lawrence, DA				Gorlatova, NV; Elokdah, H; Fan, K; Crandall, DL; Lawrence, DA			Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis - Implications for serpin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE CENTER LOOP; ATHEROSCLEROTIC HUMAN ARTERIES; INDUCED PULMONARY FIBROSIS; BETA-SHEET-A; PROTEASE COMPLEXES; ANTITHROMBIN-III; STRUCTURAL BASIS; HEPARIN-BINDING; BOND LOOP; MECHANISM	The mechanism for the conversion of plasminogen activator inhibitor-1 (PAI-1) from the active to the latent conformation is not well understood. Recently, a monoclonal antibody, 33138, was described that rapidly converts PAI-1 to the latent conformation (Verhamme, I., Kvassman, J. O., Day, D., Debrock, S., Vleugels, N., Declerck, P. J., and Shore, J. D. (1999) J. Biol. Chem. 274, 17511-17517). In an attempt to understand this interaction, and more broadly to understand the mechanism of the natural transition of PAI-1 to the latent conformation, we have used random mutagenesis to identify the 33B8 epitope in PAI-1. This site involves at least 8 amino acids scattered over more than two-thirds of the linear sequence that form a compact epitope on the PAI-1 three-dimensional structure. Surface plasmon resonance studies indicate a high affinity interaction between latent PAI-1 and 33B8 that is similar to100-fold higher than comparable binding to active PALL Structural modeling results together with surface plasmon resonance analysis of parental and site-directed PAI-1 mutants with disrupted 33B8 binding suggest the existence of a specific PAI-1 intermediate structure that is stabilized by 33B8 binding. These analyses strongly suggest that this intermediate form of PAI-1 has a partial insertion of the reactive center loop into beta-sheet A, and together, these data have significant implications for the general serpin mechanism of proteinase inhibition..	Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; Wyeth Res, Collegeville, PA 19426 USA; Wyeth Res, Princeton, NJ 08543 USA	American Red Cross; Pfizer; Pfizer	Lawrence, DA (corresponding author), Amer Red Cross, Holland Lab, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055374, R01HL055747] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 55747, HL 55374] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Belzar KJ, 2002, J BIOL CHEM, V277, P8551, DOI 10.1074/jbc.M110807200; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BJORK I, 1992, J BIOL CHEM, V267, P1976; BJORK I, 1992, J BIOL CHEM, V267, P19047; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; Carrell RW, 1992, CURR OPIN STRUC BIOL, V2, P438; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; Eitzman DT, 2000, BLOOD, V96, P4212; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; FA M, 1995, BIOCHEMISTRY-US, V34, P13833, DOI 10.1021/bi00042a015; Farrehi PM, 1998, CIRCULATION, V97, P1002; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; HAMSTEN A, 1987, LANCET, V2, P3; Hattori N, 2000, J CLIN INVEST, V106, P1341, DOI 10.1172/JCI10531; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; JUHANVAGUE I, 1987, THROMB HAEMOSTASIS, V57, P67; JuhanVague I, 1997, THROMB HAEMOSTASIS, V78, P656; Koh KK, 1997, NEW ENGL J MED, V336, P683, DOI 10.1056/NEJM199703063361002; Kvassman JO, 1998, BIOCHEMISTRY-US, V37, P15491, DOI 10.1021/bi9814787; KVASSMAN JO, 1995, J BIOL CHEM, V270, P27942, DOI 10.1074/jbc.270.46.27942; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Olson ST, 2001, BIOCHEMISTRY-US, V40, P11742, DOI 10.1021/bi0107290; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; SCHNEIDERMAN J, 1992, P NATL ACAD SCI USA, V89, P6998, DOI 10.1073/pnas.89.15.6998; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Siemens HJG, 1999, J CLIN ANESTH, V11, P622, DOI 10.1016/S0952-8180(99)00119-1; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Taatjes DJ, 1997, ULTRASTRUCT PATHOL, V21, P527, DOI 10.3109/01913129709016369; VANBOECKEL CAA, 1994, NAT STRUCT BIOL, V1, P423, DOI 10.1038/nsb0794-423; Vaughan DE, 1998, J INVEST MED, V46, P370; Verhamme I, 1999, J BIOL CHEM, V274, P17511, DOI 10.1074/jbc.274.25.17511; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	45	37	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16329	16335		10.1074/jbc.M208420200	http://dx.doi.org/10.1074/jbc.M208420200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12606560	hybrid			2022-12-27	WOS:000182680000111
J	Laursen, BS; Mortensen, KK; Sperling-Petersen, HU; Hoffman, DW				Laursen, BS; Mortensen, KK; Sperling-Petersen, HU; Hoffman, DW			A conserved structural motif at the N terminus of bacterial translation initiation factor IF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA BINDING; GLUTAMINYL-TRANSFER-RNA; ESCHERICHIA-COLI; RIBOSOMAL-SUBUNITS; BACKBONE DYNAMICS; NMR RELAXATION; INFB GENE; PROTEIN; MODEL; SYNTHETASE	The 18-kDa Domain I from the N-terminal region of translation initiation factor IF2 from Escherichia coli was expressed, purified, and structurally characterized using multidimensional NMR methods. Residues 2-50 were found to form a compact subdomain containing three short beta-strands and three a-helices, folded to form a betaalphabetabetaalpha motif with the three helices packed on the same side of a small twisted beta-sheet. The hydrophobic amino acids in the core of the subdomain are conserved in a wide range of species, indicating that a similarly structured motif is present at the N terminus of IF2 in many of the bacteria. External to the compact 50-amino acid subdomain, residues 51-97 are less conserved and do not appear to form a regular structure, whereas residues 98-157 form a helix containing a repetitive sequence of mostly hydrophilic amino acids. Nitrogen-15 relaxation rate measurements provide evidence that the first 50 residues form a well ordered subdomain, whereas other regions of Domain I are significantly more mobile. The compact subdomain at the N terminus of IF2 shows structural homology to the tRNA anticodon stem contact fold domains of the methionyl-tRNA and glutaminyl-tRNA synthetases, and a similar fold is also found in the B5 domain of the phenylalanine-tRNA synthetase. The results of the present work will provide guidance for the design of future experiments directed toward understanding the functional roles of this widely conserved structural domain within IF2.	Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus, Denmark; Univ Texas, Inst Cellular & Mol Biol, Dept Biochem & Chem, Austin, TX 78712 USA	Aarhus University; University of Texas System; University of Texas Austin	Sperling-Petersen, HU (corresponding author), Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus, Denmark.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Boelens R, 2002, CURR PROTEIN PEPT SC, V3, P107, DOI 10.2174/1389203023380765; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi SK, 1998, SCIENCE, V280, P1757, DOI 10.1126/science.280.5370.1757; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FOLKERS PJM, 1993, J AM CHEM SOC, V115, P3798, DOI 10.1021/ja00062a065; Gualerzi CO, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P477; Guenneugues M, 2000, EMBO J, V19, P5233, DOI 10.1093/emboj/19.19.5233; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOWE JG, 1983, J BIOL CHEM, V258, P1954; Kyrpides NC, 1998, P NATL ACAD SCI USA, V95, P224, DOI 10.1073/pnas.95.1.224; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Laursen BS, 2002, GENES CELLS, V7, P901, DOI 10.1046/j.1365-2443.2002.00571.x; Lillemoen J, 1998, J MOL BIOL, V281, P539, DOI 10.1006/jmbi.1998.1946; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Mechulam Y, 1999, J MOL BIOL, V294, P1287, DOI 10.1006/jmbi.1999.3339; Meunier S, 2000, EMBO J, V19, P1918, DOI 10.1093/emboj/19.8.1918; Moreno JMP, 1998, BIOCHEM BIOPH RES CO, V252, P465, DOI 10.1006/bbrc.1998.9664; Moreno JMP, 2000, IUBMB LIFE, V50, P347, DOI 10.1080/713803743; Moreno JMP, 1999, FEBS LETT, V455, P130, DOI 10.1016/S0014-5793(99)00858-3; MORTENSEN KK, 1995, BIOCHEM BIOPH RES CO, V214, P1254, DOI 10.1006/bbrc.1995.2421; Mortensen KK, 1998, BIOCHEM MOL BIOL INT, V46, P1027; NYENGAARD NR, 1991, BIOCHEM BIOPH RES CO, V181, P1572, DOI 10.1016/0006-291X(91)92118-4; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; Pestova TV, 2000, NATURE, V403, P332, DOI 10.1038/35002118; PETERSEN HU, 1981, FEBS LETT, V128, P161, DOI 10.1016/0014-5793(81)81105-2; PETERSEN HU, 1984, BIOCHIMIE, V66, P625, DOI 10.1016/0300-9084(84)90116-0; Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0; Roll-Mecak A, 2000, CELL, V103, P781, DOI 10.1016/S0092-8674(00)00181-1; SACERDOT C, 1992, J MOL BIOL, V225, P67, DOI 10.1016/0022-2836(92)91026-L; Sherman JM, 1996, J MOL BIOL, V256, P818, DOI 10.1006/jmbi.1996.0128; Sorensen HP, 2001, IUBMB LIFE, V51, P321; Spurio R, 2000, J BIOL CHEM, V275, P2447, DOI 10.1074/jbc.275.4.2447; Steffensen SAD, 1997, FEBS LETT, V419, P281; Sugiura I, 2000, STRUCTURE, V8, P197, DOI 10.1016/S0969-2126(00)00095-2; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Yusupova G, 1996, BIOCHEMISTRY-US, V35, P2978, DOI 10.1021/bi9519415	40	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16320	16328		10.1074/jbc.M212960200	http://dx.doi.org/10.1074/jbc.M212960200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600987	hybrid			2022-12-27	WOS:000182680000110
J	Loris, R; Imberty, A; Beeckmans, S; Van Driessche, E; Read, JS; Bouckaertt, J; De Greve, H; Buts, L; Wyns, L				Loris, R; Imberty, A; Beeckmans, S; Van Driessche, E; Read, JS; Bouckaertt, J; De Greve, H; Buts, L; Wyns, L			Crystal structure of Pterocarpus angolensis lectin in complex with glucose, sucrose, and turanose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; X-RAY; CARBOHYDRATE-RECOGNITION; BINDING-SITE; GRIFFONIA-SIMPLICIFOLIA; MOLECULAR-DYNAMICS; PLANT-LECTINS; LENTIL LECTIN; ISOLECTIN-I; CONCANAVALIN	The crystal structure of the Man/Glc-specific seed lectin from Pterocarpus angolensis was determined in complex with methyl-alpha-D-glucose, sucrose, and turanose. The carbohydrate binding site contains a classic Man/Glc type specificity loop. Its metal binding loop on the other hand is of the long type, different from what is observed in other Man/Glc-specific legume lectins. Glucose binding in the primary binding site is reminiscent of the glucose complexes of concanavalin A and lentil lectin. Sucrose is found to be bound in a conformation similar as seen in the binding site of lentil lectin. A direct hydrogen bond between Ser-137(OG) to Fru(02) in Pterocarpus angolensis lectin replaces a water-mediated interaction in the equivalent complex of lentil lectin. In the turanose complex, the binding site of the first molecule in the asymmetric unit contains the alphaGlc1-3betaFruf form of furanose while the second molecule contains the alphaGlc1-3betaFrup form in its binding site.	Free Univ Brussels, ULTR, Inst Mol Biol, Lab Ultrastructuur, B-1050 Brussels, Belgium; CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble 09, France; Free Univ Brussels, Lab Scheikunde Prot, Inst Mol Biol, B-1050 Brussels, Belgium; Univ Zimbabwe, Dept Biochem, Harare, Zimbabwe	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Zimbabwe	Loris, R (corresponding author), Free Univ Brussels, ULTR, Inst Mol Biol, Lab Ultrastructuur, Pleinlaan 2, B-1050 Brussels, Belgium.	reloris@vub.ac.be	Loris, Remy/GPG-0894-2022; Imberty, Anne/P-6451-2018	Bouckaert, Julie/0000-0001-8112-1442; Loris, Remy/0000-0002-8862-3338; Imberty, Anne/0000-0001-6825-9527				ALLINGER NL, 1990, J AM CHEM SOC, V112, P8293, DOI 10.1021/ja00179a012; Angata T, 2002, BBA-GEN SUBJECTS, V1572, P294, DOI 10.1016/S0304-4165(02)00316-1; ANGYAL SJ, 1984, ADV CARBOHYD CHEM BI, V42, P15, DOI 10.1016/S0065-2318(08)60122-5; Audette GF, 2000, J MOL BIOL, V304, P423, DOI 10.1006/jmbi.2000.4214; AVELEL D, 1976, ACTA CRYSTALLOGR B, V32, P2598; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Barre A, 2001, BIOCHIMIE, V83, P645, DOI 10.1016/S0300-9084(01)01315-3; BECQUART J, 1982, CARBOHYD RES, V111, P9, DOI 10.1016/0008-6215(82)85002-7; Bouckaert J, 1999, CURR OPIN STRUC BIOL, V9, P572, DOI 10.1016/S0959-440X(99)00007-X; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BOURNE Y, 1990, J MOL BIOL, V214, P571, DOI 10.1016/0022-2836(90)90199-V; Bradbrook GM, 1998, J CHEM SOC FARADAY T, V94, P1603, DOI 10.1039/a800429c; BROWN GM, 1973, ACTA CRYSTALLOGR B, VB 29, P790, DOI 10.1107/S0567740873003353; Bush CA, 1999, ANNU REV BIOPH BIOM, V28, P269, DOI 10.1146/annurev.biophys.28.1.269; Buts L, 2001, J MOL BIOL, V309, P193, DOI 10.1006/jmbi.2001.4639; CASSET F, 1995, J BIOL CHEM, V270, P25619, DOI 10.1074/jbc.270.43.25619; Cebo C, 2002, BBA-GEN SUBJECTS, V1572, P422, DOI 10.1016/S0304-4165(02)00323-9; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DODDRELL D, 1971, J AM CHEM SOC, V93, P2779; DOWD MK, 1993, J CARBOHYD CHEM, V12, P449, DOI 10.1080/07328309308019400; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; DUPENHOAT CH, 1991, J AM CHEM SOC, V113, P3720; EDELMAN GM, 1972, P NATL ACAD SCI USA, V69, P2580, DOI 10.1073/pnas.69.9.2580; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; Engelsen SB, 1997, J MOL GRAPH MODEL, V15, P122; ENGELSEN SB, 1995, J PHYS CHEM-US, V99, P13334, DOI 10.1021/j100036a005; FRENCH AD, 1990, BIOPOLYMERS, V29, P1599, DOI 10.1002/bip.360291210; Hamelryck TW, 2000, J MOL BIOL, V299, P875, DOI 10.1006/jmbi.2000.3785; HANSON JC, 1973, ACTA CRYSTALLOGR B, V29, P797, DOI 10.1107/S0567740873003365; Harrop SJ, 1996, ACTA CRYSTALLOGR D, V52, P143, DOI 10.1107/S0907444995008742; Imberty A, 2000, CHEM REV, V100, P4567, DOI 10.1021/cr990343j; Imberty A, 2000, J BIOL CHEM, V275, P17541, DOI 10.1074/jbc.M000560200; IMBERTY A, 1999, PERSPECTIVES STRUCTU, P392; Kawabata S, 2002, BBA-GEN SUBJECTS, V1572, P414, DOI 10.1016/S0304-4165(02)00322-7; Klemm P, 2000, INT J MED MICROBIOL, V290, P27; Lescar J, 2002, J BIOL CHEM, V277, P6608, DOI 10.1074/jbc.M109867200; Loris R, 2002, BBA-GEN SUBJECTS, V1572, P198, DOI 10.1016/S0304-4165(02)00309-4; LORIS R, 1994, GLYCOCONJUGATE J, V11, P507, DOI 10.1007/BF00731301; LORIS R, 1993, BIOCHEMISTRY-US, V32, P8772, DOI 10.1021/bi00085a007; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; Loris R, 2000, J MOL BIOL, V301, P987, DOI 10.1006/jmbi.2000.4016; Manoj N, 2000, J MOL BIOL, V302, P1129, DOI 10.1006/jmbi.2000.4111; Moothoo DN, 1999, GLYCOBIOLOGY, V9, P539, DOI 10.1093/glycob/9.6.539; Mouricout M, 1997, ADV EXP MED BIOL, V412, P109; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEUMAN A, 1978, ACTA CRYSTALLOGR B, V34, P242, DOI 10.1107/S056774087801451X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perez S., 2000, OLIGOSACCHARIDES CHE, P969; POPPE L, 1992, J AM CHEM SOC, V114, P1092, DOI 10.1021/ja00029a051; Prabu MM, 1998, J MOL BIOL, V276, P787, DOI 10.1006/jmbi.1997.1568; ROUSSEL A, 1989, SILICON GRAPHIC GEOM, P71; Rozwarski DA, 1998, J BIOL CHEM, V273, P32818, DOI 10.1074/jbc.273.49.32818; SanzAparicio J, 1997, FEBS LETT, V405, P114, DOI 10.1016/S0014-5793(97)00137-3; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999; Tempel W, 2002, J BIOL CHEM, V277, P6615, DOI 10.1074/jbc.M109919200; TRAN VH, 1990, BIOPOLYMERS, V29, P961, DOI 10.1002/bip.360290609; VANDRIESSCHE E, 2000, LECTINS PATHOLOGY, P133; Vijayan M, 1999, CURR OPIN STRUC BIOL, V9, P707, DOI 10.1016/S0959-440X(99)00034-2; Wah DA, 2001, J MOL BIOL, V310, P885, DOI 10.1006/jmbi.2001.4814	63	34	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16297	16303		10.1074/jbc.M211148200	http://dx.doi.org/10.1074/jbc.M211148200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595543	hybrid			2022-12-27	WOS:000182680000106
J	Meyer, RD; Latz, C; Rahimi, N				Meyer, RD; Latz, C; Rahimi, N			Recruitment and activation of phospholipase C gamma 1 by vascular endothelial growth factor receptor-2 are required for tubulogenesis and differentiation of endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; POINT MUTATION; EGF RECEPTOR; SH2 DOMAINS; PLC-GAMMA; NEUROPILIN-1; MITOGENESIS; SIGNAL	Vascular endothelial growth factor-mediated angiogenic signal transduction relay is achieved by coordinated induction of endothelial cell proliferation, migration, and differentiation. These complex cellular processes are most likely controlled by activation of both cooperative and antagonistic signals by vascular endothelial growth factor receptors (VEGFRs). Here, we investigated the contribution of tyrosine-phosphorylated residues of VEGFR-2/fetal liver kinase-1 to endothelial cell proliferation and differentiation and activation of signaling proteins. Mutation of tyrosine 1006 of VEGFR-2 to phenylalanine severely impaired the ability of this receptor to stimulate endothelial cell differentiation and tubulogenesis. Paradoxically, the mutant receptor stimulated endothelial cell proliferation far better than the wild-type receptor. Further analysis showed that tyrosine 1006 is responsible for phospholipase Cgamma1 (PLCgamma1) activation and intracellular calcium release in endothelial cells. Activation of PLCgamma1 was selectively mediated by tyrosine 1006. Mutation of tyrosines 799, 820, 949, 994, 1080, 1173, and 1221 had no measurable effect on the ability of VEGFR-2 to stimulate PLCgamma1 activation. Association of VEGFR-2 with PLCgamma1 was mainly established between tyrosine 1006 and the C-terminal SH2 domain of PLCgamma1 in vitro and in vivo. Taken together, the results indicate that phosphorylation of tyrosine 1006 is essential for VEGFR-2-mediated PLCgamma1 activation, calcium flux, and cell differentiation. More importantly, VEGFR-2-mediated endothelial cell proliferation is inversely correlated with the ability of VEGFR-2 to associate with and activate PLCgamma1.	Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Rahimi, N (corresponding author), Boston Univ, Sch Med, Dept Ophthalmol, Rm L921,715 Albany St, Boston, MA 02118 USA.	nrahimi@bu.edu	Latz, Catharina/AAM-9079-2020	Rahimi, Nader/0000-0002-6745-1725	NEI NIH HHS [R03 EY013706, EY 012997, R01 EY012997] Funding Source: Medline; NATIONAL EYE INSTITUTE [R03EY013706, R01EY012997] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Cross MJ, 2000, J CELL SCI, V113, P643; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V240, P635, DOI 10.1006/bbrc.1997.7719; Dayanir V, 2001, J BIOL CHEM, V276, P17686, DOI 10.1074/jbc.M009128200; Derman MP, 1996, J BIOL CHEM, V271, P4251; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Ji QS, 1999, MOL CELL BIOL, V19, P4961; Klepeis VE, 2001, J CELL SCI, V114, P4185; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; MARGOLIS B, 1990, SCIENCE, V248, P607, DOI 10.1126/science.2333512; Meyer RD, 2002, J BIOL CHEM, V277, P27081, DOI 10.1074/jbc.M110544200; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Poulin B, 2000, J BIOL CHEM, V275, P6411, DOI 10.1074/jbc.275.9.6411; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Rahimi N, 1999, MOL BIOL CELL, V10, P3401, DOI 10.1091/mbc.10.10.3401; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Xie ZJ, 1999, J BIOL CHEM, V274, P20421, DOI 10.1074/jbc.274.29.20421	33	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16347	16355		10.1074/jbc.M300259200	http://dx.doi.org/10.1074/jbc.M300259200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598525	Green Accepted, hybrid			2022-12-27	WOS:000182680000113
J	Qian, Y; Luo, J; Leonard, SS; Harris, GK; Millecchia, L; Flynn, DC; Shi, XL				Qian, Y; Luo, J; Leonard, SS; Harris, GK; Millecchia, L; Flynn, DC; Shi, XL			Hydrogen peroxide formation and actin filament reorganization by Cdc42 are essential for ethanol-induced in vitro angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; CELL-MIGRATION; GASTRIC-MUCOSA; GROWTH; ALCOHOL; CANCER; SRC; CYTOSKELETON; ACTIVATION; EXPRESSION	This report focuses on the identification of the molecular mechanisms of ethanol-induced in vitro angiogenesis. The manipulation of angiogenesis is an important therapeutic approach for the treatment of cancer, cardiovascular diseases, and chronic inflammation. Our results showed that ethanol stimulation altered the integrity of actin filaments and increased the formation of lamellipodia and filopodia in SVEC4-10 cells. Further experiments demonstrated that ethanol stimulation increased cell migration and invasion and induced in vitro angiogenesis in SVEC4-10 cells. Mechanistically, ethanol stimulation activated Cdc42 and produced H2O2 a reactive oxygen species intermediate in SVEC4-10 cells. Measuring the time course of Cdc42 activation and H2O2 production upon ethanol stimulation revealed that the Cdc42 activation and the increase of H2O2 lasted more than 3 h, which indicates the mechanisms of the long duration effects of ethanol on the cells. Furthermore, either overexpression. of a constitutive dominant negative Cdc42 or inhibition of H2O2 production abrogated the effects of ethanol on SVEC4-10 cells, indicating that both the activation of Cdc42 and the production of H2O2 are essential for the actions of ethanol. Interestingly, we also found that overexpression. of a constitutive dominant positive Cdc42 itself was sufficient to produce H2O2 and to induce in vitro angiogenesis. Taken together, our results suggest that ethanol stimulation can induce H2O2 production through the activation of Cdc42, which results in reorganizing actin filaments and increasing cell motility and in vitro angiogenesis.	NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA; W Virginia Univ, Mary Bobb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); West Virginia University; West Virginia University	Qian, Y (corresponding author), NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA.	yaq2@cdc.gov	Shi, Xianglin/B-8588-2012; Luo, Jia/E-4674-2012	Luo, Jia/0000-0002-6968-3618				Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BLOT WJ, 1992, CANCER RES, V52, pS2119; Brown MD, 2000, J NEUROBIOL, V43, P352, DOI 10.1002/1097-4695(20000615)43:4<352::AID-NEU4>3.0.CO;2-T; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHURCH MW, 1988, PEDIATRICS, V82, P147; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Gu JW, 2001, AM J PHYSIOL-REG I, V281, pR365, DOI 10.1152/ajpregu.2001.281.1.R365; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Jones MK, 1999, AM J PHYSIOL-GASTR L, V276, pG1345, DOI 10.1152/ajpgi.1999.276.6.G1345; Jones MK, 1998, BIOCHEM BIOPH RES CO, V249, P118, DOI 10.1006/bbrc.1998.9095; Khayat ZA, 2000, J CELL SCI, V113, P279; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59; Li SJ, 2000, CANCER RES, V60, P3927; Luo J, 1997, ALCOHOL CLIN EXP RES, V21, P1186, DOI 10.1111/j.1530-0277.1997.tb04436.x; Luo J, 1996, J NEUROCHEM, V67, P1448; Luo J, 2000, BREAST CANCER RES TR, V63, P61, DOI 10.1023/A:1006436315284; Maeda M, 1998, CANCER, V83, P1483, DOI 10.1002/(SICI)1097-0142(19981015)83:8&lt;1483::AID-CNCR2&gt;3.0.CO;2-Z; Mantle D., 1999, Adverse Drug Reactions and Toxicological Reviews, V18, P235; Meng QH, 2000, BIOCHEM BIOPH RES CO, V273, P448, DOI 10.1006/bbrc.2000.2942; MILLER MW, 1991, ALCOHOL CLIN EXP RES, V15, P229, DOI 10.1111/j.1530-0277.1991.tb01861.x; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Redmond EM, 2000, ACTA PHARMACOL SIN, V21, P385; Roberts TM, 2000, J CELL BIOL, V149, P7, DOI 10.1083/jcb.149.1.7; Sheetz MP, 1999, BIOCHEM SOC SYMP, V65, P233; Szabo IL, 2001, LIFE SCI, V69, P3035, DOI 10.1016/S0024-3205(01)01410-2; Tang SQ, 1999, J CELL BIOL, V147, P1073, DOI 10.1083/jcb.147.5.1073; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tomanek RJ, 2000, ANAT RECORD, V261, P126, DOI 10.1002/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199; Zhu YF, 2001, BREAST CANCER RES TR, V69, P29, DOI 10.1023/A:1012293507534	40	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16189	16197		10.1074/jbc.M207517200	http://dx.doi.org/10.1074/jbc.M207517200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598535	hybrid, Green Submitted			2022-12-27	WOS:000182680000093
J	Trebak, M; Bird, GSJ; McKay, RRM; Birnbaumer, L; Putney, JW				Trebak, M; Bird, GSJ; McKay, RRM; Birnbaumer, L; Putney, JW			Signaling mechanism for receptor-activated canonical transient receptor potential 3 (TRPC3) channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; INOSITOL TRISPHOSPHATE RECEPTOR; CA2+-PERMEABLE CATION CHANNEL; OPERATED HTRP3 CHANNELS; CA2+ CHANNELS; PHOSPHOLIPASE-C; FEEDBACK INHIBITION; CELLS; RELEASE; RAT	Canonical transient receptor potential 3 (TRPC3) is a receptor-activated, calcium permeant, non-selective cation channel. TRPC3 has been shown to interact physically with the N-terminal domain of the inositol 1,4,5-trisphosphate receptor, consistent with a "conformational coupling" mechanism for its activation. Here we show that low concentrations of agonists that fail to produce levels of inositol 1,4,5-trisphosphate sufficient to induce Ca2+ release from intracellular stores substantially activate TRPC3. By several experimental approaches, we demonstrate that neither inositol 1,4,5-trisphosphate nor G proteins are required for TRPC3 activation. However, diacylglycerols were sufficient to activate TRPC3 in a protein kinase C-independent manner. Surface receptor agonists and exogenously applied diacylglycerols were not additive in activating TRPC3. In addition, inhibition of metabolism of diacylglycerol slowed the reversal of receptor-dependent TRPC3 activation. We conclude that receptor-mediated activation of phospholipase C in intact cells activates TRPC3 via diacylglycerol production, independently of G proteins, protein kinase C, or inositol 1,4,5-trisphosphate.	NIEHS, NIH, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Trebak, M (corresponding author), NIEHS, NIH, Lab Signal Transduct, POB 12233, Res Triangle Pk, NC 27709 USA.		Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019; Trebak, Mohamed/E-7405-2014	Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087, ZIGES101684, Z01ES101684, Z01ES090087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1992, J BIOL CHEM, V267, P17722; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; BROWN KD, 1987, BIOCHEM J, V245, P631, DOI 10.1042/bj2450631; DECOURCELLES DD, 1985, J BIOL CHEM, V260, P5762; Elliott AC, 2001, CELL CALCIUM, V30, P73, DOI 10.1054/ceca.2001.0215; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Iwasaki H, 2001, RECEPTOR CHANNEL, V7, P429; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; OZAWA K, 1993, J BIOL CHEM, V268, P2280; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Venkatachalam K, 2001, J BIOL CHEM, V276, P33980, DOI 10.1074/jbc.C100321200; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	37	130	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16244	16252		10.1074/jbc.M300544200	http://dx.doi.org/10.1074/jbc.M300544200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12606542	hybrid			2022-12-27	WOS:000182680000100
J	Ritch, PA; Carroll, SL; Sontheimer, H				Ritch, PA; Carroll, SL; Sontheimer, H			Neuregulin-1 enhances motility and migration of human astrocytic glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ACTIVATED PROTEIN-KINASE; ERBB SIGNALING NETWORK; SRC FAMILY KINASES; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; CANCER CELLS; PROGENITOR CELLS; SURVIVAL FACTOR; TUMOR INVASION	Gliomas are the most frequently diagnosed adult primary brain malignancy. These tumors have a tendency to invade diffusely into the surrounding healthy brain tissue, thereby precluding their successful surgical removal. In this report, we examine the potential for the neuregulin-1/erbB receptor signaling network to contribute to this process by modulating glioma cell motility. Neuregulin-1 is expressed throughout the immature and adult central nervous system and has been demonstrated to influence the migration of a variety of cell types in the developing brain. In addition, erbB2, an integral member of the heterodimeric neuregulin-1 receptor, has been shown to be overexpressed in human glioma biopsies. Using antibodies specific for erbB2 and erbB3, we show that these receptors localize preferentially in regions of the plasma membrane which are involved in facilitating cellular movement. Here, erbB2 colocalizes and coimmunoprecipitates with members of the focal complex including beta(1)-integrin and focal adhesion kinase. Further, erbB receptor activation by neuregulin-1 enhances cell motility in two-dimensional scratch motility assays and stimulates cell invasion in three-dimensional Transwell migration assays. These effects of neuregulin-1 appear to involve the activation of focal adhesion kinase, which occurs downstream from erbB2 receptor stimulation. Taken together these data suggest that neuregulin-1 plays an important modulatory role in glioma cell invasion.	Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA; Univ Alabama, Civitan Int Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Sontheimer, H (corresponding author), Univ Alabama, Dept Neurobiol, 1719 6th Ave S,CIRC 589, Birmingham, AL 35294 USA.			Sontheimer, Harald/0000-0002-5843-9871; Carroll, Steven/0000-0001-6714-4373				Anton ES, 1997, DEVELOPMENT, V124, P3501; Bannerman PG, 2000, DEV BRAIN RES, V124, P93, DOI 10.1016/S0165-3806(00)00090-0; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034; Bolteus A J, 2001, Curr Neurol Neurosci Rep, V1, P225, DOI 10.1007/s11910-001-0022-x; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; Chen WT, 1999, ANN NY ACAD SCI, V878, P361, DOI 10.1111/j.1749-6632.1999.tb07695.x; CHEN WT, 1990, CELL DIFFER DEV, V32, P329, DOI 10.1016/0922-3371(90)90047-Z; Dirks PB, 2001, J NEURO-ONCOL, V53, P203, DOI 10.1023/A:1012273922478; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; ENGELHARD HH, 1995, J NEURO-ONCOL, V23, P31, DOI 10.1007/BF01058457; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Hijazi MM, 2000, INT J ONCOL, V17, P629; Hintermann E, 2001, J CELL BIOL, V153, P465, DOI 10.1083/jcb.153.3.465; Holland EC, 2001, CURR OPIN NEUROL, V14, P683, DOI 10.1097/00019052-200112000-00002; Hwang Shiuh-Lin, 1997, Kaohsiung Journal of Medical Sciences, V13, P417; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; KLEIHUES P, 2002, WHO CLASSIFICATION T, P2; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; KRISTT DA, 1993, NEUROSURGERY, V33, P106; Liu SC, 2000, J CELL SCI, V113, P3563; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; Mahanthappa NK, 1996, J NEUROSCI, V16, P4673; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; Mazumdar A, 2001, CANCER RES, V61, P400; Meintanis S, 2001, GLIA, V34, P39, DOI 10.1002/glia.1038; Murillo H, 2001, CANCER RES, V61, P7408; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; NOBLE M, 1995, GLIA, V15, P222, DOI 10.1002/glia.440150304; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; Pollock GS, 1999, EUR J NEUROSCI, V11, P769, DOI 10.1046/j.1460-9568.1999.00484.x; Raabe TD, 1997, J NEUROCHEM, V69, P1859; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; RITCH PS, 2001, SOC NEUR ABSTR; Rodriguez-Fernandez JL, 1999, BIOESSAYS, V21, P1069, DOI 10.1002/(SICI)1521-1878(199912)22:1<1069::AID-BIES13>3.0.CO;2-C; ROZENGURT E, 1995, CANCER SURV, V24, P81; Sawaya RE, 1996, CLIN EXP METASTAS, V14, P35, DOI 10.1007/BF00157684; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHWECHHEIMER K, 1994, HUM PATHOL, V25, P772, DOI 10.1016/0046-8177(94)90246-1; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Tsai CM, 1996, CANCER RES, V56, P1068; Tysnes BB, 1996, INT J CANCER, V67, P777, DOI 10.1002/(SICI)1097-0215(19960917)67:6<777::AID-IJC5>3.0.CO;2-O; Uhm J. H., 1999, FRONT BIOSCI, V4, P188; Vadlamudi R, 1999, ONCOGENE, V18, P7253, DOI 10.1038/sj.onc.1203163; Vadlamudi RK, 2002, J CELL PHYSIOL, V190, P189, DOI 10.1002/JCP.10054; Vartanian T, 2000, BIOCHEM BIOPH RES CO, V271, P414, DOI 10.1006/bbrc.2000.2624; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wells A, 2000, ADV CANCER RES, V78, P31; Westphal M, 1997, J NEURO-ONCOL, V35, P335, DOI 10.1023/A:1005837122181; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422	60	46	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20971	20978		10.1074/jbc.M213074200	http://dx.doi.org/10.1074/jbc.M213074200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12600989	hybrid			2022-12-27	WOS:000183230500069
J	Mutsuda, M; Michel, KP; Zhang, XF; Montgomery, BL; Golden, SS				Mutsuda, M; Michel, KP; Zhang, XF; Montgomery, BL; Golden, SS			Biochemical properties of CikA, an unusual phytochrome-like histidine protein kinase that resets the circadian clock in Synechococcus elongatus PCC 7942	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDO-RESPONSE REGULATORS; GAF DOMAIN; TRANSCRIPTION; INSIGHT; SENSORS; BLUE; BACTERIOPHYTOCHROMES; AUTOPHOSPHORYLATION; PHOTORECEPTORS; CRYPTOCHROMES	We recently described the cikA (circadian input kinase A) gene, whose product supplies environmental information to the circadian oscillator in the cyanobacterium Synechococcus elongatus PCC 7942. CikA possesses three distinct domains: a GAF, a histidine protein kinase (HPK), and a receiver domain similar to those of the response regulator family. To determine how CikA functions in providing circadian input, we constructed modified alleles to tag and truncate the protein, allowing analysis of each domain individually. CikA covalently bound bilin chromophores in vitro, even though it lacks the expected ligand residues, and the GAF domain influenced but did not entirely account for this function. Full-length CikA and truncated variants that carry the HPK domain showed autophosphorylation activity. Deletion of the GAF domain or the N-terminal region adjacent to GAF dramatically reduced autophosphorylation, whereas elimination of the receiver domain increased activity 10-fold. Assays to test phosphorelay from the HPK to the cryptic receiver domain, which lacks the conserved aspartyl residue that serves as a phosphoryl acceptor in response regulators, were negative. We propose that the cryptic receiver is a regulatory domain that interacts with an unknown protein partner to modulate the autokinase activity of CikA but does not work as bona fide receiver domain in a phosphorelay.	Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	Texas A&M University System; Texas A&M University College Station; University of California System; University of California Davis	Golden, SS (corresponding author), Texas A&M Univ, Dept Biol, 3258 TAMU, College Stn, TX 77843 USA.	sgolden@tamu.edu			NIGMS NIH HHS [GM62419-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1999, CURR OPIN PLANT BIOL, V2, P230, DOI 10.1016/S1369-5266(99)80040-5; Ahmad M, 1998, NATURE, V392, P720, DOI 10.1038/33701; Andersson CR, 2000, METHOD ENZYMOL, V305, P527; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; BUSTOS SA, 1991, J BACTERIOL, V173, P7525, DOI 10.1128/jb.173.23.7525-7533.1991; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Chang C, 1998, PLANT PHYSIOL, V117, P723, DOI 10.1104/pp.117.3.723; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Dunlap JC, 1999, GENES CELLS, V4, P1, DOI 10.1046/j.1365-2443.1999.00239.x; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Fankhauser C, 2001, J BIOL CHEM, V276, P11453, DOI 10.1074/jbc.R100006200; Gambetta GA, 2001, P NATL ACAD SCI USA, V98, P10566, DOI 10.1073/pnas.191375198; Giraud E, 2002, NATURE, V417, P202, DOI 10.1038/417202a; Golden S. S., 1994, MOL BIOL CYANOBACTER, P693; HERDMAN M, 2001, BERGEYS MANUAL SYSTE, V1, P776; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Jiang ZY, 1999, SCIENCE, V285, P406, DOI 10.1126/science.285.5426.406; Jorissen HJMM, 2002, PHOTOCHEM PHOTOBIOL, V75, P554, DOI 10.1562/0031-8655(2002)075<0554:PWNBCT>2.0.CO;2; Jorissen HJMM, 2002, EUR J BIOCHEM, V269, P2662, DOI 10.1046/j.1432-1033.2002.02928.x; Kamei A, 2001, J BACTERIOL, V183, P1505, DOI 10.1128/JB.183.5.1505-1510.2001; KARNIOL B, 2003, P NATL ACAD SCI US; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; LI LM, 1992, J BIOL CHEM, V267, P19204; Lindner I, 2000, ANGEW CHEM INT EDIT, V39, P3269, DOI 10.1002/1521-3773(20000915)39:18<3269::AID-ANIE3269>3.0.CO;2-I; Liu Y, 1999, CELL MOL LIFE SCI, V55, P1195, DOI 10.1007/s000180050366; Makino S, 2000, PLANT CELL PHYSIOL, V41, P791, DOI 10.1093/pcp/41.6.791; Makino S, 2001, PLANT CELL PHYSIOL, V42, P334, DOI 10.1093/pcp/pce036; Matsushika A, 2000, PLANT CELL PHYSIOL, V41, P1002, DOI 10.1093/pcp/pcd043; MCCLEARY WR, 1990, J BACTERIOL, V172, P6661, DOI 10.1128/jb.172.12.6661-6668.1990; McDowell MT, 2001, PLANT PHYSIOL, V126, P1546, DOI 10.1104/pp.126.4.1546; McWatters H, 1999, CURR BIOL, V9, pR633, DOI 10.1016/S0960-9822(99)80410-2; Montgomery BL, 2002, TRENDS PLANT SCI, V7, P357, DOI 10.1016/S1360-1385(02)02304-X; Nishiwaki T, 2000, P NATL ACAD SCI USA, V97, P495, DOI 10.1073/pnas.97.1.495; O'Hara BP, 1999, EMBO J, V18, P5175, DOI 10.1093/emboj/18.19.5175; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmitz O, 2000, SCIENCE, V289, P765, DOI 10.1126/science.289.5480.765; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Strayer C, 2000, SCIENCE, V289, P768, DOI 10.1126/science.289.5480.768; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7; Williams SB, 2002, P NATL ACAD SCI USA, V99, P15357, DOI 10.1073/pnas.232517099; Wu SH, 2000, BIOCHEMISTRY-US, V39, P13487, DOI 10.1021/bi001123z; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	52	74	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19102	19110		10.1074/jbc.M213255200	http://dx.doi.org/10.1074/jbc.M213255200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626498	hybrid			2022-12-27	WOS:000182932200051
J	Berger, I; Bieniossek, C; Schaffitzel, C; Hassler, M; Santelli, E; Richmond, TJ				Berger, I; Bieniossek, C; Schaffitzel, C; Hassler, M; Santelli, E; Richmond, TJ			Direct interaction of Ca2+/calmodulin inhibits histone deacetylase 5 repressor core binding to myocyte enhancer factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MEF2; ANGSTROM RESOLUTION; CARDIAC-HYPERTROPHY; CRYSTAL-STRUCTURE; DNA-BINDING; IN-VIVO; CALMODULIN; CHROMATIN; FAMILY; DIFFERENTIATION	Myocyte enhancer factor 2 (MEF2) proteins play a pivotal role in the differentiation of cardiac and skeletal muscle cells. MEF2 factors are regulated by histone deacetylase enzymes such as histone deacetylase 5 (HDAC5). HDAC5 in turn is responsive to Ca2+ signaling mediated by the intracellular calcium sensor calmodulin. Here a combination of proteolytic fragmentation, matrix-assisted laser desorption ionization mass spectrometry, Edman degradation, circular dichroism, gel filtration, and surface plasmon resonance studies is utilized to define and characterize a stable core domain of HDAC5 and to examine its interactions with MEF2a and calmodulin. Results from real time binding experiments provide evidence for direct interaction of Ca2+/calmodulin with HDAC5 inhibiting MEF2a association with this enzyme.	ETH Honggerberg, Inst Mol Biol & Biophys, ETH Zurich, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Richmond, TJ (corresponding author), ETH Honggerberg, Inst Mol Biol & Biophys, ETH Zurich, CH-8093 Zurich, Switzerland.			Berger, Imre/0000-0001-7518-9045; Berger-Schaffitzel, Christiane Helene/0000-0002-1516-9760; Hassler, Markus/0000-0001-9827-3477				Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; BILLINGSLEY ML, 1985, P NATL ACAD SCI USA, V82, P7585, DOI 10.1073/pnas.82.22.7585; Bouche N, 2002, J BIOL CHEM, V277, P21851, DOI 10.1074/jbc.M200268200; Chang KT, 2002, AGEING RES REV, V1, P313, DOI 10.1016/S1568-1637(02)00003-X; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; FONANA A, 1999, PROTEOLYTIC ENZYMES, P257; Gaiser F, 2000, J MOL BIOL, V302, P1119, DOI 10.1006/jmbi.2000.4110; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guarente L, 2000, GENE DEV, V14, P1021; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; HLODAN R, 1995, NAT STRUCT BIOL, V2, P587, DOI 10.1038/nsb0795-587; Huang K, 2000, EMBO J, V19, P2615, DOI 10.1093/emboj/19.11.2615; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Onions J, 2000, BIOCHEMISTRY-US, V39, P4366, DOI 10.1021/bi992533u; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Penheiter AR, 2002, J BIOL CHEM, V277, P17728, DOI 10.1074/jbc.M111608200; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Santelli E, 2000, J MOL BIOL, V297, P437, DOI 10.1006/jmbi.2000.3568; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SHATZMAN AR, 1987, ANN NY ACAD SCI, V478, P233; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; THULIN E, 1984, BIOCHEMISTRY-US, V23, P1862, DOI 10.1021/bi00303a043; Tsukiyama T, 2002, NAT REV MOL CELL BIO, V3, P422, DOI 10.1038/nrm828; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Widom J, 1998, ANNU REV BIOPH BIOM, V27, P285, DOI 10.1146/annurev.biophys.27.1.285; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2002, MOL CELL BIOL, V22, P7302, DOI 10.1128/MCB.22.20.7302-7312.2002; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	63	34	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17625	17635		10.1074/jbc.M301646200	http://dx.doi.org/10.1074/jbc.M301646200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626519	hybrid			2022-12-27	WOS:000182838300008
J	Gascoyne, DM; Kypta, RM; Vivanco, MDM				Gascoyne, DM; Kypta, RM; Vivanco, MDM			Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-x(L)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY MEMBERS; TRANSGENIC MICE; CELL-DEATH; EPITHELIAL-CELLS; X GENE; RECEPTOR; CANCER; DEXAMETHASONE; EXPRESSION; LINE	Glucocorticoids influence many physiological processes, and in particular apoptosis, often with opposite effects depending on the cell type examined. We found that during fibrosarcoma development there is a strong increase in apoptosis at the tumor stage, which is repressed by dexamethasone to levels observed in normal fibroblasts. The anti-apoptotic Bcl-2 family protein Bcl-x(L) is induced by dexamethasone at the transcriptional level at all stages of fibrosarcoma development. The ligand-activated glucocorticoid receptor (GR) activates the Bcl-x promoter in transient transfection experiments, and GR binds to specific Bcl-x promoter sequences in vitro and in vivo. Furthermore, a GR antagonist abolishes this effect, indicating that Bcl-x(L) induction is mediated by GR. Importantly, exogenous Bcl-x(L) inhibits apoptosis and caspase-3 activity in fibrosarcoma cells to levels found in dexamethasone-treated fibrosarcoma cells. We conclude that Bcl-x(L) is a key target mediating the anti-apoptotic effects of glucocorticoids during fibrosarcoma development. These observations provide further understanding of the molecular basis of glucocorticoid regulation of cell death during tumorigenesis.	Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England; Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Canc Med, Prostate Canc Res Grp, London W12 0NN, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Imperial College London	Vivanco, MDM (corresponding author), Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.		Kypta, Robert/F-7699-2011; Vivanco, Maria/G-2393-2011	Kypta, Robert/0000-0002-2389-310X; Vivanco, Maria/0000-0002-9540-247X				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Amundson SA, 2000, CANCER RES, V60, P6101; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARENDS MJ, 1994, AM J PATHOL, V144, P1045; ASKEW DS, 1991, ONCOGENE, V6, P1915; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; Bryckaert M, 1999, ONCOGENE, V18, P7584, DOI 10.1038/sj.onc.1203200; Chandran UR, 1996, J BIOL CHEM, V271, P20412, DOI 10.1074/jbc.271.34.20412; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; COLE TJ, 1995, STEROIDS, V60, P93, DOI 10.1016/0039-128X(94)00009-2; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evans-Storms RB, 2000, ENDOCRINOLOGY, V141, P1854, DOI 10.1210/en.141.5.1854; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Gorman AM, 2000, NEUROSCIENCE, V96, P417, DOI 10.1016/S0306-4522(99)00565-5; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kaufmann SH, 2000, BIOESSAYS, V22, P1007, DOI 10.1002/1521-1878(200011)22:11<1007::AID-BIES7>3.3.CO;2-W; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LACEY M, 1986, NATURE, V322, P609, DOI 10.1038/322609a0; Leonardos L, 1999, CANCER LETT, V143, P29, DOI 10.1016/S0304-3835(99)00176-7; Liu ZG, 2002, VIROLOGY, V295, P230, DOI 10.1006/viro.2001.1351; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; Messmer UK, 2000, BRIT J PHARMACOL, V129, P1673, DOI 10.1038/sj.bjp.0703255; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; PAGLIACCI MC, 1993, J ENDOCRINOL INVEST, V16, P591, DOI 10.1007/BF03347677; Pascussi JM, 2003, MOL ENDOCRINOL, V17, P42, DOI 10.1210/me.2002-0244; Pecci A, 1997, J BIOL CHEM, V272, P11791, DOI 10.1074/jbc.272.18.11791; Planey SL, 2000, BIOCHEM BIOPH RES CO, V279, P307, DOI 10.1006/bbrc.2000.3922; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Roca R, 2003, P NATL ACAD SCI USA, V100, P3113, DOI 10.1073/pnas.0634912100; Schorr K, 2000, CANCER RES, V60, P5950; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; SIPPOLATHIELE M, 1989, MOL CELL BIOL, V9, P925, DOI 10.1128/MCB.9.3.925; Sivaraman L, 2000, BREAST CANCER RES TR, V62, P185, DOI 10.1023/A:1006410111706; Smets LA, 1999, ADV EXP MED BIOL, V457, P607; Tolosa E, 1999, NEUROIMMUNOMODULAT, V6, P90, DOI 10.1159/000026368; VIVANCO MD, 1995, EMBO J, V14, P2217, DOI 10.1002/j.1460-2075.1995.tb07216.x; Weller M, 1997, NEUROLOGY, V48, P1704, DOI 10.1212/WNL.48.6.1704; William R, 1998, J IMMUNOL, V161, P957; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	53	70	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18022	18029		10.1074/jbc.M301812200	http://dx.doi.org/10.1074/jbc.M301812200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637494	hybrid			2022-12-27	WOS:000182838300056
J	Williams, RC; Rees, ML; Jacobs, MF; Pragai, Z; Thwaite, JE; Baillie, LWJ; Emmerson, PT; Harwood, CR				Williams, RC; Rees, ML; Jacobs, MF; Pragai, Z; Thwaite, JE; Baillie, LWJ; Emmerson, PT; Harwood, CR			Production of Bacillus anthracis protective antigen is dependent on the extracellular chaperone, PrsA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECRETION; SIGNAL PEPTIDASES; ALPHA-AMYLASE; SUBTILIS; EXPRESSION; GENE; BINDING; CLONING; PATHWAY; GROWTH	Protective antigen (PA) is a component of the Bacillus anthracis lethal and edema toxins and the basis of the current anthrax vaccine. In its heptameric form, PA targets host cells and internalizes the enzymatically active components of the toxins, namely lethal and edema factors. PA and other toxin components are secreted from B. anthracis using the Sec-dependent secretion pathway. This requires them to be translocated across the cytoplasmic membrane in an unfolded state and then to be folded into their native configurations on the trans side of the membrane, prior to their release from the environment of the cell wall. In this study we show that recombinant PA (rPA) requires the extracellular chaperone PrsA for efficient folding when produced in the heterologous host, B. subtilis; increasing the concentration of PrsA leads to an increase in rPA production. To determine the likelihood of PrsA being required for PA production in its native host, we have analyzed the B. anthracis genome sequence for the presence of genes encoding homologues of B. subtilis PrsA. We identified three putative B. anthracis PrsA proteins (PrsAA, PrsAB, and PrsAC) that are able to complement the activity of B. subtilis PrsA with respect to cell viability and rPA secretion, as well as that of AmyQ, a protein previously shown to be PrsA-dependent.	Univ Newcastle Upon Tyne, Sch Med, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; NIDCR, Oral Infect & Immunol Branch, NIH, Bethesda, MD 20892 USA; Def Sci & Technol Lab, Salisbury SP4 OJQ, Wilts, England	Newcastle University - UK; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Defence Science & Technology Laboratory	Harwood, CR (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Baillie, Les/AAG-7090-2020; Harwood, Colin/AGF-0120-2022	Baillie, Les/0000-0002-8186-223X; Harwood, Colin/0000-0002-3624-0001				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; AVAKYAN AA, 1965, J BACTERIOL, V90, P1082, DOI 10.1128/JB.90.4.1082-1095.1965; BAILLIE LWJ, 1994, LETT APPL MICROBIOL, V19, P225, DOI 10.1111/j.1472-765X.1994.tb00949.x; Barnard JP, 1999, INFECT IMMUN, V67, P562, DOI 10.1128/IAI.67.2.562-567.1999; BELTON FC, 1954, BRIT J EXP PATHOL, V35, P144; Bensing BA, 2002, MOL MICROBIOL, V44, P1081, DOI 10.1046/j.1365-2958.2002.02949.x; Bron S, 1998, J BIOTECHNOL, V64, P3, DOI 10.1016/S0168-1656(98)00099-6; BRON S, 1990, MOL BIOL METHODS BAC, P75; Hyyrylainen HL, 2000, J BIOL CHEM, V275, P26696; IVINS BE, 1986, INFECT IMMUN, V54, P537, DOI 10.1128/IAI.54.2.537-542.1986; Jongbloed JDH, 2000, J BIOL CHEM, V275, P41350, DOI 10.1074/jbc.M004887200; KONTINEN VP, 1993, MOL MICROBIOL, V8, P727, DOI 10.1111/j.1365-2958.1993.tb01616.x; LACEY RW, 1976, J MED MICROBIOL, V7, P285; Lenz LL, 2002, MOL MICROBIOL, V45, P1043, DOI 10.1046/j.1365-2958.2002.03072.x; LEPPLA SH, 1991, ANTHRAX TOXIN COMPLE, P277; MAKINO S, 1989, J BACTERIOL, V171, P722, DOI 10.1128/jb.171.2.722-730.1989; Miller J, 1998, LETT APPL MICROBIOL, V26, P56, DOI 10.1046/j.1472-765X.1998.00274.x; Mock M, 2001, ANNU REV MICROBIOL, V55, P647, DOI 10.1146/annurev.micro.55.1.647; PALVA I, 1982, GENE, V19, P81, DOI 10.1016/0378-1119(82)90191-3; PEZARD C, 1991, INFECT IMMUN, V59, P3472, DOI 10.1128/IAI.59.10.3472-3477.1991; Pragai Z, 2000, J BACTERIOL, V182, P6819, DOI 10.1128/JB.182.23.6819-6823.2000; SINGH Y, 1989, J BIOL CHEM, V264, P19103; Stover AG, 1999, J BACTERIOL, V181, P1664; Stover AG, 1999, J BACTERIOL, V181, P5476; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; Turnbull PCB, 2000, CURR OPIN INFECT DIS, V13, P113, DOI 10.1097/00001432-200004000-00004; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; van Dijl JM, 2002, J BIOTECHNOL, V98, P243, DOI 10.1016/S0168-1656(02)00135-9; Vitikainen M, 2001, J BACTERIOL, V183, P1881, DOI 10.1128/JB.183.6.1881-1890.2001; WU XC, 1991, J BACTERIOL, V173, P4952, DOI 10.1128/jb.173.16.4952-4958.1991	32	49	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18056	18062		10.1074/jbc.M301244200	http://dx.doi.org/10.1074/jbc.M301244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12606539	hybrid			2022-12-27	WOS:000182838300061
J	Suhre, K; Claverie, JM				Suhre, K; Claverie, JM			Genomic correlates of hyperthermostability, an update	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								It has been shown (Cambillau, C., and Claverie, J.M. (2000) J. Biol. Chem. 275, 32383-32386) that a large difference between the proportions of charged versus polar (non-charged) amino acids (CvP-bias) was an adequate, if empirical, signature of the proteome of hyperthermophilic organisms (T-growth>80degreesC). Since that study, the number of available microbial genomes has more than doubled, raising the possibility that the simple CvP-bias rule might no longer hold. Taking advantage of the new sequence data, we re-analyzed the genomes of 9 fully sequenced thermophiles, 9 hyperthermophiles, and 53 mesothermophile microorganisms to identify the genomic correlates of hyperthermostability on a wider data set. Our new results confirm that the CvP-bias previously identified on a much smaller data set still holds. Moreover, we show that it is an optimal criterion, in the sense that it corresponds to the most discriminating factor between hyperthermophilic and mesothermophilic microorganisms in a principal component analysis. In parallel, we evaluated two other recently proposed correlates of hyperthermostability, the proteome average pI and the dinucleotide statistical index (Kawashima, T., Amano, N., Koike, H., Makino, S., Higuchi, S., Kawashima-Ohya, Y., Watanabe, K., Yamazaki, M., Kanehori, K., Kawamoto, T., Nunoshiba, T., Yamamoto, Y., Aramaki, H., Makino, K., and Suzuki, M. (2000) Proc. Natl. Acad. Sci. 97, 14257-14262). We show that the CvP-bias is the sole criterion that is able to clearly discriminate hyperthermophile from mesothermophile microorganisms on a global genomic basis.	CNRS, UPR 2589, Inst Struct Biol & Microbiol, Struct & Genom Informat Lab, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Claverie, JM (corresponding author), CNRS, UPR 2589, Inst Struct Biol & Microbiol, Struct & Genom Informat Lab, Marseille, France.		Suhre, Karsten/AAF-1778-2020; Claverie, Jean Michel/Z-2183-2019; Claverie, Jean-Michel/AAG-4889-2019	Suhre, Karsten/0000-0001-9638-3912; Claverie, Jean-Michel/0000-0003-1424-0315				Brochier C, 2002, NATURE, V417, P244, DOI 10.1038/417244a; Cambillau C, 2000, J BIOL CHEM, V275, P32383, DOI 10.1074/jbc.C000497200; Kawashima T, 2000, P NATL ACAD SCI USA, V97, P14257, DOI 10.1073/pnas.97.26.14257; Kreil DP, 2001, NUCLEIC ACIDS RES, V29, P1608, DOI 10.1093/nar/29.7.1608; Kumar S, 2001, CELL MOL LIFE SCI, V58, P1216, DOI 10.1007/PL00000935; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Vieille C, 2001, EUR J BIOCHEM, V268, P6291, DOI 10.1046/j.0014-2956.2001.02587.x	7	136	138	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17198	17202		10.1074/jbc.M301327200	http://dx.doi.org/10.1074/jbc.M301327200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600994	hybrid			2022-12-27	WOS:000182818600101
J	Zou, W; Amcheslavsky, A; Bar-Shavit, Z				Zou, W; Amcheslavsky, A; Bar-Shavit, Z			CpG oligodeoxynucleotides modulate the osteoclastogenic activity of osteoblasts via toll-like receptor 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; COLONY-STIMULATING FACTOR; BONE-RESORPTION; BACTERIAL-DNA; IN-VITRO; DIFFERENTIATION FACTOR; STROMAL CELLS; OSTEOPROTEGERIN LIGAND; RHEUMATOID-ARTHRITIS	Regulation of osteoclastogenesis by lipopolysaccharide (LPS) is mediated via its interactions with toll-like receptor 4 (TLR4) on both osteoclast-and osteoblast-lineage cells. We have recently demonstrated that CpG oligodeoxynucleotides (CpG ODNs), known to mimic bacterial DNA, modulate osteoclastogenesis via interactions with osteoclast precursors. In the present study we characterize the interactions of CpG ODNs with osteoblasts, in comparison with LPS. We find that, similar to LPS, CpG ODNs modulate osteoclastogenesis in bone marrow cell/osteoblast co-cultures, although in a somewhat different pattern. Osteoblasts express receptors for both LPS and CpG ODN (TLR4 and TLR9, respectively). The osteoblastic TLR9 transmits signals into the cell as demonstrated by NFkappaB activation as well as by extracellular-regulated kinase (ERK) and p38 phosphorylation. Similar to LPS, CpG ODN increases in osteoblasts the expression of tumor necrosis factor (TNF)-alpha and macrophage-colony stimulating factor (M-CSF). The two TLR ligands do not affect osteoprotegerin expression in osteoblasts. CpG ODN does not significantly affect receptor activator of NFkappaB ligand (RANKL) expression, in contrast to LPS, which induces the expression of this molecule. In the co-cultures CpG ODN induces RANKL expression in osteoblasts as a result of the more efficient TNF-alpha induction. CpG ODN activity (modulation of osteoclastogenesis, gene expression, ERK and p38 phosphorylation, and nuclear translocation of NFkappaB) is specific, because the control oligodeoxynucleotide, not containing CpG, is inactive. Furthermore, these effects (unlike the LPS effects) are inhibited by chloroquine, suggesting a requirement for endosomal maturation/acidification, the classic CpG ODN mode of action. We conclude that CpG ODN, upon TLR9 ligation, induces osteoblasts osteoclastogenic activity.	Hebrew Univ Jerusalem, Hubert H Humphrey Ctr Expt Med & Canc Res, Fac Med, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Bar-Shavit, Z (corresponding author), Hebrew Univ Jerusalem, Hubert H Humphrey Ctr Expt Med & Canc Res, Fac Med, POB 12272, IL-91120 Jerusalem, Israel.			Zou, Wei/0000-0001-8081-268X				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Chiang CY, 1999, INFECT IMMUN, V67, P4231, DOI 10.1128/IAI.67.8.4231-4236.1999; Choi BK, 2001, J PERIODONTOL, V72, P1172, DOI 10.1902/jop.2000.72.9.1172; Collin-Osdoby P, 2002, J BONE MINER RES, V17, P1859, DOI 10.1359/jbmr.2002.17.10.1859; DALY CG, 1980, J ORAL PATHOL MED, V9, P1, DOI 10.1111/j.1600-0714.1980.tb01383.x; Doyle A., 1996, CELL TISSUE CULTURE, P11; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; GOLDMAN R, 1979, J NATL CANCER I, V63, P1009; Gravallese EM, 1998, AM J PATHOL, V152, P943; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hartmann G, 2000, J IMMUNOL, V164, P944, DOI 10.4049/jimmunol.164.2.944; Hartmann G, 2000, J IMMUNOL, V164, P1617, DOI 10.4049/jimmunol.164.3.1617; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hofbauer LC, 1999, BONE, V25, P255, DOI 10.1016/S8756-3282(99)00162-3; Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; ISHIHARA Y, 1991, J PERIODONTAL RES, V26, P155, DOI 10.1111/j.1600-0765.1991.tb01639.x; Ito HO, 1996, ARCH ORAL BIOL, V41, P439, DOI 10.1016/0003-9969(96)00002-7; Jiang YL, 2002, INFECT IMMUN, V70, P3143, DOI 10.1128/IAI.70.6.3143-3148.2002; Jimi E, 1996, ENDOCRINOLOGY, V137, P2187; Kikuchi T, 2001, J IMMUNOL, V166, P3574, DOI 10.4049/jimmunol.166.5.3574; Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Krieg AM, 2000, CURR OPIN IMMUNOL, V12, P35, DOI 10.1016/S0952-7915(99)00048-5; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lipford GB, 1998, TRENDS MICROBIOL, V6, P496, DOI 10.1016/S0966-842X(98)01408-5; MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312; Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002-9440(10)65266-2; MILLAR SJ, 1986, INFECT IMMUN, V51, P302, DOI 10.1128/IAI.51.1.302-306.1986; Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371-2380.1996; Nakashima T, 2000, BIOCHEM BIOPH RES CO, V275, P768, DOI 10.1006/bbrc.2000.3379; NOVAK JF, 1995, MICROBIOS, V81, P241; ORCEL P, 1993, AM J PHYSIOL, V264, pE391, DOI 10.1152/ajpendo.1993.264.3.E391; OURSLER MJ, 1988, DEV BIOL, V127, P170, DOI 10.1016/0012-1606(88)90198-4; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331; Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756-3282(01)00682-2; Sambrook J., 2002, MOL CLONING LAB MANU; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAKAHASHI N, 1991, ENDOCRINOLOGY, V128, P1792, DOI 10.1210/endo-128-4-1792; Takami M, 2002, J IMMUNOL, V169, P1516, DOI 10.4049/jimmunol.169.3.1516; Takeda S, 1999, ENDOCRINOLOGY, V140, P1005, DOI 10.1210/en.140.2.1005; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; Udagawa N, 1996, BONE, V18, P511, DOI 10.1016/8756-3282(96)00076-2; Weiner GJ, 2000, J LEUKOCYTE BIOL, V68, P455; Yi AK, 1999, INT IMMUNOL, V11, P2015, DOI 10.1093/intimm/11.12.2015; Yi AK, 1998, J IMMUNOL, V160, P1240; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 2001, INT IMMUNOL, V13, P1391, DOI 10.1093/intimm/13.11.1391; Zou W, 2002, FASEB J, V16, P274, DOI 10.1096/fj.01-0586com; Zou W, 2002, J BONE MINER RES, V17, P1211, DOI 10.1359/jbmr.2002.17.7.1211; Zou W, 2001, J CELL BIOCHEM, V83, P70, DOI 10.1002/jcb.1202	64	74	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16732	16740		10.1074/jbc.M212473200	http://dx.doi.org/10.1074/jbc.M212473200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611893	hybrid			2022-12-27	WOS:000182818600039
J	Balog, EM; Norton, LE; Bloomquist, RA; Cornea, RL; Black, DJ; Louis, CF; Thomas, DD; Fruen, BR				Balog, EM; Norton, LE; Bloomquist, RA; Cornea, RL; Black, DJ; Louis, CF; Thomas, DD; Fruen, BR			Calmodulin oxidation and methionine to glutamine substitutions reveal methionine residues critical for functional interaction with ryanodine receptor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNELS; SARCOPLASMIC-RETICULUM; CALCIUM-BINDING; ALPHA-HELICES; PROTEIN; INHIBITION; RECOGNITION; ACTIVATION; TROPONIN; DOMAIN	Calmodulin (CaM) binds to the skeletal muscle ryanodine receptor Ca2+ release channel (RyR1) with high affinity, and it may act as a Ca2+-sensing subunit of the channel. Apo-CaM increases RyR1 channel activity, but Ca2+-CaM is inhibitory. Here we examine the functional effects of CaM oxidation on RyR1 regulation by both apo-CaM and Ca2+-CaM, as assessed via determinations of [H-3]ryanodine and [S-35]CaM binding to skeletal muscle sarcoplasmic reticulum vesicles. Oxidation of all nine CaM Met residues abolished functional interactions of CaM with RyR1. Incomplete CaM oxidation, affecting 5-8 Met residues, increased the CaM concentration required to modulate RyR1, having a greater effect on the apo-CaM species. Mutating individual CaM Met residues to Gln demonstrated that Met-109 was required for apo-CaM activation of RyR1 but not for Ca2+-CaM inhibition of the channel. Furthermore, substitution of Gln for Met-124 increased the apo- and Ca2+-CaM concentrations required to regulate RyR1. These results thus identify Met residues critical for the productive association of CaM with RyR1 channels and suggest that oxidation of CaM may contribute to altered regulation of sarcoplasmic reticulum Ca2+ release during oxidative stress.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Ohio State Univ, Dept Mol & Cellular Biol, Columbus, OH 43210 USA; Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University of Minnesota System; University of Minnesota Twin Cities; University System of Ohio; Ohio State University; University System of Georgia; Georgia State University	Balog, EM (corresponding author), 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.		Thomas, David D/B-4257-2012	Thomas, David D./0000-0002-8822-2040; Cornea, Razvan/0000-0001-5739-0992	NIGMS NIH HHS [GM 31382] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031382] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balshaw DM, 2002, J MEMBRANE BIOL, V185, P1, DOI 10.1007/s00232-001-0111-4; Balshaw DM, 2001, J BIOL CHEM, V276, P20144, DOI 10.1074/jbc.M010771200; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; BROT N, 1983, ARCH BIOCHEM BIOPHYS, V223, P271, DOI 10.1016/0003-9861(83)90592-1; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Chin D, 1996, J BIOL CHEM, V271, P30465, DOI 10.1074/jbc.271.48.30465; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; Hamilton SL, 2000, NEWS PHYSIOL SCI, V15, P281; Jurado LA, 1999, PHYSIOL REV, V79, P661, DOI 10.1152/physrev.1999.79.3.661; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEVIT RE, 1983, METHOD ENZYMOL, V102, P82; Kranz JK, 2002, BIOCHEMISTRY-US, V41, P2599, DOI 10.1021/bi011818f; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marks AR, 2002, TRENDS CARDIOVAS MED, V12, P166, DOI 10.1016/S1050-1738(02)00156-1; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Michaelis ML, 1996, LIFE SCI, V59, P405, DOI 10.1016/0024-3205(96)00319-0; MICKELSON JR, 1990, ARCH BIOCHEM BIOPHYS, V278, P251, DOI 10.1016/0003-9861(90)90255-W; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PEDIGO S, 1995, BIOCHEMISTRY-US, V34, P10676, DOI 10.1021/bi00033a044; Rodney GG, 2001, BIOCHEMISTRY-US, V40, P12430, DOI 10.1021/bi011078a; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; STRASBURG GM, 1988, J BIOL CHEM, V263, P542; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; Tanna B, 1998, J GEN PHYSIOL, V112, P55, DOI 10.1085/jgp.112.1.55; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Wang ST, 1998, BIOCHEMISTRY-US, V37, P14539, DOI 10.1021/bi9814641; Xin HB, 1999, J BIOL CHEM, V274, P15315, DOI 10.1074/jbc.274.22.15315; YANG HC, 1994, BIOCHEMISTRY-US, V33, P518, DOI 10.1021/bi00168a017; Yin D, 1999, BIOCHEMISTRY-US, V38, P13654, DOI 10.1021/bi991152d; Yuan T, 1999, J BIOL CHEM, V274, P8411, DOI 10.1074/jbc.274.13.8411; Zhang MJ, 1998, BIOCHEM CELL BIOL, V76, P313, DOI 10.1139/bcb-76-2-3-313	34	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15615	15621		10.1074/jbc.M209180200	http://dx.doi.org/10.1074/jbc.M209180200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12586832	hybrid			2022-12-27	WOS:000182680000022
J	Braganca, J; Eloranta, JJ; Bamforth, SD; Ibbitt, JC; Hurst, HC; Bhattacharya, S				Braganca, J; Eloranta, JJ; Bamforth, SD; Ibbitt, JC; Hurst, HC; Bhattacharya, S			Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOCYTE-SPECIFIC GENE; CAUSE CHAR-SYNDROME; MICE LACKING; DNA-BINDING; MOLECULAR-CLONING; CBP; COACTIVATOR; P300; DEFECTS; FAMILY	The transcriptional co-activators and histone acetyl-transferases p300/CREB-binding protein (CBP) interact with CITED2, a transcription factor AP-2 (TFAP2) coactivator. p300/CBP, CITED2, and TFAP2A are essential for normal neural tube and cardiac development. Here we show that p300 and CBP co-activate TFAP2A in the presence of CITED2. TFAP2A transcriptional activity was modestly impaired in p300(+/-) and CBP+/- mouse embryonic fibroblasts; this was rescued by ectopic expression of p300/CBP. p300, TFAP2A, and endogenous CITED2 could be co-immunoprecipitated from transfected U2-OS cells indicating that they can interact physically in vivo. CITED2 interacted with the dimerization domain of TFAP2C, which is highly conserved in TFAP2A/B. In mammalian two-hybrid experiments, full-length p300 and TFAP2A interacted only when CITED2 was co-transfected. N-terminal residues of TFAP2A, containing the transactivation domain, are both necessary and sufficient for interaction with p300, and this interaction was independent of CITED2. Consistent with this, N-terminal residues of TFAP2A were required for p300-and CITED2-dependent co-activation. A histone acetyltransferase-deficient p300 mutant (D1399Y) did not co-activate TFAP2A and did not affect the expression or cellular localization of TFAP2A or CITED2. In mammalian two-hybrid experiments p300D1399Y failed to interact with TFAP2A, explaining, at least in part, its failure to function as a co-activator. Our results suggest a model wherein interactions among TFAP2A, CITED2, and p300/CBP are necessary for TFAP2A-mediated transcriptional activation and for normal neural tube and cardiac development.	Univ Oxford, Wellcome Trust Ctr Human Genet, Dept Cardiovasc Med, Oxford OX3 7BN, England; Hammersmith Hosp, Mol Oncol Unit, Canc Res UK, London W12 0HS, England	University of Oxford; Wellcome Centre for Human Genetics; Cancer Research UK; Imperial College London		sbhattac@well.ox.ac.uk	Braganca, Jose/F-4410-2012; Bhattacharya, Shoumo/F-4127-2010; Bamforth, Simon David/I-1277-2019	Braganca, Jose/0000-0001-9566-400X; Bhattacharya, Shoumo/0000-0002-5571-0478; Bamforth, Simon David/0000-0002-5666-4485				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bamforth SD, 2001, NAT GENET, V29, P469, DOI 10.1038/ng768; Barbera JPM, 2002, HUM MOL GENET, V11, P283, DOI 10.1093/hmg/11.3.283; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bordoli L, 2001, NUCLEIC ACIDS RES, V29, P4462, DOI 10.1093/nar/29.21.4462; Braganca J, 2002, J BIOL CHEM, V277, P8559, DOI 10.1074/jbc.M110850200; Brewer S, 2002, MECH DEVELOP, V110, P139, DOI 10.1016/S0925-4773(01)00579-2; Chan HM, 2001, J CELL SCI, V114, P2363; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eloranta JJ, 2002, J BIOL CHEM, V277, P30798, DOI 10.1074/jbc.M202780200; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kannan F, 1999, MOL CELL BIOL, V19, P899; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Leung MK, 1999, GENOMICS, V61, P307, DOI 10.1006/geno.1999.5970; LOO DT, 1989, CELL GROWTH CELL DIV, P17; Newton AL, 2000, J BIOL CHEM, V275, P15128, DOI 10.1074/jbc.M910396199; Oike Y, 1999, BLOOD, V93, P2771; Oike Y, 1999, HUM MOL GENET, V8, P387, DOI 10.1093/hmg/8.3.387; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Satoda M, 2000, NAT GENET, V25, P42, DOI 10.1038/75578; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; SKINNER A, 1993, ONCOGENE, V8, P3393; Sun HB, 1998, P NATL ACAD SCI USA, V95, P13555, DOI 10.1073/pnas.95.23.13555; Wankhade S, 2000, J BIOL CHEM, V275, P29701, DOI 10.1074/jbc.M000931200; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Yahata T, 2002, GENOMICS, V80, P601, DOI 10.1006/geno.2002.7005; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yin Z, 2002, P NATL ACAD SCI USA, V99, P10488, DOI 10.1073/pnas.162371799; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; Zhao F, 2001, AM J HUM GENET, V69, P695, DOI 10.1086/323410; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	42	127	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16021	16029		10.1074/jbc.M208144200	http://dx.doi.org/10.1074/jbc.M208144200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12586840	hybrid			2022-12-27	WOS:000182680000073
J	Dobson, DE; Scholtes, LD; Valdez, KE; Sullivan, DR; Mengeling, BJ; Cilmi, S; Turco, SJ; Beverley, SM				Dobson, DE; Scholtes, LD; Valdez, KE; Sullivan, DR; Mengeling, BJ; Cilmi, S; Turco, SJ; Beverley, SM			Functional identification of galactosyltransferases (SCGs) required for species-specific modifications of the lipophosphoglycan adhesin controlling Leishmania major-sand fly interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOZOAN PARASITE LEISHMANIA; ANTIGENIC VARIATION; CELL-SURFACE; DEVELOPMENTAL MODIFICATION; TRYPANOSOMA-BRUCEI; VIRULENCE GENES; STAGE; PROMASTIGOTES; VECTOR; EXPRESSION	Lipophosphoglycan (LPG) is an abundant surface molecule that plays key roles in the infectious cycle of Leishmania major. The dominant feature of LPG is a polymer of phosphoglycan (PG) (6Galbeta1,4Manalpha1-PO4) repeating units. In L. major these are extensively substituted with Gal(beta1,3) side chains, which are required for binding to midgut lectins and survival. We utilized evolutionary polymorphisms in LPG structure and cross-species transfections to recover genes encoding the LPG side chain beta1,3-galactosyltransferases (betaGalTs). A dispersed family of six SCG genes was recovered, whose predicted proteins exhibited characteristics of eukaryotic GalTs. At least four of these proteins showed significant LPG side chain betaGaIT activity; SCG3 exhibited initiating GaIT activity whereas SCG2 showed both initiating and elongating GaIT activity. However, the activity of SCG2 was context-dependent, being largely silent in its normal genomic milieu, and different strains show considerable variation in the extent of LPG galactosylation. Thus the L. major genome encodes a family of SCGs with varying specificity and activity, and we propose that strain-specific LPG galactosylation patterns reflect differences in their expression.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Washington University (WUSTL); University of Kentucky; Harvard University; Harvard Medical School	Dobson, DE (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.			Beverley, Stephen/0000-0001-5319-0811	NIAID NIH HHS [AI 31078, AI 20941] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031078, R37AI020941, R01AI020941] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Qahtani A, 1998, BIOCHEM J, V331, P521, DOI 10.1042/bj3310521; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; Barbour AG, 2000, EMERG INFECT DIS, V6, P449, DOI 10.3201/eid0605.000502; Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3; BEVERLEY SM, 1988, NUCLEIC ACIDS RES, V16, P925, DOI 10.1093/nar/16.3.925; Beverley SM, 2003, NAT REV GENET, V4, P11, DOI 10.1038/nrg980; Beverley SM, 1998, TRENDS MICROBIOL, V6, P35, DOI 10.1016/S0966-842X(97)01180-3; Butcher BA, 1996, J BIOL CHEM, V271, P20573, DOI 10.1074/jbc.271.34.20573; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; Cunningham ML, 2001, MOL BIOCHEM PARASIT, V113, P199, DOI 10.1016/S0166-6851(01)00213-4; Descoteaux A, 2002, EMBO J, V21, P4458, DOI 10.1093/emboj/cdf447; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; Dillon RJ, 1999, PARASITOLOGY, V118, P27, DOI 10.1017/S0031182098003588; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Ilg T, 2001, MED MICROBIOL IMMUN, V190, P13, DOI 10.1007/s004300100071; Ilg T, 1996, J BIOL CHEM, V271, P21583, DOI 10.1074/jbc.271.35.21583; Joshi PB, 1998, MOL MICROBIOL, V27, P519, DOI 10.1046/j.1365-2958.1998.00689.x; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KELLEHER M, 1994, MOL BIOCHEM PARASIT, V66, P187, DOI 10.1016/0166-6851(94)90146-5; Kyes S, 2001, ANNU REV MICROBIOL, V55, P673, DOI 10.1146/annurev.micro.55.1.673; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Mahoney AB, 1999, BIOCHEMISTRY-US, V38, P9813, DOI 10.1021/bi990741g; MCCONVILLE MJ, 1995, BIOCHEM J, V310, P807, DOI 10.1042/bj3100807; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MOODY SF, 1993, J BIOL CHEM, V268, P18457; MULVEY MA, 2000, ADHESION BACTERIAL E, V1; Ng K, 1996, BIOCHEM J, V317, P247, DOI 10.1042/bj3170247; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; Pedrosa AL, 2002, MOL BIOCHEM PARASIT, V122, P141, DOI 10.1016/S0166-6851(02)00093-2; Pelletier I, 2002, J BIOL CHEM, V277, P17663, DOI 10.1074/jbc.M201562200; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; PIMENTA PFP, 1994, P NATL ACAD SCI USA, V91, P9155, DOI 10.1073/pnas.91.19.9155; Roditi I, 2002, TRENDS MICROBIOL, V10, P128, DOI 10.1016/S0966-842X(02)02309-0; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; Sacks D, 2001, ANNU REV MICROBIOL, V55, P453, DOI 10.1146/annurev.micro.55.1.453; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SACKS DL, 1985, J IMMUNOL, V135, P564; Sacks DL, 2001, CELL MICROBIOL, V3, P189, DOI 10.1046/j.1462-5822.2001.00115.x; SACKS DL, 1995, J EXP MED, V181, P685, DOI 10.1084/jem.181.2.685; SACKS DL, 1987, J IMMUNOL, V139, P3099; SACKS DL, 1989, EXP PARASITOL, V69, P100, DOI 10.1016/0014-4894(89)90176-8; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Sundstrom P, 1999, CURR OPIN MICROBIOL, V2, P353, DOI 10.1016/S1369-5274(99)80062-9; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; Tosi LRO, 2000, NUCLEIC ACIDS RES, V28, P784, DOI 10.1093/nar/28.3.784; TURCO SJ, 1991, MOL BIOCHEM PARASIT, V45, P91, DOI 10.1016/0166-6851(91)90030-A; Wiese M, 1999, MOL BIOCHEM PARASIT, V102, P325, DOI 10.1016/S0166-6851(99)00095-X; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	52	35	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15523	15531		10.1074/jbc.M301568200	http://dx.doi.org/10.1074/jbc.M301568200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604613	hybrid			2022-12-27	WOS:000182680000010
J	Kanipes, MI; Kalb, SR; Cotter, RJ; Hozbor, DF; Lagares, A; Raetz, CRH				Kanipes, MI; Kalb, SR; Cotter, RJ; Hozbor, DF; Lagares, A; Raetz, CRH			Relaxed sugar donor selectivity of a Sinorhizobium meliloti ortholog of the Rhizobium leguminosarum mannosyl transferase LpcC - Role of the lipopolysaccharide core in symbiosis of Rhizobiaceae with plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-CHARACTERIZATION; ESCHERICHIA-COLI; BIOSYNTHESIS; IDENTIFICATION; PURIFICATION; EXPRESSION; MUTANTS; NODULES; ALFALFA; CLONING	The lpcC gene of Rhizobium leguminosarum and the lpsB gene of Sinorhizobium meliloti encode protein orthologs that are 58% identical over their entire lengths of about 350 amino acid residues. LpcC and LpsB are required for symbiosis with pea and Medicago plants, respectively. S. meliloti lpsB complements a mutant of R. leguminosarum defective in lpcC, but the converse does not occur. LpcC encodes a highly selective mannosyl transferase that utilizes GDP-mannose to glycosylate the inner 3-deoxy-D-manno-octulosonic acid (Kdo) residue of the lipopolysaccharide precursor Kdo(2)-lipid IVA. We now demonstrate that LpsB can also efficiently man-nosylate the same acceptor substrate as does LpcC. Unexpectedly, however, the sugar nucleotide selectivity of LpsB is greatly relaxed compared with that of LpcC. Membranes of the wild-type S. metiloti strain 2011 catalyze the glycosylation of Kdo(2)-[4-P-32] lipid IVA at comparable rates using a diverse set of sugar nucleotides, including GDP-mannose, ADP-mannose, UDP-glucose, and ADP-glucose. This complex pattern of glycosylation is due entirely to LpsB, since membranes of the S. meliloti lpsB mutant 6963 do not glycosylate Kdo(2)-[4-P-32]lipid IVA in the presence of any of these sugar nucleotides. Expression of lpsB in E. coli using a T7lac promoter-driven construct results in the appearance of similar multiple glycosyl transferase activities seen in S. meliloti 2011 membranes. Constructs expressing lpcC display only mannosyl transferase activity. We conclude that LpsB, despite its high degree of similarity to LpcC, is a much more versatile glycosyltransferase, probably accounting for the inability of lpcC to complement S. meliloti lpsB mutants. Our findings have important implications for the regulation of core glycosylation in S. meliloti and other bacteria containing LpcC orthologs.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Natl Univ La Plata, Fac Ciencias Exactas, Inst Bioquim & Biol Mol, RA-1900 La Plata, Argentina	Duke University; Johns Hopkins University; National University of La Plata	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Hozbor, Daniela/0000-0001-6379-0482; Kalb, Suzanne/0000-0002-8067-136X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796, R01GM054882] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM051796-07, R37 GM051796, GM 54882, R37 GM 51796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; BERGMANS HEN, 1981, J BACTERIOL, V146, P564, DOI 10.1128/JB.146.2.564-570.1981; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; Blatny JM, 1997, APPL ENVIRON MICROB, V63, P370, DOI 10.1128/AEM.63.2.370-379.1997; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Campbell GRO, 2002, P NATL ACAD SCI USA, V99, P3938, DOI 10.1073/pnas.062425699; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CASSE F, 1979, J GEN MICROBIOL, V113, P229, DOI 10.1099/00221287-113-2-229; DANKERT M, 1964, BIOCHEM BIOPH RES CO, V14, P358, DOI 10.1016/S0006-291X(64)80010-3; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; Gudlavalleti SK, 2003, J BIOL CHEM, V278, P3957, DOI 10.1074/jbc.M210491200; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; Kanipes MI, 2003, J BIOL CHEM, V278, P16356, DOI 10.1074/jbc.M301255200; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lagares A, 2001, J BACTERIOL, V183, P1248, DOI 10.1128/JB.183.4.1248-1258.2001; LAGARES A, 1992, J BACTERIOL, V174, P5941, DOI 10.1128/jb.174.18.5941-5952.1992; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; Niehaus K, 1998, MOL PLANT MICROBE IN, V11, P906, DOI 10.1094/MPMI.1998.11.9.906; PASSERON S, 1964, BIOCHIM BIOPHYS ACTA, V89, P372, DOI 10.1016/0926-6569(64)90233-0; POOLE PS, 1994, MICROBIOL-SGM, V140, P2797, DOI 10.1099/00221287-140-10-2797; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7	28	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16365	16371		10.1074/jbc.M301256200	http://dx.doi.org/10.1074/jbc.M301256200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591936	Green Accepted, Green Published, hybrid			2022-12-27	WOS:000182680000115
J	Lusetti, SL; Wood, EA; Fleming, CD; Modica, MJ; Korth, J; Abbott, L; Dwyer, DW; Roca, AI; Inman, RB; Cox, MM				Lusetti, SL; Wood, EA; Fleming, CD; Modica, MJ; Korth, J; Abbott, L; Dwyer, DW; Roca, AI; Inman, RB; Cox, MM			C-terminal deletions of the Escherichia coli RecA protein - Characterization of in vivo and in vitro effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; INTERSTRAND CROSS-LINKS; BINDING-PROTEIN; ATP HYDROLYSIS; GENETIC-RECOMBINATION; MECHANISM; PURIFICATION; REPAIR; REMOVAL; SITE	A set of C-terminal deletion mutants of the RecA protein of Escherichia coli, progressively removing 6, 13, 17, and 25 amino acid residues, has been generated, expressed, and purified. In vivo, the deletion of 13 to 17 C-terminal residues results in increased sensitivity to mitomycin C. In vitro, the deletions enhance binding to duplex DNA as previously observed. We demonstrate that much of this enhancement involves the deletion of residues between positions 339 and 346. In addition, the C-terminal deletions cause a substantial upward shift in the pH-reaction profile of DNA strand exchange reactions. The C-terminal deletions of more than 13 amino acid residues result in strong inhibition of DNA strand exchange below pH 7, where the wild-type protein promotes a proficient reaction. However, at the same time, the deletion of 13-17 C-terminal residues eliminates the reduction in DNA strand exchange seen with the wild-type protein at pH values between 7.5 and 9. The results suggest the existence of extensive interactions, possibly involving multiple salt bridges, between the C terminus and other parts of the protein. These interactions affect the pK(a) of key groups involved in DNA strand exchange as well as the direct binding of RecA protein to duplex DNA.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu		Roca, Alberto I./0000-0002-7072-5301	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; CHENG S, 1991, NUCLEIC ACIDS RES, V19, P657, DOI 10.1093/nar/19.3.657; COLE RS, 1976, J MOL BIOL, V103, P39, DOI 10.1016/0022-2836(76)90051-6; COLE RS, 1973, P NATL ACAD SCI USA, V70, P1064, DOI 10.1073/pnas.70.4.1064; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DAVIS RW, 1980, ADV BACTERIAL GENET, P70; Egelman EH, 1998, J STRUCT BIOL, V124, P123, DOI 10.1006/jsbi.1998.4050; Gomis-Ruth FX, 2001, NATURE, V409, P637, DOI 10.1038/35054586; HORII T, 1992, J MOL BIOL, V223, P105, DOI 10.1016/0022-2836(92)90719-Z; Huang LC, 1997, J BACTERIOL, V179, P6076, DOI 10.1128/jb.179.19.6076-6083.1997; Ishimori K, 1996, J MOL BIOL, V264, P696, DOI 10.1006/jmbi.1996.0670; IYER VN, 1963, P NATL ACAD SCI USA, V50, P355, DOI 10.1073/pnas.50.2.355; KARLIN S, 1995, J BACTERIOL, V177, P6881, DOI 10.1128/jb.177.23.6881-6893.1995; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARMINAT F, 1989, MOL GEN GENET, V216, P106, DOI 10.1007/BF00332237; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LOGAN KM, 1993, J MOL BIOL, V232, P1048, DOI 10.1006/jmbi.1993.1459; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; LONBERG N, 1981, J MOL BIOL, V145, P123, DOI 10.1016/0022-2836(81)90337-5; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; MacFarland KJ, 1997, J BIOL CHEM, V272, P17675, DOI 10.1074/jbc.272.28.17675; MERTENS N, 1995, BIO-TECHNOL, V13, P175, DOI 10.1038/nbt0295-175; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; PUGH BF, 1987, J BIOL CHEM, V262, P1326; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Saecker RM, 2002, CURR OPIN STRUC BIOL, V12, P311, DOI 10.1016/S0959-440X(02)00326-3; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; Shan Q, 1997, J BIOL CHEM, V272, P11063; Shan Q, 1998, MOL CELL, V1, P309, DOI 10.1016/S1097-2765(00)80031-3; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; SHIBATA T, 1981, J BIOL CHEM, V256, P7557; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; Thompson TB, 1998, BIOCHEMISTRY-US, V37, P7686, DOI 10.1021/bi973178f; WEISEMANN JM, 1985, J BACTERIOL, V163, P748, DOI 10.1128/JB.163.2.748-755.1985; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; YU X, 1991, J STRUCT BIOL, V106, P243, DOI 10.1016/1047-8477(91)90074-7	51	91	91	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16372	16380		10.1074/jbc.M212917200	http://dx.doi.org/10.1074/jbc.M212917200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598539	hybrid			2022-12-27	WOS:000182680000116
J	Rott, R; Zipor, G; Portnoy, V; Liveanu, V; Schuster, G				Rott, R; Zipor, G; Portnoy, V; Liveanu, V; Schuster, G			RNA polyadenylation and degradation in cyanobacteria are similar to the chloroplast but different from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCA-ADDING ENZYME; POLYNUCLEOTIDE PHOSPHORYLASE FUNCTIONS; MESSENGER-RNA; POLY(A) POLYMERASE; COMPLEX; NUCLEOTIDYLTRANSFERASE; SUPERFAMILY; EXONUCLEASE; MATURATION; PATHWAY	The mechanism of RNA degradation in Escherichia coli involves endonucleolytic cleavage, polyadenylation of the cleavage product by poly(A) polymerase, and exonucleolytic degradation by the exoribonucleases, polynucleotide phosphorylase (PNPase) and RNase II. The poly(A) tails are homogenous, containing only adenosines in most of the growth conditions. In the chloroplast, however, the same enzyme, PNPase, polyadenylates and degrades the RNA molecule; there is no equivalent for the E. coli poly(A) polymerase enzyme. Because cyanobacteria is a prokaryote believed to be related to the evolutionary ancestor of the chloroplast, we asked whether the molecular mechanism of RNA polyadenylation in the Synechoeystis PCC6803 cyanobacteria is similar to that in E. coli or the chloroplast. We found that RNA polyadenylation in Synechocystis is similar to that in the chloroplast but different from E. coli. No poly(A) polymerase enzyme exists, and polyadenylation is performed by PNPase, resulting in heterogeneous poly(A)-rich tails. These heterogeneous tails were found in the amino acid coding region, the 5' and 3' untranslated regions of mRNAs, as well as in rRNA and the single intron located at the tRNA(fmet). Furthermore, unlike E. coli, the inactivation of PNPase or RNase II genes caused lethality. Together, our results show that the RNA polyadenylation and degradation mechanisms in cyanobacteria and chloroplast are very similar to each other but different from E. coli.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Schuster, G (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	gadis@tx.technion.ac.il	Schuster, Gadi/AAE-2010-2019					Aloy P, 2002, EMBO REP, V3, P628, DOI 10.1093/embo-reports/kvf135; Baginsky S, 2001, RNA, V7, P1464; Bonocora RP, 2001, MOL MICROBIOL, V39, P1299, DOI 10.1111/j.1365-2958.2001.02318.x; Bralley P, 2002, MICROBIOL-SGM, V148, P1421, DOI 10.1099/00221287-148-5-1421; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; Garcia-Dominguez M, 2000, J BACTERIOL, V182, P38, DOI 10.1128/JB.182.1.38-44.2000; Hayes R, 1999, TRENDS BIOCHEM SCI, V24, P199, DOI 10.1016/S0968-0004(99)01388-2; Jager S, 2001, NUCLEIC ACIDS RES, V29, P4581, DOI 10.1093/nar/29.22.4581; Jansson C, 1998, METHOD ENZYMOL, V297, P166; Kaberdin VR, 1998, P NATL ACAD SCI USA, V95, P11637, DOI 10.1073/pnas.95.20.11637; Komine Y, 2000, RNA, V6, P598, DOI 10.1017/S1355838200992252; Kujat SL, 2000, PLANT PHYSIOL, V124, P703, DOI 10.1104/pp.124.2.703; Kushner SR, 2002, J BACTERIOL, V184, P4658, DOI 10.1128/JB.184.17.4658-4665.2002; Kusov YY, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.12.e57; Li F, 2002, CELL, V111, P815, DOI 10.1016/S0092-8674(02)01115-7; Li ZW, 2002, RNA, V8, P97, DOI 10.1017/S1355838202014929; Lilly JW, 2002, PLANT CELL, V14, P2681, DOI 10.1105/tpc.005595; Lisitsky I, 1997, PLANT J, V12, P1173, DOI 10.1046/j.1365-313X.1997.12051173.x; Lisitsky I, 1997, J BIOL CHEM, V272, P17648, DOI 10.1074/jbc.272.28.17648; Lisitsky I, 1996, P NATL ACAD SCI USA, V93, P13398, DOI 10.1073/pnas.93.23.13398; Mohanty BK, 2000, P NATL ACAD SCI USA, V97, P11966, DOI 10.1073/pnas.220295997; Monde RA, 2000, BIOCHIMIE, V82, P573, DOI 10.1016/S0300-9084(00)00606-4; Ow MC, 2002, GENE DEV, V16, P1102, DOI 10.1101/gad.983502; Raynal LC, 1998, J BACTERIOL, V180, P6276; RIPPKA R, 1988, METHOD ENZYMOL, V167, P3; Rott R, 1998, MOL CELL BIOL, V18, P4605, DOI 10.1128/MCB.18.8.4605; SACHS A, 1993, J BIOL CHEM, V268, P22955; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Schuster G, 1999, PLANT PHYSIOL, V120, P937, DOI 10.1104/pp.120.4.937; Schwarz R, 1998, P NATL ACAD SCI USA, V95, P11008, DOI 10.1073/pnas.95.18.11008; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; Symmons MF, 2002, TRENDS BIOCHEM SCI, V27, P11, DOI 10.1016/S0968-0004(01)01999-5; Symmons MF, 2000, STRUCTURE, V8, P1215, DOI 10.1016/S0969-2126(00)00521-9; TOMITA K, 2002, J BIOL CHEM, V277, P48912; Vogel J, 2002, EMBO J, V21, P3794, DOI 10.1093/emboj/cdf359; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Yehudai-Resheff S, 2001, MOL CELL BIOL, V21, P5408, DOI 10.1128/MCB.21.16.5408-5416.2001; Yue DX, 1996, RNA, V2, P895	42	84	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15771	15777		10.1074/jbc.M211571200	http://dx.doi.org/10.1074/jbc.M211571200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601000	hybrid			2022-12-27	WOS:000182680000041
J	Wiederkehr-Adam, M; Ernst, P; Muller, K; Bieck, E; Gombert, FO; Ottl, J; Graff, P; Grossmuller, F; Heim, MH				Wiederkehr-Adam, M; Ernst, P; Muller, K; Bieck, E; Gombert, FO; Ottl, J; Graff, P; Grossmuller, F; Heim, MH			Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE RESPONSE FACTOR/STAT3; I INTERFERON RECEPTOR; SH2 DOMAINS; CYTOKINE RECEPTORS; CYTOPLASMIC DOMAIN; TYROSINE PHOSPHORYLATION; DIFFERENTIAL ACTIVATION; PATHWAY; PEPTIDE; GP130	Signal transducers and activators of transcription (STAT) 1 and STAT3 are activated by overlapping but distinct sets of cytokines. STATs are recruited to the different cytokine receptors through their Src homology (SH) 2 domains that make highly specific interactions with phosphotyrosine-docking sites on the receptors. We used a degenerate phosphopeptide library synthesized on 35-mum TentaGel beads and fluorescence-activated bead sorting to determine the sequence specificity of the peptide-binding sites of the SH2 domains of STAT1 and STAT3. The large bead library allowed not only peptide sequencing of pools of beads but also of single beads. The method was validated through surface plasmon resonance measurements of the affinities of different peptides to the STAT SH2 domains. Furthermore, when selected peptides were attached to a truncated erythropoietin receptor and stably expressed in DA3 cells, activation of STAT1 or STAT3 could be achieved by stimulation with erythropoietin. The combined analysis of pool sequencing, the individual peptide sequences, and plasmon resonance measurements allowed the definition of SH2 domain binding motifs. STAT1 preferentially binds peptides with the motif phosphotyrosine-(aspartic acid/glutamic acid)-(proline/ arginine)-(arginine/proline/glutamine), whereby a negatively charged amino acid at +1 excludes a proline at +2 and vice versa. STAT3 preferentially binds peptides with the motif phosphotyrosine-(basic or hydrophobic)(proline or basic)- glutamine. For both STAT1 and STAT3, specific high affinity phosphopeptides were identified that can be used for the design of inhibitory molecules.	Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Novartis Pharma AG, CH-4002 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Novartis Res Inst, A-1235 Vienna, Austria	University of Basel; Novartis; Max Planck Society; Novartis	Heim, MH (corresponding author), Kantonsspital, Zentrum Lehre & Forsch, Hebelstr 20, CH-4031 Basel, Switzerland.	Markus.Heim@unibas.ch	Heim, Markus/A-7526-2008	Heim, Markus/0000-0002-7523-4894; GOMBERT, Frank Otto/0000-0002-7507-697X				Atherton E., 1987, PEPTIDES ANAL SYNTHE, V9, P1; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; Kessels HWHG, 2002, P NATL ACAD SCI USA, V99, P8524, DOI 10.1073/pnas.142224499; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Muller K, 1996, J BIOL CHEM, V271, P16500; Nadeau OW, 1999, J BIOL CHEM, V274, P4045, DOI 10.1074/jbc.274.7.4045; Novak U, 1996, ONCOGENE, V13, P2607; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Tomida M, 1999, BLOOD, V93, P1934, DOI 10.1182/blood.V93.6.1934.406k05_1934_1941; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WeberNordt RM, 1996, J BIOL CHEM, V271, P27954, DOI 10.1074/jbc.271.44.27954; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	52	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16117	16128		10.1074/jbc.M300261200	http://dx.doi.org/10.1074/jbc.M300261200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591923	hybrid			2022-12-27	WOS:000182680000084
J	Hong, S; Gronert, K; Devchand, PR; Moussignac, RL; Serhan, CN				Hong, S; Gronert, K; Devchand, PR; Moussignac, RL; Serhan, CN			Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells - Autacoids in anti-inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; FISH-OIL; HUMAN-PLATELETS; LEUKOTRIENE; METABOLISM; EXPRESSION; PRODUCTS; N-3; TRANSFORMATION; BIOSYNTHESIS	Docosahexaenoic acid (DHA, C22:6) is highly enriched in brain, synapses, and retina and is a major w-3 fatty acid. Deficiencies in this essential fatty acid are reportedly associated with neuronal function, cancer, and inflammation. Here, using new lipidomic analyses employing high performance liquid chromatography coupled with a photodiode-array detector and a tandem mass spectrometer, a novel series of endogenous mediators was identified in blood, leukocytes, brain, and glial cells as 17S-hydroxy-containing docosanoids denoted as docosatrienes (the main bioactive member of the series was 10,17S-docosatriene) and 17S series resolvins. These novel mediators were biosynthesized via epoxide-containing intermediates and proved potent (pico- to nanomolar range) regulators of both leukocytes reducing infiltration in vivo and glial cells blocking their cytokine production. These results indicate that DHA is the precursor to potent protective mediators generated via enzymatic oxygenations to novel docosatrienes and 17S series resolvins that each regulate events of interest in inflammation and resolution.	Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Serhan, CN (corresponding author), Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, Thorn Med Res Bldg,7th Floor, Boston, MA 02115 USA.	enserhan@zeus.bwh.harvard.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK060583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038765, R29GM038765, R01GM038765] Funding Source: NIH RePORTER; NIDCR NIH HHS [P01-DE13499] Funding Source: Medline; NIDDK NIH HHS [K01 DK060583-03, DK60583] Funding Source: Medline; NIGMS NIH HHS [GM38765] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bazan N. G., 1990, NUTR BRAIN, V8, P1; BAZAN NG, 1992, NESTLE NUTR WORKS SE, V28, P121; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1984, BIOCHEM BIOPH RES CO, V125, P741, DOI 10.1016/0006-291X(84)90601-6; BAZAN NG, 2001, NEUROPROTECTION, P195; BERGSTROM S, 1982, PRIX NOBEL NOBEL PRI, P129; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Burr GO, 1929, J BIOL CHEM, V82, P345; Calder PC, 2001, LIPIDS, V36, P1007, DOI 10.1007/s11745-001-0812-7; Chanez P, 2002, AM J RESP CELL MOL, V27, P655, DOI 10.1165/rcmb.F253; Chiang N, 1999, J CLIN INVEST, V104, P309, DOI 10.1172/JCI7016; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Clish CB, 2000, J BIOL CHEM, V275, P25372, DOI 10.1074/jbc.M002863200; COREY EJ, 1986, TETRAHEDRON LETT, V27, P5173, DOI 10.1016/S0040-4039(00)85161-8; DeCaterina R, 1993, CURR TOP CARDIOV DIS, P105; FISCHER S, 1984, BIOCHEM BIOPH RES CO, V120, P907, DOI 10.1016/S0006-291X(84)80193-X; Gallin J.I., 1999, INFLAMMATION BASIC P; Garcia MC, 1997, BRAIN RES, V768, P43, DOI 10.1016/S0006-8993(97)00583-0; George HJ, 1996, PROTEIN EXPRES PURIF, V7, P19, DOI 10.1006/prep.1996.0003; GrahamLorence S, 1997, J BIOL CHEM, V272, P1127, DOI 10.1074/jbc.272.2.1127; Gronert K, 1999, METH MOL B, V120, P119; Gronert K, 1998, J PHARMACOL EXP THER, V285, P252; Gunstone FD, 1994, LIPID HDB; Hibbeln JR, 1998, LANCET, V351, P1213, DOI 10.1016/S0140-6736(05)79168-6; KHAIRELDIN TA, 1995, J IMMUNOL, V154, P1296; KIM HY, 1990, PROSTAG OTH LIPID M, V40, P473, DOI 10.1016/0090-6980(90)90110-H; LANDS WEM, 1993, ANN NY ACAD SCI, V676, P46; LEE TH, 1984, J CLIN INVEST, V74, P1922, DOI 10.1172/JCI111612; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; McLennan P, 1996, EUR J PHARMACOL, V300, P83, DOI 10.1016/0014-2999(95)00861-6; MILLER CC, 1991, J INVEST DERMATOL, V96, P98, DOI 10.1111/1523-1747.ep12515911; Moore MAS, 1999, NEW ENGL J MED, V341, P605, DOI 10.1056/NEJM199908193410811; RAPP JH, 1991, ARTERIOSCLER THROMB, V11, P903, DOI 10.1161/01.ATV.11.4.903; ROWLEY AF, 1994, BIOCHEMISTRY-US, V33, P856, DOI 10.1021/bi00170a002; Rudberg PC, 2002, P NATL ACAD SCI USA, V99, P4215, DOI 10.1073/pnas.072090099; Rudberg PC, 2002, J BIOL CHEM, V277, P1398, DOI 10.1074/jbc.M106577200; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Salem N, 1996, P NATL ACAD SCI USA, V93, P49, DOI 10.1073/pnas.93.1.49; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Samuelsson B, 1982, PRIX NOBEL NOBEL PRI, P153; SAWAZAKI S, 1994, J NEUROCHEM, V62, P2437; Serhan Charles N., 2002, Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, V1, P177, DOI 10.2174/1568014023355881; SERHAN CN, 1993, BIOCHEMISTRY-US, V32, P6313, DOI 10.1021/bi00076a002; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2001, J IMMUNOL, V166, P3650, DOI 10.4049/jimmunol.166.6.3650; SERHAN CN, 1989, BIOCHIM BIOPHYS ACTA, V1004, P158, DOI 10.1016/0005-2760(89)90264-6; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; SOK DE, 1983, BIOCHEM BIOPH RES CO, V110, P273, DOI 10.1016/0006-291X(83)91291-3; TOU J, 1986, LIPIDS, V21, P324, DOI 10.1007/BF02535694; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Vane JR, 2001, THERAPEUTIC ROLES SE; Wallace JL, 1999, BRIT J PHARMACOL, V126, P1200, DOI 10.1038/sj.bjp.0702420; WHELAN J, 1990, BIOL OXIDATION SYSTE, V2, P765; YERGEY JA, 1986, ANAL CHEM, V58, P1344, DOI 10.1021/ac00298a016; Yokomizo T, 1996, J BIOL CHEM, V271, P2844, DOI 10.1074/jbc.271.5.2844	58	757	800	1	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14677	14687		10.1074/jbc.M300218200	http://dx.doi.org/10.1074/jbc.M300218200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590139	hybrid, Green Published			2022-12-27	WOS:000182516100014
J	Liu, GZ; Wang, H; Wang, ZX				Liu, GZ; Wang, H; Wang, ZX			Identification of a highly conserved domain in the androgen receptor that suppresses the DNA-binding domain-DNA interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL EXTENSION; GLUCOCORTICOID RECEPTORS; PROSTATE-CANCER; GENE-MUTATIONS; TRANSCRIPTION; TRANSACTIVATION; INSENSITIVITY; COREGULATORS; COACTIVATOR; PROGRESSION	The androgen receptor (AR) is a ligand-regulated and sequence-specific transcription factor that activates or represses expression of target genes. Here, we show that the N terminus of AR contains an inhibitory domain located in an 81-amino acid segment lying upstream of the DNA-binding domain (DBD). The inhibitory domain interacted directly with DBD and repressed DBD binding to the androgen response element. Mutations of the conserved amino acid residues (K520E and R538E) within the inhibitory domain decreased its inhibiting ability in vitro and increased AR trans-activation in vivo. These data demonstrate the existence of a novel inhibitory domain in the N-terminal part of AR, which might play important roles in the regulation of AR trans-activation.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Wang, ZX (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd,Unit 173, Houston, TX 77030 USA.	zhenwang@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed SF, 2000, J CLIN ENDOCR METAB, V85, P658, DOI 10.1210/jc.85.2.658; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; BRINKMANN AO, 1995, J STEROID BIOCHEM, V53, P443, DOI 10.1016/0960-0760(95)00090-M; Buchanan G, 2001, MOL ENDOCRINOL, V15, P46, DOI 10.1210/me.15.1.46; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Csaszar A, 2001, EUR J PHARMACOL, V414, P9, DOI 10.1016/S0014-2999(01)00755-5; Culig Z, 1997, DRUG AGING, V10, P50, DOI 10.2165/00002512-199710010-00005; Culig Z, 2001, Am J Pharmacogenomics, V1, P241, DOI 10.2165/00129785-200101040-00001; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; He B, 2002, MOL GENET METAB, V75, P293, DOI 10.1016/S1096-7192(02)00009-4; He B, 2002, J BIOL CHEM, V277, P10226, DOI 10.1074/jbc.M111975200; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Heinlein CA, 2001, ENDOCRINE, V14, P143, DOI 10.1385/ENDO:14:2:143; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; Kantoff P, 1998, BBA-REV CANCER, V1378, pC1; KUPFER SR, 1993, J BIOL CHEM, V268, P17519; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Lobaccaro JM, 1999, ENDOCRINOLOGY, V140, P350, DOI 10.1210/en.140.1.350; McEwan IJ, 2001, BIOCHEM SOC T, V29, P222; Melvin VS, 2002, J BIOL CHEM, V277, P25115, DOI 10.1074/jbc.M110400200; Nelson KA, 2002, AM J EPIDEMIOL, V155, P883, DOI 10.1093/aje/155.10.883; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; Schoenmakers E, 1999, BIOCHEM J, V341, P515, DOI 10.1042/0264-6021:3410515; Schoenmakers E, 2000, J BIOL CHEM, V275, P12290, DOI 10.1074/jbc.275.16.12290; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; Sutherland RW, 1996, J UROLOGY, V156, P828, DOI 10.1016/S0022-5347(01)65830-0; Thompson J, 2001, MOL ENDOCRINOL, V15, P923, DOI 10.1210/me.15.6.923; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Wang ZX, 1997, GENE DEV, V11, P1315, DOI 10.1101/gad.11.10.1315; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; WONG CI, 1993, J BIOL CHEM, V268, P19004; Xiao H, 1998, P NATL ACAD SCI USA, V95, P2146, DOI 10.1073/pnas.95.5.2146; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001	39	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14956	14960		10.1074/jbc.M212229200	http://dx.doi.org/10.1074/jbc.M212229200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12591938	hybrid			2022-12-27	WOS:000182516100050
J	Sato, S; Tomomori-Sato, C; Banks, CAS; Sorokina, I; Parmely, TJ; Kong, SE; Jin, JJ; Cai, Y; Lane, WS; Brower, CS; Conaway, RC; Conaway, JW				Sato, S; Tomomori-Sato, C; Banks, CAS; Sorokina, I; Parmely, TJ; Kong, SE; Jin, JJ; Cai, Y; Lane, WS; Brower, CS; Conaway, RC; Conaway, JW			Identification of mammalian mediator subunits with similarities to yeast mediator subunits Srb5, Srb6, Med11, and Rox3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL REGULATION; NUCLEAR RECEPTORS; COFACTOR COMPLEX; ACTIVATION; PATHWAYS; PROTEIN; SMCC	The Mediator is a multiprotein coactivator required for activation of RNA polymerase II transcription by DNA binding transactivators. We recently identified a mammalian homologue of yeast Mediator subunit Med8 and partially purified a Med8-containing Mediator complex from rat liver nuclei (Brower, C. S., Sato, S., Tomomori-Sato, C., Kamura, T., Pause, A., Stearman, R., Klausner, R. D., Malik, S., Lane, W. S., Sorokina, I., Roeder, R. G., Conaway, J. W., and Conaway, R. C. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 10353-10358). Analysis of proteins present in the most highly purified Med8-containing fractions by tandem mass spectrometry led to the identification of many known mammalian Mediator subunits, as well as four potential Mediator subunits exhibiting sequence similarity to yeast Mediator subunits Srb5, Srb6, Med11, and Rox3. Here we present direct biochemical evidence that these four proteins are bona fide mammalian Mediator subunits. In addition, we identify direct pairwise binding partners of these proteins among the known mammalian Mediator subunits. Taken together, our findings identify a collection of novel mammalian Mediator subunits and shed new light on the underlying architecture of the mammalian Mediator complex.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Harvard Univ, Harvard Microchem & Prote Anal Facil, Cambridge, MA 02138 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Stowers Institute for Medical Research; Harvard University; California Institute of Technology; University of Kansas; University of Kansas Medical Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Conaway, JW (corresponding author), Stowers Inst Med Res, Kansas City, MO 64110 USA.			Conaway, Joan/0000-0002-2786-0663; Tomomori-Sato, Chieri/0000-0002-2543-293X; Banks, Charles/0000-0002-0404-2940; Sorokina, Irina/0000-0003-1531-1832	NIGMS NIH HHS [R37 GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boube M, 2002, CELL, V110, P143, DOI 10.1016/S0092-8674(02)00830-9; Brower CS, 2002, P NATL ACAD SCI USA, V99, P10353, DOI 10.1073/pnas.162424199; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gu JY, 2002, J BIOL CHEM, V277, P27154, DOI 10.1074/jbc.M204144200; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Malik S, 2000, MOL CELL, V5, P753, DOI 10.1016/S1097-2765(00)80254-3; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141	12	42	54	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15123	15127		10.1074/jbc.C300054200	http://dx.doi.org/10.1074/jbc.C300054200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584197	hybrid, Green Accepted			2022-12-27	WOS:000182516100070
J	Fan, DP; Zheng, Y; Yang, DW; Wang, JJ				Fan, DP; Zheng, Y; Yang, DW; Wang, JJ			NMR solution structure and dynamics of an exchangeable apolipoprotein, Locusta migratoria apolipophorin III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-BINDING; SPECTROSCOPY; CONFORMATION; HELIX; RELAXATION; PARTICLES; DOMAIN; ALPHA; N-15	We report here the NMR structure and backbone dynamics of an exchangeable apolipoprotein, apoLp-III, from the insect Locusta migratoria. The NMR structure adopts an up-and-down elongated five-helix bundle, which is similar to the x-ray crystal structure of this protein. A short helix, helix 4', is observed that is perpendicular to the bundle and fully solvent-exposed. NMR experimental parameters confirm the existence of this short helix, which is proposed to serve as a recognition helix for apoLp-III binding to lipoprotein surfaces. The L. migratoria apoLp-III helix bundle displays several characteristic structural features that regulate the reversible lipoprotein binding activity of apoLp-III. The buried hydrophilic residues and exposed hydrophobic residues readily adjust the marginal stability of apoLp-III, facilitating the helix bundle opening. Specifically, upon lipoprotein binding the locations and orientations of the buried hydrophilic residues modulate the apoLp-III helix bundle to adopt a possible opening at the hinge that is opposite the recognition short helix, helix 4'. The backbone dynamics provide additional support to the recognition role of helix 4' and this preferred conformational adaptation of apoLp-III upon lipid binding. In this case, the lipid-bound open conformation contains two lobes linked by hinge loops. One lobe contains helices 2 and 3, and the other lobe contains helices 1, 4, and 5. This preferred bundle opening is different from the original proposal on the basis of the x-ray crystal structure of this protein (Breiter, D. R., Kanost, M. R., Benning, M. M., Wesenberg, G., Law, J. H., Wells, M. A., Rayment, I., and Holden, H. M. ( 1991) Biochemistry 30, 603 - 608), but it efficiently uses helix 4' as the recognition short helix. The buried interhelical H-bonds are found to be mainly located between the two lobes, potentially providing a specific driving force for the helix bundle recovery of apoLp-III from the lipid-bound open conformation. Finally, we compare the NMR structures of Manduca sexta apoLp-III and L. migratoria apoLp-III and present a united scheme for the structural basis of the reversible lipoprotein binding activity of apoLp-III.	So Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Natl Univ Singapore, Dept Chem, Singapore 117543, Singapore	Southern Illinois University System; Southern Illinois University; National University of Singapore; National University of Singapore	Wang, JJ (corresponding author), So Illinois Univ, Sch Med, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA.		yang, daiwen/H-8408-2012	yang, daiwen/0000-0002-6804-0071				Akke M, 1996, J AM CHEM SOC, V118, P911, DOI 10.1021/ja953503r; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; BRUNGER AT, 1992, XPLOR VERSION 3 1; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fan DP, 2001, J BIOMOL NMR, V19, P83, DOI 10.1023/A:1008398720439; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; LASKOWSKI RA, 1991, ACTA CRYSTALLOGR A, V47, P110; McInnes C, 1998, J BIOL CHEM, V273, P27357, DOI 10.1074/jbc.273.42.27357; Narayanaswami V, 1996, J BIOL CHEM, V271, P26855, DOI 10.1074/jbc.271.43.26855; Narayanaswami V, 1999, P NATL ACAD SCI USA, V96, P4366, DOI 10.1073/pnas.96.8.4366; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; NIGLES M, 1988, FEBS LETT, V229, P129; Okon M, 2001, FEBS LETT, V487, P390, DOI 10.1016/S0014-5793(00)02375-9; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; Rozek A, 1999, BIOCHEMISTRY-US, V38, P14475, DOI 10.1021/bi982966h; RYAN RO, 1993, J BIOL CHEM, V268, P1525; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SOULAGES JL, 1995, P NATL ACAD SCI USA, V92, P5650, DOI 10.1073/pnas.92.12.5650; Soulages JL, 2001, J BIOL CHEM, V276, P34162, DOI 10.1074/jbc.M105836200; Wang JJ, 1997, J BIOL CHEM, V272, P17912, DOI 10.1074/jbc.272.29.17912; WANG JJ, 1995, BIOCHEMISTRY-US, V34, P6755, DOI 10.1021/bi00020a021; Wang JJ, 2002, P NATL ACAD SCI USA, V99, P1188, DOI 10.1073/pnas.032565999; Wang JJ, 1998, BIOCHEM CELL BIOL, V76, P276, DOI 10.1139/bcb-76-2-3-276; Weers PMM, 2000, BIOCHEMISTRY-US, V39, P6874, DOI 10.1021/bi992891x; Weers PMM, 1999, J BIOL CHEM, V274, P21804, DOI 10.1074/jbc.274.31.21804; Weers PMM, 1998, BBA-LIPID LIPID MET, V1393, P99, DOI 10.1016/S0005-2760(98)00063-0; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WISHART DS, 1994, VADAR VERSION 1 2	34	43	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21212	21220		10.1074/jbc.M208486200	http://dx.doi.org/10.1074/jbc.M208486200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12621043	hybrid			2022-12-27	WOS:000183230500099
J	Balasubramanyam, K; Swaminathan, V; Ranganathan, A; Kundu, TK				Balasubramanyam, K; Swaminathan, V; Ranganathan, A; Kundu, TK			Small molecule modulators of histone acetyltransferase p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLATION; TRANSCRIPTION; CBP	Histone acetyltransferases (HATs) are a group of enzymes that play a significant role in the regulation of gene expression. These enzymes covalently modify the N-terminal lysine residues of histones by the addition of acetyl groups from acetyl-CoA. Dysfunction of these enzymes is often associated with the manifestation of several diseases, predominantly cancer. Here we report that anacardic acid from cashew nut shell liquid is a potent inhibitor of p300 and p300/CBP-associated factor histone acetyltranferase activities. Although it does not affect DNA transcription, HAT-dependent transcription from a chromatin template was strongly inhibited by anacardic acid. Furthermore, we describe the design and synthesis of an amide derivative N-(4-chloro-3-trifluoromethyl-phenyl)-2-ethoxy-6-pentadecyl-benzamide (CTPB) using anacardic acid as a synthon, which remarkably activates p300 HAT activity but not that of p300/CBP- associated factor. Although CTPB does not affect DNA transcription, it enhances the p300 HAT-dependent transcriptional activation from in vitro assembled chromatin template. However, it has no effect on histone deacetylase activity. These compounds would be useful as biological switching molecules for probing into the role of p300 in transcriptional studies and may also be useful as new chemical entities for the development of anticancer drugs.	Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Transript & Dis Lab, Bangalore 560064, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Chem & Phys Mat Unit, Bangalore 560064, Karnataka, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Kundu, TK (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Transript & Dis Lab, Bangalore 560064, Karnataka, India.			Venkatesh, Swaminathan/0000-0001-9837-1501; Kundu, Tapas/0000-0001-7790-214X				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; CHANG FC, 1964, TETRAHEDRON LETT, P2969; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; CULLIS PM, 1982, J BIOL CHEM, V257, P2165; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; KIONG LS, 1981, J CHEM SOC PERK T 1, P1942, DOI 10.1039/p19810001942; KUBO I, 1993, J AGR FOOD CHEM, V41, P1012, DOI 10.1021/jf00030a035; Kumar BRP, 2001, J BIOL CHEM, V276, P16804, DOI 10.1074/jbc.M100934200; Kundu TK, 1999, MOL CELL BIOL, V19, P1605; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Lau OD, 2000, MOL CELL, V5, P589, DOI 10.1016/S1097-2765(00)80452-9; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Murata T, 2001, HUM MOL GENET, V10, P1071, DOI 10.1093/hmg/10.10.1071; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SHOBHA SV, 1991, J AGR FOOD CHEM, V39, P2214, DOI 10.1021/jf00012a022; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Wang ZX, 1997, GENE DEV, V11, P1315, DOI 10.1101/gad.11.10.1315	19	378	399	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19134	19140		10.1074/jbc.M301580200	http://dx.doi.org/10.1074/jbc.M301580200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12624111	hybrid			2022-12-27	WOS:000182932200055
J	Abrahamsen, H; Vang, T; Tasken, K				Abrahamsen, H; Vang, T; Tasken, K			Protein kinase A intersects Src signaling in membrane microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; FAMILY TYROSINE KINASES; GROWTH-FACTOR RECEPTOR; LIPID RAFTS; DOWN-REGULATION; EGF RECEPTORS; PHOSPHORYLATION; PP60C-SRC; CSK; BINDING	Regulation of Src kinase activity is tightly coupled to the phosphorylation status of the C-terminal regulatory tyrosine Tyr(527), which, when phosphorylated by Csk, represses Src. Here, we demonstrate that activation of Csk through a prostaglandin E-2-cAMP-protein kinase A (PKA) pathway inhibits Src. This inhibitory pathway is operative in detergent-resistant membrane fractions where cAMP-elevating agents activate Csk, resulting in a concomitant decrease in Src activity. The inhibitory effect on Src depends on a detergent-resistant membrane-anchored Csk and co-localization of all components of the inhibitory pathway in membrane microdomains. Furthermore, epidermal growth factor-induced activation of Src and phosphorylation of the Src substrates Cbl and focal adhesion kinase are inhibited by activation of the cAMP-PKA-Csk pathway. We propose a novel mechanism whereby G protein-coupled receptors inhibit Src signaling by activation of Csk in a cAMP-PKA-dependent manner.	Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, N-0317 Oslo, Norway	University of Oslo	Tasken, K (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, Box 1112,Blindern, N-0317 Oslo, Norway.		Abrahamsen, Hilde/E-5323-2010	Tasken, Kjetil/0000-0003-2841-4697				Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Cary LA, 2000, NATURE, V404, P945, DOI 10.1038/35010257; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lowry WE, 2002, DEV CELL, V2, P733, DOI 10.1016/S1534-5807(02)00175-2; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; OKADA M, 1989, J BIOL CHEM, V264, P20886; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Ringerike T, 2002, J CELL SCI, V115, P1331; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Vang T, 1998, BBA-PROTEIN STRUCT M, V1384, P285, DOI 10.1016/S0167-4838(97)00202-1; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; YACIUK P, 1989, MOL CELL BIOL, V9, P2453, DOI 10.1128/MCB.9.6.2453; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964	44	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17170	17177		10.1074/jbc.M211426200	http://dx.doi.org/10.1074/jbc.M211426200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606547	hybrid			2022-12-27	WOS:000182818600097
J	Chung, JW; Hong, SJ; Kim, KJ; Goti, D; Stins, MF; Shin, S; Dawson, VL; Dawson, TM; Kim, KS				Chung, JW; Hong, SJ; Kim, KJ; Goti, D; Stins, MF; Shin, S; Dawson, VL; Dawson, TM; Kim, KS			37-kDa laminin receptor precursor modulates cytotoxic necrotizing factor 1-mediated RhoA activation and bacterial uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; ESCHERICHIA-COLI INVASION; BINDING-PROTEIN; PRION PROTEIN; FACTOR TYPE-1; K1 INVASION; GENE LOCUS; FACTOR-I; IDENTIFICATION; CONTRIBUTES	Cytotoxic necrotizing factor 1 (CNF1) is a bacterial toxin known to activate Rho GTPases and induce host cell cytoskeleton rearrangements. The constitutive activation of Rho GTPases by CNF1 is shown to enhance bacterial uptake in epithelial cells and human brain microvascular endothelial cells. However, it is unknown how exogenous CNF1 exhibits such phenotypes in eukaryotic cells. Here, we identified 37-kDa laminin receptor precursor (LRP) as the receptor for CNF1 from screening the cDNA library of human brain microvascular endothelial cells by the yeast two-hybrid system using the N-terminal domain of CNF1 as bait. CNF1-mediated RhoA activation and bacterial uptake were inhibited by exogenous LRP or LRP antisense oligodeoxynucleotides, whereas they were increased in LRP-overexpressing cells. These findings indicate that the CNF1 interaction with LRP is the initial step required for CNF1-mediated RhoA activation and bacterial uptake in eukaryotic cells.	Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Kim, KS (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, 600 N Wolfe St,Pk 256, Baltimore, MD 21287 USA.		Stins, Monique/W-2621-2018; Dawson, Valina/Y-9757-2019	Dawson, Valina/0000-0002-2915-3970				Backstrom M, 1997, MOL MICROBIOL, V24, P489, DOI 10.1046/j.1365-2958.1997.3541721.x; Badger JL, 2000, MOL MICROBIOL, V36, P174, DOI 10.1046/j.1365-2958.2000.01840.x; BLANCO J, 1992, FEMS MICROBIOL LETT, V96, P155, DOI 10.1016/0378-1097(92)90396-6; Broek IV, 2001, BRIT J CANCER, V85, P1387, DOI 10.1054/bjoc.2001.2078; CAPRIOLI A, 1983, INFECT IMMUN, V39, P1300, DOI 10.1128/IAI.39.3.1300-1306.1983; Clausse N, 1996, DNA CELL BIOL, V15, P1009, DOI 10.1089/dna.1996.15.1009; Contamin S, 2000, MOL BIOL CELL, V11, P1775, DOI 10.1091/mbc.11.5.1775; Donaldson Elaine A., 2000, Molecular Cell Biology Research Communications, V3, P53, DOI 10.1006/mcbr.2000.0191; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; FIORENTINI C, 1988, TOXICON, V26, P1047, DOI 10.1016/0041-0101(88)90203-6; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; Hoffman JA, 2000, INFECT IMMUN, V68, P5062, DOI 10.1128/IAI.68.9.5062-5067.2000; Huang SH, 1999, INFECT IMMUN, V67, P2103, DOI 10.1128/IAI.67.5.2103-2109.1999; Huang SH, 2001, J INFECT DIS, V183, P1071, DOI 10.1086/319290; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Khan NA, 2002, J BIOL CHEM, V277, P15607, DOI 10.1074/jbc.M112224200; Lemichez E, 1997, MOL MICROBIOL, V24, P1061, DOI 10.1046/j.1365-2958.1997.4151781.x; Lerm M, 1999, INFECT IMMUN, V67, P496, DOI 10.1128/IAI.67.2.496-503.1999; Ludwig GV, 1996, J VIROL, V70, P5592, DOI 10.1128/JVI.70.8.5592-5599.1996; McKenna DJ, 2001, EXP EYE RES, V73, P81, DOI 10.1006/exer.2001.1013; Menard S, 1998, BREAST CANCER RES TR, V52, P137, DOI 10.1023/A:1006171403765; Meysick KC, 2001, INFECT IMMUN, V69, P2066, DOI 10.1128/IAI.69.4.2066-2074.2001; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Narumi K, 1999, JPN J CANCER RES, V90, P425, DOI 10.1111/j.1349-7006.1999.tb00765.x; PELLEGRINI R, 1994, INT J CANCER S, V8, P116; Prasadarao NV, 1999, INFECT IMMUN, V67, P5775, DOI 10.1128/IAI.67.11.5775-5783.1999; Prasadarao NV, 1999, INFECT IMMUN, V67, P1131, DOI 10.1128/IAI.67.3.1131-1138.1999; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Sorokin AV, 2000, BIOCHEMISTRY-MOSCOW+, V65, P546; Stins MF, 1997, J NEUROIMMUNOL, V76, P81, DOI 10.1016/S0165-5728(97)00036-2; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; Wang Y, 1999, INFECT IMMUN, V67, P4751, DOI 10.1128/IAI.67.9.4751-4756.1999	37	86	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16857	16862		10.1074/jbc.M301028200	http://dx.doi.org/10.1074/jbc.M301028200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615923	hybrid			2022-12-27	WOS:000182818600056
J	Mould, AP; Barton, SJ; Askari, JA; McEwan, PA; Buckley, PA; Craig, SE; Humphries, MJ				Mould, AP; Barton, SJ; Askari, JA; McEwan, PA; Buckley, PA; Craig, SE; Humphries, MJ			Conformational changes in the integrin beta A domain provide a mechanism for signal transduction via hybrid domain movement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-DOMAIN; MONOCLONAL-ANTIBODY; BINDING-SITE; EXTRACELLULAR SEGMENT; REGULATORY REGION; CRYSTAL-STRUCTURE; CELL-ADHESION; ALPHA 5; LIGAND; ACTIVATION	The ligand-binding head region of integrin beta subunits contains a von Willebrand factor type A domain (betaA). Ligand binding activity is regulated through conformational changes in betaA, and ligand recognition also causes conformational changes that are transduced from this domain. The molecular basis of signal transduction to and from betaA is uncertain. The epitopes of mAbs 15/7 and HUTS-4 lie in the beta(1) subunit hybrid domain, which is connected to the lower face of betaA. Changes in the expression of these epitopes are induced by conformational changes in betaA caused by divalent cations, function perturbing mAbs, or ligand recognition. Recombinant truncated alpha(5)beta1 with a mutation L358A in the alpha7 helix of betaA has constitutively high expression of the 15/7 and HUTS-4 epitopes, mimics the conformation of the ligand-occupied receptor, and has high constitutive ligand binding activity. The epitopes of 15/7 and HUTS-4 map to a region of the hybrid domain that lies close to an interface with the alpha subunit. Taken together, these data suggest that the transduction of conformational changes through betaA involves shape shifting in the alpha7 helix region, which is linked to a swing of the hybrid domain away from the alpha subunit.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Mould, AP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	paul.mould@man.ac.uk		Mould, Paul/0000-0003-0076-6228; Humphries, Martin/0000-0002-4331-6967; mcewan, paul/0000-0001-6097-1528				Arnaout MA, 2002, IMMUNOL REV, V186, P125, DOI 10.1034/j.1600-065X.2002.18612.x; Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BELGOVA N, 2002, NAT STRUCT BIOL, V9, P282; Burrows L, 1999, BIOCHEM J, V344, P527, DOI 10.1042/0264-6021:3440527; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Coe APF, 2001, J BIOL CHEM, V276, P35854, DOI 10.1074/jbc.M103639200; Crommie D, 1998, J CELL BIOCHEM, V71, P63, DOI 10.1002/(SICI)1097-4644(19981001)71:1<63::AID-JCB7>3.0.CO;2-#; Curley GP, 1999, CELL MOL LIFE SCI, V56, P427, DOI 10.1007/s000180050443; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DU XP, 1991, CELL, V79, P659; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; Humphries JD, 2000, J BIOL CHEM, V275, P20337, DOI 10.1074/jbc.M000568200; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Liddington RC, 2002, STRUCTURE, V10, P605, DOI 10.1016/S0969-2126(02)00766-9; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Mizoue LS, 2002, CURR OPIN STRUC BIOL, V12, P459, DOI 10.1016/S0959-440X(02)00348-2; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1996, J CELL SCI, V109, P2613; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; MULLER B, 1993, J BIOL CHEM, V268, P6800; Ni HY, 1998, J BIOL CHEM, V273, P7981, DOI 10.1074/jbc.273.14.7981; Ni HY, 1998, CELL ADHES COMMUN, V5, P257, DOI 10.3109/15419069809040296; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P16580, DOI 10.1074/jbc.271.28.16580; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; Shih DT, 1997, J CELL SCI, V110, P2619; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200; Yan B, 2000, J BIOL CHEM, V275, P7249, DOI 10.1074/jbc.275.10.7249; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	53	101	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17028	17035		10.1074/jbc.M213139200	http://dx.doi.org/10.1074/jbc.M213139200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615914	hybrid			2022-12-27	WOS:000182818600079
J	Simonet, VC; Basle, A; Klose, KE; Delcour, AH				Simonet, VC; Basle, A; Klose, KE; Delcour, AH			The Vibrio cholerae Porins OmpU and OmpT have distinct channel properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; ESCHERICHIA-COLI; BACTERIAL PORINS; BILE RESISTANCE; PATCH-CLAMP; VIRULENCE; TOXR; RECONSTITUTION; ANGUILLARUM; EXPRESSION	Numerous environmental signals regulate the production of virulence factors and the composition of the outer membrane of Vibrio cholerae. In particular, bile promotes the ToxR-dependent expression of the porin OmpU. Strains expressing solely OmpU are more resistant to bile, are better able to colonize the intestine, and produce more cholera toxin than strains expressing solely the OmpT porin. To gain some understanding in the physiological relevance and the molecular mechanism underlying these porin-dependent phenotypes, we have undertaken a thorough electrophysiological characterization of the channel properties of the two porins. Purified OmpU or OmpT was reconstituted in liposomes suitable for patch clamp and in planar lipid bilayers. The high resolution of the patch clamp technique allowed us to analyze in detail the behavior of single OmpU and OmpT channels. Both channels exhibit closing transitions to various conductance states. OmpT is a much more dynamic channel than OmpU, displaying frequent and prolonged closures, even at low transmembrane potentials. With a critical voltage for closure V-c of approximately +/-90 mV, OmpT is much more voltage-sensitive than OmpU (with a V-c of approximately +/-160 mV), a feature that is also readily apparent in the voltage dependence of closing probability observed in patch clamp in the +/-100 mV range. OmpT has low ionic selectivity (P-K/P-Cl=similar to4), whereas OmpU is more cation-selective (P-K/P-Cl=similar to14). The distinct functional properties of the two porins are likely to play an integrated role with environmental regulation of their expression. For example, the higher selectivity of OmpU for cations provides a possible explanation for the protective role played by this porin in a bile-containing environment, because this type of selectivity would restrict the flux of anionic bile salts through the outer membrane and thus would reduce the exposure of the cytoplasmic membrane to this natural detergent.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol & Immunol, San Antonio, TX 78229 USA	University of Houston System; University of Houston; University of Texas System; University of Texas Health San Antonio	Delcour, AH (corresponding author), Univ Houston, Dept Biol & Biochem, 369 Sci & Res Bldg 2, Houston, TX 77204 USA.			Basle, Arnaud/0000-0002-4899-3086	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI051333, R29AI034905, R01AI051333, R01AI034905] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34905, AI51333] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALM RA, 1986, FEMS MICROBIOL LETT, V37, P99, DOI 10.1111/j.1574-6968.1986.tb01774.x; Benz Roland, 1997, Microbiologia (Madrid), V13, P321; BOLLA JM, 1995, J BACTERIOL, V177, P4266, DOI 10.1128/jb.177.15.4266-4271.1995; Chakrabarti Sr, 1996, J BACTERIOL, V178, P524, DOI 10.1128/jb.178.2.524-530.1996; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Crawford JA, 1998, MOL MICROBIOL, V29, P235, DOI 10.1046/j.1365-2958.1998.00925.x; Davey ML, 1998, APPL ENVIRON MICROB, V64, P138; De E, 2001, MOL MICROBIOL, V41, P189, DOI 10.1046/j.1365-2958.2001.02501.x; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; Delcour AH, 1997, FEMS MICROBIOL LETT, V151, P115, DOI 10.1016/S0378-1097(97)00166-3; FOUREL D, 1994, EUR J BIOCHEM, V222, P625, DOI 10.1111/j.1432-1033.1994.tb18905.x; Gupta S, 1997, INFECT IMMUN, V65, P1131, DOI 10.1128/IAI.65.3.1131-1134.1997; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B, 1992, IONIC CHANNELS EXCIT, P341; Iyer R, 1997, J BIOL CHEM, V272, P18595, DOI 10.1074/jbc.272.30.18595; Jacob-Dubuisson F, 1999, J BIOL CHEM, V274, P37731, DOI 10.1074/jbc.274.53.37731; KOGA T, 1994, MICROBIOL IMMUNOL, V38, P931, DOI 10.1111/j.1348-0421.1994.tb02149.x; LANG HN, 1993, MOL MICROBIOL, V10, P891, DOI 10.1111/j.1365-2958.1993.tb00960.x; Li CYC, 2000, MOL MICROBIOL, V35, P189, DOI 10.1046/j.1365-2958.2000.01699.x; Liu NZ, 1997, BBA-BIOMEMBRANES, V1326, P201, DOI 10.1016/S0005-2736(97)00024-2; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Nakasone N, 1998, INFECT IMMUN, V66, P4726, DOI 10.1128/IAI.66.10.4726-4728.1998; NIKAIDO H, 1996, ESCHERICHIA COLI SAL, P29; Nitzan Y, 1999, CURR MICROBIOL, V38, P1, DOI 10.1007/PL00006764; Provenzano D, 2000, P NATL ACAD SCI USA, V97, P10220, DOI 10.1073/pnas.170219997; Provenzano D, 2000, INFECT IMMUN, V68, P1491, DOI 10.1128/IAI.68.3.1491-1497.2000; Provenzano D, 2001, J BACTERIOL, V183, P3652, DOI 10.1128/JB.183.12.3652-3662.2001; SAHU GK, 1994, INFECT IMMUN, V62, P5624, DOI 10.1128/IAI.62.12.5624-5631.1994; Samartzidou H, 1998, EMBO J, V17, P93, DOI 10.1093/emboj/17.1.93; SEN K, 1988, J BIOL CHEM, V263, P1182; Simon M, 1996, J BACTERIOL, V178, P4182, DOI 10.1128/jb.178.14.4182-4188.1996; Skorupski K, 1997, MOL MICROBIOL, V25, P1003, DOI 10.1046/j.1365-2958.1997.5481909.x; SPERANDIO V, 1995, INFECT IMMUN, V63, P4433, DOI 10.1128/IAI.63.11.4433-4438.1995; Van Gelder P, 2000, BIOPHYS CHEM, V85, P153, DOI 10.1016/S0301-4622(99)00153-2; Wibbenmeyer JA, 2002, INFECT IMMUN, V70, P121, DOI 10.1128/IAI.70.1.121-126.2002	35	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17539	17545		10.1074/jbc.M301202200	http://dx.doi.org/10.1074/jbc.M301202200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606562	hybrid			2022-12-27	WOS:000182818600143
J	Huang, LL; Sexton, DJ; Skogerson, K; Devlin, M; Smith, R; Sanyal, I; Parry, T; Kent, R; Enright, J; Wu, QL; Conley, G; DeOliveira, D; Morganelli, L; Ducar, M; Wescott, CR; Ladner, RC				Huang, LL; Sexton, DJ; Skogerson, K; Devlin, M; Smith, R; Sanyal, I; Parry, T; Kent, R; Enright, J; Wu, QL; Conley, G; DeOliveira, D; Morganelli, L; Ducar, M; Wescott, CR; Ladner, RC			Novel peptide inhibitors of angiotensin-converting enzyme 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROLYSIS; CAPTOPRIL; MECHANISM	Angiotensin-converting enzyme 2 (ACE2), a recently identified human homolog of ACE, is a novel metallocarboxypeptidase with specificity, tissue distribution, and function distinct from those of ACE. ACE2 may play a unique role in the renin-angiotensin system and mediate cardiovascular and renal function. Here we report the discovery of ACE2 peptide inhibitors through selection of constrained peptide libraries displayed on phage. Six constrained peptide libraries were constructed and selected against FLAG-tagged ACE2 target. ACE2 peptide binders were identified and classified into five groups, based on their effects on ACE2 activity. Peptides from the first three classes exhibited none, weak, or mode-rate inhibition on ACE2. Peptides from the fourth class exhibited strong inhibition, with equilibrium inhibition constants (K-i values) from 0.38 to 1.7 gm. Peptides from the fifth class exhibited very strong inhibition, with K-i values <0.14 muM. The most potent inhibitor, DX600, had a Ki of 2.8 nM. Steady-state enzyme kinetic analysis showed that these potent ACE2 inhibitors exhibited a mixed competitive and non-competitive type of inhibition. They were not hydrolyzed by ACE2. Furthermore, they did not inhibit ACE activity, and thus were specific to ACE2. Finally, they also inhibited ACE2 activity toward its natural substrate angiotensin 1, suggesting that they would be functional in vivo. As novel ACE2-specific peptide inhibitors, they should be useful in elucidation of ACE2 in vivo function, thus contributing to our better understanding of the biology of cardiovascular regulation. Our results also demonstrate that library selection by phage display technology can be a rapid and efficient way to discover potent and specific protease inhibitors.	Dyax Corp, Div Res, Cambridge, MA 02139 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	GlaxoSmithKline; Human Genome Sciences Inc	Huang, LL (corresponding author), Dyax Corp, Div Res, 300 Technol Square, Cambridge, MA 02139 USA.	lhuang@dyax.com		Sexton, Daniel J/0000-0001-9604-5948				CORVOL P, 1995, METHOD ENZYMOL, V248, P283; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Dales NA, 2002, J AM CHEM SOC, V124, P11852, DOI 10.1021/ja0277226; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; DORER FE, 1974, CIRC RES, V34, P824, DOI 10.1161/01.RES.34.6.824; DRUMMER OH, 1990, BIOCHEM PHARMACOL, V39, P513, DOI 10.1016/0006-2952(90)90058-S; Eriksson U, 2002, CURR BIOL, V12, pR745, DOI 10.1016/S0960-9822(02)01255-1; Fairbrother WJ, 1998, BIOCHEMISTRY-US, V37, P17754, DOI 10.1021/bi981931e; JOHNSON H, 1989, PEPTIDES, V10, P489, DOI 10.1016/0196-9781(89)90133-2; Lemos VS, 2002, BRIT J PHARMACOL, V135, P1743, DOI 10.1038/sj.bjp.0704630; Marceau F, 1998, CLIN REV ALLERG IMMU, V16, P385, DOI 10.1007/BF02737658; MENDELSOHN FAO, 1981, CLIN SCI, V61, pS277, DOI 10.1042/cs061277s; OKUDA M, 1985, J BIOCHEM-TOKYO, V98, P621, DOI 10.1093/oxfordjournals.jbchem.a135318; OPARIL S, 1971, CIRC RES, V29, P682, DOI 10.1161/01.RES.29.6.682; Ren YL, 2002, HYPERTENSION, V39, P799, DOI 10.1161/hy0302.104673; Segel I. H., 1993, ENZYME KINETICS BEHA, P100; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; SNYDER RA, 1986, BIOCHIM BIOPHYS ACTA, V871, P1, DOI 10.1016/0167-4838(86)90125-1; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200; Turner AJ, 2002, TRENDS PHARMACOL SCI, V23, P177, DOI 10.1016/S0165-6147(00)01994-5; Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200	21	161	193	8	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15532	15540		10.1074/jbc.M212934200	http://dx.doi.org/10.1074/jbc.M212934200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12606557	hybrid			2022-12-27	WOS:000182680000011
J	Worhunsky, DJ; Godek, K; Litsch, S; Schlax, PJ				Worhunsky, DJ; Godek, K; Litsch, S; Schlax, PJ			Interactions of the non-coding RNA DsrA and RpoS mRNA with the 30 S ribosomal subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN HF-I; ESCHERICHIA-COLI; SIGMA(S) SUBUNIT; HOST FACTOR; TRANSLATION; EXPRESSION; GENE; POLYMERASE; RIBOREGULATION; ANTISILENCER	Expression of e, the gene product of rpoS, is controlled translationally in response to many environmental stresses. DsrA, a small 87-nucleotide non-coding RNA molecule, acts to increase translational efficiency of RpoS mRNA under some growth conditions. In this work, we demonstrate that DsrA binds directly to the 30 S ribosomal subunit with an observed equilibrium affinity of 2.8 x 10(7) m(-1). DsrA does not compete with RpoS mRNA or tRNA(f)(Met) for binding to the 30 S subunit. The 5' end of DsrA binds to 30 S subunits with an observed equilibrium association constant of 2.0 x 10(6) m(-1), indicating that the full affinity of the interaction requires the entire DsrA sequence. In order to investigate translational efficiency of RpoS mRNA, we examined both ribosome-binding site accessibility and the binding of RpoS mRNA to 30 S ribosomal subunits. We find that that ribosome-binding site accessibility is modulated as a function of divalent cation concentration during mRNA renaturation and by the presence of an antisense sequence that binds to nucleotides 1-16 of the RpoS mRNA fragment. The ribosome-binding site accessibility correlates with the amount of RpoS mRNA participating in 30 S-mRNA "pre-initiation" translational complex formation and provides evidence that regulation follows a competitive model of regulation.	Bates Coll, Dept Chem, Lewiston, ME 04240 USA; Bates Coll, Program Biol Chem, Lewiston, ME 04240 USA		Schlax, PJ (corresponding author), Bates Coll, Dept Chem, Lewiston, ME 04240 USA.	pschlax@bates.edu		Godek, Kristina/0000-0002-2512-9295				Azam TA, 1999, J BIOL CHEM, V274, P33105, DOI 10.1074/jbc.274.46.33105; Brescia CC, 2003, RNA, V9, P33, DOI 10.1261/rna.2570803; Brown L, 1997, J BACTERIOL, V179, P656, DOI 10.1128/jb.179.3.656-662.1997; Brown L, 1996, J BACTERIOL, V178, P3763, DOI 10.1128/jb.178.13.3763-3770.1996; Bukhman YV, 1997, J MOL BIOL, V273, P1020, DOI 10.1006/jmbi.1997.1383; CARMICHAEL GG, 1975, J BIOL CHEM, V250, P3607; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; Csonka L. N., 1996, ESCHERICHIA COLI SAL, P1210; Cunning C, 1998, J BACTERIOL, V180, P4564, DOI 10.1128/JB.180.17.4564-4570.1998; de Smit MH, 1998, COLD SPRING HARBOR M, P495; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; Donahue WF, 2002, MOL CELL, V9, P7, DOI 10.1016/S1097-2765(02)00429-X; Draper DE, 1998, COLD SPRING HARBOR M, P415; Gluick TC, 1997, J MOL BIOL, V270, P451, DOI 10.1006/jmbi.1997.1119; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HenggeAronis R, 1996, MOL MICROBIOL, V21, P887, DOI 10.1046/j.1365-2958.1996.511405.x; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; Lease RA, 2000, P NATL ACAD SCI USA, V97, P9919, DOI 10.1073/pnas.170281497; Lease RA, 1998, P NATL ACAD SCI USA, V95, P12456, DOI 10.1073/pnas.95.21.12456; Lease RA, 2000, MOL MICROBIOL, V38, P667, DOI 10.1046/j.1365-2958.2000.02162.x; Loewen PC, 1998, CAN J MICROBIOL, V44, P707, DOI 10.1139/cjm-44-8-707; Majdalani N, 1998, P NATL ACAD SCI USA, V95, P12462, DOI 10.1073/pnas.95.21.12462; Majdalani N, 2001, MOL MICROBIOL, V39, P1382, DOI 10.1111/j.1365-2958.2001.02329.x; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Misra VK, 1998, BIOPOLYMERS, V48, P113, DOI 10.1002/(SICI)1097-0282(1998)48:2<113::AID-BIP3>3.0.CO;2-Y; Moller T, 2002, MOL CELL, V9, P23, DOI 10.1016/S1097-2765(01)00436-1; Muffler A, 1996, GENE DEV, V10, P1143, DOI 10.1101/gad.10.9.1143; Muffler A, 1997, J BACTERIOL, V179, P445; Muffler A, 1996, J BACTERIOL, V178, P1607, DOI 10.1128/jb.178.6.1607-1613.1996; Record MT, 1998, TRENDS BIOCHEM SCI, V23, P143, DOI 10.1016/S0968-0004(98)01196-7; RECORD MT, 1996, ESCHERICHIA COLI SAL, V1, P792; Repoila F, 2001, J BACTERIOL, V183, P4012, DOI 10.1128/JB.183.13.4012-4023.2001; Schlax PJ, 2001, J BIOL CHEM, V276, P38494, DOI 10.1074/jbc.M106934200; SCHLAX PJ, 2003, IN PRESS MOL MICROBI; Shiman R, 2000, J MOL BIOL, V302, P79, DOI 10.1006/jmbi.2000.4031; SLEDJESKI D, 1995, P NATL ACAD SCI USA, V92, P2003, DOI 10.1073/pnas.92.6.2003; Sledjeski DD, 1996, EMBO J, V15, P3993, DOI 10.1002/j.1460-2075.1996.tb00773.x; Sledjeski DD, 2001, J BACTERIOL, V183, P1997, DOI 10.1128/JB.183.6.1997-2005.2001; Takada A, 1997, BIOCHEM BIOPH RES CO, V236, P576, DOI 10.1006/bbrc.1997.7013; Thirumalai D, 1996, ACCOUNTS CHEM RES, V29, P433, DOI 10.1021/ar9500933; Vytvytska O, 2000, GENE DEV, V14, P1109; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3; Zhang AX, 1998, EMBO J, V17, P6061, DOI 10.1093/emboj/17.20.6061; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	44	17	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15815	15824		10.1074/jbc.M301684200	http://dx.doi.org/10.1074/jbc.M301684200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600997	hybrid			2022-12-27	WOS:000182680000047
J	Yang, TTC; Chow, CW				Yang, TTC; Chow, CW			Transcription cooperation by NFAT center dot C/EBP composite enhancer complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; CCAAT/ENHANCER-BINDING PROTEIN; MUSCLE FIBER-TYPE; FACTOR-ALPHA GENE; NUCLEAR FACTOR; ADIPOCYTE DIFFERENTIATION; DNA-BINDING; PPAR-GAMMA; PHOSPHATASE CALCINEURIN; SIGNAL-TRANSDUCTION	The nuclear factor of activated T cells (NFAT) group of transcription factors regulates gene expression in immune and non-immune cells. NFAT-mediated gene transcription is orchestrated, in part, by formation of a composite regulatory element. Here we demonstrate that NFAT interacts with transcription factor CCAAT/enhancer-binding protein (C/EBP) to form a composite enhancer complex, to potentiate expression of the peroxisome proliferator-activated receptor-gamma2 gene. Formation of a ternary NFAT.C/EBP.DNA complex is required for the transcriptional cooperation. A similar NFAT.C/EBP composite element is found in the regulatory region of the insulin-like growth factor 2, angiotensin-converting enzyme homolog, and transcription factor POU4F3 genes. Thus, the NFAT.C/EBP composite element represents a novel regulatory enhancer to direct NFAT-mediated gene transcription.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Chow, CW (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NIDDK NIH HHS [R01 DK063167-05, R01 DK063167-03, R01 DK063167-01A2, R01 DK063167-04, R01 DK063167, R01 DK063167-02] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063167] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Bert AG, 2000, J IMMUNOL, V165, P5646, DOI 10.4049/jimmunol.165.10.5646; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; Bower KE, 2002, J BIOL CHEM, V277, P34967, DOI 10.1074/jbc.M205048200; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Clark MP, 1998, NUCLEIC ACIDS RES, V26, P1801, DOI 10.1093/nar/26.7.1801; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Duncliffe KN, 1997, IMMUNITY, V6, P175, DOI 10.1016/S1074-7613(00)80424-0; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Elberg G, 2000, J BIOL CHEM, V275, P27815; ELGIN SCR, 1981, CELL, V27, P413, DOI 10.1016/0092-8674(81)90381-0; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FEIL R, 1995, DEV GENET, V17, P240, DOI 10.1002/dvg.1020170309; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Greally JM, 1997, MAMM GENOME, V8, P805, DOI 10.1007/s003359900583; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; Krebs JE, 2000, CRIT REV EUKAR GENE, V10, P1; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Luo C, 1996, J EXP MED, V184, P141, DOI 10.1084/jem.184.1.141; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Macian F, 2002, CELL, V109, P719, DOI 10.1016/S0092-8674(02)00767-5; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Miskin JE, 2000, J VIROL, V74, P9412, DOI 10.1128/JVI.74.20.9412-9420.2000; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Parkin SE, 2002, J BIOL CHEM, V277, P23563, DOI 10.1074/jbc.M202184200; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Rao A, 2000, BRIT MED BULL, V56, P969, DOI 10.1258/0007142001903634; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Ren DL, 2002, GENE DEV, V16, P27, DOI 10.1101/gad.953802; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Santini MP, 2001, P NATL ACAD SCI USA, V98, P9575, DOI 10.1073/pnas.161299698; SEARS RC, 1994, MOL CELL BIOL, V14, P4855, DOI 10.1128/MCB.14.7.4855; Shi XM, 2000, J CELL BIOCHEM, V76, P518, DOI 10.1002/(SICI)1097-4644(20000301)76:3<518::AID-JCB18>3.0.CO;2-M; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; TONTONOZ P, 1995, CURR OPIN GENET DEV, V5, P571, DOI 10.1016/0959-437X(95)80025-5; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Veenstra GJC, 2001, TRENDS BIOCHEM SCI, V26, P665, DOI 10.1016/S0968-0004(01)01970-3; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zhou P, 1998, CELL, V92, P687, DOI 10.1016/S0092-8674(00)81136-8; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	84	49	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15874	15885		10.1074/jbc.M211560200	http://dx.doi.org/10.1074/jbc.M211560200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12606546	hybrid			2022-12-27	WOS:000182680000054
J	Boccuni, P; MacGrogan, D; Scandura, JM; Nimer, SD				Boccuni, P; MacGrogan, D; Scandura, JM; Nimer, SD			The human L(3)MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA SEX COMB; TUMOR-SUPPRESSOR; GENE-EXPRESSION; MIDLEG SCM; MYELOPROLIFERATIVE DISORDERS; BINDING PROTEIN; CANDIDATE GENES; FUSION PROTEIN; HUMAN LEUKEMIA; HUMAN HOMOLOG	H-L(3)MIBT, the human homolog of the Drosophila lethal(3)malignant brain tumor protein, is a member of the polycomb group (PcG) of proteins, which function as transcriptional regulators in large protein complexes. Homozygous mutations in the l(3)mbt gene cause brain tumors in Drosophila, identifying l(3)mbt as a tumor suppressor gene. The h-l(3)mbt gene maps to chromo. some 20q12, within a common deleted region associated with myeloid hematopoietic malignancies. H-L(3)MBT contains three repeats of 100 residues called NMT repeats, whose function is unknown, and a C-terminal alpha-helical structure, the SPM (SCM, PH, MBT domain, which is structurally similar to the SAM (sterile btlpha motif) protein-protein interaction domain, found in several ETS transcription factors, including TEL (translocation Ets leukemia). We report that H-L(3)MBT is a transcriptional repressor and that its activity is largely dependent on the presence of a region containing the three MBT repeats. H-L(3)MBT acts as a histone deacetylase-independent transcriptional repressor, based on its lack of sensitivity to trichostatin A. We found that H-LMMET binds in vivo to TEL, and we have mapped the region of interaction to their respective SPWSAM domains. We show that the ability of TEL to repress TEL-responsive promoters is enhanced by the presence of H-L(3)MBT, an effect dependent on the H-L(3)MIBT and the TEL interacting domains. These experiments suggest that histone deacetylase-independent transcriptional repression by TEL depends on the recruitment of PcG proteins. We speculate that the interaction of TEL with H-L(3)AMT can direct a PcG complex to genes repressed by TEL, stabilizing their repressed state.	Sloan Kettering Inst Canc Res, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Nimer, SD (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave,Box 575, New York, NY 10021 USA.		MacGrogan, Donal/E-8604-2016; MacGrogan, Donal/AAR-7392-2021	MacGrogan, Donal/0000-0003-2808-8422; MacGrogan, Donal/0000-0003-2808-8422; Scandura, Joseph/0000-0002-9525-143X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052208] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK52208] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akasaka T, 1997, IMMUNITY, V7, P135, DOI 10.1016/S1074-7613(00)80516-6; Bantignies F, 2000, MOL CELL BIOL, V20, P9317, DOI 10.1128/MCB.20.24.9317-9330.2000; Bench AJ, 2000, ONCOGENE, V19, P3902, DOI 10.1038/sj.onc.1203728; Bench AJ, 2001, BEST PRACT RES CL HA, V14, P531, DOI 10.1053/beha.2001.0153; BENSON M, 1988, EMBO J, V7, P3907, DOI 10.1002/j.1460-2075.1988.tb03277.x; Berger J, 1999, GENE, V237, P185, DOI 10.1016/S0378-1119(99)00285-1; Bornemann D, 1996, DEVELOPMENT, V122, P1621; Bornemann D, 1998, GENETICS, V150, P675; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; BUIJS A, 1995, ONCOGENE, V10, P1511; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; GATEFF E, 1993, MECH DEVELOP, V41, P15, DOI 10.1016/0925-4773(93)90052-Y; Golub TR, 1997, CURR TOP MICROBIOL, V220, P67; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gu XS, 2001, J BIOL CHEM, V276, P9421, DOI 10.1074/jbc.M010070200; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Knezevich SR, 1998, CANCER RES, V58, P5046; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; Kurtin PJ, 1996, AM J CLIN PATHOL, V106, P680; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MacGrogan D, 2001, ONCOGENE, V20, P4150, DOI 10.1038/sj.onc.1204540; Montini E, 1999, GENOMICS, V58, P65, DOI 10.1006/geno.1999.5755; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; PIRROTTA V, 1994, BIOESSAYS, V16, P549, DOI 10.1002/bies.950160808; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Poux S, 1996, EMBO J, V15, P4713, DOI 10.1002/j.1460-2075.1996.tb00848.x; Poux S, 2001, DEVELOPMENT, V128, P75; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; Schultz J, 1997, PROTEIN SCI, V6, P249; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wang PW, 2000, GENOMICS, V67, P28, DOI 10.1006/geno.2000.6215; WISMAR J, 1995, MECH DEVELOP, V53, P141, DOI 10.1016/0925-4773(95)00431-9; Wismar J, 2001, FEBS LETT, V507, P119, DOI 10.1016/S0014-5793(01)02959-3; WLODARSKA I, 1995, BLOOD, V85, P2848, DOI 10.1182/blood.V85.10.2848.bloodjournal85102848; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	67	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15412	15420		10.1074/jbc.M300592200	http://dx.doi.org/10.1074/jbc.M300592200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588862	hybrid			2022-12-27	WOS:000182516100107
J	Chandra, S; Chen, XC; Rizo, J; Jahn, R; Sudhof, TC				Chandra, S; Chen, XC; Rizo, J; Jahn, R; Sudhof, TC			A broken alpha-helix in folded alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; MEMBRANE; BINDING; PROTEIN; FAMILY; BRAIN; LOCALIZATION; SENSITIVITY; VESICLES; STATES	alpha-Synuclein is a small cytosolic protein of presynaptic nerve terminals composed of seven 11-residue repeats and a hydrophilic tail. alpha-Synuclein misfolding and dysfunction may contribute to the pathogenesis of Parkinson's disease and neurodegenerative dementias, but its normal folding and function are unknown. In solution, alpha-synuclein is natively unstructured but assumes an alpha-helical conformation upon binding to phospholipid membranes. We now show that this conformation of alpha-synuclein consists of two alpha-helical regions that are interrupted by a short break. The structural organization of the alpha-helices of alpha-synuclein was not anticipated by sequence analyses and may be important for its pathogenic role.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem & Pharmacol, Dallas, TX 75390 USA; Max Planck Inst Biophys Chem, D-37075 Gottingen, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society	Chandra, S (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Jahn, Reinhard/0000-0003-1542-3498	NINDS NIH HHS [1-R01-NS40057] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040057] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKOPIAN AN, 1995, J BIOL CHEM, V270, P21264, DOI 10.1074/jbc.270.36.21264; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BUDAVARI S, 1996, MERCK INDEX ENCY CHE, P8782; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Ji HJ, 1997, CANCER RES, V57, P759; Kahle PJ, 2000, ANN NY ACAD SCI, V920, P33; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	21	409	415	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15313	15318		10.1074/jbc.M213128200	http://dx.doi.org/10.1074/jbc.M213128200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586824	hybrid			2022-12-27	WOS:000182516100095
J	Burhenne, K; Kristensen, BK; Rasmussen, SK				Burhenne, K; Kristensen, BK; Rasmussen, SK			A new class of N-hydroxycinnamoyltransferases - Purification, cloning, and expression of a barley agmatine coumaroyltransferase (Ec 2.3.1.64)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COA-TYRAMINE N-(HYDROXYCINNAMOYL)TRANSFERASE; CELL-SUSPENSION CULTURES; SOLANUM-TUBEROSUM; ACID-AMIDES; ACCUMULATION; TOBACCO; RESISTANCE; COENZYME; PROTEINS; LOCALIZATION	Agmatine coumaroyltransferase (ACT), which catalyzes the first step in the biosynthesis of antifungal hydroxycinnamoylagmatine derivatives, was purified to apparent homogeneity from 3-day-old etiolated barley (Hordeum vulgare L.) seedlings. The enzyme was highly specific for agmatine as acyl acceptor and had the highest specificity for p-coumaroyl-CoA among various acyl donors with a specific activity of 29.7 nanokatal x mg(-1) protein. Barley ACT was found to be a single polypeptide chain of 48 kDa with a pI of 5.20 as determined by isoelectric focusing. The 15 N-terminal amino acid residues were identified by micro-sequencing of the native protein and were used to clone a full-length barley ACT cDNA that predicted a protein of 439 amino acid residues. The sequence was devoid of N-terminal signal peptide, suggesting a cytosolic localization of barley ACT. Recombinant ACT produced and affinity-purified from Escherichia coli had a specific activity of 189 nanokatal X mg(-1) protein, thus confirming the identity of the purified native protein. A partial cDNA sequence for ACT was obtained from wheat that predicted a protein of 353 amino acid residues and had 95% sequence identity to barley ACT. Two motifs in the amino acid sequence reveal that barley ACT represents a new class of N-hydroxycinnamoyltransferases belonging to the transferase superfamily. The barley ACT is unique in producing the precursor of hordatine, a proven antifungal factor that may be directed toward Blumeria graminis.	Riso Natl Lab, Plant Res Dept, DK-4000 Roskilde, Denmark	Technical University of Denmark	Rasmussen, SK (corresponding author), Riso Natl Lab, Plant Res Dept, PRD-301, DK-4000 Roskilde, Denmark.		Rasmussen, Soren K./F-6728-2014	Rasmussen, Soren K./0000-0001-6169-2504				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Back K, 2001, PLANT CELL PHYSIOL, V42, P475, DOI 10.1093/pcp/pce060; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bernards MA, 2002, CAN J BOT, V80, P227, DOI [10.1139/B02-017, 10.1139/b02-017]; Bernards MA, 1998, PHYTOCHEMISTRY, V47, P915, DOI 10.1016/S0031-9422(98)80052-6; BIRD CR, 1983, PHYTOCHEMISTRY, V22, P2401, DOI 10.1016/0031-9422(83)80127-7; BIRD CR, 1984, ANN BOT-LONDON, V53, P483, DOI 10.1093/oxfordjournals.aob.a086712; BIRD CR, 1981, PHYTOCHEMISTRY, V20, P2345, DOI 10.1016/S0031-9422(00)82662-X; BROWN NF, 1994, J BIOL CHEM, V269, P19157; Farmer MJ, 1999, EUR J BIOCHEM, V263, P686, DOI 10.1046/j.1432-1327.1999.00538.x; Fujiwara H, 1998, PLANT J, V16, P421, DOI 10.1046/j.1365-313x.1998.00312.x; GRANDMAISON J, 1993, MYCORRHIZA, V3, P155, DOI 10.1007/BF00203609; Hoffmann L, 2003, J BIOL CHEM, V278, P95, DOI 10.1074/jbc.M209362200; Hohlfeld H, 1996, PLANTA, V199, P166, DOI 10.1007/BF00196893; HOHLFELD H, 1995, PLANT PHYSIOL, V107, P545, DOI 10.1104/pp.107.2.545; Jin S, 2000, BIOSCI BIOTECH BIOCH, V64, P1614, DOI 10.1271/bbb.64.1614; Lee D, 1996, PLANT PHYSIOL, V112, P193, DOI 10.1104/pp.112.1.193; Lee J, 1997, PHYTOCHEMISTRY, V44, P589, DOI 10.1016/S0031-9422(96)00562-6; McLusky SR, 1999, PLANT J, V17, P523, DOI 10.1046/j.1365-313X.1999.00403.x; Meng HB, 1997, PHYTOCHEMISTRY, V44, P605, DOI 10.1016/S0031-9422(96)00594-8; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Negrel J, 1996, PHYTOCHEMISTRY, V43, P1195, DOI 10.1016/S0031-9422(96)00500-6; Negrel J, 1997, EUR J BIOCHEM, V247, P1127, DOI 10.1111/j.1432-1033.1997.01127.x; NEGREL J, 1992, PLANT PHYSIOL, V98, P1264, DOI 10.1104/pp.98.4.1264; NIEMANN GJ, 1993, PHYTOCHEMISTRY, V34, P319, DOI 10.1016/0031-9422(93)80003-B; Ogura Y, 2001, Z NATURFORSCH C, V56, P193; Pearce G, 1998, PHYTOCHEMISTRY, V47, P659, DOI 10.1016/S0031-9422(97)00620-1; Peipp H, 1997, PHYTOCHEMISTRY, V44, P581, DOI 10.1016/S0031-9422(96)00561-4; Schmidt A, 1999, J BIOL CHEM, V274, P4273, DOI 10.1074/jbc.274.7.4273; SMITH TA, 1978, PHYTOCHEMISTRY, V17, P1093, DOI 10.1016/S0031-9422(00)94295-X; SMITH TA, 1983, ADV POLYAMINE RES, V4, P347; St-Pierre B, 1998, PLANT J, V14, P703, DOI 10.1046/j.1365-313x.1998.00174.x; STOCKIGT J, 1975, Z NATURFORSCH C, V30, P352; STOESSL A, 1967, CAN J CHEMISTRY, V45, P1745, DOI 10.1139/v67-283; STOESSL A, 1970, CAN J BOTANY, V48, P465, DOI 10.1139/b70-066; STOESSL A, 1966, TETRAHEDRON LETT, V7, P2849; STOESSL A, 1970, RECENT ADV PHYTOCHEM, V3, P143; von Ropenack E, 1998, J BIOL CHEM, V273, P9013, DOI 10.1074/jbc.273.15.9013; WEI YD, 1994, PHYSIOL MOL PLANT P, V45, P469, DOI 10.1016/S0885-5765(05)80043-8; Yu M, 1999, PLANTA, V209, P33, DOI 10.1007/s004250050604	41	92	95	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13919	13927		10.1074/jbc.M213041200	http://dx.doi.org/10.1074/jbc.M213041200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582168	hybrid			2022-12-27	WOS:000182405000047
J	Hermant, B; Bibert, S; Concord, E; Dublet, B; Weidenhaupt, M; Vernet, T; Gulino-Debrac, D				Hermant, B; Bibert, S; Concord, E; Dublet, B; Weidenhaupt, M; Vernet, T; Gulino-Debrac, D			Identification of proteases involved in the proteolysis of vascular endothelium cadherin during neutrophil transmigration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ADHESION MOLECULE-1; RECRUITMENT IN-VIVO; VE-CADHERIN; TRANSENDOTHELIAL MIGRATION; LEUKOCYTE TRANSMIGRATION; CATALYTIC ACTIVITY; POLYMORPHONUCLEAR LEUKOCYTES; CATHEPSIN-G; ELASTASE; SURFACE	Transmigration of neutrophils across the endothelium occurs at the cell-cell junctions where the vascular endothelium cadherin WE cadherin) is expressed. This adhesive receptor was previously demonstrated to be involved in the maintenance of endothelium integrity. We propose that neutrophil transmigration across the vascular endothelium goes in parallel with cleavage of VE cadherin by elastase and cathepsin G present on the surface of neutrophils. This hypothesis is supported by the following lines of evidence. 1) Proteolytic fragments of VE cadherin are released into the culture medium upon adhesion of neutrophils to endothelial cell monolayers; 2) conditioned culture medium, obtained after neutrophil adhesion to endothelial monolayers, cleaves the recombinantly expressed VE cadherin extracellular domain; 3) these cleavages are inhibited by inhibitors of elastase; 4) VE cadherin fragments produced by conditioned culture medium or by exogenously added elastase are identical as shown by N-terminal sequencing and mass spectrometry analysis; 5) both elastase- and cathepsin G-specific VE cadherin cleavage patterns are produced upon incubation with tumor necrosis factor a-stimulated and fixed neutrophils; 6) transendothelial permeability increases in vitro upon addition of either elastase or cathepsin G; and 7) neutrophil transmigration is reduced in vitro in the presence of elastase and cathepsin G inhibitors. Our results suggest that cleavage of VE cadherin by neutrophil surface-bound proteases induces formation of gaps through which neutrophils transmigrate.	Univ Grenoble 1, CNRS, Commissariat Energie Atom, Inst Biol Struct Jean Pierre Ebel,Lab Ingn Macrom, F-38027 Grenoble, France; Univ Grenoble 1, CNRS, Inst Biol Struct Jean Pierre Ebel, Commissariat Energie Atom,Lab Spectrometrie Masse, F-38027 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Gulino-Debrac, D (corresponding author), Univ Grenoble 1, CNRS, Commissariat Energie Atom, Inst Biol Struct Jean Pierre Ebel,Lab Ingn Macrom, 41 Rue Jules Horowitz, F-38027 Grenoble, France.		Vernet, Thierry/G-1118-2012	Bibert, Stephanie/0000-0001-5170-7506				Allport JR, 2002, J LEUKOCYTE BIOL, V71, P821; Allport JR, 1997, J EXP MED, V186, P517, DOI 10.1084/jem.186.4.517; Bibert S, 2002, J BIOL CHEM, V277, P12790, DOI 10.1074/jbc.M111597200; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; Campbell EJ, 2000, J IMMUNOL, V165, P3366, DOI 10.4049/jimmunol.165.6.3366; Carden D, 1998, AM J PHYSIOL-HEART C, V275, pH385, DOI 10.1152/ajpheart.1998.275.2.H385; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Cepinskas G, 1999, J CELL SCI, V112, P1937; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; Dunon D, 1996, CURR OPIN CELL BIOL, V8, P714, DOI 10.1016/S0955-0674(96)80114-1; Feng D, 1998, J EXP MED, V187, P903, DOI 10.1084/jem.187.6.903; Ferber A, 2002, EXP CELL RES, V274, P35, DOI 10.1006/excr.2001.5436; Gotsch U, 1997, J CELL SCI, V110, P583; Gulino D, 1998, J BIOL CHEM, V273, P29786, DOI 10.1074/jbc.273.45.29786; Hordijk PL, 1999, J CELL SCI, V112, P1915; Johnson-Leger C, 2000, J CELL SCI, V113, P921; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Legrand P, 2001, J BIOL CHEM, V276, P3581, DOI 10.1074/jbc.M002667200; Moll T, 1998, J CELL BIOL, V140, P403, DOI 10.1083/jcb.140.2.403; Nawroth R, 2002, EMBO J, V21, P4885, DOI 10.1093/emboj/cdf497; Newman PJ, 1999, J CLIN INVEST, V103, P5, DOI 10.1172/JCI5928; Ostermann G, 2002, NAT IMMUNOL, V3, P151, DOI 10.1038/ni755; OWEN CA, 1995, SEMIN CELL BIOL, V6, P367, DOI 10.1016/S1043-4682(05)80007-8; OWEN CA, 1995, J IMMUNOL, V155, P5803; OWEN CA, 1995, J CELL BIOL, V131, P775, DOI 10.1083/jcb.131.3.775; OWEN CA, 1997, AM J PHYSIOL, V272, P385; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Rabiet MJP, 1996, ARTERIOSCL THROM VAS, V16, P488, DOI 10.1161/01.ATV.16.3.488; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rival Y, 1996, J IMMUNOL, V157, P1233; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Shaw SK, 2001, J IMMUNOL, V167, P2323, DOI 10.4049/jimmunol.167.4.2323; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; Stockley RA, 2001, NOVART FDN SYMP, V234, P189; Su WH, 2002, BLOOD, V100, P3597, DOI 10.1182/blood-2002-01-0303; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Ukropec JA, 2002, EXP CELL RES, V273, P240, DOI 10.1006/excr.2001.5453; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Vestweber D, 2002, CURR OPIN CELL BIOL, V14, P587, DOI 10.1016/S0955-0674(02)00372-1; Weinrauch Y, 2002, NATURE, V417, P91, DOI 10.1038/417091a; WEISS J, 1985, J CLIN INVEST, V76, P206, DOI 10.1172/JCI111947; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2	44	124	129	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14002	14012		10.1074/jbc.M300351200	http://dx.doi.org/10.1074/jbc.M300351200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584200	hybrid			2022-12-27	WOS:000182405000058
J	Marx, UC; Korsinczky, MLJ; Schirra, HJ; Jones, A; Condie, B; Otvos, L; Craik, DJ				Marx, UC; Korsinczky, MLJ; Schirra, HJ; Jones, A; Condie, B; Otvos, L; Craik, DJ			Enzymatic cyclization of a potent Bowman-Birk protease inhibitor, sunflower trypsin inhibitor-1, and solution structure of an acyclic precursor peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; SUBSTRATE-SPECIFICITY; PLANT CYCLOTIDES; KNOTTED PROTEINS; REACTIVE-SITE; SEEDS; PURIFICATION; BINDING; DOMAIN; FAMILY	The most potent known naturally occurring Bowman-Birk inhibitor, sunflower trypsin inhibitor-1 (SFTI-1), is a bicyclic 14-amino acid peptide from sunflower seeds comprising one disulfide bond and a cyclic backbone. At present, little is known about the cyclization mechanism of SFTI-1. We show here that an acyclic permutant of SFTI-1 open at its scissile bond, SFTI-1[ 6,5], also functions as an inhibitor of trypsin and that it can be enzymatically backbone-cyclized by incubation with bovine beta-trypsin. The resulting ratio of cyclic SFTI-1 to SFTI1[6,5] is similar to9:1 regardless of whether trypsin is incubated with SFTI-1[ 6,5] or SFTI-1. Enzymatic resynthesis of the scissile bond to form cyclic SFTI-1 is a novel mechanism of cyclization of SFTI-1[ 6,5]. Such a reaction could potentially occur on a trypsin affinity column as used in the original isolation procedure of SFTI-1. We therefore extracted SFTI-1 from sunflower seeds without a trypsin purification step and confirmed that the backbone of SFTI-1 is indeed naturally cyclic. Structural studies on SFTI-1[ 6,5] revealed high heterogeneity, and multiple species of SFTI-1[ 6,5] were identified. The main species closely resembles the structure of cyclic SFTI-1 with the broken binding loop able to rotate between a cis/trans geometry of the I7-P8 bond with the cis conformer being similar to the canonical binding loop conformation. The non-reactive loop adopts a beta-hairpin structure as in cyclic wild-type SFTI-1. Another species exhibits an isoaspartate residue at position 14 and provides implications for possible in vivo cyclization mechanisms.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Bayreuth, Lehrstuhl Biopolymere, D-95447 Bayreuth, Germany; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Queensland; University of Bayreuth; The Wistar Institute	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu	Craik, David/B-1695-2010; Schirra, Horst Joachim/B-4210-2009	Craik, David/0000-0003-0007-6796; Schirra, Horst Joachim/0000-0002-7541-246X; Marx, Ute C./0000-0002-7077-9940				ARDELT W, 1985, BIOCHEMISTRY-US, V24, P5313, DOI 10.1021/bi00341a007; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Brauer ABE, 2001, J MOL BIOL, V306, P799, DOI 10.1006/jmbi.2000.4410; BRUNGER AT, 1996, X PLOR MANUAL VERSIO; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2002, CURR OPIN DRUG DI DE, V5, P251; Descours A, 2002, CHEMBIOCHEM, V3, P318, DOI 10.1002/1439-7633(20020402)3:4<318::AID-CBIC318>3.0.CO;2-W; DRYJANSKI M, 1990, BIOL CHEM H-S, V371, P889, DOI 10.1515/bchm3.1990.371.2.889; FINKENSTADT WR, 1967, J BIOL CHEM, V242, P771; Gewolb J, 2002, SCIENCE, V295, P2205, DOI 10.1126/science.295.5563.2205; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; Iwai H, 1999, FEBS LETT, V459, P166, DOI 10.1016/S0014-5793(99)01220-X; Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Konarev AV, 2000, THEOR APPL GENET, V100, P82, DOI 10.1007/s001220050012; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korsinczky MLJ, 2001, J MOL BIOL, V311, P579, DOI 10.1006/jmbi.2001.4887; Laskowski M, 2000, BBA-PROTEIN STRUCT M, V1477, P324, DOI 10.1016/S0167-4838(99)00284-8; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li Peng, 2002, Current Topics in Medicinal Chemistry, V2, P325, DOI 10.2174/1568026023394209; Long YQ, 2001, BIOORG MED CHEM LETT, V11, P2515, DOI 10.1016/S0960-894X(01)00493-0; Luckett S, 1999, J MOL BIOL, V290, P525, DOI 10.1006/jmbi.1999.2891; McBride JD, 2001, CURR MED CHEM, V8, P909, DOI 10.2174/0929867013372832; Morita S, 1996, J BIOCHEM-TOKYO, V119, P1094, DOI 10.1093/oxfordjournals.jbchem.a021353; Morita S, 1996, J BIOCHEM-TOKYO, V119, P711, DOI 10.1093/oxfordjournals.jbchem.a021300; MORITA S, 1994, PLANT CELL PHYSIOL, V35, P1049; Neudecker P, 2001, J BIOL CHEM, V276, P22756, DOI 10.1074/jbc.M101657200; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; NISHINO N, 1977, J BIOCHEM, V82, P901, DOI 10.1093/oxfordjournals.jbchem.a131767; OTLEWSKI J, 1994, BIOCHEMISTRY-US, V33, P208, DOI 10.1021/bi00167a027; PAVONE V, 1994, J CHEM SOC PERK T 2, P1047, DOI 10.1039/p29940001047; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; WALTHAM MC, 1988, BIOCHEM PHARMACOL, V37, P535, DOI 10.1016/0006-2952(88)90225-0; Wei W, 1999, INT J PHARMACEUT, V185, P129, DOI 10.1016/S0378-5173(99)00152-0; WERNER MH, 1992, BIOCHEMISTRY-US, V31, P999, DOI 10.1021/bi00119a008; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WOLF MJ, 1990, PHYTOCHEMISTRY, V29, P2419, DOI 10.1016/0031-9422(90)85159-D; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zablotna E, 2002, BIOCHEM BIOPH RES CO, V292, P855, DOI 10.1006/bbrc.2002.6746	43	66	82	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21782	21789		10.1074/jbc.M212996200	http://dx.doi.org/10.1074/jbc.M212996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12621047	hybrid			2022-12-27	WOS:000183354200060
J	Dorr, C; Zaparty, M; Tjaden, B; Brinkmann, H; Siebers, B				Dorr, C; Zaparty, M; Tjaden, B; Brinkmann, H; Siebers, B			The hexokinase of the hyperthermophile Thermoproteus tenax - ATP-dependent hexokinases and ADP-dependent glucokinases, two alternatives for glucose phosphorylation in Archaea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTNER-DOUDOROFF-PATHWAY; N-ACETYLNEURAMINIC ACID; EMBDEN-MEYERHOF PATHWAY; PYROCOCCUS-FURIOSUS; BACILLUS-SUBTILIS; SUGAR KINASES; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; BIOCHEMICAL-CHARACTERIZATION; EVOLUTIONARY RELATIONSHIPS; CATABOLITE REPRESSION	The phosphorylation of glucose by different sugar kinases plays an essential role in Archaea because of the absence of a phosphoenolpyruvate-dependent transferase system characteristic for Bacteria. In the genome of the hyperthermophilic Archaeon Thermoproteus tenax a gene was identified with sequence similarity to glucokinases of the so-called ROK family (repressor protein, open reading frame, sugar kinase). The T. tenax enzyme, like the recently described ATP-dependent "glucokinase" from Aeropyrum pernix, shows the typical broad substrate specificity of hexokinases catalyzing not only phosphorylation of glucose but also of other hexoses such as fructose, mannose, or 2-deoxyglucose, and thus both enzymes represent true hexokinases. The T. tenax hexokinase shows strikingly low if at all any regulatory properties and thus fulfills no important control function at the beginning of the variant of the Embden-Meyerhof-Parnas pathway in T. tenax. Transcript analyses reveal that the hxk gene of T. tenax is cotranscribed with an upstream located orfX, which codes for an 11-kDa protein of unknown function. Growth-dependent studies and promoter analyses suggest that post-transcriptional RNA processing might be involved in the generation of the monocistronic hxk message, which is observed only under heterotrophic growth conditions. Data base searches revealed T. tenax hexokinase homologs in some archaeal, few eukaryal, and many bacterial genomes. Phylogenetic analyses confirm that the archaeal hexokinase is a member of the so-called ROK family, which, however, should be referred to as ROK group because it represents a group within the bacterial glucokinase fructokinase subfamily II of the hexokinase family. Thus, archaeal hexokinases represent a second major group of glucose-phosphorylating enzymes in Archaea beside the recently described archaeal ADP-dependent glucokinases, which were recognized as members of the ribokinase family. The distribution of the two types of sugar kinases, differing in their cosubstrate as well as substrate specificity, within Archaea is discussed on the basis of physiological constraints of the respective organisms.	Univ Duisburg Essen, Dept Microbiol, FB 9, D-45117 Essen, Germany; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada	University of Duisburg Essen; Universite de Montreal	Siebers, B (corresponding author), Univ Duisburg Essen, Dept Microbiol, FB 9, Univ Str 5, D-45117 Essen, Germany.	bettina.siebers@uni-essen.de		Siebers, Bettina/0000-0002-9905-541X				ANGELL S, 1992, MOL MICROBIOL, V6, P2833, DOI 10.1111/j.1365-2958.1992.tb01463.x; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; BORK P, 1993, PROTEIN SCI, V2, P31; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunner NA, 1998, J BIOL CHEM, V273, P6149, DOI 10.1074/jbc.273.11.6149; Brunner NA, 2001, EXTREMOPHILES, V5, P101, DOI 10.1007/s007920100181; BUDGEN N, 1986, FEBS LETT, V196, P207, DOI 10.1016/0014-5793(86)80247-2; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; CHANGHOON K, J BACTERIOL, V179, P7631; Concha MI, 2000, FEMS MICROBIOL LETT, V186, P97, DOI 10.1111/j.1574-6968.2000.tb09088.x; DOELLE HW, 1982, EUR J APPL MICROBIOL, V14, P241, DOI 10.1007/BF00498471; FISCHER F, 1983, NATURE, V301, P511, DOI 10.1038/301511a0; FOTHERGILLGILMORE LA, 1993, PROG BIOPHYS MOL BIO, V59, P105, DOI 10.1016/0079-6107(93)90001-Z; GOWARD CR, 1986, BIOCHEM J, V237, P415, DOI 10.1042/bj2370415; Hansen T, 2002, J BACTERIOL, V184, P5955, DOI 10.1128/JB.184.21.5955-5965.2002; Hansen T, 2000, ARCH MICROBIOL, V173, P103, DOI 10.1007/s002039900114; HENGARTNER H, 1973, FEBS LETT, V37, P212, DOI 10.1016/0014-5793(73)80461-2; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Ito S, 2001, STRUCTURE, V9, P205, DOI 10.1016/S0969-2126(01)00577-9; KENGEN SWM, 1994, J BIOL CHEM, V269, P17537; Kengen SWM, 1995, J BIOL CHEM, V270, P30453, DOI 10.1074/jbc.270.51.30453; Koga S, 2000, J BIOCHEM-TOKYO, V128, P1079, DOI 10.1093/oxfordjournals.jbchem.a022836; KREUZER P, 1989, J BACTERIOL, V171, P3840, DOI 10.1128/jb.171.7.3840-3845.1989; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; KWAKMAN JH, 1997, J BACTERIOL, V176, P2694; Labes A, 2001, ARCH MICROBIOL, V176, P329, DOI 10.1007/s002030100330; Park SY, 2000, FEMS MICROBIOL LETT, V188, P209, DOI 10.1016/S0378-1097(00)00238-X; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; PLUMBRIDGE J, 1995, EMBO J, V14, P3958, DOI 10.1002/j.1460-2075.1995.tb00067.x; Plumbridge J, 1999, J BACTERIOL, V181, P47, DOI 10.1128/JB.181.1.47-54.1999; PLUMBRIDGE JA, 1989, MOL MICROBIOL, V3, P505, DOI 10.1111/j.1365-2958.1989.tb00197.x; Pohl E, 2002, J BIOL CHEM, V277, P19938, DOI 10.1074/jbc.M112244200; PORTER EV, 1982, BIOCHIM BIOPHYS ACTA, V709, P178; RANGASWAMY V, 1994, J BACTERIOL, V176, P5505, DOI 10.1128/JB.176.17.5505-5512.1994; RANGASWAMY V, 1994, BIOCHIM BIOPHYS ACTA, V28, P106; Ronimus RS, 1999, EXTREMOPHILES, V3, P121, DOI 10.1007/s007920050107; Ronimus RS, 2001, BBA-GENE STRUCT EXPR, V1517, P384, DOI 10.1016/S0167-4781(00)00301-8; Ronimus RS, 2001, FEMS MICROBIOL LETT, V202, P85, DOI 10.1111/j.1574-6968.2001.tb10784.x; Rosana-Ani L, 1999, FEMS MICROBIOL LETT, V171, P89, DOI 10.1016/S0378-1097(98)00585-0; Sakuraba H, 2002, J BIOL CHEM, V277, P12495, DOI 10.1074/jbc.C200059200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHONHEIT P, 1995, WORLD J MICROB BIOT, V11, P26, DOI 10.1007/BF00339135; Schramm A, 2001, METHOD ENZYMOL, V331, P62; Schramm A, 2000, J BACTERIOL, V182, P2001, DOI 10.1128/JB.182.7.2001-2009.2000; Selig M, 1997, ARCH MICROBIOL, V167, P217, DOI 10.1007/BF03356097; Siebers B, 1997, ARCH MICROBIOL, V168, P120, DOI 10.1007/s002030050477; SIEBERS B, 1993, FEMS MICROBIOL LETT, V111, P1; Siebers B, 1998, J BACTERIOL, V180, P2137, DOI 10.1128/JB.180.8.2137-2143.1998; Siebers B, 2001, J BIOL CHEM, V276, P28710, DOI 10.1074/jbc.M103447200; Skarlatos P, 1998, J BACTERIOL, V180, P3222, DOI 10.1128/JB.180.12.3222-3226.1998; SOLS A, 1958, BIOCHIM BIOPHYS ACTA, V30, P92; Soppa J, 1999, MOL MICROBIOL, V31, P1589, DOI 10.1046/j.1365-2958.1999.01274.x; Soppa J, 1999, MOL MICROBIOL, V31, P1295, DOI 10.1046/j.1365-2958.1999.01273.x; Spath C, 1997, J BACTERIOL, V179, P7603; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Swofford D.L., 1999, PAUP PHYLOGENETIC AN; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TITGEMEYER F, 1994, MICROBIOL-UK, V140, P2349, DOI 10.1099/13500872-140-9-2349; Tuininga JE, 1999, J BIOL CHEM, V274, P21023, DOI 10.1074/jbc.274.30.21023; Verhees CH, 2002, BIOCHEM J, V366, P121, DOI 10.1042/BJ20011597; Verhees CH, 2001, J BACTERIOL, V183, P7145, DOI 10.1128/JB.183.24.7145-7153.2001; WAGNER E, 1995, J BACTERIOL, V177, P6144, DOI 10.1128/jb.177.21.6144-6152.1995; Wu G, 2001, GENE, V264, P265, DOI 10.1016/S0378-1119(01)00329-8; YU JP, 1994, J BACTERIOL, V176, P325, DOI 10.1128/JB.176.2.325-332.1994; ZEMBRZUSKI B, 1992, J BACTERIOL, V174, P3455, DOI 10.1128/JB.174.11.3455-3460.1992; ZILLIG W, 1981, ZBL BAKT MIK HYG I C, V2, P205, DOI 10.1016/S0721-9571(81)80001-4	67	46	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18744	18753		10.1074/jbc.M301914200	http://dx.doi.org/10.1074/jbc.M301914200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12626506	hybrid			2022-12-27	WOS:000182932200007
J	Levy, M; Faas, GC; Saggau, P; Craigen, WJ; Sweatt, JD				Levy, M; Faas, GC; Saggau, P; Craigen, WJ; Sweatt, JD			Mitochondrial regulation of synaptic plasticity in the hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PERMEABILITY TRANSITION PORE; DEPENDENT ANION CHANNEL; CYCLOSPORINE-A; AREA CA1; CALCIUM; TRANSMISSION; INVOLVEMENT; INHIBITION; RELEASE	Synaptic mechanisms of plasticity are calcium-dependent processes that are affected by dysfunction of mitochondrial calcium buffering. Recently, we observed that mice deficient in mitochondrial voltage-dependent anion channels, the outer component of the mitochondrial permeability transition pore, have impairments in learning and hippocampal synaptic plasticity, suggesting that the mitochondrial permeability transition pore is involved in hippocampal synaptic plasticity. In this study, we examined the effect on synaptic transmission and plasticity of blocking the permeability transition pore with low doses of cyclosporin A and found a deficit in synaptic plasticity and an increase in base-line synaptic transmission. Calcium imaging of presynaptic terminals revealed a transient increase in the resting calcium concentration immediately upon incubation with cyclosporin A that correlated with the changes in synaptic transmission and plasticity. The effect of cyclosporin A on presynaptic calcium was abolished when mitochondria were depolarized prior to cyclosporin A exposure, and the effects of cyclosporin A and mitochondrial depolarization on presynaptic resting calcium were similar, suggesting a mitochondrial locus of action of cyclosporin A. To further characterize the calcium dynamics of the mitochondrial permeability transition pore, we used an in vitro assay of calcium handling by isolated brain mitochondria. Cyclosporin A-exposed mitochondria buffered calcium more rapidly and subsequently triggered a more rapid mitochondrial depolarization. Similarly, mitochondria lacking the voltage-dependent anion channel 1 isoform depolarized more readily than littermate controls. The data suggest a role for the mitochondrial permeability transition pore and voltage-dependent anion channels in mitochondrial synaptic calcium buffering and in hippocampal synaptic plasticity.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Baylor College of Medicine	Levy, M (corresponding author), Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA.			Faas, Guido/0000-0002-1339-7698; Sweatt, J. David/0000-0003-3567-485X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS042488] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24064] Funding Source: Medline; NIMH NIH HHS [MH57014] Funding Source: Medline; NINDS NIH HHS [F31NS42488] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Billups B, 2002, J NEUROSCI, V22, P5840; Brocard JB, 2001, J PHYSIOL-LONDON, V531, P793, DOI 10.1111/j.1469-7793.2001.0793h.x; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Cavus I, 1996, J NEUROPHYSIOL, V76, P3038, DOI 10.1152/jn.1996.76.5.3038; Crompton M, 1999, BIOCHEM SOC SYMP, V66, P167, DOI 10.1042/bss0660167; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Jovanovic JN, 2001, J NEUROSCI, V21, P7944, DOI 10.1523/JNEUROSCI.21-20-07944.2001; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Lu YF, 1996, BRAIN RES, V729, P142, DOI 10.1016/0006-8993(96)00568-9; Lu YF, 1996, NEUROSCI LETT, V205, P103, DOI 10.1016/0304-3940(96)12384-3; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; Miro O, 1998, BRIT J RHEUMATOL, V37, P1047; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Pfeiffer DR, 2001, IUBMB LIFE, V52, P205, DOI 10.1080/15216540152846019; Roberson ED, 1996, J BIOL CHEM, V271, P30436, DOI 10.1074/jbc.271.48.30436; Selcher JC, 2003, LEARN MEMORY, V10, P26, DOI 10.1101/lm.51103; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Tang YG, 1997, NEURON, V18, P483, DOI 10.1016/S0896-6273(00)81248-9; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; Weeber EJ, 2002, J BIOL CHEM, V277, P18891, DOI 10.1074/jbc.M201649200; WU LG, 1994, J NEUROSCI, V14, P645	27	130	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17727	17734		10.1074/jbc.M212878200	http://dx.doi.org/10.1074/jbc.M212878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12604600	hybrid			2022-12-27	WOS:000182838300019
J	Ninomiya-Tsuji, J; Kajino, T; Ono, K; Ohtomo, T; Matsumoto, M; Shiina, M; Mihara, M; Tsuchiya, M; Matsumoto, K				Ninomiya-Tsuji, J; Kajino, T; Ono, K; Ohtomo, T; Matsumoto, M; Shiina, M; Mihara, M; Tsuchiya, M; Matsumoto, K			A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; I-KAPPA-B; BETA SIGNAL-TRANSDUCTION; PATHWAY; IL-1; INTERLEUKIN-1; MACROPHAGES; INDUCTION; RECEPTOR; CASCADE	TAK1, a member of the mitogen-activated kinase kinase kinase (MAPKKK) family, participates in proinflammatory cellular signaling pathways by activating JNK/p38 MAPKs and NF-kappaB. To identify drugs that prevent inflammation, we screened inhibitors of TAK1 catalytic activity. We identified a natural resorcylic lactone of fungal origin, 5Z-7-oxozeaenol, as a highly potent inhibitor of TAK1. This compound did not effectively inhibit the catalytic activities of the MEKK1 or ASK1 MAPKKKs, suggesting that 5Z-7-oxozeaenol is a selective inhibitor of TAK1. In cell culture, 5Z-7-oxozeaenol blocked interleukin-1- induced activation of TAK1, JNK/p38 MAPK, IkappaB kinases, and NF-kappaB, resulting in inhibition of cyclooxgenase-2 production. Furthermore, in vivo 5Z-7-oxozeaenol was able to inhibit picryl chloride-induced ear swelling. Thus, 5Z-7-oxozeaenol blocks proinflammatory signaling by selectively inhibiting TAK1 MAPKKK.	Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, Gotemba, Shizuoka 4128513, Japan; N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA	Nagoya University; Japan Science & Technology Agency (JST); Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of North Carolina; North Carolina State University	Matsumoto, K (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 4648602, Japan.			Ninomiya-Tsuji, Jun/0000-0002-5584-0176				Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Goto YS, 2000, INT ARCH ALLERGY IMM, V123, P341, DOI 10.1159/000053647; Hirai S, 1996, ONCOGENE, V12, P641; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; KRUEGER GG, 1989, J INVEST DERMATOL, V92, P32; LAVAUD P, 1991, J INVEST DERMATOL, V97, P101, DOI 10.1111/1523-1747.ep12478438; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mochida Y, 2000, J BIOL CHEM, V275, P32747, DOI 10.1074/jbc.M003042200; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Rawlins P, 1999, INT J IMMUNOPHARMACO, V21, P799, DOI 10.1016/S0192-0561(99)00047-8; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Takehana K, 1999, BIOCHEM BIOPH RES CO, V257, P19, DOI 10.1006/bbrc.1999.0401; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; WESTON WL, 1976, ANN ALLERGY, V37, P346; Williams DH, 1998, BIOCHEMISTRY-US, V37, P9579, DOI 10.1021/bi972914c; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zhao A, 1999, J ANTIBIOT, V52, P1086, DOI 10.7164/antibiotics.52.1086	34	338	349	4	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18485	18490		10.1074/jbc.M207453200	http://dx.doi.org/10.1074/jbc.M207453200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624112	hybrid			2022-12-27	WOS:000182838300117
J	Luo, BH; Springer, TA; Takagi, J				Luo, BH; Springer, TA; Takagi, J			High affinity ligand binding by Integrins does not involve head separation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; MURINE MONOCLONAL-ANTIBODY; INSIDE-OUT ACTIVATION; EXTRACELLULAR SEGMENT; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; I-DOMAIN; FIBRINOGEN; CONFORMATIONS; REVEALS	Conformational change in the integrin extracellular domain is required for high affinity ligand binding and is also involved in post-ligand binding cellular signaling. Although there is evidence to the contrary, electron microscopic studies showing that ligand binding triggers alpha- and beta-subunit dissociation in the integrin headpiece have gained popularity and support the hypothesis that head separation activates integrins. To test directly the head separation hypothesis, we enforced head association by introducing disulfide bonds across the interface between the alpha-subunit beta-propeller domain and the beta-subunit I-like domain. Basal and activation-dependent ligand binding by alpha(IIb)beta(3) and alpha(V)beta(3) was unaffected. The covalent linkage prevented dissociation of alpha(IIb)beta(3) into its subunits on EDTA-treated cells. Whereas EDTA dissociated wild type alpha(IIb)beta(3) on the cell surface, a ligand-mimetic Arg-Gly-Asp peptide did not, as judged by binding of complex-specific antibodies. Finally, a high affinity ligand-mimetic compound stabilized noncovalent association between alpha(IIb) and beta(3) headpiece fragments in the presence of SDS, indicating that ligand binding actually stabilized subunit association at the head, as opposed to the suggested subunit separation. The mechanisms of conformational regulation of integrin function should therefore be considered in the context of the associated alphabeta headpiece.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Takagi, J (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 200 Longwood Ave,Rm 238, Boston, MA 02115 USA.	takagi@cbr.med.harvard.edu			NHLBI NIH HHS [HL48675] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Billheimer JT, 2002, BLOOD, V99, P3540, DOI 10.1182/blood.V99.10.3540; BRASS LF, 1985, J BIOL CHEM, V260, P7875; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; COLLER BS, 1986, J LAB CLIN MED, V107, P384; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; DU XP, 1993, J BIOL CHEM, V268, P23087; Erb EM, 1997, BIOCHEMISTRY-US, V36, P7395, DOI 10.1021/bi9702187; FUJIMURA K, 1983, J BIOL CHEM, V258, P247; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; Hantgan RR, 2003, J BIOL CHEM, V278, P3417, DOI 10.1074/jbc.M208869200; Hantgan RR, 2001, PROTEIN SCI, V10, P1614, DOI 10.1110/ps.3001; Honda S, 1998, J CLIN INVEST, V102, P1183, DOI 10.1172/JCI3206; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Liddington RC, 2002, STRUCTURE, V10, P605, DOI 10.1016/S0969-2126(02)00766-9; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PETRUZZELLI L, 1995, LEUCOCYTE TYPING, V5, P1581; PIDARD D, 1983, J BIOL CHEM, V258, P2582; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Prueksaritanont T, 1997, DRUG METAB DISPOS, V25, P355; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Thibault G, 2001, J PHARMACOL EXP THER, V296, P690; Thibault G, 2000, MOL PHARMACOL, V58, P1137, DOI 10.1124/mol.58.5.1137; Tokuhira M, 1996, THROMB HAEMOSTASIS, V76, P1038; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Zang Q, 2000, J BIOL CHEM, V275, P22202, DOI 10.1074/jbc.M002883200; Zolotarjova NI, 2001, J BIOL CHEM, V276, P17063, DOI 10.1074/jbc.M009627200	44	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17185	17189		10.1074/jbc.M301516200	http://dx.doi.org/10.1074/jbc.M301516200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600996	Green Published, hybrid			2022-12-27	WOS:000182818600099
J	Wiley, JS; Dao-Ung, LP; Li, CP; Shemon, AN; Gu, BJ; Smart, ML; Fuller, SJ; Barden, JA; Petrou, S; Sluyter, R				Wiley, JS; Dao-Ung, LP; Li, CP; Shemon, AN; Gu, BJ; Smart, ML; Fuller, SJ; Barden, JA; Petrou, S; Sluyter, R			An Ile-568 to Asn polymorphism prevents normal trafficking and function of the human P2X(7) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LYMPHOCYTES; HUMAN MACROPHAGES; PURINERGIC RECEPTORS; CHANNEL MUTATION; CUTTING EDGE; L-SELECTIN; ATP; ACTIVATION; EXPRESSION; CELLS	The P2X(7) receptor is a ligand-gated channel that is highly expressed on mononuclear cells and that mediates ATP-induced apoptosis of these cells. Wide variations in the function of the P2X(7) receptor have been observed, in part because of a loss-of-function polymorphism that changes Glu-496 to Ala without affecting the surface expression of the receptor on lymphocytes. In this study a second polymorphism (Ile-568 to Asn) has been found in heterozygous dosage in three of 85 normal subjects and in three of 45 patients with chronic lymphocytic leukemia. P2X(7) function was measured by ATP-induced fluxes of Rb+, Ba2+, and ethidium(+) into various lymphocyte subsets and was decreased to values of similar to25% of normal. The expression of the P2X(7) receptor on lymphocytes was approximately half that of normal values as measured by the binding of fluorescein-conjugated monoclonal antibody. Transfection experiments showed that P2X(7) carrying the Ile-568 to Asn mutation was non-functional because of the failure of cell surface expression. The differentiation of monocytes to macrophages with interferon-gamma up-regulated P2X(7) function in cells heterozygous for the Ile-568 to Asn mutation to a value around 50% of normal. These data identify a second loss-of-function polymorphism within the P2X(7) receptor and show that Ile-568 is critical to the trafficking domain, which we have shown to lie between residues 551 and 581.	Univ Sydney, Nepean Hosp, Dept Med, Penrith, NSW 2750, Australia; Univ Melbourne, Dept Physiol, Parkville, Vic 3050, Australia; Univ Sydney, Dept Anat & Histol, Sydney, NSW 2006, Australia	Nepean Hospital; University of Sydney; University of Melbourne; University of Sydney	Wiley, JS (corresponding author), Univ Sydney, Nepean Hosp, Dept Med, Level 5,S Block, Penrith, NSW 2750, Australia.	wileyj@medicine.usyd.edu.au	Petrou, Steven/M-8332-2013; Fuller, Stephen/W-6646-2019; Sluyter, Ronald/B-5798-2009	Fuller, Stephen/0000-0003-4637-7391; Sluyter, Ronald/0000-0003-4909-686X; Petrou, Steven/0000-0002-4960-6375; Wiley, James/0000-0001-9421-4154; Gu, Ben/0000-0001-5500-4453				Adriouch S, 2002, J IMMUNOL, V169, P4108, DOI 10.4049/jimmunol.169.8.4108; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Bobanovic LK, 2002, J NEUROSCI, V22, P4814, DOI 10.1523/JNEUROSCI.22-12-04814.2002; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; Denlinger LC, 2001, J IMMUNOL, V167, P1871, DOI 10.4049/jimmunol.167.4.1871; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; ELMOATASSIM C, 1993, J BIOL CHEM, V268, P15571; Fairbairn IP, 2001, J IMMUNOL, V167, P3300, DOI 10.4049/jimmunol.167.6.3300; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Gargett CE, 1996, BIOCHEM J, V313, P529, DOI 10.1042/bj3130529; Gu B, 1998, BLOOD, V92, P946; Gu BJ, 2001, J BIOL CHEM, V276, P11135, DOI 10.1074/jbc.M010353200; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; HICKMAN SE, 1994, BLOOD, V84, P2452; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Jamieson GP, 1996, J CELL PHYSIOL, V166, P637, DOI 10.1002/(SICI)1097-4652(199603)166:3<637::AID-JCP19>3.0.CO;2-3; JURKATROTT K, 1994, HUM MOL GENET, V3, P1415, DOI 10.1093/hmg/3.8.1415; Kim M, 2001, J BIOL CHEM, V276, P23262, DOI 10.1074/jbc.M102253200; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Kusner DJ, 2000, J IMMUNOL, V164, P379, DOI 10.4049/jimmunol.164.1.379; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Li CM, 2002, FEBS LETT, V531, P127, DOI 10.1016/S0014-5793(02)03424-5; Moore KH, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-18-j0002.2001; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Rubtsov AM, 2000, FEBS LETT, V482, P1, DOI 10.1016/S0014-5793(00)01924-4; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; Slater M, 2002, CELL CALCIUM, V31, P201, DOI 10.1016/S0143-4160(02)00033-7; Sluyter R, 2002, INT IMMUNOL, V14, P1415, DOI 10.1093/intimm/dxf111; Sluyter R, 2001, CELL TISSUE RES, V304, P231, DOI 10.1007/s004410100372; Smart ML, 2003, J BIOL CHEM, V278, P8853, DOI 10.1074/jbc.M211094200; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Wiley JS, 2002, LANCET, V359, P1114, DOI 10.1016/S0140-6736(02)08156-4; WILEY JS, 1992, ARCH BIOCHEM BIOPHYS, V292, P411, DOI 10.1016/0003-9861(92)90010-T	41	135	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17108	17113		10.1074/jbc.M212759200	http://dx.doi.org/10.1074/jbc.M212759200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12586825	hybrid			2022-12-27	WOS:000182818600089
J	Choe, JY; Iancu, CV; Fromm, HJ; Honzatko, RB				Choe, JY; Iancu, CV; Fromm, HJ; Honzatko, RB			Metaphosphate in the active site of fructose-1,6-bisphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-KIDNEY FRUCTOSE-1,6-BISPHOSPHATASE; LIVER FRUCTOSE BISPHOSPHATASE; PHOSPHORYL-TRANSFER-REACTIONS; TRANSITION-STATE; MECHANISM; HYDROLYSIS; 1,6-BISPHOSPHATASE; CATALYSIS; PHOSPHATE; INHIBITION	The hydrolysis of a phosphate ester can proceed through an intermediate of metaphosphate (dissociative mechanism) or through a trigonal bipryamidal transition state (associative mechanism). Model systems in solution support the dissociative pathway, whereas most enzymologists favor an associative mechanism for enzyme-catalyzed reactions. Crystals of fiructose-1,6-bisphosphatase grow from an equilibrium mixture of substrates and products at near atomic resolution (1.3 Angstrom). At neutral pH, products of the reaction (orthophosphate and fructose 6-phosphate) bind to the active site in a manner consistent with an associative reaction pathway; however, in the presence of inhibitory concentrations of K+ (200 mm), or at pH 9.6, metaphosphate and water (or OH-) are in equilibrium with orthophosphate. Furthermore, one of the magnesium cations in the pH 9.6 complex resides in an alternative position, and suggests the possibility of metal cation migration as the 1-phosphoryl group of the substrate undergoes hydrolysis. To the best of our knowledge, the crystal structures reported here represent the first direct observation of metaphosphate in a condensed phase and may provide the structural basis for fundamental changes in the catalytic mechanism of fiructose-1,6-bisphosphatase in response to pH and different metal cation activators.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS010546, R01NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADMIRAAL SJ, 1995, CHEM BIOL, V2, P729, DOI 10.1016/1074-5521(95)90101-9; BARNARD DWC, 1955, CHEM IND-LONDON, P760; BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BUTCHER WW, 1955, J AM CHEM SOC, V77, P2420, DOI 10.1021/ja01614a018; CALVO KC, 1984, J AM CHEM SOC, V106, P4202, DOI 10.1021/ja00327a023; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; Choe JY, 2003, J BIOL CHEM, V278, P16008, DOI 10.1074/jbc.M212394200; DeFronzo RA, 1999, ANN INTERN MED, V131, P281, DOI 10.7326/0003-4819-131-4-199908170-00008; DOMANICO PL, 1985, BIOCHEMISTRY-US, V24, P1623, DOI 10.1021/bi00328a009; Du XL, 2000, J BIOL CHEM, V275, P8492, DOI 10.1074/jbc.275.12.8492; FREY WA, 1977, BIOCHEMISTRY-US, V16, P2479, DOI 10.1021/bi00630a025; GUTHRIE JP, 1977, J AM CHEM SOC, V99, P3991, DOI 10.1021/ja00454a018; HENCHMAN M, 1985, J AM CHEM SOC, V107, P1453, DOI 10.1021/ja00291a081; HENGGE AC, 1994, J AM CHEM SOC, V116, P5045, DOI 10.1021/ja00091a003; HENGGE AC, 1998, COMPREHENSIVE BIOL C, V1, P517; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P5172, DOI 10.1021/bi00473a025; JANKOWSKI S, 1994, J AM CHEM SOC, V116, P11675, DOI 10.1021/ja00105a008; Kelley N, 1996, BIOCHEM BIOPH RES CO, V219, P848, DOI 10.1006/bbrc.1996.0321; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurbanov FT, 1998, J BIOL CHEM, V273, P17511, DOI 10.1074/jbc.273.28.17511; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Stec B, 2000, J MOL BIOL, V299, P1303, DOI 10.1006/jmbi.2000.3799; STONE SR, 1986, BIOCHEMISTRY-US, V25, P620; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6; WESTHEIMER FH, 1987, SCIENCE, V235, P1173, DOI 10.1126/science.2434996; Wright SW, 2002, J MED CHEM, V45, P3865, DOI 10.1021/jm010496a; WU YD, 1993, J AM CHEM SOC, V115, P11997, DOI 10.1021/ja00078a042; Zhang RL, 1996, BIOCHEMISTRY-US, V35, P3038, DOI 10.1021/bi952188i; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	39	31	33	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16015	16020		10.1074/jbc.M212395200	http://dx.doi.org/10.1074/jbc.M212395200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595528	hybrid			2022-12-27	WOS:000182680000072
J	Kanipes, MI; Ribeiro, AA; Lin, SH; Cotter, RJ; Raetz, CRH				Kanipes, MI; Ribeiro, AA; Lin, SH; Cotter, RJ; Raetz, CRH			A mannosyl transferase required for lipopolysaccharide inner core assembly in Rhizobium leguminosarum - Purification, substrate specificity, and expression in Salmonella waaC mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM-TUMEFACIENS C58; LIPID-A BIOSYNTHESIS; ACYL CARRIER PROTEIN; ESCHERICHIA-COLI; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; POLYSACCHARIDE SYNTHESIS; SINORHIZOBIUM-MELILOTI; BACTERIAL-ENDOTOXINS; NMR-SPECTROSCOPY; GENOME SEQUENCE	The lipopolysaccharide (LPS) core domain of Gram-negative bacteria plays an important role in outer membrane stability and host interactions. Little is known about the biochemical properties of the glycosyltransferases that assemble the LPS core. We now report the purification and characterization of the Rhizobium leguminosarum mannosyI transferase LpcC, which adds a mannose unit to the inner 3-deoxy-D-manno-octulosonic acid (Kdo) moiety of the LPS precursor, Kdo(2)-lipid IVA. LpcC containing an N-terminal His, tag was assayed using GDP-mannose as the donor and Kdo(2)-[4'-P-32]lipid IVA as the acceptor and was purified to near homogeneity. Sequencing of the N terminus confirmed that the purified enzyme is the lpcC gene product. Mild acid hydrolysis of the glycolipid generated in vitro by pure LpcC showed that the mannosylation occurs on the inner Kdo residue Of Kdo(2)-[4'-P-32]lipid IVA. A lipid acceptor substrate containing two Kdo moieties is required by LpcC, since no activity is seen with lipid IVA or Kdo-lipid IVA. The purified enzyme can use GDP-mannose or, to a lesser extent, ADP-mannose (both of which have the alpha-anomeric configuration) for the glycosylation of Kdo2-[4'-P-32]lipid IVA. Little or no activity is seen with ADP-glucose, UDP-glucose, UDP-GlcNAc, or UDP-galactose. A Salmonella typhimurium waaC mutant, which lacks the enzyme for incorporating the inner L-glycero-D-manno-heptose moiety of LPS, regains LPS with O-antigen when complemented with lpcC. An Escherichia coli heptose-less waaC-waaF deletion mutant expressing the R. leguminosarum lpcC gene likewise generates a hybrid LPS species consisting of Kdo(2)-lipid A plus a single mannose residue. Our results demonstrate that heterologous lpcC expression can be used to modify the structure of the Salmonella and E. coli LPS cores in living cells.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, NMR Spect Ctr, Durham, NC 27710 USA; Duke Univ, Ctr Med, Dept Radiol, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Duke University; Duke University; Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.				NCI NIH HHS [P30 CA014236, P30 CA 14236] Funding Source: Medline; NIGMS NIH HHS [R37 GM051796, R37 GM051796-07, R37 GM 51796, GM 54882] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, R37GM051796] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R; Ausubel FM, 1988, MOL REPROD DEV; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; BERGMANS HEN, 1981, J BACTERIOL, V146, P564, DOI 10.1128/JB.146.2.564-570.1981; BHAT UR, 1991, J BACTERIOL, V173, P2155, DOI 10.1128/JB.173.7.2155-2159.1991; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, CARBOHYD RES, V220, P219, DOI 10.1016/0008-6215(91)80020-N; BHAT UR, 1991, INT J SYST BACTERIOL, V41, P213; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; Brade H., 1999, ENDOTOXIN HLTH DIS; Breazeale SD, 2002, J BIOL CHEM, V277, P2886, DOI 10.1074/jbc.M109377200; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; Carlson R W, 1995, Prog Clin Biol Res, V392, P25; CARLSON RW, 1995, J BIOL CHEM, V270, P11783, DOI 10.1074/jbc.270.20.11783; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; DANKERT M, 1964, BIOCHEM BIOPH RES CO, V14, P358, DOI 10.1016/S0006-291X(64)80010-3; DelVecchio VG, 2002, P NATL ACAD SCI USA, V99, P443, DOI 10.1073/pnas.221575398; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Elling L, 1996, GLYCOBIOLOGY, V6, P591, DOI 10.1093/glycob/6.6.591; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; GOTTESMAN S, 1991, MOL MICROBIOL, V5, P1599, DOI 10.1111/j.1365-2958.1991.tb01906.x; Gronow S, 2001, J ENDOTOXIN RES, V7, P263, DOI 10.1177/09680519010070040701; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kadrmas JL, 1998, J BIOL CHEM, V273, P2799, DOI 10.1074/jbc.273.5.2799; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; KOCSIS B, 1984, J BIOL CHEM, V259, P1858; KONTROHR T, 1981, J BIOL CHEM, V256, P7715; Lagares A, 2001, J BACTERIOL, V183, P1248, DOI 10.1128/JB.183.4.1248-1258.2001; Miller J.H., 1972, EXPT MOL GENETICS; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; PASSERON S, 1964, BIOCHIM BIOPHYS ACTA, V89, P372, DOI 10.1016/0926-6569(64)90233-0; PERLIN AS, 1969, TETRAHEDRON LETT, P2921; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SIRISENA DM, 1992, J BIOL CHEM, V267, P18874; UBRINOVA S, 1991, MAGN RESON CHEM, V29, P912; Vinogradov E, 2002, EUR J BIOCHEM, V269, P6112, DOI 10.1046/j.1432-1033.2002.03321.x; White KA, 1997, J BIOL CHEM, V272, P16555, DOI 10.1074/jbc.272.26.16555; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; Zamyatina A, 2000, ANGEW CHEM INT EDIT, V39, P4150, DOI 10.1002/1521-3773(20001117)39:22<4150::AID-ANIE4150>3.0.CO;2-A	57	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16356	16364		10.1074/jbc.M301255200	http://dx.doi.org/10.1074/jbc.M301255200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591937	Green Accepted, hybrid			2022-12-27	WOS:000182680000114
J	Min, KW; Hwang, JW; Lee, JS; Park, Y; Tamura, T; Yoon, JB				Min, KW; Hwang, JW; Lee, JS; Park, Y; Tamura, T; Yoon, JB			TIP120A associates with cullins and modulates ubiquitin ligase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TBP-INTERACTING PROTEIN; F-BOX PROTEINS; TUMOR-SUPPRESSOR PROTEIN; RNA POLYMERASE-II; ELONGIN-B; COMPLEX; SCF; BINDING; TRANSCRIPTION; DEGRADATION	The cullin-containing ubiquitin-protein isopeptide ligases (E3s) play an important role in regulating the abundance of key proteins involved in cellular processes such as cell cycle and cytokine signaling. They have multisubunit modular structures in which substrate recognition and the catalysis of ubiquitination are carried out by distinct polypeptides. In a search for proteins involved in regulation of cullin-containing E3 ubiquitin ligases we immunopurified CUL4B-containing complex from HeLa cells and identified TIP120A as an associated protein by mass spectrometry. Immunoprecipitation of cullins revealed that all cullins tested specifically interacted with TIP120A. Reciprocal immuno-affinity purification of TIP120A confirmed the stable interaction of TIP120A with cullin family proteins. TIP120A formed a complex with CUL1 and Rbx1; but interfered with the binding of Skp1 and F-box proteins to CULL TIP120A greatly reduced the ubiquitination of phosphorylated IkappaBalpha by SCFbeta-TrCP ubiquitin ligase. These results suggest that TIP120A functions as a negative regulator of SCF E3 ubiquitin ligases and may modulate other cullin ligases in a similar fashion.	Yonsei Univ, Dept Biochem, Seoul 120749, South Korea; Yonsei Univ, Prot Network Res Ctr, Seoul 120749, South Korea; Chiba Univ, Fac Sci, Dept Biol, Chiba 2638522, Japan	Yonsei University; Yonsei University; Chiba University	Yoon, JB (corresponding author), Yonsei Univ, Dept Biochem, Seoul 120749, South Korea.			Yoon, Jong-Bok/0000-0002-3563-0702				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Farras R, 2001, EMBO J, V20, P2742, DOI 10.1093/emboj/20.11.2742; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kayukawa K, 2001, GENES CELLS, V6, P165, DOI 10.1046/j.1365-2443.2001.00407.x; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kipreos ET, 2002, GENOME BIOL; KISHIDA T, 1995, CANCER RES, V55, P4544; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Makino Y, 1999, MOL CELL BIOL, V19, P7951; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Monni R, 2001, ONCOGENE, V20, P849, DOI 10.1038/sj.onc.1204201; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Yogosawa S, 1999, BIOCHEM BIOPH RES CO, V266, P123, DOI 10.1006/bbrc.1999.1773; Yogosawa S, 1996, BIOCHEM BIOPH RES CO, V229, P612, DOI 10.1006/bbrc.1996.1852; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	40	64	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15905	15910		10.1074/jbc.M213070200	http://dx.doi.org/10.1074/jbc.M213070200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12609982	hybrid			2022-12-27	WOS:000182680000057
J	Nufer, O; Mitrovic, S; Hauri, HP				Nufer, O; Mitrovic, S; Hauri, HP			Profile-based data base scanning for animal L-type lectins and characterization of VIPL, a novel VIP36-like endoplasmic reticulum protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI INTERMEDIATE COMPARTMENT; MANNOSIDASE-LIKE PROTEIN; FACTOR-VIII DEFICIENCY; COMBINED FACTOR-V; EARLY SECRETORY PATHWAY; MEMBRANE-PROTEIN; LEGUMINOUS LECTINS; RECYCLING PATHWAY; ERGIC-53 GENE; SACCHAROMYCES-CEREVISIAE	Consensus profiles were established to screen data bases for novel animal L-type lectins. The profiles were generated from linear sequence motifs of the human L-type lectin-like membrane proteins ERGIC-53, ERGL, and VIP36 and by optimal alignment of the entire carbohydrate recognition domain of these proteins. The search revealed numerous orthologous and homologous L-type lectin-like proteins in animals, protozoans, and yeast, as well as the sequence of a novel family member related to VIP36, named VIPL for VIP36-like. Sequence analysis suggests that VIPL is a ubiquitously expressed protein and appeared earlier in evolution than VIP36. The cDNA of VIPL was cloned and expressed in cell culture. VIPL is a high-mannose type I membrane glycoprotein with similar domain organization as VIP36. Unlike VIP36 and ERGIC-53 that are predominantly associated with postendoplasmic reticulum (ER) membranes and cycle in the early secretory pathway, VIPL is a non-cycling resident protein of the ER. Mutagenesis experiments indicate that ER retention of VIPL involves a RKR di-arginine signal. Overexpression of VIPL redistributed ERGIC-53 to the ER without affecting the cycling of the KDEL-receptor and the overall morphology of the early secretory pathway. The results suggest that VIPL may function as a regulator of ERGIC-53.	Univ Basel, Bioctr, CH-4056 Basel, Switzerland	University of Basel	Hauri, HP (corresponding author), Univ Basel, Bioctr, Klingelbergstr 70, CH-4056 Basel, Switzerland.							Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Bailey TL, 1998, J COMPUT BIOL, V5, P211, DOI 10.1089/cmb.1998.5.211; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Chevet E, 2001, CURR OPIN STRUC BIOL, V11, P120, DOI 10.1016/S0959-440X(00)00168-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dansako H, 2001, ANN HEMATOL, V80, P292; Dodd RB, 2001, GLYCOBIOLOGY, V11, p71R, DOI 10.1093/glycob/11.5.71R; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; Fiedler K, 1996, J CELL SCI, V109, P271; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Fullekrug J, 1999, J CELL SCI, V112, P2813; Golling G, 2002, NAT GENET, V31, P135, DOI 10.1038/ng896; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; Hara-Kuge S, 2002, J BIOL CHEM, V277, P16332, DOI 10.1074/jbc.M112188200; Hauri HP, 2000, J CELL SCI, V113, P587; Hauri HP, 2000, FEBS LETT, V476, P32, DOI 10.1016/S0014-5793(00)01665-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; ITIN C, 1995, J CELL BIOL, V131, P57, DOI 10.1083/jcb.131.1.57; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; Jakob CA, 2001, EMBO REP, V2, P423; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Klumperman J, 1998, J CELL SCI, V111, P3411; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Lahtinen U, 1996, J BIOL CHEM, V271, P4031; Linstedt AD, 1997, MOL BIOL CELL, V8, P1073, DOI 10.1091/mbc.8.6.1073; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Loris R, 2002, BBA-GEN SUBJECTS, V1572, P198, DOI 10.1016/S0304-4165(02)00309-4; Lupas A, 1996, METHOD ENZYMOL, V266, P513; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; Neerman-Arbez M, 1999, BLOOD, V93, P2253; Nichols WC, 1998, CELL, V93, P61, DOI 10.1016/S0092-8674(00)81146-0; Nichols WC, 1999, BLOOD, V93, P2261; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Nufer O, 2002, J CELL SCI, V115, P619; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sambrook J., 2002, MOL CLONING LAB MANU; Sato K, 2002, MOL BIOL CELL, V13, P2518, DOI 10.1091/mbc.E02-01-0027; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; Tang BL, 1995, EUR J CELL BIOL, V68, P398; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Velloso LM, 2002, J BIOL CHEM, V277, P15979, DOI 10.1074/jbc.M112098200; Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377; Yamashita K, 1999, BBA-GEN SUBJECTS, V1473, P147, DOI 10.1016/S0304-4165(99)00175-0; Yerushalmi N, 2001, GENE, V265, P55, DOI 10.1016/S0378-1119(01)00347-X; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zerangue N, 2001, P NATL ACAD SCI USA, V98, P2431, DOI 10.1073/pnas.051630198; [No title captured]	69	48	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15886	15896		10.1074/jbc.M211199200	http://dx.doi.org/10.1074/jbc.M211199200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12609988	hybrid			2022-12-27	WOS:000182680000055
J	Petrini, EM; Zacchi, P; Barberis, A; Mozrzymas, JW; Cherubini, E				Petrini, EM; Zacchi, P; Barberis, A; Mozrzymas, JW; Cherubini, E			Declusterization of GABA(A) receptors affects the kinetic properties of GABAergic currents in cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A RECEPTOR; MICROTUBULE DEPOLYMERIZATION; MOLECULAR-CLONING; GLYCINE RECEPTORS; PROTEIN GABARAP; GEPHYRIN; CYTOSKELETON; CHANNELS; DESENSITIZATION; SYNAPSES	Speed and reliability of synaptic transmission are essential for information coding in neuronal networks and require the presence of clustered neurotransmitter receptors at the plasma membrane in precise apposition to presynaptic terminals. Receptor clusterization is the result of highly regulated processes involving functional and structural proteins. Among the structural elements, microtubules are known to play a crucial role in anchoring of gamma-aminobutyric acid, type A (GABA(A)) receptors. Here we show that microtubule depolymerization with nocodazole induces the declusterization of GABA(A) receptors and modifies the kinetic properties of GABAergic currents in cultured hippocampal neurons. In particular, this drug, applied either in the bath or via the patch pipette, induced the acceleration of the onset kinetics of miniature inhibitory postsynaptic currents (mIPSCs) without significantly affecting their frequency, thus suggesting a main postsynaptic site of action. After nocodazole treatment, current responses to ultrafast applications of GABA exhibited a faster rise time and an accelerated onset of desensitization. A quantitative analysis of GABA-evoked currents and model simulations suggest that declusterization affects the gating properties of GABA(A) receptors. In particular, a faster entry into the desensitized state of declustered GABA(A) receptors may account for the changes in the kinetic properties of mIPSCs after nocodazole treatment. Hence it appears that the clustered condition of GABA(A) receptors contributes in shaping GABAergic currents.	Sch Adv Int Studies, Neurosci Program, I-34014 Trieste, Italy; Scuola Int Super Studi Avanzati, Ist Nazl Fis Mat Unit, I-34014 Trieste, Italy; Wroclaw Med Univ, Dept Biophys, PL-50368 Wroclaw, Poland	International School for Advanced Studies (SISSA); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); International School for Advanced Studies (SISSA); Wroclaw Medical University	Cherubini, E (corresponding author), Sch Adv Int Studies, Neurosci Program, Via Beirut 2-4, I-34014 Trieste, Italy.		Barberis, Andrea/AAB-8806-2019	Mozrzymas, Jerzy/0000-0003-1674-1818; Barberis, Andrea/0000-0002-5054-6517				Andjus PR, 1997, J PHYSIOL-LONDON, V504, P103, DOI 10.1111/j.1469-7793.1997.103bf.x; BAAS PW, 1991, J NEUROSCI RES, V30, P134, DOI 10.1002/jnr.490300115; Barberis A, 2000, J NEUROSCI, V20, P8618; Barnes EM, 2000, LIFE SCI, V66, P1063, DOI 10.1016/S0024-3205(99)00469-5; Beck M, 2002, J BIOL CHEM, V277, P30079, DOI 10.1074/jbc.M200438200; Bianchi MT, 2002, NEUROPHARMACOLOGY, V43, P492, DOI 10.1016/S0028-3908(02)00163-6; Bianchi MT, 2001, J NEUROSCI, V21, P9083, DOI 10.1523/JNEUROSCI.21-23-09083.2001; Birnir B, 2000, J MEMBRANE BIOL, V174, P21, DOI 10.1007/s002320001028; Birnir B, 2001, J MEMBRANE BIOL, V181, P171, DOI 10.1007/s00232-001-0021-5; Bueno OF, 1998, NEUROPHARMACOLOGY, V37, P383, DOI 10.1016/S0028-3908(98)00020-3; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Christie SB, 2002, PROG BRAIN RES, V136, P157; Christie SB, 2002, J NEUROSCI, V22, P684, DOI 10.1523/JNEUROSCI.22-03-00684.2002; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; Essrich C, 1998, NAT NEUROSCI, V1, P563, DOI 10.1038/2798; GARNER CC, 1990, J NEUROCHEM, V55, P146, DOI 10.1111/j.1471-4159.1990.tb08832.x; Ho WH, 2001, J CELL BIOCHEM, V83, P291, DOI 10.1002/jcb.1232; Jonas Peter, 1995, P231; Jones MV, 2001, BIOPHYS J, V81, P2660, DOI 10.1016/S0006-3495(01)75909-7; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Jones MV, 1998, J NEUROSCI, V18, P8590; Kannenberg K, 1999, EUR J NEUROSCI, V11, P1256, DOI 10.1046/j.1460-9568.1999.00533.x; Kilman V, 2002, J NEUROSCI, V22, P1328, DOI 10.1523/JNEUROSCI.22-04-01328.2002; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; KIRSCH J, 1995, J NEUROSCI, V15, P4148; Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999; Kneussel M, 2002, BRAIN RES REV, V39, P74, DOI 10.1016/S0165-0173(02)00159-5; Koulen P, 1996, J NEUROSCI, V16, P2127; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Legendre P, 2002, MOL PHARMACOL, V62, P817, DOI 10.1124/mol.62.4.817; Ligon LA, 2000, J COMP NEUROL, V427, P351, DOI 10.1002/1096-9861(20001120)427:3<351::AID-CNE3>3.0.CO;2-R; Meyer DK, 2000, J NEUROSCI, V20, P6743, DOI 10.1523/JNEUROSCI.20-18-06743.2000; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; Mozrzymas JW, 2003, J NEUROPHYSIOL, V89, P871, DOI 10.1152/jn.00951.2002; Mozrzymas JW, 1999, J NEUROSCI, V19, P2474; Overstreet LS, 2000, J NEUROSCI, V20, P7914; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; SASSOEPOGNETTO M, 1995, J COMP NEUROL, V357, P1, DOI 10.1002/cne.903570102; Scotti AL, 2001, P NATL ACAD SCI USA, V98, P3489, DOI 10.1073/pnas.061028798; van Zundert B, 2002, J NEUROPHYSIOL, V87, P640, DOI 10.1152/jn.00455.2001; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Weiner JL, 1998, J PHARMACOL EXP THER, V284, P95; WHATLEY VJ, 1994, J BIOL CHEM, V269, P19546; Yeung JYT, 2003, MOL PHARMACOL, V63, P2, DOI 10.1124/mol.63.1.2	48	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16271	16279		10.1074/jbc.M213081200	http://dx.doi.org/10.1074/jbc.M213081200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600990	hybrid			2022-12-27	WOS:000182680000103
J	Bailey, S; Sedelnikova, SE; Mesa, P; Ayora, S; Waltho, JP; Ashcroft, AE; Baron, AJ; Alonso, JC; Rafferty, JB				Bailey, S; Sedelnikova, SE; Mesa, P; Ayora, S; Waltho, JP; Ashcroft, AE; Baron, AJ; Alonso, JC; Rafferty, JB			Structural analysis of Bacillus subtilis SPP1 phage helicase loader protein G39P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFRACTION DATA; DNA-REPLICATION; BINDING; G40P; REPLISOME; INTERACTS; MOLSCRIPT; DISORDER; FLGM	The Bacillus subtilis SPP1 phage-encoded protein G39P is a loader and inhibitor of the phage G40P replicative helicase involved in the initiation of DNA replication. We have carried out a full x-ray crystallographic and preliminary NMR analysis of G39P and functional studies of the protein, including assays for helicase binding by a number of truncated mutant forms, in an effort to improve our understanding of how it both interacts with the helicase and with the phage replisome organizer, G38P. Our structural analyses reveal that G39P has a completely unexpected bipartite structure comprising a folded N-terminal domain and an essentially unfolded C-terminal domain. Although G39P has been shown to bind its G40P target with a 6:6 stoichiometry, our crystal structure and other biophysical characterization data reveal that the protein probably exists predominantly as a monomer in solution. The G39P protein is proteolytically sensitive, and our binding assays show that the C-terminal domain is essential for helicase interaction and that removal of just the 14 C-terminal residues abolishes interaction with the helicase in vitro. We propose a number of possible scenarios in which the flexibility of the C-terminal domain of G39P and its proteolytic sensitivity may have important roles for the function of G39P in vivo that are consistent with other data on SPP1 phage DNA replication.	Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Autonoma Madrid, Dept Mol Biol, Madrid 28049, Spain; CSIC, Ctr Nacl Biotecnol, Dept Biotecnol Microbiana, E-28049 Madrid, Spain; Univ Leeds, Sch Biol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Sheffield; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Leeds	Rafferty, JB (corresponding author), Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England.	j.rafferty@sheffield.ac.uk	Alonso, Juan Carlos/D-2595-2009; Ayora, Silvia/D-2552-2009	Alonso, Juan Carlos/0000-0002-5178-7179; Ayora, Silvia/0000-0003-3121-1786; Mesa, Pablo/0000-0002-9218-3144; Rafferty, John/0000-0003-1183-7474; Waltho, Jonathan/0000-0002-7402-5492				Ayora S, 1998, FEBS LETT, V439, P59, DOI 10.1016/S0014-5793(98)01337-4; Ayora S, 1999, J MOL BIOL, V288, P71, DOI 10.1006/jmbi.1999.2662; Ayora S, 2002, NUCLEIC ACIDS RES, V30, P2280, DOI 10.1093/nar/30.11.2280; Ayora S, 2002, J BIOL CHEM, V277, P35969, DOI 10.1074/jbc.M204467200; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Barcena M, 1998, J MOL BIOL, V283, P809, DOI 10.1006/jmbi.1998.2128; Barcena M, 2001, EMBO J, V20, P1462, DOI 10.1093/emboj/20.6.1462; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; CHAI S, 1993, GENE, V129, P41, DOI 10.1016/0378-1119(93)90694-X; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Daughdrill GW, 1997, NAT STRUCT BIOL, V4, P285, DOI 10.1038/nsb0497-285; Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Jones CE, 2001, P NATL ACAD SCI USA, V98, P8312, DOI 10.1073/pnas.121009398; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee DG, 2000, CURR OPIN CELL BIOL, V12, P280, DOI 10.1016/S0955-0674(00)00089-2; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARTIN JR, 1994, EUR J BIOCHEM, V225, P1181, DOI 10.1111/j.1432-1033.1994.1181b.x; Martinez-Jimenez MI, 2002, NUCLEIC ACIDS RES, V30, P5056, DOI 10.1093/nar/gkf650; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Missich R, 1997, J MOL BIOL, V270, P50, DOI 10.1006/jmbi.1997.1060; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PEDRE X, 1994, J MOL BIOL, V236, P1324, DOI 10.1016/0022-2836(94)90061-2; Philo JS, 2000, ANAL BIOCHEM, V279, P151, DOI 10.1006/abio.2000.4480; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Uversky VN, 2002, EUR J BIOCHEM, V269, P2, DOI 10.1046/j.0014-2956.2001.02649.x; WEISE F, 1997, THESIS FREIE U BERLI; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110	40	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15304	15312		10.1074/jbc.M209300200	http://dx.doi.org/10.1074/jbc.M209300200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588876	hybrid			2022-12-27	WOS:000182516100094
J	Brautaset, T; Borgos, SEF; Sletta, H; Ellingsen, TE; Zotchev, SB				Brautaset, T; Borgos, SEF; Sletta, H; Ellingsen, TE; Zotchev, SB			Site-specific mutagenesis and domain substitutions in the loading module of the nystatin polyketide synthase, and their effects on nystatin biosynthesis in Streptomyces noursei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-KETOACYL SYNTHASE; SUBSTRATE-SPECIFICITY; CHAIN INITIATION; ESCHERICHIA-COLI; GENE-CLUSTER; ATCC-11455	The loading module for the nystatin polyketide synthase (PKS) in Streptomyces noursei is represented by the NysA protein composed of a ketosynthase (KSS), acyltransferase, dehydratase, and an acyl carrier protein. The absolute requirement of this protein for initiation of nystatin biosynthesis was demonstrated by the in-frame deletion of the nysA gene in S. noursei. The role of the NysA KSS domain, however, remained unclear, since no data on the significance of the "active site" serine (Ser-170) residue in the loading modules of type I PKSs were available. Site-specific mutagenesis of Ser-170 both in the wild-type NysA and in the hybrid loading module containing malonyl-specific acyltransferase domain from the extender module had no effect on nystatin biosynthesis. A second mutation (S413N) of the NysA KSS domain was discovered that completely abolished the ability of the hybrids to restore nystatin biosynthesis, presumably by affecting the ability of the resulting proteins to catalyze the required substrate decarboxylation. In contrast, NysA and its Ser-170 mutants bearing the same S413N mutation were able to restore nystatin production to significant levels, probably by using acetyl-CoA as a starter unit. Together, these data suggest that the KSS domain of NysA differs from the KSQ domains found in the loading modules of several PKS type I systems in that the active site residue is not significant for its activity.	Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway; SINTEF, N-7034 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); SINTEF	Brautaset, T (corresponding author), Norwegian Univ Sci & Technol, Dept Biotechnol, N-7491 Trondheim, Norway.			Borgos, Sven Even/0000-0002-6222-9252; Zotchev, Sergey/0000-0002-9324-245X				Aparicio JF, 2000, CHEM BIOL, V7, P895, DOI 10.1016/S1074-5521(00)00038-7; Bisang C, 1999, NATURE, V401, P502, DOI 10.1038/46829; Brautaset T, 2000, CHEM BIOL, V7, P395, DOI 10.1016/S1074-5521(00)00120-4; Brautaset T, 2002, CHEM BIOL, V9, P367, DOI 10.1016/S1074-5521(02)00108-4; Caffrey P, 2001, CHEM BIOL, V8, P713, DOI 10.1016/S1074-5521(01)00046-1; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Dreier J, 2000, BIOCHEMISTRY-US, V39, P2088, DOI 10.1021/bi992121l; Flett F, 1997, FEMS MICROBIOL LETT, V155, P223, DOI 10.1111/j.1574-6968.1997.tb13882.x; HAYDOCK SF, 1995, FEBS LETT, V374, P246, DOI 10.1016/0014-5793(95)01119-Y; Jacobsen JR, 1998, BIOCHEMISTRY-US, V37, P4928, DOI 10.1021/bi9729920; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; Liou GF, 2003, BIOCHEMISTRY-US, V42, P200, DOI 10.1021/bi0268100; Long PF, 2002, MOL MICROBIOL, V43, P1215, DOI 10.1046/j.1365-2958.2002.02815.x; MACNEIL DJ, 1992, GENE, V111, P61, DOI 10.1016/0378-1119(92)90603-M; Marsden AFA, 1998, SCIENCE, V279, P199, DOI 10.1126/science.279.5348.199; Pereda A, 1998, MICROBIOL-UK, V144, P543, DOI 10.1099/00221287-144-2-543; Reeves CD, 2001, BIOCHEMISTRY-US, V40, P15464, DOI 10.1021/bi015864r; Sambrook J., 2002, MOL CLONING LAB MANU; Sekurova O, 1999, FEMS MICROBIOL LETT, V177, P297, DOI 10.1111/j.1574-6968.1999.tb13746.x; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Wilkinson CJ, 2001, CHEM BIOL, V8, P1197, DOI 10.1016/S1074-5521(01)00087-4; Witkowski A, 1999, BIOCHEMISTRY-US, V38, P11643, DOI 10.1021/bi990993h; YANISCHPERRON C, 1985, METHOD ENZYMOL, V113, P83; Zotchev S, 2000, MICROBIOL-UK, V146, P611, DOI 10.1099/00221287-146-3-611	25	25	28	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14913	14919		10.1074/jbc.M212611200	http://dx.doi.org/10.1074/jbc.M212611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594224	hybrid			2022-12-27	WOS:000182516100044
J	Romijn, RA; Westein, E; Bouma, B; Schiphorst, ME; Sixma, JJ; Lenting, PJ; Huizinga, EG				Romijn, RA; Westein, E; Bouma, B; Schiphorst, ME; Sixma, JJ; Lenting, PJ; Huizinga, EG			Mapping the collagen-binding site in the von Willebrand factor-A3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET THROMBUS FORMATION; A3 DOMAIN; VONWILLEBRAND-FACTOR; I-DOMAIN; EXTRACELLULAR-MATRIX; CRYSTAL-STRUCTURE; GLYCOPROTEIN-VI; ADHESION; VWF; RECEPTOR	The multimeric glycoprotein von Willebrand factor (VVVF) mediates platelet adhesion to collagen at sites of vascular damage. The binding site for collagen types I and III is located in the VWF-A3 domain. Recently, we showed that His(1023), located near the edge between the "front" and "bottom" faces of A3, is critical for collagen binding (Romijn, R. A., Bouma, B., Wuyster, W., Gros, P., Kroon, J., Sixma, J. J., and Huizinga, E. G. (2001) J. Biol. Chem. 276,9985-9991). To map the binding site in detail, we introduced 22 point mutations in the front and bottom faces of A3. The mutants were expressed as multimeric VWF, and binding to collagen type III was evaluated in a solid-state binding assay and by surface plasmon resonance. Mutation of residues Asp(979), Ser(1020), and His(1023) nearly abolished collagen binding, whereas mutation of residues Ile(975), Thr(977), Val(997), and Glu(1001) reduced binding affinity about 10-fold. Together, these residues define a flat and rather hydrophobic collagen-binding site located at the front face of the A3 domain. The collagen-binding site of VWF-A3 is distinctly different from that of the homologous integrin alpha(2) I domain, which has a hydrophilic binding site located at the top face of the domain. Based on the surface characteristics of the collagen-binding site of A3, we propose that it interacts with collagen sequences containing positively charged and hydrophobic residues. Docking of a collagen triple helix on the binding site suggests a range of possible engagements and predicts that at most eight consecutive residues in a collagen triple helix interact with A3.	Univ Utrecht, Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Crystal & Struct Chem, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University	Huizinga, EG (corresponding author), Univ Utrecht, Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, HP GO3-647,POB 85500, NL-3508 GA Utrecht, Netherlands.	E.G.Huizinga@chem.uu.nl	Lenting, Peter/F-8269-2013; Lenting, Peter/AAH-5663-2019	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429				Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BOCKENSTEDT P, 1986, J CLIN INVEST, V78, P551, DOI 10.1172/JCI112608; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; DENIS C, 1993, ARTERIOSCLER THROMB, V13, P398, DOI 10.1161/01.ATV.13.3.398; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Fischer BE, 1996, THROMB RES, V84, P55, DOI 10.1016/0049-3848(96)00161-2; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Goto SY, 2002, CIRCULATION, V106, P266, DOI 10.1161/01.CIR.0000021427.87256.7E; Hoylaerts MF, 1997, BIOCHEM J, V324, P185, DOI 10.1042/bj3240185; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kehrel B, 1998, BLOOD, V91, P491; KRAULIS P, 1991, J APPL CRYSTALLOGR, V25, P649; LANKHOF H, 1995, BLOOD, V86, P1035, DOI 10.1182/blood.V86.3.1035.bloodjournal8631035; Lankhof H, 1996, THROMB HAEMOSTASIS, V75, P950; LAWRIE AS, 1990, THROMB RES, V59, P369, DOI 10.1016/0049-3848(90)90139-4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Nishida N, 2003, NAT STRUCT BIOL, V10, P53, DOI 10.1038/nsb876; PIETU G, 1987, J LAB CLIN MED, V109, P637; Ribba AS, 2001, THROMB HAEMOSTASIS, V86, P848; Romijn RAP, 2001, J BIOL CHEM, V276, P9985, DOI 10.1074/jbc.M006548200; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Saenko E, 2002, ANAL BIOCHEM, V302, P252, DOI 10.1006/abio.2001.5555; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Schneppenheim R, 2001, BLOOD, V98, p41A; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; van der Plas RM, 2000, THROMB HAEMOSTASIS, V84, P1005; Wu DM, 2002, BLOOD, V99, P3623, DOI 10.1182/blood.V99.10.3623	38	78	85	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15035	15039		10.1074/jbc.M208977200	http://dx.doi.org/10.1074/jbc.M208977200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12582178	hybrid, Green Published			2022-12-27	WOS:000182516100060
J	Nekrasov, MP; Ivshina, MP; Chernov, KG; Kovrigina, EA; Evdokimova, VM; Thomas, AAM; Hershey, JWB; Ovchinnikov, LP				Nekrasov, MP; Ivshina, MP; Chernov, KG; Kovrigina, EA; Evdokimova, VM; Thomas, AAM; Hershey, JWB; Ovchinnikov, LP			The mRNA-binding protein YB-1 (p50) prevents association of the eukaryotic initiation factor eIF4G with mRNA and inhibits protein synthesis at the initiation stage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR YB-1; S RIBOSOMAL-SUBUNITS; MAJOR CORE PROTEIN; COLD-SHOCK DOMAIN; RIBONUCLEOPROTEIN PARTICLES; NUCLEAR TRANSLOCATION; GENE-EXPRESSION; TRANSLATION; POLY(A); CELLS	The cytoplasmic messenger ribonucleoprotein particles of mammalian somatic cells contain the protein YB-1, also called p50, as a major core component. YB-1 is multifunctional and involved in regulation of mRNA transcription and translation. Our previous studies demonstrated that YB-1 stimulates initiation of translation in vitro at a low YB-1/mRNA ratio, whereas an increase of YB-1 bound to mRNA resulted in inhibition of protein synthesis in vitro and in vivo. Here we show that YB-1-mediated translation inhibition in a rabbit reticulocyte cell-free system is followed by a decay of polysomes, which is not a result of mRNA degradation or its functional inactivation. The inhibition does not change the ribosome transit time, and therefore, it affects neither elongation nor termination of polypeptide chains and only occurs at the stage of initiation. YB-1 induces accumulation of mRNA in the form of free messenger ribonucleoprotein particles, i.e. it blocks mRNA association with the small ribosomal subunit. The accumulation is accompanied by eukaryotic initiation factor eIF4G dissociation from mRNA. The C-terminal domain of YB-1 is responsible for inhibition of translation as well as the disruption of mRNA interaction with eIF4G.	Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia; Univ Utrecht, Dept Dev Biol, NL-3584 CH Utrecht, Netherlands; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	Russian Academy of Sciences; Utrecht University; University of California System; University of California Davis	Ovchinnikov, LP (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.	ovchinn@vega.protres.ru	Ovchinnikov, Lev/L-2397-2015	Ivshina, Maria/0000-0002-0999-3470				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BLOBEL G, 1972, BIOCHEM BIOPH RES CO, V47, P88, DOI 10.1016/S0006-291X(72)80014-7; Borman AM, 2002, J BIOL CHEM, V277, P36818, DOI 10.1074/jbc.M205065200; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; ITO K, 1994, NUCLEIC ACIDS RES, V22, P2036, DOI 10.1093/nar/22.11.2036; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JAIN SK, 1979, MOL BIOL REP, V5, P79, DOI 10.1007/BF00777492; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; KOZAK M, 1978, J BIOL CHEM, V253, P6568; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MINICH WB, 1990, MOL BIOL REP, V14, P65, DOI 10.1007/BF00360418; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; MINICH WB, 1989, FEBS LETT, V257, P257, DOI 10.1016/0014-5793(89)81547-9; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Pisarev AV, 2002, J BIOL CHEM, V277, P15445, DOI 10.1074/jbc.M111954200; Preobrazhensky A A, 1978, Prog Nucleic Acid Res Mol Biol, V21, P1, DOI 10.1016/S0079-6603(08)60265-2; Ruzanov PV, 1999, J CELL SCI, V112, P3487; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; Shibao K, 1999, INT J CANCER, V83, P732; Skabkin MA, 2001, J BIOL CHEM, V276, P44841, DOI 10.1074/jbc.M107581200; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; SPIRIN A. S., 1964, ZH OBSHCH BIOL, V25, P321; SPIRIN AS, 1996, TRANSLATIONAL CONTRO, P319; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; VANVENROOIJ WJ, 1977, NATURE, V270, P189, DOI 10.1038/270189a0; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wilkinson MF, 2001, BIOESSAYS, V23, P775, DOI 10.1002/bies.1113; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Yurkova MS, 1997, J BIOL CHEM, V272, P10870; Zasedateleva OA, 2002, J MOL BIOL, V324, P73, DOI 10.1016/S0022-2836(02)00937-3	50	106	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13936	13943		10.1074/jbc.M209145200	http://dx.doi.org/10.1074/jbc.M209145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582179	hybrid			2022-12-27	WOS:000182405000049
J	Yang, IY; Miller, H; Wang, ZG; Frank, EG; Ohmori, H; Hanaoka, F; Moriya, M				Yang, IY; Miller, H; Wang, ZG; Frank, EG; Ohmori, H; Hanaoka, F; Moriya, M			Mammalian translesion DNA synthesis across an acrolein-derived deoxyguanosine adduct - Participation of DNA polymerase eta in error-prone synthesis in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM VARIANT; ESCHERICHIA-COLI; LOW FIDELITY; Y-FAMILY; 1,N-2-PROPANODEOXYGUANOSINE ADDUCTS; LESION-BYPASS; HUMAN HOMOLOG; HUMAN REV1; POL-KAPPA; UV-LIGHT	alpha-OH-PdG, an acrolein-derived deoxyguanosine adduct, inhibits DNA synthesis and miscodes significantly in human cells. To probe the cellular mechanism underlying the error-free and error-prone translesion DNA syntheses, in vitro primer extension experiments using purified DNA polymerases and site-specific alpha-OH-PdG were conducted. The results suggest the involvement of pol eta in the cellular error-prone translesion synthesis. Experiments with xeroderma pigmentosum variant cells, which lack pol eta, confirmed this hypothesis. The in vitro results also suggested the involvement of pol iota and/or REV1 in inserting correct dCMP opposite alpha-OH-PdG during error-free synthesis. However, none of translesion-specialized DNA polymerases catalyzed significant extension from a dC terminus when paired opposite alpha-OH-PdG. Thus, our results indicate the following. (i) Multiple DNA polymerases are involved in the bypass of alpha-OH-PdG in human cells. (ii) The accurate and inaccurate syntheses are catalyzed by different polymerases. (iii) A modification of the current eukaryotic bypass model is necessary to account for the accurate bypass synthesis in human cells.	SUNY Stony Brook, Dept Pharmacol Sci, Biol Chem Lab, Stony Brook, NY 11794 USA; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; NICHD, Sect DNA Replicat Repair & Mutagenesis, NIH, Bethesda, MD 20892 USA; Kyoto Univ, Inst Virus Res, Dept Genet & Mol Biol, Lab Genet Informat Anal, Kyoto 6068507, Japan; Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Kentucky; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Kyoto University; Osaka University	Moriya, M (corresponding author), SUNY Stony Brook, Dept Pharmacol Sci, Biol Chem Lab, Stony Brook, NY 11794 USA.	maki@pharm.sunysb.edu	Miller, Holly/I-6942-2015	Miller, Holly/0000-0002-9076-5335	NCI NIH HHS [CA76163, CA47995, CA92528] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047995, R01CA076163, R56CA076163, R01CA092528] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bresson A, 2002, EMBO J, V21, P3881, DOI 10.1093/emboj/cdf363; Chung FL, 1999, MUTAT RES-FUND MOL M, V424, P71, DOI 10.1016/S0027-5107(99)00009-3; CHUNG FL, 1984, CANCER RES, V44, P990; Cleaver JE, 1999, CANCER RES, V59, P1102; COHEN SM, 1992, CANCER RES, V52, P3577; CURREN RD, 1988, MUTAT RES, V209, P17, DOI 10.1016/0165-7992(88)90104-2; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Gearhart PJ, 2001, NAT REV IMMUNOL, V1, P187, DOI 10.1038/35105009; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Gibbs PEM, 2000, P NATL ACAD SCI USA, V97, P4186, DOI 10.1073/pnas.97.8.4186; Guo DY, 2001, NUCLEIC ACIDS RES, V29, P2875, DOI 10.1093/nar/29.13.2875; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUANG Y, 2003, IN PRESS BIOORG CHEM; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; Kawanishi M, 1998, MUTAT RES-GEN TOX EN, V417, P65, DOI 10.1016/S1383-5718(98)00093-X; KING SA, 1995, EXP CELL RES, V217, P100, DOI 10.1006/excr.1995.1068; Kokoska RJ, 2002, J BIOL CHEM, V277, P19633, DOI 10.1074/jbc.M202021200; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; MARNETT LJ, 1985, MUTAT RES, V148, P25; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Minko IG, 2003, J BIOL CHEM, V278, P784, DOI 10.1074/jbc.M207774200; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Nath RG, 1996, CANCER RES, V56, P452; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; NG L, 1991, J BIOL CHEM, V266, P11699; Ogi T, 2002, P NATL ACAD SCI USA, V99, P15548, DOI 10.1073/pnas.222377899; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Pandya GA, 1996, BIOCHEMISTRY-US, V35, P11487, DOI 10.1021/bi960170h; Pandya GA, 2000, J BACTERIOL, V182, P6598, DOI 10.1128/JB.182.23.6598-6604.2000; Parent RA, 1996, J APPL TOXICOL, V16, P103, DOI 10.1002/(SICI)1099-1263(199603)16:2<103::AID-JAT318>3.0.CO;2-Q; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; SMITH RA, 1990, CARCINOGENESIS, V11, P497, DOI 10.1093/carcin/11.3.497; Tissier A, 2000, GENE DEV, V14, P1642; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Vaisman A, 2001, EMBO J, V20, P6520, DOI 10.1093/emboj/20.22.6520; Wang Z, 2001, Mol Interv, V1, P269; Washington MT, 2001, CELL, V107, P917, DOI 10.1016/S0092-8674(01)00613-4; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Yamada A, 2000, NUCLEIC ACIDS RES, V28, P2473, DOI 10.1093/nar/28.13.2473; Yang IY, 2002, CHEM RES TOXICOL, V15, P160, DOI 10.1021/tx010123c; Yang IY, 2002, BIOCHEMISTRY-US, V41, P13826, DOI 10.1021/bi0264723; Yang IY, 2001, J BIOL CHEM, V276, P9071, DOI 10.1074/jbc.M008918200; Yuan FH, 2000, J BIOL CHEM, V275, P8233, DOI 10.1074/jbc.275.11.8233; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4147, DOI 10.1093/nar/28.21.4147; Zhang YB, 2002, NUCLEIC ACIDS RES, V30, P1630, DOI 10.1093/nar/30.7.1630	60	44	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13989	13994		10.1074/jbc.M212535200	http://dx.doi.org/10.1074/jbc.M212535200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584190	hybrid			2022-12-27	WOS:000182405000056
J	Song, JX				Song, JX			Tyrosine phosphorylation of the well packed EphrinB cytoplasmic beta-hairpin for reverse signaling - Structural consequences and binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; NUCLEAR-MAGNETIC-RESONANCE; EPH RECEPTORS; NMR-SPECTROSCOPY; IN-VIVO; MORPHOGENESIS; LIGANDS; DOMAIN	Tyrosine phosphorylation of the 22-residue cytoplasmic region of ephrinB induces its binding to the SH2 domain of Grb4, thus initiating reverse signaling pathways controlling cytoskeleton assembly and remodeling. Recently, the region corresponding to this 22-residue motif was demonstrated to adopt a well packed beta-hairpin structure with a high conformational stability in the unphosphorylated cytoplasmic subdomain. However, because the binding to Grb4 is phosphorylation-dependent and the hairpin contains three conserved tyrosine residues that may be phosphorylated, the key events remain unknown as to how tyrosine phosphorylation affects the structure of this well packed beta-hairpin and which phosphorylation site is relevant to SH2 domain binding. By characterizing the structural and binding properties of six 22-residue SH2 domain-binding motifs with different phosphorylated sites, the present study reveals that, as shown by circular dichroism and NMR, the unphosphorylated 22-residue motif adopts a well formed beta-hairpin structure in isolation from the ephrinB cytoplasmic subdomain. However, this beta-hairpin is radically abolished by tyrosine phosphorylation, regardless of the relative location and number of Tyr residues. Unexpectedly, the peptides with either Tyr(304) or Tyr(316) phosphorylated show high affinity binding to SH2 domain, whereas the peptide with Tyr(311) phosphorylated has no detectable binding. This implies that ephrinB with Tyr(311) phosphorylated might have a currently unidentified binding partner distinct from the Grb4 protein, because Tyr(311) is known to be phosphorylated in vivo. Based on the results above, it is thus proposed that the disruption of the tight side-chain packing by tyrosine phosphorylation in the well structured region of a signaling protein may represent a general activation mechanism by which a cryptic binding site is disclosed for new protein-protein interactions.	Natl Univ Singapore, Dept Biochem, Singapore, Singapore; Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	National University of Singapore; National University of Singapore; National Research Council Canada	Song, JX (corresponding author), Natl Univ Singapore, Dept Biochem, 10 Kent Rideg Crescent, Singapore, Singapore.		Song, Jianxing/J-3617-2013; Song, Jianxing/H-8026-2012	Song, Jianxing/0000-0003-0224-6322				Adams RH, 2000, TRENDS CARDIOVAS MED, V10, P183, DOI 10.1016/S1050-1738(00)00046-3; Adams RH, 2001, CELL, V104, P57, DOI 10.1016/S0092-8674(01)00191-X; [Anonymous], 1996, CIRCULAR DICHROISM C; Barbar E, 2001, BIOCHEMISTRY-US, V40, P9734, DOI 10.1021/bi010483z; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Cowan CA, 2002, TRENDS CELL BIOL, V12, P339, DOI 10.1016/S0962-8924(02)02317-6; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Dyson HJ, 1996, ANNU REV PHYS CHEM, V47, P369, DOI 10.1146/annurev.physchem.47.1.369; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Himanen JP, 2003, TRENDS NEUROSCI, V26, P46, DOI 10.1016/S0166-2236(02)00005-X; Holder N, 1999, DEVELOPMENT, V126, P2033; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON LN, 1993, ANNU REV BIOPH BIOM, V22, P199, DOI 10.1146/annurev.bb.22.060193.001215; Kalo MS, 2001, J BIOL CHEM, V276, P38940, DOI 10.1074/jbc.M105815200; Kullander K, 2001, NEURON, V29, P73, DOI 10.1016/S0896-6273(01)00181-7; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; Marks F., 1996, PROTEIN PHOSPHORYLAT; Mellitzer G, 2000, CURR OPIN NEUROBIOL, V10, P400, DOI 10.1016/S0959-4388(00)00095-7; MORTISHIRESMITH RJ, 1995, BIOCHEMISTRY-US, V34, P7603, DOI 10.1021/bi00023a006; Murai KK, 2002, NEURON, V33, P159, DOI 10.1016/S0896-6273(02)00565-2; Palmer A, 2002, MOL CELL, V9, P725, DOI 10.1016/S1097-2765(02)00488-4; Patel BN, 2002, CURR OPIN CELL BIOL, V14, P221, DOI 10.1016/S0955-0674(02)00308-3; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Song JX, 1999, NAT STRUCT BIOL, V6, P129, DOI 10.1038/5815; Song JX, 2002, BIOCHEMISTRY-US, V41, P10942, DOI 10.1021/bi025815u; Song JX, 1998, BIOCHEM CELL BIOL, V76, P177; Steinmetz MO, 2001, EMBO REP, V2, P505, DOI 10.1093/embo-reports/kve105; Szilak L, 1997, NAT STRUCT BIOL, V4, P112, DOI 10.1038/nsb0297-112; Tanaka M, 2003, EMBO J, V22, P847, DOI 10.1093/emboj/cdg088; Tholey A, 1999, BIOPHYS J, V76, P76, DOI 10.1016/S0006-3495(99)77179-1; WAGNER G, 1982, J MOL BIOL, V155, P347, DOI 10.1016/0022-2836(82)90009-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhang OW, 1997, J MOL BIOL, V272, P9, DOI 10.1006/jmbi.1997.1219; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	37	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24714	24720		10.1074/jbc.M210625200	http://dx.doi.org/10.1074/jbc.M210625200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12606549	hybrid, Green Submitted			2022-12-27	WOS:000183824800058
J	Bianconi, ML				Bianconi, ML			Calorimetric determination of thermodynamic parameters of reaction reveals different enthalpic compensations of the yeast hexokinase isozymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; SACCHAROMYCES-CEREVISIAE; REGULATORY ELEMENTS; CATALYTIC-ACTIVITY; HXK2 GENES; GLUCOSE; BINDING; PII; PHOSPHORYLATION; DISSOCIATION	The change in enthalpy and rate constants for the reactions of yeast hexokinase isozymes, PI (Hxk1) and PII (Hxk2), was determined at pH 7.6 and 25 degreesC by isothermal titration calorimetry. The reactions were done in five buffer systems with enthalpy of protonation varying from -1.22 kcal/mol ( phosphate) to -11.51 kcal/mol ( Tris), allowing the determination of the number of protons released during glucose phosphorylation. The reaction is exothermic for both isozymes with a small, but significant ( p < 0.0001), difference in the enthalpy of reaction (Delta H-R), with an Delta H-R of -5.1 +/- 0.2 ( mean +/- S. D.) kcal/mol for Hxk1, and an Delta H-R of -3.3 +/- 0.3 (mean +/- S. D.) kcal/mol for Hxk2. The K-m for ATP determined by ITC was very similar to those reported in the literature for both isozymes. The effect of NaCl and KCl, from 0 to 200 mM, showed that although the rate of reaction decreases with increasing ionic strength, no change in the Delta H-R was observed suggesting an entropic nature for the ionic strength. The differences in Delta H-R obtained here for both isozymes strongly suggest that, besides glucose phosphorylation, another side reaction such as ATP hydrolysis and/or enzyme phosphorylation is taking place.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Predio CCS, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Bianconi, ML (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, Predio CCS, Bloco E,Sala 38, BR-21941590 Rio De Janeiro, Brazil.	bianconi@bioqmed.ufrj.br						ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; ANDERSON CM, 1978, J MOL BIOL, V123, P1, DOI 10.1016/0022-2836(78)90373-X; BARCLAY K, 1975, ANAL LETT, V8, P33; BENNETT WS, 1978, P NATL ACAD SCI USA, V75, P4848, DOI 10.1073/pnas.75.10.4848; Chaves RS, 1999, BIOCHEM BIOPH RES CO, V254, P345, DOI 10.1006/bbrc.1998.9954; de la Cera T, 2002, J MOL BIOL, V319, P703, DOI 10.1016/S0022-2836(02)00377-7; DELAFUEN.G, 1970, EUR J BIOCHEM, V16, P226; deMeis L, 1997, FEBS LETT, V406, P201, DOI 10.1016/S0014-5793(97)00244-5; DERECHIN M, 1972, BIOCHEMISTRY-US, V11, P1793, DOI 10.1021/bi00760a009; DeWinde JH, 1996, EUR J BIOCHEM, V241, P633; Dynesen J, 1998, APPL MICROBIOL BIOT, V50, P579, DOI 10.1007/s002530051338; EASTERBY JS, 1972, EUR J BIOCHEM, V28, P241, DOI 10.1111/j.1432-1033.1972.tb01907.x; ENTIAN KD, 1982, J BIOL CHEM, V257, P870; ENTIAN KD, 1980, MOL GEN GENET, V178, P633, DOI 10.1007/BF00337871; FROHLICH KU, 1985, GENE, V36, P105, DOI 10.1016/0378-1119(85)90074-5; Fukada H, 1998, PROTEINS, V33, P159, DOI 10.1002/(SICI)1097-0134(19981101)33:2<159::AID-PROT2>3.0.CO;2-E; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; Herrero P, 1998, FEBS LETT, V434, P71, DOI 10.1016/S0014-5793(98)00872-2; Herrero P, 1996, NUCLEIC ACIDS RES, V24, P1822, DOI 10.1093/nar/24.10.1822; HOGGETT JG, 1976, EUR J BIOCHEM, V66, P65, DOI 10.1111/j.1432-1033.1976.tb10426.x; HOGGETT JG, 1976, EUR J BIOCHEM, V68, P347, DOI 10.1111/j.1432-1033.1976.tb10821.x; Hohmann S, 1999, MICROBIOL-UK, V145, P703, DOI 10.1099/13500872-145-3-703; KAJI A, 1965, J BIOL CHEM, V240, P4454; KODAMA T, 1982, J BIOL CHEM, V257, P4238; KOPETZKI E, 1985, GENE, V39, P95, DOI 10.1016/0378-1119(85)90113-1; Kraakman LS, 1999, BIOCHEM J, V343, P159, DOI 10.1042/0264-6021:3430159; KRIEGEL TM, 1994, BIOCHEMISTRY-US, V33, P148, DOI 10.1021/bi00167a019; Lonhienne T, 2001, BBA-PROTEIN STRUCT M, V1545, P349, DOI 10.1016/S0167-4838(00)00296-X; MA H, 1986, MOL CELL BIOL, V6, P4046, DOI 10.1128/MCB.6.11.4046; MartinezCampa C, 1996, FEMS MICROBIOL LETT, V137, P69, DOI 10.1016/0378-1097(96)00034-1; MAYES EL, 1983, EUR J BIOCHEM, V133, P127, DOI 10.1111/j.1432-1033.1983.tb07437.x; Mayordomo I, 2001, YEAST, V18, P923, DOI 10.1002/yea.737; MILLAR NC, 1987, BIOCHEM J, V248, P683, DOI 10.1042/bj2480683; MONTEROLOMELI M, 1992, BIOCHIM BIOPHYS ACTA, V1120, P305, DOI 10.1016/0167-4838(92)90252-9; Moreno F, 2002, FEMS MICROBIOL REV, V26, P83, DOI 10.1111/j.1574-6976.2002.tb00600.x; Moreno-Herrero F, 1999, FEBS LETT, V459, P427, DOI 10.1016/S0014-5793(99)01289-2; MORIN PE, 1991, BIOCHEMISTRY-US, V30, P8494, DOI 10.1021/bi00098a030; Randez-Gil F, 1998, FEBS LETT, V425, P475, DOI 10.1016/S0014-5793(98)00289-0; Rodriguez A, 2001, BIOCHEM J, V355, P625, DOI 10.1042/bj3550625; ROSE M, 1991, EUR J BIOCHEM, V199, P511, DOI 10.1111/j.1432-1033.1991.tb16149.x; Saboury AA, 2002, J BIOCHEM MOL BIOL, V35, P302, DOI 10.5483/BMBRep.2002.35.3.302; SCHMIDT JJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P458, DOI 10.1016/0003-9861(73)90537-7; SHILL JP, 1974, BIOCHEMISTRY-US, V13, P3864, DOI 10.1021/bi00716a007; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; STEITZ TA, 1977, J BIOL CHEM, V252, P4494; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P4693, DOI 10.1021/bi00519a026; Todd MJ, 2001, ANAL BIOCHEM, V296, P179, DOI 10.1006/abio.2001.5218; VOJTEK AB, 1990, EUR J BIOCHEM, V190, P371, DOI 10.1111/j.1432-1033.1990.tb15585.x; WILLIAMS BA, 1993, J ORG CHEM, V58, P3507, DOI 10.1021/jo00065a010; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WOMACK F, 1978, ARCH BIOCHEM BIOPHYS, V191, P742, DOI 10.1016/0003-9861(78)90415-0; YOURTEE DM, 1975, ANAL LETT, V8, P41, DOI 10.1080/00032717508060359	52	66	68	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18709	18713		10.1074/jbc.M211103200	http://dx.doi.org/10.1074/jbc.M211103200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12611889	hybrid			2022-12-27	WOS:000182932200002
J	Holtz, WA; O'Malley, KL				Holtz, WA; O'Malley, KL			Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; PROGRAMMED CELL-DEATH; RECESSIVE JUVENILE PARKINSONISM; DISTINCT MECHANISMS; ALPHA-SYNUCLEIN; MESSENGER-RNA; ER STRESS; DISEASE; GENE; APOPTOSIS	Genes associated with Parkinson's disease (PD) have suggested a role for ubiquitin-proteasome dysfunction and aberrant protein degradation in this disorder. Inasmuch as oxidative stress has also been implicated in PD, the present study examined transcriptional changes mediated by the Parkinsonism-inducing neurotoxins 6-hydroxydopamine (6-OHDA) and 1-methyl-4-phenylpyridinium (MPP+) in a dopaminergic cell line. Microarray analysis of RNA isolated from toxin treated samples revealed that the stress-induced transcription factor CHOP/Gadd153 was dramatically up-regulated by both 6-OHDA and MPP+. Treatment with 6-OHDA also induced a large number of genes involved in endoplasmic reticulum stress and unfolded protein response (UPR) such as ER chaperones and elements of the ubiquitin-proteasome system. Reverse transcription-PCR, Western blotting, and immunocytochemical approaches were used to quantify and temporally order the UPR pathways involved in neurotoxin-induced cell death. 6-OHDA, but not MPP+, significantly increased hallmarks of UPR such as BiP, c-Jun, and processed Xbp1 mRNA. Both toxins increased the phosphorylation of UPR proteins, PERK and eIF2alpha, but only 6-OHDA increased phosphorylation of c-Jun. Thus, 6-OHDA is capable of triggering multiple pathways associated with UPR, whereas MPP+ exhibits a more restricted response. The involvement of UPR in these widely used neurotoxin models supports the role of ubiquitin-proteasome pathway dysfunction in PD.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	O'Malley, KL (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, Box 8108,660 S Euclid Ave, St Louis, MO 63110 USA.	omalleyk@pcg.wustl.edu	Longo, Kenneth A/A-5631-2010		NATIONAL CANCER INSTITUTE [P30CA091842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039084, R56NS039084] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA91842] Funding Source: Medline; NINDS NIH HHS [NS39084] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albers DS, 2000, J NEURAL TRANSM-SUPP, P133; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Castro-Obregon S, 2002, CELL DEATH DIFFER, V9, P807, DOI 10.1038/sj.cdd.4401035; CHOI HK, 1991, BRAIN RES, V552, P67, DOI 10.1016/0006-8993(91)90661-E; Choi WS, 1999, EXP NEUROL, V159, P274, DOI 10.1006/exnr.1999.7133; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.0.CO;2-E; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; Conn KJ, 2002, J NEUROSCI RES, V68, P755, DOI 10.1002/jnr.10252; CURTIUS HC, 1974, J CHROMATOGR, V99, P529, DOI 10.1016/S0021-9673(00)90882-3; Fleming JV, 1997, MOL REPROD DEV, V48, P310, DOI 10.1002/(SICI)1098-2795(199711)48:3&lt;310::AID-MRD2&gt;3.0.CO;2-U; FORNSTEDT B, 1986, NEUROPHARMACOLOGY, V25, P451, DOI 10.1016/0028-3908(86)90242-X; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; Hattori N, 1998, ANN NEUROL, V44, P935, DOI 10.1002/ana.410440612; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LANGSTON JW, 1983, NEW ENGL J MED, V309, P310; Lansbury PT, 2002, CURR OPIN CELL BIOL, V14, P653, DOI 10.1016/S0955-0674(02)00377-0; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Liu CY, 2003, BLOOD, V101, P295, DOI 10.1182/blood-2001-12-0266; Lotharius J, 1999, J NEUROSCI, V19, P1284; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Maraganore DM, 1999, NEUROLOGY, V53, P1858, DOI 10.1212/WNL.53.8.1858; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; McNaught KS, 2002, NEUROREPORT, V13, P1437, DOI 10.1097/00001756-200208070-00018; McNaught KS, 2002, J NEUROCHEM, V81, P301, DOI 10.1046/j.1471-4159.2002.00821.x; Mengesdorf T, 2002, MOL BRAIN RES, V104, P227, DOI 10.1016/S0169-328X(02)00384-4; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; Nicotra A, 2002, NEUROTOXICOL TERATOL, V24, P599, DOI 10.1016/S0892-0362(02)00213-1; Oh YJ, 1995, NEUROBIOL DIS, V2, P157, DOI 10.1006/nbdi.1995.0017; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; OMALLEY KL, 1990, BIOCHEMISTRY-US, V29, P1367, DOI 10.1021/bi00458a003; OMALLEY KL, 2003, IN PRESS NEUROBIOL D; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Speciale SG, 2002, NEUROTOXICOL TERATOL, V24, P607, DOI 10.1016/S0892-0362(02)00222-2; Spencer JPE, 1998, J NEUROCHEM, V71, P2112; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Williams B.R., 2001, SCI STKE, V2001, pre2; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	61	307	324	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19367	19377		10.1074/jbc.M211821200	http://dx.doi.org/10.1074/jbc.M211821200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12598533	hybrid			2022-12-27	WOS:000182932200085
J	Muller, C; Richter, S; Rinas, U				Muller, C; Richter, S; Rinas, U			Kinetics control preferential heterodimer formation of platelet-derived growth factor from unfolded A- and B-chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT ESCHERICHIA-COLI; INTERCHAIN DISULFIDE BONDS; CRYSTAL-STRUCTURE; A-CHAIN; PDGF; RENATURATION; PURIFICATION; STABILITY; SEQUENCE; RECEPTOR	The folding and assembly of platelet-derived growth factor (PDGF), a potent mitogen involved in wound-healing processes and member of the cystine knot growth factor family, was studied. The kinetics of the formation of disulfide-bonded dimers were investigated under redox reshuffling conditions starting either from unfolded and reduced PDGF-A- or B-chains or an equimolar mixture of both chains. It is shown that in all cases the formation of disulfide-bonded dimers is a very slow process occurring in the time scale of hours with a first-order rate-determining step. The formation of disulfide-bonded PDGF-AA or PDGF-BB homodimers displayed identical kinetics, indicating that both monomeric forms as well as the dimerized homodimer have similar folding and assembly pathways. In contrast, the formation of the heterodimer occurred three times more rapidly compared with the formation of the homodimers. As both monomeric forms revealed similar renaturation kinetics, it can be concluded that the first-order rate-determining folding step does not occur during monomer folding but must be attributed to conformational rearrangements of the dimerized, not yet disulfide-bonded protein. These structural rearrangements allow a more rapid formation of intermolecular disulfide bonds between the two different monomers of a heterodimer compared with the formation of the disulfide bonds between two identical monomers. The preferential formation of disulfide-bonded heterodimers from an equimolar mixture of unfolded A- and B-chains is thus a kinetically controlled process. Moreover, similar activation enthalpies for the formation of all different isoforms suggest that faster heterodimerization is controlled by entropic factors.	GBF Natl Res Ctr Biotechnol, Div Biochem Engn, D-38124 Braunschweig, Germany	Helmholtz Association; Helmholtz-Center for Infection Research	Rinas, U (corresponding author), GBF Natl Res Ctr Biotechnol, Div Biochem Engn, Mascheroder Weg 1, D-38124 Braunschweig, Germany.			Rinas, Ursula/0000-0003-4940-5749				BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HANNINK M, 1989, BIOCHIM BIOPHYS ACTA, V989, P1, DOI 10.1016/0304-419X(89)90031-0; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; HOPPE J, 1990, EUR J BIOCHEM, V187, P207, DOI 10.1111/j.1432-1033.1990.tb15296.x; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JAENICKE R, 1979, BIOCHEMISTRY-US, V18, P1217, DOI 10.1021/bi00574a016; Jaenicke R, 1986, Methods Enzymol, V131, P218; KENNEY WC, 1994, J BIOL CHEM, V269, P12351; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; MEYERINGOLD W, 1993, TRENDS BIOTECHNOL, V11, P387, DOI 10.1016/0167-7799(93)90098-T; MEYERINGOLD W, 1995, CELL BIOL INT, V19, P389, DOI 10.1006/cbir.1995.1084; MILLA ME, 1994, BIOCHEMISTRY-US, V33, P1125, DOI 10.1021/bi00171a011; Muller C, 1999, J CHROMATOGR A, V855, P203, DOI 10.1016/S0021-9673(99)00660-3; Muller YA, 2002, J BIOL CHEM, V277, P43410, DOI 10.1074/jbc.M206438200; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; PHILO JS, 1993, BIOCHEMISTRY-US, V32, P10812, DOI 10.1021/bi00091a036; PRESTRELSKI SJ, 1994, INT J PEPT PROT RES, V44, P357; RAINES EW, 1985, METHOD ENZYMOL, V109, P749; Rattenholl A, 2001, J MOL BIOL, V305, P523, DOI 10.1006/jmbi.2000.4295; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; RUDOLPH R, 1986, BIOCHEMISTRY-US, V25, P1662, DOI 10.1021/bi00355a033; Scheufler C, 1999, J MOL BIOL, V287, P103, DOI 10.1006/jmbi.1999.2590; SCHNEPPE B, 1994, GENE, V143, P201, DOI 10.1016/0378-1119(94)90097-3; SEEGER A, 1995, ENZYME MICROB TECH, V17, P947, DOI 10.1016/0141-0229(94)00123-9	31	4	4	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18330	18335		10.1074/jbc.M212317200	http://dx.doi.org/10.1074/jbc.M212317200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12615918	hybrid			2022-12-27	WOS:000182838300097
J	Li, T; Southall, MD; Yi, QF; Pei, Y; Lewis, D; Al-Hassani, M; Spandau, D; Travers, JB				Li, T; Southall, MD; Yi, QF; Pei, Y; Lewis, D; Al-Hassani, M; Spandau, D; Travers, JB			The epidermal platelet-activating factor receptor augments chemotherapy-induced apoptosis in human carcinoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; HUMAN KERATINOCYTES; RAT STRIATUM; NECROSIS; BIOSYNTHESIS; DAMAGE; LIGAND	Most chemotherapeutic agents exert their cytotoxic effects in part through the induction of apoptosis. In addition, many chemotherapeutic agents are potent pro-oxidative stressors. Although the lipid mediator platelet-activating factor (PAF) is synthesized in response to oxidative stress, and many epidermal carcinomas express PAF receptors, it is not known whether PAF is involved in chemotherapeutic agent-induced apoptosis. These studies examined the role of the PAF system in chemotherapy-mediated cytotoxicity using model systems created by retroviral mediated transduction of the PAF receptor-negative human epidermal carcinoma cell line KB with the human PAF receptor (PAF-R) and ablation of the endogenous PAF-R in the carcinoma cell line HaCaT with a retroviral mediated inducible antisense PAF-R vector. The presence of the PAF-R in these models resulted in an augmentation of apoptosis induced by chemotherapeutic agents etoposide and mitomycin C but not by tumor necrosis factor-related apoptosis-inducing ligand or by C-2 ceramide. Oxidative stress and the transcription factor nuclear factor kappaB (NF-kappaB) are found to be involved in this augmentative effect because it was blocked by antioxidants and inhibition of the NF-kappaB pathway using a super-repressor form of inhibitor B. These studies provide evidence for a novel pathway whereby the epidermal PAF-R can augment chemotherapy-induced apoptotic effects through an NF-kappaB-dependent process.	Indiana Univ, Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Travers, JB (corresponding author), Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, HB Wells Ctr Pediat Res, Rm 2659,702 Barnhill Dr, Indianapolis, IN 46202 USA.		LI, TAO/AAL-5932-2020	LI, TAO/0000-0001-7343-9688; Travers, Jeffrey/0000-0001-7232-1039	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001993] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62996] Funding Source: Medline; NIAMS NIH HHS [AR01993] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alappatt C, 2000, ARCH DERMATOL RES, V292, P256, DOI 10.1007/s004030050483; Barber LA, 1998, J BIOL CHEM, V273, P18891, DOI 10.1074/jbc.273.30.18891; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Countryman NB, 2000, J INVEST DERMATOL, V115, P267, DOI 10.1046/j.1523-1747.2000.00058.x; Dy LC, 1999, J BIOL CHEM, V274, P26917, DOI 10.1074/jbc.274.38.26917; Foo SY, 1999, TRENDS GENET, V15, P229; Goldman R, 1999, BBA-MOL CELL BIOL L, V1438, P349, DOI 10.1016/S1388-1981(99)00066-9; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kagan VE, 2001, CANCER RES, V61, P7777; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; Lehr HA, 1997, J CLIN INVEST, V99, P2358, DOI 10.1172/JCI119417; Maccarrone M, 1999, EUR J BIOCHEM, V265, P27, DOI 10.1046/j.1432-1327.1999.00630.x; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; McInnis J, 2002, J PHARMACOL EXP THER, V301, P478, DOI 10.1124/jpet.301.2.478; MICHEL L, 1990, J INVEST DERMATOL, V95, P576, DOI 10.1111/1523-1747.ep12505563; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Pei Y, 1998, J IMMUNOL, V161, P1954; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Southall MD, 2001, J BIOL CHEM, V276, P45548, DOI 10.1074/jbc.M105978200; Travers JB, 1999, J INVEST DERMATOL, V112, P279, DOI 10.1046/j.1523-1747.1999.00521.x; TRAVERS JB, 1995, J INVEST DERMATOL, V105, P816, DOI 10.1111/1523-1747.ep12326581; Travers JB, 1996, J INVEST DERMATOL, V107, P88, DOI 10.1111/1523-1747.ep12298295; Walterscheid JP, 2002, J EXP MED, V195, P171, DOI 10.1084/jem.20011450; Wang Y, 1999, NEUROSCIENCE, V94, P1153, DOI 10.1016/S0306-4522(99)00264-X; Williams DA, 2000, BLOOD, V96, P1646; XU BH, 1992, CANCER LETT, V66, P49, DOI 10.1016/0304-3835(92)90279-5	29	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16614	16621		10.1074/jbc.M211287200	http://dx.doi.org/10.1074/jbc.M211287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12601006	hybrid			2022-12-27	WOS:000182818600024
J	Suzuki, YJ; Day, RM; Tan, CC; Sandven, TH; Liang, QR; Molkentin, JD; Fanburg, BL				Suzuki, YJ; Day, RM; Tan, CC; Sandven, TH; Liang, QR; Molkentin, JD; Fanburg, BL			Activation of GATA-4 by serotonin in pulmonary artery smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; EXON/INTRON ORGANIZATION; PROMOTER ACTIVITY; SUPEROXIDE ANION; CYCLIN D2; AP-1 SITE; IN-VIVO; GENE; HYPERTENSION; EXPRESSION	Serotonin (5-hydroxytryptamine (5-HT)) is a mitogen of pulmonary artery smooth muscle cells (PASMC) and plays an important role in the development of pulmonary hypertension. Signal transduction initiated by 5-HT involves serotonin transporter-dependent generation of reactive oxygen species and activation of the MEK-ERK pathway. However, the downstream transcriptional regulatory components have not been identified. In systemic smooth muscle cells, GATA-6 has been shown to regulate mitogenesis by driving cells into a quiescent state, and the down-regulation of GATA-6 induces mitogenesis. Thus, the present study tested the hypothesis that 5-HT induces mitogenesis of PASMC by down-regulating GATA-6. Quiescent bovine PASMC were treated with 5-HT, and the binding activity of nuclear extracts toward GATA DNA sequence was monitored. Surprisingly, PASMC express GATA-4, and 5-HT up-regulates the GATA DNA binding activity. Pretreatment of cells with inhibitors of serotonin transporter, reactive oxygen species, and MEK blocks GATA-4 activation by 5-HT. GATA-4 is not activated when the ERK phosphorylation site is mutated, indicating that 5-HT phosphorylates GATA-4 via the MEK/ERK pathway. GATA up-regulation is also induced by other mitogens of PASMC such as endothelin-1 and platelet-derived growth factor. Dominant negative mutants of GATA-4 suppress cyclin D2 expression and cell growth, indicating that GATA-4 activation regulates PASMC proliferation. Thus, GATA-4 mediates 5-HT-induced growth of PASMC and may be an important therapeutic target for the prevention of pulmonary hypertension.	Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Tupper Res Inst, Pulm Crit Care & Sleep Div,Dept Med, Boston, MA 02111 USA; Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA	Tufts University; United States Department of Agriculture (USDA); Tufts Medical Center; Tufts University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Suzuki, YJ (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.	yuichiro.suzuki@tufts.edu		Molkentin, Jeffery/0000-0002-3558-6529	NHLBI NIH HHS [R01-HL32723, R01 HL072844, R01-HL67340] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032723, R01HL072844, R01HL067340] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; BECKER BN, 1992, MOL PHARMACOL, V42, P817; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Eddahibi S, 1997, AM J PHYSIOL-HEART C, V272, pH1173, DOI 10.1152/ajpheart.1997.272.3.H1173; Eddahibi S, 2000, J CLIN INVEST, V105, P1555, DOI 10.1172/JCI8678; Eddahibi S, 2001, RESP RES, V3, DOI 10.1186/rr181; Eddahibi S, 2001, J CLIN INVEST, V108, P1141, DOI 10.1172/JCI12805; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; HERVE P, 1990, AM J MED, V89, P117, DOI 10.1016/0002-9343(90)90111-P; HERVE P, 1995, AM J MED, V99, P249, DOI 10.1016/S0002-9343(99)80156-9; Huang TT, 1999, MOL CELL ENDOCRINOL, V152, P21, DOI 10.1016/S0303-7207(99)00067-2; Jun DY, 1997, MOL CELLS, V7, P537; Kim Y, 2003, MOL PHARMACOL, V63, P368, DOI 10.1124/mol.63.2.368; Kitta K, 2003, J BIOL CHEM, V278, P4705, DOI 10.1074/jbc.M211616200; Kitta K, 2001, BIOCHEM J, V359, P375, DOI 10.1042/0264-6021:3590375; LEE SL, 1991, CIRC RES, V68, P1362, DOI 10.1161/01.RES.68.5.1362; LEE SL, 1992, J CELL PHYSIOL, V150, P396, DOI 10.1002/jcp.1041500224; Lee SL, 2001, AM J PHYSIOL-LUNG C, V281, pL646, DOI 10.1152/ajplung.2001.281.3.L646; Lee SL, 2001, FASEB J, V15, P1324, DOI 10.1096/fj.00-0431fje; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282; LEE SL, 1994, AM J PHYSIOL, V266, pL46, DOI 10.1152/ajplung.1994.266.1.L46; Lee SL, 1998, FREE RADICAL BIO MED, V24, P855, DOI 10.1016/S0891-5849(97)00359-6; Lee SL, 1997, AM J PHYSIOL-CELL PH, V272, pC223, DOI 10.1152/ajpcell.1997.272.1.C223; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Mano T, 1999, CIRC RES, V84, P647, DOI 10.1161/01.RES.84.6.647; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; Rothman RB, 1999, CIRCULATION, V100, P869, DOI 10.1161/01.CIR.100.8.869; SATO K, 1992, AM REV RESPIR DIS, V145, P793, DOI 10.1164/ajrccm/145.4_Pt_1.793; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; Suzuki E, 1996, GENOMICS, V38, P283, DOI 10.1006/geno.1996.0630; SUZUKI YJ, 2003, IN PRESS AM J RESP C, V167; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Tanaka H, 2000, BLOOD, V95, P1264, DOI 10.1182/blood.V95.4.1264.004k09_1264_1273; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; Wilcox CB, 2000, MOL CELL ENDOCRINOL, V170, P41, DOI 10.1016/S0303-7207(00)00327-0	41	59	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17525	17531		10.1074/jbc.M210465200	http://dx.doi.org/10.1074/jbc.M210465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615926	hybrid			2022-12-27	WOS:000182818600141
J	Perrin, MH; DiGruccio, MR; Koerber, SC; Rivier, JE; Kunitake, KS; Bain, DL; Fischer, WH; Vale, WW				Perrin, MH; DiGruccio, MR; Koerber, SC; Rivier, JE; Kunitake, KS; Bain, DL; Fischer, WH; Vale, WW			A soluble form of the first extracellular domain of mouse type 2 beta corticotropin-releasing factor receptor reveals differential ligand specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; HORMONE-BINDING DOMAIN; N-TERMINAL DOMAIN; HIGH-AFFINITY; XENOPUS-LAEVIS; AMINO-ACIDS; UROTENSIN-I; UROCORTIN; IDENTIFICATION; EXPRESSION	The heptahelical receptors for corticotropin-releasing factor (CRF), CRFR1 and CRFR2, display different specificities for CRF family ligands: CRF and urocortin I bind to CRFR1 with high affinity, whereas urocortin II and III bind to this receptor with very low affinities. In contrast, all the urocortins bind with high affinities, and CRF binds with lower affinity to CRFR2. The first extracellular domain (ECD1) of CRFR1 is important for ligand recognition. Here, we characterize a bacterially expressed soluble protein, ECD1-CRFR2,6, corresponding to the ECD1 of mouse CRFR2beta. The K-i values for binding to ECD1-CRFR2beta are: astressin = 10.7 (5.4-21.1) nM, urocortin I = 6.4 (4.7-8.7) nm, urocortin II = 6.9 (5.8-8.3) nM, CRF = 97 (22-430) nM, urocortin III sauvagine >200 nm. These affinities are similar to those for binding to a chimeric receptor in which the ECD1 of CRFR2,6 replaces the ECD of the type 1B activin receptor (ALK4). The ECD1-CRFR2beta possesses a disulfide arrangement identical to that of the ECD1 of CRFR1, namely Cys(45-)Cys(70), Cys(60)-Cys(103), and Cys(84)-Cys(118). As determined by circular dichroism, ECD1-CRFR2beta undergoes conformational changes upon binding astressin. These data reinforce the importance of the ECD1 of CRF receptors for ligand recognition and raise the interesting possibility that different ligands having similar affinity for the full-length receptor may, nevertheless, have different affinities for microdomains of the receptor.	Clayton Fdn, Labs Peptide Biol, Salk Inst, La Jolla, CA 92037 USA	Salk Institute	Perrin, MH (corresponding author), Clayton Fdn, Labs Peptide Biol, Salk Inst, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			DiGruccio, Michael/0000-0002-9375-2425	NIDDK NIH HHS [DK 26741] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK026741] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arai M, 2001, ENDOCRINOLOGY, V142, P446, DOI 10.1210/en.142.1.446; Assil IQ, 2001, BIOCHEMISTRY-US, V40, P1187, DOI 10.1021/bi001758y; Assil-Kishawi I, 2002, J BIOL CHEM, V277, P32558, DOI 10.1074/jbc.M204964200; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508; BRAR BK, 2002, ENCY HORMONES RELATE, P313; CHANG CP, 1993, NEURON, V11, P1187, DOI 10.1016/0896-6273(93)90230-O; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; Dautzenberg FM, 1997, J NEUROCHEM, V69, P1640; Dautzenberg FM, 1998, P NATL ACAD SCI USA, V95, P4941, DOI 10.1073/pnas.95.9.4941; Dautzenberg FM, 1999, J NEUROCHEM, V73, P821, DOI 10.1046/j.1471-4159.1999.0730821.x; Dautzenberg FM, 2002, MOL PHARMACOL, V61, P1132, DOI 10.1124/mol.61.5.1132; Dautzenberg FM, 2001, J PHARMACOL EXP THER, V296, P113; Donaldson CJ, 1996, ENDOCRINOLOGY, V137, P3896, DOI 10.1210/endo.137.9.8756563; Goldsmith PK, 1999, J BIOL CHEM, V274, P11303, DOI 10.1074/jbc.274.16.11303; Grammatopoulos DK, 2000, MOL ENDOCRINOL, V14, P2076, DOI 10.1210/me.14.12.2076; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Greenwald J, 1999, NAT STRUCT BIOL, V6, P18; GULYAS J, 1995, P NATL ACAD SCI USA, V92, P10575, DOI 10.1073/pnas.92.23.10575; Hofmann BA, 2001, PROTEIN SCI, V10, P2050, DOI 10.1110/ps.12101; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; KISHIMOTO T, 1995, P NATL ACAD SCI USA, V92, P1108, DOI 10.1073/pnas.92.4.1108; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Lewis K, 2001, P NATL ACAD SCI USA, V98, P7570, DOI 10.1073/pnas.121165198; Liaw CW, 1997, MOL ENDOCRINOL, V11, P980, DOI 10.1210/me.11.7.980; Liaw CW, 1997, MOL ENDOCRINOL, V11, P2048, DOI 10.1210/me.11.13.2048; LOVENBERG TW, 1995, P NATL ACAD SCI USA, V92, P836, DOI 10.1073/pnas.92.3.836; Ludvigsen S, 2001, BIOCHEMISTRY-US, V40, P9082, DOI 10.1021/bi010433u; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; PERRIN M, 1995, P NATL ACAD SCI USA, V92, P2969, DOI 10.1073/pnas.92.7.2969; Perrin MH, 1999, ANN NY ACAD SCI, V885, P312, DOI 10.1111/j.1749-6632.1999.tb08687.x; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Perrin MH, 1998, ENDOCRINOLOGY, V139, P566, DOI 10.1210/en.139.2.566; Perrin MH, 1999, J PHARMACOL EXP THER, V288, P729; Remy JJ, 2001, J BIOL CHEM, V276, P1681, DOI 10.1074/jbc.M005206200; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; Ruhmann A, 1999, PEPTIDES, V20, P1311, DOI 10.1016/S0196-9781(99)00136-9; Schmidt A, 2001, J BIOL CHEM, V276, P23373, DOI 10.1074/jbc.M100057200; STENZEL P, 1995, MOL ENDOCRINOL, V9, P637, DOI 10.1210/me.9.5.637; TENDIJKE P, 1993, ONCOGENE, V8, P2879; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; Wille S, 1999, J NEUROCHEM, V72, P388, DOI 10.1046/j.1471-4159.1999.0720388.x; Wilmen A, 1996, FEBS LETT, V398, P43, DOI 10.1016/S0014-5793(96)01214-8; Yu JX, 1996, ENDOCRINOLOGY, V137, P192, DOI 10.1210/en.137.1.192	46	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15595	15600		10.1074/jbc.M210476200	http://dx.doi.org/10.1074/jbc.M210476200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12611895	hybrid			2022-12-27	WOS:000182680000019
J	Petrie, K; Guidez, F; Howell, L; Healy, L; Waxman, S; Greaves, M; Zelent, A				Petrie, K; Guidez, F; Howell, L; Healy, L; Waxman, S; Greaves, M; Zelent, A			The histone deacetylase 9 gene encodes multiple protein isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; SAETHRE-CHOTZEN-SYNDROME; COMPARATIVE GENOMIC HYBRIDIZATION; COREPRESSOR N-COR; TRANSCRIPTIONAL REPRESSION; MEDIATED REPRESSION; CLASS-I; FAMILY; TWIST; EXPRESSION	Histone deacetylases (HDACs) perform an important function in transcriptional regulation by modifying the core histones of the nucleosome. We have now fully characterized a new member of the Class II HDAC family, HDAC9. The enzyme contains a conserved deacetylase domain, represses reporter activity when recruited to a promoter, and utilizes histones H3 and H4 as substrates in vitro and in vivo. HDAC9 is expressed in a tissue-specific pattern that partially overlaps that of HDAC4. Within the human hematopoietic system, expression of HDAC9 is biased toward cells of monocytic and lymphoid lineages. The HDAC9 gene encodes multiple protein isoforms, some of which display distinct cellular localization patterns. For example, full-length HDAC9 is localized in the nucleus, but the isoform lacking the region encoded by exon 7 is in the cytoplasm. HDAC9 interacts and co-localizes in vivo with a number of transcriptional repressors and co-repressors, including TEL and N-CoR, whose functions have been implicated in the pathogenesis of hematological malignancies. These results suggest that HDAC9 plays a role in hematopoiesis; its deregulated expression may be associated with some human cancers.	Inst Canc Res, Leukaemia Res Fund Ctr, London SW3 6JB, England; Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Icahn School of Medicine at Mount Sinai	Zelent, A (corresponding author), Inst Canc Res, Leukaemia Res Fund Ctr, 237 Fulham Rd, London SW3 6JB, England.		Guidez, Fabien/P-4220-2019; Zelent, Arthur/B-3532-2009; Petrie, Kevin/I-7115-2015; Guidez, Fabien/B-3750-2009	Guidez, Fabien/0000-0003-1380-4473; Petrie, Kevin/0000-0002-9805-9152; Zelent, Arthur/0000-0002-7968-9888; Healy, Lyn/0000-0002-7044-8789				Agape P, 1997, BRIT J HAEMATOL, V98, P234, DOI 10.1046/j.1365-2141.1997.1973014.x; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Aragane H, 2001, INT J CANCER, V94, P623, DOI 10.1002/ijc.1522; ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Benson DA, 2002, NUCLEIC ACIDS RES, V30, P17, DOI 10.1093/nar/30.1.17; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Capello D, 2000, BLOOD, V95, P651; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DAVID G, 2002, J BIOL CHEM, V17, P17; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; ElGhouzzi V, 1997, NAT GENET, V15, P42; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; ENVER T, 1985, NATURE, V318, P680, DOI 10.1038/318680a0; Fischer DD, 2002, J BIOL CHEM, V277, P6656, DOI 10.1074/jbc.M108055200; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; FURLEY AJ, 1986, BLOOD, V68, P1101; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Guidez F, 2000, BLOOD, V96, P2557; Guidez F, 2001, CURR TOP MICROBIOL, V254, P165; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Huang EY, 2000, GENE DEV, V14, P45; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Jarosova M, 2000, CANCER GENET CYTOGEN, V123, P114, DOI 10.1016/S0165-4608(00)00310-1; Johnson D, 1998, AM J HUM GENET, V63, P1282, DOI 10.1086/302122; Kao HY, 2002, J BIOL CHEM, V277, P187, DOI 10.1074/jbc.M108931200; Kao HY, 2000, GENE DEV, V14, P55; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Khochbin S, 2001, FEBS LETT, V494, P141, DOI 10.1016/S0014-5793(01)02327-4; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Krebs I, 1997, HUM MOL GENET, V6, P1079, DOI 10.1093/hmg/6.7.1079; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LEWANDA AF, 1994, AM J HUM GENET, V55, P1195; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mahlknecht U, 2000, BBA-GENE STRUCT EXPR, V1493, P342, DOI 10.1016/S0167-4781(00)00191-3; Mahlknecht U, 1999, GENOMICS, V56, P197, DOI 10.1006/geno.1998.5645; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Powlesland RM, 2000, BRIT J CANCER, V82, P323, DOI 10.1054/bjoc.1999.0922; RIO DC, 1985, SCIENCE, V227, P23, DOI 10.1126/science.2981116; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Schmidt H, 2002, GENE CHROMOSOME CANC, V34, P69, DOI 10.1002/gcc.10036; Schmidt H, 1999, GENE CHROMOSOME CANC, V25, P205, DOI 10.1002/(SICI)1098-2264(199907)25:3<205::AID-GCC2>3.0.CO;2-B; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Soderstrom M, 1997, MOL ENDOCRINOL, V11, P682, DOI 10.1210/me.11.6.682; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Stankiewicz P, 2001, AM J MED GENET, V103, P56, DOI 10.1002/ajmg.1512; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JJ, 2002, NUCLEIC ACIDS RES, V30, P1114, DOI 10.1093/nar/30.5.1114; TSUJI K, 1994, AM J MED GENET, V49, P98, DOI 10.1002/ajmg.1320490119; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Zhang CL, 2001, P NATL ACAD SCI USA, V98, P7354, DOI 10.1073/pnas.131198498; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056; Zhou XB, 2001, P NATL ACAD SCI USA, V98, P10572, DOI 10.1073/pnas.191375098	85	119	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16059	16072		10.1074/jbc.M212935200	http://dx.doi.org/10.1074/jbc.M212935200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12590135	hybrid			2022-12-27	WOS:000182680000078
J	Tjalsma, H; Bron, S; van Dijl, JM				Tjalsma, H; Bron, S; van Dijl, JM			Complementary impact of paralogous Oxa1-like proteins of Bacillus subtilis on post-translocational stages in protein secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDASE-II; ESCHERICHIA-COLI; MEMBRANE-PROTEIN; EFFICIENT SECRETION; FUNCTIONAL-ANALYSIS; THYLAKOID MEMBRANE; INNER MEMBRANE; ALPHA-AMYLASE; SPOIIIJ GENE; N-TERMINI	In mitochondria, chloroplasts, and Gram-negative eubacteria, Oxa1p(-like) proteins are critical for the biogenesis of membrane proteins. Here we show that the Gram-positive eubacterium Bacillus subtilis contains two functional Oxalp orthologues, denoted SpoIIIJ and YqjG. The presence of either SpoIIIJ or YqjG is required for cell viability. Whereas SpoIIIJ is required for sporulation, YqjG is dispensable for this developmental process. The stability of two membrane proteins was found to be mildly affected upon SpoIIIJ limitation in the absence of YqjG. Surprisingly, the topology and stability of other membrane proteins remained unaffected under these conditions. In contrast, SpoIIIJ- and YqjG-limiting conditions resulted in a strong post-translocational defect in the stability of secretory proteins. Together, these data indicate that SpoIIIJ and YqjG of B. subtilis are involved in both membrane protein hiogenesis and protein secretion. However, the reduced stability of secretory proteins seems to be the most prominent phenotype of SpoIIIJ/YqjG-depleted B. subtilis cells. In conclusion, our observations show that SpoIIIJ and YqjG have different, but overlapping, functions in R subtilis. Most importantly, it seems that different members of the Oxalp protein family have acquired at least partly distinct, species-specific, functions that are essential for life.	Groningen Biomol Sci & Biotechnol Inst, Dept Genet, NL-9750 AA Haren, Netherlands; Univ Groningen, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands	University of Groningen; University of Groningen	Bron, S (corresponding author), Groningen Biomol Sci & Biotechnol Inst, Dept Genet, POB 14, NL-9750 AA Haren, Netherlands.		van Dijl, Jan Maarten/G-1205-2013; Tjalsma, Harold/I-7146-2012					ALTEMURA N, 1996, FEBS LETT, V382, P111; Antelmann H, 2001, GENOME RES, V11, P1484, DOI 10.1101/gr.182801; Asai K, 1997, J BACTERIOL, V179, P544, DOI 10.1128/jb.179.2.544-547.1997; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; Bengtsson J, 1999, J BACTERIOL, V181, P685, DOI 10.1128/JB.181.2.685-688.1999; Bolhuis A, 1998, J BIOL CHEM, V273, P21217, DOI 10.1074/jbc.273.33.21217; Bolhuis A, 1999, J BIOL CHEM, V274, P24585, DOI 10.1074/jbc.274.35.24585; Bolhuis A, 1999, J BIOL CHEM, V274, P24531, DOI 10.1074/jbc.274.35.24531; BONNEFOY N, 1994, P NATL ACAD SCI USA, V91, P11978, DOI 10.1073/pnas.91.25.11978; Bonnefoy N, 2000, MOL MICROBIOL, V35, P1135, DOI 10.1046/j.1365-2958.2000.01781.x; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; DARTOIS V, 1994, APPL ENVIRON MICROB, V60, P1670, DOI 10.1128/AEM.60.5.1670-1673.1994; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Deuerling E, 1997, MOL MICROBIOL, V23, P921, DOI 10.1046/j.1365-2958.1997.2721636.x; ERRINGTON J, 1992, J GEN MICROBIOL, V138, P2609, DOI 10.1099/00221287-138-12-2609; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; Houben ENG, 2002, J BIOL CHEM, V277, P35880, DOI 10.1074/jbc.M205556200; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; Hyyrylainen HL, 2000, J BIOL CHEM, V275, P26696; JACOBS M, 1993, MOL MICROBIOL, V8, P957, DOI 10.1111/j.1365-2958.1993.tb01640.x; Jiang M, 2000, J BACTERIOL, V182, P303, DOI 10.1128/JB.182.2.303-310.2000; Jongbloed JDH, 2000, J BIOL CHEM, V275, P41350, DOI 10.1074/jbc.M004887200; KONTINEN VP, 1993, MOL MICROBIOL, V8, P727, DOI 10.1111/j.1365-2958.1993.tb01616.x; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; MEIJER WJJ, 1995, MOL MICROBIOL, V17, P621, DOI 10.1111/j.1365-2958.1995.mmi_17040621.x; Miller J. H., 1982, EXPT MOL GENETICS; Murakami T, 2002, J BACTERIOL, V184, P1998, DOI 10.1128/JB.184.7.1998-2004.2002; PALVA I, 1982, GENE, V19, P81, DOI 10.1016/0378-1119(82)90191-3; POGLIANO KJ, 1993, GENETICS, V133, P763; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; Pragai Z, 2000, J BACTERIOL, V182, P6819, DOI 10.1128/JB.182.23.6819-6823.2000; Pragai Z, 1997, MICROBIOL-UK, V143, P1327, DOI 10.1099/00221287-143-4-1327; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Saaf A, 1998, J BIOL CHEM, V273, P30415, DOI 10.1074/jbc.273.46.30415; Sambrook J., 2002, MOL CLONING LAB MANU; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; Samuelson JC, 2001, J BIOL CHEM, V276, P34847, DOI 10.1074/jbc.M105793200; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; Stuart RA, 2000, NATURE, V406, P575, DOI 10.1038/35020668; Tjalsma H, 2000, J BIOL CHEM, V275, P25102, DOI 10.1074/jbc.M002676200; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1999, J BIOL CHEM, V274, P1698, DOI 10.1074/jbc.274.3.1698; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; van Wely KHM, 2000, MICROBIOL-SGM, V146, P2573, DOI 10.1099/00221287-146-10-2573; van Wely KHM, 1999, J BACTERIOL, V181, P1786, DOI 10.1128/JB.181.6.1786-1792.1999; VanDijl J. M., 2001, BACILLUS SUBTILIS IT, P337; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; VIERA J, 1991, GENE, V100, P189; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6	61	60	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15622	15632		10.1074/jbc.M301205200	http://dx.doi.org/10.1074/jbc.M301205200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12586834	hybrid, Green Published			2022-12-27	WOS:000182680000023
J	Wang, CC; Bozdech, Z; Liu, CI; Shipway, A; Backes, BJ; Harris, JL; Bogyo, M				Wang, CC; Bozdech, Z; Liu, CI; Shipway, A; Backes, BJ; Harris, JL; Bogyo, M			Biochemical analysis of the 20 S proteasome of Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE ORNITHINE DECARBOXYLASE; ACTIVE-SITE FORMATION; MULTICATALYTIC PROTEINASE; SUBSTRATE-SPECIFICITY; REGULATORY PARTICLE; SUBUNIT; DEGRADATION; COMPLEX; YEAST; IDENTIFICATION	We describe here biochemical characterization of the 20 S proteasome from the parasitic protozoan Trypanosoma brucei. Similar to the mammalian proteasome, the T. brucei proteasome is made up of seven alpha- and seven beta-subunits. Of the seven beta-type subunits, five contain pro-sequences that are proteolytically removed during assembly, and three of them are predicted to be catalytic based on primary sequence. Affinity labeling studies revealed that, unlike the mammalian proteasome where three beta-subunits were labeled by the affinity reagents, only two beta-subunits of the T. brucei proteasome were labeled in the complex. These two subunits corresponded to beta2 and 135 subunits responsible for the trypsin-like and chymotrypsin-like proteolytic activities, respectively. Screening of a library of 137,180 tetrapeptide fluorogenic substrates against the T. brucei 20 S proteasome confirmed the nominal beta1-subunit (caspase-like or PGPH) activity and identified an overall substrate preference for hydrophobic residues at the P1 to P4 positions in a substrate. This overall stringency is relaxed in the 11 S regulator (PA26)-20 S proteasome complex, which shows both appreciable activities for cleavage after acidic amino acids and a broadened activity for cleavage after basic amino acids. The 20 S proteasome from T. brucei also shows appreciable activity for cleavage after P1-Gln that is minimally observed in the human counterpart. These results demonstrate the importance of substrate sequence specificity of the T. brucei proteasome and highlight its biochemical divergence from the human enzyme.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Novartis Res Fdn, Dept Chem, Genom Inst, San Diego, CA 92121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Novartis	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.		Bozdech, Zbynek/A-2205-2011	Bozdech, Zbynek/0000-0002-9830-8446; Bogyo, Matthew/0000-0003-3753-4412	NIAID NIH HHS [AI 21786] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021786, R56AI021786] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; BASS KE, 1992, J BIOL CHEM, V267, P11034; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Bogyo M, 1998, CHEM BIOL, V5, P307, DOI 10.1016/S1074-5521(98)90169-7; Borst P, 1998, ANNU REV MICROBIOL, V52, P745, DOI 10.1146/annurev.micro.52.1.745; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Groll M, 1999, P NATL ACAD SCI USA, V96, P10976, DOI 10.1073/pnas.96.20.10976; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Groll M, 2002, CHEM BIOL, V9, P655, DOI 10.1016/S1074-5521(02)00144-8; Harris JL, 2001, CHEM BIOL, V8, P1131, DOI 10.1016/S1074-5521(01)00080-1; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUA SB, 1995, J BIOL CHEM, V270, P10264, DOI 10.1074/jbc.270.17.10264; Hua SB, 1996, MOL BIOCHEM PARASIT, V78, P33, DOI 10.1016/S0166-6851(96)02599-6; Huang L, 1999, MOL BIOCHEM PARASIT, V102, P211, DOI 10.1016/S0166-6851(99)00096-1; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; Li ZY, 2002, J BIOL CHEM, V277, P42686, DOI 10.1074/jbc.M207183200; Li ZY, 2002, J BIOL CHEM, V277, P15486, DOI 10.1074/jbc.M109029200; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Maser P, 1999, SCIENCE, V285, P242, DOI 10.1126/science.285.5425.242; Nazif T, 2001, P NATL ACAD SCI USA, V98, P2967, DOI 10.1073/pnas.061028898; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Tanahashi N, 1997, GENES CELLS, V2, P195, DOI 10.1046/j.1365-2443.1997.d01-308.x; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; Yao Y, 1999, J BIOL CHEM, V274, P33921, DOI 10.1074/jbc.274.48.33921; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	41	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15800	15808		10.1074/jbc.M300195200	http://dx.doi.org/10.1074/jbc.M300195200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12600991	hybrid			2022-12-27	WOS:000182680000045
J	Yoon, JB; Kim, SJ; Hwang, SG; Chang, S; Kang, SS; Chun, JS				Yoon, JB; Kim, SJ; Hwang, SG; Chang, S; Kang, SS; Chun, JS			Non-steroidal anti-inflammatory drugs inhibit nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes independent of cyclooxygenase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; COLON-CANCER CELLS; SODIUM-SALICYLATE; SULINDAC SULFIDE; OSTEOARTHRITIS CHONDROCYTES; PROSTAGLANDIN E-2; TNF-ALPHA; IN-VIVO; CARTILAGE	Nitric oxide (NO) causes apoptosis and dedifferentiation of articular chondrocytes by the modulation of extracellular signal-regulated kinase (ERK), p38 kinase, and protein kinase C (PKC) alpha and zeta. In this study, we investigated the effects and mechanisms of non-steroidal anti-inflammatory drugs (NSAIDs), such as indo-methacin, ketoprofen, ibuprofen, sulindac sulfide, and flurbiprofen, in NO-induced apoptosis and dedifferentiation of articular chondrocytes. We found that all of the examined NSAIDs inhibited apoptosis and dedifferentiation. NO production in chondrocytes caused activation of ERK-1/2 and p38 kinase, which oppositely regulate apoptosis and dedifferentiation. NO production also caused inhibition of PKCalpha and -zeta independent of and dependent on, respectively, p38 kinase, which is required for apoptosis and dedifferentiation. Among the signaling molecules modulated by NO, NSAIDs blocked NO-induced activation of p38 kinase, potentiated ERK activation, and blocked inhibition of PKCalpha and -zeta. NSAIDs also inhibited some of the apoptotic signaling that is downstream of p38 kinase and PKC, such as NFkappaB activation, p53 accumulation, and caspase-3 activation. The inhibitory effects of NSAIDs on apoptosis and dedifferentiation were independent of the inhibition of cyclooxygenase (COX)-2 and prostaglandin E-2 (PGE(2)) production, as evidenced by the observation that specific inhibition of COX-2 activity and PGE2 production or exogenous PGE2 did not affect NO-induced apoptosis and dedifferentiation. Taken together, our results indicate that NSAIDs block NO-induced apoptosis and dedifferentiation of articular chondrocytes by the modulation of ERK, p38 kinase, and PKCalpha and -zeta in a manner independent of their ability to inhibit COX-2 and PGE2 production.	Kwangju Inst Sci & Technol, Dept Life Sci, Buk Gu, Gwangju 500712, South Korea; Kyungpook Natl Univ, Dept Biol, Taegu 702701, South Korea	Gwangju Institute of Science & Technology (GIST); Kyungpook National University	Chun, JS (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Buk Gu, Gwangju 500712, South Korea.	jschun@kjist.ac.kr	Chang, Sunghoe/J-2784-2012	chang, sunghoe/0000-0002-3446-7288				Abramson S B, 2001, Curr Rheumatol Rep, V3, P535, DOI 10.1007/s11926-001-0069-3; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; Amin Ashok R., 1999, Current Opinion in Rheumatology, V11, P202, DOI 10.1097/00002281-199905000-00009; Barnes CJ, 1998, BRIT J CANCER, V77, P573, DOI 10.1038/bjc.1998.93; Blanco FJ, 1998, ARTHRITIS RHEUM, V41, P284, DOI 10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T; Cao M, 1997, BIOCHEM J, V324, P305, DOI 10.1042/bj3240305; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Demoor-Fossard M, 1998, BBA-GENE STRUCT EXPR, V1398, P179, DOI 10.1016/S0167-4781(98)00044-X; Ding CH, 2002, INFLAMMATION, V26, P139, DOI 10.1023/A:1015504632021; Dingle JT, 1999, Z RHEUMATOL, V58, P125, DOI 10.1007/s003930050161; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; Frazer A, 1994, Osteoarthritis Cartilage, V2, P235; Giardina C, 1999, BBA-MOL CELL RES, V1448, P425, DOI 10.1016/S0167-4889(98)00156-6; Goldberg Y, 1996, ONCOGENE, V12, P893; Goldring Mary B., 1996, Am J Ther, V3, P9, DOI 10.1097/00045391-199601000-00003; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1632, DOI 10.1002/1529-0131(199809)41:9<1632::AID-ART14>3.0.CO;2-A; Herrmann C, 1998, ONCOGENE, V17, P1769, DOI 10.1038/sj.onc.1202085; HORTON WE, 1987, DEV BIOL, V123, P508, DOI 10.1016/0012-1606(87)90409-X; Huang CS, 1997, J BIOL CHEM, V272, P26325, DOI 10.1074/jbc.272.42.26325; Jones MK, 1999, NAT MED, V5, P1418; Jouzeau JY, 2002, BIORHEOLOGY, V39, P201; Kim SJ, 2003, BIOCHEM BIOPH RES CO, V303, P206, DOI 10.1016/S0006-291X(03)00305-X; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Kim SJ, 2002, J BIOL CHEM, V277, P30375, DOI 10.1074/jbc.M205193200; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Martel-Pelletier J, 1999, FRONT BIOSCI, V4, pD694; Mukherjee P, 2001, CLIN EXP RHEUMATOL, V19, pS7; Notoya K, 2000, J IMMUNOL, V165, P3402, DOI 10.4049/jimmunol.165.6.3402; Pelletier JP, 1998, ARTHRITIS RHEUM-US, V41, P1275, DOI 10.1002/1529-0131(199807)41:7<1275::AID-ART19>3.0.CO;2-T; Pillinger MH, 1998, P NATL ACAD SCI USA, V95, P14540, DOI 10.1073/pnas.95.24.14540; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Schwartz Z, 1998, ENDOCRINOLOGY, V139, P1825, DOI 10.1210/en.139.4.1825; Schwenger P, 1996, J BIOL CHEM, V271, P8089, DOI 10.1074/jbc.271.14.8089; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Tamura T, 1996, ENDOCRINOLOGY, V137, P3729, DOI 10.1210/en.137.9.3729; TASKIRAN D, 1994, BIOCHEM BIOPH RES CO, V200, P142, DOI 10.1006/bbrc.1994.1426; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Varghese J, 2001, J IMMUNOL, V166, P6570, DOI 10.4049/jimmunol.166.11.6570; VonKnethen A, 1997, FASEB J, V11, P887; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200	48	56	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15319	15325		10.1074/jbc.M212520200	http://dx.doi.org/10.1074/jbc.M212520200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12588866	hybrid			2022-12-27	WOS:000182516100096
J	Ciaccio, C; Rosati, A; De Sanctis, G; Sinibaldi, F; Marini, S; Santucci, R; Ascenzi, P; Welinder, KG; Coletta, M				Ciaccio, C; Rosati, A; De Sanctis, G; Sinibaldi, F; Marini, S; Santucci, R; Ascenzi, P; Welinder, KG; Coletta, M			Relationships of ligand binding, redox properties, and protonation in Coprinus cinereus peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; HORSERADISH-PEROXIDASE; MANGANESE PEROXIDASE; ARTHROMYCES-RAMOSUS; ASP245->ASN MUTANT; FUNGAL PEROXIDASE; HUMAN-HEMOGLOBIN	The pH dependence of the redox potentials and kinetics for CO association and dissociation was determined between pH 3.0 and 13.0 at 25 degreesC for the wild-type Coprinus cinereus fungal peroxidase and for a site-directed mutant in which Asp(245), which is H-bonded to N-delta of the imidazole of the proximal His(183), was substituted with Asn. The determination of these functional properties allowed this information to be merged in a self-consistent fashion and to formulate for the first time a complete scheme employing the minimum number of groups required to describe the whole proton-linked behavior of both redox and ligand binding properties. The overall pH dependence can be accounted for by four redox- and ligand-linked groups. The proximal H-bond, which is strictly conserved in all peroxidases, will still be present in the site-specific mutant, but will no longer have an ionic character, and this event will bring about an alteration of redox equilibria and CO binding kinetics, envisaging a relevant role played by this H-bond also in modulating redox properties and ligand binding equilibria.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Roma Tre, Dept Biol, I-00146 Rome, Italy; Univ Camerino, Dept Mol Cellular & Anim Biol, I-62032 Camerino, Italy; Univ Aalborg, Dept Biotechnol, DK-9000 Aalborg, Denmark	University of Rome Tor Vergata; Roma Tre University; University of Camerino; Aalborg University	Coletta, M (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Via Montpellier 1, I-00133 Rome, Italy.		Marini, Stefano/B-1161-2012; Coletta, Massimo/N-9049-2015; Coletta, Massimiliano/GSN-5927-2022	Marini, Stefano/0000-0003-1299-6696; COLETTA, Massimiliano/0000-0002-5489-9467; Welinder, Karen Gjesing/0000-0002-5409-0131				Abelskov AK, 1997, BIOCHEMISTRY-US, V36, P9453, DOI 10.1021/bi970387r; Brunori M, 2000, BIOPHYS CHEM, V86, P221, DOI 10.1016/S0301-4622(00)00142-3; COLETTA M, 1985, J BIOL CHEM, V260, P4151; COLETTA M, 1988, J BIOL CHEM, V263, P18286; Decatur SM, 1999, BIOCHEMISTRY-US, V38, P11086, DOI 10.1021/bi9908888; Dunford HB, 2001, J BIOL INORG CHEM, V6, P819; Ferri T, 1998, BIOELECTROCH BIOENER, V44, P177, DOI 10.1016/S0302-4598(97)00088-3; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; Fukuyama K, 1997, J BIOL CHEM, V272, P5752, DOI 10.1074/jbc.272.9.5752; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Gibson QH, 1999, BIOCHEMISTRY-US, V38, P5191, DOI 10.1021/bi982970t; HARBURY HA, 1957, J BIOL CHEM, V225, P1009; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LAMBRIGHT DG, 1994, BIOCHEMISTRY-US, V33, P5518, DOI 10.1021/bi00184a021; MILLER MA, 1990, BIOCHEMISTRY-US, V29, P9978, DOI 10.1021/bi00494a031; MILLER MA, 1990, BIOCHEMISTRY-US, V29, P1777, DOI 10.1021/bi00459a017; Mukai M, 2001, J BIOL CHEM, V276, P7272, DOI 10.1074/jbc.M009280200; MURRAY LP, 1988, P NATL ACAD SCI USA, V85, P2151, DOI 10.1073/pnas.85.7.2151; Neri F, 1998, EUR J BIOCHEM, V251, P830, DOI 10.1046/j.1432-1327.1998.2510830.x; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PETERSEN JFW, 1994, FEBS LETT, V339, P291, DOI 10.1016/0014-5793(94)80433-8; POULOS TL, 1993, J BIOL CHEM, V268, P4429; Santucci R, 2000, BIOCHEM J, V349, P85, DOI 10.1042/0264-6021:3490085; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; Smulevich G, 1996, BIOCHEMISTRY-US, V35, P10576, DOI 10.1021/bi9605898; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; Unzai S, 1998, J BIOL CHEM, V273, P23150, DOI 10.1074/jbc.273.36.23150; Veitch NC, 1996, BIOCHEMISTRY-US, V35, P14370, DOI 10.1021/bi961582t; WELINDER KG, 1995, BIOCHEM SOC T, V23, P257, DOI 10.1042/bst0230257; WELINDER KG, 1992, CURR OPIN STRUC BIOL, V2, P383; WELINDER KG, 1993, Patent No. 9324618	31	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18730	18737		10.1074/jbc.M212034200	http://dx.doi.org/10.1074/jbc.M212034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12621034	hybrid			2022-12-27	WOS:000182932200005
J	Du, LN; Zhang, XP; Han, YY; Burke, NA; Kochanek, PM; Watkins, SC; Graham, SH; Carcillo, JA; Szabo, C; Clark, RSB				Du, LN; Zhang, XP; Han, YY; Burke, NA; Kochanek, PM; Watkins, SC; Graham, SH; Carcillo, JA; Szabo, C; Clark, RSB			Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD(+) depletion and cell death induced by oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; POLYMERASE INHIBITORS; DNA DAMAGE; RAT-BRAIN; APOPTOSIS; PEROXYNITRITE; SYNTHETASE; REPAIR; ACTIVATION	Poly(ADP-ribosylation), primarily via poly(ADP-ribose) polymerase-1 (PARP-1), is a pluripotent cellular process important for maintenance of genomic integrity and RNA transcription in cells. However, during conditions of oxidative stress and energy depletion, poly(ADP-ribosylation) paradoxically contributes to mitochondrial failure and cell death. Although it has been presumed that poly(ADP-ribosylation) within the nucleus mediates this pathologic process, PARP-1 and other poly(ADP-ribosyltransferases) are also localized within mitochondria. To this end, the presence of PARP-1 and poly(ADP-ribosylation) were verified within mitochondrial fractions from primary cortical neurons and fibroblasts. Inhibition of poly(ADP-ribosylation) within the mitochondrial compartment preserved transmembrane potential (DeltaPsi(m)), NAD(+) content, and cellular respiration, prevented release of apoptosis-inducing factor, and reduced neuronal cell death triggered by oxidative stress. Treatment with liposomal NAD(+) also preserved DeltaPsi(m) and cellular respiration during oxidative stress. Furthermore, inhibition of poly(ADP-ribosylation) prevented intranuclear localization of apoptosis-inducing factor and protected neurons from excitotoxic injury; and PARP-1 null fibroblasts were protected from oxidative stress-induced cell death. Collectively these data suggest that poly(ADP-ribosylation) compartmentalized to the mitochondria can be converted from a homeostatic process to a mechanism of cell death when oxidative stress is accompanied by energy depletion. These data implicate intra-mitochondrial poly(ADP-ribosylation) as an important therapeutic target for central nervous system and other diseases associated with oxidative stress and energy failure.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA 15260 USA; Vet Affairs Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15261 USA; Inotek Pharmaceut Corp, Beverly, MA 01915 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Inotek Pharmaceuticals	Clark, RSB (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015; Watkins, Simon/ABG-2590-2021; Szabo, Csaba/D-1882-2013; Szabo, Csaba/ABG-2644-2021	Kochanek, Patrick M/0000-0002-2627-913X; Watkins, Simon/0000-0003-4092-1552; 	NICHD NIH HHS [T32 HD 40686] Funding Source: Medline; NINDS NIH HHS [R01 NS38620, P50 NS30318] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038620, P50NS030318] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUER PI, 1995, BIOCHIMIE, V77, P374, DOI 10.1016/0300-9084(96)88149-1; Brorson JR, 1999, J NEUROSCI, V19, P147, DOI 10.1523/JNEUROSCI.19-01-00147.1999; Buckman JF, 2001, J NEUROSCI, V21, P5054, DOI 10.1523/JNEUROSCI.21-14-05054.2001; BURZIO LO, 1981, BIOCHEM BIOPH RES CO, V103, P369, DOI 10.1016/0006-291X(81)91702-2; DAWSON TM, 1995, NEW HORIZONS, V3, P86; Dawson VL, 1996, NEUROCHEM INT, V29, P97, DOI 10.1016/0197-0186(95)00149-2; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; Druzhyna N, 2000, DIABETES, V49, P1849, DOI 10.2337/diabetes.49.11.1849; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Grishko VI, 1999, NUCLEIC ACIDS RES, V27, P4510, DOI 10.1093/nar/27.22.4510; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Halmosi R, 2001, MOL PHARMACOL, V59, P1497, DOI 10.1124/mol.59.6.1497; Han YY, 2001, RES COMMUN MOL PATH, V110, P107; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kleppisch T, 1999, J NEUROSCI, V19, P48, DOI 10.1523/JNEUROSCI.19-01-00048.1999; Lee HM, 2002, J NEUROCHEM, V80, P928, DOI 10.1046/j.0022-3042.2002.00774.x; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; MASMOUDI A, 1993, BIOCHEM MOL BIOL INT, V29, P77; MASMOUDI A, 1988, J NEUROCHEM, V51, P188, DOI 10.1111/j.1471-4159.1988.tb04854.x; Mosgoeller W, 1996, J CELL SCI, V109, P409; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NISSELBA.JS, 1969, ANAL BIOCHEM, V27, P212, DOI 10.1016/0003-2697(69)90025-6; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; SATCHELL MA, 2003, IN PRESS J NEUROCHEM; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Szabo C, 1996, BRAIN RES BULL, V41, P131, DOI 10.1016/S0361-9230(96)00159-1; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Virag L, 1998, J IMMUNOL, V161, P3753; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	47	266	273	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18426	18433		10.1074/jbc.M301295200	http://dx.doi.org/10.1074/jbc.M301295200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626504	hybrid			2022-12-27	WOS:000182838300109
J	Roehrich, ME; Mooser, V; Lenain, V; Herz, J; Nimpf, J; Azhar, S; Bideau, M; Capponi, A; Nicod, P; Haefliger, JA; Waeber, R				Roehrich, ME; Mooser, V; Lenain, V; Herz, J; Nimpf, J; Azhar, S; Bideau, M; Capponi, A; Nicod, P; Haefliger, JA; Waeber, R			Insulin-secreting beta-cell dysfunction induced by human lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-E RECEPTOR-2; DIABETES-MELLITUS; CLASS-B; PROTEIN; CHOLESTEROL; APOPTOSIS; BINDING; PATHWAY; DEATH	Diabetes is associated with significant changes in plasma concentrations of lipoproteins. We tested the hypothesis that lipoproteins modulate the function and survival of insulin-secreting cells. We first detected the presence of several receptors that participate in the binding and processing of plasma lipoproteins and confirmed the internalization of fluorescent low density lipoprotein (LDL) and high density lipoprotein (HDL) particles in insulin-secreting beta-cells. Purified human very low density lipoprotein (VLDL) and LDL particles reduced insulin mRNA levels and beta-cell proliferation and induced a dose-dependent increase in the rate of apoptosis. In mice lacking the LDL receptor, islets showed a dramatic decrease in LDL uptake and were partially resistant to apoptosis caused by LDL. VLDL-induced apoptosis of beta-cells involved caspase-3 cleavage and reduction in the levels of the c-Jun N-terminal kinase-interacting protein-1. In contrast, the proapoptotic signaling of lipoproteins was antagonized by HDL particles or by a small peptide inhibitor of c-Jun N-terminal kinase. The protective effects of HDL were mediated, in part, by inhibition of caspase-3 cleavage and activation of Akt/protein kinase B. In conclusion, human lipoproteins are critical regulators of beta-cell survival and may therefore contribute to the beta-cell dysfunction observed during the development of type 2 diabetes.	Univ Hosp, Dept Internal Med, CH-1011 Lausanne, Switzerland; Univ Hosp, Inst Cellular Biol & Morphol, CH-1011 Lausanne, Switzerland; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Vienna, Dept Mol Genet, A-1030 Vienna, Austria; Vet Affairs Palo Alto Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA; Univ Hosp, Div Endocrinol & Diabet, CH-1211 Geneva, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Vienna; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Geneva	Waeber, R (corresponding author), CHU Vaudois, Univ Hosp, Dept Internal Med B, BH 10-640, CH-1011 Lausanne, Switzerland.	gwaeber@chuv.hospvd.ch		Nimpf, Johannes/0000-0002-9273-3492; Haefliger, Jacques-Antoine/0000-0003-2732-1667; Waeber, Gerard/0000-0003-4193-788X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL063762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arya R, 2002, NAT GENET, V30, P102, DOI 10.1038/ng810; BANNISTER LH, 1995, GRAYS ANATOMY, P1793; Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Cherradi N, 2001, ENDOCRINOLOGY, V142, P4540, DOI 10.1210/en.142.10.4540; Cnop M, 2000, AM J PATHOL, V156, P237, DOI 10.1016/S0002-9440(10)64724-4; Cnop M, 2002, ENDOCRINOLOGY, V143, P3449, DOI 10.1210/en.2002-220273; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deeney JT, 2000, SEMIN CELL DEV BIOL, V11, P267, DOI 10.1006/scdb.2000.0175; Freeman DJ, 2001, CIRCULATION, V103, P357; Grupping AY, 1997, ENDOCRINOLOGY, V138, P4064, DOI 10.1210/en.138.10.4064; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Jeon H, 2000, J BIOL CHEM, V275, P30458, DOI 10.1074/jbc.M002583200; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Lupi R, 2002, DIABETES, V51, P1437, DOI 10.2337/diabetes.51.5.1437; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Nofer JR, 2001, THROMB HAEMOSTASIS, V85, P730; Rettenberger PM, 1999, J BIOL CHEM, V274, P8973, DOI 10.1074/jbc.274.13.8973; Ritz-Laser B, 1999, ENDOCRINOLOGY, V140, P4005, DOI 10.1210/en.140.9.4005; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Tacken PJ, 2000, BIOCHEM J, V347, P357, DOI 10.1042/0264-6021:3470357; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Waeber G, 2000, NAT GENET, V24, P291, DOI 10.1038/73523; WILSON PW, 1981, AM J EPIDEMIOL, V114, P697, DOI 10.1093/oxfordjournals.aje.a113240	28	154	163	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18368	18375		10.1074/jbc.M300102200	http://dx.doi.org/10.1074/jbc.M300102200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12594227	Green Published, hybrid			2022-12-27	WOS:000182838300102
J	He, LH; Lemasters, JJ				He, LH; Lemasters, JJ			Heat shock suppresses the permeability transition in rat liver mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL STRESS PROTEINS; ALPHA-B-CRYSTALLIN; INDUCED CELL-DEATH; OXIDATIVE STRESS; CYCLOSPORINE-A; INDUCED APOPTOSIS; PORE; INJURY; INCREASE; HSP70	Heat shock proteins inhibit apoptotic and necrotic cell death in various cell types. However, the specific mechanism underlying protection by heat shock proteins remains unclear. To test the hypothesis that heat shock proteins inhibit cell death by blocking opening of mitochondrial permeability transition (MPT) pores, mitochondria from heat-preconditioned rat livers were isolated by differential centrifugation. Heat shock inhibited MPT pore opening induced by 50 muM CaCl2 plus 5 muM HgCl2 or 1 muM mastoparan and by 200 muM CaCl2 alone. Half-maximal swelling was delayed 15 min or more after heat shock compared with control. Heat shock also increased the threshold of unregulated (Ca2+-independent and cyclosporin A-insensitive) MPT pore opening induced by higher doses of HgCl2 and mastoparan. Heat shock treatment decreased mitochondrial reactive oxygen species formation by 27% but did not change mitochondrial respiration, membrane potential, Ca2+ uptake, or total glutathione in mitochondrial and cytosolic extracts of liver. Western blot analysis showed that mitochondrial Hsp25 increased, whereas Hsp10, Hsp60, Hsp70, Hsp75, cyclophilin D, and voltage-dependent anion channel did not change after heat shock. These results indicate that heat shock causes resistance to opening of MPT pores, which may contribute to heat shock protection against cellular injury.	Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Lemasters, JJ (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, CB 7090,236 Taylor Hall, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059340, R37DK037034, R01DK037034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007218, R01AG007218] Funding Source: NIH RePORTER; NIA NIH HHS [AG07218] Funding Source: Medline; NIDDK NIH HHS [DK59340, DK37034] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn JH, 1999, MOL CELLS, V9, P200; Arrigo AP, 1998, BIOL CHEM, V379, P19; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Blattner JR, 2001, ANAL BIOCHEM, V295, P220, DOI 10.1006/abio.2001.5219; Bornman L, 1998, BIOCHEM BIOPH RES CO, V246, P836, DOI 10.1006/bbrc.1998.8717; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CASPERS GJ, 1995, J MOL EVOL, V40, P238, DOI 10.1007/BF00163229; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; Diez-Fernandez C, 2002, FREE RADICAL BIO MED, V33, P835, DOI 10.1016/S0891-5849(02)00975-9; Dokladny K, 2001, AM J PHYSIOL-REG I, V280, pR338, DOI 10.1152/ajpregu.2001.280.2.R338; Downs CA, 1999, ARCH BIOCHEM BIOPHYS, V365, P344, DOI 10.1006/abbi.1999.1177; Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350; GORNALL AG, 1949, J BIOL CHEM, V177, P751; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; Kirchhoff SR, 2002, CIRCULATION, V105, P2899, DOI 10.1161/01.CIR.0000019403.35847.23; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; LEMASTERS JJ, 1984, J BIOL CHEM, V259, P3058; LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817; Li F, 2002, AM J PHYSIOL-CELL PH, V283, pC917, DOI 10.1152/ajpcell.00517.2001; Lin DT, 2002, J BIOL CHEM, V277, P31134, DOI 10.1074/jbc.M112035200; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; Plumier JCL, 1996, CELL STRESS CHAPERON, V1, P13, DOI 10.1379/1466-1268(1996)001<0013:HSIMPA>2.3.CO;2; Polla BS, 1996, P NATL ACAD SCI USA, V93, P6458, DOI 10.1073/pnas.93.13.6458; Preville X, 1999, EXP CELL RES, V247, P61, DOI 10.1006/excr.1998.4347; Samali A, 2001, CELL STRESS CHAPERON, V6, P49, DOI 10.1379/1466-1268(2001)006<0049:HPMOTC>2.0.CO;2; Takuma K, 2002, BRAIN RES, V946, P232, DOI 10.1016/S0006-8993(02)02888-3; Uchinami H, 2002, AM J PHYSIOL-GASTR L, V282, pG962, DOI 10.1152/ajpgi.00466.2001; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Yan LJ, 2002, EMBO J, V21, P5164, DOI 10.1093/emboj/cdf528	42	64	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16755	16760		10.1074/jbc.M300153200	http://dx.doi.org/10.1074/jbc.M300153200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611884	hybrid, Green Published			2022-12-27	WOS:000182818600042
J	Lee-Kwon, W; Kawano, K; Choi, JW; Kim, JH; Donowitz, M				Lee-Kwon, W; Kawano, K; Choi, JW; Kim, JH; Donowitz, M			Lysophosphatidic acid stimulates brush border Na+/H+ exchanger 3 (NHE3) activity by increasing its exocytosis by an NHE3 kinase A regulatory protein-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN INTERACTION CONTROLS; PHOSPHATIDYLINOSITOL 3-KINASE; RECEPTOR; ACTIVATION; ENDOCYTOSIS; INHIBITION; ISOFORM; CELLS; PROLIFERATION; TRAFFICKING	Na+/H+ exchanger 3 (NHE3) kinase A regulatory protein (E3KARP) has been implicated in cAMP- and Ca2+-dependent inhibition of NHE3. In the current study, a new role of E3KARP is demonstrated in the stimulation of NHE3 activity. Lysophosphatidic acid (LPA) is a mediator of the restitution phase of inflammation but has not been studied for effects on sodium absorption. LPA has no effect on NHE3 activity in opossum kidney (OK) proximal tubule cells, which lack expression of endogenous E3KARP. However, in OK cells exogenously expressing E3KARP, LPA stimulated NHE3 activity. Consistent with the stimulatory effect on NHE3 activity, LPA treatment increased the surface NHE3 amount, which occurred by accelerating exocytic trafficking (endocytic recycling) to the apical plasma membrane. These LPA effects only occurred in OK cells transfected with E3KARP. The LPA-induced increases of NHE3 activity, surface NHE3 amounts, and exocytosis were completely inhibited by pretreatment with the PI 3-kinase inhibitor, LY294002. LPA stimulation of the phosphorylation of Akt was used as an assay for PI 3-kinase activity. LY294002 completely prevented the LPA-induced increase in Akt phosphorylation, which is consistent with the inhibitory effect of LY294002 on the LPA stimulation of NHE3 activity. The LPA-induced phosphorylation of Akt was the same in OK cells with and without E3KARP. These results show that LPA stimulates NHE3 in the apical surface of OK cells by a mechanism that is dependent on both E3KARP and PI 3-kinase. This is the first demonstration that rapid stimulation of NHE3 activity is dependent on an apical membrane PDZ domain protein.	Johns Hopkins Univ, Sch Med, Dept Physiol, Div Gastroenterol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol, Baltimore, MD 21205 USA; Pusan Natl Univ, Coll Med, Dept Physiol, Pusan 602739, South Korea	Johns Hopkins University; Johns Hopkins University; Pusan National University	Donowitz, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, Div Gastroenterol, Baltimore, MD 21205 USA.	mdonowit@jhmi.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044484, R01DK026523] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01 DK44484, R01 DK26523] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn W, 2001, J BIOL CHEM, V276, P17236, DOI 10.1074/jbc.M011763200; Akhter S, 2002, AM J PHYSIOL-CELL PH, V283, pC927, DOI 10.1152/ajpcell.00613.2001; Bianchini L, 1997, J BIOL CHEM, V272, P271; Brett CL, 2002, AM J PHYSIOL-CELL PH, V282, pC1031, DOI 10.1152/ajpcell.00420.2001; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Cavet ME, 1999, AM J PHYSIOL-CELL PH, V277, pC1111, DOI 10.1152/ajpcell.1999.277.6.C1111; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Czech MP, 2002, MOL CELL, V9, P695, DOI 10.1016/S1097-2765(02)00509-9; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Dixon RJ, 1999, AM J PHYSIOL-RENAL, V276, pF191, DOI 10.1152/ajprenal.1999.276.2.F191; Dixon RJ, 1999, KIDNEY INT, V56, P2064, DOI 10.1046/j.1523-1755.1999.00797.x; Donowitz M, 2000, ANN NY ACAD SCI, V915, P30; Donowitz M, 2001, CURR TOP MEMBR, V50, P437; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gillis D, 2001, J MEMBRANE BIOL, V181, P205, DOI 10.1007/s00232-001-0023-3; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Hines OJ, 2000, J SURG RES, V92, P23, DOI 10.1006/jsre.2000.5941; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; Hu MC, 2001, J BIOL CHEM, V276, P26906, DOI 10.1074/jbc.M011338200; Hwang JI, 2000, J BIOL CHEM, V275, P16632, DOI 10.1074/jbc.M001410200; Janecki AJ, 2000, J BIOL CHEM, V275, P8133, DOI 10.1074/jbc.275.11.8133; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; Kim JH, 2002, J BIOL CHEM, V277, P23714, DOI 10.1074/jbc.M200835200; Kurashima K, 1998, J BIOL CHEM, V273, P20828, DOI 10.1074/jbc.273.33.20828; Laghmani K, 2001, J CLIN INVEST, V107, P1563, DOI 10.1172/JCI11234; Lee-Kwon W, 2001, J BIOL CHEM, V276, P31296, DOI 10.1074/jbc.M103900200; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Li XH, 2001, J PHYSIOL-LONDON, V537, P537, DOI 10.1111/j.1469-7793.2001.00537.x; Lynch KR, 2002, BBA-MOL CELL BIOL L, V1582, P289, DOI 10.1016/S1388-1981(02)00183-X; Matsuzaki T, 2002, J BIOL CHEM, V277, P19008, DOI 10.1074/jbc.M112472200; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; Peng Y, 2001, AM J PHYSIOL-RENAL, V280, pF34, DOI 10.1152/ajprenal.2001.280.1.F34; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Sturm A, 2002, DIGESTION, V66, P23, DOI 10.1159/000064418; Sturm A, 1998, ANN NY ACAD SCI, V859, P223, DOI 10.1111/j.1749-6632.1998.tb11134.x; Sturm A, 1999, GASTROENTEROLOGY, V117, P368, DOI 10.1053/gast.1999.0029900368; Suh PG, 2001, BIOCHEM BIOPH RES CO, V288, P1, DOI 10.1006/bbrc.2001.5710; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; Xie YH, 2002, BBA-MOL CELL BIOL L, V1582, P270, DOI 10.1016/S1388-1981(02)00181-6; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Yun CC, 2002, J BIOL CHEM, V277, P7676, DOI 10.1074/jbc.M107768200; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856; Zizak M, 1999, J BIOL CHEM, V274, P24753, DOI 10.1074/jbc.274.35.24753	52	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16494	16501		10.1074/jbc.M300580200	http://dx.doi.org/10.1074/jbc.M300580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12595524	hybrid			2022-12-27	WOS:000182818600009
J	Swank, DM; Knowles, AF; Kronert, WA; Suggs, JA; Morrill, GE; Nikkhoy, M; Manipon, GG; Bernstein, SI				Swank, DM; Knowles, AF; Kronert, WA; Suggs, JA; Morrill, GE; Nikkhoy, M; Manipon, GG; Bernstein, SI			Variable N-terminal regions of muscle myosin heavy chain modulate ATPase rate and actin sliding velocity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; INTERDOMAIN INTERACTIONS; FUNCTIONAL DOMAINS; ALTERNATIVE EXONS; SKELETAL-MUSCLE; MOTOR DOMAIN; ISOFORMS; GENE; BINDING; CONTRACTION	We integratively assessed the function of alternative versions of a region near the N terminus of Drosophila muscle myosin heavy chain (encoded by exon 3a or 3b). We exchanged the alternative exon 3 regions between an embryonic isoform and the indirect flight muscle isoform. Each chimeric myosin was expressed in Drosophila indirect flight muscle, in the absence of other myosin isoforms, allowing for purified protein analysis and whole organism locomotory studies. The flight muscle isoform generates higher in vitro actin sliding velocity and solution ATPase rates than the embryonic isoform. Exchanging the embryonic exon 3 region into the flight muscle isoform decreased ATPase rates to embryonic levels but did not affect actin sliding velocity or flight muscle ultrastructure. Interestingly, this swap only slightly impaired flight ability. Exchanging the flight muscle-specific exon 3 region into the embryonic isoform increased actin sliding velocity 3-fold and improved indirect flight muscle ultrastructure integrity but failed to rescue the flightless phenotype of flies expressing embryonic myosin. These results suggest that the two structural versions of the exon 3 domain independently influence the kinetics of at least two steps of the actomyosin cross-bridge cycle.	San Diego State Univ, Dept Biol, San Diego, CA 92182 USA; San Diego State Univ, Inst Mol Biol, San Diego, CA 92182 USA; San Diego State Univ, Dept Chem, San Diego, CA 92182 USA	California State University System; San Diego State University; California State University System; San Diego State University; California State University System; San Diego State University	Swank, DM (corresponding author), San Diego State Univ, Dept Biol, San Diego, CA 92182 USA.	dswank@sunstroke.sdsu.edu		Bernstein, Sanford/0000-0001-7094-5390	NIGMS NIH HHS [GM32443, GM 58906] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM058906, R01GM032443] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alpert NR, 2002, AM J PHYSIOL-HEART C, V283, pH1446, DOI 10.1152/ajpheart.00274.2002; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BARANY M, 1967, EUR J BIOCHEM, V2, P156, DOI 10.1111/j.1432-1033.1967.tb00120.x; BERNSTEIN SI, 1983, NATURE, V302, P393, DOI 10.1038/302393a0; Bernstein SI, 1997, J MOL BIOL, V271, P1, DOI 10.1006/jmbi.1997.1160; Burghardt TP, 2001, BIOCHEMISTRY-US, V40, P4834, DOI 10.1021/bi002388g; Burghardt TP, 2001, BIOCHEMISTRY-US, V40, P4821, DOI 10.1021/bi002387o; CANDE WZ, 1986, METHOD ENZYMOL, V134, P473; CRIPPS RM, 1994, J CELL BIOL, V126, P689, DOI 10.1083/jcb.126.3.689; CRIPPS RM, 2000, INTRO DNA LIVING CEL; Dickinson MH, 1997, BIOPHYS J, V73, P3122, DOI 10.1016/S0006-3495(97)78338-3; DRUMMOND DR, 1991, MOL GEN GENET, V226, P70, DOI 10.1007/BF00273589; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GEORGE EL, 1989, MOL CELL BIOL, V9, P2957, DOI 10.1128/MCB.9.7.2957; GRIGLIATTI TA, 1998, DROSOPHILA PRACTICAL, P85; HASTINGS GA, 1991, J CELL BIOL, V114, P263, DOI 10.1083/jcb.114.2.263; HESS N, 1989, CELLULAR MOL BIOL MU, P621; Hirayama Y, 1997, EUR J BIOCHEM, V246, P380, DOI 10.1111/j.1432-1033.1997.t01-2-00380.x; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Kronert WA, 1999, J CELL BIOL, V144, P989, DOI 10.1083/jcb.144.5.989; Kurzawa-Goertz SE, 1998, BIOCHEMISTRY-US, V37, P7517, DOI 10.1021/bi972844+; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; Littlefield KP, 2003, AM J PHYSIOL-CELL PH, V284, pC1031, DOI 10.1152/ajpcell.00474.2002; LOWEY S, 1993, J BIOL CHEM, V268, P20414; Murphy CT, 2000, J MUSCLE RES CELL M, V21, P139, DOI 10.1023/A:1005610007209; Murphy CT, 1998, BIOCHEMISTRY-US, V37, P6738, DOI 10.1021/bi972903j; ODONNELL PT, 1988, J CELL BIOL, V107, P2601, DOI 10.1083/jcb.107.6.2601; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Pereira JS, 2001, J BIOL CHEM, V276, P4409, DOI 10.1074/jbc.M006441200; Razzaq A, 1999, J BIOL CHEM, V274, P28321, DOI 10.1074/jbc.274.40.28321; ROUX KH, 1995, PCR PRIMER LAB MANUA; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; ROZEK CE, 1983, CELL, V32, P23, DOI 10.1016/0092-8674(83)90493-2; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Swank DM, 2000, MICROSC RES TECHNIQ, V50, P430, DOI 10.1002/1097-0029(20000915)50:6<430::AID-JEMT2>3.0.CO;2-E; Swank DM, 2002, NAT CELL BIOL, V4, P312, DOI 10.1038/ncb776; Swank DM, 2001, J BIOL CHEM, V276, P15117, DOI 10.1074/jbc.M008379200; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Tyska MJ, 2002, CELL MOTIL CYTOSKEL, V51, P1, DOI 10.1002/cm.10014; Wells L, 1996, EMBO J, V15, P4454, DOI 10.1002/j.1460-2075.1996.tb00822.x; Yengo CM, 2002, J BIOL CHEM, V277, P24114, DOI 10.1074/jbc.M111253200; Zhang SX, 2001, MECH DEVELOP, V101, P35, DOI 10.1016/S0925-4773(00)00549-9	44	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17475	17482		10.1074/jbc.M212727200	http://dx.doi.org/10.1074/jbc.M212727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606545	hybrid			2022-12-27	WOS:000182818600135
J	Takenobu, H; Yamazaki, A; Hirata, M; Umata, T; Mekada, E				Takenobu, H; Yamazaki, A; Hirata, M; Umata, T; Mekada, E			The stress- and inflammatory cytokine-induced ectodomain shedding of heparin-binding epidermal growth factor-like growth factor is mediated by p38 MAPK, distinct from the 12-O-tetradecanoylphorbol-13-acetate- and lysophosphatidic acid-induced signaling cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; MESSENGER-RNA LEVELS; SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE-C; EGF-RECEPTOR; HB-EGF; FACTOR GENE; ACTIVATION; EXPRESSION; JUXTACRINE	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a critical growth factor for a number of physiological and pathological processes. HB-EGF is synthesized as a membrane-anchored form (pro-HBEGF), and pro-HB-EGF is cleaved at the cell surface to yield soluble HB-EGF by a mechanism called "ectodomain shedding." We show here that the ectodomain shedding of pro-HB-EGF in Vero cells is induced by various stress-inducing stimuli, including UV light, osmotic pressure, hyperoxidation, and translation inhibitors. The pro-inflammatory cytokine interleukin-1beta also stimulated the ectodomain shedding of pro-HB-EGF. An inhibitor of p38 MAPK (SB203580) or the expression of a dominant-negative (dn) form of p38 MAPK inhibited the stress-induced ectodomain shedding of pro-HB-EGF, whereas an inhibitor of JNK (SP600125) or the expression of dnJNK1 did not. 12-O-Tetradecanoylphorbol-13-acetate (TPA) and lysophosphatidic acid (LPA) are also potent inducers of pro-HB-EGF shedding in Vero cells. Stress-induced pro-HB-EGF shedding was not inhibited by the inhibitors of TPA- or LPA-induced pro-HB-EGF shedding or by dn forms of molecules involved in the TPA- or LPA-induced pro-HB-EGF shedding pathway. Reciprocally, SB203580 or dnp38 MAPK did not inhibit TPA- or LPA-induced pro-HB-EGF shedding. These results indicate that stress-induced pro-HB-EGF shedding is mediated by p38 MAPK and that the signaling pathway induced by stress is distinct from the TPA- or LPA-induced pro-HB-EGF shedding pathway.	Osaka Univ, Microbial Dis Res Inst, Dept Cell Biol, Suita, Osaka 5650871, Japan; Kurume Univ, Inst Life Sci, Fukuoka 8390861, Japan	Osaka University; Kurume University	Mekada, E (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Cell Biol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	emekada@biken.osaka-u.ac.jp		Mekada, Eisuke/0000-0001-8858-4781; Takenobu, Hisanori/0000-0001-7355-1565				Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; BRADSHAW D, 1993, AGENTS ACTIONS, V38, P135, DOI 10.1007/BF02027225; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAS SK, 1994, DEVELOPMENT, V120, P1071; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Fujino T, 1998, CARDIOVASC RES, V38, P365, DOI 10.1016/S0008-6363(98)00010-8; Fujishiro M, 2001, J BIOL CHEM, V276, P19800, DOI 10.1074/jbc.M101087200; Fujiyama S, 2001, CIRC RES, V88, P22, DOI 10.1161/01.RES.88.1.22; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Hirata M, 2001, BIOCHEM BIOPH RES CO, V283, P915, DOI 10.1006/bbrc.2001.4879; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Igura T, 1996, ARTERIOSCL THROM VAS, V16, P1524, DOI 10.1161/01.ATV.16.12.1524; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Koh YH, 2001, J BIOCHEM-TOKYO, V130, P351, DOI 10.1093/oxfordjournals.jbchem.a002993; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Levine SJ, 1996, AM J RESP CELL MOL, V14, P254, DOI 10.1165/ajrcmb.14.3.8845176; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Michalsky MP, 2001, J PEDIATR SURG, V36, P1130, DOI 10.1053/jpsu.2001.25730; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MIYAGAWA J, 1995, J CLIN INVEST, V95, P404, DOI 10.1172/JCI117669; Miyazaki Y, 2001, GASTROENTEROLOGY, V120, P108, DOI 10.1053/gast.2001.20950; Montero JC, 2002, BIOCHEM J, V363, P211, DOI 10.1042/0264-6021:3630211; MORITA T, 1993, BIOCHEM BIOPH RES CO, V197, P256, DOI 10.1006/bbrc.1993.2469; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Nguyen HT, 2000, AM J PHYSIOL-CELL PH, V279, pC1155, DOI 10.1152/ajpcell.2000.279.4.C1155; OHNO S, 1994, J BIOL CHEM, V269, P17495; PERRELLA MA, 1994, J BIOL CHEM, V269, P27045; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Rizoli SB, 1999, J BIOL CHEM, V274, P22072, DOI 10.1074/jbc.274.31.22072; Sakai M, 2001, EXP NEPHROL, V9, P28; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Takemura T, 2001, J AM SOC NEPHROL, V12, P964, DOI 10.1681/ASN.V125964; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467	63	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17255	17262		10.1074/jbc.M211835200	http://dx.doi.org/10.1074/jbc.M211835200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611888	hybrid			2022-12-27	WOS:000182818600108
J	Taouil, K; Hinnrasky, J; Hologne, C; Corlieu, P; Klossek, JM; Puchelle, E				Taouil, K; Hinnrasky, J; Hologne, C; Corlieu, P; Klossek, JM; Puchelle, E			Stimulation of beta 2-adrenergic receptor increases cystic fibrosis transmembrane conductance regulator expression in human airway epithelial cells through a cAMP/protein kinase A-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN INTERACTION CONTROLS; BETA(2)-ADRENERGIC RECEPTOR; CFTR; PROTEIN; ASSOCIATION; SYSTEM	PSD-95/Dlg-A/ZO-1 (PDZ) domains play an essential role in determining cell polarity. The Na+/H+ exchanger regulatory factor (NHERF), also known as EBP50, contains two PDZ domains that mediate the assembly of transmembrane and cytosolic proteins into functional signal transduction complexes. Moreover, it has been shown that cystic fibrosis transmembrane conductance regulator (CFTR) and beta(2)-adrenergic receptor (beta(2)AR) bind equally well to the PDZ1 domain of EBP50. We hypothesized that beta(2)AR activation may regulate CFTR protein expression. To verify this, we evaluated the effects of a pharmacologically relevant concentration of salmeterol (2.10(-7) M), a long acting beta(2)AR agonist, on CFTR expression in primary human airway epithelial cells (HAEC). beta(2)AR stimulation induced a time-dependent increase in apical CFTR protein expression, with a maximal response reached after treatment for 24 h. This effect was post-transcriptional, dependent upon the beta(2)AR agonist binding to beta(2)AR and independent of the known beta(2)AR agonist-mediated cAMP/PKA pathway. We demonstrated by immunohistochemistry that CFTR, beta(2)AR, and EBP50 localize to the apical membrane of HAEC. Analyses of anti-EBP50 protein immunoprecipitate showed that salmeterol induced an increase in the amount of CFTR that binds to EBP50. These data suggest that beta(2)AR activation regulates the association of CFTR with EBP50 in polarized HAEC.	Ctr Hosp Univ Maison Blanche, INSERM 514, IFR 53, F-51092 Reims, France; Hop Tenon, F-75020 Paris, France; Hop Jean Bernard, F-86021 Poitiers, France	CHU de Reims; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Poitiers; Universite de Poitiers	Puchelle, E (corresponding author), Ctr Hosp Univ Maison Blanche, INSERM 514, IFR 53, 45 Rue Cognacq Jay, F-51092 Reims, France.	epuche@worldnet.fr						BREZILLON S, 1995, LAB INVEST, V72, P191; Brown D, 2000, AM J PHYSIOL-RENAL, V278, pF192, DOI 10.1152/ajprenal.2000.278.2.F192; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Castillon N, 2002, LAB INVEST, V82, P989, DOI 10.1097/01.LAB.0000022221.88025.43; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DAVIS PB, 1990, AM J PHYSIOL, V258, pC71, DOI 10.1152/ajpcell.1990.258.1.C71; DUPUIT F, 1995, J CLIN INVEST, V96, P1601, DOI 10.1172/JCI118199; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Howard M, 2000, AM J PHYSIOL-CELL PH, V279, pC375, DOI 10.1152/ajpcell.2000.279.2.C375; Howard M, 1996, KIDNEY INT, V49, P1642, DOI 10.1038/ki.1996.239; Jiang TR, 1997, AM J PHYSIOL-HEART C, V273, pH1044, DOI 10.1152/ajpheart.1997.273.2.H1044; JORISSEN M, 1991, EUR RESPIR J, V4, P210; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; KELSEN SG, 1995, AM J RESP CRIT CARE, V152, P1774, DOI 10.1164/ajrccm.152.6.8520736; Kelsen SG, 1997, AM J PHYSIOL-LUNG C, V272, pL916, DOI 10.1152/ajplung.1997.272.5.L916; Loffing J, 1998, AM J PHYSIOL-CELL PH, V275, pC913, DOI 10.1152/ajpcell.1998.275.4.C913; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Milewski MI, 2001, J CELL SCI, V114, P719; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; NIJKAMP FP, 1992, PHYSIOL REV, V72, P323, DOI 10.1152/physrev.1992.72.2.323; Pilewski JM, 1999, PHYSIOL REV, V79, P215; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Spicuzza L, 2001, BRIT J PHARMACOL, V133, P1201, DOI 10.1038/sj.bjp.0704213; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; TURKI J, 1995, AM J PHYSIOL-LUNG C, V269, pL709, DOI 10.1152/ajplung.1995.269.5.L709	29	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17320	17327		10.1074/jbc.M212227200	http://dx.doi.org/10.1074/jbc.M212227200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621035	hybrid			2022-12-27	WOS:000182818600117
J	Braccia, A; Villani, M; Immerdal, L; Niels-Christiansen, LL; Nystrom, BT; Hansen, GH; Danielsen, EM				Braccia, A; Villani, M; Immerdal, L; Niels-Christiansen, LL; Nystrom, BT; Hansen, GH; Danielsen, EM			Microvillar membrane Microdomains exist at physiological temperature - Role of galectin-4 as lipid raft stabilizer revealed by "superrafts"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER ENZYMES; CELL BIOLOGY; INTRACELLULAR-TRANSPORT; AMINOPEPTIDASE-N; PLASMA-MEMBRANE; ANIMAL LECTINS; CHOLESTEROL; CAVEOLAE; DOMAINS; PROTEINS	Lipid rafts (glycosphingolipid/cholesterol-enriched membrane microdomains) have been isolated as low temperature, detergent-resistant membranes from many cell types, but despite their presumed importance as lateral sorting and signaling platforms, fundamental questions persist concerning raft function and even existence in vivo. The nonionic detergent Brij 98 was used to isolate lipid rafts from microvillar membrane vesicles of intestinal brush borders at physiological temperature to compare with rafts, obtained by "conventional" extraction using Triton X-100 at low temperature. Microvillar rafts prepared by the two protocols were morphologically different but had essentially similar profiles of protein- and lipid components, showing that raft microdomains do exist at 37 degreesC and are not "low temperature artifacts." We also employed a novel method of sequential detergent extraction at increasing temperature to define a fraction of highly detergent-resistant "superrafts." These were enriched in galectin-4, a beta-galactoside-recognizing lectin residing on the extracellular side of the membrane. Superrafts also harbored the glycosylphosphatidylinositol-linked alkaline phosphatase and the transmembrane aminopeptidase N, whereas the peripheral lipid raft protein annexin 2 was essentially absent. In conclusion, in the microvillar membrane, galectin-4,, functions as a core raft stabilizer/ organizer for other, more loosely raft-associated proteins. The superraft analysis might be applicable to other membrane microdomain systems.	Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, DK-2200 Copenhagen, Denmark	University of Copenhagen	Danielsen, EM (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.							Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bickel PE, 2002, AM J PHYSIOL-ENDOC M, V282, pE1, DOI 10.1152/ajpendo.2002.282.1.E1; Booth A G, 1974, Biochem J, V142, P575; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Campbell SM, 2001, J CLIN VIROL, V22, P217, DOI 10.1016/S1386-6532(01)00193-7; CHRISTIANSEN K, 1981, BIOCHIM BIOPHYS ACTA, V647, P188, DOI 10.1016/0005-2736(81)90245-5; Danielsen EM, 1997, MOL BIOL CELL, V8, P2241, DOI 10.1091/mbc.8.11.2241; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; Drevot P, 2002, EMBO J, V21, P1899, DOI 10.1093/emboj/21.8.1899; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Edidin M, 2001, TRENDS CELL BIOL, V11, P492, DOI 10.1016/S0962-8924(01)02139-0; Edidin M, 2001, SCI STKE; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; Hansen GH, 2001, J BIOL CHEM, V276, P32338, DOI 10.1074/jbc.M102667200; HANSEN GH, 1987, EUR J CELL BIOL, V43, P253; HANSEN GH, 1992, HISTOCHEM J, V24, P132, DOI 10.1007/BF01047462; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; McIntosh DP, 2002, P NATL ACAD SCI USA, V99, P1996, DOI 10.1073/pnas.251662398; Mirre C, 1996, AM J PHYSIOL-CELL PH, V271, pC887, DOI 10.1152/ajpcell.1996.271.3.C887; Pace KE, 1999, J IMMUNOL, V163, P3801; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Shin JS, 2001, SCIENCE, V293, P1447, DOI 10.1126/science.1061079; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SKOVBJERG H, 1982, BIOCHIM BIOPHYS ACTA, V707, P89, DOI 10.1016/0167-4838(82)90400-9; SUZUKI K, 1965, J NEUROCHEM, V12, P629, DOI 10.1111/j.1471-4159.1965.tb04256.x; Taylor CM, 2002, J NEUROCHEM, V81, P993, DOI 10.1046/j.1471-4159.2002.00884.x; TRIER JS, 1968, CODE CF HDB PHYSL AL, V6, P1125; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; Werlen G, 2002, CURR OPIN IMMUNOL, V14, P299, DOI 10.1016/S0952-7915(02)00339-4	41	126	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15679	15684		10.1074/jbc.M211228200	http://dx.doi.org/10.1074/jbc.M211228200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594212	hybrid			2022-12-27	WOS:000182680000029
J	Kang, DK; Jeong, J; Drake, SK; Wehr, NB; Rouault, TA; Levine, RL				Kang, DK; Jeong, J; Drake, SK; Wehr, NB; Rouault, TA; Levine, RL			Iron regulatory protein 2 as iron sensor - Iron-dependent oxidative modification of cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED OXIDATION; AMINOMALONIC ACID; ESCHERICHIA-COLI; BINDING PROTEIN; HIF-ALPHA; DEGRADATION; DESTRUCTION; METABOLISM; MECHANISM; CHAINS	Iron regulatory protein 2 coordinates cellular regulation of iron metabolism by binding to iron responsive elements in mRNA. The protein is synthesized constitutively but is rapidly degraded when iron stores are replete. This iron-dependent degradation requires the presence of a 73-residue degradation domain, but its functions have not yet been established. We now show that the domain can act as an iron sensor, mediating its own covalent modification. The domain forms an iron-binding site with three cysteine residues located in the middle of the domain. It then reacts with molecular oxygen to generate a reactive oxidizing species at the iron-binding site. One cysteine residue is oxidized to dehydrocysteine and other products. This covalent modification may thus mark the protein molecule for degradation by the proteasome system.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Levine, RL (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 50,Rm 2351, Bethesda, MD 20892 USA.	rlevine@nih.gov	Levine, Rodney L/D-9885-2011		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001602] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001602] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000225, Z01HL000225] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allerson CR, 2003, RNA, V9, P364, DOI 10.1261/rna.2143303; BALDWIN JE, 1991, TETRAHEDRON, V47, P457, DOI 10.1016/S0040-4020(01)90503-4; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; COPLEY SD, 1992, ANAL BIOCHEM, V201, P152, DOI 10.1016/0003-2697(92)90188-D; de Montellano PRO, 2002, NAT PROD REP, V19, P477, DOI 10.1039/b101297p; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; LEVINE RL, 1982, J CHROMATOGR, V236, P499; Levine RL, 2002, FREE RADICAL BIO MED, V32, P790, DOI 10.1016/S0891-5849(02)00765-7; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Okazaki R, 1995, ORGANOSULFUR CHEM, P225; PATCHORNIK A, 1964, J AM CHEM SOC, V86, P1206, DOI 10.1021/ja01060a049; REDDY VY, 1994, J BIOL CHEM, V269, P4683; RIVETT AJ, 1990, ARCH BIOCHEM BIOPHYS, V278, P26, DOI 10.1016/0003-9861(90)90226-O; Roach PL, 1997, NATURE, V387, P827, DOI 10.1038/42990; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Stadtman Earl R., 1999, P657; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; Taggart C, 2000, J BIOL CHEM, V275, P27258; VANBUSKIRK JJ, 1984, P NATL ACAD SCI-BIOL, V81, P722	26	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14857	14864		10.1074/jbc.M300616200	http://dx.doi.org/10.1074/jbc.M300616200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12591920	hybrid			2022-12-27	WOS:000182516100037
J	Yuan, LP; Yu, WM; Yuan, ZM; Haudenschild, CC; Qu, CK				Yuan, LP; Yu, WM; Yuan, ZM; Haudenschild, CC; Qu, CK			Role of SHP-2 tyrosine phosphatase in the DNA damage-induced cell death response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE C-ABL; ACTIVATED PROTEIN-KINASES; LARGE T-ANTIGEN; INDUCED APOPTOSIS; TRANSFORMING ACTIVITY; IONIZING-RADIATION; GENOTOXIC STRESS; GROWTH ARREST; P53; P73	SHP-2, a ubiquitously expressed Src hmology 2 (SH2) domain-containing tyrosine phosphatase, plays a critical role in the regulation of growth factor and cytokine signal transduction. Here we report a novel function of this phosphatase in DNA damage-induced cellular responses. Mutant embryonic fibroblast cells lacking functional SHP-2 showed significantly decreased apoptosis in response to DNA damage. Following cisplatin treatment, induction of p73 and its downstream effector P21(Cip1) was essentially blocked in SHP-2 mutant cells. Further investigation revealed that activation of the nuclear tyrosine kinase c-Abl, an essential mediator in DNA damage induction of p73, was impaired in the mutant cells, suggesting a functional requirement of SHP-2 in c-Abl activation. Consistent with this observation, the effect of overexpression of c-Abl kinase in SHP-2 mutant cells on sensitizing the cells to DNA damage-induced death was abolished. Additionally, we found that in embryonic fibroblast cells 30-40% of SHP-2 was localized in the nuclei, and that a fraction of nuclear SHP-2 was constitutively associated with c-Ahl via its SH3 domain. Phosphatase activity of nuclear but not cytoplasmic SHP-2 was significantly enhanced in response to DNA damage. These results together suggest a novel nuclear function for SHP-2 phosphatase in the regulation of DNA damage-induced apoptotic responses.	Amer Red Cross, Holland Lab, Dept Hematopoiesis, Rockville, MD 20855 USA; Amer Red Cross, Holland Lab, Dept Expt Pathol, Rockville, MD 20855 USA; Harvard Univ, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA; George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	American Red Cross; American Red Cross; Harvard University; Harvard T.H. Chan School of Public Health; George Washington University	Qu, CK (corresponding author), Amer Red Cross, Holland Lab, Dept Hematopoiesis, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.		Christian, Haudenschild C/D-1602-2009		NHLBI NIH HHS [R01HL68212-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068212] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Agami R, 1999, NATURE, V399, P809; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Cong F, 1999, P NATL ACAD SCI USA, V96, P13819, DOI 10.1073/pnas.96.24.13819; Craddock BL, 2001, J BIOL CHEM, V276, P24274, DOI 10.1074/jbc.M009098200; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DANIEL R, 1995, ONCOGENE, V10, P1607; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Gong JG, 1999, NATURE, V399, P806; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hendzel MJ, 1998, J BIOL CHEM, V273, P24470, DOI 10.1074/jbc.273.38.24470; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu QH, 2000, GENE DEV, V14, P1448; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; Sheppard HM, 1999, MOL CELL BIOL, V19, P2746; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; VANETTEN RA, 1995, ONCOGENE, V10, P1977; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; Wang JYJ, 1998, CURR OPIN CELL BIOL, V10, P240, DOI 10.1016/S0955-0674(98)80146-4; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; You M, 2001, J EXP MED, V193, P101, DOI 10.1084/jem.193.1.101; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	67	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15208	15216		10.1074/jbc.M211327200	http://dx.doi.org/10.1074/jbc.M211327200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594211	hybrid			2022-12-27	WOS:000182516100081
J	Heeren, J; Grewal, T; Laatsch, A; Rottke, D; Rinninger, F; Enrich, C; Beisiegel, U				Heeren, J; Grewal, T; Laatsch, A; Rottke, D; Rinninger, F; Enrich, C; Beisiegel, U			Recycling of apoprotein E is associated with cholesterol efflux and high density lipoprotein internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; MOUSE PERITONEAL-MACROPHAGES; B TYPE-I; TRIGLYCERIDE-RICH LIPOPROTEINS; RECEPTOR-RELATED PROTEIN; SELECTIVE LIPID UPTAKE; HDL PARTICLE UPTAKE; PLASMA-MEMBRANE; INTRACELLULAR TRAFFICKING; ENDOCYTIC COMPARTMENT	After receptor-mediated endocytosis of triglyceride-rich lipoproteins (TRL) into the liver, TRL particles are immediately disintegrated in peripheral endosomal compartments. Whereas core lipids and apoprotein B are delivered for degradation into lysosomes, TRL-derived apoE is efficiently recycled back to the plasma membrane. This is followed by apoE re-secretion and association of apoE with high density lipoproteins (HDL). Because HDL and apoE can independently promote cholesterol efflux, we investigated whether recycling of TRL-derived apoE in human hepatoma cells and fibroblasts could be linked to intracellular cholesterol transport. In this study we demonstrate that HDL, does not only act as an extracellular acceptor for recycled apoE but also stimulates the recycling of internalized TRL-derived apoE. Furthermore, radioactive pulse-chase experiments indicate that apoE recycling is accompanied by cholesterol efflux. Confocal imaging reveals co-localization of apoE and cholesterol in early endosome antigen 1-positive endosomes. During apoE re-secretion, HDL3-derived apoA-I is found in these early endosome antigen 1, cholesterol-containing endosomes. As shown by time-lapse fluorescence microscopy, apoE recycling involves the intracellular trafficking of apoA-I to pre-existing and TRL-derived apoE/cholesterol-containing endosomes in the periphery. Thus, these studies provide evidence for a new intracellular link between TRL-derived apoE, cellular cholesterol transport, and HDL metabolism.	Univ Hamburg, Hosp Eppendorf, Inst Med Biochem & Mol Biol, Dept Mol Cell Biol, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Internal Med, D-20246 Hamburg, Germany; Univ Barcelona, Fac Med, Inst Invest Biomed August Pi Sunyer, Dept Cellular Biol, Barcelona 08036, Spain	University of Hamburg; University of Hamburg; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Heeren, J (corresponding author), Univ Hamburg, Hosp Eppendorf, Inst Med Biochem & Mol Biol, Dept Mol Cell Biol, Martinistr 52, D-20246 Hamburg, Germany.		Eckhardt, Erik/G-1567-2010	Grewal, Thomas/0000-0002-7937-8887; Enrich, Carlos/0000-0003-0382-2993				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BASU SK, 1982, J BIOL CHEM, V257, P9788; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; Bielicki JK, 1999, J LIPID RES, V40, P85; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Calvo M, 2000, ELECTROPHORESIS, V21, P3386, DOI 10.1002/1522-2683(20001001)21:16<3386::AID-ELPS3386>3.3.CO;2-C; Chen W, 2001, J BIOL CHEM, V276, P43564, DOI 10.1074/jbc.M107938200; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; de Diego I, 2002, J BIOL CHEM, V277, P32187, DOI 10.1074/jbc.M205499200; Enrich C, 1999, HEPATOLOGY, V30, P1115, DOI 10.1002/hep.510300505; Fazio S, 1999, J BIOL CHEM, V274, P8247, DOI 10.1074/jbc.274.12.8247; Fielding CJ, 2001, ADV DRUG DELIVER REV, V49, P251, DOI 10.1016/S0169-409X(01)00140-5; Garcia A, 1996, BIOCHEMISTRY-US, V35, P13064, DOI 10.1021/bi952223l; Goldschmidt HMJ, 2001, ACCREDIT QUAL ASSUR, V6, P388, DOI 10.1007/s007690100386; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; HANDLEY DA, 1981, P NATL ACAD SCI-BIOL, V78, P368, DOI 10.1073/pnas.78.1.368; Heeren J, 1999, J CELL SCI, V112, P349; Heeren J, 2001, J BIOL CHEM, V276, P42333, DOI 10.1074/jbc.M107461200; Heeren J, 2001, CURR OPIN LIPIDOL, V12, P255, DOI 10.1097/00041433-200106000-00003; HERSCOVITZ H, 1992, J LIPID RES, V33, P791; Holtta-Vuori M, 2002, MOL BIOL CELL, V13, P3107, DOI 10.1091/mbc.E02-01-0025; Klinger A, 1997, BBA-LIPID LIPID MET, V1345, P65, DOI 10.1016/S0005-2760(96)00164-6; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; Mahley RW, 1999, J LIPID RES, V40, P1; Merkel M, 2002, J BIOL CHEM, V277, P7405, DOI 10.1074/jbc.M107914200; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Niemeier A, 1996, J LIPID RES, V37, P1733; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2002, CURR OPIN LIPIDOL, V13, P373, DOI 10.1097/00041433-200208000-00004; Ortega D, 1998, J CELL SCI, V111, P261; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; Rensen PCN, 2000, J BIOL CHEM, V275, P8564, DOI 10.1074/jbc.275.12.8564; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; ROGLER G, 1991, BIOCHIM BIOPHYS ACTA, V1095, P30, DOI 10.1016/0167-4889(91)90041-U; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; Santamarina-Fojo S, 2001, J LIPID RES, V42, P1339; SCHMITZ G, 1985, EMBO J, V4, P613, DOI 10.1002/j.1460-2075.1985.tb03674.x; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; SCHWARTZ CC, 1978, SCIENCE, V200, P62, DOI 10.1126/science.204996; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 2001, CURR OPIN LIPIDOL, V12, P497, DOI 10.1097/00041433-200110000-00004; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Swift LL, 2001, J BIOL CHEM, V276, P22965, DOI 10.1074/jbc.M100172200; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zheng P, 2001, BBA-MOL CELL BIOL L, V1534, P121, DOI 10.1016/S1388-1981(01)00183-4	56	67	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14370	14378		10.1074/jbc.M209006200	http://dx.doi.org/10.1074/jbc.M209006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12584196	hybrid			2022-12-27	WOS:000182405000102
J	Lidell, ME; Johansson, MEV; Hansson, GC				Lidell, ME; Johansson, MEV; Hansson, GC			An autocatalytic cleavage in the c terminus of the human MUC2 mucin occurs at the low pH of the late secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY MUCIN; PRE-ALPHA-INHIBITOR; MAMMARY ADENOCARCINOMA CELLS; DISULFIDE-BONDED DIMERS; VON-WILLEBRAND-FACTOR; MOLECULAR-CLONING; INTESTINAL MUCIN; HEAVY-CHAIN; SIALOMUCIN COMPLEX; EPITHELIAL MUCIN	During purification of a recombinant MUC2 C terminus expressed in CHO-K1 cells, the protein was partly cleaved when buffers with a pH of 6.0 were used. When buffers with higher pH values were used, less cleavage was found. Disulfide bonds held the two fragments generated together as these were only observed after reduction. Edman sequencing of the C-terminal 110-kDa fragment revealed that the cleavage had occurred at an Asp-Pro bond, a site described previously to generate the so-called "link peptide" after disulfide bond reduction. In vitro studies on the conditions for cleavage showed that it occurred in a time-dependent manner at a pH below 6.0. Furthermore, the reaction was not enzyme-mediated as it occurred in pure preparations of the MUC2 C terminus and was not inhibited by protease inhibitors. When expressed in the mucin producing cell line LS 174T, the C terminus was cleaved to a higher extent compared with the CHO-K1 cells. Neutralizing the secretory pathway with either N-H4Cl or bafilomycin A1 inhibited this cleavage. Altogether, our results suggest that the cleavage is an autocatalytic reaction that occurs in the acidic environment of the late secretory pathway. Furthermore, the cleavage produced a new, reactive C terminus that has the potential to attach the mucin to itself or other molecules. Because a pH below 6 can be reached in the late secretory pathway and on mucosal surfaces, the cleavage and possible cross-linking are likely to be of biological importance.	Gothenburg Univ, Dept Med Biochem, S-41390 Gothenburg, Sweden	University of Gothenburg	Hansson, GC (corresponding author), Gothenburg Univ, Dept Med Biochem, Medicinaregatan 9A, S-41390 Gothenburg, Sweden.		Hansson, Gunnar C/A-1236-2009; Hansson, Gunnar C./AAF-7324-2019; Johansson, Malin E. V./HCH-7451-2022	Hansson, Gunnar C/0000-0002-1900-1869; Hansson, Gunnar C./0000-0002-1900-1869; Johansson, Malin E. V./0000-0002-4237-6677				Asker N, 1998, J BIOL CHEM, V273, P18857, DOI 10.1074/jbc.273.30.18857; ASKER N, 1995, BIOCHEM J, V308, P873, DOI 10.1042/bj3080873; Axelsson MAB, 1998, J BIOL CHEM, V273, P18864, DOI 10.1074/jbc.273.30.18864; Axelsson MAB, 2001, GLYCOBIOLOGY, V11, P633, DOI 10.1093/glycob/11.8.633; Bell SL, 1998, EUR J BIOCHEM, V253, P123, DOI 10.1046/j.1432-1327.1998.2530123.x; Bell SL, 2001, BIOCHEM J, V357, P203, DOI 10.1042/0264-6021:3570203; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; CHAN P, 1995, BIOCHEM J, V306, P505, DOI 10.1042/bj3060505; Coakley R D, 2001, JOP, V2, P294; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; Desseyn JL, 1998, J BIOL CHEM, V273, P30157, DOI 10.1074/jbc.273.46.30157; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; FAHIM REF, 1987, BIOCHEM J, V243, P631, DOI 10.1042/bj2430631; FAHIM REF, 1983, BIOCHEM J, V209, P117, DOI 10.1042/bj2090117; Forstner G, 1989, Symp Soc Exp Biol, V43, P259; Forstner Janet F., 1995, P71; Forstner Janet F., 1994, P1255; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Goto A, 2001, BIOCHEM J, V359, P99, DOI 10.1042/0264-6021:3590099; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557; GUM JR, 1992, J BIOL CHEM, V267, P21375; Gum JR, 2002, BIOCHEM BIOPH RES CO, V291, P466, DOI 10.1006/bbrc.2002.6475; GUM JR, 1994, J BIOL CHEM, V269, P2440; HELM RM, 1981, EXP CELL RES, V135, P418, DOI 10.1016/0014-4827(81)90181-6; Herrmann A, 1999, J BIOL CHEM, V274, P15828, DOI 10.1074/jbc.274.22.15828; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; MANTLE M, 1984, BIOCHEM J, V224, P345, DOI 10.1042/bj2240345; McIlvaine TC, 1921, J BIOL CHEM, V49, P183; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; OHMORI H, 1994, J BIOL CHEM, V269, P17833; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Perez-Vilar J, 1998, J BIOL CHEM, V273, P34527, DOI 10.1074/jbc.273.51.34527; Perez-Vilar J, 1998, J BIOL CHEM, V273, P14442, DOI 10.1074/jbc.273.23.14442; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6; Poschet JF, 2001, P NATL ACAD SCI USA, V98, P13972, DOI 10.1073/pnas.241182598; Pratt WS, 2000, BIOCHEM BIOPH RES CO, V275, P916, DOI 10.1006/bbrc.2000.3406; SADLER JE, 1991, J BIOL CHEM, V266, P22777; Shankar V, 1997, AM J RESP CELL MOL, V16, P232, DOI 10.1165/ajrcmb.16.3.9070607; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; Thuveson M, 2000, J BIOL CHEM, V275, P30996, DOI 10.1074/jbc.M002399200; Thuveson M, 1999, J BIOL CHEM, V274, P6741, DOI 10.1074/jbc.274.10.6741; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; Williams SJ, 1999, CANCER RES, V59, P4083; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; XU GQ, 1992, J BIOL CHEM, V267, P5401; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200	56	73	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13944	13951		10.1074/jbc.M210069200	http://dx.doi.org/10.1074/jbc.M210069200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582180	hybrid			2022-12-27	WOS:000182405000050
J	Rolli-Derkinderen, M; Machavoine, F; Baraban, JM; Grolleau, A; Beretta, L; Dy, M				Rolli-Derkinderen, M; Machavoine, F; Baraban, JM; Grolleau, A; Beretta, L; Dy, M			ERK and p38 inhibit the expression of 4E-BP1 repressor of translation through induction of Egr-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-KINASE; CAP-DEPENDENT TRANSLATION; INITIATION-FACTOR 4E; NERVE GROWTH-FACTOR; MAP-KINASE; GENE-EXPRESSION; TRANSCRIPTION FACTOR; C-JUN; HISTIDINE-DECARBOXYLASE; DIFFERENTIAL REGULATION	4E-BP1 plays a major role in translation by inhibiting cap-dependent translation initiation. Several reports have investigated the regulation of 4E-BP1 phosphorylation, which varies along with cell differentiation and upon various stimulations, but very little is known about the regulation of its expression. In a first part, we show that the expression of 4E-BP1 protein and transcript decreases in hematopoietic cell lines cultivated in the presence of phorbol 12-myristate 13-acetate (PMA). This decrease depends on the activation of the ERK/ mitogen-activated protein kinases. 4E-BP1 expression also decreases when the p38/mitogen-activated protein kinase pathway is activated by granulocyte/macrophage colony-stimulating factor but to a lesser extent than with PMA. In a second part, we examine how 4e-bp1 promoter activity is regulated. PMA and granulocyte/ macrophage colony-stimulating factor induce Egr-1 expression through ERK and p38 activation, respectively. Using a dominant negative mutant of Egr, ZnEgr, we show that this transcription factor is responsible for the inhibition of 4e-bp1 promoter activity. In a third part we show that histidine decarboxylase, whose activity and expression are inversely correlated with 4E-BP1 expression, is a potential target for the translational machinery. These data (i) are the first evidence of a new role of ERK and p38 on the translational machinery and (ii) demonstrate that 4E-BP1 is a new target for Egr-1.	Univ Paris 05, Hop Necker, Inst Federat Rech Necker Enfants Malad, CNRS,FRE 2444, F-75015 Paris, France; Johns Hopkins Univ, Sch Med, Dept Neurosci Psychiat & Behav Sci, Baltimore, MD 21205 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Johns Hopkins University; University of Michigan System; University of Michigan	Dy, M (corresponding author), 161 Rue Sevres, F-75743 Paris 15, France.	dy@necker.fr	Julius, Annabelle/A-7276-2010; Rolli-Derkinderen, Malvyne/K-2406-2015	Baraban, Jay/0000-0002-8165-2638; Laura, Beretta/0000-0002-2054-684X				AHLERS A, 1994, MOL PHARMACOL, V46, P1077; AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Beretta L, 1998, J IMMUNOL, V160, P3269; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Beretta L, 1996, J VIROL, V70, P8993, DOI 10.1128/JVI.70.12.8993-8996.1996; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CAO XM, 1993, J BIOL CHEM, V268, P16949; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; CHENG T, 1994, J BIOL CHEM, V269, P30848; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Craxton A, 1998, J IMMUNOL, V161, P3225; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Dy M, 1999, EXP HEMATOL, V27, P1295, DOI 10.1016/S0301-472X(99)00070-3; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Grolleau A, 2000, LEUKEMIA, V14, P1909, DOI 10.1038/sj.leu.2401904; Grolleau A, 1999, J IMMUNOL, V162, P3491; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hall-Jackson CA, 1998, BRIT J CANCER, V78, P641, DOI 10.1038/bjc.1998.554; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hashimoto S, 2000, J PHARMACOL EXP THER, V293, P370; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Hu YH, 1997, ARTERIOSCL THROM VAS, V17, P2808, DOI 10.1161/01.ATV.17.11.2808; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Levkovitz Y, 2002, J NEUROSCI, V22, P3845, DOI 10.1523/JNEUROSCI.22-10-03845.2002; Liu GM, 2002, J BIOL CHEM, V277, P8810, DOI 10.1074/jbc.M110477200; LIU JW, 1992, CELL GROWTH DIFFER, V3, P307; Maeda K, 1998, EXP HEMATOL, V26, P325; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; Pietersma A, 1997, BIOCHEM BIOPH RES CO, V230, P44, DOI 10.1006/bbrc.1996.5886; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Reiser COA, 1998, BIOCHEM J, V330, P1107; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; Rolli-Derkinderen M, 2000, BIOL CHEM, V381, P193, DOI 10.1515/BC.2000.026; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Schneider R, 2001, MOL CELL BIOL, V21, P8238, DOI 10.1128/MCB.21.23.8238-8246.2001; Schultz H, 1997, J CELL PHYSIOL, V173, P310, DOI 10.1002/(SICI)1097-4652(199712)173:3<310::AID-JCP2>3.0.CO;2-Q; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tilly BC, 1996, FEBS LETT, V395, P133, DOI 10.1016/0014-5793(96)01028-9; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WANG X, 2001, EMBO J, V16, P4320; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wong WK, 2002, J BIOL CHEM, V277, P22222, DOI 10.1074/jbc.M202844200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	70	50	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18859	18867		10.1074/jbc.M211696200	http://dx.doi.org/10.1074/jbc.M211696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12618431	hybrid			2022-12-27	WOS:000182932200021
J	Dolder, M; Walzel, B; Speer, O; Schlattner, U; Wallimann, T				Dolder, M; Walzel, B; Speer, O; Schlattner, U; Wallimann, T			Inhibition of the mitochondrial permeability transition by creatine kinase substrates - Requirement for microcompartmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE TRANSLOCASE; ADP/ATP CARRIER; SKELETAL-MUSCLE; PHOSPHORYLCREATINE SHUTTLE; LYMPHOCYTE APOPTOSIS; CRYSTAL-STRUCTURE; CYCLOSPORINE-A; CYCLOPHILIN-D; BRAIN-TYPE; IN-SITU	Mitochondria from transgenic mice, expressing enzymatically active mitochondrial creatine kinase in liver, were analyzed for opening of the permeability transition pore in the absence and presence of creatine kinase substrates but with no external adenine nucleotides added. In mitochondria from these transgenic mice, cyclosporin A-inhibited pore opening was delayed by creatine or cyclocreatine but not by beta-guanidinopropionic acid. This observation correlated with the ability of these substrates to stimulate state 3 respiration in the presence of extramitochondrial ATP. The dependence of transition pore opening on calcium and magnesium concentration was studied in the presence and absence of creatine. If mitochondrial creatine kinase activity decreased (i.e. by omitting magnesium from the medium), protection of permeability transition pore opening by creatine or cyclocreatine was no longer seen. Likewise, when creatine kinase was added externally to liver mitochondria from wild-type mice that do not express mitochondrial creatine kinase in liver, no protective effect on pore opening by creatine and its analog was observed. All these findings indicate that mitochondrial creatine kinase activity located within the intermembrane and intercristae space, in conjunction with its tight functional coupling to oxidative phosphorylation, via the adenine nucleotide translocase, can modulate mitochondrial permeability transition in the presence of creatine. These results are of relevance for the design of creatine analogs for cell protection as potential adjuvant therapeutic tools against neurodegenerative diseases.	ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Dolder, M (corresponding author), ETH Honggerberg, Inst Biotechnol, CH-8093 Zurich, Switzerland.		Schlattner, Uwe/D-1267-2009; Wallimann, Theo/C-6047-2008	Schlattner, Uwe/0000-0003-1159-5911; Wallimann, Theo/0000-0003-4957-5836				ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BERNARDI P, 1993, J BIOL CHEM, V268, P1005; Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Boehm EA, 1996, BBA-BIOENERGETICS, V1274, P119, DOI 10.1016/0005-2728(96)00018-7; Brdiczka D, 1998, BIOFACTORS, V8, P235, DOI 10.1002/biof.5520080311; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; Brustovetsky N, 2002, BIOCHEMISTRY-US, V41, P11804, DOI 10.1021/bi0200110; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Castedo M, 1996, J IMMUNOL, V157, P512; CLARK JF, 1994, BIOCHEM J, V300, P211, DOI 10.1042/bj3000211; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; Eder M, 1999, PROTEIN SCI, V8, P2258; Eder M, 2000, PROTEINS, V39, P216, DOI 10.1002/(SICI)1097-0134(20000515)39:3<216::AID-PROT40>3.0.CO;2-#; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; GROSS M, 1993, BIOCHEMISTRY-US, V32, P13933, DOI 10.1021/bi00213a024; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Huang SG, 2001, ARCH BIOCHEM BIOPHYS, V394, P67, DOI 10.1006/abbi.2001.2520; INDIVERI C, 1992, BIOCHIM BIOPHYS ACTA, V1140, P53, DOI 10.1016/0005-2728(92)90019-X; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Kaldis Philipp, 1997, Advances in Developmental Biology, V5, P275, DOI 10.1016/S1566-3116(08)60040-7; Kay L, 2000, J BIOL CHEM, V275, P6937, DOI 10.1074/jbc.275.10.6937; KLINGENBERG M, 1985, ENZYMES BIOL MEMBR, V4, P511; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kraft T, 2000, J MUSCLE RES CELL M, V21, P691, DOI 10.1023/A:1005623002979; Linder MD, 2002, J BIOL CHEM, V277, P937, DOI 10.1074/jbc.M107610200; Lohret TA, 1996, J BIOL CHEM, V271, P4846; Marchetti P, 1996, J IMMUNOL, V157, P4830; Matthews RT, 1998, J NEUROSCI, V18, P156; Matthews RT, 1999, EXP NEUROL, V157, P142, DOI 10.1006/exnr.1999.7049; Miller K, 1997, AM J PHYSIOL-CELL PH, V272, pC1193, DOI 10.1152/ajpcell.1997.272.4.C1193; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; Passaquin AC, 2002, NEUROMUSCULAR DISORD, V12, P174, DOI 10.1016/S0960-8966(01)00273-5; PASTORINO JG, 1994, J BIOL CHEM, V269, P31041; Pulido SM, 1998, FEBS LETT, V439, P357, DOI 10.1016/S0014-5793(98)01399-4; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; Saks VA, 1996, BBA-BIOENERGETICS, V1274, P81, DOI 10.1016/0005-2728(96)00011-4; SAKS VA, 1995, J MOL CELL CARDIOL, V27, P625, DOI 10.1016/S0022-2828(08)80056-9; Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257; Schlattner U, 1998, MOL CELL BIOCHEM, V184, P125, DOI 10.1023/A:1006851330913; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; Tarnopolsky MA, 2001, ANN NEUROL, V49, P561, DOI 10.1002/ana.1028; Ventura-Clapier R, 1998, MOL CELL BIOCHEM, V184, P231, DOI 10.1023/A:1006840508139; WALLIMANN T, 1994, CURR BIOL, V4, P42, DOI 10.1016/S0960-9822(00)00008-7; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; WEGMANN G, 1991, DIFFERENTIATION, V46, P77, DOI 10.1111/j.1432-0436.1991.tb00868.x; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	63	160	168	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17760	17766		10.1074/jbc.M208705200	http://dx.doi.org/10.1074/jbc.M208705200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621025	hybrid			2022-12-27	WOS:000182838300023
J	Macdonald, A; Crowder, K; Street, A; McCormick, C; Saksela, K; Harris, M				Macdonald, A; Crowder, K; Street, A; McCormick, C; Saksela, K; Harris, M			The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing Ras-ERK pathway signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; FULL-LENGTH; MAP KINASE; X-PROTEIN; TRANSCRIPTION FACTORS; HBX PROTEIN; TYPE-1 NEF; HIV-1 NEF; GROWTH; EXPRESSION	The hepatitis C virus nonstructural 5A (NS5A) protein is a pleiotropic phosphoprotein that has been shown to associate with a wide variety of cellular signaling proteins. Of particular interest is the observation that a highly conserved C-terminal Class II polyproline motif within NS5A mediated association with the Src homology 3 domains of members of the Src family of tyrosine kinases and the mitogenic adaptor protein Grb2 (A. Macdonald, K. Crowder, A. Street, C. McCormick, and M. Harris, submitted for publication). In this study, we analyzed the consequences of NS5A expression on mitogenic signaling pathways within a variety of cell lines. Utilizing a transient luciferase reporter system, we observed that NS5A inhibited the activity of the mitogenic and stress-activated transcription factor activating protein-1 (AP1). This inhibition was dependent upon a Class II polyproline motif within NS5A. Using a combination of dominant active and negative mutants of components of the MAPK signaling pathways, selective inhibitors, together with immunoblotting with phospho-specific and phosphorylation-independent antibodies, we determined the signaling pathways targeted by NS5A to inhibit AP1. These studies demonstrated that in both stable NS5A-expressing cells and Huh-7-derived cells harboring subgenomic hepatitis C virus (HCV) replicons, this inhibition was mediated through the ERK signaling pathway. Importantly, a comparable inhibition of AP1 reporter activity was observed in hepatocyte-derived cell lines transduced with a baculovirus vector driving expression of full-length HCV polyprotein. In conclusion, these data strongly suggest a role for the NS5A protein in the perturbation of mitogenic signaling pathways in HCV-infected hepatocytes.	Univ Leeds, Dept Biochem & Mol Biol, Div Microbiol, Leeds LS2 9JT, W Yorkshire, England; Tampere Univ Hosp, Inst Med Technol, FIN-33014 Tampere, Finland	University of Leeds; Tampere University; Tampere University Hospital	Harris, M (corresponding author), Univ Leeds, Dept Biochem & Mol Biol, Div Microbiol, Leeds LS2 9JT, W Yorkshire, England.	mharris@bmb.leeds.ac.uk		Harris, Mark/0000-0002-9821-1003; McCormick, Christopher/0000-0002-6155-9161; Macdonald, Andrew/0000-0002-5978-4693				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Aoubala M, 2001, J GEN VIROL, V82, P1637, DOI 10.1099/0022-1317-82-7-1637; Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; Arima N, 2001, J BIOL CHEM, V276, P12675, DOI 10.1074/jbc.M008329200; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Biggs TE, 1999, J MOL BIOL, V290, P21, DOI 10.1006/jmbi.1999.2849; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Erhardt A, 2002, VIROLOGY, V292, P272, DOI 10.1006/viro.2001.1227; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; FURUKAWA T, 1979, J GEN VIROL, V45, P81, DOI 10.1099/0022-1317-45-1-81; Gale MJ, 1998, CLIN DIAGN VIROL, V10, P157; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAYSTEAD TAJ, 1992, FEBS LETT, V306, P17, DOI 10.1016/0014-5793(92)80828-5; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; He YP, 2001, J VIROL, V75, P5090, DOI 10.1128/JVI.75.11.5090-5098.2001; Heim MH, 1999, J VIROL, V73, P8469, DOI 10.1128/JVI.73.10.8469-8475.1999; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; Higuchi R., 1992, PCR TECHNOLOGY, P61; HSU JC, 1993, CANCER RES, V53, P3789; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; KANEKO T, 1994, BIOCHEM BIOPH RES CO, V205, P320, DOI 10.1006/bbrc.1994.2667; Kim WR, 2002, HEPATOLOGY, V36, pS30, DOI 10.1053/jhep.2002.36791; Korkaya H, 2001, J BIOL CHEM, V276, P42389, DOI 10.1074/jbc.M101546200; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; LANGECARTER CA, 1994, RECENT PROG HORM RES, V49, P341; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Manninen A, 2000, J BIOL CHEM, V275, P16513, DOI 10.1074/jbc.M910032199; Manninen A, 1998, VIROLOGY, V250, P273, DOI 10.1006/viro.1998.9381; McCormick CJ, 2002, J GEN VIROL, V83, P383, DOI 10.1099/0022-1317-83-2-383; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nijhara R, 2001, J VIROL, V75, P10348, DOI 10.1128/JVI.75.21.10348-10358.2001; Poggioli GJ, 2001, J VIROL, V75, P7429, DOI 10.1128/JVI.75.16.7429-7434.2001; RAO VN, 1993, CANCER RES, V53, P215; Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X; Renkema GH, 2001, J VIROL, V75, P2154, DOI 10.1128/JVI.75.5.2154-2160.2001; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; Saragovi HU, 1999, DNA CELL BIOL, V18, P763, DOI 10.1089/104454999314908; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Tyler KL, 2001, TRENDS MICROBIOL, V9, P560, DOI 10.1016/S0966-842X(01)02103-5; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yoon K, 1999, J GEN VIROL, V80, P2951, DOI 10.1099/0022-1317-80-11-2951; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; Yu CF, 2002, J BIOL CHEM, V277, P19382, DOI 10.1074/jbc.M200732200	66	131	133	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17775	17784		10.1074/jbc.M210900200	http://dx.doi.org/10.1074/jbc.M210900200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621033	hybrid			2022-12-27	WOS:000182838300025
J	Nagata, K; Kawajiri, A; Matsui, S; Takagishi, M; Shiromizu, T; Saitoh, N; Izawa, I; Kiyono, T; Itoh, TJ; Hotani, H; Inagaki, M				Nagata, K; Kawajiri, A; Matsui, S; Takagishi, M; Shiromizu, T; Saitoh, N; Izawa, I; Kiyono, T; Itoh, TJ; Hotani, H; Inagaki, M			Filament formation of MSF-A, a mammalian septin, in human mammary epithelial cells depends on interactions with microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; OVARIAN-TUMORS; DIVISION CYCLE; CHROMOSOME 17Q; ALLELIC LOSS; MDCK CELLS; BUD NECK; PROTEIN; GENE; REGION	Septins are a family of conserved proteins implicated in a variety of cellular functions such as cytokinesis and vesicle trafficking, but their properties and modes of action are largely unknown. Here we now report findings of immunocytochemical and biochemical characterization of a mammalian septin, MSF-A. Using an antibody specific for MSF subfamily proteins, MSF-A was found to be expressed predominantly in mammary human mammary epithelial cells (HMEC). MSF-A was associated with microtubules in interphase HMEC cells as it localized with the mitotic spindle and the bundle of microtubule at midzone during mitosis. Biochemical analysis revealed direct binding of MSF-A with polymerized tubulin through its central region containing guanine nucleotide-interactive motifs. GTPase activity, however, was not required for the association. Conditions that disrupt the microtubule network also disrupted the MSF-A-containing filament structure, resulting in a punctate cytoplasmic pattern. Depletion of MSF-A using small interfering RNAs caused incomplete cell division and resulted in the accumulation of binucleated cells. Unlike Nedd5, an MSF mutant deficient in GTPase activity forms filament indistinguishable from that of the wild type in COS cells. These results strongly suggest that septin filaments may interact not only with actin filaments but also with microtubule networks and that GTPase activity of MSF-A is not indispensable to incorporation of MSF-A into septin filaments.	Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr, Res Inst, Div Virol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Univ, Sch Med, Dept Pathol, Nagoya, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4648602, Japan	Aichi Cancer Center; Aichi Cancer Center; Nagoya University; Nagoya University	Inagaki, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Biochem, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Inagaki, Masaki/B-9920-2016; Kiyono, Tohru/H-5834-2011					Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITFELD PP, 1990, J CELL BIOL, V111, P2365, DOI 10.1083/jcb.111.6.2365; Carroll CW, 1998, J CELL BIOL, V143, P709, DOI 10.1083/jcb.143.3.709; Chant J, 1996, CELL, V84, P187, DOI 10.1016/S0092-8674(00)80972-1; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Gladfelter AS, 2001, CURR OPIN MICROBIOL, V4, P681, DOI 10.1016/S1369-5274(01)00269-7; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Hsu SC, 1998, NEURON, V20, P1111, DOI 10.1016/S0896-6273(00)80493-6; HUNZIKER W, 1990, EMBO J, V9, P3515, DOI 10.1002/j.1460-2075.1990.tb07560.x; Itoh TJ, 1997, BIOCHEMISTRY-US, V36, P12574, DOI 10.1021/bi962606z; Kalikin LM, 1997, ONCOGENE, V14, P1991, DOI 10.1038/sj.onc.1201013; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; LAFONT F, 1994, NATURE, V372, P801; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Longtine MS, 1998, J CELL BIOL, V143, P719, DOI 10.1083/jcb.143.3.719; McIlhatton MA, 2001, ONCOGENE, V20, P5930, DOI 10.1038/sj.onc.1204752; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; MURATA M, 1992, BIOL CELL, V75, P127, DOI 10.1016/0248-4900(92)90132-K; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; NAGATA KI, 1992, J BIOL CHEM, V267, P19600; NEUFELD TP, 1994, CELL, V77, P371, DOI 10.1016/0092-8674(94)90152-X; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; Phelan CM, 1998, CANCER RES, V58, P1004; Russell SEH, 2000, CANCER RES, V60, P4729; SAITO H, 1993, CANCER RES, V53, P3382; Surka MC, 2002, MOL BIOL CELL, V13, P3532, DOI 10.1091/mbc.E02-01-0042; Taki T, 1999, CANCER RES, V59, P4261; THEILE M, 1995, ONCOGENE, V10, P439; Trimble WS, 1999, J MEMBRANE BIOL, V169, P75, DOI 10.1007/s002329900519; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	36	155	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18538	18543		10.1074/jbc.M205246200	http://dx.doi.org/10.1074/jbc.M205246200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626509	hybrid			2022-12-27	WOS:000182838300124
J	Otto, GP; Wu, MY; Kazgan, N; Anderson, OR; Kessin, RH				Otto, GP; Wu, MY; Kazgan, N; Anderson, OR; Kessin, RH			Macroautophagy is required for multicellular development of the social amoeba Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN CONJUGATION SYSTEM; AUTOPHAGOSOME FORMATION; VACUOLE; GENE; CYTOPLASM; MEMBRANE; PATHWAYS; COMPLEX; AUTOPHAGOCYTOSIS	Macroautophagy is a mechanism employed by eukaryotic cells to recycle non-essential cellular components during starvation, differentiation, and development. Two conjugation reactions related to ubiquitination are essential for autophagy: Apg12p conjugation to Apg5p, and Apg8p conjugation to the lipid phosphatidylethanolamine. These reactions require the action of the E1-like enzyme, Apg7p, and the E2-like enzymes, Apg3p and Apg10p. In Dictyostelium, development is induced by starvation, conditions under which autophagy is required for survival in yeast and plants. We have identified Dictyostelium homologues of 10 budding yeast autophagy genes. We have generated mutations in apg5 and apg7 that produce defects typically associated with an abrogation of autophagy. Mutants are not grossly affected in growth, but survival during nitrogen starvation is severely reduced. Starved mutant cells show little turnover of cellular constituents by electron microscopy, whereas wild-type cells show significant cytoplasmic degradation and reduced organelle number. Bulk protein degradation during starvation-induced development is reduced in the autophagy mutants. Development is aberrant; the autophagy mutants do not aggregate in plaques on bacterial lawns, but they do proceed further in development on nitrocellulose filters, forming defective fruiting bodies. The autophagy mutations are cell autonomous, because wild-type cells in a chimaera do not rescue development of the autophagy mutants. We have complemented the mutant phenotypes by expression of the cognate gene fused to green fluorescent protein. A green fluorescent protein fusion of the autophagosome marker Apg8 mislocalizes in the two autophagy mutants. We show that the Apg5-Apg12 conjugation system is conserved in Dictyostelium.	Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Lamont Doherty Earth Observ, Dept Biol, Palisades, NY 10964 USA	Columbia University; Columbia University	Kessin, RH (corresponding author), Columbia Univ, Dept Anat & Cell Biol, Rm 12-517,630 W 168th St, New York, NY 10032 USA.			Otto, Grant/0000-0001-8709-3366; Wu, Mary Y./0000-0002-2074-6171	NIGMS NIH HHS [GM33136] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON OR, 1994, J EUKARYOT MICROBIOL, V41, P124, DOI 10.1111/j.1550-7408.1994.tb01484.x; Cuervo AM, 2000, TRAFFIC, V1, P570, DOI 10.1034/j.1600-0854.2000.010707.x; Cuervo AM, 2000, J CELL SCI, V113, P4441; Dice J F, 1990, Semin Cell Biol, V1, P449; Doelling JH, 2002, J BIOL CHEM, V277, P33105, DOI 10.1074/jbc.M204630200; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; Hanaoka H, 2002, PLANT PHYSIOL, V129, P1181, DOI 10.1104/pp.011024; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Kessin R.H., 2001, DICTYOSTELIUM EVOLUT; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; Lang T, 2000, J BACTERIOL, V182, P2125, DOI 10.1128/JB.182.8.2125-2133.2000; Levi S, 2000, PLASMID, V44, P231, DOI 10.1006/plas.2000.1487; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; MORTIMORE GE, 1988, J BIOL CHEM, V263, P2506; Niemann A, 2000, J HISTOCHEM CYTOCHEM, V48, P251, DOI 10.1177/002215540004800210; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; PAPADOPOULOS T, 1987, EXP CELL RES, V171, P110, DOI 10.1016/0014-4827(87)90255-2; PODGORSKI GJ, 1989, MOL CELL BIOL, V9, P3938, DOI 10.1128/MCB.9.9.3938; Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002; Schlumpberger M, 1997, J BACTERIOL, V179, P1068, DOI 10.1128/jb.179.4.1068-1076.1997; Shintani T, 2001, J BIOL CHEM, V276, P30452, DOI 10.1074/jbc.M102346200; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Souza GM, 1998, DEVELOPMENT, V125, P2291; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; TUTTLE DL, 1995, J CELL SCI, V108, P25; Wang CW, 2001, J BIOL CHEM, V276, P30442, DOI 10.1074/jbc.M102342200; WHITE GJ, 1961, BIOCHIM BIOPHYS ACTA, V53, P285, DOI 10.1016/0006-3002(61)90441-3; WU L, 1990, GENE, V91, P51, DOI 10.1016/0378-1119(90)90161-J; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	45	179	193	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17636	17645		10.1074/jbc.M212467200	http://dx.doi.org/10.1074/jbc.M212467200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626495	hybrid			2022-12-27	WOS:000182838300009
J	Antonyak, MA; McNeill, CJ; Wakshlag, JJ; Boehm, JE; Cerione, RA				Antonyak, MA; McNeill, CJ; Wakshlag, JJ; Boehm, JE; Cerione, RA			Activation of the Ras-ERK pathway inhibits retinoic acid-induced stimulation of tissue transglutaminase expression in NIH3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN NEUROBLASTOMA-CELLS; GTP-BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; APOPTOSIS; KINASE; DIFFERENTIATION; TRANSFORMATION; INDUCTION	Retinoic acid (RA) is a potent activator of tissue transglutaminase (TGase) expression, and it was recently shown that phosphoinositide 3-kinase (PI3K) activity was required for RA to increase TGase protein levels. To better understand how RA-mediated TGase expression is regulated, we considered whether co-stimulation of NIH3T3 cells with RA and epidermal growth factor (EGF), a known activator of PI3K, would facilitate the induction or increase the levels of TGase expression. Instead of enhancing these parameters, EGF inhibited RA-induced TGase expression. Activation of the Ras-ERK pathway by EGF was sufficient to elicit this effect, since continuous Ras signaling mimicked the actions of EGF and inhibited RA-induced TGase expression, whereas blocking ERK activity in these same cells restored the ability of RA to up-regulate TGase expression. However, TGase activity is not antagonistic to EGF signaling. The mitogenic and anti-apoptotic effects of EGF were not compromised by TGase overexpression, and in fact, exogenous TGase expression promoted basal cell growth and resistance to serum deprivation-induced apoptosis. Moreover, analysis of TGase expression and GTP binding activity in a number of cell lines revealed high basal TGase GTP binding activity in tumor cell lines U87 and MDAMB231, indicating that constitutively active TGase may be a characteristic of certain cancer cells. These findings demonstrate that TGase may serve as a survival factor and RA-induced TGase expression requires the activation of PI3K but is antagonized by the Ras-ERK pathway.	Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA	Cornell University	Cerione, RA (corresponding author), Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061762] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 61762, GM 208052] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonyak MA, 2002, J BIOL CHEM, V277, P14712, DOI 10.1074/jbc.M112259200; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DADABAY CY, 1987, BIOCHEMISTRY-US, V26, P6587, DOI 10.1021/bi00395a004; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Katoh S, 1996, BIOCHEM J, V313, P305, DOI 10.1042/bj3130305; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOSA K, 1993, BIOCHEM BIOPH RES CO, V196, P1025, DOI 10.1006/bbrc.1993.2354; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; MEHTA K, 1994, INT J CANCER, V58, P400, DOI 10.1002/ijc.2910580316; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MIRZA A, 1997, AM J PHYSIOL, V272, P281; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; Nemes Z, 1997, J BIOL CHEM, V272, P20577, DOI 10.1074/jbc.272.33.20577; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; Paillaud E, 2002, J NEUROSCI RES, V67, P670, DOI 10.1002/jnr.10110; Piacentini M, 2002, J NEUROCHEM, V81, P1061; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; SPORN MB, 1983, CANCER RES, V43, P3034; SUTO N, 1993, J BIOL CHEM, V268, P7469; Tucholski J, 2002, J NEUROCHEM, V81, P780, DOI 10.1046/j.1471-4159.2002.00859.x; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819	47	43	43	4	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15859	15866		10.1074/jbc.M300037200	http://dx.doi.org/10.1074/jbc.M300037200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604597	hybrid			2022-12-27	WOS:000182680000052
J	Carr, BA; Wan, J; Hines, RN; Yost, GS				Carr, BA; Wan, J; Hines, RN; Yost, GS			Characterization of the human lung CYP2F1 gene and identification of a novel lung-specific binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-4; CYTOCHROMES P450; BRONCHOALVEOLAR MACROPHAGES; XENOBIOTIC METABOLISM; DNA-SEQUENCE; EXPRESSION; SUBFAMILY; PROTEIN; 3-METHYLINDOLE; PULMONARY	The CYP2F1 gene encodes a cytochrome P450 enzyme capable of bioactivating a number of pulmonary-selective toxicants. The expression of CYP2F1 is highly tissue-selective; the highest expression is observed in the lung with little or no hepatic expression. The objective of these studies was to elucidate the mechanisms that govern the unique tissue-specific regulation of CYP2F1. Cosmid and bacterial artificial chromosome clones were screened and sequenced to identify a gene that spanned 14 kbp containing 10 exons, including an untranslated exon 1. Primer extension analysis and 5'-rapid amplification of cDNA ends were used to identify the transcription start site. Several sequences homologous to known cis-elements were identified in the 5'-upstream region of the CYP2F1 promoter. Transient transfection studies with luciferase reporter constructs demonstrated a significant functional lung cell-specific CYP2F1 promoter region (from position -129 to + 115). DNase footprinting analysis of 1.6 kbp of the upstream sequence with nuclear extracts from human lung tissues revealed one strong DNA-protein complex at -152 to -182. This nuclear protein (called lung-specific factor, LSF) was present only in lung but not liver or heart tissues. Competitive electrophoretic mobility shift assays characterized a DNA consensus site, within the LSF-binding domain, that was highly similar to two E box motifs, but no known "E box" trans-factors were identified. These studies identified a novel LSF and its consensus sequence that may control tissue-specific expression of CYP2F1.	Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA	Utah System of Higher Education; University of Utah; Medical College of Wisconsin	Yost, GS (corresponding author), Univ Utah, Dept Pharmacol & Toxicol, 30 S 2000 E,Rm 201, Salt Lake City, UT 84112 USA.	gyost@pharm.utah.edu		Hines, Ronald/0000-0002-3094-4200	NHLBI NIH HHS [HL 60143] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060143] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anttila S, 1997, AM J RESP CELL MOL, V16, P242, DOI 10.1165/ajrcmb.16.3.9070608; Aranburu A, 2001, BIOCHEM J, V354, P431, DOI 10.1042/0264-6021:3540431; BRAUN T, 1991, NUCLEIC ACIDS RES, V19, P5645, DOI 10.1093/nar/19.20.5645; Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; Cassel Tobias N., 2000, Molecular Cell Biology Research Communications, V3, P42, DOI 10.1006/mcbr.2000.0187; Chen N, 2002, MUTAT RES-FUND MOL M, V499, P155, DOI 10.1016/S0027-5107(01)00274-3; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; CZERWINSKI M, 1994, CANCER RES, V54, P1085; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding XX, 2003, ANNU REV PHARMACOL, V43, P149, DOI 10.1146/annurev.pharmtox.43.100901.140251; GUENGERICH FP, 1993, DRUG METAB DISPOS, V21, P1; Hoffman SMG, 1995, J MOL EVOL, V41, P894; Hoffman SMG, 2001, PHARMACOGENETICS, V11, P687, DOI 10.1097/00008571-200111000-00007; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; Hukkanen J, 1997, MOL CARCINOGEN, V20, P224, DOI 10.1002/(SICI)1098-2744(199710)20:2<224::AID-MC9>3.0.CO;2-M; Ikeda K, 1998, MOL CELL BIOL, V18, P10, DOI 10.1128/MCB.18.1.10; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Kaczynski JA, 2002, BIOCHEM J, V366, P873, DOI 10.1042/BJ20020388; Kim UJ, 1996, GENOMICS, V34, P213, DOI 10.1006/geno.1996.0268; Lanza DL, 1999, DRUG METAB DISPOS, V27, P798; Lanza DL, 2001, DRUG METAB DISPOS, V29, P950; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Maxam A M, 1980, Methods Enzymol, V65, P499; NAKAJIMA T, 1994, CHEM RES TOXICOL, V7, P891, DOI 10.1021/tx00042a026; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NHAMBURO PT, 1990, BIOCHEMISTRY-US, V29, P5491, DOI 10.1021/bi00475a012; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Piipari R, 2000, INT J CANCER, V86, P610, DOI 10.1002/(SICI)1097-0215(20000601)86:5<610::AID-IJC2>3.0.CO;2-M; Powley MW, 2000, J BIOCHEM MOL TOXIC, V14, P303, DOI 10.1002/1099-0461(2000)14:6<303::AID-JBT2>3.0.CO;2-8; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Rivera SP, 2002, MOL PHARMACOL, V61, P255, DOI 10.1124/mol.61.2.255; SEKIDO R, 1994, MOL CELL BIOL, V14, P5692, DOI 10.1128/MCB.14.9.5692; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; Skarin T, 1999, AM J RESP CELL MOL, V21, P177, DOI 10.1165/ajrcmb.21.2.3378; SMITH TJ, 1992, CANCER RES, V52, P1757; ThorntonManning J, 1996, J PHARMACOL EXP THER, V276, P21; UENO T, 1990, MOL CELL BIOL, V10, P4495, DOI 10.1128/MCB.10.9.4495; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; Willey JC, 1996, AM J RESP CELL MOL, V14, P262, DOI 10.1165/ajrcmb.14.3.8845177; Willey JC, 1997, AM J RESP CELL MOL, V17, P114, DOI 10.1165/ajrcmb.17.1.2783; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Yost GS, 1996, ADV EXP MED BIOL, V387, P221; Yost GS, 2001, ADV EXP MED BIOL, V500, P53; Zhang JH, 1998, J BIOL CHEM, V273, P23454, DOI 10.1074/jbc.273.36.23454; Zhang JH, 2000, J BIOL CHEM, V275, P8895, DOI 10.1074/jbc.275.12.8895; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	50	29	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15473	15483		10.1074/jbc.M300319200	http://dx.doi.org/10.1074/jbc.M300319200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598524	hybrid			2022-12-27	WOS:000182680000005
J	Sung, YJ; Dolzhanskaya, N; Nolin, SL; Brown, T; Currie, JR; Denman, RB				Sung, YJ; Dolzhanskaya, N; Nolin, SL; Brown, T; Currie, JR; Denman, RB			The fragile X mental retardation protein FMRP binds elongation factor 1A mRNA and negatively regulates its translation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PEPTIDE PRECURSOR; DENDRITIC SPINES; HUMAN-BRAIN; KH DOMAINS; GENE; IDENTIFICATION; EXPRESSION; MUTATION; MRNP; RAT	Loss of the RNA-binding protein FMRP (fragile X mental retardation protein) leads to fragile X syndrome, the most common form of inherited mental retardation. Although some of the messenger RNA targets of this protein, including FMR1, have been ascertained, many have yet to be identified. We have found that Xenopus elongation factor 1A (EF-1A) mRNA binds tightly to recombinant human FMRP in vitro. Binding depended on protein determinants located primarily in the C-terminal end of hFMRP, but the hnRNP K homology domain influenced binding as well. When hFMRP was expressed in cultured cells, it dramatically reduced endogenous EF-1A protein expression but had no effect on EF-1A mRNA levels. In contrast, the translation of several other mRNAs, including those coding for dynamin and constitutive heat shock 70 protein, was not affected by the hFMRP expression. Most importantly, EF-1A mRNA and hFMR1 mRNA were coimmunoprecipitated with hFMRP. Finally, in fragile X lymphoblastoid cells in which hFMRP is absent, human EF-1A protein but not its corresponding mRNA is elevated compared with normal lymphoblastoid cells. These data suggest that hFMRP binds to EF-1A mRNA and also strongly argue that FAMP negatively regulates EF-1A expression in vivo.	New York State Inst Basic Res Dev Disabil, Biochem Mol Neurobiol Lab, Dept Mol Biol, Staten Isl, NY 10314 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; New York State Inst Basic Res Dev Disabil, Mol Genet Lab, Staten Isl, NY 10314 USA; New York State Inst Basic Res Dev Disabil, Dept Human Genet, Staten Isl, NY 10314 USA	Institute for Basic Research in Developmental Disabilities; Columbia University; Institute for Basic Research in Developmental Disabilities; Institute for Basic Research in Developmental Disabilities	Denman, RB (corresponding author), New York State Inst Basic Res Dev Disabil, Biochem Mol Neurobiol Lab, Dept Mol Biol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	rbdenman@yahoo.com		Nolin, Sarah/0000-0001-5209-289X				Agulhon C, 1999, J NEUROPATH EXP NEUR, V58, P867, DOI 10.1097/00005072-199908000-00009; ANN DK, 1992, J BIOL CHEM, V267, P699; ANN DK, 1991, J BIOL CHEM, V266, P10429; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; Bakker CE, 2000, EXP CELL RES, V258, P162, DOI 10.1006/excr.2000.4932; Bardoni B, 1999, HUM MOL GENET, V8, P2557, DOI 10.1093/hmg/8.13.2557; Brown V, 1998, J BIOL CHEM, V273, P15521, DOI 10.1074/jbc.273.25.15521; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Ceman S, 1999, MOL CELL BIOL, V19, P7925; Ceman S, 2000, BIOCHEM BIOPH RES CO, V279, P904, DOI 10.1006/bbrc.2000.4035; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Comery TA, 1997, P NATL ACAD SCI USA, V94, P5401, DOI 10.1073/pnas.94.10.5401; Comery TA, 1996, NEUROBIOL LEARN MEM, V66, P93, DOI 10.1006/nlme.1996.0049; Corbin F, 1997, HUM MOL GENET, V6, P1465, DOI 10.1093/hmg/6.9.1465; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DENMAN R, 1991, ARCH BIOCHEM BIOPHYS, V288, P29, DOI 10.1016/0003-9861(91)90161-B; Denman RB, 1997, BIOCHEM BIOPH RES CO, V230, P226, DOI 10.1006/bbrc.1996.5926; Denman RB, 2002, BIOCHEM BIOPH RES CO, V292, P1063, DOI 10.1006/bbrc.2002.6768; DENMAN RB, 1995, ARCH BIOCHEM BIOPHYS, V323, P71, DOI 10.1006/abbi.1995.0011; Dolzhanskaya N, 2001, ARCH BIOCHEM BIOPHYS, V387, P223, DOI 10.1006/abbi.2000.2262; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; GIBSON TJ, 1993, TRENDS BIOCHEM SCI, V18, P331, DOI 10.1016/0968-0004(93)90068-X; HAGERMAN RJ, 1996, FRAGILE X SYNDROME D, P3; Inoue Shunsuke B., 2000, Journal of Medical Investigation, V47, P101; Irwin SA, 2000, CEREB CORTEX, V10, P1038, DOI 10.1093/cercor/10.10.1038; Jin P, 2000, HUM MOL GENET, V9, P901, DOI 10.1093/hmg/9.6.901; Khandjian EW, 1999, BIOCHEM CELL BIOL, V77, P331, DOI 10.1139/bcb-77-4-331; Khandjian EW, 1996, NAT GENET, V12, P91, DOI 10.1038/ng0196-91; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KNUDSEN SM, 1993, EUR J BIOCHEM, V215, P549, DOI 10.1111/j.1432-1033.1993.tb18064.x; Laggerbauer B, 2001, HUM MOL GENET, V10, P329, DOI 10.1093/hmg/10.4.329; LEE S, 1994, BIOCHEM BIOPH RES CO, V203, P1371, DOI 10.1006/bbrc.1994.2336; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; Li JX, 2002, MOL CELL NEUROSCI, V19, P138, DOI 10.1006/mcne.2001.1085; Li ZZ, 2001, NUCLEIC ACIDS RES, V29, P2276, DOI 10.1093/nar/29.11.2276; Mazroui R, 2002, HUM MOL GENET, V11, P3007, DOI 10.1093/hmg/11.24.3007; Moine H, 2001, SCIENCE, V294, P2487, DOI 10.1126/science.1068352; Munshi R, 2001, GENETICS, V157, P1425; O'Donnell WT, 2002, ANNU REV NEUROSCI, V25, P315, DOI 10.1146/annurev.neuro.25.112701.142909; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; Setzer DA, 1999, METH MOL B, V118, P115; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; SLOBIN LI, 1993, EUR J BIOCHEM, V213, P919, DOI 10.1111/j.1432-1033.1993.tb17836.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONG JM, 1989, MOL CELL BIOL, V9, P4571, DOI 10.1128/MCB.9.10.4571; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; Sung YJ, 2000, BIOCHEM BIOPH RES CO, V275, P973, DOI 10.1006/bbrc.2000.3405; SUNG YJ, 2001, RRD BIO BIO, V1, P109; Tamanini F, 1997, HUM MOL GENET, V6, P1315, DOI 10.1093/hmg/6.8.1315; TANAKA KJ, 1998, TECHNICAL TIPS ONLIN; Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395; Zhang YQ, 2001, CELL, V107, P591, DOI 10.1016/S0092-8674(01)00589-X	56	74	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15669	15678		10.1074/jbc.M211117200	http://dx.doi.org/10.1074/jbc.M211117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594214	hybrid			2022-12-27	WOS:000182680000028
J	Hwang, HY; Olson, SK; Brown, JR; Esko, JD; Horvitz, HR				Hwang, HY; Olson, SK; Brown, JR; Esko, JD; Horvitz, HR			The Caenorhabditis elegans genes sqv-2 and sqv-6, which are required for vulval morphogenesis, encode glycosaminoglycan galactosyltransferase II and xylosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GLUCURONIC ACID; HEPARAN-SULFATE; C-ELEGANS; EPITHELIAL INVAGINATION; BIOSYNTHESIS; PROTEOGLYCAN; EXPRESSION; MUTANTS; GALACTOSE; MUTATIONS	In mutants defective in any of eight Caenorhabditis elegans sqv (squashed vulva) genes, the vulval extracellular space fails to expand during vulval morphogenesis. Strong sqv mutations result in maternal-effect lethality, caused in part by the failure of the progeny of homozygous mutants to initiate cytokinesis and associated with the failure to form an extracellular space between the egg and the eggshell. Recent studies have implicated glycosaminoglycans in these processes. Here we report the cloning and characterization of sqv-2 and sqv-6. sqv-6 encodes a protein similar to human xylosyltransferases. Transfection of sqv-6 restored xylosyltransferase activity to and rescued the glycosaminoglycan biosynthesis defect of a xylosyltransferase mutant hamster cell line. sqv-2 encodes a protein similar to human galactosyltransferase II. A recombinant SQV-2 fusion protein had galactosyltransferase II activity with substrate specificity similar to that of human galactosyltransferase II. We conclude that C. elegans SQV-6 and SQV-2 likely act in concert with other SQV proteins to catalyze the stepwise formation of the proteoglycan core protein linkage tetrasaccharide GlcAbeta1,3Galbeta1 3Gabeta1,4Xylbeta-O-(Ser), which is common to the two major types of glycosaminoglycans in vertebrates, chondroitin and heparan sulfate. Our results strongly support a model in which C. elegans vulval morphogenesis and zygotic cytokinesis depend on the expression of glycosaminoglycans.	MIT, Dept Biol, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Biol, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego	Horvitz, HR (corresponding author), MIT, Dept Biol, Howard Hughes Med Inst, 77 Massachusetts Ave,Rm 68-425, Cambridge, MA 02139 USA.			Hwang, Ho-Yon/0000-0003-0204-8932	NIGMS NIH HHS [GM24663, GM33063] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063, R37GM024663, R01GM024663, R01GM033063] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; BAME KJ, 1989, J BIOL CHEM, V264, P8059; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; BRENNER S, 1974, GENETICS, V77, P71; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Herman T, 1997, COLD SPRING HARB SYM, V62, P353, DOI 10.1101/SQB.1997.062.01.042; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14218, DOI 10.1073/pnas.172522199; Hwang HY, 2002, P NATL ACAD SCI USA, V99, P14224, DOI 10.1073/pnas.172522499; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Okajima T, 1999, J BIOL CHEM, V274, P28841, DOI 10.1074/jbc.274.41.28841; QUENTIN E, 1990, P NATL ACAD SCI USA, V87, P1342, DOI 10.1073/pnas.87.4.1342; Sambrook J., 2002, MOL CLONING LAB MANU; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	27	55	61	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 4	2003	278	14					11735	11738		10.1074/jbc.C200518200	http://dx.doi.org/10.1074/jbc.C200518200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	663QF	12584198	hybrid			2022-12-27	WOS:000182015700003
J	Wang, PB; Valentijn, AJ; Gilmore, AP; Streuli, CH				Wang, PB; Valentijn, AJ; Gilmore, AP; Streuli, CH			Early events in the anoikis program occur in the absence of caspase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CYTOCHROME-C RELEASE; JUN NH2-TERMINAL KINASE; EXTRACELLULAR-MATRIX; MAMMARY-GLAND; SIGNAL-TRANSDUCTION; BAX TRANSLOCATION; INDUCED APOPTOSIS; TUMOR-REGRESSION; EPITHELIAL-CELLS	Adhesion of many cell types to the extracellular matrix is essential to maintain their survival. In the absence of integrin-mediated signals, normal epithelial cells undergo a form of apoptosis termed anoikis. It has been proposed that the activation of initiator caspases is an early event in anoikis, resulting in Bid cleavage and cytochrome c release from mitochondria. We have previously demonstrated that the loss of integrin signaling in mammary epithelial cells results in apoptosis and that this is dependent upon translocation of Bax from the cytosol to the mitochondria. In this paper, we ask whether caspases are required for Bax activation and the associated changes within mitochondria. We show that Bax activation occurs extremely rapidly, within 15 min after loss of integrin-mediated adhesion to extracellular matrix. The conformational changes associated with Bax activation are independent of caspases including the initiator caspase-8. We also examined downstream events in the apoptosis program and found that cytochrome c release occurs after a delay of at least 1 h, with subsequent activation of the effector caspase-3. This delay is not due to a requirement for new protein synthesis, since cycloheximide has no effect on the kinetics of Bax activation, cytochrome c release, caspase-3 cleavage, or apoptosis. Together, our data indicate that the cellular decision for anoikis in mammary epithelial cells occurs in the absence of caspase activation. Moreover, although the conformational changes in Bax are rapid and synchronous, the subsequent events occur stochastically and with considerable delays.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Streuli, CH (corresponding author), Univ Manchester, Sch Biol Sci, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.							Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DiPersio CM, 2000, J CELL SCI, V113, P3051; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Ilic D, 1998, J CELL BIOL, V143, P547; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KITTRELL FS, 1992, CANCER RES, V52, P1924; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Marti A, 2001, MECH DEVELOP, V104, P89, DOI 10.1016/S0925-4773(01)00381-1; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; MIYASHITA T, 1995, CELL, V80, P293; Pullan S, 1996, J CELL SCI, V109, P631; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Rehm M, 2002, J BIOL CHEM, V277, P24506, DOI 10.1074/jbc.M110789200; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Sohn BH, 2001, BIOCHEM J, V360, P31, DOI 10.1042/0264-6021:3600031; Song J, 2000, J CLIN INVEST, V106, P1209, DOI 10.1172/JCI10411; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	46	48	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19917	19925		10.1074/jbc.M210337200	http://dx.doi.org/10.1074/jbc.M210337200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12621032	hybrid			2022-12-27	WOS:000183078000046
J	Benach, J; Lee, I; Edstrom, W; Kuzin, AP; Chiang, YW; Acton, TB; Montelione, GT; Hunt, JF				Benach, J; Lee, I; Edstrom, W; Kuzin, AP; Chiang, YW; Acton, TB; Montelione, GT; Hunt, JF			The 2.3-angstrom crystal structure of the shikimate 5-dehydrogenase orthologue YdiB from Escherichia coli suggests a novel catalytic environment for an NAD-dependent dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; X-RAY ANALYSIS; ALCOHOL-DEHYDROGENASE; PROTEIN; ACID; CRYSTALLIZATION; RECOGNITION; CLONING; ENZYME; DEHYDROQUINASE	We present here the 2.3-Angstrom crystal structure of the Escherichia coli YdiB protein, an orthologue of shikimate 5-dehydrogenase. This enzyme catalyzes the reduction of 3-dehydroshikimate to shikimate as part of the shikimate pathway, which is absent in mammals but required for the de novo synthesis of aromatic amino acids, quinones, and folate in many other organisms. In this context, the shikimate pathway has been promoted as a target for the development of antimicrobial agents. The crystal structure of YdiB shows that the protomer contains two alpha/beta domains connected by two alpha-helices, with the N-terminal domain being novel and the C-terminal domain being a Rossmann fold. The NAD(+) cofactor, which co-purified with the enzyme, is bound to the Rossmann domain in an elongated fashion with the nicotinamide ring in the pro-R conformation. Its binding site contains several unusual features, including a cysteine residue in close apposition to the nicotinamide ring and a clamp over the ribose of the adenosine moiety formed by phenylalanine and lysine residues. The structure explains the specificity for NAD versus NADP in different members of the shikimate dehydrogenase family on the basis of variations in the amino acid identity of several other residues in the vicinity of this ribose group. A cavity lined by residues that are 100% conserved among all shikimate dehydrogenases is found between the two domains of YdiB, in close proximity to the hydride acceptor site on the nicotinamide ring. Shikimate was modeled into this site in a geometry such that all of its heteroatoms form high quality hydrogen bonds with these invariant residues. Their strong conservation in all orthologues supports the possibility of developing broad spectrum inhibitors of this enzyme. The nature and disposition of the active site residues suggest a novel reaction mechanism in which an aspartate acts as the general acid/base catalyst during the hydride transfer reaction.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Columbia Univ, NE Struct Genom Consortium, New York, NY 10027 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, NE Struct Genom Consortium, Piscataway, NJ 08854 USA	Columbia University; Columbia University; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Hunt, JF (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	hunt@sid.bio.columbia.edu		Montelione, Gaetano/0000-0002-9440-3059	NIGMS NIH HHS [P50-GM62413] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062413] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANTON IA, 1988, BIOCHEM J, V249, P319, DOI 10.1042/bj2490319; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BONNER CA, 1994, BIOCHEM J, V302, P11, DOI 10.1042/bj3020011; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAIN RB, 1972, BIOCHEM J, V127, pP15; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHAUDHURI S, 1987, METHOD ENZYMOL, V142, P315; CHAUDHURI S, 1985, BIOCHEM J, V226, P217, DOI 10.1042/bj2260217; DAVIES GM, 1994, ANTIMICROB AGENTS CH, V38, P403, DOI 10.1128/AAC.38.2.403; Doublie S, 1996, FEBS LETT, V384, P219, DOI 10.1016/0014-5793(96)00316-X; DOWSETT JR, 1972, BIOCHIM BIOPHYS ACTA, V276, P344, DOI 10.1016/0005-2744(72)90994-1; Ermler U, 2002, STRUCTURE, V10, P1127, DOI 10.1016/S0969-2126(02)00802-X; Eschenburg S, 2002, PLANTA, V216, P129, DOI 10.1007/s00425-002-0908-0; EWART CDC, 1995, ANTIMICROB AGENTS CH, V39, P87, DOI 10.1128/AAC.39.1.87; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; Hoffman SL, 2002, NATURE, V415, P702, DOI 10.1038/415702a; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; INOUE T, 1989, J BACTERIOL, V171, P3115, DOI 10.1128/jb.171.6.3115-3122.1989; Jansson M, 1996, J BIOMOL NMR, V7, P131; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORNVALL H, 1981, P NATL ACAD SCI-BIOL, V78, P4226, DOI 10.1073/pnas.78.7.4226; Jude DA, 1996, BBA-BIOMEMBRANES, V1279, P125, DOI 10.1016/0005-2736(95)00295-2; KARLE IL, 1961, ACTA CRYSTALLOGR, V14, P497, DOI 10.1107/S0365110X61001583; Knop DR, 2001, J AM CHEM SOC, V123, P10173, DOI 10.1021/ja0109444; KROOK M, 1990, BIOCHEMISTRY-US, V29, P738, DOI 10.1021/bi00455a021; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Li K, 1999, BIOTECHNOL BIOENG, V64, P61; Maclean J, 2000, ACTA CRYSTALLOGR D, V56, P512, DOI 10.1107/S0907444900002377; Madsen D, 2002, J APPL CRYSTALLOGR, V35, P137, DOI 10.1107/S0021889802000602; Magalhaes MLB, 2002, PROTEIN EXPRES PURIF, V26, P59, DOI 10.1016/S1046-5928(02)00509-0; McDevitt D, 2002, J APPL MICROBIOL, V92, p28S, DOI 10.1046/j.1365-2672.92.5s1.16.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERSSON B, 1991, EUR J BIOCHEM, V200, P537, DOI 10.1111/j.1432-1033.1991.tb16215.x; RAMASWAMY S, 1994, BIOCHEMISTRY-US, V33, P5230, DOI 10.1021/bi00183a028; Roberts CW, 2002, J INFECT DIS, V185, pS25, DOI 10.1086/338004; Roberts F, 1998, NATURE, V393, P801, DOI 10.1038/31723; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Roszak AW, 2002, STRUCTURE, V10, P493, DOI 10.1016/S0969-2126(02)00747-5; Schonbrunn E, 2001, P NATL ACAD SCI USA, V98, P1376, DOI 10.1073/pnas.98.4.1376; SCOPES RK, 1983, FEBS LETT, V156, P303, DOI 10.1016/0014-5793(83)80517-1; TANAKA N, 1995, J BIOCHEM-TOKYO, V118, P871, DOI 10.1093/jb/118.5.871; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; vanMontfort RLM, 1997, STRUCTURE, V5, P217, DOI 10.1016/S0969-2126(97)00180-9; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; Zhou JJ, 1997, MOL MICROBIOL, V23, P799, DOI 10.1046/j.1365-2958.1997.2681633.x	50	42	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19176	19182		10.1074/jbc.M301348200	http://dx.doi.org/10.1074/jbc.M301348200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12624088	hybrid			2022-12-27	WOS:000182932200061
J	Golemi-Kotra, D; Cha, JY; Meroueh, SO; Vakulenko, SB; Mobashery, S				Golemi-Kotra, D; Cha, JY; Meroueh, SO; Vakulenko, SB; Mobashery, S			Resistance to beta-lactam antibiotics and its mediation by the sensor domain of the transmembrane BlaR signaling pathway in Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-LICHENIFORMIS; METHICILLIN RESISTANCE; PROTEIN; TRANSDUCER; ENZYME	Staphylococci, a leading cause of infections worldwide, have devised two mechanisms for resistance to beta-lactam antibiotics. One is production of beta-lactamases, hydrolytic resistance enzymes, and the other is the expression of penicillin-binding protein 2a (PBP 2a), which is not susceptible to inhibition by beta-lactam antibiotics. The beta-lactam sensor-transducer (BlaR), an integral membrane protein, binds beta-lactam antibiotics on the cell surface and transduces the information to the cytoplasm, where gene expression is derepressed for both beta-lactamase and penicillin-binding protein 2a. The gene for the sensor domain of the sensor-transducer protein (BlaR(S)) of Staphylococcus aureus was cloned, and the protein was purified to homogeneity. It is shown that beta-lactam antibiotics covalently modify the BlaR(S) protein. The protein was shown to contain the unusual carboxylated lysine that activates the active site serine residue for acylation by the beta-lactam antibiotics. The details of the kinetics of interactions of the BlaR(S) protein with a series of beta-lactam antibiotics were investigated. The protein undergoes acylation by beta-lactam antibiotics with microscopic rate constants (k(2)) of 1-26 s(-1), yet the deacylation process was essentially irreversible within one cell cycle. The protein undergoes a significant conformational change on binding with beta-lactam antibiotics, a process that commences at the preacylation complex and reaches its full effect after protein acylation has been accomplished. These conformational changes are likely to be central to the signal transduction events when the organism is exposed to the beta-lactam antibiotic.	Wayne State Univ, Inst Drug Design, Dept Chem, Detroit, MI 48202 USA; Wayne State Univ, Inst Drug Design, Dept Pharmacol, Detroit, MI 48202 USA; Wayne State Univ, Inst Drug Design, Dept Biochem & Mol Biol, Detroit, MI 48202 USA	Wayne State University; Wayne State University; Wayne State University	Mobashery, S (corresponding author), Wayne State Univ, Inst Drug Design, Dept Chem, Detroit, MI 48202 USA.	som@chem.wayne.edu	/N-6611-2013	/0000-0003-1299-6987	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061629] Funding Source: NIH RePORTER; NIAID NIH HHS [AI331790] Funding Source: Medline; NIGMS NIH HHS [GM61629] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Archer GL, 2001, SCIENCE, V291, P1915, DOI 10.1126/science.1059671; Bernat BA, 2001, BIOCHEMISTRY-US, V40, P12712, DOI 10.1021/bi0114832; BOYCE JM, 1997, STAPHYLOCOCCI HUMAN, P309, DOI DOI 10.1002/9781444308464.CH15; Bush K, 1998, ADV EXP MED BIOL, V456, P71; Case D.A., 2002, AMBER, V7; Fung HB, 2001, CLIN THER, V23, P356, DOI 10.1016/S0149-2918(01)80043-6; Golemi D, 2001, P NATL ACAD SCI USA, V98, P14280, DOI 10.1073/pnas.241442898; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; JORIS B, 1990, FEMS MICROBIOL LETT, V70, P107, DOI 10.1016/0378-1097(90)90111-3; KOTRA LP, 2001, BACTERIAL RESISTANCE, P123; KREISWIRTH B, 1993, SCIENCE, V259, P227, DOI 10.1126/science.8093647; Lietz EJ, 2000, BIOCHEMISTRY-US, V39, P4971, DOI 10.1021/bi992681k; Massova I, 1998, ANTIMICROB AGENTS CH, V42, P1; Maveyraud L, 2002, J AM CHEM SOC, V124, P2461, DOI 10.1021/ja016736t; Maveyraud L, 2000, STRUCTURE, V8, P1289, DOI 10.1016/S0969-2126(00)00534-7; McKinney TK, 2001, J BACTERIOL, V183, P6862, DOI 10.1128/JB.183.23.6862-6868.2001; Novick RP, 2001, MICROBES INFECT, V3, P585, DOI 10.1016/S1286-4579(01)01414-9; OLSON ST, 1981, J BIOL CHEM, V256, P1065; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Tien M, 1999, P NATL ACAD SCI USA, V96, P7809, DOI 10.1073/pnas.96.14.7809; Tsiodras S, 2001, LANCET, V358, P207, DOI 10.1016/S0140-6736(01)05410-1; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; Walsh TR, 2001, J CLIN MICROBIOL, V39, P2439, DOI 10.1128/JCM.39.7.2439-2444.2001; WANG PZ, 1991, NUCLEIC ACIDS RES, V19, P4000, DOI 10.1093/nar/19.14.4000; WOODWARDGRAVES K, 1998, BIOCHEM J, V332, P755; Zhang HZ, 2001, SCIENCE, V291, P1962, DOI 10.1126/science.1055144; Zhao GS, 1999, ANTIMICROB AGENTS CH, V43, P1124, DOI 10.1128/AAC.43.5.1124; ZHU YF, 1990, J BACTERIOL, V172, P1137, DOI 10.1128/jb.172.2.1137-1141.1990	30	68	71	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18419	18425		10.1074/jbc.M300611200	http://dx.doi.org/10.1074/jbc.M300611200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12591921	hybrid			2022-12-27	WOS:000182838300108
J	Rochdi, MD; Parent, JL				Rochdi, MD; Parent, JL			G alpha(q)-coupled receptor internalization specifically induced by G alpha(q) signaling - Regulation by EBP50	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CONSTITUTIVE INTERNALIZATION; THROMBOXANE A(2); OPIOID RECEPTOR; DOWN-REGULATION; ACTIVATION; BETA; ENDOCYTOSIS; ALPHA; RHOA	In the present report, we investigated the effect of ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) expression on the agonist-induced internalization of the thromboxane A(2) beta receptor (TPbeta receptor). Interestingly, we found that EBP50 almost completely blocked TPbeta receptor internalization, which could not be reversed by overexpression of G protein-coupled receptor (GPCR) kinases and arrestins. Because we recently demonstrated that EBP50 can bind to and inhibit Galpha(q), we next studied whether Galpha(q) signaling could induce TPbeta receptor internalization, addressing the long standing question about the relationship between GPCR signaling and their internalization. Expression of a constitutively active Galpha(q) mutant (Galpha(q)-R183C) resulted in a robust internalization of the TPbeta receptor, which was unaffected by expression of dominant negative mutants of arrestin-2 and -3, but inhibited by expression of EBP50 or dynamin-K44A, a dominant negative mutant of dynamin. Phospholipase Cbeta and protein kinase C did not appear to significantly contribute to internalization of the TPbeta receptor, suggesting that Galpha(q) induces receptor internalization through a phospholipase Cbeta- and protein kinase C-independent pathway. Surprisingly, there appears to be specificity in Galpha protein-mediated GPCR internalization. Galpha(q)-R183C also induced the internalization of CXCR4 (Galpha(q)-coupled), whereas it failed to do so for the beta(2)-adrenergic receptor (Galpha(s)-coupled). Moreover, Galpha(s)-R201C, a constitutively active form of Galpha(s), had no effect on internalization of the TPbeta, CXCR4, and beta(2)-adrenergic receptors. Thus, we showed that Galpha protein signaling can lead to internalization of GPCRs, with specificity in both the Galpha proteins and GPCRs that are involved. Furthermore, a new function has been described for EBP50 in its capacity to inhibit receptor endocytosis.	Univ Sherbrooke, Fac Med, Serv Rhumatol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Ctr Rech Clin, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke; University of Sherbrooke	Parent, JL (corresponding author), Univ Sherbrooke, Fac Med, Serv Rhumatol, 3001,12 Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.							BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; Booden MA, 2002, MOL CELL BIOL, V22, P4053, DOI 10.1128/MCB.22.12.4053-4061.2002; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cavalli V, 2001, FEBS LETT, V498, P190, DOI 10.1016/S0014-5793(01)02484-X; Chikumi H, 2002, J BIOL CHEM, V277, P27130, DOI 10.1074/jbc.M204715200; Conchon S, 1998, AM J PHYSIOL-ENDOC M, V274, pE336, DOI 10.1152/ajpendo.1998.274.2.E336; da Rocha AB, 2002, ONCOLOGIST, V7, P17, DOI 10.1634/theoncologist.7-1-17; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Li J, 2001, MOL PHARMACOL, V60, P1064, DOI 10.1124/mol.60.5.1064; Miserey-Lenkei S, 2002, J BIOL CHEM, V277, P5891, DOI 10.1074/jbc.M108398200; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; Parent JL, 2001, J BIOL CHEM, V276, P7079, DOI 10.1074/jbc.M009375200; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Rochdi MD, 2002, J BIOL CHEM, V277, P40751, DOI 10.1074/jbc.M207910200; Sakurada S, 2001, AM J PHYSIOL-CELL PH, V281, pC571, DOI 10.1152/ajpcell.2001.281.2.C571; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; Tsao P, 2001, TRENDS PHARMACOL SCI, V22, P91, DOI 10.1016/S0165-6147(00)01620-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Xiang B, 2001, J BIOL CHEM, V276, P4709, DOI 10.1074/jbc.M006187200; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200	29	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17827	17837		10.1074/jbc.M210319200	http://dx.doi.org/10.1074/jbc.M210319200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626493	hybrid			2022-12-27	WOS:000182838300031
J	Chen, CY; Luo, SC; Kuo, CF; Lin, YS; Wu, JJ; Lin, MT; Liu, CC; Jeng, WY; Chuang, WJ				Chen, CY; Luo, SC; Kuo, CF; Lin, YS; Wu, JJ; Lin, MT; Liu, CC; Jeng, WY; Chuang, WJ			Maturation processing and characterization of streptopain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR CYSTEINE PROTEASE; GROUP-A STREPTOCOCCUS; PYROGENIC EXOTOXIN-B; PAPAIN PRECURSOR; VIRULENCE FACTOR; PROTEOLYTIC ACTIVITY; ENDOTHELIAL-CELLS; IN-VITRO; EXPRESSION; ZYMOGEN	Streptopain is a cysteine protease expressed by Streptococcus pyogenes. To study the maturation mechanism of streptopain, wild-type and Q186N, C192S, H340R, N356D and W357A mutant proteins were expressed in Escherichia coli and purified to homogeneity. Proteolytic analyses showed that the maturation of prostreptococcal pyrogenic exotoxin B zymogen (pro-SPE B) involves eight intermediates with a combination of cis- and trans-processing. Based on the sequences of these intermediates, the substrate specificity of streptopain favors a hydrophobic residue at the P2 site. The relative autocatalytic rates of these mutants exhibited the order Q186N > W357A > N356D, C192S, H340R. Interestingly, the N356D mutant containing protease activity could not be converted into the 28-kDa form by autoprocessing. This observation suggested that Asn(356) might involve the cis- processing of the propeptide. In addition, the maturation rates of pro-SPE B with trypsin and plasmin were 10- and 60-fold slower than that with active mature streptopain. These findings indicate that active mature streptopain likely plays the most important role in the maturation of pro-SPE B under physiological conditions.	Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Med Technol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Pediat, Tainan 701, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University	Chuang, WJ (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Biochem, 1 Univ Rd, Tainan 701, Taiwan.	wjcnmr@mail.ncku.edu.tw	Wu, Jiunn-Jong/E-6075-2011; Luo, Shih-Chi/C-1042-2011	Luo, Shih-Chi/0000-0001-7723-3230				Aiyar A, 1996, Methods Mol Biol, V57, P177; Berquin IM, 1996, ADV EXP MED BIOL, V389, P281; BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; Burns EH, 1998, MICROB PATHOGENESIS, V24, P333, DOI 10.1006/mpat.1998.0204; Doran JD, 1999, EUR J BIOCHEM, V263, P145, DOI 10.1046/j.1432-1327.1999.00473.x; GORDON VM, 1994, INFECT IMMUN, V62, P333, DOI 10.1128/IAI.62.2.333-340.1994; Groves MR, 1998, PROTEINS, V32, P504, DOI 10.1002/(SICI)1097-0134(19980901)32:4<504::AID-PROT8>3.0.CO;2-F; Gubba S, 2000, INFECT IMMUN, V68, P3716, DOI 10.1128/IAI.68.6.3716-3719.2000; Gubba S, 1998, INFECT IMMUN, V66, P765, DOI 10.1128/IAI.66.2.765-770.1998; HAUSER AR, 1990, J BACTERIOL, V172, P4536, DOI 10.1128/jb.172.8.4536-4542.1990; HOGE CW, 1993, JAMA-J AM MED ASSOC, V269, P384, DOI 10.1001/jama.269.3.384; Kagawa TF, 2000, P NATL ACAD SCI USA, V97, P2235, DOI 10.1073/pnas.040549997; KAPUR V, 1993, MICROB PATHOGENESIS, V15, P327, DOI 10.1006/mpat.1993.1083; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; Kazmi SU, 2001, INFECT IMMUN, V69, P4988, DOI 10.1128/IAI.69.8.4988-4995.2001; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kuo CF, 1999, INFECT IMMUN, V67, P126, DOI 10.1128/IAI.67.1.126-130.1999; Kuo CF, 1998, INFECT IMMUN, V66, P3931, DOI 10.1128/IAI.66.8.3931-3935.1998; LIU TY, 1965, J BIOL CHEM, V240, P1138; Lukomski S, 1999, INFECT IMMUN, V67, P1779; Matsuka YV, 1999, INFECT IMMUN, V67, P4326, DOI 10.1128/IAI.67.9.4326-4333.1999; McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; Molinari G, 1999, CURR OPIN MICROBIOL, V2, P56, DOI 10.1016/S1369-5274(99)80010-1; Musser JM, 1996, INFECT IMMUN, V64, P1913, DOI 10.1128/IAI.64.6.1913-1917.1996; Nomizu M, 2001, J BIOL CHEM, V276, P44551, DOI 10.1074/jbc.M106306200; OHARANEMOTO Y, 1994, CAN J MICROBIOL, V40, P930, DOI 10.1139/m94-149; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; POONKING R, 1993, J EXP MED, V178, P759, DOI 10.1084/jem.178.2.759; *QIAGEN INC, 1992, QIAGEN MAN; Rozman J, 1999, FEBS LETT, V459, P358, DOI 10.1016/S0014-5793(99)01302-2; Stockbauer KE, 1999, P NATL ACAD SCI USA, V96, P242, DOI 10.1073/pnas.96.1.242; TAI JY, 1976, J BIOL CHEM, V251, P1955; Tarui T, 2002, J BIOL CHEM, V277, P33564, DOI 10.1074/jbc.M205514200; TRAVIS J, 1995, TRENDS MICROBIOL, V3, P405, DOI 10.1016/S0966-842X(00)88988-X; Tsai PJ, 1998, INFECT IMMUN, V66, P1460, DOI 10.1128/IAI.66.4.1460-1466.1998; Turk B, 1997, BIOL CHEM, V378, P141; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1995, J BIOL CHEM, V270, P10838, DOI 10.1074/jbc.270.18.10838; VERNET T, 1993, PROTEIN ENG, V6, P213, DOI 10.1093/protein/6.2.213	41	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17336	17343		10.1074/jbc.M209038200	http://dx.doi.org/10.1074/jbc.M209038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621045	hybrid			2022-12-27	WOS:000182818600119
J	Kumar, S; Scott, EE; Liu, H; Halpert, JR				Kumar, S; Scott, EE; Liu, H; Halpert, JR			A rational approach to re-engineer cytochrome P4502B1 regioselectivity based on the crystal structure of cytochrome P4502C5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SUBSTRATE RECOGNITION SITES; AMINO-ACID; HYDROXYLASE-ACTIVITY; CATALYTIC PROPERTIES; MEMBRANE-BINDING; MOLECULAR-BASIS; SPECIFICITY; RESIDUES; ENZYME	The regioselectivity for progesterone hydroxylation by cytochrome P450 2B1 was re-engineered based on the x-ray crystal structure of cytochrome P450 2C5. 2B1 is a high K-m progesterone 16alpha-hydroxylase, whereas 2C5 is a low K-m progesterone 21-hydroxylase. Initially, nine individual 2B1 active-site residues were changed to the corresponding 2C5 residues, and the mutants were purified from an Escherichia coli expression system and assayed for progesterone hydroxylation. At 150 muM progesterone, I114A, F297G, and V363L showed 5-15% of the 21-hydroxylase activity of 2C5, whereas F206V showed high activity for an unknown product and a 13-fold decrease in K-m. Therefore, a quadruple mutant, I114A/F206V/F297G/V363L (Q), was constructed that showed 60% of 2C5 progesterone 21-hydroxylase activity and 57% regioselectivity. Based on their 2C5-like testosterone hydroxylation profiles, S294D and I477F alone and in combination were added to the quadruple mutant. All three mutants showed enhanced regioselectivity (70%) for progesterone 21-hydroxylation, whereas only Q/I477F had a higher k(cat). Finally, the remaining three single mutants, V103I, V367L, and G478V, were added to Q/I477F and Q/S294D/I477F, yielding seven additional multiple mutants. Among these, Q/V103I/S294D/I477F showed the highest k(cat) (3-fold higher than that of 2C5) and 80% regioselectivity for progesterone 21-hydroxylation. Docking of progesterone into a three-dimensional model of this mutant indicated that 21-hydroxylation is favored. In conclusion, a systematic approach to convert P450 regioselectivity across subfamilies suggests that active-site residues are mainly responsible for regioselectivity differences between 2B1 and 2C5 and validates the reliability of 2B1 models based on the crystal structure of 2C5.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Kumar, S (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd, Galveston, TX 77555 USA.	sakumar@utmb.edu			NIEHS NIH HHS [ES03619, ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES003619] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Afzelius L, 2001, MOL PHARMACOL, V59, P909, DOI 10.1124/mol.59.4.909; CIACCIO PJ, 1989, ARCH BIOCHEM BIOPHYS, V271, P284, DOI 10.1016/0003-9861(89)90279-8; Cirino PC, 2002, CURR OPIN CHEM BIOL, V6, P130, DOI 10.1016/S1367-5931(02)00305-8; Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; Domanski TL, 1999, J PHARMACOL EXP THER, V290, P1141; Domanski TL, 2001, CURR DRUG METAB, V2, P117, DOI 10.2174/1389200013338612; Domanski TL, 2001, ARCH BIOCHEM BIOPHYS, V394, P21, DOI 10.1006/abbi.2001.2504; Farinas ET, 2001, CURR OPIN BIOTECH, V12, P545, DOI 10.1016/S0958-1669(01)00261-0; GOLDSTEIN JA, 1994, PHARMACOGENETICS, V4, P285, DOI 10.1097/00008571-199412000-00001; GOTOH O, 1992, J BIOL CHEM, V267, P83; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; Harlow GR, 1997, BBA-PROTEIN STRUCT M, V1338, P259, DOI 10.1016/S0167-4838(96)00209-9; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HE YA, 1994, BIOCHEMISTRY-US, V33, P4419, DOI 10.1021/bi00180a040; He YQ, 1996, ARCH BIOCHEM BIOPHYS, V335, P152, DOI 10.1006/abbi.1996.0493; He YQ, 1998, ARCH BIOCHEM BIOPHYS, V350, P333, DOI 10.1006/abbi.1997.0516; Hoch U, 2000, J BIOL CHEM, V275, P26952; Ibeanu GC, 1996, J BIOL CHEM, V271, P12496, DOI 10.1074/jbc.271.21.12496; JUVONEN RO, 1991, J BIOL CHEM, V266, P16431; KEDZIE KM, 1991, J BIOL CHEM, V266, P22515; Kobayashi Y, 1998, DRUG METAB DISPOS, V26, P1026; Lewis DFV, 2002, J INORG BIOCHEM, V91, P502, DOI 10.1016/S0162-0134(02)00429-4; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; Luo Zongshu, 1994, Archives of Biochemistry and Biophysics, V309, P52; Miles CS, 2000, BBA-PROTEIN STRUCT M, V1543, P383, DOI 10.1016/S0167-4838(00)00236-3; Nakayama K, 2001, J BIOL CHEM, V276, P31459, DOI 10.1074/jbc.M103943200; Negishi M, 1996, FASEB J, V10, P683, DOI 10.1096/fasebj.10.7.8635685; Negishi M, 1996, BIOCHIMIE, V78, P685, DOI 10.1016/S0300-9084(97)82525-4; OMURA T, 1964, J BIOL CHEM, V239, P2379; Parikh A, 1999, BIOCHEMISTRY-US, V38, P5283, DOI 10.1021/bi990142+; PAULSEN MD, 1992, J COMPUT AID MOL DES, V6, P449, DOI 10.1007/BF00130396; PAULSEN MD, 1991, PROTEINS, V11, P184, DOI 10.1002/prot.340110304; Pikuleva IA, 2001, BIOCHEMISTRY-US, V40, P7621, DOI 10.1021/bi010193i; Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898; Poulos Thomas L., 1995, P125; POULOS TL, 1985, J BIOL CHEM, V260, P6122; Scott EE, 2001, ARCH BIOCHEM BIOPHYS, V395, P57, DOI 10.1006/abbi.2001.2574; Scott EE, 2002, CHEM RES TOXICOL, V15, P1407, DOI 10.1021/tx020057u; Spatzenegger M, 2003, J PHARMACOL EXP THER, V304, P477, DOI 10.1124/jpet.102.043323; Spatzenegger M, 2001, MOL PHARMACOL, V59, P475, DOI 10.1124/mol.59.3.475; Strobel SM, 1997, BIOCHEMISTRY-US, V36, P11697, DOI 10.1021/bi9710176; SZKLARZ GD, 1995, BIOCHEMISTRY-US, V34, P14312, DOI 10.1021/bi00044a008; Tsao CC, 2001, BIOCHEMISTRY-US, V40, P1937, DOI 10.1021/bi001678u; Uno T, 1997, BIOCHEMISTRY-US, V36, P3193, DOI 10.1021/bi962654j; Waller CL, 1996, DRUG METAB DISPOS, V24, P203; Williams D, 2000, PERFORM RES, V5, P131	47	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17178	17184		10.1074/jbc.M212515200	http://dx.doi.org/10.1074/jbc.M212515200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609983	hybrid			2022-12-27	WOS:000182818600098
J	Leung, YM; Kang, YH; Gao, XD; Xia, FZ; Xie, HL; Sheu, L; Tsuk, S; Lotan, I; Tsushima, RG; Gaisano, HY				Leung, YM; Kang, YH; Gao, XD; Xia, FZ; Xie, HL; Sheu, L; Tsuk, S; Lotan, I; Tsushima, RG; Gaisano, HY			Syntaxin 1A binds to the cytoplasmic C terminus of Kv2.1 to regulate channel gating and trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT K+ CHANNELS; PANCREATIC BETA-CELLS; INSULIN-SECRETION; CALCIUM CHANNELS; CA2+ CHANNELS; SMOOTH-MUSCLE; PROTEINS; EXOCYTOSIS; EXPRESSION; SNAP-25	Voltage-gated K+ (Kv) 2.1 is the dominant Kv channel that controls membrane repolarization in rat islet beta-cells and downstream insulin exocytosis. We recently showed that exocytotic SNARE protein SNAP-25 directly binds and modulates rat islet beta-cell Kv 2.1 channel protein at the cytoplasmic N terminus. We now show that SNARE protein syntaxin 1A (Syn-1A) binds and modulates rat islet beta-cell Kv2.1 at its cytoplasmic C terminus (Kv2.1C). In HEK293 cells overexpressing Kv2.1, we observed identical effects of channel inhibition by dialyzed GST-Syn-1A, which could be blocked by Kv2.1C domain proteins (C1: amino acids 412-633, C2: amino acids 634-853), but not the Kv2.1 cytoplasmic N terminus (amino acids 1-182). This was confirmed by direct binding of GST-Syn-1A to the Kv2.1C1 and C2 domains proteins. These findings are in contrast to our recent report showing that Syn-1A binds and modulates the cytoplasmic N terminus of neuronal Kv1.1 and not by its C terminus. Co-expression of Syn-1A in Kv2.1-expressing HEK293 cells inhibited Kv2.1 surfacing, which caused a reduction of Kv2.1 current density. In addition, Syn-1A caused a slowing of Kv2.1 current activation and reduction in the slope factor of steady-state inactivation, but had no affect on inactivation kinetics or voltage dependence of activation. Taken together, SNAP-25 and Syn-1A mediate secretion not only through its participation in the exocytotic SNARE complex, but also by regulating membrane potential and calcium entry through their interaction with Kv and Ca2(+) channels. In contrast to Ca2+ channels, where these SNARE proteins act on a common synprint site, the SNARE proteins act not only on distinct sites within a Kv channel, but also on distinct sites between different Kv channel families.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Tel Aviv Univ, Sackler Sch Med, Dept Physiol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Pharmacol, IL-69978 Tel Aviv, Israel	University of Toronto; University of Toronto; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Tsushima, RG (corresponding author), Univ Toronto, Dept Med, Med Sci Bldg,Rm 7226,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	r.tsushima@utoronto.ca			NIDDK NIH HHS [DK55160] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK055160] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; Fili O, 2001, J NEUROSCI, V21, P1964, DOI 10.1523/JNEUROSCI.21-06-01964.2001; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENQUIN JC, 1979, BIOCHIM BIOPHYS ACTA, V587, P579, DOI 10.1016/0304-4165(79)90010-2; Hille B., 1992, IONIC CHANNELS EXCIT, V2 ed, P115; Jarvis SE, 2001, J NEUROSCI, V21, P2939, DOI 10.1523/JNEUROSCI.21-09-02939.2001; Ji JZ, 2002, DIABETES, V51, P1425, DOI 10.2337/diabetes.51.5.1425; Ji JZ, 2002, J BIOL CHEM, V277, P20195, DOI 10.1074/jbc.M201034200; Ji JZ, 2002, GASTROENTEROLOGY, V122, P994, DOI 10.1053/gast.2002.32412; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; MacDonald PE, 2002, J BIOL CHEM, V277, P44938, DOI 10.1074/jbc.M205532200; MacDonald PE, 2002, MOL ENDOCRINOL, V16, P2452, DOI 10.1210/me.2002-0058; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; Michaelevski L, 2002, J BIOL CHEM, V277, P34909, DOI 10.1074/jbc.M203943200; Nichols CG, 2002, AM J PHYSIOL-ENDOC M, V283, pE403, DOI 10.1152/ajpendo.00168.2002; Rettig J, 2002, SCIENCE, V298, P781, DOI 10.1126/science.1075375; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Roe MW, 1996, J BIOL CHEM, V271, P32241, DOI 10.1074/jbc.271.50.32241; Schultz JH, 2001, CIRC RES, V88, P483, DOI 10.1161/01.RES.88.5.483; Seagar M, 1998, J BIOENERG BIOMEMBR, V30, P347, DOI 10.1023/A:1021937605818; SMITH PA, 1990, J GEN PHYSIOL, V95, P1041, DOI 10.1085/jgp.95.6.1041; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Xu CL, 1999, AM J PHYSIOL-GASTR L, V277, pG1055, DOI 10.1152/ajpgi.1999.277.5.G1055; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978	27	107	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17532	17538		10.1074/jbc.M213088200	http://dx.doi.org/10.1074/jbc.M213088200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621036	hybrid			2022-12-27	WOS:000182818600142
J	Li, XL; Gould, SJ				Li, XL; Gould, SJ			The dynamin-like GTPase DLP1 is essential for peroxisome division and is recruited to peroxisomes in part by PEX11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; PLECKSTRIN HOMOLOGY DOMAIN; SACCHAROMYCES-CEREVISIAE; MAMMALIAN-CELLS; ENDOPLASMIC-RETICULUM; BIOGENESIS DISORDERS; PROLIFERATION; IDENTIFICATION; DEFICIENCY; ABUNDANCE	Peroxisome division involves the conserved PEX11 peroxisomal membrane proteins and in yeast has been shown to require Vps1p, a dynamin-like protein. We show here that DLP1, the human homolog of the yeast DNM1 and VPS1 genes, plays an important role in peroxisome division in human cells. Disruption of DLP1 function by either RNA interference or overexpressing dominant negative DLP1 mutants causes a dramatic reduction in peroxisome abundance, although overexpression of functional DLP1 has no effect on peroxisome abundance. Overexpression of PEX11 induces peroxisome division in a multistep process involving elongation of preexisting peroxisomes followed by their division. We find that DLP1 is dispensable for the first phase of this process but essential for the second. Furthermore, we show that DLP1 associates with peroxisomes and that PEX11 overexpression recruits DLP1 to peroxisome membranes. However, we were unable to detect physical interaction between PEX11 and DLP1, and the stoichiometry of PEX11 and peroxisome-associated DLP1 was far less than 1:1. Based on these and other aspects, we propose that DLP1 performs an essential but transient role in peroxisome division and that PEX11 promotes peroxisome division by recruiting DLP1 to peroxisome membranes through an indirect mechanism.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.		Li, Xiaoling/A-2994-2015	Li, Xiaoling/0000-0001-5920-7784				Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Brachmann CB, 1998, YEAST, V14, P115; Chang CC, 1999, J CELL SCI, V112, P1579; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; Danino D, 2001, CURR OPIN CELL BIOL, V13, P454, DOI 10.1016/S0955-0674(00)00236-2; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ERDMANN R, 1995, J CELL BIOL, V128, P509, DOI 10.1083/jcb.128.4.509; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gurvitz A, 2001, J BIOL CHEM, V276, P31825, DOI 10.1074/jbc.M105989200; Guthrie C, 1991, GUIDE YEAST GENETICS; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Jones JM, 2000, BIOCHEM BIOPH RES CO, V275, P233, DOI 10.1006/bbrc.2000.3285; Kamimoto T, 1998, J BIOL CHEM, V273, P1044, DOI 10.1074/jbc.273.2.1044; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Li XL, 2002, MOL CELL BIOL, V22, P4358, DOI 10.1128/MCB.22.12.4358-4365.2002; Li XL, 2002, MOL CELL BIOL, V22, P8226, DOI 10.1128/MCB.22.23.8226-8240.2002; Li XL, 2002, J CELL BIOL, V156, P643, DOI 10.1083/jcb.200112028; Lorenz P, 1998, EMBO J, V17, P3542, DOI 10.1093/emboj/17.13.3542; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; MARSHALL PA, 1995, J CELL BIOL, V129, P345, DOI 10.1083/jcb.129.2.345; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; MIHALIK SJ, 1992, PROG CLIN BIOL RES, V357, P239; Passreiter M, 1998, J CELL BIOL, V141, P373, DOI 10.1083/jcb.141.2.373; Pitts KR, 1999, MOL BIOL CELL, V10, P4403, DOI 10.1091/mbc.10.12.4403; POLLTHE BT, 1988, AM J HUM GENET, V42, P422; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Sacksteder KA, 2000, ANNU REV GENET, V34, P623, DOI 10.1146/annurev.genet.34.1.623; SAKAI Y, 1995, J BACTERIOL, V177, P6773, DOI 10.1128/jb.177.23.6773-6781.1995; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Schrader M, 1998, J BIOL CHEM, V273, P29607, DOI 10.1074/jbc.273.45.29607; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; SLAWECKI ML, 1995, J CELL SCI, V108, P1817; South ST, 2000, J CELL BIOL, V149, P1345, DOI 10.1083/jcb.149.7.1345; South ST, 2001, P NATL ACAD SCI USA, V98, P12027, DOI 10.1073/pnas.221289498; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; Yoon Y, 1998, J CELL BIOL, V140, P779, DOI 10.1083/jcb.140.4.779	44	167	174	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17012	17020		10.1074/jbc.M212031200	http://dx.doi.org/10.1074/jbc.M212031200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12618434	hybrid			2022-12-27	WOS:000182818600077
J	Lievens, PMJ; Liboi, E				Lievens, PMJ; Liboi, E			The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-MYELOMA; PROLIFERATION; SPECIFICITY; DWARFISM; SULFATE	The K650E substitution in the fibroblast growth factor receptor 3 (FGFR3) causes constitutive tyrosine kinase activity of the receptor and is associated to the lethal skeletal disorder, thanatophoric dysplasia type II (TDII). The underlying mechanisms of how the activated FGFR3 causes TDII remains to be elucidated. FGFR3 is a transmembrane glycoprotein, which is synthesized through three isoforms, with various degrees of N-glycosylation. We have studied whether immature FGFR3 isoforms mediate the abnormal signaling in TDII. We show that synthesis of TDII-FGFR3 presents two phosphorylated forms: the immature non-glycosylated 98-kDa peptides and the intermediate 120-kDa glycomers. The mature, fully glycosylated 130-kDa forms, detected in wild type FGFR3, are not present in TDII. Endoglycosidase H cleaves the sugars on TDII intermediates thus indicating their intracellular localization in the endoplasmic reticulum. Accordingly, TDII-FGFR3-GFP co-localizes with calreticulin in the endoplasmic reticulum. Furthermore, following TDII transfection, signal transducer and activator of transcription 1 (STAT1) is phosphorylated in the absence of FGFR3 ligand and brefeldin A does not inhibit its activation. On the contrary, the cell membrane-anchored FRS2alpha protein is not activated in TDII cells. The opposite situation is observed in stable TDII cell clones where, despite the presence of phosphorylated mature receptor, STAT1 is not activated whereas FRS2alpha is phosphorylated. We speculate that the selection process favors cells defective in STAT1 activation through the 120-kDa TDII-FGFR3, thus allowing growth of the TDII cell clones. Accordingly, apoptosis is observed following TDII- FGFR3 transfection. These observations highlight the importance of the immature TDII- FGFR3 proteins as mediators of an abnormal signaling in TDII.	Univ Verona, Sch Med, Dept Neurol Sci, Div Biochem, I-37134 Verona, Italy	University of Verona	Liboi, E (corresponding author), Univ Verona, Sch Med, Dept Neurol Sci, Div Biochem, I-37134 Verona, Italy.	elio.liboi@univr.it			Telethon [GP0164Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Iwata T, 2000, HUM MOL GENET, V9, P1603, DOI 10.1093/hmg/9.11.1603; KEEGAN K, 1991, ONCOGENE, V6, P2229; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; MALIKA S, 1999, GENE DEV, V13, P1361; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; O'Brien MA, 2001, BIOTECHNIQUES, V30, P886, DOI 10.2144/01304pf01; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; Ronchetti D, 2001, ONCOGENE, V20, P3553, DOI 10.1038/sj.onc.1204465; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SILLENCE DO, 1979, AM J PATHOL, V96, P813; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Webster MK, 1996, MOL CELL BIOL, V16, P4081; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899	28	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17344	17349		10.1074/jbc.M212710200	http://dx.doi.org/10.1074/jbc.M212710200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624096	hybrid			2022-12-27	WOS:000182818600120
J	Tseng, CN; Zhang, LL; Cascio, M; Wang, ZZ				Tseng, CN; Zhang, LL; Cascio, M; Wang, ZZ			Calcium plays a critical role in determining the acetylcholine receptor-clustering activities of alternatively spliced isoforms of agrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; VERTEBRATE NEUROMUSCULAR-JUNCTION; ALPHA-DYSTROGLYCAN; SYNAPTIC DIFFERENTIATION; POSTSYNAPTIC APPARATUS; MUSCLE-FIBERS; MESSENGER-RNA; CELL-SURFACE; BINDING; PROTEIN	Neural agrin, an extracellular matrix protein secreted by motor neurons, plays a key role in clustering of nicotinic acetylcholine receptors (AChR) on postsynaptic membranes of the neuromuscular junction. The action of agrin is critically dependent on an eight-amino acid insert (z8 insert) in the third of three consecutive laminin-like globular (G3) domains near the C terminus of neural agrin. Alternatively spliced agrin isoforms in non-neural tissue including muscle lack the z8 insert and are biologically inactive. Extracellular calcium has been shown to be imperative for the AChR-clustering activity of neural agrin. It is unclear, however, whether calcium preferentially interacts with the neural isoform or whether it acts solely as an intracellular messenger that mediates agrin signaling. Here, we report the G3 domain of rat neural agrin (AgG3z8) expressed in Pichia pastoris promoted AChR clustering on surface of C2C12 myotubes in a calcium-dependent manner. Direct binding of calcium to AgG3z8 was demonstrated by trypsin digestion and thermal denaturation experiments. Moreover, calcium induced a significant change in the conformation of AgG3z8, and the effect was correlated with an enhanced binding affinity of the protein to muscle receptor. Mutation of calcium-binding residues in the G3 domain diminished the conformational change of neural agrin, reduced its binding affinity to muscle membrane, and inhibited AChR-clustering activity. Conversely, the G3 domain of muscle agrin (AgG3z0) displayed little structural change in the presence of calcium, bound poorly to muscle surface, and was inactive in AChR-clustering assays. We conclude that distinct interactions of the G3 domain with calcium determine the biological activities of alternatively spliced agrin isoforms during synapse formation.	Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, ZZ (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurobiol, 3500 Terrace St,E1440 BST, Pittsburgh, PA 15261 USA.		Tseng, Chao-Neng/A-3798-2014	Tseng, Chao-Neng/0000-0001-9972-7987	NCRR NIH HHS [1S10RR11998] Funding Source: Medline; NINDS NIH HHS [NS38301] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038301] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexandrescu AT, 2001, J BIOMOL NMR, V20, P295, DOI 10.1023/A:1011256008944; BLOCH RJ, 1983, J NEUROSCI, V3, P2670; Borges LS, 2002, J NEUROBIOL, V50, P69, DOI 10.1002/neu.10020; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; Bowen DC, 1996, J NEUROCHEM, V66, P2580; CAMPANELLI JT, 1991, CELL, V67, P909, DOI 10.1016/0092-8674(91)90364-5; Campanelli JT, 1996, DEVELOPMENT, V122, P1663; Cornish T, 1999, J CELL SCI, V112, P1213; Denzer AJ, 1997, CELL TISSUE RES, V290, P357, DOI 10.1007/s004410050941; Deyst KA, 1998, DEV BRAIN RES, V110, P185, DOI 10.1016/S0165-3806(98)00105-9; Escher G, 1996, J CELL SCI, V109, P2959; FALLON JR, 1994, TRENDS NEUROSCI, V17, P469, DOI 10.1016/0166-2236(94)90135-X; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Glass DJ, 1996, COLD SPRING HARB SYM, V61, P435; Glass DJ, 1997, CURR OPIN NEUROBIOL, V7, P379, DOI 10.1016/S0959-4388(97)80066-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hoch W, 1999, EUR J BIOCHEM, V265, P1, DOI 10.1046/j.1432-1327.1999.00765.x; HOCH W, 1994, EMBO J, V13, P2814, DOI 10.1002/j.1460-2075.1994.tb06575.x; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; HUNTER WM, 1964, BIOCHEM J, V91, P43, DOI 10.1042/bj0910043; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Jones G, 1999, J NEUROSCI, V19, P3376; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Megeath LJ, 1998, J NEUROSCI, V18, P672; Meier T, 1997, J NEUROSCI, V17, P6534; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OToole JJ, 1996, P NATL ACAD SCI USA, V93, P7369, DOI 10.1073/pnas.93.14.7369; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SHADIACK AM, 1991, J NEUROBIOL, V22, P617, DOI 10.1002/neu.480220607; SMITH MA, 1994, NEURON, V12, P795, DOI 10.1016/0896-6273(94)90332-8; Sreerama N, 2000, ANAL BIOCHEM, V287, P243, DOI 10.1006/abio.2000.4879; Sreerama N, 2001, ANAL BIOCHEM, V299, P271, DOI 10.1006/abio.2001.5420; STONE DM, 1995, J NEUROSCI, V15, P6767; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; TSEN GS, 1995, J BIOL CHEM, V270, P15934, DOI 10.1074/jbc.270.27.15934; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WALLACE BG, 1988, J CELL BIOL, V107, P267, DOI 10.1083/jcb.107.1.267	47	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17236	17245		10.1074/jbc.M300282200	http://dx.doi.org/10.1074/jbc.M300282200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621054	hybrid			2022-12-27	WOS:000182818600106
J	Zhu, M; Fink, AL				Zhu, M; Fink, AL			Lipid binding inhibits alpha-synuclein fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; SECONDARY STRUCTURE; AMPHIPATHIC HELIX; PROTEIN; MEMBRANE; ASSOCIATION; FAMILY	Parkinson's disease is the second most common neurodegenerative disorder, and the cause is unknown; however, substantial evidence implicates the aggregation of alpha-synuclein as a critical factor in the etiology of the disease. alpha-Synuclein is a relatively abundant brain protein of unknown function, and the purified protein is intrinsically unfolded. The amino acid sequence has seven repeats with an apolipoprotein lipid-binding motif, which are predicted to form amphiphilic helices. We have investigated the interaction of alpha-synuclein with lipid vesicles of different sizes and properties by monitoring the effects on the conformation of the protein and the kinetics of fibrillation. The nature of the interaction of alpha-synuclein with vesicles was highly dependent on the phospholipid composition, the ratio of alpha-synuclein to phospholipid, and the size of the vesicles. The strongest interactions were between alpha-synuclein and vesicles composed of 1,2-dipalmitoyl-sn-glycero-3-phosphate/1,2-dipalmitoyl-sn-glycero-3-phosphocholine and 1,2-dipalmitoyl-sn-glycero-3-phospho-RAC-(1-glycerol)/1,2-dipalmitoyl-sn- glycero-3-phosphocholine and involved formation of helical structure in alpha-synuclein. A strong correlation was observed between the induction of alpha-helix in alpha-synuclein and the inhibition of fibril formation. Thus, helical, membrane-bound alpha-synuclein is unlikely to contribute to aggregation and fibrillation. Given that a significant fraction of alpha-synuclein is membrane-bound in dopaminergic neurons, this observation has significant physiological significance.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039985] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39985] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P8397, DOI 10.1021/bi0105983; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1992, J LIPID RES, V33, P141; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Uversky VN, 2002, FEBS LETT, V515, P99, DOI 10.1016/S0014-5793(02)02446-8; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Uversky VN, 2001, FEBS LETT, V500, P105, DOI 10.1016/S0014-5793(01)02597-2; Uversky VN, 2001, FEBS LETT, V509, P31, DOI 10.1016/S0014-5793(01)03121-0; Walde P, 2001, BIOMOL ENG, V18, P143, DOI 10.1016/S1389-0344(01)00088-0	24	249	253	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16873	16877		10.1074/jbc.M210136200	http://dx.doi.org/10.1074/jbc.M210136200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621030	hybrid			2022-12-27	WOS:000182818600058
J	Molinari, P; Ambrosio, C; Riitano, D; Sbraccia, M; Gro, MC; Costa, T				Molinari, P; Ambrosio, C; Riitano, D; Sbraccia, M; Gro, MC; Costa, T			Promiscuous coupling at receptor-G alpha fusion proteins - The receptor of one covalent complex interacts with the alpha-subunit of another	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; SIGNAL-TRANSDUCTION; GTPASE ACTIVITY; BETA(2)-ADRENERGIC RECEPTOR; GAMMA-SUBUNIT; ACTIVATION; G(I1)ALPHA; G(S)ALPHA; CELLS; ALPHA(2A)-ADRENOCEPTOR	Fusion proteins between heptahelical receptors (GPCR) and G protein alpha-subunits show enhanced signaling efficiency in transfected cells. This is believed to be the result of molecular proximity, because the interaction between linked modules of one protein chain, if not constrained by structure, should be strongly favored compared with the same in which partners react as free species. To test this assumption we made a series of fusion proteins (type 1 and 4 opioid receptors with G(o) and beta(2) adrenergic and dopamine I receptors with G(sL)) and some mutated analogs carrying different tags and defective GPCR or Galpha subunits. Using cotransfection experiments with readout protocols able to distinguish activation at fused and non-fused alpha-subunits, we found that both the GPCR and the Got limb of one fusion protein can freely interact with non-fused proteins and the tethered partners of a neighboring fusion complex. Moreover, a bulky polyanionic inhibitor can suppress with identical potency receptor-Galpha interaction, either when occurring between latched domains of a fused system or separate elements of distinct molecules, indicating that the binding surfaces are equally accessible in both cases. These data demonstrate that there is no entropy drive from the linked condition of fusion proteins and suggest that their signaling may result from the GPCR of one complex interacting with the alpha-subunit of another. Moreover, the enhanced coupling efficiency commonly observed for fusion proteins is not due to the receptor tether, but to the transmembrane helix that anchors Go to the membrane.	Ist Super Sanita, Dept Pharmacol, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Costa, T (corresponding author), Ist Super Sanita, Dept Pharmacol, Viale Regina Elena 299, I-00161 Rome, Italy.	tomcosta@iss.it	costa, tommaso/AAD-3714-2019; ambrosio, caterina/M-7952-2017	costa, tommaso/0000-0002-8729-3357; gro, maria cristina/0000-0001-9106-2191; ambrosio, caterina/0000-0002-0807-9003; molinari, paola/0000-0002-8454-0121				ABOOD ME, 1982, J BIOL CHEM, V257, P540; AKSAMIT RR, 1985, P NATL ACAD SCI USA, V82, P7475, DOI 10.1073/pnas.82.22.7475; Ambrosio C, 2000, MOL PHARMACOL, V57, P198; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; Burt AR, 1998, J BIOL CHEM, V273, P10367, DOI 10.1074/jbc.273.17.10367; BUTLER SJ, 1988, BIOCHEM J, V251, P201, DOI 10.1042/bj2510201; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Fanelli F, 1999, PROTEINS, V37, P145, DOI 10.1002/(SICI)1097-0134(19991101)37:2<145::AID-PROT1>3.0.CO;2-R; Fong CW, 1999, BIOCHEM J, V342, P457, DOI 10.1042/0264-6021:3420457; Freissmuth M, 1996, MOL PHARMACOL, V49, P602; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Guzzi F, 2001, BIOCHEM J, V355, P323, DOI 10.1042/0264-6021:3550323; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Holst B, 2001, J BIOL CHEM, V276, P19793, DOI 10.1074/jbc.M100621200; HUANG RRC, 1990, MOL PHARMACOL, V37, P304; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kellett E, 1999, MOL PHARMACOL, V56, P684; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; KLINZ FJ, 1989, BIOCHEM BIOPH RES CO, V165, P554, DOI 10.1016/S0006-291X(89)80002-6; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Lee TW, 1999, BIOCHEMISTRY-US, V38, P13801, DOI 10.1021/bi9908282; LISANTI MP, 1995, MOL MEMBR BIOL, V12, P121, DOI 10.3109/09687689509038506; McAllister G, 2000, MOL PHARMACOL, V58, P407, DOI 10.1124/mol.58.2.407; Medici R, 1997, EMBO J, V16, P7241, DOI 10.1093/emboj/16.24.7241; Milligan G, 2000, TRENDS PHARMACOL SCI, V21, P24, DOI 10.1016/S0165-6147(99)01404-2; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; OGINO Y, 1992, MOL PHARMACOL, V42, P6; Pauwels PJ, 2001, N-S ARCH PHARMACOL, V363, P526, DOI 10.1007/s002100000395; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Rodbell M, 1997, ADV ENZYME REGUL, V37, P427, DOI 10.1016/S0065-2571(96)00020-9; Scheer A, 2000, MOL PHARMACOL, V57, P219; Seifert R, 1998, EUR J BIOCHEM, V255, P369, DOI 10.1046/j.1432-1327.1998.2550369.x; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; SEIFERTWENZEL K, 2000, MOL PHARM, V58, P954; Small KM, 2000, BIOCHEMISTRY-US, V39, P2815, DOI 10.1021/bi992497z; Taylor JM, 1996, J BIOL CHEM, V271, P3336; VACHON L, 1987, MOL PHARMACOL, V31, P159; Waldhoer M, 1999, J BIOL CHEM, V274, P30571, DOI 10.1074/jbc.274.43.30571; Wang YR, 1999, J BIOL CHEM, V274, P37435, DOI 10.1074/jbc.274.52.37435; Ward RJ, 1999, FEBS LETT, V462, P459, DOI 10.1016/S0014-5793(99)01581-1; Wenzel-Seifert K, 1999, J BIOL CHEM, V274, P33259, DOI 10.1074/jbc.274.47.33259; Wenzel-Seifert K, 1998, BIOCHEM J, V334, P519, DOI 10.1042/bj3340519; Wise A, 1997, J BIOL CHEM, V272, P24673, DOI 10.1074/jbc.272.39.24673; Wise A, 1997, BIOCHEM J, V325, P17, DOI 10.1042/bj3250017; Wise A, 1999, BIOCHEMISTRY-US, V38, P2272, DOI 10.1021/bi982054f; Wurch T, 2001, J PHARMACOL TOX MET, V45, P3, DOI 10.1016/S1056-8719(01)00126-5; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015; Yu B, 1998, J BIOL CHEM, V273, P30183, DOI 10.1074/jbc.273.46.30183	55	47	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15778	15788		10.1074/jbc.M300731200	http://dx.doi.org/10.1074/jbc.M300731200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598520	hybrid			2022-12-27	WOS:000182680000042
J	Olivares, C; Solano, F; Garcia-Borron, JC				Olivares, C; Solano, F; Garcia-Borron, JC			Conformation-dependent post-translational glycosylation of tyrosinase - Requirement of a specific interaction involving the cub metal binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCULOCUTANEOUS ALBINISM TYPE-1; ENDOPLASMIC-RETICULUM; DOPACHROME TAUTOMERASE; MELANOMA-CELLS; MAMMALIAN TYROSINASE; MOUSE TYROSINASE; N-GLYCOSYLATION; BROWN LOCUS; PROTEIN; GENE	Tyrosinase, the rate-limiting enzyme in mammalian melanogenesis, is a copper-containing transmembrane glycoprotein. Tyrosinase undergoes a complex post-translational processing before reaching the melanosomal membrane. This processing involves N-glycosylation in several sites, including one located in the CuB copper binding site, movement from the endoplasmic reticulum (ER) to the Golgi, copper binding, and sorting to the melanosome. Aberrant processing is causally related to the depigmented phenotype of human melanomas. Moreover, some forms of albinism and several other pigmentary syndromes are considered ER retention diseases or trafficking defects. A critical step in tyrosinase maturation is the acquisition of an ER export-competent conformation recognized positively by the ER quality control system. However, the minimal structural requirements allowing exit from the ER to the Golgi have not yet been identified for tyrosinase or other melanosomal proteins. We addressed this question by analyzing the enzymatic activity and glycosylation pattern of mouse tyrosinase point mutants and chimeric constructs, where selected portions of tyrosinase were replaced by the homologous fragments of the highly similar tyrosinase-related protein 1. We show that a completely inactive tyrosinase point mutant lacking a critical histidine residue involved in copper binding is nevertheless able to exit from the ER and undergo further processing. Moreover, we demonstrate that tyrosinase displays at least two sites whose glycosylation is post-translational and most likely conformation-dependent and that a highly specific interaction involving the CuB site is essential not only for correct glycosylation but also for exit from the ER and enzymatic activity.	Univ Murcia, Sch Med, Dept Biochem & Mol Biol, E-30100 Murcia, Spain	University of Murcia	Garcia-Borron, JC (corresponding author), Univ Murcia, Sch Med, Dept Biochem & Mol Biol, Apto 4021,Campus Espinardo, E-30100 Murcia, Spain.	gborron@um.es	Solano, Francisco/G-5001-2013; Garcia-Borron, Jose Carlos/H-2247-2015; Olivares, Conchi/H-2794-2015	Solano, Francisco/0000-0001-9612-761X; Garcia-Borron, Jose Carlos/0000-0002-9192-588X; Olivares, Conchi/0000-0001-7518-3858				AROCA P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P266, DOI 10.1016/0304-4165(90)90088-E; BEERMANN F, 1995, EXP EYE RES, V61, P599, DOI 10.1016/S0014-4835(05)80053-3; Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; BINGHAM MJ, 1995, J PHYSIOL-LONDON, V482, P583, DOI 10.1113/jphysiol.1995.sp020542; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Chen K, 2002, MOL BIOL CELL, V13, P1953, DOI 10.1091/mbc.02-02-0022; Cooksey CJ, 1997, J BIOL CHEM, V272, P26226, DOI 10.1074/jbc.272.42.26226; Garcia-Borron JC, 2002, PIGM CELL RES, V15, P162, DOI 10.1034/j.1600-0749.2002.02012.x; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; Halaban R, 2001, J BIOL CHEM, V276, P11933, DOI 10.1074/jbc.M008703200; Harrison MD, 2000, TRENDS BIOCHEM SCI, V25, P29, DOI 10.1016/S0968-0004(99)01492-9; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JARA JR, 1988, PIGM CELL RES, V1, P332, DOI 10.1111/j.1600-0749.1988.tb00128.x; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; Jimenez-Cervantes C, 2001, FEBS LETT, V508, P44, DOI 10.1016/S0014-5793(01)03025-3; JIMENEZCERVANTES C, 1993, EUR J BIOCHEM, V217, P549, DOI 10.1111/j.1432-1033.1993.tb18276.x; JIMENEZCERVANTES C, 1994, J BIOL CHEM, V269, P17993; JIMENEZCERVANTES C, 1993, PIGM CELL RES, V6, P394, DOI 10.1111/j.1600-0749.1993.tb00621.x; KOBAYASHI T, 1994, EMBO J, V13, P5818, DOI 10.1002/j.1460-2075.1994.tb06925.x; Kobayashi T, 1998, J BIOL CHEM, V273, P31801, DOI 10.1074/jbc.273.48.31801; Kolhekar AS, 1998, J BIOL CHEM, V273, P23012, DOI 10.1074/jbc.273.36.23012; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; LEE ST, 1994, NEW ENGL J MED, V330, P529, DOI 10.1056/NEJM199402243300803; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MartinezEsparza M, 1997, J BIOL CHEM, V272, P3967, DOI 10.1074/jbc.272.7.3967; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; Negroiu G, 1999, CELL MOL BIOL, V45, P1001; Oetting WS, 2000, PIGM CELL RES, V13, P320, DOI 10.1034/j.1600-0749.2000.130503.x; OHKURA T, 1984, ARCH BIOCHEM BIOPHYS, V235, P63, DOI 10.1016/0003-9861(84)90255-8; Olivares C, 2002, BIOCHEMISTRY-US, V41, P679, DOI 10.1021/bi011535n; Olivares C, 2001, BIOCHEM J, V354, P131, DOI 10.1042/0264-6021:3540131; PALUMBO A, 1991, BIOCHIM BIOPHYS ACTA, V1115, P1, DOI 10.1016/0304-4165(91)90003-Y; PARK KC, 1993, AM J HUM GENET, V52, P406; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; Petrescu SM, 2000, BIOCHEMISTRY-US, V39, P5229, DOI 10.1021/bi000107z; Petris MJ, 2000, HUM MOL GENET, V9, P2845, DOI 10.1093/hmg/9.19.2845; Prota G., 1992, MELANINS MELANOGENES; Rodan AR, 1996, EMBO J, V15, P6921, DOI 10.1002/j.1460-2075.1996.tb01084.x; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; Spritz RA, 1997, J INVEST DERMATOL, V109, P207, DOI 10.1111/1523-1747.ep12319351; SPRITZ RA, 1990, NEW ENGL J MED, V322, P1724, DOI 10.1056/NEJM199006143222407; Toyofuku K, 1999, J BIOCHEM, V125, P82, DOI 10.1093/oxfordjournals.jbchem.a022272; Toyofuku K, 2001, FASEB J, V15, P2149, DOI 10.1096/fj.01-0216com; Toyofuku K, 2001, BIOCHEM J, V355, P259, DOI 10.1042/0264-6021:3550259; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Ujvari A, 2001, J BIOL CHEM, V276, P5924, DOI 10.1074/jbc.M009203200; Wang Y, 2000, BIOCHEM BIOPH RES CO, V271, P22, DOI 10.1006/bbrc.2000.2577; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x; Xu YQ, 2001, EXP CELL RES, V267, P115, DOI 10.1006/excr.2001.5232	52	33	34	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15735	15743		10.1074/jbc.M300658200	http://dx.doi.org/10.1074/jbc.M300658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595535	hybrid			2022-12-27	WOS:000182680000036
J	Pirola, L; Bonnafous, S; Johnston, AM; Chaussade, C; Portis, F; Van Obberghen, E				Pirola, L; Bonnafous, S; Johnston, AM; Chaussade, C; Portis, F; Van Obberghen, E			Phosphoinositide 3-kinase-mediated reduction of insulin receptor substrate-1/2 protein expression via different mechanisms contributes to the insulin-induced desensitization of its signalling pathways in L6 muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; HUMAN SKELETAL-MUSCLE; AMINO-ACID-TRANSPORT; SYNTHASE KINASE 3; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; IRS 1; DEGRADATION; ACTIVATION; RESISTANCE	Impaired glucose tolerance precedes type 2 diabetes and is characterized by hyperinsulinemia, which develops to balance peripheral insulin resistance. To gain insight into the deleterious effects of hyperinsulinemia on skeletal muscle, we studied the consequences of prolonged insulin treatment of L6 myoblasts on insulin-dependent signaling pathways. A 24-h long insulin treatment desensitized the phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB) and p42/p44 MAPK pathways toward a second stimulation with insulin or insulin-like growth factor-1 and led to decreased insulin-induced glucose uptake. Desensitization was correlated to a reduction in insulin receptor substrate (IRS)-1 and IRS-2 protein levels, which was reversed by the PI3K inhibitor LY294002. Co-treatment of cells with insulin and LY294002, while reducing total IRS-1 phosphorylation, increased its phosphotyrosine content, enhancing IRS-1/PI3K association. PDK1, mTOR, and MAPK inhibitors did not block insulin-induced reduction of IRS-1, suggesting that the PI3K serine-kinase activity causes IRS-1 serine phosphorylation and its commitment to proteasomal degradation. Contrarily, insulin-induced IRS-2 down-regulation occurred via a PI3K/mTOR pathway. Suppression of IRS-1/2 down-regulation by LY294002 rescued the responsiveness of PKB and MAPK toward acute insulin stimulation. Conversely, adenovira-driven expression of constitutively active PI3K induced an insulin-independent reduction in IRS-1/2 protein levels. IRS-2 appears to be the chief molecule responsible for MAPK and PKB activation by insulin, as knockdown of IRS-2 (but not IRS-1) by RNA interference severely impaired activation of both kinases. In summary, (i) PI3K mediates insulin-induced reduction of IRS-1 by phosphorylating it while a PI3K/mTOR pathway controls insulin-induced reduction of IRS-2, (ii) in L6 cells, IRS-2 is the major adapter molecule linking the insulin receptor to activation of PKB and MAPK, (iii) the mechanism of IRS-1/2 down-regulation is different in L6 cells compared with 3T3-L1 adipocytes. In conclusion, the reduction in IRS proteins via different PI3K-mediated mechanisms contributes to the development of an insulin-resistant state in L6 myoblasts.	INSERM, U145, IFR50, Fac Med, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Van Obberghen, E (corresponding author), INSERM, U145, IFR50, Fac Med, F-06107 Nice 2, France.	vanobbeg@unice.fr	Pirola, Luciano/I-5250-2018	Pirola, Luciano/0000-0001-6539-5435				Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; ARNER P, 1987, DIABETOLOGIA, V30, P437, DOI 10.1007/BF00292549; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Ballif BA, 2001, J BIOL CHEM, V276, P12466, DOI 10.1074/jbc.M009939200; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; BEGUINOT F, 1985, J BIOL CHEM, V260, P5892; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; Carvalho Eugenia, 2001, FASEB Journal, V15, P1101; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Dalle S, 2002, MOL CELL BIOL, V22, P6272, DOI 10.1128/MCB.22.17.6272-6285.2002; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Fucini RV, 1999, J BIOL CHEM, V274, P18651, DOI 10.1074/jbc.274.26.18651; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEYDRICK SJ, 1993, J CLIN INVEST, V91, P1358, DOI 10.1172/JCI116337; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; Janez A, 2000, ENDOCRINOLOGY, V141, P4657, DOI 10.1210/en.141.12.4657; Kersten S, 2001, EMBO REP, V2, P282, DOI 10.1093/embo-reports/kve071; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KLEIN HH, 1995, DIABETES, V44, P1310, DOI 10.2337/diabetes.44.11.1310; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kraegen EW, 2001, EXP CLIN ENDOCR DIAB, V109, pS516; Krook A, 2000, DIABETES, V49, P284, DOI 10.2337/diabetes.49.2.284; LAMPHERE L, 1992, ENDOCRINOLOGY, V131, P2196, DOI 10.1210/en.131.5.2196; MAEGAWA H, 1991, DIABETES, V40, P815, DOI 10.2337/diabetes.40.7.815; NOLAN JJ, 1994, J CLIN ENDOCR METAB, V78, P471, DOI 10.1210/jc.78.2.471; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Pirola L, 2001, J BIOL CHEM, V276, P21544, DOI 10.1074/jbc.M011330200; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Shao J, 2000, J ENDOCRINOL, V167, P107, DOI 10.1677/joe.0.1670107; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Simpson L, 2001, MOL CELL BIOL, V21, P3947, DOI 10.1128/MCB.21.12.3947-3958.2001; SMITH LK, 1995, MOL CELL ENDOCRINOL, V113, P73, DOI 10.1016/0303-7207(95)03622-E; Somwar R, 1998, CLIN THER, V20, P125, DOI 10.1016/S0149-2918(98)80040-4; Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; TANTI JF, 1994, BIOCHEM J, V304, P17, DOI 10.1042/bj3040017; TRISCHITTA V, 1989, J BIOL CHEM, V264, P5041; White MF, 1997, DIABETOLOGIA, V40, pS2, DOI 10.1007/s001250051387; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhang JD, 2001, P NATL ACAD SCI USA, V98, P3756, DOI 10.1073/pnas.071054598; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	60	97	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15641	15651		10.1074/jbc.M208984200	http://dx.doi.org/10.1074/jbc.M208984200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594228	hybrid			2022-12-27	WOS:000182680000025
J	Rich, JN; Shi, Q; Hjelmeland, M; Cummings, TJ; Kuan, CT; Bigner, DD; Counter, CM; Wang, XF				Rich, JN; Shi, Q; Hjelmeland, M; Cummings, TJ; Kuan, CT; Bigner, DD; Counter, CM; Wang, XF			Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA; NEOPLASTIC PROGRESSION; SPARC EXPRESSION; CELL-LINES; PROTEIN; CYSTEINE; RICH; OSTEONECTIN/SPARC; ASTROCYTOMA; DATABASE	We employed a genetically defined human cancer model to investigate the contributions of two genes up-regulated in several cancers to phenotypic changes associated with late stages of tumorigenesis. Specifically, tumor cells expressing two structurally unrelated bone-related genes, osteonectin and osteoactivin, acquired a highly invasive phenotype when implanted intracranially in immunocompromised mice. Mimicking a subset of gliomas, tumor cells invaded brain along blood vessels and developed altered vasculature at the brain-tumor interface, suggesting that production of those two proteins by tumor cells may create a complex relationship between invading tumor and vasculature co-opted during tumor invasion. Interestingly, the same tumor cells formed massive spontaneous metastases when implanted subcutaneously. This dramatic alteration in tumor phenotype indicates that cellular microenvironment plays an important role in defining the specific effects of those gene products in tumor behavior. In vitro examination of tumor cells expressing either osteonectin or osteoactivin revealed that there was no impact on cellular growth or death but increased invasiveness and expression of MMP-9 and MMP-3. Specific pharmacologic inhibitors of MMP-2/9 and MMP-3 blocked the increased in vitro invasion associated with osteoactivin expression, but only MMP-3 inhibition altered the invasive in vitro phenotype mediated by osteonectin. Results from this genetically defined model system are supported by similar findings obtained from several established tumor cell lines derived originally from human patients. In sum, these results reveal that the expression of a single bone-related gene can dramatically alter or modify tumor cell behavior and may confer differential growth characteristics in different microenvironments. Genetically defined human cancer models offer useful tools in functional genomics to define the roles of specific genes in late stages of carcinogenesis.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University; Duke University	Rich, JN (corresponding author), Duke Univ, Med Ctr, Dept Med, Box 2900, Durham, NC 27710 USA.	rich0001@mc.duke.edu; wang0011@mc.duke.edu	Rich, Jeremy/AAM-1445-2021	Counter, Christopher M/0000-0003-0748-3079	NCI NIH HHS [CA 82481, R01 CA 94184, R01 CA 83770] Funding Source: Medline; NINDS NIH HHS [K08 NS 02055, NS 20023] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082481, R01CA083770, R01CA094184] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS002055, P50NS020023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Basu A, 1999, CELL GROWTH DIFFER, V10, P721; Bradshaw AD, 1999, MOL BIOL CELL, V10, P1569, DOI 10.1091/mbc.10.5.1569; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Gilles C, 1998, CANCER RES, V58, P5529; Golembieski WA, 1999, INT J DEV NEUROSCI, V17, P463, DOI 10.1016/S0736-5748(99)00009-X; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Lal A, 1999, CANCER RES, V59, P5403; LAWS ER, 1993, INT J DEV NEUROSCI, V11, P691, DOI 10.1016/0736-5748(93)90056-J; Le Bail B, 1999, J PATHOL, V189, P46; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Loging WT, 2000, GENOME RES, V10, P1393, DOI 10.1101/gr.138000; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; Rempel SA, 1998, J NEUROPATH EXP NEUR, V57, P1112, DOI 10.1097/00005072-199812000-00002; Rempel SA, 1999, CLIN CANCER RES, V5, P237; Rich JN, 2001, CANCER RES, V61, P3556; Safadi FF, 2002, J CELL BIOCHEM, V84, P12, DOI 10.1002/jcb.1259; Shikano S, 2001, J BIOL CHEM, V276, P8125, DOI 10.1074/jbc.M008539200; Sonoda Y, 2001, CANCER RES, V61, P4956; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Thomas R, 2000, CLIN CANCER RES, V6, P1140; Vajkoczy P, 2000, INT J CANCER, V87, P261, DOI 10.1002/1097-0215(20000715)87:2<261::AID-IJC18>3.0.CO;2-6; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4	29	135	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15951	15957		10.1074/jbc.M211498200	http://dx.doi.org/10.1074/jbc.M211498200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12590137	hybrid			2022-12-27	WOS:000182680000064
J	Zhang, W; Chu, X; Tong, Q; Cheung, JY; Conrad, K; Masker, K; Miller, BA				Zhang, W; Chu, X; Tong, Q; Cheung, JY; Conrad, K; Masker, K; Miller, BA			A novel TRPM2 isoform inhibits calcium influx and susceptibility to cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION CHANNEL; ADP-RIBOSE; HUMAN ERYTHROBLASTS; HYDROGEN-PEROXIDE; ERYTHROPOIETIN; GENE; MELASTATIN; ACTIVATION; RECEPTOR; LTRPC2	TRPM2 is a Ca2+-permeable channel that is activated by oxidative stress and confers susceptibility to cell death. Here, an isoform of TRPM2 was identified in normal human bone marrow that consists of the TRPM2 N terminus and the first two predicted transmembrane domains. Because of alternative splicing, a stop codon (TAG) is located at the splice junction between exons 16 and 17, resulting in deletion of the four C-terminal transmembrane domains, the putative calcium-permeable pore region, and the entire C terminus. This splice variant was found in other hematopoietic cells including human burst forming unit-erythroid-derived erythroblasts and TF-1 erythroleukemia cells. Endogenous expression of both the short form of TRPM2 (TRPM2-S) and the full length (TRPM2-L) was determined by reverse transcriptase-PCR, and localization of endogenous TRPM2 to the plasma membrane was demonstrated by confocal microscopy. Heterologous expression of TRPM2-S in HEK 293T cells demonstrated similar membrane localization as TRPM2-L, and coexpression of TRPM2-S did not alter the subcellular localization of TRPM2-L. The direct interaction of TRPM2-S with TRPM2-L was demonstrated with immunoprecipitation. H2O2 induced calcium influx through TRPM2-L expressed in 293T cells. Coexpression of TRPM2-S suppressed H2O2-induced calcium influx through TRPM2-L. Furthermore, expression of TRPM2-S inhibited susceptibility to cell death and onset of apoptosis induced by H2O2 in cells expressing TRPM2-L. These data demonstrate that TRPM2-S is an important physiologic isoform of TRPM2 and modulates channel activity and induction of cell death by oxidative stress through TRPM2-L.	Geisinger Med Clin, Dept Med, Danville, PA 17822 USA; Geisinger Med Clin, Dept Pediat, Danville, PA 17822 USA	Geisinger Medical Center; Geisinger Medical Center	Miller, BA (corresponding author), Geisinger Med Clin, Sigfried & Janet Weis Ctr Res, Henry Hood Res Program, 100 N Acad Ave, Danville, PA 17822 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046778, R56DK046778] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58672] Funding Source: Medline; NIDDK NIH HHS [DK 46778] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balzer M, 1999, CARDIOVASC RES, V42, P543, DOI 10.1016/S0008-6363(99)00025-5; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; CHEUNG JY, 1992, J CLIN INVEST, V90, P1850, DOI 10.1172/JCI116061; Chu X, 2002, J BIOL CHEM, V277, P34375, DOI 10.1074/jbc.M205541200; Duncan LM, 1998, CANCER RES, V58, P1515; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Herson PS, 1999, J BIOL CHEM, V274, P833, DOI 10.1074/jbc.274.2.833; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Hunter JJ, 1998, GENOMICS, V54, P116, DOI 10.1006/geno.1998.5549; KlonowskiStumpe H, 1997, AM J PHYSIOL-GASTR L, V272, pG1489, DOI 10.1152/ajpgi.1997.272.6.G1489; MILLER BA, 1989, BLOOD, V73, P1188; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; Nagamine K, 1998, GENOMICS, V54, P124, DOI 10.1006/geno.1998.5551; Paulsen M, 2000, HUM MOL GENET, V9, P1829, DOI 10.1093/hmg/9.12.1829; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Prawitt D, 2000, HUM MOL GENET, V9, P203, DOI 10.1093/hmg/9.2.203; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Tsavaler L, 2001, CANCER RES, V61, P3760; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Wilson HL, 2001, J BIOL CHEM, V276, P11180, DOI 10.1074/jbc.M004849200; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234	30	191	199	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16222	16229		10.1074/jbc.M300298200	http://dx.doi.org/10.1074/jbc.M300298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594222	hybrid			2022-12-27	WOS:000182680000097
J	Kramata, P; Zajc, B; Sayer, JM; Jerina, DM; Wei, CSJ				Kramata, P; Zajc, B; Sayer, JM; Jerina, DM; Wei, CSJ			A single site-specific trans-opened 7,8,9,10-tetrahydrobenzo[alpha]pyrene 7,8-diol 9,10-epoxide N-2-deoxyguanosine adduct induces mutations at multiple sites in DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; DIASTEREOMERIC BENZO<A>PYRENE 7,8-DIOL-9,10-EPOXIDES; GUANINE PHOSPHORIBOSYLTRANSFERASE GENE; (+)-ANTI-BENZO<A>PYRENE DIOL EPOXIDE; DOSE-DEPENDENT DIFFERENCES; OPTICAL ENANTIOMERS; SEQUENCE CONTEXT; STRUCTURAL CHARACTERIZATION; DEOXYGUANOSINE ADDUCTS; ENERGY MINIMIZATION	Site-specific mutagenicity of trans-opened adducts at the exocyclic N-2-imino group of guanine by the (+)-(7R,8S,9S,10R)- and (-)-(7S,8R,9R,10S)-enantiomers of a benzo[a]pyrene 7,8-diol 9,10-epoxide (7-hydroxyl and epoxide oxygen are trans, BPDE-2) has been determined in Chinese hamster V79 cells and their repair-deficient counterpart, V-H1 cells. Four vectors containing single 10S-BPDE-dG or 10R-BPDE-dG adducts positioned at Go or G(-1) in the analyzed 5'-ACTG(0)G(-1)GA sequence of the non-transcribed strand were separately transfected into the cells. Mutations at each of the seven nucleotides were analyzed by a novel primer extension assay using a mixture of one dNTP complementary to the mutated nucleotide and three other ddNTPs and were optimized to quantify levels of a mutation as low as 1%. Only G --> T mutations were detected at the adducted sites; the 10S adduct derived from the highly carcinogenic (+)-diol epoxide was 40-50 and 75-140% more mutagenic than the 10R adduct in V79 and V-H1 cells, respectively. Importantly, the 10S adducts, but not the 10R adducts, induced separate non-targeted mutations at sites 5' to the G(-1) and G(0) lesions (G(0) --> T and C --> T, respectively) in both cell lines. Neither the T 5' to G(0) nor sites 3' to the lesions showed mutations. Non-targeted mutations may enhance overall mutagenicity of the 10S-BPDE-dG lesion and contribute to the much higher carcinogenicity and mutagenicity of (+)-BPDE-2 compared with its (-)enantiomer. Our study reports a definitive demonstration of mutations distal to a site-specific polycyclic aromatic hydrocarbon adduct.	Rutgers State Univ, Coll Pharm, Dept Biol Chem, Susan Lehman Cullman Lab Canc Res, Piscataway, NJ 08854 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Kramata, P (corresponding author), Rutgers State Univ, Coll Pharm, Dept Biol Chem, Susan Lehman Cullman Lab Canc Res, 164 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	kramata@rci.rutgers.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bailey EA, 1996, P NATL ACAD SCI USA, V93, P1535, DOI 10.1073/pnas.93.4.1535; BUENING MK, 1978, P NATL ACAD SCI USA, V75, P5358, DOI 10.1073/pnas.75.11.5358; CHEN RH, 1990, P NATL ACAD SCI USA, V87, P8680, DOI 10.1073/pnas.87.21.8680; CHENG SC, 1989, CHEM RES TOXICOL, V2, P334, DOI 10.1021/tx00011a011; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; Courtemanche C, 1999, MUTAT RES-FUND MOL M, V430, P23, DOI 10.1016/S0027-5107(99)00113-X; Custer L, 1999, BIOCHEMISTRY-US, V38, P569, DOI 10.1021/bi9813330; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; Dipple A., 1984, ACS MONOGR SER, V182, P41, DOI DOI 10.1074/JBC.M409155200; FOUNTAIN MA, 1995, BIOCHEMISTRY-US, V34, P3152, DOI 10.1021/bi00010a004; Giri I, 2002, CHEM RES TOXICOL, V15, P638, DOI 10.1021/tx010187n; GOPALAKRISHNAN S, 1990, BIOCHEMISTRY-US, V29, P10438, DOI 10.1021/bi00498a002; Haff LA, 1997, GENOME RES, V7, P378, DOI 10.1101/gr.7.4.378; Hess MT, 1997, MOL CELL BIOL, V17, P7069, DOI 10.1128/MCB.17.12.7069; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; JELINSKY SA, 1995, BIOCHEMISTRY-US, V34, P13545, DOI 10.1021/bi00041a034; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Kadkhodayan S, 1997, MUTAT RES-DNA REPAIR, V385, P47, DOI 10.1016/S0921-8777(97)00030-X; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; MOORE PD, 1977, ACS SYM SER, V44, P127; Moriya M, 1996, BIOCHEMISTRY-US, V35, P16646, DOI 10.1021/bi9608875; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Page JE, 1998, BIOCHEMISTRY-US, V37, P9127, DOI 10.1021/bi980273v; Ponten I, 2001, CHEM RES TOXICOL, V14, P720, DOI 10.1021/tx0002684; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; Sambrook J., 2001, MOL CLONING LAB MANU, V3rd ed.; SAYER JM, 1991, J ORG CHEM, V56, P20, DOI 10.1021/jo00001a007; Schiltz M, 1999, CARCINOGENESIS, V20, P2279, DOI 10.1093/carcin/20.12.2279; Shibutani S, 2001, BIOCHEMISTRY-US, V40, P3717, DOI 10.1021/bi0027581; Simhadri S, 2002, MUTAT RES-FUND MOL M, V508, P137, DOI 10.1016/S0027-5107(02)00211-7; SIMS P, 1974, NATURE, V252, P326, DOI 10.1038/252326a0; SLAGA TJ, 1979, CANCER RES, V39, P67; Smela ME, 2002, P NATL ACAD SCI USA, V99, P6655, DOI 10.1073/pnas.102167699; Suzuki N, 2001, BIOCHEMISTRY-US, V40, P15176, DOI 10.1021/bi010702g; Syvanen AC, 1999, HUM MUTAT, V13, P1; THAKKER DR, 1977, CHEM-BIOL INTERACT, V16, P281, DOI 10.1016/0009-2797(77)90108-9; Vaisman A, 2001, J BIOL CHEM, V276, P30615, DOI 10.1074/jbc.M102694200; Vepachedu SR, 2000, CHEM RES TOXICOL, V13, P883, DOI 10.1021/tx000073w; WEI D, 1995, P NATL ACAD SCI USA, V92, P2204, DOI 10.1073/pnas.92.6.2204; WEI SJC, 1993, CANCER RES, V53, P3294; WEI SJC, 1994, CARCINOGENESIS, V15, P1729, DOI 10.1093/carcin/15.8.1729; WEI SJC, 1991, P NATL ACAD SCI USA, V88, P11227, DOI 10.1073/pnas.88.24.11227; WOOD AW, 1977, BIOCHEM BIOPH RES CO, V77, P1389, DOI 10.1016/S0006-291X(77)80133-2; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; YAGI H, 1977, J AM CHEM SOC, V99, P2358, DOI 10.1021/ja00449a066; YAGI H, 1975, J AM CHEM SOC, V97, P6881, DOI 10.1021/ja00856a057; ZDZIENICKA MZ, 1987, MUTAT RES, V178, P235, DOI 10.1016/0027-5107(87)90274-0; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4147, DOI 10.1093/nar/28.21.4147	51	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14940	14948		10.1074/jbc.M211557200	http://dx.doi.org/10.1074/jbc.M211557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12595542	hybrid			2022-12-27	WOS:000182516100048
J	Agazie, YM; Hayman, MJ				Agazie, YM; Hayman, MJ			Development of an efficient "substrate-trapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; T-CELL; KINASE ACTIVATION; SH2 DOMAINS; CATALYTIC MECHANISM; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; BINDING-SITE; MAP KINASE; SHP-2	Src homology containing phosphotyrosine phosphatase 2 (SHP2) is a positive effector of growth factor, cytokine, and integrin signaling. However, neither its physiological substrate nor its mechanism of action in tyrosine kinase signaling has been demonstrated. We reasoned that the identification of physiological substrates of SHP2 would be a stepping stone in elucidating its mechanism of action, and, thus, we constructed a potent trapping mutant of SHP2. Surprisingly, the frequently used Asp to Ala substitution did not give rise to a trapping mutant. However, we were able to develop an efficient trapping mutant of SHP2 by introducing Asp to Ala and Cys to Ser double mutations. The double mutant (DM) protein identified the epidermal growth factor receptor (EGFR), the Grb2 binder 1, and three other, as yet unidentified, phosphotyrosyl. proteins as candidate physiological substrates. Given that substrate trapping occurred in intact cells and that the interaction was very specific, it is highly likely that EGFR and Gab1 represent physiological SHP2 substrates. Therefore, the DM protein would serve as an important tool in future SHP2 studies, including identification of p190, p150, and P90.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [P01CA028146, R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 1996, CELL, V85, P15; Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Allard JD, 1996, DEVELOPMENT, V122, P1137; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Buist A, 2000, J BIOL CHEM, V275, P20754, DOI 10.1074/jbc.M001626200; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; Elchebly M, 2000, J MOL MED-JMM, V78, P473, DOI 10.1007/s001090000141; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Krautwald S, 1996, MOL CELL BIOL, V16, P5955; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; Odaka M, 1997, J BIOCHEM-TOKYO, V122, P116; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; PALKA HL, 2002, J BIOL CHEM; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; Saxton TM, 2000, NAT GENET, V24, P420, DOI 10.1038/74279; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schlessinger J, 1993, Harvey Lect, V89, P105; SCHLESSINGER J, 1992, COLD SPRING HARB SYM, V57, P67, DOI 10.1101/SQB.1992.057.01.009; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Xie LP, 2002, BIOCHEMISTRY-US, V41, P4032, DOI 10.1021/bi015904r; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066; Yang J, 1998, J BIOL CHEM, V273, P28199, DOI 10.1074/jbc.273.43.28199; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	61	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13952	13958		10.1074/jbc.M210670200	http://dx.doi.org/10.1074/jbc.M210670200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582165	hybrid			2022-12-27	WOS:000182405000051
J	Bland, CE; Kimberly, P; Rand, MD				Bland, CE; Kimberly, P; Rand, MD			Notch-induced proteolysis and nuclear localization of the delta ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CONVERTING ENZYME; 4-AMINOPHENYLMERCURIC ACETATE; SIGNAL-TRANSDUCTION; CELL FATE; DROSOPHILA; PROTEIN; ACTIVATION; CLEAVAGE; TRANSCRIPTION; PATHWAYS	The Delta protein is a single-pass transmembrane ligand for the Notch family of receptors. Delta binding to Notch invokes regulated intramembrane proteolysis and nuclear translocation of the Notch intracellular domain. Delta is proteolytically processed at two sites, Ala(581) and Ala(593) in the juxtamembrane and transmembrane domains, respectively (Mishra-Gorur, K., Rand, M. D., Perez-Villamil, B., and Artavanis-Tsakonas, S. (2002) J. Cell Biol. 159, 313-324). Controversy over the role of Delta processing in propagating Notch signals has stemmed from conflicting reports on the activity or inactivity of soluble extracellular domain products of Delta. We have examined Delta proteolysis in greater detail and report that Delta undergoes three proteolytic cleavages in the region of the juxtamembrane and transmembrane domains. Only one of these cleavages, analogous to cleavage at Ala(581), is dependent on the Kuzbanian ADAM metalloprotease. The two additional cleavages correspond to the previously described cleavage at Ala593 and a novel unidentified site within or close to the transmembrane domain. Delta processing is up-regulated in co-cultures with Notch-expressing cells and is similarly induced by p-aminophenylmercuric acetate, a well documented activator of metalloproteases. Furthermore, expression of a truncated intracellular isoform of Delta shows prominent nuclear localization. Altogether, these data demonstrate a role for Notch in inducing Delta proteolysis and implicate a nuclear function for Delta, consistent with a model of bi-directional signaling through Notch-Delta interactions.	Univ Vermont, Coll Med, Dept Anat & Neurobiol, Burlington, VT 05405 USA	University of Vermont	Rand, MD (corresponding author), Univ Vermont, Coll Med, Dept Anat & Neurobiol, HSRF 426C, Burlington, VT 05405 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016435] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR16435-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; deCelis JF, 1997, DEVELOPMENT, V124, P3241; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; HANCOCK ML, 2002, P SOC NEUR NOV 2 7 O, V28; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Heitzler P, 1996, DEVELOPMENT, V122, P161; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Hicks C, 2002, J NEUROSCI RES, V68, P655, DOI 10.1002/jnr.10263; Hukriede NA, 1997, DEVELOPMENT, V124, P3427; Huppert SS, 1997, DEVELOPMENT, V124, P3283; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Kinoshita A, 2002, J NEUROCHEM, V82, P839, DOI 10.1046/j.1471-4159.2002.01016.x; Kopan R, 2002, J CELL SCI, V115, P1095; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Shimizu K, 2002, EMBO J, V21, P294, DOI 10.1093/emboj/21.3.294; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Sun X, 1996, DEVELOPMENT, V122, P2465; Urban S, 2002, CURR OPIN GENET DEV, V12, P512, DOI 10.1016/S0959-437X(02)00334-9; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Weinmaster G, 2000, CURR OPIN GENET DEV, V10, P363, DOI 10.1016/S0959-437X(00)00097-6; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844	37	110	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13607	13610		10.1074/jbc.C300016200	http://dx.doi.org/10.1074/jbc.C300016200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12591935	hybrid			2022-12-27	WOS:000182405000005
J	Cheng, D; Nelson, TC; Chen, J; Walker, SG; Wardwell-Swanson, J; Meegalla, R; Taub, R; Billheimer, JT; Ramaker, M; Feder, JN				Cheng, D; Nelson, TC; Chen, J; Walker, SG; Wardwell-Swanson, J; Meegalla, R; Taub, R; Billheimer, JT; Ramaker, M; Feder, JN			Identification of acyl coenzyme A : Monoacylglycerol acyltransferase 3, an intestinal specific enzyme implicated in dietary fat absorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE; TRIACYLGLYCEROL; ORLISTAT; CLONING; FAMILY; DGAT2	Acyl coenzyme A:monoacylglycerol acyltransferase (MGAT) catalyzes the synthesis of diacylglycerol using 2-monoacylglycerol and fatty acyl coenzyme A. This enzymatic reaction is believed to be an essential and rate-limiting step for the absorption of fat in the small intestine. Although the first MGAT-encoding cDNA, designated MGAT1, has been recently isolated, it is not expressed in the small intestine and hence cannot account for the high intestinal MGAT enzyme activity that is important for the physiology of fat absorption. In the current study, we report the identification of a novel MGAT, designated MGAT3, and present evidence that it fulfills the criteria to be the elusive intestinal MGAT. MGAT3 encodes a -36kDa transmembrane protein that is highly homologous to MGAT1 and -2. In humans, expression of MGAT3 is restricted to gastrointestinal tract with the highest level found in the ileum. At the cellular level, recombinant MGAT3 is localized to the endoplasmic reticulum. Recombinant MGAT3 enzyme activity produced in insect Sf`9 cells selectively acylates 2-monoacylglycerol with higher efficiency than other stereoisomers. The molecular identification of MGAT3 will facilitate the evaluation of using intestinal MGAT as a potential point of intervention for antiobesity therapies.	Bristol Myers Squibb Co, Pharmaceut Res Inst, Princeton, NJ 08543 USA	Bristol-Myers Squibb	Cheng, D (corresponding author), Bristol Myers Squibb Co, Pharmaceut Res Inst, POB 5400, Princeton, NJ 08543 USA.							BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BRINDLEY DN, 1966, BIOCHIM BIOPHYS ACTA, V125, P92, DOI 10.1016/0005-2760(66)90147-0; BRINDLEY DN, 1965, BIOCHIM BIOPHYS ACTA, V106, P495, DOI 10.1016/0005-2760(65)90066-4; Buhman KK, 2002, J BIOL CHEM, V277, P25474, DOI 10.1074/jbc.M202013200; CAO J, 2003, J BIOL CHEM; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; COLEMAN RA, 1992, METHOD ENZYMOL, V209, P98; Kolanowski J, 1999, DRUG SAFETY, V20, P119, DOI 10.2165/00002018-199920020-00003; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lardizabal KD, 2001, J BIOL CHEM, V276, P38862, DOI 10.1074/jbc.M106168200; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; LEHNER R, 1995, J BIOL CHEM, V270, P13630, DOI 10.1074/jbc.270.23.13630; LEVY E, 1992, CAN J PHYSIOL PHARM, V70, P413, DOI 10.1139/y92-052; Lucas KH, 2001, ANN PHARMACOTHER, V35, P314; LYKIDIS A, 1995, EUR J BIOCHEM, V230, P892, DOI 10.1111/j.1432-1033.1995.tb20633.x; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899; ZHI JG, 1995, J CLIN PHARMACOL, V35, P1103, DOI 10.1002/j.1552-4604.1995.tb04034.x	18	110	133	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13611	13614		10.1074/jbc.C300042200	http://dx.doi.org/10.1074/jbc.C300042200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12618427	hybrid			2022-12-27	WOS:000182405000006
J	Loo, TW; Bartlett, MC; Clarke, DM				Loo, TW; Bartlett, MC; Clarke, DM			Substrate-induced conformational, changes in the transmembrane segments of human P-glycoprotein - Direct evidence for the substrate-induced fit mechanism for drug binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; DISULFIDE CROSS-LINKING; CYSTEINE-SCANNING MUTAGENESIS; MULTIDRUG-RESISTANCE; FUNCTIONAL CONSEQUENCES; MEMBRANE TOPOLOGY; DOMAIN; TRANSPORT; IDENTIFICATION; RESIDUES	The human multidrug resistance P-glycoprotein (Pgp, ABCB1) is quite promiscuous in that it can transport a broad range of structurally diverse compounds out of the cell. We hypothesized that the transmembrane (TM) segments that constitute the drug-binding site are quite mobile such that drug binding occurs through a "substrate-induced fit" mechanism. Here, we used cysteine-scanning mutagenesis and oxidative cross-linking to test for substrate-induced changes in the TM segments. Pairs of cysteines were introduced into a Cys-less P-gp and the mutants treated with oxidant (copper phenanthroline) in the presence or absence of various drug,substrates. We show that cyclosporin A promoted cross-linking between residues P350C(TM6)/G939C(TM11), while colchicine and demecolcine promoted cross-linking between residues P350C(TM6)/V991C(TM12). Progesterone promoted. cross-linking between residues P350C(TM6)/A935C(TM11), P350C(TM6)/G939C(TM11), as well as between residues P350C(TM6)/V991C(TM12). Other substrates such as vinblastine, verapamil, cis-(Z)-flupenthixol or trans-(E)-flupenthixol did not induce cross-linking at these sites. These results provide direct evidence that the packing of the TM segments in the drug-binding site is changed when P-gp binds to a particular substrate. The induced-fit mechanism explains how P-gp can accommodate a broad range of compounds.	Univ Toronto, Dept Med, Canadian Inst Hlth, Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth, Res Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NCI NIH HHS [CA80900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CHOI K, 1991, P NATL ACAD SCI USA, V88, P7386, DOI 10.1073/pnas.88.16.7386; Dayan G, 1996, J BIOL CHEM, V271, P11652, DOI 10.1074/jbc.271.20.11652; Dey S, 1999, BIOCHEMISTRY-US, V38, P6630, DOI 10.1021/bi983038l; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; HORIO M, 1989, J BIOL CHEM, V264, P14880; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1996, J BIOL CHEM, V271, P27482, DOI 10.1074/jbc.271.44.27482; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOO TW, 1994, J BIOL CHEM, V269, P28683; Sarkadi B, 1997, SEMIN CANCER BIOL, V8, P171, DOI 10.1006/scbi.1997.0069; TAMAI I, 1991, J BIOL CHEM, V266, P16796; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; Vo QD, 1999, J BIOL CHEM, V274, P20318, DOI 10.1074/jbc.274.29.20318; YANG CPH, 1990, J BIOL CHEM, V265, P10282	39	153	161	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13603	13606		10.1074/jbc.C300073200	http://dx.doi.org/10.1074/jbc.C300073200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12609990	hybrid			2022-12-27	WOS:000182405000004
J	Khabar, KSA; Siddiqui, YM; al-Zoghaibi, F; al-Haj, L; Dhalla, M; Zhou, AM; Dong, BH; Whitmore, M; Paranjape, J; Al-Ahdal, MN; Al-Mohanna, F; Williams, BRG; Silverman, RH				Khabar, KSA; Siddiqui, YM; al-Zoghaibi, F; al-Haj, L; Dhalla, M; Zhou, AM; Dong, BH; Whitmore, M; Paranjape, J; Al-Ahdal, MN; Al-Mohanna, F; Williams, BRG; Silverman, RH			RNase L mediates transient control of the interferon response through modulation of the double-stranded RNA-dependent protein kinase PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ENCEPHALOMYOCARDITIS VIRUS; ANTIVIRAL ACTIVITY; VIRAL-INFECTION; TREATED CELLS; IN-VITRO; TRANSLATION; ACTIVATION; INITIATION; INHIBITOR	The transient control of diverse biological responses that occurs in response to varied forms of stress is often a highly regulated process. During the interferon (IFN) response, translational repression due to phosphorylation of eukaryotic initiation factor 2alpha, eIF2alpha, by the double-stranded RNA-dependent protein kinase, PKR, constitutes a means of inhibiting viral replication. Here we show that the transient nature of the IFN response against acute viral infections is regulated, at least in part, by RNase L. During the IFN antiviral response in RNase L-null cells, PKR mRNA stability was enhanced, PKR induction was increased, and the phosphorylated form of eIF2alpha appeared with extended kinetics compared with similarly treated wild type cells. An enhanced IFN response in RNase L-null cells was also demonstrated by monitoring inhibition of viral protein synthesis. Furthermore, ectopic expression of RNase L from a plasmid vector prevented the IFN induction of PKR. These results suggest a role for RNase L in the transient control of the IFN response and possibly of other cytokine and stress responses.	King Faisal Specialist Hosp & Res Ctr, Interferon & Cytokine Res Unit, Dept Biol & Med Res, Riyadh 11211, Saudi Arabia; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA	King Faisal Specialist Hospital & Research Center; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University	Khabar, KSA (corresponding author), King Faisal Specialist Hosp & Res Ctr, Interferon & Cytokine Res Unit, Dept Biol & Med Res, POB 3354,MBC-03, Riyadh 11211, Saudi Arabia.		Khabar, Khalid/AAG-3487-2019; Williams, Bryan R. G./A-5021-2009; Khabar, Khalid/A-4772-2011	Khabar, Khalid/0000-0003-1003-9788; Williams, Bryan R. G./0000-0002-4969-1151; Khabar, Khalid/0000-0003-1003-9788	NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NCI NIH HHS [CA44059] Funding Source: Medline; NIAID NIH HHS [AI343039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Biron C.A., 2001, FIELDS VIROLOGY, P321; Bisbal C, 2000, MOL CELL BIOL, V20, P4959, DOI 10.1128/MCB.20.14.4959-4969.2000; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; Cirino NM, 1997, P NATL ACAD SCI USA, V94, P1937, DOI 10.1073/pnas.94.5.1937; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DER SD, 1995, P NATL ACAD SCI USA, V92, P8841, DOI 10.1073/pnas.92.19.8841; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; EHRENFELD E, 1971, P NATL ACAD SCI USA, V68, P1075, DOI 10.1073/pnas.68.5.1075; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; GANGEMI JD, 1989, J INTERFERON RES, V9, P227, DOI 10.1089/jir.1989.9.227; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Greenhalgh CJ, 2001, J LEUKOCYTE BIOL, V70, P348; Haghighat A, 1996, J VIROL, V70, P8444, DOI 10.1128/JVI.70.12.8444-8450.1996; Hartmann R, 1998, J BIOL CHEM, V273, P3236, DOI 10.1074/jbc.273.6.3236; HOVANESSIAN AG, 1987, VIROLOGY, V159, P126, DOI 10.1016/0042-6822(87)90355-2; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; Khabar KSA, 2000, J INTERF CYTOK RES, V20, P653, DOI 10.1089/107999000414835; Khabar KSA, 1997, J EXP MED, V186, P1077, DOI 10.1084/jem.186.7.1077; Kleijn M, 1996, VIROLOGY, V217, P486, DOI 10.1006/viro.1996.0143; Le Roy F, 2001, J BIOL CHEM, V276, P48473, DOI 10.1074/jbc.M107482200; LEWIS JA, 1987, LYMPHOKINES INTERFER, P73; Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880; Li XL, 1998, J VIROL, V72, P2752, DOI 10.1128/JVI.72.4.2752-2759.1998; MESTAN J, 1986, NATURE, V323, P816, DOI 10.1038/323816a0; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5804; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; Peery T, 1997, METHODS, V11, P371, DOI 10.1006/meth.1996.0435; Pitchford S, 1997, METHOD ENZYMOL, V288, P84; PRATT G, 1988, NUCLEIC ACIDS RES, V16, P3497, DOI 10.1093/nar/16.8.3497; Rajagopalan LE, 1996, J BIOL CHEM, V271, P19871, DOI 10.1074/jbc.271.33.19871; SHARP TV, 1993, EUR J BIOCHEM, V214, P945, DOI 10.1111/j.1432-1033.1993.tb17998.x; Silverman R., 1997, RIBONUCLEASES STRUCT, P515; Silverman RH, 1999, NATURE, V397, P208, DOI 10.1038/16586; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; WRESCHNER DH, 1981, NUCLEIC ACIDS RES, V9, P1571, DOI 10.1093/nar/9.7.1571; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zhou AM, 2000, MAMM GENOME, V11, P989, DOI 10.1007/s003350010194; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355; Zhou AM, 1999, VIROLOGY, V258, P435, DOI 10.1006/viro.1999.9738	45	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20124	20132		10.1074/jbc.M208766200	http://dx.doi.org/10.1074/jbc.M208766200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12582177	Green Published, hybrid			2022-12-27	WOS:000183078000071
J	Zargarian, L; Benleumi, MS; Renisio, JG; Merad, H; Maroun, RG; Wieber, F; Mauffret, O; Porumb, H; Troalen, F; Fermandjian, S				Zargarian, L; Benleumi, MS; Renisio, JG; Merad, H; Maroun, RG; Wieber, F; Mauffret, O; Porumb, H; Troalen, F; Fermandjian, S			Strategy to discriminate between high and low affinity bindings of human immunodeficiency virus, type 1 integrase to viral DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTO-CROSS-LINKING; CARBOXYL-TERMINAL DOMAINS; HIV-1 INTEGRASE; CATALYTIC DOMAIN; CRYSTAL-STRUCTURE; ACTIVE-SITE; SECONDARY STRUCTURE; STRAND TRANSFER; PROTEIN; SEQUENCE	The last decade has contributed to our understanding of the three-dimensional structure of the human immunodeficiency virus, type 1 (HIV-1) integrase (IN) and to the description of how the enzyme catalyzes the viral DNA integration into the host DNA. Recognition of the viral DNA termini by IN is sequence-specific, and that of the host DNA does not require particular sequence, although in physicochemical studies IN fails to discriminate between the two interactions. Here, such discrimination was allowed thanks to a model system using designed oligonucleotides and peptides as binding structures. Spectroscopic (circular dichroism, NMR, and fluorescence anisotropy) techniques and biochemical (enzymatic and filter binding) assays clearly indicated that the amphipathic helix alpha4, located at the catalytic domain surface, is responsible for the specific high affinity binding of the enzyme to viral DNA. Analogues of the alpha4 peptide having increased helicity and still bearing the biologically relevant lysines 156 and 159 on the DNA binding face, and oligonucleotides conserving an intact attachment site, are required to achieve high affinity complexes (K-d of 1.5 nM). Data corroborate previous in vivo results obtained with mutated viruses.	Inst Gustave Roussy, Dept Biol & Pharmacol Struct, CNRS, UMR 8113, F-94805 Villejuif, France; Ecole Normale Super, F-94235 Cachan, France; Univ St Joseph, CST Mar Roukos, Fac Sci, Dept Sci Vie & Terre, Beirut 11072050, Lebanon; Inst Gustave Roussy, Dept Biol Clin, Lab Microchim & Immunol Mol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Saint Joseph University Beirut; UNICANCER; Gustave Roussy	Fermandjian, S (corresponding author), Inst Gustave Roussy, Dept Biol & Pharmacol Struct, CNRS, UMR 8113, PR2,39 Rue Camille Desmoulins, F-94805 Villejuif, France.			Wieber, Frederic/0000-0001-7167-9813				Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1; Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; Austin RJ, 2002, J AM CHEM SOC, V124, P10966, DOI 10.1021/ja026610b; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Brown P. O., 1997, P161; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Chen ZG, 2000, J MOL BIOL, V296, P521, DOI 10.1006/jmbi.1999.3451; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; CRAM DJ, 1988, SCIENCE, V240, P760, DOI 10.1126/science.3283937; Debyser Zeger, 2002, Antiviral Chemistry & Chemotherapy, V13, P1; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Eijkelenboom APAM, 1997, CURR BIOL, V7, P739, DOI 10.1016/S0960-9822(06)00332-0; EJKELENBOOM APA, 1995, NAT STRUCT BIOL, V2, P807; Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Fasman G.D., 1996, CIRCULAR DICHROISM C; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Greenwald J, 1999, BIOCHEMISTRY-US, V38, P8892, DOI 10.1021/bi9907173; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Hansen MST, 1998, GENET ENG P, V20, P41; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Heuer TS, 1997, BIOCHEMISTRY-US, V36, P10655, DOI 10.1021/bi970782h; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; Hill JJ, 1997, METHOD ENZYMOL, V278, P390; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; Jamin N, 1996, INT J QUANTUM CHEM, V59, P333, DOI 10.1002/(SICI)1097-461X(1996)59:4<333::AID-QUA7>3.0.CO;2-Z; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; Katzman M, 1996, J VIROL, V70, P9069, DOI 10.1128/JVI.70.12.9069-9073.1996; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; Katzman M, 1999, ADV VIRUS RES, V52, P371, DOI 10.1016/S0065-3527(08)60307-3; Krebs D, 1998, EUR J BIOCHEM, V253, P236, DOI 10.1046/j.1432-1327.1998.2530236.x; KUMAR A, 1981, BIOCHEM BIOPH RES CO, V95, P1; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Maroun RG, 1999, EUR J BIOCHEM, V260, P145, DOI 10.1046/j.1432-1327.1999.00130.x; Maroun RG, 1999, J BIOL CHEM, V274, P34174, DOI 10.1074/jbc.274.48.34174; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; Nabel GJ, 2001, NATURE, V410, P1002, DOI 10.1038/35073500; Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Pommier Y, 2000, ANTIVIR RES, V47, P139, DOI 10.1016/S0166-3542(00)00112-1; Pommier Y, 1997, ANTIVIR CHEM CHEMOTH, V8, P463, DOI 10.1177/095632029700800601; Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3; Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; Sourgen F, 1996, EUR J BIOCHEM, V240, P765, DOI 10.1111/j.1432-1033.1996.0765h.x; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Weiss RA, 2001, NATURE, V410, P963, DOI 10.1038/35073632; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wuthrich K, 1986, NMR PROTEIN NUCL ACI; Yang ZN, 2000, J MOL BIOL, V296, P535, DOI 10.1006/jmbi.1999.3463; ZHONG LX, 1992, P NATL ACAD SCI USA, V89, P4462, DOI 10.1073/pnas.89.10.4462	71	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19966	19973		10.1074/jbc.M211711200	http://dx.doi.org/10.1074/jbc.M211711200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12626494	hybrid			2022-12-27	WOS:000183078000052
J	McDonald, C; Vacratsis, PO; Bliska, JB; Dixon, JE				McDonald, C; Vacratsis, PO; Bliska, JB; Dixon, JE			The Yersinia virulence factor YopM forms a novel protein complex with two cellular kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-RELATED KINASE-2; LEUCINE-RICH REPEAT; SIGNAL-TRANSDUCTION; POTENTIAL EFFECTOR; DOWN-REGULATION; MAP KINASES; PESTIS YOPM; HELA-CELLS; S6 KINASE; IDENTIFICATION	Pathogenic Yersinia contain a virulence plasmid that encodes genes for intracellular effectors, which neutralize the host immune response. One effector, YopM, is necessary for Yersinia virulence, but its function in host cells is unknown. To identify potential cellular pathways affected by YopM, proteins that co-immunoprecipitate with YopM in mammalian cells were isolated and identified by mass spectrometry. Results demonstrate that two kinases, protein kinase C-like 2 (PRK2) and ribosomal S6 protein kinase 1 (RSK1), interact directly with YopM. These two kinases associate only when YopM is present, and expression of YopM in cells stimulates the activity of both kinases. RSK1 is activated directly by interaction with YopM, and RSK1 kinase activity is required for YopM-stimulated PRK2 activity. YopM activation of RSK1 occurs independently of the actions of YopJ on the MAPK pathway. YopM is also required for Yersinia-induced changes in RSK1 mobility in infected macrophage cells. These results identify the first intracellular targets of YopM and suggest YopM acts to stimulate the activity of PRK2 and RSK1.	Univ Michigan, Sch Med, Dept Biol Chem, Inst Life Sci, Ann Arbor, MI 48109 USA; SUNY Stony Brook, Ctr Infect Dis, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	University of Michigan System; University of Michigan; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Dixon, JE (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Inst Life Sci, Ann Arbor, MI 48109 USA.			McDonald, Christine/0000-0002-6745-9487	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043389, F32AI054053] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018024, R01DK018849] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI43389, F32 AI054053-02, F32 AI054053] Funding Source: Medline; NIDDK NIH HHS [R37 DK18024, R01 DK18849] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bauman AL, 2002, NAT CELL BIOL, V4, pE203, DOI 10.1038/ncb0802-e203; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Boland A, 1996, EMBO J, V15, P5191, DOI 10.1002/j.1460-2075.1996.tb00904.x; Boland A, 1998, MICROB PATHOGENESIS, V25, P343, DOI 10.1006/mpat.1998.0247; Bottone EJ, 1997, CLIN MICROBIOL REV, V10, P257, DOI 10.1128/CMR.10.2.257; Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Evdokimov AG, 2001, J MOL BIOL, V312, P807, DOI 10.1006/jmbi.2001.4973; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; Juris SJ, 2002, CELL MICROBIOL, V4, P201, DOI 10.1046/j.1462-5822.2002.00182.x; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; Lee SJ, 2000, DEV BIOL, V228, P166, DOI 10.1006/dbio.2000.9943; Lee VT, 1998, MOL MICROBIOL, V28, P593, DOI 10.1046/j.1365-2958.1998.00822.x; LEUNG KY, 1990, INFECT IMMUN, V58, P3262, DOI 10.1128/IAI.58.10.3262-3271.1990; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; MULDER B, 1989, INFECT IMMUN, V57, P2534, DOI 10.1128/IAI.57.8.2534-2541.1989; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Palmer LE, 1998, MOL MICROBIOL, V27, P953, DOI 10.1046/j.1365-2958.1998.00740.x; Palmer LE, 1999, INFECT IMMUN, V67, P708, DOI 10.1128/IAI.67.2.708-716.1999; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PALMER RH, 1994, FEBS LETT, V356, P5, DOI 10.1016/0014-5793(94)01202-4; Perry RD, 1997, CLIN MICROBIOL REV, V10, P35, DOI 10.1128/CMR.10.1.35; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; REISNER BS, 1992, INFECT IMMUN, V60, P5242, DOI 10.1128/IAI.60.12.5242-5252.1992; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Sauvonnet N, 2002, J BIOL CHEM, V277, P25133, DOI 10.1074/jbc.M203239200; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Skrzypek E, 2003, INFECT IMMUN, V71, P937, DOI 10.1128/IAI.71.2.937-947.2003; Skrzypek E, 1998, MOL MICROBIOL, V30, P1051, DOI 10.1046/j.1365-2958.1998.01135.x; Sun WY, 2000, J BIOL CHEM, V275, P24421, DOI 10.1074/jbc.M003148200; Vacratsis PO, 2002, BIOCHEMISTRY-US, V41, P5613, DOI 10.1021/bi016075c; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Yu WP, 1997, J BIOL CHEM, V272, P10030; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o; Zong H, 1999, J BIOL CHEM, V274, P4551, DOI 10.1074/jbc.274.8.4551	41	122	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18514	18523		10.1074/jbc.M301226200	http://dx.doi.org/10.1074/jbc.M301226200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626518	hybrid			2022-12-27	WOS:000182838300121
J	Kang, KW; Choi, SY; Cho, MK; Lee, CH; Kim, SG				Kang, KW; Choi, SY; Cho, MK; Lee, CH; Kim, SG			Thrombin induces nitric-oxide synthase via G alpha(12/13)-coupled protein kinase C-dependent I-kappa B alpha phosphorylation and JNK-mediated I-kappa B alpha degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTOXIN-INDUCED HYPOTENSION; SEVERE SEPSIS; SEPTIC SHOCK; COAGULATION INHIBITORS; MURINE MACROPHAGES; SIGNALING PATHWAYS; ACTIVATION; RECEPTOR; CELLS; INFLAMMATION	An imbalance between thrombin and antithrombin III contributed to vascular hyporeactivity in sepsis, which can be attributed to excess NO production by inducible nitric-oxide synthase (iNOS). In view of the importance of the thrombin-activated coagulation pathway and excess NO as the culminating factors in vascular hyporeactivity, this study investigated the effects of thrombin on the induction of iNOS and NO production in macrophages. Thrombin induced iNOS protein in the Raw264.7 cells, which was inhibited by a thrombin inhibitor, LB30057. Thrombin increased NF-kappaB DNA binding, whose band was supershifted with anti-p65 and anti-p50 antibodies. Thrombin elicited the phosphorylation and degradation of I-kappaBalpha prior to the nuclear translocation of p65. The NF-kappaB-mediated iNOS induction was stimulated by the overexpression of activated mutants of Galpha(12/13) (Galpha(12/13)QL). Protein kinase C depletion inhibited I-kappaBalpha degradation, NF-kappaB activation, and iNOS induction by thrombin or the iNOS induction by Galpha(12/13)QL. JNK, p38 kinase, and ERK were all activated by thrombin. JNK inhibition by the stable transfection with a dominant negative mutant of JNK1 (JNK1(-)) completely suppressed the NF-kappaB-mediated iNOS induction by thrombin. Conversely, the inhibition of p38 kinase enhanced the expression of iNOS. In addition, JNK and p38 kinase oppositely controlled the NF-kappaB-mediated iNOS induction by Galpha(12/13)QL. Hence, iNOS induction by thrombin was regulated by the opposed functions of JNK and p38 kinase downstream of Galpha(12/13). In the JNK1(-) cells, thrombin did not increase either the NF-kappaB binding activity or I-kappaBalpha degradation despite I-kappaBalpha phosphorylation. These results demonstrated that thrombin induces iNOS in macrophages via Galpha(12) and Galpha(13), which leads to NF-kappaB activation involving the protein kinase C-dependent phosphorylation of I-kappaBalpha and the JNK-dependent degradation of phosphorylated I-kappaBalpha.	Seoul Natl Univ, Coll Pharm, Natl Res Lab, Seoul 151742, South Korea; Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; Hanyang Univ, Coll Med, Inst Biomed Sci, Seoul 133791, South Korea	Seoul National University (SNU); Seoul National University (SNU); Hanyang University	Kim, SG (corresponding author), Seoul Natl Univ, Coll Pharm, Natl Res Lab, Sillim Dong, Seoul 151742, South Korea.	sgk@snu.ac.kr						Bogatkevich GS, 2001, J BIOL CHEM, V276, P45184, DOI 10.1074/jbc.M106441200; Bokarewa MI, 2001, MICROB PATHOGENESIS, V30, P247, DOI 10.1006/mpat.2000.0425; Chen BC, 2001, BRIT J PHARMACOL, V134, P1055, DOI 10.1038/sj.bjp.0704334; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHESROWN SE, 1994, BIOCHEM BIOPH RES CO, V200, P126, DOI 10.1006/bbrc.1994.1424; Chi LG, 2001, J THROMB THROMBOLYS, V11, P19, DOI 10.1023/A:1008900109285; Cho MK, 2002, NITRIC OXIDE-BIOL CH, V6, P319, DOI 10.1006/niox.2001.0415; Esmon CT, 2000, HAEMOSTASIS, V30, P34; Esmon CT, 2001, THROMB HAEMOSTASIS, V86, P51; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; Evans TJ, 1996, IMMUNOBIOLOGY, V195, P655, DOI 10.1016/S0171-2985(96)80029-5; Gardner A, 2002, CELL SIGNAL, V14, P499, DOI 10.1016/S0898-6568(01)00279-0; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; HESSELVIK JF, 1989, CRIT CARE MED, V17, P724, DOI 10.1097/00003246-198908000-00002; Isobe H, 2002, BLOOD, V99, P1638, DOI 10.1182/blood.V99.5.1638; Isobe H, 2001, CIRCULATION, V104, P1171, DOI 10.1161/hc3501.093799; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Kaur J, 2003, AM J PHYSIOL-HEART C, V284, pH1095, DOI 10.1152/ajpheart.00016.2002; Kim SG, 1997, MOL PHARMACOL, V51, P225, DOI 10.1124/mol.51.2.225; Komatsuzaki K, 2001, BIOCHEM BIOPH RES CO, V289, P1211, DOI 10.1006/bbrc.2001.6085; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kristof AS, 2001, J BIOL CHEM, V276, P8445, DOI 10.1074/jbc.M009563200; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; Luchi M, 2000, INFECT IMMUN, V68, P1899, DOI 10.1128/IAI.68.4.1899-1904.2000; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Mann HJ, 2002, AM J HEALTH-SYST PH, V59, pS19, DOI 10.1093/ajhp/59.suppl_1.S19; Martin CB, 2001, ONCOGENE, V20, P1953, DOI 10.1038/sj.onc.1204281; Maruyama I, 1997, ANN NY ACAD SCI, V811, P429, DOI 10.1111/j.1749-6632.1997.tb52024.x; Mavrommatis AC, 2001, INTENS CARE MED, V27, P1853, DOI 10.1007/s00134-001-1139-8; Mavrommatis AC, 2000, CRIT CARE MED, V28, P451, DOI 10.1097/00003246-200002000-00027; Meli R, 2001, J NEUROCHEM, V79, P556, DOI 10.1046/j.1471-4159.2001.00617.x; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nadal-Wollbold F, 2002, FEBS LETT, V531, P475, DOI 10.1016/S0014-5793(02)03587-1; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; Naor Z, 1998, FRONT NEUROENDOCRIN, V19, P1, DOI 10.1006/frne.1997.0162; Nguyen QD, 2002, FASEB J, V16, P565, DOI 10.1096/fj.01-0525com; Nielsen JD, 1998, BLOOD COAGUL FIBRIN, V9, pS11; Nieuwland R, 2000, BLOOD, V95, P930, DOI 10.1182/blood.V95.3.930.003k46_930_935; Oelschlager C, 2002, BLOOD, V99, P4015, DOI 10.1182/blood.V99.11.4015; Offermanns S, 1996, J BIOL CHEM, V271, P26044, DOI 10.1074/jbc.271.42.26044; PHILIPPE J, 1991, THROMB HAEMOSTASIS, V65, P291; Prins JM, 1996, FEMS IMMUNOL MED MIC, V16, P283; Salvucci O, 1998, BLOOD, V92, P2093, DOI 10.1182/blood.V92.6.2093.418k31_2093_2102; Silkoff PE, 2000, J ALLERGY CLIN IMMUN, V105, P438, DOI 10.1067/mai.2000.104938; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Strukova SM, 2001, BIOCHEMISTRY-MOSCOW+, V66, P8, DOI 10.1023/A:1002869310180; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; Symeonides S, 1999, INFECT DIS CLIN N AM, V13, P449, DOI 10.1016/S0891-5520(05)70085-4; SZABO C, 1994, P NATL ACAD SCI USA, V91, P271, DOI 10.1073/pnas.91.1.271; SZABO C, 1994, SHOCK, V2, P145, DOI 10.1097/00024382-199408000-00011; Thijs LG, 2000, CRIT CARE MED, V28, pS68, DOI 10.1097/00003246-200009001-00015; van der Poll T, 2001, J ENDOTOXIN RES, V7, P301, DOI 10.1177/09680519010070040301; Venet C, 2000, INTENS CARE MED, V26, P538, DOI 10.1007/s001340051201; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wang TL, 2002, INT IMMUNOPHARMACOL, V2, P1509, DOI 10.1016/S1567-5769(02)00058-9; Williams BY, 1998, MOL PHARMACOL, V54, P889, DOI 10.1124/mol.54.5.889; Wong J M, 1995, Adv Pharmacol, V34, P155; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	59	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17368	17378		10.1074/jbc.M300471200	http://dx.doi.org/10.1074/jbc.M300471200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606553	hybrid			2022-12-27	WOS:000182818600123
J	Malakhov, MP; Kim, KI; Malakhova, OA; Jacobs, BS; Borden, EC; Zhang, DE				Malakhov, MP; Kim, KI; Malakhova, OA; Jacobs, BS; Borden, EC; Zhang, DE			High-throughput immunoblotting - Ubiquitin-like protein ISG15 modifies key regulators of signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-GAMMA; TARGETED DISRUPTION; INTERFERON; UBP43; HOMOLOG; MACROPHAGES; CONJUGATION; MECHANISMS; CLONING; KINASE	ISG15 is a ubiquitin-like protein that conjugates to numerous proteins in cells treated with interferon or lipopolysaccharide. Dysregulation of protein ISG15 modification (ISGylation) in mice leads to decreased life expectancy, brain cell injury, and hypersensitivity to interferon. Although ISG15 was identified more than two decades ago, the exact biochemical and physiological functions of ISG15-modification remain unknown, and the proteins targeted by ISG15 have not been identified. The major purpose of this work was to identify ISG15 targets among well characterized proteins that could be used as models for biological studies. We purified ISGylated proteins from human thymus by immunoaffinity chromatography and analyzed ISG15 conjugates by a high-throughput Western blot screen (PowerBlot(TM)). We found that three key regulators of signal transduction, phospholipase Cgamma1, Jak1, and ERK1 are modified by ISG15. In addition to that, we demonstrate that transcription factor Stat1, an immediate substrate of Jak1 kinase, is also ISGylated. Using whole cell protein extracts and phospholipase Cgamma1 as an example we demonstrate that ISG15 conjugates are not accumulated in cells treated with specific inhibitors of proteasomes. Our work suggests a role for ISG15 in the regulation of multiple signal transduction pathways and offers attractive models to further elucidate the biochemical function of ISGylation.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Scripps Research Institute; Cleveland Clinic Foundation	Zhang, DE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-L51,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dzhang@scripps.edu	KIM, KEUN IL/D-2959-2011		NATIONAL CANCER INSTITUTE [R01CA079849] Funding Source: NIH RePORTER; NCI NIH HHS [CA79849] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; DCunha J, 1996, J IMMUNOL, V157, P4100; DeMali KA, 1997, J BIOL CHEM, V272, P9011; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hamerman JA, 2002, J IMMUNOL, V168, P2415, DOI 10.4049/jimmunol.168.5.2415; Hansen TR, 1999, J REPROD FERTIL, P329; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hochstrasser M, 2000, SCIENCE, V289, P563, DOI 10.1126/science.289.5479.563; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5; KNIGHT E, 1991, J IMMUNOL, V146, P2280; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Li J, 2001, J BIOL CHEM, V276, P18579, DOI 10.1074/jbc.M100846200; Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhova O, 2002, J BIOL CHEM, V277, P14703, DOI 10.1074/jbc.M111527200; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; McLaughlin PMJ, 2000, INT J CANCER, V85, P871, DOI 10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; Narasimhan J, 1996, J BIOL CHEM, V271, P324, DOI 10.1074/jbc.271.1.324; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Ritchie KJ, 2002, GENE DEV, V16, P2207, DOI 10.1101/gad.1010202; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Schwer H, 2000, GENOMICS, V65, P44, DOI 10.1006/geno.2000.6148; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zhang XX, 1999, VIROLOGY, V262, P152, DOI 10.1006/viro.1999.9914	39	205	217	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16608	16613		10.1074/jbc.M208435200	http://dx.doi.org/10.1074/jbc.M208435200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12582176	hybrid			2022-12-27	WOS:000182818600023
J	Sutton, A; Shia, WJ; Band, D; Kaufman, PD; Osada, S; Workman, JL; Sternglanz, R				Sutton, A; Shia, WJ; Band, D; Kaufman, PD; Osada, S; Workman, JL; Sternglanz, R			Sas4 and Sas5 are required for the histone acetyltransferase activity of Sas2 in the SAS complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSEMBLY FACTOR-I; RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; SILENCING PROTEIN; DNA-REPLICATION; CHROMATIN; ACETYLATION; ASF1; HETEROCHROMATIN; TRANSCRIPTION	The SAS2 gene is involved in transcriptional silencing in Saccharomyces cerevisiae. Based on its primary sequence, the Sas2 protein is predicted to be a member of the MYST family of histone acetyltransferases (HATs). Sas2 forms a complex with Sas4 and Sas5, which are required for its silencing function. Here we show that recombinant Sas2 has HAT activity that absolutely requires Sas4 and is stimulated by Sas5. The recombinant SAS complex acetylates H4 lysine 16 and H3 lysine 14. Furthermore, a purified SAS complex from yeast shows similar activity and specificity. In contrast to other MYST HATs, neither the recombinant nor the native SAS complex acetylated nucleosomal histones under conditions that were optimum for acetylating free histones. Finally, although the SAS subunits interact genetically and physically with Asf1, a histone deposition factor, association of H3 and H4 with Asf1 blocks their acetylation by the SAS complex, raising the possibility that the SAS HAT complex may acetylate free histones prior to their deposition onto DNA by Asf1 or CAF-I.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Penn State Univ, Dept Biochem & Mol Biol, Howard Hughes Med Inst, University Pk, PA 16802 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; Osaka Univ, Grad Sch Pharmaceut Sci, Lab Environm Biochem, Suita, Osaka 5650871, Japan	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Osaka University	Sternglanz, R (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.			Kaufman, Paul/0000-0003-3089-313X				Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Carruthers LM, 1999, METHOD ENZYMOL, V304, P19; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; EhrenhoferMurray AE, 1997, GENETICS, V145, P923; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; GRAZIANO V, 1988, J MOL BIOL, V203, P997, DOI 10.1016/0022-2836(88)90124-6; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; John S, 2000, GENE DEV, V14, P1196; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Krawitz DC, 2002, MOL CELL BIOL, V22, P614, DOI 10.1128/MCB.22.2.614-625.2002; Levenstein ME, 2002, J BIOL CHEM, V277, P8749, DOI 10.1074/jbc.M111212200; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; Osada S, 2001, GENE DEV, V15, P3155, DOI 10.1101/gad.907201; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Reifsnyder C, 1996, NAT GENET, V14, P42, DOI 10.1038/ng0996-42; Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X; Sharp JA, 2001, CURR BIOL, V11, P463, DOI 10.1016/S0960-9822(01)00140-3; Sherman JM, 1997, TRENDS GENET, V13, P308, DOI 10.1016/S0168-9525(97)01198-0; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; Singer MS, 1998, GENETICS, V150, P613; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Sutton A, 2001, GENETICS, V158, P587; Tan S, 2001, PROTEIN EXPRES PURIF, V21, P224, DOI 10.1006/prep.2000.1363; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Tyler JK, 2001, MOL CELL BIOL, V21, P6574, DOI 10.1128/MCB.21.19.6574-6584.2001; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Xu EY, 1999, GENETICS, V153, P25	36	68	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16887	16892		10.1074/jbc.M210709200	http://dx.doi.org/10.1074/jbc.M210709200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12626510	hybrid			2022-12-27	WOS:000182818600060
J	Baumann, H; Kunapuli, P; Tracy, E; Cowell, JK				Baumann, H; Kunapuli, P; Tracy, E; Cowell, JK			The oncogenic fusion protein-tyrosine kinase ZNF198/fibroblast growth factor receptor-1 has signaling function comparable with interleukin-6 cytokine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATYPICAL MYELOPROLIFERATIVE DISORDER; LEUKEMIA INHIBITORY FACTOR; HEPATIC CELLS; OLIGOMERIZATION DOMAIN; TRANSFORMING ACTIVITY; GENE-EXPRESSION; ONCOSTATIN-M; BCR-ABL; TRANSLOCATION; ZNF198	The reciprocal t(8;13) chromosome translocation results in a fusion gene (FUS) in which the N-terminal half of the zinc finger protein ZNF198 is combined with the cytoplasmic domain of the fibroblast growth factor receptor-1 (FGFR1). Expression of FUS is suggested to provide growth-promoting activity to myeloid cells similar to the activity of hematopoietic cytokine receptors. This study determined the specificity of FUS to activate signal transduction pathways. Because no tumor cell line expressing FUS was available, the mode of FUS action was identified in cells transiently and stably transfected with an expression vector for FUS. FUS acted as a constitutively active protein-tyrosine kinase and mediated phosphorylation of STAT1, 3, and 5 but not STAT4 and 6. The same specificity but lower activity was determined for normal FGFR1. STAT activation by FUS, similar to that by interleukin-6-type cytokines, promoted STAT-specific induction of genes. The functionality of FUS, as well as the relative recruitment of STAT isoforms, was determined by the dimerizing function of the zinc finger domain. Replacement of the ZNF198 portion by the Bcr portion as present in the t(8;22) translocation shifted the signaling toward a more prominent STAT5 activation. This study documents that both gene partners forming the fusion oncogene define the activity and the signaling specificity of the protein-tyrosine kinase of FGFR1.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute	Baumann, H (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.			Cowell, John/0000-0002-2079-5950	NATIONAL CANCER INSTITUTE [R01CA076167, R01CA085580] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76167, CA 85580] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRUZZO LV, 1992, AM J SURG PATHOL, V16, P236, DOI 10.1097/00000478-199203000-00003; Chernova O, 1998, GENE CHROMOSOME CANC, V21, P160, DOI 10.1002/(SICI)1098-2264(199802)21:2<160::AID-GCC12>3.0.CO;2-V; Cross NCP, 2002, LEUKEMIA, V16, P1207, DOI 10.1038/sj.leu.2402556; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Demiroglu A, 2001, BLOOD, V98, P3778, DOI 10.1182/blood.V98.13.3778; Fioretos T, 2001, GENE CHROMOSOME CANC, V32, P302, DOI 10.1002/gcc.1195; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Guasch G, 2001, MOL CELL BIOL, V21, P8129, DOI 10.1128/MCB.21.23.8129-8142.2001; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KANAPULI P, 2003, IN PRESS ONCOGENE; KEMPSKI H, 1995, GENE CHROMOSOME CANC, V12, P283, DOI 10.1002/gcc.2870120408; KLINT P, 1999, FRONT BIOSCI, V4, P165; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Kulkarni S, 1999, GENOMICS, V55, P118, DOI 10.1006/geno.1998.5634; Kuropatwinski KK, 1997, J BIOL CHEM, V272, P15135, DOI 10.1074/jbc.272.24.15135; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; Lai CF, 1999, J BIOL CHEM, V274, P7793, DOI 10.1074/jbc.274.12.7793; Macdonald D, 2002, ACTA HAEMATOL-BASEL, V107, P101, DOI 10.1159/000046639; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; Ollendorff V, 1999, J BIOL CHEM, V274, P26922, DOI 10.1074/jbc.274.38.26922; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; RABBITTS TH, 1994, SCIENCE, V372, P143; SCOTT ML, 1991, P NATL ACAD SCI USA, V88, P6506, DOI 10.1073/pnas.88.15.6506; Smedley D, 1998, HUM MOL GENET, V7, P637, DOI 10.1093/hmg/7.4.637; Smedley Damian, 1999, Neoplasia (New York), V1, P349, DOI 10.1038/sj.neo.7900035; Still IH, 1997, BLOOD, V90, P3136, DOI 10.1182/blood.V90.8.3136; Still IH, 1998, BLOOD, V92, P1456, DOI 10.1182/blood.V92.4.1456.splL3_1456_1458; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200; WHEELER EF, 1986, J VIROL, V59, P224, DOI 10.1128/JVI.59.2.224-233.1986; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Xiao S, 2000, BLOOD, V96, P699	36	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16198	16208		10.1074/jbc.M300018200	http://dx.doi.org/10.1074/jbc.M300018200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594223	hybrid			2022-12-27	WOS:000182680000094
J	Eggler, AL; Lusetti, SL; Cox, MM				Eggler, AL; Lusetti, SL; Cox, MM			The C terminus of the Escherichia coli RecA protein modulates the DNA binding competition with single-stranded DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ATPASE ACTIVITY; HOMOLOGOUS RECOMBINATION; PARTIAL SUPPRESSOR; BIOCHEMICAL BASIS; STABLE COMPLEXES; SSB PROTEIN; DUPLEX DNA; EXCHANGE; REPLICATION; FILAMENTS	The nucleation step of Escherichia coli RecA filament formation on single-stranded DNA (ssDNA) is strongly inhibited by prebound E. coli ssDNA-binding protein (SSB). The capacity of RecA protein to displace SSB is dramatically enhanced in RecA proteins with C-terminal deletions. The displacement of SSB by RecA protein is progressively improved when 6,13, and 17 C-terminal amino acids are removed from the RecA protein relative to the full-length protein. The C-terminal deletion mutants also more readily displace yeast replication protein A than does the full-length protein. Thus, the RecA protein has an inherent and robust capacity to displace SSB from ssDNA. However, the displacement function is suppressed by the RecA C terminus, providing another example of a RecA activity with C-terminal modulation. RecADeltaC17 also has an enhanced capacity relative to wild-type RecA protein to bind ssDNA containing secondary structure. Added Mg2+ enhances the ability of wild-type RecA and the RecA C-terminal deletion mutants to compete with SSB and replication protein A. The overall binding of RecADeltaC17 mutant protein to linear ssDNA is increased further by the mutation E38K, previously shown to enhance SSB displacement from ssDNA. The double mutant RecADeltaC17/E38K displaces SSB somewhat better than either individual mutant protein under some conditions and exhibits a higher steady-state level of binding to linear ssDNA under all conditions.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu		Eggler, Aimee/0000-0002-7286-2107	NIGMS NIH HHS [GM 32335] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; ASAI T, 1994, J BACTERIOL, V176, P7113, DOI 10.1128/JB.176.22.7113-7114.1994; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; Bork JM, 2001, J BIOL CHEM, V276, P45740, DOI 10.1074/jbc.M109247200; Bork JM, 2001, EMBO J, V20, P7313, DOI 10.1093/emboj/20.24.7313; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; CHOW SA, 1988, J BIOL CHEM, V263, P200; Courcelle J, 1997, P NATL ACAD SCI USA, V94, P3714, DOI 10.1073/pnas.94.8.3714; COX MM, 1982, J BIOL CHEM, V257, P8523; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Eggler AL, 2002, J BIOL CHEM, V277, P39280, DOI 10.1074/jbc.M204328200; ENNIS DG, 1995, MUTAT RES-DNA REPAIR, V336, P39, DOI 10.1016/0921-8777(94)00045-8; Galitski T, 1997, GENETICS, V146, P751; KNIGHT KL, 1984, J BIOL CHEM, V259, P1279; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1987, P NATL ACAD SCI USA, V84, P3127, DOI 10.1073/pnas.84.10.3127; LARMINAT F, 1989, MOL GEN GENET, V216, P106, DOI 10.1007/BF00332237; LAVERY PE, 1992, J BIOL CHEM, V267, P20648; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; LAVERY PE, 1992, J BIOL CHEM, V267, P9307; LAVERY PE, 1990, J BIOL CHEM, V265, P4004; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P250; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; MADIRAJU MVVS, 1988, P NATL ACAD SCI USA, V85, P6592, DOI 10.1073/pnas.85.18.6592; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MOREAU PL, 1988, J BACTERIOL, V170, P2493, DOI 10.1128/jb.170.6.2493-2500.1988; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; PUGH BF, 1987, J BIOL CHEM, V262, P1326; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; RUSCHE JR, 1985, J BIOL CHEM, V260, P949; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; SMITH KC, 1987, MUTAT RES, V183, P1, DOI 10.1016/0167-8817(87)90039-3; Steiner WW, 1998, J BACTERIOL, V180, P6269; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; THOMAS A, 1983, J GEN MICROBIOL, V129, P681; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; VanLoock MS, 2003, STRUCTURE, V11, P187, DOI 10.1016/S0969-2126(03)00003-0; VOLKERT MR, 1984, J BACTERIOL, V160, P702, DOI 10.1128/JB.160.2.702-705.1984; WANG TCV, 1993, MUTAT RES, V294, P157, DOI 10.1016/0921-8777(93)90024-B; WANG TCV, 1986, J BACTERIOL, V168, P940, DOI 10.1128/jb.168.2.940-946.1986; WANG TCV, 1991, BIOCHIMIE, V73, P335, DOI 10.1016/0300-9084(91)90221-L; YARRANTON GT, 1982, MOL GEN GENET, V185, P99, DOI 10.1007/BF00333797; YU X, 1991, J STRUCT BIOL, V106, P243, DOI 10.1016/1047-8477(91)90074-7; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	63	78	90	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16389	16396		10.1074/jbc.M212920200	http://dx.doi.org/10.1074/jbc.M212920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598538	hybrid			2022-12-27	WOS:000182680000118
J	Targett-Adams, P; Chambers, D; Gledhill, S; Hope, RG; Coy, JF; Girod, A; McLauchlan, J				Targett-Adams, P; Chambers, D; Gledhill, S; Hope, RG; Coy, JF; Girod, A; McLauchlan, J			Live cell analysis and targeting of the lipid droplet-binding adipocyte differentiation-related protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; LEYDIG TUMOR-CELLS; CORE PROTEIN; MESSENGER-RNA; LIVING CELLS; PERILIPIN-A; EXPRESSION; ADIPOPHILIN; ASSOCIATION; STORAGE	Neutral lipid is stored in spherical organelles called lipid droplets that are bounded by a coat of proteins. The protein that is most frequently found at the surface of lipid droplets is adipocyte differentiation-related protein (ADRP). In this study, we demonstrate that fusion of either the human or mouse ADRP coding sequences to green fluorescent protein (GFP) does not disrupt the ability of the protein to associate with lipid droplets. Using this system to identify targeting elements, discontinuous segments within the coding region were required for directing ADRP to lipid droplets. GFP-tagged protein was employed also to examine the behavior of lipid droplets in live cells. Time lapse microscopy demonstrated that in HuH-7 cells, which are derived from a human hepatoma, a small number of lipid droplets could move rapidly, indicating transient association with intracellular transport pathways. Most lipid droplets did not show such movement but oscillated within a confined area; these droplets were in close association with the endoplasmic reticulum. membrane and moved in concert with the endoplasmic reticulum. Fluorescence recovery analysis of GFP-tagged ADRP in live cells revealed that surface proteins do not rapidly diffuse between lipid droplets, even in conditions where they are closely packed. This system provides new insights into the properties of lipid droplets and their interaction with cellular processes.	MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland; MRC Technol, Edinburgh EH4 2SP, Midlothian, Scotland; MTM Labs AG, D-69120 Heidelberg, Germany; European Mol Biol Lab, Cell Biol & Biophys Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	McLauchlan, J (corresponding author), MRC, Virol Unit, Church St, Glasgow G11 5JR, Lanark, Scotland.			Targett-Adams, Paul/0000-0003-4967-1668				Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; Buechler C, 2001, BBA-MOL CELL BIOL L, V1532, P97, DOI 10.1016/S1388-1981(01)00121-4; Burt AD, 1998, SEMIN DIAGN PATHOL, V15, P246; Charron AJ, 2002, J CELL SCI, V115, P3049; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Coy JF, 1996, CELL DEATH DIFFER, V3, P199; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; FREEMAN DA, 1982, J BIOL CHEM, V257, P4231; Gao J, 2000, J CELL PHYSIOL, V182, P297; Garcia A, 2003, J BIOL CHEM, V278, P625, DOI 10.1074/jbc.M206602200; Gibbons GF, 2000, BBA-MOL CELL BIOL L, V1483, P37, DOI 10.1016/S1388-1981(99)00182-1; GOCZE PM, 1994, CYTOMETRY, V17, P151, DOI 10.1002/cyto.990170207; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; Hope RG, 2000, J GEN VIROL, V81, P1913, DOI 10.1099/0022-1317-81-8-1913; Hope RG, 2002, J BIOL CHEM, V277, P4261, DOI 10.1074/jbc.M108798200; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; Litvak V, 2002, CURR BIOL, V12, P1513, DOI 10.1016/S0960-9822(02)01107-7; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Lu XY, 2001, MAMM GENOME, V12, P741, DOI 10.1007/s00335-01-2055-5; Mather IH, 1998, J MAMMARY GLAND BIOL, V3, P259, DOI 10.1023/A:1018711410270; McLauchlan J, 2002, EMBO J, V21, P3980, DOI 10.1093/emboj/cdf414; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; Reits EAJ, 2001, NAT CELL BIOL, V3, pE145, DOI 10.1038/35078615; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; Schrader M, 2001, J HISTOCHEM CYTOCHEM, V49, P1421, DOI 10.1177/002215540104901110; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Steiner S, 1996, BIOCHEM BIOPH RES CO, V218, P777, DOI 10.1006/bbrc.1996.0138; VANROOIJEN GJH, 1995, PLANT PHYSIOL, V109, P1353, DOI 10.1104/pp.109.4.1353; Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5; Wu CC, 2000, ELECTROPHORESIS, V21, P3470, DOI 10.1002/1522-2683(20001001)21:16<3470::AID-ELPS3470>3.3.CO;2-7	42	161	163	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15998	16007		10.1074/jbc.M211289200	http://dx.doi.org/10.1074/jbc.M211289200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12591929	hybrid			2022-12-27	WOS:000182680000070
J	Yu, XW; Kennedy, RH; Liu, SJ				Yu, XW; Kennedy, RH; Liu, SJ			JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAK-STAT; SIGNAL-TRANSDUCTION; SERUM INTERLEUKIN-6; CARDIAC MYOCYTES; CYTOKINES; GP130; PATHWAY; JAK/STAT; RELEASE; FAMILY	Interleukin (IL)-6 decreases cardiac contractility via a nitric oxide (NO)-dependent pathway. However, mechanisms underlying IL-6-induced NO production remain unclear. JAK2/STAT3 and ERK1/2 are two well known signaling pathways activated by IL-6 in non-cardiac cells. However, these IL-6-activated pathways have not been identified in adult cardiac myocytes. In this study, we identified activation of these two pathways during IL-6 stimulation and examined their roles in IL-6-induced NO production and decrease in contractility of adult ventricular myocytes. IL-6 increased phosphorylation. of STAT3 (at Tyr(705)) and ERK1/2 (at Tyr(204)) within 5 min that peaked at 15-30 min and returned to basal levels at 2 h. Phosphorylation of STAT3 was blocked by genistein, a protein tyrosine kinase inhibitor, and AG490, a JAK2 inhibitor, but not PD98059, an ERK1/2 kinase inhibitor. The phosphorylation of ERK1/2 was blocked by PD98059 and genistein but not AG490. Furthermore, IL-6 enhanced de novo synthesis of iNOS protein, increased NO production, and decreased cardiac contractility after 2 h of incubation. These effects were blocked by genistein and AG490 but not PD98059. We conclude that IL-6 activated independently the JAK2/STAT3 and ERK1/2 pathways, but only JAK2/STAT3 signaling mediated the NO-associated decrease in contractility.	Univ Arkansas Med Sci, Dept Pharmaceut Sci, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Liu, SJ (corresponding author), Univ Arkansas Med Sci, Dept Pharmaceut Sci, 4301 W Markham St,MS 522-3, Little Rock, AR 72205 USA.	sliu@uams.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062226] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 62226] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BASSANI JWM, 1993, AM J PHYSIOL, V265, pC533, DOI 10.1152/ajpcell.1993.265.2.C533; Bers DM, 1998, ANN NY ACAD SCI, V853, P157, DOI 10.1111/j.1749-6632.1998.tb08264.x; Debonera F, 2001, J SURG RES, V96, P289, DOI 10.1006/jsre.2001.6086; Decker T, 1999, CELL MOL LIFE SCI, V55, P1505, DOI 10.1007/s000180050390; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GUILLEN I, 1995, AM J PHYSIOL-REG I, V269, pR229, DOI 10.1152/ajpregu.1995.269.2.R229; HACK CE, 1989, BLOOD, V74, P1704; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; IKEDA U, 1992, J MOL CELL CARDIOL, V24, P579, DOI 10.1016/0022-2828(92)91042-4; JOURDAN M, 1990, ARTHRITIS RHEUM-US, V33, P398, DOI 10.1002/art.1780330313; Kammuller ME, 1995, TOXICOLOGY, V105, P91, DOI 10.1016/0300-483X(95)03128-3; KINUGAWA K, 1994, CIRC RES, V75, P285, DOI 10.1161/01.RES.75.2.285; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Kodama H, 2000, AM J PHYSIOL-HEART C, V279, pH1635, DOI 10.1152/ajpheart.2000.279.4.H1635; Kunisada K, 1996, CIRCULATION, V94, P2626, DOI 10.1161/01.CIR.94.10.2626; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; LIU S, 1995, AM J PHYSIOL-CELL PH, V268, pC339, DOI 10.1152/ajpcell.1995.268.2.C339; Liu SJ, 2003, AM J PHYSIOL-CELL PH, V284, pC826, DOI 10.1152/ajpcell.00465.2002; Liu SJ, 1998, AM J PHYSIOL-HEART C, V275, pH1462, DOI 10.1152/ajpheart.1998.275.4.H1462; Mascareno E, 2001, CIRCULATION, V104, P325, DOI 10.1161/01.CIR.104.3.325; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; NEUMANN FJ, 1995, CIRCULATION, V92, P748, DOI 10.1161/01.CIR.92.4.748; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Omura T, 2001, J MOL CELL CARDIOL, V33, P307, DOI 10.1006/jmcc.2000.1303; Roig E, 1998, AM J CARDIOL, V82, P688, DOI 10.1016/S0002-9149(98)00388-9; Satoh M, 1996, VIRCHOWS ARCH, V427, P503; Sawa Y, 1998, J THORAC CARDIOV SUR, V116, P511, DOI 10.1016/S0022-5223(98)70018-2; Schindler C, 1999, EXP CELL RES, V253, P7, DOI 10.1006/excr.1999.4670; Schumann G, 1999, J NEUROCHEM, V73, P2009; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; Steele IC, 1996, EUR J CLIN INVEST, V26, P1018, DOI 10.1046/j.1365-2362.1996.2560587.x; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Wan S, 1996, J THORAC CARDIOV SUR, V112, P806, DOI 10.1016/S0022-5223(96)70068-5; Wollert K C, 2001, Heart Fail Rev, V6, P95; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yamauchi-Takihara K, 2000, INT J EXP PATHOL, V81, P1; YU XW, 2000, J MOL CELL CARDIOL, V32, pA72	44	104	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16304	16309		10.1074/jbc.M212321200	http://dx.doi.org/10.1074/jbc.M212321200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595539	hybrid			2022-12-27	WOS:000182680000107
J	Buxton, DB; Golomb, E; Adelstein, RS				Buxton, DB; Golomb, E; Adelstein, RS			Induction of nonmuscle myosin heavy chain II-C by butyrate in RAW 264.7 mouse macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; SP1 BINDING; SODIUM-BUTYRATE; CELLULAR MYOSIN; MESSENGER-RNAS; CELLS; PROTEIN; LIPOPOLYSACCHARIDE; PROMOTER	RAW 264.7 macrophages express nonmuscle myosin heavy chain II-A as the only significant nonmuscle myosin heavy chain isoform,with expression of nonmuscle myosin heavy chain II-B and II-C low or absent. Treatment of the cells with sodium butyrate, an inhibitor of historic deacetylase, led to the dose-dependent induction of nonniuscle myosin heavy chain II-C. Trichostatin A, another inhibitor of histone deacetylase, also induced nonmuscle myosin heavy chain II-C. Induction of nonmuscle myosin heavy chain II-C in response to these histone deacetylase inhibitors was attenuated by mithramycin, an inhibitor of Spl binding to GC-rich DNA sequences. Bacterial lipopolysaccharide alone had no effect on basal nonmuscle myosin heavy chain II-C expression, but attenuated butyrate-mediated induction of nonmuscle myosin heavy chain II-C. The effects of lipopolysaccharide were mimicked by the nitric oxide donors sodium nitroprusside and spermine NONOate, suggesting a role for nitric oxide in the lipopolysaccharide-mediated down-regulation of nonmuscle myosin heavy chain II-C induction. This was supported by experiments with the inducible nitric-oxide synthase inhibitor 1400W, which partially blocked the lipopolysaccharide-mediated attenuation of nonmuscle myosin heavy chain induction. 8-Bromo-cGMP had no effect on nonmuscle myosin heavy chain induction, consistent with a cGMP-independent mechanism for nitric oxide-mediated inhibition of nonmuscle myosin heavy chain II-C induction.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Buxton, DB (corresponding author), Rockledge Ctr 2, Heart Res Program, 6701 Rockledge Dr,Suite 9044,MSC 7940, Bethesda, MD 20892 USA.			Buxton, Denis/0000-0003-3077-6435; Adelstein, Robert/0000-0002-8683-2144	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004230, Z01HL004230] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beohar N, 1998, J BIOL CHEM, V273, P9168, DOI 10.1074/jbc.273.15.9168; Berendji D, 1999, MOL MED, V5, P721, DOI 10.1007/BF03402096; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cesari M, 1998, BIOCHEM J, V336, P619, DOI 10.1042/bj3360619; Chakravortty D, 2000, J ENDOTOXIN RES, V6, P243, DOI 10.1179/096805100101532108; CHESNOKOV V N, 1990, Biokhimiya, V55, P1276; Choi OH, 1996, J MUSCLE RES CELL M, V17, P69, DOI 10.1007/BF00140325; Collins SM, 2001, GUT, V49, P743, DOI 10.1136/gut.49.6.743; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Fukushima K, 1998, DIGESTION, V59, P683, DOI 10.1159/000007576; Fusunyan RD, 1998, PEDIATR RES, V43, P84, DOI 10.1203/00006450-199801000-00013; GOLD ME, 1990, P NATL ACAD SCI USA, V87, P4430, DOI 10.1073/pnas.87.12.4430; IKEDA K, 1990, J BIOL CHEM, V265, P5398; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; KOYAMA H, 1976, J CELL PHYSIOL, V88, P49, DOI 10.1002/jcp.1040880107; Kroncke KD, 2000, FASEB J, V14, P166; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; Litvak DA, 1998, SURGERY, V124, P161, DOI 10.1067/msy.1998.90365; Lu Y, 1999, BBA-GENE STRUCT EXPR, V1444, P85, DOI 10.1016/S0167-4781(98)00257-7; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Penhoat A, 1996, MOL CELL ENDOCRINOL, V121, P57, DOI 10.1016/0303-7207(96)03851-8; Sekiguchi K, 2001, CIRC RES, V88, P52, DOI 10.1161/01.RES.88.1.52; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; TOOTHAKER LE, 1991, BLOOD, V78, P1826; Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031; Tsuji Y, 1999, J BIOL CHEM, V274, P7501, DOI 10.1074/jbc.274.11.7501; Tullio AN, 1997, P NATL ACAD SCI USA, V94, P12407, DOI 10.1073/pnas.94.23.12407; Tullio AN, 2001, J COMP NEUROL, V433, P62, DOI 10.1002/cne.1125; Walker GE, 2001, ENDOCRINOLOGY, V142, P3817, DOI 10.1210/en.142.9.3817; Wang SB, 1999, J BIOL CHEM, V274, P33190, DOI 10.1074/jbc.274.47.33190; Yam JWP, 1999, BIOCHEM BIOPH RES CO, V266, P472, DOI 10.1006/bbrc.1999.1852; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; Ye XB, 2002, J BIOL CHEM, V277, P31863, DOI 10.1074/jbc.M205544200; ZHANG JW, 1990, DEV GENET, V11, P168, DOI 10.1002/dvg.1020110207	42	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15449	15455		10.1074/jbc.M210145200	http://dx.doi.org/10.1074/jbc.M210145200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12598534	hybrid			2022-12-27	WOS:000182516100112
J	Berenbaum, F; Humbert, L; Bereziat, G; Thirion, S				Berenbaum, F; Humbert, L; Bereziat, G; Thirion, S			Concomitant recruitment of ERK1/2 and p38 MAPK signalling pathway is required for activation of cytoplasmic phospholipase A(2) via ATP in articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; PROTEIN-KINASE; INORGANIC PYROPHOSPHATE; PROSTAGLANDIN E-2; GENE-EXPRESSION; SYNOVIAL-FLUID; RECEPTORS; RELEASE; INDUCTION; INTERLEUKIN-1-BETA	Extracellular ATP is a pro-inflammatory mediator involved in the release of prostaglandin from articular chondrocytes, but little is known about its effects on intracellular signaling. ATP triggered the rapid release of prostaglandin E-2 (PGE(2)) by acting on P2Y(2) receptors in rabbit articular chondrocytes. We have explored the signaling events involved in this synthesis. ATP significantly increased arachidonic acid production, which involved the activation of the 85-kDa cytosolic phospholipase A(2) (cPLA(2)) but not a secreted form of PLA(2), as demonstrated by various PLA(2) inhibitors and translocation experiments. We also showed that ATP induced the phosphorylation of p38 and ERK1/2 mitogen-activated protein kinases (MAPKs). Both PD98059, an inhibitor of the ERK pathway, and SB203580, an inhibitor of p38 MAPK, completely inhibited the ATP-induced release of PGE(2). Finally, dominant-negative plasmids encoding p38 and ERK transfected alone into the cells impaired the ATP-induced release of PGE(2) to about the same extent as both plasmids transfected together. These results suggest that PGE(2) production induced by ATP requires the activation of both ERK1/2 and p38 MAPKs. Thus, ATP acts via P2Y(2)-purine receptors to recruit cPLA(2) by activating both ERK1/2 and p38 MAPKs and stimulates the release of PGE(2) from articular chondrocytes.	Univ Paris 06, UMR 7079, CNRS, Physiol & Physiopathol Lab, F-75252 Paris 5, France; Unite Format Rech St Antoine, Dept Rheumatol, F-75012 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Thirion, S (corresponding author), Univ Paris 06, UMR 7079, CNRS, Physiol & Physiopathol Lab, 7 Quai St Bernard,Bat A, F-75252 Paris 5, France.		Berenbaum, Francis/AAO-5690-2020	Berenbaum, Francis/0000-0001-8252-7815; Thirion, Sylvie/0000-0001-5361-8275				Abramson S B, 2001, Curr Rheumatol Rep, V3, P535, DOI 10.1007/s11926-001-0069-3; Aimond F, 2000, J BIOL CHEM, V275, P39110, DOI 10.1074/jbc.M008192200; Ayyanathan K, 1996, BIOCHEM BIOPH RES CO, V218, P783, DOI 10.1006/bbrc.1996.0139; Bingham CO, 1999, P ASSOC AM PHYSICIAN, V111, P516, DOI 10.1046/j.1525-1381.1999.99321.x; Bodin P, 1998, INFLAMM RES, V47, P351, DOI 10.1007/s000110050341; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; Borsch-Haubold AG, 1999, EUR J BIOCHEM, V265, P195, DOI 10.1046/j.1432-1327.1999.00722.x; BOWLER WB, 1995, J BONE MINER RES, V10, P1137; Burnstock G, 2000, J PHARMACOL EXP THER, V295, P862; CASWELL AM, 1991, BIOCHIM BIOPHYS ACTA, V1074, P151, DOI 10.1016/0304-4165(91)90054-K; CASWELL AM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P52, DOI 10.1016/0167-4889(92)90099-W; Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898-6568(00)00083-8; Croucher LJ, 2000, BBA-MOL BASIS DIS, V1502, P297, DOI 10.1016/S0925-4439(00)00055-7; Dangelmaier C, 2000, EUR J BIOCHEM, V267, P2283, DOI 10.1046/j.1432-1327.2000.01235.x; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Graff RD, 2000, ARTHRITIS RHEUM-US, V43, P1571, DOI 10.1002/1529-0131(200007)43:7<1571::AID-ANR22>3.3.CO;2-C; HATORI M, 1995, J CELL PHYSIOL, V165, P468, DOI 10.1002/jcp.1041650304; Hedbom E, 2002, CELL MOL LIFE SCI, V59, P45, DOI 10.1007/s00018-002-8404-z; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; Hou MY, 2000, ARTERIOSCL THROM VAS, V20, P2064, DOI 10.1161/01.ATV.20.9.2064; Jacques C, 1997, J CLIN INVEST, V99, P1864, DOI 10.1172/JCI119353; John GR, 2001, J NEUROSCI, V21, P4134, DOI 10.1523/JNEUROSCI.21-12-04134.2001; John GR, 1999, P NATL ACAD SCI USA, V96, P11613, DOI 10.1073/pnas.96.20.11613; Koolpe M, 1997, J ORTHOP RES, V15, P204, DOI 10.1002/jor.1100150208; Koolpe M, 1999, ARTHRITIS RHEUM, V42, P258, DOI 10.1002/1529-0131(199902)42:2<258::AID-ANR7>3.0.CO;2-O; Kumar Sanjay, 2001, Current Opinion in Pharmacology, V1, P307, DOI 10.1016/S1471-4892(01)00054-6; LEONG WS, 1994, BBA-GEN SUBJECTS, V1201, P298, DOI 10.1016/0304-4165(94)90054-X; LEONG WS, 1993, CLIN SCI, V85, P569, DOI 10.1042/cs0850569; Massaad C, 2000, J BIOL CHEM, V275, P22686, DOI 10.1074/jbc.M001250200; McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528; Miwa M, 2000, OSTEOARTHR CARTILAGE, V8, P17, DOI 10.1053/joca.1999.0266; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; Park W, 1996, J RHEUMATOL, V23, P665; Pelletier JP, 2001, J RHEUMATOL, V28, P2509; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; PRUZANSKI W, 1995, J RHEUMATOL, V22, P2114; RADVANYI F, 1989, ANAL BIOCHEM, V177, P103, DOI 10.1016/0003-2697(89)90022-5; Ralevic V, 1998, PHARMACOL REV, V50, P413; RYAN LM, 1991, J RHEUMATOL, V18, P716; Swanson KD, 1998, J BIOL CHEM, V273, P19965, DOI 10.1074/jbc.273.32.19965; Thomas B, 2002, BIOCHEM J, V362, P367, DOI 10.1042/0264-6021:3620367; Troadec JD, 1998, J PHYSIOL-LONDON, V511, P89, DOI 10.1111/j.1469-7793.1998.089bi.x	45	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13680	13687		10.1074/jbc.M211570200	http://dx.doi.org/10.1074/jbc.M211570200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12591927	hybrid			2022-12-27	WOS:000182405000017
J	Sang, NL; Stiehl, DP; Bohensky, J; Leshchinsky, I; Srinivas, V; Caro, J				Sang, NL; Stiehl, DP; Bohensky, J; Leshchinsky, I; Srinivas, V; Caro, J			MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 1-ALPHA HIF-1-ALPHA; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVITY; HIF-ALPHA; DEGRADATION DOMAIN; STRUCTURAL BASIS; ACTIVATION; TRANSACTIVATION; VHL; COMPLEX	Hypoxia-inducible factors (HIF) are a family of heterodimeric transcriptional regulators that play pivotal roles in the regulation of cellular utilization of oxygen and glucose and are essential transcriptional regulators of angiogenesis in solid tumor and ischemic disorders. The transactivation activity of HIF complexes requires the recruitment of p300/CREB-binding protein (CBP) by HIF-1alpha and HIF-2alpha that undergo oxygen-dependent degradation. HIF activation in tumors is caused by several factors including mitogen-activated protein kinase (MAPK) signaling. Here we investigated the molecular basis for HIF activation by MAPK. We show that MAPK is required for the transactivation activity of HIF-1alpha. Furthermore, inhibition of MAPK disrupts the HIF-p300 interaction and suppresses the transactivation activity of p300. Overexpression of MEK1, an upstream MAPK activator, stimulates the transactivation of both p300 and HIF-1alpha. Interestingly, the C-terminal transactivation domain of HIF-1alpha is not a direct substrate of MAPK, and HIF-1alpha phosphorylation is not required for HIFCAD/p300 interaction. Taken together, our data suggest that MAPK signaling facilitates HIF activation through p300/CBP.	Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Dept Physiol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University	Caro, J (corresponding author), Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Dept Med, 1015 Walnut St,Curtis Bldg,Rm 809, Philadelphia, PA 19107 USA.	Jamie.caro@mail.tju.edu	Stiehl, Daniel/A-3622-2008	Stiehl, Daniel/0000-0002-0076-4874	NATIONAL CANCER INSTITUTE [R01CA089212, K01CA098809] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007821] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA098809, R01 CA089212, R01CA89212] Funding Source: Medline; NHLBI NIH HHS [T32-HL007821] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Avots A, 1999, IMMUNITY, V10, P515, DOI 10.1016/S1074-7613(00)80051-5; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Caro J, 2001, HIGH ALT MED BIOL, V2, P145, DOI 10.1089/152702901750265251; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Fedele Anthony O, 2002, Mol Interv, V2, P229, DOI 10.1124/mi.2.4.229; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Gradin K, 2002, J BIOL CHEM, V277, P23508, DOI 10.1074/jbc.M201307200; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; Gusterson R, 2002, J BIOL CHEM, V277, P2517, DOI 10.1074/jbc.M104626200; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Pei L, 2000, J BIOL CHEM, V275, P31191, DOI 10.1074/jbc.M002451200; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salceda S, 1997, KIDNEY INT, V51, P556, DOI 10.1038/ki.1997.78; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Sang NL, 2002, FRONT BIOSCI, V7, pD407, DOI 10.2741/sang; Sang NL, 1997, J CELL PHYSIOL, V170, P182, DOI 10.1002/(SICI)1097-4652(199702)170:2<182::AID-JCP10>3.0.CO;2-K; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; See RH, 2001, J BIOL CHEM, V276, P16310, DOI 10.1074/jbc.M008113200; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	55	271	289	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14013	14019		10.1074/jbc.M209702200	http://dx.doi.org/10.1074/jbc.M209702200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12588875	Green Accepted, hybrid			2022-12-27	WOS:000182405000059
J	Wang, SW; Zhu, JY				Wang, SW; Zhu, JY			Evidence for a relief of repression mechanism for activation of the human telomerase reverse transcriptase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITOR; HUMAN-CELLS; HTERT GENE; C-MYC; CELLULAR SENESCENCE; DNA METHYLATION; TUMOR-CELLS; IN-VIVO; SUBUNIT; CHROMATIN	The transcriptional activation of human telomerase reverse transcriptase ( hTERT) is an important step during cellular immortalization and tumorigenesis. To study how this activation occurs during immortalization, we have established a set of genetically related pre-crisis cells and their immortal progeny. As expected, hTERT mRNA was detected in our telomerase-positive immortal cells but not in pre-crisis cells or telomerase-negative immortal cells. However, transiently transfected luciferase reporters controlled by hTERT promoter sequences exhibited similar levels of luciferase activity in both telomerase-positive and -negative cells, suggesting that the endogenous chromatin context is likely required for hTERT regulation. Analysis of chromatin susceptibility to DNase I digestion consistently identified a DNase I hypersensitivity site (DHS) near the hTERT transcription initiation site in telomerase-positive cells. In addition, the histone deacetylase inhibitor trichostatin A (TSA) induced hTERT transcription and also a general increase in chromatin sensitivity to DNase treatment in telomerase-negative cells. The TSA-induced hTERT transcription in pre-crisis cells was accompanied by the formation of a DHS at the hTERT promoter. Furthermore, the TSA-induced hTERT transcription and chromatin alterations were not blocked by cycloheximide, suggesting that this induction does not require de novo protein synthesis and that TSA induces hTERT expression through the inhibition of histone deacetylation at the hTERT promoter. Taken together, our results suggest that the endogenous chromatin environment plays a critical role in the regulation of hTERT expression during cellular immortalization.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Zhu, JY (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA.		zhu, ji/HDM-1538-2022					Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; Dessain SK, 2000, CANCER RES, V60, P537; Devereux TR, 1999, CANCER RES, V59, P6087; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; Ducrest AL, 2001, CANCER RES, V61, P7594; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Hodny Z, 2000, BIOCHEM J, V346, P93, DOI 10.1042/0264-6021:3460093; Horikawa I, 2002, MOL BIOL CELL, V13, P2585, DOI 10.1091/mbc.E01-11-0107; Horikawa I, 1999, CANCER RES, V59, P826; Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; Kang SS, 1999, J BIOL CHEM, V274, P13085, DOI 10.1074/jbc.274.19.13085; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Krupp G, 1997, NUCLEIC ACIDS RES, V25, P919, DOI 10.1093/nar/25.4.919; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Kyo S, 1999, CANCER RES, V59, P5917; LI BY, 1994, J BIOL CHEM, V269, P7756; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; PENG J, 1995, SCIENCE, V269, P1236; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Shay JW, 2000, NEOPLASIA, V2, P195, DOI 10.1038/sj.neo.7900093; Sjottem E, 1997, J MOL BIOL, V267, P490, DOI 10.1006/jmbi.1997.0893; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	49	56	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18842	18850		10.1074/jbc.M209544200	http://dx.doi.org/10.1074/jbc.M209544200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12611896	hybrid			2022-12-27	WOS:000182932200019
J	Baldwin, RL				Baldwin, RL			In search of the energetic role of peptide hydrogen bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDRATION FREE-ENERGIES; ALANINE-BASED PEPTIDES; HELIX-COIL TRANSITION; VARYING CHAIN LENGTHS; ALPHA-HELIX; BACKBONE SOLVATION; PROPENSITIES; WATER; STABILIZATION; ENTHALPY		Stanford Univ, Beckman Ctr, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Baldwin, RL (corresponding author), Stanford Univ, Beckman Ctr, Sch Med, Dept Biochem, Stanford, CA 94305 USA.							Avbelj F, 2000, P NATL ACAD SCI USA, V97, P10786, DOI 10.1073/pnas.200343197; AVBELJ F, 1995, BIOCHEMISTRY-US, V34, P755, DOI 10.1021/bi00003a008; Avbelj F, 2000, J MOL BIOL, V300, P1335, DOI 10.1006/jmbi.2000.3901; Avbelj F, 2002, P NATL ACAD SCI USA, V99, P1309, DOI 10.1073/pnas.032665499; Baldwin RL, 2002, BIOPHYS CHEM, V101, P203, DOI 10.1016/S0301-4622(02)00195-3; BENNAIM A, 1991, J PHYS CHEM-US, V95, P1437, DOI 10.1021/j100156a074; BenTal N, 1997, J PHYS CHEM B, V101, P450, DOI 10.1021/jp961825r; BIERZYNSKI A, 1982, P NATL ACAD SCI-BIOL, V79, P2470, DOI 10.1073/pnas.79.8.2470; Born M, 1920, Z PHYS, V1, P45, DOI 10.1007/BF01881023; BROWN JE, 1971, BIOCHEMISTRY-US, V10, P470, DOI 10.1021/bi00779a019; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOIG AJ, 1994, BIOCHEMISTRY-US, V33, P3396, DOI 10.1021/bi00177a033; EPAND RM, 1968, BIOCHEMISTRY-US, V7, P2864, DOI 10.1021/bi00848a024; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0; Florian J, 1997, J PHYS CHEM B, V101, P5583, DOI 10.1021/jp9705075; GANGANI RA, 2002, BIOCHEMISTRY-US, V41, P15296; HIRATA F, 1988, INT J QUANTUM CHEM, P179; HONIG B, 1995, ADV PROTEIN CHEM, V46, P27, DOI 10.1016/S0065-3233(08)60331-9; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KLOTZ IM, 1962, J AM CHEM SOC, V84, P3461, DOI 10.1021/ja00877a009; Krantz BA, 2002, NAT STRUCT BIOL, V9, P458, DOI 10.1038/nsb794; LIFSON S, 1961, J CHEM PHYS, V34, P1963, DOI 10.1063/1.1731802; LIFSON S, 1979, J AM CHEM SOC, V101, P5111, DOI 10.1021/ja00512a001; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; Lopez MM, 2002, P NATL ACAD SCI USA, V99, P1298, DOI 10.1073/pnas.032665199; Luo PZ, 1999, P NATL ACAD SCI USA, V96, P4930, DOI 10.1073/pnas.96.9.4930; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MITCHELL JBO, 1990, J COMPUT CHEM, V11, P1217, DOI 10.1002/jcc.540111014; MITCHELL JBO, 1991, CHEM PHYS LETT, V180, P517, DOI 10.1016/0009-2614(91)85003-F; Park C, 2000, J PHYS CHEM B, V104, P7784, DOI 10.1021/jp0001743; PAULING L, 1951, P NATL ACAD SCI USA, V37, P729, DOI 10.1073/pnas.37.11.729; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; QIAN H, 1992, J PHYS CHEM-US, V96, P3987, DOI 10.1021/j100189a015; RASHIN AA, 1985, J PHYS CHEM-US, V89, P5588, DOI 10.1021/j100272a006; Robertson AD, 1997, CHEM REV, V97, P1251, DOI 10.1021/cr960383c; Rohl CA, 1996, PROTEIN SCI, V5, P2623, DOI 10.1002/pro.5560051225; ROHL CA, 1992, BIOCHEMISTRY-US, V31, P1263, DOI 10.1021/bi00120a001; SCHELLMAN JOHN A., 1955, COMPT REND TRAV LAB CARLSBERG SER CHIM, V29, P223; SCHELLMAN JOHN A., 1955, COMPT REND TRAV LAB CARLSBERG SER CHIM, V29, P230; SCHERAGA HA, 1978, PURE APPL CHEM, V50, P315, DOI 10.1351/pac197850040315; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; SCHOLTZ JM, 1991, P NATL ACAD SCI USA, V88, P2854, DOI 10.1073/pnas.88.7.2854; Shi ZS, 2002, P NATL ACAD SCI USA, V99, P9190, DOI 10.1073/pnas.112193999; Siedlecka M, 1999, P NATL ACAD SCI USA, V96, P903, DOI 10.1073/pnas.96.3.903; SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043; Spek EJ, 1999, J AM CHEM SOC, V121, P5571, DOI 10.1021/ja990056x; STICKLE DF, 1992, J MOL BIOL, V226, P1143, DOI 10.1016/0022-2836(92)91058-W; TANIUCHI H, 1969, J BIOL CHEM, V244, P3864; Vila JA, 2000, P NATL ACAD SCI USA, V97, P13075, DOI 10.1073/pnas.240455797; ZIMM BH, 1959, J CHEM PHYS, V31, P526, DOI 10.1063/1.1730390; [No title captured]	53	105	108	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17581	17588		10.1074/jbc.X200009200	http://dx.doi.org/10.1074/jbc.X200009200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12582164	hybrid, Green Submitted			2022-12-27	WOS:000182838300001
J	Fan, HZ; Turck, CW; Derynck, R				Fan, HZ; Turck, CW; Derynck, R			Characterization of growth factor-induced serine phosphorylation of tumor necrosis factor-alpha converting enzyme and of an alternatively translated polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; ACTIVATED PROTEIN-KINASE; SELECTIN ADHESION MOLECULE; MAP KINASE; TGF-ALPHA; METALLOPROTEASE-DISINTEGRIN; CELL-SURFACE; TRANSMEMBRANE PROTEINS; DEPENDENT MECHANISM; SIGNAL-TRANSDUCTION	Tumor necrosis factor-alpha converting enzyme (TACE) is a prototype member of the adamalysin family of transmembrane metalloproteases that effects ectodomain cleavage and release of many transmembrane proteins, including transforming growth factor-alpha. Growth factors that act through tyrosine kinase receptors, as well as other stimuli, induce shedding through activation of the Erk mitogen-activated protein (MAP) kinase pathway without the need of new protein synthesis. How MAP kinase regulates shedding by TACE is not known. We now report that the cytoplasmic domain of TACE is phosphorylated in response to growth factor stimulation. We also identified a naturally expressed smaller polypeptide corresponding to most of the cytoplasmic domain of TACE. This protein, which we named SPRACT, is derived through alternative translation of the TACE-coding sequence and is, similarly to TACE, phosphorylated in response to growth factor and phorbol 12-myristate 13-acetate stimulation. Phosphoamino acid analysis revealed that growth factor-induced phosphorylation of TACE occurs only on serine and not on threonine or tyrosine. Tryptic mapping experiments coupled with site-directed mutagenesis identified Ser(819) as the major target of growth factor-induced phosphorylation, whereas Ser(791) undergoes dephosphorylation in response to growth factor stimulation. The phosphorylation of Ser(819), but not the dephosphorylation of Ser(791), depends on activation of the Erk MAP kinase pathway. Increased SPRACT expression or mutation of the TACE cytoplasmic domain to inactivate growth factor-induced phosphorylation did not detectably affect growth factor-induced shedding of transmembrane transforming growth factor-alpha by TACE. The roles of SPRACT and the cytoplasmic phosphorylation of TACE remain to be defined.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Program Dev Biol, San Francisco, CA 94143 USA; Canc Inst New Jersey, Piscataway, NJ 08854 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Fan, HZ (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane R514, Piscataway, NJ 08854 USA.		Fan, Huizhou/E-5835-2012	FAN, HUIZHOU/0000-0002-4903-926X	NATIONAL CANCER INSTITUTE [R01CA054826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE013904] Funding Source: NIH RePORTER; NCI NIH HHS [CA54826] Funding Source: Medline; NIDCR NIH HHS [DE13904] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aguilar Z, 2001, J BIOL CHEM, V276, P44099, DOI 10.1074/jbc.M103442200; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Boissel JP, 1998, NITRIC OXIDE-BIOL CH, V2, P337, DOI 10.1006/niox.1998.0189; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; BUTCHER EC, 1992, ADV EXP MED BIOL, V323, P181; Cerretti DP, 1999, BIOCHEM BIOPH RES CO, V263, P810, DOI 10.1006/bbrc.1999.1322; Conway JG, 2001, J PHARMACOL EXP THER, V298, P900; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Gerli R, 2001, J IMMUNOL, V166, P832, DOI 10.4049/jimmunol.166.2.832; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Imperiale M J, 1995, Curr Top Microbiol Immunol, V199 ( Pt 2), P139; Iwamoto R, 2000, CYTOKINE GROWTH F R, V11, P335, DOI 10.1016/S1359-6101(00)00013-7; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Luetteke N C, 1990, Semin Cancer Biol, V1, P265; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Merlos-Suarez A, 1999, BIOCHEM SOC T, V27, P243, DOI 10.1042/bst0270243; Montero JC, 2000, MOL CELL NEUROSCI, V16, P631, DOI 10.1006/mcne.2000.0896; Montero JC, 2002, BIOCHEM J, V363, P211, DOI 10.1042/0264-6021:3630211; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Namchuk M, 1997, J BIOL CHEM, V272, P1548, DOI 10.1074/jbc.272.3.1548; Nelson KK, 1999, BIOCHEM J, V343, P673, DOI 10.1042/0264-6021:3430673; Okada-Ban M, 2000, INT J BIOCHEM CELL B, V32, P263, DOI 10.1016/S1357-2725(99)00133-8; PANDIELLA A, 1991, BIOCHEM SOC T, V19, P259, DOI 10.1042/bst0190259; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Rizoli SB, 1999, J BIOL CHEM, V274, P22072, DOI 10.1074/jbc.274.31.22072; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Solomon KA, 1997, J IMMUNOL, V159, P4524; Strausbaugh HJ, 1999, NAT MED, V5, P1057, DOI 10.1038/12497; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Umata T, 2001, J BIOL CHEM, V276, P30475, DOI 10.1074/jbc.M103673200; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Xu KP, 2001, AM J PHYSIOL-CELL PH, V281, pC603, DOI 10.1152/ajpcell.2001.281.2.C603; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Zheng YF, 2002, J BIOL CHEM, V277, P42463, DOI 10.1074/jbc.M207459200; Zhou W, 2002, INFLAMM RES, V51, P91, DOI 10.1007/BF02684009; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200; Zhu GZ, 1999, GENE, V234, P227, DOI 10.1016/S0378-1119(99)00208-5	69	97	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18617	18627		10.1074/jbc.M300331200	http://dx.doi.org/10.1074/jbc.M300331200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621058	hybrid			2022-12-27	WOS:000182838300134
J	Mead, JR; Hughes, TR; Irvine, SA; Singh, NN; Ramji, DP				Mead, JR; Hughes, TR; Irvine, SA; Singh, NN; Ramji, DP			Interferon-gamma stimulates the expression of the inducible cAMP early repressor in macrophages through the activation of casein kinase 2 - A potentially novel pathway for interferon-gamma-mediated inhibition of gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN ISOFORMS; CYCLE-REGULATED PHOSPHORYLATION; DENSITY-LIPOPROTEIN RECEPTOR; LONG-TERM DESENSITIZATION; NECROSIS-FACTOR-ALPHA; FOAM CELL-FORMATION; IFN-GAMMA; DIFFERENTIAL REGULATION; HUMAN MONOCYTES; SELECTIVE-INHIBITION	Interferon-gamma (IFN-gamma) is a pleiotropic cytokine that modulates the immune function, cell proliferation, apoptosis, macrophage activation, and numerous other cellular responses. These biological actions of IFN-gamma are characterized by both the activation and the inhibition of gene transcription. Unfortunately, in contrast to gene activation, the mechanisms through which the cytokine suppresses gene transcription remain largely unclear. We show here for the first time that exposure of macrophages to IFN-gamma leads to a dramatic induction in the expression of the inducible cAMP early repressor (ICER), a potent inhibitor of gene transcription. In addition, a synergistic action of IFN-gamma and calcium in the activation of ICER expression was identified. The IFN-gamma-mediated activation of ICER expression was not blocked by H89, bisindoylmaleimide, SB202190, PD98059, W7, and AG490, which inhibit protein kinase A, protein kinase C, p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, calcium-calmodulin-dependent protein kinase, and Janus kinase-2, respectively. In contrast, apigenin, a selective casein kinase 2 (CK2) inhibitor, was found to inhibit response. Consistent with this finding, IFN-gamma stimulated CK2 activity and the level of phosphorylated cAMP response element-binding protein, which is known to induce ICER gene transcription, and this response was inhibited in the presence of apigenin. These studies, therefore, identify a previously uncharacterized pathway, involving the IFN-gamma-mediated stimulation of CK2 activity, activation of cAMP response element-binding protein, and increased production of ICER, which may then play an important role in the inhibition of macrophage gene transcription by this cytokine.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	Cardiff University	Ramji, DP (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.	ramji@cardiff.ac.uk	irvine, scott/B-1090-2019; irvine, scott/A-2392-2019; Ramji, Dipak/A-7092-2010	irvine, scott/0000-0002-8926-1543; Ramji, Dipak/0000-0002-6419-5578				Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Antoine M, 1996, MOL CELL ENDOCRINOL, V120, P1, DOI 10.1016/0303-7207(96)03806-3; AUWERX JH, 1989, BIOCHEMISTRY-US, V28, P4563, DOI 10.1021/bi00437a009; Bodor J, 2002, EUR J IMMUNOL, V32, P203, DOI 10.1002/1521-4141(200201)32:1<203::AID-IMMU203>3.0.CO;2-C; Bodor J, 1998, J BIOL CHEM, V273, P9544, DOI 10.1074/jbc.273.16.9544; Bodor J, 2001, J LEUKOCYTE BIOL, V69, P1053; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Buechler C, 2000, J LEUKOCYTE BIOL, V67, P97, DOI 10.1002/jlb.67.1.97; BYRON KA, 1991, CLIN EXP IMMUNOL, V85, P307; Channavajhala P, 2002, ONCOGENE, V21, P5280, DOI 10.1038/sj.onc.1205640; Chujor CSN, 1996, EUR J IMMUNOL, V26, P1253, DOI 10.1002/eji.1830260611; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davies GE, 2000, BIOCHEM BIOPH RES CO, V271, P346, DOI 10.1006/bbrc.2000.2630; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; DESANCTIS JB, 1994, IMMUNOLOGY, V81, P605; Diaz A, 1997, INT J BIOCHEM CELL B, V29, P251, DOI 10.1016/S1357-2725(96)00112-4; Dowd DR, 1997, MOL CELL ENDOCRINOL, V128, P29, DOI 10.1016/S0303-7207(96)04012-9; Egwuagu CE, 2002, J IMMUNOL, V168, P3181, DOI 10.4049/jimmunol.168.7.3181; Fitzgerald LR, 1996, J NEUROCHEM, V67, P490; Foka P, 2001, BIOCHEM BIOPH RES CO, V285, P430, DOI 10.1006/bbrc.2001.5203; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Granger RL, 2000, BBA-MOL BASIS DIS, V1501, P171, DOI 10.1016/S0925-4439(00)00016-8; Heninger E, 2000, INFLAMM RES, V49, P393, DOI 10.1007/s000110050606; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hughes TR, 2002, J BIOL CHEM, V277, P11097, DOI 10.1074/jbc.M106774200; Hussain MA, 2000, DIABETES, V49, P1681, DOI 10.2337/diabetes.49.10.1681; Ikeda Y, 1999, BIOCHEM BIOPH RES CO, V262, P494, DOI 10.1006/bbrc.1999.1226; Iwata M, 2001, JPN J OPHTHALMOL, V45, P13, DOI 10.1016/S0021-5155(00)00296-3; Jikihara H, 1996, BIOL REPROD, V54, P1311, DOI 10.1095/biolreprod54.6.1311; Kameda T, 1999, BBA-GENE STRUCT EXPR, V1445, P31, DOI 10.1016/S0167-4781(99)00018-4; Kamolmatyakul S, 2001, J DENT RES, V80, P351, DOI 10.1177/00220345010800011001; Katsanakis KD, 2002, ANTICANCER RES, V22, P755; Kockar FT, 2001, NUCLEIC ACIDS RES, V29, P362, DOI 10.1093/nar/29.2.362; Kominsky SL, 2000, CANCER RES, V60, P3904; Kong SE, 1999, ANAL BIOCHEM, V271, P111, DOI 10.1006/abio.1999.4123; Kosaka S, 2001, CIRCULATION, V103, P1142, DOI 10.1161/01.CIR.103.8.1142; Kousteni S, 1998, MECH DEVELOP, V77, P143, DOI 10.1016/S0925-4773(98)00128-2; KOVACS EJ, 1988, J IMMUNOL, V141, P3101; Krueger DA, 1999, MOL ENDOCRINOL, V13, P1207, DOI 10.1210/me.13.7.1207; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; LAMARRE J, 1993, J CLIN INVEST, V91, P1219, DOI 10.1172/JCI116283; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Lewis M, 1999, J CELL BIOCHEM, V72, P373, DOI 10.1002/(SICI)1097-4644(19990301)72:3<373::AID-JCB7>3.0.CO;2-N; Lodie TA, 1997, J IMMUNOL, V158, P1848; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Mao DL, 1998, MOL ENDOCRINOL, V12, P492, DOI 10.1210/me.12.4.492; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Monaco L, 1997, ONCOGENE, V15, P2493, DOI 10.1038/sj.onc.1201636; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; NISHIKAWA T, 1993, J CLIN ENDOCR METAB, V77, P1084, DOI 10.1210/jc.77.4.1084; OSANTO S, 1992, EUR J CANCER, V28A, P1622, DOI 10.1016/0959-8049(92)90055-7; Penton-Rol G, 1998, J IMMUNOL, V160, P3869; Peri A, 2002, EUR J ENDOCRINOL, V146, P759, DOI 10.1530/eje.0.1460759; Peri A, 2001, J CLIN ENDOCR METAB, V86, P2111, DOI 10.1210/jc.86.5.2111; Polentarutti N, 1998, EUR J IMMUNOL, V28, P496, DOI 10.1002/(SICI)1521-4141(199802)28:02<496::AID-IMMU496>3.0.CO;2-V; Qin HW, 1998, J IMMUNOL, V161, P6664; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; Regenhard P, 2001, J LEUKOCYTE BIOL, V69, P651; Ringheim GE, 1996, BIOCHEM BIOPH RES CO, V224, P246, DOI 10.1006/bbrc.1996.1015; Ruetten H, 1997, BRIT J PHARMACOL, V122, P59, DOI 10.1038/sj.bjp.0701345; Saavedra AP, 2000, ENDOCRINOLOGY, V141, P606, DOI 10.1210/en.141.2.606; Sabatakos G, 1998, BIOCHEM J, V334, P205, DOI 10.1042/bj3340205; Saeki K, 1999, BIOCHEM J, V338, P49, DOI 10.1042/0264-6021:3380049; SCHNYDERCANDRIAN S, 1995, J LEUKOCYTE BIOL, V57, P929, DOI 10.1002/jlb.57.6.929; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Shirazi Y, 1998, J Hum Virol, V1, P69; Sibinga NES, 1999, J BIOL CHEM, V274, P12139, DOI 10.1074/jbc.274.17.12139; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Storvik M, 2000, J PHARMACOL EXP THER, V294, P52; Sung JY, 2001, J BIOL CHEM, V276, P13858, DOI 10.1074/jbc.M010610200; Tengku-Muhammad TS, 1998, CYTOKINE, V10, P38, DOI 10.1006/cyto.1997.0254; Tengku-Muhammad TS, 2000, CYTOKINE, V12, P1430, DOI 10.1006/cyto.2000.0711; Tengku-Muhammad TS, 2000, CYTOKINE, V12, P720, DOI 10.1006/cyto.1999.0620; TengkuMuhammad TS, 1996, CYTOKINE, V8, P525, DOI 10.1006/cyto.1996.0071; Thommesen L, 2000, J BIOL CHEM, V275, P4244, DOI 10.1074/jbc.275.6.4244; Thommesen L, 2001, AM J PHYSIOL-ENDOC M, V281, pE1316, DOI 10.1152/ajpendo.2001.281.6.E1316; THORNBERG H, 2001, BIOCHEM J, V354, P169; Tinti C, 1996, J BIOL CHEM, V271, P25375, DOI 10.1074/jbc.271.41.25375; Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200; TURAKOCKAR F, 2001, NUCLEIC ACIDS RES, V29, P3632; Uyttersprot N, 1999, EUR J BIOCHEM, V259, P370, DOI 10.1046/j.1432-1327.1999.00049.x; VARGA J, 1995, J CLIN INVEST, V96, P475, DOI 10.1172/JCI118058; Yehia G, 2001, J BIOL CHEM, V276, P35272, DOI 10.1074/jbc.M105404200; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yuan WH, 1999, J CELL PHYSIOL, V179, P97, DOI 10.1002/(SICI)1097-4652(199904)179:1<97::AID-JCP12>3.3.CO;2-5; Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342	95	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17741	17751		10.1074/jbc.M301602200	http://dx.doi.org/10.1074/jbc.M301602200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12609974	hybrid			2022-12-27	WOS:000182838300021
J	Schramm, G; Falcone, FH; Gronow, A; Haisch, K; Mamat, U; Doenhoff, MJ; Oliveira, G; Galle, J; Dahinden, CA; Haas, H				Schramm, G; Falcone, FH; Gronow, A; Haisch, K; Mamat, U; Doenhoff, MJ; Oliveira, G; Galle, J; Dahinden, CA; Haas, H			Molecular characterization of an interleukin-4-inducing factor from Schistosoma mansoni eggs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BLOOD BASOPHILS; EPSILON-RI+ CELLS; TH2 RESPONSES; PERIPHERAL-BLOOD; IMMUNOGLOBULIN-E; V(H)3 REGION; T-CELLS; IGE; INDUCTION; IL-4	The eggs of the parasitic trematode Schistosoma mansoni are powerful inducers of a T helper type 2 (Th2) immune response and immunoglobulin E (IgE) production. S. mansoni egg extract (SmEA) stimulates human basophils to rapidly release large amounts of interleukin (IL)-4, the key promoter of a Th2 response. Here we show purification and sequence of the IL-4-inducing principle of S. mansoni eggs (IPSE). Stimulation studies with human basophils using SmEA fractions and natural and recombinant IPSE as well as neutralization and immunodepletion studies using antibodies to recombinant IPSE demonstrate that IPSE is the bioactive principle in SmEA leading to activation of basophils and to expression of IL-4 and IL-13. Regarding the mechanism of action, blot analysis showed that IPSE is an IgE-binding factor, suggesting that it becomes effective via cross-linking receptor-bound IgE on basophils. Immunohistology revealed that IPSE is enriched in and secreted from the subshell area of the schistosome egg. We conclude from these data that IPSE may be an important parasite-derived component for skewing the immune response toward Th2.	Forschungszentrum Borstel, Div Cellular Allergol, D-23845 Borstel, Germany; Univ Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales; Fiocruz MS, Ctr Pesquisas Rene Rachou, BR-30190002 Belo Horizonte, MG, Brazil; Univ Hosp Bern, Inselspital, Inst Immunol & Allergol, CH-3010 Bern, Switzerland	Forschungszentrum Borstel; Bangor University; Fundacao Oswaldo Cruz; University of Bern; University Hospital of Bern	Haas, H (corresponding author), Forschungszentrum Borstel, Div Cellular Allergol, Parkallee 22, D-23845 Borstel, Germany.	hhaas@fz-borstel.de	Falcone, Franco H/F-9210-2013; Falcone, Franco/AAE-8026-2021; Oliveira, Guilherme/E-2624-2014	Falcone, Franco H/0000-0002-1732-9932; Falcone, Franco/0000-0002-1732-9932; Oliveira, Guilherme/0000-0003-0054-3438; Doenhoff, Michael/0000-0002-0163-6903				Ashton PD, 2001, PARASITOLOGY, V122, P329, DOI 10.1017/S0031182001007351; BOROS DL, 1970, J EXP MED, V132, P488, DOI 10.1084/jem.132.3.488; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; CARTER CE, 1978, J PARASITOL, V64, P385, DOI 10.2307/3279763; DEBRAY H, 1989, CARBOHYD RES, V185, P15, DOI 10.1016/0008-6215(89)84017-0; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811, DOI 10.1016/S0091-6749(99)70292-7; DOENHOFF MJ, 1981, T ROY SOC TROP MED H, V75, P41, DOI 10.1016/0035-9203(81)90012-2; DUNNE DW, 1991, PARASITOLOGY, V103, P225, DOI 10.1017/S0031182000059503; Dunzendorfer S, 2001, J ALLERGY CLIN IMMUN, V108, P581, DOI 10.1067/mai.2001.118518; Eglite S, 2000, J IMMUNOL, V165, P2183, DOI 10.4049/jimmunol.165.4.2183; Falcone FH, 1996, EUR J IMMUNOL, V26, P1147, DOI 10.1002/eji.1830260528; Haas H, 1999, INT ARCH ALLERGY IMM, V119, P86, DOI 10.1159/000024182; Haas H, 1999, EUR J IMMUNOL, V29, P918, DOI 10.1002/(SICI)1521-4141(199903)29:03&lt;918::AID-IMMU918&gt;3.0.CO;2-T; Haisch K, 1999, J IMMUNOL METHODS, V226, P129, DOI 10.1016/S0022-1759(99)00059-9; Haisch K, 2001, PARASITE IMMUNOL, V23, P427, DOI 10.1046/j.1365-3024.2001.00392.x; Haselhorst T, 2001, J AM CHEM SOC, V123, P10705, DOI 10.1021/ja011156h; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; Kaplan AP, 2001, INT ARCH ALLERGY IMM, V124, P423, DOI 10.1159/000053777; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; Marone G, 2000, CRIT REV IMMUNOL, V20, P477; Marone G., 2000, MAST CELLS BASOPHILS; OCHENSBERGER B, 1995, BLOOD, V86, P4039, DOI 10.1182/blood.V86.11.4039.bloodjournal86114039; Okano M, 2001, J IMMUNOL, V167, P442, DOI 10.4049/jimmunol.167.1.442; Okano M, 1999, ALLERGY, V54, P593, DOI 10.1034/j.1398-9995.1999.00063.x; Okano M, 1999, J IMMUNOL, V163, P6712; Oliveira G, 2001, TRENDS PARASITOL, V17, P108, DOI 10.1016/S1471-4922(00)01802-X; Oliveira GC, 1995, MOL BIOCHEM PARASIT, V75, P119, DOI 10.1016/0166-6851(95)02508-1; Patella V, 2000, J IMMUNOL, V164, P589, DOI 10.4049/jimmunol.164.2.589; Patella V, 1998, J IMMUNOL, V161, P5647; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; Sambrook J., 2001, MOL CLONING; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; VANDAM GJ, 1995, CIRCULATING GUT ASS, P21; VELLA AT, 1992, J IMMUNOL, V148, P2283; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18	42	139	146	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18384	18392		10.1074/jbc.M300497200	http://dx.doi.org/10.1074/jbc.M300497200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624091	hybrid			2022-12-27	WOS:000182838300104
J	Chandra, D; Tang, DG				Chandra, D; Tang, DG			Mitochondrially localized active caspase-9 and caspase-3 result mostly from translocation from the cytosol and partly from caspase-mediated activation in the organelle - Lack of evidence for Apaf-1-mediated procaspase-9 activation in the mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM STRESS; ETOPOSIDE-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; NUCLEAR-LOCALIZATION; MOUSE-LIVER; MEMBRANE; APAF-1; PATHWAY; EXPRESSION	Active caspase-9 and caspase-3 have been observed in the mitochondria, but their origins are unclear. Theoretically, procaspase-9 might be activated in the mitochondria in a cytochrome c/Apaf-1-dependent manner, or activated caspase-9 and -3 may translocate to the mitochondria, or the mitochondrially localized procaspases may be activated by the translocated active caspases. Here we present evidence that the mitochondrially localized active caspase-9 and -3 result mostly from translocation from the cytosol ( into the intermembrane space) and partly from caspase-mediated activation in the organelle rather than from the Apaf-1-mediated activation. Apaf-1 localizes exclusively in the cytosol and, upon apoptotic stimulation, translocates to the perinuclear area but not to the mitochondria. In most cases, the mitochondrially localized procaspase-9 and -3 are released early during apoptosis and translocate to the cytosol and/or perinuclear area. Cytochrome c and the mitochondrial matrix protein Hsp60 are also rapidly released to the cytosol early during apoptosis. Both the early release of proteins like cytochrome c and Hsp60 from the mitochondria as well as the later translocation of the active caspase-9/-3 are partially inhibited by cyclosporin A, an inhibitor of mitochondrial membrane permeabilization. The mitochondrial active caspases may function as a positive feedback mechanism to further activate other or residual mitochondrial procaspases, degrade mitochondrial constituents, and disintegrate mitochondrial functions.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Pk Rd 1C, Smithville, TX 78957 USA.	dtang@sprd1.mdacc.tmc.edu	Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384	NCI NIH HHS [CA 90297] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Angelastro JM, 2001, J BIOL CHEM, V276, P12190, DOI 10.1074/jbc.M009523200; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bratton SB, 2001, CELL DEATH DIFFER, V8, P425, DOI 10.1038/sj.cdd.4400834; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chandra D, 2002, J BIOL CHEM, V277, P50842, DOI 10.1074/jbc.M207622200; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Costantini P, 2002, CELL DEATH DIFFER, V9, P82, DOI 10.1038/sj.cdd.4400932; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Fujita E, 2002, CELL DEATH DIFFER, V9, P1108, DOI 10.1038/sj.cdd.4401080; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; Horvitz HR, 1999, CANCER RES, V59, p1701S; Jemmerson R, 2002, CELL DEATH DIFFER, V9, P538, DOI 10.1038/sj.cdd.4400981; Joshi B, 1999, CANCER RES, V59, P4343; Krajewska M, 1997, CANCER RES, V57, P1605; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Krebs JF, 1999, J CELL BIOL, V144, P915, DOI 10.1083/jcb.144.5.915; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li SC, 2002, J BIOL CHEM, V277, P26912, DOI 10.1074/jbc.M200726200; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Mao PL, 1998, J BIOL CHEM, V273, P23621, DOI 10.1074/jbc.273.37.23621; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawara A, 1997, CANCER RES, V57, P4578; Nakanishi K, 2001, J BIOL CHEM, V276, P41237, DOI 10.1074/jbc.M105648200; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Qin ZH, 2001, J BIOL CHEM, V276, P8079, DOI 10.1074/jbc.M007028200; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Ruiz-Vela A, 2002, FEBS LETT, V517, P133, DOI 10.1016/S0014-5793(02)02607-8; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samali A, 1998, FEBS LETT, V431, P167, DOI 10.1016/S0014-5793(98)00740-6; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Tang DG, 1998, CANCER RES, V58, P3466; Tang DG, 1998, BIOCHEM BIOPH RES CO, V242, P380, DOI 10.1006/bbrc.1997.7969; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; van Loo G, 2002, CELL DEATH DIFFER, V9, P1207, DOI 10.1038/sj.cdd.4401101; Wang XD, 2001, GENE DEV, V15, P2922; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	58	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17408	17420		10.1074/jbc.M300750200	http://dx.doi.org/10.1074/jbc.M300750200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12611882	hybrid			2022-12-27	WOS:000182818600128
J	Grobler, JA; Markel, EJ; Fay, JF; Graham, DJ; Simcoe, AL; Ludmerer, SW; Murray, EM; Migliaccio, G; Flores, OA				Grobler, JA; Markel, EJ; Fay, JF; Graham, DJ; Simcoe, AL; Ludmerer, SW; Murray, EM; Migliaccio, G; Flores, OA			Identification of a key determinant of hepatitis C virus cell culture adaptation in domain II of NS3 helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTIOUS MOLECULAR CLONE; CDNA-CLONE; CRYSTAL-STRUCTURE; RNA REPLICATION; GENOTYPE 1B; MUTATIONS; SEQUENCE; INTERFERON-ALPHA-2B; TRANSCRIPTS; RIBAVIRIN	Efficient replication of hepatitis C virus (HCV) replicons in cell culture is associated with specific sequences not generally observed in vivo. These cell culture adaptive mutations dramatically increase the frequency with which replication is established in vitro. However, replicons derived from HCV isolates that have been shown to replicate in chimpanzees do not replicate in cell culture even when these adaptive mutations are introduced. To better understand this apparent paradox, we performed a gain-of-function screen to identify sequences that could confer cell culture replication competence to replicons derived from chimpanzee infectious HCV isolates. We found that residue 470 in domain II of the NS3 helicase is a critical determinant in cell culture adaptation. Substitutions in residue 470 when combined with the NS5A-S232I adaptive mutation are both necessary and sufficient to confer cell culture replication to otherwise inactive replicons, including those derived from genotype 1b HCV-BK and genotype 1a HCV-H77 isolates. The specific substitution at residue 470 required for replication is context-dependent, with R470M and P470L being optimal for the activity of HCV-BK and HCV-H77 replicons, respectively. Together these data indicate that mutations in the NS3 helicase domain II act in concert with previously identified adaptive mutations and predict that introduction of compatible residues at these positions can confer cell culture replication activity to diverse HCV isolates.	Merck Res Labs, Dept Biol Chem, West Point, PA 19486 USA; Ist Ric Biol Mol P Angeletti, I-00040 Pomezia, Italy	Merck & Company; Merck & Company	Flores, OA (corresponding author), Merck Res Labs, Dept Biol Chem, POB 4,WP26A-4000, West Point, PA 19486 USA.	osvaldo_flores@merck.com						Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Beard MR, 1999, HEPATOLOGY, V30, P316, DOI 10.1002/hep.510300137; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bukh J, 2002, P NATL ACAD SCI USA, V99, P14416, DOI 10.1073/pnas.212532699; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Conley AJ, 1998, HEPATOLOGY, V28, p560A; Farci P, 2000, SEMIN LIVER DIS, V20, P103; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Hong Z, 1999, VIROLOGY, V256, P36, DOI 10.1006/viro.1999.9603; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; Lanford RE, 2001, J GEN VIROL, V82, P1291, DOI 10.1099/0022-1317-82-6-1291; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Murray EM, 2003, J VIROL, V77, P2928, DOI 10.1128/JVI.77.5.2928-2935.2003; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Thomson M, 2001, GASTROENTEROLOGY, V121, P1226, DOI 10.1053/gast.2001.28669; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WANT C, 1993, J VIROL, V67, P3338; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; Yanagi M, 1998, VIROLOGY, V244, P161, DOI 10.1006/viro.1998.9092; Yanagi M, 1999, VIROLOGY, V262, P250, DOI 10.1006/viro.1999.9889; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	34	38	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16741	16746		10.1074/jbc.M212602200	http://dx.doi.org/10.1074/jbc.M212602200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615931	hybrid			2022-12-27	WOS:000182818600040
J	Jores, L; Wagner, R				Jores, L; Wagner, R			Essential steps in the ppGpp-dependent regulation of bacterial ribosomal RNA promoters can be explained by substrate competition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-RATE CONTROL; ESCHERICHIA-COLI; GUANOSINE TETRAPHOSPHATE; TRANSCRIPTION INITIATION; STRINGENT CONTROL; COMPLEX-FORMATION; IN-VIVO; POLYMERASE; MECHANISM; MUTANTS	Transcription of stable RNA genes is known to be dramatically reduced in the presence of guanosine tetraphosphate (ppGpp), the mediator of the stringent response. Using in vitro transcription systems with ribosomal RNA P1 promoters, we have analyzed which step of the initiation cycle is inhibited by the effector ppGpp. We show that formation of the ternary transcription initiation complex consisting of RNA polymerase holoenzyme, the promoter DNA, and the first initiating nucleotide triphosphate is the major step at which ppGpp exerts its regulation. Neither primary binding of RNA polymerase to the promoter nor isomerization to the open binary complexes or the subsequent promoter clearance steps contributes notably to the observed inhibition. The effect of ppGpp-dependent inhibition in the formation of the ternary transcription initiation complex could be mimicked by nucleotide derivatives known to bind to the RNA polymerase active center. Using these model compounds, almost identical inhibition characteristics were observed as seen with ppGpp. The results support the previously published model, which suggests that ppGpp-dependent inhibition is based on competition between the inhibitor molecules and NTP substrates for access to the active center of RNA polymerase.	Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Wagner, R (corresponding author), Univ Dusseldorf, Inst Phys Biol, Univ Str 1, D-40225 Dusseldorf, Germany.	r.wagner@rz.uni-duesseldorf.de						BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; Barker MM, 2001, J BACTERIOL, V183, P6315, DOI 10.1128/JB.183.21.6315-6323.2001; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Barker MM, 2001, J MOL BIOL, V305, P689, DOI 10.1006/jmbi.2000.4328; BECK C, 1973, J MOL BIOL, V78, P117, DOI 10.1016/0022-2836(73)90431-2; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Carmona M, 2000, J BACTERIOL, V182, P4711, DOI 10.1128/JB.182.17.4711-4718.2000; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; Choy HE, 2000, J BIOL CHEM, V275, P6783, DOI 10.1074/jbc.275.10.6783; Colland F, 2002, GENES CELLS, V7, P233, DOI 10.1046/j.1365-2443.2002.00517.x; Epshtein V, 2002, MOL CELL, V10, P623, DOI 10.1016/S1097-2765(02)00640-8; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; GESTELAND RF, 1966, J MOL BIOL, V16, P67, DOI 10.1016/S0022-2836(66)80263-2; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; Heinemann M, 1997, EUR J BIOCHEM, V247, P990, DOI 10.1111/j.1432-1033.1997.00990.x; HERNANDEZ VJ, 1995, J MOL BIOL, V252, P536; Hsu LM, 1996, METHOD ENZYMOL, V273, P59; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; Jishage M, 2002, GENE DEV, V16, P1260, DOI 10.1101/gad.227902; KINGSTON RE, 1981, J BIOL CHEM, V256, P2787; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Krohn M, 1996, J BIOL CHEM, V271, P23884, DOI 10.1074/jbc.271.39.23884; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; Kvint K, 2000, J BIOL CHEM, V275, P14795, DOI 10.1074/jbc.C000128200; Lacour S, 2002, BIOCHEM BIOPH RES CO, V292, P922, DOI 10.1006/bbrc.2002.6744; LANGERT W, 1991, J BIOL CHEM, V266, P21608; Laurie AD, 2003, J BIOL CHEM, V278, P1494, DOI 10.1074/jbc.M209268200; MIZUSHIMASUGANO J, 1985, EMBO J, V4, P1053, DOI 10.1002/j.1460-2075.1985.tb03738.x; OHLSEN KL, 1992, J BIOL CHEM, V267, P19813; Potrykus K, 2002, J BIOL CHEM, V277, P43785, DOI 10.1074/jbc.M208768200; Raghavan A, 1998, BIOPHYS CHEM, V75, P7, DOI 10.1016/S0301-4622(98)00185-9; REDDY PS, 1995, MOL MICROBIOL, V15, P255, DOI 10.1111/j.1365-2958.1995.tb02240.x; RIGGS DL, 1986, P NATL ACAD SCI USA, V83, P9333, DOI 10.1073/pnas.83.24.9333; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; Schroder O, 2000, J MOL BIOL, V298, P737, DOI 10.1006/jmbi.2000.3708; SHAND RF, 1989, J BACTERIOL, V171, P737, DOI 10.1128/jb.171.2.737-743.1989; STEFANO JE, 1979, BIOCHEMISTRY-US, V18, P1063, DOI 10.1021/bi00573a020; SZALEWSKAPALASZ A, 1994, EMBO J, V13, P5779, DOI 10.1002/j.1460-2075.1994.tb06916.x; Toulokhonov II, 2001, J BIOL CHEM, V276, P1220, DOI 10.1074/jbc.M007184200; TRAVERS AA, 1980, J BACTERIOL, V141, P973, DOI 10.1128/JB.141.2.973-976.1980; TRAVERS AA, 1984, NUCLEIC ACIDS RES, V12, P2605, DOI 10.1093/nar/12.6.2605; VOGEL U, 1994, J BACTERIOL, V176, P2807, DOI 10.1128/JB.176.10.2807-2813.1994; VOGEL U, 1994, J BIOL CHEM, V269, P16236; Wagner R, 2002, J MOL MICROB BIOTECH, V4, P331; Wagner R, 2000, TRANSCRIPTION REGULA; ZACHARIAS M, 1990, NUCLEIC ACIDS RES, V18, P6271, DOI 10.1093/nar/18.21.6271; ZACHARIAS M, 1989, EMBO J, V8, P3357, DOI 10.1002/j.1460-2075.1989.tb08498.x; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908	51	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16834	16843		10.1074/jbc.M300196200	http://dx.doi.org/10.1074/jbc.M300196200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621053	hybrid			2022-12-27	WOS:000182818600053
J	Miyake, S; Yanagisawa, Y; Yuasa, Y				Miyake, S; Yanagisawa, Y; Yuasa, Y			A novel EID-1 family member, EID-2, associates with histone deacetylases and inhibits muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; TRANSCRIPTIONAL ACTIVITY; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; CELL-GROWTH; BINDING; MYOD; REPRESSES; HDAC4; CYCLE	An EID-1 ((E) under bar 1A-like (i) under bar nhibitor of (d) under bar ifferentiation-(1) under bar) inhibits differentiation by blocking the histone acetyltransferase activity of p300. Here we report a novel inhibitor of differentiation exhibiting homology to EID-1, termed EID-2 ((E) under bar ID-1- like (i) under bar nhibitor of (d) under bar ifferentiation-(2) under bar). EID-2 inhibited MyoD-dependent transcription and muscle differentiation. Unlike EID-1, EID-2 did not block p300 activity. Interestingly, EID-2 associated with class I histone deacetylases (HDACs). The N-terminal portion of EID-2 was required for the binding to HDACs. This region was also involved in the transcriptional repression and nuclear localization, suggesting the importance of the involvement of HDACs in the EID-2 function. These results indicate a new family of differentiation inhibitors, although there are several differences in the biochemical mechanisms between EID-2 and EID-1.	Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Miyake, S (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med & Dent, Dept Mol Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.							Bavner A, 2002, EMBO REP, V3, P478, DOI 10.1093/embo-reports/kvf087; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; MARUYAMA K, 1994, GENE, V138, P171; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Norton JD, 2000, J CELL SCI, V113, P3897; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Rescan PY, 2001, COMP BIOCHEM PHYS B, V130, P1, DOI 10.1016/S1096-4959(01)00412-2; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wen H, 2001, GENE, V263, P85, DOI 10.1016/S0378-1119(00)00585-0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	27	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17060	17065		10.1074/jbc.M212212200	http://dx.doi.org/10.1074/jbc.M212212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12586827	hybrid			2022-12-27	WOS:000182818600083
J	Choe, JY; Nelson, SW; Fromm, HJ; Honzatko, RB				Choe, JY; Nelson, SW; Fromm, HJ; Honzatko, RB			Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE 2,6-BISPHOSPHATE; RECOMBINANT PORCINE; DYNAMIC LOOP; LIVER FRUCTOSE-1,6-BISPHOSPHATASE; ALLOSTERIC INHIBITION; CRYSTAL-STRUCTURE; NEUTRAL FORM; MECHANISM; AMP; CATALYSIS	Fructose-1,6-bisphosphatase requires divalent cations (Mg2+, Mn2+, or Zn2+) for catalysis, but a diverse set of monovalent cations (K+, Tl+, Rb+, or NH4+) will further enhance enzyme activity. Here, the interaction of Tl+ with fructose-1,6-bisphosphatase is explored under conditions that support catalysis. On the basis of initial velocity kinetics, TV enhances catalysis by 20% with a K-alpha of 1.3 mM and a Hill coefficient near unity. Crystal structures of enzyme complexes with Mg2+, Tl+, and reaction products, in which the concentration of Tl+ is 1 mm or less, reveal Mg2+ at metal sites 1, 2, and 3 of the active site, but little or no bound Tl+. Intermediate concentrations of Tl+ (5-20 mm) displace Mg2+ from site 3 and the 1-OH group of fructose 6-phosphate from in-line geometry with respect to bound orthophosphate. Loop 52-72 appears in a new conformational state, differing from its engaged conformation by disorder in residues 61-69. Tl+ does not bind to metal sites 1 or 2 in the presence of Mg2+, but does bind to four other sites with partial occupancy. Two of four Tl+ sites probably represent alternative binding sites for the site 3 catalytic Mg2+, whereas the other sites could play roles in monovalent cation activation.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	honzatko@iastate.edu			NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURTON VA, 1993, BIOCHEM BIOPH RES CO, V192, P511, DOI 10.1006/bbrc.1993.1445; Cho JH, 2003, J BIOL CHEM, V278, P187, DOI 10.1074/jbc.M206236200; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; HERS HG, 1983, ANNU REV BIOCHEM, V52, P617, DOI 10.1146/annurev.bi.52.070183.003153; KE HM, 1991, P NATL ACAD SCI USA, V88, P2989, DOI 10.1073/pnas.88.8.2989; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; Kelley N, 1996, BIOCHEM BIOPH RES CO, V219, P848, DOI 10.1006/bbrc.1996.0321; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREBS HA, 1963, ADV ENZYME REGUL, V1, P385; Kurbanov FT, 1998, J BIOL CHEM, V273, P17511, DOI 10.1074/jbc.273.28.17511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LEE AG, 1971, CHEM THALLIUM; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; MARCUS F, 1980, J BIOL CHEM, V255, P2481; MARCUS F, 1981, REGULATION CARBOHYDR, P269; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nelson SW, 2001, J BIOL CHEM, V276, P6119, DOI 10.1074/jbc.M009485200; Nelson SW, 2000, BIOCHEMISTRY-US, V39, P11100, DOI 10.1021/bi000609c; Nelson SW, 2000, J BIOL CHEM, V275, P29986, DOI 10.1074/jbc.M000473200; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; *RIG MOL STRUCT CO, 2001, CRYST RIG MOL STRUCT; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; SHELDRICK GM, 1995, ACTA CRYSTALLOGR B, V51, P423, DOI 10.1107/S0108768195003661; SOLA MM, 1993, INT J BIOCHEM, V25, P1963, DOI 10.1016/0020-711X(88)90332-1; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TAKETA K, 1965, J BIOL CHEM, V240, P651; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P8916, DOI 10.1073/pnas.92.19.8916; Zhang RL, 1996, BIOCHEMISTRY-US, V35, P3038, DOI 10.1021/bi952188i; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P1844, DOI 10.1021/bi00058a019	44	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16008	16014		10.1074/jbc.M212394200	http://dx.doi.org/10.1074/jbc.M212394200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595529	Green Published, hybrid			2022-12-27	WOS:000182680000071
J	Esposti, MD; Ferry, G; Masdehors, P; Boutin, JA; Hickman, JA; Dive, C				Esposti, MD; Ferry, G; Masdehors, P; Boutin, JA; Hickman, JA; Dive, C			Post-translational modification of bid has differential effects on its susceptibility to cleavage by caspase 8 or caspase 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; DRUG-INDUCED APOPTOSIS; KAPPA-B-ALPHA; PROTEIN-KINASE; DEATH RECEPTOR; IN-VITRO; MITOCHONDRIAL-MEMBRANE; INTERACTING PROTEIN; T-CELLS; PHOSPHORYLATION	Bid is instrumental in death receptor-mediated apoptosis where it is cleaved by caspase 8 at aspartate 60 and aspartate 75 to generate truncated Bid (tBID) forms that facilitate release of mitochondrial cytochrome c. Bid is also cleaved at these sites by caspase 3 that is activated downstream of cytochrome c release after diverse apoptotic stimuli. In this context, tBid may amplify the apoptotic process. Bid is phosphorylated in vitro by casein kinases that regulate its cleavage by caspase 8 (Desagher, S., Osen-Sand, A., Montessuit, S., Magnenat, E., Vilbois, F., Hochmann, A., Journot, L. Antonsson, A., and Martinou, J.-C. (2001) Mol. Cell 8, 601-611). Using a Bid decapeptide substrate, we observed that phosphorylation at threonine 59 inhibited cleavage by caspase 8. This was also seen when recombinant Bid (rBid) and Bid isolated from murine kidney were incubated with casein kinase II. However, there were differences in the susceptibility of rBid and isolated Bid to cleavage by caspases 3 and 8. Caspase 8 cleaved rBid to generate two C-terminal products, p15 and p13 tBid, but produced only p15 tBid from isolated Bid. Contrary to rBid, isolated Bid was resistant to cleavage by caspase 3, yet was readily cleaved within the cytosolic milieu. Our data suggest that one or more distinct cellular mechanisms regulate Bid cleavage by caspases 8 and 3 in situ.	Univ Manchester, Sch Biol Sci, Canc Res UK Cellular & Mol Pharmacol Grp, Manchester M13 9PT, Lancs, England; Inst Rech Servier, F-78290 Croissy sur Seine, France	University of Manchester; Servier; Institut de Recherches Internationales Servier	Dive, C (corresponding author), Univ Manchester, Sch Biol Sci, Canc Res UK Cellular & Mol Pharmacol Grp, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	cdive@man.ac.uk	Degli Esposti, Mauro/C-3270-2012; Boutin, Jean Albert/W-9103-2019	Boutin, Jean Albert/0000-0003-0068-7204; Dive, Caroline/0000-0002-1726-8850; Degli Esposti, Mauro/0000-0002-0977-119X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; DEGLIESPOSTI M, 2001, MOL CELL BIOL, V21, P7268; DEL PL, 1997, SCIENCE, V278, P687; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Ravi R, 2002, CANCER RES, V62, P4180; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Taylor JA, 1999, J MOL BIOL, V290, P839, DOI 10.1006/jmbi.1999.2912; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wilson M, 1996, J BIOL CHEM, V271, P8537, DOI 10.1074/jbc.271.15.8537; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xu K, 2001, BRIT J CANCER, V84, P670, DOI 10.1054/bjoc.2000.1636; Yuan XJ, 2002, ONCOGENE, V21, P319, DOI 10.1038/sj/onc/1205054; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhuang SG, 2001, ONCOGENE, V20, P6764, DOI 10.1038/sj.onc.1204867	44	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15749	15757		10.1074/jbc.M209208200	http://dx.doi.org/10.1074/jbc.M209208200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598529	hybrid			2022-12-27	WOS:000182680000038
J	Shah, OJ; Ghosh, S; Hunter, T				Shah, OJ; Ghosh, S; Hunter, T			Mitotic regulation of ribosomal S6 kinase 1 involves Ser/Thr, Pro phosphorylation of consensus and non-consensus sites by Cdc2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; CELL-CYCLE; IN-VIVO; RAPAMYCIN; ACTIVATION; P70(S6K); INHIBITION; MITOSIS; CANCER; PDK1	During mitosis, the cyclin-dependent kinase, Cdc2, signals the inactivation of major anabolic processes such as transcription, mRNA processing, translation, and ribosome biogenesis, thereby providing energy needed for the radical and energetically costly structural reorganization of the cell. This is accomplished by phosphorylation and inactivation of several key anabolic elements, including TFIIIB, TFIID, RNA polymerase 11, poly(A) polymerase, and translation elongation factor 1gamma. We report here that ribosomal S6 kinase I (S6K1), a protein kinase linked to the translation of ribosomal protein mRNAs, is also subject to regulation by Cdc2 in mitosis. In mitotic HeLa cells, when the activity of Cdc2 is high, S6K1 is phosphorylated at multiple Ser/Thr, Pro (S/TP) sites, including Ser(371), Ser(411), Thr(421), and Ser(424). Concomitant with this, the phosphorylation of the hydrophobic motif site, Thr(389), is reduced resulting in a decrease in the specific activity of S6K1. The mitotic S/TP phosphorylation sites are readily phosphorylated by Cdc2-cyclin B in vitro. These proline-directed phosphorylations are sensitive to chemical inhibitors of Cdc2 but not to inhibitors of mammalian target of rapamycin, phosphatidylinositol 3-kinase, MEK1/2, or p38. In murine FT210 cells arrested in mitosis, conditional inactivation of Cdc2 reduces phosphorylation of S6K1 at S/TP sites while simultaneously increasing phosphorylation of Thr(389). and of the S6K1 substrate, RPS6. A physical interaction exists between Cdc2 and S6K1, and this interaction is enhanced in mitotic cells. These results suggest that Cdc2 provides a signal that triggers inactivation of S6K1 in mitosis, presumably serving to spare energy for costly mitotic processes at the expense of ribosomal protein synthesis.	Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA	Salk Institute	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hunter@salk.edu		Ghosh, Sourav/0000-0001-5990-8708	NATIONAL CANCER INSTITUTE [P30CA014195, R01CA082683, T32CA009523] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14195, CA 82683, T32 CA 09523-18] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Calastretti A, 2001, ONCOGENE, V20, P6172, DOI 10.1038/sj.onc.1204751; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; CORMIER P, 1991, NUCLEIC ACIDS RES, V19, P6644, DOI 10.1093/nar/19.23.6644; Couch FJ, 1999, CANCER RES, V59, P1408; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Derenzini M, 2000, J PATHOL, V191, P181, DOI 10.1002/(SICI)1096-9896(200006)191:2<181::AID-PATH607>3.0.CO;2-V; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; EREMENKO T, 1975, EUR J BIOCHEM, V52, P203, DOI 10.1111/j.1432-1033.1975.tb03988.x; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Gottesfeld JM, 1997, TRENDS BIOCHEM SCI, V22, P197, DOI 10.1016/S0968-0004(97)01045-1; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; Heesom KJ, 2001, CURR BIOL, V11, P1374, DOI 10.1016/S0960-9822(01)00422-5; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nigg E A, 1991, Semin Cell Biol, V2, P261; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shah OJ, 2000, BIOCHEM J, V347, P389, DOI 10.1042/0264-6021:3470389; Sirri V, 2000, J CELL BIOL, V148, P259, DOI 10.1083/jcb.148.2.259; STEWARD DL, 1968, SCIENCE, V161, P791, DOI 10.1126/science.161.3843.791; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; Sugiyama H, 1997, ONCOGENE, V15, P443, DOI 10.1038/sj.onc.1201207; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1993, J CELL PHYSIOL, V154, P7, DOI 10.1002/jcp.1041540103; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Wong AST, 2001, GYNECOL ONCOL, V82, P305, DOI 10.1006/gyno.2001.6280; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	65	55	55	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16433	16442		10.1074/jbc.M300435200	http://dx.doi.org/10.1074/jbc.M300435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12586835	hybrid			2022-12-27	WOS:000182680000123
J	Small, D; Kovalenko, D; Soldi, R; Mandinova, A; Kolev, V; Trifonova, R; Bagala, C; Kacer, D; Battelli, C; Liaw, L; Prudovsky, I; Maciag, T				Small, D; Kovalenko, D; Soldi, R; Mandinova, A; Kolev, V; Trifonova, R; Bagala, C; Kacer, D; Battelli, C; Liaw, L; Prudovsky, I; Maciag, T			Notch activation suppresses fibroblast growth factor-dependent cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; INTRACELLULAR DOMAIN; ALAGILLE-SYNDROME; DROSOPHILA NOTCH; MAMMALIAN NOTCH; SECRETED FORMS; CYCLE ARREST; CANCER CELLS; STEM-CELLS; DIFFERENTIATION	Aberrant activations of the Notch and fibroblast growth factor receptor (FGFR) signaling pathways have been correlated with neoplastic growth in humans and other mammals. Here we report that the suppression of Notch signaling in NIH 3T3 cells by the expression of either the extracellular domain of the Notch ligand Jagged1 or dominant-negative forms of Notch1 and Notch2 results in the appearance of an exaggerated fibroblast growth factor (FGF)-dependent transformed phenotype characterized by anchorage-independent growth in soft agar. Anchorage-independent growth exhibited by Notch-repressed NIH 3T3 cells may result from prolonged FGFR stimulation caused by both an increase in the expression of prototypic and oneogenic FGF gene family members and the nonclassical export of FGF1 into the extracellular compartment. Interestingly, FGF exerts a negative effect on Notch by suppressing CSL (CBF-1/RBP-Jk/KBF2 in mammals, Su(H) in Drosophila and Xenopus, and Lag-2 in Caenorhabditis elegans)-dependent transcription, and the ectopic expression of constitutively active forms of Notch1 or Notch2 abrogates FGF1 release and the phenotypic effects of FGFR stimulation. These data suggest that communication between the Notch and FGFR pathways may represent an important reciprocal autoregulatory mechanism for the regulation of normal cell growth.	Maine Med Ctr, Inst Res, Ctr Mol Med, Scarborough, ME 04074 USA	Maine Medical Center	Maciag, T (corresponding author), Maine Med Ctr, Inst Res, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.	maciat@mmc.org	Bagalà, Cinzia/AAB-8981-2019; Prudovsky, Igor/GVU-1521-2022		NCI NIH HHS [CA 92255] Funding Source: Medline; NCRR NIH HHS [RR 15555] Funding Source: Medline; NHLBI NIH HHS [HL 32348, HL 35627] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA092255] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627, R01HL032348] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbass SAA, 1997, J CLIN ENDOCR METAB, V82, P1160, DOI 10.1210/jc.82.4.1160; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bongarzone ER, 2000, J NEUROSCI RES, V62, P319, DOI 10.1002/1097-4547(20001101)62:3<319::AID-JNR1>3.0.CO;2-G; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; Burgar HR, 2002, J BIOL CHEM, V277, P4018, DOI 10.1074/jbc.M107785200; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; CHITNIS A, 1995, NATURE, V375, P761, DOI 10.1038/375761a0; Chu JL, 2002, J BIOL CHEM, V277, P7587, DOI 10.1074/jbc.M111044200; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; DELAMO FF, 1993, GENOMICS, V15, P259, DOI 10.1006/geno.1993.1055; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Faux CH, 2001, J NEUROSCI, V21, P5587, DOI 10.1523/JNEUROSCI.21-15-05587.2001; Fitzgerald K, 1995, DEVELOPMENT, V121, P4275; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; Gray GE, 1999, AM J PATHOL, V154, P785, DOI 10.1016/S0002-9440(10)65325-4; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Harada H, 1999, J CELL BIOL, V147, P105, DOI 10.1083/jcb.147.1.105; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Hukriede NA, 1997, DEVELOPMENT, V124, P3427; Ikeya T, 1999, DEVELOPMENT, V126, P4455; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAING R, 1998, GENE DEV, V12, P1046; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Krebs LT, 2000, GENE DEV, V14, P1343; Landriscina M, 2001, J BIOL CHEM, V276, P25549, DOI 10.1074/jbc.M102925200; Landriscina M, 2001, J BIOL CHEM, V276, P22544, DOI 10.1074/jbc.M100546200; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; Leung HY, 1997, ONCOGENE, V15, P1115, DOI 10.1038/sj.onc.1201256; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Lindner V, 2001, AM J PATHOL, V159, P875, DOI 10.1016/S0002-9440(10)61763-4; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Maerz WJ, 1998, ONCOGENE, V17, P761, DOI 10.1038/sj.onc.1201992; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Mishra-Gorur K, 2002, J CELL BIOL, V159, P313, DOI 10.1083/jcb.200203117; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Mustonen T, 2002, DEV BIOL, V248, P281, DOI 10.1006/dbio.2002.0734; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Ozawa K, 1998, J BIOL CHEM, V273, P29262, DOI 10.1074/jbc.273.44.29262; Panek RL, 1998, J PHARMACOL EXP THER, V286, P569; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Shawber C, 1996, DEVELOPMENT, V122, P3765; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; Shimizu K, 2000, MOL CELL BIOL, V20, P6913, DOI 10.1128/MCB.20.18.6913-6922.2000; Shimizu K, 2002, EMBO J, V21, P294, DOI 10.1093/emboj/21.3.294; Shutter JR, 2000, GENE DEV, V14, P1313; Small D, 2001, J BIOL CHEM, V276, P32022, DOI 10.1074/jbc.M100933200; Spinner NB, 2001, HUM MUTAT, V17, P18, DOI 10.1002/1098-1004(2001)17:1<18::AID-HUMU3>3.0.CO;2-T; Sriuranpong V, 2001, CANCER RES, V61, P3200; Sun X, 1997, DEVELOPMENT, V124, P3439; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; Varnum-Finney B, 2000, J CELL SCI, V113, P4313; Walker L, 1999, STEM CELLS, V17, P162, DOI 10.1002/stem.170162; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Wong MKK, 2000, BIOCHEM BIOPH RES CO, V268, P853, DOI 10.1006/bbrc.2000.2173; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	73	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16405	16413		10.1074/jbc.M300464200	http://dx.doi.org/10.1074/jbc.M300464200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12598523	hybrid			2022-12-27	WOS:000182680000120
J	Wissmann, R; Bildl, W; Oliver, D; Beyermann, M; Kalbitzer, HR; Bentrop, D; Fakler, B				Wissmann, R; Bildl, W; Oliver, D; Beyermann, M; Kalbitzer, HR; Bentrop, D; Fakler, B			Solution structure and function of the "Tandem inactivation domain" of the neuronal A-type potassium channel Kv1.4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED K+ CHANNELS; NMR STRUCTURE; COUPLING-CONSTANTS; BACKBONE DYNAMICS; BETA-SUBUNIT; MECHANISMS; PROTEIN; GATE; HIPPOCAMPUS; PORE	Cumulative inactivation of voltage-gated (Kv) K+ channels shapes the presynaptic action potential and determines timing and strength of synaptic transmission. Kv1.4 channels exhibit rapid "ball-and-chain"-type inactivation gating. Different from all other Kvalpha subunits, Kv1.4 harbors two inactivation domains at its N terminus. Here we report the solution structure and function of this "tandem inactivation domain" using NMR spectroscopy and patch clamp recordings. Inactivation domain I (ID1, residues 1-38) consists of a flexible N terminus anchored at a 5-turn helix, whereas ID2 (residues 40-50) is a 2.5-turn helix made up of small hydrophobic amino acids. Functional analysis suggests that only ID1 may work as a pore-occluding ball domain, whereas ID2 most likely acts as a "docking domain" that attaches ID1 to the cytoplasmic face of the channel. Deletion of ID2 slows inactivation considerably and largely impairs cumulative inactivation. Together, the concerted action of ID1 and ID2 may promote rapid inactivation of Kv1.4 that is crucial for the channel function in short term plasticity.	Univ Freiburg, Dept Physiol 2, D-79104 Freiburg, Germany; Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Univ Regensburg, Dept Biophys & Phys Biochem, D-93053 Regensburg, Germany	University of Freiburg; University of Regensburg	Fakler, B (corresponding author), Univ Freiburg, Dept Physiol 2, Hermann Herder Str 7, D-79104 Freiburg, Germany.	bernd.fakler@physiologie.uni-freiburg.de	Oliver, Dominik/F-5845-2013	Oliver, Dominik/0000-0002-8368-0923; Kalbitzer, Hans Robert/0000-0002-6514-2355				Antz C, 1999, NAT STRUCT BIOL, V6, P146; Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BAUKROWITZ T, 1995, NEURON, V15, P951, DOI 10.1016/0896-6273(95)90185-X; Baukrowitz T, 1996, P NATL ACAD SCI USA, V93, P13357, DOI 10.1073/pnas.93.23.13357; Baukrowitz T, 1996, SCIENCE, V271, P653, DOI 10.1126/science.271.5249.653; Bentrop D, 2001, J BIOL CHEM, V276, P42116, DOI 10.1074/jbc.M107118200; Billeter M, 1995, J BIOMOL NMR, V5, P1; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; Cooper EC, 1998, J NEUROSCI, V18, P965; Debanne D, 1997, NATURE, V389, P286, DOI 10.1038/38502; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Geiger JRP, 2000, NEURON, V28, P927, DOI 10.1016/S0896-6273(00)00164-1; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hines ML, 2000, NEURAL COMPUT, V12, P995, DOI 10.1162/089976600300015475; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; Hollerer-Beitz G, 1999, PFLUG ARCH EUR J PHY, V438, P141, DOI 10.1007/s004240050891; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISHIMA R, 1995, BIOCHEMISTRY-US, V34, P3162, DOI 10.1021/bi00010a005; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kondoh S, 1997, J BIOL CHEM, V272, P19333, DOI 10.1074/jbc.272.31.19333; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Ludwig J, 2001, P NATL ACAD SCI USA, V98, P4178, DOI 10.1073/pnas.071613498; MA MH, 1995, J NEUROSCI, V15, P6720; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MURRELLLAGNADO RD, 1993, J GEN PHYSIOL, V102, P949, DOI 10.1085/jgp.102.6.949; Oliver D, 2001, SCIENCE, V292, P2340, DOI 10.1126/science.1060939; PENG JW, 1994, METHOD ENZYMOL, V239, P563; PFAFFINGER PJ, 1995, J BIOL CHEM, V270, P28595, DOI 10.1074/jbc.270.48.28595; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; Schmitz D, 2001, P NATL ACAD SCI USA, V98, P11003, DOI 10.1073/pnas.191351498; Schott MK, 1998, EUR BIOPHYS J BIOPHY, V27, P99, DOI 10.1007/s002490050115; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; Smith LJ, 1996, J MOL BIOL, V255, P494, DOI 10.1006/jmbi.1996.0041; STEPHENS GJ, 1995, J PHYSIOL-LONDON, V484, P1; Vakser IA, 1996, BIOPOLYMERS, V39, P455, DOI 10.1002/(SICI)1097-0282(199609)39:3<455::AID-BIP16>3.3.CO;2-8; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wiebe SP, 1999, J NEUROSCI, V19, P10562; Wissmann R, 1999, J BIOL CHEM, V274, P35521, DOI 10.1074/jbc.274.50.35521; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	51	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16142	16150		10.1074/jbc.M210191200	http://dx.doi.org/10.1074/jbc.M210191200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12590144	hybrid			2022-12-27	WOS:000182680000087
J	Yuan, Y; Hilliard, G; Ferguson, T; Millhorn, DE				Yuan, Y; Hilliard, G; Ferguson, T; Millhorn, DE			Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; PAS DOMAIN PROTEIN-1; PROLYL HYDROXYLATION; HIF-ALPHA; TRANSACTIVATION; UBIQUITYLATION; ERYTHROPOIETIN; FACTOR-1-ALPHA; DESTRUCTION; EXPRESSION	The hypoxia-inducible factor (HIF) activates the expression of genes that contain a hypoxia response element. The alpha-subunits of the HIF transcription factors are degraded by proteasomal pathways during normoxia but are stabilized under hypoxic conditions. The von Hippel-Lindau protein (pVHL) mediates the ubiquitination and rapid degradation of HIF-alpha (including HIF-1alpha and HIF-2alpha). Post-translational hydroxylation of a proline residue in the oxygen-dependent degradation (ODD) domain of HIF-alpha is required for the interaction between HIF and VHL. It has previously been established that cobalt mimics hypoxia and causes accumulation of HIF-1alpha and HIF-2alpha. However, little is known about the mechanism by which this occurs. In an earlier study, we demonstrated that cobalt binds directly to the ODD domain of HIF-2alpha. Here we provide the first evidence that cobalt inhibits pVHL binding to HIF-alpha even when HIF-alpha is hydroxylated. Deletion of 17 amino acids within the ODD domain of HIF-2alpha that are required for pVHL binding prevented the binding of cobalt and stabilized HIF-2alpha during normoxia. These findings show that cobalt mimics hypoxia, at least in part, by occupying the VHL-binding domain of HIF-alpha and thereby preventing the degradation of HIF-alpha.	Univ Cincinnati, Dept Genome Sci, Genome Res Inst, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Millhorn, DE (corresponding author), Univ Cincinnati, Dept Genome Sci, Genome Res Inst, 231 Albert Sabin Way,POB 670505, Cincinnati, OH 45267 USA.				NHLBI NIH HHS [HL 59945, HL 33831] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033831, R37HL033831, R01HL059945] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lehmann E, 1999, J AM SOC MASS SPECTR, V10, P27, DOI 10.1016/S1044-0305(98)00116-0; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yuan Y, 2001, BIOCHEM BIOPH RES CO, V288, P849, DOI 10.1006/bbrc.2001.5835	23	472	501	0	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15911	15916		10.1074/jbc.M300463200	http://dx.doi.org/10.1074/jbc.M300463200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12606543	hybrid			2022-12-27	WOS:000182680000058
J	Buensuceso, C; de Virgilio, M; Shattil, SJ				Buensuceso, C; de Virgilio, M; Shattil, SJ			Detection of integrin alpha(IIb)beta(3) clustering in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; BETA-GALACTOSIDASE COMPLEMENTATION; IIB-IIIA COMPLEX; LIGAND-BINDING; PLATELET RECEPTOR; TRANSFER BRET; PROTEIN INTERACTIONS; CYTOPLASMIC DOMAINS; HUMAN-FIBRINOGEN; ACTIN-FILAMENTS	In platelets, bidirectional signaling across integrin alpha(IIb)beta(3), regulates fibrinogen binding, cytoskeletal reorganization, cell aggregation, and spreading. Because these responses may be influenced by the clustering Of alpha(IIb)beta(3) heterodimers into larger oligomers, we established two independent methods to detect integrin clustering and evaluate factors that regulate this process. In the first, weakly complementing beta-galactosidase mutants were fused to the C terminus of individual alpha(IIb) subunits, and the chimeras were stably expressed with beta(3) in Chinese hamster ovary cells. Clustering of alpha(IIb)beta(3) should bring the mutants into proximity and reconstitute beta-galactosidase activity. In the second method, alpha(IIb) was fused to either a green fluorescent protein (GFP) or Renilla luciferase and transiently expressed with beta(3). Here, integrin clustering should stimulate bioluminescence resonance energy transfer between a cell-permeable luciferase substrate and GFP. These methods successfully detected integrin clustering induced by anti-alpha(IIb)beta(3), antibodies. Significantly, they also detected clustering upon soluble fibrinogen binding to alpha(IIb)beta(3). In contrast, no clustering was observed following direct activation of alpha(IIb)beta(3) by MnCl2 or an anti-alpha(IIb)beta(3)-activating antibody Fab in the absence of fibrinogen. Intracellular events also influenced alpha(IIb)beta(3) clustering. For example, a cell-permeable, bivalent FK506-binding protein (FKBP) ligand stimulated clustering when added to cells expressing an alpha(IIb)(FKBP)(2) chimera complexed with beta(3). Furthermore, alpha(IIb)beta(3) clustering occurred in the presence of latrunculin A or cytochalasin D, inhibitors of actin polymerization. These effects were enhanced by fibrinogen, suggesting that actin-regulated clustering modulates alpha(IIb)beta(3) interaction with ligands. These studies in living cells establish that alpha(IIb)beta(3) clustering is modulated by fibrinogen and actin dynamics. More broadly, they should facilitate investigations of the mechanisms and consequences of integrin clustering.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Shattil, SJ (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd,VB-5, La Jolla, CA 92037 USA.				NHLBI NIH HHS [HL-56595, HL-57900] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056595, P01HL057900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JC, 2001, CELL MOL LIFE SCI, V58, P371, DOI 10.1007/PL00000864; Ambo H, 1998, BIOCHEM BIOPH RES CO, V251, P763, DOI 10.1006/bbrc.1998.9526; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Blakely BT, 2000, NAT BIOTECHNOL, V18, P218, DOI 10.1038/72686; Boute N, 2002, TRENDS PHARMACOL SCI, V23, P351, DOI 10.1016/S0165-6147(02)02062-X; BRAY PF, 1986, P NATL ACAD SCI USA, V83, P1480, DOI 10.1073/pnas.83.5.1480; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Edlund M, 2001, CELL MOTIL CYTOSKEL, V48, P190, DOI 10.1002/1097-0169(200103)48:3<190::AID-CM1008>3.0.CO;2-C; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Galbraith CG, 2002, J CELL BIOL, V159, P695, DOI 10.1083/jcb.200204153; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; Hantgan RR, 2003, J BIOL CHEM, V278, P3417, DOI 10.1074/jbc.M208869200; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kashiwagi H, 1999, BLOOD, V93, P2559, DOI 10.1182/blood.V93.8.2559.408k12_2559_2568; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; KLOCZEWIAK M, 1989, BIOCHEMISTRY-US, V28, P2915, DOI 10.1021/bi00433a025; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Rossi F, 1997, P NATL ACAD SCI USA, V94, P8405, DOI 10.1073/pnas.94.16.8405; Rossi FMV, 2000, TRENDS CELL BIOL, V10, P119, DOI 10.1016/S0962-8924(99)01707-9; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Simmons SR, 1997, ARTERIOSCL THROM VAS, V17, P3311, DOI 10.1161/01.ATV.17.11.3311; Simmons SR, 1996, J LAB CLIN MED, V128, P39, DOI 10.1016/S0022-2143(96)90112-2; Stock J, 1996, CURR BIOL, V6, P825, DOI 10.1016/S0960-9822(02)00605-X; Sun QH, 2002, BLOOD, V100, P2094, DOI 10.1182/blood-2002-02-0418; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Yauch RL, 1997, J EXP MED, V186, P1347, DOI 10.1084/jem.186.8.1347; Zamir E, 2001, J CELL SCI, V114, P3583	61	62	63	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15217	15224		10.1074/jbc.M213234200	http://dx.doi.org/10.1074/jbc.M213234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12595537	hybrid			2022-12-27	WOS:000182516100082
J	Koutsoupakis, K; Stavrakis, S; Soulimane, T; Varotsis, C				Koutsoupakis, K; Stavrakis, S; Soulimane, T; Varotsis, C			Oxygen-linked Equilibrium CUB-CO species in cytochrome ba(3) oxidase from Thermus thermophilus - Implications for an oxygen channel at the Cu-B site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED FTIR; HEME-COPPER OXIDASES; TEMPERATURE; COMPLEX	We report the first study of O-2 migration in the putative O-2 channel of cytochrome ba(3) and its effect to the properties of the binuclear heme a(3)-Cu-B center of cytochrome ba(3) from Thermus thermophilus. The Fourier transform infrared spectra of the ba(3)-CO complex demonstrate that in the presence of 60-80 mum O-2 the nu(C-O) of Cu-B(1+)-C-O at 2053 cm(-1) (complex A) shifts to 2045 cm(-1) and remains unchanged in H2O/D2O exchanges and in the pH 6.5-9.0 range. The frequencies but not the intensities of the C-O stretching modes of heme a(3)-CO (complex B), however, remain unchanged. The change in the P(C-O) of complex A results in an increase of k(-2), and thus in a higher affinity Of CUB for exogenous ligands. The time-resolved step-scan Fourier transform infrared difference spectra indicate that the rate of decay of the transient Cu-B(1+)-CO complex at pH 6.5 is 30.4 s(-1) and 28.3 s(-1) in the presence of O-2. Similarly, the rebinding to heme a(3) is slightly affected and occurs with k(2) = 26.3 s(-1) and 24.6 s(-1) in the presence of O-2. These results provide solid evidence that in cytochrome ba(3), the ligand delivery channel is located at the Cu-B site, which is the ligand entry to the heme a(3) pocket. We suggest that the properties of the O-2 channel are not limited to facilitating ligand diffusion to the active site but are extended in controlling the dynamics and reactivity of the reactions of ba(3) with O-2 and NO.	Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece; Paul Scherrer Inst, OSRA 008, CH-5232 Villigen, Switzerland	University of Crete; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Varotsis, C (corresponding author), Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece.		Stavrakis, Stavros/P-6267-2019	Stavrakis, Stavros/0000-0002-0888-5953; Varotsis, Constantinos/0000-0003-2771-8891				Giuffre A, 1999, BIOCHEMISTRY-US, V38, P1057, DOI 10.1021/bi9815389; Giuffre A, 1999, P NATL ACAD SCI USA, V96, P14718, DOI 10.1073/pnas.96.26.14718; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Koutsoupakis K, 2002, J BIOL CHEM, V277, P32860, DOI 10.1074/jbc.M204943200; Pinakoulaki E, 2002, J BIOL CHEM, V277, P32867, DOI 10.1074/jbc.M205568200; Pinakoulaki E, 2002, J BIOL CHEM, V277, P13563, DOI 10.1074/jbc.M112200200; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Stavrakis S, 2002, J AM CHEM SOC, V124, P3814, DOI 10.1021/ja0169825; Than M. E., 2001, HDB METALLOPROTEINS, P363; Varotsis C, 1996, BIOSPECTROSCOPY, V2, P331; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	12	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14893	14896		10.1074/jbc.M210293200	http://dx.doi.org/10.1074/jbc.M210293200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594218	hybrid			2022-12-27	WOS:000182516100041
J	Ward, DG; Cavieres, JD				Ward, DG; Cavieres, JD			Inactivation of Na,K-ATPase following Co(NH3)(4)ATP binding at a low affinity site in the protomeric enzyme unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/K+-TRANSPORTING ATPASE; ALPHA-BETA-UNITS; SARCOPLASMIC-RETICULUM; NUCLEOTIDE SITES; ACTIVE-SITE; FLUORESCEIN ISOTHIOCYANATE; AMINO-ACID; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL-CHANGES; MAMMALIAN KIDNEY	The Na+-dependent or El stages of the Na,K-ATPase reaction require a few micromolar ATP, but submillimolar concentrations are needed to accelerate the K+-dependent or E2 half of the cycle. Here we use Co(NH3)(4)ATP as a tool to study ATP sites in Na,K-ATPase. The analogue inactivates the K+ phosphatase activity (an E2 partial reaction) and the Na,K-ATPase activity in parallel, whereas ATP-[H-3]ADP exchange (an El reaction) is affected less or not at all. Although the inactivation occurs as a consequence of low affinity Co(NH3)(4)ATP binding (K-m approximate to 0.4-0.6 mm), we can also measure high affinity equilibrium binding of Co(NH3)(4)[H-3]ATP (K-D = 0.1 mum) to the native enzyme. Crucially, we find that covalent enzyme modification with fluorescein isothiocyanate (which blocks El reactions) causes little or no effect on the affinity of the binding step preceding Co(NH3)(4)ATP inactivation and only a 20% decrease in maximal inactivation rate. This suggests that fluorescein isothiocyanate and Co(NH3)(4)ATP bind within different enzyme pockets. The Co(NH3)(4)ATP enzyme was solubilized with C12E8 to a homogeneous population of alphabeta protomers, as verified by analytical ultracentrifugation; the solubilization did not increase the Na,K-ATPase activity of the Co(NH3)(4)ATP enzyme with respect to parallel controls. This was contrary to the expectation for a hypothetical (alphabeta)(2) membrane dimer with a single ATP site per protomer, with or without fast dimer/protomer equilibrium in detergent solution. Besides, the solubilized alphabeta protomer could be directly inactivated by Co(NH3)(4)ATP, to less than 10% of the control Na,K-ATPase activity. This suggests that the inactivation must follow Co(NH3)(4)ATP binding at a low affinity site in every protomeric unit, thus still allowing ATP and ADP access to phosphorylation and high affinity ATP sites.	Univ Leicester, Dept Cell Physiol & Pharmacol, Transport ATPase Lab, Fac Med & Biol Sci, Leicester LE1 9HN, Leics, England	University of Leicester	Cavieres, JD (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Transport ATPase Lab, Fac Med & Biol Sci, Leicester LE1 9HN, Leics, England.	jdc7@le.ac.uk		Ward, Douglas/0000-0002-2328-1445				ASKARI A, 1982, BIOCHEM BIOPH RES CO, V104, P1447, DOI 10.1016/0006-291X(82)91412-7; Askari A, 2000, INT CONGR SER, V1207, P17; BASTIDE F, 1973, J BIOL CHEM, V248, P8485; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; Burden D, 2000, INT CONGR SER, V1207, P417; BUXBAUM E, 1991, EUR J BIOCHEM, V195, P407, DOI 10.1111/j.1432-1033.1991.tb15720.x; CAVIERES JD, 1987, BIOCHIM BIOPHYS ACTA, V899, P83, DOI 10.1016/0005-2736(87)90242-2; Cavieres JD, 2000, INT CONGR SER, V1207, P115; CORNELIUS RD, 1977, INORG CHEM, V16, P2799, DOI 10.1021/ic50177a025; DAVIS RL, 1988, J BIOENERG BIOMEMBR, V20, P571, DOI 10.1007/BF00768920; DAVIS RL, 1988, BIOCHIM BIOPHYS ACTA, V953, P26, DOI 10.1016/0167-4838(88)90006-4; DUPONT Y, 1985, J BIOL CHEM, V260, P7241; ECKERT K, 1977, ACTA BIOL MED GER, V36, pK1; ELLISDAVIES GCR, 1990, J BIOL CHEM, V265, P20570; Faller LD, 2000, BIOPHYS J, V78, p77A; FALLER LD, 1989, BIOCHEMISTRY-US, V28, P6771, DOI 10.1021/bi00442a034; Faller LD, 2000, INT CONGR SER, V1207, P389; FARLEY RA, 1984, J BIOL CHEM, V259, P9532; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1976, J PHYSIOL-LONDON, V256, P465, DOI 10.1113/jphysiol.1976.sp011333; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; HAMER E, 1993, EUR J BIOCHEM, V213, P743, DOI 10.1111/j.1432-1033.1993.tb17815.x; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; Hayashi Y, 1997, ANN NY ACAD SCI, V834, P19, DOI 10.1111/j.1749-6632.1997.tb52222.x; HEGYVARY C, 1971, J BIOL CHEM, V246, P5234; Huang SH, 1998, BIOCHEMISTRY-US, V37, P6949, DOI 10.1021/bi980275f; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KANAZAWA T, 1967, J BIOCHEM-TOKYO, V61, P555, DOI 10.1093/oxfordjournals.jbchem.a128586; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; KAPLAN JH, 1982, ANN NY ACAD SCI, V402, P292, DOI 10.1111/j.1749-6632.1982.tb25750.x; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; KARLISH SJD, 1982, J PHYSIOL-LONDON, V328, P333, DOI 10.1113/jphysiol.1982.sp014267; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LINNERTZ H, 1995, EUR J BIOCHEM, V232, P420, DOI 10.1111/j.1432-1033.1995.tb20827.x; LLEWELLYN DJ, 1978, ARCH BIOCHEM BIOPHYS, V190, P483, DOI 10.1016/0003-9861(78)90302-8; Martin DW, 1999, BIOCHEMISTRY-US, V38, P7485, DOI 10.1021/bi983019b; Martin DW, 2000, J BIOL CHEM, V275, P24512, DOI 10.1074/jbc.M003179200; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; Mildvan A S, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P103; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; NESLUND GG, 1984, CURR TOP CELL REGUL, V24, P447; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; OHTA T, 1985, SODIUM PUMP, P237; POST RL, 1972, J BIOL CHEM, V247, P6530; SACHS JR, 1994, BBA-BIOMEMBRANES, V1193, P199, DOI 10.1016/0005-2736(94)90349-2; SCHACHMAN, 1959, ULTRACENTRIFUGATION, P82; SCHEINERBOBIS G, 1989, EUR J BIOCHEM, V183, P173, DOI 10.1111/j.1432-1033.1989.tb14910.x; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SCHLESSINGER G, 1960, INORG SYN, V6, P173, DOI 10.1002/9780470132371.ch55; SERPERSU EH, 1990, EUR J BIOCHEM, V191, P397, DOI 10.1111/j.1432-1033.1990.tb19135.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUSUKI H, 2000, BIOCHEMISTRY-US, V29, P7040; SUZUKI K, 1987, J BIOL CHEM, V262, P11752; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; TANIGUCHI K, 1993, J BIOL CHEM, V268, P15588; Teramachi S, 2002, J BIOL CHEM, V277, P37394, DOI 10.1074/jbc.M204772200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; Tran CM, 1996, BIOCHEMISTRY-US, V35, P47, DOI 10.1021/bi951238g; VILSEN B, 1987, J BIOL CHEM, V262, P10511; Ward DG, 1998, J PHYSIOL-LONDON, V511P, p29P; Ward DG, 1998, J BIOL CHEM, V273, P33759, DOI 10.1074/jbc.273.50.33759; Ward DG, 1998, J BIOL CHEM, V273, P14277, DOI 10.1074/jbc.273.23.14277; Ward DG, 1996, J BIOL CHEM, V271, P12317, DOI 10.1074/jbc.271.21.12317; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; WEBB MR, 1981, J BIOL CHEM, V256, P4884	72	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14688	14697		10.1074/jbc.M211128200	http://dx.doi.org/10.1074/jbc.M211128200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12591931	hybrid			2022-12-27	WOS:000182516100015
J	Gupta, RA; Sarraf, P; Mueller, E; Brockman, JA; Prusakiewicz, JJ; Eng, C; Willson, TM; DuBois, RN				Gupta, RA; Sarraf, P; Mueller, E; Brockman, JA; Prusakiewicz, JJ; Eng, C; Willson, TM; DuBois, RN			Peroxisome proliferator-activated receptor gamma-mediated differentiation - A mutation in colon cancer cells reveals divergent and cell type-specific mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; ORPHAN RECEPTORS; CO-REPRESSOR; IN-VITRO; GENE; LIGAND; ADIPOGENESIS; EXPRESSION	Activation of the nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARgamma) inhibits cell growth and induces differentiation in both adipocyte and epithelial cell lineages, although it is unclear whether this occurs through common or cell-type specific mechanisms. We have identified four human colon cancer cell lines that do no undergo growth inhibition or induce markers of differentiation after exposure to PPARgamma agonists. Sequence analysis of the PPARgamma gene revealed that all four cell lines contain a previously unidentified point mutation in the ninth alpha-helix of the ligand binding domain at codon 422 (K422Q). The mutant receptor did not exhibit any defects in DNA binding or retinoid X receptor heterodimerization and was transcriptionally active in an artificial reporter assay. However, only retroviral transduction of the wild-type (WT), but not mutant, receptor could restore PPARgamma ligand-induced growth inhibition and differentiation in resistant colon cancer cell lines. In contrast, there was no difference in the ability of fibroblast cells expressing WT or K422Q mutant receptor to undergo growth inhibition, express adipocyte differentiation markers, or uptake lipid after treatment with a PPARgamma agonist. Finally, analysis of direct PPARgamma target genes in colon cancer cells expressing the WT or K422Q mutant allele suggests that the mutation may disrupt the ability of PPARgamma to repress the basal expression of a subset of genes in the absence of exogenous ligand. Collectively, these data argue that codon 422 may be a part of a co-factor(s) interaction domain necessary for PPARgamma to induce terminal differentiation in epithelial, but not adipocyte, cell lineages and argues that the receptor induces growth inhibition and differentiation via cell lineage-specific mechanisms.	Vanderbilt Univ, Med Ctr, Dept Cellular & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Canc Biol, Boston, MA 02115 USA; Psychiat Genom Inc, Gaithersburg, MD 20878 USA; Ohio State Univ, Ctr Comprehens Canc, Human Genet Program, Columbus, OH 43210 USA; GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; GlaxoSmithKline	DuBois, RN (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med GI, MCN C-2104,1161 21st Ave S, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020; feinstein, doug/M-9414-2019	Eng, Charis/0000-0002-3693-5145	NCI NIH HHS [P01CA-77839] Funding Source: Medline; NIDDK NIH HHS [R01DK 47279] Funding Source: Medline; NIEHS NIH HHS [P030 ES-00267-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Brockman JA, 1998, GASTROENTEROLOGY, V115, P1049, DOI 10.1016/S0016-5085(98)70072-1; Chang TH, 2000, CANCER RES, V60, P1129; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Girnun GD, 2002, P NATL ACAD SCI USA, V99, P13771, DOI 10.1073/pnas.162480299; Glass CK, 2000, GENE DEV, V14, P121; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; GUPTA RA, 2001, J BIOL CHEM, V7, P7; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Ikezoe T, 2001, CANCER RES, V61, P5307; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Komiya T, 1999, BBA-GENE STRUCT EXPR, V1444, P434, DOI 10.1016/S0167-4781(99)00010-X; Kubota T, 1998, CANCER RES, V58, P3344; Lefebvre AM, 1999, J ENDOCRINOL, V162, P331, DOI 10.1677/joe.0.1620331; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ristow M, 1998, NEW ENGL J MED, V339, P953, DOI 10.1056/NEJM199810013391403; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; SHIBANUMA M, 1992, J BIOL CHEM, V267, P10219; Takahashi N, 1999, FEBS LETT, V455, P135, DOI 10.1016/S0014-5793(99)00871-6; Tanaka T, 2001, CANCER RES, V61, P2424; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Willson TM, 1996, ANN NY ACAD SCI, V804, P276, DOI 10.1111/j.1749-6632.1996.tb18622.x; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Yen CJ, 1997, BIOCHEM BIOPH RES CO, V241, P270, DOI 10.1006/bbrc.1997.7798; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhou XP, 2000, J MED GENET, V37, P410, DOI 10.1136/jmg.37.6.410	47	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22669	22677		10.1074/jbc.M300637200	http://dx.doi.org/10.1074/jbc.M300637200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12591919	hybrid			2022-12-27	WOS:000183503900067
J	Bianchi, E; Denti, S; Catena, R; Rossetti, G; Polo, S; Gasparian, S; Putignano, S; Rogge, L; Pardi, R				Bianchi, E; Denti, S; Catena, R; Rossetti, G; Polo, S; Gasparian, S; Putignano, S; Rogge, L; Pardi, R			Characterization of human constitutive photomorphogenesis protein 1, a RING finger ubiquitin ligase that interacts with Jun transcription factors and modulates their transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CONTROL; C-JUN; AP-1; COP1; GENE; BINDING; IDENTIFICATION; DEGRADATION; REPRESSION; COMPLEX	RING finger proteins have been implicated in many fundamental cellular processes, including the control of gene expression. A key regulator of light-dependent development in Arabidopsis thaliana is the constitutive photomorphogenesis protein 1 (atCOP1), a RING finger protein that plays an essential role in translating light/ dark signals into specific changes in gene transcription. atCOP1 binds the basic leucine zipper factor HY5 and suppresses its transcriptional activity through a yet undefined mechanism that results in HY5 degradation in response to darkness. Furthermore, the pleiotropic phenotype of atCOP1 mutants indicates that atCOP1 may be a central regulator of several transcriptional pathways. Here we report the cloning and characterization of the human orthologue of atCOP1. Human COP1 (huCOP1) distributes both to the cytoplasm and the nucleus of cells and shows a striking degree of sequence conservation with atCOP1, suggesting the possibility of a functional conservation as well. In co-immunoprecipitation assays huCOP1 specifically binds basic leucine zipper factors of the Jun family. As a functional consequence of this interaction, expression of huCOP1 in mammalian cells downregulates c-Jun-dependent transcription and the expression of the AP-1 target genes, urokinase and matrix metalloproteinase 1. The RING domain of huCOP1 displays ubiquitin ligase activity in an autoubiquitination assay in vitro; however, suppression of AP-1-dependent transcription by huCOP1 occurs in the absence of changes in c-Jun protein levels, suggesting that this inhibitory effect is independent of c-Jun degradation. Our findings indicate that huCOP1 is a novel regulator of AP-1-dependent transcription sharing the important properties of Arabidopsis COP1 in the control of gene expression.	DIBIT, Lab Leukocyte Biol, I-20132 Milan, Italy; Univ Vita Salute San Raffaele, I-20132 Milan, Italy; Inst Pasteur, Dept Immunol, Immunoregulat Lab, F-75724 Paris, France; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	Vita-Salute San Raffaele University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; IRCCS European Institute of Oncology (IEO)	Bianchi, E (corresponding author), DIBIT, Lab Leukocyte Biol, Via Olgettina 58, I-20132 Milan, Italy.	ebianchi@pasteur.fr	Polo, Simona/P-3509-2014; rossetti, grazisa/C-3722-2015; Rogge, Lars/GYJ-6142-2022	rossetti, grazisa/0000-0001-6361-311X; Polo, Simona/0000-0001-5536-9399; Rogge, Lars/0000-0003-1262-9204	Telethon [E.1300] Funding Source: Medline	Telethon(Fondazione Telethon)		Akasaka T, 2001, DEVELOPMENT, V128, P1587; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ang LH, 1998, MOL CELL, V1, P213, DOI 10.1016/S1097-2765(00)80022-2; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; Casey Graham, 1997, Current Opinion in Oncology, V9, P88; Chamovitz DA, 1996, CELL, V86, P115, DOI 10.1016/S0092-8674(00)80082-3; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; DECESARE D, 1995, ONCOGENE, V11, P365; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Hardtke CS, 2002, PLANT J, V30, P385, DOI 10.1046/j.1365-313X.2002.01298.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Holm M, 2001, EMBO J, V20, P118, DOI 10.1093/emboj/20.1.118; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Ibanez-Tallon I, 2002, BLOOD, V100, P3325, DOI 10.1182/blood.V100.9.3325; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; Kwok SF, 1996, PLANT PHYSIOL, V110, P731, DOI 10.1104/pp.110.3.731; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mizuno Y, 2001, CURR OPIN NEUROL, V14, P477, DOI 10.1097/00019052-200108000-00008; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Ostendorff HP, 2002, NATURE, V416, P99, DOI 10.1038/416099a; Osterlund MT, 2000, NATURE, V405, P462, DOI 10.1038/35013076; Osterlund MT, 1999, TRENDS CELL BIOL, V9, P113, DOI 10.1016/S0962-8924(99)01499-3; Peterson CL, 2002, EMBO REP, V3, P319, DOI 10.1093/embo-reports/kvf075; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Reyes JC, 2001, TRENDS BIOCHEM SCI, V26, P18, DOI 10.1016/S0968-0004(00)01732-1; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Sasaki A, 2002, J BIOL CHEM, V277, P22541, DOI 10.1074/jbc.M109728200; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Torii KU, 1998, EMBO J, V17, P5577, DOI 10.1093/emboj/17.19.5577; vonArnim AG, 1997, PLANT PHYSIOL, V114, P779, DOI 10.1104/pp.114.3.779; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; Wang HY, 1999, CURR BIOL, V9, P711, DOI 10.1016/S0960-9822(99)80314-5; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yin XY, 2001, ONCOGENE, V20, P2908, DOI 10.1038/sj.onc.1204417; Zhang YG, 2001, J VIROL, V75, P9571, DOI 10.1128/JVI.75.20.9571-9578.2001	55	80	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19682	19690		10.1074/jbc.M212681200	http://dx.doi.org/10.1074/jbc.M212681200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12615916	Green Published, hybrid			2022-12-27	WOS:000183078000017
J	Beuers, U; Denk, GU; Soroka, CJ; Wimmer, R; Rust, C; Paumgartner, G; Boyer, JL				Beuers, U; Denk, GU; Soroka, CJ; Wimmer, R; Rust, C; Paumgartner, G; Boyer, JL			Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; 3-KINASE LIPID PRODUCTS; PHOSPHOINOSITIDE 3-KINASE; TAUROURSODEOXYCHOLIC ACID; BILE-ACIDS; URSODEOXYCHOLIC ACID; TRANSPORT; PATHOGENESIS; SECRETION; PATHWAYS	Taurolithocholic acid (TLCA) is a potent cholestatic agent. Our recent work suggested that TLCA impairs hepatobiliary exocytosis, insertion of transport proteins into apical hepatocyte membranes, and bile flow by protein kinase Cepsilon (PKCepsilon)-dependent mechanisms. Products of phosphatidylinositol 3-kinases (PI3K) stimulate PKCepsilon. We studied the role of PI3K for TLCA-induced cholestasis in isolated perfused rat liver (IPRL) and isolated rat hepatocyte couplets (IRHC). In IPRL, TLCA (10 mumol/liter) impaired bile flow by 51%, biliary secretion of horseradish peroxidase, a marker of vesicular exocytosis, by 46%, and the Mrp2 substrate, 2,4-dinitrophenyl-S-glutathione, by 95% and stimulated PI3K-dependent protein kinase B, a marker of PI3K activity, by 154% and PKCepsilon membrane binding by 23%. In IRHC, TLCA (2.5 mumol/liter) impaired canalicular secretion of the fluorescent bile acid, cholylglycylamido fluorescein, by 50%. The selective PI3K inhibitor, wortmannin (100 nmol/liter), and the anticholestatic bile acid tauroursodeoxycholic acid (TUDCA, 25 mumol/liter) independently and additively reversed the effects of TLCA on bile flow, exocytosis, organic anion secretion, PI3K-dependent protein kinase B activity, and PKCepsilon membrane binding in IPRL. Wortmannin also reversed impaired bile acid secretion in IRHC. These data strongly suggest that TLCA exerts cholestatic effects by PI3K- and PKCepsilon-dependent mechanisms that are reversed by tauroursodeoxycholic acid in a PI3K-independent way.	Univ Munich, Klinikum Grosshadern, Dept Med 2, D-81377 Munich, Germany; Yale Univ, Sch Med, Ctr Liver, New Haven, CT 06510 USA	University of Munich; Yale University	Beuers, U (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Med 2, Marchioninistr 15, D-81377 Munich, Germany.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025636, R37DK025636, P30DK034989] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25636, DK P30-34989] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANWER MS, 1988, HEPATOLOGY, V8, P887, DOI 10.1002/hep.1840080430; BERGMEYER HU, 1983, METHOD ENZYMAT AN, V3, P574; Beuers U, 1996, GASTROENTEROLOGY, V110, P1553, DOI 10.1053/gast.1996.v110.pm8613063; Beuers U, 2001, HEPATOLOGY, V33, P1206, DOI 10.1053/jhep.2001.24034; BEUERS U, 1993, GASTROENTEROLOGY, V104, P604, DOI 10.1016/0016-5085(93)90433-D; Beuers U, 1999, HEPATOLOGY, V29, P477, DOI 10.1002/hep.510290227; Beuers U, 1998, HEPATOLOGY, V28, P1449, DOI 10.1002/hep.510280601; BEUERS U, 1993, J CLIN INVEST, V92, P2984, DOI 10.1172/JCI116921; BEUERS U, 1999, BILE ACIDS CHOLESTAS, P180; BOYER JL, 1995, GASTROENTEROLOGY, V109, P1600, DOI 10.1016/0016-5085(95)90649-5; BURGOYNE RD, 1993, BIOCHEM J, V293, P305, DOI 10.1042/bj2930305; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; COMBETTES L, 1990, EUR J BIOCHEM, V190, P619, DOI 10.1111/j.1432-1033.1990.tb15617.x; COMBETTES L, 1988, J BIOL CHEM, V263, P2299; Crawford JM, 1996, SEMIN LIVER DIS, V16, P169, DOI 10.1055/s-2007-1007230; Folli F, 1997, GASTROENTEROLOGY, V113, P954, DOI 10.1016/S0016-5085(97)70192-6; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; JAVITT NB, 1968, J CLIN INVEST, V47, P1002, DOI 10.1172/JCI105790; JAVITT NB, 1966, NATURE, V210, P1262, DOI 10.1038/2101262a0; KAKIS G, 1978, GASTROENTEROLOGY, V75, P595; KAKIS G, 1980, LAB INVEST, V43, P73; Kullak-Ublick GA, 2000, J HEPATOL, V32, P3, DOI 10.1016/S0168-8278(00)80411-0; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; Lazaridis KN, 2001, J HEPATOL, V35, P134, DOI 10.1016/S0168-8278(01)00092-7; MARINELLI RA, 1992, BIOCHIM BIOPHYS ACTA, V1125, P44, DOI 10.1016/0005-2760(92)90153-M; Milkiewicz P, 1999, HEPATOLOGY, V29, P471, DOI 10.1002/hep.510290215; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; POWIS G, 1994, CANCER RES, V54, P2419; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; ROMA MG, 1994, J HEPATOL, V20, P603, DOI 10.1016/S0168-8278(05)80347-2; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Sapin C, 1997, EXP CELL RES, V231, P308, DOI 10.1006/excr.1997.3488; SCHOLMERICH J, 1990, J HEPATOL, V10, P280, DOI 10.1016/0168-8278(90)90133-C; SCHTEINGART DC, 1994, BILE ACIDS HEPATOBIL, P177; STRAVITZ RT, 1996, AM J PHYSIOL, V271, P293; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; TOKER A, 1994, J BIOL CHEM, V269, P32358; Trauner M, 1998, NEW ENGL J MED, V339, P1217, DOI 10.1056/NEJM199810223391707; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; WAHLLANDER A, 1979, EUR J BIOCHEM, V96, P441, DOI 10.1111/j.1432-1033.1979.tb13056.x; Webster CRL, 2000, J BIOL CHEM, V275, P29754, DOI 10.1074/jbc.M002831200	44	66	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17810	17818		10.1074/jbc.M209898200	http://dx.doi.org/10.1074/jbc.M209898200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626520	hybrid			2022-12-27	WOS:000182838300029
J	Lesne, S; Docagne, F; Gabriel, C; Liot, R; Lahiri, DK; Buee, L; Plawinski, L; Delacourte, A; MacKenzie, ET; Buisson, A; Vivien, D				Lesne, S; Docagne, F; Gabriel, C; Liot, R; Lahiri, DK; Buee, L; Plawinski, L; Delacourte, A; MacKenzie, ET; Buisson, A; Vivien, D			Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CEREBRAL-ISCHEMIA; NEURONAL ORIGIN; MESSENGER-RNAS; EXPRESSION; GROWTH-FACTOR-BETA-1; GENE; CULTURES; CELLS	Accumulation of the amyloid-beta peptide (Abeta) in the brain is crucial for development of Alzheimer's disease. Expression of transforming growth factor-beta1 (TGF-beta1), an immunosuppressive cytokine, has been correlated in vivo with Abeta accumulation in transgenic mice and recently with Abeta clearance by activated microglia. Here, we demonstrate that TGF-beta1 drives the production of Abeta40/42 by astrocytes leading to Abeta production in TGF-beta1 transgenic mice. First, TGF-beta1 induces the overexpression of the amyloid precursor protein (APP) in astrocytes but not in neurons, involving a highly conserved TGF-B1-responsive element in the 5'-untranslated region (+54/ +74) of the APP promotor. Second, we demonstrated an increased release of soluble APP-beta which led to TGF-beta1-induced Abeta generation in both murine and human astrocytes. These results demonstrate that TGF-beta1 potentiates Abeta production in human astrocytes and may enhance the formation of plaques burden in the brain of Alzheimer's disease patients.	Univ Caen, Ctr Cyceron, CNRS, UMR 6551, F-14074 Caen, France; Indiana Univ, Sch Med, Inst Psychiat Res, Dept Psychiat, Indianapolis, IN 46202 USA; INSERM, U422, F-59045 Lille, France	Centre National de la Recherche Scientifique (CNRS); Universite de Caen Normandie; Indiana University System; Indiana University-Purdue University Indianapolis; Institut National de la Sante et de la Recherche Medicale (Inserm)	Vivien, D (corresponding author), Univ Caen, Ctr Cyceron, CNRS, UMR 6551, IFR47,Blvd Henri Becquerel,BP 5229, F-14074 Caen, France.	d.vivien@neuro.unicaen.fr	buisson, alain/AAI-8218-2020; Lahiri, Debomoy/AAZ-3322-2020; Mackenzie, Eric Thomson/L-1938-2015; Docagne, Fabian/S-8308-2018; BUEE, Luc/B-3126-2010	buisson, alain/0000-0002-4281-7911; BUEE, Luc/0000-0002-6261-4230; Docagne, Fabian/0000-0003-1745-0625; Lesne, Sylvain/0000-0001-9411-1868; MacKenzie, Eric T/0000-0003-1057-7033; Plawinski, Laurent/0000-0002-5288-4413; Liot, Geraldine/0000-0002-4784-7693; VIVIEN, DENIS/0000-0002-7636-2185				Amara FM, 1999, MOL BRAIN RES, V71, P42, DOI 10.1016/S0169-328X(99)00158-8; Apelt J, 2001, BRAIN RES, V894, P21, DOI 10.1016/S0006-8993(00)03176-0; Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; BERKENBOSCH F, 1990, J NEUROSCI RES, V25, P431, DOI 10.1002/jnr.490250321; Buisson A, 1998, FASEB J, V12, P1683, DOI 10.1096/fasebj.12.15.1683; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CRAS P, 1990, AM J PATHOL, V137, P241; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; DELACOURTE A, 1989, CR ACAD SCI III-VIE, V308, P359; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Docagne F, 1999, FASEB J, V13, P1315, DOI 10.1096/fasebj.13.11.1315; FILLIT H, 1991, NEUROSCI LETT, V129, P318, DOI 10.1016/0304-3940(91)90490-K; FLANDERS KC, 1995, NEUROLOGY, V45, P1561, DOI 10.1212/WNL.45.8.1561; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GRAY CW, 1993, MOL BRAIN RES, V19, P251, DOI 10.1016/0169-328X(93)90037-P; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HUELL M, 1995, ACTA NEUROPATHOL, V89, P544; KANG J, 1989, NUCLEIC ACIDS RES, V17, P2130, DOI 10.1093/nar/17.5.2130; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Komesli S, 1998, EUR J BIOCHEM, V254, P505, DOI 10.1046/j.1432-1327.1998.2540505.x; Lahiri DK, 2000, MOL BRAIN RES, V77, P185, DOI 10.1016/S0169-328X(00)00051-6; LeBlanc AC, 1996, J NEUROCHEM, V66, P2300; LeBlanc AC, 1997, J NEUROCHEM, V68, P1183; LEBLANC AC, 1991, FEBS LETT, V292, P171, DOI 10.1016/0014-5793(91)80861-V; Luedecking EK, 2000, HUM GENET, V106, P565, DOI 10.1007/s004390050026; MANN DMA, 1992, ACTA NEUROPATHOL, V83, P415, DOI 10.1007/BF00713534; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; Rose K, 1993, IN VITRO BIOL METHOD, P46; Ruocco A, 1999, J CEREBR BLOOD F MET, V19, P1345, DOI 10.1097/00004647-199912000-00008; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SOLA C, 1993, MOL BRAIN RES, V17, P41, DOI 10.1016/0169-328X(93)90071-V; Song WH, 1998, GENE, V217, P151, DOI 10.1016/S0378-1119(98)00337-0; Tomoda T, 1996, DEV BIOL, V179, P79, DOI 10.1006/dbio.1996.0242; VANDERWAL EA, 1993, NEUROREPORT, V4, P69, DOI 10.1097/00001756-199301000-00018; Vivien D, 1998, J NEUROCHEM, V70, P2296; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; WYSSCORAY T, 1995, AM J PATHOL, V147, P53; Zhao J, 1996, J BIOL CHEM, V271, P31407, DOI 10.1074/jbc.271.49.31407	48	100	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18408	18418		10.1074/jbc.M300819200	http://dx.doi.org/10.1074/jbc.M300819200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626500	hybrid			2022-12-27	WOS:000182838300107
J	Rome, S; Clement, K; Rabasa-Lhoret, R; Loizon, E; Poitou, C; Barsh, GS; Riou, JP; Laville, M; Vidal, H				Rome, S; Clement, K; Rabasa-Lhoret, R; Loizon, E; Poitou, C; Barsh, GS; Riou, JP; Laville, M; Vidal, H			Microarray profiling of human skeletal muscle reveals that insulin regulates not similar to 800 genes during a hyperinsulinemic clamp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME INHIBITORS; SIGNALING PATHWAY; RECEPTOR-ALPHA; EXPRESSION; PROTEIN; GLUT4; UBIQUITIN; SYSTEM; PHOSPHORYLATION; TRANSCRIPTION	Insulin action in target tissues involved precise regulation of gene expression. To define the set of insulin-regulated genes in human skeletal muscle, we analyzed the global changes in mRNA levels during a 3-h hyperinsulinemic euglycemic clamp in vastus lateralis muscle of six healthy subjects. Using 29,308 cDNA element microarrays, we found that the mRNA expression of 762 genes, including 353 expressed sequence tags, was significantly modified during insulin infusion. 478 were up-regulated and 284 down-regulated. Most of the genes with known function are novel targets of insulin. They are involved in the transcriptional and translational regulation (29%), intermediary and energy metabolisms (14%), intracellular signaling (12%), and cytoskeleton and vesicle traffic (9%). Other categories consisted of genes coding for receptors, carriers, and transporters (8%), components of the ubiquitin/proteasome pathways (7%) and elements of the immune response (5.5%). These results thus define a transcriptional signature of insulin action in human skeletal muscle. They will help to better define the mechanisms involved in the reduction of insulin effectiveness in pathologies such as type 2 diabetes mellitus, a disease characterized by defective regulation of gene expression in response to insulin.	Fac Med R Laennec, INSERM, U449, F-69372 Lyon 08, France; Fac Med R Laennec, Human Nutr Res Ctr, F-69372 Lyon 08, France; Univ Paris 06, Dept Nutr, Hotel Dieu, EA3502, F-75004 Paris, France; Stanford Univ, Sch Med, Beckman Ctr, Howard Hughes Med Inst,Dept Pediat & Genet, Stanford, CA 94305 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Sorbonne Universite; Howard Hughes Medical Institute; Stanford University	Rome, S (corresponding author), Fac Med R Laennec, INSERM, U449, Rue G Paradin, F-69372 Lyon 08, France.	srome@univ-lyon1.fr	Clément, karine/R-1120-2017; Vidal, Hubert/M-6674-2017	Vidal, Hubert/0000-0002-9467-0317; LOIZON, Emmanuelle/0000-0002-0723-0736; ROME, SOPHIE/0000-0003-3986-5936				ANDERSEN PH, 1993, J CLIN ENDOCR METAB, V77, P27, DOI 10.1210/jc.77.1.27; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; BAUGH LR, 2001, NUCLEIC ACIDS RES, V29, P2; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bevan P, 2001, J CELL SCI, V114, P1429; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; Bortoluzzi S, 2000, GENOME RES, V10, P344, DOI 10.1101/gr.10.3.344; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Carayannopoulos MO, 2000, P NATL ACAD SCI USA, V97, P7313, DOI 10.1073/pnas.97.13.7313; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Clement K, 2002, GENOME RES, V12, P281, DOI 10.1101/gr.207702; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; Dyck DJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE600, DOI 10.1152/ajpendo.2001.281.3.E600; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; GELFAND RA, 1987, J CLIN INVEST, V80, P1, DOI 10.1172/JCI113033; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; GOLDSTEIN BJ, 1992, J CELL BIOCHEM, V48, P33, DOI 10.1002/jcb.240480107; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Huang J, 2001, P NATL ACAD SCI USA, V98, P13084, DOI 10.1073/pnas.241368698; Ibberson M, 2000, J BIOL CHEM, V275, P4607, DOI 10.1074/jbc.275.7.4607; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; KELLEY DE, 1990, AM J PHYSIOL, V258, pE923, DOI 10.1152/ajpendo.1990.258.6.E923; Laville M, 1996, J CLIN INVEST, V98, P43, DOI 10.1172/JCI118775; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Luiken JJFP, 2002, DIABETES, V51, P3113, DOI 10.2337/diabetes.51.10.3113; Matsushima-Nishiwaki R, 2001, CANCER RES, V61, P7675; Mimnaugh EG, 1997, BIOCHEMISTRY-US, V36, P14418, DOI 10.1021/bi970998j; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Pendergrass M, 1998, DIABETES, V47, P387, DOI 10.2337/diabetes.47.3.387; Pietu G, 1999, GENOME RES, V9, P195; Rankinen T, 2002, MED SCI SPORT EXER, V34, P1219, DOI 10.1097/00005768-200208000-00001; Rondinone CM, 2002, BIOCHEM BIOPH RES CO, V296, P1257, DOI 10.1016/S0006-291X(02)02083-1; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; Sreekumar R, 2002, DIABETES, V51, P1913, DOI 10.2337/diabetes.51.6.1913; Thurmond DC, 2001, MOL MEMBR BIOL, V18, P237; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wang J, 2000, ANAL SCI, V16, P457, DOI 10.2116/analsci.16.457; Welle S, 1999, GENOME RES, V9, P506; White MF, 1998, RECENT PROG HORM RES, V53, P119; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999	46	153	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18063	18068		10.1074/jbc.M300293200	http://dx.doi.org/10.1074/jbc.M300293200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621037	hybrid			2022-12-27	WOS:000182838300062
J	Yen, CLE; Farese, RV				Yen, CLE; Farese, RV			MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL ACYLTRANSFERASE; PURIFICATION; ACTIVATION; CLONING; FAMILY; DGAT2; CELLS	Acyl CoA:monoacylglycerol acyltransferase (MGAT) catalyzes the synthesis of diacylglycerol, a precursor of triacylglycerol. In the intestine, MGAT plays a major role in the absorption of dietary fat by catalyzing the resynthesis of triacylglycerol in enterocytes. This resynthesis is required for the assembly of lipoproteins that transport absorbed fat to other tissues. Despite intense efforts, a gene encoding an intestinal MGAT has not been found. Previously, we identified a gene encoding MGAT1, which in mice is expressed in the stomach, kidney, adipose tissue, and liver but not in the intestine. We now report the identification of homologous genes in humans and mice encoding MGAT2. Expression of the MGAT2 cDNA in either insect or mammalian cells markedly increased MGAT activity in cell membranes. MGAT activity was proportional to the level of MGAT2 protein expressed, and the amount of diacylglycerol produced depended on the concentration of MGAT substrates (fatty acyl CoA or monoacylglycerol). In humans, the MGAT2 gene is highly expressed in the small intestine, liver, stomach, kidney, colon, and white adipose tissue; in mice, it is expressed predominantly in the small intestine. The discovery of the MGAT2 gene will facilitate studies to determine the functional role of MGAT2 in fat absorption in the intestine and to determine whether blocking MGAT activity in enterocytes is a feasible approach to inhibit fat absorption and treat obesity.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Farese, RV (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.		Adiels, Martin/C-9278-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK056084, R01DK056084] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56084, R01 DK056084] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BHAT BG, 1993, ARCH BIOCHEM BIOPHYS, V300, P663, DOI 10.1006/abbi.1993.1092; Brockerhoff H., 1974, LIPOLYTIC ENZYMES, P25; CAO J, 2003, J BIOL CHEM; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; COLEMAN RA, 1984, J BIOL CHEM, V259, P8934; GREENSPAN MD, 1968, J BIOL CHEM, V243, P6273; GRIGOR MR, 1982, BIOCHIM BIOPHYS ACTA, V712, P464, DOI 10.1016/0005-2760(82)90273-9; HOFFMAN AGD, 1982, BIOCHIM BIOPHYS ACTA, V710, P53, DOI 10.1016/0005-2760(82)90189-8; JAMDAR SC, 1992, ARCH BIOCHEM BIOPHYS, V296, P419, DOI 10.1016/0003-9861(92)90592-K; JOHNSTON JM, 1977, LIPID METABOLISM MAM, P151; Johnston JM, 1976, LIPID ABSORPTION BIO, P85; Kayden H. J., 1967, J CLIN INVEST, V46, P1965; Kuksis A, 2001, INTESTINAL LIPID MET, P185; Lardizabal KD, 2001, J BIOL CHEM, V276, P38862, DOI 10.1074/jbc.M106168200; LEHNER R, 1993, LIPIDS, V28, P29, DOI 10.1007/BF02536356; MANGANARO F, 1985, CAN J BIOCHEM CELL B, V63, P341, DOI 10.1139/o85-050; MOSTAFA N, 1994, LIPIDS, V29, P785, DOI 10.1007/BF02536701; Phan CT, 2001, FRONT BIOSCI-LANDMRK, V6, pD299, DOI 10.2741/Phan; SANSBURY K, 1989, J LIPID RES, V30, P1251; TENU JP, 1972, EUR J BIOCHEM, V26, P112, DOI 10.1111/j.1432-1033.1972.tb01746.x; WHITMAN WB, 1979, J BIOL CHEM, V254, P184; XIA T, 1993, AM J PHYSIOL, V265, pR414, DOI 10.1152/ajpregu.1993.265.2.R414; Yen CLE, 2002, P NATL ACAD SCI USA, V99, P8512, DOI 10.1073/pnas.132274899	25	134	155	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18532	18537		10.1074/jbc.M301633200	http://dx.doi.org/10.1074/jbc.M301633200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12621063	hybrid			2022-12-27	WOS:000182838300123
J	Carrino, DA; Onnerfjord, P; Sandy, JD; Cs-Szabo, G; Scott, PG; Sorrell, JM; Heinegard, D; Caplan, AI				Carrino, DA; Onnerfjord, P; Sandy, JD; Cs-Szabo, G; Scott, PG; Sorrell, JM; Heinegard, D; Caplan, AI			Age-related changes in the proteoglycans of human skin - Specific cleavage of decorin to yield a major catabolic fragment in adult skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; LEUCINE-RICH REPEAT; ARTICULAR-CARTILAGE; MATRIX METALLOPROTEINASES; CORE PROTEINS; I COLLAGEN; DEGRADATION; AGGRECAN; BINDING; GROWTH	Dramatic changes occur in skin as a function of age, including changes in morphology, physiology, and mechanical properties. Changes in extracellular matrix molecules also occur, and these changes likely contribute to the overall age-related changes in the physical properties of skin. The major proteoglycans detected in extracts of human skin are decorin and versican. In addition, adult human skin contains a truncated form of decorin, whereas fetal skin contains virtually undetectable levels of this truncated decorin. Analysis of this molecule, herein referred to as decorunt, indicates that it is a catabolic fragment of decorin rather than a splice variant. With antibody probes to the core protein, decorunt is found to lack the carboxyl-terminal portion of decorin. Further analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry shows that the carboxyl terminus of decorunt is at Phe(170) of decorin. This result indicates that decorunt represents the amino-terminal 43% of the mature decorin molecule. Such a structure is inconsistent with alternative splicing of decorin and suggests that decorunt is a catabolic fragment of decorin. A neoepitope antiserum, anti-VRKVTF, was generated against the carboxyl terminus of decorunt. This antiserum does not recognize intact decorin in any skin proteoglycan sample tested on immunoblots but recognizes every sample of decorunt tested. The results with anti-VRKVTF confirm the identification of the carboxyl terminus of decorunt. Analysis of collagen binding by surface plasmon resonance indicates that the affinity of decorunt for type I collagen is 100-fold less than that of decorin. This observation correlates with the structural analysis of decorunt, in that it lacks regions of decorin previously shown to be important for interaction with type I collagen. The detection of a catabolic fragment of decorin suggests the existence of a specific catabolic pathway for this proteoglycan. Because of the capacity of decorin to influence collagen fibrillogenesis, catabolism of decorin may have important functional implications with respect to the dermal collagen network.	Case Western Reserve Univ, Dept Biol, Skeletal Res Ctr, Cleveland, OH 44106 USA; Lund Univ, Ctr Biomed, Dept Cell & Mol Biol, Sect Connect Tissue Biol, SE-22184 Lund, Sweden; Shriners Hosp Children, Ctr Skeletal Dev & Pediat Orthoped Res, Tampa, FL 33612 USA; Univ S Florida, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	Case Western Reserve University; Lund University; State University System of Florida; University of South Florida; Rush University; University of Alberta	Carrino, DA (corresponding author), Case Western Reserve Univ, Dept Biol, Skeletal Res Ctr, Cleveland, OH 44106 USA.		Onnerfjord, Patrik/R-3131-2019	Onnerfjord, Patrik/0000-0002-2345-2937; Caplan, Arnold/0000-0002-8677-6621				Agren UM, 1997, J INVEST DERMATOL, V109, P219, DOI 10.1111/1523-1747.ep12319412; BENTLEY JP, 1979, J INVEST DERMATOL, V73, P80, DOI 10.1111/1523-1747.ep12532769; Breen M., 1972, CONNECT TISSUE RES, V1, P291, DOI [10.3109/03008207209152087, DOI 10.3109/03008207209152087]; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CARRINO DA, 1991, BIOCHEM INT, V24, P485; Carrino DA, 2000, ARCH BIOCHEM BIOPHYS, V373, P91, DOI 10.1006/abbi.1999.1545; Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0; CHOI HU, 1989, J BIOL CHEM, V264, P2876; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; DALY CH, 1979, J INVEST DERMATOL, V73, P84, DOI 10.1111/1523-1747.ep12532770; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; FLEISCHMAJER R, 1991, J STRUCT BIOL, V106, P82, DOI 10.1016/1047-8477(91)90065-5; FLEISCHMAJER R, 1972, BIOCHIM BIOPHYS ACTA, V279, P265, DOI 10.1016/0304-4165(72)90142-0; FUSHIMI H, 1989, J INTERN MED, V226, P409, DOI 10.1111/j.1365-2796.1989.tb01416.x; GARG HG, 1990, CARBOHYD RES, V207, P295, DOI 10.1016/0008-6215(90)84056-Z; Gearing AJH, 2002, IMMUNOL LETT, V81, P41, DOI 10.1016/S0165-2478(01)00333-9; Gronski TJ, 1997, J BIOL CHEM, V272, P12189, DOI 10.1074/jbc.272.18.12189; HABUCHI H, 1986, J BIOL CHEM, V261, P1031; HONDA T, 1986, Journal of Dermatology (Tokyo), V13, P326; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Jeanmaire C, 2001, BRIT J DERMATOL, V145, P10, DOI 10.1046/j.1365-2133.2001.04275.x; Kamada A, 1996, ARCH ORAL BIOL, V41, P951, DOI 10.1016/S0003-9969(96)00031-3; Kresse H, 1997, J BIOL CHEM, V272, P18404, DOI 10.1074/jbc.272.29.18404; LAVKER RM, 1987, J INVEST DERMATOL, V88, pS44, DOI 10.1111/1523-1747.ep12468934; LONGAS MO, 1987, CARBOHYD RES, V159, P127, DOI 10.1016/S0008-6215(00)90010-7; MATSUNAGA E, 1986, J INVEST DERMATOL, V87, P221, DOI 10.1111/1523-1747.ep12696553; MAYS PK, 1988, MECH AGEING DEV, V45, P203, DOI 10.1016/0047-6374(88)90002-4; MEYER LJM, 1994, J INVEST DERMATOL, V102, P385, DOI 10.1111/1523-1747.ep12371800; Mohan MJ, 2002, BIOCHEMISTRY-US, V41, P9462, DOI 10.1021/bi0260132; Moragas A, 1998, ANAL QUANT CYTOL, V20, P493; Mort JS, 2001, ARTHRITIS RES, V3, P337, DOI 10.1186/ar325; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; NAKANO T, 1988, BIOMED RES-TOKYO, V9, P269, DOI 10.2220/biomedres.9.269; Parks WC, 1998, BIOL EXTRAC, P263; PEARCE RH, 1972, J INVEST DERMATOL, V58, P347, DOI 10.1111/1523-1747.ep12540531; Pinnell SR, 1983, BIOCH PHYSL SKIN, P385; Pratta MA, 2000, J BIOL CHEM, V275, P39096, DOI 10.1074/jbc.M006201200; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; RICHARD S, 1993, J INVEST DERMATOL, V100, P705, DOI 10.1111/1523-1747.ep12472356; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; ROUGHLEY PJ, 1993, BIOCHEM J, V295, P421, DOI 10.1042/bj2950421; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; SCOTT PG, 1993, J BIOL CHEM, V268, P11558; Soejima K, 2001, J BIOCHEM-TOKYO, V130, P475, DOI 10.1093/oxfordjournals.jbchem.a003009; STEUER S, 1993, DERMATAN SULFATE PRO, P115; Stracke JO, 2000, FEBS LETT, V478, P52, DOI 10.1016/S0014-5793(00)01819-6; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Sztrolovics R, 1999, BIOCHEM J, V339, P571, DOI 10.1042/0264-6021:3390571; TAKEMA Y, 1994, BRIT J DERMATOL, V131, P641, DOI 10.1111/j.1365-2133.1994.tb04975.x; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; VETTER U, 1993, GENOMICS, V15, P161, DOI 10.1006/geno.1993.1023; Westling J, 2002, J BIOL CHEM, V277, P16059, DOI 10.1074/jbc.M108607200; WILLEN MD, 1991, J INVEST DERMATOL, V96, P968, DOI 10.1111/1523-1747.ep12476335; YAMAUCHI M, 1988, BIOCHEM BIOPH RES CO, V152, P898, DOI 10.1016/S0006-291X(88)80124-4	59	68	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17566	17572		10.1074/jbc.M300124200	http://dx.doi.org/10.1074/jbc.M300124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12621051	hybrid			2022-12-27	WOS:000182818600146
J	Carvalho, J; Zheng, XFS				Carvalho, J; Zheng, XFS			Domains of Gln3p interacting with karyopherins, Ure2p, and the target of rapamycin protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION; SIGNALING PATHWAYS; GATA FACTORS; TOR; NITROGEN; EXPRESSION; GENE; ACTIVATION; COMPLEXES	Gln3p is a GATA-type transcription factor responsive to the quality of nitrogen and carbon. In preferred nitrogen such as glutamine, Gln3p is phosphorylated and sequestered in the cytoplasm in a manner that is dependent on the target of rapamycin (TOR) protein and Ure2p. In nonpreferred nitrogen or nitrogen starvation, Gln3p is dephosphorylated and imported into the nucleus via karyopherin alpha/Srp1p. Upon reintroduction of preferred nitrogen, Gln3p is exported from the nucleus by Crm1p/Xpo1p. Although recent work has provided insights into Gln3p, a more detailed understanding is needed to elucidate the mechanism of its localization and function. In this study, we show that Gln3p contains canonical nuclear localization signal and nuclear export signal sequences necessary for its localization and interaction with its relevant karyopherins. In addition, we identify an N-terminal domain of Gln3p interacting with Ure2p and a C-terminal region for binding to TOR. Finally, we find a lysine/arginine-rich domain essential for the rapamycin-sensitive function, but dispensable for its localization. Our results reveal key domains of Gln3p important for its function and regulation.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL)	Zheng, XFS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8069,660 S Euclid Ave, St Louis, MO 63110 USA.	zheng@pathology.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA077668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062817] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA77668] Funding Source: Medline; NIGMS NIH HHS [R01GM62817] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2002, CELL, V111, P9, DOI 10.1016/S0092-8674(02)01009-7; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Blinder D, 1996, J BACTERIOL, V178, P4734, DOI 10.1128/jb.178.15.4734-4736.1996; BLINDER D, 1995, J BACTERIOL, V177, P4190, DOI 10.1128/jb.177.14.4190-4193.1995; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Carvalho J, 2001, J BIOL CHEM, V276, P25359, DOI 10.1074/jbc.M103050200; Chan TF, 2000, P NATL ACAD SCI USA, V97, P13227, DOI 10.1073/pnas.240444197; Chan TF, 2001, J BIOL CHEM, V276, P6463, DOI 10.1074/jbc.M008162200; Coffman JA, 1996, MOL CELL BIOL, V16, P847; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; Crespo JL, 2001, J BIOL CHEM, V276, P34441, DOI 10.1074/jbc.M103601200; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Kulkarni AA, 2001, J BIOL CHEM, V276, P32136, DOI 10.1074/jbc.M104580200; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; STANBROUGH M, 1995, P NATL ACAD SCI USA, V92, P9450, DOI 10.1073/pnas.92.21.9450; Svetlov V, 1997, J BACTERIOL, V179, P7644, DOI 10.1128/jb.179.24.7644-7652.1997; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	37	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16878	16886		10.1074/jbc.M300429200	http://dx.doi.org/10.1074/jbc.M300429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624103	hybrid			2022-12-27	WOS:000182818600059
J	Harding, A; Giles, N; Burgess, A; Hancock, JF; Gabrielli, BG				Harding, A; Giles, N; Burgess, A; Hancock, JF; Gabrielli, BG			Mechanism of mitosis-specific activation of MEK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; SOMATIC-CELL MITOSIS; PROTEIN-KINASE; MAP-KINASE; PHOSPHOINOSITIDE 3-KINASE; G(2)/M TRANSITION; N-RAS; CYCLE; PATHWAY; BINDING	Activation of cyclin B-Cdc2 is an absolute requirement for entry into mitosis, but other protein kinase pathways that also have mitotic functions are activated during G(2)/M progression. The MAPK cascade has well established roles in entry and exit from mitosis in Xenopus, but relatively little is known about the regulation and function of this pathway in mammalian mitosis. Here we report a detailed analysis of the activity of all components of the Ras/Raf/MEK/ERK pathway in HeLa cells during normal G(2)/M. The focus of this pathway is the dramatic activation of an endomembrane-associated MEK1 without the corresponding activation of the MEK substrate ERK. This is because of the uncoupling of MEK1 activation from ERK activation. The mechanism of this uncoupling involves the cyclin B-Cdc2-dependent proteolytic cleavage of the N-terminal ERK-binding domain of MEK1 and the phosphorylation of Thr(286). These results demonstrate that cyclin B-Cdc2 activity regulates signaling through the MAPK pathway in mitosis.	Univ Queensland, Canc Biol Program, Ctr Immunol & Canc Res, Brisbane, Qld 4102, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4102, Australia	University of Queensland; University of Queensland	Gabrielli, BG (corresponding author), Univ Queensland, Ctr Immunol & Canc Res, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.		Harding, Angus/B-4120-2012; Gabrielli, Brian G/B-3655-2011; Burgess, Andrew/H-3339-2019; Burgess, Andrew/C-7952-2009	Gabrielli, Brian G/0000-0003-3933-1651; Burgess, Andrew/0000-0003-4536-9226; Burgess, Andrew/0000-0003-4536-9226; Hancock, John/0000-0003-0542-4710				Bardwell AJ, 2001, J BIOL CHEM, V276, P10374, DOI 10.1074/jbc.M010271200; Bitangcol JC, 1998, MOL BIOL CELL, V9, P451, DOI 10.1091/mbc.9.2.451; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Colanzi A, 2000, J CELL BIOL, V149, P331, DOI 10.1083/jcb.149.2.331; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Laird AD, 1999, J BIOL CHEM, V274, P4430, DOI 10.1074/jbc.274.7.4430; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; McGuire TF, 2001, J BIOL CHEM, V276, P26365, DOI 10.1074/jbc.M010101200; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; Roberts EC, 2002, MOL CELL BIOL, V22, P7226, DOI 10.1128/MCB.22.20.7226-7241.2002; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; Tamura K, 2000, CANCER RES, V60, P1317; Walter SA, 2000, MOL BIOL CELL, V11, P887, DOI 10.1091/mbc.11.3.887; Wang XQ, 1996, CANCER RES, V56, P2510; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	31	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16747	16754		10.1074/jbc.M301015200	http://dx.doi.org/10.1074/jbc.M301015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609978	hybrid			2022-12-27	WOS:000182818600041
J	Laliberte, RE; Perregaux, DG; Hoth, LR; Rosner, PJ; Jordan, CK; Peese, KM; Eggler, JF; Dombroski, MA; Geoghegan, KF; Gabel, CA				Laliberte, RE; Perregaux, DG; Hoth, LR; Rosner, PJ; Jordan, CK; Peese, KM; Eggler, JF; Dombroski, MA; Geoghegan, KF; Gabel, CA			Glutathione S-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1 beta posttranslational processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-INDUCED ARTHRITIS; CHLORIDE-ION CHANNEL; MOLECULAR-CLONING; TNF-ALPHA; CRYSTAL-STRUCTURE; HUMAN MONOCYTES; P2Z RECEPTOR; ATP; IDENTIFICATION; ACTIVATION	Stimulus-induced posttranslational processing of human monocyte interleukin-1beta(IL-1beta) is accompanied by major changes to the intracellular ionic environment, activation of caspase-1, and cell death. Certain diarylsulfonylureas inhibit this response, and are designated cytokine release inhibitory drugs (CRIDs). CRIDs arrest activated monocytes so that caspase-1 remains inactive and plasma membrane latency is preserved. Affinity labeling with [C-14] CRIDs and affinity chromatography on immobilized CRID were used in seeking potential protein targets of their action. Following treatment of intact human monocytes with an epoxide-bearing [C-14] CRID, glutathione S-transferase (GST) Omega 1-1 was identified as a preferred target. Moreover, labeling of this polypeptide correlated with irreversible inhibition of ATP-induced IL-1beta posttranslational processing. When extracts of human monocytic cells were chromatographed on a CRID affinity column, GST Omega 1-1 bound selectively to the affinity matrix and was eluted by soluble CRID. Recombinant GST Omega 1-1 readily incorporated [C-14] CRID epoxides, but labeling was negated by co-incubation with S-substituted glutathiones or by mutagenesis of the catalytic center Cys(32) to alanine. Peptide mapping by high performance liquid chromatography-mass spectrometry also demonstrated that Cys(32) was the site of modification. Although S-alkylglutathiones did not arrest ATP-induced IL-1beta posttranslational processing or inhibit [C-14] CRID incorporation into cell-associated GST Omega 1-1, a glutathione-CRID adduct effectively demonstrated these attributes. Therefore, the ability of CRIDs to arrest stimulus-induced IL-1beta posttranslational processing may be attributable to their interaction with GST Omega 1-1.	Pfizer Inc, Pfizer Global Res & Dev, Dept Antibacterials Immunol & Inflammat, Groton, CT 06340 USA; Pfizer Inc, Pfizer Global Res & Dev, Dept Exploratory Med Sci, Groton, CT 06340 USA	Pfizer; Pfizer	Gabel, CA (corresponding author), Pfizer Inc, Pfizer Global Res & Dev, Dept Antibacterials Immunol & Inflammat, Mailstop 8220-2123, Groton, CT 06340 USA.	christopher_a_gabel@groton.pfizer.com						AHOKAS JT, 1985, BIOCHEM PHARMACOL, V34, P2157, DOI 10.1016/0006-2952(85)90411-3; Alzola E, 1998, J BIOL CHEM, V273, P30208, DOI 10.1074/jbc.273.46.30208; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; BHAKDI S, 1990, J CLIN INVEST, V85, P1746, DOI 10.1172/JCI114631; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Borges CR, 2002, J BIOL CHEM, V277, P48295, DOI 10.1074/jbc.M209042200; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Cheneval D, 1998, J BIOL CHEM, V273, P17846, DOI 10.1074/jbc.273.28.17846; CLELLAND JD, 1992, BIOCHEM PHARMACOL, V44, P1953, DOI 10.1016/0006-2952(92)90097-3; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dixon DP, 2002, J BIOL CHEM, V277, P30859, DOI 10.1074/jbc.M202919200; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Eaton P, 2002, J BIOL CHEM, V277, P21189, DOI 10.1074/jbc.M200591200; Eggler JF, 2002, J LABELLED COMPD RAD, V45, P785, DOI 10.1002/jlcr.602; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1997, J IMMUNOL, V159, P1451; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Geoghegan K. F., 1996, CURRENT PROTOCOLS PR; Harrop SJ, 2001, J BIOL CHEM, V276, P44993, DOI 10.1074/jbc.M107804200; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Hentze H, 2002, J BIOL CHEM, V277, P5588, DOI 10.1074/jbc.M110766200; Hide I, 2000, J NEUROCHEM, V75, P965, DOI 10.1046/j.1471-4159.2000.0750965.x; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Ishikawa T, 1998, J BIOL CHEM, V273, P28708, DOI 10.1074/jbc.273.44.28708; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; JASYS VJ, 2003, INPRESS SYN COMM, V33; Jonscher KR, 1997, ANAL BIOCHEM, V244, P1, DOI 10.1006/abio.1996.9877; Joosten LAB, 1999, J IMMUNOL, V163, P5049; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; LALIBERTE R, 1994, J IMMUNOL, V153, P2168; Laliberte RE, 1999, J BIOL CHEM, V274, P36944, DOI 10.1074/jbc.274.52.36944; Liebau E, 2000, MOL BIOCHEM PARASIT, V109, P101, DOI 10.1016/S0166-6851(00)00232-2; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; Marrs KA, 1996, ANNU REV PLANT PHYS, V47, P127, DOI 10.1146/annurev.arplant.47.1.127; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; MEURY J, 1990, ARCH MICROBIOL, V154, P475, DOI 10.1007/BF00245231; Michel AD, 1998, BRIT J PHARMACOL, V125, P1194, DOI 10.1038/sj.bjp.0702205; MILLER BE, 1995, J IMMUNOL, V154, P1331; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; MUNGER JS, 1991, J BIOL CHEM, V266, P18832; Ness LS, 1999, J BIOL CHEM, V274, P9524, DOI 10.1074/jbc.274.14.9524; Nobel CSI, 1997, CHEM RES TOXICOL, V10, P1319, DOI 10.1021/tx970131m; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Perregaux DG, 1998, AM J PHYSIOL-CELL PH, V275, pC1538, DOI 10.1152/ajpcell.1998.275.6.C1538; Perregaux DG, 1996, J BIOL CHEM, V271, P29830, DOI 10.1074/jbc.271.47.29830; Perregaux DG, 2002, J IMMUNOL, V168, P3024, DOI 10.4049/jimmunol.168.6.3024; Perregaux DG, 2001, J PHARMACOL EXP THER, V299, P187; Perregaux DG, 1996, J IMMUNOL, V157, P57; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Ridderstrom M, 1997, BIOCHEM J, V328, P231, DOI 10.1042/bj3280231; Rossjohn J, 1996, PROTEIN ENG, V9, P327, DOI 10.1093/protein/9.4.327; Rouimi P, 2001, BIOCHEM J, V358, P257, DOI 10.1042/0264-6021:3580257; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Schilling WP, 1999, AM J PHYSIOL-CELL PH, V277, pC766, DOI 10.1152/ajpcell.1999.277.4.C766; Seres T, 1996, J IMMUNOL, V156, P1973; Shenton D, 2002, J BIOL CHEM, V277, P16853, DOI 10.1074/jbc.M200559200; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; STEVENSON FT, 1992, J CELL PHYSIOL, V152, P223, DOI 10.1002/jcp.1041520202; Stone K. L., 1993, PRACTICAL GUIDE PROT, P43; Sullivan DM, 2000, BIOCHEMISTRY-US, V39, P11121, DOI 10.1021/bi0007674; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Thompson GJ, 2001, BIOCHEM J, V357, P137, DOI 10.1042/0264-6021:3570137; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; Tulk BM, 1998, AM J PHYSIOL-RENAL, V274, pF1140, DOI 10.1152/ajprenal.1998.274.6.F1140; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; VEJDELEK ZJ, 1977, COLLECT CZECH CHEM C, V42, P1992, DOI 10.1135/cccc19771992; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WANG RW, 1992, J BIOL CHEM, V267, P19866; WELLS WW, 1995, METHOD ENZYMOL, V252, P30; Williams RO, 2000, J IMMUNOL, V165, P7240, DOI 10.4049/jimmunol.165.12.7240; Xia B, 2001, J MOL BIOL, V310, P907, DOI 10.1006/jmbi.2001.4721	90	150	162	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16567	16578		10.1074/jbc.M211596200	http://dx.doi.org/10.1074/jbc.M211596200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12624100	hybrid			2022-12-27	WOS:000182818600018
J	Martinez, J; Moeller, I; Erdjument-Bromage, H; Tempst, P; Lauring, B				Martinez, J; Moeller, I; Erdjument-Bromage, H; Tempst, P; Lauring, B			Parkinson's disease-associated alpha-synuclein is a calmodulin substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; LEWY-BODY-DISEASE; CENTRAL-NERVOUS-SYSTEM; A-BETA COMPONENT; NACP/ALPHA-SYNUCLEIN; IN-VITRO; NEURODEGENERATIVE DISORDERS; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; CROSS-LINKING	alpha-Synuclein is a neuronal protein thought to be central in the pathogenesis of Parkinson's disease (PD) because it comprises the fibrillar core of Lewy bodies, one of the histologically defining lesions of PD, and because mutations in alpha-synuclein cause autosomal dominant PD. Although its physiologic role is uncertain, alpha-synuclein is a synaptic protein that may contribute to plasticity. We produced synuclein with incorporated photoprobes to identify and purify novel synuclein-interacting proteins both to begin to clarify the physiology of synuclein and to identify factors that may regulate synuclein conformation. We detected several cross-links and purified and identified one as calmodulin (CaM). CaM binds to both wild type and PD-associated mutant alpha-synucleins in a calcium-dependent manner. We further demonstrate that CaM and alpha-synuclein interact in intact cells in a calcium-dependent manner and that activated CaM accelerates the formation of synuclein fibrils in vitro. We hypothesize that the known calcium control of synuclein function is mediated through CaM interaction and that CaM potentially alters synuclein conformation.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Columbia University; Columbia University; Memorial Sloan Kettering Cancer Center	Lauring, B (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, BB-1427 650 W 168th St, New York, NY 10032 USA.	bl320@columbia.edu		Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Arai T, 1999, NEUROSCI LETT, V259, P83, DOI 10.1016/S0304-3940(98)00890-8; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; Bofill-Cardona E, 2000, J BIOL CHEM, V275, P32672, DOI 10.1074/jbc.M002780200; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2000, ANN NY ACAD SCI, V920, P42; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; de Silva HA, 2000, CURR OPIN GENET DEV, V10, P292; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Fenyo D, 1998, ELECTROPHORESIS, V19, P998, DOI 10.1002/elps.1150190615; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Geromanos S, 2000, ANAL CHEM, V72, P777, DOI 10.1021/ac991071n; GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pa.33.040193.000401; GORLICH D, 1991, METHOD CELL BIOL, V34, P241; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Martin JB, 1999, NEW ENGL J MED, V340, P1970, DOI 10.1056/NEJM199906243402507; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Moller I, 1998, P NATL ACAD SCI USA, V95, P13425, DOI 10.1073/pnas.95.23.13425; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nielsen MS, 2001, J BIOL CHEM, V276, P22680, DOI 10.1074/jbc.M101181200; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Polymeropoulos MH, 2000, ANN NY ACAD SCI, V920, P28; Polymeropoulos MH, 1998, J NEUROL, V245, pP1, DOI 10.1007/PL00007740; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Sveinbjornsdottir S, 2000, NEW ENGL J MED, V343, P1765, DOI 10.1056/NEJM200012143432404; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Wakabayashi K, 1999, NEUROPATH APPL NEURO, V25, P363; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0	60	65	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17379	17387		10.1074/jbc.M209020200	http://dx.doi.org/10.1074/jbc.M209020200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12610000	hybrid			2022-12-27	WOS:000182818600124
J	Tiran, Z; Peretz, A; Attali, B; Elson, A				Tiran, Z; Peretz, A; Attali, B; Elson, A			Phosphorylation-dependent regulation of Kv2.1 channel activity at tyrosine 124 by Src and by protein-tyrosine phosphatase epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNEL; K+ CHANNEL; CYTOPLASMIC FORMS; SCHWANN-CELLS; ION CHANNELS; T1 DOMAIN; MODULATION; KINASES; INHIBITION; CURRENTS	Voltage-gated potassium (Kv) channels are a complex and heterogeneous family of proteins that play major roles in brain and cardiac excitability. Although Kv channels are activated by changes in cell membrane potential, tyrosine phosphorylation of channel subunits can modulate the extent of channel activation by depolarization. We have previously shown that dephosphorylation of Kv2.1 by the nonreceptor-type tyrosine phosphatase PTPepsilon (cyt-PTPepsilon) down-regulates channel activity and counters its phosphorylation and upregulation by Src or Fyn. In the present study, we identify tyrosine 124 within the T1 cytosolic domain of Kv2.1 as a target site for the activities of Src and cyt-PTPepsilon. Tyr124 is phosphorylated by Src in vitro; in whole cells, Y124F Kv2.1 is significantly less phosphorylated by Src and loses most of its ability to bind the D245A substrate-trapping mutant of cyt-PTPepsilon. Phosphorylation of Tyr124 is critical for Src-mediated up-regulation of Kv2.1 channel activity, since Y124F Kv2.1-mediated K+ currents are only marginally up-regulated by Src, in contrast with a 3-fold up-regulation of wild-type Kv2.1 channels by the kinase. Other properties of Kv2.1, such as expression levels, subcellular localization, and voltage dependence of channel activation, are unchanged in Y124F Kv2.1, indicating that the effects of the Y124F mutation are specific. Together, these results indicate that Tyr124 is a significant site at which the mutually antagonistic activities of Src and cyt-PTPepsilon affect Kv2.1 phosphorylation and activity.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Physiol, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine	Elson, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Elson, Ari/0000-0001-9808-9135				Abitbol I, 1999, EMBO J, V18, P4137, DOI 10.1093/emboj/18.15.4137; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Baranauskas G, 1999, J NEUROSCI, V19, P6394; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; Davis MJ, 2001, AM J PHYSIOL-HEART C, V281, pH1835, DOI 10.1152/ajpheart.2001.281.5.H1835; Du J, 1998, NEUROSCIENCE, V84, P37, DOI 10.1016/S0306-4522(97)00519-8; Du J, 2000, J PHYSIOL-LONDON, V522, P19, DOI 10.1111/j.1469-7793.2000.t01-2-00019.xm; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Fadool DA, 1998, J NEUROSCI, V18, P6126; Fadool DA, 1997, J NEUROPHYSIOL, V78, P1563, DOI 10.1152/jn.1997.78.3.1563; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gil-Henn H, 2000, ONCOGENE, V19, P4375, DOI 10.1038/sj.onc.1203790; GILHENN H, 2003, J BIOL CHEM     0221; Gulbins E, 1997, P NATL ACAD SCI USA, V94, P7661, DOI 10.1073/pnas.94.14.7661; Holmes TC, 1996, J NEUROSCI, V16, P1581; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Holmes TC, 1997, J NEUROSCI, V17, P8964; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Imbrici P, 2000, PFLUG ARCH EUR J PHY, V441, P257, DOI 10.1007/s004240000406; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Kraut J, 2002, EXP CELL RES, V281, P182, DOI 10.1006/excr.2002.5661; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; Levitan IB, 1999, ADV SEC MESS PHOSPH, V33, P3; MacFarlane SN, 2000, J NEUROSCI, V20, P5245, DOI 10.1523/JNEUROSCI.20-14-05245.2000; Malin SA, 2002, J NEUROSCI, V22, P10094; Martens JR, 1999, TRENDS CARDIOVAS MED, V9, P253, DOI 10.1016/S1050-1738(00)00037-2; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; Nitabach MN, 2001, P NATL ACAD SCI USA, V98, P705, DOI 10.1073/pnas.031446198; Peretz A, 2000, EMBO J, V19, P4036, DOI 10.1093/emboj/19.15.4036; Peretz A, 1999, J PHYSIOL-LONDON, V519, P373, DOI 10.1111/j.1469-7793.1999.0373m.x; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; SIEGELBAUM SA, 1994, CURR BIOL, V4, P242, DOI 10.1016/S0960-9822(00)00054-3; Sobko A, 1998, EMBO J, V17, P4723, DOI 10.1093/emboj/17.16.4723; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Strang C, 2001, J BIOL CHEM, V276, P28493, DOI 10.1074/jbc.M010540200; Strauss O, 2002, INVEST OPHTH VIS SCI, V43, P1645; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; Toledano-Katchalski H, 1999, ONCOGENE, V18, P5024, DOI 10.1038/sj.onc.1202883; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Tsai W, 1999, EMBO J, V18, P109, DOI 10.1093/emboj/18.1.109; Weinreich F, 2000, CURR OPIN NEUROBIOL, V10, P409, DOI 10.1016/S0959-4388(00)00089-1; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Yi BA, 2001, P NATL ACAD SCI USA, V98, P11016, DOI 10.1073/pnas.191351798; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	51	48	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17509	17514		10.1074/jbc.M212766200	http://dx.doi.org/10.1074/jbc.M212766200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615930	hybrid			2022-12-27	WOS:000182818600139
J	Derebail, SS; Heath, MJ; DeStefano, JJ				Derebail, SS; Heath, MJ; DeStefano, JJ			Evidence for the differential effects of nucleocapsid protein on strand transfer in various regions of the HIV genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RNA SECONDARY STRUCTURE; ZINC-FINGER STRUCTURES; MURINE LEUKEMIA-VIRUS; REVERSE-TRANSCRIPTASE; INTERNAL REGIONS; VIRAL-RNA; RETROVIRAL RECOMBINATION; ESCHERICHIA-COLI; DNA-SYNTHESIS	An in vitro strand transfer assay that mimicked recombinational events occurring during reverse transcription in HIV-1 was used to assess the role of nucleocapsid protein (NC) in strand transfer. Strand transfer in highly structured nucleic acid species from the U3 3' long terminal repeats, gag-pol frameshift region, and Rev response element were strongly enhanced by NC. In contrast, weakly structured templates from the env and pol-vif regions transferred well without NC and showed lower enhancement. The lack of strong polymerase pause sites in the latter regions demonstrated that non-pause driven mechanisms could also promote transfer. Assays conducted using NC zinc finger mutants supported a differential role for the two fingers in strand transfer with finger 1 (N-terminal) being more important on highly structured RNAs. Overall this report suggests a role for structural intricacies of RNA templates in determining the extent of influence of NC on recombination and illustrates that strand transfer may occur by several different mechanisms depending on the structural nature of the RNA.	Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	DeStefano, JJ (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, Bldg 231, College Pk, MD 20742 USA.	jd146@umail.umd.edu			NIGMS NIH HHS [GM 51140, R01 GM051140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051140, R01GM051140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2002.5429; Berthoux L, 1999, J VIROL, V73, P10000, DOI 10.1128/JVI.73.12.10000-10009.1999; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; Carteau S, 1999, J VIROL, V73, P6670, DOI 10.1128/JVI.73.8.6670-6679.1999; CASSAN M, 1994, J VIROL, V68, P1501, DOI 10.1128/JVI.68.3.1501-1508.1994; CHRISTIANSEN C, 1977, J MOL BIOL, V115, P441, DOI 10.1016/0022-2836(77)90164-4; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1995, ARCH VIROL, V140, P1775, DOI 10.1007/BF01384341; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DeStefano JJ, 1996, J BIOL CHEM, V271, P16350; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; Dinman JD, 2002, P NATL ACAD SCI USA, V99, P5331, DOI 10.1073/pnas.082102199; Driscoll MD, 2000, J VIROL, V74, P8785, DOI 10.1128/JVI.74.19.8785-8792.2000; Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577; Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1; FU W, 1994, J VIROL, V68, P5013, DOI 10.1128/JVI.68.8.5013-5018.1994; FU W, 1993, J VIROL, V67, P5443, DOI 10.1128/JVI.67.9.5443-5449.1993; Gorelick RJ, 1999, VIROLOGY, V256, P92, DOI 10.1006/viro.1999.9629; GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Guo JH, 2002, J VIROL, V76, P4370, DOI 10.1128/JVI.76.9.4370-4378.2002; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000; Johnson PE, 2000, BIOCHEMISTRY-US, V39, P9084, DOI 10.1021/bi000841i; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; KHAN R, 1992, J BIOL CHEM, V267, P6689; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; KOLLMUS H, 1994, J VIROL, V68, P6087, DOI 10.1128/JVI.68.9.6087-6091.1994; LAPADATTAPOLSKY M, 1993, NUCLEIC ACIDS RES, V21, P831, DOI 10.1093/nar/21.4.831; LE SY, 1989, NUCLEIC ACIDS RES, V17, P6143, DOI 10.1093/nar/17.15.6143; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MANN DA, 1994, J MOL BIOL, V241, P193, DOI 10.1006/jmbi.1994.1488; Matzura O, 1996, COMPUT APPL BIOSCI, V12, P247; MELY Y, 1994, BIOCHEMISTRY-US, V33, P12085, DOI 10.1021/bi00206a011; Mely Y, 1996, BIOCHEMISTRY-US, V35, P5175, DOI 10.1021/bi952587d; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; NAGY K, 1994, J VIROL, V68, P757, DOI 10.1128/JVI.68.2.757-765.1994; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; NEGRONI M, 1995, P NATL ACAD SCI USA, V92, P6971, DOI 10.1073/pnas.92.15.6971; Negroni M, 2001, ANNU REV GENET, V35, P275, DOI 10.1146/annurev.genet.35.102401.090551; Negroni M, 2001, NAT REV MOL CELL BIO, V2, P151, DOI 10.1038/35052098; PARKIN NT, 1992, J VIROL, V66, P5147, DOI 10.1128/JVI.66.8.5147-5151.1992; PONTIUS BW, 1992, J BIOL CHEM, V267, P13815; Poon DTK, 1998, J VIROL, V72, P1983, DOI 10.1128/JVI.72.3.1983-1993.1998; Poon DTK, 1996, J VIROL, V70, P6607, DOI 10.1128/JVI.70.10.6607-6616.1996; Raja A, 1999, BIOCHEMISTRY-US, V38, P5178, DOI 10.1021/bi9828019; Remy E, 1998, J BIOL CHEM, V273, P4819, DOI 10.1074/jbc.273.9.4819; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; RODA RH, 2002, J BIOL CHEM; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Rossio JL, 1998, J VIROL, V72, P7992, DOI 10.1128/JVI.72.10.7992-8001.1998; Sambrook J., 2001, MOL CLONING LAB MANU; Schmalzbauer E, 1996, J VIROL, V70, P771, DOI 10.1128/JVI.70.2.771-777.1996; SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P14778, DOI 10.1021/bi971963m; TRITCH RJ, 1991, J VIROL, V65, P922, DOI 10.1128/JVI.65.2.922-930.1991; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Williams MC, 2002, P NATL ACAD SCI USA, V99, P8614, DOI 10.1073/pnas.132128999; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; YOU JC, 1993, J BIOL CHEM, V268, P16519; YOU JC, 1994, J BIOL CHEM, V269, P31491; Yu H, 1998, J BIOL CHEM, V273, P28384, DOI 10.1074/jbc.273.43.28384; Zhuang JL, 2002, J VIROL, V76, P11273, DOI 10.1128/JVI.76.22.11273-11282.2002; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	83	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15702	15712		10.1074/jbc.M211701200	http://dx.doi.org/10.1074/jbc.M211701200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595541	hybrid			2022-12-27	WOS:000182680000032
J	Miyaso, H; Okumura, M; Kondo, S; Higashide, S; Miyajima, H; Imaizumi, K				Miyaso, H; Okumura, M; Kondo, S; Higashide, S; Miyajima, H; Imaizumi, K			An intronic splicing enhancer element in survival motor neuron (SMN) Pre-mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; MOLECULAR ANALYSIS; GENE; BINDING; PROTEIN; IDENTIFICATION; DUPLICATION; EXPRESSION; INCLUSION; MUTATIONS	Spinal muscular atrophy is caused by the homozygous loss of survival motor neuron 1 (SMN1). SMN2, a nearly identical copy gene, differs from SMN1 only by a single nonpolymorphic C to T transition in exon 7, which leads to alteration of exon 7 splicing; SMN2 leads to exon 7 skipping and expression of a nonfunctional gene product and fails to compensate for the loss of SMN1. The exclusion of SMN exon 7 is critical for the onset of this disease. Regulation of SMN exon 7 splicing was determined by analyzing the roles of the cis-acting element in intron 7 (element 2), which we previously identified as a splicing enhancer element of SMN exon 7 containing the C to T transition. The minimum sequence essential for activation of the splicing was determined to be 24 nucleotides, and RNA structural analyses showed a stem-loop structure. Deletion of this element or disruption of the stem-loop structure resulted in a decrease in exon 7 inclusion. A gel shift assay using element 2 revealed formation of RNA-protein complexes, suggesting that the binding of the trans-acting proteins to element 2 plays a crucial role in the splicing of SMN exon 7 containing the C to T transition.	Nara Inst Sci & Technol, Div Struct Cellular Biol, Nara 6300101, Japan	Nara Institute of Science & Technology	Imaizumi, K (corresponding author), Nara Inst Sci & Technol, Div Struct Cellular Biol, 8916-5 Takayama, Nara 6300101, Japan.	imaizumi@bs.aist-nara.ac.jp		Miyaso, Hidenobu/0000-0003-2212-1500				Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Brahe C, 1996, HUM MOL GENET, V5, P1971, DOI 10.1093/hmg/5.12.1971; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cartegni L, 2002, NAT GENET, V30, P377, DOI 10.1038/ng854; Charlet-B N, 2002, MOL CELL, V9, P649, DOI 10.1016/S1097-2765(02)00479-3; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; DiDonato CJ, 1997, ANN NEUROL, V41, P230, DOI 10.1002/ana.410410214; Gavrilov DK, 1998, NAT GENET, V20, P230, DOI 10.1038/3030; GENNARELLI M, 1995, BIOCHEM BIOPH RES CO, V213, P342, DOI 10.1006/bbrc.1995.2135; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; Lefebvre S, 1997, NAT GENET, V16, P265, DOI 10.1038/ng0797-265; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lorson CL, 1999, P NATL ACAD SCI USA, V96, P6307, DOI 10.1073/pnas.96.11.6307; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Lorson CL, 2000, HUM MOL GENET, V9, P259, DOI 10.1093/hmg/9.2.259; Lou H, 1999, MOL CELL BIOL, V19, P78; Miyajima H, 2002, J BIOL CHEM, V277, P23271, DOI 10.1074/jbc.M200851200; Parsons DW, 1996, HUM MOL GENET, V5, P1727, DOI 10.1093/hmg/5.11.1727; PEARN J, 1980, LANCET, V1, P919; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Rochette CF, 2001, HUM GENET, V108, P255, DOI 10.1007/s004390100473; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Simard LR, 1997, AM J MED GENET, V72, P51, DOI 10.1002/(SICI)1096-8628(19971003)72:1<51::AID-AJMG11>3.0.CO;2-T; vanderSteege G, 1996, AM J HUM GENET, V59, P834; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257; Wirth B, 2000, HUM MUTAT, V15, P228, DOI 10.1002/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	31	63	75	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15825	15831		10.1074/jbc.M209271200	http://dx.doi.org/10.1074/jbc.M209271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604607	hybrid			2022-12-27	WOS:000182680000048
J	Cox, DM; Du, M; Marback, M; Yang, ECC; Chan, J; Siu, KWM; McDermott, JC				Cox, DM; Du, M; Marback, M; Yang, ECC; Chan, J; Siu, KWM; McDermott, JC			Phosphorylation motifs regulating the stability and function of myocyte enhancer factor 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR; NEUROFILAMENT PROTEINS; GENE-EXPRESSION; T-CELLS; MEF2; P38; DIFFERENTIATION; PURIFICATION; MYOGENESIS	The phosphorylation status of the myocyte enhancer factor 2 (MEF2) transcriptional regulator is a critical determinant of its tissue-specific functions. However, due to the complexity of its phosphorylation pattern in vivo, a systematic inventory of MEF2A phosphorylation sites in mammalian cells has been difficult to obtain. We employed modern affinity purification techniques, combined with mass spectrometry, to identify several novel MEF2 phosphoacceptor sites. These include an evolutionarily conserved KSP motif, which we show is important in regulating the stability and function of MEF2A. Also, an indirect pathway in which a protein kinase casein kinase 2 phosphoacceptor site is phosphorylated by activation of p38 MAPK signaling was documented. Together, these findings identify several novel aspects of MEF2 regulation that may prove important in the control of gene expression in neuronal and muscle cells.	York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada; York Univ, Ctr Res Mass Spectrometry, Toronto, ON M3J 1P3, Canada; York Univ, Dept Chem, Toronto, ON M3J 1P3, Canada	York University - Canada; York University - Canada; York University - Canada	McDermott, JC (corresponding author), York Univ, Dept Biol, 4700 Keele St,247 Farquharson Bldg, Toronto, ON M3J 1P3, Canada.	jmcderm@yorku.ca						Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cox D M, 2000, Exerc Sport Sci Rev, V28, P33; Cox DM, 2002, BIOTECHNIQUES, V33, P267, DOI 10.2144/02332bm02; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dodou E, 1997, MOL CELL BIOL, V17, P1848, DOI 10.1128/MCB.17.4.1848; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Giasson BI, 1997, J NEUROSCI, V17, P9466; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Lazaro JB, 1997, J CELL SCI, V110, P1251; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Okamoto S, 2000, P NATL ACAD SCI USA, V97, P7561, DOI 10.1073/pnas.130502697; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Quinn ZA, 2001, NUCLEIC ACIDS RES, V29, P732, DOI 10.1093/nar/29.3.732; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SHETTY KT, 1993, P NATL ACAD SCI USA, V90, P6844, DOI 10.1073/pnas.90.14.6844; Swanson BJ, 1998, MOL IMMUNOL, V35, P445, DOI 10.1016/S0161-5890(98)00058-3; Veeranna, 1998, J NEUROSCI, V18, P4008; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zhao M, 1999, MOL CELL BIOL, V19, P21	42	61	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					15297	15303		10.1074/jbc.M211312200	http://dx.doi.org/10.1074/jbc.M211312200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12586839	hybrid			2022-12-27	WOS:000182516100093
J	Park, EJ; Park, SY; Joe, EH; Jou, I				Park, EJ; Park, SY; Joe, EH; Jou, I			15d-PGJ(2) and rosilglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; PPAR-GAMMA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CYCLOPENTENONE PROSTAGLANDINS; INHIBITION; RESPONSES; PROTEIN; GENE; TRANSCRIPTION; EXPRESSION	Peroxisome proliferator-activated receptor (PPAR)-gamma agonists are now emerging as therapeutic drugs for various inflammatory diseases. However, their molecular mechanism of action remains to be elucidated. Here we report a novel mechanism that underlies the PPAR-gamma agonist-mediated suppression of brain inflammation. We show that 15-deoxy-Delta12,14-prostaglandin J(2) (15d-PGJ,) and rosiglitazone reduce the phosphorylation of STAT1 and STAT3 as well as Janus kinase 1 (JAK1) and JAK2 in activated astrocytes and microglia. The PPAR-gamma agonist-mediated reduction in phosphorylation leads to the suppression of JAK-STAT-dependent inflammatory responses. The effects of 15d-PGJ2 and rosiglitazone are not mediated by activation of PPAR-gamma. 15d-PGJ2 and rosiglitazone rapidly induce the transcription of suppressor of cytokine signaling (SOCS) 1 and 3, which in turn inhibit JAK activity in activated glial cells. In addition, Src homology, 2, domain-containing protein phosphatase 2 (SHP2), another negative regulator of JAK activity, is also involved in their anti-inflammatory action. Our data suggest that 15d-PGJ, and rosiglitazone suppress the initiation of JAK-STAT inflammatory signaling independently of PPAR-gamma, thus attenuating brain inflammation.	Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442721, South Korea	Ajou University	Jou, I (corresponding author), Ajou Univ, Sch Med, Dept Pharmacol, Suwon 442721, South Korea.	jouilo@madang.ajou.ac.kr						Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Balasingam V, 1996, J NEUROSCI, V16, P2945; Bousquet C, 2001, MOL ENDOCRINOL, V15, P1880, DOI 10.1210/me.15.11.1880; Cattaneo E, 1999, TRENDS NEUROSCI, V22, P365, DOI 10.1016/S0166-2236(98)01378-2; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Diab A, 2002, J IMMUNOL, V168, P2508, DOI 10.4049/jimmunol.168.5.2508; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jee Y, 2001, J NEUROIMMUNOL, V114, P40, DOI 10.1016/S0165-5728(00)00446-X; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kim OS, 2002, J BIOL CHEM, V277, P40594, DOI 10.1074/jbc.M203885200; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MURPHY GJ, 2002, TRENDS PHARMACOL SCI, V21, P469; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; OHMORI Y, 1993, J BIOL CHEM, V268, P6677; Petrova TV, 1999, P NATL ACAD SCI USA, V96, P4668, DOI 10.1073/pnas.96.8.4668; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rogaev EI, 1997, GENOMICS, V40, P415, DOI 10.1006/geno.1996.4523; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI200113568; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; STROLL G, 1998, PROG NEUROBIOL, V56, P149; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Terstegen L, 2000, J BIOL CHEM, V275, P18810, DOI 10.1074/jbc.M904148199; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; Wesemann DR, 2002, J IMMUNOL, V169, P2354, DOI 10.4049/jimmunol.169.5.2354; Xiao BG, 1999, IMMUNOL TODAY, V20, P477, DOI 10.1016/S0167-5699(99)01501-7; Xuan YT, 2001, P NATL ACAD SCI USA, V98, P9050, DOI 10.1073/pnas.161283798; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YONG VW, 1991, P NATL ACAD SCI USA, V88, P7016, DOI 10.1073/pnas.88.16.7016; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	45	193	207	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14747	14752		10.1074/jbc.M210819200	http://dx.doi.org/10.1074/jbc.M210819200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12584205	hybrid			2022-12-27	WOS:000182516100022
J	Lin, P; Ye, RD				Lin, P; Ye, RD			The lysophospholipid receptor G2A activates a specific combination of G proteins and promotes apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; COUPLED RECEPTOR; DEPENDENT ACTIVATION; LYSOPHOSPHATIDYLCHOLINE; CELLS; KINASE; RGS; SPHINGOSYLPHOSPHORYLCHOLINE; G-ALPHA(13); PATHWAY	G2A, a G protein-coupled receptor for which lysophosphatidylcholine (LPC) is a high affinity ligand, belongs to a newly defined lysophospholipid receptor subfamily. Expression of G2A is transcriptionally up-regulated by stress-inducing and cell-damaging agents, and ectopic expression of G2A leads to growth inhibition. However, the G proteins that functionally couple to G2A have not been elucidated in detail. We report here that G2A ligand independently stimulates the accumulation of both inositol phosphates and cAMP. LPC does not further enhance inositol phosphate accumulation but dose-dependently augments intracellular cAMP concentration. Expression of Galpha(q) and Galpha(13) with G2A potentiates G2A-mediated activation of a NF-kappaB-luciferase reporter. These results demonstrate that G2A differentially couples to multiple G proteins including Galpha(s), Galpha(q), and Galpha(13), depending on whether it is bound to ligand. G2A-transfected HeLa cells display apoptotic signs including membrane blebbing, nuclear condensation, and reduction of mitochondrial membrane potential. Furthermore, G2A-induced apoptosis can be rescued by the caspase inhibitors, z-vad-fmk and CrmA. Although apoptosis occurs without LPC stimulation, LPC further enhances G2A-mediated apoptosis and correlates with its ability to induce cAMP elevation in both HeLa cells and primary lymphocytes. Rescue from G2A-induced apoptosis was achieved by co-expression of a Galpha(12/13)-specific inhibitor, p115RGS (regulator of G protein signaling), in combination with 2',5'-dideoxyadenosine treatment. These results demonstrate the ability of G2A to activate a specific combination of G proteins, and that G2A/LPC-induced apoptosis involves both Galpha(13)- and Galpha(s)-mediated pathways.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ye, RD (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA.		Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NIAID NIH HHS [AI40176] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040176, R56AI040176] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams JW, 2001, ONCOGENE, V20, P1626, DOI 10.1038/sj.onc.1204275; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Choi JW, 1996, CELL IMMUNOL, V168, P78, DOI 10.1006/cimm.1996.0051; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Goldman FD, 2002, CLIN IMMUNOL, V104, P31, DOI 10.1006/clim.2002.5249; Hildeman DA, 2002, CURR OPIN IMMUNOL, V14, P354, DOI 10.1016/S0952-7915(02)00335-7; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hsieh CC, 2000, ATHEROSCLEROSIS, V151, P481, DOI 10.1016/S0021-9150(00)00453-6; Jing Q, 2000, CIRC RES, V87, P52, DOI 10.1161/01.RES.87.1.52; Kabarowski JHS, 2000, P NATL ACAD SCI USA, V97, P12109, DOI 10.1073/pnas.97.22.12109; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Le LQ, 2002, CANCER CELL, V1, P381, DOI 10.1016/S1535-6108(02)00058-2; Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5; Pirnia F, 2002, CELL DEATH DIFFER, V9, P905, DOI 10.1038/sj.cdd.4401062; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; Shi CS, 2001, J BIOL CHEM, V276, P31845, DOI 10.1074/jbc.M101043200; Teitler Milt, 2002, Current Topics in Medicinal Chemistry, V2, P529, DOI 10.2174/1568026023393859; Ueda H, 2001, J BIOL CHEM, V276, P42527, DOI 10.1074/jbc.M102529200; Weng ZG, 1998, P NATL ACAD SCI USA, V95, P12334, DOI 10.1073/pnas.95.21.12334; Xie P, 2000, J BIOL CHEM, V275, P24907, DOI 10.1074/jbc.M001051200; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Yuan YP, 1996, J BIOL CHEM, V271, P27090, DOI 10.1074/jbc.271.43.27090; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200; Zohn IE, 2000, ONCOGENE, V19, P3866, DOI 10.1038/sj.onc.1203731	33	98	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14379	14386		10.1074/jbc.M209101200	http://dx.doi.org/10.1074/jbc.M209101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12586833	hybrid			2022-12-27	WOS:000182405000103
J	Lou, ZK; Chini, CCS; Minter-Dykhouse, K; Chen, JJ				Lou, ZK; Chini, CCS; Minter-Dykhouse, K; Chen, JJ			Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; HISTONE H2AX; GENOMIC INSTABILITY; NUCLEAR FOCI; FHA DOMAIN; IN-VIVO; 53BP1; REPAIR; ATM; PATHWAYS	BRCA1 is a tumor suppressor involved in DNA repair and damage-induced checkpoint controls. In response to DNA damage, BRCA1 relocalizes to nuclear foci at the sites of DNA lesions. However, little is known about the regulation of BRCA1 relocalization following DNA damage. Here we show that mediator of DNA damage checkpoint protein 1 (MDC1) previously named NFBD1 or Kiaa0170,is a proximate mediator of DNA damage responses that regulates BRCA1 function. MDC1 regulates ataxia-telangiectasia-mutated (ATM)-dependent phosphorylation events at the site of DNA damage. Importantly down-regulation of MDC1 abolishes the relocalization and hyperphosphorylation of BRCA1 following DNA damage, which coincides with defective G(2)/M checkpoint control in response to DNA damage. Taken together these data suggest that MDC1 regulates BRCA1 function in DNA damage checkpoint control.	Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA	Mayo Clinic	Chen, JJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, Guggenheim Bldg,Rm 1342,200 1st St SW, Rochester, MN 55905 USA.		Minter Dykhouse, Katherine/L-4573-2013	Minter Dykhouse, Katherine/0000-0003-4363-5826	NATIONAL CANCER INSTITUTE [R01CA092312, R01CA089239] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA89239, CA92312] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gatei M, 2000, CANCER RES, V60, P3299; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	29	106	120	4	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13599	13602		10.1074/jbc.C300060200	http://dx.doi.org/10.1074/jbc.C300060200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12611903	hybrid			2022-12-27	WOS:000182405000003
J	Wang, JL; de Montellano, PRO				Wang, JL; de Montellano, PRO			The binding sites on human heme oxygenase-1 for cytochrome P450 reductase and biliverdin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; P450 REDUCTASE; ELECTROSTATIC INTERACTIONS; DIRECTED MUTAGENESIS; RESIDUES; PROTEIN; 2B4; ASSOCIATION; BILIRUBIN; COMPLEX	Human heme oxygenase-1 (hHO-1) catalyzes the NADPH-cytochrome P450 reductase-dependent oxidation of heme to biliverdin, CO, and free iron. The biliverdin is subsequently reduced to bilirubin by biliverdin reductase. Earlier kinetic studies suggested that biliverdin reductase facilitates the release of biliverdin from hHO-1 (Liu, Y., and Ortiz de Montellano, P. R. (2000) J. Biol. Chem. 275, 5297-5307). We have investigated the binding of P450 reductase and biliverdin reductase to truncated, soluble hHO-1 by fluorescence resonance energy transfer and site-specific mutagenesis. P450 reductase and biliverdin reductase bind to truncated hHO-1 with K-d=0.4+/-0.1 and 0.2+/-0.1 muM, respectively. FRET experiments indicate that biliverdin reductase and P450 reductase compete for binding to truncated hHO-1. Mutation of surface ionic residues shows that hHO-1 residues Lys(18), Lys(22), Lys(179), Arg(183), Arg(198), Glu(19), Glu(127), and Glu(190) contribute to the binding of cytochrome P450 reductase. The mutagenesis results and a computational analysis of the protein surfaces partially define the binding site for P450 reductase. An overlapping binding site including Lys(18), Lys(22), Lys(179), Arg(183), and Arg(185) is similarly defined for biliverdin reductase. These results confirm the binding of biliverdin reductase to hHO-1 and define binding sites of the two reductases.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St,N572D, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030297] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30297] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auclair K., 2003, PORPHYRIN HDB, V12, P183; Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; Davydov DR, 2000, BIOCHEMISTRY-US, V39, P6489, DOI 10.1021/bi992936u; Davydov DR, 1996, BIOCHIMIE, V78, P734, DOI 10.1016/S0300-9084(97)82531-X; DAVYDOV DR, 1995, ARCH BIOCHEM BIOPHYS, V320, P330, DOI 10.1016/0003-9861(95)90017-9; De Montellano PRO, 2001, ADV INORG CHEM, V51, P359; Dolphin, 1979, PORPHYRINS, VVI, P257; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; IYANAGI T, 1981, BIOCHEMISTRY-US, V20, P1722, DOI 10.1021/bi00510a004; IYANAGI T, 1974, BIOCHEMISTRY-US, V13, P1701, DOI 10.1021/bi00705a023; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kikuchi A, 2001, NAT STRUCT BIOL, V8, P221, DOI 10.1038/84955; KUTTY RK, 1981, J BIOL CHEM, V256, P3956; Lightning LK, 2001, J BIOL CHEM, V276, P10612, DOI 10.1074/jbc.M010349200; Liu Y, 2000, J BIOL CHEM, V275, P5297, DOI 10.1074/jbc.275.8.5297; MCCOUBREY WK, 1994, EUR J BIOCHEM, V222, P597, DOI 10.1111/j.1432-1033.1994.tb18902.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Pereira PJB, 2001, NAT STRUCT BIOL, V8, P215, DOI 10.1038/84948; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; Schuller DJ, 1999, NAT STRUCT BIOL, V6, P860; Schuller DJ, 2001, BIOCHEMISTRY-US, V40, P11552, DOI 10.1021/bi0110239; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; Shen A.L., 1993, HDB EXPT PHARM, P35; SHEN AL, 1991, J BIOL CHEM, V266, P19976; SHEN AL, 1995, J BIOL CHEM, V270, P27475, DOI 10.1074/jbc.270.46.27475; SHEN SJ, 1993, ARCH BIOCHEM BIOPHYS, V304, P257, DOI 10.1006/abbi.1993.1347; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Sugishima M, 2000, FEBS LETT, V471, P61, DOI 10.1016/S0014-5793(00)01353-3; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Uzel C, 1998, SEMIN HEMATOL, V35, P27; Vakser IA, 1999, P NATL ACAD SCI USA, V96, P8477, DOI 10.1073/pnas.96.15.8477; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; VOZNESENSKY AI, 1994, J BIOL CHEM, V269, P15724; VOZNESENSKY AI, 1992, J BIOL CHEM, V267, P14669; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Whitby FG, 2002, J MOL BIOL, V319, P1199, DOI 10.1016/S0022-2836(02)00383-2; Wilks A, 1998, BIOCHEMISTRY-US, V37, P2889, DOI 10.1021/bi972720x; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; Zakhary R, 1997, P NATL ACAD SCI USA, V94, P14848, DOI 10.1073/pnas.94.26.14848	46	70	72	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20069	20076		10.1074/jbc.M300989200	http://dx.doi.org/10.1074/jbc.M300989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12626517	hybrid			2022-12-27	WOS:000183078000064
J	Banumathy, G; Singh, V; Pavithra, SR; Tatu, U				Banumathy, G; Singh, V; Pavithra, SR; Tatu, U			Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; HETEROPROTEIN COMPLEX; STRESS-PROTEINS; HSP90; PHOSPHORYLATION; CHAPERONE; CAPACITOR; LOCALIZATION; GELDANAMYCIN; SEQUENCE	Hsp90 is important for normal growth and development in eukaryotes. Together with Hsp70 and other accessory proteins, Hsp90 not only helps newly synthesized proteins to fold but also regulates activities of transcription factors and protein kinases. Although the gene coding for heat shock protein 90 from Plasmodium falciparum (PfHsp90) has been characterized previously, there is very little known regarding its function in the parasite. We have analyzed PfHsp90 complexes and addressed its role in parasite life cycle using Geldanamycin (GA), a drug known to interfere with Hsp90 function. Sedimentation analysis and size exclusion chromatography showed PfHsp90 to be in 11 s(20,w) complexes of similar to300 kDa in size. Similar to the hetero-oligomeric complexes of Hsp90 in mammals, PfHsp70 was found to be present in PfHsp90 complexes. Homology modeling revealed a putative GA-binding pocket at the amino terminus of PfHsp90. The addition of GA inhibited parasite growth with LD50 of 0.2 muM. GA inhibited parasite growth by arresting transition from Ring to trophozoite. Transition from trophozoite to schizonts and reinvasion of new erythrocytes were less significantly affected. While inducing the synthesis of PfHsp70 and PfHsp90, GA did not significantly alter the pattern of newly synthesized proteins. Pre-exposure to heat shock attenuated GA-mediated growth inhibition, suggesting the involvement of heat shock proteins. Specificity of GA action on PfHsp90 was evident from selective inhibition of PfHsp90 phosphorylation in GA-treated cultures. In addition to suggesting an essential role for PfHsp90 during parasite growth, our results highlight PfHsp90 as a potential drug target to control malaria.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Tatu, U (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	tatu@biochem.iisc.ernet.in	Viswanath, Pavithra/I-4318-2015	Viswanath, Pavithra/0000-0003-2980-3109; Tatu, Utpal/0000-0003-0404-8872				Bagatell R, 2001, CLIN CANCER RES, V7, P2076; Bannister LH, 2000, PARASITOL TODAY, V16, P427, DOI 10.1016/S0169-4758(00)01755-5; Banumathy G, 2002, J BIOL CHEM, V277, P3902, DOI 10.1074/jbc.M110513200; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; BONNEFOY S, 1994, MOL BIOCHEM PARASIT, V67, P157, DOI 10.1016/0166-6851(94)90105-8; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BUCHBERGER A, 1997, GUIDEBOOK MOL CHAPER, P147; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Das A, 1997, MOL BIOCHEM PARASIT, V88, P95, DOI 10.1016/S0166-6851(97)00081-9; Eggers DK, 1997, MOL BIOL CELL, V8, P1559, DOI 10.1091/mbc.8.8.1559; Gardner MJ, 2002, NATURE, V419, P531, DOI 10.1038/nature01094; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, P400; JENDOUBI M, 1985, J IMMUNOL, V134, P1941; JENDOUBI M, 1988, NUCLEIC ACIDS RES, V16, P10928, DOI 10.1093/nar/16.22.10928; KUMAR N, 1991, MOL BIOCHEM PARASIT, V48, P47, DOI 10.1016/0166-6851(91)90163-Z; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; MIZZEN LA, 1988, J CELL BIOL, V106, P1105, DOI 10.1083/jcb.106.4.1105; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; Neckers L, 1999, HANDB EXP PHARM, V136, P9; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SCHLICHTHERLE M, 2000, METHODS MALARIA RES, P30; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; SU Q, 1994, GENE, V151, P225; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wiesgigl M, 2001, MOL BIOL CELL, V12, P3307, DOI 10.1091/mbc.12.11.3307; Zhao YG, 2001, J BIOL CHEM, V276, P32822, DOI 10.1074/jbc.M105562200	34	169	172	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18336	18345		10.1074/jbc.M211309200	http://dx.doi.org/10.1074/jbc.M211309200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12584193	hybrid			2022-12-27	WOS:000182838300098
J	Burkart, A; Samii, B; Corvera, S; Shpetner, HS				Burkart, A; Samii, B; Corvera, S; Shpetner, HS			Regulation of the SHP-2 tyrosine phosphatase by a novel cholesterol- and cell confluence-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ANNEXIN-II TETRAMER; ENDOTHELIAL-CELLS; FACTOR RECEPTOR; F-ACTIN; SIGNAL-TRANSDUCTION; PROTEIN COMPLEX; LIPID RAFTS; MDCK CELLS; PHOSPHORYLATION	Endothelial cells approaching confluence exhibit marked decreases in tyrosine phosphorylation of receptor tyrosine kinases and adherens junctions proteins, required for cell cycle arrest and adherens junctions stability. Recently, we demonstrated a close correlation in endothelial cells between membrane cholesterol and tyrosine phosphorylation of adherens junctions proteins. Here, we probe the mechanistic basis for this correlation. We find that as endothelial cells reach confluence, the tyrosine phosphatase SHP-2 is recruited to a low-density membrane fraction in a cholesterol-dependent manner. Binding of SHP-2 to this fraction was not abolished by phenyl phosphate, strongly suggesting that this binding was mediated by other regions of SHP-2 beside its SH2 domains. Annexin II, previously implicated in cholesterol trafficking, was associated in a complex with SHP-2, and both proteins localized to adhesion bands in confluent endothelial monolayers. These studies reveal a novel, cholesterol-dependent mechanism for the recruitment of signaling proteins to specific plasma membrane domains via their interactions with annexin II.	Univ Massachusetts, Med Ctr, Dept Mol Med, Sch Med, Worcester, MA 01605 USA; Worcester Polytech Inst, Dept Biotechnol, Worcester, MA 01609 USA	University of Massachusetts System; University of Massachusetts Worcester; Worcester Polytechnic Institute	Shpetner, HS (corresponding author), Univ Massachusetts, Med Ctr, Dept Mol Med, Sch Med, 373 Plantat St,Suite 107, Worcester, MA 01605 USA.							Ayala-Sanmartin J, 2001, BBA-BIOMEMBRANES, V1510, P18, DOI 10.1016/S0005-2736(00)00262-5; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Barabe F, 2002, J BIOL CHEM, V277, P13473, DOI 10.1074/jbc.M112149200; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CASE RD, 1994, J BIOL CHEM, V269, P10467; Corvera S, 2000, J BIOL CHEM, V275, P31414, DOI 10.1074/jbc.M001708200; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; ELIAS PM, 1978, J CELL BIOL, V78, P577, DOI 10.1083/jcb.78.2.577; ESPARISOGANDO A, 1994, AM J PHYSIOL, V267, pC166, DOI 10.1152/ajpcell.1994.267.1.C166; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; HARDER T, 1994, BBA-MOL CELL RES, V1223, P375, DOI 10.1016/0167-4889(94)90098-1; Harder T, 1997, MOL BIOL CELL, V8, P533, DOI 10.1091/mbc.8.3.533; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; Hu YY, 2001, J BIOL CHEM, V276, P48549, DOI 10.1074/jbc.M105513200; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; JONES PG, 1992, J BIOL CHEM, V267, P13993; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Masuda M, 1997, FEBS LETT, V408, P331, DOI 10.1016/S0014-5793(97)00457-2; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Rahimi N, 1999, MOL BIOL CELL, V10, P3401, DOI 10.1091/mbc.10.10.3401; Sagot I, 1997, FEBS LETT, V410, P229, DOI 10.1016/S0014-5793(97)00594-2; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Siminovitch KA, 1998, SEMIN IMMUNOL, V10, P329, DOI 10.1006/smim.1998.0125; Sorby M, 1996, J BIOL CHEM, V271, P10963; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; Uittenbogaard A, 2002, J BIOL CHEM, V277, P4925, DOI 10.1074/jbc.M109278200; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; Xu FP, 2001, J BIOL CHEM, V276, P29479, DOI 10.1074/jbc.M104428200; Zeuschner D, 2001, EUR J CELL BIOL, V80, P499, DOI 10.1078/0171-9335-00184	36	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18360	18367		10.1074/jbc.M210701200	http://dx.doi.org/10.1074/jbc.M210701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12611902	hybrid			2022-12-27	WOS:000182838300101
J	Cabral, A; Fischer, DF; Vermeij, WP; Backendorf, C				Cabral, A; Fischer, DF; Vermeij, WP; Backendorf, C			Distinct functional interactions of human Skn-1 isoforms with Ese-1 during keratinocyte terminal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETS TRANSCRIPTION FACTORS; PROLINE-RICH PROTEINS; POU DOMAIN FACTORS; EPIDERMAL DIFFERENTIATION; ENVELOPE PRECURSOR; DNA-BINDING; EXPRESSION; FAMILY; GENE; CONTAINS	Among the three major POU proteins expressed in human skin, Oct-1, Tst-1/Oct-6, and Skn-1/Oct-11, only the latter induced SPRR2A, a marker of keratinocyte terminal differentiation. In this study, we have identified three Skn-1 isoforms, which encode proteins with various N termini, generated by alternative promoter usage. These isotypes showed distinct expression patterns in various skin samples, internal squamous epithelia, and cultured human keratinocytes. Skn-1a and Skn-1d1 bound the SPRR2A octamer site with comparable affinity and functioned as transcriptional activators. Skn-1d2 did not affect SPRR2A expression. Skn-1a, the largest protein, functionally cooperated with Ese-1/Elf-3, an epithelial-specific transcription factor, previously implicated in SPRR2A induction. This cooperativity, which depended on an N-terminal pointed-like domain in Skn-1a, was not found for Skn-1d1. Actually, Skn-1d1 counteracted the cooperativity between Skn-1a and Ese-1. Apparently, the human Skn-1 locus encodes multifunctional protein isotypes, subjected to biochemical cross-talk, which are likely to play a major role in the fine-tuning of keratinocyte terminal differentiation.	Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, Mol Genet Lab, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Backendorf, C (corresponding author), Leiden Univ, Leiden Inst Chem, Gorlaeus Labs, Mol Genet Lab, POB 9502, NL-2300 RA Leiden, Netherlands.		Cabral, Adriana/AAX-3284-2021	Fischer, David/0000-0002-6690-0197; Vermeij, Wilbert/0000-0002-9690-1385				ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; Andersen B, 1997, J BIOL CHEM, V272, P15905, DOI 10.1074/jbc.272.25.15905; Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Cabral A, 2001, J CELL SCI, V114, P3837; Cabral A, 2001, J BIOL CHEM, V276, P19231, DOI 10.1074/jbc.M100336200; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; Eckert RL, 1997, J INVEST DERMATOL, V109, P501, DOI 10.1111/1523-1747.ep12336477; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; GOLDSBOROUGH AS, 1993, NUCLEIC ACIDS RES, V21, P127, DOI 10.1093/nar/21.1.127; Hildesheim J, 2001, J CELL SCI, V114, P1913; Hildesheim J, 1999, J BIOL CHEM, V274, P26399, DOI 10.1074/jbc.274.37.26399; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; Holbrook K., 1994, KERATINOCYTE HDB, P3; Jang SI, 2000, J BIOL CHEM, V275, P15295, DOI 10.1074/jbc.275.20.15295; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Lee JH, 1996, J BIOL CHEM, V271, P4561; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lohman FP, 1997, ONCOGENE, V14, P1623, DOI 10.1038/sj.onc.1200974; Marenholz I, 2001, GENOME RES, V11, P341, DOI 10.1101/gr.114801; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; PRESLAND RB, 2000, BRIT J DERMATOL, V11, P383; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sark MWJ, 1999, EXP CELL RES, V250, P475, DOI 10.1006/excr.1999.4532; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Sugihara TM, 2001, J BIOL CHEM, V276, P33036, DOI 10.1074/jbc.M103000200; Wang WK, 2001, ACTA CRYSTALLOGR D, V57, P545, DOI 10.1107/S0907444901002529; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; Yukawa K, 1996, J VIROL, V70, P10, DOI 10.1128/JVI.70.1.10-16.1996	37	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17792	17799		10.1074/jbc.M300508200	http://dx.doi.org/10.1074/jbc.M300508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624109	hybrid, Green Published			2022-12-27	WOS:000182838300027
J	Mogk, A; Schlieker, C; Strub, C; Rist, W; Weibezahn, J; Bukau, B				Mogk, A; Schlieker, C; Strub, C; Rist, W; Weibezahn, J; Bukau, B			Roles of individual domains and conserved motifs of the AAA plus chaperone ClpB in oligomerization, ATP hydrolysis, and chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ACTIVATED ATPASE; ESCHERICHIA-COLI; BINDING-SITES; CYANOBACTERIUM SYNECHOCOCCUS; SACCHAROMYCES-CEREVISIAE; THERMUS-THERMOPHILUS; POLYACRYLAMIDE GELS; CRYSTAL-STRUCTURE; MECHANISM; COMPLEX	ClpB of Escherichia coli is an ATP-dependent ring-forming chaperone that mediates the resolubilization of aggregated proteins in cooperation with the DnaK chaperone system. ClpB belongs to the Hsp100/Clp subfamily of AAA+ proteins and is composed of an N-terminal domain and two AAA-domains that are separated by a "linker" region. Here we present a detailed structure-function analysis of ClpB, dissecting the individual roles of ClpB domains and conserved motifs in oligomerization, ATP hydrolysis, and chaperone activity. Our results show that ClpB oligomerization is strictly dependent on the presence of the C-terminal domain of the second AAA-domain, while ATP binding to the first AAA-domains stabilized the ClpB oligomer. Analysis of mutants of conserved residues in Walker A and B and sensor 2 motifs revealed that both AAA-domains contribute to the basal ATPase activity of ClpB and communicate in a complex manner. Chaperone activity strictly depends on ClpB oligomerization and the presence of a residual ATPase activity. The N-domain is dispensable for oligomerization and for the disaggregating activity in vitro and in vivo. In contrast the presence of the linker region, although not involved in oligomerization, is essential for ClpB chaperone activity.	Zentrum Mol Biol, D-69120 Heidelberg, Germany; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	Ruprecht Karls University Heidelberg; University of Freiburg	Mogk, A (corresponding author), Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	a.mogk@zmbh-uni-heidelberg.de; bukau@zmbh.uni-heidelberg.de		Rist, Wolfgang/0000-0002-0626-3544; Bukau, Bernd/0000-0003-0521-7199				Banecki B, 2001, J BIOL CHEM, V276, P18843, DOI 10.1074/jbc.M007507200; Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Beinker P, 2002, J BIOL CHEM, V277, P47160, DOI 10.1074/jbc.M207853200; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Celerin M, 1998, J BACTERIOL, V180, P5173, DOI 10.1128/JB.180.19.5173-5182.1998; Clarke AK, 2000, J BACTERIOL, V182, P7092, DOI 10.1128/JB.182.24.7092-7096.2000; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; Eriksson MJ, 2001, J BACTERIOL, V183, P7392, DOI 10.1128/JB.183.24.7392-7396.2001; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; Karata K, 1999, J BIOL CHEM, V274, P26225, DOI 10.1074/jbc.274.37.26225; Kim KI, 2000, J MOL BIOL, V303, P655, DOI 10.1006/jmbi.2000.4165; Kim YI, 2001, NAT STRUCT BIOL, V8, P230, DOI 10.1038/84967; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Li JZ, 2002, J MOL BIOL, V318, P1127, DOI 10.1016/S0022-2836(02)00188-2; Lo JH, 2001, PROTEIN SCI, V10, P551, DOI 10.1110/ps.41401; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Neuwald AF, 1999, GENOME RES, V9, P27; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; PARK JH, 1988, J BACTERIOL, V170, P921, DOI 10.1128/jb.170.2.921-926.1988; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; Schmid FX, 1991, CURR OPIN STRUC BIOL, V1, P36, DOI 10.1016/0959-440X(91)90008-H; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SINGH SK, 1994, J BIOL CHEM, V269, P29537; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Tek V, 2002, PROTEIN SCI, V11, P1192, DOI 10.1110/ps.4860102; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; Zolkiewski M, 1999, PROTEIN SCI, V8, P1899, DOI 10.1110/ps.8.9.1899	47	205	207	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17615	17624		10.1074/jbc.M209686200	http://dx.doi.org/10.1074/jbc.M209686200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12624113	hybrid			2022-12-27	WOS:000182838300007
J	Bach, D; Pich, S; Soriano, FX; Vega, N; Baumgartner, B; Oriola, J; Daugaard, JR; Lloberas, J; Camps, M; Zierath, JR; Rabasa-Lhoret, R; Wallberg-Henriksson, H; Laville, M; Palacin, M; Vidal, H; Rivera, F; Brand, M; Zorzano, A				Bach, D; Pich, S; Soriano, FX; Vega, N; Baumgartner, B; Oriola, J; Daugaard, JR; Lloberas, J; Camps, M; Zierath, JR; Rabasa-Lhoret, R; Wallberg-Henriksson, H; Laville, M; Palacin, M; Vidal, H; Rivera, F; Brand, M; Zorzano, A			Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism - A novel regulatory mechanism altered in obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYNAMIN-RELATED GTPASE; HUMAN SKELETAL-MUSCLE; INSULIN-RESISTANCE; OUTER-MEMBRANE; GENE-EXPRESSION; ADIPOSE-TISSUE; SOLEUS MUSCLE; PROTEIN; FUSION; MORPHOLOGY	In many cells and specially in muscle, mitochondria form elongated filaments or a branched reticulum. We show that Mfn2 (mitofusin 2), a mitochondrial membrane protein that participates in mitochondrial fusion in mammalian cells, is induced during myogenesis and contributes to the maintenance and operation of the mitochondrial network. Repression of Mfn2 caused morphological and functional fragmentation of the mitochondrial network into independent clusters. Concomitantly, repression of Mfn2 reduced glucose oxidation, mitochondrial membrane potential, cell respiration, and mitochondrial proton leak. We also show that the Mfn2-dependent mechanism of mitochondrial control is disturbed in obesity by reduced Mfn2 expression. In all, our data indicate that Mfn2 expression is crucial in mitochondrial metabolism through the maintenance of the mitochondrial network architecture, and reduced Mfn2 expression may explain some of the metabolic alterations associated with obesity.	Univ Barcelona, PArc Cient Barcelona, E-08028 Barcelona, Spain; Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Fac Med RTH Laennec, INSERM, U449, F-69372 Lyon, France; Fac Med RTH Laennec, Ctr Rech Nutr Humaine Lyon, F-69372 Lyon, France; Hosp Clin Barcelona, Serv Hormonal, Barcelona 08036, Spain; Univ Barcelona, Fac Biol, Dept Fisiol Biol Macrofago Immunol, E-08028 Barcelona, Spain; Karolinska Hosp, Dept Clin Physiol, SE-17177 Stockholm, Sweden; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	University of Barcelona; University of Barcelona; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Karolinska Institutet; Karolinska University Hospital; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Zorzano, A (corresponding author), Univ Barcelona, PArc Cient Barcelona, E-08028 Barcelona, Spain.	azorzano@bio.ub.es	Camps, Marta/F-6557-2016; Brand, Martin D/A-9423-2012; Vidal, Hubert/M-6674-2017; Palacín, Manuel/G-9786-2015; Díaz, Nicanor Vega/R-4903-2019; Lloberas, Jorge/D-4303-2014; Soriano, Francesc X/U-7552-2017; Zorzano, Antonio/R-5479-2018	Camps, Marta/0000-0001-5392-1792; Brand, Martin D/0000-0003-4418-6153; Vidal, Hubert/0000-0002-9467-0317; Lloberas, Jorge/0000-0001-7075-4201; Soriano, Francesc X/0000-0003-1678-7162; Zierath, Juleen/0000-0001-6891-7497; Palacin, Manuel/0000-0002-8670-293X				Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; AMCHENKOVA AA, 1988, J CELL BIOL, V107, P481, DOI 10.1083/jcb.107.2.481; Amessou M, 1998, MOL CELL ENDOCRINOL, V144, P139, DOI 10.1016/S0303-7207(98)00132-4; Andreelli F, 1999, DIABETOLOGIA, V42, P358, DOI 10.1007/s001250051163; ASTRUP A, 1987, INT J OBESITY, V11, P51; Auboeuf D, 1997, ANAL BIOCHEM, V245, P141, DOI 10.1006/abio.1996.9986; AUESTAD N, 1991, J NEUROCHEM, V56, P1376, DOI 10.1111/j.1471-4159.1991.tb11435.x; BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x; BAKEEVA LE, 1978, BIOCHIM BIOPHYS ACTA, V501, P349, DOI 10.1016/0005-2728(78)90104-4; Bereiter-Hahn J., 1990, International Review of Cytology, V122, P1, DOI 10.1016/S0074-7696(08)61205-X; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Buchberger P, 1996, AM J PHYSIOL-REG I, V271, pR472, DOI 10.1152/ajpregu.1996.271.2.R472; Canicio J, 1998, ENDOCRINOLOGY, V139, P5042, DOI 10.1210/en.139.12.5042; CASTELLO A, 1994, J BIOL CHEM, V269, P5905; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; CRETTAZ M, 1980, BIOCHEM J, V186, P525, DOI 10.1042/bj1860525; CUENDET GS, 1976, J CLIN INVEST, V58, P1078, DOI 10.1172/JCI108559; Damdimopoulos AE, 2002, J BIOL CHEM, V277, P33249, DOI 10.1074/jbc.M203036200; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; DILISA F, 1995, J PHYSIOL-LONDON, V486, P1; Fekkes P, 2000, J CELL BIOL, V151, P333, DOI 10.1083/jcb.151.2.333; GUAN KL, 1993, CURR GENET, V24, P141, DOI 10.1007/BF00324678; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; KAPLAN ML, 1991, INT J OBESITY, V15, P809; Kelley DE, 2000, DIABETES, V49, P677, DOI 10.2337/diabetes.49.5.677; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; KEMMER FW, 1979, BIOCHEM J, V178, P733, DOI 10.1042/bj1780733; KIRKWOOD SP, 1986, AM J PHYSIOL, V251, pC395, DOI 10.1152/ajpcell.1986.251.3.C395; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Mora S, 1997, BIOCHEM J, V324, P455, DOI 10.1042/bj3240455; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Rojo M, 2002, J CELL SCI, V115, P1663; Santalucia T, 1999, J BIOL CHEM, V274, P17626, DOI 10.1074/jbc.274.25.17626; Santel A, 2001, J CELL SCI, V114, P867; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Simoneau JA, 1998, FASEB J, V12, P1739, DOI 10.1096/fasebj.12.15.1739; Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Suelmann R, 2000, CELL MOTIL CYTOSKEL, V45, P42, DOI 10.1002/(SICI)1097-0169(200001)45:1<42::AID-CM4>3.0.CO;2-C; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; TORGAN CE, 1989, J APPL PHYSIOL, V67, P1807, DOI 10.1152/jappl.1989.67.5.1807; Turcotte LP, 2001, DIABETES, V50, P1389, DOI 10.2337/diabetes.50.6.1389; WARDLAW GM, 1986, J NUTR, V116, P1841, DOI 10.1093/jn/116.9.1841; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; ZORZANO A, 2002, FRONT ANIM DIAB RES, V4, P297	52	613	659	1	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17190	17197		10.1074/jbc.M212754200	http://dx.doi.org/10.1074/jbc.M212754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12598526	hybrid			2022-12-27	WOS:000182818600100
J	Garnovskaya, MN; Mukhin, YV; Vlasova, TM; Raymond, JR				Garnovskaya, MN; Mukhin, YV; Vlasova, TM; Raymond, JR			Hypertonicity activates Na+/H+ exchange through Janus kinase 2 and calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-STIMULATED PHOSPHORYLATION; CELL-VOLUME REGULATION; ASCITES TUMOR-CELLS; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; 5-HT1A RECEPTOR; GROWTH-FACTOR; ISOFORM-1 NHE1; OSMOTIC SHOCK; H+ EXCHANGER	The type 1 sodium-hydrogen exchanger (NHE-1) is a ubiquitous electroneutral membrane transporter that is activated by hypertonicity in many cells. NHE-1 may be an important pathway for Na+ entry during volume restoration, yet the molecular mechanisms underlying the osmotic regulation of NHE-1 are poorly understood. In the present study we conducted a screen for important signaling molecules that could be involved in hypertonicity-induced activation of NHE-1 in CHO-K1 cells. Hypertonicity rapidly activated NHE-1 in a concentration-dependent manner as assessed by proton microphysiometry and by measurements of intracellular pH on a FLIPR(TM) (fluorometric imaging plate reader). Inhibitors of Ca2+/calmodulin (CaM) and Janus kinase 2 (Jak2) attenuated this activation, whereas neither calcium chelation nor inhibitors of protein kinase C, the Ras-ERK1/2 pathway, Src kinase, and Ca2+/calmodulin-dependent enzymes had significant effects. Hypertonicity also resulted in the rapid tyrosine phosphorylation of Jak2 and STAT3 (the major substrate of Jak2) and CaM. Phosphorylation of Jak2 and CaM were blocked by AG490, an inhibitor of Jak2. Immunoprecipitation studies showed that hypertonicity stimulates the assembly of a signaling complex that includes CaM, Jak2, and NHE-1. Formation of the complex could be blocked by AG490. Thus, we propose that hypertonicity induces activation of NHE-1 in CHO-K1 cells in large part through the following pathway: hypertonicity 3 Jak2 phosphorylation and activation 3 tyrosine phosphorylation of CaM 3 association of CaM with NHE-1 --> NHE-1 activation.	Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Garnovskaya, MN (corresponding author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,Rm 829 CSB,POB 250623, Charleston, SC 29425 USA.			Garnovskaya, Maria/0000-0002-6216-038X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052448, K01DK002694, R56DK052448] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52448, KO1-DK02694] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; Benaim G, 1998, COMP BIOCHEM PHYS C, V120, P57, DOI 10.1016/S0742-8413(98)00006-1; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIANCHINI L, 1995, AM J PHYSIOL-CELL PH, V269, pC998, DOI 10.1152/ajpcell.1995.269.4.C998; Bianchini L, 1997, J BIOL CHEM, V272, P271; BORON WF, 1977, AM J PHYSIOL, V233, pC61, DOI 10.1152/ajpcell.1977.233.3.C61; Bouaboula M, 1999, FEBS LETT, V449, P61, DOI 10.1016/S0014-5793(99)00395-6; BUSCH S, 1995, J BIOL CHEM, V270, P17898, DOI 10.1074/jbc.270.30.17898; Corti C, 1999, EUR J BIOCHEM, V262, P790, DOI 10.1046/j.1432-1327.1999.00441.x; DeFrutos T, 1997, BIOL CHEM, V378, P31, DOI 10.1515/bchm.1997.378.1.31; FUKAMI Y, 1986, P NATL ACAD SCI USA, V83, P4190, DOI 10.1073/pnas.83.12.4190; Garnovskaya MN, 1996, BIOCHEMISTRY-US, V35, P13716, DOI 10.1021/bi961764n; Garnovskaya MN, 1998, BIOCHEM J, V330, P489; Garnovskaya MN, 1997, J BIOL CHEM, V272, P7770, DOI 10.1074/jbc.272.12.7770; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; Joyal JL, 1996, BIOCHEMISTRY-US, V35, P6267, DOI 10.1021/bi9600198; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; Mukhin YV, 2001, J BIOL CHEM, V276, P17339, DOI 10.1074/jbc.M010834200; Pedersen SF, 1996, J MEMBRANE BIOL, V149, P141, DOI 10.1007/s002329900015; Prpic V, 1998, AM J PHYSIOL-GASTR L, V275, pG689, DOI 10.1152/ajpgi.1998.275.4.G689; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; SACKS DB, 1989, BIOCHEM J, V263, P803, DOI 10.1042/bj2630803; SACKS DB, 1992, BIOCHEM BIOPH RES CO, V188, P754, DOI 10.1016/0006-291X(92)91120-F; SACKS DB, 1992, BIOCHEM J, V286, P211, DOI 10.1042/bj2860211; Sacks DB, 1996, EUR J BIOCHEM, V239, P98, DOI 10.1111/j.1432-1033.1996.0098u.x; Sauvage M, 2000, EUR J BIOCHEM, V267, P955, DOI 10.1046/j.1432-1327.2000.01084.x; SAVILLE MK, 1994, BIOCHEM J, V299, P863, DOI 10.1042/bj2990863; Schroeder K.S., 1996, J BIOMOL SCREEN, V1, P75, DOI DOI 10.1177/108705719600100205; Shrode LD, 1997, AM J PHYSIOL-CELL PH, V272, pC1968, DOI 10.1152/ajpcell.1997.272.6.C1968; SHRODE LD, 1995, AM J PHYSIOL-CELL PH, V269, pC257, DOI 10.1152/ajpcell.1995.269.1.C257; Snabaitis AK, 2000, CIRC RES, V86, P214, DOI 10.1161/01.RES.86.2.214; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Voyno-Yasenetskaya TA, 1998, BIOL SIGNAL RECEPT, V7, P118; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; Yan WH, 2001, J BIOL CHEM, V276, P31349, DOI 10.1074/jbc.M102679200	45	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16908	16915		10.1074/jbc.M209883200	http://dx.doi.org/10.1074/jbc.M209883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12626508	hybrid			2022-12-27	WOS:000182818600063
J	Hirano, Y; Murata, S; Tanaka, K; Shimizu, M; Sato, R				Hirano, Y; Murata, S; Tanaka, K; Shimizu, M; Sato, R			Sterol regulatory element-binding proteins are negatively regulated through SUMO-1 modification independent of the ubiquitin/26 S proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENT MODIFICATION; TRANSCRIPTION FACTOR; CONJUGATING ENZYME; P53 ACTIVITY; GENE; CLEAVAGE; PML; ACTIVATION; ATTACHMENT; MEMBRANES	Sterol regulatory element-binding proteins (SREBPs) are major transcription factors that activate the genes involved in cholesterol and fatty acid biosynthesis. We here report that the nuclear forms of SREBPs are modified by the small ubiquitin-related modifier (SUMO)-1. Mutational analyses identified two major sumoylation sites (Lys(123) and Lys(418)) in SREBP-1a and a single site (Lys(464)) in SREBP-2. Mutant SREBPs lacking one or two sumoylation sites exhibited increased transactivation capacity on an SREBP-responsive promoter. Overexpression of SUMO-1 reduced whereas its dominant negative form increased mRNA levels of SREBP-responsive genes. Nuclear SREBPs interacted with the SUMO-1-conjugating enzyme Ubc9, and overexpression of a dominant negative form of Ubc9 increased the mRNA levels of SREBP-responsive genes. Pulse-chase experiments revealed that sumoylation did not affect the degradation of SREBPs through the ubiquitin-proteasome pathway. In vitro ubiquitylation assay showed no competition between ubiquitin and SUMO-1 for the same lysine. Considered together, our results indicate that SUMO-1 modification suppresses the transactivation capacity of nuclear SREBPs in a manner different from the negative regulatory mechanism mediated by proteolysis.	Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Tokyo 1138613, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science	Sato, R (corresponding author), Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan.	aroysato@mail.ecc.u-tokyo.ac.jp	Murata, Shigeo/A-1426-2010	Murata, Shigeo/0000-0002-3177-3503				Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; Inoue J, 2001, BIOCHEM BIOPH RES CO, V283, P1157, DOI 10.1006/bbrc.2001.4915; Jin CW, 2001, INT J BIOL MACROMOL, V28, P227, DOI 10.1016/S0141-8130(00)00169-0; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nakahara M, 2002, J BIOL CHEM, V277, P37229, DOI 10.1074/jbc.M206749200; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SATO R, 1994, J BIOL CHEM, V269, P17267; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	51	89	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16809	16819		10.1074/jbc.M212448200	http://dx.doi.org/10.1074/jbc.M212448200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12615929	hybrid			2022-12-27	WOS:000182818600050
J	Hou, YL; Lascola, J; Dulin, NO; Ye, RD; Browning, DD				Hou, YL; Lascola, J; Dulin, NO; Ye, RD; Browning, DD			Activation of cGMP-dependent protein kinase by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP; NITRIC-OXIDE; SMOOTH-MUSCLE; AUTOPHOSPHORYLATION SITE; FUNCTIONAL-ANALYSIS; PHOSPHORYLATION; RECEPTOR; SIGNAL; AUTOINHIBITION; PROLIFERATION	The cGMP-dependent protein kinases (PKG) are emerging as important components of mainstream signal transduction pathways. Nitric oxide-induced cGMP formation by stimulation of soluble guanylate cyclase is generally accepted as being the most widespread mechanism underlying PKG activation. In the present study, PKG was found to be a target for phorbol 12-myristate 13-acetate (PMA)-responsive protein kinase C (PKC). PKG1alpha became phosphorylated in HEK-293 cells stimulated with PMA and also in vitro using purified components. PKC-dependent phosphorylation was found to activate PKG as measured by phosphorylation of vasodilator-stimulated phosphoprotein, and by in vitro kinase assays. Although there are 11 potential PKC substrate recognition sites in PKG1alpha, threonine 58 was examined due to its proximity to the pseudosubstrate domain. Antibodies generated against the phosphorylated form of this region were used to demonstrate phosphorylation in response to PMA treatment of the cells with kinetics similar to vasodilator-stimulated phosphoprotein phosphorylation. A phospho-mimetic mutation at this site (T58E) generated a partially activated PKG that was more sensitive to cGMP levels. A phospho-null mutation (T58A) revealed that this residue is important but not sufficient for PKG activation by PKC. Taken together, these findings outline a novel signal transduction pathway that links PKC stimulation with cyclic nucleotide-independent activation of PKG.	Med Coll Georgia, Dept Biochem, Augusta, GA 30912 USA; Univ Chicago, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University System of Georgia; Augusta University; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Browning, DD (corresponding author), Med Coll Georgia, Dept Biochem, CB2510,1120 15th St, Augusta, GA 30912 USA.	dbrowning@mail.mcg.edu	Ye, Richard/ABF-2413-2020; Ye, Richard/O-5223-2016	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620; Browning, Darren/0000-0003-0497-7620				AITKEN A, 1984, BIOCHIM BIOPHYS ACTA, V790, P219, DOI 10.1016/0167-4838(84)90025-6; Browning DD, 1999, J BIOL CHEM, V274, P537, DOI 10.1074/jbc.274.1.537; Browning DD, 2001, J BIOL CHEM, V276, P13039, DOI 10.1074/jbc.M009187200; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; Chu DM, 1998, J BIOL CHEM, V273, P14649, DOI 10.1074/jbc.273.23.14649; Davis A, 2003, CELL SIGNAL, V15, P597, DOI 10.1016/S0898-6568(02)00148-1; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; FELBEL J, 1988, J BIOL CHEM, V263, P16764; Fischer TA, 2001, J BIOL CHEM, V276, P5967, DOI 10.1074/jbc.M009781200; FOSTER JL, 1981, J BIOL CHEM, V256, P5029; Francis S H, 1988, Second Messengers Phosphoproteins, V12, P301; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Francis SH, 2002, FRONT BIOSCI-LANDMRK, V7, pD580, DOI 10.2741/francis; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; Francis SH, 1998, METHODS, V14, P81, DOI 10.1006/meth.1997.0567; GAMM DM, 1995, J BIOL CHEM, V270, P27380, DOI 10.1074/jbc.270.45.27380; GLASS DB, 1983, J BIOL CHEM, V258, P4797; Hofmann F, 2000, J CELL SCI, V113, P1671; HOFMANN F, 1985, EUR J BIOCHEM, V147, P361, DOI 10.1111/j.1432-1033.1985.tb08758.x; Hood J, 1998, J BIOL CHEM, V273, P23504, DOI 10.1074/jbc.273.36.23504; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; LANDGRAF W, 1986, EUR J BIOCHEM, V154, P113, DOI 10.1111/j.1432-1033.1986.tb09365.x; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Lincoln TM, 1996, METHOD ENZYMOL, V269, P149; MACKENZIE CW, 1982, J BIOL CHEM, V257, P5589; Mochly-Rosen D, 1998, FASEB J, V12, P35; Orstavik S, 1997, GENOMICS, V42, P311, DOI 10.1006/geno.1997.4743; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PRYZWANSKY KB, 1995, BLOOD, V85, P222, DOI 10.1182/blood.V85.1.222.bloodjournal851222; Ruth P, 1999, PHARMACOL THERAPEUT, V82, P355, DOI 10.1016/S0163-7258(98)00067-9; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Silberbach M, 1999, J BIOL CHEM, V274, P24858, DOI 10.1074/jbc.274.35.24858; Silberbach M, 2001, CELL SIGNAL, V13, P221, DOI 10.1016/S0898-6568(01)00139-5; Smith JA, 1996, J BIOL CHEM, V271, P20756, DOI 10.1074/jbc.271.34.20756; Smolenski A, 1998, N-S ARCH PHARMACOL, V358, P134, DOI 10.1007/PL00005234; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; TAKIO K, 1983, J BIOL CHEM, V258, P5531; Taylor MK, 2002, J BIOL CHEM, V277, P37242, DOI 10.1074/jbc.M202060200; Vandecasteele G, 2001, J PHYSIOL-LONDON, V533, P329, DOI 10.1111/j.1469-7793.2001.0329a.x; WYATT TA, 1991, J BIOL CHEM, V266, P21274; Yao X, 2000, FASEB J, V14, P932, DOI 10.1096/fasebj.14.7.932	42	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16706	16712		10.1074/jbc.M300045200	http://dx.doi.org/10.1074/jbc.M300045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609995	hybrid			2022-12-27	WOS:000182818600035
J	Liu, G; Xia, T; Chen, XB				Liu, G; Xia, T; Chen, XB			The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; CELL-CYCLE ARREST; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL REGULATION; COLORECTAL-CANCER; DNA-BINDING; GENE; APOPTOSIS; RECRUITMENT; COACTIVATORS	The p53 transcription factor contains two separate tandem activation domains (AD1 and AD2), a proline-rich domain (PRD), and a C-terminal basic domain (BD). Previously, we have shown that these domains are necessary for transcriptional activity. To further characterize the role of these domains in transactivation, we analyzed the regulation of p21, a well characterized p53 target gene, by various p53 mutants deficient in one or more of these domains. We found that the induction of endogenous p21 is compromised by AD1-deficient p53 (p53(AD1(-))), AD2-deficient p53 (p53(AD2(-))), both AD1- and AD2-deficient p53 (p53(AD1(-) AD2(-))), p53(DeltaPRD), which lacks PRD, and p53(DeltaBD), which lacks BD. However, p53(AD2(-)), p53(DeltaPRD), and p53(DeltaBD) are still capable of activating exogenous p21 promoter to an extent comparable with that by wild-type p53. Thus, we performed chromatin immunoprecipitation assay to measure the DNA binding ability of various p53 mutants in vivo. We found that like wild-type p53, these p53 mutants are capable of binding to the p53 response elements in the p21 promoter. In contrast, we found that the extent of acetylated histones on the p21 promoter, especially the proximal promoter, and the amount of interaction with p300/CREB-binding protein, which contain histone acetyltransferase activity, directly correlate with the activity of p53 to induce endogenous p21. Furthermore, we showed that down-regulation of p300/CBP by short interference RNA markedly decreases the ability of p53 to induce endogenous p21. These data lead us to hypothesize that when p53 binds to the responsive element(s) of a target gene, its ability to interact with histone acetyltransferase-containing proteins and subsequently the acetylation of histones bound to the proximal promoter dictate the induction level of a target gene.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660,1530 3rd Ave S, Birmingham, AL 35294 USA.			Liu, Gang/0000-0003-2615-131X; , Gang/0000-0002-6999-7633	NATIONAL CANCER INSTITUTE [R01CA081237, R01CA076069, R29CA076069] Funding Source: NIH RePORTER; NCI NIH HHS [CA81237, CA76069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; Dickman S, 1997, SCIENCE, V277, P1605, DOI 10.1126/science.277.5332.1605; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Emerson BM, 2002, CELL, V109, P267, DOI 10.1016/S0092-8674(02)00740-7; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Featherstone M, 2002, CURR OPIN GENET DEV, V12, P149, DOI 10.1016/S0959-437X(02)00280-0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kadam S, 2002, CURR OPIN CELL BIOL, V14, P262, DOI 10.1016/S0955-0674(02)00330-7; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Liu L, 1999, MOL CELL BIOL, V19, P1202; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Scolnick DM, 1997, CANCER RES, V57, P3693; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu KC, 1999, ONCOGENE, V18, P7740, DOI 10.1038/sj.onc.1203235	43	93	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17557	17565		10.1074/jbc.M210696200	http://dx.doi.org/10.1074/jbc.M210696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609999	hybrid			2022-12-27	WOS:000182818600145
J	Pattingre, S; Bauvy, C; Codogno, P				Pattingre, S; Bauvy, C; Codogno, P			Amino acids interfere with the ERK1/2-dependent control of macroautophagy by controlling the activation of Raf-1 in human colon cancer HT-29 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLS AUTOPHAGIC SEQUESTRATION; ALPHA-INTERACTING PROTEIN; ISOLATED RAT HEPATOCYTES; EPIDERMAL GROWTH-FACTOR; OKADAIC ACID; KINASE ACTIVATION; PHOSPHATASE 2A; IN-VIVO; PHOSPHORYLATION; INHIBITION	Activation of ERK1/2 stimulates macroautophagy in the human colon cancer cell line HT-29 by favoring the phosphorylation of the Galpha-interacting protein (GAIP) in an amino acid-dependent manner (Ogier-Denis, E., Pattingre, S., El Benna, J., and Codogno, P. (2000) J. Biol. Chem. 275, 39090-39095). Here we show that ERK1/2 activation by aurintricarboxylic acid (ATA) treatment induces the phosphorylation of GAIP in an amino acid-dependent manner. Accordingly, ATA challenge increased the rate of macroautophagy, whereas epidermal growth factor did not significantly affect macroautophagy and GAIP phosphorylation status. In fact, ATA activated the ERK1/2 signaling pathway, whereas epidermal growth factor stimulated both the ERK1/2 pathway and the class I phosphoinositide 3-kinase pathway, known to decrease the rate of macroautophagy. Amino acids interfered with the ATA-induced macroautophagy by inhibiting the activation of the kinase Raf-1. The role of the Ras/Raf-1/ERK1/2 signaling pathway in the GAIP- and amino acid-dependent control of macroautophagy was confirmed in HT-29 cells expressing the Ras(G12V, T35S) mutant. Similar to the protein phosphatase 2A inhibitor okadaic acid, amino acids sustained the phosphorylation of Ser(259), which is involved in the negative regulation of Raf-1. In conclusion, these results add a novel target to the amino acid signaling-dependent control of macroautophagy in intestinal cells.	INSERM, U504, F-94807 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Codogno, P (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.		Codogno, Patrice/G-1384-2013	Codogno, Patrice/0000-0002-5492-3180; Ogier-Denis, Eric/0000-0002-0057-7593; Pattingre, Sophie/0000-0001-6284-6050				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Avruch J, 2001, RECENT PROG HORM RES, V56, P127, DOI 10.1210/rp.56.1.127; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; BALLARD FJ, 1985, EXP CELL RES, V157, P172, DOI 10.1016/0014-4827(85)90160-0; BLANKSON H, 1995, EXP CELL RES, V218, P522, DOI 10.1006/excr.1995.1187; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; Franch HA, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134903; Franch HA, 2001, J BIOL CHEM, V276, P19126, DOI 10.1074/jbc.M101777200; Hariri M, 2000, MOL BIOL CELL, V11, P255, DOI 10.1091/mbc.11.1.255; Haussinger D, 1999, GASTROENTEROLOGY, V116, P921, DOI 10.1016/S0016-5085(99)70076-4; HOLEN I, 1992, BIOCHEM J, V284, P633, DOI 10.1042/bj2840633; HOLEN I, 1993, EUR J BIOCHEM, V215, P113, DOI 10.1111/j.1432-1033.1993.tb18013.x; Holm TM, 2002, BLOOD, V99, P1817, DOI 10.1182/blood.V99.5.1817; HOURI JJ, 1993, BIOCHEM BIOPH RES CO, V197, P805, DOI 10.1006/bbrc.1993.2550; HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; Munafo DB, 2002, TRAFFIC, V3, P472, DOI 10.1034/j.1600-0854.2002.30704.x; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; OgierDenis E, 1997, J BIOL CHEM, V272, P24599, DOI 10.1074/jbc.272.39.24599; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; OKADA N, 1995, J BIOL CHEM, V270, P16464, DOI 10.1074/jbc.270.27.16464; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Taupin D, 1999, GASTROENTEROLOGY, V116, P1072, DOI 10.1016/S0016-5085(99)70010-7; Thumm M, 2000, MICROSC RES TECHNIQ, V51, P563, DOI 10.1002/1097-0029(20001215)51:6<563::AID-JEMT6>3.0.CO;2-8; van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Waguri S, 1999, ARCH HISTOL CYTOL, V62, P423, DOI 10.1679/aohc.62.423; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wurmser AE, 2002, J CELL BIOL, V158, P761, DOI 10.1083/jcb.200112050; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	56	232	251	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16667	16674		10.1074/jbc.M210998200	http://dx.doi.org/10.1074/jbc.M210998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12609989	hybrid			2022-12-27	WOS:000182818600030
J	Blanca, G; Baldanti, F; Paolucci, S; Skoblov, AY; Victorova, L; Hubscher, U; Gerna, G; Spadari, S; Maga, G				Blanca, G; Baldanti, F; Paolucci, S; Skoblov, AY; Victorova, L; Hubscher, U; Gerna, G; Spadari, S; Maga, G			Nevirapine resistance mutation at codon 181 of the HIV-1 reverse transcriptase confers stavudine resistance by increasing nucleotide substrate discrimination and phosphorolytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDINE-ANALOG; CONTAINING REGIMENS; ZIDOVUDINE-NAIVE; THERAPY; EMERGENCE; VIREMIA	Recombinant HIV-1 reverse transcriptase (RT) carrying non-nucleoside inhibitors (NNRTIs) resistance mutation at codon 181 showed reduced incorporation and high efficiency of phosphorolytic removal of stavudine, a nucleoside RT inhibitor. These results reveal a new mechanism for cross-resistance between different classes of HIV-1 RT inhibitors.	CNR, IGM, I-27100 Pavia, Italy; Policlin San Matteo, Serv Virol, Ist Ric & Cura Carattere Sci, I-27100 Pavia, Italy; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 117984, Russia; Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	Consiglio Nazionale delle Ricerche (CNR); IRCCS Fondazione San Matteo; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Zurich	Maga, G (corresponding author), CNR, IGM, Via Abbiategrasso 207, I-27100 Pavia, Italy.		Paolucci, Stefania/J-4055-2018; Baldanti, Fausto/J-4924-2018; Maga, Giovanni/C-5409-2009	Paolucci, Stefania/0000-0001-8447-8586; Baldanti, Fausto/0000-0002-3358-8969; Maga, Giovanni/0000-0001-8092-1552; Gerna, Giuseppe/0000-0001-5956-2786				DYATKINA NB, 1987, BIOORG KHIM+, V13, P1366; Iversen AKN, 1996, J VIROL, V70, P1086, DOI 10.1128/JVI.70.2.1086-1090.1996; Larder BA, 1999, ANTIMICROB AGENTS CH, V43, P1961, DOI 10.1128/AAC.43.8.1961; Loveday C, 2001, J ACQ IMMUN DEF SYND, V26, pS10, DOI 10.1097/00126334-200103011-00003; Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427; Maga G, 2002, CURR DRUG METAB, V3, P73, DOI 10.2174/1389200023337982; Mouroux M, 2001, ANTIVIR THER, V6, P179; Ross L, 2001, J HUMAN VIROL, V4, P217; Ross L, 2001, AIDS RES HUM RETROV, V17, P1107, DOI 10.1089/088922201316912718; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; Sluis-Cremer N, 2000, CELL MOL LIFE SCI, V57, P1408, DOI 10.1007/PL00000626	11	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15469	15472		10.1074/jbc.C300022200	http://dx.doi.org/10.1074/jbc.C300022200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601008	Green Accepted, hybrid			2022-12-27	WOS:000182680000004
J	Zou, ZY; Tong, FM; Faergeman, NJ; Borsting, C; Black, PN; DiRusso, CC				Zou, ZY; Tong, FM; Faergeman, NJ; Borsting, C; Black, PN; DiRusso, CC			Vectorial acylation in Saccharomyces cerevisiae - Fat1p and fatty acyl-CoA synthetase are interacting components of a fatty acid import complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN N-MYRISTOYLATION; TRANSPORT PROTEIN; PLASMA-MEMBRANE; YEAST; ACTIVATION; DISRUPTION; MECHANISM; COENZYME; CLONING; BINDING	In Saccharomyces cerevisiae Fat1p and fatty acyl-CoA synthetase (FACS) are hypothesized to couple import and activation of exogenous fatty acids by a process called vectorial acylation. Molecular genetic and biochemical studies were used to define further the functional and physical interactions between these proteins. Multicopy extragenic suppressors were selected in strains carrying deletions in FAA1 and FAA4 or FAA1 and FAT1. Each strain is unable to grow under synthetic lethal conditions when exogenous long-chain fatty acids are required, and neither strain accumulates the fluorescent long-chain fatty acid C-1-BODIPY-C-12 indicating a fatty acid transport defect. By using these phenotypes as selective screens, plasmids were identified encoding FAA1, FAT1, and FAA4 in the faa1Delta faa4Delta strain and encoding FAA1 and FAT1 in the faa1Delta fat1Delta strain. Multicopy FAA4 could not suppress the growth defect in the faa1Delta fat1Delta strain indicating some essential functions of Fat1p cannot be performed by Faa4p. Chromosomally encoded FAA1 and FAT1 are not able to suppress the growth deficiencies of the fat1Delta faa1Delta and faa1Delta faa4Delta strains, respectively, indicating Faa1p and Fat1p play distinct roles in the fatty acid import process. When expressed from a 2mu plasmid, Fat1p contributes significant oleoyl-CoA synthetase activity, which indicates vectorial esterification and metabolic trapping are the driving forces behind import. Evidence of a physical interaction between Fat1p and FACS was provided using three independent biochemical approaches. First, a C-terminal peptide of Fat1p deficient in fatty acid transport exerted a dominant negative effect against long-chain acyl-CoA synthetase activity. Second, protein fusions employing Faa1p as bait and portions of Fat1p as trap were active when tested using the yeast two-hybrid system. Third, co-expressed, differentially tagged Fat1p and Faa1p or Faa4p were co-immunoprecipitated. Collectively, these data support the hypothesis that fatty acid import by vectorial acylation in yeast requires a multiprotein complex, which consists of Fat1p and Faa1p or Faa4p.	Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA	Albany Medical College	DiRusso, CC (corresponding author), Albany Med Coll, Ctr Cardiovasc Sci, MC-8,47 New Scotland Ave, Albany, NY 12208 USA.		DiRusso, Concetta C/M-1884-2014	Black, Paul/0000-0002-6272-6881; Borsting, Claus/0000-0003-0421-7429; Faergeman, Nils/0000-0002-9281-5287	NIGMS NIH HHS [GM 56840] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056840] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abumrad N, 1999, BBA-MOL CELL BIOL L, V1441, P4, DOI 10.1016/S1388-1981(99)00137-7; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Azizan A, 1999, ARCH BIOCHEM BIOPHYS, V365, P299, DOI 10.1006/abbi.1999.1171; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Bartel P. L., 1997, YEAST 2 HYBRID SYSTE; Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; Coe NR, 1999, J BIOL CHEM, V274, P36300, DOI 10.1074/jbc.274.51.36300; DiRusso CC, 1999, MOL CELL BIOCHEM, V192, P41, DOI 10.1023/A:1006823831984; DiRusso CC, 2000, EUR J BIOCHEM, V267, P4422, DOI 10.1046/j.1432-1327.2000.01489.x; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; Faergeman NJ, 2001, J BIOL CHEM, V276, P37051, DOI 10.1074/jbc.M100884200; Faergeman NJ, 1997, J BIOL CHEM, V272, P8531, DOI 10.1074/jbc.272.13.8531; FRERMAN FE, 1973, ARCH BIOCHEM BIOPHYS, V159, P434, DOI 10.1016/0003-9861(73)90471-2; Gargiulo CE, 1999, J LIPID RES, V40, P881; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hamilton JA, 2001, J MOL NEUROSCI, V16, P99, DOI 10.1385/JMN:16:2-3:99; HARMON CM, 1991, J MEMBRANE BIOL, V121, P261, DOI 10.1007/BF01951559; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; Kaiser C., 1994, METHODS YEAST GENETI; KLEIN K, 1971, EUR J BIOCHEM, V19, P422; KNOLL LJ, 1995, J BIOL CHEM, V270, P20090, DOI 10.1074/jbc.270.34.20090; RHINE J, 1991, METHOD ENZYMOL, V194, P239; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; Schneiter R, 1996, MOL CELL BIOL, V16, P7161; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; Watkins PA, 1998, J BIOL CHEM, V273, P18210, DOI 10.1074/jbc.273.29.18210; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	30	93	95	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16414	16422		10.1074/jbc.M210557200	http://dx.doi.org/10.1074/jbc.M210557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12601005	Green Published, hybrid			2022-12-27	WOS:000182680000121
J	Baron, GS; Caughey, B				Baron, GS; Caughey, B			Effect of glycosylphosphatidylinositol anchor-dependent and -independent prion protein association with model raft membranes on conversion to the protease-resistant isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL TRUNCATION; CELL-FREE FORMATION; SCRAPIE ISOFORM; BINDING-SITES; CULTURED-CELLS; COPPER-BINDING; NEUROBLASTOMA-CELLS; MASS-SPECTROMETRY; SULFATED GLYCANS; IN-VITRO	Prion protein (PrP) is usually bound to membranes by a glycosylphosphatidylinositol (GPI) anchor that associates with detergent-resistant membranes, or rafts. To examine the effect of membrane association on the interaction between the normal protease-sensitive PrP isoform (PrP-sen) and the protease-resistant isoform (PrP-res), a model system was employed using PrP-sen reconstituted into sphingolipid-cholesterol-rich raftlike liposomes (SCRLs). Both full-length (GPI(+)) and GPI anchor-deficient (GPI(-)) PrP-sen produced in fibroblasts stably associated with SCRLs. The latter, alternative mode of membrane association was not detectably altered by glycosylation and was markedly reduced by deletion of residues 34-94. The SCRL-associated PrP molecules were not removed by treatments with either high salt or carbonate buffer. However, only GPI(+) PrP-sen resisted extraction with cold Triton X-100. PrP-sen association with SCRLs was pH-independent. PrP-sen was also one of a small subset of phosphatidylinositol-specific phospholipase C (PI-PLC)-released proteins from fibroblast cells found to bind SCRLs. A cell-free conversion assay was used to measure the interaction of SCRL-bound PrP-sen with exogenous PrP-res as contained in microsomes. SCRL-bound GPI(+) PrP-sen was not converted to PrP-res until PI-PLC was added to the reaction or the combined membrane fractions were treated with the membrane-fusing agent polyethylene glycol (PEG). In contrast, SCRL-bound GPI(-) PrP-sen was converted to PrP-res without PI-PLC or PEG treatment. Thus, of the two forms of raft membrane association by PrP-sen, only the GPI anchor-directed form resists conversion induced by exogenous PrP-res.	NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Caughey, B (corresponding author), NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000580, Z01AI000580] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Angrand M, 1997, EUR J BIOCHEM, V250, P168, DOI 10.1111/j.1432-1033.1997.t01-1-00168.x; Aronoff-Spencer E, 2000, BIOCHEMISTRY-US, V39, P13760, DOI 10.1021/bi001472t; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1993, GLYCOBIOLOGY, V3, P319, DOI 10.1093/glycob/3.4.319; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1990, J VIROL, V64, P1093, DOI 10.1128/JVI.64.3.1093-1101.1990; CAUGHEY B, 1988, P NATL ACAD SCI USA, V85, P4657, DOI 10.1073/pnas.85.13.4657; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; Caughey B, 1999, METHOD ENZYMOL, V309, P122; Caughey B, 2001, ADV PROTEIN CHEM, V57, P139; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; Chabry J, 1999, J VIROL, V73, P6245, DOI 10.1128/JVI.73.8.6245-6250.1999; CHESEBRO B, 1993, DEV BIOL STAND, V80, P131; DeArmond SJ, 1999, J NEUROPATH EXP NEUR, V58, P1000, DOI 10.1097/00005072-199909000-00010; Gonzalez-Iglesias R, 2002, J MOL BIOL, V319, P527, DOI 10.1016/S0022-2836(02)00341-8; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Horiuchi M, 2001, J BIOL CHEM, V276, P15489, DOI 10.1074/jbc.M100288200; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Jackson GS, 2001, P NATL ACAD SCI USA, V98, P8531, DOI 10.1073/pnas.151038498; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Klein TR, 1998, BIOL CHEM, V379, P655, DOI 10.1515/bchm.1998.379.6.655; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Lawson VA, 2001, J BIOL CHEM, V276, P35265, DOI 10.1074/jbc.M103799200; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Mange A, 2000, J VIROL, V74, P3135, DOI 10.1128/JVI.74.7.3135-3140.2000; MASSENBURG D, 1993, BIOCHEMISTRY-US, V32, P9172, DOI 10.1021/bi00086a024; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Narwa R, 1999, BIOCHEMISTRY-US, V38, P8770, DOI 10.1021/bi990736c; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Nosjean O, 1999, EUR J BIOCHEM, V263, P865, DOI 10.1046/j.1432-1327.1999.00573.x; Parizek P, 2001, J BIOL CHEM, V276, P44627, DOI 10.1074/jbc.M107458200; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STAHL N, 1990, BIOCHEMISTRY-US, V29, P8879, DOI 10.1021/bi00490a001; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; VIGUERA AR, 1993, BIOCHEMISTRY-US, V32, P3708, DOI 10.1021/bi00065a024; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; Whittal RM, 2000, PROTEIN SCI, V9, P332; Williamson RA, 1998, J VIROL, V72, P9413, DOI 10.1128/JVI.72.11.9413-9418.1998; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Zuegg J, 2000, GLYCOBIOLOGY, V10, P959, DOI 10.1093/glycob/10.10.959	57	98	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14883	14892		10.1074/jbc.M210840200	http://dx.doi.org/10.1074/jbc.M210840200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12594216	hybrid			2022-12-27	WOS:000182516100040
J	Bauer, PM; Fulton, D; Boo, YC; Sorescu, GP; Kemp, BE; Jo, H; Sessa, WC				Bauer, PM; Fulton, D; Boo, YC; Sorescu, GP; Kemp, BE; Jo, H; Sessa, WC			Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple-serine phosphorylation sites in endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AKT-DEPENDENT PHOSPHORYLATION; MOLECULAR-CLONING; SHEAR-STRESS; ACTIVATION; KINASE; CELLS; HSP90; ENOS; RECONSTITUTION; CAVEOLIN-1	We examined the influence of individual serine phosphorylation sites in endothelial nitric-oxide synthase (eNOS) on basal and stimulated NO release, cooperative phosphorylation, and co-association with hsp90 and Akt. Mutation of the serine phosphorylation sites 116, 617, and 1179 to alanines affected the phospho-state of at least one other site, demonstrating cooperation between multiple phosphorylation events, whereas mutation of serine 635 to alanine did not cause compensation. Mutation of serines 116 and 617 to alanine promoted a greater protein-protein interaction with hsp90 and Akt and greater phosphorylation on serine 1179, the major site for Akt phosphorylation. More importantly, using alanine substitutions, Ser-116 is important for agonist, but not basal NO release, Ser-635 is important for basal, but not stimulated, Ser-617 negatively regulates basal and stimulated NO release, and Ser-1179 phosphorylation is stimulatory for both basal and agonist-mediated NO release. Using putative "gain of function" mutants (serine to aspartate) serines 635 and 1179 are important positive regulators of basal and stimulated NO release. S635D eNOS is the most efficacious, yielding 5-fold increases in basal and 2-fold increases in stimulated NO release from cells. However, S617A and S617D eNOS both increased NO release with opposite actions in NOS activity assays. Thus, multiple serine phosphorylation events regulate basal and stimulate NO release with Ser-635 and Ser-1179 being important positive regulatory sites and Ser-116 as a negative regulatory. Ser-617 may not be important for directly regulating NO release but is important as a modulator of phosphorylation at other sites and protein-protein interactions.	Yale Univ, Sch Med, Vasc Cell Signaling & Therapeut Program, Boyer Ctr Mol Med,Dept Pharmacol, New Haven, CT 06536 USA; Georgia Tech, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30322 USA; Emory Univ, Atlanta, GA 30322 USA; St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	Yale University; University System of Georgia; Georgia Institute of Technology; Emory University; St Vincent's Hospital Melbourne; St. Vincent's Institute of Medical Research	Sessa, WC (corresponding author), Yale Univ, Sch Med, Vasc Cell Signaling & Therapeut Program, Boyer Ctr Mol Med,Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.		Kemp, Bruce E/L-2633-2014; Jo, Hanjoong/L-6216-2019; Kemp, Bruce/G-9602-2019; Sessa, William C/B-6844-2011	Kemp, Bruce E/0000-0001-6735-5082; Jo, Hanjoong/0000-0003-1833-372X; Kemp, Bruce/0000-0001-6735-5082; Sessa, William C/0000-0001-5759-1938; Boo, Yong Chool/0000-0001-9895-2066	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007950, R01HL061371, R01HL064793, R01HL057665, R37HL061371] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61371, T32 HL07950-02, R01 HL57665, HL64793] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boo YC, 2002, AM J PHYSIOL-HEART C, V283, pH1819, DOI 10.1152/ajpheart.00214.2002; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Fulton D, 2002, J BIOL CHEM, V277, P4277, DOI 10.1074/jbc.M106302200; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; Gonzalez E, 2002, J BIOL CHEM, V277, P39554, DOI 10.1074/jbc.M207299200; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Kou RQ, 2002, J BIOL CHEM, V277, P29669, DOI 10.1074/jbc.M204519200; Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Marrero MB, 1999, BIOCHEM J, V343, P335, DOI 10.1042/0264-6021:3430335; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; POLLOCK JS, 1992, FEBS LETT, V309, P402, DOI 10.1016/0014-5793(92)80816-Y; Scotland RS, 2002, CIRC RES, V90, P904, DOI 10.1161/01.RES.0000016506.04193.96; SESSA WC, 1992, J BIOL CHEM, V267, P15274; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773	31	186	197	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14841	14849		10.1074/jbc.M211926200	http://dx.doi.org/10.1074/jbc.M211926200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12591925	hybrid			2022-12-27	WOS:000182516100035
J	Viswanathan, P; Chen, JJ; Chiang, YC; Denis, CL				Viswanathan, P; Chen, JJ; Chiang, YC; Denis, CL			Identification of multiple RNA features that influence CCR4 deadenylation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; DNA-REPAIR; EXONUCLEASE; YEAST; PROTEINS; ENDONUCLEASE; DEGRADATION	The CCR4 family proteins are 3'-5'-deadenylases that function in the first step of the degradation of poly(A) mRNA. Here we report the purification to homogeneity of the yeast CCR4 protein and the analysis of its substrate specificities. CCR4 deadenylated a 7N+23A substrate (seven nucleotides followed by 23 A residues) in a distributive manner. Only small differences in CCR4 activity for different A length substrates were observed until only 1 A residue remained. Correspondingly, the K-m for a 25N+2A substrate was found to be at least 20-fold lower than that for a 26N+1A substrate, although their V-max values differed by only 2-fold. In addition, the total length of the RNA was found to contribute to CCR4 activity: up to 17 nucleotides (not necessarily poly(A)) could be recognized by CCR4. Poly(U), poly(C), and poly(G) were also found to be 12-30-fold better inhibitors of CCR4 compared with poly(A), supporting the observation that CCR4 contains a non-poly(A)-specific binding site. Surprisingly, even longer substrates (greater than or equal to45 nucleotides) stimulated CCR4 to become a processive enzyme, suggesting that CCR4 undergoes an additional transition in the presence of such substrates. CCR4 also displayed no difference in its activity with capped or uncapped RNA substrates. These results indicate that CCR4 recognition of its RNA substrates involves several features of the RNA that could be sites in vivo for controlling the rate of specific mRNA deadenylation.	Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Denis, CL (corresponding author), Univ New Hampshire, Dept Biochem & Mol Biol, Rudman Hall,Rm 387,46 Coll Rd, Durham, NH 03824 USA.				NIGMS NIH HHS [GM41215] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; ASTROM J, 1992, J BIOL CHEM, V267, P18154; Cao D, 2001, RNA, V7, P1192, DOI 10.1017/S1355838201010330; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Dlakic M, 2000, TRENDS BIOCHEM SCI, V25, P272, DOI 10.1016/S0968-0004(00)01582-6; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; Liker E, 2000, EMBO J, V19, P5587, DOI 10.1093/emboj/19.21.5587; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; Nguyen LH, 2000, J MOL BIOL, V298, P447, DOI 10.1006/jmbi.2000.3653; Olivas W, 2000, EMBO J, V19, P6602, DOI 10.1093/emboj/19.23.6602; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	23	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14949	14955		10.1074/jbc.M211794200	http://dx.doi.org/10.1074/jbc.M211794200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12590136	hybrid			2022-12-27	WOS:000182516100049
J	Johnson, A; O'Donnell, M				Johnson, A; O'Donnell, M			Ordered ATP hydrolysis in the gamma complex clamp loader AAA plus machine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; REPLICATION FACTOR-C; ONE HOLOENZYME PARTICLE; BETA-SLIDING CLAMP; ESCHERICHIA-COLI; ACCESSORY PROTEINS; BIOCHEMICAL-CHARACTERIZATION; PYROCOCCUS-FURIOSUS; CRYSTAL-STRUCTURE; DEPENDENT ATPASE	The gamma complex couples ATP hydrolysis to the loading of beta sliding clamps onto DNA for processive replication. The gamma complex structure shows that the clamp loader subunits are arranged as a circular heteropentamer. The three gamma motor subunits bind ATP, the delta wrench opens the beta ring, and the delta' stator modulates the delta-beta interaction. Neither delta nor delta' bind ATP. This report demonstrates that the delta' stator contributes a catalytic arginine for hydrolysis of ATP bound to the adjacent gamma(1) subunit. Thus, the delta' stator contributes to the motor function of the gamma trimer. Mutation of arginine 169 of gamma, which removes the catalytic arginines from only the gamma(2) and gamma3 ATP sites, abolishes ATPase activity even though ATP site 1 is intact and all three sites are filled. This result implies that hydrolysis of the three ATP molecules occurs in a particular order, the reverse of ATP binding, where ATP in site 1 is not hydrolyzed until ATP in sites 2 and/or 3 is hydrolyzed. Implications of these results to clamp loaders of other systems are discussed.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY USA	Rockefeller University; Howard Hughes Medical Institute	Johnson, A (corresponding author), Rockefeller Univ, 1230 York Ave,Box 228, New York, NY 10021 USA.			O'Donnell, Michael/0000-0001-9002-4214				Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; BONNER CA, 1992, J BIOL CHEM, V267, P11431; Bruck I, 2002, J BIOL CHEM, V277, P17334, DOI 10.1074/jbc.M110198200; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; Cann IKO, 2001, J BACTERIOL, V183, P2614, DOI 10.1128/JB.183.8.2614-2623.2001; Cann IKO, 1999, GENETICS, V152, P1249; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Davey MJ, 1997, J BIOL CHEM, V272, P15286, DOI 10.1074/jbc.272.24.15286; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; DONG ZM, 1993, J BIOL CHEM, V268, P11758; Ellison V, 1998, J BIOL CHEM, V273, P5979, DOI 10.1074/jbc.273.10.5979; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; HUGHES AJ, 1991, J BIOL CHEM, V266, P4568; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Leu FP, 2000, J BIOL CHEM, V275, P34609, DOI 10.1074/jbc.M005495200; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; Oyama T, 2001, MOL CELL, V8, P455, DOI 10.1016/S1097-2765(01)00328-8; Pietroni P, 2001, J MOL BIOL, V309, P869, DOI 10.1006/jmbi.2001.4687; Pisani FM, 2000, J MOL BIOL, V301, P61, DOI 10.1006/jmbi.2000.3964; PODOBNIK M, 2003, IN PRESS STRUCTURE; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; Schmidt SLG, 2001, J BIOL CHEM, V276, P34784, DOI 10.1074/jbc.M011633200; Sexton DJ, 1998, BIOCHEMISTRY-US, V37, P7749, DOI 10.1021/bi980088h; Seybert A, 2002, NUCLEIC ACIDS RES, V30, P4329, DOI 10.1093/nar/gkf584; STEWART J, 2001, J BIOL CHEM, V6, P6; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; Turner J, 1995, METHOD ENZYMOL, V262, P442; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Walker JR, 2000, J BACTERIOL, V182, P6106, DOI 10.1128/JB.182.21.6106-6113.2000; XIAO H, 1993, J BIOL CHEM, V268, P11779; Yao N, 2000, J BIOL CHEM, V275, P11440, DOI 10.1074/jbc.275.15.11440; Young MC, 1996, J MOL BIOL, V264, P440, DOI 10.1006/jmbi.1996.0652; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	64	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14406	14413		10.1074/jbc.M212708200	http://dx.doi.org/10.1074/jbc.M212708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12582167	hybrid			2022-12-27	WOS:000182405000107
J	Kovalenko, D; Yang, XH; Nadeau, RJ; Harkins, LK; Friesel, R				Kovalenko, D; Yang, XH; Nadeau, RJ; Harkins, LK; Friesel, R			Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTORS; INDUCED ANTAGONIST; KINASE PATHWAY; IN-VIVO; PROTEINS; BINDING; GENE; EMBRYOGENESIS; ADENOVIRUS; EXPRESSION	Signaling through fibroblast growth factor receptors (FGFRs) is essential for many cellular processes including proliferation and migration as well as differentiation events such as angiogenesis, osteogenesis, and chondrogenesis. Recently, genetic screens in Drosophila and gene expression screens in zebrafish have resulted in the identification of several feedback inhibitors of FGF signaling. One of these, Sef (similar expression to fgf genes), encodes a transmembrane protein that belongs to the FGF synexpression group. Here we show that like zebrafish Sef (zSef), mouse Sef (mSef) interacts with FGFR1 and that the cytoplasmic domain of mSef mediates this interaction. Overexpression of mSef in NIH3T3 cells results in a decrease in FGF-induced cell proliferation associated with a decrease in Tyr phosphorylation of FGFR1 and FRS2. As a consequence, there is a reduction in the phosphorylation of Raf-1 at Ser(338), MEK1/2 at Ser(217) and Ser(221), and ERK1/2 at Thr(202) and Tyr(204). Furthermore, mSef inhibits ERK activation mediated by a constitutively activated FGFR1 but not by a constitutively active Ras and decreases FGF but not PDGF-mediated activation of Akt. These results indicate that Sef exerts its inhibitory effects at the level of FGFR and upstream of Ras providing an additional level of negative regulation of FGF signaling.	Maine Med Ctr, Inst Res, Ctr Mol Med, Scarborough, ME 04074 USA; Univ Maine, Cooperat Grad Program Mol Genet & Cell Biol, Orono, ME 04469 USA	Maine Medical Center; University of Maine System; University of Maine Orono	Friesel, R (corresponding author), Maine Med Ctr, Inst Res, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.				NCRR NIH HHS [RR15555] Funding Source: Medline; NHLBI NIH HHS [HL65301] Funding Source: Medline; NIDCR NIH HHS [DE13248] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015555] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013248] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; Chong LD, 2000, MOL CELL BIOL, V20, P724, DOI 10.1128/MCB.20.2.724-734.2000; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Fasbender A, 1997, J BIOL CHEM, V272, P6479, DOI 10.1074/jbc.272.10.6479; Friesel R, 1999, THROMB HAEMOSTASIS, V82, P748; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; Furthauer M, 2001, DEVELOPMENT, V128, P2175; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Kudoh T, 2001, GENOME RES, V11, P1979, DOI 10.1101/gr.209601; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Lin W, 2002, MECH DEVELOP, V113, P163, DOI 10.1016/S0925-4773(02)00018-7; Minowada G, 1999, DEVELOPMENT, V126, P4465; Mood K, 2002, J BIOL CHEM, V277, P33196, DOI 10.1074/jbc.M203894200; Naski M.C., 1998, FRONT BIOSCI-LANDMRK, V3, pd781, DOI [10.2741/a321, DOI 10.2741/A321]; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; ORNITZ DM, 2001, GENOME BIOL; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	28	125	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14087	14091		10.1074/jbc.C200606200	http://dx.doi.org/10.1074/jbc.C200606200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12604616	hybrid			2022-12-27	WOS:000182405000069
J	Hardie, RC; Martin, F; Chyb, S; Raghu, P				Hardie, RC; Martin, F; Chyb, S; Raghu, P			Rescue of light responses in the Drosophila "null" phospholipase C mutant, norpAP(24), by the diacylglycerol kinase mutant, rdgA, and by metabolic inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CHANNELS TRP; IN-VIVO; SIGNAL-TRANSDUCTION; VISUAL TRANSDUCTION; G-PROTEIN; PHOTORECEPTORS; PHOTOTRANSDUCTION; PHOSPHORYLATION; GENE; ACTIVATION	Light responses in Drosophila are reportedly abolished in severe mutants of the phospholipase C ( PLC) gene, norpA. However, on establishing the whole-cell recording configuration in photoreceptors of the supposedly null allele, norpA(P24), we detected a small (similar to15 pA) inward current that represented spontaneous light channel activity. The current decayed during similar to20 min, after which tiny residual responses (< 2 pA) were elicited by intense flashes. Both spontaneous currents and light responses appeared to be mediated by residual PLC activity, because they were enhanced by impairing diacylglycerol (DAG) kinase function by mutation (rdgA) or by restricting ATP but were reduced or abolished by a mutation of the PLC-specific G(q) alpha subunit. It was reported recently that metabolic inhibition activated the light-sensitive transient receptor potential and transient receptor potential-like channels, even in norpAP24, leading to the conclusion that this action was independent of PLC (Agam, K., von Campenhausen, M., Levy, S., Ben-Ami, H. C., Cook, B., Kirschfeld, K., and Minke, B. ( 2000) J. Neurosci. 20, 5748-5755). However, we found that channel activation by metabolic inhibitors in norpAP24 was strictly dependent on the residual PLC activity underlying the spontaneous current, because the inhibitors failed to activate any channels after the spontaneous current had decayed. By contrast, polyunsaturated fatty acids invariably activated the channels independently of PLC. The results strongly support the obligatory requirement for PLC and DAG in Drosophila phototransduction, suggest that activation by metabolic inhibition is primarily because of the failure of diacylglycerol kinase, and are consistent with the proposal that polyunsaturated fatty acids, which are potential DAG metabolites, act directly on the channels.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England	University of Cambridge	Hardie, RC (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.		Chyb, Sylwester/B-5783-2009; Martin, Fernando/AAZ-1300-2020; Padinjat, Raghu/Z-5578-2019	Hardie, Roger/0000-0001-5531-3264; Martin, Fernando/0000-0003-4380-567X				Agam K, 2000, J NEUROSCI, V20, P5748, DOI 10.1523/JNEUROSCI.20-15-05748.2000; Alloway PG, 1999, P NATL ACAD SCI USA, V96, P6072, DOI 10.1073/pnas.96.11.6072; Benham CD, 2002, NEUROPHARMACOLOGY, V42, P873, DOI 10.1016/S0028-3908(02)00047-3; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Chorna-Ornan I, 2001, J NEUROSCI, V21, P2622, DOI 10.1523/JNEUROSCI.21-08-02622.2001; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Cook B, 2000, NAT CELL BIOL, V2, P296, DOI 10.1038/35010571; DOZA YN, 1992, EUR J BIOCHEM, V209, P1035, DOI 10.1111/j.1432-1033.1992.tb17379.x; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; Hardie RC, 2002, NEURON, V36, P689, DOI 10.1016/S0896-6273(02)01048-6; Hardie RC, 2003, ANNU REV PHYSIOL, V65, P735, DOI 10.1146/annurev.physiol.65.092101.142505; Hardie RC, 1996, J NEUROSCI, V16, P2924; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1994, J GEN PHYSIOL, V103, P389, DOI 10.1085/jgp.103.3.389; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Hardie RC, 2001, NATURE, V413, P186, DOI 10.1038/35093002; Hardie RC, 2001, NEURON, V30, P149, DOI 10.1016/S0896-6273(01)00269-0; Huber A, 1996, J BIOL CHEM, V271, P11710, DOI 10.1074/jbc.271.20.11710; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; Liu MY, 2000, J BIOL CHEM, V275, P12194, DOI 10.1074/jbc.275.16.12194; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; MINKE B, 1992, SOC GEN PHY, V47, P201; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; Montell C., 2001, SCI STKE; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; PAK WL, 1976, SCIENCE, V194, P956, DOI 10.1126/science.824732; Pearn MT, 1996, J BIOL CHEM, V271, P4937; Raghu P, 2000, NEURON, V26, P169, DOI 10.1016/S0896-6273(00)81147-2; Reuss H, 1997, NEURON, V19, P1249, DOI 10.1016/S0896-6273(00)80416-X; Scott K, 1998, NATURE, V395, P805, DOI 10.1038/27448; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Sekiya F, 1999, CHEM PHYS LIPIDS, V98, P3, DOI 10.1016/S0009-3084(99)00013-4; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; Thackeray JR, 1998, DEVELOPMENT, V125, P5033; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447	39	33	34	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18851	18858		10.1074/jbc.M300310200	http://dx.doi.org/10.1074/jbc.M300310200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12621055	hybrid			2022-12-27	WOS:000182932200020
J	Imamura, H; Fushinobu, S; Yamamoto, M; Kumasaka, T; Jeon, BS; Wakagi, T; Matsuzawa, H				Imamura, H; Fushinobu, S; Yamamoto, M; Kumasaka, T; Jeon, BS; Wakagi, T; Matsuzawa, H			Crystal structures of 4-alpha-glucanotransferase from Thermococcus litoralis and its complex with an inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE CYCLIC GLUCANS; CYCLODEXTRIN GLYCOSYLTRANSFERASE; GLYCOSYL HYDROLASES; THERMUS-AQUATICUS; 3-DIMENSIONAL STRUCTURE; ESCHERICHIA-COLI; ELECTRON-DENSITY; AQUEOUS-SOLUTION; ALPHA-AMYLASE; GENE CLONING	Thermococcus litoralis 4-alpha-glucanotransferase (TLGT) belongs to glucoside hydrolase family 57 and catalyzes the disproportionation of amylose and the formation of large cyclic alpha-1,4-glucan ( cycloamylose) from linear amylose. We determined the crystal structure of TLGT with and without an inhibitor, acarbose. TLGT is composed of two domains: an N-terminal domain ( domain I), which contains a (beta/alpha)(7) barrel fold, and a C-terminal domain ( domain II), which has a twisted beta-sandwich fold. In the structure of TLGT complexed with acarbose, the inhibitor was bound at the cleft within domain I, indicating that domain I is a catalytic domain of TLGT. The acarbose-bound structure also clarified that Glu(123) and Asp(214) were the catalytic nucleophile and acid/base catalyst, respectively, and revealed the residues involved in substrate binding. It seemed that TLGT produces large cyclic glucans by preventing the production of small cyclic glucans by steric hindrance, which is achieved by three lids protruding into the active site cleft, as well as an extended active site cleft. Interestingly, domain I of TLGT shares some structural features with the catalytic domain of Golgi alpha-mannosidase from Drosophila melanogaster, which belongs to glucoside hydrolase family 38. Furthermore, the catalytic residue of the two enzymes is located in the same position. These observations suggest that families 57 and 38 evolved from a common ancestor.	Aomori Univ, Dept Biosci & Biotechnol, Kohbata, Aomori 0300943, Japan; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; RIKEN, Inst Phys & Chem Res, Harima Inst, Mikazuki, Hyogo 6785148, Japan	University of Tokyo; RIKEN	Matsuzawa, H (corresponding author), JST, ERATO, ATP Syst Project, Midori Ku, 5800-3 Nagatsuta, Yokohama, Kanagawa 2260026, Japan.		Imamura, Hiromi/AAD-5109-2019; Yamamoto, Masaki/B-7844-2015; Fushinobu, Shinya/E-4987-2011; Kumasaka, Takashi/D-7428-2018; Wakagi, Takayoshi/AAJ-4145-2021	Imamura, Hiromi/0000-0002-1896-0443; Yamamoto, Masaki/0000-0002-1311-1768; Fushinobu, Shinya/0000-0003-1346-6435; Kumasaka, Takashi/0000-0001-9289-1557; 				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christopher JA, 1998, J MOL GRAPH MODEL, V16, P285; COUTINHO PM, 1999, CARBOHYDRATE ACTIVE; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Imamura H, 1999, FEBS LETT, V457, P393, DOI 10.1016/S0014-5793(99)01081-9; Imamura H., 2001, Journal of Applied Glycoscience, V48, P171; Imamura H, 2001, BIOCHEMISTRY-US, V40, P12400, DOI 10.1021/bi011017c; Jeon BS, 1997, EUR J BIOCHEM, V248, P171, DOI 10.1111/j.1432-1033.1997.00171.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Juers DH, 1999, PROTEIN SCI, V8, P122; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Katsuya Y, 1998, J MOL BIOL, V281, P885, DOI 10.1006/jmbi.1998.1992; Kim MJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P277, DOI 10.1006/abbi.1999.1423; Kitamura S, 1999, MACROMOL RAPID COMM, V20, P612, DOI 10.1002/(SICI)1521-3927(19991201)20:12<612::AID-MARC612>3.0.CO;2-E; Kitamura S, 1997, CARBOHYD RES, V304, P303, DOI 10.1016/S0008-6215(97)00278-4; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P1878, DOI 10.1107/S0907444999010495; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Machida S, 2000, FEBS LETT, V486, P131, DOI 10.1016/S0014-5793(00)02258-4; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nagano N, 1999, PROTEIN SCI, V8, P2072, DOI 10.1110/ps.8.10.2072; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Przylas I, 2000, J MOL BIOL, V296, P873, DOI 10.1006/jmbi.1999.3503; Przylas I, 2000, EUR J BIOCHEM, V267, P6903, DOI 10.1046/j.1432-1033.2000.01790.x; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SPEZIO M, 1993, BIOCHEMISTRY-US, V32, P9906, DOI 10.1021/bi00089a006; SVENSSON B, 1994, PLANT MOL BIOL, V25, P141, DOI 10.1007/BF00023233; Tachibana Y, 2000, J BIOSCI BIOENG, V90, P406, DOI [10.1016/S1389-1723(01)80009-8, 10.1263/jbb.90.406]; Takaha T, 1996, J BIOL CHEM, V271, P2902, DOI 10.1074/jbc.271.6.2902; Takaha T, 1999, BIOTECHNOL GENET ENG, V16, P257, DOI 10.1080/02648725.1999.10647978; Terada Y, 1999, APPL ENVIRON MICROB, V65, P910; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uitdehaag JCM, 1999, J BIOL CHEM, V274, P34868, DOI 10.1074/jbc.274.49.34868; Uitdehaag JCM, 2001, PROTEINS, V43, P327, DOI 10.1002/prot.1044; van den Elsen JMH, 2001, EMBO J, V20, P3008, DOI 10.1093/emboj/20.12.3008; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; WAKARCHUK WW, 1994, PROTEIN SCI, V3, P467; Xavier KB, 1999, J BACTERIOL, V181, P3358, DOI 10.1128/JB.181.11.3358-3367.1999	49	66	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19378	19386		10.1074/jbc.M213134200	http://dx.doi.org/10.1074/jbc.M213134200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12618437	hybrid			2022-12-27	WOS:000182932200086
J	Lodge, JA; Maier, T; Liebl, W; Hoffmann, V; Strater, N				Lodge, JA; Maier, T; Liebl, W; Hoffmann, V; Strater, N			Crystal structure of Thermotoga maritima alpha-glucosidase AglA defines a new clan of NAD(+)-dependent glycosidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSOBACTERIUM-MORTIFERUM ATCC-25557; ELECTRON-DENSITY MAPS; CATALYTIC-BASE MUTANT; ESCHERICHIA-COLI; PROTEIN MODELS; FAMILY 4; HYDROLASE; SEQUENCE; GLUCOAMYLASE; SPECIFICITY	Glycoside hydrolase family 4 represents an unusual group of glucosidases with a requirement for NAD(+), divalent metal cations, and reducing conditions. The family is also unique in its inclusion of both alpha- and beta-specific enzymes. The alpha-glucosidase A, AglA, from Thermotoga maritima is a typical glycoside hydrolase family 4 enzyme, requiring NAD(+) and Mn2+ as well as strongly reducing conditions for activity. Here we present the crystal structure of the protein complexed with NAD(+) and maltose, refined at a resolution of 1.9 Angstrom. The NAD(+) is bound to a typical Rossman fold NAD(+)-binding site, and the nicotinamide moiety is localized close to the maltose substrate. Within the active site the conserved Cys-174 and surrounding histidines are positioned to play a role in the hydrolysis reaction. The electron density maps indicate that Cys-174 is oxidized to a sulfinic acid. Most likely, the strongly reducing conditions are necessary to reduce the oxidized cysteine side chain. Notably, the canonical set of catalytic acidic residues common to other glucosidases is not present in the active site. This, combined with a high structural homology to NAD-dependent dehydrogenases, suggests an unusual and possibly unique mechanism of action for a glycoside-hydrolyzing enzyme.	Univ Gottingen, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany; Free Univ Berlin, Inst Chem, D-14195 Berlin, Germany; Biotechnol Biomed Zentrum, D-04103 Leipzig, Germany	University of Gottingen; Free University of Berlin	Liebl, W (corresponding author), Univ Gottingen, Inst Mikrobiol & Genet, Grisebachstr 8, D-37077 Gottingen, Germany.	wliebl@gwdg.de; strater@chemie.fu-berlin.de	Liebl, Wolfgang/D-3766-2014; Maier, Timm/A-8835-2016; Strater, Norbert/P-4856-2018	Liebl, Wolfgang/0000-0002-8421-2478; Maier, Timm/0000-0002-7459-1363; Strater, Norbert/0000-0002-2001-0500				Allard STM, 2001, J MOL BIOL, V307, P283, DOI 10.1006/jmbi.2000.4470; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Castagnetto JM, 2002, NUCLEIC ACIDS RES, V30, P379, DOI 10.1093/nar/30.1.379; Chapman ADM, 1999, J MOL BIOL, V285, P703, DOI 10.1006/jmbi.1998.2357; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Fierobe HP, 1998, BIOCHEMISTRY-US, V37, P3753, DOI 10.1021/bi972232p; Fierobe HP, 1998, BIOCHEMISTRY-US, V37, P3743, DOI 10.1021/bi972231x; Goodsell DS, 2000, ANNU REV BIOPH BIOM, V29, P105, DOI 10.1146/annurev.biophys.29.1.105; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; Kleywegt GJ, 1997, J MOL BIOL, V273, P371, DOI 10.1006/jmbi.1997.1309; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; LILJESTROM PL, 1987, NUCLEIC ACIDS RES, V15, P2213, DOI 10.1093/nar/15.5.2213; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Michel G, 2001, STRUCTURE, V9, P513, DOI 10.1016/S0969-2126(01)00612-8; Nagashima S, 1998, NAT STRUCT BIOL, V5, P347, DOI 10.1038/nsb0598-347; Orengo CA, 1997, STRUCTURE, V5, P1093, DOI 10.1016/S0969-2126(97)00260-8; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Raasch C, 2002, FEBS LETT, V517, P267, DOI 10.1016/S0014-5793(02)02641-8; Raasch C, 2000, EXTREMOPHILES, V4, P189, DOI 10.1007/PL00010711; ROBRISH SA, 1994, J BACTERIOL, V176, P3250, DOI 10.1128/jb.176.11.3250-3256.1994; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; Rye CS, 2000, CURR OPIN CHEM BIOL, V4, P573, DOI 10.1016/S1367-5931(00)00135-6; Suresh C, 2002, FEBS LETT, V517, P159, DOI 10.1016/S0014-5793(02)02611-X; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thompson J, 1999, J BACTERIOL, V181, P7339, DOI 10.1128/JB.181.23.7339-7345.1999; Thompson J, 1998, J BIOL CHEM, V273, P27347, DOI 10.1074/jbc.273.42.27347; Thompson J, 2001, J BIOL CHEM, V276, P37415, DOI 10.1074/jbc.M106504200; THOMPSON J, 1995, J BACTERIOL, V177, P2505, DOI 10.1128/jb.177.9.2505-2512.1995; Westhead DR, 1999, PROTEIN SCI, V8, P897; Wolfenden R, 1998, J AM CHEM SOC, V120, P6814, DOI 10.1021/ja9813055; Zechel DL, 2000, ACCOUNTS CHEM RES, V33, P11, DOI 10.1021/ar970172+	44	50	53	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19151	19158		10.1074/jbc.M211626200	http://dx.doi.org/10.1074/jbc.M211626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12588867	Green Accepted, hybrid			2022-12-27	WOS:000182932200057
J	Oehrl, W; Rubio, I; Wetzker, R				Oehrl, W; Rubio, I; Wetzker, R			Serine 338 phosphorylation is dispensable for activation of c-Raf1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE SIGNALING PATHWAY; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; PHOSPHOINOSITIDE 3-KINASE; RAF ACTIVATION; AMINO-TERMINUS; GTPASE RAC2; B-RAF	Numerous extracellular agonists induce consecutive stimulation of Ras guanine nucleotide exchange factors, Ras and c-Raf1, as the starting point of the intracellular mitogen-activated protein kinase cascade. Recent data point to a more complex reaction pattern of this simple sequence. This study was aimed at elucidating the activation process of endogenous c-Raf1 in U937 cells. Treatment of permeabilized U937 cells with the nonhydrolyzable nucleotide guanosine 5'-3-O-(thio) triphosphate (GTPgammaS) induced prolonged stimulation of Ras and c-Raf1 activity. Intriguingly, both signaling proteins expressed differential responses toward specific inhibitors of phosphoinositide 3-kinases and tyrosine kinases, which indicates diverse signaling reactions feeding into Ras and cRaf-1. Phosphorylation of c-Raf1 serine 338 by p21-activated kinase has been recently reported to contribute to phosphoinositide 3-kinase-dependent activation of c-Raf1. However, in U937 cells stimulation of c-Raf1 activity by GTPgammaS did not correlate with p21-activated kinase activity and Ser-338 phosphorylation. Thus Ser-338 phosphorylation appears dispensable for c-Raf1 activation under the conditions used. Together these data deny an essential role for serine 338 phosphorylation in c-Raf1 activation and disclose divergent signaling connections of Ras and c-Raf1 in U937 cells.	Univ Jena, Inst Mol Cell Biol, D-07747 Jena, Germany	Friedrich Schiller University of Jena	Wetzker, R (corresponding author), Univ Jena, Inst Mol Cell Biol, D-07747 Jena, Germany.		Wetzker, Reinhard/AAD-8713-2019					Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Arai H, 1996, MOL PHARMACOL, V50, P522; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; BUDAY L, 1995, ONCOGENE, V11, P1327; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rubio I, 2000, CURR BIOL, V10, P1225, DOI 10.1016/S0960-9822(00)00731-4; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	48	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17819	17826		10.1074/jbc.M209951200	http://dx.doi.org/10.1074/jbc.M209951200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12626521	hybrid			2022-12-27	WOS:000182838300030
J	Mukai, K; Mitani, F; Nagasawa, H; Suzuki, R; Suzuki, T; Suematsu, M; Ishimura, Y				Mukai, K; Mitani, F; Nagasawa, H; Suzuki, R; Suzuki, T; Suematsu, M; Ishimura, Y			An inverse correlation between expression of a preprocathepsin B-related protein with cysteine-rich sequences and steroid 11 beta-hydroxylase in adrenocortical cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADRENAL-CORTEX; TUBULOINTERSTITIAL NEPHRITIS ANTIGEN; ALDOSTERONE SYNTHASE CYTOCHROME-P-450; ZONE-SPECIFIC EXPRESSION; FUNCTIONAL ZONATION; CYP11B1 GENE; CATHEPSIN-B; DIFFERENTIATION; IDENTIFICATION; LOCALIZATION	A cDNA encoding a secretory protein hitherto unknown was cloned from mouse adrenocortical cells by subtractive hybridization between the cells without and with expressing steroid 11beta-hydroxylase (Cyp11b-1), a marker for the functional differentiation of cells in the zonae fasciculata reticularis (zFR). The deduced protein consisting of 466 amino acids contained a secretory signal, epidermal growth factor-like repeats, and a proteolytically inactive cathepsin B-related sequence. The amino acid sequence was 89% identical with that of human tubulointerstitial nephritis antigen-related protein. Among the mouse organs examined, adrenal glands prominently expressed its mRNA. The mRNA and its encoded protein were detected in the outer adrenocortical zones that do not express Cyp11b-1, i.e. the zona glomerulosa and the undifferentiated cell zone, while being undetectable in zFR that express Cyp11b-1. The new protein was designated as adrenocortical zonation factor 1 (AZ-1). Clonal lines with different levels of AZ-1 expression were established from Y-1 adrenocortical cells that originally express Cyp11b-1 but little AZ-1. Analyses of the clonal lines revealed that Cyp11b-1 is detected in the clonal lines maintaining little AZ-1 expression and becomes undetectable in those expressing AZ-1. On the other hand, irrespective of the AZ-1 expression, all clones expressed cholesterol side-chain cleavage enzyme, which occurs throughout the cortical zones. These results demonstrated that adrenocortical cells expressing AZ-1 do not express Cyp11b-1, whereas those with little AZ-1 express this zFR marker in vitro and in vivo, implying a putative role of AZ-1 in determining the zonal differentiation of adrenocortical cells.	Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Shinjuku Ku, Tokyo 1608582, Japan; Minophagen Pharmaceut Co, Kanagawa 2280002, Japan	Keio University	Mukai, K (corresponding author), Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	mukaik@sc.itc.keio.ac.jp	Suematsu, Makoto/I-8135-2013; Suematsu, Makoto/O-5762-2018	Suematsu, Makoto/0000-0002-7165-6336; Suematsu, Makoto/0000-0002-7165-6336; Mukai, Kuniaki/0000-0002-9590-5077				BAKER SC, 1993, J VIROL, V67, P6056, DOI 10.1128/JVI.67.10.6056-6063.1993; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CAIN AJ, 1950, J ANAT, V84, P196; CATER DB, 1954, J ANAT, V88, P437; DEANE HW, 1946, AM J ANAT, V79, P117, DOI 10.1002/aja.1000790104; DOMALIK LJ, 1991, MOL ENDOCRINOL, V5, P1853, DOI 10.1210/mend-5-12-1853; Halder SK, 1998, ENDOCRINOLOGY, V139, P3316, DOI 10.1210/en.139.7.3316; Hall K, 1937, NATURE, V140, P318, DOI 10.1038/140318a0; HARTROFT PM, 1957, ENDOCRINOLOGY, V60, P641; IANNACCONE PM, 1987, J EXP ZOOL, V243, P217, DOI 10.1002/jez.1402430207; Ikeda M, 2000, BIOCHEM BIOPH RES CO, V268, P225, DOI 10.1006/bbrc.2000.2103; KALFA TA, 1994, J BIOL CHEM, V269, P1654; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; Kanwar YS, 1999, P NATL ACAD SCI USA, V96, P11323, DOI 10.1073/pnas.96.20.11323; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAIRD SM, 1988, ACTA ENDOCRINOL-COP, V119, P420, DOI 10.1530/acta.0.1190420; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Mitani F, 1999, ENDOCRINOLOGY, V140, P3342, DOI 10.1210/en.140.7.3342; Mitani F, 2003, BBA-GEN SUBJECTS, V1619, P317, DOI 10.1016/S0304-4165(02)00490-7; Mitani F, 1996, ENDOCR RES, V22, P421, DOI 10.1080/07435809609043728; Mitani F, 1998, ENDOCR RES, V24, P983, DOI 10.3109/07435809809032721; Mitani F, 1997, STEROIDS, V62, P57, DOI 10.1016/S0039-128X(96)00160-2; MITANI F, 1995, ENDOCR RES, V21, P413, DOI 10.3109/07435809509030457; MITANI F, 1994, ENDOCRINOLOGY, V135, P431, DOI 10.1210/en.135.1.431; MITCHELL RM, 1948, ANAT REC, V101, P161, DOI 10.1002/ar.1091010204; Miyamoto H, 2000, ENDOCR RES, V26, P899, DOI 10.3109/07435800009048614; Morley SD, 1996, MOL ENDOCRINOL, V10, P585, DOI 10.1210/me.10.5.585; MOROHASHI K, 1994, MOL ENDOCRINOL, V8, P643, DOI 10.1210/me.8.5.643; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; MUKAI K, 1991, BIOCHEM BIOPH RES CO, V180, P1187, DOI 10.1016/S0006-291X(05)81321-X; MUKAI K, 1993, J BIOL CHEM, V268, P9130; Mukai K, 1998, EUR J BIOCHEM, V256, P190, DOI 10.1046/j.1432-1327.1998.2560190.x; MUKAI K, 1995, MOL CELL BIOL, V15, P6003; Mukai K, 2002, EUR J BIOCHEM, V269, P69, DOI 10.1046/j.0014-2956.2002.02624.x; NELSON TR, 1995, J BIOL CHEM, V270, P16265, DOI 10.1074/jbc.270.27.16265; NICANDER L, 1952, ACTA ANAT          S, V14, P16; Obinata M, 1997, GENES CELLS, V2, P235, DOI 10.1046/j.1365-2443.1997.1160314.x; Obinata M, 2001, BIOCHEM BIOPH RES CO, V286, P667, DOI 10.1006/bbrc.2001.5247; OGISHIMA T, 1992, ENDOCRINOLOGY, V130, P2971, DOI 10.1210/en.130.5.2971; OGISHIMA T, 1989, J BIOL CHEM, V264, P10935; Okamoto M, 1998, ENDOCR RES, V24, P515, DOI 10.3109/07435809809032640; Orth DN, 1992, WILLIAMS TXB ENDOCRI, P489; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Raza FS, 1998, ENDOCR RES, V24, P977, DOI 10.3109/07435809809032720; Raza FS, 2001, EUR J BIOCHEM, V268, P2141, DOI 10.1046/j.1432-1327.2001.02096.x; REISS M, 1936, ENDOKRINOLOGIE, V18, P1; Schimmer B P, 1979, Methods Enzymol, V58, P570; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; VERNET T, 1991, J BIOL CHEM, V266, P21451; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; Wex T, 2001, BIOCHEMISTRY-US, V40, P1350, DOI 10.1021/bi002266o	51	19	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					17084	17092		10.1074/jbc.M301477200	http://dx.doi.org/10.1074/jbc.M301477200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12600995	hybrid			2022-12-27	WOS:000182818600086
J	Rossenu, S; Leyman, S; Dewitte, D; Peelaers, D; Jonckheere, V; Van Troys, M; Vandekerckhove, J; Ampe, C				Rossenu, S; Leyman, S; Dewitte, D; Peelaers, D; Jonckheere, V; Van Troys, M; Vandekerckhove, J; Ampe, C			A phage display-based method for determination of relative affinities of mutants - Application to the actin-binding motifs in thymosin beta 4 and the villin headpiece	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; F-ACTIN; NMR-SPECTROSCOPY; SITE; CONFORMATION; TECHNOLOGY; BETA(4); MUTAGENESIS; INTERFACES; SELECTION	We propose phage display combined with enzyme-linked immunosorbent assay as a tool for the systematic analysis of protein-protein interactions by investigating the binding behavior of variants to a partner protein. Via enzyme-linked immunosorbent assay we determine both the amount of fusion protein presented at the phage surface and the amount of complex formed, the ratio of which is proportional to the affinity. Hence this method enables us to calculate the relative affinities of a large number of mutants. As model systems, we investigated actin-binding motifs conserved in a number of proteins binding monomeric or filamentous actin. The hexapeptide motifs LKKTET, present in thymosin beta4, and LKKEKG, present in the villin headpiece, were mutated, and the variants were analyzed. Study of the positional tolerance allows postulating that the motifs, although similar in primary structures adopt different conformations when bound to actin. In addition, our data show that the second and the fourth amino acid of the thymosin beta4 motif and the first three residues of the villin headpiece motif are most important for actin binding. The latter result challenges the charged crown hypothesis for the villin headpiece filamentous actin interaction.	Univ Ghent, Dept Biochem, Fac Med & Hlth Sci, B-9000 Ghent, Belgium; State Univ Ghent VIB, Dept Med Prot Res, Fac Med & Hlth Sci, B-9000 Ghent, Belgium	Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University	Ampe, C (corresponding author), Univ Ghent, Dept Biochem, Fac Med & Hlth Sci, Baertsoenkaai 3, B-9000 Ghent, Belgium.	christophe.ampe@rug.ac.be	Ampe, Christophe/B-5534-2012	Van Troys, Marleen/0000-0003-4283-8103				Ballweber E, 2002, J MOL BIOL, V315, P613, DOI 10.1006/jmbi.2001.5281; BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; Bennett KL, 2000, PROTEIN SCI, V9, P1503, DOI 10.1110/ps.9.8.1503; Bourdet-Sicard R, 1999, EMBO J, V18, P5853, DOI 10.1093/emboj/18.21.5853; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168; CZISCH M, 1993, EUR J BIOCHEM, V218, P335, DOI 10.1111/j.1432-1033.1993.tb18382.x; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699; Ehrlich GK, 2000, METHODS MOL BIOL, V147, P195; Englander SW, 1996, CURR OPIN STRUC BIOL, V6, P18, DOI 10.1016/S0959-440X(96)80090-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; JIN L, 1994, J PROTEIN SCI, V12, P2351; KISHCHENKO G, 1994, J MOL BIOL, V241, P208, DOI 10.1006/jmbi.1994.1489; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; McKnight CJ, 1997, NAT STRUCT BIOL, V4, P180, DOI 10.1038/nsb0397-180; Meloen RH, 2000, J MOL RECOGNIT, V13, P352, DOI 10.1002/1099-1352(200011/12)13:6<352::AID-JMR509>3.0.CO;2-C; MERTENS N, 1995, BIO-TECHNOL, V13, P175, DOI 10.1038/nbt0295-175; Reineke U, 2001, CURR OPIN BIOTECH, V12, P59, DOI 10.1016/S0958-1669(00)00178-6; Rhyner Claudio, 2002, Current Pharmaceutical Biotechnology, V3, P13, DOI 10.2174/1389201023378535; Rossenu S, 1997, J PROTEIN CHEM, V16, P499, DOI 10.1023/A:1026317612554; Safer D, 1997, BIOCHEMISTRY-US, V36, P5806, DOI 10.1021/bi970185v; Safer D, 1997, CELL MOTIL CYTOSKEL, V38, P163, DOI 10.1002/(SICI)1097-0169(1997)38:2<163::AID-CM5>3.0.CO;2-8; SAGGIO I, 1995, GENE, V152, P35, DOI 10.1016/0378-1119(94)00733-9; Serebriiskii IG, 2001, BIOTECHNIQUES, V30, P634, DOI 10.2144/01303dd02; Simenel C, 2000, EUR J BIOCHEM, V267, P3530, DOI 10.1046/j.1432-1327.2000.01380.x; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWINDELLS MB, 1995, NAT STRUCT BIOL, V2, P596, DOI 10.1038/nsb0795-596; TAKASHI R, 1988, BIOCHEMISTRY-US, V27, P938, DOI 10.1021/bi00403a015; VANCOMPERNOLLE K, 1992, EMBO J, V11, P4739, DOI 10.1002/j.1460-2075.1992.tb05579.x; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; VANTROYS M, 1999, BIOCHIM BIOPHYS ACTA, V1447, P323; Vardar D, 1999, J MOL BIOL, V294, P1299, DOI 10.1006/jmbi.1999.3321; Vardar D, 2002, CELL MOTIL CYTOSKEL, V52, P9, DOI 10.1002/cm.10027; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; ZARBOCK J, 1990, BIOCHEMISTRY-US, V29, P7814, DOI 10.1021/bi00486a006; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	45	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16642	16650		10.1074/jbc.M208311200	http://dx.doi.org/10.1074/jbc.M208311200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12606551	hybrid			2022-12-27	WOS:000182818600027
J	Alani, E; Lee, JY; Schofield, MJ; Kijas, AW; Hsieh, P; Yang, W				Alani, E; Lee, JY; Schofield, MJ; Kijas, AW; Hsieh, P; Yang, W			Crystal structure and biochemical analysis of the MutS center dot ADP center dot Beryllium fluoride complex suggests a conserved mechanism for ATP interactions in mismatch repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; DNA HELICASE-II; RECOGNITION COMPLEX; MOLECULAR SWITCH; YEAST MSH2-MSH6; STRAND BREAK; PROTEIN MUTS; HMUTS-ALPHA; ABC-ATPASE; BINDING	During mismatch repair ATP binding and hydrolysis activities by the MutS family proteins are important for both mismatch recognition and for transducing mismatch recognition signals to downstream repair factors. Despite intensive. efforts, a MutS(.)ATP(.)DNA complex has eluded crystallographic analysis. Searching for ATP analogs that strongly bound to Thermus aquaticus (Taq) MutS, we found that ADP-beryllium fluoride (ABF), acted as a strong inhibitor of several MutS family ATPases. Furthermore, ABF promoted the formation of a ternary complex containing the Saccharomyces cerevisiae MSH2(.)MSH6 and MLH1(.)PMS1 proteins bound to mismatch DNA but did not promote dissociation of MSH2(.)MSH6 from mismatch DNA. Crystallographic analysis of the Taq MutS(.)DNA(.)ABF complex indicated that although this complex was very similar to that of MutS(.)DNA(.)ADP, both ADP(.)Mg(2+) moieties in the MutS(.)DNA(.)ADP structure were replaced by ABF. Furthermore, a disordered region near the ATP-binding pocket in the MutS B subunit became traceable, whereas the equivalent region in the A subunit that interacts with the mismatched nucleotide remained disordered. Finally, the DNA binding domains of MutS together with the mismatched DNA were shifted upon binding of ABF. We hypothesize that the presence of ABF is communicated between the two MutS subunits through the contact between the ordered loop and Domain III in addition to the intra-subunit helical lever arm that links the ATPase and DNA binding domains.	Cornell Univ, Dept Genet & Mol Biol, Ithaca, NY 14853 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDKD, Genet Biochem Branch, NIH, Bethesda, MD 20892 USA	Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Alani, E (corresponding author), 459 Biotechnol Bldg, Ithaca, NY 14853 USA.		Yang, Wei/ABB-4785-2020; Yang, Wei/D-4926-2011	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195; Kijas, Amanda/0000-0001-8538-7766	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053085] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53085, R01 GM053085] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alani E, 1996, MOL CELL BIOL, V16, P5604; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Biswas I, 2001, J MOL BIOL, V305, P805, DOI 10.1006/jmbi.2000.4367; Bjornson KP, 2000, BIOCHEMISTRY-US, V39, P3176, DOI 10.1021/bi992286u; Blackwell LJ, 1998, J BIOL CHEM, V273, P32049, DOI 10.1074/jbc.273.48.32049; Bowers J, 2000, J MOL BIOL, V302, P327, DOI 10.1006/jmbi.2000.4081; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Habraken Y, 1997, CURR BIOL, V7, P790, DOI 10.1016/S0960-9822(06)00337-X; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; Hall MC, 2001, PROTEIN EXPRES PURIF, V21, P333, DOI 10.1006/prep.2000.1379; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Junop MS, 2001, MOL CELL, V7, P1, DOI 10.1016/S1097-2765(01)00149-6; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lau PJ, 2003, J BIOL CHEM, V278, P14, DOI 10.1074/jbc.C200627200; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petsko CA, 2000, P NATL ACAD SCI USA, V97, P538, DOI 10.1073/pnas.97.2.538; Pezza RJ, 2002, NUCLEIC ACIDS RES, V30, P4700, DOI 10.1093/nar/gkf606; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Stavridi ES, 2002, STRUCTURE, V10, P891, DOI 10.1016/S0969-2126(02)00776-1; Studamire B, 1998, MOL CELL BIOL, V18, P7590, DOI 10.1128/MCB.18.12.7590; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Yamaguchi M, 1998, J BIOL CHEM, V273, P9197, DOI 10.1074/jbc.273.15.9197	45	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16088	16094		10.1074/jbc.M213193200	http://dx.doi.org/10.1074/jbc.M213193200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12582174	hybrid			2022-12-27	WOS:000182680000081
J	Boura-Halfon, S; Voliovitch, H; Feinstein, R; Paz, K; Zick, Y				Boura-Halfon, S; Voliovitch, H; Feinstein, R; Paz, K; Zick, Y			Extracellular matrix proteins modulate endocytosis of the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELL-ADHESION; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN CYTOSKELETON; INTERNALIZATION; PHOSPHORYLATION; GALECTIN-8; ACTIVATION; ADIPOCYTES; RESISTANCE	Internalization of the insulin receptor (IR) is a highly regulated multi-step process whose underlying molecular basis is not fully understood. Here we undertook to study the role of extracellular matrix (ECM) proteins in the modulation of IR internalization. Employing Chinese hamster ovary cells that overexpress IR (CHO-T cells), our results indicate that IR internalization proceeds unaffected even when Tyr phosphorylation of IR substrates, such as IRS-1, is impaired (e.g. in CHO-T cells overexpressing IRS-1 whose pleckstrin-homology domain has been deleted or in CHO-T cells that overexpress the PH/PTB domain of IRS-1). In contrast, IR internalization is affected by the context of the ECM proteins to which the cells adhere. Hence, IR internalization was inhibited 40-60% in CHO-T cells adherent onto galectin-8 (an ECM protein and an integrin ligand of the galectin family) when compared with cells adherent onto fibronectin, collagen, or laminin. Cells adherent to galectin-8 manifested a unique cytoskeletal organization, which involved formation of cortical actin and generation of F-actin microspikes that contrasted with the prominent stress-fibers formed when cells adhered to fibronectin. To better establish a role for actin filament organization in IR endocytosis, this process was assayed in CHO-T cells (adherent onto fibronectin), whose actin filaments were disrupted upon treatment with latrunculin B. Latrunculin B did not affect insulin-induced Tyr phosphorylation of IR or its ability to phosphorylate its substrates; still, a 30-50% reduction in the rate of IR internalization was observed in cells treated with latrunculin B. Treatment of cells with nocodazole, which disrupts formation of microtubules, did not affect IR internalization. These results indicate that proper actin, but not microtubular, organization is a critical requirement for IR internalization and suggest that integrin-mediated signaling pathways emitted upon cell adhesion to different extracellular matrices and the altered cytoskeletal organizations generated thereof affect the itinerary of the insulin receptor.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Zick, Y (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Zick, Yehiel/K-1479-2012					BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; Bergeron JJM, 1995, BIOSCIENCE REP, V15, P411, DOI 10.1007/BF01204345; Bevan AP, 1995, MOL CELL BIOCHEM, V153, P49, DOI 10.1007/BF01075918; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9; CARPENTIER JL, 1994, ANN NY ACAD SCI, V733, P266, DOI 10.1111/j.1749-6632.1994.tb17276.x; CARPENTIER JL, 1995, J BIOL CHEM, V270, P5001, DOI 10.1074/jbc.270.10.5001; CARPENTIER JL, 1993, J CELL BIOL, V118, P831; Fasching P, 1996, DIABETOLOGIA, V39, P1242, DOI 10.1007/BF02658518; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 2000, J BIOL CHEM, V275, P38151, DOI 10.1074/jbc.M003432200; Hadari YR, 2000, J CELL SCI, V113, P2385; HADARI YR, 1992, J BIOL CHEM, V267, P17483; Hadari YR, 1997, TRENDS GLYCOSCI GLYC, V9, P103, DOI 10.4052/tigg.9.103; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hamer I, 1997, J BIOL CHEM, V272, P21685, DOI 10.1074/jbc.272.35.21685; Jager A, 2000, DIABETES, V49, P485, DOI 10.2337/diabetes.49.3.485; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; Kanzaki M, 2001, J BIOL CHEM, V276, P49331, DOI 10.1074/jbc.M109657200; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Le Roith D, 2001, DIABETES CARE, V24, P588, DOI 10.2337/diacare.24.3.588; Levy Y, 2001, J BIOL CHEM, V276, P31285, DOI 10.1074/jbc.M100340200; LEVY Y, 2003, J BIOL CHEM; LI CZS, 1997, AM J PHYSIOL, V273, pE801; Maggi D, 1998, ENDOCRINOLOGY, V139, P496, DOI 10.1210/en.139.2.496; Matsumoto K, 2000, ATHEROSCLEROSIS, V152, P415, DOI 10.1016/S0021-9150(99)00487-6; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Najjar SM, 2002, TRENDS ENDOCRIN MET, V13, P240, DOI 10.1016/S1043-2760(02)00608-2; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sasaoka T, 1999, ENDOCRINOLOGY, V140, P3826, DOI 10.1210/en.140.8.3826; Soni P, 1999, Mol Cell Biol Res Commun, V1, P102, DOI 10.1006/mcbr.1999.0116; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Tsakiridis T, 1999, MICROSC RES TECHNIQ, V47, P79, DOI 10.1002/(SICI)1097-0029(19991015)47:2<79::AID-JEMT1>3.0.CO;2-S; Tsakiridis T, 1998, J BIOL CHEM, V273, P28322, DOI 10.1074/jbc.273.43.28322; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	44	15	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16397	16404		10.1074/jbc.M212385200	http://dx.doi.org/10.1074/jbc.M212385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594209	hybrid			2022-12-27	WOS:000182680000119
J	Derrien, A; Zheng, B; Osterhout, JL; Ma, YC; Milligan, G; Farquhar, MG; Druey, KM				Derrien, A; Zheng, B; Osterhout, JL; Ma, YC; Milligan, G; Farquhar, MG; Druey, KM			Src-mediated RGS16 tyrosine phosphorylation promotes RGS16 stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FUNCTIONAL-CHARACTERIZATION; PROTEIN-KINASE; UP-REGULATION; REGULATOR; MODULATION; TRANSLOCATION; ASSOCIATION; ACTIVATION; EXPRESSION	The amplitude of signaling evoked by stimulation of G protein-coupled receptors may be controlled in part by the GTPase accelerating activity of the regulator of G protein signaling (RGS) proteins. In turn, subcellular targeting, protein-protein interactions, or post-translational modifications such as phosphorylation may shape RGS activity and specificity. We found previously that RGS16 undergoes tyrosine phosphorylation on conserved tyrosine residues in the RGS box. Phosphorylation on Tyr(168) was mediated by the epidermal growth factor receptor (EGFR). We show here that endogenous RGS16 is phosphorylated after epidermal growth factor stimulation of MCF-7 cells. In addition, p60-Src or Lyn kinase phosphorylated recombinant RGS16 in vitro, and RGS16 underwent phosphorylation in the presence of constitutively active Src (Y529F) in EGFR- CHO-K1 cells. Blockade of endogenous Src activity by selective inhibitors attenuated RGS16 phosphorylation induced by pervanadate or receptor stimulation. Furthermore, the rate of RGS16 degradation was reduced in cells expressing active Src or treated with pervanadate or a G protein-coupled receptor ligand (CXCL12). Induction of RGS16 tyrosine phosphorylation was associated with increased RGS16 protein levels and enhanced GAP activity in cell membranes. These results suggest that Src mediates RGS16 tyrosine phosphorylation, which may promote RGS16 stability.	NIAID, Lab Allerg Dis, NIH, Rockville, MD 20852 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Cornell Univ, Weill Med Coll, Dept Physiol, New York, NY 10021 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Diego; Cornell University; University of Glasgow	Druey, KM (corresponding author), NIAID, Lab Allerg Dis, NIH, 12441 Parklawn Dr, Rockville, MD 20852 USA.	kdruey@nih.gov	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519; Zheng, Bin/0000-0002-0998-7177; Ma, Yongchao/0000-0002-2469-4356	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000840] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Benzing T, 2002, J BIOL CHEM, V277, P32954, DOI 10.1074/jbc.M200859200; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bjornstrom L, 2002, MOL ENDOCRINOL, V16, P2202, DOI 10.1210/me.2002-0072; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Cavalli A, 2000, J BIOL CHEM, V275, P23693, DOI 10.1074/jbc.M910395199; Chausovsky A, 2000, ONCOGENE, V19, P878, DOI 10.1038/sj.onc.1203410; Chen CH, 2001, FEBS LETT, V504, P16, DOI 10.1016/S0014-5793(01)02757-0; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Davydov IV, 2000, J BIOL CHEM, V275, P22931, DOI 10.1074/jbc.M001605200; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Derrien A, 2001, J BIOL CHEM, V276, P48532, DOI 10.1074/jbc.M108862200; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hsieh HG, 2002, CYTOKINE, V19, P159, DOI 10.1006/cyto.2002.1952; Hu G, 2001, J BIOL CHEM, V276, P22287, DOI 10.1074/jbc.M011539200; Johnson EN, 2002, J BIOL CHEM, V277, P16768, DOI 10.1074/jbc.M200751200; Kawai H, 2002, MOL CELL BIOL, V22, P6079, DOI 10.1128/MCB.22.17.6079-6088.2002; Kellett E, 1999, MOL PHARMACOL, V56, P684; Krug AW, 2002, J BIOL CHEM, V277, P45892, DOI 10.1074/jbc.M208851200; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Mittmann C, 2002, CARDIOVASC RES, V55, P778, DOI 10.1016/S0008-6363(02)00459-5; Moore KJ, 2002, J BIOL CHEM, V277, P47373, DOI 10.1074/jbc.M208788200; Moy FJ, 2000, BIOCHEMISTRY-US, V39, P7063, DOI 10.1021/bi992760w; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; Sullivan BM, 2000, MOL BIOL CELL, V11, P3155, DOI 10.1091/mbc.11.9.3155; Takeda S, 2002, FEBS LETT, V520, P97, DOI 10.1016/S0014-5793(02)02775-8; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1	46	35	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16107	16116		10.1074/jbc.M210371200	http://dx.doi.org/10.1074/jbc.M210371200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12588871	hybrid			2022-12-27	WOS:000182680000083
J	Holtje, M; Winter, S; Walther, D; Pahner, I; Hortnagl, H; Ottersen, OP; Bader, M; Ahnert-Hilger, G				Holtje, M; Winter, S; Walther, D; Pahner, I; Hortnagl, H; Ottersen, OP; Bader, M; Ahnert-Hilger, G			The vesicular monoamine content regulates VMAT2 activity through G alpha(q) mouse platelets - Evidence for autoregulation of vesicular transmitter uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN HETEROTRIMERS; SMALL SYNAPTIC VESICLES; LARGE DENSE CORE; QUANTAL SIZE; DOPAMINE-RECEPTORS; TRANSPORTER VMAT2; ALPHA-SUBUNITS; CELLS; EXPRESSION; BINDING	Variations in the neurotransmitter content of secretory vesicles enable neurons to adapt to network changes. Vesicular content may be modulated by vesicle-associated Go(2), which down-regulates the activity of the vesicular monoamine transmitter transporters VMAT1 in neuroendocrine cells and VMAT2 in neurons. Blood platelets resemble serotonergic neurons with respect to transmitter storage and release. In streptolysin O-permeabilized platelets, VMAT2 activity is also down-regulated by the G protein activator guanosine 5'-(beta(i)gamma-imido)triphosphate (GMppNp). Using serotonin-depleted platelets from peripheral tryptophan hydroxylase knockout (Tph1-/-) mice, we show here that the vesicular filling initiates the G protein-mediated down-regulation of VMAT2 activity. GMppNp did not influence VMAT2 activity in naive platelets from Tph1-/-mice. GMppNp-mediated inhibition could be reconstituted, however, when preloading Tph1-/- platelets with serotonin or noradrenaline. Galpha(q) mediates the down-regulation of VMAT2 activity as revealed from uptake studies performed with platelets from Gaq deletion mutants. Serotonergic, noradrenergic, as well as thromboxane A(2) receptors are not directly involved in the down-regulation of VMAT2 activity. It is concluded that in platelets the vesicle itself regulates transmitter transporter activity via its content and vesicle-associated Galpha(q).	Humboldt Univ, Inst Anat, Charite, D-10115 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Univ Oslo, Inst Basic Med Sci, Ctr Mol Biol & Neurosci, N-0317 Oslo, Norway; Univ Oslo, Inst Basic Med Sci, Dept Anat, N-0317 Oslo, Norway; Humboldt Univ, Inst Pharmakol, Charite, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Oslo; University of Oslo; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Ahnert-Hilger, G (corresponding author), Humboldt Univ, Inst Anat, Charite, Philippstr 12, D-10115 Berlin, Germany.		Bader, Michael/K-2124-2013	Bader, Michael/0000-0003-4780-4164; Holtje, Markus/0000-0003-3193-4140				Ahnert-Hilger G, 1998, EMBO J, V17, P406, DOI 10.1093/emboj/17.2.406; AHNERTHILGER G, 1994, EUR J CELL BIOL, V65, P26; Berk M, 2001, EUR NEUROPSYCHOPHARM, V11, P183, DOI 10.1016/S0924-977X(01)00074-8; Brouillet E, 1999, J NEUROSCI, V19, P1717; Brunk I, 1999, EUR J CELL BIOL, V78, P311, DOI 10.1016/S0171-9335(99)80065-X; Bruns D, 2000, NEURON, V28, P205, DOI 10.1016/S0896-6273(00)00097-0; CESURA AM, 1990, EUR J PHARMACOL, V186, P95, DOI 10.1016/0014-2999(90)94064-5; Colliver TL, 2000, J NEUROSCI, V20, P5276, DOI 10.1523/JNEUROSCI.20-14-05276.2000; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Engel D, 2001, J PHYSIOL-LONDON, V535, P473, DOI 10.1111/j.1469-7793.2001.00473.x; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Gasman S, 1998, J BIOL CHEM, V273, P16913, DOI 10.1074/jbc.273.27.16913; Giesberts AN, 1997, BIOCHEM BIOPH RES CO, V234, P439, DOI 10.1006/bbrc.1997.6662; HINSCH KD, 1989, BIOCHIM BIOPHYS ACTA, V1013, P60, DOI 10.1016/0167-4889(89)90128-6; Holtje M, 2000, J NEUROSCI, V20, P2131; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; Krantz DE, 1997, J BIOL CHEM, V272, P6752, DOI 10.1074/jbc.272.10.6752; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; Mendelson SD, 2000, J AFFECT DISORDERS, V57, P13, DOI 10.1016/S0165-0327(99)00177-9; Miller GW, 1999, EXP NEUROL, V156, P138, DOI 10.1006/exnr.1998.7008; MORGENSTERN E, 1995, EUR J CELL BIOL, V68, P183; NIRENBERG MJ, 1995, P NATL ACAD SCI USA, V92, P8773, DOI 10.1073/pnas.92.19.8773; Offermanns S, 2000, BIOL CHEM, V381, P389, DOI 10.1515/BC.2000.051; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Pahner I, 2002, EUR J CELL BIOL, V81, P449, DOI 10.1078/0171-9335-00269; PETER D, 1994, J BIOL CHEM, V269, P7231; Pothos EN, 1998, J NEUROSCI, V18, P5575; Pothos EN, 1998, J NEUROSCI, V18, P4106; Pothos EN, 2000, J NEUROSCI, V20, P7297; Ricci A, 2001, N-S ARCH PHARMACOL, V363, P376, DOI 10.1007/s002100000339; Song HJ, 1997, NEURON, V18, P815, DOI 10.1016/S0896-6273(00)80320-7; SPICHER K, 1994, BIOCHEM BIOPH RES CO, V198, P906, DOI 10.1006/bbrc.1994.1129; Takumi Y, 1999, NAT NEUROSCI, V2, P618, DOI 10.1038/10172; Van der Kloot W, 2000, J PHYSIOL-LONDON, V523, P247, DOI 10.1111/j.1469-7793.2000.00247.x; Walther DJ, 1999, MOL BRAIN RES, V68, P55, DOI 10.1016/S0169-328X(99)00046-7; WALTHER DJ, 2002, SCIENCE, V299, P5603; Watts VJ, 1998, J NEUROSCI, V18, P8692; Weller U, 1996, EUR J BIOCHEM, V236, P34, DOI 10.1111/j.1432-1033.1996.00034.x; Wenzel HJ, 1997, HIPPOCAMPUS, V7, P559; WURZINGER LJ, 1990, ADV ANAT EMBRYOL CEL, V120, P1; Youssefian T, 1997, BLOOD, V89, P4047, DOI 10.1182/blood.V89.11.4047; Zucker M, 2001, LIFE SCI, V69, P2311, DOI 10.1016/S0024-3205(01)01301-7	46	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15850	15858		10.1074/jbc.M212816200	http://dx.doi.org/10.1074/jbc.M212816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12604601	hybrid			2022-12-27	WOS:000182680000051
J	Lin, DY; Lai, MZ; Ann, DK; Shih, HM				Lin, DY; Lai, MZ; Ann, DK; Shih, HM			Promyelocytic leukemia protein (PML) functions as a glucocorticoid receptor Co-activator by sequestering Daxx to the PML oncogenic domains (PODs) to enhance its transactivation potential	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; FAS-INDUCED APOPTOSIS; BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVITY; MOLECULAR MECHANISMS; INTERACTING PROTEIN; NUCLEAR RECEPTORS; MODULATION; SEQUESTRATION; ONCOPROTEIN	Daxx has been reported to function as a transcriptional modulator in the nucleus. In the present study, we have explored the role of Daxx in regulating the transcriptional activity of the glucocorticoid receptor (GR). Overexpression of Daxx suppressed GR-mediated activation of the mouse mammary tumor virus promoter in COS-1, HeLa, and 293T cells. In vitro and in vivo studies revealed that Daxx could directly bind to GR. The mapping analysis further demonstrated that the C-terminal region of Daxx-(501-740) mediates the interaction and transcriptional repression of GR. The repressive effect of Daxx and Daxx-(501-740) on GR could be alleviated by co-expression of promyelocytic leukemia protein (PML). Furthermore, immunofluorescence analysis showed that overexpression of wild-type PML results in the translocation of Daxx and Daxx-(501-740) to the PML oncogenic domains (PODs). By contrast, a PML sumoylation-defective mutant failed to recruit Daxx to PODs and to reverse the Daxx repression effect on GR. Accordingly, As,03 treatment rendered the sequestration of endogenous Daxx to the PODs, leading to an enhancement of GR transactivation in COS-1 cells. Taken together, these findings suggest that recruitment of Daxx into the suhnuclear POD structures sequesters it from the GR/co-activators complex, thereby alleviating its repressive effects. Our present studies provide the important link between Daxx/PML interaction and GR transcriptional activation.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 11529, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA	National Health Research Institutes - Taiwan; National Defense Medical Center; Academia Sinica - Taiwan; University of Southern California	Shih, HM (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128 Sec2,Yen Chiu Yuan Rd, Taipei 11529, Taiwan.		Shih, Hsiu-Ming/S-7023-2018; Lai, Ming-Zong/AAA-4408-2021	Lai, Ming-Zong/0000-0002-3237-4803	NIDCR NIH HHS [DE 14183, R01 DE 10742] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014183] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; Almawi WY, 2002, J LEUKOCYTE BIOL, V71, P9; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Charette SJ, 2000, ANN NY ACAD SCI, V926, P126; Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; HATTA M, 2001, SCI STKE; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Lalioti VS, 2002, J BIOL CHEM, V277, P19783, DOI 10.1074/jbc.M110294200; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lin DY, 2002, J BIOL CHEM, V277, P25446, DOI 10.1074/jbc.M200633200; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; Pluta AF, 1998, J CELL SCI, V111, P2029; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Ryu SW, 2000, BIOCHEM BIOPH RES CO, V279, P6, DOI 10.1006/bbrc.2000.3882; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Sengupta S, 2000, EMBO J, V19, P6051, DOI 10.1093/emboj/19.22.6051; Singh P, 2001, J BIOL CHEM, V276, P13762, DOI 10.1074/jbc.M100137200; Tian S, 2002, BIOCHEM J, V367, P907, DOI 10.1042/BJ20021085; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463	37	67	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15958	15965		10.1074/jbc.M300387200	http://dx.doi.org/10.1074/jbc.M300387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12595526	hybrid			2022-12-27	WOS:000182680000065
J	Park, HJ; Wu, S; Dunker, AK; Kang, C				Park, HJ; Wu, S; Dunker, AK; Kang, C			Polymerization of calsequestrin - Implications for Ca2+ regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM VESICLES; CANINE CARDIAC CALSEQUESTRIN; RYANODINE RECEPTOR; CALCIUM-RELEASE; BINDING PROTEIN; CRYSTALLIZATION; SPECTROSCOPY; TRIADIN	Two distinct dimerization contacts in calsequestrin crystals suggested a mechanism for Ca2+ regulation resulting from the occurrence of coupled Ca2+ binding and protein polymerization. Ca2+-induced formation of one contact was proposed to lead to dimerization followed by Ca2+-induced formation of the second contact to bring about polymerization (1). To test this mechanism, we compared canine cardiac calsequestrin and four truncation mutants with regard to their folding properties, structures, and Ca2+-induced polymerization. The wild-type calsequestrin and truncation mutants exhibited similar K+-induced folding and end-point structures as indicated by intrinsic fluorescence and circular dichroism, respectively, whereas the polymerization tendencies of the wild-type calsequestrin differed markedly from the polymerization tendencies of the truncation mutants. Static laser light scattering and 3,3'-dithiobis sulfosuccinimidyl-propionate cross-linking indicated that wild-type protein exhibited an initial Ca2+-induced dimerization, followed by additional oligomerization as the Ca2+ concentration was raised or as the K+ concentration was lowered. None of the truncation mutants exhibited clear stepwise oligomerization that depended on increasing Ca2+ concentration. Comparison of the three-dimensional structure of rabbit skeletal calsequestrin with a homology, model of canine cardiac calsequestrin from the point of view of our coupled Ca2+ binding and polymerization mechanism leads to a possible explanation for the 2-fold reduced Ca2+ binding capacity of cardiac calsequestrin despite very similar overall net negative charge for the two proteins.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Washington State Univ, Dept Chem, Pullman, WA 99164 USA	Washington State University; Washington State University	Kang, C (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.	chkang@wsunix.wsu.edu		Park, HaJeung/0000-0003-4898-7919				AARON BMB, 1984, J BIOL CHEM, V259, P1876; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; Donoso P, 1996, BIOCHEMISTRY-US, V35, P13419, DOI 10.1021/bi9616209; FASMAN GD, 1996, CIRCULAR DICHROISM C, P109; FRANZINIARMSTRONG C, 1987, J CELL BIOL, V105, P49, DOI 10.1083/jcb.105.1.49; Glover L, 2001, BBA-BIOMEMBRANES, V1515, P120, DOI 10.1016/S0005-2736(01)00406-0; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; HAYAKAWA K, 1994, J MOL BIOL, V235, P357, DOI 10.1016/S0022-2836(05)80039-7; HE ZP, 1993, J BIOL CHEM, V268, P24635; Hidalgo C, 1996, BIOPHYS J, V71, P2130, DOI 10.1016/S0006-3495(96)79413-4; IKEMOTO N, 1974, J BIOL CHEM, V249, P2357; IKEMOTO N, 1972, J BIOL CHEM, V247, P7835; Kang ChulHee, 2002, Methods Mol Biol, V172, P281; KRAUSE KH, 1991, J BIOL CHEM, V266, P9453; MacLennan DH, 1998, NAT STRUCT BIOL, V5, P409, DOI 10.1038/nsb0698-409; MACLENNAN DH, 1974, J BIOL CHEM, V249, P980; MacLennan DH, 2002, J MOL CELL CARDIOL, V34, P897, DOI 10.1006/jmcc.2002.2031; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; Maguire PB, 1997, BIOCHEM BIOPH RES CO, V240, P721, DOI 10.1006/bbrc.1997.7729; MAURER A, 1985, P NATL ACAD SCI USA, V82, P4036, DOI 10.1073/pnas.82.12.4036; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SLUPSKY JR, 1987, BIOCHEMISTRY-US, V26, P6539, DOI 10.1021/bi00394a038; SOMLYO AV, 1981, J CELL BIOL, V90, P577, DOI 10.1083/jcb.90.3.577; TANAKA M, 1986, ARCH BIOCHEM BIOPHYS, V251, P369, DOI 10.1016/0003-9861(86)90084-6; Wang SR, 1998, NAT STRUCT BIOL, V5, P476, DOI 10.1038/nsb0698-476; WILLIAMS RJP, 1978, BIOCHIM BIOPHYS ACTA, V505, P1, DOI 10.1016/0304-4173(78)90007-1; WILLIAMS RW, 1986, J BIOL CHEM, V261, P2408; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389	29	97	97	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					16176	16182		10.1074/jbc.M300120200	http://dx.doi.org/10.1074/jbc.M300120200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594204	hybrid			2022-12-27	WOS:000182680000091
J	Schroder, NWJ; Morath, S; Alexander, C; Hamann, L; Hartung, T; Zahringer, U; Gobel, UB; Weber, JR; Schumann, RR				Schroder, NWJ; Morath, S; Alexander, C; Hamann, L; Hartung, T; Zahringer, U; Gobel, UB; Weber, JR; Schumann, RR			Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE DIFFERENTIATION ANTIGEN; GRAM-NEGATIVE BACTERIA; WALL COMPONENTS; BLOOD-STREAM; SEPTIC SHOCK; CUTTING EDGE; ANTIMICROBIAL SUSCEPTIBILITY; CYTOKINE INDUCTION; INNATE IMMUNITY; PEPTIDOGLYCAN	Lipoteichoic acid (LTA) derived from Streptococcus pneumoniae, purified employing a chloroform/methanol protocol, and from Staphylococcus aureus, prepared by the recently described butanol extraction procedure, was investigated regarding its interaction with lipopolysaccharide (LPS)-binding protein (LBP), CD14, Toll-like receptors (TLRs)-2 and -4, and MD-2. LTA from both organisms induced cytokine synthesis in human mononuclear phagocytes. Activation was LBP- and CD14-dependent, and formation of complexes of LTA with LBP and soluble CD14 as well as catalytic transfer of LTA to CD14 by LBP was verified by PhastGel(TM) native gel electrophoresis. Human embryonic kidney (HEK) 293/CD14 cells and Chinese hamster ovary (CHO) cells were responsive to LTA only after transfection with TLR-2. Additional transfection with MD-2 did not affect stimulation of these cells by LTA. Our data suggest that innate immune recognition of LTA via LBP, CD14, and TLR-2 represents an important mechanism in the pathogenesis of systemic, complications in the course of infectious diseases brought about by the clinically most important Gram-positive pathogens. However, the involvement of TLR-4 and AW-2 in this process was ruled out.	Humboldt Univ, Klinikum Charite, Inst Mikrobiol & Hyg, Fak Med, D-10117 Berlin, Germany; Univ Konstanz, D-78457 Constance, Germany; Forschungszentrum Borstel, Abt Immunchem & Med Mikrobiol, Zentrum Med & Biowissensch, D-23845 Borstel, Germany; Humboldt Univ, Fak Med, Klinikum Charite, Neurol Klin, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Konstanz; Forschungszentrum Borstel; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schumann, RR (corresponding author), Humboldt Univ, Klinikum Charite, Inst Mikrobiol & Hyg, Fak Med, Dorotheenstr 96, D-10117 Berlin, Germany.			Hamann, Lutz/0000-0003-4719-2583				Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; BEHR T, 1992, EUR J BIOCHEM, V207, P1063, DOI 10.1111/j.1432-1033.1992.tb17143.x; Beutler B, 2001, J ENDOTOXIN RES, V7, P277, DOI 10.1177/09680519010070040901; BHAKDI S, 1991, INFECT IMMUN, V59, P4614, DOI 10.1128/IAI.59.12.4614-4620.1991; COSENZA H, 1975, EUR J IMMUNOL, V5, P343, DOI 10.1002/eji.1830050510; DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359; Diekema DJ, 2000, INT J ANTIMICROB AG, V13, P257, DOI 10.1016/S0924-8579(99)00131-4; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; Dziarski R, 2001, J IMMUNOL, V166, P1938, DOI 10.4049/jimmunol.166.3.1938; Echchannaoui H, 2002, J INFECT DIS, V186, P798, DOI 10.1086/342845; Fan XL, 1999, INFECT IMMUN, V67, P2964, DOI 10.1128/IAI.67.6.2964-2968.1999; FISCHER W, 1990, BIOCHEM CELL BIOL, V68, P33, DOI 10.1139/o90-005; FISCHER W, 1994, MED MICROBIOL IMMUN, V183, P61, DOI 10.1007/BF00277157; Fluit AC, 2001, EUR J CLIN MICROBIOL, V20, P188, DOI 10.1007/s10096-001-8078-8; Gao JJ, 2001, INFECT IMMUN, V69, P751, DOI 10.1128/IAI.69.2.751-757.2001; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; Ginsburg I, 2002, LANCET INFECT DIS, V2, P171, DOI 10.1016/S1473-3099(02)00226-8; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; Greenberg JW, 1996, INFECT IMMUN, V64, P3318, DOI 10.1128/IAI.64.8.3318-3325.1996; Greenwood B, 1999, PHILOS T R SOC B, V354, P777, DOI 10.1098/rstb.1999.0430; Gupta D, 1999, J BIOL CHEM, V274, P14012, DOI 10.1074/jbc.274.20.14012; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; Hamann L, 2000, EUR J IMMUNOL, V30, P211, DOI 10.1002/1521-4141(200001)30:1<211::AID-IMMU211>3.3.CO;2-F; HAZIOT A, 1988, J IMMUNOL, V141, P547; Heer C, 2000, INFECTION, V28, P13, DOI 10.1007/s150100050004; Heine H, 1999, J IMMUNOL, V162, P6971; Hermann C, 2002, EUR J IMMUNOL, V32, P541, DOI 10.1002/1521-4141(200202)32:2<541::AID-IMMU541>3.0.CO;2-P; HEUMANN D, 1994, INFECT IMMUN, V62, P2715, DOI 10.1128/IAI.62.7.2715-2721.1994; HOLTJE JV, 1975, P NATL ACAD SCI USA, V72, P1690, DOI 10.1073/pnas.72.5.1690; HOLTJE JV, 1975, J BIOL CHEM, V250, P6072; INGRAHAM JL, 1983, GROWTH BACTERIAL CEL, P3; KELLER R, 1992, INFECT IMMUN, V60, P3664, DOI 10.1128/IAI.60.9.3664-3672.1992; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kitchens RL, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P521; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamping N, 1998, J CLIN INVEST, V101, P2065, DOI 10.1172/JCI2338; LEESON MC, 1994, INFECT IMMUN, V62, P4975, DOI 10.1128/IAI.62.11.4975-4980.1994; MANTHOUS CA, 1993, CHEST, V104, P1872, DOI 10.1378/chest.104.6.1872; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Metlay JP, 2002, CURR OPIN INFECT DIS, V15, P163, DOI 10.1097/00001432-200204000-00011; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; Morath S, 2002, J EXP MED, V195, P1635, DOI 10.1084/jem.20020322; Morath S, 2002, INFECT IMMUN, V70, P938, DOI 10.1128/IAI.70.2.938-944.2002; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; Munford RS, 2001, AM J RESP CRIT CARE, V163, P316, DOI 10.1164/ajrccm.163.2.2007102; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Opitz B, 2001, J BIOL CHEM, V276, P22041, DOI 10.1074/jbc.M010481200; Pfaller MA, 1998, ANTIMICROB AGENTS CH, V42, P1762, DOI 10.1128/AAC.42.7.1762; Rietschel ET, 1996, CURR TOP MICROBIOL, V216, P39; Schneider O, 1999, NEUROLOGY, V53, P1584, DOI 10.1212/WNL.53.7.1584; Schroder NW, 2001, J BIOL CHEM, V276, P9713, DOI 10.1074/jbc.M008954200; Schroder NWJ, 2000, J IMMUNOL, V165, P2683, DOI 10.4049/jimmunol.165.5.2683; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Schumann RR, 2000, CHEM IMMUNOL, V74, P42; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; van Deventer SJH, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P379; van Langevelde P, 1998, ANTIMICROB AGENTS CH, V42, P3073, DOI 10.1128/AAC.42.12.3073; Wolfert MA, 2002, J BIOL CHEM, V277, P39179, DOI 10.1074/jbc.M204885200; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang SH, 2001, INFECT IMMUN, V69, P2045, DOI 10.1128/IAI.69.4.2045-2053.2001; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zweigner J, 2001, BLOOD, V98, P3800, DOI 10.1182/blood.V98.13.3800	69	511	530	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15587	15594		10.1074/jbc.M212829200	http://dx.doi.org/10.1074/jbc.M212829200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12594207	hybrid			2022-12-27	WOS:000182680000018
J	Hiromura, M; Choi, CH; Sabourin, NA; Jones, H; Bachvarov, D; Usheva, A				Hiromura, M; Choi, CH; Sabourin, NA; Jones, H; Bachvarov, D; Usheva, A			YY1 is regulated by O-linked N-acetylglucosaminylation (O-GlcNAcylation)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR YY1; RNA-POLYMERASE-II; TATA-BINDING PROTEIN; TETRATRICOPEPTIDE REPEATS; CYTOSOLIC PROTEINS; GLCNAC TRANSFERASE; DYNAMIC INTERPLAY; CELL-DEATH; GLYCOSYLATION; NUCLEAR	YY1 is a zinc finger DNA-binding transcription factor that influences expression of a wide variety of cellular and viral genes. YY1 is essential for the development of mammalian embryos. It regulates the expression of genes with important functions in DNA replication, protein synthesis, and cellular response to external stimuli during cell growth and differentiation. How YY1 accomplishes such a variety of functions is unknown. Here, we show that a subset of the nuclear YY1 appears to be O-GleNAcylated regardless of the differentiation status of the cells. We found that glucose strongly stimulates O-linked N-acetylglucosaminylation (O-GlcNAcylation) on YY1. Glycosylated YY1 no longer binds the retinoblastoma protein (Rb). Upon dissociation from Rb, the glycosylated YY1 is free to bind DNA. The ability of the O-glycosylation on YY1 to disrupt the complex with Rb leads us to propose that O-glycosylation might have a profound effect on cell cycle transitions that regulate the YY1-Rb heterodimerization and promote the activity of YY1. Our observations provide strong evidence that YY1-regulated transcription is very likely connected to the pathway of glucose metabolism that culminates in the O-GlcNAcylation on YY1, changing its function in transcription.	Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; CHUQ, Hop Hotel Dieu, Ctr Rech, Quebec City, PQ G1R 2J6, Canada; Univ Laval, Quebec City, PQ G1R 2J6, Canada	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Laval University; Laval University	Usheva, A (corresponding author), Harvard Univ, Sch Med, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.	ausheva@bidmc.harvard.edu		Bachvarov, Dimcho/0000-0001-6509-9599	NHLBI NIH HHS [HL62458] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062458] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; DEBRAY H, 1981, EUR J BIOCHEM, V117, P41; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Fiordaliso F, 2001, DIABETES, V50, P2363, DOI 10.2337/diabetes.50.10.2363; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; HOLT GD, 1986, J BIOL CHEM, V261, P8049; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; Lefebvre T, 2002, J CELL BIOCHEM, V85, P208, DOI 10.1002/jcb.10119; Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820; Lubas WA, 1997, J BIOL CHEM, V272, P9316; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; Petkova V, 2001, J BIOL CHEM, V276, P7932, DOI 10.1074/jbc.M007411200; REASON AJ, 1992, J BIOL CHEM, V267, P16911; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; Vosseller K, 2002, CURR OPIN CHEM BIOL, V6, P851, DOI 10.1016/S1367-5931(02)00384-8; WHITEHEART SW, 1989, METHOD ENZYMOL, V179, P82; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001	37	92	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					14046	14052		10.1074/jbc.M300789200	http://dx.doi.org/10.1074/jbc.M300789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12588874	hybrid			2022-12-27	WOS:000182405000063
J	Koopman, WJH; Bosch, RR; van Emst-de Vries, SE; Spaargaren, M; De Pont, JJHHM; Willems, PHGM				Koopman, WJH; Bosch, RR; van Emst-de Vries, SE; Spaargaren, M; De Pont, JJHHM; Willems, PHGM			R-Ras alters Ca2+ homeostasis by increasing the Ca2+ leak across the endoplasmic reticular membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DOWN-REGULATION; CALCIUM; BCL-2; CELLS; APOPTOSIS; STORES; PROLIFERATION; OSCILLATIONS; DEPRIVATION	Evidence in the literature implicating both Ras-like Ras (R-Ras) and intracellular Ca2+ in programmed cell death and integrin-mediated adhesion prompted us to investigate the possibility that R-Ras alters cellular Ca2+ handling. Chinese hamster ovary cells expressing the cholecystokinin (CCK)-A receptor were loaded with indo-1 to study the effects of constitutively active V38R-Ras and dominant negative N43R-Ras on the kinetics of the thapsigargin (Tg)- and CCK8-induced Ca2+ rises using high speed confocal microscopy. In the absence of extracellular Ca2+, both 1 pm Tg, a potent and selective inhibitor of the Ca2+ pump of the intracellular Ca2+ store, and 100 nm CCK8 evoked a transient rise in Ca2+, the size of which was decreased significantly after expression of V38R-Ras. At 0.1 nm, CCK, evoked periodic Ca2+ rises. The frequency of these Ca2+ oscillations was reduced significantly in V38R-Ras-expressing cells. In contrast to V38R-Ras, N43R-Ras did not alter the kinetics of the Tg- and CCK8-induced Ca2+ rises. The present findings are compatible with the idea that V38R-Ras expression increases the passive leak of Ca2+ of the store leading to a decrease in Ca2+ content of this store, which, in turn, leads to a decrease in frequency of the CCK8-induced cytosolic Ca2+ oscillations. The effect of V38R-Ras on the Ca2+ content of the intracellular Ca2+ store closely resembles that of the antiapoptotic protein Bcl-2 observed earlier. Together with reports on the role of dynamic Ca2+ changes in integrin-mediated adhesion, this leads us to propose that the reduction in endoplasmic reticulum Ca2+ content may underlie the antiapoptotic effect of R-Ras, whereas the decrease in frequency of stimulus-induced Ca2+ oscillations may play a role in the inhibitory effect of R-Ras on stimulus-induced cell detachment and migration.	Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands	Radboud University Nijmegen; University of Amsterdam; Academic Medical Center Amsterdam	Willems, PHGM (corresponding author), Univ Nijmegen, Ctr Med, Biochem NCMLS 160, POB 9101, NL-6500 HB Nijmegen, Netherlands.	P.Willems@ncmls.kun.nl	Spaargaren, Marcel/AAU-1298-2021; Koopman, Werner J.H./AAC-9668-2020; Willems, P.H.G.M./L-4759-2015; Koopman, Werner J.H./D-3592-2009	Spaargaren, Marcel/0000-0002-3135-5109; Koopman, Werner J.H./0000-0002-5340-6747; Willems, P.H.G.M./0000-0002-0915-1599; Koopman, Werner J.H./0000-0002-5340-6747				Bhatt A, 2002, J CELL SCI, V115, P3415; Bosch RR, 1999, BIOCHEM J, V337, P263, DOI 10.1042/0264-6021:3370263; Broadway NM, 1998, FEBS LETT, V437, P122, DOI 10.1016/S0014-5793(98)01155-7; Chaves-Olarte E, 1999, J BIOL CHEM, V274, P11046, DOI 10.1074/jbc.274.16.11046; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; Hansen M, 2002, ONCOGENE, V21, P4448, DOI 10.1038/sj.onc.1205538; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; INCE C, 1985, PFLUG ARCH EUR J PHY, V403, P240, DOI 10.1007/BF00583594; Kihara T, 2002, J NEUROSCI RES, V70, P274, DOI 10.1002/jnr.10426; Koopman WJH, 2001, BIOPHYS J, V81, P57, DOI 10.1016/S0006-3495(01)75679-2; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; Leitinger B, 2000, BBA-MOL CELL RES, V1498, P91, DOI 10.1016/S0167-4889(00)00086-0; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Oertli B, 2000, ONCOGENE, V19, P4961, DOI 10.1038/sj.onc.1203876; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Osada M, 1999, MOL CELL BIOL, V19, P6333; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Pinton P, 2002, BIOCHIMIE, V84, P195, DOI 10.1016/S0300-9084(02)01373-1; Putney JW, 2001, J CELL SCI, V114, P2223; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Self AJ, 2001, J CELL SCI, V114, P1357; Smeets RLL, 1998, BRIT J PHARMACOL, V124, P935, DOI 10.1038/sj.bjp.0701913; Smeets RLL, 1996, CELL CALCIUM, V20, P1, DOI 10.1016/S0143-4160(96)90045-7; Suzuki J, 1997, ONCOGENE, V15, P1689, DOI 10.1038/sj.onc.1201333; Torres JJ, 2001, EUROPHYS LETT, V55, P746, DOI 10.1209/epl/i2001-00477-3; VANDEPUT FHMM, 1995, CELL CALCIUM, V17, P85, DOI 10.1016/0143-4160(95)90078-0; VANDEPUT FHMM, 1994, J BIOL CHEM, V269, P12438; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WILLEMS PHGM, 1993, CELL CALCIUM, V14, P145, DOI 10.1016/0143-4160(93)90084-J; WILLEMS PHGM, 1994, PFLUG ARCH EUR J PHY, V427, P233, DOI 10.1007/BF00374529; Yoo JK, 2002, J IMMUNOL, V169, P3637, DOI 10.4049/jimmunol.169.7.3637; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	41	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 18	2003	278	16					13672	13679		10.1074/jbc.M211256200	http://dx.doi.org/10.1074/jbc.M211256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	670JV	12586830	hybrid, Green Published			2022-12-27	WOS:000182405000016
